PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Hermisson, M; Wagenknecht, B; Wolburg, H; Glaser, T; Dichgans, J; Weller, M				Hermisson, M; Wagenknecht, B; Wolburg, H; Glaser, T; Dichgans, J; Weller, M			Sensitization to CD95 ligand-induced apoptosis in human glioma cells by hyperthermia involves enhanced cytochrome c release	ONCOGENE			English	Article						CD95; hyperthermia; cytochrome c; glioma; mitochondria	HUMAN-MALIGNANT GLIOMA; ANTIBODY-MEDIATED APOPTOSIS; TUMOR-NECROSIS-FACTOR; CD95L-INDUCED APOPTOSIS; GENE-TRANSFER; FUNCTIONS DOWNSTREAM; CASPASE ACTIVATION; DEATH RECEPTORS; LETHAL WEAPON; MITOCHONDRIA	CD95L-induced apoptosis involves caspase activation and is facilitated when RNA and protein synthesis are inhibited. Here, we report that hyperthermia sensitizes malignant glioma cells to CD95L- and APO2L-induced apoptosis in the absence, but not in the presence, of inhibitors of RNA and protein synthesis. Hyperthermia does not alter CD95 expression at the cell surface and does not modulate the morphology of CD95-mediated cell death on electron microscopy, Bcl-2 gene transfer inhibits apoptosis and abrogates the sensitization mediated by hyperthermia, Hyperthermia does not overcome resistance to apoptosis conferred by the viral caspase inhibitor, crm-A, indicating the absolute requirement for the activation of crm-A-sensitive caspases, probably caspase 8, for apoptosis, CD95L-evoked DEVD-amc-cleaving caspase activity is enhanced by hyperthermia, suggesting that hyperthermia operates up-stream of caspase processing to promote apoptosis, There is no uniformly enhanced processing of three caspase 3 substrate, poly-ADP ribose polymerase (PARP), protein kinase C (PKC) delta and DNA fragmentation factor (DFF) 45, Yet, hyperthermia promotes CD95L-evoked DNA fragmentation, Interestingly, hyperthermia enhances the CD95L-evoked release of cytochrome c in the absence, but not in the presence, of CHX. In contrast, the reduction of the mitochondrial membrane potential is enhanced by hyperthermia both in the absence and presence of CHX, and enhanced cytochrome c release is not associated with significantly enhanced caspase 9 processing. The potentiation of cytochrome c release at hyperthermic conditions in the absence of CHX is abrogated by Bcl-2, Thus, either hyperthermia or inhibition of protein synthesis by CHX potentiate cytotoxic cytokine-induced apoptosis, These pathways show no synergy, but rather redundance, indicating that CHX may function to promote apoptosis in response to cytotoxic cytokines by inhibiting the synthesis of specific proteins whose synthesis, function or degradation is temperature-sensitive.	Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany; Univ Tubingen, Sch Med, Inst Pathol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.			Weller, Michael/0000-0002-1748-174X				Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; KLOSTERGAARD J, 1992, CANCER RES, V52, P5271; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krammer P H, 1999, Adv Immunol, V71, P163; Kroemer G, 1997, CELL DEATH DIFFER, V4, P443, DOI 10.1038/sj.cdd.4400266; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Naumann U, 1998, INT J CANCER, V77, P645, DOI 10.1002/(SICI)1097-0215(19980812)77:4<645::AID-IJC27>3.0.CO;2-3; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pohl U, 1999, CELL PHYSIOL BIOCHEM, V9, P29, DOI 10.1159/000016300; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Roth W, 1997, CANCER IMMUNOL IMMUN, V44, P55, DOI 10.1007/s002620050355; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SMINIA P, 1994, INT J HYPERTHER, V10, P1, DOI 10.3109/02656739409009328; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wagenknecht B, 1999, CELL DEATH DIFFER, V6, P370, DOI 10.1038/sj.cdd.4400503; Wagenknecht B, 1998, CELL DEATH DIFFER, V5, P894, DOI 10.1038/sj.cdd.4400435; WATANABE N, 1988, CANCER RES, V48, P650; Weller M, 1998, BRAIN PATHOL, V8, P285; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yount GL, 1998, CANCER RES, V58, P3819	37	39	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2000	19	19					2338	2345		10.1038/sj.onc.1203554	http://dx.doi.org/10.1038/sj.onc.1203554			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822385				2022-12-17	WOS:000086974300009
J	Plyte, S; Majolini, MB; Pacini, S; Scarpini, F; Bianchini, C; Lanfrancone, L; Pelicci, P; Baldari, CT				Plyte, S; Majolini, MB; Pacini, S; Scarpini, F; Bianchini, C; Lanfrancone, L; Pelicci, P; Baldari, CT			Constitutive activation of the Ras/MAP kinase pathway and enhanced TCR signaling by targeting the Shc adaptor to membrane rafts	ONCOGENE			English	Article						Shc adaptor; Ras; TCR; lipid raft; membrane localization	T-CELL RECEPTOR; PHOSPHOTYROSINE-BINDING DOMAIN; DEPENDENT GENE ACTIVATION; ANTIGEN-RECEPTOR; TYROSINE KINASES; PLASMA-MEMBRANE; NUCLEAR FACTOR; ZAP-70; PROTEIN; RAS	The Shc adaptor is responsible for coupling receptor tyrosine kinases and tyrosine kinase-associated receptors to the Ras/MAP kinase pathway. Shc is believed to be regulated by a change in subcellular localization from the cytosol to the plasma membrane, where it recruits Grb2/Sos complexes and hence permits juxtaposition of the guanine nucleotide exchange factor Sos to Ras, resulting in GDP/GTP exchange and Ras activation. Shc has been recently shown to inducibly colocalize in detergent-resistant membrane rafts together with the activated TCR and associated signaling molecules, To understand whether Shc localization in membrane rafts is sufficient to regulate Shc function, we constructed a Shc chimera containing the Ras membrane localization motif at the C-terminus, We show that membrane targeted Shc was constitutively localized in the plasma membrane of T-cells, and was mostly compartmentalized in lipid rafts. Membrane targeted Shc was phosphorylated on tyrosine residues and bound Grb-2/Sos in the absence of TCR engagement. Furthermore, expression of membrane targeted Shc resulted in constitutive downstream signaling, including Erk2 activation and enhancement of TCR dependent activation of the TCR responsive transcription factor NF-AT, Hence localization of Shc in membrane rafts is sufficient for Shc to acquire a signaling competent state. Interestingly, a membrane targeted Shc mutant lacking both Grb-2 binding sites was not only incapable of signaling in the absence of TCR triggering, but transdominantly inhibited endogenous Shc, supporting a non redundant role for Shc in the activation of the Ras/MAP kinase pathway in T-cells.	Univ Siena, Dept Evolutionary Biol, I-53100 Siena, Italy; European Inst Oncol, Milan, Italy	University of Siena; IRCCS European Institute of Oncology (IEO)	Baldari, CT (corresponding author), Univ Siena, Dept Evolutionary Biol, Via Mattioli 4, I-53100 Siena, Italy.		Pelicci, Pier Giuseppe/AAL-6572-2020; Lanfrancone, Luisa/AAC-8671-2019	Lanfrancone, Luisa/0000-0002-4523-3815; Baldari, Cosima/0000-0002-4414-6744	Telethon [E.0651] Funding Source: Medline	Telethon(Fondazione Telethon)		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Baldari CT, 1999, BIOL CHEM, V380, P129, DOI 10.1515/BC.1999.020; BALDARI CT, 1993, J BIOL CHEM, V268, P2693; BALDARI CT, 1995, ONCOGENE, V10, P1141; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/0968-0004(96)10033-5; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Graef IA, 1997, EMBO J, V16, P5618, DOI 10.1093/emboj/16.18.5618; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Koretzky GA, 1997, IMMUNOL TODAY, V18, P401, DOI 10.1016/S0167-5699(97)01088-8; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Milia E, 1996, ONCOGENE, V13, P767; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; Pacini S, 1998, J BIOL CHEM, V273, P20487, DOI 10.1074/jbc.273.32.20487; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Peterson EJ, 1998, CURR OPIN IMMUNOL, V10, P337, DOI 10.1016/S0952-7915(98)80173-8; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; ULIVIERI C, 1999, IN PRESS EUR J IMMUN, V29; Walk SF, 1998, EUR J IMMUNOL, V28, P2265, DOI 10.1002/(SICI)1521-4141(199808)28:08<2265::AID-IMMU2265>3.0.CO;2-P; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WOODROW MA, 1993, J IMMUNOL, V150, P3853; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yamasaki S, 1996, MOL CELL BIOL, V16, P7151; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	40	39	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	2000	19	12					1529	1537		10.1038/sj.onc.1203451	http://dx.doi.org/10.1038/sj.onc.1203451			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734312				2022-12-17	WOS:000086108100005
J	Bishay, K; Ory, K; Lebeau, J; Levalois, C; Olivier, MF; Chevillard, S				Bishay, K; Ory, K; Lebeau, J; Levalois, C; Olivier, MF; Chevillard, S			DNA damage-related gene expression as biomarkers to assess cellular response after gamma irradiation of a human lymphoblastoid cell line	ONCOGENE			English	Article						irradiation; DNA damage-related genes; apoptosis; cell cycle; micronucleus assay	WILD-TYPE P53; POLYMERASE-DELTA; GROWTH-ARREST; PCNA; REPLICATION; APOPTOSIS; DEATH; REPAIR; P21; RADIATION	Since defects in molecular mechanisms controlling DNA repair, cell cycle checkpoint and apoptosis could modify cellular sensitivity to DNA damaging agents, we have conducted a multiparametric molecular analysis for better understanding the regulation pathways leading to cell survival or cell death after irradiation, Using a human lymphoblastoid cell line, we have analysed, following gamma irradiation (0.5, 1, 2, 4, 8, 16 and 32 Gy, at 0.5, 24, 48 and 72 h after treatment), the correlation between proliferation, cell cycle analysis, apoptosis and micronuclei frequency with the expression of TP53, WAF1, DNA LIGASE 1, PCNA, BAX, BLC-2, BAK, DAD1, ICH1-Long and -Short forms mRNAs. We have found that whereas TP53, BAK, ICH1-Short form, and DAD1 were expressed at constant levels, WAF1, PCNA, BAX were up-regulated, ICH1-Long form, DNA LIGASE 1, and BCL-2 were downregulated. These modifications of expression were significantly correlated with doses, survival, proliferation, cell cycle delays, and apoptosis, A positive correlation of WAF1 and BAX, and a borderline negative correlation with BCL-2 expressions were observed with micronuclei frequency for doses ranging from 0.5 to 4 Gy, In conclusion, our data clearly demonstrate that gene expression profiling, which is easier and more rapid to conduct than the assessments of classical phenotypic responses, could be useful to improve knowledge concerning pathways in involved in cellular response to irradiation, knowing that such biomarkers could constitute tools to assess radio-sensitivity/radio-resistance.	CEA, DSV, DRR, Expt Cancerol Lab, F-92265 Fontenay Aux Roses, France	CEA	Chevillard, S (corresponding author), CEA, DSV, DRR, Expt Cancerol Lab, 60-68 Ave Gen Leclerc,BP6, F-92265 Fontenay Aux Roses, France.			Chevillard, Sylvie/0000-0001-5889-4041				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chevillard S, 1997, LEUKEMIA, V11, P1095, DOI 10.1038/sj.leu.2400657; Chevillard S, 1996, CANCER, V77, P292, DOI 10.1002/(SICI)1097-0142(19960115)77:2<292::AID-CNCR11>3.0.CO;2-X; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; FENECH M, 1985, MUTAT RES, V147, P29, DOI 10.1016/0165-1161(85)90015-9; Fenech M, 1997, MUTAT RES-GEN TOX EN, V392, P11, DOI 10.1016/S0165-1218(97)00041-4; Foray N, 1997, BIOCHIMIE, V79, P567, DOI 10.1016/S0300-9084(97)82005-6; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; Kelleher DJ, 1997, P NATL ACAD SCI USA, V94, P4994, DOI 10.1073/pnas.94.10.4994; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Kroemer G, 1998, CELL DEATH DIFFER, V5, P547, DOI 10.1038/sj.cdd.4400387; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LITTLEFIELD LG, 1989, MUTAGENESIS, V4, P265, DOI 10.1093/mutage/4.4.265; MIYASHITA T, 1995, CELL, V80, P293; NAKASHIMA T, 1993, MOL CELL BIOL, V13, P6367, DOI 10.1128/MCB.13.10.6367; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Oku T, 1998, GENES CELLS, V3, P357, DOI 10.1046/j.1365-2443.1998.00199.x; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Schwartz D, 1997, ONCOGENE, V15, P2597, DOI 10.1038/sj.onc.1201436; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; Shu HKG, 1998, P NATL ACAD SCI USA, V95, P14453, DOI 10.1073/pnas.95.24.14453; TERAOKA H, 1992, BIOCHEM INT, V26, P963; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wenz F, 1998, RADIAT RES, V149, P32, DOI 10.2307/3579679; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Xu J, 1999, MOL CELL BIOL, V19, P12; ZENG XR, 1994, J BIOL CHEM, V269, P13748; ZHAN QM, 1994, ONCOGENE, V9, P3743	40	39	43	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2000	19	7					916	923		10.1038/sj.onc.1203405	http://dx.doi.org/10.1038/sj.onc.1203405			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702800				2022-12-17	WOS:000085567700009
J	Caldeira, S; de Villiers, EM; Tommasino, M				Caldeira, S; de Villiers, EM; Tommasino, M			Human papillomavirus E7 proteins stimulate proliferation independently of their ability to associate with retinoblastoma protein	ONCOGENE			English	Article						human papillomaviruses; E7 proteins; pocket proteins; S phase induction	CELL-CYCLE REGULATION; TYPE-16 E7; EPIDERMODYSPLASIA VERRUCIFORMIS; TRANSFORMING ACTIVITY; RB-BINDING; IN-VIVO; GENE; ONCOPROTEIN; DNA; DIMERIZATION	Studies on human papillomavirus type 16 have demonstrated that the product of the early gene, E7, plays a key role in the immortalization and malignant transformation of the host cell. Several of the biological activities of HPV16 E7 are mediated by inactivation of the members of the pocket protein family, pRb, p107 and p130. In this study, we have characterized the in vitro properties of five E7 proteins from benign and malignant HPV types (10, 32, 48, 54, 77), We show that these E7 proteins associate with pRb and p107 with different efficiencies. All E7s increased the proliferative rate of immortalized rodent fibroblasts cultured in 10% calf serum containing medium. This property is completely independent of their ability to associate with the pocket proteins. Furthermore, all E7s, except HPV10 E7, stimulate G1/S progression and activated the cyclin E and cyclin A promoter in the absence of growth factors, This activity also does not correlate with the E7-efficiency of binding the pocket proteins. Together these data provide evidence that different E7s alter the regulation of the cell cycle by diverse mechanism(s). Finally, this comparative analysis of the different E7 proteins demonstrates that the oncogenicity of a HPV type is not determined by the ability of E7 to associate with the pocket proteins.	Deutsch Krebsforschungszentrum, Angew Tumorvirol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Tommasino, M (corresponding author), Deutsch Krebsforschungszentrum, Angew Tumorvirol, INF 242, D-69120 Heidelberg, Germany.		Caldeira, Sandra/Y-3652-2019	Caldeira, Sandra/0000-0002-6057-5979				BANKS L, 1990, ONCOGENE, V5, P1383; BEAUDENON S, 1986, NATURE, V321, P246, DOI 10.1038/321246a0; Botz J, 1996, MOL CELL BIOL, V16, P3401; CICCOLINI F, 1994, ONCOGENE, V9, P2633; CLEMENS KE, 1995, VIROLOGY, V214, P289, DOI 10.1006/viro.1995.9926; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; Delius H, 1998, VIROLOGY, V240, P359, DOI 10.1006/viro.1997.8943; deVilliers EM, 1997, CLIN DERMATOL, V15, P199, DOI 10.1016/S0738-081X(96)00164-2; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HU TH, 1995, INT J ONCOL, V6, P167; JansenDurr P, 1996, TRENDS GENET, V12, P270, DOI 10.1016/0168-9525(96)81455-7; KREMSDORF D, 1983, J VIROL, V48, P340, DOI 10.1128/JVI.48.2.340-351.1983; Lavia P, 1999, BIOESSAYS, V21, P221; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLER M, 1989, J VIROL, V63, P4907; ORTH G, 1978, P NATL ACAD SCI USA, V75, P1537, DOI 10.1073/pnas.75.3.1537; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SEEDORF K, 1985, VIROLOGY, V145, P181, DOI 10.1016/0042-6822(85)90214-4; Shamanin V, 1996, JNCI-J NATL CANCER I, V88, P802, DOI 10.1093/jnci/88.12.802; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; Tommasino M, 1997, PAPILLOMAVIRUSES HUM; WATANABE S, 1992, VIROLOGY, V190, P872, DOI 10.1016/0042-6822(92)90928-I; WU EW, 1993, J VIROL, V67, P2402, DOI 10.1128/JVI.67.4.2402-2407.1993; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	35	39	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2000	19	6					821	826		10.1038/sj.onc.1203375	http://dx.doi.org/10.1038/sj.onc.1203375			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698500				2022-12-17	WOS:000085192100012
J	De Falco, G; Bagella, L; Claudio, PP; De Luca, A; Fu, Y; Calabretta, B; Sala, A; Giordano, A				De Falco, G; Bagella, L; Claudio, PP; De Luca, A; Fu, Y; Calabretta, B; Sala, A; Giordano, A			Physical interaction between CDK9 and B-Myb results in suppression of B-Myb gene autoregulation	ONCOGENE			English	Article						CDK9; B-Myb; oncogenes	CYCLIN-DEPENDENT KINASE-5; C-MYB; V-MYB; TERMINAL DIFFERENTIATION; CDC2-RELATED KINASE; MYELOID-LEUKEMIA; EXPRESSION; ACTIVATION; BINDING; TRANSCRIPTION	B-Myb is a transcription factor belonging to the myb family, whose activity has been associated with augmented DNA synthesis and cell cycle progression, We showed recently that B-Myb autoregulates its own expression through promoter transactivation. We report in this study that CDK9, the cyclin T associated kinase, which phosphorylates and activates RNA-Polymerase II, suppresses B-Myb autoregulation through direct interaction with the carboxyl-terminus of the B-Myb protein, Downregulation of the transactivating ability of B-Myb is independent of the kinase activity of CDK9, because a kinase deficient mutant (dn-CDK9) also represses B-myb gene autoregulation, Overexpression of CDK9 did not result in suppression of p53-dependent transactivation or inhibition of the basal activity of the promoters tested so far, demonstrating that CDK9 is a B-Myb-specific repressor, Rather, transfection of the dominant negative dn-CDK9 construct inhibited the basal activity of the reporter genes, confirming an essential role for CDK9 in gene transcription. In addition, Cyclin T1 restores B-Myb transactivating activity when co-transfected along with CDK9, suggesting that the down-regulatory effect observed on B-Myb is specifically due to CDK9 alone. Thus, our data suggest that CDK9 is involved in the negative regulation of activated transcription mediated by certain transcription factors, such as B-Myb, This may indicate the existence of a feedback loop, mediated by the different activities of CDK9, which links basal with activated transcription.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Jefferson Med Coll, Philadelphia, PA 19107 USA; Univ Naples Federico II, Dept Sci Odontostomatol & Maxillo Facciali, Naples, Italy; Ist Regina Elena, Lab Cell Metab & Pharmacokinet, Ctr Expt Res, I-00158 Rome, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Dept Microbiol, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Consorzio Mario Negri Sud, Dept Mol Pharmacol & Pathol, I-66030 Santa Maria Imbaro, CH, Italy	Jefferson University; University of Naples Federico II; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Jefferson University; Consorzio Mario Negri Sud	Giordano, A (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Jefferson Med Coll, Jefferson Alumni Hall,Room 226,1020 Locust St, Philadelphia, PA 19107 USA.		De Luca, Antonio/AAD-9562-2020; sala, arturo/C-4959-2008; Giordano, Antonio/F-1927-2010; Claudio, Pier Paolo/AAW-7282-2021	De Luca, Antonio/0000-0002-3905-6154; Giordano, Antonio/0000-0002-5959-016X; Claudio, Pier Paolo/0000-0001-7790-1622; BAGELLA, Luigi/0000-0003-2815-037X; Sala, Arturo/0000-0002-2841-7866				Bagella L, 1998, J CELL PHYSIOL, V177, P206, DOI 10.1002/(SICI)1097-4652(199811)177:2<206::AID-JCP2>3.3.CO;2-W; Bies J, 1996, ONCOGENE, V12, P355; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4; DeLuca A, 1997, J CELL PHYSIOL, V172, P265, DOI 10.1002/(SICI)1097-4652(199708)172:2<265::AID-JCP13>3.3.CO;2-C; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; KALKBRENNER F, 1990, ONCOGENE, V5, P657; Katzen AL, 1996, P NATL ACAD SCI USA, V93, P13955, DOI 10.1073/pnas.93.24.13955; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P467, DOI 10.1002/(SICI)1097-4644(19981215)71:4<467::AID-JCB2>3.3.CO;2-7; Majello B, 1999, ONCOGENE, V18, P4598, DOI 10.1038/sj.onc.1202822; Napolitano G, 1999, AIDS, V13, P1453, DOI 10.1097/00002030-199908200-00003; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; Raschella G, 1997, J CELL BIOCHEM, V67, P297, DOI 10.1002/(SICI)1097-4644(19971201)67:3<297::AID-JCB2>3.0.CO;2-R; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; Romano G, 1999, J CELL BIOCHEM, V75, P357, DOI 10.1002/(SICI)1097-4644(19991201)75:3<357::AID-JCB1>3.0.CO;2-K; Sala A, 1996, CANCER RES, V56, P1991; Sala A, 1999, ONCOGENE, V18, P1333, DOI 10.1038/sj.onc.1202421; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; Sala A, 1999, J CELL PHYSIOL, V179, P245; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Saville MK, 1998, ADV CANCER RES, V72, P109; Sitzmann J, 1996, ONCOGENE, V12, P1889; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	41	39	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					373	379		10.1038/sj.onc.1203305	http://dx.doi.org/10.1038/sj.onc.1203305			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656684				2022-12-17	WOS:000084873700007
J	Sandy, P; Gostissa, M; Fogal, V; De Cecco, L; Szalay, K; Rooney, RJ; Schneider, C; Del Sal, G				Sandy, P; Gostissa, M; Fogal, V; De Cecco, L; Szalay, K; Rooney, RJ; Schneider, C; Del Sal, G			p53 is involved in the p120E4F-mediated growth arrest	ONCOGENE			English	Article						E4F; p53; growth suppression; transcriptional repression	TRANSCRIPTION FACTOR E4F; DNA-BINDING ACTIVITY; WILD-TYPE P53; NUCLEAR-LOCALIZATION; PROTEIN; IDENTIFICATION; CELLS; GENE; MODULATION; EXPRESSION	Control of cell growth and division by the p53 tumor suppressor protein requires its abilities to transactivate and repress specific target genes and to associate in complex with other proteins. Here we demonstrate that p53 binds to the E1A-regulated transcription factor p120E4F, a transcriptional repressor of the adenovirus E4 promoter. The interaction involves carboxy-terminal half of p120E4F and sequences located at the end of the sequence-specific DNA-binding domain of p53, Ectopic expression of p120E4F leads to a block of cell proliferation in several human and murine cell lines and this effect requires the association with wild-type (wt) p53, Although p120E4F can also bind to mutant p53, the growth suppression induced by overexpression of the protein is severely reduced in a cell line that contains mutant p53. These data suggest that p120E4F may represent an important element within the complex network of p53 checkpoint functions.	Consorzio Interuniv Biotecnol, Lab Nazl, I-34012 Trieste, Italy; Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, I-34012 Trieste, Italy; Univ Udine, Dipartimento Sci & Technol Biomed, I-33100 Udine, Italy; Duke Univ, Med Ctr, Dept Genet, Durham, NC 27710 USA	University of Trieste; University of Udine; Duke University	Del Sal, G (corresponding author), Consorzio Interuniv Biotecnol, Lab Nazl, Padriciano 99,AREA Sci Pk, I-34012 Trieste, Italy.		De Cecco, Loris/K-7036-2016	De Cecco, Loris/0000-0002-7066-473X; DEL SAL, GIANNINO/0000-0003-2185-6003				An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; Fernandes ER, 1997, MOL CELL BIOL, V17, P1890, DOI 10.1128/MCB.17.4.1890; Fernandes ER, 1998, MOL CELL BIOL, V18, P459, DOI 10.1128/MCB.18.1.459; FOGNANI C, 1993, EMBO J, V12, P1985; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lamphere L, 1997, ONCOGENE, V14, P1999, DOI 10.1038/sj.onc.1201036; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Muller H, 1997, MOL CELL BIOL, V17, P5508; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; PAVIETICH NP, 1993, GENE DEV, V7, P2556; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; Rooney RJ, 1998, MAMM GENOME, V9, P320, DOI 10.1007/s003359900758; Rooney RJ, 1998, NUCLEIC ACIDS RES, V26, P1681, DOI 10.1093/nar/26.7.1681; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Saccone S, 1998, CYTOGENET CELL GENET, V82, P99, DOI 10.1159/000015075; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; TARUNINA M, 1993, ONCOGENE, V8, P3165; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	40	39	44	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					188	199		10.1038/sj.onc.1203250	http://dx.doi.org/10.1038/sj.onc.1203250			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10644996				2022-12-17	WOS:000084844400003
J	Baasiri, RA; Glasser, SR; Steffen, DL; Wheeler, DA				Baasiri, RA; Glasser, SR; Steffen, DL; Wheeler, DA			The Breast Cancer Gene Database: a collaborative information resource	ONCOGENE			English	Article						electronic publishing; breast cancer; database; information retrieval		The Breast Cancer Gene Database (BCGD) is a compendium of molecular genetic data relating to genes involved in breast cancer, and which is freely available via the World Wide Web. The data in BCGD is extracted from the published biomedical research literature and stored as a collection of 'Facts', which in turn are collected into topical categories organized by gene, This organization facilitates quick searches and rapid retrievals of specific data such as gene characteristics, functions and role in oncogenesis, and is an important factor allowing for continuous updates, BCGD can be searched either by gene name or keyword, Data is deposited and retrieved from the database through a set of interactive Web forms, making it both platform-independent and universally accessible in facilitating worldwide collaborative authoring of the database. Data in BCGD is linked to other on-line resources such as Entrez, GeneCards and On-Line Mendelian Inheritance in Man, BCGD is located at http://mbcr.bcm.tmc.edu/ ermb/bcgd/bcgd.html.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Biomed Comp Inc, Houston, TX 77005 USA	Baylor College of Medicine	Wheeler, DA (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		Wheeler, David A/M-9740-2018	Wheeler, David A/0000-0002-9056-6299	NCI NIH HHS [CA70532] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA070532] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bairoch A, 1999, NUCLEIC ACIDS RES, V27, P49, DOI 10.1093/nar/27.1.49; Barker WC, 1999, NUCLEIC ACIDS RES, V27, P39, DOI 10.1093/nar/27.1.39; Benson DA, 1999, NUCLEIC ACIDS RES, V27, P12, DOI 10.1093/nar/27.1.12; Blake JA, 1999, NUCLEIC ACIDS RES, V27, P95, DOI 10.1093/nar/27.1.95; BUHLE EL, 1994, J AM MED INFORM ASSN, P103; Kuska B, 1996, J NATL CANCER I, V88, P1801, DOI 10.1093/jnci/88.24.1801; OHKAWA H, 1995, ISMB, V3, P259; Rebhan M, 1998, BIOINFORMATICS, V14, P656, DOI 10.1093/bioinformatics/14.8.656; Stoesser G, 1999, NUCLEIC ACIDS RES, V27, P18, DOI 10.1093/nar/27.1.18; Tateno Y, 1997, NUCLEIC ACIDS RES, V25, P14, DOI 10.1093/nar/25.1.14	10	39	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 23	1999	18	56					7958	7965		10.1038/sj.onc.1203335	http://dx.doi.org/10.1038/sj.onc.1203335			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637506				2022-12-17	WOS:000084634600004
J	Vaziri, H; Benchimol, S				Vaziri, H; Benchimol, S			Alternative pathways for the extension of cellular life span: inactivation of p53/pRb and expression of telomerase	ONCOGENE			English	Review						telomerase; hTERT; telomere; senescence; aging; p53; pRb; TIEL; PARP	HUMAN-DIPLOID FIBROBLASTS; CATALYTIC SUBUNIT GENE; P53 TUMOR SUPPRESSION; NORMAL HUMAN-CELLS; WILD-TYPE P53; CYCLE ARREST; DNA-DAMAGE; IN-VITRO; EPITHELIAL-CELLS; RNA COMPONENT	Telomere shortening may be one of several factors that contribute to the onset of senescence in human cells, The p53 and pRb pathways are involved in the regulation of cell cycle progression from G1 into S phase and inactivation of these pathways leads to extension of life span, Short dysfunctional telomeres may be perceived as damaged DNA and may activate these pathways, leading to prolonged arrest in G1, typical of cells in senescence. Inactivation of the p53 and pRb pathways, however, does not lead to cell immortalization, Cells that overcome senescence and have an extended life span continue to lose telomeric DNA and subsequently enter a second phase of growth arrest termed 'crisis', Forced expression of telomerase in human cells leads to the elongation of telomeres and immortalization, The development of human cancer is frequently associated with the inactivation of the pRb and p53 pathways, attesting to the importance of senescence in restricting the tumor-forming ability of human cells, Cancer cells must also maintain telomere length and, in the majority of cases, this is associated with expression of telomerase activity.	Univ Toronto, Ontario Canc Inst Princess Margaret Hosp, Toronto, ON M5G 2M9, Canada; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Stanford University; University of Toronto	Benchimol, S (corresponding author), Univ Toronto, Ontario Canc Inst Princess Margaret Hosp, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Benchimol, Samuel/0000-0003-3433-890X				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ALMASAN A, 1995, CANCER METAST REV, V14, P59, DOI 10.1007/BF00690212; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOND JA, 1994, ONCOGENE, V9, P1885; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Foster SA, 1996, ONCOGENE, V12, P1773; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; Hara E, 1996, MOL CELL BIOL, V16, P859; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HARVEY M, 1993, ONCOGENE, V8, P2457; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Milas M, 1998, CLIN CANCER RES, V4, P1573; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; VAZIRI H, 1993, AM J HUM GENET, V52, P661; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Vaziri H, 1996, EXP GERONTOL, V31, P295, DOI 10.1016/0531-5565(95)02025-X; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; WOLMAN S. R., 1964, CYTOGENETICS [BASEL], V3, P45, DOI 10.1159/000129797; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	70	39	40	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	1999	18	53					7676	7680		10.1038/sj.onc.1203016	http://dx.doi.org/10.1038/sj.onc.1203016			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DD	10618707				2022-12-17	WOS:000084634500006
J	Grignani, F; Gelmetti, V; Fanelli, M; Rogaia, D; De Matteis, S; Ferrara, FF; Bonci, D; Grignani, F; Nervi, C; Pelicci, PG				Grignani, F; Gelmetti, V; Fanelli, M; Rogaia, D; De Matteis, S; Ferrara, FF; Bonci, D; Grignani, F; Nervi, C; Pelicci, PG			Formation of PML/RAR alpha high molecular weight nuclear complexes through the PML coiled-coil region is essential for the PML/RAR alpha-mediated retinoic acid response	ONCOGENE			English	Article						retinoic acid; leukaemia; protein complexes; PML/RAR alpha	ACUTE PROMYELOCYTIC LEUKEMIA; PLZF-RAR-ALPHA; RECEPTOR-ALPHA; FUSION PROTEINS; HISTONE DEACETYLASE; GENE-PRODUCT; CELLS; TRANSLOCATION; ONCOPROTEIN; BINDING	Retinoic Acid (RA) treatment induces disease remission of Acute Promyelocytic Leukaemia (APL) patients by triggering terminal differentiation of neoplastic cells. RA-sensitivity in APL is mediated by its oncogenic protein, which results from the recombination of the PML and the RA receptor alpha (RAR alpha) genes (PML/RAR alpha fusion protein). Ectopic expression of PML/RAR alpha into haemopoietic cell lines results in increased response to RA-induced differentiation. By structure-function analysis of PML/RAR alpha-mediated RA-differentiation, we demonstrated that fusion of PML and RAR alpha sequences and integrity of the PML dimerization domain and of the RAR alpha DNA binding region are required for the effect of PML/RAR alpha on RA-differentiation. Indeed, direct fusion of the PML dimerization domain to the Nor C-terminal extremities' of RAR alpha retained full biological activity. All the biologically active PML/RAR alpha mutants formed high molecular weight complexes in vivo. Functional analysis of mutations within the PML dimerization domain revealed that the capacity to form PML/RAR alpha homodimers, but not PML/RAR alpha-PML heterodimers, correlated with the RA response. These results suggest that targeting of RAR alpha sequences by the PML dimerization domain and formation of nuclear PML/RAR alpha homodimeric complexes are crucial for the ability of PML/RAR alpha to mediate RA-response.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Perugia, Monteluce Policlin, Ist Med Interna & Sci Oncol, I-06100 Perugia, Italy; Ist Super Sanita, Dept Hematol & Oncol, I-00161 Rome, Italy; Univ La Sapienza, Dipartimento Istol & Embriol Umana, I-00161 Rome, Italy	IRCCS European Institute of Oncology (IEO); University of Perugia; Istituto Superiore di Sanita (ISS); Sapienza University Rome	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Pelicci, Pier Giuseppe/AAL-6572-2020; Grignani, Francesco/AAC-2565-2022; Bonci, Desiree/K-6488-2016; Fanelli, Mirco/F-2665-2011	Bonci, Desiree/0000-0002-2472-5140; Fanelli, Mirco/0000-0002-9649-8661; NERVI, Clara/0000-0001-9341-0188				Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; CASINI T, 1998, IN PRESS ONCOGENE; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FANELLI M, 1998, IN PRESS BLOOD; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; GAUB MP, 1989, P NATL ACAD SCI USA, V86, P3089, DOI 10.1073/pnas.86.9.3089; GRIGNANI F, 1994, BLOOD, V83, P10; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; GRIGNANI F, 1993, CELL, V74, P1; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; LIZHEN H, 1997, PNAS, V94, P5302; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NERVI C, 1992, CANCER RES, V52, P3687; NERVI C, 1998, IN PRESS BLOOD; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; ROGAIA D, 1995, LEUKEMIA, V9, P1467; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Wang ZG, 1998, SCIENCE, V279, P1547; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yoshida H, 1996, CANCER RES, V56, P2945	35	39	40	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6313	6321		10.1038/sj.onc.1203029	http://dx.doi.org/10.1038/sj.onc.1203029			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597230				2022-12-17	WOS:000083934100015
J	Majumder, S; Ghoshal, K; Li, ZL; Bo, Y; Jacob, ST				Majumder, S; Ghoshal, K; Li, ZL; Bo, Y; Jacob, ST			Silencing of metallothionein-I gene in mouse lymphosarcoma cells by methylation	ONCOGENE			English	Article						metallothionein; methylation; lymphosarcoma; thymus; bisulfite sequencing	CCAAT-HOMOLOGOUS SEQUENCES; TRANSCRIPTION FACTOR MTF-1; DNA METHYLATION; BINDING-SITES; HEAVY-METALS; PROMOTER; INDUCTION; PROTEIN; METHYLTRANSFERASE; HYPERMETHYLATION	Metallothionein-I (MT-I) gene is silenced by methylation of CpG islands in mouse lymphosarcoma P1798 cells but not in the thymus, the cell type from which the tumor was derived. Bisulfite genomic sequencing revealed that all 21 CpG dinucleotides present within -216 bp to +1 bp with respect to transcription start site are methylated in the tumor cell line, but none is methylated in the thymus. The lymphosarcoma cells induced MT-I in response to heavy metals only after demethylation with 5-azacytidine (5-AsaC). The electrophoretic mobility shift assay using specific oligonucleotide probes showed that the key transcription factors regulating MT-I gene (e.g., MTF-1, Sp 1 and MLTF/USF) are active in P1798 cells. In vivo footprinting of the proximal promoter region showed that none of the metal regulatory elements (MREs) or MLTF/USF are occupied in response to heavy metals. Demethylation of the lymphosarcoma cells with 5-AzaC resulted in constitutive footprinting at MLTF/ARE, and zinc-inducible footprinting at MRE-c, MRE-d and MRE-e sites. Demethylation of just 10-20% of the CpG islands was sufficient to render the gene inducible by cadmium or zinc. The MT-I induction persisted in the cancer cells for several generations even after withdrawal of 5-AzaC from the culture medium.	Ohio State Univ, Coll Med, Dept Med Biochem, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Jacob, ST (corresponding author), Ohio State Univ, Coll Med, Dept Med Biochem, 333 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.		Jacob, Samson/H-3135-2011; bo, yu/AAB-3064-2019		NATIONAL CANCER INSTITUTE [R01CA061321] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA061321-05, CA61321] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aniskovitch LP, 1997, ARCH BIOCHEM BIOPHYS, V341, P337, DOI 10.1006/abbi.1997.9976; Aniskovitch LP, 1998, ONCOGENE, V16, P1475, DOI 10.1038/sj.onc.1201659; Aschner M, 1997, TOXICOL APPL PHARM, V142, P229, DOI 10.1006/taap.1996.8054; Baylin SB, 1998, ADV CANCER RES, V72, P141; Baylin SB, 1997, SCIENCE, V277, P1948, DOI 10.1126/science.277.5334.1948; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHUBATSU LS, 1993, BIOCHEM J, V291, P193, DOI 10.1042/bj2910193; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; COMPERE SJ, 1981, CELL, V25, P233, DOI 10.1016/0092-8674(81)90248-8; DATTA PK, 1993, CELL MOL BIOL RES, V39, P439; Datta PK, 1997, BIOCHEM BIOPH RES CO, V230, P159, DOI 10.1006/bbrc.1996.5655; Deng J, 1998, J BIOL CHEM, V273, P22869, DOI 10.1074/jbc.273.36.22869; FEINBERG AP, 1988, CANCER RES, V48, P1159; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Ghoshal K, 1998, P NATL ACAD SCI USA, V95, P10390, DOI 10.1073/pnas.95.18.10390; Ghoshal K, 1996, BIOCHEM J, V317, P689, DOI 10.1042/bj3170689; Ghoshal K, 1998, J BIOL CHEM, V273, P27904, DOI 10.1074/jbc.273.43.27904; Harrison J, 1998, ANAL BIOCHEM, V264, P129, DOI 10.1006/abio.1998.2833; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; KELLEY SL, 1988, SCIENCE, V241, P1813, DOI 10.1126/science.3175622; Klein CB, 1997, MUTAT RES-REV MUTAT, V386, P163, DOI 10.1016/S1383-5742(96)00052-X; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Lewin B, 1998, CELL, V93, P301, DOI 10.1016/S0092-8674(00)81154-X; LI E, 1993, COLD SPRING HARB SYM, V58, P297, DOI 10.1101/SQB.1993.058.01.035; Li QW, 1998, NUCLEIC ACIDS RES, V26, P5182, DOI 10.1093/nar/26.22.5182; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Ng MHL, 1997, BLOOD, V89, P2500, DOI 10.1182/blood.V89.7.2500; NORRIS DP, 1994, CELL, V77, P41, DOI 10.1016/0092-8674(94)90233-X; Palmiter R D, 1987, Experientia Suppl, V52, P63; Ping DS, 1996, IMMUNITY, V4, P455, DOI 10.1016/S1074-7613(00)80412-4; Pitt BR, 1997, AM J PHYSIOL-LUNG C, V273, pL856, DOI 10.1152/ajplung.1997.273.4.L856; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; Radtke F, 1996, BIOL CHEM H-S, V377, P47, DOI 10.1515/bchm3.1996.377.1.47; ROBERTSON KD, 1995, MOL CELL BIOL, V15, P6150; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; SCHWARZ MA, 1995, P NATL ACAD SCI USA, V92, P4452, DOI 10.1073/pnas.92.10.4452; Szyf M, 1996, PHARMACOL THERAPEUT, V70, P1, DOI 10.1016/0163-7258(96)00002-2; Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422; WATT F, 1990, PHILOS T R SOC LON B, V326, P267; WOOD KM, 1984, MOL CELL ENDOCRINOL, V37, P169, DOI 10.1016/0303-7207(84)90049-2; YAGLE MK, 1985, MOL CELL BIOL, V5, P291, DOI 10.1128/MCB.5.2.291	51	39	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	1999	18	46					6287	6295		10.1038/sj.onc.1203004	http://dx.doi.org/10.1038/sj.onc.1203004			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597227	Green Accepted			2022-12-17	WOS:000083934100012
J	Carter, PS; Jarquin-Pardo, M; De Benedetti, A				Carter, PS; Jarquin-Pardo, M; De Benedetti, A			Differential expression of Myc1 and Myc2 isoforms in cells transformed by eIF4E: evidence for internal ribosome repositioning in the human c-myc 5 ' UTR	ONCOGENE			English	Article						translation initiation factor 4E; c-myc expression; internal ribosome repositioning; oncogenic transformation; alternate start-codon selection	INITIATION-FACTOR 4G; 5' NONCODING REGION; PROTEIN-SYNTHESIS; MESSENGER-RNA; BURKITT-LYMPHOMA; TRANSLATIONAL INITIATION; EUKARYOTIC RIBOSOMES; SECONDARY STRUCTURE; AUG CODONS; ONCOGENE	eIF4E is essential for translation initiation, but its overexpression causes malignant transformation. Recent work demonstrated that eIF4E/F participates in exposing and locating alternate translation start codons during scanning. Translation initiation of several important protooncogenes and growth-regulators, such as Myc and FGF-2, can start at CUG start codon(s) upstream of the normal open reading frame (ORF), The resulting amino-terminal extension alters the properties of these proteins and their intracellular distribution, In cells overexpressing eIF4E, c-myc is overexpressed and particularly the larger, CUG-initiated form (Myc1), Recent reports suggest that synthesis of Myc2, the normally expressed AUG-initiated form, is mediated by an IRES. To determine,what role eIF4E might play in c-myc expression, the c-myc 5' untranslated region (UTR) was fused in-frame to CAT reporters, and several more derivative constructs were made. In vitro translation experiments (with and without eIF4E/F); expression in CHO cells transformed with eIF4E; and deletion/mutation analysis demonstrated that Myc1 is translated by a scanning mechanism, while Myc2 is translated by Internal Ribosome Repositioning. Moreover, the existence of a true IRES in the 5'UTR was contradicted by its failure to direct translation of a circular transcript, in contrast to hsp70, The c-myc 5'UTR also failed to engage in translation in the absence of functional eIF4F, after cleavage of the eIF4G component with CVB4 protease-2A, The Internal Repositioning Element (IRPE) in c-myc 5'UTR was delimited to nucleotides (nt) 394-440 from the P1 transcription start site.	Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	De Benedetti, A (corresponding author), Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.			de benedetti, arrigo/0000-0002-4198-8647	NATIONAL CANCER INSTITUTE [R29CA069148] Funding Source: NIH RePORTER; NCI NIH HHS [CA69148-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; Borman AM, 1997, VIROLOGY, V237, P129, DOI 10.1006/viro.1997.8761; CHEN CY, 1995, SCIENCE, V268, P415, DOI 10.1126/science.7536344; CLEMENS MJ, 1987, TRANSCRIPTION TRANSL, P263; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DOSAKAAKITA H, 1991, ONCOGENE, V6, P371; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; Fraser SD, 1996, ONCOGENE, V12, P1223; FUTTERER J, 1993, TIBS, V22, P177; GANDORI C, 1997, TIBS, V22, P177; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; JACKSON RJ, 1996, TRANSLATIONAL CONTRO, P7; JOSHIBARVE S, 1992, J BIOL CHEM, V267, P21038; Kevil C, 1995, ONCOGENE, V11, P2339; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; Lamphear BJ, 1996, BIOCHEMISTRY-US, V35, P15726, DOI 10.1021/bi961864t; Latorre P, 1998, MOL CELL BIOL, V18, P5021, DOI 10.1128/MCB.18.9.5021; LAZARUS P, 1992, ONCOGENE, V7, P1037; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Nathan CA, 1997, ONCOGENE, V15, P1087, DOI 10.1038/sj.onc.1201272; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; Paulin FEM, 1996, ONCOGENE, V13, P505; Paus R, 1993, Exp Dermatol, V2, P3, DOI 10.1111/j.1600-0625.1993.tb00192.x; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; Reddy KS, 1997, CANCER GENET CYTOGEN, V95, P206, DOI 10.1016/S0165-4608(96)00424-4; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990; West MJ, 1995, ONCOGENE, V11, P2515; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557; ZUKER M, 1989, METHOD ENZYMOL, P262	42	39	41	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	1999	18	30					4326	4335		10.1038/sj.onc.1202890	http://dx.doi.org/10.1038/sj.onc.1202890			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439040				2022-12-17	WOS:000081732700005
J	Metcalfe, S; Weeds, A; Okorokov, AL; Milner, J; Cockman, M; Pope, B				Metcalfe, S; Weeds, A; Okorokov, AL; Milner, J; Cockman, M; Pope, B			Wild-type p53 protein shows calcium-dependent binding to F-actin	ONCOGENE			English	Article						p53; actin; calcium	TUMOR-SUPPRESSOR P53; MUTANT P53; DISRUPTION; CLEAVAGE; CELLS	Nuclear localization of p53 is required for p53 to detect and respond to DNA strand abnormalities and breaks following DNA damage. This leads to activation of the tumour suppressive functions of p53 resulting in either cell cycle arrest and DNA repair; or apoptosis, Critical functional changes in DNA which require strand breaks, including gene rearrangement, may transiently mimic DNA damage: here it is important not to trigger a p53 response. The fine control of p53 in these different circumstances is unknown but may include transient sequestering of p53 in the cytoplasm, Reversible nuclear-cytoplasmic shuttling is an intrinsic property of p53 (Middeler et al,, 1997) associated with cell cycle-related changes in p53's subcellular distribution, Takahashi and Suzuki (1994) described p53 inactivation by shuttling to the cytoplasm and Katsumoto et al, (1995) found wildtype p53 to be closely associated,vith cytoplasmic actin filaments during DNA synthesis. Here we show that, in the presence of free calcium ions, p53 binds directly to F-actin with a dissocation constant of about 10 mu M. Thus, part of the regulatory machinery in normal cell cycling may involve p53-actin interactions regulated by calcium fluxes and the dynamic turnover of F-actin.	Addenbrookes Hosp, Dept Surg, Cambridge CB2 2QQ, England; MRC, Mol Biol Lab, Cambridge CB2 2QQ, England; Univ York, YCRC P53 Lab, York YO1 5DD, N Yorkshire, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; MRC Laboratory Molecular Biology; University of York - UK	Metcalfe, S (corresponding author), Addenbrookes Hosp, Dept Surg, Hills Rd,Box 202, Cambridge CB2 2QQ, England.		Cockman, Matthew/V-9619-2019	Cockman, Matthew/0000-0002-3310-4821; Okorokov, Andrei/0000-0003-2477-3254				Ayscough KR, 1998, CURR OPIN CELL BIOL, V10, P102, DOI 10.1016/S0955-0674(98)80092-6; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; FOURIE AM, 1997, J BIOL CHEM, V272, P1947; GANNON JV, 1991, NATURE, V349, P802; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Guenal I, 1997, J CELL SCI, V110, P489; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; Katsumoto T, 1995, BIOL CELL, V84, P167, DOI 10.1016/0248-4900(96)89426-3; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; Maki CG, 1996, CANCER RES, V56, P2649; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; Molinari M, 1996, ONCOGENE, V13, P2077; POPE B, 1994, FEBS LETT, V338, P58, DOI 10.1016/0014-5793(94)80116-9; Pope BJ, 1997, BIOCHEMISTRY-US, V36, P15848, DOI 10.1021/bi972192p; Rubtsova SN, 1998, FEBS LETT, V430, P353, DOI 10.1016/S0014-5793(98)00692-9; TAKAHASHI K, 1994, ONCOGENE, V9, P183; TAYLOR RS, 1976, BIOCHEM J, V159, P301, DOI 10.1042/bj1590301; WAY M, 1992, J CELL BIOL, V116, P1135, DOI 10.1083/jcb.116.5.1135; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517	22	39	39	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2351	2355		10.1038/sj.onc.1202559	http://dx.doi.org/10.1038/sj.onc.1202559			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327055				2022-12-17	WOS:000079595500007
J	Nevels, M; Spruss, T; Wolf, H; Dobner, T				Nevels, M; Spruss, T; Wolf, H; Dobner, T			The adenovirus E4orf6 protein contributes to malignant transformation by antagonizing E1A-induced accumulation of the tumor suppressor protein p53	ONCOGENE			English	Article						DNA tumor virus; viral oncogene	TRANSCRIPTIONAL ACTIVATION; 55-KILODALTON PROTEIN; MONOCLONAL-ANTIBODIES; INFECTED-CELLS; E1B PROTEINS; 5 DNA; APOPTOSIS; GENE; BINDING; ANTIGEN	The adenovirus type 5 (Ad5) E4orf6 protein promotes focus formation of primary baby rat kidney (BRK) cells in cooperation with Ad5 E1 proteins. This activity is most likely related to the ability of the E4orf6 protein to bind to p53 and modulate its tumor suppressor functions. In this study we report that transformed BRK cells that stably express E40rf6 in addition to E1A and E1B (ABS cells) displayed multiple additional properties commonly associated with a high grade of oncogenic transformation compared to cells expressing only E1A and E1B (AB cells). These properties included morphological alterations, markedly enhanced growth rates and growth to much higher saturation densities. Following injection into nude mice ABS-derived tumors exhibited accelerated growth and, based on histopathological criteria, proofed to be much more malignant compared to tumors generated by AB cells. Interestingly, these highly transformed properties of ABS cells correlated with a dramatic reduction of p53 steady-state levels which inversely correlated with E40rf6 expression. From these results we conclude that expression of the Ad5 E40rf6 protein (i) confers additional transformed in vitro properties to primary rat cells expressing the Ad5 Fl proteins, and (ii) increases the tumorigenic and malignant potential of these cells in vivo. Our data suggest that the Ad5 E40rf6 protein enhances the intrinsic ability of E1-transformed rat cells to grow in a neoplastic state by completely inactivating p53 tumor suppressor function in combination with the E1A and E1B proteins.	Univ Regensburg, Inst Med Mikrobiol & Hyg, D-93053 Regensburg, Germany	University of Regensburg	Dobner, T (corresponding author), Univ Regensburg, Inst Med Mikrobiol & Hyg, D-93053 Regensburg, Germany.		Nevels, Michael M/J-4783-2014	Nevels, Michael M/0000-0002-7115-407X				BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BERNARDS R, 1986, VIROLOGY, V150, P126, DOI 10.1016/0042-6822(86)90272-2; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1984, ADENOVIRUSES, P339; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Logan J, 1984, CANCER CELL, V2, P527; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MCLORIE W, 1991, J GEN VIROL, V72, P1467, DOI 10.1099/0022-1317-72-6-1467; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; MORAN E, 1994, SEMIN VIROL, V5, P327, DOI 10.1006/smvy.1994.1037; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; NEVINS JR, 1996, FIELDS VIROLOGY, V1, P301; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Rubenwolf S, 1997, J VIROL, V71, P1115, DOI 10.1128/JVI.71.2.1115-1123.1997; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHENK T, 1996, FIELDS VIROLOGY, V2, P2111; SHIROKI K, 1981, J VIROL, V38, P1048, DOI 10.1128/JVI.38.3.1048-1054.1981; Spruss T, 1996, CONTR ONCOL, V51, P12; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TOOZE J, 1981, COLD SPRING HARBOR, P943; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; WHITE E, 1994, SEMIN VIROL, V5, P341, DOI 10.1006/smvy.1994.1038; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAJDEL MEB, 1988, ONCOGENE, V2, P579; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0	55	39	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					9	17		10.1038/sj.onc.1202284	http://dx.doi.org/10.1038/sj.onc.1202284			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926915				2022-12-17	WOS:000078166000002
J	Nason-Burchenal, K; Takle, G; Pace, U; Flynn, S; Allopenna, J; Martin, P; George, ST; Goldberg, AR; Dmitrovsky, E				Nason-Burchenal, K; Takle, G; Pace, U; Flynn, S; Allopenna, J; Martin, P; George, ST; Goldberg, AR; Dmitrovsky, E			Targeting the PML/RAR alpha translocation product triggers apoptosis in promyelocytic leukemia cells	ONCOGENE			English	Article						acute promyelocytic leukemia; PML/RAR alpha; retinoic acid; differentiation; apoptosis	RETINOIC ACID RECEPTOR; PML-RAR-ALPHA; INDUCED GRANULOCYTIC DIFFERENTIATION; BRONCHIAL EPITHELIAL-CELLS; FUSION PROTEIN; T(15-17) TRANSLOCATION; T(15,17) TRANSLOCATION; NONREARRANGED ALLELES; TRANSCRIPTION FACTOR; GROWTH SUPPRESSION	The t(15;17) rearrangement found in acute promyelocytic leukemia (APL) yields a fusion transcript, PML/RAR alpha. PML/RAR alpha. expression is linked to leukemogenesis and to clinical sensitivity to all-trans retinoic acid (RA), Paradoxically, RA treatment causes transient complete remissions in most t(15;17) APL cases. The precise roles of PML/RAR alpha in triggering leukemia or in causing a maturation block are not yet known. This study explores directly these PML/RAR alpha. functions in the growth and differentiation of APL cells using a hammerhead ribozyme to target PML/RAR alpha mRNA in the NB4 APL cell line. When the PML/RAR alpha cleaving but not the non-catalytic control ribozyme is introduced into the NB4 APL cell line, PML/RAR alpha protein expression is reduced. This catalysis signals growth suppression, cytotoxicity, and apoptosis without overcoming the maturation block found in these leukemic cells. These biologic effects depend on the selective pressure used to express the ribozyme from an episomal vector. Introduction of a non-catalytic, control ribozyme into NB4 cells caused no observed phenotype due to anti-sense activities, Expression of the catalytic or non-catalytic ribozymes in control cells lacking PML/RAR alpha mRNA yielded no apparent growth or differentiation effects. Thus, use of a hammerhead ribozyme that targets PML/RAR alpha. expression in APL cells reveals the anti-apoptotic function of this translocation product and demonstrates that PML/RAR alpha cleavage is insufficient to overcome the differentiation block observed in these leukemic cells. Taken together, these findings indicate that persistent PML/RAR alpha expression is required to maintain basal leukemic cell growth and point to the therapeutic potential of targeting PML/RAR alpha in APL.	Mem Hosp, Dept Med, Mol Med Lab, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Mol Pharmacol & Therapeut Program, New York, NY 10021 USA; Innovir Labs, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Nason-Burchenal, K (corresponding author), Mem Hosp, Dept Med, Mol Med Lab, 1272 York Ave, New York, NY 10021 USA.				NCI NIH HHS [1F32CA61646-01A1, 2PO1-CA29502-14A2, R01-CA62275-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA061646, P01CA029502, R01CA062275] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn MJ, 1995, ONCOGENE, V11, P2357; AHN MJ, 1995, ONCOGENE, V10, P2307; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; BRUEL A, 1995, LEUKEMIA, V9, P1173; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chen GQ, 1996, BLOOD, V88, P1052; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DELIA D, 1993, CANCER RES, V53, P6036; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DERMIME S, 1993, BLOOD, V82, P1573; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DUPREZ E, 1992, LEUKEMIA, V6, P1281; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; Fu SQ, 1995, CLIN CANCER RES, V1, P583; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GRIGNANI F, 1995, CANCER RES, V55, P440; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; IKEDA K, 1994, AM J HEMATOL, V45, P212, DOI 10.1002/ajh.2830450304; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LANOTTE M, 1991, BLOOD, V77, P1080; LINRJ, 1998, NATURE, V391, P811; LOCOCO F, 1992, EUR J HAEMATOL, V48, P173; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; Mangelsdorf David J., 1994, P319; MILLER WH, 1992, P NATL ACAD SCI USA, V89, P2694, DOI 10.1073/pnas.89.7.2694; MOASSER MM, 1995, ONCOGENE, V10, P1537; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NasonBurchenal K, 1997, DIFFERENTIATION, V61, P321, DOI 10.1046/j.1432-0436.1997.6150321.x; NASONBURCHENAL K, IN PRESS BLOOD; NERVI C, 1992, CANCER RES, V52, P3687; PACE U, 1994, CANCER RES, V54, P6365; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; REDDEL RR, 1988, CANCER RES, V48, P1904; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; ROGAIA D, 1995, LEUKEMIA, V9, P1467; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; TAIRA K, 1991, NUCLEIC ACIDS RES, V19, P5125, DOI 10.1093/nar/19.19.5125; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Yoshida H, 1996, CANCER RES, V56, P2945; YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009	59	39	39	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1759	1768		10.1038/sj.onc.1202075	http://dx.doi.org/10.1038/sj.onc.1202075			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778041				2022-12-17	WOS:000076303300001
J	Koga, H; Araki, N; Takeshima, H; Nishi, T; Hirota, T; Kimura, Y; Nakao, M; Saya, H				Koga, H; Araki, N; Takeshima, H; Nishi, T; Hirota, T; Kimura, Y; Nakao, M; Saya, H			Impairment of cell adhesion by expression of the mutant neurofibromatosis type 2 (NF2) genes which lack exons in the ERM-homology domain	ONCOGENE			English	Article						NF2 gene; MBPs binding domain; exon-missing; protein truncation test (PTT); nuclear microinjection	PROTEIN TRUNCATION TEST; COLI APC GENE; TUMOR-SUPPRESSOR; ADENOMATOUS POLYPOSIS; MUTATION; PRODUCT; MEMBRANE; MERLIN; CYTOSKELETON; SCHWANNOMAS	Neurofibromatosis 2 (NF2) is an inherited disorder characterized by a predisposition to multiple intracranial tumors. The protein encoded by the NF2 gene has striking similarities to ezrin, radixin and moesin (ERM) proteins which link membrane proteins to the cytoskeleton, Therefore, it can be speculated that the disruption of cytoskeletal organization by alterations in the Nn gene is involved in the development of tumors. It has been reported that the majority of NF2 mutations were nonsense or frameshift mutations that result in premature termination of translation. To facilitate the detection of these mutations, we performed protein truncation test and found that 11 of 14 NF2 patients had truncational mutations (79%). Seven of the 11 patients (64%) had a splicing abnormality which lead to absence of exons in the ERM homology domain. To examine the biological significance of the exon-missing mutations in the ERM homology domain, we expressed the wild-type (wt-NF2) and the various mutant NF2s (mu-NF2s) in a fibroblast cell line by using both liposome-mediated transfection and nuclear microinjection of the expression plasmids, The wt-NF2 showed intense punctate staining in the perinuclear cytoplasm in addition to overall staining of the submembranous area, whereas the mu-NF2s lacking exons in the ERM homology domain showed granular staining at the perinuclear region without any accumulation at the submembrane region. Microinjection of wt-NF2 cDNA into the nucleus of VA13 cells revealed that wt-NF2 protein induced a progressive elongation of cell processes. Furthermore, cells that expressed mu-NF2 had decreased adhesion, which resulted in detachment from the substratum. These findings suggested that the exon-missing mutations in the ERM-homology domain may affect cell membrane-cytoskeleton signaling and consequently disrupt cell-to-cell or cell-to-matrix interaction.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 860, Japan; Kumamoto Univ, Sch Med, Dept Neurosurg, Kumamoto 860, Japan	Kumamoto University; Kumamoto University	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 860, Japan.		Saya, Hideyuki/J-4325-2013					ARAKAWA H, 1994, HUM MOL GENET, V3, P565, DOI 10.1093/hmg/3.4.565; Bala S, 1996, HUM GENET, V98, P528, DOI 10.1007/s004390050254; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; DENBAKKER MA, 1995, ONCOGENE, V10, P757; DENBAKKER MA, 1995, AM J PATHOL, V147, P1339; DeVitis LR, 1996, HUM GENET, V97, P632; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; JACOBY LB, 1994, HUM MOL GENET, V3, P413, DOI 10.1093/hmg/3.3.413; LUTCHMAN M, 1995, CANCER RES, V55, P2270; MACCOLLIN M, 1994, AM J HUM GENET, V55, P314; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; Nishi T, 1997, INT J ONCOL, V10, P1025; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUBIO MP, 1994, CANCER RES, V54, P45; Scherer SS, 1996, J NEUROSCI RES, V46, P595, DOI 10.1002/(SICI)1097-4547(19961201)46:5<595::AID-JNR8>3.0.CO;2-E; SIEBERT PD, 1993, NUCLEIC ACIDS RES, V21, P2019, DOI 10.1093/nar/21.8.2019; StemmerRachamimov AO, 1997, J NEUROPATH EXP NEUR, V56, P735; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; VANDERLUIJT R, 1994, GENOMICS, V20, P1, DOI 10.1006/geno.1994.1119; Welling DB, 1996, HUM GENET, V98, P189, DOI 10.1007/s004390050188	26	39	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					801	810		10.1038/sj.onc.1202010	http://dx.doi.org/10.1038/sj.onc.1202010			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9779996				2022-12-17	WOS:000075448800001
J	Sawyer, C; Hiles, I; Page, M; Crompton, M; Dean, C				Sawyer, C; Hiles, I; Page, M; Crompton, M; Dean, C			Two erbB-4 transcripts are expressed in normal breast and in most breast cancers	ONCOGENE			English	Article						receptor tyrosine kinase; breast cancer; erbB-4; signal transduction; phosphatidylinositol 3-kinase	GROWTH-FACTOR RECEPTOR; DIFFERENTIATION FACTOR; MONOCLONAL-ANTIBODY; SIGNAL-TRANSDUCTION; CELLULAR-RESPONSE; HEREGULIN; CELLS; FAMILY; ACTIVATION; NEUREGULIN	ErbB-4 is a recently described member of the epidermal growth factor receptor (EGFR) family which together with erbB-3 acts as a receptor for a group of ligands known as the neuregulins (NRGs) or heregulins (HRGs), Unlike the EGFR and erbB-2 relatively little is known about the expression of erbB-4 in human tumours. Using RT-PCR and Southern blotting analysis we have investigated the expression of erbB-4 mRNA in a range of human tumour cell lines and in normal and malignant breast tissue. Using primers which amplified a 658 base pair (bp) region corresponding to part of the cytoplasmic domain of c-erbB-4 we found the receptor was expressed in some but not all breast and ovarian tumour cell lines and also in a glioma cell line. The highest level of erbB-4 expression was found in the ovarian carcinoma OVCAR-3 and the breast carcinoma T-47D, In all cell lines where the 'full-length' erbB-4 was detected, a second previously undescribed c-erbB-4 sequence was also found as a 610 bp PCR product. The alternative PCR product was identical in sequence to c-erbB-4 except for a deletion of 48 bp which encodes a consensus phosphatidylinositol 3-kinase (PI3K) binding site. This suggested that the two forms of erbB-4 might interact with different intracellular signalling pathways and therefore influence a wider variety of cellular responses to heregulin than previously thought. Expression of both erbB-4 variants was found in 7/7 normal breast tissues but only in 9/12 breast tumours analysed. In line with the terminology of Elenius et nl, (1997b) we have designated the two isoforms of the C-terminal transcripts as CT-a (full-length) and CT-b which lacks the PI3K binding motif, These results identify suitable cell lines for the further investigation of erbB-4 expression and function and suggest that the role of erbB-4 in breast cancer warrants further investigation with larger numbers of normal and malignant breast tissues.	Inst Canc Res, Immunol Sect, McElwain Labs, Sutton SM2 5NG, Surrey, England; Inst Canc Res, Sect Cell Biol & Expt Pathol, Sutton SM2 5NG, Surrey, England; Glaxo Wellcome Res Labs, Oncol Res Unit, Stevenage, Herts, England	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; GlaxoSmithKline; Wellcome Research Laboratories	Sawyer, C (corresponding author), Inst Canc Res, Immunol Sect, McElwain Labs, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.			Box, Carol/0000-0002-8919-8724				ANDERSEN AS, 1992, BIOTECHNIQUES, V13, P678; Bacus SS, 1996, ONCOGENE, V12, P2535; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; CHAN SDH, 1995, J BIOL CHEM, V270, P22608, DOI 10.1074/jbc.270.38.22608; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cohen BD, 1996, J BIOL CHEM, V271, P30897, DOI 10.1074/jbc.271.48.30897; Cohen BM, 1996, J BIOL CHEM, V271, P4813; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MODJTAHEDI H, 1994, INT J ONCOL, V4, P277; Modjtahedi H, 1996, BRIT J CANCER, V73, P228, DOI 10.1038/bjc.1996.40; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYER C, 1997, THESIS U LONDON; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	33	39	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					919	924		10.1038/sj.onc.1202015	http://dx.doi.org/10.1038/sj.onc.1202015			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780009				2022-12-17	WOS:000075448800014
J	Barley, RDC; Enns, L; Paterson, MC; Mirzayans, R				Barley, RDC; Enns, L; Paterson, MC; Mirzayans, R			Aberrant p21(WAF1)-dependent growth arrest as the possible mechanism of abnormal resistance to ultraviolet light cytotoxicity in Li-Fraumeni syndrome fibroblast strains heterozygous for TP53 mutations	ONCOGENE			English	Article						Li-Fraumeni syndrome; UV; apoptosis; DNA repair; p53; p21(WAF1)	CANCER-PRONE FAMILY; P53 TUMOR-SUPPRESSOR; TRANSCRIPTION-COUPLED REPAIR; WILD-TYPE P53; CELL-CYCLE; DNA-DAMAGE; EXCISION-REPAIR; ATAXIA-TELANGIECTASIA; PYRIMIDINE DIMERS; AFFECTED MEMBERS	The purpose of this study is to better understand the roles of the p53 tumor suppressor protein and the product of the p53-regulated gene p21(WAF1) in the response of diploid human dermal fibroblast cultures to 254 nm ultraviolet (UV) light. We report that Li - Fraumeni syndrome (LFS) fibroblast strains heterozygous for TP53 mutation at either codon 245 or 234 exhibit markedly reduced or no expression of p21(WAF1) following UV irradiation, respectively. These strains also exhibit defective nucleotide excision repair and pronounced inhibition of RNA synthesis following UV exposure, both of which are molecular hallmarks of cells derived from patients with the UV-sensitive syndrome xeroderma pigmentosum, In sharp contrast to xeroderma pigmentosum cells, however, the repair-deficient LFS cells show abnormal resistance, rather than hypersensitivity, to the killing effect of UV light. We further demonstrate that exposure of normal human fibroblasts to biologically relevant fluences (less than or equal to 15 J/m(2)) of UV does not induce apoptotic cell death, indicating that UV resistant phenotype displayed by LFS strains is not associated with deregulated apoptosis, In normal fibroblasts, such treatment results in a moderate (similar to threefold) up-regulation of p53 protein, induction of the p21(WAF1) gene, and a senescence-like growth arrest. On the other hand, exposure to greater than or equal to,20 J/m(2) UV results in a striking up-regulation of p53, inhibition of p21(WAF1) expression, and activation of an apoptotic pathway. We conclude that: (i) p21(WAF1)-mediated senescence is the principal mode of cell death induced by less than or equal to 15 J/m(2) UV light in normal human fibroblasts; (ii) there is a threshold effect for p53-dependent apoptosis and that, in normal human cells, this threshold level is induced upon exposure to similar to 20 J/m(2) UV; (iii) the p53 signaling pathway is malfunctional in the TP53 heterozygous LFS strains examined; and (iv) the enhanced resistance to UV-induced cell killing displayed by these LFS strains is a consequence of diminished growth arrest, which is presumably mediated by p21(WAF1) nd not abnormalities in an apoptotic pathway.	Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res MBC 03, Riyadh 11211, Saudi Arabia	University of Alberta; King Faisal Specialist Hospital & Research Center	Mirzayans, R (corresponding author), Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada.							ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ANDREWS AD, 1978, P NATL ACAD SCI USA, V75, P1984, DOI 10.1073/pnas.75.4.1984; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Baylin SB, 1997, SCIENCE, V277, P1948, DOI 10.1126/science.277.5334.1948; BECHHANSEN NT, 1981, LANCET, V1, P1335; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOOTSMA D, 1995, PHILOS T ROY SOC B, V347, P75, DOI 10.1098/rstb.1995.0012; Bristow RG, 1996, RADIOTHER ONCOL, V40, P197, DOI 10.1016/0167-8140(96)01806-3; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Chung DH, 1998, RADIAT RES, V149, P187, DOI 10.2307/3579929; Cistulli CA, 1998, CANCER RES, V58, P1993; DeFrank JS, 1996, CANCER RES, V56, P5365; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DOVER R, 1994, J CELL SCI, V107, P1181; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Enns L, 1998, RADIAT RES, V150, P11, DOI 10.2307/3579639; Ford JM, 1998, CANCER RES, V58, P599; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Gadbois DM, 1997, CANCER RES, V57, P1151; GALLOWAY AM, 1994, J BIOL CHEM, V269, P974; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; JARVIS WD, 1994, CANCER RES, V54, P1707; JONES JC, 1991, MUTAT RES, V255, P155, DOI 10.1016/0921-8777(91)90049-U; JUVAN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; LI CY, 1995, INT J ONCOL, V6, P233; LI Y, 1994, ONCOGENE, V9, P2261; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Ljungman M, 1996, ONCOGENE, V13, P823; Loignon M, 1997, CANCER RES, V57, P3390; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Martin Seamus J., 1994, Current Opinion in Oncology, V6, P616, DOI 10.1097/00001622-199411000-00015; MEYN MS, 1995, CANCER RES, V55, P5991; Milas Luka, 1994, In Vivo (Attiki), V8, P665; MIRZAYANS R, 1992, INT J RADIAT BIOL, V62, P417, DOI 10.1080/09553009214552301; MIRZAYANS R, 1993, CARCINOGENESIS, V14, P2621, DOI 10.1093/carcin/14.12.2621; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; MIRZAYANS R, 1995, BRIT J CANCER, V71, P1221, DOI 10.1038/bjc.1995.237; Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OConnor PM, 1997, CANCER RES, V57, P4285; Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5; PALCIC B, 1990, BIOINSTRUMENTATION D, P923; PARSHAD R, 1993, RADIAT RES, V136, P236, DOI 10.2307/3578616; PAVELETICH NP, 1993, GENE DEV, V7, P2556; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1997, CANCER RES, V57, P3434; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1993, ONCOGENE, V8, P2449; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; STRONG LC, 1992, AM J EPIDEMIOL, V135, P190, DOI 10.1093/oxfordjournals.aje.a116271; TOMMASI S, 1996, ONCOGENE, V13, P413; VARLEY JM, 1997, BRIT J CANCER, V75, P1; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Worner W, 1996, CANCER RES, V56, P1272; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2; Yount GL, 1996, CANCER RES, V56, P500	76	39	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					533	543		10.1038/sj.onc.1202271	http://dx.doi.org/10.1038/sj.onc.1202271			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704919				2022-12-17	WOS:000075195300001
J	Marchetti, D; Parikh, N; Sudol, M; Gallick, GE				Marchetti, D; Parikh, N; Sudol, M; Gallick, GE			Stimulation of the protein tyrosine kinase c-Yes but not c-Src by neurotrophins in human brain-metastatic melanoma cells	ONCOGENE			English	Article						c-Yes, c-Src; neurotrophins; nerve growth factor; neurotrophin-3; brain-metastatic melanoma	NERVE GROWTH-FACTOR; HUMAN-MALIGNANT MELANOMA; ELEVATED EXPRESSION; HUMAN MELANOCYTES; TUMOR-METASTASIS; NUDE-MICE; PP60C-SRC; PARACRINE; RECEPTOR; INVASION	The c-Yes proto-oncogene (pp62(c-Yes)) encodes a nonreceptor-type protein tyrosine kinase (NRPTK) of the Src family. c-Yes activities and protein levels are elevated in human melanoma and melanocyte cell lines. Because the neurotrophins (NT) are important in the progression of melanoma to the brain-metastatic phenotype, we determined whether NT stimulate c-Yes activity in human MeWo melanoma cells and two variant sublines with opposite metastatic capabilities, 3 S 5 and 70W, The highly brain-metastatic 70W subline had an intrinsically higher c-Yes activity than parental MeWo or poorly metastatic 3 S 5 cells, c-Yes kinase was further induced by the prototypic human NT, nerve growth factor (NGF) in a dose and time-dependent manner. In contrast, c-Src activity (pp60(c-Src)) was similar in all these cells and unaffected by NGF exposure. Additionally, human NGF and neurotrophin-3 stimulated c-Yes in brain-metastatic 70W cells. The magnitude of c-Yes activation correlated with the degree of invasion of 70 W cells following incubation of these neurotrophins. To further examine NT stimulation of c-Yes in melanoma cells, three additional cell lines were examined. Metastatic TXM-13 and TXM-18 increased c-Yes activity in response to NGF. In contrast, no increase was observed in low-metastatic TXM-40 cells. Together, these data suggest that altered c-Yes expression may play a role in the malignant progression of the human melanocyte towards the brain-metastatic phenotype and that NT enhance the activity of c-Yes in signaling penetration into the matrix of NT-rich stromal microenvironments such as the brain.	Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA; CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA	University of Texas System; UTMD Anderson Cancer Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Marchetti, D (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA.				NCI NIH HHS [CA 63617, R-29 CA 64178, CA 01605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064178] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKSLEN LA, 1987, INVAS METAST, V7, P253; ALBINO AP, 1991, CANCER RES, V51, P4815; BARBACID M, 1993, ONCOGENE, V8, P2033; BARNEKOW A, 1987, CANCER RES, V47, P235; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; FANNING P, 1992, CANCER RES, V52, P1457; GOLDEN A, 1988, SRC ONCOGENE ONCOGEN, P149; GRANDORI C, 1991, ONCOGENE, V6, P1063; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUTMAN M, 1994, ANTICANCER RES, V14, P1759; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HERLYN M, 1985, CANCER RES, V45, P5670; HERRMANN JL, 1993, MOL BIOL CELL, V4, P1205, DOI 10.1091/mbc.4.11.1205; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; ISHIKAWA M, 1988, CANCER RES, V48, P665; ISHIKAWA M, 1988, CANCER RES, V48, P4897; JAKOBOVITS EB, 1984, CELL, V38, P757, DOI 10.1016/0092-8674(84)90271-X; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LOGANZO F, 1993, ONCOGENE, V8, P2637; Marchetti D, 1996, CANCER RES, V56, P2856; MARCHETTI D, 1993, INT J CANCER, V55, P692, DOI 10.1002/ijc.2910550430; Marchetti D, 1997, ADV ENZYME REGUL, V37, P111, DOI 10.1016/S0065-2571(96)00019-2; Marchetti D, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P99, DOI 10.1038/jidsymp.1997.19; MARCHETTI D, 1995, INT J ONCOL, V7, P87; NICOLSON GL, 1993, EXP CELL RES, V204, P171, DOI 10.1006/excr.1993.1022; NICOLSON GL, 1986, INT J CANCER, V38, P289, DOI 10.1002/ijc.2910380221; NICOLSON GL, 1993, CANCER METAST REV, V12, P325, DOI 10.1007/BF00665961; NICOLSON GL, 1994, CRIT REV ONCOGENESIS, V5, P451, DOI 10.1615/CritRevOncog.v5.i5.20; NICOLSON GL, 1994, J NEURO-ONCOL, V18, P139, DOI 10.1007/BF01050420; OCONNOR TJ, 1992, CELL GROWTH DIFFER, V3, P435; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Steck Peter A., 1993, P371; SUDOL M, 1988, BRAIN RES REV, V13, P391, DOI 10.1016/0165-0173(88)90014-8; SUDOL M, 1989, MOL CELL BIOL, V9, P4545, DOI 10.1128/MCB.9.10.4545; SUDOL M, 1992, MOL BASIS HUMAN CANC; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; WHITTEMORE SR, 1987, BRAIN RES REV, V12, P439, DOI 10.1016/0165-0173(87)90008-7; WRIGHT DC, 1989, CANCER PRINCIPLES PR, P2245; ZHANG RD, 1991, CANCER RES, V51, P2029; ZHAO YH, 1990, ONCOGENE, V5, P1629	49	39	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 25	1998	16	25					3253	3260		10.1038/sj.onc.1201877	http://dx.doi.org/10.1038/sj.onc.1201877			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681823	Bronze			2022-12-17	WOS:000074343600005
J	Van Zee, KJ; Calvano, JE; Bisogna, M				Van Zee, KJ; Calvano, JE; Bisogna, M			Hypomethylation and increased gene expression of p16(INK4a) in primary and metastatic breast carcinoma as compared to normal breast tissue	ONCOGENE			English	Article; Proceedings Paper	88th Annual Meeting of the American-Association-for-Cancer-Research	APR 12-16, 1997	SAN DIEGO, CALIFORNIA	Amer Assoc Canc Res		methylation; expression; p16(INK4a); breast carcinoma; normal breast tissue	TUMOR-SUPPRESSOR GENE; DNA METHYLATION; HUMAN CANCERS; CELL-CYCLE; MUTATIONAL ANALYSIS; DELETIONS; INACTIVATION; P15(INK4B); ISLAND; MOUSE	Controversy continues to surround the role of p16(INK4a) in cell cycle control and carcinogenesis. Mutations, deletions and changes in methylation patterns of p16(INK4a) have been proposed as mechanisms leading to abnormal expression of the gene. We show here that primary and metastatic breast carcinomas demonstrate hypomethylation of p16(INK4a) which is associated,vith expression of p16(INK4a) mRNA, as compared to normal breast tissue which demonstrates a relative hypermethylation of p16(INK4a) associated with the absence of p16(INK4a) expression. These data suggest that methylation and lack of expression of p16(INK4a) is not a central mechanism in the development of breast carcinoma, but rather that the gene is functioning and expressed in breast carcinoma more frequently than in normal breast tissue. The role of p16(INK4a) is much more complex than has been previously hypothesized.	Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Canc Res Lab, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Van Zee, KJ (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Canc Res Lab, 1275 York Ave,MRI-1026, New York, NY 10021 USA.			Van Zee, Kimberly/0000-0001-9550-4647				ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; ARAP W, 1995, CANCER RES, V55, P1351; BAYLIN SB, 1992, AIDS RES HUM RETROV, V8, P811; Brenner AJ, 1996, CLIN CANCER RES, V2, P1993; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; Calvano JE, 1997, ANN SURG ONCOL, V4, P416, DOI 10.1007/BF02305555; Costello JF, 1996, CANCER RES, V56, P2405; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MOHANDAS T, 1981, SCIENCE, V211, P393, DOI 10.1126/science.6164095; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; RUSH EB, 1995, CANCER LETT, V89, P223, DOI 10.1016/0304-3835(95)03691-O; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; XU L, 1994, CANCER RES, V54, P5262; Zariwala M, 1996, ONCOGENE, V12, P451	25	39	41	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2723	2727						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652738				2022-12-17	WOS:000073812200003
J	Bristow, RG; Hu, QY; Jang, A; Chung, S; Peacock, J; Benchimol, S; Hill, R				Bristow, RG; Hu, QY; Jang, A; Chung, S; Peacock, J; Benchimol, S; Hill, R			Radioresistant MTp53-expressing rat embryo cell transformants exhibit increased DNA-dsb rejoining during exposure to ionizing radiation	ONCOGENE			English	Review						p53; H-ras; radioresistance; apoptosis; cell cycle arrests; DNA repair	P53-DEPENDENT G(1) ARREST; C-TERMINAL DOMAIN; P53 TUMOR-SUPPRESSOR; LI-FRAUMENI SYNDROME; DOUBLE-STRAND BREAKS; ACTIVATED H-RAS; WILD-TYPE P53; INDUCED APOPTOSIS; MUTANT P53; CLONOGENIC SURVIVAL	Recent data suggest that aberrant function of the wild type p53 protein (WTp53) may alter cellular survival following DNA damage through cellular pathways involving apoptosis and cell-cycle checkpoints, but little is known concerning it's possible role in DNA repair. In the present study, the ionizing radiation sensitivity was determined for a series of rat embryo fibroblast (REF) cell lines transfected with an activated form of the H-ras oncogene alone, or in combination with a variety of missense-mutant p53 (MTp53) alleles. Transformed REF clones which expressed exogenous MTp53 and p21(ras) proteins (CLASS II clones) were generally radioresistant in culture as determined by higher values surviving fraction after 2 Gy (SF2 value) radiation dose required to reduce survival to a fraction of 0.1 (D10 value), compared either to transformed REF clones expressing p21(ras) protein alone (CLASS I clones), or to non-transfected REF control cell lines expressing baseline endogenous levels of p21(ras) and WTp53 protein. The increased radioresistance observed in the CLASS II clones (following both HDR-and LDR-irradiation), was significantly correlated with increased expression of MTp53 protein, and a decreased radiation-induced G1 arrest response, The variability observed in clonogenic radiosensitivity among REF clones was not explained by differential radiation-induced apoptosis. Using the Comet assay performed after continuous low dose-rate (LDR)irradiation, MTp53-expressing REF clones were also found to be more proficient at the rejoining of DNA double-strand breaks (DNA-dsb), compared to WTp53-expressing REF clones. These results suggest that an enhanced DNA and cellular repair capacity may, in part, explain the increased radiation survival observed in some MTp53-expressing transformed fibroblasts and tumours.	Princess Margaret Hosp, Ontario Canc Inst, Dept Res, Div Expt Therapeut, Toronto, ON M5G 2M9, Canada; Princess Margaret Hosp, Ontario Canc Inst, Dept Res, Div Cellular & Mol Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Radiat Oncol, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto	Bristow, RG (corresponding author), Erasmus Univ, Room EE734,Dr Molenwaterplein 50, NL-3015 GE Rotterdam, Netherlands.			Bristow, Robert/0000-0002-8553-9544; Hill, Richard Peter/0000-0001-5331-8045; Benchimol, Samuel/0000-0003-3433-890X				AFZAL V, 1995, MUTAGENESIS, V10, P457, DOI 10.1093/mutage/10.5.457; ALDRIDGE DR, 1995, BRIT J CANCER, V71, P571, DOI 10.1038/bjc.1995.111; ALLALUNISTURNER MJ, 1995, CANCER RES, V55, P5200; ALLALUNISTURNER MJ, 1997, RADIAT RES, V147, P284; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; BLONDAL JA, 1994, SEMIN CANCER BIOL, V5, P177; Brezden CB, 1996, ONCOGENE, V12, P201; BRISTOW RG, 1994, ONCOGENE, V9, P1527; Bristow RG, 1996, RADIOTHER ONCOL, V40, P197, DOI 10.1016/0167-8140(96)01806-3; Bristow RG, 1996, INT J RADIAT ONCOL, V34, P341, DOI 10.1016/0360-3016(95)02023-3; BRISTOW RG, 1990, INT J RADIAT ONCOL, V18, P331, DOI 10.1016/0360-3016(90)90098-5; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CASSONI AM, 1992, EUR J CANCER, V28A, P1610, DOI 10.1016/0959-8049(92)90052-4; CHANG WP, 1992, CARCINOGENESIS, V13, P923, DOI 10.1093/carcin/13.6.923; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; CHEONG N, 1993, INT J RADIAT BIOL, V63, P623, DOI 10.1080/09553009314450811; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; Daza P, 1997, INT J RADIAT BIOL, V72, P91, DOI 10.1080/095530097143572; DeFrank JS, 1996, CANCER RES, V56, P5365; DENG C, 1995, CELL, V82, P657; DeWeese TL, 1997, INT J RADIAT ONCOL, V37, P145, DOI 10.1016/S0360-3016(96)00448-8; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULLIC V, 1994, CELL, V76, P1013; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FAIRBAIRN DW, 1995, MUTAT RES-REV GENET, V339, P37, DOI 10.1016/0165-1110(94)00013-3; FAN SJ, 1994, CANCER RES, V54, P5824; Fernandes RS, 1996, ANTICANCER RES, V16, P1691; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FUKS Z, 1995, IMP ADV ONCOL, V1, P19; Gallo O, 1996, CLIN CANCER RES, V2, P1577; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; Gupta N, 1996, RADIAT RES, V145, P289, DOI 10.2307/3578984; Hill R. P., 1992, BASIC SCI ONCOLOGY, P259; HOY CA, 1989, CYTOMETRY, V10, P718, DOI 10.1002/cyto.990100608; Hu QY, 1996, RADIAT RES, V146, P636, DOI 10.2307/3579379; Huang LC, 1996, CANCER RES, V56, P2940; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Kanaar Roland, 1997, Genes and Function, V1, P165; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khanna KK, 1996, CELL DEATH DIFFER, V3, P315; KIKUCHIYANOSHITA R, 1995, ONCOGENE, V11, P1339; Kitada S, 1996, ONCOGENE, V12, P187; Koch WM, 1996, JNCI-J NATL CANCER I, V88, P1580, DOI 10.1093/jnci/88.21.1580; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI CY, 1995, ONCOGENE, V11, P1885; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Linke SP, 1997, CANCER RES, V57, P1171; LITTLE JB, 1994, RADIAT RES, V140, P299, DOI 10.2307/3579106; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; Mateos S, 1996, INT J RADIAT BIOL, V69, P687, DOI 10.1080/095530096145427; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; McKay BC, 1997, CARCINOGENESIS, V18, P245, DOI 10.1093/carcin/18.2.245; MCMILLAN TJ, 1994, INT J RADIAT BIOL, V65, P49, DOI 10.1080/09553009414550071; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MIRZAYANS R, 1995, BRIT J CANCER, V71, P1221, DOI 10.1038/bjc.1995.237; MORGAN WF, 1995, CANCER METAST REV, V14, P49, DOI 10.1007/BF00690211; Muller BF, 1996, ONCOGENE, V12, P1941; NAGASAWA H, 1995, CANCER RES, V55, P1842; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nunez MI, 1996, RADIOTHER ONCOL, V39, P155, DOI 10.1016/0167-8140(96)01732-X; OLIVE PL, 1994, CANCER RES, V54, P3939; PEACOCK JW, 1995, MOL CELL BIOL, V15, P1446; Pocard M, 1996, ONCOGENE, V12, P875; POHL J, 1988, MOL CELL BIOL, V8, P2078, DOI 10.1128/MCB.8.5.2078; POWELL SN, 1994, INT J RADIAT ONCOL, V29, P1035, DOI 10.1016/0360-3016(94)90399-9; RADFORD IR, 1994, INT J RADIAT BIOL, V66, P557, DOI 10.1080/09553009414551621; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; ROVINSKI B, 1988, ONCOGENE, V2, P445; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; Schwartz JL, 1996, RADIAT RES, V146, P139, DOI 10.2307/3579585; Schwartz JL, 1996, BRIT J CANCER, V74, P37, DOI 10.1038/bjc.1996.312; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAULSKY G, 1991, CANCER RES, V51, P5232; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siles E, 1996, BRIT J CANCER, V73, P581, DOI 10.1038/bjc.1996.101; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SMITH ML, 1995, ONCOGENE, V10, P1053; STAPPER NJ, 1995, INT J CANCER, V62, P58; STEEL GG, 1991, RADIOTHER ONCOL, V20, P71; TISTY T, 1995, METHOD ENZYMOL, V254, P125; TSANG NM, 1995, ONCOGENE, V10, P2403; TSANG NM, 1994, RADIAT RES, V140, P172, DOI 10.2307/3578900; Vidair CA, 1996, CANCER RES, V56, P4116; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; WHITE E, 1994, COLD SPRING HARB SYM, V59, P395, DOI 10.1101/SQB.1994.059.01.044; Williams KJ, 1997, ONCOGENE, V14, P277, DOI 10.1038/sj.onc.1200838; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; YIN DX, 1995, CANCER RES, V55, P4922; ZOLZER F, 1995, RADIOTHER ONCOL, V37, P20, DOI 10.1016/0167-8140(95)01618-Q	106	39	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 9	1998	16	14					1789	1802		10.1038/sj.onc.1201935	http://dx.doi.org/10.1038/sj.onc.1201935			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583677				2022-12-17	WOS:000072994600003
J	Colitti, CV; Rodabaugh, KJ; Welch, WR; Berkowitz, RS; Mok, SC				Colitti, CV; Rodabaugh, KJ; Welch, WR; Berkowitz, RS; Mok, SC			A novel 4 cM minimal deletion unit on chromosome 6q25.1-q25.2 associated with high grade invasive epithelial ovarian carcinomas	ONCOGENE			English	Article						ovary; cancer; loss of heterozygosity; chromosome 6	HUMAN BORDERLINE; BREAST-CANCER; FREQUENT LOSS; ALLELE LOSS; LONG ARM; HETEROZYGOSITY; 6Q; TUMORS; ALLELOTYPE; REGION	Detailed deletion mapping of chromosome 6q has shown that the highest percentage of loss of heterozygosity (LOH) is located at 6q25-q27 and suggested that an ovarian cancer associated tumor suppressor gene may reside in this region. To further define the smallest region of common loss, we used 12 tandem repeat markers spanning a region no more than 18 cM, located between 6q25.1 and 6q26, to examine allelic loss in 54 fresh and paraffin embedded invasive ovarian epithelial tumor tissues. Loss of heterozygosity was observed more frequently at the loci defined by marker D6S473 (14 of 32 informative cases, 44%) and marker D6S448 (17 of 40 informative cases, 43%). Detailed mapping of chromosome 6q25-q26 in these tumor samples identified a 4 cM minimal region of LOH between markers D6S473 and D6S448 (6q25.1-q25.2). Loss of heterozygosity at DGS473 correlated significantly both with serous versus non-serous ovarian tumors (P=0.040) and with high grade versus low grade specimens (P=0.023). The results suggest that a 4 chi deletion unit located at 6q25.1-q25.2 may contain the putative tumor suppressor gene which may play a role in the development and progression of human invasive epithelial ovarian carcinomas (IEOC).	Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Mok, SC (corresponding author), Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA069291, R01CA069453, R01CA063381] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA69453, R01CA63381, R01CA69291] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CLIBY W, 1993, CANCER RES, V53, P2393; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Cooke IE, 1996, MAMM GENOME, V7, P157, DOI 10.1007/s003359900040; DEVILEE P, 1991, ONCOGENE, V6, P1705; Edelson MI, 1997, ONCOGENE, V14, P2979, DOI 10.1038/sj.onc.1201271; EHLEN T, 1990, ONCOGENE, V5, P219; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; GALLION HH, 1992, GYNECOL ONCOL, V47, P137, DOI 10.1016/0090-8258(92)90096-2; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; IWASE H, 1995, BRIT J CANCER, V71, P448, DOI 10.1038/bjc.1995.91; LEARY JA, 1993, INT J GYNECOL CANCER, V3, P293, DOI 10.1046/j.1525-1438.1993.03050293.x; LEE JH, 1990, CANCER RES, V50, P2724; Lee WC, 1996, CANCER RES, V56, P4297; MERLO A, 1994, CANCER RES, V54, P2322; MILLIKIN D, 1991, CANCER RES, V51, P5449; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; QUEIMADO L, 1995, GENE CHROMOSOME CANC, V14, P28, DOI 10.1002/gcc.2870140106; RODABAUGH KJ, 1995, ONCOGENE, V11, P1249; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; SAITO S, 1992, CANCER RES, V52, P5815; SATO T, 1991, CANCER RES, V51, P5118; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; VOLZ A, 1994, GENOMICS, V21, P464, DOI 10.1006/geno.1994.1302; Wertheim I, 1996, ONCOGENE, V12, P2147; ZHENG JP, 1991, CANCER RES, V51, P4045	28	39	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					555	559		10.1038/sj.onc.1201523	http://dx.doi.org/10.1038/sj.onc.1201523			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484846				2022-12-17	WOS:000071739400015
J	deAnta, JM; Jassem, E; Rosell, R; MartinezRoca, M; Jassem, J; MartinezLopez, E; Monzo, M; SanchezHernandez, JJ; Moreno, I; SanchezCespedes, M				deAnta, JM; Jassem, E; Rosell, R; MartinezRoca, M; Jassem, J; MartinezLopez, E; Monzo, M; SanchezHernandez, JJ; Moreno, I; SanchezCespedes, M			TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis	ONCOGENE			English	Article						NSCLC; TP53 null mutations; prognosis; TP53 mutational profile	TUMOR-SUPPRESSOR GENE; P53 GENE; K-RAS; BREAST-CANCER; CARCINOMAS; EXPRESSION; PROTEIN; DNA; ACCUMULATION; SURVIVAL	Inactivation of TP53 tumor suppressor gene is the most frequent molecular alteration in NSCLC, involving up to 60% of cases, Furthermore, TP53 mutational spectrum is related to the type of mutagen exposure, as well as racial and/or diet differences, Nearly 95% of TP53 perturbations affect codons included within exons 5-8 which encode for almost the entire DNA-binding domain, In this study we addressed the possible prognostic value of the molecular alterations identified in exons 5-8 of the TP53 gene in DNAs from 151 paraffin-embedded NSCLC sections corresponding to 59 Spanish and 92 Polish stage I-IIIA resected patients, PCR/single-strand conformation polymorphism (SSCP) analysis revealed that the occurrence of TP53 exon 5-8 mutations was 17/59 (29%) in the Spanish cohort and 17/92 (18%) in the Polish group, However, when DNA sequencing analysis was performed, these frequencies were reduced because of the presence of SSCP-false positive, intronic and silent mutations and polymorphisms, Fifteen of the 59 Spanish NSCLC tumors (25%) harbored TP53 mutations affecting exons 5-8 coding sequences, whereas only 12 of 92 Polish neoplasms (13%) contained alterations in the central hydrophobic region of p53, Our results indicate that the occurrence of TP53 mutations affecting exon 5-8 coding sequences in some European NSCLC populations may be lower than previously reported, and that the TP53 mutational patterns of these cohorts differ somewhat, The Spanish NSCLC patients contained missense mutations (9/59, 15%) and a relatively high percentage of null mutations (5/59, 8%) while the Polish patients mostly harbored missense mutations (9/92, 10%) and only one tumor contained a null type (1/92, 1%), Moreover, most TP53 missense mutations in the Spanish group were located outside the conserved regions, whereas the same mutations in the Polish group affected conserved amino acids, Furthermore, the Polish patients harbored a high percentage of G-->A transitions (most of them at non-CpG sites), while G-->T transversions were predominant in the Spanish group, Our findings suggest that there may be different racial or exogenous factors in these two populations which may help to explain both the distinct TP53 mutational pattern and the lower frequency obtained in the Polish group, The presence of missense mutations did not confer a worse clinical outcome in these subsets of NSCLC patients, However, patients whose tumors contained null TP53 gene mutations had a 5 month median disease-free survival time in contrast with 42 months in those patients without mutations (P=0.008), These findings suggest that loss of p53 function may enhance tumor progression in NSCLC patients independently of whether dominant negative TP53 missense mutations are present.	UNIV AUTONOMA BARCELONA,HOSP GERMANS TRIAS & PUJOL,MED ONCOL SERV,BADALONA 08916,BARCELONA,SPAIN; UNIV AUTONOMA BARCELONA,HOSP GERMANS TRIAS & PUJOL,LAB MOL BIOL CANC,BADALONA 08916,BARCELONA,SPAIN; GDANSK SCH MED,DEPT RADIOTHERAPY & ONCOL,PL-80211 GDANSK,POLAND; UNIV AUTONOMA MADRID,DEPT PREVENT MED STAT,MADRID 28029,SPAIN	Autonomous University of Barcelona; Hospital Germans Trias i Pujol; Autonomous University of Barcelona; Hospital Germans Trias i Pujol; Fahrenheit Universities; Medical University Gdansk; Autonomous University of Madrid			Sanchez-Cespedes, Montse/H-8485-2012; de Anta, Josep M/K-8993-2014	Sanchez-Cespedes, Montse/0000-0002-6045-5627; de Anta, Josep M/0000-0003-3499-8297; MONZO, MARIANO/0000-0003-2322-4851; Jassem, Ewa/0000-0003-4239-4776				Bonfill X, 1996, INT J CANCER, V65, P751, DOI 10.1002/(SICI)1097-0215(19960315)65:6<751::AID-IJC7>3.0.CO;2-Y; CARBONE DP, 1994, CHEST, V106, pS377, DOI 10.1378/chest.106.6.377S; Casey G, 1996, ONCOGENE, V13, P1971; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, P1; DIX B, 1994, BRIT J CANCER, V70, P585, DOI 10.1038/bjc.1994.355; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARIS CC, 1996, J NCI, V88, P1442; Harpole DH, 1995, CLIN CANCER RES, V1, P659; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARTMANN A, 1995, ONCOGENE, V10, P681; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIO Y, 1993, CANCER RES, V53, P1; HUANG C, 1997, P ASCO, V16, pA457; Inga A, 1997, ONCOGENE, V14, P1307, DOI 10.1038/sj.onc.1200952; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Law JC, 1995, CLIN CANCER RES, V1, P763; LEE JS, 1995, J CLIN ONCOL, V13, P1893, DOI 10.1200/JCO.1995.13.8.1893; LEE LN, 1994, AM J RESP CRIT CARE, V150, P1667, DOI 10.1164/ajrccm.150.6.7952630; Liloglou T, 1997, BRIT J CANCER, V75, P1119, DOI 10.1038/bjc.1997.193; Lomax ME, 1997, ONCOGENE, V14, P1869, DOI 10.1038/sj.onc.1201133; MILLER CW, 1992, CANCER RES, V52, P1695; MITSUDOMI T, 1993, JNCI-J NATL CANCER I, V85, P2018, DOI 10.1093/jnci/85.24.2018; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; NAVONE NM, 1993, J NCI, V85, P1687; Nishio M, 1996, J CLIN ONCOL, V14, P497, DOI 10.1200/JCO.1996.14.2.497; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PASSLICK B, 1995, J THORAC CARDIOV SUR, V109, P1205, DOI 10.1016/S0022-5223(95)70204-0; QUINLAN DC, 1992, CANCER RES, V52, P4828; REID TM, 1992, CANCER RES, V52, P1082; RIDANPAA M, 1994, INT J ONCOL, V5, P1109; ROSELL R, 1993, ONCOGENE, V8, P2407; Rosell R, 1996, CLIN CANCER RES, V2, P1083; RYBERG D, 1994, CANCER RES, V54, P1551; SAITOH S, 1994, ONCOGENE, V9, P2869; SHIAO YH, 1995, CANCER RES, V55, P1485; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; TAKAGI Y, 1995, CANCER RES, V55, P5354; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; TAKESHIMA Y, 1993, LANCET, V342, P1520, DOI 10.1016/S0140-6736(05)80087-X; TAYLOR JA, 1996, CANCER RES, V55, P294; THORLACIUS S, 1993, CANCER RES, V53, P1637; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2; WYNFORDTHOMAS D, 1992, J PATHOL, V166, P329, DOI 10.1002/path.1711660402; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	48	39	39	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2951	2958		10.1038/sj.onc.1201475	http://dx.doi.org/10.1038/sj.onc.1201475			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416838				2022-12-17	WOS:A1997YK37700007
J	Muller, C; Salles, B				Muller, C; Salles, B			Regulation of DNA-dependent protein kinase activity in leukemic cells	ONCOGENE			English	Article						DNA-PK; Ku autoantigen; CLL lymphocytes	CHRONIC LYMPHOCYTIC-LEUKEMIA; STRAND BREAK REPAIR; V(D)J RECOMBINATION; KU-PROTEIN; BINDING; EXPRESSION; AUTOANTIGEN; RESISTANCE; ANTIBODIES; ENDS	The DNA-dependent protein kinase (DNA-PK) complex is composed of a catalytic (DNA-PKcs), and a regulatory subunit (Ku70/Ku86 heterodimer), The expression and function of DNA-PK subunits was investigated in purified blood lymphocytes obtained from patients with chronic lymphocytic leukemia (CLL) either refractory to chemotherapy or untreated, Variations in DNA-PK activity were found amongst CLL samples by comparison to human cell lines, It was noticeable that the low DNA-PK activity was associated with samples from untreated patients that exhibited a sensitivity phenotype, determined in vitro, to the radiomimetic agent neocarcinostatin by comparison to samples from refractory patients, The regulation in DNA-PK activity was associated with Ku heterodimer expression while DNA-PKcs was unaffected, Moreover, the presence of an altered form of the Ku86 subunit was identified in samples with low DNA-PK activity, These results suggest a regulation process of the DNA-PK activity in fresh human cells.	CNRS,UPR 9062,INST PHARMACOL & BIOL STRUCT,F-31077 TOULOUSE,FRANCE; CHU PURPAN,SERV HEMATOL,F-31300 TOULOUSE,FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse			salles, bernard/B-8531-2008; MULLER, Catherine/M-2185-2018; MULLER, Catherine/E-2060-2011					ANDERSON CW, 1994, J PROTEIN CHEM, V13, P500; Barret JM, 1996, MOL PHARMACOL, V49, P766; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BRAMSON J, 1995, MUTAT RES-DNA REPAIR, V336, P269, DOI 10.1016/0921-8777(94)00063-C; BRAMSON J, 1995, CANCER LETT, V90, P139, DOI 10.1016/0304-3835(95)03696-T; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; FALZON M, 1993, J BIOL CHEM, V268, P10546; Finnie NJ, 1996, PHILOS T ROY SOC B, V351, P173, DOI 10.1098/rstb.1996.0014; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Han ZY, 1996, J BIOL CHEM, V271, P14098, DOI 10.1074/jbc.271.24.14098; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; KIPPS TJ, 1995, CHRONIC LYMPHOCYTIC, P1017; MINORI T, 1986, J BIOL CHEM, V261, P10375; MULLER C, 1994, INT J CANCER, V56, P749, DOI 10.1002/ijc.2910560523; ORFAO A, 1992, LEUKEMIA, V6, P47; PANASCI L, 1988, CANCER RES, V48, P1972; REEVES WH, 1987, J RHEUMATOL, V14, P97; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; WANG JS, 1993, MOL BIOL REP, V18, P15, DOI 10.1007/BF01006891; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7; YANEVA M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P181, DOI 10.1016/0167-4781(91)90099-8; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2	25	39	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 6	1997	15	19					2343	2348		10.1038/sj.onc.1201402	http://dx.doi.org/10.1038/sj.onc.1201402			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393878				2022-12-17	WOS:A1997YE15700008
J	Mitchell, PJ; Barker, KT; Shipley, J; Crompton, MR				Mitchell, PJ; Barker, KT; Shipley, J; Crompton, MR			Characterisation and chromosome mapping of the human non receptor tyrosine kinase gene, brk	ONCOGENE			English	Article						brk; genomic structure; alternate splicing; SH3; chromosome 19q; protein tyrosine kinase	COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN BREAST-CANCER; C-SRC; PROTEIN-KINASE; LINKED AGAMMAGLOBULINEMIA; TRANSCRIPTION FACTOR; DNA; PP60C-SRC; PHOSPHORYLATION; ACTIVATION	The brk gene encodes a non-receptor protein tyrosine kinase that consists of single SH3, SH2 and catalytic domains. Although BRK shows strongest sequence similarity to members of the SRC family of PTKs, there are several key structural and regulatory differences that place it on its own amongst non-receptor PTKs. In this study we have isolated genomic DNA clones corresponding to the human brk locus and used these to determine the intron-exon structure of the brk gene. The genomic structure of brk consists of 8 exons, whose boundaries are distinct from other non-receptor PTK family members, again indicating a structural and functional divergence. Alternate splicing of the primary brk transcript generates a distinct mRNA which encodes a truncated protein consisting of an SH3 domain and a novel C-terminal proline rich sequence. Using an antiserum raised to the SH3 domain, we have demonstrated that the product of this alternate brk transcript is expressed in the human breast tumour cell line T-47D. We have previously reported that expression of a tumour derived brk cDNA in mouse embryonic fibroblasts and human mammary epithelial cells supports anchorage independent growth, and in the latter potentiates the mitogenic response to epidermal growth factor. The protein encoded by the genomic sequence derived from normal human tissue is identical to that encoded by the tumour derived cDNA, and therefore the altered growth regulation is not associated with mutations within brk. In addition, we have identified a 5' genomic region that has promoter activity. The brk gene has been assigned to chromosome 19q 13.3-13.4 using fluorescence in situ hybridisation (FISH).			Mitchell, PJ (corresponding author), INST CANC RES, HADDOW LABS, SECT CELL BIOL & EXPT PATHOL, 15 COTSWOLD RD, SUTTON SM2 5NG, SURREY, ENGLAND.		Mitchell, Philip J/F-6393-2013	Shipley, Janet/0000-0001-6748-8678	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; AVRAHAM S, 1995, J BIOL CHEM, V270, P1833, DOI 10.1074/jbc.270.4.1833; BARKER KT, 1997, IN PRESS ONCOGENE; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOLLA M, 1993, BREAST CANCER RES TR, V26, P283, DOI 10.1007/BF00665806; BRAUNINGER A, 1993, ONCOGENE, V8, P1365; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COOKE M P, 1989, New Biologist, V1, P66; DAVIDSON D, 1994, MOL CELL BIOL, V14, P4554, DOI 10.1128/MCB.14.7.4554; DAVIDSON D, 1994, J BIOL CHEM, V269, P10956; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; HAGEMANN TL, 1994, HUM MOL GENET, V3, P1743, DOI 10.1093/hmg/3.10.1743; HENNIPMAN A, 1989, CANCER RES, V49, P516; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LOWER EE, 1993, BREAST CANCER RES TR, V26, P217, DOI 10.1007/BF00665799; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Ohta Y, 1996, ONCOGENE, V12, P937; OHTA Y, 1994, P NATL ACAD SCI USA, V91, P9062, DOI 10.1073/pnas.91.19.9062; OKADA M, 1991, J BIOL CHEM, V266, P24249; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PARKER RC, 1985, MOL CELL BIOL, V5, P831, DOI 10.1128/MCB.5.4.831; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; RIED T, 1995, CANCER RES, V55, P5415; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIPLEY JM, 1993, CYTOGENET CELL GENET, V64, P233, DOI 10.1159/000133585; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; STAMPS AC, 1994, INT J CANCER, V57, P865, DOI 10.1002/ijc.2910570616; Takahashi F, 1996, GENE DEV, V10, P1645, DOI 10.1101/gad.10.13.1645; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; THOMPSON F, 1993, GENE CHROMOSOME CANC, V7, P185, DOI 10.1002/gcc.2870070402; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZIEGLER SF, 1989, MOL CELL BIOL, V9, P2724, DOI 10.1128/MCB.9.6.2724	48	39	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	1997	15	12					1497	1502		10.1038/sj.onc.1201292	http://dx.doi.org/10.1038/sj.onc.1201292			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333026				2022-12-17	WOS:A1997XW41100014
J	Huang, CC; Papas, TS; Bhat, NK				Huang, CC; Papas, TS; Bhat, NK			A variant form of ETS1 induces apoptosis in human colon cancer cells	ONCOGENE			English	Article						oncogene; tumor suppressor gene; colon cancer; ETS1 protein; epithelial cancer	TRANSCRIPTION FACTORS; EXPRESSION; GENES; ISOFORMS; PROTEINS; BINDING; FAMILY	We have previously shown that the human ETS1 protein (pS1-ETS1), when ectopically expressed in colon cancer cell lines, is able to reduce its tumorigenicity without affecting its growth properties, To understand the mechanism of tumor reduction, we have expressed two different forms of ETS1 in colon cancer cell lines, Data presented in this paper indicate that the naturally occurring spliced variant protein, p42-ETS1, lacking the region encoded by ETS1 exon VII, represses the tumorigenicity, while p51-ETS1 reduces the tumorigenicity, Repression of tumorigenicity mediated by p42-ETS1 appears to be caused by its ability to induce apoptosis in epithelial cancer cells, This work can have profound medical significance in that it may open up new insights into the potential role of the p42-ETS1 in the induction of apoptosis in epithelial cell cancers and may provide a rationale for its use for potential gene therapy experiments to initiate cell death in cancer cells.	NCI,FREDERICK CANC RES & DEV CTR,SAIC,RECOMBINANT DNA LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Huang, CC (corresponding author), MED UNIV S CAROLINA,HOLLINGS CANC CTR,CTR MOL & STRUCT BIOL,CHARLESTON,SC 29425, USA.							BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; Bhat NK, 1996, INT J ONCOL, V8, P841; BHAT NK, 1994, CHALLENGES MODERN ME, V5, P63; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FISHER RJ, 1992, J BIOL CHEM, V267, P17957; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; JORCYK CL, 1991, ONCOGENE, V6, P523; KOIZUMI S, 1990, ONCOGENE, V5, P675; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROMANOSPICA V, 1994, INT J ONCOL, V4, P521; ROMANOSPICA V, 1995, J IMMUNOL, V154, P2726; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; SUZUKI H, 1993, INT J ONCOL, V3, P56; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862	20	39	39	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					851	856		10.1038/sj.onc.1201408	http://dx.doi.org/10.1038/sj.onc.1201408			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266972				2022-12-17	WOS:A1997XQ11700012
J	Flick, MB; Sapi, E; Perrotta, PL; Maher, MG; Halaban, R; Carter, D; Kacinski, BM				Flick, MB; Sapi, E; Perrotta, PL; Maher, MG; Halaban, R; Carter, D; Kacinski, BM			Recognition of activated CSF-1 receptor in breast carcinomas by a tyrosine 723 phosphospecific antibody	ONCOGENE			English	Article						c-fms proto-oncogene; phosphotyrosine; immunohistochemistry; tyrosine kinase; breast carcinoma	COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; MACROPHAGE CELL-LINE; FMS PROTO-ONCOGENE; SIGNAL-TRANSDUCTION; PHOSPHORYLATED PROTEINS; SH2 DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE; HUMAN MELANOCYTES	The macrophage colony stimulating factor receptor (CSF-1R), the product of the c-fms proto-oncogene, plays an important role in regulating the normal proliferation and differentiation of macrophages and trophoblasts. However, the abnormal expression of CSF-1R transcripts and protein by human breast carcinomas has been shown to correlate with advanced stage and poor prognosis. Ligand activated CSF-1R dimers transphosphorylate several tyrosines in their cytoplasmic domains which provide recognition sites for various effector proteins in multiple signal transduction pathways. In cells transformed by the c-fms oncogene, one of the major CSF-1R phosphotyrosines, pTyr723 is important for phenotypic expression of anchorage-independent growth and metastasis. In order to investigate the relationship between receptor activation/phosphorylation and cellular phenotypes in vitro and in vivo, we prepared a CSF-1R phosphorylation-state specific antibody raised against a specific phosphopeptide of CSF-1R, which included phosphorylated tyrosine 723. On immunoblots of lysates from cells expressing CSF-1R, this antibody recognizes phosphorylated CSF-1R in CSF-1 stimulated cells but not in unstimulated cells. As an immunohistochemical reagent, this antibody stained 52% of invasive human breast tumors (72% of CSF-1R positive cases) in a sample of 114 cases and 38% of carcinoma in situ. This data represents the first direct evidence of in vivo phosphorylation of CSF-1R in human breast carcinomas.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT DERMATOL, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT OBSTET & GYNECOL, NEW HAVEN, CT 06520 USA	Yale University; Yale University; Yale University	Flick, MB (corresponding author), YALE UNIV, SCH MED, DEPT THERAPEUT RADIOL, 333 CEDAR ST, NEW HAVEN, CT 06520 USA.				PHS HHS [CF47292] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; Bacus SS, 1996, AM J PATHOL, V148, P549; BAIOCCHI G, 1991, CANCER, V67, P990, DOI 10.1002/1097-0142(19910215)67:4<990::AID-CNCR2820670422>3.0.CO;2-8; BANGALORE L, 1992, P NATL ACAD SCI USA, V89, P11637, DOI 10.1073/pnas.89.23.11637; BISHAYEE S, 1988, MOL CELL BIOL, V8, P3696, DOI 10.1128/MCB.8.9.3696; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; BRUCKNER A, 1992, CANCER RES, V52, P3043; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAMBERS SK, 1995, CANCER RES, V55, P1578; COMOGLIO PM, 1990, AM REV RESPIR DIS, V142, pS16, DOI 10.1164/ajrccm/142.6_Pt_2.S16; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; DOWNING JR, 1991, MOL CELL BIOL, V11, P2489, DOI 10.1128/MCB.11.5.2489; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FILDERMAN AE, 1992, CANCER RES, V52, P3661; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; HALABAN R, 1992, ONCOGENE, V7, P2195; KACINSKI BM, 1989, INT J RADIAT ONCOL, V17, P159, DOI 10.1016/0360-3016(89)90383-0; KACINSKI BM, 1988, INT J RADIAT ONCOL, V15, P823, DOI 10.1016/0360-3016(88)90113-7; KACINSKI BM, 1991, ONCOGENE, V6, P941; KACINSKI BM, 1989, CANCER CEL, V7, P333; KACINSKI BM, 1990, AM J PATHOL, V137, P135; KACINSKI BM, 1990, MOL CELLULAR BIOL CY, P393; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KEATING MT, 1988, J BIOL CHEM, V263, P12805; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LOWER EE, 1993, BREAST CANCER RES TR, V26, P217, DOI 10.1007/BF00665799; MANGER R, 1984, CELL, V39, P327, DOI 10.1016/0092-8674(84)90011-4; MARCUSSEN J, 1991, ANAL BIOCHEM, V198, P318, DOI 10.1016/0003-2697(91)90432-S; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; NICHOLS EJ, 1985, MOL CELL BIOL, V5, P3467, DOI 10.1128/MCB.5.12.3467; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; OHTSUKA M, 1990, MOL CELL BIOL, V10, P1664, DOI 10.1128/MCB.10.4.1664; PANNEERSELVAM K, 1995, J BIOL CHEM, V270, P7975, DOI 10.1074/jbc.270.14.7975; POLLARD JW, 1991, DEV BIOL, V148, P273, DOI 10.1016/0012-1606(91)90336-2; POLLARD JW, 1987, NATURE, V330, P484, DOI 10.1038/330484a0; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROHRSCHNEIDER LR, 1989, ONCOGENE, V4, P1015; ROHRSCHNEIDER LR, 1994, GUIDEBOOK CYTOKINES, P168; ROSS AH, 1981, NATURE, V294, P654, DOI 10.1038/294654a0; Sapi E, 1996, CANCER RES, V56, P5704; SCHOLL SM, 1994, JNCI-J NATL CANCER I, V86, P120, DOI 10.1093/jnci/86.2.120; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STERN DF, 1991, METHOD ENZYMOL, V198, P494; TANG RP, 1992, J CELL BIOCHEM, V50, P350, DOI 10.1002/jcb.240500403; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TROULIARIS S, 1995, J VIROL, V69, P6010, DOI 10.1128/JVI.69.10.6010-6020.1995; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WANG JYJ, 1988, ANAL BIOCHEM, V172, P1, DOI 10.1016/0003-2697(88)90403-4; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WOOLFORD J, 1985, MOL CELL BIOL, V5, P3458, DOI 10.1128/MCB.5.12.3458; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	66	39	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	1997	14	21					2553	2561		10.1038/sj.onc.1201092	http://dx.doi.org/10.1038/sj.onc.1201092			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191055				2022-12-17	WOS:A1997XA94900007
J	Soucek, T; Pusch, O; HengstschlagerOttnad, E; Adams, PD; Hengstschlager, M				Soucek, T; Pusch, O; HengstschlagerOttnad, E; Adams, PD; Hengstschlager, M			Deregulated expression of E2F-1 induces cyclin A- and E-associated kinase activities independently from cell cycle position	ONCOGENE			English	Article						E2F; cyclin E; cyclin A; CDK; centrifugal elutriation	TUMOR-SUPPRESSOR PROTEIN; S-PHASE ENTRY; TRANSCRIPTION FACTOR; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; DNA-SYNTHESIS; G(1); FIBROBLASTS; APOPTOSIS; GENES	The transcription factor E2F activates genes required for S phase, such as cyclin E and cyclin A, We show that, contrary to long term effects of E2F-1 overexpression, short ectopic overexpression of this transcription factor in logarithmically growing cells does neither affect the cell cycle distribution nor the cell size, but heavily induces cyclin E and A expression as well as cyclin E- and A-dependent kinase activities, We further separated logarithmically growing E2F-1-overexpressing cells according to their different cell cycle phases by centrifugal elutriation, These experiments revealed that deregulated E2F-1 expression triggers high levels of cyclin E and A expression and kinase activities in small early G(1) cells, normally not exhibiting these activities, These effects on the regulation of cyclin E- and A-associated kinases are not accompanied by any detectable alteration in the rate of progression through the cell cycle, suggesting that these changes are independent of any mitogenic properties of E2F-1.	UNIV VIENNA,DEPT PRENATAL DIAGNOSIS & THERAPY,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,INST MOL GENET,A-1030 VIENNA,AUSTRIA; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV NEOPLAST DIS MECHANISMS,BOSTON,MA 02115	University of Vienna; University of Vienna; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School				Pusch, Oliver/0000-0001-7166-2800; Adams, Peter/0000-0002-0684-1770				BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; Botz J, 1996, MOL CELL BIOL, V16, P3401; CHEN PL, 1995, CRIT REV EUKAR GENE, V5, P79; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Geng Y, 1996, ONCOGENE, V12, P1173; GRANA X, 1995, ONCOGENE, V11, P211; HENGSTSCHLAGER M, 1994, J BIOL CHEM, V269, P13836; HENGSTSCHLAGER M, 1994, CELL GROWTH DIFFER, V5, P1389; Hengstschlager M, 1996, ONCOGENE, V12, P1635; HINDS PW, 1995, CURR OPIN GENET DEV, V5, P79, DOI 10.1016/S0959-437X(95)90057-8; JANSENDURR P, 1995, CELL CYCLE, P243; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KATO J, 1993, GENE DEV, V7, P331; Khleif SN, 1996, P NATL ACAD SCI USA, V93, P4350, DOI 10.1073/pnas.93.9.4350; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LUKAS B, 1996, MOL CELL BIOL, V16, P1047; MELILLO RM, 1994, MOL CELL BIOL, V14, P8241, DOI 10.1128/MCB.14.12.8241; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NEVINS JR, 1992, SCIENCE, V258, P424; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Pusch O, 1996, FEBS LETT, V385, P143, DOI 10.1016/0014-5793(96)00369-9; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Shan B, 1996, CELL GROWTH DIFFER, V7, P689; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	44	39	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 15	1997	14	19					2251	2257		10.1038/sj.onc.1201061	http://dx.doi.org/10.1038/sj.onc.1201061			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178900				2022-12-17	WOS:A1997WY88300001
J	Dear, TN; Hainzl, T; Follo, M; Nehls, M; Wilmore, H; Matena, K; Boehm, T				Dear, TN; Hainzl, T; Follo, M; Nehls, M; Wilmore, H; Matena, K; Boehm, T			Identification of interaction partners for the basic-helix-loop-helix protein E47	ONCOGENE			English	Article						E47; helix-loop-helix; eip1	REPLICATION FACTOR-C; DNA-BINDING; DROSOPHILA-MELANOGASTER; IMMUNOGLOBULIN ENHANCER; DEVELOPING SOMITES; EXPRESSION VECTOR; HLH PROTEINS; GENE; E2A; CLONING	Helix-loop-helix proteins constitute a family of transcription factors with the potential to form homo- and hetero-dimers mediated by the helix-loop-helix domain, Oncogenic mutations in such genes can disrupt the equilibrium of protein-protein interactions in the affected cell, In order to assess the biological consequences of such mutations, the full complement of interacting proteins must be known, To identify proteins interacting with the basic-helix-loop-helix domain of the ubiquitously expressed E47 protein, a 'sandwich'-screening procedure was developed which distinguishes between homo- and hetero-oligomers, and specifically excludes the detection of complexes which cannot bind DNA, Nine distinct cDNAs were identified which encode proteins with apparent basic-helix-loop-helix domains, including a novel clone termed eip1 which is distantly related in the basic-helix-loop-helix domain to the Drosophila enhancer-of-split m7 protein, Using epitope-tagging, interaction of E47 basic-helix-loop-helix protein with the eip1 protein encoded by this novel cDNA was confirmed by immunoprecipitation experiments in COS7 cells, Interaction was also observed in the yeast two-hybrid system, Three cDNAs encoding proteins without basic-helix-loop-helix domains were also found to interact in the sandwich-expression screen, Interactions with human PARP and mouse replication factor la were confirmed using glutathione transferase-tagged cDNAs, A cDNA encoding part of the nucleolin protein sequence interacted with the E47 basic-helix-loop-helix only when fused to a beta-galactosidase tag.	DEUTSCH KREBSFORSCHUNGSZENTRUM,D-69120 HEIDELBERG,GERMANY; MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; INNERE MED ABT 1,D-79106 FREIBURG,GERMANY; UNIV FRANKFURT,MED KLIN 4,ZENTRUM INNERE MED,D-60590 FRANKFURT,GERMANY; UNIV BATH,SCH BIOL & BIOCHEM,BATH BA2 7AY,AVON,ENGLAND	Helmholtz Association; German Cancer Research Center (DKFZ); MRC Laboratory Molecular Biology; Goethe University Frankfurt; University of Bath				Follo, Marie/0000-0002-3090-7442				APERLO C, 1996, IN PRESS GENOMICS; BAER R, 1987, CELL, V50, P97, DOI 10.1016/0092-8674(87)90666-0; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BURBELO PD, 1993, P NATL ACAD SCI USA, V90, P11543, DOI 10.1073/pnas.90.24.11543; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CLINE TW, 1976, GENETICS, V84, P723; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; HAINZL T, 1994, ONCOGENE, V9, P885; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU JS, 1992, MOL CELL BIOL, V12, P1031; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; LUCKOW B, 1994, MOL CELL BIOL, V14, P1626, DOI 10.1128/MCB.14.3.1626; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEUMAN T, 1993, EUR J NEUROSCI, V5, P311, DOI 10.1111/j.1460-9568.1993.tb00498.x; NIELSEN AL, 1992, MOL CELL BIOL, V12, P3449, DOI 10.1128/MCB.12.8.3449; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; VASTRIK I, 1993, ONCOGENE, V8, P503; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	41	39	40	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 27	1997	14	8					891	898		10.1038/sj.onc.1200912	http://dx.doi.org/10.1038/sj.onc.1200912			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050988				2022-12-17	WOS:A1997WK34400002
J	Columbano, A; LeddaColumbano, GM; Pibiri, M; Piga, R; Shinozuka, H; DeLuca, V; Cerignoli, F; Tripodi, M				Columbano, A; LeddaColumbano, GM; Pibiri, M; Piga, R; Shinozuka, H; DeLuca, V; Cerignoli, F; Tripodi, M			Increased expression of c-fos, c-jun and LRF-1 is not required for in vivo priming of hepatocytes by the mitogen TCPOBOP	ONCOGENE			English	Article						immediate early genes; liver; priming; cell proliferation; TCPOBOP; CCl4	MYC MESSENGER-RNA; FACTOR KAPPA-B; REGENERATING LIVER; RAT-LIVER; CELL-PROLIFERATION; GROWTH-FACTORS; GENE; 1,4-BIS<2-(3,5-DICHLOROPYRIDYLOXY)>BENZENE; INDUCTION; IDENTIFICATION	The notion that an increased expression of immediate early genes such as c-fos and c-jun is an absolute requirement for the G(0)-G(1) transition of the hepatocytes has recently been challenged by the finding that rat liver cell proliferation induced by primary mitogens may occur in the absence of such changes (Columbano and Shinozuka, 1996). To further investigate the relationship between immediate early genes and hepatocyte proliferation, we have compared the hepatic levels of c-fos, c-jun and LRF-1 transcripts during mouse liver cell proliferation in two conditions: (i) direct hyperplasia induced by the non-genotoxic hepatocarcinogen 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene, and (ii) compensatory regeneration caused by a necrogenic dose of carbon tetrachloride. The results show striking differences in the activation of early genes. In spite of a rapid stimulation of S phase by 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (approximately 8% of hepatocytes were BrdU-positive as early as 24 h after mitogen treatment versus 1% of labelled hepatocytes after 2/3 partial hepatectomy), no changes in the expression of c-fos, c-jun and LRF-1 could be observed. Moreover, no change in steady state mRNA hepatic levels of IGFBP-1 (a gene highly expressed in rat liver following partial hepatectomy), and only a slight increase in c-myc and PRL-1, was found after mitogen administration. On the contrary, a rapid, massive and transient increase in the hepatic mRNA levels of all these genes was observed during carbon tetrachloride induced regeneration. The results indicate that increased expression of immediate early genes may be dependent upon the nature of the proliferative stimulus, and it may not be a prerequisite in certain in vivo conditions such as proliferation induced in the absence of liver tissue damage.	UNIV PITTSBURGH,DEPT PATHOL,PITTSBURGH,PA 15260; UNIV ROMA LA SAPIENZA,DIP BIOPATOL UMANA,SEZ BIOL CELLULARE,FDN IST PASTEUR CENCI BOLOGNETTI,ROME,ITALY	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Fondazione Cenci Bolognetti; Sapienza University Rome	Columbano, A (corresponding author), UNIV CAGLIARI,IST PATOL SPERIMENTALE,I-09124 CAGLIARI,ITALY.		Tripodi, Marco/F-1143-2011; Tripodi, Marco/ABO-1160-2022; Columbano, Amedeo/C-7463-2011	Tripodi, Marco/0000-0001-6135-971X; Tripodi, Marco/0000-0001-6135-971X; Columbano, Amedeo/0000-0002-6956-9030; PIBIRI, MONICA/0000-0002-9660-9616	NCI NIH HHS [CA53453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Columbano A, 1996, FASEB J, V10, P1118, DOI 10.1096/fasebj.10.10.8751714; COLUMBANO A, 1996, P AM ASSOC CANC RES, V37, P1466; CONI P, 1990, CARCINOGENESIS, V11, P835, DOI 10.1093/carcin/11.5.835; CONI P, 1993, HEPATOLOGY, V17, P1109, DOI 10.1002/hep.1840170626; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; DIWAN BA, 1992, CARCINOGENESIS, V13, P1893, DOI 10.1093/carcin/13.10.1893; DRAGANI TA, 1985, CARCINOGENESIS, V6, P225, DOI 10.1093/carcin/6.2.225; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; FRANCAVILLA A, 1994, HEPATOLOGY, V20, P1237, DOI 10.1002/hep.1840200521; GARIBOLDI M, 1995, MOL CARCINOGEN, V14, P71, DOI 10.1002/mc.2940140202; GOLDSWORTHY TL, 1994, CELL PROLIFERAT, V27, P269, DOI 10.1111/j.1365-2184.1994.tb01424.x; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; Higgins GM, 1931, ARCH PATHOL, V12, P186; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MANENTI G, 1987, CHEM-BIOL INTERACT, V64, P83, DOI 10.1016/0009-2797(87)90062-7; MENEGAZZI M, 1996, IN PRESS HEPATOLOGY; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; Ohmura T, 1996, LIFE SCI, V58, pPL211, DOI 10.1016/0024-3205(96)00039-2; Ohmura T, 1996, AM J PATHOL, V148, P815; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SCEARCE LM, 1996, CELL DEATH DIFFER, V3, P51; SHINOZUKA H, 1994, LAB INVEST, V71, P35; SHORT J, 1972, J BIOL CHEM, V247, P1757; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0	33	39	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					857	863		10.1038/sj.onc.1200891	http://dx.doi.org/10.1038/sj.onc.1200891			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047393				2022-12-17	WOS:A1997WJ11200012
J	Salvucci, M; Lemoine, A; Azoulay, D; Sebagh, M; Bismuth, H; Reynes, M; May, E; Debuire, B				Salvucci, M; Lemoine, A; Azoulay, D; Sebagh, M; Bismuth, H; Reynes, M; May, E; Debuire, B			Frequent microsatellite instability in post hepatitis B viral cirrhosis	ONCOGENE			English	Article						microsatellite; liver; cirrhosis; HBV; PCR	LIVER-TRANSPLANTATION; GENETIC INSTABILITY; CANCER; POLYMORPHISMS; NEOPLASMS; CARCINOMA; VIRUS	The molecular basis of cirrhosis, the most frequent underlying liver disease in hepatocellular carcinoma, remains unclear, We investigated microsatellite instability at six different loci on chromosomes 2p, 3p, 5q, 9p, 13q and 17p, in DNA from 38 cirrhotic livers of viral (n = 28) and nonviral (n = 10) origin. Sixty percent of the patients exhibited microsatellite alterations in at least one chromosome locus, A striking feature was the close association between genomic instability and cirrhosis linked to hepatitis B viral infection (P<0.01), This high instability may be a clue to the etiology of cancer induced by the hepatitis B virus.	HOP PAUL BROUSSE,SERV BIOCHIM,F-94804 VILLEJUIF,FRANCE; HOP PAUL BROUSSE,CTR HEPATOBILIAIRE,F-94804 VILLEJUIF,FRANCE; HOP PAUL BROUSSE,SERV ANAT PATHOL,F-94804 VILLEJUIF,FRANCE; FAC MED PARIS SUD,FONTENAY ROSES,FRANCE; CEA,UMR 217 CNRS,FONTENAY ROSES,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; UDICE-French Research Universities; Universite Paris Saclay; CEA			SEBAGH, Mylène/T-7464-2018; Azoulay, Daniel/Q-7887-2018					BEDI GC, 1995, NAT MED, V1, P65, DOI 10.1038/nm0195-65; BOURDON JC, 1995, GASTROENTEROLOGY, V108, P1176, DOI 10.1016/0016-5085(95)90217-1; CHONG JM, 1994, CANCER RES, V54, P4595; FERAY C, 1994, HEPATOLOGY, V20, P1137, DOI 10.1016/0270-9139(94)90748-X; HAN HJ, 1993, CANCER RES, V53, P5087; KING BL, 1995, BRIT J CANCER, V72, P376, DOI 10.1038/bjc.1995.341; MARTINSSON T, 1995, CANCER RES, V55, P5681; MERLO A, 1994, CANCER RES, V54, P2098; RISINGER JI, 1995, CANCER RES, V55, P5664; SAMUEL D, 1995, HEPATOLOGY, V21, P333, DOI 10.1016/0270-9139(95)90089-6; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHRIDHAR V, 1994, CANCER RES, V54, P2084; TAMURA G, 1995, CANCER RES, V55, P1933; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; UCHIDA T, 1995, ONCOGENE, V10, P1019; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; YEE CJ, 1994, CANCER RES, V54, P1641	19	39	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2681	2685						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000142				2022-12-17	WOS:A1996VZ65400018
J	Li, J; Hu, SX; Perng, GS; Zhou, YL; Xu, K; Zhang, CY; Seigne, J; Benedict, WF; Xu, HJ				Li, J; Hu, SX; Perng, GS; Zhou, YL; Xu, K; Zhang, CY; Seigne, J; Benedict, WF; Xu, HJ			Expression of the retinoblastoma (RB) tumor suppressor gene inhibits tumor cell invasion in vitro	ONCOGENE			English	Article						tumor suppressor gene; retinoblastoma (RB) gene; p53; tumor invasion; inducible gene expression	QUANTITATIVE ASSAY; BASEMENT-MEMBRANE; PROTEIN; CARCINOMA; MATRIX; TRANSCRIPTION; ASSOCIATION; ACTIVATION; GROWTH; CYCLE	To determine if replacement of the retinoblastoma (RE) tumor suppressor gene could inhibit invasion of RB-defective tumor cells, the capacity of tumor cells to migrate or invade was quantitated by the Boyden chamber assay, The studies were done in a diverse group of stable RE-reconstituted human tumor cell lines, including those derived from the osteosarcoma and carcinomas of the lung, breast and bladder, The expression of the exogenous wildtype RE protein in these tumor cell lines was driven by either a constitutively active promoter or an inducible promoter, It was found that significantly more tumor cells from the parental RE-defective cell lines and the RB(-) revertants than from the RE-reconstituted RB(+) cell lines penetrated through the Matrigel (P < 0.001, two-tailed t-test), although both RB(+) and RB(-) cells migrated at approximately the same rate on uncoated polycarbonate filters in the Boyden chambers, Of note, the inhibition of invasiveness of various RE-defective tumor cells by RE replacement was apparently web correlated with suppression of their tumorigenicity in vivo. In contrast, although either functional RE or p53 re-expression effectively suppressed tumor formation in nude mice of the RB(-)/p53(nuII) osteosarcoma cell line, Saos-2, replacement of the wild-type p53 gene had much less impact on their invasiveness as compared to the RE gene, These studies provided an insight into the broader biological basis of the RE-mediated tumor suppression in RE-defective tumor cells.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOL ONCOL,THE WOODLANDS,TX 77381; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,THE WOODLANDS,TX 77381; BAYLOR COLL MED,CTR BIOTECHNOL,THE WOODLANDS,TX 77381	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine				Zhou, Yunli/0000-0003-4831-209X	NATIONAL CANCER INSTITUTE [R01CA067274] Funding Source: NIH RePORTER; NCI NIH HHS [CA-67274] Funding Source: Medline; NEI NIH HHS [EY-06195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBINI A, 1987, CANCER RES, V47, P3239; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BIGNON YJ, 1993, GENE DEV, V7, P1654, DOI 10.1101/gad.7.9.1654; BROWN PD, 1993, J NATL CANCER I, V85, P574, DOI 10.1093/jnci/85.7.574; Dawson D. W., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P88; FIECK A, 1992, NUCLEIC ACIDS RES, V20, P1785, DOI 10.1093/nar/20.7.1785; Geng Y, 1996, ONCOGENE, V12, P1173; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P3; HART IR, 1978, CANCER RES, V38, P3218; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KARIKO K, 1993, CANCER RES, V53, P3109; KLEIN G, 1990, BIOESSAYS, V12, P347, DOI 10.1002/bies.950120708; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KRATZKE RA, 1993, CELL GROWTH DIFFER, V4, P629; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1980, CANCER LETT, V11, P141, DOI 10.1016/0304-3835(80)90105-6; LU YM, 1994, ONCOGENE, V9, P1015; Lu YM, 1996, J IMMUNOL, V156, P2495; NEVINS JR, 1992, SCIENCE, V258, P424; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; STARKEY JR, 1984, CANCER RES, V44, P1585; TERANOVA VP, 1986, P NATL ACAD SCI USA, V83, P465; XU HJ, 1991, ONCOGENE, V6, P1139; Xu HJ, 1996, CANCER RES, V56, P2245; XU HJ, 1995, ADV ANAT PATHOL, V2, P213; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165	30	39	40	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2379	2386						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957079				2022-12-17	WOS:A1996VX10800010
J	Zabludoff, SD; Wright, WW; Harshman, K; Wold, BJ				Zabludoff, SD; Wright, WW; Harshman, K; Wold, BJ			BRCA1 mRNA is expressed highly during meiosis and spermiogenesis but not during mitosis of male germ cells	ONCOGENE			English	Article						BRCA1; spermatogenesis; meiosis	ADVANCED SPERMATOGENIC CELLS; ANDROGEN-BINDING PROTEIN; RAT TESTIS; TESTOSTERONE CONCENTRATION; QUANTITATIVE RELATIONSHIP; OVARIAN-CANCER; BREAST-CANCER; MESSENGER-RNA; SERTOLI CELLS; ADULT-RAT	The 17q-linked breast and ovarian cancer susceptibility gene (BRCA1) is believed to function as a tumor suppressor gene (Miki et al., 1994). In this report BRCA1 RNA expression has been analysed in adult mouse tissues with detailed attention to its expression in prepuberal and adult testis. Measurements of BRCA1 mRNA levels in highly purified somatic cells of the testis and in staged germ cells showed that high level BRCA1 mRNA expression is limited to the germ cells. Within the germ cell lineage, the high level expression was detected in meiotic cells, specifically pachytene spermatocytes and in post-meiotic round spermatids. This is in contrast to premeiotic germ cells which were found to express little or no BRCA1 mRNA. These observations, considered together with recent data on the expression of BRCA1 in breast epithelium, argues against a function for BRCA1 in early progenitor cells in both tissues and calls attention instead to roles intimately associated with terminal differentiation or with final rounds of cell division.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT POPULAT DYNAM,DIV REPROD BIOL,BALTIMORE,MD 21205; MYRIAD GENET INC,SALT LAKE CITY,UT 84108	Johns Hopkins University; Myriad Genetics, Inc	Zabludoff, SD (corresponding author), CALTECH,DIV BIOL 156 29,PASADENA,CA 91125, USA.				NIAMS NIH HHS [AR 40780, AR 42671] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040780, P01AR042671] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AWONIYI CA, 1989, ENDOCRINOLOGY, V124, P1217, DOI 10.1210/endo-124-3-1217; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BERNDTSON WE, 1974, J ENDOCRINOL, V62, P125, DOI 10.1677/joe.0.0620125; BREMNER WJ, 1994, ENDOCRINOLOGY, V135, P1227, DOI 10.1210/en.135.3.1227; CHAGANTI RSK, 1994, LANCET, V343, P1130, DOI 10.1016/S0140-6736(94)90235-6; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; EASTON DF, 1993, AM J HUM GENET, V52, P678; GERARD A, 1995, J STEROID BIOCHEM, V53, P533, DOI 10.1016/0960-0760(95)00109-D; GERARD H, 1994, ENDOCRINOLOGY, V134, P1515, DOI 10.1210/en.134.3.1515; GOLD B, 1983, DEV BIOL, V98, P392, DOI 10.1016/0012-1606(83)90368-8; GONCZY P, 1994, CELL, V77, P1015, DOI 10.1016/0092-8674(94)90441-3; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; KARZAI AW, 1992, BIOL REPROD, V47, P823, DOI 10.1095/biolreprod47.5.823; KERR JB, 1992, CELL TISSUE RES, V268, P179, DOI 10.1007/BF00338067; KLEENE KC, 1984, DEV BIOL, V105, P71, DOI 10.1016/0012-1606(84)90262-8; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MCLACHLAN RI, 1994, BIOL REPROD, V51, P945, DOI 10.1095/biolreprod51.5.945; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; SHARPER NL, 1990, PNAS, V87, P791; SUN YT, 1989, ENDOCRINOLOGY, V125, P1000, DOI 10.1210/endo-125-2-1000; TAVTIGIAN SV, 1994, MOL BIOL CELL, V5, P375, DOI 10.1091/mbc.5.3.375; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; TUNG PS, 1980, BIOL REPROD, V23, P207, DOI 10.1093/biolreprod/23.1.207; VORNBERGER W, 1994, ENDOCRINOLOGY, V134, P2307, DOI 10.1210/en.134.5.2307; WANG N, 1981, CANCER RES, V41, P2135; ZIRKIN BR, 1989, ENDOCRINOLOGY, V124, P3043, DOI 10.1210/endo-124-6-3043	29	39	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					649	653						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760307				2022-12-17	WOS:A1996VB32800023
J	Payson, RA; Wu, J; Liu, Y; Chiu, IM				Payson, RA; Wu, J; Liu, Y; Chiu, IM			The human FGF-8 gene localizes on chromosome 10q24 and is subjected to induction by androgen in breast cancer cells	ONCOGENE			English	Article						breast cancer; steroid hormone; fibroblast growth factor; cloning; fluorescence in situ hybridization	GROWTH-FACTOR; EXPRESSION; CLONING; MOUSE; TISSUES; FAMILY; ACID	Androgen-induced growth factor (AIGP or FGF-8) was originally isolated from the conditioned medium of an androgen-dependent Shionogi carcinoma, SC-3, cell line, It shares structural similarity with other members of the FGF family, The temporal and spatial expression patterns of the FGF-8 gene suggest its involvement in gastrulation, regionalization of the brain, and organogenesis of the limb and face as an embryonic epithelial factor, In the adult, expression of FGF-8 is restricted to gonads including testes and ovaries, Since FGF-8 is identified as a corroborating gene in MMTV-induced mammary tumors in Wnt-1 transgenic mice and because FGF-8 manifested its autocrine mitogenic activity in SC-3 cells, it is possible that aberrant expression of FGF-8 may be present in human cancers which are hormone dependent. However, very little is known about human FGF-8, To determine whether FGF-8 plays a role in human breast cancer, we have isolated the full-length cDNA from SK-BR-3 breast cancer cells. We have also isolated the corresponding genomic DNA in a P1 cloning vector, The FGF-8 gene has been mapped to chromosome 10q24 using both somatic cell hybrid genetic analysis and fluorescence in situ hybridization. Finally, we show that FGF-8 gene expression in a human breast cancer cell line, MDA-MB-231, is inducible by androgen, The findings presented here will facilitate our understanding of the molecular mechanism underlying hormone-responsive breast and prostate cancers.	OHIO STATE UNIV,DEPT INTERNAL MED,COLUMBUS,OH 43210; OHIO STATE UNIV,CTR COMPREHENS CANC,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University			Chiu, Ing-Ming/B-1534-2008		NATIONAL CANCER INSTITUTE [R01CA045611, K04CA001369] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047506] Funding Source: NIH RePORTER; NCI NIH HHS [K04 CA01369, R01 CA45611] Funding Source: Medline; NIDDK NIH HHS [R01 DK47506] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; HALL RE, 1992, INT J CANCER, V52, P778, DOI 10.1002/ijc.2910520518; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; KOUHARA H, 1994, ONCOGENE, V9, P455; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; LORENZI MV, 1995, ONCOGENE, V10, P2051; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MYERS RL, 1995, ONCOGENE, V11, P785; MYERS RL, 1995, J BIOL CHEM, V270, P8257, DOI 10.1074/jbc.270.14.8257; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PETERS KG, 1992, DEVELOPMENT, V114, P233; POULIN ML, 1993, DEVELOPMENT, V119, P353; POULIN ML, 1995, DEV DYNAM, V202, P378, DOI 10.1002/aja.1002020407; PRIEST JH, 1977, MED CYTOGENETICS CEL; RUOHOLA JK, 1995, ENDOCRINOLOGY, V136, P2179, DOI 10.1210/en.136.5.2179; Sambrook J, 1989, MOL CLONING LAB MANU; SATO B, 1993, J STEROID BIOCHEM, V47, P91, DOI 10.1016/0960-0760(93)90061-Z; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; TABIN C, 1995, CELL, V80, P671, DOI 10.1016/0092-8674(95)90343-7; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; YAMANISHI H, 1995, J STEROID BIOCHEM, V52, P49, DOI 10.1016/0960-0760(94)00148-F; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123	37	39	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					47	53						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700553				2022-12-17	WOS:A1996UX31900006
J	Takahashi, C; Akiyama, N; Matsuzaki, T; Takai, S; Kitayama, H; Noda, M				Takahashi, C; Akiyama, N; Matsuzaki, T; Takai, S; Kitayama, H; Noda, M			Characterization of a human MSX-2 cDNA and its fragment isolated as a transformation suppressor gene against v-Ki-ras oncogene	ONCOGENE			English	Article						MSX-2 homeobox gene; cellular transformation; revertant; ras oncogene; myogenic differentiation; MyoD gene	RETROVIRAL VECTORS; LEUKEMIA-VIRUS; CELL-LINES; EXPRESSION; MOUSE; DNA; FIBROBLASTS; EFFICIENCY; POLYMERASE; MYOGENESIS	A cDNA (termed CT124) encoding a carboxyl-terminal fragment of the human homeobox protein MSX-2 was found to induce flat reversion when expressed in v-Ki-ras-transformed NIH3T3 cells, Although the expression of endogenous MSX-2 gene is low in most of the normal adult tissues examined, it is frequently carcinoma-derived cell Likewise, inactive in NIH3T3 but is transcriptionally activated after transformation v-Ki-ras oncogene, suggesting that the intact MSX-2. may play a positive, rather than suppressive, role in cell transformation, To test this possibility, we isolated a near full-length human and tested its activities in two cell fibroblast and myoblast, In NIH3T3 fibroblasts, although the gene by itself failed to confer a transformed phenotype, antisense MSX-2 cDNA as well as truncated CT124 cDNA interfered with the transforming activities of v-Ki-ras oncogene, In C2C12 myoblasts, MSX-2 was found to suppress MyoD gene expression, as do activated ras oncogenes, under certain culture conditions, and CT124 was found to inhibit the activities of both MSX-2 and ras in this system as well, Our findings not only suggest that CT124 may act as a dominant suppressor of MSX-2 but also raise the possibility that MSX-2 gene may be an important downstream target for the Ras signaling pathways.	KYOTO UNIV,GRAD SCH MED,DEPT MOLEC ONCOL,SAKYO KU,KYOTO 606,JAPAN; JAPANESE FDN CANC RES,INST CANC,DEPT VIRAL ONCOL,TOSHIMA KU,TOKYO 170,JAPAN; INT MED CTR JAPAN,CLIN RES INST,DEPT GENET,SHINJUKU KU,TOKYO 162,JAPAN	Kyoto University; Japanese Foundation for Cancer Research; National Center for Global Health & Medicine - Japan								ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASSIN RH, 1970, INT J CANCER, V6, P95, DOI 10.1002/ijc.2910060114; BOS JL, 1989, CANCER RES, V49, P4682; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COELHO CND, 1991, MECH DEVELOP, V34, P143, DOI 10.1016/0925-4773(91)90051-7; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DAVIDSON D, 1995, TRENDS GENET, V11, P405, DOI 10.1016/S0168-9525(00)89124-6; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; ERLICH HA, 1991, SCIENCE, V252, P1643, DOI 10.1126/science.2047872; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; HOLLAND PWH, 1991, GENE, V98, P253, DOI 10.1016/0378-1119(91)90182-B; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; JOWETT AK, 1993, DEVELOPMENT, V117, P461; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MONAGHAN AP, 1991, DEVELOPMENT, V112, P1053; MONTARRAS D, 1991, NEW BIOL, V3, P592; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; MYERS TW, 1991, BIOCHEMISTRY-US, V30, P7661, DOI 10.1021/bi00245a001; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; NOSA M, 1993, FASEB J, V7, P834; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; Sambrook J, 1989, MOL CLONING LAB MANU; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SONG KN, 1992, NATURE, V360, P477, DOI 10.1038/360477a0; SUZUKI M, 1993, BIOCHEM BIOPH RES CO, V194, P187, DOI 10.1006/bbrc.1993.1802; TAKAI S, 1994, HUM GENET, V93, P198; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/0092-8674(93)90678-J; VALENZUELA DM, 1986, NUCLEIC ACIDS RES, V14, P843, DOI 10.1093/nar/14.2.843; WANG YQ, 1995, DEV BIOL, V168, P374, DOI 10.1006/dbio.1995.1087; WOLOSHIN P, 1995, CELL, V82, P611, DOI 10.1016/0092-8674(95)90033-0; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	45	39	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2137	2146						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668339				2022-12-17	WOS:A1996UP28300012
J	Luber, B; Arnold, N; Sturzl, M; Hohne, M; Schirmacher, P; Lauer, U; Wienberg, J; Hofschneider, PH; Kekule, AS				Luber, B; Arnold, N; Sturzl, M; Hohne, M; Schirmacher, P; Lauer, U; Wienberg, J; Hofschneider, PH; Kekule, AS			Hepatoma-derived integrated HBV DNA causes multi-stage transformation in vitro	ONCOGENE			English	Article						hepatitis B virus; X gene; liver carcinogenesis; incomplete oncogenes; transactivation	B VIRUS-DNA; HUMAN HEPATOCELLULAR-CARCINOMA; WOODCHUCK LIVER-TUMORS; X-GENE; INSITU HYBRIDIZATION; CELL-LINES; T-ANTIGEN; TRANSACTIVATOR; EXPRESSION; MECHANISMS	The hepatoma-derived hepatitis B virus (HBV) DNA insert HU-a has recently been shown to contain two viral transactivator genes, X and preS2/S-t, We report here that HU-a induces malignant transformation after stable transfection of the fetal mouse hepatocyte line FMH202, as indicated by soft agar growth and nude mouse tumorigenicity, Transfections with HU-a subclones, containing the X gene or the preS2/S-t gene alone or sequences without transactivator gene, respectively, suggested that the X gene is essential for transformation, Sequential stages of transformation and tumor progression were analysed by injection of the stably transfected FMH202 lines into nude mice, explantation of the resulting tumors and re-establishment of cell lines from the tumors, Comparison of two HU-a-transformed cell lines by HBV mRNA hybridization, Southern analysis and chromosomal in situ hybridization revealed that integrated HBV DNAs were involved in major chromosomal rearrangements in both cases, Interestingly, recombination of the HBV DNA insert during the nude mouse passage had completely abolished HBV-specific transcription in one case, indicating that expression of integrated HBV genes, while presumably involved in early transformation, is dispensable at later stages of tumor progression, The sequential transformation observed in this experimental system suggests that expression of the X gene by integrated viral DNA and subsequent hepatocyte genome mutations might both contribute to HBV-associated liver carcinogenesis.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; INST ANTHROPOL & HUMAN GENET,D-80333 MUNICH,GERMANY; INST MED VIROL,D-35392 GIESSEN,GERMANY; INST PATHOL,D-55131 MAINZ,GERMANY	Max Planck Society			Arnold, Norbert/E-3012-2010; Stürzl, Michael/B-3019-2015	Arnold, Norbert/0000-0003-4523-8808; Stürzl, Michael/0000-0002-9276-2824				ARNOLD N, 1992, BIOTECH HISTOCHEM, V67, P59, DOI 10.3109/10520299209110009; BALSANO C, 1991, BIOCHEM BIOPH RES CO, V176, P985, DOI 10.1016/0006-291X(91)90379-L; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BRECHOT C, 1987, J HEPATOL, V4, P269, DOI 10.1016/S0168-8278(87)80090-9; BREIVIK J, 1994, BRIT J CANCER, V69, P367, DOI 10.1038/bjc.1994.67; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; CASELMANN WH, 1990, P NATL ACAD SCI USA, V87, P2970, DOI 10.1073/pnas.87.8.2970; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DIAMANTIS ID, 1992, J HEPATOL, V15, P400, DOI 10.1016/0168-8278(92)90077-3; FANNING E, 1992, MALIGNANT TRANSFORMA, P1; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; FUJIYAMA A, 1983, NUCLEIC ACIDS RES, V11, P4601, DOI 10.1093/nar/11.13.4601; GRAEF E, 1994, ONCOGENE, V9, P81; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HILGER C, 1991, J VIROL, V65, P4284, DOI 10.1128/JVI.65.8.4284-4291.1991; HINO O, 1991, P NATL ACAD SCI USA, V88, P9248, DOI 10.1073/pnas.88.20.9248; HINO O, 1989, J VIROL, V63, P2638, DOI 10.1128/JVI.63.6.2638-2643.1989; HOFFMANN B, 1989, J CELL PHYSIOL, V139, P654, DOI 10.1002/jcp.1041390328; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HUH N, 1981, GANN, V72, P178; KEKULE A, 1994, PRIMARY LIVER CANC E, P191; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; KOCH S, 1984, EMBO J, V3, P2185, DOI 10.1002/j.1460-2075.1984.tb02111.x; KOIKE K, 1994, J CLIN INVEST, V94, P44, DOI 10.1172/JCI117343; MARTIN RG, 1979, J VIROL, V31, P596, DOI 10.1128/JVI.31.3.596-607.1979; MATSUBARA K, 1991, MOL BIOL HEPATITIS B; MEYER M, 1992, HEPATOLOGY, V15, P665, DOI 10.1002/hep.1840150419; PAUL D, 1988, EXP CELL RES, V175, P354, DOI 10.1016/0014-4827(88)90199-1; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; RENNER M, 1995, J HEPATOL, V23, P53, DOI 10.1016/0168-8278(95)80311-4; RIED T, 1992, P NATL ACAD SCI USA, V89, P1388, DOI 10.1073/pnas.89.4.1388; RIED T, 1993, GENOMICS, V18, P381, DOI 10.1006/geno.1993.1479; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; Sambrook J., 1989, MOL CLONING; SCHLUTER V, 1994, ONCOGENE, V9, P3335; SEIFER M, 1991, J HEPATOL, V13, pS61, DOI 10.1016/0168-8278(91)90026-8; SETO E, 1991, J VIROL, V65, P2351, DOI 10.1128/JVI.65.5.2351-2356.1991; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; STURZL M, 1992, P NATL ACAD SCI USA, V89, P7046, DOI 10.1073/pnas.89.15.7046; TUCKER RW, 1977, CANCER RES, V37, P1571; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; WANG J, 1992, ONCOGENE, V7, P1653; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG WL, 1991, CANCER RES, V51, P4971; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WEI Y, 1992, J VIROL, V66, P5265, DOI 10.1128/JVI.66.9.5265-5276.1992; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	54	39	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1597	1608						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622879				2022-12-17	WOS:A1996UG45800001
J	Michieli, P; Li, WQ; Lorenzi, MV; Miki, T; Zakut, R; Givol, D; Pierce, JH				Michieli, P; Li, WQ; Lorenzi, MV; Miki, T; Zakut, R; Givol, D; Pierce, JH			Inhibition of oncogene-mediated transformation by ectopic expression of p21(Waf1) in NIH3T3 cells	ONCOGENE			English	Article						cellular transformation; oncogenes; tumor suppressor genes; p53 effectors; cyclin-dependent kinase inhibitors	PROTEIN; FIBROBLASTS; RAS; P21; DIFFERENTIATION; LOCALIZATION; KINASES; P53	The p53-regulated p21(Waf1) protein is a universal inhibitor of cyclin-dependent kinases (CDKs). To study the potential tumor-suppressive properties of CDK inhibitors, the ability of p21(Waf1) to interfere with oncogene-mediated cellular transformation was analysed in the NIH3T3 cell system. Cotransfection of waf1 together with activated ras or several other oncogenes into NIH3T3 cells potently inhibited the formation of transformed foci in a dose-dependent manner, Expression of the CDK-binding N-terminal half of p21(Waf1) (N-p21(Waf1)) was necessary and sufficient to inhibit Ras-induced focus formation. In contrast, expression of the C-terminal domain (C-p21(Waf1)) had no effect on Ras-induced focus formation. Immunofluorescence analysis revealed that ectopically expressed p21(Waf1) and C-p21(Waf1) were localized in the nucleus, while N-p21(Waf1) was found in the cytoplasm, with the tendency to accumulate around the nuclear membrane. Surprisingly, stable NIH3T3 transfectants expressing ectopic p21(Waf1) grew at the same rate and displayed similar cell cycle distribution as NIH3T3 cells transfected with the same vector containing no insert. However ectopic p21(Waf1) expression did inhibit Ras-mediated anchorage-independent colony formation, indicating that p21(Waf1) can selectively interfere with oncogene-mediated transformation without affecting NIH3T3 cell growth, at least at the levels of p21(Waf1) expression experiments. Transient NIH3T3 cells inhibited Ras-indnced transcription from a E2F-responsive element but not from a serum-responsive element, indicating that p21(Waf1) acts downstream of early transcriptional events induced by Ras but upstream of E2F-controlled gene transcription. These results provide evidence that p21(Waf1) potently suppresses oncogene-mediated cellular transformation of NIH3T3 cells and that it may do so by inhibiting E2F-driven transcription of S phase genes.	WEIZMANN INST SCI,DEPT MOLEC CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science	Michieli, P (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,NIH,BLDG 37,BETHESDA,MD 20892, USA.		Michieli, Paolo/A-2588-2011	Michieli, Paolo/0000-0002-3093-8871				ATADJA PW, 1994, MOL CELL BIOL, V14, P4991, DOI 10.1128/MCB.14.7.4991; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BLAM SB, 1988, ONCOGENE, V3, P129; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEDID M, 1994, ONCOGENE, V9, P3021; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CUADRADO A, 1993, ONCOGENE, V8, P2443; CURRAN T, 1984, CELL, V36, P259; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; GRANA X, 1995, ONCOGENE, V11, P211; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JIANG HP, 1994, ONCOGENE, V9, P3397; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MICHIELI P, 1994, CANCER RES, V54, P3391; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NEVINS JR, 1992, SCIENCE, V258, P424; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAKUT R, 1995, ONCOGENE, V11, P393; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	49	39	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					775	784						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632899				2022-12-17	WOS:A1996TW68600008
J	Kamps, MP; Wright, DD; Lu, Q				Kamps, MP; Wright, DD; Lu, Q			DNA-binding by oncoprotein E2A-Pbx1 is important for blocking differentiation but dispensable for fibroblast transformation	ONCOGENE			English	Article						E2A-Pbx1; oncoprotein; differentiation; leukemia	PRE-B; MAMMALIAN-CELLS; TRANSLOCATION PROTEIN; CRYSTAL-STRUCTURE; HOMEOBOX GENES; LEUKEMIA; MICE; COMPLEX; DOMAIN; PBX1	The t(1;19) chromosomal translocation of pediatric pre-B cell lymphoblastic leukemia produces the E2A-PBX1 oncogene, which can transform fibroblasts, induce acute myeloid leukemia and T cell lymphomas in mice, and immortalize factor-dependent myeloid progenitors in cultured marrow. The homeodomain of Pbx1 binds ATCAATCAA, and while Pbx1 does not activate transcription through this motif, E2A-Pbx1 induces constitutive transactivation. Here, we investigate whether DNA-binding by Pbx1 or transcriptional activation by E2A are essential for the transforming abilities off E2A-Pbx1. Elimination of DNA-binding in E2A-Pbx1 by point mutations in the Pbx1 homeodomain or by large deletions that removed the Pbx1 homeodomain and carboxyl terminus did not alter ability of E2A-Pbx1 to induce focus-formation in fibroblast, even though these mutations completely eliminated its ability to activate transcription through the PRS. These same DNA-binding mutations, however, severely impaired or eliminated the ability of E2A-Pbx1 to immortalize factor-dependent myeloid progenitors in marrow cultures. Elimination of the first transcriptional activation domain of E2A abolished both fibroblast and myeloid transforming activities while elimination of the second altered neither of these activities. We conclude that DNA-binding is important for the ability of E2A-Pbx1 to disrupt differentiation, as evidenced in myeloblast immortalization, but dispensable for its ability to induce focus-formation, and that the aminoterminal domain of E2A, which strongly activates transcription, is essential for both transforming activities.	UNIV CALIF SAN DIEGO,SCH MED,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego	Kamps, MP (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT PATHOL,9500 GILMAN DR,LA JOLLA,CA 92093, USA.				NATIONAL CANCER INSTITUTE [R01CA056876] Funding Source: NIH RePORTER; NCI NIH HHS [5 RO1 CA56876] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; CARROLL A, 1984, BLOOD, V63, P716; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; FITZPATRICK VD, 1992, NATURE, V356, P610, DOI 10.1038/356610a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAMPS MP, 1994, ONCOGENE, V9, P3159; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; LU Q, 1996, IN PRESS P NATL ACAD; LU QA, 1995, MOL CELL BIOL, V15, P3786; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PEERS B, 1995, UNPUB; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VERSHON AK, 1995, GENE DEV, V9, P182, DOI 10.1101/gad.9.2.182; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5	32	39	39	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					19	30						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552391				2022-12-17	WOS:A1996TQ01400003
J	Casares, S; Ionov, Y; Ge, HY; Stanbridge, E; Perucho, M				Casares, S; Ionov, Y; Ge, HY; Stanbridge, E; Perucho, M			The microsatellite mutator phenotype of colon cancer cells is often recessive	ONCOGENE			English	Article						mutator mutations; genomic instability; microsatellites; somatic cell hybrids	COLORECTAL-CANCER; MISMATCH REPAIR; GENETIC INSTABILITY; CHAIN-REACTION; DNA; MUTATIONS; CARCINOMA; CARCINOGENESIS; SEQUENCES; HISTORY	A new mutator mechanism for tumorigenesis, characterized by somatic genomic instability (SGI) at simple repeated sequences (SRS) or microsatellites, underlies hereditary nonpolyposis colorectal cancer (HNPCC) and some sporadic tumors of the colon and other types, To determine whether the microsatellite mutator phenotype (MMP) is dominant or recessive, we generated somatic cell hybrids between a tumor cell line without SGI at SRS (D98OR) and colon carcinoma cell lines with relative low (HCT-15) and high (LS174-T) SGI at SRS, The normal fidelity of replication of these unstable sequences was observed in each of these cell hybrids, Fusion of HCT-1S/DLD-1 low instability cells, with LS174-T, HCT116 and LoVo cell Lines, all exhibiting relative high instability, also restored the replication fidelity of SRS in all of the hybrids, Hybrids between the high instability cell lines did not grow possibly because of senescence or apoptosis, These results indicate that, in the cell lines analysed, the characterized mutator phenotype of the mismatch repair system resulting in high SGI at SRS, and the uncharacterized mutator phenotype underlying low SGI at SRS, are both recessive, The results also suggest that different tumor cells of the MMP harbor distinct altered growth-related genes.	CALIF INST BIOL RES,LA JOLLA,CA 92037; UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine				Perucho, Manuel/0000-0002-2169-2662				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRANCH P, 1995, NAT GENET, V9, P232; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BURKS RT, 1994, ONCOGENE, V9, P1163; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; HAN HJ, 1993, CANCER RES, V53, P5087; HEARNE CM, 1992, TRENDS GENET, V8, P288, DOI 10.1016/0168-9525(92)90256-4; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KAHN SM, 1995, CARCINOGENESIS, V16, P1223, DOI 10.1093/carcin/16.5.1223; KNUDSON AG, 1985, CANCER RES, V45, P1437; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOI M, 1994, CANCER RES, V54, P4308; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOEB LA, 1991, CANCER RES, V51, P3075; LOEB LA, 1974, CANCER RES, V34, P2311; LOTHE RA, 1993, CANCER RES, V53, P5849; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PEINADO MA, 1993, INT J ONCOL, V2, P123; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1993, CANCER RES, V53, P5853; REENAN RAG, 1992, GENETICS, V132, P963; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; Saxon P J, 1987, Methods Enzymol, V151, P313, DOI 10.1016/S0076-6879(87)51026-6; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; WEISSMAN B, 1980, CYTOGENET CELL GENET, V28, P227, DOI 10.1159/000131536; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YEE CJ, 1994, CANCER RES, V54, P1641	51	39	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2303	2310						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570181				2022-12-17	WOS:A1995TK70200014
J	BATTISTA, S; MARTELLI, ML; FEDELE, M; CHIAPPETTA, G; TRAPASSO, F; DEVITA, G; BATTAGLIA, C; SANTORO, M; VIGLIETTO, G; FAGIN, JA; FUSCO, A				BATTISTA, S; MARTELLI, ML; FEDELE, M; CHIAPPETTA, G; TRAPASSO, F; DEVITA, G; BATTAGLIA, C; SANTORO, M; VIGLIETTO, G; FAGIN, JA; FUSCO, A			A MUTATED P53 GENE ALTERS THYROID-CELL DIFFERENTIATION	ONCOGENE			English	Article						P53; THYROID; DIFFERENTIATION	WILD-TYPE P53; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; THYROGLOBULIN PROMOTER; THYROTROPIN RECEPTOR; MAMMALIAN-CELLS; MESSENGER-RNA; DNA-BINDING; EXPRESSION; MUTATIONS	p53 is the gene most frequently found mutated in human neoplasias. In the majority of tumors, p53 mutations contribute to the progression towards stages of increasing malignancy with the appearance of an undifferentiated phenotype. Also in thyroid cancerogenesis, p53 mutations correlate with the loss of the differentiated phenotype. The results presented here, suggest a direct involvement of p53 in the molecular mechanisms regulating cellular differentiation in thyroid since a mutated p53 gene markedly affects the growth potential and differentiated functions of the rat thyroid cell line PC Cl 3. Blockage in the expression of the PAX-8 transcription factor seems to be a key event in the loss of thyroid differentiated functions induced by the mutated p53 gene. Thyroid cells carrying a mutated p53 gene did not form colonies in soft agar or tumors in athymic mice, suggesting that a mutation of the p53 gene is not sufficient for the induction of the malignant phenotype and probably a cooperation with other oncogenes is necessary to accomplish full malignancy. No effect on either growth or differentiation of thyroid cells was exerted either by overexpression of the wild-type p53 gene, or by the vector alone.	UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY; FDN PASCALE,IST NAZL TUMORI,I-80131 NAPLES,ITALY; UNIV NAPLES,FAC MED & CHIRURG NAPOLI,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,CNR,I-80131 NAPLES,ITALY; UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DIV ENDOCRINOL,LOS ANGELES,CA 90048	Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; IRCCS Fondazione Pascale; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Viglietto, Giuseppe/AAC-2852-2019; De Vita, Gabriella/H-4422-2011; Fedele, Monica/C-1417-2015; Battista, Sabrina/AAY-2981-2020	Viglietto, Giuseppe/0000-0003-2327-7515; De Vita, Gabriella/0000-0002-7302-1174; Fedele, Monica/0000-0002-9171-1312; Battista, Sabrina/0000-0001-5899-9759; Fusco, Alfredo/0000-0003-3332-5197				AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AVVEDIMENTO EV, 1989, CELL, V58, P1135, DOI 10.1016/0092-8674(89)90511-4; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; AVVEDIMENTO VE, 1988, P NATL ACAD SCI USA, V85, P1744, DOI 10.1073/pnas.85.6.1744; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARTEK J, 1990, ONCOGENE, V5, P893; BERLINGIERI MT, 1990, BIOCHEM BIOPH RES CO, V173, P172, DOI 10.1016/S0006-291X(05)81037-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DILAURO R, 1982, GENE, V19, P117, DOI 10.1016/0378-1119(82)90196-2; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DOBASHI Y, 1993, AM J SURG PATHOL, V14, P375; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; FUSCO A, 1981, CANCER RES, V42, P618; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ITO T, 1992, CANCER RES, V52, P1369; KERN SE, 1991, ONCOGENE, V6, P131; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LI FP, 1988, CANCER RES, V48, P5358; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MUSTI AM, 1987, NUCLEIC ACIDS RES, V15, P8149, DOI 10.1093/nar/15.20.8149; NAKAMURA T, 1992, JPN J CANCER RES, V83, P1293, DOI 10.1111/j.1349-7006.1992.tb02761.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Sambrook J., 1989, MOL CLONING LAB MANU; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SODDU S, 1994, BLOOD, V83, P2230, DOI 10.1182/blood.V83.8.2230.bloodjournal8382230; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WRIGHT PA, 1991, ONCOGENE, V6, P1693; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; ZARRILLI R, 1990, MOL ENDOCRINOL, V4, P39, DOI 10.1210/mend-4-1-39; ZHANG W, 1993, ONCOGENE, V8, P2555	55	39	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2029	2037						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478522				2022-12-17	WOS:A1995TF29700013
J	DARVILLE, MI; ANTOINE, IV; MERTENSSTRIJTHAGEN, JR; DUPRIEZ, VJ; ROUSSEAU, GG				DARVILLE, MI; ANTOINE, IV; MERTENSSTRIJTHAGEN, JR; DUPRIEZ, VJ; ROUSSEAU, GG			AN E2F-DEPENDENT LATE-SERUM-RESPONSE PROMOTER IN A GENE THAT CONTROLS GLYCOLYSIS	ONCOGENE			English	Article						CELL CYCLE; E2F; FRUCTOSE-2,6-BISPHOSPHATE; GLYCOLYSIS; SRC; ETS	TRANSCRIPTION FACTOR E2F; EPIDERMAL GROWTH-FACTOR; THYMIDINE KINASE; MESSENGER-RNA; 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; CELL-PROLIFERATION; BINDING-SITE; STIMULATION; ASSOCIATION; FIBROBLASTS	The F-type mRNA of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase is found in proliferating, but not in quiescent, cells. This bifunctional enzyme catalyses the synthesis and degradation of fructose-2,6-bisphosphate, a potent stimulator of glycolysis. F-type mRNA concentration decreased upon differentiation of rat rhabdomyosarcoma cells; it increased in Rat-1. fibroblasts stimulated to proliferate by serum, by epidermal growth factor, or by the v-src oncogene product. This increase resulted, at least in part, from a stimulation of F promoter activity. The stimulation occurred at the G(1)/S transition of the cell cycle. It depended on a binding site for the oncogenic transcription factor E2F located in the first exon of F-type mRNA, This effect was inhibited by agents that increase cAMP concentration. The data provide the first evidence that a gene involved in the control of glycolysis can be regulated by a late-serum-response promoter in an E2F-dependent way.	UNIV LOUVAIN,SCH MED,HORMONE & METAB RES UNIT,B-1200 BRUSSELS,BELGIUM; INT INST CELLULAR & MOLEC PATHOL,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel								BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DARVILLE MI, 1989, P NATL ACAD SCI USA, V86, P6543, DOI 10.1073/pnas.86.17.6543; DARVILLE MI, 1992, NUCLEIC ACIDS RES, V20, P3575, DOI 10.1093/nar/20.14.3575; DIAMOND I, 1978, J BIOL CHEM, V253, P866; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; DUPRIEZ VJ, 1993, P NATL ACAD SCI USA, V90, P8224, DOI 10.1073/pnas.90.17.8224; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EIGENBRODT E, 1985, REGULATION CARBOHYDR, V2, P141; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GAUTRON S, 1991, NUCLEIC ACIDS RES, V19, P767, DOI 10.1093/nar/19.4.767; GERHARZ CD, 1989, CANCER RES, V49, P7132; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HUE L, 1993, ADV ENZYME REGUL, V33, P97; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; MARCHAND MJ, 1992, BIOCHEM J, V285, P413, DOI 10.1042/bj2850413; MATRISIAN LM, 1985, NUCLEIC ACIDS RES, V13, P711, DOI 10.1093/nar/13.3.711; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MEIENHOFER MC, 1983, BIOCHEM J, V214, P195, DOI 10.1042/bj2140195; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PEPPEL K, 1990, BIOTECHNIQUES, V9, P711; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; REICHEL R, 1987, CELL, V48, P501, DOI 10.1016/0092-8674(87)90200-5; ROUSSEAU GG, 1993, PROG NUCLEIC ACID RE, V45, P99, DOI 10.1016/S0079-6603(08)60868-5; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; WEINHOUSE S, 1976, Z KREBSFORSCH KLIN O, V87, P115; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357	47	39	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1509	1517						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478575				2022-12-17	WOS:A1995TC53500009
J	RIESE, DJ; DIMAIO, D				RIESE, DJ; DIMAIO, D			AN INTACT PDGF SIGNALING PATHWAY IS REQUIRED FOR EFFICIENT GROWTH TRANSFORMATION OF MOUSE C127 CELLS BY THE BOVINE PAPILLOMAVIRUS E5 PROTEIN	ONCOGENE			English	Article						VIRAL ONCOGENE; PDGF RECEPTOR; GROWTH FACTOR RECEPTORS	EARLY REGION TRANSFORMATION; OPEN READING FRAME; FACTOR RECEPTOR; TUMORIGENIC TRANSFORMATION; MORPHOLOGIC TRANSFORMATION; DNA-SYNTHESIS; AMINO-ACIDS; GENE; TYPE-1; VIRUS	The bovine papillomavirus type 1 (BPV) E5 protein is a 44 amino acid, membrane-associated protein that induces growth transformation of cultured rodent and;bovine fibroblasts. In transformed fibroblasts, the BPV E5 protein activates the endogenous platelet-derived growth factor (PDGF) beta receptor, and the introduction of the PDGF beta receptor gene into heterologous cell types normally lacking PDGF beta receptor expression permits transformation by the E5 protein. However, neither the endogenous PDGF beta receptor nor its signaling pathway has been shown to be required for efficient growth transformation of fibroblasts by the BPV E5 gene. Here we have tested whether the endogenous PDGF beta receptor serves as a target for the BPV E5 protein in mouse C127 fibroblasts. We isolated variant C127 cell Lines that displayed reduced DNA synthesis in response to PDGF but a normal response to other mitogens, suggesting that they harbor specific defects in the PDGF signaling pathway. The variant lines also exhibited a specific reduction in the level of DNA synthesis induced by the acute expression of the BPV E5 gene, and a variant cell line containing a reduced level of PDGF beta receptor also displayed reduced stable growth transformation by the BPV E5 and v-sis oncogenes. These results provide genetic support for the model that the PDGF beta receptor signaling pathway is required for efficient growth transformation of C127 cells by the BPV E5 gene.	YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA	Yale University			Riese, David/AAF-3581-2020	Riese, David/0000-0002-8823-5802	NCI NIH HHS [CA37157, CA16038] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037157, R37CA037157, P01CA016038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGMAN P, 1988, ONCOGENE, V2, P453; BERNARD HU, 1985, EXP CELL RES, V158, P237, DOI 10.1016/0014-4827(85)90446-X; BURKHARDT A, 1987, EMBO J, V6, P2381, DOI 10.1002/j.1460-2075.1987.tb02515.x; COHEN BD, 1993, MOL CELL BIOL, V13, P6462, DOI 10.1128/MCB.13.10.6462; COHEN BD, 1993, J VIROL, V67, P5303, DOI 10.1128/JVI.67.9.5303-5311.1993; CUADRADO A, 1990, CELL GROWTH DIFFER, V1, P9; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DIMAIO D, 1991, ADV CANCER RES, V56, P133; DOTTO GP, 1985, NATURE, V318, P472; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOLDSTEIN DJ, 1994, J VIROL, V68, P4432, DOI 10.1128/JVI.68.7.4432-4441.1994; GROFF DE, 1986, VIROLOGY, V150, P221, DOI 10.1016/0042-6822(86)90281-3; HORWITZ BH, 1989, J VIROL, V63, P4515, DOI 10.1128/JVI.63.11.4515-4519.1989; HORWITZ BH, 1988, MOL CELL BIOL, V8, P4071, DOI 10.1128/MCB.8.10.4071; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KULKE R, 1991, J VIROL, V65, P4943, DOI 10.1128/JVI.65.9.4943-4949.1991; KULKE R, 1992, J VIROL, V66, P505, DOI 10.1128/JVI.66.1.505-511.1992; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; LEPTAK C, 1992, J VIROL, V66, P1833; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MEYER AN, 1994, P NATL ACAD SCI USA, V91, P4634, DOI 10.1073/pnas.91.11.4634; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; PETTI L, 1991, ORIGINS OF HUMAN CANCER, P707; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; RABSON MS, 1986, J VIROL, V60, P626, DOI 10.1128/JVI.60.2.626-634.1986; SCHILLER JT, 1986, J VIROL, V57, P1; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SEFTON BM, 1978, J VIROL, V28, P957, DOI 10.1128/JVI.28.3.957-971.1978; SETTLEMAN J, 1989, MOL CELL BIOL, V9, P5563, DOI 10.1128/MCB.9.12.5563; SETTLEMAN J, 1988, P NATL ACAD SCI USA, V85, P9007, DOI 10.1073/pnas.85.23.9007; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STETTEN G, 1977, EXP CELL RES, V108, P447, DOI 10.1016/S0014-4827(77)80055-4; WATERS CM, 1992, J CELL PHYSIOL, V152, P253, DOI 10.1002/jcp.1041520206; YANG YC, 1985, NATURE, V318, P575, DOI 10.1038/318575a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; Zar JH, 1999, BIOSTAT ANAL, V4th	48	39	40	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1431	1439						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731695				2022-12-17	WOS:A1995QR65100022
J	CARRASCO, D; BRAVO, R				CARRASCO, D; BRAVO, R			TISSUE-SPECIFIC EXPRESSION OF THE FOS-RELATED TRANSCRIPTION FACTOR FRA-2 DURING MOUSE DEVELOPMENT	ONCOGENE			English	Article						FRA-2 EXPRESSION; DEVELOPMENT; JUN AND FOS EXPRESSION	C-JUN; DNA-BINDING; NEGATIVE REGULATOR; GENE-EXPRESSION; CARCINOMA-CELLS; GROWTH-FACTORS; NULL MUTATION; FACTOR AP-1; PROTEINS; COMPLEXES	The fra-2 gene is related to the proto-oncogene c-fos and encodes a member of the AP-1 transcription factor gene family. We have studied the expression of fra-2 during mouse embryonic development and compared it to the pattern of expression of other fos and jun family members. By in situ hybridization and immunohistochemical analysis we have shown fra-2 expression during late organogenesis. fra-2 transcripts are detected in several differentiating epithelia, developing cartilage and central nervous system. The pattern of fra-2 expression is distinct from that observed for other fos related genes, suggesting that fra-2 has a unique role in cellular differentiation during fetal development.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543	Bristol-Myers Squibb								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUFDERHEIDE E, 1987, J CELL BIOL, V15, P599; CARRASCO D, 1994, DEVELOPMENT, V120, P2991; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; CARRASCO D, 1994, CELL BIOL LABORATORY, P466; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; FISHER C, 1991, DEVELOPMENT, V111, P253; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1988, TRENDS GENET, V4, P272; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MATSUI M, 1990, ONCOGENE, V5, P249; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OKADA S, 1994, MOL CELL BIOL, V14, P382, DOI 10.1128/MCB.14.1.382; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; PARAKKAL PF, 1967, AM J ANAT, V121, P175, DOI 10.1002/aja.1001210202; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; REDEMANNFIBI B, 1991, DIFFERENTIATION, V46, P43, DOI 10.1111/j.1432-0436.1991.tb00864.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1991, ONCOGENE, V6, P533; RYSECK RP, 1988, NATURE, V334, P532; SANDBERG M, 1988, DEVELOPMENT, V102, P461; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SUZUKI T, 1992, NUCLEIC ACIDS RES, V19, P5537; TELFORD NA, 1990, MOL REPROD DEV, V27, P81, DOI 10.1002/mrd.1080270202; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	49	39	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1069	1079						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700631				2022-12-17	WOS:A1995QN35300006
J	BORG, JP; DELAPEYRIERE, O; NOGUCHI, T; ROTTAPEL, R; DUBREUIL, P; BIRNBAUM, D				BORG, JP; DELAPEYRIERE, O; NOGUCHI, T; ROTTAPEL, R; DUBREUIL, P; BIRNBAUM, D			BIOCHEMICAL-CHARACTERIZATION OF 2 ISOFORMS OF FLT4, A VEGF RECEPTOR-RELATED TYROSINE KINASE	ONCOGENE			English	Article						ANGIOGENESIS; ENDOTHELIUM; CYTOPLASMIC SUBSTRATES; FLT1; FLK1; KDR; FLT4; IN SITU HYBRIDIZATION; ONCOGENE; VEGF; TYROSINE KINASE; RECEPTORS	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; SIGNAL TRANSDUCTION; MOUSE DEVELOPMENT; FMS PROTEIN; CELL-LINES; EXPRESSION; FAMILY; INVIVO; CDNA	The FLT4 gene encodes a tyrosine kinase receptor related to the two identified receptors for vascular endothelial growth factor (VEGF), FLT1 and FLK1/KDR. Two isoforms of FLT4, differing by their C-terminal ends, have been identified. The long form has 65 additional amino acid residues. We have shown that FLT4 is a highly glycosylated, relatively stable, cell surface associated kinase of approximately 180 kDa. In order to study the signal transduction molecules associated with the FLT4 pathway, and in the absence of a known ligand, we constructed two chimeric molecules (FF4S and FF4L) made of the extracellular region of the CSF1 receptor (Fms gene product) and of the transmembrane and intracellular regions of either form of FLT4. These two chimeric forms were expressed in Rat 2 transfectants. We assayed the ligand-induced capacity of the FF4 short and long forms to sustain growth of Rat 2 cells in semisolid medium. In a soft agar assay, only the long form was able to induce the growth of Rat 2 cells upon ligand treatment. The two forms of FLT4 therefore have different functional capacities. We looked for association and/or phosphorylation of phospholipase C gamma (PLC gamma) and phosphatidylinositol-3'-phosphate (PI3K), after stimulation of the FF4 molecules by CSF1. Finally, we have studied the expression of the Flt4 gene in mouse embryos and in the adult by in situ hybridization. Flt4 transcripts were found at day 12.5 post-coitum and thereafter, including the adult mouse, predominantly in the pericardium, pleural membranes and in the lung.	INSERM,U119,ONCOL LAB,F-13009 MARSEILLE,FRANCE; WELLESLEY COLL HOSP,RES INST,TORONTO,ON,CANADA; INSERM,U119,HEMATOL FONCT & MOLEC LAB,F-13009 MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Institut National de la Sante et de la Recherche Medicale (Inserm)			Dubreuil, Patrice/V-4816-2019; dubreuil, patrice/F-5346-2011; Borg, Jean-Paul/AAX-8096-2020	Dubreuil, Patrice/0000-0003-1155-1150; dubreuil, patrice/0000-0003-1155-1150; Borg, Jean-Paul/0000-0001-8418-3382; Rottapel, Robert/0000-0002-6024-5558; Birnbaum, Daniel/0000-0001-7920-9883				BROWN LF, 1993, AM J PATHOL, V143, P1255; BROWN LF, 1993, CANCER RES, V53, P4727; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAO Y, 1990, Technique (Philadelphia), V2, P109; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DELAPEYRIERE O, 1993, DEVELOPMENT, V118, P601; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; EICHMANN A, 1993, MECH DEVELOP, V42, P33, DOI 10.1016/0925-4773(93)90096-G; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FINNERTY H, 1993, ONCOGENE, V8, P2293; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GALLAND F, 1993, ONCOGENE, V8, P1233; GALLAND F, 1992, GENOMICS, V13, P475, DOI 10.1016/0888-7543(92)90277-Y; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; IHLE J, 1994, ITBC, V19, P222; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; KORHONEN J, 1994, ONCOGENE, V9, P395; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MAROC N, 1993, ONCOGENE, V8, P909; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1993, NATURE, V367, P576; OELRICHS RB, 1993, ONCOGENE, V8, P11; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PEBUSQUE MJ, 1993, GENE CHROMOSOME CANC, V8, P119, DOI 10.1002/gcc.2870080209; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROSNET O, 1993, CRIT REV ONCOGENESIS, V4, P595; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROTTAPEL R, 1994, ONCOGENE, V9, P1755; SARZANI R, 1992, BIOCHEM BIOPH RES CO, V186, P706, DOI 10.1016/0006-291X(92)90804-T; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; SHIBUYA M, 1990, ONCOGENE, V5, P519; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STANTON B, 1989, THESIS U MARYLAND BA; TAYLOR GR, 1989, EMBO J, V8, P2029, DOI 10.1002/j.1460-2075.1989.tb03611.x; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; WILKS AF, 1993, ADV CANCER RES, V60, P43; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489	62	39	53	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					973	984						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898938				2022-12-17	WOS:A1995QL03800019
J	RUVEN, HJT; SEELEN, CMJ; LOHMAN, PHM; VANKRANEN, H; VANZEELAND, AA; MULLENDERS, LHF				RUVEN, HJT; SEELEN, CMJ; LOHMAN, PHM; VANKRANEN, H; VANZEELAND, AA; MULLENDERS, LHF			STRAND-SPECIFIC REMOVAL OF CYCLOBUTANE PYRIMIDINE DIMERS FROM THE P53 GENE IN THE EPIDERMIS OF UVB-IRRADIATED HAIRLESS MICE	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMAS; GROUP-C FIBROBLASTS; DNA-REPAIR; ULTRAVIOLET RADIATION; TRANSCRIBED STRAND; ACTIVE GENES; DHFR GENE; MUTATIONS; MOUSE; SKIN	Removal of UVB-induced cyclobutane pyrimidine dimers (CPD) from each of the two strands of the transcriptionally active p53 tumor suppressor gene and the hypoxanthine-guanine phosphoribosyltransferase (HPRT) gene was determined in the epidermis of the hairless mouse using the CPD-specific enzyme T4 endonuclease V. Mice were exposed to a single dose of UVB (2 kJ/m(2)) and kept in darkness for up to 24 h. About 80% of the CPD were removed from the transcribed strand of the p53 and HPRT genes within 24 h. Most rapid removal was observed during the first 4 h. Tn contrast, very little removal of CPD from the nontranscribed strand of the p53 and the HPRT genes was observed in 24 h. The same low level of repair was observed in the inactive cmos proto-oncogene. The efficient repair of the transcribed strand compared to the nontranscribed strand of transcriptionally active genes in the epidermis of the hairless mouse resembles the repair of CPD in cultured rodent cells. Moreover, the selective removal of CPD from the transcribed strand of the p53 gene correlates well with the known strand bias of u.v.-induced mutations at dipyrimidine sites in the p53 gene of u.v.- induced mouse skin tumors.	LEIDEN UNIV,MGC,DEPT RADIAT GENET & CHEM MUTAGENESIS,2333 AL LEIDEN,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,3720 BA BILTHOVEN,NETHERLANDS; INTERUNIV RES INST RADIOPATHOL & RADIAT,JA COHEN INST,LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Netherlands National Institute for Public Health & the Environment								BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P3782; BRUNET S, 1989, MUTAT RES, V219, P217, DOI 10.1016/0921-8734(89)90003-9; CHRISTIANS FC, 1992, MUTAT RES, V274, P93, DOI 10.1016/0921-8777(92)90056-9; EPSTEIN JH, 1970, PHOTOCHEM PHOTOBIOL, V12, P57, DOI 10.1111/j.1751-1097.1970.tb06038.x; EVANS MK, 1993, CANCER RES, V53, P5377; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GATTONI S, 1982, MOL CELL BIOL, V2, P42, DOI 10.1128/MCB.2.1.42; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KANJILAL S, 1993, CANCER RES, V53, P2961; KONECKI DS, 1982, NUCLEIC ACIDS RES, V81, P2147; KRESS S, 1992, CANCER RES, V52, P6400; MADHANI HD, 1986, CELL, V45, P417, DOI 10.1016/0092-8674(86)90327-2; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; NEKABEPPU Y, 1982, J BIOL CHEM, V257, P2556; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P445, DOI 10.1002/mc.2940040606; PROPST F, 1984, NUCLEIC ACIDS RES, V12, P8381, DOI 10.1093/nar/12.22.8381; RADY P, 1992, CANCER RES, V52, P3804; RUVEN HJT, 1993, CANCER RES, V53, P1642; RUVEN HJT, 1994, MUTAT RES-DNA REPAIR, V315, P189, DOI 10.1016/0921-8777(94)90018-3; TORMANEN VT, 1992, ONCOGENE, V7, P1729; VANWEELDEN H, 1988, BRIT J DERMATOL, V119, P11; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VRIELING H, 1989, MOL CELL BIOL, V9, P1277, DOI 10.1128/MCB.9.3.1277; VRIELING H, 1991, NUCLEIC ACIDS RES, V19, P2411, DOI 10.1093/nar/19.9.2411; YUSPA SH, 1981, J INVEST DERMATOL, V76, P144, DOI 10.1111/1523-1747.ep12525490; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	32	39	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3427	3432						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970701				2022-12-17	WOS:A1994PT39200003
J	MOSNER, J; DEPPERT, W				MOSNER, J; DEPPERT, W			P53 AND MDM2 ARE EXPRESSED INDEPENDENTLY DURING CELLULAR PROLIFERATION	ONCOGENE			English	Article							WILD-TYPE P53; AUTOREGULATORY FEEDBACK LOOP; TUMOR-SUPPRESSOR PROTEIN; A MOUSE CELLS; DNA-REPLICATION; CYCLE CONTROL; GROWTH-REGULATION; NUCLEAR ANTIGEN; NORMAL 3T3; GENE	We analysed p53 expression during proliferation of serum stimulated Swiss mouse 3T3 cells and of concanavalin A stimulated mouse spleen lymphocytes and correlated it to rate of DNA synthesis and to expression of PCNA. We also analysed mdm2 gene expression, as rising p53 levels during proliferation might require MDM2 protein expression to functionally antagonize p53 mediated growth inhibition. p53 protein synthesis closely paralleled DNA synthesis and PCNA expression, suggesting a direct involvement of p53 in cellular DNA synthesis. mdm2 expression in 3T3 cells could not be correlated with p53 expression and DNA synthesis and was not detected at all in stimulated lymphocytes. We conclude that p53 and mdm2 expression during proliferation are not functionally related and that mdm2 expression is not required for proliferation.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,D-20251 HAMBURG,GERMANY	Heinrich Pette Institute; University of Hamburg								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BASERGA R, 1991, J CELL SCI, V98, P433; BOYUM A, 1968, SCAND J CLIN LAB INV, V97, P76; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DEPPERT W, 1990, ONCOGENE, V5, P1701; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FEINBERG AP, 1983, ANAL BIOCHEM, V136, P6; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FRITSCHE M, 1993, ONCOGENE, V8, P307; FROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lane David P., 1992, Current Biology, V2, P581, DOI 10.1016/0960-9822(92)90154-3; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIU YC, 1989, BIOCHEMISTRY-US, V28, P2967, DOI 10.1021/bi00433a034; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSNER J, 1992, ONCOGENE, V7, P661; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; OTTO A, 1993, ONCOGENE, V8, P2591; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PERRY ME, 1993, CURR OPIN CELL BIOL, V5, P1378; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; Prives C, 1993, CURR OPIN CELL BIOL, V5, P214, DOI 10.1016/0955-0674(93)90105-Y; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SHOHAT O, 1987, ONCOGENE, V1, P277; SKINNER MK, 1983, BIOCHEM J, V209, P281, DOI 10.1042/bj2090281; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STURZBECHER HW, 1994, ONCOL REP, V1, P301; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	53	39	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3321	3328						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936657				2022-12-17	WOS:A1994PM65800026
J	OSHIMA, J; STEINMANN, KE; CAMPISI, J; SCHLEGEL, R				OSHIMA, J; STEINMANN, KE; CAMPISI, J; SCHLEGEL, R			MODULATION OF CELL-GROWTH, P34(CDC2) AND CYCLIN-A LEVELS BY SV40 LARGE T-ANTIGEN	ONCOGENE			English	Article							DNA-REPLICATION; PROTEIN-KINASE; FISSION YEAST; INDEPENDENT GROWTH; HUMAN-FIBROBLASTS; SENESCENT HUMAN; C-FOS; CDC2; GENE; TEMPERATURE	Immortalization of rat lung epithelial cells by either wild-type SV-40 T antigen, a mutant form of T antigen that cannot bind pRb, or a temperature-sensitive T antigen increased by five- to 20-fold the steady state levels of p34cdc2 and cyclin A, positive regulators of progression through the cell cycle. Increased abundance of p34cdc2 was not accompanied by equivalent increases in cdc2 mRNA, indicating that increased expression of p34cdc2 is due, at least partially, to post-transcriptional mechanisms. Levels of p34cdc2 and cyclin A protein in cells immortalized with a temperature-sensitive T antigen remained elevated at the restrictive temperature unless T antigen was reduced to levels significantly below those where proliferation ceased, indicating that these two functions can be dissociated. These results show that SV-40 T antigen can dramatically enhance the expression of certain cell cycle regulatory proteins by mechanisms that are independent of pRb binding and cell growth status.	HARVARD UNIV,SCH PUBL HLTH,DEPT MOLEC & CELLULAR TOXICOL,DIV BIOL SCI,665 HUNTINGTON AVE,BOSTON,MA 02115; LAWRENCE BERKELEY LAB,DIV CELL & MOLEC BIOL,BERKELEY,CA 94720	Harvard University; Harvard T.H. Chan School of Public Health; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory					NATIONAL CANCER INSTITUTE [R01CA049749, F32CA009235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG010004] Funding Source: NIH RePORTER; NCI NIH HHS [NCI CA09235, NCI CA49749] Funding Source: Medline; NIA NIH HHS [AG10004] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMENT A, 1990, P NATL ACAD SCI USA, V87, P318, DOI 10.1073/pnas.87.1.318; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DRAETTA G, 1988, ONCOGENE, V2, P553; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FLOROS J, 1981, EXP CELL RES, V132, P215, DOI 10.1016/0014-4827(81)90097-5; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; KIT S, 1964, VIROLOGY, V1, P69; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCCAFFREY P, 1987, J BIOL CHEM, V262, P1442; MIGNOTTE B, 1990, ONCOGENE, V5, P1529; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OSHIMA J, 1992, THESIS BOSTON U MED; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RICHTER KH, 1991, CANCER RES, V51, P6010; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SESHADRI T, 1993, IN PRESS J BIOL CHEM; SOPRANO KJ, 1983, MOL CELL BIOL, V3, P214, DOI 10.1128/MCB.3.2.214; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; STUDIER FW, 1990, ANNU REV BIOCHEM, V185, P60; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253	41	39	39	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2987	2993						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414501				2022-12-17	WOS:A1993MC09300012
J	CUADRADO, A; BRUDER, JT; HEIDARAN, MA; APP, H; RAPP, UR; AARONSON, SA				CUADRADO, A; BRUDER, JT; HEIDARAN, MA; APP, H; RAPP, UR; AARONSON, SA			H-RAS AND RAF-1 COOPERATE IN TRANSFORMATION OF NIH3T3 FIBROBLASTS	ONCOGENE			English	Article							PROTEIN-KINASE-C; SIGNAL TRANSDUCTION; TYROSINE PHOSPHORYLATION; ONCOGENE PRODUCTS; GROWTH-FACTOR; 3T3 CELLS; EXPRESSION; ACTIVATION; GENE; HETEROGENEITY	We examined the effect of overexpression of growth factor-regulated second messenger enzymes, alone and in combination, on transformation of NIH3T3 cells. Signal transducers included phospholipase C-gamma (PLC-gamma), protein kinase C-gamma (PKC-gamma), and two proto-oncogenes, c-H-ras and c-raf-1. Three of these proteins, PLC-gamma PKC-gamma and Raf-1, did not transform NIH3T3 cells alone or in combination. c-H-ras, which under its own promoter control has low transforming activity, also did not cooperate with PLC-gamma or PKC-gamma. In contrast, the combination of normal or oncogenic p21 H-Ras with the Raf-I kinase dramatically increased transformation efficiency. The level of Ras protein required for transformation was reduced in Raf-1 co-transfectants, implying that, at low levels of p21 Ras, p74 Raf-I is rate limiting. As transformation by Ras depends on jun-mediated transcriptional events, we also examined H-ras and c-raf-1 cooperation in transcriptional transactivation of TPA-responsive element (TRE)-dependent reporters. Like the H-ras/c-raf-1 cooperation in transformation, we observed this synergistic stimulation of TRE-dependent transcription. This pathway for transformation and transcriptional activation by increased levels of normal Ras and Raf may be important in tumors that show overexpression but lack mutationally activated forms of these two proto-oncogenes.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; NCI, FREDERICK CANC RES & DEV CTR, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21702 USA; SUGEN INC, REDWOOD CITY, CA 94063 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Cuadrado, Antonio/0000-0002-3444-9012; Cuadrado, Antonio/0000-0002-4039-7140				BLUMBERG PM, 1991, MOL CARCINOGEN, V4, P339, DOI 10.1002/mc.2940040502; BOS JL, 1989, CANCER RES, V49, P4682; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUDER JT, 1992, IN PRESS J VIROL; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CLANTON DJ, 1987, MOL CELL BIOL, V7, P3092, DOI 10.1128/MCB.7.9.3092; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; CUADRADO A, 1990, BIOCHEM BIOPH RES CO, V170, P526, DOI 10.1016/0006-291X(90)92123-H; CUADRADO A, 1990, CELL GROWTH DIFFER, V1, P9; CUADRADO A, 1990, MOL CELL BIOL, V10, P6069, DOI 10.1128/MCB.10.11.6069; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HARRIS CC, 1991, IARC SCI PUBL, V105, P294; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HIDAKA H, 1988, J BIOL CHEM, V263, P4523; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MARSHALL CJ, 1989, INT J CANCER, P29; MCBRIDE K, 1991, P NATL ACAD SCI USA, V88, P7111, DOI 10.1073/pnas.88.16.7111; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MILLS GB, 1988, CELL, V55, P91, DOI 10.1016/0092-8674(88)90012-8; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRIS JDH, 1989, ONCOGENE, V4, P27; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1992, IN PRESS J BIOL CHEM; RAPP UR, 1991, ONCOGENE, V6, P495; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SITHANANDAM G, 1989, ONCOGENE, V4, P451; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P38, DOI 10.1073/pnas.82.1.38; STACEY DW, 1991, ONCOGENE, V6, P2297; STORM S M, 1990, Critical Reviews in Oncogenesis, V2, P1; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, IN PRESS ONCOGENE; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VIALLET J, 1990, AM J RESP CELL MOL, V2, P225, DOI 10.1165/ajrcmb/2.3.225; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	55	39	39	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1993	8	9					2443	2448						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361757				2022-12-17	WOS:A1993LT36800015
J	LEVY, LS; LOBELLERICH, PA; OVERBAUGH, J				LEVY, LS; LOBELLERICH, PA; OVERBAUGH, J			FLVI-2, A TARGET OF RETROVIRAL INSERTIONAL MUTAGENESIS IN FELINE THYMIC LYMPHOSARCOMAS, ENCODES BMI-1	ONCOGENE			English	Article							MYC TRANSGENIC MICE; LEUKEMIA-VIRUS; GENE; TRANSDUCTION; SEQUENCES; PROTEINS; ONCOGENE; LYMPHOMA; PROVIRUS; TUMORS	LC-FeLV is a myc-containing strain of feline leukemia virus which induces thymic lymphosarcoma in the domestic cat with short latency. A locus in feline DNA, termed flvi-2, is commonly interrupted in naturally occurring and experimentally induced thymic lymphosarcomas containing LC-FeLV; thus, interruption of a gene encoded by flvi-2 may cooperate with the myc oncogene in the induction of T-cell tumors by LC-FeLV. Clones homologous to flvi-2 have been isolated from a normal human thymus cDNA library. Nucleotide sequence analysis of the cDNA clones demonstrates that flvi-2 encodes bmi-1, a gene previously identified as a target for MoMuLV integration and as a myc-collaborator in retrovirally-induced B-cell lymphomas in Emu-myc transgenic mice. In feline thymic lymphomas, retroviral integrations occur downstream of the gene, and result in enhanced expression of a bmi-1 transcript of normal size. These findings demonstrate the interruption of bmi-1 in natural as well as experimentally induced tumors, implicate the activation of bmi-1 in the induction of T-cell as well as B-cell lymphoma, and support the premise that bmi-1 functions as a myc collaborator.	UNIV WASHINGTON,DEPT MICROBIOL SC-42,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	LEVY, LS (corresponding author), TULANE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,1430 TULANE AVE,NEW ORLEANS,LA 70112, USA.				NATIONAL CANCER INSTITUTE [R01CA048801, R01CA051080] Funding Source: NIH RePORTER; NCI NIH HHS [CA-48801, CA-51080] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BONHAM L, 1987, J VIROL, V61, P3072, DOI 10.1128/JVI.61.10.3072-3081.1987; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; HARDY WD, 1990, RETROVIRUS BIOL HUMA, P33; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; LEVY LS, 1988, J VIROL, V62, P4770, DOI 10.1128/JVI.62.12.4770-4773.1988; LEVY LS, 1992, J VIROL, V66, P2885, DOI 10.1128/JVI.66.5.2885-2892.1992; LEVY LS, 1984, NATURE, V308, P853, DOI 10.1038/308853a0; MATTHEWS EA, 1989, INT J CANCER, V43, P1120, DOI 10.1002/ijc.2910430627; MULLINS JI, 1984, NATURE, V308, P856, DOI 10.1038/308856a0; NEIL JC, 1984, NATURE, V308, P814, DOI 10.1038/308814a0; ONIONS D, 1987, INT J CANCER, V40, P40, DOI 10.1002/ijc.2910400108; OVERBAUGH J, 1992, VIROLOGY, V188, P558, DOI 10.1016/0042-6822(92)90510-V; PATANJALI SR, 1991, P NATL ACAD SCI USA, V88, P1943, DOI 10.1073/pnas.88.5.1943; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0	25	39	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1833	1838						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8390036				2022-12-17	WOS:A1993LG68200015
J	LEUNG, S; MCCRACKEN, S; GHYSDAEL, J; MIYAMOTO, NG				LEUNG, S; MCCRACKEN, S; GHYSDAEL, J; MIYAMOTO, NG			REQUIREMENT OF AN ETS-BINDING ELEMENT FOR TRANSCRIPTION OF THE HUMAN LCK TYPE-I PROMOTER	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASES; RECEPTOR ALPHA-GENE; HUMAN LYMPHOCYTES-T; LYMPHOMA CELL-LINE; NUCLEAR FACTOR-I; C-FOS; EXPRESSION; ACTIVATION; SEQUENCE; ENHANCER	The requirement for cis-acting DNA sequences for transcriptional activity of the human lck type I promoter was investigated in two human cell lines that express type I transcripts, the leukemic T-cell line, Jurkat, and the colon carcinoma line, SW620. Transient transfection assays in Jurkat and SW620 cells revealed negative and positive cis-acting regulatory elements in the lck type I promoter between -570 and -480 and between -128 and -63 respectively. For the latter, a triple point mutation of a sequence, GCAGGAAGT, from -99 and -91, resulted in complete loss of lck type I promoter activity in both Jurkat and SW620 cells. In vitro binding assays indicated that this sequence, denoted the ETS-binding element or EBE, can interact with the lymphoid-specific transcription factor ETS-1. Thus, a protein(s) in the ETS family appears to be required for transcription of the lck type I promoter in T cells and may be important for the activation of the lck gene in human colon carcinoma.	PRINCESS MARGARET HOSP,ONTARIO CANC INST,DIV CELLULAR & MOLEC BIOL,500 SHERBOURNE ST,TORONTO M4X 1K9,ONTARIO,CANADA; INST CURIE,BIOL SECT,CNRS,UNITE 1443,F-91405 ORSAY,FRANCE; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Toronto			GHYSDAEL, Jacques/F-3377-2013					ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; ALLEN JM, 1992, MOL CELL BIOL, V12, P2758, DOI 10.1128/MCB.12.6.2758; BHAT NK, 1989, J IMMUNOL, V142, P672; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; CASNELLIE JE, 1983, J BIOL CHEM, V258, P738; DAILEY L, 1986, P NATL ACAD SCI USA, V83, P7241, DOI 10.1073/pnas.83.19.7241; DANILITION SL, 1991, NUCLEIC ACIDS RES, V19, P6913, DOI 10.1093/nar/19.24.6913; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FREDERICKSON RM, 1989, NUCLEIC ACIDS RES, V17, P253, DOI 10.1093/nar/17.1.253; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GORMAN C, 1985, DNA CLONING, V2, P152; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; GUNTHER CV, 1990, GENE DEV, V4, P67; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KOGA Y, 1989, J IMMUNOL, V142, P4493; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; LEIDEN JM, 1992, IMMUNOL TODAY, V13, P22, DOI 10.1016/0167-5699(92)90200-Q; LEUNG S, 1991, J CELL PHYSIOL, V148, P344, DOI 10.1002/jcp.1041480304; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LEUNG S, 1992, THESIS U TORONTO; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MARTH JD, 1987, EMBO J, V6, P2727, DOI 10.1002/j.1460-2075.1987.tb02566.x; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MILLS GB, 1992, INT IMMUNOL, V4, P1233, DOI 10.1093/intimm/4.11.1233; OOSTERWEGEL M, 1991, J EXP MED, V173, P1133, DOI 10.1084/jem.173.5.1133; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SACCHI N, 1988, LEUKEMIA, V2, P12; SARTOR O, 1989, MOL CELL BIOL, V9, P2983, DOI 10.1128/MCB.9.7.2983; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; TREVILLYAN JM, 1986, BIOCHIM BIOPHYS ACTA, V888, P286, DOI 10.1016/0167-4889(86)90228-4; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VORONOVA AF, 1987, MOL CELL BIOL, V7, P4407, DOI 10.1128/MCB.7.12.4407; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383	56	39	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					989	997						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455950				2022-12-17	WOS:A1993KT22000022
J	SZEPETOWSKI, P; OLLENDORFF, V; GROSGEORGE, J; COURSEAUX, A; BIRNBAUM, D; THEILLET, C; GAUDRAY, P				SZEPETOWSKI, P; OLLENDORFF, V; GROSGEORGE, J; COURSEAUX, A; BIRNBAUM, D; THEILLET, C; GAUDRAY, P			DNA AMPLIFICATION AT 11Q13.5-Q14 IN HUMAN BREAST-CANCER	ONCOGENE			English	Note							GENE; 11Q13; CELL; TUMORS; CHROMOSOME-11Q13; CARCINOMAS; SEQUENCES; HST	Band q13 of chromosome 11 is frequently amplified in human breast cancers, but the gene(s) responsible for the emergence of this amplicon remain(s) elusive as yet. As a tribute to the complexity of the amplification events involving 11q13 sequences in human breast cancer, we have now studied a more telomeric region at 11q13.5-q14 defined by a new transcription unit, D11S833E. We have observed that amplicons present in cell lines and primary tumors amplified for both BCL1 and D11S833E could be interrupted between these two loci. Such discontinuities were demonstrated by using a probe for the KRN1 gene, which we have localized between the BCL1/FGF4 region and D11S833E. In fact, KRN1 was not present in 4 out of 10 amplicons bearing both BCL1 and D11S833E. Furthermore, we have observed tumors in which D11S833E could be amplified in the absence of amplification of other known markers of 11q13. Therefore, D11S833E defines a new and independent amplification unit in this region.	FAC MED NICE,LGMCH,CNRS,URA 1462,F-06107 NICE,FRANCE; UNIV MONTPELLIER 2,CNRS,URA 1191,F-34095 MONTPELLIER,FRANCE; INSERM,U119,F-13009 MARSEILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm)	GAUDRAY, P (corresponding author), FAC MED NICE,LGMCH,CNRS,URA 1462,F-06107 NICE,FRANCE.		Theillet, Charles/O-7634-2018	Birnbaum, Daniel/0000-0001-7920-9883; Ollendorff, Vincent/0000-0001-9751-2202; Theillet, Charles/0000-0001-5555-2759				ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; HAGEMEIJER A, 1991, GENE CHROMOSOME CANC, V3, P210, DOI 10.1002/gcc.2870030307; LAFAGE M, 1990, GENE CHROMOSOME CANC, V2, P171, DOI 10.1002/gcc.2870020302; LAFAGE M, 1992, IN PRESS GENES CHROM, V4; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; MACKINNON PJ, 1991, MAMM GENOME, V1, P53, DOI 10.1007/BF00350846; OLLENDORFF V, 1992, MAMM GENOME, V2, P195, DOI 10.1007/BF00302877; PROCTOR AJ, 1991, ONCOGENE, V6, P789; RICHARD CW, 1991, AM J HUM GENET, V49, P1189; SAITO I, 1989, MOL CELL BIOL, V9, P2445, DOI 10.1128/MCB.9.6.2445; SHILOH Y, 1985, P NATL ACAD SCI USA, V82, P3761, DOI 10.1073/pnas.82.11.3761; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; SZEPETOWSKI P, 1992, ONCOGENE, V7, P751; SZEPETOWSKI P, 1992, GENOMICS, V122, P738; THEILLET C, 1990, ONCOGENE, V5, P147; THEILLET C, 1989, ONCOGENE, V4, P915; WADA A, 1988, BIOCHEM BIOPH RES CO, V157, P828, DOI 10.1016/S0006-291X(88)80324-3	20	39	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2513	2517						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461654				2022-12-17	WOS:A1992KA85600017
J	MANGUES, R; SEIDMAN, I; GORDON, JW; PELLICER, A				MANGUES, R; SEIDMAN, I; GORDON, JW; PELLICER, A			OVEREXPRESSION OF THE N-RAS PROTOONCOGENE, NOT SOMATIC MUTATIONAL ACTIVATION, ASSOCIATED WITH MALIGNANT-TUMORS IN TRANSGENIC MICE	ONCOGENE			English	Note							MURINE SARCOMA-VIRUS; HA-RAS; EXPRESSION; GENE; TRANSFORMATION; DNA; TUMORIGENESIS; INVIVO; CELLS	We have produced transgenic mice that carry a foreign gene construct consisting of the N-ras proto-oncogene driven by the mouse mammary tumor virus (MMTV) long terminal repeat. Overexpression of the normal N-ras gene is associated with development of hyperplasias and tumors in a variety of tissues. The tumors are clearly malignant, as evidenced by the presence of metastatic lesions. Extensive analysis of the foreign ras gene in these tumors by use of polymerase chain reaction and sequencing demonstrates in all cases the absence of somatically acquired mutations at those codons normally associated with activation of the ras genes. Thus, these tumors develop from overexpression of the proto-oncogene rather than the presence of the mutated oncogene. These data demonstrate that overexpression of a proto-oncogene of the ras family can predispose cells in vivo to fully malignant behavior.	NYU MED CTR, DEPT PATHOL, NEW YORK, NY 10016 USA; NYU MED CTR, KAPLAN CANC CTR, NEW YORK, NY 10016 USA; CUNY MT SINAI SCH MED, DEPT GERIATR & ADULT DEV, CTR MOLEC BIOL, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT OBSTET GYNECOL & REPROD SCI, NEW YORK, NY 10029 USA	New York University; New York University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai				Pellicer, Angel/0000-0002-5062-0692; Mangues, Ramon/0000-0003-2661-9525	NCI NIH HHS [CA 50434, CA 42103, CA 36327] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042103, R01CA036327, R01CA050434, R37CA036327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; CARDIFF RD, 1991, AM J PATHOL, V139, P495; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; GEORGE DL, 1986, P NATL ACAD SCI USA, V83, P1651, DOI 10.1073/pnas.83.6.1651; GEROSA MA, 1989, J NATL CANCER I, V81, P63, DOI 10.1093/jnci/81.1.63; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GUERRERO I, 1984, SCIENCE, V225, P1041, DOI 10.1126/science.6089339; GUERRERO I, 1988, BIOCHEM BIOPH RES CO, V150, P1185, DOI 10.1016/0006-291X(88)90754-1; HARRIS AW, 1988, CURR TOP MICROBIOL, V141, P82; HIGUCHI R, 1988, NATURE, V332, P543, DOI 10.1038/332543a0; HOFLER H, 1988, VIRCHOWS ARCH B, V55, P355; MANGUES R, 1990, ONCOGENE, V5, P1491; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITOH A, 1990, ONCOGENE, V5, P1195; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SOUYRI M, 1989, J VIROL, V63, P3944, DOI 10.1128/JVI.63.9.3944-3953.1989; SPANDIDOS DA, 1984, BRIT J CANCER, V49, P681, DOI 10.1038/bjc.1984.108; TANAKA T, 1986, CANCER RES, V46, P1465; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; VELU TJ, 1989, J VIROL, V63, P1384, DOI 10.1128/JVI.63.3.1384-1392.1989; WESTAWAY D, 1986, EMBO J, V5, P301, DOI 10.1002/j.1460-2075.1986.tb04213.x	25	39	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1992	7	10					2073	2076						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1328989				2022-12-17	WOS:A1992JP42400024
J	SLADEK, TL; JACOBBERGER, JW				SLADEK, TL; JACOBBERGER, JW			DEPENDENCE OF SV40 LARGE T-ANTIGEN CELL-CYCLE REGULATION ON T-ANTIGEN EXPRESSION LEVELS	ONCOGENE			English	Article							ANCHORAGE-INDEPENDENT GROWTH; SIMIAN VIRUS-40; FLOW-CYTOMETRY; RECOMBINANT RETROVIRUSES; INTRACELLULAR ANTIGENS; MOUSE FIBROBLASTS; TUMOR-ANTIGEN; P53; TRANSFORMATION; GENE	Simian virus 40 (SV40) large T antigen (Tag) expression results in reduced percentages of G1-phase cells and increased percentages of S- and G2 + M-phase cells in exponentially growing fibroblast populations as compared with identical cell populations not expressing Tag. This effect is the result of reduced G1 and increased G2 + M cell cycle phase durations caused by Tag [Sladek, T.L. & Jacobberger, J.W. (1992). J. Virol., 66, 1059-1065]. Using recombinant retroviruses to manipulate Tag expression over a 25-fold range, it is shown here that the magnitude of this cell cycle phenotype increases as a function of increasing intracellular Tag concentration. This effect of Tag on the cell cycle is not independent of negative regulation by cellular mechanisms since exponentially growing cell populations producing high and increasing levels of Tag, increase the fraction of cells residing in G1 and decrease the fraction in S and G2 + M as a function of cell density. Therefore, the data in this paper show, first, that Tag is a concentration-dependent, positive cell cycle regulator in exponentially proliferating cells and, second, that endogenous cellular mechanisms negatively regulating the cell cycle in response to cell density override the effect of Tag.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT GENET,2109 ADELBERT RD,CLEVELAND,OH 44106	Case Western Reserve University			Jacobberger, James/P-9183-2014	Jacobberger, James/0000-0002-3092-5157	NCI NIH HHS [CA43703] Funding Source: Medline; NHLBI NIH HHS [HL41945] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041945] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BAISCH H, 1988, CYTOMETRY, V9, P325, DOI 10.1002/cyto.990090409; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; BUTEL JS, 1986, BIOCHIM BIOPHYS ACTA, V865, P171, DOI 10.1016/0304-419X(86)90027-2; CHANG SMW, 1987, MOL CELL BIOL, V7, P854, DOI 10.1128/MCB.7.2.854; COSENZA SC, 1991, J CELL PHYSIOL, V147, P231, DOI 10.1002/jcp.1041470207; CRAWFORD L, 1982, J VIROL, V41, P709, DOI 10.1128/JVI.41.2.709-709.1982; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DEAN PN, 1987, CYCLE ANAL, P207; DEAN PN, 1990, FLOW CYTOMETRY SORTI, P415; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, V1, P99; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAYLES J, 1986, J CELL SCI S, V4, P155; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; JACOBBERGER JW, 1986, CYTOMETRY, V7, P356, DOI 10.1002/cyto.990070410; JACOBBERGER JW, 1989, FLOW CYTOMETRY ADV R, P305; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; LAFFIN J, 1989, CYTOMETRY, V10, P205, DOI 10.1002/cyto.990100212; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEHMAN JM, 1988, CYTOMETRY, V9, P52, DOI 10.1002/cyto.990090109; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LINNEY E, 1987, J VIROL, V61, P3248, DOI 10.1128/JVI.61.10.3248-3253.1987; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; MILNER J, 1986, VIROLOGY, V147, P206; RISSER R, 1974, VIROLOGY, V59, P477, DOI 10.1016/0042-6822(74)90457-7; SCHIMENTI KJ, 1992, CYTOMETRY, V13, P48, DOI 10.1002/cyto.990130109; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SLADEK TL, 1990, J VIROL, V64, P3135, DOI 10.1128/JVI.64.6.3135-3138.1990; SLADEK TL, 1992, J VIROL, V66, P1059, DOI 10.1128/JVI.66.2.1059-1065.1992; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4	38	39	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1305	1313						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620545				2022-12-17	WOS:A1992HZ97100008
J	GALLAND, F; KATZAV, S; BIRNBAUM, D				GALLAND, F; KATZAV, S; BIRNBAUM, D			THE PRODUCTS OF THE MCF-2 AND VAV PROTOONCOGENES AND OF THE YEAST GENE CDC-24 SHARE SEQUENCE SIMILARITIES	ONCOGENE			English	Note							SACCHAROMYCES-CEREVISIAE; DBL-ONCOGENE; CDC24 GENE; OVEREXPRESSION; CELLS	Comparison of MCF-2, VAV and CDC-24 amino acids sequences shows similarities in a near central portion of the molecules, constituting a domain of around 250 residues, the role of which remains undefined.	INSERM, U119, DEPT MOLEC ONCOL, 27 BD LEI ROURE, F-13009 MARSEILLE, FRANCE; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); St Jude Children's Research Hospital				Birnbaum, Daniel/0000-0001-7920-9883	NCI NIH HHS [P30 CA 21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAPETANAKI Y, 1989, J CELL BIOL, V109, P1653, DOI 10.1083/jcb.109.4.1653; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; EVA A, 1991, NEW BIOL, V3, P158; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; GALLAND F, 1991, ONCOGENE, V6, P833; GRAZIANI G, 1989, ONCOGENE, V4, P823; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOCH A, 1991, SCIENCE, V252, P68; MARGOLIS B, 1992, IN PRESS NATURE; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; NOGUCHI T, 1988, ONCOGENE, V3, P709; Pringle JR, 1991, CURR OPIN CELL BIOL, V3, P235, DOI 10.1016/0955-0674(91)90145-O; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113	20	39	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					585	587						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549372				2022-12-17	WOS:A1992HK00500028
J	CAPOBIANCO, AJ; GILMORE, TD				CAPOBIANCO, AJ; GILMORE, TD			REPRESSION OF THE CHICKEN C-REL PROMOTER BY VREL IN CHICKEN-EMBRYO FIBROBLASTS IS NOT MEDIATED THROUGH A CONSENSUS NF-KAPPA-B BINDING-SITE	ONCOGENE			English	Article							VIRUS STRAIN-T; V-REL; RETICULOENDOTHELIOSIS VIRUS; PROTO-ONCOGENE; CELLULAR HOMOLOG; MAMMALIAN-CELLS; SPLEEN-CELLS; DNA; EXPRESSION; GENE	To understand the regulation of expression of the chicken c-rel gene, we cloned genomic sequences upstream of the start site of transcription of c-rel Sequence analysis shows that the c-rel promoter is a GC-rich promoter that lacks a TATA box. In addition, there are putative binding sites for several transcription factors, including an NF-kappa-B consensus binding site. Primer extension showed that there is one major start site (site 1) for transcription in chicken embryo fibroblasts and two major start sites in a v-rel-transformed chicken spleen cell line. In transient assays using c-rel promoter sequences and the CAT reporter gene, we found that vRel repressed expression from the c-rel promoter. Other viral oncoproteins and a non-transforming v-rel deletion mutant did not repress the: c-rel promoter. Repression occurred through sequences located within 125 bp of the start of transcription. However, mutation of the consensus NF-kappa-B binding site did not affect the level of transcription from the c-rel promoter, nor did it interfere with repression by v-Rel, even though vRel could bind to the wild-type, but not the mutant, version of this sequence in vitro. These results suggest that the vRel protein can repress transcription through an indirect mechanism.	BOSTON UNIV, DEPT BIOL, BOSTON, MA 02215 USA	Boston University				Capobianco, Anthony/0000-0002-3706-6797	NCI NIH HHS [CA-47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; BOORSTEIN WR, 1989, METHOD ENZYMOL, V180, P347; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRAVO R, 1988, COLD SPRING HARB SYM, V53, P901, DOI 10.1101/SQB.1988.053.01.103; BROWNELL E, 1988, ONCOGENE, V3, P93; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; BULL P, 1989, MOL CELL BIOL, V9, P5239, DOI 10.1128/MCB.9.11.5239; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CHEN ISY, 1983, J VIROL, V45, P104, DOI 10.1128/JVI.45.1.104-113.1983; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; EMBRETSON JE, 1987, J VIROL, V61, P3454, DOI 10.1128/JVI.61.11.3454-3462.1987; GARSON K, 1986, BIOCHEM BIOPH RES CO, V134, P716, DOI 10.1016/S0006-291X(86)80479-X; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1991, IN PRESS TRENDS GENE; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRUMONT RJ, 1990, ONCOGENE RES, V5, P245; HANNINK M, 1990, ONCOGENE, V5, P1843; HERZOG NK, 1986, P NATL ACAD SCI USA, V83, P812, DOI 10.1073/pnas.83.3.812; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; IP YT, 1991, CELL, V64, P439; JORCYK CL, 1991, ONCOGENE, V6, P523; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOHWISHIGEMATSU T, 1983, P NATL ACAD SCI-BIOL, V80, P4389, DOI 10.1073/pnas.80.14.4389; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOORE BE, 1989, ONCOGENE, V4, P845; MOSIALOS G, 1991, IN PRESS MOL CELL BI; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; RICE NR, 1986, VIROLOGY, V149, P217, DOI 10.1016/0042-6822(86)90123-6; RICE NR, 1988, ONCOGENE HDB, P495; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SALIER JP, 1989, BIOTECHNIQUES, V7, P30; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIMEK S, 1988, ONCOGENE RES, V2, P103; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; WILHELMSEN KC, 1984, J VIROL, V49, P521, DOI 10.1128/JVI.49.2.521-529.1984; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	55	39	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1991	6	12					2203	2210						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766669				2022-12-17	WOS:A1991GX73500005
J	MAHESWARAN, S; MCCORMACK, JE; SONENSHEIN, GE				MAHESWARAN, S; MCCORMACK, JE; SONENSHEIN, GE			CHANGES IN PHOSPHORYLATION OF MYC ONCOGENE AND RB ANTIONCOGENE PROTEIN PRODUCTS DURING GROWTH ARREST OF THE MURINE LYMPHOMA WEHI-231 CELL-LINE	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; C-MYC; EXPRESSION; IMMUNOGLOBULIN; CYCLE; TRANSLOCATION; ACTIVATION; SARCOMA; VIRUS; RNA	The expression of the protein products of the c-myc oncogene and retinoblastoma susceptibility gene (RB) was investigated during either goat anti-mouse immunoglobulin (GaMIg)- or phorbol ester (TPA)-induced growth arrest of the murine B-lymphoma cell line WEHI 231. Previously we have demonstrated that c-myc mRNA levels increase within 1-2 h of treatment, return to control levels by 4 h, and decline below these values by 24 h of treatment. Here we demonstrate that the level of c-myc protein synthesis and mRNA change in parallel. The predominant c-myc protein expressed during the time course is the one initiated at the AUG codon (P2). The myc protein synthesized following 1-2 h of anti-immunoglobulin or TPA treatment migrates more slowly in a polyacrylamide gel as a result of increased phosphorylation. This hyperphosphorylation was no longer detectable by 4-6 h of treatment. Furthermore, the hyper-phosphorylated myc protein appears to be more readily extractable with salt than the hypophosphorylated form. The product of the RB gene is present in multiple phosphorylation states in exponentially growing WEHI 231 cells. By 8 h of GaMIg or TPA treatment, a hypophosphorylated form begins to be detectable and significant levels were seen by 15 h. Thus post-translational control of both c-myc and RB expression occurs during the growth arrest of WEHI 231 cells. These changes in phosphorylation may play a role in mediating the cessation of proliferation of these cells.	BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA	Boston University					NCI NIH HHS [CA 36355] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036355] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1982, P NATL ACAD SCI-BIOL, V79, P6966, DOI 10.1073/pnas.79.22.6966; BISTER K, 1980, J VIROL, V36, P617, DOI 10.1128/JVI.36.2.617-621.1980; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOYD AW, 1981, J IMMUNOL, V126, P2266; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DEAN M, 1983, NATURE, V305, P443, DOI 10.1038/305443a0; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1988, CELL, V56, P67; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; GUY GR, 1989, BIOCHEM J, V263, P57, DOI 10.1042/bj2630057; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HORNBECK P, 1986, J BIOL CHEM, V261, P4817; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MCCORMACK JE, 1984, P NATL ACAD SCI-BIOL, V81, P5546, DOI 10.1073/pnas.81.17.5546; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PONTE PA, 1981, NATURE, V291, P594, DOI 10.1038/291594a0; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RALPH P, 1979, IMMUNOL REV, V48, P107, DOI 10.1111/j.1600-065X.1979.tb00300.x; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SHEW JY, 1989, ONCOGENE RES, V4, P205; STRAUSS F, 1984, CELL, V33, P741; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; XU HJ, 1989, ONCOGENE, V4, P807	39	39	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					1965	1971						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1719463				2022-12-17	WOS:A1991GX11900004
J	TRAVALI, S; FERBER, A; REISS, K; SELL, C; KONIECKI, J; CALABRETTA, B; BASERGA, R				TRAVALI, S; FERBER, A; REISS, K; SELL, C; KONIECKI, J; CALABRETTA, B; BASERGA, R			EFFECT OF THE MYB GENE-PRODUCT ON EXPRESSION OF THE PCNA GENE IN FIBROBLASTS	ONCOGENE			English	Article							CELL NUCLEAR ANTIGEN; TEMPERATURE-SENSITIVE MUTANTS; KINASE MESSENGER-RNA; C-MYB; THYMIDINE KINASE; DNA-REPLICATION; PROTO-ONCOGENE; GROWTH-FACTOR; CDNA CLONES; NUCLEOTIDE-SEQUENCE	Tk-ts13 cells are BHK-derived fibroblasts that have a G1-specific temperature sensitive (ts) mutation so that the cells arrest in the G1 phase of the cell cycle at the restrictive temperature of 39.6-degrees. We have introduced into these cells a plasmid carrying the human c-myb cDNA under the control of the early SV40 promoter. The resulting cell line, ts13 myb cells, express the c-myb RNA and protein and, when serum-stimulated, they undergo one round of DNA replication even at the restrictive temperature. Under the same conditions, the parent cell line (tk-ts13 cells) are blocked in G1 and fail to replicate DNA. We have investigated the expression of two late growth-regulated genes, PCNA and histone H3, in tk-ts13 and in ts 13 myb cells, both at permissive and restrictive temperature. At the permissive temperature of 34-degrees, the mRNA levels for PCNA and histone H3 increase markedly after serum stimulation in both cell lines, reaching a peak at the time of DNA synthesis. At the restrictive temperature of 39.6-degrees, the mRNA's for PCNA, and histone H3 are detectable in serum-stimulated ts13 myb cells while they are not detectable in the parent tk-ts13 cell line. Run-on transcription assays indicate that these 2 genes are transcribed in tk-ts13 cells equally well at permissive and nonpermissive temperatures, and that the presence of the myb product does not significantly increase their rates of transcription. The stability of the respective mRNA's is roughly the same at either temperature and in both types of cells. These results indicate: (1) a constitutively expressed c-myb gene product confers to fibroblasts the ability of temporarily by-passing a ts block in the G1 phase of the cell cycle and (2) the myb product, under these conditions, regulates the mRNA levels of PCNA and histone H3 either directly or indirectly by a post-transcriptional mechanism.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT PATHOL,3400 N BROAD ST,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	BASERGA, R (corresponding author), TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT PATHOL,3400 N BROAD ST,PHILADELPHIA,PA 19140, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033694] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33694] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BAUMBACH LL, 1987, BIOCHEMISTRY-US, V26, P6178, DOI 10.1021/bi00393a034; BISTER K, 1982, P NATL ACAD SCI-BIOL, V79, P3677, DOI 10.1073/pnas.79.12.3677; BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; CAMPISI J, 1984, MOL CELL BIOL, V4, P1807, DOI 10.1128/MCB.4.9.1807; CHANG CD, 1990, MOL CELL BIOL, V10, P3289, DOI 10.1128/MCB.10.7.3289; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DASGUPTA P, 1990, P NATL ACAD SCI USA, V87, P8090, DOI 10.1073/pnas.87.20.8090; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLOROS J, 1981, EXP CELL RES, V132, P215, DOI 10.1016/0014-4827(81)90097-5; Gai X X, 1988, Oncogene Res, V3, P377; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HIRSCHHORN RR, 1984, P NATL ACAD SCI-BIOL, V81, P6004, DOI 10.1073/pnas.81.19.6004; HIRSCHHORN RR, 1984, BIOCHEMISTRY-US, V23, P3731, DOI 10.1021/bi00311a025; IDE T, 1986, BIOCHEMISTRY-US, V25, P7041, DOI 10.1021/bi00370a043; JASKULSKI D, 1988, J BIOL CHEM, V263, P10175; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KONIECKI J, 1991, IN PRESS CANCER RES; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEOF EB, 1982, EXP CELL RES, V141, P107, DOI 10.1016/0014-4827(82)90073-8; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P6848, DOI 10.1073/pnas.86.18.6848; LIU HT, 1985, J BIOL CHEM, V260, P3269; LIU HT, 1985, MOL CELL BIOL, V5, P2926; LIU YC, 1989, BIOCHEMISTRY-US, V28, P2967, DOI 10.1021/bi00433a034; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NINOMIYATSUJI J, 1987, EXP CELL RES, V171, P509, DOI 10.1016/0014-4827(87)90183-2; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OHNO K, 1984, SOMAT CELL GENET, V10, P9; OTTAVIO L, 1990, MOL CELL BIOL, V10, P303, DOI 10.1128/MCB.10.1.303; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; ROSSINI M, 1979, P NATL ACAD SCI USA, V76, P4441, DOI 10.1073/pnas.76.9.4441; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHEN YM, 1982, MOL CELL BIOL, V2, P1145, DOI 10.1128/MCB.2.9.1145; SIERRA F, 1982, P NATL ACAD SCI-BIOL, V79, P1795, DOI 10.1073/pnas.79.6.1795; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; THOMAS PS, 1983, METHOD ENZYMOL, V100, P225; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; TRAVALI S, IN PRESS MOL CELL BI; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTIN K, 1989, CELL, V85, P93; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WONG SW, 1988, EMBO J, V7, P3767	63	39	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					887	894						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1712444				2022-12-17	WOS:A1991GU62200001
J	SAINTRUF, C; MALFOY, B; SCHOLL, S; ZAFRANI, B; DUTRILLAUX, B				SAINTRUF, C; MALFOY, B; SCHOLL, S; ZAFRANI, B; DUTRILLAUX, B			GST-PI-GENE IS FREQUENTLY COAMPLIFIED WITH INT2 AND HSTF1 PROTOONCOGENES IN HUMAN BREAST CANCERS	ONCOGENE			English	Article							GLUTATHIONE-S-TRANSFERASE; HUMAN DESMIN GENE; TUMOR-CELL-LINES; SV40 DNA; AMPLIFICATION; EXPRESSION; ASSIGNMENT; MARKER; BCL-1	The glutathione S-transferase gene (GST-pi) is located on the same chromosome band (11q13) as proto-oncogenes INT2 and HSTF1 which are frequently amplified in breast cancer. Using the Southern blot technique, we looked for the amplification of the GST-pi gene in 17 fresh tumors from human mammary carcinoma. The tumors were preselected because either they had an amplification of the INT2 proto-oncogene detected by dot blot, or their karyotypes exhibited or did not exhibit homogeneously staining regions, a cytogenetic character indicating amplification. Coamplification of GST-pi, HSTF1 and INT2 was observed in five tumors, and coamplification of GST-pi and HSTF1 without amplification of INT2 in another tumor. We also observed coamplification of GST-pi, INT2, HSTF1 in the mammary carcinoma cell line MDA/MB134, whereas GST-pi alone was amplified in the mammary epithelial cell line HBL100. These results indicate that INT2, HSTF1 and GST-pi belong to the same large amplicon. Since GST-pi is involved in intracellular detoxication and since chemotherapeutic drugs are among its substrates, it will be of interest to study GST-pi gene expression as well as the response to chemotherapy in patients presenting this amplicon.	INST CURIE,BIOL SECT,CNRS,URA 620,26 RUE ULM,F-75231 PARIS 05,FRANCE; INST CURIE,MED SECT,F-75231 PARIS 05,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie								ADELAIDE J, 1988, ONCOGENE, V2, P413; ALI IU, 1989, ONCOGENE, V4, P89; BIEDLER JL, 1976, SCIENCE, V191, P185, DOI 10.1126/science.942798; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; COWELL IG, 1988, BIOCHEM J, V255, P79, DOI 10.1042/bj2550079; DIILIO C, 1988, CARCINOGENESIS, V9, P335; DULIK DM, 1986, BIOCHEM PHARMACOL, V35, P3405, DOI 10.1016/0006-2952(86)90444-2; DUTRILLAUX B, IN PRESS CANCER GENE; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; GERBAULTSEUREAU M, 1987, ANN GENET-PARIS, V30, P146; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HILL DL, 1976, P AM ASSOC CANC RES, V17, P52; HOWIE AF, 1990, CARCINOGENESIS, V11, P295, DOI 10.1093/carcin/11.2.295; Jakoby W B, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P383; JOLLY DJ, 1982, P NATL ACAD SCI-BIOL, V79, P5038, DOI 10.1073/pnas.79.16.5038; KANO T, 1987, CANCER RES, V47, P5626; LI YC, 1988, P NATL ACAD SCI USA, V85, P344, DOI 10.1073/pnas.85.2.344; LILIENBAUM A, 1988, CELL MOL BIOL, V34, P663; MARLHENS F, 1988, ANN GENET-PARIS, V31, P81; MOSCOW JA, 1988, P NATL ACAD SCI USA, V85, P6518, DOI 10.1073/pnas.85.17.6518; MOSCOW JA, 1989, CANCER RES, V49, P1422; NGUYEN C, 1988, ONCOGENE, V3, P703; SAINTRUF C, 1989, INT J CANCER, V44, P367, DOI 10.1002/ijc.2910440230; SAINTRUF C, IN PRESS CANCER GENE; SAINTRUF C, 1990, GENES CHROMOSOMES CA, V2, P63; SHEA TC, 1988, CANCER RES, V48, P527; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SODROSKI JG, 1984, P NATL ACAD SCI-BIOL, V81, P3039, DOI 10.1073/pnas.81.10.3039; THEILLET C, 1990, ONCOGENE, V5, P147; VIEGASPEQUIGNOT E, 1989, HUM GENET, V83, P33, DOI 10.1007/BF00274143; WADA A, 1988, BIOCHEM BIOPH RES CO, V157, P828, DOI 10.1016/S0006-291X(88)80324-3; 1981, CLASSIFICATION HISTO; 1982, TNM VICC TNM ATLAS; 1989, CYTOGENET CELL GENET, V51, P1	36	39	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					403	406						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1826346				2022-12-17	WOS:A1991FT34400008
J	WIEHLE, RD; HELFTENBEIN, G; LAND, H; NEUMANN, K; BEATO, M				WIEHLE, RD; HELFTENBEIN, G; LAND, H; NEUMANN, K; BEATO, M			ESTABLISHMENT OF RAT ENDOMETRIAL CELL-LINES BY RETROVIRAL MEDIATED TRANSFER OF IMMORTALIZING AND TRANSFORMING ONCOGENES	ONCOGENE			English	Article									INST MOLEK BIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,W-3550 MARBURG,GERMANY; IMPERIAL CANC RES FUND,LONDON WC2X 3PX,ENGLAND; UNIV MARBURG,INST PATHOL,W-3550 MARBURG,GERMANY	Cancer Research UK; Philipps University Marburg			Beato, Miguel/B-5564-2015	Beato, Miguel/0000-0002-2878-2222				AMSTERDAM A, 1988, P NATL ACAD SCI USA, V85, P582; BADER BL, 1988, EUR J CELL BIOL, V47, P300; BEATO M, 1987, ENDOMETRIAL CANCER, P20; BEIER HM, 1976, J REPROD FERT      S, V25, P53; BOUK N, 1979, METHOD ENZYMOL, V58, P296; CATO ACB, 1985, ANTICANCER RES, V5, P65; CHOU JY, 1983, MOL CELL BIOL, V3, P1013, DOI 10.1128/MCB.3.6.1013; CHOU JY, 1978, P NATL ACAD SCI USA, V75, P1854, DOI 10.1073/pnas.75.4.1854; DORMAN BH, 1982, IN VITRO, V18, P911; DOTTO GP, 1985, NATURE, V318, P472; EVRARD C, 1986, EMBO J, V5, P3157, DOI 10.1002/j.1460-2075.1986.tb04623.x; GARCIA I, 1986, MOL CELL BIOL, V6, P1974, DOI 10.1128/MCB.6.6.1974; GLASSER SR, 1988, J CELL BIOL, V107, P2409, DOI 10.1083/jcb.107.6.2409; HALL JE, 1950, AM J OBSTET GYNECOL, V60, P212, DOI 10.1016/S0002-9378(16)39062-7; HEINS B, 1981, MOL CELL ENDOCRINOL, V21, P139, DOI 10.1016/0303-7207(81)90051-4; HOLINKA CF, 1986, CANCER RES, V46, P2771; HORWITZ KB, 1978, J BIOL CHEM, V253, P2223; HURLIN PJ, 1989, P NATL ACAD SCI USA, V86, P187, DOI 10.1073/pnas.86.1.187; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; JORDEN VC, 1978, J ENDOCRINOL, V7, P363; KURUC N, 1988, DIFFERENTIATION, V38, P177, DOI 10.1111/j.1432-0436.1988.tb00212.x; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; MCCORMACK SA, 1980, ENDOCRINOLOGY, V106, P1634, DOI 10.1210/endo-106-5-1634; MILGROM E, 1973, J BIOL CHEM, V248, P6366; MOYER MP, 1987, IN VITRO CELL DEV B, V23, P141, DOI 10.1007/BF02623595; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; ROBERTS BE, 1985, J VIROL, V56, P404, DOI 10.1128/JVI.56.2.404-413.1985; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SCOTT DM, 1986, EXP CELL RES, V166, P391, DOI 10.1016/0014-4827(86)90485-4; SINGH G, 1988, BIOCHIM BIOPHYS ACTA, V950, P329, DOI 10.1016/0167-4781(88)90129-7; SINGH G, 1987, EXP LUNG RES, V13, P299, DOI 10.3109/01902148709069595; SYNE JS, 1982, CANCER RES, V42, P4449; VARMA VA, 1982, IN VITRO CELL DEV B, V18, P911; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WOODWORTH C, 1986, CANCER RES, V46, P4018; ZARET KS, 1988, P NATL ACAD SCI USA, V85, P9076, DOI 10.1073/pnas.85.23.9076	39	39	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1990	5	6					787	794						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	1694289				2022-12-17	WOS:A1990DP55300002
J	THEURING, F; GOTZ, W; BALLING, R; KORF, HW; SCHULZE, F; HERKEN, R; GRUSS, P				THEURING, F; GOTZ, W; BALLING, R; KORF, HW; SCHULZE, F; HERKEN, R; GRUSS, P			TUMORIGENESIS AND EYE ABNORMALITIES IN TRANSGENIC MICE EXPRESSING MSV-SV40 LARGE T-ANTIGEN	ONCOGENE			English	Article									UNIV GOTTINGEN, ZENTRUM ANAT, HISTOL ABT, W-3400 GOTTINGEN, GERMANY; UNIV GIESSEN, ANAT & ZYTOBIOL ABT, W-6300 GIESSEN, GERMANY	University of Gottingen; Justus Liebig University Giessen	THEURING, F (corresponding author), MAX PLANCK INST BIOPHYS CHEM, MOLEK ZELLBIOL ABT, W-3400 GOTTINGEN, GERMANY.		Korf, Horst/ACX-9860-2022; Balling, Rudi/E-9680-2010	Korf, Horst/0000-0002-5051-0303; Balling, Rudi/0000-0003-2902-5650				BECKER LE, 1983, HUM PATHOL, V14, P538, DOI 10.1016/S0046-8177(83)80006-9; BREITMAN ML, 1987, SCIENCE, V238, P1563, DOI 10.1126/science.3685993; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; BURGER PC, 1987, ACTA NEUROPATHOL, V73, P115, DOI 10.1007/BF00693776; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cruickshank AH, 1986, PATHOLOGY PANCREAS; CUTHBERTSON RA, 1988, LAB INVEST, V58, P484; FUJITA T, 1979, TRENDS NEUROSCI, V2, P27, DOI 10.1016/0166-2236(79)90013-4; Gabe M, 1976, HISTOLOGICAL TECHNIQ; GELATT KN, 1984, CURR EYE RES, V3, P765, DOI 10.3109/02713688409065600; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HOGAN B, 1986, MAINPULATING MOUSE E; KHILLAN JS, 1987, GENE DEV, V1, P1327, DOI 10.1101/gad.1.10.1327; KHILLAN JS, 1988, NUCLEIC ACIDS RES, V16, P1423, DOI 10.1093/nar/16.4.1423; KLOPPEL G, 1981, SPEZIELLE PATHOLOGIS, V14, P523; LAHAV M, 1973, AM J OPHTHALMOL, V75, P648, DOI 10.1016/0002-9394(73)90817-9; LAIMINS LA, 1982, P NATL ACAD SCI-BIOL, V79, P6453, DOI 10.1073/pnas.79.21.6453; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; LANDEL CP, 1988, GENE DEV, V2, P1168, DOI 10.1101/gad.2.9.1168; LEVINSON BG, 1982, NATURE, V295, P658; MACKAY K, 1988, KIDNEY INT, V33, P677, DOI 10.1038/ki.1988.53; MACKAY K, 1987, KIDNEY INT, V32, P827, DOI 10.1038/ki.1987.283; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MESSING A, 1985, NATURE, V316, P461, DOI 10.1038/316461a0; MUGGLETONHARRIS AL, 1986, INT REV CYTOL, V104, P25, DOI 10.1016/S0074-7696(08)61922-1; MURPHY D, 1987, AM J PATHOL, V129, P552; NAUMANN GOH, 1980, SPEZIELLE PATHOLOGIS, V12, P501; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PEARSE AGE, 1968, PROC R SOC SER B-BIO, V170, P71, DOI 10.1098/rspb.1968.0025; POCHEDLY C, 1982, NEUROBLASTOMA CLIN B; POULSOM R, 1988, GRAEF ARCH CLIN EXP, V226, P31, DOI 10.1007/BF02172713; POWER RF, 1987, GUT, V28, P121, DOI 10.1136/gut.28.Suppl.121; Romeis B., 1968, MIKROSKOPISCHE TECHN; SCHULZE F, 1985, DNA-J MOLEC CELL BIO, V4, P193, DOI 10.1089/dna.1985.4.193; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TABUCHI K, 1988, ATLAS BRAIN TUMORS L; VANDOORENMAALEN WJ, 1981, MOL CELLULAR BIOL EY, P415; WESTPHAL H, 1988, REGULATORY MECHANISM, P33	39	39	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1990	5	2					225	232						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU029	2157185				2022-12-17	WOS:A1990CU02900009
J	ROHRSCHNEIDER, LR; ROTHWELL, VM; NICOLA, NA				ROHRSCHNEIDER, LR; ROTHWELL, VM; NICOLA, NA			TRANSFORMATION OF MURINE FIBROBLASTS BY A RETROVIRUS ENCODING THE MURINE C-FMS PROTO-ONCOGENE	ONCOGENE			English	Article									ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute	ROHRSCHNEIDER, LR (corresponding author), FRED HUTCHINSON CANC RES CTR,DEPT CELL BIOL,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.		Nicola, Nicos/D-2989-2011	Nicola, Nicos/0000-0003-1054-7889	NATIONAL CANCER INSTITUTE [R01CA040987, R01CA022556, R37CA022556, R01CA020551] Funding Source: NIH RePORTER; NCI NIH HHS [CA 20551, CA 40987, CA 22556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAIN SB, 1988, ONCOGENE, V3, P129; BOWTELL DDL, 1988, J VIROL, V62, P2464, DOI 10.1128/JVI.62.7.2464-2473.1988; BYRNE PV, 1981, J CELL BIOL, V91, P848, DOI 10.1083/jcb.91.3.848; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DELAMARTER JF, 1987, NUCLEIC ACIDS RES, V15, P2389, DOI 10.1093/nar/15.5.2389; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GENTRY LE, 1983, J BIOL CHEM, V258, P1219; HUANG SS, 1988, J BIOL CHEM, V263, P12608; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; JAYE M, 1988, ONCOGENE, V3, P963; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; KACINSKI BM, 1988, IN PRESS AM J PATHOL; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; MANGER R, 1984, CELL, V39, P327, DOI 10.1016/0092-8674(84)90011-4; Maniatis T., 1982, MOL CLONING; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MULLER R, 1983, MOL CELL BIOL, V3, P1062; MULLER R, 1983, NATURE, V304, P484; NICOLA NA, 1988, IN PRESS GROWTH FACT; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STANLEY ER, 1981, J IMMUNOL METHODS, V42, P253, DOI 10.1016/0022-1759(81)90156-3; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; STEWART CC, 1978, J RETICULOENDOTH SOC, V23, P269; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; WOOLFORD J, 1985, MOL CELL BIOL, V5, P3458, DOI 10.1128/MCB.5.12.3458	40	39	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					1015	1022						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2548144				2022-12-17	WOS:A1989AJ29700011
J	DOTTO, GP; ELFOULY, MH; NELSON, C; TROSKO, JE				DOTTO, GP; ELFOULY, MH; NELSON, C; TROSKO, JE			SIMILAR AND SYNERGISTIC INHIBITION OF GAP-JUNCTIONAL COMMUNICATION BY RAS TRANSFORMATION AND TUMOR PROMOTER TREATMENT OF MOUSE PRIMARY KERATINOCYTES	ONCOGENE			English	Article									MICHIGAN STATE UNIV, DEPT PEDIAT & HUMAN DEV, E LANSING, MI 48824 USA	Michigan State University	DOTTO, GP (corresponding author), YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06510 USA.		Trosko, James/J-5954-2019		NATIONAL CANCER INSTITUTE [R01CA021104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039190] Funding Source: NIH RePORTER; NCI NIH HHS [CA21104] Funding Source: Medline; NIAMS NIH HHS [AR-39190-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BIGNAMI M, 1981, IN PRESS MOL CARCINO, V1; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CHANG CC, 1985, P NATL ACAD SCI USA, V82, P5360, DOI 10.1073/pnas.82.16.5360; CHANG CC, 1987, CANCER RES, V47, P1634; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; DOTTO GP, 1985, NATURE, V318, P472; EL-FOULY M H, 1986, American Journal of Human Genetics, V39, pA30; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HENNINGS H, 1983, NATURE, V304, P67, DOI 10.1038/304067a0; HSIAO WLW, 1984, SCIENCE, V226, P552, DOI 10.1126/science.6436974; JANSSENTIMMEN U, 1986, CARCINOGENESIS, V7, P1475, DOI 10.1093/carcin/7.9.1475; KALIMI GH, 1984, CARCINOGENESIS, V5, P1671, DOI 10.1093/carcin/5.12.1671; KAM E, 1987, EXP CELL RES, V173, P431, DOI 10.1016/0014-4827(87)90283-7; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; MURRAY AW, 1979, BIOCHEM BIOPH RES CO, V91, P395, DOI 10.1016/0006-291X(79)91535-3; PASTI G, 1988, CANCER RES, V48, P447; PITTS JD, 1986, J CELL SCI, P239, DOI 10.1242/jcs.1986.Supplement_4.15; POTTER VR, 1983, PROG NUCLEIC ACID RE, V29, P161, DOI 10.1016/S0079-6603(08)60445-6; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; YAMASAKI H, 1987, CANCER RES, V47, P5658; YOTTI LP, 1979, SCIENCE, V206, P1089, DOI 10.1126/science.493994; YUSPA SH, 1985, NATURE, V314, P459, DOI 10.1038/314459a0	30	39	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1989	4	5					637	641						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2657578				2022-12-17	WOS:A1989U768800015
J	LACAL, PM; PENNINGTON, CY; LACAL, JC				LACAL, PM; PENNINGTON, CY; LACAL, JC			TRANSFORMING ACTIVITY OF RAS-PROTEINS TRANSLOCATED TO THE PLASMA-MEMBRANE BY A MYRISTOYLATION SEQUENCE FROM THE SRC-GENE PRODUCT	ONCOGENE			English	Article									NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,ROOM 1E24,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Lacal, Pedro M/A-1481-2013; Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	Lacal, Pedro M/0000-0003-1166-4593; Lacal, Juan Carlos/0000-0002-1908-2777				BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; BUSS JE, 1984, J VIROL, V53, P7; CHEN ZQ, 1985, J VIROL, V56, P607, DOI 10.1128/JVI.56.2.607-612.1985; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; FUJIYAMA A, 1986, P NATL ACAD SCI USA, V83, P1266, DOI 10.1073/pnas.83.5.1266; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GARBER EA, 1983, NATURE, V302, P161, DOI 10.1038/302161a0; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; KRUEGER JG, 1983, CURR TOP MICROBIOL, V107, P51; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; LACAL JC, 1986, EMBO J, V5, P679, DOI 10.1002/j.1460-2075.1986.tb04267.x; LACAL JC, 1986, MOL CELL BIOL, V6, P4214, DOI 10.1128/MCB.6.12.4214; LACAL JC, 1988, IN PRESS ONCOGENE HD; LAUTENBERGER JA, 1983, SCIENCE, V221, P858, DOI 10.1126/science.6308763; MANNE V, 1985, P NATL ACAD SCI USA, V82, P376, DOI 10.1073/pnas.82.2.376; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; PELLMAN D, 1985, P NATL ACAD SCI USA, V82, P1623, DOI 10.1073/pnas.82.6.1623; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SCOLNICK EM, 1979, P NATL ACAD SCI USA, V76, P5355, DOI 10.1073/pnas.76.10.5355; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SHIH TY, 1980, NATURE, V287, P686, DOI 10.1038/287686a0; SHIH TY, 1982, J VIROL, V42, P253, DOI 10.1128/JVI.42.1.253-261.1982; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; WEEKS MO, 1985, J VIROL, V54, P586, DOI 10.1128/JVI.54.2.586-597.1985; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILLINGHAM MC, 1979, CELL, V18, P125, DOI 10.1016/0092-8674(79)90361-1; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0	34	39	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					533	537						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	2455265				2022-12-17	WOS:A1988N841500001
J	BERNARDS, A; PASKIND, M; BALTIMORE, D				BERNARDS, A; PASKIND, M; BALTIMORE, D			4 MURINE C-ABL MESSENGER-RNAS ARISE BY USAGE OF 2 TRANSCRIPTIONAL PROMOTERS AND ALTERNATIVE SPLICING	ONCOGENE			English	Article									MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	BERNARDS, A (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.				NCI NIH HHS [CA 38497] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA038497] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELSON HT, 1970, CANCER RES, V30, P2213; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BERNARDS A, 1987, MOL CELL BIOL, V7, P3231, DOI 10.1128/MCB.7.9.3231; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; GODDARD JM, 1986, P NATL ACAD SCI USA, V83, P2172, DOI 10.1073/pnas.83.7.2172; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HOFFMANFALK H, 1983, CELL, V32, P589, DOI 10.1016/0092-8674(83)90478-6; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; LAUGHON A, 1986, MOL CELL BIOL, V6, P4676, DOI 10.1128/MCB.6.12.4676; LAVIA P, 1987, EMBO J, V6, P2773, DOI 10.1002/j.1460-2075.1987.tb02572.x; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; Maxam A M, 1980, Methods Enzymol, V65, P499; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; ROSENBERG N, 1975, P NATL ACAD SCI USA, V72, P1932, DOI 10.1073/pnas.72.5.1932; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SIVE HL, 1986, MOL CELL BIOL, V6, P3329, DOI 10.1128/MCB.6.10.3329; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WANG JYJ, 1984, CELL, V36, P349; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0	35	39	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1988	2	4					297	304						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	3283651				2022-12-17	WOS:A1988M947200001
J	EDWARDS, PAW; WARD, JL; BRADBURY, JM				EDWARDS, PAW; WARD, JL; BRADBURY, JM			ALTERATION OF MORPHOGENESIS BY THE V-MYC ONCOGENE IN TRANSPLANTS OF MAMMARY-GLAND	ONCOGENE			English	Article											EDWARDS, PAW (corresponding author), UNIV CAMBRIDGE,DEPT PATHOL,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND.		Edwards, Paul A/M-8291-2014	Edwards, Paul A/0000-0002-4789-3374				BOTTERI FM, 1987, MOL CELL BIOL, V7, P3178, DOI 10.1128/MCB.7.9.3178; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CARDIFF RD, 1984, ADV CANCER RES, V42, P167, DOI 10.1016/S0065-230X(08)60458-3; DECOSSE JJ, 1983, CANCER SURVEYS, V2, P1; DEOME KB, 1959, CANCER RES, V19, P515; DOTTO GP, 1985, NATURE, V318, P472; EDWARDS PAW, 1984, DIFFERENTIATION, V25, P247, DOI 10.1111/j.1432-0436.1984.tb01363.x; ETHIER SP, 1984, CANCER RES, V44, P4517; FAULKIN LJ, 1960, J NATL CANCER I, V24, P953; FRANZ T, 1986, P NATL ACAD SCI USA, V83, P3292, DOI 10.1073/pnas.83.10.3292; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Jones W., 1983, J TISSUE CULTURE MET, V8, P17; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.iy.04.040186.001533; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MANIATIS T, 1982, MOL CLONING LABORATO; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; Medina D., 1982, MOUSE BIOMEDICAL RES, VIV, P373; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; ROTHSTEIN SJ, 1980, CELL, V19, P795, DOI 10.1016/S0092-8674(80)80055-9; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SINGH L, 1984, NUCLEIC ACIDS RES, V12, P5627, DOI 10.1093/nar/12.14.5627; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STACEY A, 1984, J VIROL, V50, P725, DOI 10.1128/JVI.50.3.725-732.1984; STEWART CL, 1985, EMBO J, V4, P3701, DOI 10.1002/j.1460-2075.1985.tb04138.x; STOCKING C, 1985, P NATL ACAD SCI USA, V82, P5746, DOI 10.1073/pnas.82.17.5746; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; WAGNER EF, 1985, EMBO J, V4, P663, DOI 10.1002/j.1460-2075.1985.tb03680.x; WEISS R, 1985, RNA TUMOUR VIRUSES S, V2	31	39	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1988	2	4					407	412						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	3283657				2022-12-17	WOS:A1988M947200015
J	ZERLIN, M; JULIUS, MA; CERNI, C; MARCU, KB				ZERLIN, M; JULIUS, MA; CERNI, C; MARCU, KB			ELEVATED EXPRESSION OF AN EXOGENOUS C-MYC GENE IS INSUFFICIENT FOR TRANSFORMATION AND TUMORIGENIC CONVERSION OF ESTABLISHED FIBROBLASTS	ONCOGENE			English	Article									SUNY STONY BROOK,DEPT BIOCHEM,STONY BROOK,NY 11794; VIENNA UNIV,INST TUMORBIOL CANC RES,A-1090 VIENNA,AUSTRIA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Vienna					NCI NIH HHS [CA36246, CA 09176] Funding Source: Medline; NIAID NIH HHS [AI00416] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009176, R01CA036246] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI000416] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1983, P NATL ACAD SCI-BIOL, V80, P1982, DOI 10.1073/pnas.80.7.1982; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BAUMBACH WR, 1986, CURR TOP MICROBIOL, V132, P23; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; CONNAN G, 1985, NATURE, V314, P277, DOI 10.1038/314277a0; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DALLAFAVERA R, 1982, NATURE, V299, P61; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DUNNICK W, 1983, P NATL ACAD SCI-BIOL, V80, P7269, DOI 10.1073/pnas.80.23.7269; FAHRLANDER PD, 1985, EMBO J, V4, P3195, DOI 10.1002/j.1460-2075.1985.tb04065.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMLYN PH, 1983, NATURE, V304, P135, DOI 10.1038/304135a0; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KAHN P, 1979, J CELL BIOL, V82, P1, DOI 10.1083/jcb.82.1.1; KAPLAN PL, 1981, VIROLOGY, V108, P484, DOI 10.1016/0042-6822(81)90455-4; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KRIEGLER M, 1984, CELL, V38, P483, DOI 10.1016/0092-8674(84)90503-8; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; LI Y, 1984, P NATL ACAD SCI-BIOL, V81, P6808, DOI 10.1073/pnas.81.21.6808; MANIATIS T, 1982, MOL CLONING LABORATO; MARCU KB, 1983, P NATL ACAD SCI-BIOL, V80, P519, DOI 10.1073/pnas.80.2.519; MARCU KB, 1987, IN PRESS BIOESSAYS; MARTIN P, 1986, EMBO J, V5, P1529, DOI 10.1002/j.1460-2075.1986.tb04393.x; MEDRANO EE, 1980, P NATL ACAD SCI-BIOL, V77, P4123, DOI 10.1073/pnas.77.7.4123; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; NISHIKURA K, 1983, P NATL ACAD SCI-BIOL, V80, P4822, DOI 10.1073/pnas.80.15.4822; ODONNELL PV, 1985, J VIROL, V55, P500, DOI 10.1128/JVI.55.2.500-503.1985; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; OSHIMURA M, 1985, NATURE, V316, P636, DOI 10.1038/316636a0; OSHIRO Y, 1974, J CELL PHYSIOL, V83, P193, DOI 10.1002/jcp.1040830205; OZANNE B, 1980, J CELL PHYSIOL, V105, P163, DOI 10.1002/jcp.1041050118; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; PELLEGRINI S, 1986, J CELL PHYSIOL, V126, P107, DOI 10.1002/jcp.1041260115; POLLACK R, 1975, PROTEASES BIOL CONTR, P885; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; RISSER R, 1974, VIROLOGY, V59, P477, DOI 10.1016/0042-6822(74)90457-7; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SEIF R, 1977, J VIROL, V24, P721, DOI 10.1128/JVI.24.3.721-728.1977; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; WOLFF L, 1986, CURR TOP MICROBIOL, V132, P33; WURM FM, 1986, P NATL ACAD SCI USA, V83, P5414, DOI 10.1073/pnas.83.15.5414; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x; ZEEVI M, 1981, CELL, V26, P39, DOI 10.1016/0092-8674(81)90031-3	83	39	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1987	1	1					19	27						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6351	3325875				2022-12-17	WOS:A1987J635100003
J	Lin, WH; Chang, YW; Hong, MX; Hsu, TC; Lee, KC; Lin, C; Lee, JL				Lin, Wei-Hsin; Chang, Yi-Wen; Hong, Min-Xiang; Hsu, Te-Cheng; Lee, Ko-Chuan; Lin, Che; Lee, Jia-Lin			STAT3 phosphorylation at Ser727 and Tyr705 differentially regulates the EMT-MET switch and cancer metastasis	ONCOGENE			English	Article							STEM-CELL PROPERTIES; BREAST-CANCER; TRANSITION; CARCINOMA	Epithelial-mesenchymal transition (EMT)/mesenchymal-epithelial transition (MET) processes are proposed to be a driving force of cancer metastasis. By studying metastasis in bone marrow-derived mesenchymal stem cell (BM-MSC)-driven lung cancer models, microarray time-series data analysis by systems biology approaches revealed BM-MSC-induced signaling triggers early dissemination of CD133(+)/CD83(+) cancer stem cells (CSCs) from primary sites shortly after STAT3 activation but promotes proliferation towards secondary sites. The switch from migration to proliferation was regulated by BM-MSC-secreted LIF and activated LIFR/p-ERK/pS727-STAT3 signaling to promote early disseminated cancer cells MET and premetastatic niche formation. Then, tumor-tropic BM-MSCs circulated to primary sites and triggered CD151(+)/CD38(+) cells acquiring EMT-associated CSC properties through IL6R/pY705-STAT3 signaling to promote tumor initiation and were also attracted by and migrated towards the premetastatic niche. In summary, STAT3 phosphorylation at tyrosine 705 and serine 727 differentially regulates the EMT-MET switch within the distinct molecular subtypes of CSCs to complete the metastatic process.	[Lin, Wei-Hsin; Chang, Yi-Wen; Lee, Ko-Chuan; Lee, Jia-Lin] Natl Tsing Hua Univ, Inst Mol & Cellular Biol, Hsinchu 30013, Taiwan; [Lin, Wei-Hsin] Natl Taiwan Univ Hosp, Dept Orthoped Surg, Taipei 100225, Taiwan; [Hong, Min-Xiang; Hsu, Te-Cheng] Natl Tsing Hua Univ, Inst Commun Engn, Hsinchu 30013, Taiwan; [Lin, Che] Natl Taiwan Univ, Dept Elect Engn, Taipei 10617, Taiwan; [Lin, Che] Natl Taiwan Univ, Grad Inst Commun Engn, Taipei 10617, Taiwan; [Lee, Jia-Lin] Natl Tsing Hua Univ, Dept Med Sci, Hsinchu 30013, Taiwan	National Tsing Hua University; National Taiwan University; National Taiwan University Hospital; National Tsing Hua University; National Taiwan University; National Taiwan University; National Tsing Hua University	Lee, JL (corresponding author), Natl Tsing Hua Univ, Inst Mol & Cellular Biol, Hsinchu 30013, Taiwan.; Lin, C (corresponding author), Natl Taiwan Univ, Dept Elect Engn, Taipei 10617, Taiwan.; Lin, C (corresponding author), Natl Taiwan Univ, Grad Inst Commun Engn, Taipei 10617, Taiwan.; Lee, JL (corresponding author), Natl Tsing Hua Univ, Dept Med Sci, Hsinchu 30013, Taiwan.	chelin@ntu.edu.tw; jllee@life.nthu.edu.tw	Hsu, Te-Cheng/ABG-6674-2021	Hsu, Te-Cheng/0000-0003-2686-925X; LIN, WEI-HSIN/0000-0001-6291-392X; Lin, Che/0000-0002-4986-311X; Lee, Jia-Lin/0000-0002-6984-1313	Taiwan Ministry of Science and Technology [NSC 104-2314-B-007-003]; National Taiwan University Hospital Hsin-Chu Branch; National Tsing Hua University Joint Research Program [106-J00XHV7, 107-Q2509E1]	Taiwan Ministry of Science and Technology; National Taiwan University Hospital Hsin-Chu Branch; National Tsing Hua University Joint Research Program	We acknowledge the Biomedical Science and Engineering Center, National Tsing Hua University, Hsinchu, Taiwan, for providing us with access and Wen-Ching Wang for providing technical advice regarding the use of the FACSAria III (BD Biosciences) flow cytometer. This work was supported by funds from the Taiwan Ministry of Science and Technology (grant NSC 104-2314-B-007-003) and the National Taiwan University Hospital Hsin-Chu Branch and National Tsing Hua University Joint Research Program (grants 106-J00XHV7 and 107-Q2509E1).	Bianco P, 2014, ANNU REV CELL DEV BI, V30, P677, DOI 10.1146/annurev-cellbio-100913-013132; Biddle A, 2011, CANCER RES, V71, P5317, DOI 10.1158/0008-5472.CAN-11-1059; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434; Chang YW, 2015, CANCER RES, V75, P3398, DOI 10.1158/0008-5472.CAN-14-3265; Chaturvedi P, 2013, J CLIN INVEST, V123, P189, DOI 10.1172/JCI64993; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Eyles J, 2010, J CLIN INVEST, V120, P2030, DOI 10.1172/JCI42002; Huang GY, 2014, STEM CELLS, V32, P1149, DOI 10.1002/stem.1609; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Kidd S, 2009, STEM CELLS, V27, P2614, DOI 10.1002/stem.187; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Klein CA, 2011, CURR OPIN GENET DEV, V21, P42, DOI 10.1016/j.gde.2010.10.011; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Liang CJ, 2019, CELL REP, V28, P1511, DOI 10.1016/j.celrep.2019.07.023; Liu SC, 2013, J CLIN INVEST, V123, P5269, DOI 10.1172/JCI63428; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Markopoulos GS, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101143; Nicola NA, 2015, CYTOKINE GROWTH F R, V26, P533, DOI 10.1016/j.cytogfr.2015.07.001; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Pantel K, 2008, NAT REV CANCER, V8, P329, DOI 10.1038/nrc2375; Pavlidis N, 2015, J ADV RES, V6, P375, DOI 10.1016/j.jare.2014.11.007; Pierga JY, 2008, CLIN CANCER RES, V14, P7004, DOI 10.1158/1078-0432.CCR-08-0030; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Santamaria PG, 2017, MOL ONCOL, V11, P718, DOI 10.1002/1878-0261.12091; Schardt JA, 2005, CANCER CELL, V8, P227, DOI 10.1016/j.ccr.2005.08.003; Su YJ, 2011, EMBO J, V30, P3186, DOI 10.1038/emboj.2011.211; van der Pluijm G, 2011, BONE, V48, P37, DOI 10.1016/j.bone.2010.07.023; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Yang M, 1998, CANCER RES, V58, P4217	33	38	39	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					791	805		10.1038/s41388-020-01566-8	http://dx.doi.org/10.1038/s41388-020-01566-8		DEC 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA4GO	33262462	Green Published, hybrid			2022-12-17	WOS:000595928700003
J	Shin, SB; Jang, HR; Xu, R; Won, JY; Yim, H				Shin, Sol-Bi; Jang, Hay-Ran; Xu, Rong; Won, Jae-Yeon; Yim, Hyungshin			Active PLK1-driven metastasis is amplified by TGF-beta signaling that forms a positive feedback loop in non-small cell lung cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; POLO-LIKE KINASES; PLK1; EXPRESSION; CARCINOMA; MIGRATION; INVASION; TSG-6; PHOSPHORYLATION; SURVIVAL	Early findings that PLK1 is highly expressed in cancer have driven an exploration of its functions in metastasis. However, whether PLK1 induces metastasis in vivo and its underlying mechanisms in NSCLC have not yet been determined. Here, we show that the expression of active PLK1 phosphorylated at T210, abundant in TGF-beta-treated lung cells, potently induced metastasis in a tail-vein injection model. Active PLK1 with intact polo-box and ATP-binding domains accelerated cell motility and invasiveness by triggering EMT reprogramming, whereas a phosphomimetic version of p-S137-PLK1 did not, indicating that the phosphorylation status of PLK1 may determine the cell traits. Active PLK1-driven invasiveness upregulated TGF-beta signaling and TSG6 encoded by TNFAIP6. Loss of TNFAIP6 disturbed the metastatic activity induced by active PLK1 or TGF-beta. Clinical relevance shows that PLK1 and TNFAIP6 are strong predictors of poor survival rates in metastatic NSCLC patients. Therefore, we suggest that active PLK1 promotes metastasis by upregulating TGF-beta signaling, which amplifies its metastatic properties by forming a positive feedback loop and that the PLK1/TGF-beta-driven metastasis is effectively blocked by targeting PLK1 and TSG6, providing PLK1 and TSG6 as negative markers for prognostics and therapeutic targets in metastatic NSCLC.	[Shin, Sol-Bi; Jang, Hay-Ran; Xu, Rong; Won, Jae-Yeon; Yim, Hyungshin] Hanyang Univ, Coll Pharm, Inst Pharmaceut Sci & Technol, Dept Pharm, Ansan, Gyeonggi Do, South Korea	Hanyang University	Yim, H (corresponding author), Hanyang Univ, Coll Pharm, Inst Pharmaceut Sci & Technol, Dept Pharm, Ansan, Gyeonggi Do, South Korea.	hsyim@hanyang.ac.kr			National Research Foundation of Korea (NRF) - Ministry of Science and ICT [NRF- 2014R1A2A1A11049701, NRF-2017R1A2B2012301]	National Research Foundation of Korea (NRF) - Ministry of Science and ICT	We thank Dr. Raymond L. Erikson (Harvard University, MA, USA) for his generous support for experimental materials. We also thank Dr. Jadranka Loncarek (National Cancer Institute, MD, USA) and Dr. Young-Joo Jang (Dankook University, Korea) for help with plasmid pLVX-TRE3G-RFP-PLK1-T210D and pCMV-PLK1-S137D, respectively. We appreciate the helpful discussions about the manuscript by Dr. Chang K. Sung (Texas A&M University, USA) and the technical support by Dr. Gyeoung-Jin Kang (Dongguk University, Korea) for big data analysis. This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (NRF- 2014R1A2A1A11049701, NRF-2017R1A2B2012301) to H. Y.	Acharya PS, 2008, J CELL SCI, V121, P1393, DOI 10.1242/jcs.021683; Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Ali A, 2013, CURR ONCOL, V20, pE300, DOI 10.3747/co.20.1481; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bednarz-Knoll N, 2012, CANCER METAST REV, V31, P673, DOI 10.1007/s10555-012-9370-z; Bommaya G, 2011, INT J BIOCHEM CELL B, V43, P1739, DOI 10.1016/j.biocel.2011.08.009; Cai XP, 2016, AM J TRANSL RES, V8, P4172; Chen QY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108528; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fransvea E, 2008, HEPATOLOGY, V47, P1557, DOI 10.1002/hep.22201; Gordian Edna, 2019, Oncotarget, V10, P810, DOI 10.18632/oncotarget.26574; Grosse-Wilde A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126522; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Han DP, 2012, MED SCI MONITOR, V18, pBR237, DOI 10.12659/MSM.882900; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Kong D, 2014, J CELL BIOL, V206, P855, DOI 10.1083/jcb.201407087; Kothe M, 2007, CHEM BIOL DRUG DES, V70, P540, DOI 10.1111/j.1747-0285.2007.00594.x; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Larsen JE, 2011, CLIN CHEST MED, V32, P703, DOI 10.1016/j.ccm.2011.08.003; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; Maier R, 1996, ARTHRITIS RHEUM, V39, P552, DOI 10.1002/art.1780390403; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; Mittal M, 2016, P NATL ACAD SCI USA, V113, pE8151, DOI 10.1073/pnas.1614935113; Pickup M, 2013, NAT REV CANCER, V13, P788, DOI 10.1038/nrc3603; Rizki A, 2007, CANCER RES, V67, P11106, DOI 10.1158/0008-5472.CAN-07-2348; Sancisi V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075489; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Su J, 2016, MOL CARCINOGEN, V55, P1962, DOI 10.1002/mc.22443; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Tamura T, 2015, MOL CLIN ONCOL, V3, P217, DOI 10.3892/mco.2014.410; Tsvetkov L, 2005, CELL CYCLE, V4, P166, DOI 10.4161/cc.4.1.1348; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Wu JG, 2016, ELIFE, V5, DOI 10.7554/eLife.10734; Yim H, 2014, MUTAT RES-REV MUTAT, V761, P31, DOI 10.1016/j.mrrev.2014.02.005; Yim HS, 2009, MOL CELL BIOL, V29, P2609, DOI 10.1128/MCB.01277-08; Yoo HY, 2004, CELL, V117, P575, DOI 10.1016/S0092-8674(04)00417-9; Zhang Z, 2013, UROL ONCOL-SEMIN ORI, V31, P1222, DOI 10.1016/j.urolonc.2011.11.028; Zheng H, 2014, ONCOGENE, V33, P1755, DOI 10.1038/onc.2013.128	42	38	39	3	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					767	785		10.1038/s41388-019-1023-z	http://dx.doi.org/10.1038/s41388-019-1023-z			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31548612	hybrid, Green Published			2022-12-17	WOS:000509197200003
J	Sirkisoon, SR; Carpenter, RL; Rimkus, T; Doheny, D; Zhu, DQ; Aguayo, NR; Xing, F; Chan, M; Ruiz, J; Metheny-Barlow, LJ; Strowd, R; Lin, J; Regua, AT; Arrigo, A; Anguelov, M; Pasche, B; Debinski, W; Watabe, K; Lo, HW				Sirkisoon, Sherona R.; Carpenter, Richard L.; Rimkus, Tadas; Doheny, Daniel; Zhu, Dongqin; Aguayo, Noah R.; Xing, Fei; Chan, Michael; Ruiz, Jimmy; Metheny-Barlow, Linda J.; Strowd, Roy; Lin, Jiayuh; Regua, Angelina T.; Arrigo, Austin; Anguelov, Marlyn; Pasche, Boris; Debinski, Waldemar; Watabe, Kounosuke; Lo, Hui-Wen			TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment	ONCOGENE			English	Article							PROGNOSTIC-FACTORS; PREFERENTIAL SITE; SPLICE VARIANT; EXPRESSION; GLIOBLASTOMA; OCT4; GLI1; ANGIOGENESIS; RESISTANCE; SUBTYPES	Mechanisms for breast cancer metastasis remain unclear. Whether truncated glioma-associated oncogene homolog 1 (TGLI1), a transcription factor known to promote angiogenesis, migration and invasion, plays any role in metastasis of any tumor type has never been investigated. In this study, results of two mouse models of breast cancer metastasis showed that ectopic expression of TGLI1, but not GLI1, promoted preferential metastasis to the brain. Conversely, selective TGLI1 knockdown using antisense oligonucleotides led to decreased breast cancer brain metastasis (BCBM) in vivo. Immunohistochemical staining showed that TGLI1, but not GLI1, was increased in lymph node metastases compared to matched primary tumors, and that TGLI1 was expressed at higher levels in BCBM specimens compared to primary tumors. TGLI1 activation is associated with a shortened time to develop BCBM and enriched in HER2-enriched and triple-negative breast cancers. Radioresistant BCBM cell lines and specimens expressed higher levels of TGLI1, but not GLI1, than radiosensitive counterparts. Since cancer stem cells (CSCs) are radioresistant and metastasis-initiating cells, we examined TGLI1 for its involvement in breast CSCs and found TGLI1 to transcriptionally activate stemness genes CD44, Nanog, Sox2, and OCT4 leading to CSC renewal, and TGLI1 outcompetes with GLI1 for binding to target promoters. We next examined whether astrocyte-priming underlies TGLI1-mediated brain tropism and found that TGLI1-positive CSCs strongly activated and interacted with astrocytes in vitro and in vivo. These findings demonstrate, for the first time, that TGLI1 mediates breast cancer metastasis to the brain, in part, through promoting metastasis-initiating CSCs and activating astrocytes in BCBM microenvironment.	[Sirkisoon, Sherona R.; Carpenter, Richard L.; Rimkus, Tadas; Doheny, Daniel; Zhu, Dongqin; Aguayo, Noah R.; Regua, Angelina T.; Arrigo, Austin; Anguelov, Marlyn; Pasche, Boris; Debinski, Waldemar; Watabe, Kounosuke; Lo, Hui-Wen] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, 300 S Hawthorne Rd, Winston Salem, NC 27103 USA; [Xing, Fei; Chan, Michael; Ruiz, Jimmy; Metheny-Barlow, Linda J.; Strowd, Roy; Pasche, Boris; Debinski, Waldemar; Watabe, Kounosuke; Lo, Hui-Wen] Wake Forest Univ, Bowman Gray Sch Med, Comprehens Canc Ctr, 300 S Hawthorne Rd, Winston Salem, NC 27103 USA; [Chan, Michael; Metheny-Barlow, Linda J.] Wake Forest Univ, Bowman Gray Sch Med, Dept Radiat Oncol, 300 S Hawthorne Rd, Winston Salem, NC 27103 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Hematol & Oncol, 300 S Hawthorne Rd, Winston Salem, NC 27103 USA; [Ruiz, Jimmy] Wake Forest Univ, Bowman Gray Sch Med, Dept Neurol, 300 S Hawthorne Rd, Winston Salem, NC 27103 USA; [Strowd, Roy] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Lin, Jiayuh] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Bloomington, IN USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; University System of Maryland; University of Maryland Baltimore; Indiana University System; Indiana University Bloomington	Lo, HW (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, 300 S Hawthorne Rd, Winston Salem, NC 27103 USA.; Lo, HW (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Comprehens Canc Ctr, 300 S Hawthorne Rd, Winston Salem, NC 27103 USA.	hlo@wakehealth.edu		Carpenter, Richard/0000-0001-9986-6493; Doheny, Daniel/0000-0002-1455-3090; Regua, Angelina/0000-0003-2595-8242; Strowd, Roy/0000-0001-6651-5267	NIH [R01NS087169, F31CA224805-01A1, T32CA079448, R01NS087169-3S1, P30CA012197]; DoD [W81XWH-17-1-0044, W81XWH-19-1-0072, BC181274]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD(United States Department of Defense)	We thank Dr. Shadi Qasem for providing pathology support. We acknowledge the funding support from NIH grants R01NS087169 (to H-WL), F31CA224805-01A1 (to SRS, HWL), T32CA079448 (to SK, RLC), R01NS087169-3S1 (to H-WL, SRS), P30CA012197 (to BP; core facility), and DoD grants W81XWH-17-1-0044 (to H-WL), W81XWH-19-1-0072 (to H-WL), and BC181274 (to H-WL).	Abraham BK, 2005, CLIN CANCER RES, V11, P1154; Ahmed MAH, 2012, BREAST CANCER RES TR, V133, P979, DOI 10.1007/s10549-011-1865-8; Akrap N, 2016, STEM CELL REP, V6, P121, DOI 10.1016/j.stemcr.2015.12.006; Almeida MI, 2011, MUTAT RES-FUND MOL M, V717, P1, DOI 10.1016/j.mrfmmm.2011.03.009; Bora-Singhal N, 2015, NEOPLASIA, V17, P538, DOI 10.1016/j.neo.2015.07.001; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Cao X, 2012, ONCOGENE, V31, P104, DOI 10.1038/onc.2011.219; Carpenter RL, 2015, ONCOTARGET, V6, P22653, DOI 10.18632/oncotarget.4248; Dahmane N, 2001, DEVELOPMENT, V128, P5201; Deleidi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019926; Di Mauro C, 2017, BRIT J CANCER, V116, P1425, DOI 10.1038/bjc.2017.116; Duex JE, 2017, CANCER RES, V77, P4858, DOI 10.1158/0008-5472.CAN-17-0367; Ekici K, 2016, J BUON, V21, P958; Fan YH, 2016, ONCOGENE, V35, P116, DOI 10.1038/onc.2015.67; Gril B, 2013, AM J PATHOL, V182, P2368, DOI 10.1016/j.ajpath.2013.02.043; Gwak JM, 2017, ONCOTARGET, V8, P36305, DOI 10.18632/oncotarget.16750; Han W, 2013, CANC HALLMARKS, V1, P28, DOI DOI 10.1166/CH.2013.1006; He DX, 2015, J PHARMACEUT BIOMED, V102, P500, DOI 10.1016/j.jpba.2014.10.018; Huang DL, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0917-x; Komada M, 2008, BIOCHEM BIOPH RES CO, V369, P350, DOI 10.1016/j.bbrc.2008.02.015; Li Q, 2016, J BIOL CHEM, V291, P7171, DOI 10.1074/jbc.M116.714857; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lo HW, 2009, CANCER RES, V69, P6790, DOI 10.1158/0008-5472.CAN-09-0886; Lorger M, 2010, AM J PATHOL, V176, P2958, DOI 10.2353/ajpath.2010.090838; Miyake A, 2005, DEV BIOL, V288, P259, DOI 10.1016/j.ydbio.2005.09.042; Niikura N, 2014, BREAST CANCER RES TR, V147, P103, DOI 10.1007/s10549-014-3090-8; Rimkus TK, 2018, CANCER RES, V78, P2589, DOI 10.1158/0008-5472.CAN-17-2933; Shen L, 2014, BBA-MOL BASIS DIS, V1842, P2087, DOI 10.1016/j.bbadis.2014.07.015; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sirkisoon SR, 2018, ONCOGENE, V37, P2502, DOI 10.1038/s41388-018-0132-4; Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008-5472.CAN-07-5644; Wang JX, 2017, EUR REV MED PHARMACO, V21, P3857; Wang L, 2018, METHODS MOL BIOL, V1692, P31, DOI 10.1007/978-1-4939-7401-6_3; Wang T, 2015, ONCOTARGET, V6, P44191, DOI 10.18632/oncotarget.6176; Wang Z, 2012, CELL STEM CELL, V10, P440, DOI 10.1016/j.stem.2012.02.016; Wang Z, 2017, INT J BIOL MARKER, V32, pE75, DOI 10.5301/jbm.5000224; Wu Q, 2017, ONCOTARGET, V8, P27990, DOI 10.18632/oncotarget.15856; Zhang XM, 2013, CANCER RES, V73, P4885, DOI 10.1158/0008-5472.CAN-12-4081; Zhao XD, 2018, MOL CARCINOGEN, V57, P1616, DOI 10.1002/mc.22884; Zhu H, 2014, CANCER LETT, V343, P51, DOI 10.1016/j.canlet.2013.09.014; Zucchi I, 2004, P NATL ACAD SCI USA, V101, P18147, DOI 10.1073/pnas.0408260101	42	38	40	2	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					64	78		10.1038/s41388-019-0959-3	http://dx.doi.org/10.1038/s41388-019-0959-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31462709	Green Submitted, Green Accepted			2022-12-17	WOS:000509849200006
J	Zheng, J; Zhang, H; Ma, RR; Liu, HT; Gao, P				Zheng, Jie; Zhang, Hui; Ma, Ranran; Liu, Haiting; Gao, Peng			Long non-coding RNA KRT19P3 suppresses proliferation and metastasis through COPS7A-mediated NF-kappa B pathway in gastric cancer	ONCOGENE			English	Article							COP9 SIGNALOSOME; BREAST-CANCER; EXPRESSION; DEGRADATION; HOMOLOG; P53	Long non-coding RNAs (lncRNAs) have emerged as critical regulators in gastric cancer (GC). LncRNA expression microarray data indicate that KRT19P3 (Keratin 19 Pseudogene 3) is downregulated in GC samples. However, the expression pattern and molecular mechanism of KRT19P3 in GC have not been characterized. The present study confirmed the downregulation of KRT19P3 in GC tissues and cells. Decreased expression of KRT19P3 was correlated with larger tumor size, advanced TNM stage, Lauren's classification, positive lymph node metastasis, and poor prognosis. Enforced expression of KRT19P3 significantly inhibited cell proliferation, migration, and invasion in vitro, as well as tumorigenesis and metastasis in vivo. Conversely, KRT19P3 knockdown had opposite effects. Mechanistically, RNA pull-down and RNA immunoprecipitation assay revealed that KRT19P3 could directly bind COPS7A. KRT19P3 enhanced COPS7A protein stability in GC cells, and KRT19P3 suppressed GC cell proliferation and metastasis partly through regulation of COPS7A expression. COPS7A could promote deubiquitinylation of I kappa B alpha, which was executed by CSN-associated deubiquitinylase USP15, and then KRT19P3 inactivated nuclear factor kappa-B (NF-kappa B) signaling pathway in a COPS7A-dependent manner. For the first time, we revealed that KRT19P3 could suppress tumor growth and metastasis through COPS7A-mediated NF-kappa B pathway, which may serve as potential targets for treatment of GC in the future.	[Zheng, Jie; Zhang, Hui; Ma, Ranran; Liu, Haiting; Gao, Peng] Shandong Univ, Minist Educ, Key Lab Expt Teratol, Jinan, Shandong, Peoples R China; [Zheng, Jie; Zhang, Hui; Ma, Ranran; Liu, Haiting; Gao, Peng] Shandong Univ, Sch Med, Dept Pathol, Jinan, Shandong, Peoples R China; [Zheng, Jie] Weifang Med Univ, Dept Pathol, Weifang, Shandong, Peoples R China; [Zhang, Hui; Ma, Ranran; Liu, Haiting; Gao, Peng] Shandong Univ, Qilu Hosp, Dept Pathol, Jinan, Shandong, Peoples R China	Shandong University; Shandong University; Weifang Medical University; Shandong University	Gao, P (corresponding author), Shandong Univ, Minist Educ, Key Lab Expt Teratol, Jinan, Shandong, Peoples R China.; Gao, P (corresponding author), Shandong Univ, Sch Med, Dept Pathol, Jinan, Shandong, Peoples R China.; Gao, P (corresponding author), Shandong Univ, Qilu Hosp, Dept Pathol, Jinan, Shandong, Peoples R China.	gaopeng@sdu.edu.cn			National Science Foundation of China [81672842, 81802474]; Taishan Scholars Program of Shandong Province [ts201511096]; Natural Scientific Foundation of Shandong Province [ZR2015HL091]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Taishan Scholars Program of Shandong Province; Natural Scientific Foundation of Shandong Province(Natural Science Foundation of Shandong Province)	This study was supported by the National Science Foundation of China (Grant No. 81672842 and 81802474), the Taishan Scholars Program of Shandong Province (Grant No. ts201511096), the Natural Scientific Foundation of Shandong Province (ZR2015HL091).	Alves KH, 2002, FEBS LETT, V527, P15, DOI 10.1016/S0014-5793(02)03147-2; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Chen RB, 2017, NUCLEIC ACIDS RES, V45, P9947, DOI 10.1093/nar/gkx600; de Groen FLM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132495; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gong CG, 2011, NATURE, V470, P284, DOI 10.1038/nature09701; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Hou J, 2017, ONCOGENE, V36, P1134, DOI 10.1038/onc.2016.280; Hsu MC, 2008, MODERN PATHOL, V21, P609, DOI [10.1038/modpathol.2008.23, 10.1038/mpath.2008.23]; Hu Y, 2014, CANCER RES, V74, P6890, DOI 10.1158/0008-5472.CAN-14-0686; Kouvaraki MA, 2003, CANCER RES, V63, P2977; Liu TY, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0873-2; Lu MH, 2016, ONCOGENE, V35, P3524, DOI 10.1038/onc.2015.413; Mao LX, 2019, EXP CELL RES, V374, P274, DOI 10.1016/j.yexcr.2018.10.012; Qi FZ, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0420-4; Sasaki N, 2001, CLIN CANCER RES, V7, P4136; Schweitzer K, 2007, EMBO J, V26, P1532, DOI 10.1038/sj.emboj.7601600; Shackleford TJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2902; Shi XF, 2013, CANCER LETT, V339, P159, DOI 10.1016/j.canlet.2013.06.013; Sokolova O, 2017, TOXINS, V9, DOI 10.3390/toxins9040119; Uhle S, 2003, EMBO J, V22, P1302, DOI 10.1093/emboj/cdg127; Wang H, 2018, THERANOSTICS, V8, P2814, DOI 10.7150/thno.23012; Wang YL, 2002, BIOCHEM J, V366, P79, DOI 10.1042/bj20020211; Wicker CA, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3313-y; Yang F, 2011, HEPATOLOGY, V54, P1679, DOI 10.1002/hep.24563; Zhao RY, 2011, J CLIN INVEST, V121, P851, DOI 10.1172/JCI44111; Zhu YP, 2014, ONCOL LETT, V7, P1197, DOI 10.3892/ol.2014.1843	28	38	41	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2019	38	45					7073	7088		10.1038/s41388-019-0934-z	http://dx.doi.org/10.1038/s41388-019-0934-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JL9XI	31409899				2022-12-17	WOS:000495878400004
J	Zhou, LS; Jiang, YY; Liu, XJ; Li, LH; Yang, XG; Dong, CS; Liu, XL; Lin, YL; Li, Y; Yu, JH; He, R; Huang, SL; Liu, GW; Zhang, YM; Jeong, LS; Hoffman, RM; Jia, LJ				Zhou, Lisha; Jiang, Yanyu; Liu, Xiaojun; Li, Lihui; Yang, Xuguang; Dong, Changsheng; Liu, Xiaoli; Lin, Yuli; Li, Yan; Yu, Jinha; He, Rui; Huang, Shenglin; Liu, Guangwei; Zhang, Yanmei; Jeong, Lak Shin; Hoffman, Robert M.; Jia, Lijun			Promotion of tumor-associated macrophages infiltration by elevated neddylation pathway via NF-kappa B-CCL2 signaling in lung cancer	ONCOGENE			English	Article							NEDD8-ACTIVATING ENZYME-INHIBITOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1; PEVONEDISTAT TAK-924/MLN4924; BREAST-CANCER; PHASE-I; EXPRESSION; MLN4924; PROGRESSION; SURVIVAL; GROWTH	Tumor-associated macrophages (TAMs) are the most abundant cancer stromal cells and play an essential role in tumor immunosuppression, providing a suitable microenvironment for cancer development and progression. However, mechanisms of regulating TAMs infiltration in tumor sites are not fully understood. Here, we show that inactivation of neddylation pathway significantly inhibits infiltration of TAMs, leading to the suppression of lung cancer metastasis. RNA-sequencing analysis revealed that neddylation inactivation suppresses the transactivation of chemotactic cytokine ligand 2 (CCL2). Mechanistically, neddylation inactivation inhibits the activity of Cullin-RING ligases (CRLs) and induces the accumulation of its substrate I kappa B alpha to block NF-kappa B transcriptional activity and CCL2 transactivation. As a result, neddylation inactivation exhibits lower chemotaxis of monocytes, thereby decreasing TAMs infiltration, which can be alleviated by CCL2 addition. Moreover, the expression level of NEDD8 is positively correlated with high CCL2 expression in lung adenocarcinoma, conferring a worse overall patient survival. Together, neddylation pathway promotes CCL2 transactivation and TAMs infiltration in lung cancer to provide a tumor-promoting microenvironment, which validates neddylation pathway as a promising target for anti-TAMs therapeutic strategies.	[Zhou, Lisha; Li, Lihui; Yang, Xuguang; Dong, Changsheng; Jia, Lijun] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Canc Inst, Shanghai, Peoples R China; [Jiang, Yanyu; Liu, Xiaojun; Liu, Xiaoli; Huang, Shenglin] Fudan Univ, Shanghai Canc Ctr, Canc Inst, Shanghai, Peoples R China; [Lin, Yuli; He, Rui] Fudan Univ, Sch Basic Med Sci, Dept Immunol, Shanghai, Peoples R China; [Li, Yan; Liu, Guangwei] Beijing Normal Univ, Coll Life Sci, Beijing, Peoples R China; [Yu, Jinha; Jeong, Lak Shin] Seoul Natl Univ, Coll Pharm, Seoul, South Korea; [Zhang, Yanmei] Fudan Univ, Huaong Hosp, Dept Lab Med, Shanghai, Peoples R China; [Hoffman, Robert M.] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA	Shanghai University of Traditional Chinese Medicine; Fudan University; Fudan University; Beijing Normal University; Seoul National University (SNU); Fudan University; University of California System; University of California San Diego	Jia, LJ (corresponding author), Shanghai Univ Tradit Chinese Med, Longhua Hosp, Canc Inst, Shanghai, Peoples R China.	ljjia@shutcm.edu.cn	Dong, Changsheng/HCH-9181-2022; He, Rui/P-7302-2019; Yang, Xuguang/GNP-2847-2022; Dong, Changsheng/AAX-2495-2020; Yu, Jinha/AAS-6463-2021; Liu, Xiaoli/HGE-7614-2022; Huang, Shenglin/N-9472-2018	He, Rui/0000-0001-5288-9786; Yang, Xuguang/0000-0002-6198-6008; Liu, Guangwei/0000-0002-6008-2891; YU, JINHA/0000-0002-0495-5686; Huang, Shenglin/0000-0003-1279-0794	Chinese Minister of Science and Technology grant [2016YFA0501800]; National Natural Science Foundation of China [81820108022, 81625018, 81572340, 81772470, 81602072, 81401893, 81702244, 81871870]; Innovation Program of Shanghai Municipal Education Commission [2019-01-07-00-10-E00056]; National Thirteenth Five-Year Science and Technology Major Special Project for New Drug and Development [2017ZX09304001]; Program of Shanghai Academic/Technology Research Leader [18XD1403800]	Chinese Minister of Science and Technology grant; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation Program of Shanghai Municipal Education Commission(Innovation Program of Shanghai Municipal Education Commission); National Thirteenth Five-Year Science and Technology Major Special Project for New Drug and Development; Program of Shanghai Academic/Technology Research Leader	The Chinese Minister of Science and Technology grant (2016YFA0501800), National Natural Science Foundation of China (Grant Nos. 81820108022, 81625018, 81572340, 81772470, 81602072, 81401893, 81702244 and 81871870), Innovation Program of Shanghai Municipal Education Commission (2019-01-07-00-10-E00056), National Thirteenth Five-Year Science and Technology Major Special Project for New Drug and Development (2017ZX09304001), and Program of Shanghai Academic/Technology Research Leader (18XD1403800), supported this work.	Bhatia S, 2016, INVEST NEW DRUG, V34, P439, DOI 10.1007/s10637-016-0348-5; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Brownell JE, 2010, MOL CELL, V37, P102, DOI 10.1016/j.molcel.2009.12.024; Chanmee T, 2014, CANCERS, V6, P1670, DOI 10.3390/cancers6031670; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013; Enchev RI, 2015, NAT REV MOL CELL BIO, V16, P30, DOI 10.1038/nrm3919; EZEKOWITZ RAB, 1984, CONTEMP TOP IMMUNOBI, V13, P33; Fridlender ZG, 2011, AM J RESP CELL MOL, V44, P230, DOI 10.1165/rcmb.2010-0080OC; Gao Q, 2014, ONCOTARGET, V5, P7820, DOI 10.18632/oncotarget.2309; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hao JQ, 2018, CANCER RES, V78, P2343, DOI 10.1158/0008-5472.CAN-17-2465; Heagerty PJ, 2000, BIOMETRICS, V56, P337, DOI 10.1111/j.0006-341X.2000.00337.x; Heusinkveld M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-216; Hildebrand DG, 2013, J IMMUNOL, V190, P4812, DOI 10.4049/jimmunol.1300089; Hua W, 2015, NEURO-ONCOLOGY, V17, P1333, DOI 10.1093/neuonc/nov066; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Lee HW, 2011, J ORG CHEM, V76, P3557, DOI 10.1021/jo2001897; Li LH, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju083; Li XG, 2017, GUT, V66, P157, DOI 10.1136/gutjnl-2015-310514; Li XJ, 2016, NAT CELL BIOL, V18, P561, DOI 10.1038/ncb3338; Lu Y, 2006, PROSTATE, V66, P1311, DOI 10.1002/pros.20464; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Pachynski RK, 2012, J EXP MED, V209, P1427, DOI 10.1084/jem.20112124; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Sarantopoulos J, 2016, CLIN CANCER RES, V22, P847, DOI 10.1158/1078-0432.CCR-15-1338; Shah JJ, 2016, CLIN CANCER RES, V22, P34, DOI 10.1158/1078-0432.CCR-15-1237; Soria G, 2008, CYTOKINE, V44, P191, DOI 10.1016/j.cyto.2008.08.002; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Swords RT, 2018, BLOOD, V131, P1415, DOI 10.1182/blood-2017-09-805895; Swords RT, 2015, BRIT J HAEMATOL, V169, P534, DOI 10.1111/bjh.13323; Tan M, 2014, ONCOGENE, V33, P5211, DOI 10.1038/onc.2013.473; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Wang YC, 2015, CANCER BIOL THER, V16, P420, DOI 10.1080/15384047.2014.1003003; Williams CB, 2016, NPJ BREAST CANCER, V2, DOI 10.1038/npjbcancer.2015.25; Xie P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.195; Xirodimas DP, 2008, BIOCHEM SOC T, V36, P802, DOI 10.1042/BST0360802; Yao WT, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.21; Yoshidome H, 2009, INT J ONCOL, V34, P923, DOI 10.3892/ijo_00000218; Yu GZ, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0462-6; Zhang JX, 2013, LANCET ONCOL, V14, P1295, DOI 10.1016/S1470-2045(13)70491-1; Zhou LS, 2018, CELL SIGNAL, V44, P92, DOI 10.1016/j.cellsig.2018.01.009	47	38	39	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2019	38	29					5792	5804		10.1038/s41388-019-0840-4	http://dx.doi.org/10.1038/s41388-019-0840-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IQ4WS	31243299				2022-12-17	WOS:000480752800004
J	Fletcher, CE; Sulpice, E; Combe, S; Shibakawa, A; Leach, DA; Hamilton, MP; Chrysostomou, SL; Sharp, A; Welti, J; Yuan, W; Dart, DA; Knight, E; Ning, J; Francis, JC; Kounatidou, EE; Gaughan, L; Swain, A; Lupold, SE; de Bono, JS; McGuire, SE; Gidrol, X; Bevan, CL				Fletcher, Claire E.; Sulpice, Eric; Combe, Stephanie; Shibakawa, Akifumi; Leach, Damien A.; Hamilton, Mark P.; Chrysostomou, Stelios L.; Sharp, Adam; Welti, Jon; Yuan, Wei; Dart, Dafydd A.; Knight, Eleanor; Ning, Jian; Francis, Jeffrey C.; Kounatidou, Evangelia E.; Gaughan, Luke; Swain, Amanda; Lupold, Shawn E.; de Bono, Johann S.; McGuire, Sean E.; Gidrol, Xavier; Bevan, Charlotte L.			Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer	ONCOGENE			English	Article							EXPRESSION SIGNATURE; CELLS; GENE; PROLIFERATION; PROHIBITIN; VARIANTS; IDENTIFICATION; REGIONS; PROTEIN; TUMORS	Androgen receptor (AR) signalling is a key prostate cancer (PC) driver, even in advanced 'castrate-resistant' disease (CRPC). To systematically identify microRNAs (miRs) modulating AR activity in lethal disease, hormone-responsive and -resistant PC cells expressing a luciferase-based AR reporter were transfected with a miR inhibitor library; 78 inhibitors significantly altered AR activity. Upon validation, miR-346, miR-361-3p and miR-197 inhibitors markedly reduced AR transcriptional activity, mRNA and protein levels, increased apoptosis, reduced proliferation, repressed EMT, and inhibited PC migration and invasion, demonstrating additive effects with AR inhibition. Corresponding miRs increased AR activity through a novel and anti-dogmatic mechanism of direct association with AR 6.9 kb 3' UTR and transcript stabilisation. In addition, miR-346 and miR-361-3p modulation altered levels of constitutively active AR variants, and inhibited variantdriven PC cell proliferation, so may contribute to persistent AR signalling in CRPC in the absence of circulating androgens. Pathway analysis of AGO-PAR-CLIP-identified miR targets revealed roles in DNA replication and repair, cell cycle, signal transduction and immune function. Silencing these targets, including tumour suppressors ARHGDIA and TAGLN2, phenocopied miR effects, demonstrating physiological relevance. MiR-346 additionally upregulated the oncogene, YWHAZ, which correlated with grade, biochemical relapse and metastasis in patients. These AR-modulatory miRs and targets correlated with AR activity in patient biopsies, and were elevated in response to long-term enzalutamide treatment of patient-derived CRPC xenografts. In summary, we identified miRs that modulate AR activity in PC and CRPC, via novel mechanisms, and may represent novel PC therapeutic targets.	[Fletcher, Claire E.; Shibakawa, Akifumi; Leach, Damien A.; Chrysostomou, Stelios L.; Dart, Dafydd A.; Bevan, Charlotte L.] Hammersmith Hosp, Imperial Ctr Translat & Expt Med, Dept Surg & Canc, Imperial Coll London, Du Cane Rd, London W12 0NN, England; [Sulpice, Eric; Combe, Stephanie; Knight, Eleanor; Gidrol, Xavier] Univ Grenoble Alpes, CEA, INSERM, BIG,BGE, 17 Ave Martyrs, F-38054 Grenoble, France; [Hamilton, Mark P.] Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza Houston M822, Houston, TX 77030 USA; [Sharp, Adam; Welti, Jon; Yuan, Wei; de Bono, Johann S.] Inst Canc Res, Prostate Canc Target Therapy Grp, Sutton, Surrey, England; [Sharp, Adam; Welti, Jon; Yuan, Wei; de Bono, Johann S.] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England; [Ning, Jian; Francis, Jeffrey C.; Swain, Amanda] Inst Canc Res, Tumour Profiling Unit, London SW3 6JB, England; [Kounatidou, Evangelia E.; Gaughan, Luke] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Lupold, Shawn E.] Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD USA; [McGuire, Sean E.] Med Hosp, Dept Mol & Cell Biol, Baylor Coll, Houston, TX USA; [McGuire, Sean E.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [McGuire, Sean E.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA	Imperial College London; CEA; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); Baylor College of Medicine; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Newcastle University - UK; Johns Hopkins University; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Bevan, CL (corresponding author), Hammersmith Hosp, Imperial Ctr Translat & Expt Med, Dept Surg & Canc, Imperial Coll London, Du Cane Rd, London W12 0NN, England.	charlotte.bevan@imperial.ac.uk	Bevan, Charlotte L/K-2276-2012	Bevan, Charlotte L/0000-0002-7533-0552; Leach, Damien/0000-0003-3203-9826; de Bono, Johann S/0000-0002-2034-595X; Sulpice, Eric/0000-0001-7695-0561; Fletcher, Claire/0000-0003-2083-2798; Sharp, Adam/0000-0002-3740-1612; Gidrol, Xavier/0000-0002-4233-3749	Prostate Cancer UK; Movember Foundation through the London Movember Centre of Excellence [CEO13_2-002]; Prostate Cancer Foundation; Movember; MRC [MR/M018318/1] Funding Source: UKRI	Prostate Cancer UK; Movember Foundation through the London Movember Centre of Excellence; Prostate Cancer Foundation; Movember; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We are grateful for the assistance of Laurent Guyon and Kristina Skare with statistical analysis of screening data. This work was supported by Prostate Cancer UK and the Movember Foundation through the London Movember Centre of Excellence (CEO13_2-002). We also gratefully acknowledge funding from Movember, Prostate Cancer UK and also the Prostate Cancer Foundation, and infrastructure support from the Cancer Research UK Imperial Centre, the Imperial Experimental Cancer Medicine Centre and the National Institute for Health Research Imperial Biomedical Research Centre.	Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Brideau C, 2003, J BIOMOL SCREEN, V8, P634, DOI 10.1177/1087057103258285; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Cheng HL, 2011, METHODS MOL BIOL, V776, P95, DOI 10.1007/978-1-61779-243-4_7; Dart DA, 2009, ENDOCR-RELAT CANCER, V16, P1157, DOI 10.1677/ERC-09-0028; Epis MR, 2009, J BIOL CHEM, V284, P24696, DOI 10.1074/jbc.M109.030098; Gamble SC, 2007, ONCOGENE, V26, P1757, DOI 10.1038/sj.onc.1209967; Gamble SC, 2004, ONCOGENE, V23, P2996, DOI 10.1038/sj.onc.1207444; Gandellini P, 2010, DISCOV MED, V9, P212; Goc A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040594; Guo JF, 2015, J BIOL CHEM, V290, P30342, DOI 10.1074/jbc.M115.691857; Guzel E, 2015, INT J CANCER, V136, P875, DOI 10.1002/ijc.29054; Hagman Z, 2013, BRIT J CANCER, V108, P1668, DOI 10.1038/bjc.2013.131; Hamilton MP, 2016, NEOPLASIA, V18, P356, DOI 10.1016/j.neo.2016.04.008; Hu R, 2011, PROSTATE, V71, P1656, DOI 10.1002/pros.21382; James ND, 2017, NEW ENGL J MED, V377, P338, DOI 10.1056/NEJMoa1702900; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kashat M, 2012, AM J TRANSL RES, V4, P432; Kim D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r72; Koivisto P, 1998, AM J PATHOL, V152, P1; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Kumar A, 2016, NAT MED, V22, P369, DOI 10.1038/nm.4053; Kumar B, 2016, ONCOTARGET, V7, P72593, DOI 10.18632/oncotarget.12241; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Larne O, 2015, EUR UROL, V68, P581, DOI 10.1016/j.eururo.2014.12.025; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031; Murata T, 2012, CLIN CANCER RES, V18, P5617, DOI 10.1158/1078-0432.CCR-12-0281; Nadiminty N, 2012, J BIOL CHEM, V287, P1527, DOI 10.1074/jbc.M111.278705; Nyquist MD, 2013, P NATL ACAD SCI USA, V110, P17492, DOI 10.1073/pnas.1308587110; Ostling P, 2011, CANCER RES, V71, P1956, DOI 10.1158/0008-5472.CAN-10-2421; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Pang YX, 2010, ACTA BIOCH BIOPH SIN, V42, P363, DOI 10.1093/abbs/gmq038; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Qu FJ, 2013, MOL CELL BIOCHEM, V377, P121, DOI 10.1007/s11010-013-1576-z; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sikand Kavleen, 2011, Mol Cell Pharmacol, V3, P107; Sikand K, 2011, INT J CANCER, V129, P810, DOI 10.1002/ijc.25753; Song G, 2015, SCI REP-UK, V5, DOI 10.1038/srep15793; Takkunen M, 2006, J HISTOCHEM CYTOCHEM, V54, P1263, DOI 10.1369/jhc.6A6958.2006; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Van Etten JL, 2017, CANCER RES, V77, P5228, DOI 10.1158/0008-5472.CAN-17-0320; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wadosky KM, 2016, ONCOTARGET, V7, P64447, DOI 10.18632/oncotarget.10901; Waltering KK, 2006, PROSTATE, V66, P1585, DOI 10.1002/pros.20387; Wang G, 2006, ONCOGENE, V25, P7311, DOI 10.1038/sj.onc.1209715; Ware KE, 2014, ENDOCR-RELAT CANCER, V21, pT87, DOI 10.1530/ERC-13-0470; Yang ZM, 2007, MOL ENDOCRINOL, V21, P343, DOI 10.1210/me.2006-0104; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Zhang BL, 2005, CANCER RES, V65, P6054, DOI 10.1158/0008-5472.CAN-05-0175; Zhang ZW, 2010, ASIAN J ANDROL, V12, P186, DOI 10.1038/aja.2009.76; Zhu YZ, 2013, PROSTATE, V73, P1614, DOI 10.1002/pros.22615; Zohn IE, 2006, CELL, V125, P957, DOI 10.1016/j.cell.2006.03.048	56	38	41	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5700	5724		10.1038/s41388-019-0823-5	http://dx.doi.org/10.1038/s41388-019-0823-5			25	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	31043708	hybrid, Green Published			2022-12-17	WOS:000474845100011
J	McLean, K; Tan, LJ; Bolland, DE; Coffman, LG; Peterson, LF; Talpaz, M; Neamati, N; Buckanovich, RJ				McLean, Karen; Tan, Lijun; Bolland, Danielle E.; Coffman, Lan G.; Peterson, Luke F.; Talpaz, Moshe; Neamati, Nouri; Buckanovich, Ronald J.			Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth	ONCOGENE			English	Article							STEM-CELLS; PROGNOSTIC-SIGNIFICANCE; CARCINOMA; TUMORIGENESIS; METASTASIS; EXPRESSION; RESISTANCE; MODEL; LINE	Ovarian carcinoma-associated mesenchymal stem cells (CA-MSC) produce not only high levels of interleukin-6 (IL6) but also the related cytokine leukemia inhibitory factor (LIF). IL6-mediated activation of STAT3 is implicated as a critical therapeutic target for cancer therapy. Less is known about the role of LIF, which can similarly activate STAT3, in ovarian cancer. We therefore sought to evaluate the tumorigenic effects of CA-MSC paracrine LIF signaling and the redundancy of IL6 and LIF in activating ovarian cancer STAT3 mediated cancer growth. As expected, we found that both IL6 and LIF induce STAT3 phosphorylation in tumor cells. In addition, both IL6 and LIF increased the percentage of ALDH+ ovarian cancer stem-like cells (CSC). Supporting redundancy of function by the two cytokines, CA-MSC induced STAT3 phosphorylation and increased cancer cell "stemness". This effect was not inhibited by LIF or IL6 blocking antibodies alone, but was prevented by dual IL6/LIF blockade or JAK2 inhibition. Similarly, small hairpin RNA (shRNA)-mediated reduction of IL6 or LIF in CA-MSC partially decreased but could not completely abrograte the ability of CA-MSC to induce STAT3 phosphorylation and stemness. Importantly, the in vivo pro-tumorigenic effect of CA-MSC is abrogated by dual blockade with the JAK2 inhibitor ruxolitinib to a much greater extent than treatment with anti-IL6 or anti-LIF antibody alone. Ruxolitinib treatment also improves survival in the immunocompetent ovarian cancer mouse model system with ID8 tumor cells plus MSC. Ruxolitinib-treated tumors in both the immunocompromised and immunocompetent animal models demonstrate decreased phospho-STAT3, indicating on-target activity. In conclusion, CA-MSC activate ovarian cancer cell STAT3 signaling via IL6 and LIF and increase tumor cell stemness. This functional redundancy suggests that therapeutic targeting of a single cytokine may be less effective than strategies such as dual inhibitor therapy or targeting shared downstream factors of the JAK/STAT pathway.	[McLean, Karen; Tan, Lijun; Bolland, Danielle E.] Univ Michigan, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Ann Arbor, MI 48109 USA; [Coffman, Lan G.; Buckanovich, Ronald J.] Univ Pittsburgh, Sch Med, Magee Womens Res Inst, Pittsburgh, PA USA; [Peterson, Luke F.; Talpaz, Moshe] Univ Michigan, Med Ctr, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; [Neamati, Nouri] Coll Pharm, Dept Med Chem, North Campus Res Complex, Ann Arbor, MI USA	University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; University of Michigan System; University of Michigan	McLean, K (corresponding author), Univ Michigan, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Ann Arbor, MI 48109 USA.	karenmcl@umich.edu	Coffman, Lan/AAP-7600-2021	Talpaz, Moshe/0000-0003-3361-3981; Coffman, Lan/0000-0002-3753-1652	Women's Reproductive Health Research (WRHR) Career Development Program Award [K12 HD065257]; Department of Defense Ovarian Cancer Academy Early-Career Investigator Award [DOD W81XWH-15-0194]; Goldberg Family; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD065257] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K08CA211362] Funding Source: NIH RePORTER	Women's Reproductive Health Research (WRHR) Career Development Program Award; Department of Defense Ovarian Cancer Academy Early-Career Investigator Award; Goldberg Family; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors would like to thank Yusong Gong for her technical assistance in the beginning stages of this project. Funding for this work has been provided in part by the Women's Reproductive Health Research (WRHR) Career Development Program Award to KM (National Institutes of Health, K12 HD065257), the Department of Defense Ovarian Cancer Academy Early-Career Investigator Award to KM (DOD W81XWH-15-0194), and the generous support of the Goldberg Family.	American Cancer Society, SURV RAT OV CANC STA; Anglesio MS, 2011, CLIN CANCER RES, V17, P2538, DOI 10.1158/1078-0432.CCR-10-3314; Burgos-Ojeda D, 2013, CANCER RES, V73, P3555, DOI 10.1158/0008-5472.CAN-12-2845; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Coffman LG, 2016, ONCOTARGET, V7, P6916, DOI 10.18632/oncotarget.6870; Corcoran RB, 2011, CANCER RES, V71, P5020, DOI 10.1158/0008-5472.CAN-11-0908; Coward J, 2011, CLIN CANCER RES, V17, P6083, DOI 10.1158/1078-0432.CCR-11-0945; Dijkgraaf EM, 2015, ANN ONCOL, V26, P2141, DOI 10.1093/annonc/mdv309; Ding DC, 2016, J CANCER, V7, P1815, DOI 10.7150/jca.16116; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Gritsina G, 2015, MOL CANCER THER, V14, P1035, DOI 10.1158/1535-7163.MCT-14-0800; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Kenny HA, 2011, CANCER DISCOV, V1, P100, DOI 10.1158/2159-8290.CD-11-0117; Kim B, 2017, CANCER RES TREAT, V49, P338, DOI 10.4143/crt.2016.175; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Lane D, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-210; McLean K, 2011, J CLIN INVEST, V121, P3206, DOI 10.1172/JCI45273; Musrap N, 2012, MOL CANCER RES, V10, P1254, DOI 10.1158/1541-7786.MCR-12-0353; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Pardanani A, 2007, LEUKEMIA, V21, P1658, DOI 10.1038/sj.leu.2404750; Penuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Saini U, 2017, ONCOGENE, V36, P168, DOI 10.1038/onc.2016.197; SCAMBIA G, 1995, BRIT J CANCER, V71, P354, DOI 10.1038/bjc.1995.71; VANDAM M, 1993, J BIOL CHEM, V268, P15285; Wang WM, 2016, CELL, V165, P1092, DOI 10.1016/j.cell.2016.04.009; Xu SL, 2013, MOL CANCER THER, V12, P937, DOI 10.1158/1535-7163.MCT-12-1082; Ye F, 2008, HISTOPATHOLOGY, V53, P224, DOI 10.1111/j.1365-2559.2008.03068.x; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Zhou T, 2014, LEUKEMIA, V28, P471, DOI 10.1038/leu.2013.299	30	38	39	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1576	1584		10.1038/s41388-018-0523-6	http://dx.doi.org/10.1038/s41388-018-0523-6			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30305729	Green Accepted			2022-12-17	WOS:000459945800015
J	Liu, ZX; Zhang, WL; Phillips, JB; Arora, R; McClellan, S; Li, JF; Kim, JH; Sobol, RW; Tan, M				Liu, Zixing; Zhang, Wenling; Phillips, Joshua B.; Arora, Ritu; McClellan, Steven; Li, Jiangfeng; Kim, Jin-Hwan; Sobol, Robert W.; Tan, Ming			Immunoregulatory protein B7-H3 regulates cancer stem cell enrichment and drug resistance through MVP-mediated MEK activation	ONCOGENE			English	Article							MAJOR VAULT PROTEIN; RAS-INDEPENDENT ACTIVATION; PROSTATE-CANCER; LIGAND EXPRESSION; BREAST-CANCER; PROLIFERATION; INHIBITION; POLARITY; PATHWAY; GROWTH	B7-H3 is a tumor-promoting glycoprotein that is expressed at low levels in most normal tissues, but is overexpressed in various human cancers which is associated with disease progression and poor patient outcome. Although numerous publications have reported the correlation between B7-H3 and cancer progression in many types of cancers, mechanistic studies on how B7-H3 regulates cancer malignancy are rare, and the mechanisms underlying the role of B7-H3 in drug resistance are almost unknown. Here we report a novel finding that upregulation of B7-H3 increases the breast cancer stem cell population and promotes cancer development. Depletion of B7-H3 in breast cancer significantly inhibits the cancer stem cells. By immunoprecipitation and mass spectrometry, we found that B7-H3 is associated with the major vault protein (MVP) and activates MEK through MVP-enhancing B-RAF and MEK interaction. B7-H3 expression increases stem cell population by binding to MVP which regulates the activation of the MAPK kinase pathway. Depletion of MVP blocks the activation of MEK induced by B7-H3 and dramatically inhibits B7-H3 induced stem cells. This study reports novel functions of B7-H3 in regulating breast cancer stem cell enrichment. The novel mechanism for B7-H3-induced stem cell propagation by regulating MVP/MEK signaling axis independent of the classic Ras pathway may have important implications in the development of strategies for overcoming cancer cell resistance to chemotherapy.	[Liu, Zixing; Phillips, Joshua B.; Arora, Ritu; McClellan, Steven; Li, Jiangfeng; Kim, Jin-Hwan; Sobol, Robert W.; Tan, Ming] Univ S Alabama, Mitchell Canc Inst, Mobile, AL 36688 USA; [Zhang, Wenling] Cent S Univ, Xiangya Sch Med, Dept Med Lab Sci, Changsha, Hunan, Peoples R China; [Tan, Ming] Univ S Alabama, Dept Biochem & Mol Biol, 307N Univ Blvd, Mobile, AL 36688 USA	University of South Alabama; Central South University; University of South Alabama	Tan, M (corresponding author), Univ S Alabama, Mitchell Canc Inst, Mobile, AL 36688 USA.; Tan, M (corresponding author), Univ S Alabama, Dept Biochem & Mol Biol, 307N Univ Blvd, Mobile, AL 36688 USA.	mtan@health.southalabama.edu	Tan, Ming/ABD-5847-2021; Sobol, Robert W./E-4125-2013	Tan, Ming/0000-0003-2007-9898; Sobol, Robert W./0000-0001-7385-3563	NIH [CA148629, R01CA149646]; Vincent F. Kilborn, Jr. Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R01CA149646, R01CA148629] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Vincent F. Kilborn, Jr. Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH grants R01CA149646 (to M. Tan), the Vincent F. Kilborn, Jr. Cancer Research Foundation (to MT). NIH CA148629 to RWS. RWS is an Abraham A. Mitchell Distinguished Investigator.	Abubaker K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-317; Henriquez-Hernandez LA, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-147; Arigami T, 2010, ANN SURG, V252, P1044, DOI 10.1097/SLA.0b013e3181f1939d; Bender RHF, 2015, STEM CELLS, V33, P1998, DOI 10.1002/stem.1990; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Chavin G, 2009, CLIN CANCER RES, V15, P2174, DOI 10.1158/1078-0432.CCR-08-2262; Drosten M, 2014, P NATL ACAD SCI USA, V111, P15155, DOI 10.1073/pnas.1417549111; Galuppo R, 2014, ANTICANCER RES, V34, P1709; Gandalovicova A, 2016, ONCOTARGET, V7, P25022, DOI 10.18632/oncotarget.7214; Godde NJ, 2010, J MAMMARY GLAND BIOL, V15, P149, DOI 10.1007/s10911-010-9180-2; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Halaoui R, 2015, ONCOGENE, V34, P939, DOI 10.1038/onc.2014.59; Haling JR, 2014, CANCER CELL, V26, P402, DOI 10.1016/j.ccr.2014.07.007; Ingebrigtsen VA, 2012, INT J CANCER, V131, P2528, DOI 10.1002/ijc.27566; Kim E, 2006, FEBS J, V273, P793, DOI 10.1111/j.1742-4658.2006.05112.x; Kolli S, 2004, J BIOL CHEM, V279, P29374, DOI 10.1074/jbc.M313955200; Leitner J, 2009, EUR J IMMUNOL, V39, P1754, DOI 10.1002/eji.200839028; Lemke D, 2012, CLIN CANCER RES, V18, P105, DOI 10.1158/1078-0432.CCR-11-0880; Lim S, 2016, CANCER RES, V76, P2231, DOI 10.1158/0008-5472.CAN-15-1538; Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011; Liu H, 2011, MOL CANCER THER, V10, P960, DOI 10.1158/1535-7163.MCT-11-0072; Luo LQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130126; Luo LQ, 2004, J IMMUNOL, V173, P5445, DOI 10.4049/jimmunol.173.9.5445; Macara IG, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2013.0012; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Minaguchi T, 2006, CANCER RES, V66, P11677, DOI 10.1158/0008-5472.CAN-06-2240; Parker AS, 2011, INT J RADIAT ONCOL, V79, P1343, DOI 10.1016/j.ijrobp.2010.01.061; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Roth TJ, 2007, CANCER RES, V67, P7893, DOI 10.1158/0008-5472.CAN-07-1068; Rycaj K, 2015, CANCER RES, V75, P4003, DOI 10.1158/0008-5472.CAN-15-0798; Scheffer GL, 2000, CURR OPIN ONCOL, V12, P550, DOI 10.1097/00001622-200011000-00007; Schmidt M, 2000, J BIOL CHEM, V275, P41011, DOI 10.1074/jbc.M003716200; Teng Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14448; Vigdorovich V, 2013, STRUCTURE, V21, P707, DOI 10.1016/j.str.2013.03.003; Vinogradov S, 2012, NANOMEDICINE-UK, V7, P597, DOI [10.2217/NNM.12.22, 10.2217/nnm.12.22]; Wang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070689; Wang ZS, 2016, ONCOTARGET, V7, P44266, DOI 10.18632/oncotarget.10023; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; Xu H, 2009, CANCER RES, V69, P6275, DOI 10.1158/0008-5472.CAN-08-4517; Yi CL, 2005, CANCER RES, V65, P5835, DOI 10.1158/0008-5472.CAN-05-0423; Zang X, 2007, P NATL ACAD SCI USA, V104, P19458, DOI 10.1073/pnas.0709802104; Zang XX, 2010, MODERN PATHOL, V23, P1104, DOI 10.1038/modpathol.2010.95; Zhang GB, 2009, LUNG CANCER, V66, P245, DOI 10.1016/j.lungcan.2009.01.017; Zhang W, 2015, CELL SIGNAL, V27, P436, DOI 10.1016/j.cellsig.2014.12.010; Zhou B, 2014, J SURG RES, V188, P396, DOI 10.1016/j.jss.2014.01.014	47	38	40	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					88	102		10.1038/s41388-018-0407-9	http://dx.doi.org/10.1038/s41388-018-0407-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30082909	Green Accepted			2022-12-17	WOS:000454775900007
J	Yui, OM; Benitez, JA; Plouffe, SW; Ryback, D; Klein, A; Smith, J; Greenbaum, J; Delatte, B; Rao, A; Guan, KL; Furnari, FB; Chaim, OM; Miyamoto, S; Brown, JH				Yui, Olivia M.; Benitez, Jorge A.; Plouffe, Steven W.; Ryback, Daniel; Klein, Andrea; Smith, Jeff; Greenbaum, Jason; Delatte, Benjamin; Rao, Anjana; Guan, Kun-Liang; Furnari, Frank B.; Chaim, Olga Meiri; Miyamoto, Shigeki; Brown, Joan Heller			YAP and MRTF-A, transcriptional co-activators of RhoA-mediated gene expression, are critical for glioblastoma tumorigenicity	ONCOGENE			English	Article							PROTEIN-COUPLED RECEPTOR; YES-ASSOCIATED PROTEIN; NUCLEOTIDE EXCHANGE FACTOR; TISSUE FACTOR EXPRESSION; LEUKEMIA-ASSOCIATED RHO; CELL-PROLIFERATION; THROMBIN RECEPTOR; CAUSES TRANSFORMATION; RAS TRANSFORMATION; ACTIVATES YAP/TAZ	The role of YAP (Yes-associated protein 1) and MRTF-A (myocardin-related transcription factor A), two transcriptional coactivators regulated downstream of GPCRs (G protein-coupled receptors) and RhoA, in the growth of glioblastoma cells and in vivo glioblastoma multiforme (GBM) tumor development was explored using human glioblastoma cell lines and tumor-initiating cells derived from patient-derived xenografts (PDX). Knockdown of these co-activators in GSC-23 PDX cells using short hairpin RNA significantly attenuated in vitro self-renewal capability assessed by limiting dilution, oncogene expression, and neurosphere formation. Orthotopic xenografts of the MRTF-A and YAP knockdown PDX cells formed significantly smaller tumors and were of lower morbidity than wild-type cells. In vitro studies used PDX and 1321N1 glioblastoma cells to examine functional responses to sphingosine 1-phosphate (S1P), a GPCR agonist that activates RhoA signaling, demonstrated that YAP signaling was required for cell migration and invasion, whereas MRTF-A was required for cell adhesion; both YAP and MRTF-A were required for proliferation. Gene expression analysis by RNA-sequencing of S1P-treated MRTF-A or YAP knockout cells identified 44 genes that were induced through RhoA and highly dependent on YAP, MRTF-A, or both. Knockdown of F3 (tissue factor (TF)), a target gene regulated selectively through YAP, blocked cell invasion and migration, whereas knockdown of HBEGF (heparin-binding epidermal growth factor-like growth factor), a gene selectively induced through MRTF-A, prevented cell adhesion in response to S1P. Proliferation was sensitive to knockdown of target genes regulated through either or both YAP and MRTF-A. Expression of TF and HBEGF was also selectively decreased in tumors from PDX cells lacking YAP or MRTF-A, indicating that these transcriptional pathways are regulated in preclinical GBM models and suggesting that their activation through GPCRs and RhoA contributes to growth and maintenance of human GBM.	[Yui, Olivia M.; Plouffe, Steven W.; Ryback, Daniel; Klein, Andrea; Smith, Jeff; Guan, Kun-Liang; Chaim, Olga Meiri; Miyamoto, Shigeki; Brown, Joan Heller] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Yui, Olivia M.; Plouffe, Steven W.] Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; [Benitez, Jorge A.; Furnari, Frank B.] Ludwig Inst Canc Res, San Diego Branch, San Diego, CA USA; [Greenbaum, Jason; Delatte, Benjamin; Rao, Anjana] La Jolla Inst Allergy & Immunol, Div Signaling & Gene Express, La Jolla, CA USA; [Rao, Anjana; Guan, Kun-Liang; Furnari, Frank B.; Brown, Joan Heller] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA; [Rao, Anjana; Furnari, Frank B.] Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA; [Chaim, Olga Meiri] Univ Fed Parana, Dept Cell Biol, Curitiba, Parana, Brazil	University of California System; University of California San Diego; University of California System; University of California San Diego; Ludwig Institute for Cancer Research; La Jolla Institute for Immunology; University of California System; University of California San Diego; University of California System; University of California San Diego; Universidade Federal do Parana	Brown, JH (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.; Brown, JH (corresponding author), Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA.	jhbrown@ucsd.edu	Delatte, Benjamin/AAE-9276-2020; Chaim, Olga Meiri/Y-7559-2019; Guan, Kun-Liang/ADK-7088-2022; Chaim, Olga M/H-5179-2012; Miyamoto, Shigeki/L-4004-2019	Chaim, Olga Meiri/0000-0002-3854-3292; Chaim, Olga M/0000-0002-3854-3292; Klein, Andrea/0000-0003-4146-3493; Delatte, Benjamin/0000-0002-6798-0600	NIH [GM036927, HL028143, HL085577, CA170682, HL097037, NS080939, AI40127, AI109842];  [T32 GM007752];  [T32 DK00754]; NATIONAL CANCER INSTITUTE [R35CA196878, R01CA218859] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL028143, R01HL028143, P01HL085577, R01HL097037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI109842, R01AI109842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS080939] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by NIH Grants GM036927, HL028143, HL085577. and CA170682 to JHB; HL097037 to SM; NS080939 to FBF and JAB; AI40127 and AI109842 to AR. OMY and SWP were supported by T32 GM007752; OMY also received support from T32 DK00754; BD is an HHMI postdoctoral fellow from the Jane Coffin Childs Fund; OMC is a PDE fellow from The Brazilian National Council for Scientific and Technological Development.	Anelli V, 2008, J BIOL CHEM, V283, P3365, DOI 10.1074/jbc.M708241200; Annibali D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5632; Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042; Balasubramaniyan V, 2015, ONCOTARGET, V6, P31007, DOI 10.18632/oncotarget.5219; Bien-Moller S, 2016, ONCOTARGET, V7, P13031, DOI 10.18632/oncotarget.7366; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Cen B, 2004, J CELL BIOCHEM, V93, P74, DOI 10.1002/jcb.20199; Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Cheng G, 2015, TUMOR BIOL, V36, P2869, DOI 10.1007/s13277-014-2915-8; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cui YD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7333; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Ensign SPF, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00241; Esnault C, 2014, GENE DEV, V28, P943, DOI 10.1101/gad.239327.114; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Feng X, 2016, J BIOL CHEM, V291, P18947, DOI 10.1074/jbc.M116.739722; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Gaviglio AL, 2017, FASEB J, V31, P1903, DOI 10.1096/fj.201600828R; Giannini C, 2005, NEURO-ONCOLOGY, V7, P164, DOI 10.1215/S1152851704000821; Guettler S, 2008, MOL CELL BIOL, V28, P732, DOI 10.1128/MCB.01623-07; Hamada K, 1996, CANCER, V77, P1877, DOI 10.1002/(SICI)1097-0142(19960501)77:9<1877::AID-CNCR18>3.0.CO;2-X; Haseley A, 2012, CANCER RES, V72, P1353, DOI 10.1158/0008-5472.CAN-11-2526; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Houben AJS, 2011, CANCER METAST REV, V30, P557, DOI 10.1007/s10555-011-9319-7; Hua Y, 2005, J THROMB HAEMOST, V3, P1917, DOI 10.1111/j.1538-7836.2005.01446.x; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Juneja J, 2009, BRIT J PHARMACOL, V158, P32, DOI 10.1111/j.1476-5381.2009.00180.x; Kapitonov D, 2009, CANCER RES, V69, P6915, DOI 10.1158/0008-5472.CAN-09-0664; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kishi Y, 2006, J BIOL CHEM, V281, P17492, DOI 10.1074/jbc.M601803200; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Li L, 2014, ONCOGENE, V33, P4253, DOI 10.1038/onc.2013.400; Magnus N, 2014, BIOCHEM BIOPH RES CO, V454, P262, DOI 10.1016/j.bbrc.2014.10.041; Magnus N, 2014, P NATL ACAD SCI USA, V111, P3544, DOI 10.1073/pnas.1314118111; Martin CB, 2001, ONCOGENE, V20, P1953, DOI 10.1038/sj.onc.1204281; Menendez JA, 2005, ONCOGENE, V24, P761, DOI 10.1038/sj.onc.1208238; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Mishima K, 1998, ACTA NEUROPATHOL, V96, P322, DOI 10.1007/s004010050901; Mo JS, 2012, GENE DEV, V26, P2138, DOI 10.1101/gad.197582.112; Nierodzik ML, 2006, CANCER CELL, V10, P355, DOI 10.1016/j.ccr.2006.10.002; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Park HW, 2015, CELL, V162, P780, DOI 10.1016/j.cell.2015.07.013; Plouffe SW, 2015, TRENDS MOL MED, V21, P212, DOI 10.1016/j.molmed.2015.01.003; PONTEN J, 1968, ACTA PATHOL MIC SC, V74, P465; Post GR, 1996, MOL BIOL CELL, V7, P1679, DOI 10.1091/mbc.7.11.1679; Qiao YT, 2017, CELL REP, V19, P1495, DOI 10.1016/j.celrep.2017.04.075; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Quan TH, 2014, AM J PATHOL, V184, P937, DOI 10.1016/j.ajpath.2013.12.017; Rak J, 2009, BEST PRACT RES CL HA, V22, P71, DOI 10.1016/j.beha.2008.12.008; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Reuther GW, 2001, J BIOL CHEM, V276, P27145, DOI 10.1074/jbc.M103565200; Rossol-Allisone J, 2009, CELL SIGNAL, V21, P1559, DOI 10.1016/j.cellsig.2009.05.010; Ruf W, 2011, J THROMB HAEMOST, V9, P306, DOI 10.1111/j.1538-7836.2011.04318.x; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sarkaria JN, 2007, MOL CANCER THER, V6, P1167, DOI 10.1158/1535-7163.MCT-06-0691; Sarkaria JN, 2006, CLIN CANCER RES, V12, P2264, DOI 10.1158/1078-0432.CCR-05-2510; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shah SR, 2016, NEUROSURGERY, V63, P185, DOI DOI 10.1227/01.NEU.0000489786.22041.2D; Siney EJ, 2017, MOL NEUROBIOL, V54, P3893, DOI 10.1007/s12035-016-0053-6; Suva ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184; TOKSOZ D, 1994, ONCOGENE, V9, P621; Walsh CT, 2008, FASEB J, V22, P4011, DOI 10.1096/fj.08-113266; Wang J., 2008, PLOS ONE, V3, P3769; Wang SB, 2016, THROMB RES, V141, pS65, DOI 10.1016/S0049-3848(16)30369-3; Xie D, 2004, CLIN CANCER RES, V10, P2072, DOI 10.1158/1078-0432.CCR-0659-03; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; Yotsumoto F, 2008, BIOCHEM BIOPH RES CO, V365, P555, DOI 10.1016/j.bbrc.2007.11.015; Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Yu OM, 2016, MOL CELL BIOL, V36, P39, DOI 10.1128/MCB.00772-15; Yu OM, 2015, MOL PHARMACOL, V88, P171, DOI 10.1124/mol.115.097857; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2009, CANCER RES, V69, P1089, DOI 10.1158/0008-5472.CAN-08-2997	78	38	41	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2018	37	41					5492	5507		10.1038/s41388-018-0301-5	http://dx.doi.org/10.1038/s41388-018-0301-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GW5QO	29887596	Green Accepted, Green Published			2022-12-17	WOS:000446991200002
J	Parekh, A; Das, S; Parida, S; Das, CK; Dutta, D; Mallick, SK; Wu, PH; Kumar, BNP; Bharti, R; Dey, G; Banerjee, K; Rajput, S; Bharadwaj, D; Pal, I; Dey, KK; Rajesh, Y; Jena, BC; Biswas, A; Banik, P; Pradhan, AK; Das, SK; Das, AK; Dhara, S; Fisher, PB; Wirtz, D; Mills, GB; Mandal, M				Parekh, Aditya; Das, Subhayan; Parida, Sheetal; Das, Chandan Kanta; Dutta, Debabrata; Mallick, Sanjaya K.; Wu, Pei-Hsun; Kumar, B. N. Prashanth; Bharti, Rashmi; Dey, Goutam; Banerjee, Kacoli; Rajput, Shashi; Bharadwaj, Deblina; Pal, Ipsita; Dey, Kaushik Kumar; Rajesh, Yetirajam; Jena, Bikash Chandra; Biswas, Angana; Banik, Payel; Pradhan, Anjan K.; Das, Swadesh K.; Das, Amit Kumar; Dhara, Santanu; Fisher, Paul B.; Wirtz, Denis; Mills, Gordon B.; Mandal, Mahitosh			Multi-nucleated cells use ROS to induce breast cancer chemoresistance in vitro and in vivo	ONCOGENE			English	Article							MULTINUCLEATED GIANT-CELLS; MITOTIC CATASTROPHE; REACTIVE OXYGEN; SECRETORY PHENOTYPE; TUMOR-CELLS; POLYPLOIDY; SENESCENCE; HYPOXIA; APOPTOSIS; DOXORUBICIN	Although there is a strong correlation between multinucleated cells (MNCs) and cancer chemo-resistance in variety of cancers, our understanding of how multinucleated cells modulate the tumor micro-environment is limited. We captured multinucleated cells from triple-negative chemo-resistant breast cancers cells in a time frame, where they do not proliferate but rather significantly regulate their micro-environment. We show that oxidatively stressed MNCs induce chemo-resistance in vitro and in vivo by secreting VEGF and MIF. These factors act through the RAS/MAPK pathway to induce chemoresistance by upregulating anti-apoptotic proteins. In MNCs, elevated reactive oxygen species (ROS) stabilizes HIF-1 alpha contributing to increase production of VEGF and MIF. Together the data indicate, that the ROS-HIF-1 alpha signaling axis is very crucial in regulation of chemo-resistance by MNCs. Targeting ROS-HIF-1 alpha in future may help to abrogate drug resistance in breast cancer.	[Parekh, Aditya; Das, Subhayan; Parida, Sheetal; Das, Chandan Kanta; Kumar, B. N. Prashanth; Bharti, Rashmi; Dey, Goutam; Banerjee, Kacoli; Rajput, Shashi; Bharadwaj, Deblina; Pal, Ipsita; Dey, Kaushik Kumar; Rajesh, Yetirajam; Jena, Bikash Chandra; Biswas, Angana; Banik, Payel; Dhara, Santanu; Mandal, Mahitosh] Indian Inst Technol Kharagpur, Sch Med Sci & Technol, Kharagpur 721302, W Bengal, India; [Dutta, Debabrata; Das, Amit Kumar] Indian Inst Technol Kharagpur, Dept Biotechnol, Kharagpur, W Bengal, India; [Mallick, Sanjaya K.] Univ Calcutta, BD Biosci Ctr Res Nanosci & Nanotechnol, Kolkata, W Bengal, India; [Wu, Pei-Hsun; Wirtz, Denis] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; [Pradhan, Anjan K.; Das, Swadesh K.; Fisher, Paul B.] Virginia Commonwealth Univ, Sch Med, VCU Inst Mol Med, VCU Inst Mol Med,Dept Human & Mol Genet, Richmond, VA 23298 USA; [Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Div Canc Med, Houston, TX 77030 USA	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kharagpur; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kharagpur; University of Calcutta; Johns Hopkins University; Virginia Commonwealth University; University of Texas System; UTMD Anderson Cancer Center	Mandal, M (corresponding author), Indian Inst Technol Kharagpur, Sch Med Sci & Technol, Kharagpur 721302, W Bengal, India.	mahitosh@smst.iitkgp.ernet.in	Dhara, Santanu/AAS-5872-2020; Pal, Ipsita/AAX-4410-2020; Pradhan, Anjan K/O-2555-2014; Bhusetty Nagesh, Prashanth Kumar/ABH-4999-2020; das, subhayan/G-3453-2018; Dey, Kaushik Kumar/H-5997-2018; JAIN, SHASHI/N-8877-2017; jain, shashi/AAF-4706-2020; Mandal, Mahitosh/GMW-6195-2022	Bhusetty Nagesh, Prashanth Kumar/0000-0003-3518-405X; das, subhayan/0000-0002-8628-5128; Dey, Kaushik Kumar/0000-0002-9594-6362; JAIN, SHASHI/0000-0001-9428-0135; jain, shashi/0000-0001-9428-0135; Mandal, Mahitosh/0000-0003-3861-3323; Jena, Bikash Chandra/0000-0002-6672-9254; Rajesh, Yetirajam/0000-0002-0277-3942; Rajesh, Yetirajam/0000-0001-8882-8854; Mills, Gordon/0000-0002-0144-9614; Dey, Goutam/0000-0002-8210-3219; Biswas, Angana/0000-0002-0983-0428	Department of Biotechnology [BT/PR13996/Med/30/309/2010]; Department of Atomic Energy [35/14/05/2015-BRNS/3053]; Ministry of Human Resource Development [4-23/2014-TS]; University Grants Commission, Department of Biotechnology, and Fulbright; NATIONAL CANCER INSTITUTE [R01CA174388] Funding Source: NIH RePORTER	Department of Biotechnology; Department of Atomic Energy(Department of Atomic Energy (DAE)); Ministry of Human Resource Development; University Grants Commission, Department of Biotechnology, and Fulbright; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Anji Anura, Bodhisatwa Das, Raunak Kumar Das, and Prof. Jyotirmoy Chaterjee from IIT Kharagpur for their help in microscopy. We also thank Hasini Jayatilaka and Michelle Karl from Johns Hopkins University for their support. We also thank Sanat Dey, Purna Patra, and other staffs of central research facility of IIT Kharagpur for technical assistance. The research was supported by Department of Biotechnology (BT/PR13996/Med/30/309/2010), Department of Atomic Energy, (35/14/05/2015-BRNS/3053), and Ministry of Human Resource Development (F. NO. 4-23/2014-TS. I). University Grants Commission, Department of Biotechnology, and Fulbright is also hereby acknowledged for scholarship support.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Balsas P, 2012, LEUKEMIA RES, V36, P212, DOI 10.1016/j.leukres.2011.09.011; Bar-Shavit Z, 2007, J CELL BIOCHEM, V102, P1130, DOI 10.1002/jcb.21553; Baugh JA, 2006, BIOCHEM BIOPH RES CO, V347, P895, DOI 10.1016/j.bbrc.2006.06.148; Blajeski AL, 2001, EXP CELL RES, V270, P277, DOI 10.1006/excr.2001.5349; Brown NS, 2001, BREAST CANCER RES, V3, P323, DOI 10.1186/bcr315; Bucala R, 2000, NATURE, V408, P146, DOI 10.1038/35041654; Carloni V, 2013, ONCOGENE, V32, P2649, DOI 10.1038/onc.2012.268; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Conklin Kenneth A, 2004, Integr Cancer Ther, V3, P294, DOI 10.1177/1534735404270335; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; da Costa CET, 2005, J EXP MED, V201, P687, DOI 10.1084/jem.20041785; DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235; Dey G, 2015, SCI REP-UK, V5, DOI 10.1038/srep10316; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Erenpreisa J, 2008, CELL BIOL INT, V32, P1044, DOI 10.1016/j.cellbi.2008.06.003; FISHBACK NF, 1994, CANCER-AM CANCER SOC, V73, P2936, DOI 10.1002/1097-0142(19940615)73:12<2936::AID-CNCR2820731210>3.0.CO;2-U; Holt DJ, 2011, BIOMATERIALS, V32, P3977, DOI 10.1016/j.biomaterials.2011.02.021; Jung SN, 2008, CARCINOGENESIS, V29, P713, DOI 10.1093/carcin/bgn032; Kotchetkov R, 2003, INT J CANCER, V104, P36, DOI 10.1002/ijc.10917; Krajcovic M, 2011, NAT CELL BIOL, V13, P324, DOI 10.1038/ncb2174; Kumar BN, 2013, BMC CANCER, V13, P1; Kuo CH, 2014, BREAST CANCER-TOKYO, V21, P358, DOI 10.1007/s12282-012-0400-z; Lee HO, 2009, GENE DEV, V23, P2461, DOI 10.1101/gad.1829209; Leikam C, 2008, ONCOGENE, V27, P7070, DOI 10.1038/onc.2008.323; Liu B, 2003, J ORAL PATHOL MED, V32, P367, DOI 10.1034/j.1600-0714.2003.00126.x; Lu YC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158587; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; Mosieniak G, 2010, CURR PHARM DESIGN, V16, P734, DOI 10.2174/138161210790883714; Mosieniak G, 2015, NEOPLASIA, V17, P882, DOI 10.1016/j.neo.2015.11.008; Most J, 1997, BLOOD, V89, P662, DOI 10.1182/blood.V89.2.662; Nakayama Y, 2015, CELL STRUCT FUNCT, V40, P51, DOI 10.1247/csf.14005; Ogden A, 2015, CANCER LETT, V367, P89, DOI 10.1016/j.canlet.2015.06.025; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Pirker R, 2012, LANCET ONCOL, V13, P33, DOI 10.1016/S1470-2045(11)70318-7; Portugal J, 2010, CURR PHARM DESIGN, V16, P69, DOI 10.2174/138161210789941801; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Puig PE, 2008, CELL BIOL INT, V32, P1031, DOI 10.1016/j.cellbi.2008.04.021; Rajput S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061342; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Rohnalter V, 2015, ONCOTARGET, V6, P40005, DOI 10.18632/oncotarget.5552; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Ryska A, 2001, VIRCHOWS ARCH, V439, P768, DOI 10.1007/s004280100470; Sharma S, 2013, MOL CANCER THER, V12, P725, DOI 10.1158/1535-7163.MCT-12-1079; Sliwinska MA, 2009, MECH AGEING DEV, V130, P24, DOI 10.1016/j.mad.2008.04.011; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Sundaram M, 2004, CANCER BIOL THER, V3, P207, DOI 10.4161/cbt.3.2.663; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; Vignery A, 2005, J EXP MED, V202, P337, DOI 10.1084/jem.20051123; Zhang S, 2014, ONCOGENE, V33, P134, DOI 10.1038/onc.2013.318; Zhang S, 2014, ONCOGENE, V33, P116, DOI 10.1038/onc.2013.96; Zhang SW, 2014, INT J CANCER, V134, P508, DOI 10.1002/ijc.28319; Zhang WH, 2011, CANCER-AM CANCER SOC, V117, P4092, DOI 10.1002/cncr.26021; Zheng L, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1825	55	38	40	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2018	37	33					4546	4561		10.1038/s41388-018-0272-6	http://dx.doi.org/10.1038/s41388-018-0272-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GQ5OV	29743594				2022-12-17	WOS:000441736700005
J	Ireland, L; Santos, A; Campbell, F; Figueiredo, C; Hammond, D; Ellies, LG; Weyer-Czernilofsky, U; Bogenrieder, T; Schmid, M; Mielgo, A				Ireland, Lucy; Santos, Almudena; Campbell, Fiona; Figueiredo, Carlos; Hammond, Dean; Ellies, Lesley G.; Weyer-Czernilofsky, Ulrike; Bogenrieder, Thomas; Schmid, Michael; Mielgo, Ainhoa			Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer	ONCOGENE			English	Article							MOUSE MAMMARY-TUMOR; PANCREATIC-CANCER; ANTICANCER THERAPIES; FACTOR-I; PHASE-I; RESISTANCE; PROGRESSION; MICROENVIRONMENT; MACROPHAGES; DISEASE	Breast cancer remains the leading cause of cancer death in women owing to metastasis and the development of resistance to established therapies. Macrophages are the most abundant immune cells in the breast tumor microenvironment and can both inhibit and support cancer progression. Thus, gaining a better understanding of how macrophages support cancer could lead to the development of more effective therapies. In this study, we find that breast cancer-associated macrophages express high levels of insulin-like growth factors 1 and 2 (IGFs) and are the main source of IGFs within both primary and metastatic tumors. In total, 75% of breast cancer patients show activation of insulin/IGF-1 receptor signaling and this correlates with increased macrophage infiltration and advanced tumor stage. In patients with invasive breast cancer, activation of Insulin/IGF-1 receptors increased to 87%. Blocking IGF in combination with paclitaxel, a chemotherapeutic agent commonly used to treat breast cancer, showed a significant reduction in tumor cell proliferation and lung metastasis in pre-clinical breast cancer models compared to paclitaxel monotherapy. Our findings provide the rationale for further developing the combination of paclitaxel with IGF blockers for the treatment of invasive breast cancer, and Insulin/IGF1R activation and IGF+ stroma cells as potential biomarker candidates for further evaluation.	[Ireland, Lucy; Santos, Almudena; Campbell, Fiona; Figueiredo, Carlos; Schmid, Michael; Mielgo, Ainhoa] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool, Merseyside, England; [Hammond, Dean] Univ Liverpool, Dept Physiol, Liverpool, Merseyside, England; [Ellies, Lesley G.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Weyer-Czernilofsky, Ulrike] Boehringer Ingelheim RCV GmbH & Co KG, Pharmacol & Translat Res, Vienna, Austria; [Bogenrieder, Thomas] Boehringer Ingelheim RCV GmbH & Co KG Med & Trans, Vienna, Austria; [Bogenrieder, Thomas] Ludwig Maximilians Univ Munchen, Univ Hosp Grosshadem, Dept Urol, Munich, Germany	University of Liverpool; University of Liverpool; University of California System; University of California San Diego; Boehringer Ingelheim; University of Munich	Mielgo, A (corresponding author), Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool, Merseyside, England.	amielgo@liverpool.ac.uk	Figueiredo, Carlos Rogerio de/H-1236-2014	Figueiredo, Carlos Rogerio de/0000-0003-3680-4070; Schmid, Michael/0000-0002-3445-0013	Sir Henry Dale research fellowship - Wellcome Trust [102521/Z/13/Z]; Sir Henry Dale research fellowship - Royal Society [102521/Z/13/Z]; Medical Research Council [MR/L000512/1]; North West Cancer Research fund;  [K22CA118182]; Medical Research Council [MR/P018920/1] Funding Source: researchfish; MRC [MR/L000512/1, MR/P018920/1] Funding Source: UKRI; NATIONAL CANCER INSTITUTE [K22CA118182] Funding Source: NIH RePORTER	Sir Henry Dale research fellowship - Wellcome Trust; Sir Henry Dale research fellowship - Royal Society; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); North West Cancer Research fund; ; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	These studies were supported by a Sir Henry Dale research fellowship to Dr. Ainhoa Mielgo, jointly funded by the Wellcome Trust and the Royal Society (grant number 102521/Z/13/Z), a New Investigator research grant from the Medical Research Council to Dr. Michael Schmid (grant number MR/L000512/1) and North West Cancer Research funding. Generation of primary breast cancer cells was supported by funding provided to Dr. Lesley Ellies (K22CA118182).	ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Augsten M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00062; Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Bronte V, 2015, NAT MED, V21, P117, DOI 10.1038/nm.3794; Bussard KM, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0740-2; Campbell MJ, 2011, BREAST CANCER RES TR, V128, P703, DOI 10.1007/s10549-010-1154-y; Davie SA, 2007, TRANSGENIC RES, V16, P193, DOI 10.1007/s11248-006-9056-9; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Denduluri SK, 2015, GENES DIS, V2, P13, DOI 10.1016/j.gendis.2014.10.004; DEXTER DL, 1978, CANCER RES, V38, P3174; Fagan DH, 2012, CANCER RES, V72, P3372, DOI 10.1158/0008-5472.CAN-12-0684; Fantozzi A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1530; Farabaugh SM, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00059; Fox EM, 2011, CANCER RES, V71, P6773, DOI 10.1158/0008-5472.CAN-11-1295; Friedbichler K, 2014, MOL CANCER THER, V13, P399, DOI 10.1158/1535-7163.MCT-13-0598; Gibby K, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3174; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Gradishar WJ, 2016, CLIN CANCER RES, V22, P301, DOI 10.1158/1078-0432.CCR-15-0588; Guha M, 2013, NAT REV DRUG DISCOV, V12, P250, DOI 10.1038/nrd3992; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Ireland L, 2016, CANCER RES, V76, P6851, DOI 10.1158/0008-5472.CAN-16-1201; Jones RL, 2015, CLIN CANCER RES, V21, P693, DOI 10.1158/1078-0432.CCR-14-0265; Klemm F, 2015, TRENDS CELL BIOL, V25, P198, DOI 10.1016/j.tcb.2014.11.006; Leek RD, 1996, CANCER RES, V56, P4625; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lodhia KA, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00142; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Ma CX, 2013, BREAST CANCER RES TR, V139, P145, DOI 10.1007/s10549-013-2528-8; Maglione JE, 2001, CANCER RES, V61, P8298; Mao Y, 2013, CANCER METAST REV, V32, P303, DOI 10.1007/s10555-012-9415-3; Marquette C, 2012, CURR TREAT OPTION ON, V13, P263, DOI 10.1007/s11864-012-0184-6; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; Mills CD, 2016, CANCER RES, V76, P513, DOI 10.1158/0008-5472.CAN-15-1737; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Nielsen SR, 2016, NAT CELL BIOL, V18, P549, DOI 10.1038/ncb3340; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Olson OC, 2013, CELL RES, V23, P179, DOI 10.1038/cr.2012.123; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Pulaski BA, 1998, CANCER RES, V58, P1486; Qian BZ, 2015, J EXP MED, V212, P1433, DOI 10.1084/jem.20141555; Quail DF, 2016, SCIENCE, V352, DOI 10.1126/science.aad3018; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rakha EA, 2007, CANCER-AM CANCER SOC, V109, P25, DOI 10.1002/cncr.22381; Robertson JFR, 2013, LANCET ONCOL, V14, P228, DOI 10.1016/S1470-2045(13)70026-3; Ruffell B, 2012, TRENDS IMMUNOL, V33, P119, DOI 10.1016/j.it.2011.12.001; Schmid MC, 2011, CANCER CELL, V19, P715, DOI 10.1016/j.ccr.2011.04.016; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Schneider BP, 2008, CLIN CANCER RES, V14, P8010, DOI 10.1158/1078-0432.CCR-08-1208; Shree T, 2011, GENE DEV, V25, P2465, DOI 10.1101/gad.180331.111; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Wahba HA, 2015, CANCER BIOL MED, V12, P106, DOI 10.7497/j.issn.2095-3941.2015.0030; Wan YW, 2016, BIOINFORMATICS, V32, P952, DOI 10.1093/bioinformatics/btv677; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Williams CB, 2016, NPJ BREAST CANCER, V2, DOI 10.1038/npjbcancer.2015.25; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823; Zhang XHF, 2013, CELL, V154, P1060, DOI 10.1016/j.cell.2013.07.036; Zhang YH, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2883	59	38	38	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	15					2022	2036		10.1038/s41388-017-0115-x	http://dx.doi.org/10.1038/s41388-017-0115-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GC6KH	29367764	hybrid, Green Published, Green Submitted			2022-12-17	WOS:000429899400006
J	Lai, Q; Wang, HY; Li, AG; Xu, YH; Tang, L; Chen, Q; Zhang, CF; Gao, Y; Song, JF; Du, ZZ				Lai, Qi; Wang, Haiyong; Li, Angui; Xu, Yinhui; Tang, Liang; Chen, Qiang; Zhang, Chunfang; Gao, Yang; Song, Jianfei; Du, Zhenzong			Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells	ONCOGENE			English	Article							PD-L1 EXPRESSION; GENE-EXPRESSION; IFN-GAMMA; IMMUNOTHERAPY; PATHWAY	IFN-gamma-induced PD-L1 expression represents the existence of tumor-specific T cells, which predicts high-response rate to anti-PD-1/L1 therapy, but loss-of-function of IFN signals (e.g., JAK mutation) induces adaptive immune resistance in patients with low-response rate. Interferon regulatory factors (IRF) are frequently epigenetic silenced in carcinogenesis, while the role of methylation in anti-PD-1/L1 therapy remains unclear. We here investigated the methylation status of IFN-gamma related genes IRF1/8 and IFN-alpha/beta-related genes IRF3/7 in lung cancer tissues and found that only highly methylated IRF1 and 7 negatively correlated to cd274 (coding PD-L1) expression, similar to JAK mutation. Interestingly, decitibine (DAC) as methylation inhibitor could hypomethylate IRF1/7 to restore PD-L1 level. Meanwhile, IRF7 enhanced constitutive PD-L1 expression, which was independent of IFN-gamma though directly promote transcription of PD-L1, leading to abrogating cytotoxic T lymphocytes (CTLs) generation which could be restored by anti-PD-L1 antibody, or siRNA-IRF7. The supplement of DAC to anti-PD-1 therapy in vivo improve the efficiency of anti-tumor with less methylated IRF1/7, more interferon-related genes expression (e.g., CXCL9) and IFN-gamma/CD8+ T-cells infiltrations, suggesting that additional treatment of DAC could rescue the ability to response to IFN in lung cancer patients with anti-PD-1/L1 therapy resistance.	[Lai, Qi; Zhang, Chunfang; Gao, Yang; Du, Zhenzong] Cental South Univ, Dept Thorac Surg, Xiangya Hosp, Changsha, Hunan, Peoples R China; [Lai, Qi] Southwest Med Univ, Dept Thorac Surg, Affiliated Tradit Med Hosp, Luzhou, Sichuan, Peoples R China; [Wang, Haiyong; Li, Angui] Guilin Med Univ, Affiliated Hosp, Dept Thorac & Cardiovasc Surg, Guilin, Peoples R China; [Xu, Yinhui; Tang, Liang; Du, Zhenzong] Guilin Med Univ, Affiliated Nanxi Shan Hosp, Dept Cardiothorac Surg, Guilin, Guangxi, Peoples R China; [Xu, Yinhui; Tang, Liang; Du, Zhenzong] Nanxi Shan Hosp Guangxi Zhuang Autonomous Reg, Guilin, Guangxi, Peoples R China; [Chen, Qiang; Song, Jianfei] Guilin Med Univ, Affiliated Hosp 2, Dept Thorac & Cardiovasc Surg, Guilin, Peoples R China	Central South University; Southwest Medical University; Guilin Medical University; Guilin Medical University; Guilin Medical University	Du, ZZ (corresponding author), Cental South Univ, Dept Thorac Surg, Xiangya Hosp, Changsha, Hunan, Peoples R China.; Du, ZZ (corresponding author), Guilin Med Univ, Affiliated Nanxi Shan Hosp, Dept Cardiothorac Surg, Guilin, Guangxi, Peoples R China.; Du, ZZ (corresponding author), Nanxi Shan Hosp Guangxi Zhuang Autonomous Reg, Guilin, Guangxi, Peoples R China.; Song, JF (corresponding author), Guilin Med Univ, Affiliated Hosp 2, Dept Thorac & Cardiovasc Surg, Guilin, Peoples R China.	guilinsjf@163.com; duzhenzong@sina.com			Natural Science Foundation of Guangxi [2016GXNSFAA380138]; Science Research and Technology Development Plan of Guangxi [2015BC12007]	Natural Science Foundation of Guangxi(National Natural Science Foundation of Guangxi Province); Science Research and Technology Development Plan of Guangxi	This work was supported by the Natural Science Foundation of Guangxi (2016GXNSFAA380138) and Science Research and Technology Development Plan of Guangxi (2015BC12007).	Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Breugom AJ, 2015, LANCET ONCOL, V16, P200, DOI 10.1016/S1470-2045(14)71199-4; Ding L, 2017, MOL CANCER THER, V16, P1068, DOI 10.1158/1535-7163.MCT-16-0454; Dunn GP, 2005, CANCER RES, V65, P3447, DOI 10.1158/0008-5472.CAN-04-4316; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Lee SJ, 2006, FEBS LETT, V580, P755, DOI 10.1016/j.febslet.2005.12.093; Liu JZ, 2007, BLOOD, V110, P296, DOI 10.1182/blood-2006-10-051482; Ma D, 2014, SCI REP-UK, V4, DOI 10.1038/srep06331; McLaughlin J, 2016, JAMA ONCOL, V2, P46, DOI 10.1001/jamaoncol.2015.3638; Mehta A, 2015, CANCER METAST REV, V34, P229, DOI 10.1007/s10555-015-9563-3; Naylor EC, 2016, SURG ONCOL CLIN N AM, V25, P601, DOI 10.1016/j.soc.2016.02.011; Ortmann CA, 2005, NUCLEIC ACIDS RES, V33, P6895, DOI 10.1093/nar/gki1001; Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983; Ribas A, 2016, J EXP MED, V213, P2835, DOI 10.1084/jem.20161462; Sacher AG, 2016, JAMA ONCOL, V2, P1217, DOI 10.1001/jamaoncol.2016.0639; Shin DS, 2017, CANCER DISCOV, V7, P188, DOI 10.1158/2159-8290.CD-16-1223; Socinski MA, 2016, J THORAC ONCOL, V11, P1411, DOI 10.1016/j.jtho.2016.05.024; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Wrangle J, 2013, ONCOTARGET, V4, P2067, DOI 10.18632/oncotarget.1542; Yamashita M, 2010, CANCER SCI, V101, P1708, DOI 10.1111/j.1349-7006.2010.01581.x; Yang H, 2014, LEUKEMIA, V28, P1280, DOI 10.1038/leu.2013.355; Zhang Z, 2017, LEUKEMIA LYMPHOMA, V58, P969, DOI 10.1080/10428194.2016.1219903	22	38	40	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	17					2302	2312		10.1038/s41388-018-0125-3	http://dx.doi.org/10.1038/s41388-018-0125-3			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE3FW	29422611				2022-12-17	WOS:000431100200007
J	Jiang, X; Bao, Y; Liu, H; Kou, X; Zhang, Z; Sun, F; Qian, Z; Lin, Z; Li, X; Liu, X; Jiang, L; Yang, Y				Jiang, X.; Bao, Y.; Liu, H.; Kou, X.; Zhang, Z.; Sun, F.; Qian, Z.; Lin, Z.; Li, X.; Liu, X.; Jiang, L.; Yang, Y.			VPS34 stimulation of p62 phosphorylation for cancer progression	ONCOGENE			English	Article							TRANSCRIPTION FACTOR NRF2; INTERACTING PROTEIN P62; KAPPA-B ACTIVATION; BECLIN 1; SELECTIVE AUTOPHAGY; BREAST-CANCER; MEDIATED CLEAVAGE; P62/SQSTM1; APOPTOSIS; TUMORIGENESIS	Vps34, a class III PtdIns3 lipid kinase involved in the control of both autophagic and endocytic systems, has been studied extensively in numerous fundamental cellular processes. Accumulating evidence indicates that Vps34 may also contribute to the development and progression of human cancers. However, the mechanism of Vps34 in tumorigenesis remains elusive. Here, we report an unanticipated role of Vps34 in the activation of p62 for cancer development. We identified that Vps34 is a transcriptional activator of p62 through competition of Nrf2 (nuclear factor erythroid 2-related factor 2) for Keap1 binding. Vps34 augments the association of PKC-delta with p62 for its phosphorylation at Serine 349, which leads to positive feedback on the Nrf2-dependent transcription of oncogenes. Additionally, we found that the expression of Vps34 is correlated with the tumorigenic activity of human breast cancer cells. Normally inactive in breast cancer, caspase 8 can cleave Vps34 at residue D285, which directly abolished its lipid kinase activity and dramatically altered cell invasion potential, colony formation, as well as tumorigenesis in orthotopic engraftments in mice. The cleavage at D285 blocks expression of LC3-II, Nrf2 and subsequently, p62, in addition to blocking tumor growth, indicating that the intact structure of Vps34 is essential for its activity. Moreover, either knockout of PKC-delta or knockdown of p62 by small interfering RNA in MCF-7 cells abrogates Vps34-dependent tumor growth. Data presented here suggested that Vps34 stimulates tumor development mainly through PKC-delta-activation of p62.	[Jiang, X.; Bao, Y.; Liu, H.; Kou, X.; Zhang, Z.; Sun, F.; Qian, Z.; Yang, Y.] Fudan Univ, Sch Pharm, Dept Pharmacol & Biochem, 826 Zhangheng Rd, Shanghai 201203, Peoples R China; [Lin, Z.] Roche Innovat Ctr Shanghai, Chem Biol Roche Pharmaceut Res & Early Dev, Shanghai, Peoples R China; [Li, X.] Shanghai Eight People Hosp, Dept Gastroenterol, Shanghai, Peoples R China; [Liu, X.] Georgetown Univ, Med Ctr, Dept Pathol, Washington, DC 20007 USA; [Jiang, L.] Oakland Univ, Dept Biol Sci, Rochester, MI USA	Fudan University; Georgetown University; Oakland University	Yang, Y (corresponding author), Fudan Univ, Sch Pharm, Dept Pharmacol & Biochem, 826 Zhangheng Rd, Shanghai 201203, Peoples R China.	yonghuayang@hotmail.com	Qian, Zhong Ming/E-8884-2016	Qian, Zhong Ming/0000-0002-6399-938X	National Natural Science Foundation of China [81572721, 81272391]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Natural Science Foundation of China (No. 81572721 and 81272391 to YY).	Betin VMS, 2009, J CELL SCI, V122, P2554, DOI 10.1242/jcs.046250; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Burdelski C, 2015, CLIN CANCER RES, V21, P3471, DOI 10.1158/1078-0432.CCR-14-0620; Cai-McRae X, 2015, ONCOGENE, V34, P2968, DOI 10.1038/onc.2014.244; Djavaheri-Mergny M, 2010, ONCOGENE, V29, P1717, DOI 10.1038/onc.2009.519; Duran A, 2004, DEV CELL, V6, P303, DOI 10.1016/S1534-5807(03)00403-9; Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001; Ebi H, 2013, P NATL ACAD SCI USA, V110, P21124, DOI 10.1073/pnas.1314124110; Fujita KI, 2011, P NATL ACAD SCI USA, V108, P1427, DOI 10.1073/pnas.1014156108; Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002; Furuya T, 2010, MOL CELL, V38, P500, DOI 10.1016/j.molcel.2010.05.009; Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006; Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012; Germain M, 2011, EMBO J, V30, P395, DOI 10.1038/emboj.2010.327; Hirsch DS, 2010, CANCER RES, V70, P5974, DOI 10.1158/0008-5472.CAN-09-2682; Ichimura Y, 2013, MOL CELL, V51, P618, DOI 10.1016/j.molcel.2013.08.003; Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031; Jaber N, 2012, P NATL ACAD SCI USA, V109, P2003, DOI 10.1073/pnas.1112848109; Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976; Jin MY, 2013, CELL, V152, P368, DOI 10.1016/j.cell.2013.01.004; Kang R, 2012, AUTOPHAGY, V8, P989, DOI 10.4161/auto.20258; Katsuragi Y, 2015, FEBS J, V282, P4672, DOI 10.1111/febs.13540; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Lee E, 2016, ONCOTARGET, V7, P67919, DOI 10.18632/oncotarget.12084; Li H, 2011, CANCER RES, V71, P3625, DOI 10.1158/0008-5472.CAN-10-4475; Li LJ, 2013, CANCER CELL, V24, P738, DOI 10.1016/j.ccr.2013.10.025; Lindmo K, 2006, J CELL SCI, V119, P605, DOI 10.1242/jcs.02855; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Matsumoto G, 2011, MOL CELL, V44, P279, DOI 10.1016/j.molcel.2011.07.039; Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846; Mbengue A, 2015, NATURE, V520, P683, DOI 10.1038/nature14412; Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023; Narendra DP, 2010, AUTOPHAGY, V6, P1090, DOI 10.4161/auto.6.8.13426; Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Paulus P, 2006, CANCER RES, V66, P4349, DOI 10.1158/0008-5472.CAN-05-3523; Sakakura K, 2015, CANCER SCI, V106, P1, DOI [10.1111/cas.12559, 10.1111/cas.12579]; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Shapiro G, 2015, CLIN CANCER RES, V21; Shi J, 2014, CELL DEATH DIFFER, V21, P1432, DOI 10.1038/cdd.2014.58; Simonsen A, 2009, J CELL BIOL, V186, P773, DOI 10.1083/jcb.200907014; Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51; Sun QM, 2008, P NATL ACAD SCI USA, V105, P19211, DOI 10.1073/pnas.0810452105; Tang FC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021208; Thompson HGR, 2003, ONCOGENE, V22, P2322, DOI 10.1038/sj.onc.1206325; Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882; Watanabe Y, 2011, J CELL SCI, V124, P2692, DOI 10.1242/jcs.081232; Wee LJK, 2007, BIOINFORMATICS, V23, P3241, DOI 10.1093/bioinformatics/btm334; Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16; Yang YH, 2008, CANCER RES, V68, P4833, DOI 10.1158/0008-5472.CAN-08-0644; Yang YH, 2013, P NATL ACAD SCI USA, V110, P6841, DOI 10.1073/pnas.1217692110; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482	58	38	38	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2017	36	50					6850	6862		10.1038/onc.2017.295	http://dx.doi.org/10.1038/onc.2017.295			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FQ0JM	28846113	Green Published, hybrid			2022-12-17	WOS:000418041800002
J	Somasagara, RR; Spencer, SM; Tripathi, K; Clark, DW; Mani, C; da Silva, LM; Scalici, J; Kothayer, H; Westwell, AD; Rocconi, RP; Palle, K				Somasagara, R. R.; Spencer, S. M.; Tripathi, K.; Clark, D. W.; Mani, C.; da Silva, L. Madeira; Scalici, J.; Kothayer, H.; Westwell, A. D.; Rocconi, R. P.; Palle, K.			RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance	ONCOGENE			English	Article							UBIQUITIN-CONJUGATING ENZYME; HISTONE H2B MONOUBIQUITINATION; VITRO ANTICANCER EVALUATION; DAMAGE-INDUCED RESPONSE; S-PHASE CHECKPOINT; BETA-CATENIN; POTENTIAL MECHANISM; POLYMERASE SWITCH; COMPLEX-FORMATION; H3K4 METHYLATION	Ovarian cancer (OC) is the most deadly gynecological cancer and unlike most other neoplasms, survival rates for OC have not significantly improved in recent decades. We show that RAD6, an ubiquitin-conjugating enzyme, is significantly overexpressed in ovarian tumors and its expression increases in response to carboplatin chemotherapy. RAD6 expression correlated strongly with acquired chemoresistance and malignant behavior of OC cells, expression of stem cell genes and poor prognosis of OC patients, suggesting an important role for RAD6 in ovarian tumor progression. Upregulated RAD6 enhances DNA damage tolerance and repair efficiency of OC cells and promotes their survival. Increased RAD6 levels cause histone 2B ubiquitination-mediated epigenetic changes that stimulate transcription of stem cell genes, including ALDH1A1 and SOX2, leading to a cancer stem cell phenotype, which is implicated in disease recurrence and metastasis. Downregulation of RAD6 or its inhibition using a small molecule inhibitor attenuated DNA repair signaling and expression of cancer stem cells markers and sensitized chemoresistant OC cells to carboplatin. Together, these results suggest that RAD6 could be a therapeutic target to prevent and treat acquired chemoresistance and disease recurrence in OC and enhance the efficacy of standard chemotherapy.	[Somasagara, R. R.; Spencer, S. M.; Tripathi, K.; Clark, D. W.; Mani, C.; da Silva, L. Madeira; Scalici, J.; Rocconi, R. P.; Palle, K.] Univ S Alabama, Mitchell Canc Inst, Dept Oncol Sci, Mobile, AL 36604 USA; [Kothayer, H.] Zagazig Univ, Dept Med Chem, Zagazig, Egypt; [Westwell, A. D.] Cardiff Univ, Sch Pharm & Pharmaceut Sci, Cardiff, Wales	University of South Alabama; Egyptian Knowledge Bank (EKB); Zagazig University; Cardiff University	Palle, K (corresponding author), Univ S Alabama, Mitchell Canc Inst, 1660 Springhill Ave, Mobile, AL 36604 USA.	kpalle@health.southalabama.edu	Westwell, Andrew David/M-8126-2014; Kothayer, Hend/GRJ-5827-2022	Westwell, Andrew David/0000-0002-5166-9236; Kothayer, Hend/0000-0002-2954-0751	Abraham Mitchell Cancer Research Scholar Endowment grant; National Institutes of Health [R01GM098956]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM098956] Funding Source: NIH RePORTER	Abraham Mitchell Cancer Research Scholar Endowment grant; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by Abraham Mitchell Cancer Research Scholar Endowment grant, and by National Institutes of Health grant [R01GM098956] to KP. We would like to thank Joel Andrews, PhD and Steve McClellan for assistance with microscopy and flow cytometry, respectively.	Abdullah LN, 2013, CLIN TRANSL MED, V2, DOI 10.1186/2001-1326-2-3; de la Rocha AMA, 2014, AM J CANCER RES, V4, P312; Nguyen AT, 2011, GENE DEV, V25, P1345, DOI 10.1101/gad.2057811; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Bi XH, 2006, MOL CELL BIOL, V26, P3527, DOI 10.1128/MCB.26.9.3527-3540.2006; Braun S, 2012, EMBO REP, V13, P619, DOI 10.1038/embor.2012.78; Cadigan Ken M., 2002, Trends in Genetics, V18, P340, DOI 10.1016/S0168-9525(02)02707-5; Chandrasekharan MB, 2010, EPIGENETICS-US, V5, DOI 10.4161/epi.5.6.12314; Chen S, 2012, CELL RES, V22, P1402, DOI 10.1038/cr.2012.114; Chirnomas D, 2006, MOL CANCER THER, V5, P952, DOI 10.1158/1535-7163.MCT-05-0493; Clark DW, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.11.82; Clark DW, 2015, ONCOTARGET, V6, P28816, DOI 10.18632/oncotarget.5006; Condello S, 2015, ONCOGENE, V34, P2297, DOI 10.1038/onc.2014.178; Davis A, 2014, GYNECOL ONCOL, V133, P624, DOI 10.1016/j.ygyno.2014.02.038; Djordjevic B, 2012, J BUON, V17, P627; Ferrer Miriam, 2005, Clin Lung Cancer, V6, P250, DOI 10.3816/CLC.2005.n.005; Foley OW, 2013, ONCOLOGY-NY, V27, P288; Geng LY, 2010, J CELL BIOL, V191, P249, DOI 10.1083/jcb.201005101; Gerard B, 2012, BBA-MOL CELL RES, V1823, P1686, DOI 10.1016/j.bbamcr.2012.05.032; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Haynes B, 2016, NANOMED-NANOTECHNOL, V12, P745, DOI 10.1016/j.nano.2015.10.010; Helchowski CM, 2013, CELL CYCLE, V12, P3749, DOI 10.4161/cc.26640; Houghtaling S, 2003, GENE DEV, V17, P2021, DOI 10.1101/gad.1103403; Hung SH, 2017, P NATL ACAD SCI USA, V114, pE2205, DOI 10.1073/pnas.1612633114; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; Ishiguro T, 2016, CANCER RES, V76, P150, DOI 10.1158/0008-5472.CAN-15-0361; Jazaeri AA, 2011, NEOPLASIA, V13, P899, DOI 10.1593/neo.11138; Kandalaft LE, 2011, J CLIN ONCOL, V29, P925, DOI 10.1200/JCO.2009.27.2369; Kannouche PL, 2004, CELL CYCLE, V3, P1011; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kao CF, 2004, GENE DEV, V18, P184, DOI 10.1101/gad.1149604; Khan IN, 2015, DRUG DISCOV TODAY, V20, P1205, DOI 10.1016/j.drudis.2015.06.013; Kim J, 2009, CELL, V137, P459, DOI 10.1016/j.cell.2009.02.027; Kobayashi S, 2015, ONCOGENE, V34, P4403, DOI 10.1038/onc.2014.371; KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865; Kothayer H, 2016, BIOORG MED CHEM LETT, V26, P2030, DOI 10.1016/j.bmcl.2016.02.085; Kothayer H, 2014, TETRAHEDRON LETT, V55, P7015, DOI 10.1016/j.tetlet.2014.10.122; Kothayer H, 2013, BIOORG MED CHEM LETT, V23, P6886, DOI 10.1016/j.bmcl.2013.09.087; Kuhl SJ, 2013, BBA-GEN SUBJECTS, V1830, P2297, DOI 10.1016/j.bbagen.2012.08.010; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; Lee JS, 2007, CELL, V131, P1084, DOI 10.1016/j.cell.2007.09.046; Lyakhovich A, 2004, ONCOGENE, V23, P3097, DOI 10.1038/sj.onc.1207449; Lyakhovich A, 2003, MOL CELL BIOL, V23, P2463, DOI 10.1128/MCB.23.7.2463-2475.2003; Meng E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107142; Miki T, 2011, STEM CELL REV REP, V7, P836, DOI 10.1007/s12015-011-9275-1; Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200; Palle K, 2011, CELL CYCLE, V10, P1625, DOI 10.4161/cc.10.10.15617; Pavri R, 2006, CELL, V125, P703, DOI 10.1016/j.cell.2006.04.029; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; Ring A, 2014, STEM CELL REV REP, V10, P512, DOI 10.1007/s12015-014-9515-2; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Rosner K, 2014, J SKIN CANCER, V2014, DOI 10.1155/2014/439205; Rosner K, 2014, TRANSL ONCOL, V7, P384, DOI 10.1016/j.tranon.2014.04.009; Sanders MA, 2013, MOL CANCER THER, V12, P373, DOI 10.1158/1535-7163.MCT-12-0793; Shekhar MPV, 2008, CANCER RES, V68, P1741, DOI 10.1158/0008-5472.CAN-07-2111; Shekhar MPV, 2006, MOL CANCER RES, V4, P729, DOI 10.1158/1541-7786.MCR-06-0136; Shekhar MPV, 2002, CANCER RES, V62, P2115; Soares LM, 2013, MOL CELL, V49, P1019, DOI 10.1016/j.molcel.2013.03.012; Somasagara RR, 2016, BIOCHEM BIOPH RES CO, V469, P449, DOI 10.1016/j.bbrc.2015.11.134; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Tripathi K, 2014, J BIOL CHEM, V289, P31513, DOI 10.1074/jbc.M114.606483; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Yochum GS, 2008, MOL CELL BIOL, V28, P7368, DOI 10.1128/MCB.00744-08; Zhang F, 2011, MOL CELL, V41, P384, DOI 10.1016/j.molcel.2011.01.024; Zhang Z, 2013, GENE DEV, V27, P1581, DOI 10.1101/gad.211037.112	66	38	38	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2017	36	48					6680	6690		10.1038/onc.2017.279	http://dx.doi.org/10.1038/onc.2017.279			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FO4AJ	28806395	Green Accepted			2022-12-17	WOS:000416780800003
J	Jain, P; Fierst, TM; Han, HJ; Smith, TE; Vakil, A; Storm, PB; Resnick, AC; Waanders, AJ				Jain, P.; Fierst, T. M.; Han, H. J.; Smith, T. E.; Vakil, A.; Storm, P. B.; Resnick, A. C.; Waanders, A. J.			CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles	ONCOGENE			English	Article							RNA-BINDING PROTEIN; RAF INHIBITORS; MAPK PATHWAY; PARADOXICAL ACTIVATION; PROSTATE-CANCER; KINASE FUSIONS; NERVOUS-SYSTEM; GASTRIC-CANCER; SOLID TUMORS; BRAF	Pediatric low-grade gliomas (PLGGs) are commonly associated with BRAF gene fusions that aberrantly activate the mitogenactivated protein kinase (MAPK) signaling pathway. This has led to PLGG clinical trials utilizing RAF- and MAPK pathway-targeted therapeutics. Whole-genome profiling of PLGGs has also identified rare gene fusions involving another RAF isoform, CRAF/RAF1, in PLGGs and cancers occuring in adults. Whereas BRAF fusions primarily dysregulate MAPK signaling, the CRAF fusions QKI-RAF1 and SRGAP3-RAF1 aberrantly activate both the MAPK and phosphoinositide-3 kinase/mammalian target of rapamycin (PI3K/mTOR) signaling pathways. Although ATP-competitive, first-generation RAF inhibitors (vemurafenib/PLX4720, RAFi) cause paradoxical activation of the MAPK pathway in BRAF-fusion tumors, inhibition can be achieved with 'paradox breaker' RAFi, such as PLX8394. Here we report that, unlike BRAF fusions, CRAF fusions are unresponsive to both generations of RAFi, vemurafenib and PLX8394, highlighting a distinct responsiveness of CRAF fusions to clinically relevant RAFi. Whereas PLX8394 decreased BRAF-fusion dimerization, CRAF-fusion dimerization is unaffected primarily because of robust protein-protein interactions mediated by the N-terminal non-kinase fusion partner, such as QKI. The pan-RAF dimer inhibitor, LY3009120, could suppress CRAF-fusion oncogenicity by inhibiting dimer-mediated signaling. In addition, as CRAF fusions activate both the MAPK and PI3K/mTOR signaling pathways, we identify combinatorial inhibition of the MAPK/mTOR pathway as a potential therapeutic strategy for CRAF-fusiondriven tumors. Overall, we define a mechanistic distinction between PLGG-associated BRAF-and CRAF/RAF1 fusions in response to RAFi, highlighting the importance of molecularly classifying PLGG patients for targeted therapy. Furthermore, our study uncovers an important contribution of the non-kinase fusion partner to oncogenesis and potential therapeutic strategies against PLGG-associated CRAF fusions and possibly pan-cancer CRAF fusions.	[Jain, P.; Han, H. J.; Storm, P. B.; Resnick, A. C.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Jain, P.] Univ Penn, Perelman Sch Med, Cell & Mol Grad Grp, Philadelphia, PA 19104 USA; [Jain, P.; Fierst, T. M.; Han, H. J.; Smith, T. E.; Vakil, A.; Storm, P. B.; Resnick, A. C.] Childrens Hosp Philadelphia, Div Neurosurg, CTRB 4052,3501 Civ Ctr Blvd, Philadelphia, PA 19104 USA; [Fierst, T. M.] Temple Univ, Sch Med, Dept Neurosurg, Philadelphia, PA USA; [Storm, P. B.; Resnick, A. C.; Waanders, A. J.] Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA; [Storm, P. B.; Resnick, A. C.; Waanders, A. J.] Childrens Hosp Philadelphia, Ctr Data Driven Discovery Biomed D3b, Philadelphia, PA 19104 USA; [Resnick, A. C.] Childrens Hosp Philadelphia, Dept Biomed & Hlth Informat, Philadelphia, PA 19104 USA; [Waanders, A. J.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Waanders, A. J.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine	Resnick, AC (corresponding author), Childrens Hosp Philadelphia, Div Neurosurg, CTRB 4052,3501 Civ Ctr Blvd, Philadelphia, PA 19104 USA.; Waanders, AJ (corresponding author), Dept Pediat, CTRB 4030,3501 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	RESNICK@email.chop.edu; WAANDERSA@email.chop.edu		Jain, Payal/0000-0002-5914-9083	Kids' Brain Tumor Cure Foundation Pediatric Low-Grade Astrocytoma Foundation; Voices Against Brain Cancer; Children's Brain Tumor Foundation; Damon-Runyon Sohn Pediatric Fellowship Award; Hyundai Scholar Grant; Bear Necessities Pediatric Cancer Foundation; Rally Foundation for Childhood Cancer Research; Thea's Star of HopeNIH National Center for Advancing Translational Sciences Award [TL1TR000138]; National Institute of Health grant [R01NS085336]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR000138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS085336] Funding Source: NIH RePORTER	Kids' Brain Tumor Cure Foundation Pediatric Low-Grade Astrocytoma Foundation; Voices Against Brain Cancer; Children's Brain Tumor Foundation; Damon-Runyon Sohn Pediatric Fellowship Award; Hyundai Scholar Grant; Bear Necessities Pediatric Cancer Foundation; Rally Foundation for Childhood Cancer Research; Thea's Star of HopeNIH National Center for Advancing Translational Sciences Award; National Institute of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Plexxikon Inc. for providing PLX4720 and PLX8394/PB-3 compounds and GlaxoSmithKline for providing trametinib. We greatly appreciate Jake Budlow, Tim Delaney, Namrata Choudhari and Katie Boucher for excellent technical assistance, and all members of the Resnick Lab for helpful discussion. We thank Dr Matthew Weitzman and Dr Mateusz P Koptyra for careful reading of the manuscript, and Dr Koptyra for helping with revision. This work was funded by the A Kids' Brain Tumor Cure Foundation Pediatric Low-Grade Astrocytoma Foundation (ACR), Voices Against Brain Cancer (ACR), the Children's Brain Tumor Foundation (ACR, AJW), the Damon-Runyon Sohn Pediatric Fellowship Award (AJW), a Hyundai Scholar Grant (AJW), the Bear Necessities Pediatric Cancer Foundation (AJW, ACR), the Rally Foundation for Childhood Cancer Research (AJW), Thea's Star of Hope (ACR, AJW), NIH National Center for Advancing Translational Sciences Award TL1TR000138 (HJH) and the National Institute of Health grant R01NS085336 (ACR).	Ali M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057345; Antony R, 2013, CANCER RES, V73, P4840, DOI 10.1158/0008-5472.CAN-12-4089; Bandopadhayay P, 2016, NAT GENET, V48, P273, DOI 10.1038/ng.3500; Bax DA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005209; Beuck C, 2012, J MOL BIOL, V423, P766, DOI 10.1016/j.jmb.2012.08.027; Bian YQ, 2012, BIOCHEM BIOPH RES CO, V422, P187, DOI 10.1016/j.bbrc.2012.04.138; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Carlson BR, 2011, J NEUROSCI, V31, P2447, DOI 10.1523/JNEUROSCI.4433-10.2011; Chen AJ, 2012, GENE DEV, V26, P1459, DOI 10.1101/gad.189001.112; Chen SH, 2016, CANCER DISCOV, V6, P300, DOI 10.1158/2159-8290.CD-15-0896; Chen TP, 1998, MOL CELL BIOL, V18, P4863, DOI 10.1128/MCB.18.8.4863; Chmielecki J, 2014, CANCER DISCOV, V4, P1398, DOI 10.1158/2159-8290.CD-14-0617; Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014; Danan-Gotthold M, 2015, NUCLEIC ACIDS RES, V43, P5130, DOI 10.1093/nar/gkv210; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Freeman Alyson K, 2013, Small GTPases, V4, P180, DOI 10.4161/sgtp.26117; Freeman AK, 2013, MOL CELL, V49, P751, DOI 10.1016/j.molcel.2012.12.018; FRIEDRIC.VL, 1974, BRAIN RES, V82, P168, DOI 10.1016/0006-8993(74)90902-0; Galarneau A, 2005, NAT STRUCT MOL BIOL, V12, P691, DOI 10.1038/nsmb963; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Henne WM, 2007, STRUCTURE, V15, P839, DOI 10.1016/j.str.2007.05.002; Henry JR, 2015, J MED CHEM, V58, P4165, DOI 10.1021/acs.jmedchem.5b00067; Jones DTW, 2009, ONCOGENE, V28, P2119, DOI 10.1038/onc.2009.73; Jones DTW, 2006, J NEUROPATH EXP NEUR, V65, P1049, DOI 10.1097/01.jnen.0000240465.33628.87; Karajannis MA, 2014, NEURO-ONCOLOGY, V16, P1408, DOI 10.1093/neuonc/nou059; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Lahoz A, 2013, ONCOGENE, V32, P4854, DOI 10.1038/onc.2012.489; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Li ZZ, 2002, JPN J CANCER RES, V93, P167, DOI 10.1111/j.1349-7006.2002.tb01255.x; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Olow A, 2016, CLIN CANCER RES, V22, P5312, DOI 10.1158/1078-0432.CCR-15-1101; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Peng SB, 2015, CANCER CELL, V28, P384, DOI 10.1016/j.ccell.2015.08.002; Phillips JJ, 2016, ACTA NEUROPATHOL, V132, P757, DOI 10.1007/s00401-016-1616-3; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Rajakulendran T, 2009, NATURE, V461, P542, DOI 10.1038/nature08314; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Rothrock CR, 2005, EMBO J, V24, P2792, DOI 10.1038/sj.emboj.7600745; Selt F, 2017, ONCOTARGET, V8, P11460, DOI 10.18632/oncotarget.14004; Shingu T, 2017, NAT GENET, V49, P75, DOI 10.1038/ng.3711; Sievert AJ, 2013, P NATL ACAD SCI USA, V110, P5957, DOI 10.1073/pnas.1219232110; Sievert AJ, 2009, BRAIN PATHOL, V19, P449, DOI 10.1111/j.1750-3639.2008.00225.x; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; Stransky N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5846; Tolcher AW, 2015, ANN ONCOL, V26, P58, DOI 10.1093/annonc/mdu482; Varga A, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aai8482; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; Wu X, 2012, MOL CELL BIOL, V32, P3872, DOI 10.1128/MCB.00751-12; Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001; Yoshihara K, 2015, ONCOGENE, V34, P4845, DOI 10.1038/onc.2014.406; Zhang C, 2015, NATURE, V526, P583, DOI 10.1038/nature14982; Zhang JH, 2013, NAT GENET, V45, P602, DOI 10.1038/ng.2611; Zhao Y, 2014, CANCER BIOL THER, V15, P108, DOI 10.4161/cbt.26722; Zong FY, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004289	55	38	38	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6348	6358		10.1038/onc.2017.276	http://dx.doi.org/10.1038/onc.2017.276			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28806393	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000414774800013
J	Szczepny, A; Rogers, S; Jayasekara, WSN; Park, K; McCloy, RA; Cochrane, CR; Ganju, V; Cooper, WA; Sage, J; Peacock, CD; Cain, JE; Burgess, A; Watkins, DN				Szczepny, A.; Rogers, S.; Jayasekara, W. S. N.; Park, K.; McCloy, R. A.; Cochrane, C. R.; Ganju, V.; Cooper, W. A.; Sage, J.; Peacock, C. D.; Cain, J. E.; Burgess, A.; Watkins, D. N.			The role of canonical and non-canonical Hedgehog signaling in tumor progression in a mouse model of small cell lung cancer	ONCOGENE			English	Article							CHROMOSOMAL INSTABILITY; CYCLE PROGRESSION; SONIC HEDGEHOG; TUMORIGENESIS; CARCINOMAS; ANEUPLOIDY; RECEPTOR; PATHWAY	Hedgehog (Hh) signaling regulates cell fate and self-renewal in development and cancer. Canonical Hh signaling is mediated by Hh ligand binding to the receptor Patched (Ptch), which in turn activates Gli-mediated transcription through Smoothened (Smo), the molecular target of the Hh pathway inhibitors used as cancer therapeutics. Small cell lung cancer (SCLC) is a common, aggressive malignancy with universally poor prognosis. Although preclinical studies have shown that Hh inhibitors block the self-renewal capacity of SCLC cells, the lack of activating pathway mutations have cast doubt over the significance of these observations. In particular, the existence of autocrine, ligand-dependent Hh signaling in SCLC has been disputed. In a conditional Tp53;Rb1 mutant mouse model of SCLC, we now demonstrate a requirement for the Hh ligand Sonic Hedgehog (Shh) for the progression of SCLC. Conversely, we show that conditional Shh overexpression activates canonical Hh signaling in SCLC cells, and markedly accelerates tumor progression. When compared to mouse SCLC tumors expressing an activating, ligand-independent Smo mutant, tumors overexpressing Shh exhibited marked chromosomal instability and Smoothened-independent upregulation of Cyclin B1, a putative non-canonical arm of the Hh pathway. In turn, we show that overexpression of Cyclin B1 induces chromosomal instability in mouse embryonic fibroblasts lacking both Tp53 and Rb1. These results provide strong support for an autocrine, ligand-dependent model of Hh signaling in SCLC pathogenesis, and reveal a novel role for non-canonical Hh signaling through the induction of chromosomal instability.	[Szczepny, A.; Jayasekara, W. S. N.; Cochrane, C. R.; Ganju, V.; Cain, J. E.] Hudson Inst Med Res, Ctr Canc Res, Clayton, Vic, Australia; [Rogers, S.; McCloy, R. A.; Burgess, A.; Watkins, D. N.] Garvan Inst Med Res, Kinghorn Canc Ctr, 384 Victoria St, Darlinghurst, NSW 2010, Australia; [Rogers, S.; Burgess, A.; Watkins, D. N.] UNSW Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia; [Park, K.] Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA; [Cochrane, C. R.; Ganju, V.] Monash Univ, Sch Clin Sci, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia; [Ganju, V.] Monash Hlth, Dept Med Oncol, Clayton, Vic, Australia; [Cooper, W. A.] Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Camperdown, NSW, Australia; [Sage, J.] Stanford Univ, Dept Pediat, Stanford Canc Inst, Sch Med, Stanford, CA 94305 USA; [Sage, J.] Stanford Univ, Dept Genet, Stanford Canc Inst, Sch Med, Stanford, CA 94305 USA; [Peacock, C. D.] Cleveland Clin, Dept Translat Hematol Oncol Res, Cleveland, OH 44106 USA; [Watkins, D. N.] St Vincents Hosp, Dept Thorac Med, Sydney, NSW, Australia	Hudson Institute of Medical Research; Garvan Institute of Medical Research; University of New South Wales Sydney; University of Virginia; Monash University; University of Sydney; Stanford Cancer Institute; Stanford University; Stanford Cancer Institute; Stanford University; Cleveland Clinic Foundation; St Vincents Hospital Sydney	Burgess, A; Watkins, DN (corresponding author), Garvan Inst Med Res, Kinghorn Canc Ctr, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	a.burgess@garvan.org.au; n.watkins@garvan.org.au	Burgess, Andrew/C-7952-2009; Burgess, Andrew/H-3339-2019	Burgess, Andrew/0000-0003-4536-9226; Burgess, Andrew/0000-0003-4536-9226; Rogers, Samuel/0000-0002-5345-5741; Cochrane, Catherine/0000-0001-9683-8905; Park, Kwon-Sik/0000-0003-3346-9086; McCloy, Rachael/0000-0001-7791-4044	National Health and Medical Research Council of Australia [GNT1048669]; Victorian Cancer Agency [TS10-01]; Petre Foundation; Victorian Government's Operational Infrastructure Support Program; National Institutes of Health (NCI) [CA201513]; Cancer Institute of NSW Fellowship [10/FRL/3-02]; Patricia Helen Guest Fellowship; NATIONAL CANCER INSTITUTE [R01CA201513] Funding Source: NIH RePORTER	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Victorian Cancer Agency; Petre Foundation; Victorian Government's Operational Infrastructure Support Program; National Institutes of Health (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Institute of NSW Fellowship; Patricia Helen Guest Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Health and Medical Research Council of Australia (GNT1048669), The Victorian Cancer Agency (TS10-01), The Petre Foundation, the Victorian Government's Operational Infrastructure Support Program, and the National Institutes of Health (NCI CA201513). Also, Cancer Institute of NSW Fellowship (10/FRL/3-02) and the Patricia Helen Guest Fellowship was awarded to JS and AB, respectively.	Adolphe C, 2006, CANCER RES, V66, P2081, DOI 10.1158/0008-5472.CAN-05-2146; Amakye D, 2013, NAT MED, V19, P1410, DOI 10.1038/nm.3389; Badea TC, 2003, J NEUROSCI, V23, P2314; Barnes EA, 2001, EMBO J, V20, P2214, DOI 10.1093/emboj/20.9.2214; Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598; Casimiro MC, 2015, ONCOTARGET, V6, P8525, DOI 10.18632/oncotarget.3267; Cui M, 2014, MOL CANCER RES, V12, P654, DOI 10.1158/1541-7786.MCR-13-0554; de Carcer G, 2014, NAT CELL BIOL, V16, P504, DOI 10.1038/ncb2978; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Fombonne J, 2012, P NATL ACAD SCI USA, V109, P10510, DOI 10.1073/pnas.1200094109; Gazdar AF, 2016, J THORAC ONCOL, V11, P287, DOI 10.1016/j.jtho.2015.10.009; Gazdar AF, 2015, J THORAC ONCOL, V10, P553, DOI 10.1097/JTO.0000000000000459; Geigl JB, 2008, TRENDS GENET, V24, P64, DOI 10.1016/j.tig.2007.11.006; Heng HH, 2013, CANCER METAST REV, V32, P325, DOI 10.1007/s10555-013-9427-7; Lewis PM, 2001, CELL, V105, P599, DOI 10.1016/S0092-8674(01)00369-5; Marini KD, 2011, GROWTH FACTORS, V29, P221, DOI 10.3109/08977194.2011.610756; McCloy RA, 2014, CELL CYCLE, V13, P1400, DOI 10.4161/cc.28401; McFadden DG, 2014, CELL, V156, P1298, DOI 10.1016/j.cell.2014.02.031; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Nagy Andras, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot4706; Nam HJ, 2014, NAT CELL BIOL, V16, P535, DOI 10.1038/ncb2952; O'Toole SA, 2011, CANCER RES, V71, P4002, DOI 10.1158/0008-5472.CAN-10-3738; Pak E, 2016, DEV CELL, V38, P333, DOI 10.1016/j.devcel.2016.07.026; Park KS, 2011, NAT MED, V17, P1504, DOI 10.1038/nm.2473; Pfau SJ, 2012, EMBO REP, V13, P515, DOI 10.1038/embor.2012.65; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Robles-Oteiza C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9783; Rogers S, 2016, J CELL SCI, V129, P1340, DOI 10.1242/jcs.179754; ROOS G, 1993, LAB INVEST, V68, P204; Shaukat Z, 2015, ONCOGENE, V34, P4044, DOI 10.1038/onc.2014.344; Sheltzer JM, 2013, CANCER RES, V73, P6401, DOI 10.1158/0008-5472.CAN-13-0749; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stevens JB, 2013, CANCER METAST REV, V32, P391, DOI 10.1007/s10555-013-9428-6; Wang DH, 2010, GASTROENTEROLOGY, V138, P1810, DOI 10.1053/j.gastro.2010.01.048; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Wong SY, 2009, NAT MED, V15, P1055, DOI 10.1038/nm.2011; Wu N, 2016, ONCOTARGET, V7, P57514, DOI 10.18632/oncotarget.11583; Youssef KK, 2010, NAT CELL BIOL, V12, P299, DOI 10.1038/ncb2031	40	38	38	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2017	36	39					5544	5550		10.1038/onc.2017.173	http://dx.doi.org/10.1038/onc.2017.173			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI4RG	28581526	hybrid, Green Accepted			2022-12-17	WOS:000411960500010
J	Zhu, C; Chrifi, I; Mustafa, D; van der Weiden, M; Leenen, PJM; Duncker, DJ; Kros, JM; Cheng, C				Zhu, C.; Chrifi, I.; Mustafa, D.; van der Weiden, M.; Leenen, P. J. M.; Duncker, D. J.; Kros, J. M.; Cheng, C.			CECR1-mediated cross talk between macrophages and vascular mural cells promotes neovascularization in malignant glioma	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; ANTIANGIOGENIC THERAPY; VESSEL FORMATION; STROMAL CELLS; ANGIOGENESIS; GLIOBLASTOMA; PERICYTES; PERIOSTIN; MICROGLIA; GROWTH	Glioblastomas (glioblastoma multiforme, GBM) are most malignant brain tumors characterized by profound vascularization. The activation of macrophages strongly contributes to tumor angiogenesis during GBM development. Previously, we showed that extracellular adenosine deaminase protein Cat Eye Syndrome Critical Region Protein 1 (CECR1) is highly expressed by M2-like macrophages in GBM where it defines macrophage M2 polarization and contributes to tumor expansion. In this study, the effect of CECR1 in macrophages on tumor angiogenesis was investigated. Immunohistochemical evaluation of GBM tissue samples showed that the expression of CECR1 correlates with microvascular density in the tumors, confirming data from the TCGA set. In a threedimensional co-culture system consisting of human pericytes, human umbilical vein endothelial cells and THP1-derived macrophages, CECR1 knockdown by siRNA and CECR1 stimulation of macrophages inhibited and promoted new vessel formation, respectively. Loss and gain of function studies demonstrated that PDGFB mRNA and protein levels in macrophages are modulated by CECR1. The proangiogenic properties of CECR1 in macrophages were partially mediated via paracrine activation of pericytes by PDGFB-PDGFR beta signaling. CECR1-PDGFB-PDGFR beta cross-activation between macrophages and pericytes promoted pericyte migration, shown by transwell migration assay, and enhanced expression and deposition of periostin, a matrix component with proangiogenic properties. CECR1 function in (M2-like) macrophages mediates cross talk between macrophages and pericytes in GBM via paracrine PDGFB-PDGFR beta signaling, promoting pericyte recruitment and migration, and tumor angiogenesis. Therefore, CECR1 offers a new portent target for anti-angiogenic therapy in GBM via immune modulation.	[Zhu, C.; Mustafa, D.; van der Weiden, M.; Kros, J. M.] Erasmus MC, Dept Pathol, Room Be 230c,Wytemaweg 80,POB 2040,3015 CN, NL-3000 CA Rotterdam, Netherlands; [Zhu, C.] Shanghai Jiao Tong Univ, Shanghai Xinhua Hosp, Sch Med, Dept Pediat Neurosurg, Shanghai, Peoples R China; [Chrifi, I.; Duncker, D. J.; Cheng, C.] Erasmus MC, Thoraxctr, Div Expt Cardiol, Dept Cardiol, Rotterdam, Netherlands; [Leenen, P. J. M.] Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Cheng, C.] Univ Med Ctr Utrecht, Dept Hypertens & Nephrol, DIGD, Utrecht, Netherlands	Erasmus University Rotterdam; Erasmus MC; Shanghai Jiao Tong University; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Utrecht University; Utrecht University Medical Center	Kros, JM (corresponding author), Erasmus MC, Dept Pathol, Room Be 230c,Wytemaweg 80,POB 2040,3015 CN, NL-3000 CA Rotterdam, Netherlands.	j.m.kros@erasmusmc.nl	Leenen, Pieter JM/I-5839-2013; Mustafa, Dana/AAQ-6530-2021	Leenen, Pieter JM/0000-0001-9860-2920; Mustafa, Dana/0000-0003-0644-078X	Chinese Scholar Council [201206230102]; Netherlands Foundation for Cardiovascular Excellence; Netherlands Cardiovascular Research Initiative; Dutch Heart Foundation [CVON2014-11 RECONNECT]; VIDI grant [91714302]; Erasmus MC fellowship; RM fellowship grant of the UMC Utrecht	Chinese Scholar Council; Netherlands Foundation for Cardiovascular Excellence; Netherlands Cardiovascular Research Initiative; Dutch Heart Foundation(Netherlands Heart Foundation); VIDI grant; Erasmus MC fellowship; RM fellowship grant of the UMC Utrecht	CZ was supported by the Chinese Scholar Council (201206230102). CC was supported by the Netherlands Foundation for Cardiovascular Excellence and by The Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation, (CVON2014-11 RECONNECT), VIDI grant 91714302, the Erasmus MC fellowship grant and the RM fellowship grant of the UMC Utrecht. We thank CardioGenx B.V. for providing the recombinant CECR1.	Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232; Bowman RL, 2016, CELL REP, V17, P2445, DOI 10.1016/j.celrep.2016.10.052; Brandenburg S, 2016, ACTA NEUROPATHOL, V131, P365, DOI 10.1007/s00401-015-1529-6; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Chen XB, 2014, CANCER RES, V74, P7285, DOI 10.1158/0008-5472.CAN-14-1240; Das S, 2013, NEW ENGL J MED, V369, P1561, DOI 10.1056/NEJMcibr1309402; Elkan PN, 2014, NEW ENGL J MED, V370, P921, DOI 10.1056/NEJMoa1307362; Erkan M, 2007, GASTROENTEROLOGY, V132, P1447, DOI 10.1053/j.gastro.2007.01.031; Ferrara N, 2010, CYTOKINE GROWTH F R, V21, P21, DOI 10.1016/j.cytogfr.2009.11.003; Gabrusiewicz K, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85841; Garcia-Quintans N, 2016, ANGIOGENESIS, V19, P217, DOI 10.1007/s10456-016-9502-0; Gilbert MR, 2016, J CLIN ONCOL, V34, P1567, DOI 10.1200/JCO.2016.66.5364; Hambardzumyan D, 2016, NAT NEUROSCI, V19, P20, DOI 10.1038/nn.4185; Jetten N, 2014, ANGIOGENESIS, V17, P109, DOI 10.1007/s10456-013-9381-6; Koh W, 2008, METHOD ENZYMOL, V443, P83, DOI 10.1016/S0076-6879(08)02005-3; Komohara Y, 2008, J PATHOL, V216, P15, DOI 10.1002/path.2370; Li W, 2012, NEURO-ONCOLOGY, V14, P958, DOI 10.1093/neuonc/nos116; Lin L, 2015, ONCOTARGET, V6, P34758, DOI 10.18632/oncotarget.5325; Liu AY, 2014, MATRIX BIOL, V37, P150, DOI 10.1016/j.matbio.2014.04.007; Lu-Emerson C, 2013, NEURO-ONCOLOGY, V15, P1079, DOI 10.1093/neuonc/not082; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847; Nijaguna MB, 2015, J BIOL CHEM, V290, P23401, DOI 10.1074/jbc.M115.664037; Ochs K, 2013, J NEUROIMMUNOL, V265, P106, DOI 10.1016/j.jneuroim.2013.09.011; Park SY, 2016, MOL CANCER THER, V15, P2187, DOI 10.1158/1535-7163.MCT-15-0427; Pong WW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077571; Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039; Prosniak M, 2013, CLIN CANCER RES, V19, P3776, DOI 10.1158/1078-0432.CCR-12-1940; Riabov V, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00075; Roma-Lavisse C, 2015, DIABETES VASC DIS RE, V12, P279, DOI 10.1177/1479164115582351; Squadrito ML, 2015, NAT CELL BIOL, V17, P107, DOI 10.1038/ncb3095; Stark K, 2013, NAT IMMUNOL, V14, P41, DOI 10.1038/ni.2477; Sun HQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114246; Sweeney MD, 2016, NAT NEUROSCI, V19, P771, DOI 10.1038/nn.4288; Takano S, 2012, BRAIN TUMOR PATHOL, V29, P73, DOI 10.1007/s10014-011-0077-6; VIGNAUD JM, 1994, CANCER RES, V54, P5455; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Xue Y, 2012, NAT MED, V18, P100, DOI 10.1038/nm.2575; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Yang YL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11385; Zheng PP, 2014, J CELL PHYSIOL, V229, P967, DOI 10.1002/jcp.24538; Zhong XL, 2016, ONCOTARGET, V7, P44365, DOI 10.18632/oncotarget.9744; Zhou Q, 2014, NEW ENGL J MED, V370, P911, DOI 10.1056/NEJMoa1307361; ZHU CB, 2015, CANCER RES S15, V75; Zhu CB, 2017, NEURO-ONCOLOGY, V19, P648, DOI 10.1093/neuonc/now251; Zhu CB, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-016-0405-5	48	38	38	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2017	36	38					5356	5368		10.1038/onc.2017.145	http://dx.doi.org/10.1038/onc.2017.145			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FH7PJ	28534507	Green Published, hybrid			2022-12-17	WOS:000411382100003
J	Chen, Y; Li, C; Xie, H; Fan, Y; Yang, Z; Ma, J; He, D; Li, L				Chen, Y.; Li, C.; Xie, H.; Fan, Y.; Yang, Z.; Ma, J.; He, D.; Li, L.			Infiltrating mast cells promote renal cell carcinoma angiogenesis by modulating PI3K -> AKT -> GSK3 beta -> AM signaling	ONCOGENE			English	Article							PROSTATE-CANCER; MICROVESSEL DENSITY; THERAPEUTIC TARGET; TUMOR ANGIOGENESIS; ADRENOMEDULLIN; ACTIVATION; EXPRESSION; AXIS	The recruitment of vascular endothelial cells from the tumor microenvironment (TME) to promote angiogenesis plays key roles in the progression of renal cell carcinoma (RCC). The potential impact of immune cells in the TME on RCC angiogenesis, however, remains unclear. Here, we found that recruitment of mast cells resulted in increased RCC angiogenesis in both in vitro cell lines and in vivo mouse models. Mechanistic analyses revealed that RCC recruited mast cells by modulating PI3K -> AKT -> GSK3 beta -> AM signaling. A clinical survey of human RCC samples also showed that higher expression of the PI3K -> AKT -> GSK3 beta -> AM signaling pathway correlated with increased angiogenesis. Interruption of PI3K -> AKT -> GSK3 beta -> AM signaling via specific inhibitors led to decreased recruitment of mast cells, and targeting this infiltrating mast cell-related signaling via an AKT-specific inhibitor suppressed RCC angiogenesis in xenograft mouse models. Together, these results identified a novel role of infiltrating mast cells in RCC angiogenesis and metastasis and suggest a new strategy for treating RCC by targeting this newly identified signaling pathway.	[Chen, Y.; Xie, H.; Fan, Y.; Yang, Z.; Ma, J.; He, D.; Li, L.] Xi An Jiao Tong Univ, Dept Urol, Affiliated Hosp 1, 277 Yanta Wast Rd, Xian 710061, Peoples R China; [Li, C.] Chinese Acad Sci, Inst Biophys, Core Facil Prot Res, Beijing, Peoples R China; [Li, C.] Beijing Jianlan Inst Med, Beijing, Peoples R China	Xi'an Jiaotong University; Chinese Academy of Sciences; Institute of Biophysics, CAS	Li, L (corresponding author), Xi An Jiao Tong Univ, Dept Urol, Affiliated Hosp 1, 277 Yanta Wast Rd, Xian 710061, Peoples R China.	lilydr@hotmail.com			The National High Technology Research and Development Program of China (863 Program) [SS2014AA020607]; National Natural Science Foundation of China [81072107, 81472679, 81302227, 81130041]; National Key Research and Development Program [2016YFC0902603]	The National High Technology Research and Development Program of China (863 Program)(National High Technology Research and Development Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program	This work was supported by The National High Technology Research and Development Program of China (863 Program, NO SS2014AA020607) and National Natural Science Foundation of China grant (No. 81072107, 81472679, 81302227, 81130041), and the National Key Research and Development Program (2016YFC0902603).	Cairns P, 2011, CANCER BIOMARK, V9, P461, DOI 10.3233/CBM-2011-0176; Crivellato E, 2008, CANCER LETT, V269, P1, DOI 10.1016/j.canlet.2008.03.031; Dang Q, 2015, MOL ONCOL, V9, P1241, DOI 10.1016/j.molonc.2015.02.010; Deville JL, 2010, EXPERT OPIN THER TAR, V14, P1059, DOI 10.1517/14728222.2010.522328; Deville JL, 2009, INT J CANCER, V125, P2307, DOI 10.1002/ijc.24568; Eddy AA, 2001, KIDNEY INT, V60, P375, DOI 10.1046/j.1523-1755.2001.00811.x; Forster A, 2015, ALLERGY, V70, P764, DOI 10.1111/all.12612; Fujita Y, 2002, INT J UROL, V9, P285, DOI 10.1046/j.1442-2042.2002.00469.x; Galinsky DST, 2008, CRIT REV ONCOL HEMAT, V68, P115, DOI 10.1016/j.critrevonc.2008.06.001; Guldur ME, 2014, J PAK MED ASSOC, V64, P300; Hollins F, 2008, J IMMUNOL, V181, P2772, DOI 10.4049/jimmunol.181.4.2772; Horstmann M, 2012, ANTICANCER RES, V32, P4339; Juengel E, 2015, J CELL MOL MED, V19, P430, DOI 10.1111/jcmm.12471; Kinoshita T, 1999, BLOOD, V94, P496, DOI 10.1182/blood.V94.2.496.414k19_496_508; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Kitamura Y, 2007, P JPN ACAD B-PHYS, V83, P164, DOI 10.2183/pjab.83.164; Kornakiewicz A, 2013, CURR SIGNAL TRANSD T, V8, P210; Li L, 2015, ONCOTARGET, V6, P14179, DOI 10.18632/oncotarget.3651; Liu XD, 2015, CANCER IMMUNOL RES, V3, P1017, DOI 10.1158/2326-6066.CIR-14-0244; Maltby S, 2009, BBA-REV CANCER, V1796, P19, DOI 10.1016/j.bbcan.2009.02.001; Mohseni MG, 2010, INT UROL NEPHROL, V42, P109, DOI 10.1007/s11255-009-9577-2; Nikitenko LL, 2006, BRIT J CANCER, V94, P1, DOI 10.1038/sj.bjc.6602832; Ning H, 2012, CHINESE MED J-PEKING, V125, P2120, DOI 10.3760/cma.j.issn.0366-6999.2012.12.008; Park JY, 2007, EXPERT REV ANTICANC, V7, P863, DOI 10.1586/14737140.7.6.863; Patel PH, 2006, BRIT J CANCER, V94, P614, DOI 10.1038/sj.bjc.6602978; PAVONE-MACALUSO M, 1960, Acta Pathol Microbiol Scand, V50, P337; Ribatti D, 2016, EUR J PHARMACOL, V778, P152, DOI 10.1016/j.ejphar.2015.02.056; Ribatti D, 2012, BBA-MOL BASIS DIS, V1822, P2, DOI 10.1016/j.bbadis.2010.11.010; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Safdari Y, 2015, PHARMACOL RES, V93, P1, DOI 10.1016/j.phrs.2014.12.004; Samayawardhena LA, 2008, J BIOL CHEM, V283, P29175, DOI 10.1074/jbc.M804077200; SARUTA T, 1977, Keio Journal of Medicine, V26, P163; Shen C, 2013, SEMIN CANCER BIOL, V23, P18, DOI 10.1016/j.semcancer.2012.06.001; Shi GP, 2013, CURR VASC PHARMACOL, V11, P314, DOI 10.2174/1570161111311030006; Siebenhaar F, 2014, EXP DERMATOL, V23, P159, DOI 10.1111/exd.12328; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Toge H, 2009, INT J UROL, V16, P801, DOI 10.1111/j.1442-2042.2009.02377.x; Trojan L, 2004, ANTICANCER RES, V24, P1651; Tuna B, 2006, EUR UROL, V50, P530, DOI 10.1016/j.eururo.2005.12.040; Watanabe S, 2012, HUM PATHOL, V43, P888, DOI 10.1016/j.humpath.2011.07.019; Wickenden JA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2558; Zhang L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019144; Zhang W, 2000, CANCER RES, V60, P6757	43	38	40	2	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2879	2888		10.1038/onc.2016.442	http://dx.doi.org/10.1038/onc.2016.442			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	28114284	hybrid, Green Published			2022-12-17	WOS:000401697800010
J	Smith, CIE				Smith, C. I. E.			From identification of the BTK kinase to effective management of leukemia	ONCOGENE			English	Review							CHRONIC LYMPHOCYTIC-LEUKEMIA; BRUTONS-TYROSINE-KINASE; X-LINKED AGAMMAGLOBULINEMIA; MANTLE-CELL LYMPHOMA; NON-HODGKIN-LYMPHOMA; FACTOR-KAPPA-B; TEC-FAMILY; PH DOMAIN; IBRUTINIB RESISTANCE; INHIBITOR IBRUTINIB	BTK is a cytoplasmic protein-tyrosine kinase, whose corresponding gene was isolated in the early 1990s. BTK was initially identified by positional cloning of the gene causing X-linked agammaglobulinemia and independently in a search for new kinases. Given the phenotype of affected patients, namely lack of B-lymphocytes and plasma cells with the ensuing inability to mount humoral immune responses, BTK inhibitors were anticipated to have beneficial effects on antibody-mediated pathologies, such as autoimmunity. In contrast to, for example, the SRC-family of cytoplasmic kinases, there was no obvious way in which structural alterations would yield constitutively active forms of BTK, and such mutations were also not found in leukemias or lymphomas. In 2007, the first efficient inhibitor, ibrutinib, was reported and soon became approved both in the United States and in Europe for the treatment of three B-cell malignancies, mantle cell lymphoma, chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia. Over the past few years, additional inhibitors have been developed, with acalabrutinib being more selective, and recently demonstrating fewer clinical adverse effects. The antitumor mechanism is also not related to mutations in BTK. Instead tumor residency in lymphoid organs is inhibited, making these drugs highly versatile. BTK is one of the only 10 human kinases that carry a cysteine in the adenosine triphosphate-binding cleft. As this allows for covalent, irreversible inhibitor binding, it provides these compounds with a highly advantageous character. This quality may be crucial and bodes well for the future of BTK-modifying medicines, which have been estimated to reach annual multi-billion dollar sales in the future.	[Smith, C. I. E.] Karolinska Inst, Karolinska Univ Hosp, Dept Lab Med, Clin Res Ctr, SE-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska University Hospital	Smith, CIE (corresponding author), Karolinska Inst, Karolinska Univ Hosp, Dept Lab Med, Clin Res Ctr, SE-14186 Huddinge, Sweden.	edvard.smith@ki.se		SMITH, C. I. Edvard/0000-0003-1907-3392	Swedish Cancer Society [CAN2013/389]; Swedish Medical Research Council [K2015-68X-11247-21-3]; Swedish County Council [ALF-project 2012006]	Swedish Cancer Society(Swedish Cancer Society); Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Swedish County Council	This work was supported by the Swedish Cancer Society (CAN2013/389), the Swedish Medical Research Council (K2015-68X-11247-21-3) and the Swedish County Council (ALF-project 2012006). I thank Anna Berglof, Qing Wang, Abdulrahman Hamasy and Rula Zain for their kind help and Anthony Wright, Birgitta Sander and Anders Osterborg for valuable comments on the manuscript.	Advani RH, 2013, J CLIN ONCOL, V31, P88, DOI 10.1200/JCO.2012.42.7906; Baba K, 1999, MOL CELL BIOL, V19, P4405; Baba Y, 2016, CURR TOP MICROBIOL, V393, P143, DOI 10.1007/82_2015_477; Bajpai UD, 2000, J EXP MED, V191, P1735, DOI 10.1084/jem.191.10.1735; Berglof A, 2015, SCAND J IMMUNOL, V82, P208, DOI 10.1111/sji.12333; Berglof A, 2013, EXPERT REV CLIN IMMU, V9, P1205, DOI 10.1586/1744666X.2013.850030; Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; Brown JR, 2016, HAEMATOLOGICA, V101, P295, DOI 10.3324/haematol.2015.140806; BRUTON OC, 1952, PEDIATRICS, V9, P722; Burger JA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11589; Byrd JC, 2016, NEW ENGL J MED, V374, P323, DOI 10.1056/NEJMoa1509981; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; Chen SS, 2016, LEUKEMIA, V30, P833, DOI 10.1038/leu.2015.316; Cheng S, 2015, LEUKEMIA, V29, P895, DOI 10.1038/leu.2014.263; Chiron D, 2014, CANCER DISCOV, V4, P1022, DOI 10.1158/2159-8290.CD-14-0098; COHN E J, 1947, Praxis, V36, P280; Conley ME, 2009, ANNU REV IMMUNOL, V27, P199, DOI 10.1146/annurev.immunol.021908.132649; COOPER MD, 1971, LANCET, V2, P791; Davids MS, 2012, OPEN J HEMATOL, V3, pi, DOI DOI 10.13055/OJHMT_3_S1_03; de Rooij MFM, 2015, BLOOD, V125, P2306, DOI 10.1182/blood-2014-12-619163; de Rooij MFM, 2012, BLOOD, V119, P2590, DOI 10.1182/blood-2011-11-390989; Derudder E, 2016, P NATL ACAD SCI USA, V113, P5065, DOI 10.1073/pnas.1604529113; Dreyling M, 2016, LANCET, V387, P770, DOI 10.1016/S0140-6736(15)00667-4; Evans EK, 2013, J PHARMACOL EXP THER, V346, P219, DOI 10.1124/jpet.113.203489; Farooqui MZH, 2015, LANCET ONCOL, V16, P169, DOI 10.1016/S1470-2045(14)71182-9; Furman RR, 2014, NEW ENGL J MED, V370, P2352, DOI 10.1056/NEJMc1402716; GARDULF A, 1991, LANCET, V338, P162; Guarnieri DJ, 1998, MOL CELL, V1, P831, DOI 10.1016/S1097-2765(00)80082-9; GUIOLI S, 1989, HUM GENET, V84, P19, DOI 10.1007/BF00210664; Hamada N, 2005, FEBS LETT, V579, P4131, DOI 10.1016/j.febslet.2005.06.042; Hamada-Kawaguchi N, 2014, SCIENCE, V343, P294, DOI 10.1126/science.1244512; Hamasy A, 2017, LEUKEMIA, V31, P177, DOI 10.1038/leu.2016.153; Herman SEM, 2011, BLOOD, V117, P6287, DOI 10.1182/blood-2011-01-328484; Honigberg LA, 2010, P NATL ACAD SCI USA, V107, P13075, DOI 10.1073/pnas.1004594107; Jolles S, 2015, CLIN EXP IMMUNOL, V179, P146, DOI 10.1111/cei.12485; Kang SW, 2001, EMBO J, V20, P5692, DOI 10.1093/emboj/20.20.5692; Kersseboom R, 2003, J EXP MED, V198, P91, DOI 10.1084/jem.20030615; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; KWAN SP, 1990, GENOMICS, V6, P238, DOI 10.1016/0888-7543(90)90562-9; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Lindvall JM, 2005, IMMUNOL REV, V203, P200, DOI 10.1111/j.0105-2896.2005.00225.x; Maddocks K, 2015, BLOOD, V125, P242, DOI 10.1182/blood-2014-08-597914; Maddocks KJ, 2015, JAMA ONCOL, V1, P80, DOI 10.1001/jamaoncol.2014.218; Mahajan S, 1999, J BIOL CHEM, V274, P9587, DOI 10.1074/jbc.274.14.9587; Martin P, 2016, BLOOD, V127, P1559, DOI 10.1182/blood-2015-10-673145; MENGLEGAW L, 1987, EMBO J, V6, P2273, DOI 10.1002/j.1460-2075.1987.tb02501.x; Mohamed AJ, 2009, IMMUNOL REV, V228, P58, DOI 10.1111/j.1600-065X.2008.00741.x; Mohammad DK, 2013, MOL CELL BIOL, V33, P3214, DOI 10.1128/MCB.00247-13; Muller S, 1996, ONCOGENE, V13, P1955; NAOR D, 1969, AUST J EXP BIOL MED, V47, P759, DOI 10.1038/icb.1969.173; Nawaz HM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035640; Noordzij JG, 2002, PEDIATR RES, V51, P159, DOI 10.1203/00006450-200202000-00007; O'Brien S, 2014, LANCET ONCOL, V15, P48, DOI 10.1016/S1470-2045(13)70513-8; Ortutay C, 2008, ADV GENET, V64, P51, DOI 10.1016/S0065-2660(08)00803-1; Pan ZY, 2007, CHEMMEDCHEM, V2, P58, DOI 10.1002/cmdc.200600221; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; Ponader S, 2012, BLOOD, V119, P1182, DOI 10.1182/blood-2011-10-386417; RABBITTS TH, 1985, EMBO J, V4, P2217, DOI 10.1002/j.1460-2075.1985.tb03917.x; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SANGER R, 1963, LANCET, V1, P859; SIDERAS P, 1995, ADV IMMUNOL, V59, P135, DOI 10.1016/S0065-2776(08)60631-8; SMITH CIE, 1987, ANN CLIN RES, V19, P220; Smith CIE, 1997, ADV GENET, V35, P57, DOI 10.1016/S0065-2660(08)60448-4; SMITH CIE, 1994, IMMUNOL REV, V138, P159, DOI 10.1111/j.1600-065X.1994.tb00851.x; Smith CIE, 2001, BIOESSAYS, V23, P436, DOI 10.1002/bies.1062; Smith CIE, 1996, IMMUNOL TODAY, V17, P495, DOI 10.1016/0167-5699(96)30063-7; Stiff A, 2016, CANCER RES, V76, P2125, DOI 10.1158/0008-5472.CAN-15-1490; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; Tiselius A, 1937, BIOCHEM J, V31, P313, DOI 10.1042/bj0310313; Treon SP, 2015, NEW ENGL J MED, V372, P1430, DOI 10.1056/NEJMoa1501548; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Valiaho J, 2006, HUM MUTAT, V27, P1209, DOI 10.1002/humu.20410; Valiaho J, 2015, HUM MUTAT, V36, P638, DOI 10.1002/humu.22791; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1995, IMMUNOL TODAY, V16, P460, DOI 10.1016/0167-5699(95)80027-1; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; Vihinen M, 1998, NUCLEIC ACIDS RES, V26, P242, DOI 10.1093/nar/26.1.242; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; Waldenstrom J, 1944, ACTA MED SCAND, V117, P216; Walter HS, 2016, BLOOD, V127, P411, DOI 10.1182/blood-2015-08-664086; Wang ML, 2016, LANCET ONCOL, V17, P48, DOI 10.1016/S1470-2045(15)00438-6; Wang ML, 2013, NEW ENGL J MED, V369, P507, DOI 10.1056/NEJMoa1306220; Wilson WH, 2016, NEW ENGL J MED, V374, P386, DOI 10.1056/NEJMe1515235; Winkelstein JA, 2014, PRIMARY IMMUNODEFICIENCY DISORDERS: A HISTORIC AND SCIENTIFIC PERSPECTIVE, P128; Winqvist M, 2016, HAEMATOLOGICA, V101, P1573, DOI 10.3324/haematol.2016.144576; Woyach JA, 2014, NEW ENGL J MED, V370, P2286, DOI 10.1056/NEJMoa1400029; Woyach JA, 2014, BLOOD, V123, P1207, DOI 10.1182/blood-2013-07-515361; Yang G, 2016, BLOOD, V127, P3237, DOI 10.1182/blood-2016-01-695098; Yigit B, 2016, ONCOTARGET, V7, P26346, DOI 10.18632/oncotarget.8378; Younes A, 2014, LANCET ONCOL, V15, P1019, DOI 10.1016/S1470-2045(14)70311-0; Yu L, 2008, BLOOD, V111, P4617, DOI 10.1182/blood-2007-10-121137; Yu L, 2006, J BIOL CHEM, V281, P18201, DOI 10.1074/jbc.M603090200; ZECH L, 1983, INT J CANCER, V32, P431, DOI 10.1002/ijc.2910320406; ZECH L, 1984, NATURE, V308, P858, DOI 10.1038/308858a0; Zoncu R, 2009, CELL, V136, P1110, DOI 10.1016/j.cell.2009.01.032	99	38	38	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2045	2053		10.1038/onc.2016.343	http://dx.doi.org/10.1038/onc.2016.343			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27669440	Green Published, hybrid			2022-12-17	WOS:000399782500001
J	Garg, N; Bakhshinyan, D; Venugopal, C; Mahendram, S; Rosa, DA; Vijayakumar, T; Manoranjan, B; Hallett, R; McFarlane, N; Delaney, KH; Kwiecien, JM; Arpin, CC; Lai, PS; Gomez-Biagi, RF; Ali, AM; de Araujo, ED; Ajani, OA; Hassell, JA; Gunning, PT; Singh, SK				Garg, N.; Bakhshinyan, D.; Venugopal, C.; Mahendram, S.; Rosa, D. A.; Vijayakumar, T.; Manoranjan, B.; Hallett, R.; McFarlane, N.; Delaney, K. H.; Kwiecien, J. M.; Arpin, C. C.; Lai, P-S; Gomez-Biagi, R. F.; Ali, A. M.; de Araujo, E. D.; Ajani, O. A.; Hassell, J. A.; Gunning, P. T.; Singh, S. K.			CD133(+) brain tumor-initiating cells are dependent on STAT3 signaling to drive medulloblastoma recurrence	ONCOGENE			English	Article							CANCER STEM-CELLS; SMALL-MOLECULE INHIBITOR; SUPPRESSES GROWTH; CYCLE ARREST; EXPRESSION; APOPTOSIS; PROLIFERATION; SUBGROUPS; PATHWAY; TARGET	Medulloblastoma (MB), the most common malignant paediatric brain tumor, is currently treated using a combination of surgery, craniospinal radiotherapy and chemotherapy. Owing to MB stem cells (MBSCs), a subset of MB patients remains untreatable despite standard therapy. CD133 is used to identify MBSCs although its functional role in tumorigenesis has yet to be determined. In this work, we showed enrichment of CD133 in Group 3 MB is associated with increased rate of metastasis and poor clinical outcome. The signal transducers and activators of transcription-3 (STAT3) pathway are selectively activated in CD133(+) MBSCs and promote tumorigenesis through regulation of c-MYC, a key genetic driver of Group 3 MB. We screened compound libraries for STAT3 inhibitors and treatment with the selected STAT3 inhibitors resulted in tumor size reduction in vivo. We propose that inhibition of STAT3 signaling in MBSCs may represent a potential therapeutic strategy to treat patients with recurrent MB.	[Garg, N.; Bakhshinyan, D.; Venugopal, C.; Mahendram, S.; Vijayakumar, T.; Manoranjan, B.; McFarlane, N.; Hassell, J. A.; Singh, S. K.] McMaster Stem Cell & Canc Res Inst, Hamilton, ON, Canada; [Garg, N.; Venugopal, C.; Mahendram, S.; Vijayakumar, T.; McFarlane, N.; Ajani, O. A.; Singh, S. K.] McMaster Univ, Dept Surg, Fac Hlth Sci, Hamilton, ON, Canada; [Bakhshinyan, D.; Vijayakumar, T.; Manoranjan, B.; Hassell, J. A.; Singh, S. K.] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON, Canada; [Rosa, D. A.; Arpin, C. C.; Lai, P-S; Gomez-Biagi, R. F.; de Araujo, E. D.; Gunning, P. T.] Univ Toronto, Dept Chem, Mississauga, ON, Canada; [Manoranjan, B.; Singh, S. K.] McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON, Canada; [Hallett, R.; Hassell, J. A.] McMaster Univ, McMaster Ctr Funct Genom, Hamilton, ON, Canada; [Delaney, K. H.; Kwiecien, J. M.] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada; [Kwiecien, J. M.] Med Univ Lublin, Dept Neurosurg & Paediat Neurosurg, Lublin, Poland; [Ali, A. M.] Assiut Univ, Dept Med Chem, Fac Pharm, Assiut, Egypt; [Hassell, J. A.] McMaster Univ, Dept Pathol, Hamilton, ON, Canada; [Hassell, J. A.] McMaster Univ, Dept Mol Med, Hamilton, ON, Canada	McMaster University; McMaster University; McMaster University; University of Toronto; University Toronto Mississauga; McMaster University; McMaster University; McMaster University; Medical University of Lublin; Egyptian Knowledge Bank (EKB); Assiut University; McMaster University; McMaster University	Singh, SK (corresponding author), McMaster Univ, Stem Cell & Canc Res Inst, MDCL 5027,1280 Main St West, Hamilton, ON L8S 4K1, Canada.	ssingh@mcmaster.ca	Singh, Sheila K/W-2799-2018; Garg, Neha/AAG-5180-2020	Singh, Sheila K/0000-0003-1272-5300; Garg, Neha/0000-0003-2227-8292; Ali, Ahmed Magdy/0000-0001-7913-8544	Department of Surgery at McMaster University; Canada Research Chair award; Canadian Institutes of Health Research (CIHR) Operating Grant [RN193483-299211, MOP-142353]; Stem Cell Network Drug Discovery Grant; Ontario Institute for Cancer Research Cancer Stem Cell Program; Canadian Cancer Society Research Institute; Terry Fox Research Institute New Investigator Award; Alberta Innovates; Stem Cell Network; CIHR; ORF; CFI	Department of Surgery at McMaster University; Canada Research Chair award(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs); Canadian Institutes of Health Research (CIHR) Operating Grant(Canadian Institutes of Health Research (CIHR)); Stem Cell Network Drug Discovery Grant; Ontario Institute for Cancer Research Cancer Stem Cell Program; Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Terry Fox Research Institute New Investigator Award; Alberta Innovates; Stem Cell Network; CIHR(Canadian Institutes of Health Research (CIHR)); ORF; CFI(Canada Foundation for Innovation)	Dr Sheila K Singh is supported by funds from the Department of Surgery at McMaster University, Canada Research Chair award, Canadian Institutes of Health Research (CIHR) Operating Grant #RN193483-299211, Stem Cell Network Drug Discovery Grant, Ontario Institute for Cancer Research Cancer Stem Cell Program, the Canadian Cancer Society Research Institute and Terry Fox Research Institute New Investigator Award. The Alberta Innovates, Stem Cell Network, CIHR, ORF and CFI fund Dr Patrick T. Gunning's research. Dr John A. Hassell is supported by the funds from CIHR Operating Grant # MOP-142353	Abdulghani J, 2008, AM J PATHOL, V172, P1717, DOI 10.2353/ajpath.2008.071054; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Ashizawa T, 2013, INT J ONCOL, V43, P219, DOI 10.3892/ijo.2013.1916; Bandopadhayay P, 2014, CLIN CANCER RES, V20, P912, DOI 10.1158/1078-0432.CCR-13-2281; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chang CJ, 2012, CHILD NERV SYST, V28, P363, DOI 10.1007/s00381-011-1672-x; Chen FX, 2010, J MOL NEUROSCI, V40, P353, DOI 10.1007/s12031-009-9323-3; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; Cox CV, 2009, BLOOD, V113, P3287, DOI 10.1182/blood-2008-04-154187; Ding BB, 2008, BLOOD, V111, P1515, DOI 10.1182/blood-2007-04-087734; Eiring AM, 2015, LEUKEMIA, V29, P586, DOI 10.1038/leu.2014.245; FRIEDMAN HS, 1992, CANCER RES, V52, P5373; Gajjar A, 2006, LANCET ONCOL, V7, P813, DOI 10.1016/S1470-2045(06)70867-1; Grosse-Gehling P, 2013, J PATHOL, V229, P355, DOI 10.1002/path.4086; Gu CY, 2011, ONCOL LETT, V2, P357, DOI 10.3892/ol.2011.235; Haftchenary S, 2013, ACS MED CHEM LETT, V4, P1102, DOI 10.1021/ml4003138; Haftchenary S, 2011, ANTI-CANCER DRUG, V22, P115, DOI 10.1097/CAD.0b013e328341185b; Holtick U, 2005, LEUKEMIA, V19, P936, DOI 10.1038/sj.leu.2403750; Huang MJ, 2006, EXP HEMATOL, V34, P1480, DOI 10.1016/j.exphem.2006.06.019; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Kawauchi D, 2012, CANCER CELL, V21, P168, DOI 10.1016/j.ccr.2011.12.023; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Kool M, 2012, ACTA NEUROPATHOL, V123, P473, DOI 10.1007/s00401-012-0958-8; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Li GH, 2010, INT J ONCOL, V37, P103, DOI 10.3892/ijo_00000658; Lin L, 2011, BIOCHEM BIOPH RES CO, V416, P246, DOI 10.1016/j.bbrc.2011.10.112; Mabbott DJ, 2005, J CLIN ONCOL, V23, P2256, DOI 10.1200/JCO.2005.01.158; Northcott PA, 2012, NAT REV CANCER, V12, P818, DOI 10.1038/nrc3410; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Pei YX, 2012, CANCER CELL, V21, P155, DOI 10.1016/j.ccr.2011.12.021; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Sai K, 2012, J NEURO-ONCOL, V107, P487, DOI 10.1007/s11060-011-0786-z; Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263; Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401; Singh M, 2015, ONCOTARGET, V6, P27461, DOI 10.18632/oncotarget.4742; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Song H, 2005, P NATL ACAD SCI USA, V102, P4700, DOI 10.1073/pnas.0409894102; Stechishin OD, 2013, NEURO-ONCOLOGY, V15, P198, DOI 10.1093/neuonc/nos302; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Venugopal C, 2015, CLIN CANCER RES, V21, P5324, DOI 10.1158/1078-0432.CCR-14-3147; Venugopal C, 2012, JOVE-J VIS EXP, DOI 10.3791/4111; Wang XiaoLi, 2012, Agricultural Biotechnology, V1, P1; Won C, 2015, HEPATOLOGY, V62, P1160, DOI 10.1002/hep.27968; Xiao H, 2015, J BIOL CHEM, V290, P3418, DOI 10.1074/jbc.M114.616748; Zeppernick F, 2008, CLIN CANCER RES, V14, P123, DOI 10.1158/1078-0432.CCR-07-0932; Zhang XL, 2012, P NATL ACAD SCI USA, V109, P9623, DOI 10.1073/pnas.1121606109; Zhao D, 2015, ONCOGENE, V34, P3107, DOI 10.1038/onc.2014.257	55	38	38	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					606	617		10.1038/onc.2016.235	http://dx.doi.org/10.1038/onc.2016.235			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27775079	Green Published, hybrid			2022-12-17	WOS:000394167700003
J	Behnan, J; Stangeland, B; Hosainey, SAM; Joel, M; Olsen, TK; Micci, F; Glover, JC; Isakson, P; Brinchmann, JE				Behnan, J.; Stangeland, B.; Hosainey, S. A. M.; Joel, M.; Olsen, T. K.; Micci, F.; Glover, J. C.; Isakson, P.; Brinchmann, J. E.			Differential propagation of stroma and cancer stem cells dictates tumorigenesis and multipotency	ONCOGENE			English	Article							TUMOR-INITIATING CELLS; HUMAN GLIOBLASTOMA; HUMAN GLIOMAS; LINES; BONE; IDENTIFICATION; HETEROGENEITY; PROLIFERATION; ANGIOGENESIS; PROGRESSION	Glioblastoma Multiforme (GBM) is characterized by high cancer cell heterogeneity and the presence of a complex tumor microenvironment. Those factors are a key obstacle for the treatment of this tumor type. To model the disease in mice, the current strategy is to grow GBM cells in serum-free non-adherent condition, which maintains their tumor-initiating potential. However, the so-generated tumors are histologically different from the one of origin. In this work, we performed high-throughput marker expression analysis and investigated the tumorigenicity of GBM cells enriched under different culture conditions. We identified a marker panel that distinguished tumorigenic sphere cultures from non-tumorigenic serum cultures (high CD56, SOX2, SOX9, and low CD105, CD248, aSMA). Contrary to previous work, we found that 'mixed cell cultures' grown in serum conditions are tumorigenic and express cancer stem cell (CSC) markers. As well, 1% serum plus bFGF and TGF-alpha preserved the tumorigenicity of sphere cultures and induced epithelial-to-mesenchymal transition gene expression. Furthermore, we identified 12 genes that could replace the 840 genes of The Cancer Genome Atlas (TCGA) used for GBM-subtyping. Our data suggest that the tumorigenicity of GBM cultures depend on cell culture strategies that retain CSCs in culture rather than the presence of serum in the cell culture medium.	[Behnan, J.; Stangeland, B.; Glover, J. C.; Brinchmann, J. E.] Oslo Univ Hosp, Norwegian Ctr Stem Cell Res, Dept Immunol, 4950 Nydalen, N-0424 Oslo, Norway; [Behnan, J.; Stangeland, B.; Glover, J. C.; Brinchmann, J. E.] Univ Oslo, Fac Med, Inst Basic Med Sci, Dept Mol Med, Oslo, Norway; [Stangeland, B.] Oslo Univ Hosp, Inst Surg Res, Dept Neurosurg, Oslo, Norway; [Hosainey, S. A. M.] St Olavs Univ Hosp, Dept Neurosurg, Trondheim, Norway; [Hosainey, S. A. M.] Oslo Univ Hosp, Dept Neurosurg, Oslo, Norway; [Joel, M.] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Radiat Biol, Oslo, Norway; [Olsen, T. K.; Micci, F.] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Genet & Informat, Sect Canc Cytogenet, Oslo, Norway; [Olsen, T. K.; Micci, F.] Univ Oslo, Ctr Canc Biomed, Oslo, Norway; [Isakson, P.] Sahlgrens Univ Hosp, Dept Clin Immunol & Transfus Med, Gothenburg, Sweden	University of Oslo; University of Oslo; Norwegian University of Science & Technology (NTNU); University of Oslo; University of Oslo; University of Oslo; University of Oslo; Sahlgrenska University Hospital	Behnan, J (corresponding author), Oslo Univ Hosp, Norwegian Ctr Stem Cell Res, Dept Immunol, 4950 Nydalen, N-0424 Oslo, Norway.	jinan.bahnan@rr-research.no	Behnan, Jinan/C-9263-2009; Stangeland, Biljana/W-4912-2019	Behnan, Jinan/0000-0001-5780-0971; Stangeland, Biljana/0000-0002-1723-9742	Neurosurgery Department and Institute for Surgical Research; Research Council of Norway; Helse Sor-Ost; Oslo University Hospital	Neurosurgery Department and Institute for Surgical Research; Research Council of Norway(Research Council of Norway); Helse Sor-Ost; Oslo University Hospital	We thank Neurosurgery Department and Institute for Surgical Research for provision of patients' samples and financial support. Grazyna Babinska, Hong Qu, Birthe Mikkelsen, Aphirak Juthajan and Petter Brandal for technical support; Yan Zhang for flow cytometry core facility. High-resolution histological images were acquired at the Norbrain Slide Scanning Facility at the Institute of Basic Medical Sciences, the University of Oslo, funded by the Research Council of Norway. We also thank Marianne Hanna for participating in the graphic drawing; Wayne Murrell for improving the language clarity; Jan Helge Solbakk and Peter Kierulf for guidance. This work was funded by Helse Sor-Ost and Oslo University Hospital. Microarray data have been deposited in the Gene Expression Omnibus (GEO) database (accession number GSE74571).	[Anonymous], 2011, GUIDE CARE USE LAB A; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barrantes-Freer A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130519; Behnan J, 2014, STEM CELLS, V32, P1110, DOI 10.1002/stem.1614; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Charles NA, 2012, GLIA, V60, P502, DOI 10.1002/glia.21264; Cheng L, 2013, CELL, V153, P139, DOI 10.1016/j.cell.2013.02.021; Clara CA, 2014, NEUROPATHOLOGY, V34, P343, DOI 10.1111/neup.12111; DeCarvalho AC, 2010, STEM CELLS, V28, P181, DOI 10.1002/stem.264; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gunther HS, 2008, ONCOGENE, V27, P2897, DOI 10.1038/sj.onc.1210949; Hadjipanayis CG, 2009, J MOL MED, V87, P363, DOI 10.1007/s00109-009-0440-9; Hagerstrand D, 2011, NEURO-ONCOLOGY, V13, P1178, DOI 10.1093/neuonc/nor113; Herlofsen SR, 2011, TISSUE ENG PT A, V17, P1003, DOI [10.1089/ten.tea.2010.0499, 10.1089/ten.TEA.2010.0499]; Hong X, 2012, INT J ONCOL, V41, P1693, DOI 10.3892/ijo.2012.1592; Hossain A, 2015, STEM CELLS, V33, P2400, DOI 10.1002/stem.2053; Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626; Kemper K, 2010, CANCER RES, V70, P719, DOI 10.1158/0008-5472.CAN-09-1820; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lim DA, 2007, NEURO-ONCOLOGY, V9, P424, DOI 10.1215/15228517-2007-023; Lottaz C, 2010, CANCER RES, V70, P2030, DOI 10.1158/0008-5472.CAN-09-1707; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Murrell W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071334; Ogden AT, 2008, NEUROSURGERY, V62, P505, DOI 10.1227/01.neu.0000316019.28421.95; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Pollard SM, 2009, CELL STEM CELL, V4, P568, DOI 10.1016/j.stem.2009.03.014; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sneddon JB, 2006, P NATL ACAD SCI USA, V103, P14842, DOI 10.1073/pnas.0606857103; Soeda A, 2015, SCI REP-UK, V5, DOI 10.1038/srep07979; Son MJ, 2009, CELL STEM CELL, V4, P440, DOI 10.1016/j.stem.2009.03.003; Stoczynska-Fidelus E, 2014, TUMOR BIOL, V35, P11311, DOI 10.1007/s13277-014-2444-5; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang L, 2012, MED ONCOL, V29, P3484, DOI 10.1007/s12032-012-0267-z; Worthley DL, 2015, CELL, V160, P269, DOI 10.1016/j.cell.2014.11.042	39	38	38	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					570	584		10.1038/onc.2016.230	http://dx.doi.org/10.1038/onc.2016.230			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27345406	Green Published, hybrid			2022-12-17	WOS:000394166700013
J	Murray-Stewart, T; Sierra, JC; Piazuelo, MB; Mera, RM; Chaturvedi, R; Bravo, LE; Correa, P; Schneider, BG; Wilson, KT; Casero, RA				Murray-Stewart, T.; Sierra, J. C.; Piazuelo, M. B.; Mera, R. M.; Chaturvedi, R.; Bravo, L. E.; Correa, P.; Schneider, B. G.; Wilson, K. T.; Casero, R. A.			Epigenetic silencing of miR-124 prevents spermine oxidase regulation: implications for Helicobacter pylori-induced gastric cancer	ONCOGENE			English	Article							ABERRANT DNA METHYLATION; HUMAN POLYAMINE OXIDASE; ULCERATIVE-COLITIS; EPITHELIAL-CELLS; INHIBITS PROLIFERATION; HYDROGEN-PEROXIDE; PROSTATE-CANCER; MICRORNA GENES; FIELD DEFECT; RISK	Chronic inflammation contributes to the development of various forms of cancer. The polyamine catabolic enzyme spermine oxidase (SMOX) is induced in chronic inflammatory conditions, including Helicobacter pylori-associated gastritis, where its production of hydrogen peroxide contributes to DNA damage and subsequent tumorigenesis. MicroRNA expression levels are also altered in inflammatory conditions; specifically, the tumor suppressor miR-124 becomes silenced by DNA methylation. We sought to determine if this repression of miR-124 is associated with elevated SMOX activity and concluded that miR-124 is indeed a negative regulator of SMOX. In gastric adenocarcinoma cells harboring highly methylated and silenced mir-124 gene loci, 5-azacytidine treatment allowed miR-124 re-expression and decreased SMOX expression. Overexpression of an exogenous miR-124-3p mimic repressed SMOX mRNA and protein expression as well as H2O2 production by >50% within 24 h. Reporter assays indicated that direct interaction of miR-124 with the 3 '-untranslated region of SMOX mRNA contributes to this negative regulation. Importantly, overexpression of miR-124 before infection with H. pylori prevented the induction of SMOX believed to contribute to inflammation-associated tumorigenesis. Compelling human in vivo data from H. pylori-positive gastritis tissues indicated that the mir-124 gene loci are more heavily methylated in a Colombian population characterized by elevated SMOX expression and a high risk for gastric cancer. Furthermore, the degree of mir-124 methylation significantly correlated with SMOX expression throughout the population. These results indicate a protective role for miR-124 through the inhibition of SMOX-mediated DNA damage in the etiology of H. pylori-associated gastric cancer.	[Murray-Stewart, T.; Casero, R. A.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Bunting Blaustein Bldg,Room 551,1650 Orleans St, Baltimore, MD 21287 USA; [Sierra, J. C.; Piazuelo, M. B.; Mera, R. M.; Chaturvedi, R.; Correa, P.; Schneider, B. G.; Wilson, K. T.] Vanderbilt Univ, Med Ctr, Div Gastroenterol, Nashville, TN USA; [Chaturvedi, R.] Jawaharlal Nehru Univ, Sch Biotechnol, New Delhi, India; [Bravo, L. E.] Univ Valle, Sch Med, Dept Pathol, Cali, Colombia; [Wilson, K. T.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN USA	Johns Hopkins University; Johns Hopkins Medicine; Vanderbilt University; Jawaharlal Nehru University, New Delhi; Universidad del Valle; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Casero, RA (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Bunting Blaustein Bldg,Room 551,1650 Orleans St, Baltimore, MD 21287 USA.	rcasero@jhmi.edu	Stewart, Tracy Murray/B-6137-2017; Bravo, Luis Eduardo/G-9671-2013; Bravo, Luis Eduardo/AAB-7209-2019	Stewart, Tracy Murray/0000-0001-8679-6414; Bravo, Luis Eduardo/0000-0002-9708-0312; Wilson, Keith/0000-0003-4421-1830; Casero, Robert/0000-0001-5653-3306	National Institutes of Health [R01CA051085, R01CA098454, R01DK053620, R01CA190612, P01CA028842, P01CA116087, K01AT007324]; Samuel Waxman Cancer Research Foundation; Vanderbilt Digestive Disease Research Center [P30DK058404, UL1RR024975]; Office of Medical Research, Department of Veterans Affairs [1I01BX001453]; NATIONAL CANCER INSTITUTE [P01CA028842, R01CA098454, R01CA051085, P01CA116087, R01CA190612] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [K01AT007324] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT004821] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404, R01DK053620] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001453] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Samuel Waxman Cancer Research Foundation; Vanderbilt Digestive Disease Research Center; Office of Medical Research, Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	We thank Alberto Delgado for his technical expertise and performance of SMOX immunohistochemistry studies. This study was supported by National Institutes of Health Grants R01CA051085 and R01CA098454 (to RAC), R01DK053620 and R01CA190612 (to KTW), P01CA028842 (to PC and KTW), P01CA116087 (to KTW), K01AT007324 (to RC), the Samuel Waxman Cancer Research Foundation (to RAC), the Vanderbilt Digestive Disease Research Center grant (P30DK058404), UL1RR024975 (Vanderbilt CTSA, Pilot Project to KTW) and Merit Review Grant 1I01BX001453 from the Office of Medical Research, Department of Veterans Affairs (to KTW).	Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219; Asada K, 2015, GUT, V64, P388, DOI 10.1136/gutjnl-2014-307094; Babbar N, 2006, CANCER RES, V66, P11125, DOI 10.1158/0008-5472.CAN-06-3174; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Camargo MC, 2004, HELICOBACTER, V9, P262, DOI 10.1111/j.1083-4389.2004.00221.x; Cervelli M, 2004, EUR J BIOCHEM, V271, P760, DOI 10.1111/j.1432-1033.2004.03979.x; Chaturvedi R, 2015, ONCOGENE, V34, P3429, DOI 10.1038/onc.2014.273; Chaturvedi R, 2004, J BIOL CHEM, V279, P40161, DOI 10.1074/jbc.M401370200; Chaturvedi R, 2014, GASTROENTEROLOGY, V146, P1739, DOI 10.1053/j.gastro.2014.02.005; Chaturvedi R, 2011, GASTROENTEROLOGY, V141, P1696, DOI 10.1053/j.gastro.2011.07.045; CORREA P, 1976, JNCI-J NATL CANCER I, V57, P1027, DOI 10.1093/jnci/57.5.1027; Dalal RS, 2014, J LEUKOCYTE BIOL, V96, P213, DOI 10.1189/jlb.4BT0214-100R; de Sablet T, 2011, GUT, V60, P1189, DOI 10.1136/gut.2010.234468; Ford Alexander C, 2014, BMJ, V348, pg3174, DOI 10.1136/bmj.g3174; Goodwin AC, 2008, PROSTATE, V68, P766, DOI 10.1002/pros.20735; Goodwin AC, 2011, P NATL ACAD SCI USA, V108, P15354, DOI 10.1073/pnas.1010203108; Goodwin CS, 1997, CLIN INFECT DIS, V25, P1017, DOI 10.1086/516077; Ha HC, 1998, P NATL ACAD SCI USA, V95, P11140, DOI 10.1073/pnas.95.19.11140; Hardbower DM, 2013, GUT MICROBES, V4, P475, DOI 10.4161/gmic.25583; Hong SKS, 2010, INFLAMM BOWEL DIS, V16, P1557, DOI 10.1002/ibd.21224; KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X; Kodaman N, 2014, P NATL ACAD SCI USA, V111, P1455, DOI 10.1073/pnas.1318093111; Koukos G, 2013, GASTROENTEROLOGY, V145, P842, DOI 10.1053/j.gastro.2013.07.001; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Maekita T, 2006, CLIN CANCER RES, V12, P989, DOI 10.1158/1078-0432.CCR-05-2096; Malfertheiner P, 2005, AM J GASTROENTEROL, V100, P2100, DOI 10.1111/j.1572-0241.2005.41688.x; Murray-Stewart T, 2008, FEBS J, V275, P2795, DOI 10.1111/j.1742-4658.2008.06419.x; Nakajima T, 2006, CANCER EPIDEM BIOMAR, V15, P2317, DOI 10.1158/1055-9965.EPI-06-0436; Niwa T, 2010, CANCER RES, V70, P1430, DOI 10.1158/0008-5472.CAN-09-2755; O'Hagan HM, 2011, CANCER CELL, V20, P606, DOI 10.1016/j.ccr.2011.09.012; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Pegg AE, 1998, BIOCHEM SOC T, V26, P580, DOI 10.1042/bst0260580; Plummer M, 2015, INT J CANCER, V136, P487, DOI 10.1002/ijc.28999; Rider JE, 2007, AMINO ACIDS, V33, P231, DOI 10.1007/s00726-007-0513-4; Schneider BG, 2013, EPIGENETICS-US, V8, P1153, DOI 10.4161/epi.26072; Schneider BG, 2010, INT J CANCER, V127, P2588, DOI 10.1002/ijc.25274; Shi XB, 2013, ONCOGENE, V32, P4130, DOI 10.1038/onc.2012.425; Shimizu T, 2013, EUR UROL, V63, P1091, DOI 10.1016/j.eururo.2012.11.030; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029; Ueda Y, 2014, DIGEST DIS SCI, V59, P2444, DOI 10.1007/s10620-014-3193-4; Ushijima T, 2012, CLIN CANCER RES, V18, P923, DOI 10.1158/1078-0432.CCR-11-2011; Wang HY, 2015, ADV DRUG DELIVER REV, V81, P142, DOI 10.1016/j.addr.2014.10.031; Wang YL, 2001, CANCER RES, V61, P5370; Wang YL, 2003, BIOCHEM BIOPH RES CO, V304, P605, DOI 10.1016/S0006-291X(03)00636-3; Wilting SM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-167; Xie LM, 2014, MOL CELL BIOCHEM, V392, P153, DOI 10.1007/s11010-014-2028-0; Xu HX, 2004, CANCER RES, V64, P8521, DOI 10.1158/0008-5472.CAN-04-3511	50	38	42	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5480	5488		10.1038/onc.2016.91	http://dx.doi.org/10.1038/onc.2016.91			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	27041578	Green Accepted			2022-12-17	WOS:000386998200003
J	Muralidharan, SV; Bhadury, J; Nilsson, LM; Green, LC; McLure, KG; Nilsson, JA				Muralidharan, S. V.; Bhadury, J.; Nilsson, L. M.; Green, L. C.; McLure, K. G.; Nilsson, J. A.			BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells	ONCOGENE			English	Article							NF-KAPPA-B; RNA-POLYMERASE-II; C-MYC; PROTEIN BRD4; CANCER-CELLS; P-TEFB; KINASE; CHROMATIN; TRANSCRIPTION; ELONGATION	Inhibiting the bromodomain and extra-terminal (BET) domain family of epigenetic reader proteins has been shown to have potent anti-tumoral activity, which is commonly attributed to suppression of transcription. In this study, we show that two structurally distinct BET inhibitors (BETi) interfere with replication and cell cycle progression of murine Myc-induced lymphoma cells at sublethal concentrations when the transcriptome remains largely unaltered. This inhibition of replication coincides with a DNA-damage response and enhanced sensitivity to inhibitors of the upstream replication stress sensor ATR in vitro and in mouse models of B-cell lymphoma. Mechanistically, ATR and BETi combination therapy cause robust transcriptional changes of genes involved in cell death, senescence-associated secretory pathway, NFkB signaling and ER stress. Our data reveal that BETi can potentiate the cell stress and death caused by ATR inhibitors. This suggests that ATRi can be used in combination therapies of lymphomas without the use of genotoxic drugs.	[Muralidharan, S. V.; Bhadury, J.; Nilsson, L. M.; Green, L. C.; Nilsson, J. A.] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Surg,Sahlgrenska Canc Ctr, Medicinaregatan 1G,Plan 6, SE-40530 Gothenburg, Sweden; [McLure, K. G.] Zenith Epigenet Corp, Calgary, AB, Canada; [McLure, K. G.] Ermaris Bio Corp, Calgary, AB, Canada	University of Gothenburg	Nilsson, JA (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Surg,Sahlgrenska Canc Ctr, Medicinaregatan 1G,Plan 6, SE-40530 Gothenburg, Sweden.	jonas.a.nilsson@surgery.gu.se	Bhadury, Joydeep/I-5059-2014; Bhadury, Joydeep/GPX-3446-2022; Bhadury, Joydeep/ABB-9252-2021	Bhadury, Joydeep/0000-0002-4333-9974; Bhadury, Joydeep/0000-0002-4333-9974; Nilsson, Jonas/0000-0003-0346-6837	Swedish Cancer Society; Swedish Research Council; Region Vastra Gataland (Sahlgrenska University Hospital, Gothenburg); Knut and Alice Wallenberg Foundation; Sahlgrenska Academy; BioCARE-a National Strategic Cancer Research Program at University of Gothenburg; Assar Gabrielsson Foundation; W&M Lundgren Foundation	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Region Vastra Gataland (Sahlgrenska University Hospital, Gothenburg); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Sahlgrenska Academy; BioCARE-a National Strategic Cancer Research Program at University of Gothenburg; Assar Gabrielsson Foundation; W&M Lundgren Foundation	We thank Sofia Nordstrand for animal care, and Eric Campeau and Zenith Epigenetics for RVX2135 and helpful discussions. This work was supported by grants from the Swedish Cancer Society, the Swedish Research Council, the Region Vastra Gataland (Sahlgrenska University Hospital, Gothenburg), the Knut and Alice Wallenberg Foundation, the Sahlgrenska Academy and BioCARE-a National Strategic Cancer Research Program at University of Gothenburg (to JAN), and from the Assar Gabrielsson Foundation and the W&M Lundgren Foundation (to SVM, JB and LCG).	Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Bandopadhayay P, 2014, CLIN CANCER RES, V20, P912, DOI 10.1158/1078-0432.CCR-13-2281; Belkina AC, 2012, NAT REV CANCER, V12, P465, DOI 10.1038/nrc3256; Bhadury J, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.8; Bhadury J, 2014, P NATL ACAD SCI USA, V111, pE2721, DOI 10.1073/pnas.1406722111; Boi M, 2015, CLIN CANCER RES, V21, P1628, DOI 10.1158/1078-0432.CCR-14-1561; Bolden JE, 2014, CELL REP, V8, P1919, DOI 10.1016/j.celrep.2014.08.025; Cheng ZX, 2013, CLIN CANCER RES, V19, P1748, DOI 10.1158/1078-0432.CCR-12-3066; Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711; Ciceri P, 2014, NAT CHEM BIOL, V10, P305, DOI 10.1038/nchembio.1471; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Denis GV, 2006, J PROTEOME RES, V5, P502, DOI 10.1021/pr050430u; Denis GV, 2000, CELL GROWTH DIFFER, V11, P417; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Dorr JR, 2013, NATURE, V501, P421, DOI 10.1038/nature12437; Ember SWJ, 2014, ACS CHEM BIOL, V9, P1160, DOI 10.1021/cb500072z; Fang J, 2014, CELL REP, V8, P1328, DOI 10.1016/j.celrep.2014.07.062; Ferrao PT, 2012, ONCOGENE, V31, P1661, DOI 10.1038/onc.2011.358; Fiskus W, 2014, MOL CANCER THER, V13, P1142, DOI 10.1158/1535-7163.MCT-13-0770; Floyd SR, 2013, NATURE, V498, P246, DOI 10.1038/nature12147; Foote KM, 2013, J MED CHEM, V56, P2125, DOI 10.1021/jm301859s; Gao LN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063563; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hoglund A, 2011, CLIN CANCER RES, V17, P7067, DOI 10.1158/1078-0432.CCR-11-1198; Hoglund A, 2011, CELL CYCLE, V10, P3598, DOI 10.4161/cc.10.20.17887; Huang B, 2009, MOL CELL BIOL, V29, P1375, DOI 10.1128/MCB.01365-08; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Jing H, 2011, GENE DEV, V25, P2137, DOI 10.1101/gad.17620611; Josse R, 2014, CANCER RES, V74, P6968, DOI 10.1158/0008-5472.CAN-13-3369; Keene RG, 1999, NUCLEIC ACIDS RES, V27, P3173, DOI 10.1093/nar/27.15.3173; Keller U, 2005, ONCOGENE, V24, P6231, DOI 10.1038/sj.onc.1208779; Keller U, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-348; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; Klapproth K, 2009, BLOOD, V114, P2448, DOI 10.1182/blood-2008-09-181008; Lecona E, 2014, EXP CELL RES, V329, P26, DOI 10.1016/j.yexcr.2014.09.019; Loosveld M, 2014, ONCOTARGET, V5, P3168, DOI 10.18632/oncotarget.1873; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Maruyama T, 2002, MOL CELL BIOL, V22, P6509, DOI 10.1128/MCB.22.18.6509-6520.2002; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Pastori C, 2014, EPIGENETICS-US, V9, P611, DOI 10.4161/epi.27906; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Reaper PM, 2011, NAT CHEM BIOL, V7, P428, DOI [10.1038/NCHEMBIO.573, 10.1038/nchembio.573]; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Shortt J, 2013, BLOOD, V121, P2964, DOI 10.1182/blood-2012-08-446096; Sinha A, 2005, BIOCHEM J, V387, P257, DOI 10.1042/BJ20041793; Stanlie A, 2014, MOL CELL, V55, P97, DOI 10.1016/j.molcel.2014.05.018; Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006; Tang C, 2014, CANCER IMMUNOL RES, V2, P831, DOI 10.1158/2326-6066.CIR-14-0069; Tolani B, 2014, ONCOGENE, V33, P2928, DOI 10.1038/onc.2013.242; Toledo LI, 2011, NAT STRUCT MOL BIOL, V18, P721, DOI 10.1038/nsmb.2076; Venkataraman S, 2014, ONCOTARGET, V5, P2355; Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029; Zou Z, 2014, ONCOGENE, V33, P2395, DOI 10.1038/onc.2013.179	57	38	40	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4689	4697		10.1038/onc.2015.521	http://dx.doi.org/10.1038/onc.2015.521			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26804177				2022-12-17	WOS:000383324700002
J	Guo, ST; Chi, MN; Yang, RH; Guo, XY; Zan, LK; Wang, CY; Xi, YF; Jin, L; Croft, A; Tseng, HY; Yan, XG; Farrelly, M; Wang, FH; Lai, F; Wang, JF; Li, YP; Ackland, S; Scott, R; Agoulnik, IU; Hondermarck, H; Thorne, RF; Liu, T; Zhang, XD; Jiang, CC				Guo, S. T.; Chi, M. N.; Yang, R. H.; Guo, X. Y.; Zan, L. K.; Wang, C. Y.; Xi, Y. F.; Jin, L.; Croft, A.; Tseng, H-Y; Yan, X. G.; Farrelly, M.; Wang, F. H.; Lai, F.; Wang, J. F.; Li, Y. P.; Ackland, S.; Scott, R.; Agoulnik, I. U.; Hondermarck, H.; Thorne, R. F.; Liu, T.; Zhang, X. D.; Jiang, C. C.			INPP4B is an oncogenic regulator in human colon cancer	ONCOGENE			English	Article							LASER CAPTURE MICRODISSECTION; TUMOR-SUPPRESSOR; HUMAN-MELANOMA; BREAST-CANCER; PHOSPHORYLATION; PROTEIN; ACTIVATION; EXPRESSION; PATHWAY; ETS-1	Inositol polyphosphate 4-phosphatase type II (INPP4B) negatively regulates phosphatidylinositol 3-kinase signaling and is a tumor suppressor in some types of cancers. However, we have found that it is frequently upregulated in human colon cancer cells. Here we show that silencing of INPP4B blocks activation of Akt and serum-and glucocorticoid-regulated kinase 3 (SGK3), inhibits colon cancer cell proliferation and retards colon cancer xenograft growth. Conversely, overexpression of INPP4B increases proliferation and triggers anchorage-independent growth of normal colon epithelial cells. Moreover, we demonstrate that the effect of INPP4B on Akt and SGK3 is associated with inactivation of phosphate and tensin homolog through its protein phosphatase activity and that the increase in INPP4B is due to Ets-1-mediated transcriptional upregulation in colon cancer cells. Collectively, these results suggest that INPP4B may function as an oncogenic driver in colon cancer, with potential implications for targeting INPP4B as a novel approach to treat this disease.	[Guo, S. T.; Yang, R. H.; Guo, X. Y.; Wang, C. Y.; Wang, F. H.] Shanxi Med Univ, Affiliated Hosp, Shanxi Canc Hosp & Inst, Dept Mol Biol, Taiyuan, Shanxi, Peoples R China; [Chi, M. N.; Jin, L.; Yan, X. G.; Lai, F.; Jiang, C. C.] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW 2308, Australia; [Zan, L. K.; Xi, Y. F.; Wang, J. F.] Shanxi Canc Hosp & Inst, Dept Pathol, Taiyuan, Shanxi, Peoples R China; [Croft, A.; Ackland, S.] Calvary Mater Newcastle Hosp, Dept Med Oncol, Newcastle, NSW, Australia; [Tseng, H-Y; Farrelly, M.; Scott, R.; Hondermarck, H.; Zhang, X. D.] Univ Newcastle, Sch Biomed Sci & Pharm, Newcastle, NSW 2300, Australia; [Li, Y. P.] Shanxi Canc Hosp & Inst, Dept Colorectal Surg, Taiyuan, Shanxi, Peoples R China; [Agoulnik, I. U.] Herbert Wertheim Coll Med, Dept Cellular Biol & Pharmacol, Miami, FL USA; [Thorne, R. F.] Univ Newcastle, Sch Environm & Life Sci, Callaghan, NSW 2308, Australia; [Liu, T.] Univ New S Wales, Childrens Canc Inst Australia Med Res, Sydney, NSW, Australia	Shanxi Medical University; University of Newcastle; Calvary Mater Newcastle Hospital; University of Newcastle; University of Newcastle; Children's Cancer Institute; Children's Medical Research Institute - Australia; University of New South Wales Sydney	Zhang, XD; Jiang, CC (corresponding author), Univ Newcastle, Prior Res Ctr Canc Res, Sch Med & Publ Hlth, LS3-49,Life Sci Bldg, Callaghan, NSW 2308, Australia.	Xu.Zhang@newcastle.edu.au; Chenchen.Jiang@newcastle.edu.au	Ackland, Stephen P./G-7460-2013; Liu, Tao/A-3922-2015; zhang, xu/GRX-9733-2022; Zhang, xiaoyu/GXA-3206-2022; zhang, xian/GYA-0290-2022; Tseng, Cindy Hsin-Yi/AAB-8958-2022; zhang, xu/GYE-3558-2022; Jin, Lei/K-2315-2019; Jin, Lei/J-1896-2019; Agoulnik, Irina/AAD-4687-2020; Scott, Rodney/B-2827-2013	Ackland, Stephen P./0000-0001-5303-0017; Tseng, Cindy Hsin-Yi/0000-0002-7499-7515; Jin, Lei/0000-0001-7187-9671; Agoulnik, Irina/0000-0003-4889-0324; Scott, Rodney/0000-0001-7724-3404; Zhang, Xu Dong/0000-0001-9457-8003; Liu, Tao/0000-0001-6244-7316	National Health and Medical Research Council (NHMRC) [APP1026458]; Cancer Council NSW, Australia [RG13-04, RG 13-15]; Shanxi Scholarship Council [2013-133]; Shanxi Natural Science Foundation, China [2013011043-3]; National Natural Science Foundation of China [81472837]; NATIONAL CANCER INSTITUTE [R15CA179287] Funding Source: NIH RePORTER	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council NSW, Australia(Cancer Council New South Wales); Shanxi Scholarship Council; Shanxi Natural Science Foundation, China(Natural Science Foundation of Shanxi Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Health and Medical Research Council (NHMRC) (APP1026458), the Cancer Council NSW (RG13-04 and RG 13-15), Australia, the Shanxi Scholarship Council (2013-133), Shanxi Natural Science Foundation (2013011043-3), China and National Natural Science Foundation of China (81472837). We thank Professor James R Woodgett (Samuel Lunenfeld Research Institute, Canada) for providing the Flag-myristoylated SGK3-CMV construct.	Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Bruhn MA, 2010, GROWTH FACTORS, V28, P394, DOI 10.3109/08977194.2010.518616; Carracedo A, 2011, CANCER RES, V71, P629, DOI 10.1158/0008-5472.CAN-10-2488; Colakoglu T, 2008, AM J SURG, V195, P719, DOI 10.1016/j.amjsurg.2007.05.061; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Dzneladze I, 2015, LEUKEMIA, V29, P1485, DOI 10.1038/leu.2015.51; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Fedele CG, 2010, P NATL ACAD SCI USA, V107, P22231, DOI 10.1073/pnas.1015245107; Ferte C, 2010, NAT REV CLIN ONCOL, V7, P367, DOI 10.1038/nrclinonc.2010.84; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gasser JA, 2014, MOL CELL, V56, P595, DOI 10.1016/j.molcel.2014.09.023; Gewinner C, 2009, CANCER CELL, V16, P115, DOI 10.1016/j.ccr.2009.06.006; Guo ST, 2013, ONCOGENE, V32, P1910, DOI 10.1038/onc.2012.214; Hodgson MC, 2011, CANCER RES, V71, P572, DOI 10.1158/0008-5472.CAN-10-2314; Hopkins BD, 2014, TRENDS BIOCHEM SCI, V39, P183, DOI 10.1016/j.tibs.2014.02.006; Ito Y, 2002, ANTICANCER RES, V22, P1581; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; Jin L, 2011, P NATL ACAD SCI USA, V108, P15840, DOI 10.1073/pnas.1019312108; Kisseleva MV, 2002, J BIOL CHEM, V277, P6266, DOI 10.1074/jbc.M105969200; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Lopez SM, 2013, BIOCHEM BIOPH RES CO, V440, P277, DOI 10.1016/j.bbrc.2013.09.077; Ma K, 2008, CELL SIGNAL, V20, P684, DOI 10.1016/j.cellsig.2007.12.004; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Moniz Larissa S, 2013, Biochem J, V452, pe11, DOI 10.1042/BJ20130617; Nakayama T, 2001, MODERN PATHOL, V14, P415, DOI 10.1038/modpathol.3880328; Nystrom A, 2009, BLOOD, V114, P4897, DOI 10.1182/blood-2009-02-207134; Ooms LM, 2006, MOL BIOL CELL, V17, P607, DOI 10.1091/mbc.E05-05-0469; Papakonstanti EA, 2008, J CELL SCI, V121, P4124, DOI 10.1242/jcs.032763; Park SJ, 2001, J BIOL CHEM, V276, P4781, DOI 10.1074/jbc.M010177200; Rijal S, 2015, BLOOD, V125, P2815, DOI 10.1182/blood-2014-09-603555; Satoh-Nagasawa N, 2006, NATURE, V441, P227, DOI 10.1038/nature04725; Scheid MP, 2002, J BIOL CHEM, V277, P9027, DOI 10.1074/jbc.M106755200; Scortegagna M, 2015, CANCER RES, V75, P1399, DOI 10.1158/0008-5472.CAN-14-2785; Struglics A, 2000, FEBS LETT, V475, P213, DOI 10.1016/S0014-5793(00)01680-X; Switzer CH, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3319; Ye Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2489	38	38	43	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					3049	3061		10.1038/onc.2015.361	http://dx.doi.org/10.1038/onc.2015.361			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26411369	Green Published, hybrid			2022-12-17	WOS:000377474500010
J	Su, CM; Wang, MY; Hong, CC; Chen, HA; Su, YH; Wu, CH; Huang, MT; Chang, YW; Jiang, SS; Sung, SY; Chang, JY; Chen, LT; Chen, PS; Su, JL				Su, C-M; Wang, M-Y; Hong, C-C; Chen, H-A; Su, Y-H; Wu, C-H; Huang, M-T; Chang, Y-W; Jiang, S-S; Sung, S-Y; Chang, J-Y; Chen, L-T; Chen, P-S; Su, J-L			miR-520h is crucial for DAPK2 regulation and breast cancer progression	ONCOGENE			English	Article							DRUG-RESISTANCE; TARGETING BCL2; PROTEIN-KINASE; FOLLOW-UP; MICRORNA; CELLS; SURVIVAL; DEATH; CHEMOTHERAPY; METASTASIS	MicroRNAs (miRNAs) are small RNAs that suppress gene expression by their interaction with 3'untranslated region of specific target mRNAs. Although the dysregulation of miRNAs has been identified in human cancer, only a few of these miRNAs have been functionally documented in breast cancer. Thus, defining the important miRNA and functional target involved in chemoresistance is an urgent need for human breast cancer treatment. In this study, we, for the first time, identified a key role of miRNA 520h (miR-520h) in drug resistance. Through protecting cells from paclitaxel-induced apoptosis, expression of miR-520h promoted the drug resistance of human breast cancer cells. Bioinformatics prediction, compensatory mutation and functional validation further confirmed the essential role of miR-520h-suppressed Death-associated protein kinase 2 (DAPK2) expression, as restoring DAPK2 abolished miR-520h-promoted drug resistance, and knockdown of DAPK2 mitigated cell death caused by the depletion of miR-520h. Furthermore, we observed that higher level of miR-520h is associated with poor prognosis and lymph node metastasis in human breast cancer patients. These results show that miR-520h is not only an independent prognostic factor, but is also a potential functional target for future applications in cancer therapeutics.	[Su, C-M; Chen, H-A; Wu, C-H] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan; [Su, C-M; Chen, H-A; Su, Y-H; Wu, C-H; Huang, M-T] Taipei Med Univ, Shuang Ho Hosp, Dept Surg, Div Gen Surg, Taipei, Taiwan; [Wang, M-Y] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan; [Hong, C-C; Chang, Y-W; Jiang, S-S; Chang, J-Y; Chen, L-T; Su, J-L] Natl Hlth Res Inst, Natl Inst Canc Res, 35 Keyan Rd, Zhunan 35053, Miaoli, Taiwan; [Sung, S-Y] Taipei Med Univ, Coll Med Sci & Technol, Program Translat Med, Taipei, Taiwan; [Chen, P-S] Natl Cheng Kung Univ, Inst Basic Med Sci, 1 Univ Rd, Tainan 70101, Taiwan; [Chen, P-S] Natl Cheng Kung Univ, Dept Med Lab Sci & Biotechnol, 1 Univ Rd, Tainan 70101, Taiwan; [Su, J-L] China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan; [Su, J-L] Asia Univ, Dept Biotechnol, Taichung, Taiwan; [Su, J-L] China Med Univ Hosp, Ctr Mol Med, Taichung, Taiwan	Taipei Medical University; Taipei Medical University; Shuang Ho Hospital; National Taiwan University; National Taiwan University Hospital; National Health Research Institutes - Taiwan; Taipei Medical University; National Cheng Kung University; National Cheng Kung University; China Medical University Taiwan; Asia University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan	Su, JL (corresponding author), Natl Hlth Res Inst, Natl Inst Canc Res, 35 Keyan Rd, Zhunan 35053, Miaoli, Taiwan.; Chen, PS (corresponding author), Natl Cheng Kung Univ, Dept Med Lab Sci & Biotechnol, 1 Univ Rd, Tainan 70101, Taiwan.	bio.benson@gmail.com; jlsu@nhri.org.tw	Chen, Pai-Sheng/G-2130-2012; Jiang, Shih Sheng/J-9671-2019	Chen, Pai-Sheng/0000-0003-0513-1467; Jiang, Shih Sheng/0000-0003-1909-437X	National Science Council grant from Taiwan [NSC 101-2320-B-400-016-MY3, NSC 102-2314-B-038-028-MY3, NSC 103-2314-B-038-059, NSC 101-2320-B-006-045-MY2, MOST 103-2628-B-006-003-MY3]; National Health Research Institutes grant from Taiwan [CA-102-PP-41, CA-104-SP-01, CA-104-PP-12, MOHW104-TDU-B-212-124-008]; Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare grant from Taiwan [103TMU-SHH-26]; Ministry of Education, Taiwan, R.O.C.	National Science Council grant from Taiwan; National Health Research Institutes grant from Taiwan; Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare grant from Taiwan; Ministry of Education, Taiwan, R.O.C.(Ministry of Education, Taiwan)	This work was supported by the National Science Council grant from Taiwan (NSC 101-2320-B-400-016-MY3, NSC 102-2314-B-038-028-MY3, NSC 103-2314-B-038-059, NSC 101-2320-B-006-045-MY2, MOST 103-2628-B-006-003-MY3); National Health Research Institutes grant from Taiwan (CA-102-PP-41, CA-104-SP-01, CA-104-PP-12, MOHW104-TDU-B-212-124-008); Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare grant from Taiwan (103TMU-SHH-26). We thank National RNAi Core Facility (Academia Sinica, Taiwan) for providing specific shRNAs. We thank Ms Fang-Yu Tsai and Dr I-Shou Chang of Taiwan Bioinformatics Institute Core Facility for assistances on using Oncomine (National Core Facility Program for Biotechnology, NSC-100-2319-B-400-001). This research was, in part, supported by the Ministry of Education, Taiwan, R.O.C. The Aim for the Top University Project to the National Cheng Kung University (NCKU).	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Barthel FMS, 2006, STAT MED, V25, P2521, DOI 10.1002/sim.2517; Baselga J, 2011, ONCOLOGIST, V16, P12, DOI 10.1634/theoncologist.2011-S1-12; Chen PS, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-90; Chen PS, 2011, J CLIN INVEST, V121, P3442, DOI 10.1172/JCI45390; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; DelBufalo D, 1997, FASEB J, V11, P947, DOI 10.1096/fasebj.11.12.9337147; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Giordano SH, 2004, CANCER, V100, P44, DOI 10.1002/cncr.11859; Glinsky GV, 1997, CANCER LETT, V115, P185, DOI 10.1016/S0304-3835(97)04738-1; Gordon V, 2013, CLIN CANCER RES, V19, P3738, DOI 10.1158/1078-0432.CCR-12-0274; Greenberg PAC, 1996, J CLIN ONCOL, V14, P2197, DOI 10.1200/JCO.1996.14.8.2197; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Kovalchuk O, 2008, MOL CANCER THER, V7, P2152, DOI 10.1158/1535-7163.MCT-08-0021; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Kutanzi KR, 2011, CLIN EPIGENETICS, V2, P171, DOI 10.1007/s13148-011-0040-8; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Ogawa T, 2012, CELL CYCLE, V11, P1656, DOI 10.4161/cc.20120; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sobin LH, 1997, CANCER, V80, P1803, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9; Su JL, 2010, CANCER RES, V70, P5096, DOI 10.1158/0008-5472.CAN-09-4148; Tanaka T, 2012, ONCOL REP, V28, P330, DOI 10.3892/or.2012.1774; To KKW, 2009, MOL CANCER THER, V8, P2959, DOI 10.1158/1535-7163.MCT-09-0292; Xia L, 2008, INT J CANCER, V123, P372, DOI 10.1002/ijc.23501; Yu YH, 2013, ONCOGENE, V32, P431, DOI 10.1038/onc.2012.74; Zhang XT, 2010, ANTICANCER RES, V30, P915; Zheng TS, 2010, INT J CANCER, V126, P2, DOI 10.1002/ijc.24782	28	38	38	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1134	1142		10.1038/onc.2015.168	http://dx.doi.org/10.1038/onc.2015.168			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	25982274				2022-12-17	WOS:000371351700007
J	Shvab, A; Haase, G; Ben-Shmuel, A; Gavert, N; Brabletz, T; Dedhar, S; Ben-Ze'ev, A				Shvab, A.; Haase, G.; Ben-Shmuel, A.; Gavert, N.; Brabletz, T.; Dedhar, S.; Ben-Ze'ev, A.			Induction of the intestinal stem cell signature gene SMOC-2 is required for L1-mediated colon cancer progression	ONCOGENE			English	Article							INTEGRIN-LINKED KINASE; COLORECTAL-CANCER; EXPRESSION; METASTASIS; DISEASE; TARGET; L1; OVEREXPRESSION; TUMORIGENESIS; PROTEINS	Overactivation of Wnt-beta-catenin signaling, including beta-catenin-TCF target gene expression, is a hallmark of colorectal cancer (CRC) development. We identified the immunoglobulin family of cell-adhesion receptors member L1 as a beta-catenin-TCF target gene preferentially expressed at the invasive edge of human CRC tissue. L1 can confer enhanced motility and liver metastasis when expressed in CRC cells. This ability of L1-mediated metastasis is exerted by a mechanism involving ezrin and the activation of NF-kappa B target genes. In this study, we identified the secreted modular calcium-binding matricellular protein-2 (SMOC-2) as a gene activated by L1-ezrin-NF-kappa B signaling. SMOC-2 is also known as an intestinal stem cell signature gene in mice expressing Lgr5 in cells at the bottom of intestinal crypts. The induction of SMOC-2 expression in L1-expressing CRC cells was necessary for the increase in cell motility, proliferation under stress and liver metastasis conferred by L1. SMOC-2 expression induced a more mesenchymal like phenotype in CRC cells, a decrease in E-cadherin and an increase in Snail by signaling that involves integrin-linked kinase (ILK). SMOC-2 was localized at the bottom of normal human colonic crypts and at increased levels in CRC tissue with preferential expression in invasive areas of the tumor. We found an increase in Lgr5 levels in CRC cells overexpressing L1, p65 or SMOC-2, suggesting that L1-mediated CRC progression involves the acquisition of a stem cell-like phenotype, and that SMOC-2 elevation is necessary for L1-mediated induction of more aggressive/invasive CRC properties.	[Shvab, A.; Haase, G.; Ben-Shmuel, A.; Gavert, N.; Ben-Ze'ev, A.] Weizmann Inst Sci, Dept Mol & Cell Biol, 234 Hertzl St, IL-76100 Rehovot, Israel; [Brabletz, T.] Univ Erlangen Nuernberg, Dept Expt Med 1, Erlangen, Germany; [Dedhar, S.] British Columbia Canc Res Ctr, Dept Integrat Oncol, Vancouver, BC V5Z 1L3, Canada	Weizmann Institute of Science; University of Erlangen Nuremberg; British Columbia Cancer Agency	Ben-Ze'ev, A (corresponding author), Weizmann Inst Sci, Dept Mol & Cell Biol, 234 Hertzl St, IL-76100 Rehovot, Israel.	avri.ben-zeev@weizmann.ac.il		Gavert, Nancy/0000-0003-1639-4684; Dedhar, Shoukat/0000-0003-4355-1657; ben-ze'ev, avri/0000-0001-6113-3921	Israel Cancer Research Fund (ICRF); Israel Science Foundation (ISF)	Israel Cancer Research Fund (ICRF); Israel Science Foundation (ISF)(Israel Science Foundation)	We thank Drs C Vaziri, U Hartmann, B Lenarcic, S Milano, R Cerione and P McDonald for reagents. This study was supported by grants from the Israel Cancer Research Fund (ICRF) and from the Israel Science Foundation (ISF).	Ben-Shmuel A, 2013, ONCOGENE, V32, P3220, DOI 10.1038/onc.2012.340; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Brabletz T, 2012, CANCER CELL, V22, P699, DOI 10.1016/j.ccr.2012.11.009; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Conacci-Sorrell ME, 2002, GENE DEV, V16, P2058, DOI 10.1101/gad.227502; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Gavert N, 2007, CANCER RES, V67, P7703, DOI 10.1158/0008-5472.CAN-07-0991; Gavert N, 2013, CANCER RES, V73, P5754, DOI 10.1158/0008-5472.CAN-13-0576; Gavert N, 2011, MOL CANCER RES, V9, P14, DOI 10.1158/1541-7786.MCR-10-0406; Gavert N, 2010, J CELL SCI, V123, P2134, DOI 10.1242/jcs.069542; Hortsch M, 2000, MOL CELL NEUROSCI, V15, P1, DOI 10.1006/mcne.1999.0809; Liu PJ, 2008, MOL BIOL CELL, V19, P248, DOI 10.1091/mbc.E07-05-0510; Liu P, 2009, GENE, V433, P72, DOI 10.1016/j.gene.2008.12.010; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Milano SK, 2012, J BIOL CHEM, V287, P24955, DOI 10.1074/jbc.M111.306514; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Novinec M, 2008, PROTEIN EXPRES PURIF, V62, P75, DOI 10.1016/j.pep.2008.07.009; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Rocnik EF, 2006, J BIOL CHEM, V281, P22855, DOI 10.1074/jbc.M513463200; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Serrano I, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3976; Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401; Simons BD, 2011, EXP CELL RES, V317, P2719, DOI 10.1016/j.yexcr.2011.07.010; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Uchida H, 2010, CANCER SCI, V101, P1731, DOI 10.1111/j.1349-7006.2010.01571.x; Vannahme C, 2003, BIOCHEM J, V373, P805, DOI 10.1042/BJ20030532; Yan ZP, 2014, ACTA HISTOCHEM, V116, P527, DOI 10.1016/j.acthis.2013.11.001	30	38	39	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					549	557		10.1038/onc.2015.127	http://dx.doi.org/10.1038/onc.2015.127			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25915847				2022-12-17	WOS:000369548800002
J	Engelmann, D; Meier, C; Alla, V; Putzer, BM				Engelmann, D.; Meier, C.; Alla, V.; Puetzer, B. M.			A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression	ONCOGENE			English	Review							SQUAMOUS-CELL CARCINOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; SPINDLE ASSEMBLY CHECKPOINT; HIGH ANTITUMOR-ACTIVITY; YES-ASSOCIATED PROTEIN; ABL TYROSINE KINASE; P53 FAMILY-MEMBERS; GROWTH-FACTOR-BETA; C-ABL; APOPTOTIC RESPONSE	p73 is the older sibling of p53 and mimics most of its tumor-suppressor functions. Through alternative promoter usage and splicing, the TP73 gene generates more than two dozen isoforms of which N-terminal truncated DNp73 variants have a decisive role in cancer pathogenesis as they outweigh the positive effects of full-length TAp73 and p53 in acting as a barrier to tumor development. Beyond the prevailing view that DNp73 predominantly counteract cell cycle arrest and apoptosis, latest progress indicates that these isoforms acquire novel functions in epithelial-to-mesenchymal transition, metastasis and therapy resistance. New insight into the mechanisms underlying this behavior reinforced the expectation that DNp73 variants contribute to aggressive cellular traits through both loss of wild-type tumor-suppressor activity and gain-of-function, suggesting an equally important role in cancer progression as mutant p53. In this review, we describe the novel properties of DNp73 in the invasion metastasis cascade and outline the comprehensive p73 regulatome with an emphasis on molecular processes putting TAp73 out of action in advanced tumors. These intriguing insights provoke a new understanding of the acquisition of aggressive traits by cancer cells and may help to set novel therapies for a broad range of metastatic tumors.	[Engelmann, D.; Meier, C.; Alla, V.; Puetzer, B. M.] Univ Rostock, Med Ctr, Inst Expt Gene Therapy & Canc Res, D-18057 Rostock, Germany	University of Rostock	Putzer, BM (corresponding author), Univ Rostock, Med Ctr, Inst Expt Gene Therapy & Canc Res, Schillingallee 69, D-18057 Rostock, Germany.	brigitte.puetzer@med.uni-rostock.de			German Cancer Aid; Federal Ministry of Education and Research as part of the project eBio: SysMet; FORUN program of Rostock University Medical Center	German Cancer Aid(Deutsche Krebshilfe); Federal Ministry of Education and Research as part of the project eBio: SysMet; FORUN program of Rostock University Medical Center	This work was supported by funds from the German Cancer Aid, Federal Ministry of Education and Research as part of the project eBio: SysMet and FORUN program of Rostock University Medical Center. We apologize to colleagues whose studies we did not cite owing to space limitations.	Achour M, 2013, BIOCHEM BIOPH RES CO, V430, P208, DOI 10.1016/j.bbrc.2012.11.087; Adamovich Y, 2014, CELL DEATH DIFFER, V21, P1451, DOI 10.1038/cdd.2014.60; Agami R, 1999, NATURE, V399, P809; Alhosin M, 2012, INVEST NEW DRUG, V30, P1813, DOI 10.1007/s10637-011-9734-1; Alhosin M, 2010, BIOCHEM PHARMACOL, V79, P1251, DOI 10.1016/j.bcp.2009.12.015; Alla V, 2012, CELL CYCLE, V11, P3067, DOI 10.4161/cc.21476; Alonso R, 2009, BLOOD, V114, P1563, DOI 10.1182/blood-2009-02-207654; Amelio I, 2014, ONCOGENE, V33, P5039, DOI 10.1038/onc.2013.456; Asher G, 2005, GENE DEV, V19, P316, DOI 10.1101/gad.319905; Azmi AS, 2011, AM J TRANSL RES, V3, P374; Bailey SG, 2011, INT J BIOCHEM CELL B, V43, P482, DOI 10.1016/j.biocel.2010.12.022; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Baxter RC, 2014, NAT REV CANCER, V14, P329, DOI 10.1038/nrc3720; Beitzinger M, 2006, ONCOGENE, V25, P813, DOI 10.1038/sj.onc.1209125; Beitzinger M, 2008, EMBO J, V27, P792, DOI 10.1038/emboj.2008.13; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Blanch A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066436; Blum R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.38; Bon G, 2009, CANCER RES, V69, P5978, DOI 10.1158/0008-5472.CAN-09-0244; Broadhead ML, 2009, TRENDS MOL MED, V15, P461, DOI 10.1016/j.molmed.2009.08.003; Buhlmann S, 2008, BBA-REV CANCER, V1785, P207, DOI 10.1016/j.bbcan.2008.01.002; Bunjobpo W, 2014, CELL DEATH DIFFER, V21, P1240, DOI 10.1038/cdd.2014.41; Cam H, 2006, CANCER CELL, V10, P281, DOI 10.1016/j.ccr.2006.08.024; Candi E, 2014, HUM MUTAT, V35, P702, DOI 10.1002/humu.22523; Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; Casciano I, 2002, CELL DEATH DIFFER, V9, P343, DOI 10.1038/sj.cdd.4400992; Castillo J, 2009, GASTROENTEROLOGY, V137, P1805, DOI 10.1053/j.gastro.2009.07.065; Chen WJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4472; Christopherson RI, 2014, NUCLEOS NUCLEOT NUCL, V33, P375, DOI 10.1080/15257770.2013.863334; Concin N, 2004, CANCER RES, V64, P2449, DOI 10.1158/0008-5472.CAN-03-1060; Concin N, 2005, CLIN CANCER RES, V11, P8372, DOI 10.1158/1078-0432.CCR-05-0899; Conforti F, 2012, AGING-US, V4, P202, DOI 10.18632/aging.100441; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Crighton D, 2007, CELL DEATH DIFFER, V14, P1071, DOI 10.1038/sj.cdd.4402108; Dar AA, 2008, CANCER RES, V68, P8998, DOI 10.1158/0008-5472.CAN-08-2658; Das R, 2014, APOPTOSIS, V19, P149, DOI 10.1007/s10495-013-0907-6; Daskalos A, 2011, CANCER LETT, V300, P79, DOI 10.1016/j.canlet.2010.09.009; Decrion-Barthod AZ, 2010, ANTICANCER RES, V30, P4049; Di CX, 2013, CELL CYCLE, V12, P1861, DOI 10.4161/cc.24967; Di Vinci A, 2009, INT J ONCOL, V34, P449, DOI 10.3892/ijo_00000169; Diaz R, 2008, INT J CANCER, V123, P1060, DOI 10.1002/ijc.23619; Dixit D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.179; Dominguez G, 2006, J CLIN ONCOL, V24, P805, DOI 10.1200/JCO.2005.02.2350; Du WJ, 2013, NAT CELL BIOL, V15, P991, DOI 10.1038/ncb2789; Dulloo I, 2010, P NATL ACAD SCI USA, V107, P4902, DOI 10.1073/pnas.0906782107; Emmrich S, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-61; Gaiddon C, 2003, J BIOL CHEM, V278, P27421, DOI 10.1074/jbc.M300251200; Gong JG, 1999, NATURE, V399, P806; Guerrieri F, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.302; Hackzell A, 2002, J BIOL CHEM, V277, P39769, DOI 10.1074/jbc.M204483200; Hamilton G, 2014, ONCOTARGET, V5, P6142, DOI 10.18632/oncotarget.2178; Harms KL, 2005, MOL CELL BIOL, V25, P2014, DOI 10.1128/MCB.25.5.2014-2030.2005; He Z, 2013, CELL DEATH DIFFER, V20, P1415, DOI 10.1038/cdd.2013.104; Herzog A, 2013, CLIN CANCER RES, V19, P3808, DOI 10.1158/1078-0432.CCR-12-2716; Ho TC, 2007, CARDIOVASC RES, V76, P213, DOI 10.1016/j.cardiores.2007.06.032; Hong B, 2014, CANCER RES, V74, P1153, DOI 10.1158/0008-5472.CAN-13-0955; Hosoda M, 2005, ONCOGENE, V24, P7156, DOI 10.1038/sj.onc.1208872; Huttinger-Kirchhof N, 2006, CELL DEATH DIFFER, V13, P174, DOI 10.1038/sj.cdd.4401809; Ishimoto O, 2002, CANCER RES, V62, P636; John K, 2011, CELL DEATH DIFFER, V18, P874, DOI 10.1038/cdd.2010.153; Jones EV, 2007, BIOCHEM J, V405, P617, DOI 10.1042/BJ20061778; Katayama H, 2012, CANCER CELL, V21, P196, DOI 10.1016/j.ccr.2011.12.025; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Klanrit P, 2009, ONCOGENE, V28, P3499, DOI 10.1038/onc.2009.191; Koida N, 2008, J BIOL CHEM, V283, P8555, DOI 10.1074/jbc.M710608200; Kravchenko JE, 2008, P NATL ACAD SCI USA, V105, P6302, DOI 10.1073/pnas.0802091105; Kubo N, 2010, BIOCHEM BIOPH RES CO, V403, P405, DOI 10.1016/j.bbrc.2010.11.043; Kunimoto Y, 2011, ORL-J OTO-RHIN-LARYN, V73, P17, DOI 10.1159/000320997; Lai J, 2014, ONCOTARGET, V5, P6909, DOI 10.18632/oncotarget.2230; Lapalombella R, 2010, BLOOD, V115, P2619, DOI 10.1182/blood-2009-09-242438; Lapi E, 2008, MOL CELL, V32, P803, DOI 10.1016/j.molcel.2008.11.019; Lau LMS, 2009, ONCOGENE, V28, P2024, DOI 10.1038/onc.2009.59; Lee AF, 2004, J NEUROSCI, V24, P9174, DOI 10.1523/JNEUROSCI.1588-04.2004; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Lehman JA, 2011, J BIOL CHEM, V286, P36631, DOI 10.1074/jbc.M110.217620; Leung THY, 2013, BRIT J CANCER, V109, P965, DOI 10.1038/bjc.2013.397; Leung THY, 2010, CANCER RES, V70, P6486, DOI 10.1158/0008-5472.CAN-10-0688; Levy D, 2007, CELL DEATH DIFFER, V14, P743, DOI 10.1038/sj.cdd.4402063; Levy D, 2008, J BIOL CHEM, V283, P27462, DOI 10.1074/jbc.M803941200; Levy D, 2008, MOL CELL, V29, P350, DOI 10.1016/j.molcel.2007.12.022; Li LH, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju083; Lin Y, 2012, BMC CELL BIOL, V13, DOI 10.1186/1471-2121-13-9; Lin YL, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000680; Liu KG, 2014, J NANOMATER, V2014, DOI 10.1155/2014/910639; Liu SS, 2004, CLIN CANCER RES, V10, P3309, DOI 10.1158/1078-0432.CCR-03-0119; Liu SS, 2006, CLIN CANCER RES, V12, P3922, DOI 10.1158/1078-0432.CCR-05-2573; Liu T, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.203; Liu Y, 2013, TUMOR BIOL, V34, P1641, DOI 10.1007/s13277-013-0697-z; Logotheti S, 2013, CANCER METAST REV, V32, P511, DOI 10.1007/s10555-013-9424-x; Luh LM, 2013, CELL DEATH DIFFER, V20, P1008, DOI 10.1038/cdd.2013.23; Maddika S, 2014, MOL CELL BIOL; Mancini M, 2011, J PHARMACOL EXP THER, V336, P596, DOI 10.1124/jpet.110.172536; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Merlo P, 2005, J BIOL CHEM, V280, P30354, DOI 10.1074/jbc.M500635200; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Moll UM, 2004, MOL CANCER RES, V2, P371; Momeny M, 2010, MED ONCOL, V27, P833, DOI 10.1007/s12032-009-9294-9; Muller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774; Munarriz E, 2004, MOL CELL BIOL, V24, P10593, DOI 10.1128/MCB.24.24.10593-10610.2004; Nahor I, 2005, GROWTH HORM IGF RES, V15, P388, DOI 10.1016/j.ghir.2005.07.005; Niemantsverdriet M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050815; Oberst A, 2007, P NATL ACAD SCI USA, V104, P11280, DOI 10.1073/pnas.0701773104; Onoda C, 2011, INT J ONCOL, V38, P1403, DOI 10.3892/ijo.2011.951; Paliwal P, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-45; Pan C, 2013, SCI REP-UK, V3, DOI 10.1038/srep02333; Papoutsaki M, 2004, J INVEST DERMATOL, V123, P1162, DOI 10.1111/j.0022-202X.2004.23498.x; Park GB, 2013, J IMMUNOL, V191, P6281, DOI 10.4049/jimmunol.1203442; Patel S, 2008, NUCLEIC ACIDS RES, V36, P5139, DOI 10.1093/nar/gkn490; Peschiaroli A, 2009, ONCOGENE, V28, P3157, DOI 10.1038/onc.2009.177; Petrenko O, 2003, MOL CELL BIOL, V23, P5540, DOI 10.1128/MCB.23.16.5540-5555.2003; Pietsch EC, 2008, ONCOGENE, V27, P6507, DOI 10.1038/onc.2008.315; Potu H, 2014, ONCOTARGET, V5, P5559, DOI 10.18632/oncotarget.2140; Puppin C, 2011, CELL ONCOL, V34, P131, DOI 10.1007/s13402-011-0009-9; Puri N, 2014, CANCER LETT, V343, P14, DOI 10.1016/j.canlet.2013.09.010; Qian YJ, 2008, J BIOL CHEM, V283, P2896, DOI 10.1074/jbc.M708624200; Qian YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084015; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Raab MS, 2009, BLOOD, V113, P1513, DOI 10.1182/blood-2008-05-157040; Racek T, 2005, J BIOL CHEM, V280, P40402, DOI 10.1074/jbc.C500193200; Rastogi S, 2012, CELL DEATH DIFFER, V19, P274, DOI 10.1038/cdd.2011.93; Ray RM, 2011, APOPTOSIS, V16, P35, DOI 10.1007/s10495-010-0538-0; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Rokaeus N, 2010, ONCOGENE, V29, P6442, DOI 10.1038/onc.2010.382; Rosenbluth JM, 2008, MOL CELL BIOL, V28, P5951, DOI 10.1128/MCB.00305-08; Rosenbluth JM, 2011, P NATL ACAD SCI USA, V108, P2076, DOI 10.1073/pnas.1011936108; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Rufini A, 2012, GENE DEV, V26, P2009, DOI 10.1101/gad.197640.112; Saha MN, 2013, MOL CANCER THER, V12, P2331, DOI 10.1158/1535-7163.MCT-12-1166; Sampath D, 2009, BLOOD, V113, P3744, DOI 10.1182/blood-2008-09-178707; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; Sang MX, 2006, BIOCHEM BIOPH RES CO, V347, P327, DOI 10.1016/j.bbrc.2006.06.079; Sang MX, 2009, GENES CELLS, V14, P775, DOI 10.1111/j.1365-2443.2009.01309.x; Sasaki Y, 2005, ONCOGENE, V24, P5131, DOI 10.1038/sj.onc.1208695; Sasaki Y, 2003, CANCER RES, V63, P8145; Sayan AE, 2008, ONCOGENE, V27, P4363, DOI 10.1038/onc.2008.64; Sayan BS, 2010, P NATL ACAD SCI USA, V107, P12877, DOI 10.1073/pnas.0911828107; Schipper H, 2014, ONCOTARGET, V5, P5893, DOI 10.18632/oncotarget.1839; Schuster A, 2010, CELL CYCLE, V9, P2629, DOI 10.4161/cc.9.13.12110; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Sharif T, 2010, EUR J CANCER, V46, P983, DOI 10.1016/j.ejca.2009.12.029; Shimodaira H, 2003, P NATL ACAD SCI USA, V100, P2420, DOI 10.1073/pnas.0438031100; Simoes-Wust AP, 2005, J NEURO-ONCOL, V72, P29, DOI 10.1007/s11060-004-3118-8; Soldevilla B, 2013, GENE CHROMOSOME CANC, V52, P989, DOI 10.1002/gcc.22095; Soldevilla B, 2011, CLIN CANCER RES, V17, P6029, DOI 10.1158/1078-0432.CCR-10-2388; Sooriakumaran P., 2009, Cancer Genomics & Proteomics, V6, P93; Stearns ME, 2011, TRANSL ONCOL, V4, P147, DOI 10.1593/tlo.10286; Steder M, 2013, CANCER CELL, V24, P512, DOI 10.1016/j.ccr.2013.08.023; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Stiewe T, 2002, CANCER RES, V62, P3598; Stiewe T, 2004, CLIN CANCER RES, V10, P626, DOI 10.1158/1078-0432.CCR-0153-03; Stiewe T, 2003, J BIOL CHEM, V278, P14230, DOI 10.1074/jbc.M300357200; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Talos F, 2007, MOL CELL, V27, P647, DOI 10.1016/j.molcel.2007.06.036; Tannapfel A, 2008, CARCINOGENESIS, V29, P211, DOI 10.1093/carcin/bgm236; Tebbi A, 2011, J BIOL CHEM, V286, P7873, DOI 10.1074/jbc.M110.184879; Terrinoni A, 2004, ONCOGENE, V23, P3721, DOI 10.1038/sj.onc.1207342; Testoni B, 2011, ONCOGENE, V30, P2670, DOI 10.1038/onc.2010.635; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tiwary R, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2801; Toh WH, 2010, CELL DEATH DIFFER, V17, P787, DOI 10.1038/cdd.2009.181; Toh WH, 2004, J BIOL CHEM, V279, P44713, DOI 10.1074/jbc.M407672200; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Tomasini R, 2009, P NATL ACAD SCI USA, V106, P797, DOI 10.1073/pnas.0812096106; Tordella L, 2013, P NATL ACAD SCI USA, V110, P17969, DOI 10.1073/pnas.1309362110; Tuve S, 2004, INT J CANCER, V108, P162, DOI 10.1002/ijc.11552; Tyagi S, 2010, BIOCHEM PHARMACOL, V80, P1326, DOI 10.1016/j.bcp.2010.07.025; Uppada SB, 2014, INT J NANOMED, V9, P43, DOI 10.2147/IJN.S55133; Uramoto H, 2004, CLIN CANCER RES, V10, P6905, DOI 10.1158/1078-0432.CCR-04-0290; Vella V, 2009, INT J CANCER, V124, P2539, DOI 10.1002/ijc.24221; Vera J, 2013, CANCER RES, V73, P3511, DOI 10.1158/0008-5472.CAN-12-4095; Vilgelm A, 2008, ONCOGENE, V27, P2170, DOI 10.1038/sj.onc.1210862; Vilgelm AE, 2010, ONCOGENE, V29, P5861, DOI 10.1038/onc.2010.319; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Watson IR, 2006, J BIOL CHEM, V281, P34096, DOI 10.1074/jbc.M603654200; Wei Wan-li, 2011, Chinese Journal of Pathology, V40, P532, DOI 10.3760/cma.j.issn.0529-5807.2011.08.007; Weissmueller S, 2014, CELL, V157, P382, DOI 10.1016/j.cell.2014.01.066; Wetterskog D, 2009, MOL CANCER RES, V7, P2031, DOI 10.1158/1541-7786.MCR-08-0501; Wilhelm MT, 2010, GENE DEV, V24, P549, DOI 10.1101/gad.1873910; Wojdyla L, 2014, BIOCHEM BIOPH RES CO, V446, P596, DOI 10.1016/j.bbrc.2014.03.013; Wolter JK, 2014, ONCOTARGET, V5, P161, DOI 10.18632/oncotarget.1083; Wong SW, 2011, BREAST CANCER RES TR, V128, P301, DOI 10.1007/s10549-010-1055-0; Yamamura Y, 2008, FEBS LETT, V582, P2663, DOI 10.1016/j.febslet.2008.06.046; Yan WS, 2012, MOL CELL BIOL, V32, P2336, DOI 10.1128/MCB.00215-12; Yoshida K, 2005, NAT CELL BIOL, V7, P278, DOI 10.1038/ncb1228; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zaika E, 2011, FASEB J, V25, P4406, DOI 10.1096/fj.11-192815; Zhang J, 2013, J BIOL CHEM, V288, P7727, DOI 10.1074/jbc.M112.429522; Zhang PD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042985; Zhang YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066464; Zhang YH, 2012, J BIOL CHEM, V287, P17746, DOI 10.1074/jbc.M112.358143; Zheng TS, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-133; Zheng TS, 2010, J CANCER RES CLIN, V136, P1597, DOI 10.1007/s00432-010-0817-8; Zitterbart K, 2007, ACTA NEUROPATHOL, V114, P641, DOI 10.1007/s00401-007-0298-2	200	38	40	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4287	4299		10.1038/onc.2014.365	http://dx.doi.org/10.1038/onc.2014.365			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25381823				2022-12-17	WOS:000359494400001
J	Thrane, S; Pedersen, AM; Thomsen, MBH; Kirkegaard, T; Rasmussen, BB; Duun-Henriksen, AK; Laenkholm, AV; Bak, M; Lykkesfeldt, AE; Yde, CW				Thrane, S.; Pedersen, A. M.; Thomsen, M. B. H.; Kirkegaard, T.; Rasmussen, B. B.; Duun-Henriksen, A. K.; Laenkholm, A. V.; Bak, M.; Lykkesfeldt, A. E.; Yde, C. W.			A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; D ANALOG EB1089; ESTROGEN-RECEPTOR; TAMOXIFEN-RESISTANT; POSTMENOPAUSAL WOMEN; PREDICTIVE MARKERS; SIGNALING PATHWAY; SMALL-MOLECULE; HISTONE H3; PHOSPHORYLATION	Antiestrogen resistance is a major problem in breast cancer treatment. Therefore, the search for new therapeutic targets and biomarkers for antiestrogen resistance is crucial. In this study, we performed a kinase inhibitor screen on antiestrogen responsive MCF-7 cells and a panel of MCF-7-derived tamoxifen- and fulvestrant-resistant cell lines. Our focus was to identify common and distinct molecular mechanisms involved in tamoxifen- and fulvestrant-resistant cell growth. We identified 18 inhibitors, of which the majority was common for both tamoxifen- and fulvestrant-resistant cell lines. Two compounds, WP1130 and JNJ-7706621, exhibiting prominent preferential growth inhibition of antiestrogen-resistant cell lines, were selected for further studies. WP1130, a deubiquitinase inhibitor, induced caspase-mediated cell death in both tamoxifen- and fulvestrant-resistant cell lines by destabilization of the anti-apoptotic protein Mcl-1. Mcl-1 expression was found upregulated in the antiestrogen-resistant cell lines and depletion of Mcl-1 in resistant cells caused decreased viability. JNJ-7706621, a dual Aurora kinase and cyclin-dependent kinase inhibitor, specifically inhibited growth and caused G2 phase cell cycle arrest of the tamoxifen-resistant cell lines. Knockdown studies showed that Aurora kinase A is essential for growth of the tamoxifen-resistant cells and inhibition of Aurora kinase A resensitized tamoxifen-resistant cells to tamoxifen treatment. Preferential growth inhibition by WP1130 and JNJ-7706621 was also found in T47D-derived tamoxifen-resistant cell lines, pointing at Mcl-1 and Aurora kinase A as potential treatment targets. In addition, tumor samples from 244 estrogen receptor-positive breast cancer patients treated with adjuvant tamoxifen showed that higher expression level of Aurora kinase A was significantly associated with shorter disease-free and overall survival, demonstrating the potential of Aurora kinase A as a biomarker for tamoxifen resistance.	[Thrane, S.; Pedersen, A. M.; Thomsen, M. B. H.; Kirkegaard, T.; Lykkesfeldt, A. E.; Yde, C. W.] Danish Canc Soc Res Ctr, Unit Cell Death & Metab, Breast Canc Grp, DK-2100 Copenhagen O, Denmark; [Rasmussen, B. B.] Herlev Hosp, Dept Pathol, DK-2730 Herlev, Denmark; [Duun-Henriksen, A. K.] Danish Canc Soc Res Ctr, Stat Bioinformat & Registry, Copenhagen, Denmark; [Laenkholm, A. V.] Slagelse Hosp, Dept Pathol, Slagelse, Denmark; [Bak, M.] Odense Univ Hosp, Dept Clin Pathol, DK-5000 Odense, Denmark	Danish Cancer Society; University of Copenhagen; Herlev & Gentofte Hospital; Danish Cancer Society; University of Southern Denmark; Odense University Hospital	Yde, CW (corresponding author), Danish Canc Soc Res Ctr, Unit Cell Death & Metab, Breast Canc Grp, Strandblvd 49, DK-2100 Copenhagen O, Denmark.	cwy@cancer.dk	Bak, Martin/D-1392-2012	Laenkholm, Anne-Vibeke/0000-0003-2166-8686; Thrane, Susan/0000-0001-6596-3527	Race Against Breast Cancer, Astrid Thaysen's grant [ATL12/01]; A.P. Moller Foundation for the Advancement of Medical Science [12-374]; Danish Cancer Research Foundation; Danish Cancer Society; Danske Bank Foundation; Hede Nielsen Family Foundation; Leo Nielsen's grant [LN12/07]; Novo Nordisk Foundation; Sigvald and Edith Rasmussen's grant	Race Against Breast Cancer, Astrid Thaysen's grant; A.P. Moller Foundation for the Advancement of Medical Science; Danish Cancer Research Foundation; Danish Cancer Society(Danish Cancer Society); Danske Bank Foundation; Hede Nielsen Family Foundation; Leo Nielsen's grant; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Sigvald and Edith Rasmussen's grant	We thank Jane Lind Christensen and Birgit Reiter for excellent technical assistance and Klaus Kaae Andersen and Ann-Sophie Sogaard for help with statistical analysis. This study was supported by A Race Against Breast Cancer, Astrid Thaysen's grant (ATL12/01), A.P. Moller Foundation for the Advancement of Medical Science (12-374), Danish Cancer Research Foundation, Danish Cancer Society, Danske Bank Foundation, Hede Nielsen Family Foundation, Leo Nielsen's grant (LN12/07), Novo Nordisk Foundation and Sigvald and Edith Rasmussen's grant.	Ali HR, 2012, BRIT J CANCER, V106, P1798, DOI 10.1038/bjc.2012.167; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Bartholomeusz GA, 2007, BLOOD, V109, P3470, DOI 10.1182/blood-2006-02-005579; Booy EP, 2011, ONCOGENE, V30, P2367, DOI 10.1038/onc.2010.616; BRIAND P, 1984, CANCER RES, V44, P1114; Chan SK, 2006, J MAMMARY GLAND BIOL, V11, P3, DOI 10.1007/s10911-006-9008-2; Christensen GL, 2004, BREAST CANCER RES TR, V85, P53, DOI 10.1023/B:BREA.0000021047.37869.95; Cohen NA, 2012, CHEM BIOL, V19, P1175, DOI 10.1016/j.chembiol.2012.07.018; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; Dar AA, 2010, MOL CANCER THER, V9, P268, DOI 10.1158/1535-7163.MCT-09-0765; Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8; Ding QQ, 2007, CANCER RES, V67, P4564, DOI 10.1158/0008-5472.CAN-06-1788; Drury SC, 2011, ENDOCR-RELAT CANCER, V18, P565, DOI 10.1530/ERC-10-0046; Emanuel S, 2005, CANCER RES, V65, P9038, DOI 10.1158/0008-5472.CAN-05-0882; Frankel LB, 2007, BREAST CANCER RES TR, V104, P165, DOI 10.1007/s10549-006-9399-1; Frogne T, 2005, ENDOCR-RELAT CANCER, V12, P599, DOI 10.1677/erc.1.00946; Frogne T, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2230; Frogne T, 2009, BREAST CANCER RES TR, V114, P263, DOI 10.1007/s10549-008-0011-8; Goldenson B, 2015, ONCOGENE, V34, P537, DOI 10.1038/onc.2014.14; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Henriksen KL, 2007, J CLIN PATHOL, V60, P397, DOI 10.1136/jcp.2005.034447; Henriksen K, 2009, ACTA ONCOL, V48, P522, DOI 10.1080/02841860802676383; Henson ES, 2006, CLIN CANCER RES, V12, P845, DOI 10.1158/1078-0432.CCR-05-0754; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Howell A, 2000, CANCER-AM CANCER SOC, V89, P817, DOI 10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6; HOWELL A, 1995, LANCET, V345, P29, DOI 10.1016/S0140-6736(95)91156-1; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Hutcheson IR, 2003, BREAST CANCER RES TR, V81, P81, DOI 10.1023/A:1025484908380; Kallio MJ, 2002, CURR BIOL, V12, P900, DOI 10.1016/S0960-9822(02)00887-4; Kapuria V, 2010, CANCER RES, V70, P9265, DOI 10.1158/0008-5472.CAN-10-1530; Larsen SS, 2001, BRIT J CANCER, V84, P686, DOI 10.1054/bjoc.2000.1646; Le Gouill S, 2004, CELL CYCLE, V3, P1259; Leary AF, 2010, CLIN CANCER RES, V16, P1486, DOI 10.1158/1078-0432.CCR-09-1764; Lundholt BK, 2001, BREAST CANCER RES TR, V67, P199, DOI 10.1023/A:1017977406429; LYKKESFELDT AE, 1994, CANCER RES, V54, P1587; LYKKESFELDT AE, 1995, INT J CANCER, V61, P529, DOI 10.1002/ijc.2910610417; Moller S, 2008, ACTA ONCOL, V47, P506, DOI 10.1080/02841860802059259; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nahta R, 2012, BREAST CANCER RES TR, V135, P39, DOI 10.1007/s10549-012-2067-8; Palmieri C, 2014, MOL CELL ENDOCRINOL, V382, P695, DOI 10.1016/j.mce.2013.08.001; Pancholi S, 2008, ENDOCR-RELAT CANCER, V15, P985, DOI 10.1677/ERC-07-0240; Rasmussen BB, 2008, LANCET ONCOL, V9, P23, DOI 10.1016/S1470-2045(07)70386-8; Robertson JFR, 2003, CANCER, V98, P229, DOI 10.1002/cncr.11468; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Siggelkow W, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-562; Sonne-Hansen K, 2010, BREAST CANCER RES TR, V121, P601, DOI 10.1007/s10549-009-0506-y; Sun HS, 2011, BLOOD, V117, P3151, DOI 10.1182/blood-2010-03-276477; TEIXEIRA C, 1995, CANCER RES, V55, P3902; Thomas LW, 2010, FEBS LETT, V584, P2981, DOI 10.1016/j.febslet.2010.05.061; Thrane S, 2013, BREAST CANCER RES TR, V139, P71, DOI 10.1007/s10549-013-2485-2; Vogler M, 2009, CELL DEATH DIFFER, V16, P360, DOI 10.1038/cdd.2008.137; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Yde CW, 2008, ONCOGENE, V27, P4986, DOI 10.1038/onc.2008.146; Yde CW, 2012, BREAST CANCER RES TR, V135, P67, DOI 10.1007/s10549-012-2053-1; Yde CW, 2007, MOL CANCER THER, V6, P1869, DOI 10.1158/1535-7163.MCT-07-0072; Zhang H, 2011, ONCOGENE, V30, P1963, DOI 10.1038/onc.2010.559; Zheng XQ, 2014, ONCOGENE, V33, P4985, DOI 10.1038/onc.2013.444	57	38	38	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4199	4210		10.1038/onc.2014.351	http://dx.doi.org/10.1038/onc.2014.351			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25362855				2022-12-17	WOS:000359199800006
J	Li, MY; Lai, PL; Chou, YT; Chi, AP; Mi, YZ; Khoo, KH; Chang, GD; Wu, CW; Meng, TC; Chen, GC				Li, M-Y; Lai, P-L; Chou, Y-T; Chi, A-P; Mi, Y-Z; Khoo, K-H; Chang, G-D; Wu, C-W; Meng, T-C; Chen, G-C			Protein tyrosine phosphatase PTPN3 inhibits lung cancer cell proliferation and migration by promoting EGFR endocytic degradation	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; DOWN-REGULATION; DROSOPHILA; EPS15; PTPMEG; INTERNALIZATION; ACTIVATION; PATHWAY; TUMORIGENESIS; ORGANIZATION	Epidermal growth factor receptor (EGFR) regulates multiple signaling cascades essential for cell proliferation, growth and differentiation. Using a genetic approach, we found that Drosophila FERM and PDZ domain-containing protein tyrosine phosphatase, dPtpmeg, negatively regulates border cell migration and inhibits the EGFR/Ras/mitogen-activated protein kinase signaling pathway during wing morphogenesis. We further identified EGFR pathway substrate 15 (Eps15) as a target of dPtpmeg and its human homolog PTPN3. Eps15 is a scaffolding adaptor protein known to be involved in EGFR endocytosis and trafficking. Interestingly, PTPN3-mediated tyrosine dephosphorylation of Eps15 promotes EGFR for lipid raft-mediated endocytosis and lysosomal degradation. PTPN3 and the Eps15 tyrosine phosphorylation-deficient mutant suppress non-small-cell lung cancer cell growth and migration in vitro and reduce lung tumor xenograft growth in vivo. Moreover, depletion of PTPN3 impairs the degradation of EGFR and enhances proliferation and tumorigenicity of lung cancer cells. Taken together, these results indicate that PTPN3 may act as a tumor suppressor in lung cancer through its modulation of EGFR signaling.	[Li, M-Y; Lai, P-L; Chi, A-P; Mi, Y-Z; Khoo, K-H; Meng, T-C; Chen, G-C] Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; [Li, M-Y; Khoo, K-H; Chang, G-D; Meng, T-C; Chen, G-C] Natl Taiwan Univ, Inst Biochem Sci, Coll Life Sci, Taipei, Taiwan; [Chou, Y-T; Wu, C-W] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan	Academia Sinica - Taiwan; National Taiwan University; Academia Sinica - Taiwan	Chen, GC (corresponding author), Acad Sinica, Inst Biol Chem, 128 Acad Rd,Sect 2, Taipei 115, Taiwan.	gcchen@gate.sinica.edu.tw	Khoo, Kay-Hooi/E-1989-2019; Chen, Guang-Chao/P-1262-2019; Meng, Tzu-Ching/G-5426-2019; Chi, Aiping/AAB-8010-2021	Khoo, Kay-Hooi/0000-0003-2906-406X; Chen, Guang-Chao/0000-0002-4980-4718; Meng, Tzu-Ching/0000-0001-7693-2021; Chou, Yu-Ting/0000-0001-9274-8603	National Science Council of Taiwan [NSC102-2311-B-001-027-MY3]; Academia Sinica	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Academia Sinica(Academia Sinica - Taiwan)	We thank Drs J Borst, PP Di Fiore, M McNiven, N Tonks, H Sun, KE Chen, the Bloomington Stock Center and Fly Core Taiwan for reagents. We are grateful to Dr J Settleman for helpful comments on the manuscript, Dr C-C Hung for confocal microscopy assistance and Y-L Huang for peptide synthesis. This work was supported by the National Science Council of Taiwan (NSC102-2311-B-001-027-MY3) and Academia Sinica.	Ali N, 2013, CURR BIOL, V23, P453, DOI 10.1016/j.cub.2013.02.033; Benmerah A, 1999, J CELL SCI, V112, P1303; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Bogdan S, 2001, CURR BIOL, V11, pR292, DOI 10.1016/S0960-9822(01)00167-1; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Chen DY, 2012, J CELL SCI, V125, P4841, DOI 10.1242/jcs.108597; Chi S, 2008, MOL BIOL CELL, V19, P3564, DOI 10.1091/mbc.E07-10-0997; Chou YT, 2010, CANCER RES, V70, P8822, DOI 10.1158/0008-5472.CAN-10-0638; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Confalonieri S, 2000, J CELL BIOL, V150, P905, DOI 10.1083/jcb.150.4.905; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Duchek P, 2001, CELL, V107, P17, DOI 10.1016/S0092-8674(01)00502-5; Duchek P, 2001, SCIENCE, V291, P131, DOI 10.1126/science.291.5501.131; Eden ER, 2010, NAT CELL BIOL, V12, P267, DOI 10.1038/ncb2026; Eden ER, 2009, BIOCHEM SOC T, V37, P173, DOI 10.1042/BST0370173; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Grandal MV, 2008, J CELL MOL MED, V12, P1527, DOI 10.1111/j.1582-4934.2008.00298.x; Gu MX, 1996, P NATL ACAD SCI USA, V93, P12980, DOI 10.1073/pnas.93.23.12980; Hawash IY, 2002, J BIOL CHEM, V277, P5683, DOI 10.1074/jbc.M110002200; Henegouwen PMPVE, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-24; Hironaka K, 2000, J BIOL CHEM, V275, P16167, DOI 10.1074/jbc.M909302199; Hong CF, 2009, J BIOL CHEM, V284, P19613, DOI 10.1074/jbc.M109.005017; Hou SW, 2010, CANCER RES, V70, P2901, DOI 10.1158/0008-5472.CAN-09-3229; Huang F, 2007, P NATL ACAD SCI USA, V104, P16904, DOI 10.1073/pnas.0707416104; Hunter T, 2009, CURR OPIN CELL BIOL, V21, P140, DOI 10.1016/j.ceb.2009.01.028; Jung Y, 2012, GENE CHROMOSOME CANC, V51, P590, DOI 10.1002/gcc.21945; Kina S, 2007, EUR J NEUROSCI, V26, P2269, DOI 10.1111/j.1460-9568.2007.05829.x; Ku HY, 2009, MOL CELL BIOL, V29, P3623, DOI 10.1128/MCB.00229-09; Labbe DP, 2012, PROG MOL BIOL TRANSL, V106, P253, DOI 10.1016/B978-0-12-396456-4.00009-2; Lessard L, 2010, BBA-PROTEINS PROTEOM, V1804, P613, DOI 10.1016/j.bbapap.2009.09.018; Martin-Blanco E, 1999, DEVELOPMENT, V126, P5739; Nomura M, 2007, PLOS MED, V4, P715, DOI 10.1371/journal.pmed.0040125; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Parachoniak CA, 2009, J BIOL CHEM, V284, P8382, DOI 10.1074/jbc.M807607200; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; Pignoni F, 1997, DEVELOPMENT, V124, P271; Roxrud I, 2008, J CELL BIOL, V180, P1205, DOI 10.1083/jcb.200708115; Sebastian S, 2006, BBA-REV CANCER, V1766, P120, DOI 10.1016/j.bbcan.2006.06.001; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shilo BZ, 2003, EXP CELL RES, V284, P140, DOI 10.1016/S0014-4827(02)00094-0; Sibilia M, 2007, DIFFERENTIATION, V75, P770, DOI 10.1111/j.1432-0436.2007.00238.x; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Sigismund S, 2008, DEV CELL, V15, P209, DOI 10.1016/j.devcel.2008.06.012; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Sun TT, 2011, CELL, V144, P703, DOI 10.1016/j.cell.2011.02.003; Tarcic G, 2009, CURR BIOL, V19, P1788, DOI 10.1016/j.cub.2009.09.048; Tiganis T, 2002, IUBMB LIFE, V53, P3, DOI 10.1080/15216540210811; Tonks NK, 2006, NAT REV MOL CELL BIO, V7, P833, DOI 10.1038/nrm2039; Tonks NK, 2003, FEBS LETT, V546, P140, DOI 10.1016/S0014-5793(03)00603-3; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Whited JL, 2007, DEVELOPMENT, V134, P43, DOI 10.1242/dev.02718; Woodman P, 2009, BIOCHEM SOC T, V37, P146, DOI 10.1042/BST0370146; Wu CW, 2006, ANTICANCER RES, V26, P1643; Xu YR, 2005, J BIOL CHEM, V280, P42694, DOI 10.1074/jbc.M507722200; Yuan TC, 2010, J BIOL CHEM, V285, P14861, DOI 10.1074/jbc.M109.099879; Zhang SH, 1999, J BIOL CHEM, V274, P17806, DOI 10.1074/jbc.274.25.17806; Zhi HY, 2011, ONCOGENE, V30, P1706, DOI 10.1038/onc.2010.543	59	38	40	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3791	3803		10.1038/onc.2014.312	http://dx.doi.org/10.1038/onc.2014.312			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25263444				2022-12-17	WOS:000358001600005
J	Seong, BKA; Lau, J; Adderley, T; Kee, L; Chaukos, D; Pienkowska, M; Malkin, D; Thorner, P; Irwin, MS				Seong, B. K. A.; Lau, J.; Adderley, T.; Kee, L.; Chaukos, D.; Pienkowska, M.; Malkin, D.; Thorner, P.; Irwin, M. S.			SATB2 enhances migration and invasion in osteosarcoma by regulating genes involved in cytoskeletal organization	ONCOGENE			English	Article							EPITHELIAL PROTEIN LOST; TUMOR GROWTH; RHO-GTPASES; EXPRESSION; EPLIN; DIFFERENTIATION; CANCER; METASTASIS; PATHOGENESIS; DETERMINANT	Osteosarcoma (OS) is the most common malignant bone tumor and the majority of recurrences are due to metastasis. However, the molecular mechanisms that regulate OS metastatic spread are largely unknown. In this study, we report that special AT-rich-binding protein 2 (SATB2) is highly expressed in OS cells and tumors. Short hairpin RNA-mediated knockdown of SATB2 (sh-SATB2) decreases migration and invasion of OS cells without affecting proliferation or viability. Microarray analysis identified genes that were differentially regulated by SATB2 including the actin-binding protein Epithelial Protein Lost In Neoplasm (EPLIN), which was upregulated in sh-SATB2 cells. Silencing EPLIN rescues the decreased invasion observed in sh-SATB2 cells. Pathway analyses of SATB2-regulated genes revealed enrichment of those involved in cytoskeleton dynamics, and increased stress fiber formation was detected in cells with SATB2 knockdown. Furthermore, sh-SATB2 cells exhibit increased RhoA, decreased Rac1 and increased phosphorylation of focal adhesion kinase (FAK) and paxillin. These findings identify SATB2 as a novel regulator of OS invasion, in part via effects on EPLIN and the cytoskeleton.	[Seong, B. K. A.; Malkin, D.; Irwin, M. S.] Univ Toronto, Dept Pediat, Toronto, ON, Canada; [Seong, B. K. A.; Malkin, D.; Irwin, M. S.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Seong, B. K. A.; Lau, J.; Adderley, T.; Kee, L.; Chaukos, D.; Irwin, M. S.] Hosp Sick Children, Res Inst, Peter Gilgan Ctr Res & Learning, Cell Biol Program, Toronto, ON M5G 1X8, Canada; [Pienkowska, M.; Malkin, D.] Hosp Sick Children, Res Inst, Peter Gilgan Ctr Res & Learning, Program Genet & Genome Biol, Toronto, ON M5G 1X8, Canada; [Malkin, D.; Irwin, M. S.] Hosp Sick Children, Dept Pediat, Div Hematol Oncol, Toronto, ON M5G 1X8, Canada; [Thorner, P.] Hosp Sick Children, Dept Pediat Lab Med, Toronto, ON M5G 1X8, Canada; [Thorner, P.; Irwin, M. S.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Irwin, MS (corresponding author), Hosp Sick Children, Dept Paediat & Cell Biol, 555 Univ Ave,Black Wing,9th Floor, Toronto, ON M5G 1X8, Canada.	meredith.irwin@sickkids.ca	Malkin, David/AAW-8715-2021		Canadian Cancer Society Research Institute [2010-700580]; Ontario Research Fund; Canada Research Chair in Cancer Biology; Hospital for Sick Children Research Training Centre (Restracomp)	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Ontario Research Fund; Canada Research Chair in Cancer Biology; Hospital for Sick Children Research Training Centre (Restracomp)	This study was supported by funds from the Canadian Cancer Society Research Institute (#2010-700580, MSI), Ontario Research Fund (MSI, DM) and a Canada Research Chair in Cancer Biology (MSI). BKAS and JL received scholarships from Hospital for Sick Children Research Training Centre (Restracomp). We are grateful for assistance with microarray analyses from Daniel Picard and Dr Annie Huang.	Abe K, 2008, P NATL ACAD SCI USA, V105, P13, DOI 10.1073/pnas.0710504105; Abou Zeid Nancy, 2006, Cell Commun Signal, V4, P8, DOI 10.1186/1478-811X-4-8; Aprelikova O, 2010, CELL CYCLE, V9, P4387, DOI 10.4161/cc.9.21.13674; Britanova O, 2008, NEURON, V57, P378, DOI 10.1016/j.neuron.2007.12.028; Britanova O, 2006, AM J HUM GENET, V79, P668, DOI 10.1086/508214; Broadhead Matthew L., 2011, Sarcoma, V2011, P959248, DOI 10.1155/2011/959248; Chung J, 2010, EMBO REP, V11, P777, DOI 10.1038/embor.2010.125; Conner JR, 2013, HISTOPATHOLOGY, V63, P36, DOI 10.1111/his.12138; Dobreva G, 2003, GENE DEV, V17, P3048, DOI 10.1101/gad.1153003; Dobreva G, 2006, CELL, V125, P971, DOI 10.1016/j.cell.2006.05.012; Eberhard J, 2012, BRIT J CANCER, V106, P931, DOI 10.1038/bjc.2012.34; Flores RJ, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-50; Hall A, 2009, CANCER METAST REV, V28, P5, DOI 10.1007/s10555-008-9166-3; Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781; Hassan MQ, 2010, P NATL ACAD SCI USA, V107, P19879, DOI 10.1073/pnas.1007698107; Huveneers S, 2009, J CELL SCI, V122, P1059, DOI 10.1242/jcs.039446; Jones KB, 2012, CANCER RES, V72, P1865, DOI 10.1158/0008-5472.CAN-11-2663; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Khanna C, 2001, CANCER RES, V61, P3750; Latini FRM, 2008, ENDOCR-RELAT CANCER, V15, P787, DOI 10.1677/ERC-08-0079; Leoyklang P, 2007, HUM MUTAT, V28, P732, DOI 10.1002/humu.20515; Maul RS, 2003, J CELL BIOL, V160, P399, DOI 10.1083/jcb.200212057; Maul RS, 1999, ONCOGENE, V18, P7838, DOI 10.1038/sj.onc.1203206; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Molyneux SD, 2010, J CLIN INVEST, V120, P3310, DOI 10.1172/JCI42391; O'Donoghue LE, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-506; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23; Patani N, 2009, CANCER CELL INT, V9, DOI 10.1186/1475-2867-9-18; Quizi JL, 2013, ONCOGENE, V32, P4656, DOI 10.1038/onc.2012.488; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sanders AJ, 2010, ANGIOGENESIS, V13, P317, DOI 10.1007/s10456-010-9188-7; Satoh Y, 2013, IMMUNITY, V38, P1105, DOI 10.1016/j.immuni.2013.05.014; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Steder M, 2013, CANCER CELL, V24, P512, DOI 10.1016/j.ccr.2013.08.023; Stehn JR, 2013, CANCER RES, V73, P5169, DOI 10.1158/0008-5472.CAN-12-4501; Tsurumi H, 2014, KIDNEY INT, V86, P548, DOI 10.1038/ki.2014.85; Wei JW, 2012, J CELL BIOL, V197, P509, DOI 10.1083/jcb.201201057; Yuan XL, 2013, CANCER RES, V73, P3625, DOI 10.1158/0008-5472.CAN-12-3879; Zaidel-Bar R, 2007, J CELL SCI, V120, P137, DOI 10.1242/jcs.03314; Zech T, 2011, J CELL SCI, V124, P3753, DOI 10.1242/jcs.080986; Zhang S, 2011, ONCOGENE, V30, P4941, DOI 10.1038/onc.2011.199; Zhao XY, 2014, CYTOKINE GROWTH F R, V25, P35, DOI 10.1016/j.cytogfr.2013.12.010; Zucchini C, 2014, ONCOGENE, V33, P1912, DOI 10.1038/onc.2013.152	44	38	39	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3582	3592		10.1038/onc.2014.289	http://dx.doi.org/10.1038/onc.2014.289			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25220418				2022-12-17	WOS:000357434900010
J	Bandey, I; Chiou, SH; Huang, AP; Tsai, JC; Tu, PH				Bandey, I.; Chiou, S-H; Huang, A-P; Tsai, J-C; Tu, P-h			Progranulin promotes Temozolomide resistance of glioblastoma by orchestrating DNA repair and tumor stemness	ONCOGENE			English	Article							GROWTH-FACTOR; ADJUVANT TEMOZOLOMIDE; GLIOMA PATIENTS; IN-VIVO; CELLS; EXPRESSION; BRAIN; CHEMORESISTANCE; IDENTIFICATION; RADIOTHERAPY	Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults with a dismal prognosis. Current therapy of surgical removal combined with Temozolomide (TMZ) and radiation therapy only slightly prolongs the survival of GBM patients. Thus, it is essential to elucidate mechanism underlying its highly malignant properties in order to develop efficacious therapeutic regimens. In this study, we showed that progranulin (PGRN) was overexpressed in most GBM cell lines and the majority of human tumor samples. PGRN overexpression conferred GBM cells with tumorigenic properties and TMZ resistance by upregulating DNA repair (PARP, ATM, BRCA1, Rad51, XRCC1 and so on) and cancer stemness (CD133, CD44, ABCG2) genes, in part via an AP-1 transcription factor, specifically cFos/JunB. Curcumin, an AP-1 inhibitor, was also found to regulate PGRN promoter activity and expression including its downstream effectors aforementioned. These data suggested a feedforward loop between PGRN signaling and AP-1. PGRN depletion significantly decreased unlimited self-renewal and multilineage differentiation and the malignant properties of GBMs cells S1R1, and enhanced their vulnerability to TMZ. In addition, S1R1 depleted of PGRN also lost the ability to form tumor in an orthotopic xenograft mouse model. In conclusion, PGRN had a critical role in the pathogenesis and chemoresistance of GBM and functioned at the top of the hierarchy of cellular machinery that modulates both DNA repair pathways and cancer stemness. Our data suggest that a new strategy combining current regimens with compounds targeting PGRN/AP-1 loop like curcumin may significantly improve the therapeutic outcome of GBM.	[Bandey, I.; Tu, P-h] Natl Yang Ming Univ, Taiwan Int Grad Program Mol Med, Taipei 112, Taiwan; [Bandey, I.; Tu, P-h] Acad Sinica, Taipei 11529, Taiwan; [Bandey, I.; Tu, P-h] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; [Chiou, S-H] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan; [Chiou, S-H] Natl Yang Ming Univ, Taipei 112, Taiwan; [Huang, A-P; Tsai, J-C] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Coll Med, Sect Neurosurg,Dept Surg, Taipei 10764, Taiwan; [Tsai, J-C] Natl Taiwan Univ, Coll Med, Ctr Optoelect Med, Taipei 10764, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; Academia Sinica - Taiwan; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Tu, PH (corresponding author), Acad Sinica, Inst Biomed Sci, IBMS, N701,128,Sec 2,Acad Rd Nankang, Taipei 11529, Taiwan.	btu@ibms.sinica.edu.tw		bandey, irfan N/0000-0002-9330-2432; TSAI, JUI-CHANG/0000-0003-2723-6841; HUANG, ABEL PO-HAO/0000-0002-5689-6761	National Science Council; Academia Sinica of Taiwan	National Science Council(Ministry of Science and Technology, Taiwan); Academia Sinica of Taiwan(Academia Sinica - Taiwan)	We thank the Core Facility of the Institute of Biomedical Sciences (IBMS), National RNAi Core of Taiwan, and Taiwan Mouse Clinic for their excellent services; Dr Chen Chang and the staff Y.Y. Tung and C.M. Shih for MRI analysis, and Dr Anupam Agarwal, University of Birmingham, USA for the JunB construct. The study was funded by grants from the National Science Council and Academia Sinica of Taiwan.	Assimakopoulou M, 2001, J CANCER RES CLIN, V127, P727; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barazzuol L, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-65; Bateman A, 1998, J ENDOCRINOL, V158, P145, DOI 10.1677/joe.0.1580145; Beier D, 2008, BRAIN PATHOL, V18, P370, DOI 10.1111/j.1750-3639.2008.00130.x; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Cheung ST, 2011, GASTROENTEROLOGY, V140, P344, DOI 10.1053/j.gastro.2010.07.049; Debinski W, 2011, CANCER BIOL THER, V11, P254, DOI 10.4161/cbt.11.2.13953; Dhandapani KM, 2007, J NEUROCHEM, V102, P522, DOI 10.1111/j.1471-4159.2007.04633.x; Donald CD, 2001, ANTICANCER RES, V21, P3739; Filiano AJ, 2013, J NEUROSCI, V33, P5352, DOI 10.1523/JNEUROSCI.6103-11.2013; Frampton G, 2012, GUT, V61, P268, DOI 10.1136/gutjnl-2011-300643; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Garcia-Alloza M, 2007, J NEUROCHEM, V102, P1095, DOI 10.1111/j.1471-4159.2007.04613.x; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Jin LJ, 2013, CANCER RES, V73, P2884, DOI 10.1158/0008-5472.CAN-12-2162; Kang MK, 2007, STEM CELLS DEV, V16, P837, DOI 10.1089/scd.2007.0006; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Khoshyomn S, 2000, PEDIATR NEUROSURG, V33, P123, DOI 10.1159/000028993; Krishnamurthy P, 2004, J BIOL CHEM, V279, P24218, DOI 10.1074/jbc.M313599200; Lee PC, 2010, NEOPLASIA, V12, P376, DOI 10.1593/neo.10110; Lee PY, 2013, ONCOLOGY-BASEL, V84, P326, DOI 10.1159/000347021; Liau LM, 2000, CANCER RES, V60, P1353; Lin LT, 2013, MOL IMAGING BIOL, V15, P262, DOI 10.1007/s11307-012-0591-x; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Matsuwaki T, 2011, J REPROD DEVELOP, V57, P113, DOI 10.1262/jrd.10-116S; Nandhakumar S, 2011, J PHARMACOL PHARMACO, V2, P107, DOI 10.4103/0976-500X.81903; Pallini R, 2008, CLIN CANCER RES, V14, P8205, DOI 10.1158/1078-0432.CCR-08-0644; Pan CX, 2004, CLIN CANCER RES, V10, P1333, DOI 10.1158/1078-0432.CCR-1123-03; Piscopo P, 2010, NEUROCHEM INT, V57, P893, DOI 10.1016/j.neuint.2010.09.008; Rademakers R, 2007, CURR NEUROL NEUROSCI, V7, P434, DOI 10.1007/s11910-007-0067-6; Rebetz J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001936; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Seidel S, 2010, BRAIN, V133, P983, DOI 10.1093/brain/awq042; Serrero G, 2003, HUM PATHOL, V34, P1148, DOI 10.1016/S0046-8177(03)00425-8; Shervington A, 2008, CANCER INVEST, V26, P535, DOI 10.1080/07357900801904140; SHOYAB M, 1990, P NATL ACAD SCI USA, V87, P7912, DOI 10.1073/pnas.87.20.7912; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Swamydas M, 2011, CELL COMMUN ADHES, V18, P119, DOI 10.3109/15419061.2011.641042; Tao T, 2013, EUR J CANCER, V49, P3055, DOI 10.1016/j.ejca.2013.05.010; Wang MQ, 2012, MED ONCOL, V29, P2423, DOI 10.1007/s12032-011-0131-6; Xu Y, 2010, CANCER RES, V70, P2455, DOI 10.1158/0008-5472.CAN-09-2505; Zeppernick F, 2008, CLIN CANCER RES, V14, P123, DOI 10.1158/1078-0432.CCR-07-0932; Zhang Jihong, 2012, Curr Mol Pharmacol, V5, P102; Zhang MY, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-85; Zhang WD, 2003, FASEB J, V17, P2085, DOI 10.1096/fj.02-1131fje	49	38	41	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1853	1864		10.1038/onc.2014.92	http://dx.doi.org/10.1038/onc.2014.92			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24793792				2022-12-17	WOS:000352158000012
J	Eden, CJ; Ju, B; Murugesan, M; Phoenix, TN; Nimmervoll, B; Tong, Y; Ellison, DW; Finkelstein, D; Wright, K; Boulos, N; Dapper, J; Thiruvenkatam, R; Lessman, CA; Taylor, MR; Gilbertson, RJ				Eden, C. J.; Ju, B.; Murugesan, M.; Phoenix, T. N.; Nimmervoll, B.; Tong, Y.; Ellison, D. W.; Finkelstein, D.; Wright, K.; Boulos, N.; Dapper, J.; Thiruvenkatam, R.; Lessman, C. A.; Taylor, M. R.; Gilbertson, R. J.			Orthotopic models of pediatric brain tumors in zebrafish	ONCOGENE			English	Article							NEURAL CREST; CANCER; MEDULLOBLASTOMA	High-throughput screens (HTS) of compound toxicity against cancer cells can identify thousands of potential new drug-leads. But only limited numbers of these compounds can progress to expensive and labor-intensive efficacy studies in mice, creating a 'bottle neck' in the drug development pipeline. Approaches that triage drug-leads for further study are greatly needed. Here we provide an intermediary platform between HTS and mice by adapting mouse models of pediatric brain tumors to grow as orthotopic xenografts in the brains of zebrafish. Freshly isolated mouse ependymoma, glioma and choroid plexus carcinoma cells expressing red fluorescence protein were conditioned to grow at 34 degrees C. Conditioned tumor cells were then transplanted orthotopically into the brains of zebrafish acclimatized to ambient temperatures of 34 degrees C. Live in vivo fluorescence imaging identified robust, quantifiable and reproducible brain tumor growth as well as spinal metastasis in zebrafish. All tumor xenografts in zebrafish retained the histological characteristics of the corresponding parent mouse tumor and efficiently recruited fish endothelial cells to form a tumor vasculature. Finally, by treating zebrafish harboring ERBB2-driven gliomas with an appropriate cytotoxic chemotherapy (5-fluorouracil) or tyrosine kinase inhibitor (erlotinib), we show that these models can effectively assess drug efficacy. Our data demonstrate, for the first time, that mouse brain tumors can grow orthotopically in fish and serve as a platform to study drug efficacy. As large cohorts of brain tumor-bearing zebrafish can be generated rapidly and inexpensively, these models may serve as a powerful tool to triage drug-leads from HTS for formal efficacy testing in mice.	[Eden, C. J.; Murugesan, M.; Phoenix, T. N.; Nimmervoll, B.; Tong, Y.; Boulos, N.; Dapper, J.; Thiruvenkatam, R.; Gilbertson, R. J.] St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; [Ju, B.; Taylor, M. R.] St Jude Childrens Res Hosp, Dept Chem Biol & Therapeut, Memphis, TN 38105 USA; [Ellison, D. W.] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; [Finkelstein, D.] St Jude Childrens Res Hosp, Dept Computat Biol & Bioinformat, Memphis, TN 38105 USA; [Wright, K.] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA; [Lessman, C. A.] St Jude Childrens Res Hosp, Dept Biol Sci, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Taylor, MR (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA.	Michael.Taylor@stjude.org; Richard.Gilbertson@stjude.org	Gilbertson, Richard James/ABE-1346-2021	Gilbertson, Richard James/0000-0001-7539-9472; Nimmervoll, Birgit/0000-0002-3324-092X; KM, Mohankumar/0000-0001-9407-1800	National Institutes of Health [R01CA129541, P01CA96832, P30CA021765]; Collaborative Ependymoma Research Network (CERN); ALSAC; NATIONAL CANCER INSTITUTE [P01CA096832, R01CA129541, P30CA021765] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Collaborative Ependymoma Research Network (CERN); ALSAC(American Lebanese Syrian Associated Charities (ALSAC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Institutes of Health (R01CA129541, P01CA96832 and P30CA021765, RJG), the Collaborative Ependymoma Research Network (CERN) and by ALSAC. We are grateful to the staff of the Hartwell Center for Bioinformatics and Biotechnology, and Flow Cytometry & Cell Sorting Shared Resource at St Jude Children's Research Hospital for technical assistance.	Atkinson JM, 2011, CANCER CELL, V20, P384, DOI 10.1016/j.ccr.2011.08.013; Caponigro G, 2011, NAT REV DRUG DISCOV, V10, P179, DOI 10.1038/nrd3385; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chow LML, 2011, CANCER CELL, V19, P305, DOI 10.1016/j.ccr.2011.01.039; Collymore C, 2013, JOVE-J VIS EXP, DOI 10.3791/50691; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HERBERT J, 1990, AM J PATHOL, V136, P1317; Hernan R, 2003, CANCER RES, V63, P140; Hong SK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002029; Johnson RA, 2010, NATURE, V466, P632, DOI 10.1038/nature09173; Kawauchi D, 2012, CANCER CELL, V21, P168, DOI 10.1016/j.ccr.2011.12.023; Lacy J, 2012, HEMATOL ONCOL CLIN N, V26, P779, DOI 10.1016/j.hoc.2012.04.007; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Lin NU, 2013, LANCET ONCOL, V14, pE407, DOI 10.1016/S1470-2045(13)70308-5; Macarron R, 2011, NAT REV DRUG DISCOV, V10, P188, DOI 10.1038/nrd3368; Pei YX, 2012, CANCER CELL, V21, P155, DOI 10.1016/j.ccr.2011.12.021; Pounds S, 2011, BIOINFORMATICS, V27, P2098, DOI 10.1093/bioinformatics/btr362; Prados MD, 2006, NEURO-ONCOLOGY, V8, P67, DOI 10.1215/S1522851705000451; Ridges S, 2012, BLOOD, V119, P5621, DOI 10.1182/blood-2011-12-398818; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Smith MA, 2010, J CLIN ONCOL, V28, P2625, DOI 10.1200/JCO.2009.27.0421; Stoletov K, 2008, ONCOGENE, V27, P4509, DOI 10.1038/onc.2008.95; Stoletov K, 2007, P NATL ACAD SCI USA, V104, P17406, DOI 10.1073/pnas.0703446104; Swartling FJ, 2010, GENE DEV, V24, P1059, DOI 10.1101/gad.1907510; Walbert T, 2011, J NEURO-ONCOL, V102, P273, DOI 10.1007/s11060-010-0313-7; White R, 2013, NAT REV CANCER, V13, P624, DOI 10.1038/nrc3589; White RM, 2008, CELL STEM CELL, V2, P183, DOI 10.1016/j.stem.2007.11.002; White RM, 2011, NATURE, V471, P518, DOI 10.1038/nature09882; Wienholds E, 2002, SCIENCE, V297, P99, DOI 10.1126/science.1071762	30	38	38	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1736	1742		10.1038/onc.2014.107	http://dx.doi.org/10.1038/onc.2014.107			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24747973	Green Accepted			2022-12-17	WOS:000351848400014
J	Shah, PP; Lockwood, WW; Saurabh, K; Kurlawala, Z; Shannon, SP; Waigel, S; Zacharias, W; Beverly, LJ				Shah, P. P.; Lockwood, W. W.; Saurabh, K.; Kurlawala, Z.; Shannon, S. P.; Waigel, S.; Zacharias, W.; Beverly, L. J.			Ubiquilin1 represses migration and epithelial-to-mesenchymal transition of human non-small cell lung cancer cells	ONCOGENE			English	Article							PROTEIN; METASTASIS; EXPRESSION; REVEALS; STRESS; ZEB1; GENE	Ubiquilin1 (UBQLN1) is a ubiquitin-like domain and a ubiquitin-associated domain containing protein that has been reported to be involved in shuttling proteins to the proteasome, especially during endoplasmic reticulum-associated protein degradation. Thus, UBQLN1 function has been shown to be critical for combating a number of neurological disorders caused by protein aggregation, such as amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's disease. A role for UBQLN1 in regulating processes involved in tumorigenesis has not been demonstrated. Herein, we show that loss of UBQLN1 causes increased cell migration and invasion, actin cytoskeleton reorganization and induction of epithelial-to-mesenchymal transition (EMT). Loss of UBQLN1 results in a significant decrease in the expression of epithelial markers including E-cadherin and claudin1, whereas expression of mesenchymal markers including Vimentin, Snail and ZEB1 are significantly elevated. Interestingly, we found that ZEB1 is required for induction of mesenchymal-like properties following loss of UBQLN1 and ZEB1 is capable of repressing expression of UBQLN1, suggesting a physiological, reciprocal regulation of EMT by UBQLN1 and ZEB1. Further, we find evidence for a role for UBQLN2 in also regulating EMT and cell migration. These observations have potential clinical relevance because the UBQLN1 gene is lost and underexpressed in a large percentage of human cancer cell lines, and primary human lung cancer samples and recurrent mutations in all five UBQLN family members have been identified in human lung cancers. Taken together, our results suggest for the first time a role for UBQLN family members in cancer biology.	[Shah, P. P.; Saurabh, K.; Kurlawala, Z.; Shannon, S. P.; Waigel, S.; Zacharias, W.; Beverly, L. J.] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40202 USA; [Lockwood, W. W.] NHGRI, Canc Biol & Genet Sect, Canc Genet Branch, NIH, Bethesda, MD USA; [Saurabh, K.; Zacharias, W.; Beverly, L. J.] Univ Louisville, Sch Med, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA; [Zacharias, W.; Beverly, L. J.] Univ Louisville, Dept Med, Div Hematol & Oncol, Louisville, KY 40202 USA	University of Louisville; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Louisville; University of Louisville	Beverly, LJ (corresponding author), Univ Louisville, James Graham Brown Canc Ctr, Sch Med, Dept Med,Div Hematol & Oncol, 505 South Hancock St,CTRB Room 204, Louisville, KY 40202 USA.	Levi.Beverly@Louisville.edu	Kurlawala, Zimple/AAK-8303-2020	Kurlawala, Zimple/0000-0003-3925-9290	James Graham Brown Cancer Center, University of Louisville; Molecular Targets COBRE from NIH [8P20GM103482-10]; Lung Cancer Research Foundation; Rounsavall Foundation; Wendy Will Case Cancer Fund; National Cancer Institute [R25-CA-134283]; NIH/NIGMS Phase III COBRE [1P30 GM106396-01]; James Graham Brown Foundation; Kosair Pediatric Cancer Program; NIH/NIGMS KY-INBRE [P20GM103436]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007505] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R25CA134283] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM106396, P20GM103482, P20GM103436] Funding Source: NIH RePORTER	James Graham Brown Cancer Center, University of Louisville; Molecular Targets COBRE from NIH; Lung Cancer Research Foundation; Rounsavall Foundation; Wendy Will Case Cancer Fund; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIGMS Phase III COBRE; James Graham Brown Foundation; Kosair Pediatric Cancer Program; NIH/NIGMS KY-INBRE; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Lavona Casson and current members of the Beverly lab for technical assistance and Dr Mohammad T Malik for valuable comments, discussion and technical advice. We would like to thank Douglas Darling for the gift of the ZEB1 antibody. The work was supported by the start-up funds from James Graham Brown Cancer Center, University of Louisville and Kosair Pediatric Cancer Program and Molecular Targets COBRE 8P20GM103482-10 from NIH, an award from the Lung Cancer Research Foundation to LJB, an award from the Rounsavall Foundation to LJB, an award from the Wendy Will Case Cancer Fund to LJB, R25-CA-134283 from the National Cancer Institute to SPS. Part of this work was performed with assistance of the UofL Genomics Facility, which is supported by NIH/NIGMS Phase III COBRE 1P30 GM106396-01, NIH/NIGMS KY-INBRE P20GM103436, the James Graham Brown Foundation, and user fees.	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Arias-Vasquez A, 2007, NEUROSCI LETT, V424, P1, DOI 10.1016/j.neulet.2007.07.015; Beverly LJ, 2012, P NATL ACAD SCI USA, V109, P119, DOI 10.1073/pnas.1119167109; Bevilacqua E, 2010, J BIOL CHEM, V285, P17098, DOI 10.1074/jbc.M110.109439; Chen GA, 2007, CANCER RES, V67, P3461, DOI 10.1158/0008-5472.CAN-06-4475; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Dohadwala M, 2006, CANCER RES, V66, P5338, DOI 10.1158/0008-5472.CAN-05-3635; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Iwatsuki M, 2010, CANCER SCI, V101, P293, DOI 10.1111/j.1349-7006.2009.01419.x; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kamiya T, 2011, FREE RADICAL RES, V45, P692, DOI 10.3109/10715762.2011.567985; Keshamouni VG, 2006, J PROTEOME RES, V5, P1143, DOI 10.1021/pr050455t; Kim SH, 2009, J BIOL CHEM, V284, P8083, DOI 10.1074/jbc.M808064200; Lilley BN, 2004, NATURE, V429, P834, DOI 10.1038/nature02592; Lim PJ, 2009, J CELL BIOL, V187, P201, DOI 10.1083/jcb.200903024; Liu YH, 2010, J AM SOC NEPHROL, V21, P212, DOI 10.1681/ASN.2008121226; Lu A, 2009, J MOL NEUROSCI, V38, P19, DOI 10.1007/s12031-008-9155-6; Nurwidya F, 2012, CANCER RES TREAT, V44, P151, DOI 10.4143/crt.2012.44.3.151; Olzmann JA, 2008, CURR MED CHEM, V15, P47; Oyanagi J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053209; Rutherford NJ, 2013, BRAIN RES, V1524, P62, DOI 10.1016/j.brainres.2013.06.006; Shah PP, 2012, ONCOGENE, V31, P3124, DOI 10.1038/onc.2011.488; Soetandyo N, 2010, J CELL SCI, V123, P1031, DOI 10.1242/jcs.059758; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Vandewalle C, 2009, CELL MOL LIFE SCI, V66, P773, DOI 10.1007/s00018-008-8465-8; Wang QY, 2006, J CELL BIOL, V174, P963, DOI 10.1083/jcb.200605100; Wojcik C, 2006, MOL BIOL CELL, V17, P4606, DOI 10.1091/mbc.E06-05-0432; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang GJ, 2013, ONCOL LETT, V5, P564, DOI 10.3892/ol.2012.1026	31	38	41	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1709	1717		10.1038/onc.2014.97	http://dx.doi.org/10.1038/onc.2014.97			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24747970	Green Accepted			2022-12-17	WOS:000351848400011
J	Jude, JG; Spencer, GJ; Huang, X; Somerville, TDD; Jones, DR; Divecha, N; Somervaille, TCP				Jude, J. G.; Spencer, G. J.; Huang, X.; Somerville, T. D. D.; Jones, D. R.; Divecha, N.; Somervaille, T. C. P.			A targeted knockdown screen of genes coding for phosphoinositide modulators identifies PIP4K2A as required for acute myeloid leukemia cell proliferation and survival	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; BREAST-CANCER; PTDINS5P; EXPRESSION; KINASE; INHIBITION; APOPTOSIS; PATHWAY; RATHER	Given the importance of deregulated phosphoinositide (PI) signaling in leukemic hematopoiesis, genes coding for proteins that regulate PI metabolism may have significant and as yet unappreciated roles in leukemia. We performed a targeted knockdown (KD) screen of PI modulator genes in human acute myeloid leukemia (AML) cells and identified candidates required to sustain proliferation or prevent apoptosis. One of these, the lipid kinase phosphatidylinositol-5-phosphate 4-kinase, type II, alpha (PIP4K2A) regulates cellular levels of phosphatidylinositol-5-phosphate (Ptslns5P) and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5) P-2). We found PIP4K2A to be essential for the clonogenic and leukemia-initiating potential of human AML cells, and for the clonogenic potential of murine MLL-AF9 AML cells. Importantly, PIP4K2A is also required for the clonogenic potential of primary human AML cells. Its KD results in accumulation of the cyclin-dependent kinase inhibitors CDKN1A and CDKN1B, G1 cell cycle arrest and apoptosis. Both CDKN1A accumulation and apoptosis were partially dependent on activation of the mTOR pathway. Critically, however, PIP4K2A KD in normal hematopoietic stem and progenitor cells, both murine and human, did not adversely impact either clonogenic or multilineage differentiation potential, indicating a selective dependency that we suggest may be the consequence of the regulation of different transcriptional programs in normal versus malignant cells. Thus, PIP4K2A is a novel candidate therapeutic target in myeloid malignancy.	[Jude, J. G.; Divecha, N.] Univ Manchester, Canc Res UK Manchester Inst, Inositide Lab, Manchester, Lancs, England; [Jude, J. G.; Spencer, G. J.; Huang, X.; Somerville, T. D. D.; Somervaille, T. C. P.] Univ Manchester, Canc Res UK Manchester Inst, Leukaemia Biol Lab, Manchester, Lancs, England	Cancer Research UK; University of Manchester; Cancer Research UK; University of Manchester	Divecha, N (corresponding author), Canc Res UK Manchester Inst, Manchester M20 4BX, Lancs, England.	nullin.divecha@cruk.manchester.ac.uk; tim.somervaille@cruk.manchester.ac.uk	Huang, Xu/N-5609-2019	Huang, Xu/0000-0001-6706-199X; Jude, Julian/0000-0002-9091-9867; divecha, nullin/0000-0001-9695-6039; Somervaille, Tim/0000-0002-9188-4379	Cancer Research UK [C5759/A12328]; Cancer Research UK [19280] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	We thank Morgan Blaylock, Jeff Barry, Michael Hughes, Gail Bruder, Angela Cooke and Yaoyong Li for technical support. This work was supported by Cancer Research UK grant number C5759/A12328.	Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bertagnolo V, 2006, INT J ONCOL, V28, P863; Bertagnolo V, 2007, CARCINOGENESIS, V28, P1638, DOI 10.1093/carcin/bgm078; Beuvink I, 2005, CELL, V120, P747, DOI 10.1016/j.cell.2004.12.040; Bunney TD, 2010, NAT REV CANCER, V10, P342, DOI 10.1038/nrc2842; Davis MI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054127; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; Emerling BM, 2013, CELL, V155, P844, DOI 10.1016/j.cell.2013.09.057; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Goardon N, 2011, CANCER CELL, V19, P138, DOI 10.1016/j.ccr.2010.12.012; Grimwade D, 2010, BLOOD, V116, P354, DOI 10.1182/blood-2009-11-254441; Halstead JR, 2001, CURR BIOL, V11, P386, DOI 10.1016/S0960-9822(01)00121-X; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Huang X, 2014, LEUKEMIA, V28, P1081, DOI 10.1038/leu.2013.316; Jones DR, 2006, MOL CELL, V23, P685, DOI 10.1016/j.molcel.2006.07.014; Jones DR, 2013, NAT PROTOC, V8, P1058, DOI 10.1038/nprot.2013.040; Jones DR, 2013, FASEB J, V27, P1644, DOI 10.1096/fj.12-218842; Keune WJ, 2013, CANCER RES, V73, P6913, DOI 10.1158/0008-5472.CAN-13-0424; Keune WJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003223; Kubota Y, 2004, LEUKEMIA, V18, P1438, DOI 10.1038/sj.leu.2403402; Lemmon MA, 2008, NAT REV MOL CELL BIO, V9, P99, DOI 10.1038/nrm2328; LING LE, 1989, J BIOL CHEM, V264, P5080; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245; Migliorini G, 2013, BLOOD, V122, P3298, DOI 10.1182/blood-2013-03-491316; Min YH, 2003, LEUKEMIA, V17, P995, DOI 10.1038/sj.leu.2402874; Myhre S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014002; Ndamukong I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013396; Polak R, 2012, BLOOD, V119, P911, DOI 10.1182/blood-2011-07-366203; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Saito Y, 2010, NAT BIOTECHNOL, V28, P275, DOI 10.1038/nbt.1607; Sarkes D, 2010, BIOCHEM J, V428, P375, DOI 10.1042/BJ20100129; Schulze H, 2006, BLOOD, V107, P3868, DOI 10.1182/blood-2005-07-2755; Somervaille TCP, 2003, BRIT J HAEMATOL, V120, P876, DOI 10.1046/j.1365-2141.2003.04204.x; Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020; Somervaille TCP, 2009, CELL STEM CELL, V4, P129, DOI 10.1016/j.stem.2008.11.015; Sykes SM, 2011, CELL, V146, P697, DOI 10.1016/j.cell.2011.07.032; Szczepanek J, 2012, J APPL GENET, V53, P83, DOI 10.1007/s13353-011-0073-x; van den Bout I, 2009, J CELL SCI, V122, P3837, DOI 10.1242/jcs.056127; Vergez F, 2012, CURR TOP MICROBIOL, V362, P163, DOI 10.1007/978-94-007-5025-8_8; Viale A, 2009, NATURE, V457, P51, DOI 10.1038/nature07618; Wilcox A, 2008, FEBS LETT, V582, P1391, DOI 10.1016/j.febslet.2008.03.022; Wiseman DH, 2014, ONCOGENE, V33, P3091, DOI 10.1038/onc.2013.269; Wouters BJ, 2007, BLOOD, V109, P389, DOI 10.1182/blood-2006-08-042325; Xu H, 2013, JNCI-J NATL CANCER I, V105, P733, DOI 10.1093/jnci/djt042; Xu Q, 2003, BLOOD, V102, P972, DOI 10.1182/blood-2002-11-3429; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zhang L, 2007, CLIN CANCER RES, V13, P5314, DOI 10.1158/1078-0432.CCR-06-2660; Zhao S, 2004, LEUKEMIA, V18, P267, DOI 10.1038/sj.leu.2403220	51	38	41	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1253	1262		10.1038/onc.2014.77	http://dx.doi.org/10.1038/onc.2014.77			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24681948	Green Accepted			2022-12-17	WOS:000350687100005
J	Akeno, N; Miller, AL; Ma, X; Wikenheiser-Brokamp, KA				Akeno, N.; Miller, A. L.; Ma, X.; Wikenheiser-Brokamp, K. A.			p53 suppresses carcinoma progression by inhibiting mTOR pathway activation	ONCOGENE			English	Article						p53; Rb; medullary thyroid cancer; mTOR	MEDULLARY-THYROID CARCINOMA; SOMATIC INACTIVATION; CELL LINEAGES; LUNG-CANCER; MUTANT MICE; MOUSE MODEL; RETINOBLASTOMA; RB; MUTATION; TUMORIGENESIS	Genetic alterations in human cancers and murine models indicate that retinoblastoma (Rb) and p53 have critical tumor suppressive functions in retinoblastoma, a tumor of neural origin, and neuroendocrine tumors including small cell lung cancer and medullary thyroid cancer (MTC). Rb inactivation is the initiating lesion in retinoblastoma and current models propose that induction of apoptosis is a key p53 tumor suppressive function. Genetic studies in mice, however, indicate that other undefined p53 tumor suppressive functions are operative in vivo. How p53 loss cooperates with Rb inactivation to promote carcinogenesis is also not fully understood. In the current study, genetically engineered mice were generated to determine the role of Rb and p53 in MTC pathogenesis and test the hypothesis that p53 suppresses carcinogenesis by inhibiting mammalian target of rapamycin (mTOR) signaling. Conditional Rb ablation resulted in thyroid tumors mimicking human MTC, and additional p53 loss led to rapid tumor progression. p53 suppressed tumorigenesis by inhibiting cell cycle progression, but did not induce apoptosis. On the contrary, p53 loss led to increased apoptosis that had to be overcome for tumor progression. The mTOR activity was markedly increased in p53-deficient tumors and rapamycin treatment suppressed tumor cell growth, identifying mTOR inhibition as a critical p53 tumor suppressive function. Rapamycin treatment did not result in AKT/mitogen-activated protein kinase activation, providing evidence that this feedback mechanism operative in other cancers is not a general response to mTORC1 inhibition. Together, these studies provide mechanistic links between genetic alterations and aberrant signaling pathways critical in carcinogenesis, and identify essential Rb and p53 tumor suppressive functions in vivo.	[Akeno, N.; Miller, A. L.; Ma, X.; Wikenheiser-Brokamp, K. A.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Wikenheiser-Brokamp, K. A.] Univ Cincinnati, Coll Med, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Wikenheiser-Brokamp, KA (corresponding author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Kathryn.Wikenheiser-Brokamp@cchmc.org			American Cancer Society [RSG-10-194-01-TBG]; NIH/NHLBI [RO1 HL079193]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079193] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Mingyan Yang and Susan E Wert for technical expertise, Veterinary Services for excellent animal care, and Susanne I Wells and Elizabeth E Hoskins for reagents and technical expertise. This work was supported by grants from the American Cancer Society RSG-10-194-01-TBG and NIH/NHLBI RO1 HL079193 (to KAW-B).	Almeida MQ, 2012, CURR OPIN ONCOL, V24, P229, DOI 10.1097/CCO.0b013e328351c71a; Anwar F, 2000, MODERN PATHOL, V13, P562, DOI 10.1038/modpathol.3880097; Basolo F, 2000, THYROID, V10, P741, DOI 10.1089/thy.2000.10.741; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Cerrato A, 2009, J MOL ENDOCRINOL, V43, P143, DOI 10.1677/JME-09-0024; Conkrite K, 2012, J CLIN INVEST, V122, P1726, DOI 10.1172/JCI61403; Dong M, 2012, CLIN CANCER RES, V18, P1830, DOI 10.1158/1078-0432.CCR-11-2105; Faggiano A, 2012, J CELL MOL MED, V16, P1563, DOI 10.1111/j.1582-4934.2011.01438.x; Feng ZH, 2010, TRENDS CELL BIOL, V20, P427, DOI 10.1016/j.tcb.2010.03.004; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Frisk T, 2001, INT J ONCOL, V18, P1219; Goutas N, 2008, ANTICANCER RES, V28, P305; Grozinsky-Glasberg S, 2010, MOL CELL ENDOCRINOL, V315, P87, DOI 10.1016/j.mce.2009.09.027; HARVEY M, 1995, CANCER RES, V55, P1146; Hasty P, 2013, CELL CYCLE, V12, P20, DOI 10.4161/cc.22912; Hemmer S, 1999, AM J PATHOL, V154, P1539, DOI 10.1016/S0002-9440(10)65407-7; Herfarth KKF, 1997, GENE CHROMOSOME CANC, V20, P24, DOI 10.1002/(SICI)1098-2264(199709)20:1<24::AID-GCC4>3.3.CO;2-V; Hinze R, 2000, VIRCHOWS ARCH, V437, P256, DOI 10.1007/s004280000233; HOLM R, 1994, J PATHOL, V172, P267, DOI 10.1002/path.1711720307; Kouvaraki MA, 2011, SURGERY, V150, P1258, DOI 10.1016/j.surg.2011.09.022; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Marino S, 2000, GENE DEV, V14, P994; Marsh DJ, 2003, J CLIN ENDOCR METAB, V88, P1866, DOI 10.1210/jc.2002-021155; Matthew EM, 2009, CELL CYCLE, V8, P4168, DOI 10.4161/cc.8.24.10800; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Moura MM, 2011, J CLIN ENDOCR METAB, V96, pE863, DOI 10.1210/jc.2010-1921; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; Pavelic K, 2006, MUTAT RES-FUND MOL M, V599, P45, DOI 10.1016/j.mrfmmm.2006.01.021; Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499; Pitt SC, 2010, SEMIN ONCOL, V37, P567, DOI 10.1053/j.seminoncol.2010.10.010; Rapa I, 2011, J CLIN ENDOCR METAB, V96, P2146, DOI 10.1210/jc.2010-2655; Sheikh HA, 2004, AM J SURG PATHOL, V28, P101, DOI 10.1097/00000478-200401000-00012; Simpson DS, 2009, CANCER RES, V69, P8733, DOI 10.1158/0008-5472.CAN-09-1359; Sippel RS, 2008, ONCOLOGIST, V13, P539, DOI 10.1634/theoncologist.2007-0239; Smith-Hicks CL, 2000, EMBO J, V19, P612, DOI 10.1093/emboj/19.4.612; Stiewe T, 2007, NAT REV CANCER, V7, P165, DOI 10.1038/nrc2072; Tamburrino A, 2012, CLIN CANCER RES, V18, P3532, DOI 10.1158/1078-0432.CCR-11-2700; Vilar E, 2011, MOL CANCER THER, V10, P395, DOI 10.1158/1535-7163.MCT-10-0905; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wander SA, 2011, J CLIN INVEST, V121, P1231, DOI 10.1172/JCI44145; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Wikenheiser-Brokamp KA, 2004, DEVELOPMENT, V131, P4299, DOI 10.1242/dev.01232; Wikenheiser-Brokamp KA, 2006, CURR MOL MED, V6, P783; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Wise-Draper TM, 2006, MOL CELL BIOL, V26, P7506, DOI 10.1128/MCB.00430-06; Wu LS, 2011, CURR OPIN ONCOL, V23, P22, DOI 10.1097/CCO.0b013e328340b527; YOSHIMOTO K, 1992, CANCER RES, V52, P5061	50	38	40	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					589	599		10.1038/onc.2013.589	http://dx.doi.org/10.1038/onc.2013.589			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24469052	Green Accepted			2022-12-17	WOS:000348853500006
J	Cyr, AR; Kulak, MV; Park, JM; Bogachek, MV; Spanheimer, PM; Woodfield, GW; White-Baer, LS; O'Malley, YQ; Sugg, SL; Olivier, AK; Zhang, W; Domann, FE; Weigel, RJ				Cyr, A. R.; Kulak, M. V.; Park, J. M.; Bogachek, M. V.; Spanheimer, P. M.; Woodfield, G. W.; White-Baer, L. S.; O'Malley, Y. Q.; Sugg, S. L.; Olivier, A. K.; Zhang, W.; Domann, F. E.; Weigel, R. J.			TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis	ONCOGENE			English	Article						TFAP2C; breast cancer; mammary development; luminal; gene expression; EMT	BREAST-CANCER CELLS; STEM-CELLS; MESENCHYMAL TRANSITION; EXPRESSION PATTERNS; ESTROGEN-RECEPTOR; TRANSCRIPTION; AP-2-GAMMA; IDENTIFICATION; MARKERS; DIFFERENTIATION	Molecular subtypes of breast cancer are characterized by distinct patterns of gene expression that are predictive of outcome and response to therapy. The luminal breast cancer subtypes are defined by the expression of estrogen receptor-alpha (ER alpha)-associated genes, many of which are directly responsive to the transcription factor activator protein 2C (TFAP2C). TFAP2C participates in a gene regulatory network controlling cell growth and differentiation during ectodermal development and regulating ESR1/ER alpha and other luminal cell-associated genes in breast cancer. TFAP2C has been established as a prognostic factor in human breast cancer, however, its role in the establishment and maintenance of the luminal cell phenotype during carcinogenesis and mammary gland development have remained elusive. Herein, we demonstrate a critical role for TFAP2C in maintaining the luminal phenotype in human breast cancer and in influencing the luminal cell phenotype during normal mammary development. Knockdown of TFAP2C in luminal breast carcinoma cells induced epithelial-mesenchymal transition with morphological and phenotypic changes characterized by a loss of luminal-associated gene expression and a concomitant gain of basal-associated gene expression. Conditional knockout of the mouse homolog of TFAP2C, Tcfap2c, in mouse mammary epithelium driven by MMTV-Cre promoted aberrant growth of the mammary tree leading to a reduction in the CD24(hi)/CD49f(mid) luminal cell population and concomitant gain of the CD24(mid)/CD49f(hi) basal cell population at maturity. Our results establish TFAP2C as a key transcriptional regulator for maintaining the luminal phenotype in human breast carcinoma. Furthermore, Tcfap2c influences development of the luminal cell type during mammary development. The data suggest that TFAP2C has an important role in regulated luminal-specific genes and may be a viable therapeutic target in breast cancer.	[Cyr, A. R.; Kulak, M. V.; Park, J. M.; Bogachek, M. V.; Spanheimer, P. M.; Woodfield, G. W.; White-Baer, L. S.; O'Malley, Y. Q.; Sugg, S. L.; Domann, F. E.; Weigel, R. J.] Univ Iowa, Dept Surg, Iowa City, IA 52242 USA; [Cyr, A. R.; Domann, F. E.] Univ Iowa, Dept Radiat Oncol, Iowa City, IA 52242 USA; [Olivier, A. K.; Zhang, W.; Domann, F. E.] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; [Weigel, R. J.] Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa	Weigel, RJ (corresponding author), Univ Iowa, Dept Surg, 200 Hawkins Dr, Iowa City, IA 52242 USA.	Ronald-Weigel@uiowa.edu		Weigel, Ronald/0000-0002-9249-0793; Kulak, Mikhail/0000-0002-4307-5868; Sugg, Sonia/0000-0001-7530-8526; Domann, Frederick/0000-0002-0489-2179	National Institutes of Health [R01CA109294, T32CA148062, K99/R00CA158055]; Department of Pathology; NIH [T32CA148062]; NATIONAL CANCER INSTITUTE [R00CA158055, R01CA109294, K99CA158055, T32CA148062, T32CA078586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Pathology; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the National Institutes of Health grants R01CA109294 (PI: RJW), T32CA148062 (PI: RJW), K99/R00CA158055 (PI: WZ), a Startup Fund from the Department of Pathology (PI: WZ) and by a generous gift from the Kristen Olewine Milke Breast Cancer Research Fund. PMS was supported by the NIH grant T32CA148062.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Auman HJ, 2002, DEVELOPMENT, V129, P2733; Bai F, 2013, ONCOGENE, V32, P2715, DOI 10.1038/onc.2012.293; Balko JM, 2012, P NATL ACAD SCI USA, V109, P221, DOI 10.1073/pnas.1115802109; Bernardo GM, 2013, ONCOGENE, V32, P554, DOI 10.1038/onc.2012.62; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Buchwalter G, 2013, CANCER CELL, V23, P753, DOI 10.1016/j.ccr.2013.04.026; Carr JR, 2012, CELL REP, V1, P715, DOI 10.1016/j.celrep.2012.05.005; DECONINCK EC, 1995, MOL CELL BIOL, V15, P2191; Delacroix L, 2005, DNA CELL BIOL, V24, P582, DOI 10.1089/dna.2005.24.582; dos Santos CO, 2013, P NATL ACAD SCI USA, V110, P7123, DOI 10.1073/pnas.1303919110; Friedrichs N, 2007, HISTOPATHOLOGY, V51, P814, DOI 10.1111/j.1365-2559.2007.02887.x; Friedrichs N, 2005, MODERN PATHOL, V18, P431, DOI 10.1038/modpathol.3800292; Gee JMW, 2009, J PATHOL, V217, P32, DOI 10.1002/path.2430; Groger CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051136; Guttormsen J, 2008, DEV BIOL, V317, P187, DOI 10.1016/j.ydbio.2008.02.017; He AL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-279; Hoffman TL, 2007, J EXP ZOOL PART B, V308B, P679, DOI 10.1002/jez.b.21189; Jager R, 2010, DEV DYNAM, V239, P1027, DOI 10.1002/dvdy.22239; Jager R, 2005, BREAST CANCER RES TR, V90, P273, DOI 10.1007/s10549-004-4815-x; Kalyuga M, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001461; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Lee HE, 2011, BRIT J CANCER, V104, P1730, DOI 10.1038/bjc.2011.159; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; Park SY, 2010, CLIN CANCER RES, V16, P876, DOI 10.1158/1078-0432.CCR-09-1532; Plante I, 2011, JOVE-J VIS EXP, DOI 10.3791/2828; Qiao YB, 2012, CELL RES, V22, P1546, DOI 10.1038/cr.2012.122; Ricardo S, 2011, J CLIN PATHOL, V64, P937, DOI 10.1136/jcp.2011.090456; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Smalley MJ, 2010, METHODS MOL BIOL, V633, P139, DOI 10.1007/978-1-59745-019-5_11; Spanheimer PM, 2013, J SURG RES, V184, P519, DOI 10.1016/j.jss.2013.04.042; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Tan SK, 2011, EMBO J, V30, P2569, DOI 10.1038/emboj.2011.151; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Woodfield GW, 2007, CANCER RES, V67, P8439, DOI 10.1158/0008-5472.CAN-07-2293; Woodfield GW, 2010, GENE CHROMOSOME CANC, V49, P948, DOI 10.1002/gcc.20807	37	38	38	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					436	444		10.1038/onc.2013.569	http://dx.doi.org/10.1038/onc.2013.569			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24469049	Green Accepted			2022-12-17	WOS:000348451300004
J	Nguyen, HN; Afkari, Y; Senoo, H; Sesaki, H; Devreotes, PN; Iijima, M				Nguyen, H. N.; Afkari, Y.; Senoo, H.; Sesaki, H.; Devreotes, P. N.; Iijima, M.			Mechanism of human PTEN localization revealed by heterologous expression in Dictyostelium	ONCOGENE			English	Article						PTEN; membrane localization; mutational analysis; Dictyostelium	TUMOR-SUPPRESSOR; PHOSPHATASE-ACTIVITY; BINDING; PHOSPHORYLATION	Phosphatase and tensin homolog (PTEN) is one of the most frequently mutated tumor suppressor genes in cancers. PTEN has a central role in phosphatidylinositol (3,4,5)-trisphosphate (PIP3) signaling and converts PIP3 to phosphatidylinositol (4,5)bisphosphate at the plasma membrane. Despite its importance, the mechanism that mediates membrane localization of PTEN is poorly understood. Here, we generated a library that contains green fluorescent protein fused to randomly mutated human PTEN and expressed the library in Dictyostelium cells. Using live cell imaging, we identified mutations that enhance the association of PTEN with the plasma membrane. These mutations were located in four separate regions, including the phosphatase catalytic site, the calcium-binding region 3 (CBR3) loop, the C alpha 2 loop and the C-terminal tail phosphorylation site. The phosphatase catalytic site, the CBR3 loop and the C alpha 2 loop formed the membrane-binding regulatory interface and interacted with the inhibitory phosphorylated C-terminal tail. Furthermore, we showed that membrane recruitment of PTEN is required for PTEN function in cells. Thus, heterologous expression system in Dictyostelium cells provides mechanistic and functional insight into membrane localization of PTEN.	[Nguyen, H. N.; Afkari, Y.; Senoo, H.; Sesaki, H.; Devreotes, P. N.; Iijima, M.] Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA	Johns Hopkins University	Devreotes, PN (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, 725 N Wolfe St, Baltimore, MD 21205 USA.	pnd@jhmi.edu; miijima@jhmi.edu			NIH [GM084015, GM28007, GM34933, GM089853, NS084154]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034933, R37GM028007, R01GM084015, R01GM028007, R01GM089853] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS084154] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by NIH grants to MI (GM084015), PND (GM28007 and GM34933) and HS (GM089853 and NS084154). We thank M Rahdar and KF Swaney for providing plasmids.	Baker SJ, 2007, CELL, V128, P25, DOI 10.1016/j.cell.2006.12.023; Cai HQ, 2011, METHODS MOL BIOL, V757, P451, DOI 10.1007/978-1-61779-166-6_26; Carracedo A, 2011, CANCER RES, V71, P629, DOI 10.1158/0008-5472.CAN-10-2488; Chen CL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002446; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Denning G, 2007, ONCOGENE, V26, P3930, DOI 10.1038/sj.onc.1210175; Fey P, 2007, NAT PROTOC, V2, P1307, DOI 10.1038/nprot.2007.178; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Iijima M, 2004, J BIOL CHEM, V279, P16606, DOI 10.1074/jbc.M312098200; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Iijima M, 2002, DEV CELL, V3, P469, DOI 10.1016/S1534-5807(02)00292-7; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie Nick R, 2012, Adv Biol Regul, V52, P205; Lumb CN, 2013, BIOPHYS J, V104, P613, DOI 10.1016/j.bpj.2012.12.002; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Rahdar M, 2009, P NATL ACAD SCI USA, V106, P480, DOI 10.1073/pnas.0811212106; Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10; Shenoy S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032591; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Tamguney T, 2007, J CELL SCI, V120, P4071, DOI 10.1242/jcs.015230; Vanhaesebroeck B, 2012, NAT REV MOL CELL BIO, V13, P195, DOI 10.1038/nrm3290; Vazquez F, 2006, P NATL ACAD SCI USA, V103, P3633, DOI 10.1073/pnas.0510570103; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Walker SM, 2004, BIOCHEM J, V379, P301, DOI 10.1042/BJ20031839; Wang Y, 2011, MOL BIOL CELL, V22, P2270, DOI 10.1091/mbc.E10-11-0926; Zhang PB, 2010, P NATL ACAD SCI USA, V107, P11829, DOI 10.1073/pnas.1006153107	26	38	38	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2014	33	50					5688	5696		10.1038/onc.2013.507	http://dx.doi.org/10.1038/onc.2013.507			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW2AB	24292679	Green Accepted			2022-12-17	WOS:000346089300004
J	Elsum, IA; Yates, LL; Pearson, HB; Phesse, TJ; Long, F; O'Donoghue, R; Ernst, M; Cullinane, C; Humbert, PO				Elsum, I. A.; Yates, L. L.; Pearson, H. B.; Phesse, T. J.; Long, F.; O'Donoghue, R.; Ernst, M.; Cullinane, C.; Humbert, P. O.			Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo	ONCOGENE			English	Article						polarity; scrib; ras; lung; cancer	CELL POLARITY; K-RAS; ACTIVATION; EXPRESSION; PATHWAY; GROWTH; TUMORIGENESIS; DEREGULATION; INFLAMMATION; MACROPHAGES	Lung cancer is the leading cause of cancer deaths worldwide with non small-cell lung cancer (NSCLC) accounting for 80% of all lung cancers. Although activating mutations in genes of the RAS-MAPK pathway occur in up to 30% of all NSCLC, the cooperating genetic lesions that are required for lung cancer initiation and progression remain poorly understood. Here we identify a role for the cell polarity regulator Scribble (Scrib) in NSCLC. A survey of genomic databases reveals deregulation of SCRIB in human lung cancer and we show that Scrib(-/-) mutant mice develop lung cancer by 540 days with a penetrance of 43%. To model NSCLC development in vivo, we used the extensively characterized LSL-KRas(G12D) murine model of NSCLC. We show that loss of Scrib and activated oncogenic KRas cooperate in vivo, resulting in more aggressive lung tumors, likely due to a synergistic elevation in RAS-MAPK signaling. Finally, we provide data consistent with immune infiltration having an important role in the acceleration of tumorigenesis in KRas(G12D) lung tumors following Scrib loss.	[Elsum, I. A.; Yates, L. L.; Pearson, H. B.; Long, F.; Humbert, P. O.] Peter MacCallum Canc Ctr, Div Res, Melbourne, Vic 3002, Australia; [Pearson, H. B.; Cullinane, C.; Humbert, P. O.] Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Phesse, T. J.; O'Donoghue, R.; Ernst, M.] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Cell Signaling & Cell Death Div, Parkville, Vic 3050, Australia; [Cullinane, C.] Peter MacCallum Canc Ctr, Translat Res Lab, Canc Therapeut Program, Melbourne, Vic 3002, Australia; [Humbert, P. O.] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; [Humbert, P. O.] Univ Melbourne, Dept Mol Biol & Biochem, Parkville, Vic 3052, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne	Humbert, PO (corresponding author), Peter MacCallum Canc Ctr, St Andrews Pl, Melbourne, Vic 3002, Australia.	Patrick.Humbert@petermac.org	Humbert, Patrick O/L-4264-2016; Ernst, Matthias/D-5111-2012	Humbert, Patrick O/0000-0002-1366-6691; Ernst, Matthias/0000-0002-6399-1177; Yates, Laura/0000-0002-1620-1603; Pearson, Helen/0000-0002-3284-0843; Elsum, Imogen/0000-0003-4525-0727; Phesse, Toby/0000-0001-9568-4916; Cullinane, Carleen/0000-0001-5833-6605	NHMRC of Australia [1025239, 1004434]; Movember/PCFA; Richard Pratt Foundation; Cancer Council Victoria Postgraduate Research Scholarship; Biomedical Career Development Award from the NHMRC of Australia	NHMRC of Australia(National Health and Medical Research Council (NHMRC) of Australia); Movember/PCFA; Richard Pratt Foundation; Cancer Council Victoria Postgraduate Research Scholarship(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Biomedical Career Development Award from the NHMRC of Australia(National Health and Medical Research Council (NHMRC) of Australia)	We thank Dr Jason Li, Dr David Bimms, Sam Williams, Olivia Cakebread, Tanja Kinwel and the microscopy and histology core at the Peter MacCallum Cancer Centre. We also thank Dr Alison Dooley and Prof Roderick Bronson from the Massachusetts Institute of Technology for their technical advice and to Drs Helena Richardson and Sarah Russell for critical reading of the manuscript. This study was supported by grants from the NHMRC of Australia (no. 1025239 for TJP and RJO; no. 1004434 for IAE and LLY), Movember/PCFA and Richard Pratt Foundation (for HBP). IAE was supported by a Cancer Council Victoria Postgraduate Research Scholarship and POH was supported by a Biomedical Career Development Award from the NHMRC of Australia.	Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Borrello MG, 2008, CANCER LETT, V267, P262, DOI 10.1016/j.canlet.2008.03.060; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Bryant PJ, 2000, NAT CELL BIOL, V2, pE141, DOI 10.1038/35019616; Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1; Chatterjee S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034343; Cullinane C, 2011, J NUCL MED, V52, P1261, DOI 10.2967/jnumed.110.086967; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Dow LE, 2008, ONCOGENE, V27, P5988, DOI 10.1038/onc.2008.219; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Elsum I, 2012, ESSAYS BIOCHEM, V53, P141, DOI [10.1042/BSE0530141, 10.1042/bse0530141]; Elsum IA, 2013, J CELL SCI, V126, P3990, DOI 10.1242/jcs.129387; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064; Funaba M, 2002, J BIOL CHEM, V277, P41361, DOI 10.1074/jbc.M204597200; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao NB, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/948098; Huang L, 2010, CURR OPIN GENET DEV, V20, P41, DOI 10.1016/j.gde.2009.12.001; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Ji H, 2006, ONCOGENE, V25, P2105, DOI 10.1038/sj.onc.1209237; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kamei Y, 2007, HUM PATHOL, V38, P1273, DOI 10.1016/j.humpath.2007.01.026; Karreth FA, 2009, CURR OPIN GENET DEV, V19, P4, DOI 10.1016/j.gde.2008.12.006; Kass DJ, 2012, AM J PATHOL, V180, P1963, DOI 10.1016/j.ajpath.2012.01.010; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kissil JL, 2007, CANCER RES, V67, P8089, DOI 10.1158/0008-5472.CAN-07-2300; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; Muthuswamy SK, 2012, ANNU REV CELL DEV BI, V28, P599, DOI 10.1146/annurev-cellbio-092910-154244; Nagasaka K, 2010, ONCOGENE, V29, P5311, DOI 10.1038/onc.2010.265; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Pages F, 2010, ONCOGENE, V29, P1093, DOI 10.1038/onc.2009.416; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pearson HB, 2011, J CLIN INVEST, V121, P4257, DOI 10.1172/JCI58509; Ramakrishna GT, 2000, MOL CARCINOGEN, V28, P156, DOI 10.1002/1098-2744(200007)28:3<156::AID-MC4>3.0.CO;2-M; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Shaw AT, 2007, GENE DEV, V21, P694, DOI 10.1101/gad.1526207; Sica A, 2008, CANCER LETT, V267, P204, DOI 10.1016/j.canlet.2008.03.028; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Travis WD, 2002, CLIN CHEST MED, V23, P65, DOI 10.1016/S0272-5231(03)00061-3; Vaira V, 2011, AM J PATHOL, V178, P2478, DOI 10.1016/j.ajpath.2011.02.028; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045; Zhou YH, 2010, NAT BIOTECHNOL, V28, P71, DOI 10.1038/nbt.1595; Zhuo OY, 2010, ONCOL RES, V18, P593, DOI 10.3727/096504010X12767359114045	52	38	39	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2014	33	48					5523	5533		10.1038/onc.2013.498	http://dx.doi.org/10.1038/onc.2013.498			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZO	24276238				2022-12-17	WOS:000346087900005
J	Zhu, B; Ferry, CH; Blazanin, N; Bility, MT; Khozoie, C; Kang, BH; Glick, AB; Gonzalez, FJ; Peters, JM				Zhu, B.; Ferry, C. H.; Blazanin, N.; Bility, M. T.; Khozoie, C.; Kang, B-H; Glick, A. B.; Gonzalez, F. J.; Peters, J. M.			PPAR beta/delta promotes HRAS-induced senescence and tumor suppression by potentiating p-ERK and repressing p-AKT signaling	ONCOGENE			English	Article						peroxisome proliferator-activated receptor-beta/delta; HRAS-induced senescence; mechanisms of senescence; inhibition of tumorigenesis	ACTIVATED RECEPTOR-BETA/DELTA; INTEGRIN-LINKED KINASE; INHIBITS CELL-PROLIFERATION; LIGAND ACTIVATION; TRANSCRIPTION FACTORS; PROTEIN-KINASE; RAS ONCOGENE; MOUSE SKIN; HA-RAS; EXPRESSION	Peroxisome proliferator-activated receptor-beta/delta (PPAR beta/delta) inhibits skin tumorigenesis through mechanisms that may be dependent on HRAS signaling. The present study examined the hypothesis that PPAR beta/delta promotes HRAS-induced senescence resulting in suppression of tumorigenesis. PPAR beta/delta expression increased p-ERK and decreased p-AKT activity. Increased p-ERK activity results from the dampened HRAS-induced negative feedback response mediated in part through transcriptional upregulation of RAS guanyl-releasing protein 1 (RASGRP1) by PPAR beta/delta. Decreased p-AKT activity results from repression of integrin-linked kinase (ILK) and phosphoinositide-dependent protein kinase-1 (PDPK1) expression. Decreased p-AKT activity in turn promotes cellular senescence through upregulation of p53 and p27 expression. Both over-expression of RASGRP1 and shRNA-mediated knockdown of ILK partially restore cellular senescence in Ppar beta/delta-null cells. Higher PPAR beta/delta expression is also correlated with increased senescence observed in human benign neurofibromas and colon adenoma lesions in vivo. These results demonstrate that PPAR beta/delta promotes senescence to inhibit tumorigenesis and provide new mechanistic insights into HRAS-induced cellular senescence.	[Zhu, B.; Ferry, C. H.; Blazanin, N.; Bility, M. T.; Khozoie, C.; Glick, A. B.; Peters, J. M.] Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, Dept Vet & Biomed Sci, University Pk, PA 16802 USA; [Kang, B-H] Preclin Res Ctr, Chemon, Yongin Si, South Korea; [Gonzalez, F. J.] NCI, Lab Metab, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Peters, JM (corresponding author), Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, Dept Vet & Biomed Sci, University Pk, PA 16802 USA.	jmp21@psu.edu	Zhu, Bokai/AAF-7502-2020	Zhu, Bokai/0000-0003-0827-5757; Peters, Jeffrey/0000-0003-2782-2998; Bility, Moses/0000-0001-5153-2718	National Institutes of Health [CA124533, CA141029, CA140369, AA018863, CA122109, CA117957]; National Cancer Institute Intramural Research Program [ZIABC005561, ZIABC005562, ZIABC005708]; NATIONAL CANCER INSTITUTE [R01CA126826, R01CA124533, R01CA117957, R01CA141029, R01CA140369, ZIABC005708, ZIABC005562, ZIABC005561, R01CA122109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA018863] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute Intramural Research Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	We gratefully acknowledge Drs Andrew Billin and Timothy Willson for providing the GW0742, the Center for Quantitative Cell Analysis and the Genomic Core Facility at the Huck Institutes of Life Sciences of The Pennsylvania State University for their technical support with flow cytometry and data analysis. This work was supported by the National Institutes of Health (CA124533, CA141029, CA140369 and AA018863 to JMP; CA122109 and CA117957 to ABG) and the National Cancer Institute Intramural Research Program (ZIABC005561, ZIABC005562 and ZIABC005708 to FJG).	Adhikary T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016344; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alexander K, 2001, MOL CELL BIOL, V21, P3616, DOI 10.1128/MCB.21.11.3616-3631.2001; Bility MT, 2010, TOXICOL SCI, V113, P27, DOI 10.1093/toxsci/kfp212; Bility MT, 2008, CARCINOGENESIS, V29, P2406, DOI 10.1093/carcin/bgn219; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Borland MG, 2008, MOL PHARMACOL, V74, P1429, DOI 10.1124/mol.108.050609; Borland MG, 2011, CELL SIGNAL, V23, P2039, DOI 10.1016/j.cellsig.2011.07.020; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; Burdick AD, 2006, CELL SIGNAL, V18, P9, DOI 10.1016/j.cellsig.2005.07.009; Burdick AD, 2007, CELL SIGNAL, V19, P1163, DOI 10.1016/j.cellsig.2006.12.007; Busuttil V, 2010, P NATL ACAD SCI USA, V107, P18061, DOI 10.1073/pnas.1006163107; Cao XX, 2011, J BIOL CHEM, V286, P33447, DOI 10.1074/jbc.M111.225565; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Dai CY, 2000, GASTROENTEROLOGY, V119, P929, DOI 10.1053/gast.2000.17952; Dai DL, 2003, CLIN CANCER RES, V9, P4409; de Keizer PLJ, 2010, CANCER RES, V70, P8526, DOI 10.1158/0008-5472.CAN-10-1563; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Foreman JE, 2011, MOL CARCINOGEN, V50, P884, DOI 10.1002/mc.20757; Girroir EE, 2008, BIOCHEM BIOPH RES CO, V371, P456, DOI 10.1016/j.bbrc.2008.04.086; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Grimaldi PA, 2010, CURR OPIN LIPIDOL, V21, P186, DOI 10.1097/MOL.0b013e32833884a4; He PF, 2008, TOXICOLOGY, V254, P112, DOI 10.1016/j.tox.2008.09.023; Hong Y, 2010, CLIN EXP METASTAS, V27, P83, DOI 10.1007/s10585-010-9305-4; Kaiser S, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r131; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kennedy AL, 2011, MOL CELL, V42, P36, DOI 10.1016/j.molcel.2011.02.020; Kilgore KS, 2008, CURR OPIN INVEST DR, V9, P463; Kim DJ, 2004, J BIOL CHEM, V279, P23719, DOI 10.1074/jbc.M312063200; KNUTSEN GL, 1986, ENVIRON HEALTH PERSP, V68, P91, DOI 10.2307/3430253; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Majumder PK, 2008, CANCER CELL, V14, P146, DOI 10.1016/j.ccr.2008.06.002; Mandard S, 2004, J BIOL CHEM, V279, P34411, DOI 10.1074/jbc.M403058200; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Marin HE, 2006, CANCER RES, V66, P4394, DOI 10.1158/0008-5472.CAN-05-4277; Maurer M, 2009, CANCER RES, V69, P6299, DOI 10.1158/0008-5472.CAN-09-0820; Miller SJ, 2009, EMBO MOL MED, V1, P236, DOI 10.1002/emmm.200900027; Modica S, 2010, GASTROENTEROLOGY, V138, P636, DOI 10.1053/j.gastro.2009.09.060; MORGAN D, 1992, CANCER RES, V52, P3145; Nagashima T, 2010, MOL PHARMACOL, V78, P961, DOI 10.1124/mol.110.065714; Notterman DA, 2001, CANCER RES, V61, P3124; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Palkar PS, 2010, MOL PHARMACOL, V78, P419, DOI 10.1124/mol.110.065508; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Peters JM, 2008, CLIN SCI, V115, P107, DOI 10.1042/CS20080022; Peters Jeffrey M, 2011, Drug Discov Today Dis Mech, V8, pe85; Peters JM, 2012, NAT REV CANCER, V12, P181, DOI 10.1038/nrc3214; Peters JM, 2011, CANCER METAST REV, V30, P619, DOI 10.1007/s10555-011-9320-1; Peters JM, 2009, BBA-REV CANCER, V1796, P230, DOI 10.1016/j.bbcan.2009.06.002; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; Sabates-Beliver J, 2007, MOL CANCER RES, V5, P1263, DOI 10.1158/1541-7786.MCR-07-0267; Satyanarayana A, 2004, MOL CELL BIOL, V24, P5459, DOI 10.1128/MCB.24.12.5459-5474.2004; Schramek H, 1997, J BIOL CHEM, V272, P11426; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharma A, 2010, J BIOL CHEM, V285, P15724, DOI 10.1074/jbc.M109.100016; Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099; Skrzypczak M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013091; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; Uhlen M, 2010, NAT BIOTECHNOL, V28, P1248, DOI 10.1038/nbt1210-1248; Vijayachandra K, 2003, CANCER RES, V63, P3447; Yang L, 2010, ONCOGENE, V29, P516, DOI 10.1038/onc.2009.370; Yang L, 2011, CLIN CANCER RES, V17, P3760, DOI 10.1158/1078-0432.CCR-10-2779; Yu JH, 2011, VIRCHOWS ARCH, V458, P99, DOI 10.1007/s00428-010-1016-3; Zhu BK, 2012, MOL CELL BIOL, V32, P2065, DOI 10.1128/MCB.00092-12; Zhu BK, 2010, MOL CANCER THER, V9, P3267, DOI 10.1158/1535-7163.MCT-10-0820; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	72	38	38	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2014	33	46					5348	5359		10.1038/onc.2013.477	http://dx.doi.org/10.1038/onc.2013.477			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MF	24213576	Green Accepted			2022-12-17	WOS:000345120600005
J	Ye, H; Zhang, C; Wang, BJ; Tan, XH; Zhang, WP; Teng, Y; Yang, X				Ye, H.; Zhang, C.; Wang, B-J; Tan, X-H; Zhang, W-P; Teng, Y.; Yang, X.			Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice	ONCOGENE			English	Article						hepatocellular carcinoma; Kras(G12D); HBx; mouse model; Cre-LoxP; transgenic mice	HEPATITIS-B-VIRUS; X-PROTEIN; UP-REGULATION; SIGNALING PATHWAY; RAS ONCOGENES; BETA-CATENIN; GENE; EXPRESSION; LIVER; HEPATOCARCINOGENESIS	Although the activation of Ras pathway is frequently observed in human hepatocellular carcinoma (HCC), the in vivo role of Ras activation in HCC initiation and progression is underdetermined. To test the consequence of Kras activation in hepatocyte, we generated a hepatocyte-specific Kras(G12D) transgenic mouse strain and observed spontaneous development of HCC in these mice. Remarkably, HBV X protein (HBx) expression significantly promotes the formation and malignant progression of Kras(G12D)-driven HCC as shown with the accelerated tumor onset, the increased tumor burden and the more poorly differentiated lesions. At the cellular level, concomitant expression of Kras(G12D) and HBx results in a robust increase in hepatocellular proliferation. We reveal that the Akt, MAPK, p53 and TGF-beta pathways are deregulated in the Kras(G12D)-driven HCCs. Also, the dysregulation is more pronounced in the HCCs developed in Kras(G12D) and HBx double transgenic mice. In addition, the altered expressions of beta-catenin, CD44 and E-cadherin are only observed in the Kras(G12D) and HBx double transgenic mice. These results demonstrate a crucial role of Ras activation in hepatocellular carcinogenesis and the functional synergy between Kras(G12D) and HBx in HCC initiation and progression. The novel genetic mouse models that closely recapitulate the histopathologic progression and molecular alterations of human HCC may potentially facilitate the future therapeutic studies.	[Ye, H.; Zhang, C.; Yang, X.] Shanghai Jiao Tong Univ, Sch Med, E Inst Shanghai Univ, Model Organism Div, Shanghai, Peoples R China; [Ye, H.; Zhang, C.; Wang, B-J; Tan, X-H; Teng, Y.; Yang, X.] Inst Biotechnol, Genet Lab Dev & Dis, State Key Lab Prote, Beijing 100071, Peoples R China; [Zhang, W-P] Second Mil Med Univ, Dept Pathophysiol, Shanghai, Peoples R China	Shanghai Jiao Tong University; Naval Medical University	Teng, Y (corresponding author), Inst Biotechnol, Genet Lab Dev & Dis, State Key Lab Prote, 20 Dongdajie, Beijing 100071, Peoples R China.	tengyan0919@163.com; yangx@bmi.ac.cn	XIAO, YANG/GPW-5529-2022	Yang, Xiao/0000-0002-0298-9831	National Natural Science Foundation of China [81272702, 31171249, 31071295, 81123001]; Chinese National Key Program on Basic Research [2011CB504202, 2012CB945103, 2011CB910601]; National High Technology Research and Development program of China [2012AA022402]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese National Key Program on Basic Research; National High Technology Research and Development program of China(National High Technology Research and Development Program of China)	This work was supported by National Natural Science Foundation of China (81272702; 31171249; 31071295; 81123001), Chinese National Key Program on Basic Research (2011CB504202; 2012CB945103; 2011CB910601) and National High Technology Research and Development program of China (2012AA022402). We thank Xiao-Yan Chang for histopathologic analysis, You-Liang Wang, Xiu-Bin Li, Xiao-Jie Xu, Qi-Long Ye and Xin Chen for technical support.	Arzumanyan A, 2013, NAT REV CANCER, V13, P123, DOI 10.1038/nrc3449; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Bock CT, 2008, INTERVIROLOGY, V51, P432, DOI 10.1159/000209672; Calvisi DF, 2006, GASTROENTEROLOGY, V130, P1117, DOI 10.1053/j.gastro.2006.01.006; Cha MY, 2004, HEPATOLOGY, V39, P1683, DOI 10.1002/hep.20245; Chappell WH, 2011, ONCOTARGET, V2, P135, DOI 10.18632/oncotarget.240; Colnot S, 2004, P NATL ACAD SCI USA, V101, P17216, DOI 10.1073/pnas.0404761101; Cui F, 2006, PROTEOMICS, V6, P498, DOI 10.1002/pmic.200500218; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Fan RH, 2011, J MOL HISTOL, V42, P473, DOI 10.1007/s10735-011-9353-3; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Harada N, 2004, CANCER RES, V64, P48, DOI 10.1158/0008-5472.CAN-03-2123; Hsieh A, 2011, CANCER LETT, V300, P162, DOI 10.1016/j.canlet.2010.09.018; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Keng VW, 2011, HEPATOLOGY, V53, P781, DOI 10.1002/hep.24091; Kim HR, 2010, FEBS LETT, V584, P525, DOI 10.1016/j.febslet.2009.11.091; Kim YC, 2001, ONCOGENE, V20, P16, DOI 10.1038/sj.onc.1203840; Lara-Pezzi E, 2001, HEPATOLOGY, V33, P1270, DOI 10.1053/jhep.2001.1270; Lee SG, 2000, ONCOGENE, V19, P468, DOI 10.1038/sj.onc.1203312; Lee YI, 2001, J BIOL CHEM, V276, P16969, DOI 10.1074/jbc.M011263200; Li Y, 2012, NAT REV GASTRO HEPAT, V9, P32, DOI 10.1038/nrgastro.2011.196; Liu J, 2006, ONCOGENE, V25, P1008, DOI 10.1038/sj.onc.1209138; Longato L, 2009, HEPATOLOGY, V49, P1935, DOI 10.1002/hep.22856; MacNee W, 2013, THORAX, V68, P738, DOI 10.1136/thoraxjnl-2012-202744; Miyoshi K, 2011, J INVEST DERMATOL, V131, P108, DOI 10.1038/jid.2010.255; Morris SM, 2012, HEPATOLOGY, V55, P121, DOI 10.1002/hep.24653; NISHIDA N, 1994, INT J ONCOL, V4, P615; O'Dell MR, 2012, CANCER RES, V72, P1557, DOI 10.1158/0008-5472.CAN-11-3596; Oishi N, 2007, CANCER SCI, V98, P1540, DOI 10.1111/j.1349-7006.2007.00579.x; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Schmitz KJ, 2008, J HEPATOL, V48, P83, DOI 10.1016/j.jhep.2007.08.018; Sun Q, 2007, CANCER BIOL THER, V6, P668, DOI 10.4161/cbt.6.5.3955; Sun Q, 2007, CANCER BIOL THER, V6, P1532, DOI 10.4161/cbt.6.10.4683; Tang H, 2006, CANCER SCI, V97, P977, DOI 10.1111/j.1349-7006.2006.00299.x; Tarn C, 2002, J VIROL, V76, P9763, DOI 10.1128/JVI.76.19.9763-9772.2002; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Tuveson DA, 2006, CANCER RES, V66, P242, DOI 10.1158/0008-5472.CAN-05-2305; Wang SN, 2012, EUR J CLIN INVEST, V42, P1295, DOI 10.1111/eci.12003; Wang YL, 2004, HEPATOLOGY, V39, P318, DOI 10.1002/hep.20076; Xia LM, 2012, J IMMUNOL, V188, P753, DOI 10.4049/jimmunol.1101652; Yang SF, 2007, J CLIN PATHOL, V60, P642, DOI 10.1136/jcp.2006.036970; Zhang XD, 2006, J LAB CLIN MED, V147, P58, DOI 10.1016/j.lab.2005.10.003	45	38	40	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2014	33	43					5133	5138		10.1038/onc.2013.468	http://dx.doi.org/10.1038/onc.2013.468			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OF	24213574				2022-12-17	WOS:000343768400008
J	Timme, S; Ihde, S; Fichter, CD; Waehle, V; Bogatyreva, L; Atanasov, K; Kohler, I; Schopflin, A; Geddert, H; Faller, G; Klimstra, D; Tang, L; Reinheckel, T; Hauschke, D; Busch, H; Boerries, M; Werner, M; Lassmann, S				Timme, S.; Ihde, S.; Fichter, C. D.; Waehle, V.; Bogatyreva, L.; Atanasov, K.; Kohler, I.; Schoepflin, A.; Geddert, H.; Faller, G.; Klimstra, D.; Tang, L.; Reinheckel, T.; Hauschke, D.; Busch, H.; Boerries, M.; Werner, M.; Lassmann, S.			STAT3 expression, activity and functional consequences of STAT3 inhibition in esophageal squamous cell carcinomas and Barrett's adenocarcinomas	ONCOGENE			English	Article						STAT3; esophageal cancer; inhibition; cell proliferation; cell migration	GROWTH-FACTOR RECEPTOR; TYROSINE-PHOSPHORYLATED STAT3; ACTIVATED SIGNAL TRANSDUCER; MULTIPOLAR MITOSES; GENE AMPLIFICATION; COLORECTAL-CANCER; TRANSCRIPTION 3; IN-VIVO; PROTEIN; PATHWAY	Signal transducer and activator of transcription 3 (STAT3) is altered in several epithelial cancers and represents a potential therapeutic target. Here, STAT3 expression, activity and cellular functions were examined in two main histotypes of esophageal carcinomas. In situ, immunohistochemistry for STAT3 and STAT3-Tyr705 phosphorylation (P-STAT3) in esophageal squamous cell carcinomas (ESCC, n = 49) and Barrett's adenocarcinomas (BAC, n = 61) revealed similar STAT3 expression in ESCCs and BACs (P = 0.109), but preferentially activated P-STAT3 in ESCCs (P = 0.013). In vitro, strong STAT3 activation was seen by epidermal growth factor (EGF) stimulation in OE21 (ESCC) cells, whereas OE33 (BAC) cells showed constitutive weak STAT3 activation. STAT3 knockdown significantly reduced cell proliferation of OE21 (P = 0.0148) and OE33 (P = 0.0243) cells. Importantly, STAT3 knockdown reduced cell migration of OE33 cells by 2.5-fold in two types of migration assays (P = 0.073, P = 0.015), but not in OE21 cells (P = 0.1079, P = 0.386). Investigation of transcriptome analysis of STAT3 knockdown revealed a reduced STAT3 level associated with significant downregulation of cell cycle genes in both OE21 (P<0.0001) and OE33 (P = 0.01) cells. In contrast, genes promoting cell migration (CTHRC1) were markedly upregulated in OE21 cells, whereas a gene linked to tight-junction stabilization and restricted cell motility (SHROOM2) was downregulated in OE21 but upregulated in OE33 cells. This study shows frequent, but distinct, patterns of STAT3 expression and activation in ESCCs and BACs. STAT3 knockdown reduces cell proliferation in ESCC and BAC cells, inhibits migration of BAC cells and may support cell migration of ESCC cells. Thereby, novel STAT3-regulated genes involved in ESCC and BAC cell proliferation and cell migration were identified. Thus, STAT3 may be further exploited as a potential novel therapeutic target, however, by careful distinction between the two histotypes of esophageal cancers.	[Timme, S.; Ihde, S.; Fichter, C. D.; Waehle, V.; Atanasov, K.; Kohler, I.; Schoepflin, A.; Werner, M.; Lassmann, S.] Univ Freiburg, Univ Med Ctr, Inst Clin Pathol, D-79106 Freiburg, Germany; [Fichter, C. D.] Univ Freiburg, Fac Biol, D-79106 Freiburg, Germany; [Bogatyreva, L.; Hauschke, D.] Univ Freiburg, Univ Med Ctr, Inst Med Biometry & Med Informat, D-79106 Freiburg, Germany; [Geddert, H.; Faller, G.] St Vincentius Kliniken, Dept Pathol, Karlsruhe, Germany; [Klimstra, D.; Tang, L.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Reinheckel, T.; Busch, H.; Boerries, M.] Univ Freiburg, Univ Med Ctr, Inst Mol Med & Cell Res, D-79106 Freiburg, Germany; [Reinheckel, T.; Lassmann, S.] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, D-79106 Freiburg, Germany; [Reinheckel, T.; Werner, M.; Lassmann, S.] Univ Freiburg, Univ Med Ctr, Comprehens Canc Ctr Freiburg, D-79106 Freiburg, Germany; [Busch, H.; Boerries, M.; Werner, M.; Lassmann, S.] German Canc Consortium DKTK, Heidelberg, Germany; [Busch, H.; Boerries, M.; Werner, M.; Lassmann, S.] German Canc Res Ctr, Heidelberg, Germany	University of Freiburg; University of Freiburg; University of Freiburg; Memorial Sloan Kettering Cancer Center; University of Freiburg; University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Lassmann, S (corresponding author), Univ Med Ctr, Inst Clin Pathol, Breisacherstr 115A, D-79106 Freiburg, Germany.	silke.lassmann@uniklinik-freiburg.de	Boerries, Melanie/AAM-2602-2021; Reinheckel, Thomas/AAL-9761-2021; Busch, Hauke/R-6452-2016	Reinheckel, Thomas/0000-0001-9866-9105; Busch, Hauke/0000-0003-4763-4521; Waehle, Verena/0000-0003-0189-8812	Deutsche Forschungsgemeinschaft [SFB850]; Mushett Family Foundation, Chester, NJ, USA; DFG [SFB850]; Mushett Family Foundation, Chester, NJ	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Mushett Family Foundation, Chester, NJ, USA; DFG(German Research Foundation (DFG)); Mushett Family Foundation, Chester, NJ	We thank Martina Gansz for assistance with Cathepsin analyses. We acknowledge the support of the study by the Deutsche Forschungsgemeinschaft (SFB850 project C5 to SL, MW; SFB850 project B7 to TR; Gerok stipend of SFB850 project Z1 to ST). Preliminary work for this study has been supported by the Mushett Family Foundation, Chester, NJ, USA (grant to SL, MW, LT, DK). TR and SL are member and associate members of BIOSS Centre for Biological Signalling Studies, Albert-Ludwigs-University, Freiburg, Germany. This study was supported by DFG SFB850 C5 (MW, SL); DFG SFB850 B7 (TR); DFG SFB850 Z1 (Gerok position to ST); and Mushett Family Foundation, Chester, NJ (DK, LT, MW, SL).	Aggarwal BB, 2009, ANN NY ACAD SCI, V1171, P59, DOI 10.1111/j.1749-6632.2009.04911.x; Andl CD, 2004, AM J PHYSIOL-GASTR L, V287, pG1227, DOI 10.1152/ajpgi.00253.2004; Boehm AL, 2008, MOL PHARMACOL, V73, P1632, DOI 10.1124/mol.107.044636; Boerries M, 2013, KIDNEY INT, V83, P1052, DOI 10.1038/ki.2012.487; Bonner JA, 2011, RADIOTHER ONCOL, V99, P339, DOI 10.1016/j.radonc.2011.05.070; Boonstra JJ, 2010, JNCI-J NATL CANCER I, V102, P271, DOI 10.1093/jnci/djp499; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Dvorak K, 2007, CLIN CANCER RES, V13, P5305, DOI 10.1158/1078-0432.CCR-07-0483; Etournay R, 2007, J CELL SCI, V120, P2838, DOI 10.1242/jcs.002568; Farber MJ, 2011, MOL BIOL CELL, V22, P795, DOI 10.1091/mbc.E10-06-0505; Fichter CD, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-13; Gabbert HE, WHO CLASSIFICATION T, V3; Gerlach U, 2006, J PATHOL, V208, P462, DOI 10.1002/path.1914; Gong WD, 2005, CLIN CANCER RES, V11, P1386, DOI 10.1158/1078-0432.CCR-04-0487; Hanawa M, 2006, INT J CANCER, V118, P1173, DOI 10.1002/ijc.21454; Haura EB, 2005, CLIN CANCER RES, V11, P8288, DOI 10.1158/1078-0432.CCR-05-0827; Herz C, 2012, MOL CARCINOGEN, V51, P696, DOI 10.1002/mc.20823; Jaganathan S, 2010, J PHARMACOL EXP THER, V333, P373, DOI 10.1124/jpet.109.162669; Jiang RC, 2011, MOL DIAGN THER, V15, P347, DOI 10.2165/11599190-000000000-00000; Jove R, 2000, ONCOGENE, V19, P2466, DOI 10.1038/sj.onc.1203549; Kamburov A, 2013, NUCLEIC ACIDS RES, V41, pD793, DOI 10.1093/nar/gks1055; Khoury JD, 2003, CLIN CANCER RES, V9, P3692; Kreuzaler PA, 2011, NAT CELL BIOL, V13, P303, DOI 10.1038/ncb2171; Lassmann S, 2007, J CLIN PATHOL, V60, P173, DOI 10.1136/jcp.2005.035113; Lassmann S, 2009, MODERN PATHOL, V22, P1385, DOI 10.1038/modpathol.2009.111; Lassmann S, 2009, J MOL MED, V87, P211, DOI 10.1007/s00109-008-0419-y; Lee J, 2009, APMIS, V117, P598, DOI 10.1111/j.1600-0463.2009.02512.x; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo WJ, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-161; Morikawa T, 2011, CLIN CANCER RES, V17, P1452, DOI 10.1158/1078-0432.CCR-10-2694; Nagaraj NS, 2011, CLIN CANCER RES, V17, P483, DOI 10.1158/1078-0432.CCR-10-1670; Nasr MR, 2007, AM J CLIN PATHOL, V127, P770, DOI 10.1309/FNY8Y4H6PK1V2MGE; Park EH, 2013, CARCINOGENESIS, V34, P694, DOI 10.1093/carcin/bgs378; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Rauser S, 2007, CLIN CANCER RES, V13, P5115, DOI 10.1158/1078-0432.CCR-07-0465; Reipschlager S, 2012, J BIOL CHEM, V287, P11183, DOI 10.1074/jbc.M111.313395; Reiser J, 2010, J CLIN INVEST, V120, P3421, DOI 10.1172/JCI42918; Sansone P, 2012, J CLIN ONCOL, V30, P1005, DOI 10.1200/JCO.2010.31.8907; Seethala RR, 2008, CLIN CANCER RES, V14, P1303, DOI 10.1158/1078-0432.CCR-07-1543; Sobin LH, 2009, TNM CLASSIFICATION M; Souissi I, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-14; Tischoff I, 2007, GUT, V56, P1047, DOI 10.1136/gut.2006.111633; Vinkemeier U, 2004, J CELL BIOL, V167, P197, DOI 10.1083/jcb.200407163; Werner M, WHO CLASSIFICATION T, V3; Yan S, 2008, CANCER LETT, V271, P85, DOI 10.1016/j.canlet.2008.05.035; Yoon HH, 2012, CLIN CANCER RES, V18, P546, DOI 10.1158/1078-0432.CCR-11-2272; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Yu WW, 2011, HEPATO-GASTROENTEROL, V58, P426; Zhang HY, 2011, AM J PHYSIOL-GASTR L, V300, pG454, DOI 10.1152/ajpgi.00458.2010; Zhang Y, 2012, GASTROENTEROLOGY, V142, P521, DOI 10.1053/j.gastro.2011.11.023; Zhao W, 2010, J BIOL CHEM, V285, P35855, DOI 10.1074/jbc.M110.154088	52	38	45	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3256	3266		10.1038/onc.2013.298	http://dx.doi.org/10.1038/onc.2013.298			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23912451				2022-12-17	WOS:000338443400005
J	Allen-Petersen, BL; Carter, CJ; Ohm, AM; Reyland, ME				Allen-Petersen, B. L.; Carter, C. J.; Ohm, A. M.; Reyland, M. E.			Protein kinase C delta is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer	ONCOGENE			English	Article						PKC delta; breast cancer; ErbB2; Src	GROWTH-FACTOR RECEPTOR; SRC FAMILY KINASES; ERBB RECEPTORS; PKC-DELTA; PANCREATIC-CANCER; NEU PROTOONCOGENE; EPITHELIAL ACINI; CELL-MIGRATION; NUCLEAR IMPORT; ACTIVATION	Protein kinase C delta (PKC delta) regulates apoptosis in the mammary gland, however, the functional contribution of PKC delta to the development or progression of breast cancer has yet to be determined. Meta-analysis of ErbB2-positive breast cancers shows increased PKC delta expression, and a negative correlation between PKC delta expression and prognosis. Here, we present in-vivo evidence that PKC delta is essential for the development of mammary gland tumors in a ErbB2-overexpressing transgenic mouse model, and in-vitro evidence that PKC delta is required for proliferative signaling downstream of the ErbB2 receptor. Mouse mammary tumor virus (MMTV)-ErbB2 mice lacking PKC delta (delta KO) have increased tumor latency compared with MMTV-ErbB2 wild-type (delta WT) mice, and the tumors show a dramatic decrease in Ki-67 staining. To explore the relationship between PKC delta and ErbB2-driven proliferation more directly, we used MCF-10A cells engineered to express a synthetic ligand-inducible form of the ErbB2 receptor. Depletion of PKC delta with short hairpin RNA inhibited ligand-induced growth in both two-dimensional (2D) (plastic) and three-dimensional (3D) (Matrigel) culture, and correlated with decreased phosphorylation of the ErbB2 receptor and reduced activation of Src and MAPK/ERK pathways. Similarly, in human breast cancer cell lines in which ErbB2 is overexpressed, depletion of PKC delta suppresses proliferation, Src and ERK activation. PKC delta appears to drive proliferation through the formation of an active ErbB2/PKC delta/Src signaling complex, as depletion of PKC delta disrupts association of Src with the ErbB2 receptor. Taken together, our studies present the first evidence that PKC delta is a critical regulator of ErbB2-mediated tumorigenesis, and suggest further investigation of PKC delta as a target in ErbB2-positive breast cancer.	[Allen-Petersen, B. L.] Univ Colorado, Sch Med, Program Cell Biol Stem Cells & Dev, Aurora, CO 80045 USA; [Carter, C. J.; Ohm, A. M.; Reyland, M. E.] Univ Colorado, Sch Dent Med, Dept Craniofacial Biol, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Reyland, ME (corresponding author), Univ Colorado, Sch Dent Med, Dept Craniofacial Biol, Anschutz Med Campus,Mail Stop 8120,POB 6511, Aurora, CO 80045 USA.	Mary.Reyland@UCDenver.edu	Allen-Petersen, Brittany/AAC-8504-2020	Allen-Petersen, Brittany/0000-0002-7436-9412	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD038129] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015648] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA046934] Funding Source: Medline; NICHD NIH HHS [P01 HD038129] Funding Source: Medline; NIDCR NIH HHS [R01 DE015648] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adwan TS, 2011, J BIOL CHEM, V286, P35716, DOI 10.1074/jbc.M111.255950; Allen-Petersen BL, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.20; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Cheng J, 2007, ENDOCRINOLOGY, V148, P2066, DOI 10.1210/en.2006-1465; D'Costa AM, 2006, ONCOGENE, V25, P378, DOI 10.1038/sj.onc.1209065; Dankort D, 2001, J BIOL CHEM, V276, P38921, DOI 10.1074/jbc.M106239200; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; DeVries-Seimon TA, 2007, J BIOL CHEM, V282, P22307, DOI 10.1074/jbc.M703661200; Evans JD, 2003, AM J CLIN PATHOL, V119, P392, DOI 10.1309/BKPC9DX98R781B87; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Grossoni VC, 2007, MOL CARCINOGEN, V46, P381, DOI 10.1002/mc.20287; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Humphries MJ, 2006, J BIOL CHEM, V281, P9728, DOI 10.1074/jbc.M507851200; Iwabu A, 2004, J BIOL CHEM, V279, P14551, DOI 10.1074/jbc.M311981200; Jackson D, 2005, ONCOGENE, V24, P3067, DOI 10.1038/sj.onc.1208465; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; Kiley SC, 1999, ONCOGENE, V18, P6748, DOI 10.1038/sj.onc.1203101; Kiley SC, 1999, CANCER RES, V59, P3230; Kraus S, 2003, J BIOL CHEM, V278, P32618, DOI 10.1074/jbc.M303886200; Kruger JS, 2003, MOL CANCER RES, V1, P801; Kwon YK, 1997, J NEUROSCI, V17, P8293; Liu Dong, 2000, Shengli Xuebao, V52, P483; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Marcotte R, 2009, MOL CELL BIOL, V29, P5858, DOI 10.1128/MCB.01731-08; Marmor MD, 2004, INT J RADIAT ONCOL, V58, P903, DOI 10.1016/j.ijrobp.2003.06.002; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; Mauro LV, 2010, PANCREAS, V39, pE31, DOI 10.1097/MPA.0b013e3181bce796; McKiernan E, 2008, BRIT J CANCER, V99, P1644, DOI 10.1038/sj.bjc.6604728; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PONGRACZ J, 1995, INT J CANCER, V61, P35, DOI 10.1002/ijc.2910610107; Rexer BN, 2011, ONCOGENE, V30, P4163, DOI 10.1038/onc.2011.130; Reyland ME, 2009, FRONT BIOSCI-LANDMRK, V14, P2386, DOI 10.2741/3385; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ringner M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911; Schade B, 2007, CANCER RES, V67, P7579, DOI 10.1158/0008-5472.CAN-06-4724; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Symonds JM, 2011, CANCER RES, V71, P2087, DOI 10.1158/0008-5472.CAN-10-1511; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Tolwinski NS, 1999, J BIOL CHEM, V274, P6168, DOI 10.1074/jbc.274.10.6168; Varga A, 2004, EUR UROL, V46, P462, DOI 10.1016/j.eururo.2004.04.014; Xu WP, 2007, MOL CELL BIOL, V27, P220, DOI 10.1128/MCB.00899-06; Zhang HT, 1998, ONCOGENE, V16, P2835, DOI 10.1038/sj.onc.1201820; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zhou XD, 2009, J BIOL CHEM, V284, P12226, DOI 10.1074/jbc.M900020200	61	38	39	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1306	1315		10.1038/onc.2013.59	http://dx.doi.org/10.1038/onc.2013.59			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23474764	Green Accepted			2022-12-17	WOS:000332631100011
J	Gonzalez-Flores, A; Aguilar-Quesada, R; Siles, E; Pozo, S; Rodriguez-Lara, MI; Lopez-Jimenez, L; Lopez-Rodriguez, M; Peralta-Leal, A; Villar, D; Martin-Oliva, D; del Peso, L; Berra, E; Oliver, FJ				Gonzalez-Flores, A.; Aguilar-Quesada, R.; Siles, E.; Pozo, S.; Rodriguez-Lara, M. I.; Lopez-Jimenez, L.; Lopez-Rodriguez, M.; Peralta-Leal, A.; Villar, D.; Martin-Oliva, D.; del Peso, L.; Berra, E.; Oliver, F. J.			Interaction between PARP-1 and HIF-2 alpha in the hypoxic response	ONCOGENE			English	Article						hypoxia; PARP-1; HIF-2	RENAL-CELL CARCINOMA; INDUCIBLE FACTOR-I; TRANSCRIPTIONAL ACTIVITY; EMBRYONIC-DEVELOPMENT; PROLYL HYDROXYLATION; HIF-ALPHA; HIF-1-ALPHA; PROMOTES; GENE; POLY(ADP-RIBOSE)	Hypoxia-inducible factors (HIFs) mediate the transcriptional adaptation of hypoxic cells. The extensive transcriptional programm regulated by HIFs involves the induction of genes controlling angiogenesis, cellular metabolism, cell growth, metastasis, apoptosis, extracellular matrix remodeling and others. HIF is a heterodimer of HIF-alpha and HIF-beta subunits. In addition to HIF-1 alpha, HIF-2 alpha has evolved as an isoform that contributes differently to the hypoxic adaptation by performing non-redundant functions. Poly (ADPribose) polymerase-1 (PARP-1) is a nuclear protein involved in the control of DNA repair and gene transcription by modulating chromatin structure and acting as part of gene-specific enhancer/promoter-binding complexes. Previous results have shown that PARP-1 regulates HIF-1 activity. In this study, we focused on the cross-talk between HIF-2 alpha and PARP-1. By using different approaches to suppress PARP-1, we show that HIF-2 alpha mRNA expression, protein levels and HIF-2-dependent gene expression, such as ANGPTL4 and erythropoietin (EPO), are regulated by PARP-1. This regulation occurs at both the transcriptional and post-trancriptional level. We also show a complex formation between HIF-2 alpha with PARP-1. This complex is sensitive to PARP inhibition and seems to protect against the von Hippel-Lindau-dependent HIF-2 alpha degradation. Finally, we show that parp-1(-/-) mice display a significant reduction in the circulating hypoxia-induced EPO levels, number of red cells and hemoglobin concentration. Altogether, these results reveal a complex functional interaction between PARP-1 and the HIF system and suggest that PARP-1 is involved in the fine tuning of the HIF-mediated hypoxic response in vivo.	[Gonzalez-Flores, A.; Aguilar-Quesada, R.; Rodriguez-Lara, M. I.; Lopez-Jimenez, L.; Lopez-Rodriguez, M.; Peralta-Leal, A.; Oliver, F. J.] CSIC, Inst Parasitol & Biomed Lopez Neyra, Granada 18100, Spain; [Siles, E.] Univ Jaen, Dept Expt Biol, Jaen, Spain; [Pozo, S.; Berra, E.] CIC bioGUNE, Derio 48160, Spain; [Villar, D.; del Peso, L.] Autonomous Univ Madrid, Fac Med, CSIC, Inst Biomed Res Alberto Sols, E-28049 Madrid, Spain; [Martin-Oliva, D.] Univ Granada, Fac Sci, Dept Cellular Biol, Granada, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Universidad de Jaen; CIC bioGUNE; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Granada	Berra, E (corresponding author), CIC bioGUNE, Parque Tecnol Bizkaia Ed 801A, Derio 48160, Spain.	eberra@cicbiogune.es; joliver@ipb.csic.es	Lara, María Isabel Rodríguez/A-1961-2017; Oliver, Javier/S-1725-2018; Peralta Leal, Andreína Cecilia/AAE-8342-2022; Martín-Oliva, David/L-8472-2014; cancer, biogune/H-7276-2012; Villar, Diego/K-8595-2017; Berra, Edurne/F-9692-2011; del Peso, Luis/K-9391-2014	Lara, María Isabel Rodríguez/0000-0002-2270-0070; Oliver, Javier/0000-0001-8468-1998; Peralta Leal, Andreína Cecilia/0000-0001-7120-9870; Martín-Oliva, David/0000-0002-8095-5442; Villar, Diego/0000-0002-8614-6232; Berra, Edurne/0000-0002-3820-5744; del Peso, Luis/0000-0003-4014-5688; Siles Rivas, Eva/0000-0003-4192-7008; Aguilar-Quesada, Rocio/0000-0003-3125-6634	Ministerio de Ciencia e Innovacion [SAF2006-01094, SAF2009-13281-C02-01]; Fundacion La Caixa [BM06-219-0]; Junta de Andalucia [P07-CTS-0239]; Ministerio de Educacion y Ciencia [SAF2007-64597, SAF-2010-20067]; BIZKAIA XEDE Program from the Bizkaia County	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Fundacion La Caixa(La Caixa Foundation); Junta de Andalucia(Junta de Andalucia); Ministerio de Educacion y Ciencia(Spanish Government); BIZKAIA XEDE Program from the Bizkaia County	We thank Dr Francoise Dantzer, CNRS, Strasbourg (France), for providing the pEGFP-PARP-1 construct. This work was supported by Ministerio de Ciencia e Innovacion (SAF2006-01094 and SAF2009-13281-C02-01), Fundacion La Caixa (BM06-219-0) and Junta de Andalucia (P07-CTS-0239) to FJO; Ministerio de Educacion y Ciencia (SAF2007-64597 and SAF-2010-20067) and the BIZKAIA XEDE Program from the Bizkaia County to EB.	Aguilar-Quesada R, 2007, CURR MED CHEM, V14, P1179, DOI 10.2174/092986707780597998; Aprelikova O, 2006, CANCER RES, V66, P5641, DOI 10.1158/0008-5472.CAN-05-3345; Benizri E, 2008, CELL MOL LIFE SCI, V65, P1133, DOI 10.1007/s00018-008-7472-0; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Elser M, 2008, MOL CANCER RES, V6, P282, DOI 10.1158/1541-7786.MCR-07-0377; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Flamme I, 1998, AM J PATHOL, V153, P25, DOI 10.1016/S0002-9440(10)65541-1; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Loboda A, 2012, VASC PHARMACOL, V56, P245, DOI 10.1016/j.vph.2012.02.006; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Martinez-Romero R, 2012, J APPL PHYSIOL, V112, P816, DOI 10.1152/japplphysiol.00898.2011; Mastrogiannaki M, 2009, J CLIN INVEST, V119, P1159, DOI 10.1172/JCI38499; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; Pescador N, 2005, BIOCHEM J, V390, P189, DOI 10.1042/BJ20042121; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; Rankin EB, 2007, J CLIN INVEST, V117, P1068, DOI 10.1172/JCI30117; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Rosenberger C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017223.49823.2A; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Schodel J, 2011, BLOOD, V117, pE207, DOI 10.1182/blood-2010-10-314427; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Yoon D, 2011, AM J PHYSIOL-CELL PH, V300, pC1215, DOI 10.1152/ajpcell.00044.2011	41	38	39	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					891	898		10.1038/onc.2013.9	http://dx.doi.org/10.1038/onc.2013.9			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23455322				2022-12-17	WOS:000331626900010
J	Kahali, B; Gramling, SJB; Marquez, SB; Thompson, K; Lu, L; Reisman, D				Kahali, B.; Gramling, S. J. B.; Marquez, S. B.; Thompson, K.; Lu, L.; Reisman, D.			Identifying targets for the restoration and reactivation of BRM	ONCOGENE			English	Article						epigenetic; histone transferase; SWI/SNF; histone deacetylase complex; tumor suppressor; brahma	HUMAN LUNG-CANCER; CHROMATIN-REMODELING FACTOR; II HISTONE DEACETYLASES; SWI/SNF COMPLEX; GENE-EXPRESSION; BREAST-CANCER; CELL-LINES; TRANSCRIPTIONAL ACTIVITY; RAS MUTATIONS; DNA-BINDING	Brahma (BRM) is a novel anticancer gene, which is frequently inactivated in a variety of tumor types. Unlike many anticancer genes, BRM is not mutated, but rather epigenetically silenced. In addition, histone deacetylase complex (HDAC) inhibitors are known to reverse BRM silencing, but they also inactivate it via acetylation of its C-terminus. High-throughput screening has uncovered many compounds that are effective at pharmacologically restoring BRM and thereby inhibit cancer cell growth. As we do not know which specific proteins, if any, regulate BRM, we sought to identify the proteins, which underlie the epigenetic suppression of BRM. By selectively knocking down each HDAC, we found that HDAC3 and HDAC9 regulate BRM expression, whereas HDAC2 controls its acetylation. Similarly, we ectopically overexpressed 21 different histone acetyltransferases and found that KAT6A, KAT6B and KAT7 induce BRM expression, whereas KAT2B and KAT8 induce its acetylation. We also investigated the role of two transcription factors (TFs) linked to either BRM (GATA3) or HDAC9 (MEF2D) expression. Knockdown of either GATA3 and/or MEF2D downregulated HDAC9 and induced BRM. As targets for molecular biotherapy are typically uniquely, or simply differentially expressed in cancer cells, we also determined if any of these proteins are dysregulated. However, by sequencing, no mutations were found in any of these BRM-regulating HDACs, HATs or TFs. We selectively knocked down GATA3, MEF2D, HDAC3 and HDAC9, and found that each gene-specific knockdown induced growth inhibition. We observed that both GATA3 and HDAC9 were greatly overexpressed only in BRM-negative cell lines indicating that HDAC9 may be a good target for therapy. We also found that the mitogen-activated protein (MAP) kinase pathway regulates both BRM acetylation and BRM silencing as MAP kinase pathway inhibitors both induced BRM as well as caused BRM deacetylation. Together, these data identify a cadre of key proteins, which underlie the epigenetic regulation of BRM.	[Kahali, B.; Gramling, S. J. B.; Marquez, S. B.; Thompson, K.; Reisman, D.] Univ Florida, Dept Med, Dept Hematol Oncol, Gainesville, FL 32610 USA; [Lu, L.] Univ Florida, Dept Pathol, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Reisman, D (corresponding author), Univ Florida, Dept Med, Dept Hematol Oncol, Gainesville, FL 32610 USA.	dnreisman@ufl.edu	Kahali, Bhaskar/N-6398-2018	Kahali, Bhaskar/0000-0003-4160-7979	 [5R01CA136683-03]; NATIONAL CANCER INSTITUTE [R01CA136683] Funding Source: NIH RePORTER	; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Rachel Dresbeck for her time and effort in editing the manuscript. This research was supported by 5R01CA136683-03 Identifying Agents which Restored BRM expression.	Albergaria A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2327; Avvakumov N, 2007, ONCOGENE, V26, P5395, DOI 10.1038/sj.onc.1210608; Avvakumov Nikita, 2007, Subcell Biochem, V41, P295; Balch C, 2005, FRONT BIOSCI-LANDMRK, V10, P1897, DOI 10.2741/1668; Berger AH, 2011, NATURE, V476, P163, DOI 10.1038/nature10275; Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Bilanges B, 2007, ONCOGENE, V26, P5973, DOI 10.1038/sj.onc.1210431; Bock VL, 2011, BRIT J DERMATOL, V164, P1221, DOI 10.1111/j.1365-2133.2011.10267.x; Bourachot B, 2003, EMBO J, V22, P6505, DOI 10.1093/emboj/cdg621; Brose MS, 2002, CANCER RES, V62, P6997; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Bultman SJ, 2008, ONCOGENE, V27, P460, DOI 10.1038/sj.onc.1210664; Califano R, 2012, DRUGS, V72, P28, DOI 10.2165/1163012-S0-000000000-00000; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; de Castro-Carpeno J, 2008, CLIN TRANSL ONCOL, V10, P6, DOI 10.1007/s12094-008-0147-3; DelBove J, 2011, EPIGENETICS-US, V6, P1444, DOI 10.4161/epi.6.12.18492; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Duong V, 2008, MOL CANCER RES, V6, P1908, DOI 10.1158/1541-7786.MCR-08-0299; Dwarakanath BS, 2008, INDIAN J MED RES, V128, P13; Fukuoka J, 2004, CLIN CANCER RES, V10, P4314, DOI 10.1158/1078-0432.CCR-03-0489; Gervais C, 2008, LEUKEMIA, V22, P1567, DOI 10.1038/leu.2008.128; Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514; Glaros S, 2008, CANCER RES, V68, P3689, DOI 10.1158/0008-5472.CAN-07-6652; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Gordon VS, 2010, ONCOL REV, V4, P89, DOI 10.1007/s12156-010-0040-5; Gramling S, 2011, ONCOGENE, V30, P3289, DOI 10.1038/onc.2011.80; Gramling S, 2011, LETT DRUG DES DISCOV, V8, P93, DOI 10.2174/157018011793663840; Gregoire S, 2006, J BIOL CHEM, V281, P4423, DOI 10.1074/jbc.M509471200; Gregoire S, 2007, MOL CELL BIOL, V27, P1280, DOI 10.1128/MCB.00882-06; Haber DA, 2005, COLD SH Q B, V70, P419, DOI 10.1101/sqb.2005.70.043; Haberland M, 2007, MOL CELL BIOL, V27, P518, DOI 10.1128/MCB.01415-06; Hess-Stumpp H, 2005, EUR J CELL BIOL, V84, P109, DOI 10.1016/j.ejcb.2004.12.010; Ho IC, 2007, CELL MOL IMMUNOL, V4, P15; Itoh T, 2008, BIOCHEM BIOPH RES CO, V366, P827, DOI 10.1016/j.bbrc.2007.12.026; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Konofaos P, 2006, SURG ONCOL, V15, P257, DOI 10.1016/j.suronc.2007.03.004; Lamonica JM, 2006, BLOOD, V108, P3736, DOI 10.1182/blood-2006-07-032847; LAURENT BC, 1993, COLD SPRING HARB SYM, V58, P257, DOI 10.1101/SQB.1993.058.01.030; Lee JH, 2005, MOL CELLS, V19, P289; Liu G, 2011, ONCOGENE, V30, P3295, DOI 10.1038/onc.2011.81; Ma KW, 2005, MOL CELL BIOL, V25, P3575, DOI 10.1128/MCB.25.9.3575-3582.2005; Mai A, 2005, MED RES REV, V25, P261, DOI 10.1002/med.20024; Maneechotesuwan K, 2007, J IMMUNOL, V178, P2491, DOI 10.4049/jimmunol.178.4.2491; Marijon H, 2011, B CANCER, V98, P1011, DOI 10.1684/bdc.2011.1379; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Medina PP, 2004, GENE CHROMOSOME CANC, V41, P170, DOI 10.1002/gcc.20068; Milde T, 2010, CLIN CANCER RES, V16, P3240, DOI 10.1158/1078-0432.CCR-10-0395; Mizutani T, 2002, J BIOL CHEM, V277, P15859, DOI 10.1074/jbc.M112421200; Moore SDP, 2004, CANCER RES, V64, P5570, DOI 10.1158/0008-5472.CAN-04-0050; Moreno DA, 2010, BRIT J HAEMATOL, V150, P665, DOI 10.1111/j.1365-2141.2010.08301.x; Muchardt C, 1999, SEMIN CELL DEV BIOL, V10, P189, DOI 10.1006/scdb.1999.0300; Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223; Muchardt C, 1999, J MOL BIOL, V293, P187, DOI 10.1006/jmbi.1999.2999; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Nakada S, 2001, ANTICANCER RES, V21, P167; Oh J, 2008, J BIOL CHEM, V283, P11924, DOI 10.1074/jbc.M705401200; Ozawa Y, 2001, BLOOD, V98, P2116, DOI 10.1182/blood.V98.7.2116; Petrie K, 2003, J BIOL CHEM, V278, P16059, DOI 10.1074/jbc.M212935200; Potthoff MJ, 2007, DEVELOPMENT, V134, P4131, DOI 10.1242/dev.008367; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Reisman DN, 2005, APPL IMMUNOHISTO M M, V13, P66, DOI 10.1097/00129039-200503000-00011; Reisman DN, 2003, CANCER RES, V63, P560; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Rodriguez-Nieto S, 2011, HUM MUTAT, V32, pE1999, DOI 10.1002/humu.21415; Sakurai K, 2011, CANCER RES, V71, P1680, DOI 10.1158/0008-5472.CAN-10-2345; Skov V, 2012, LEUKEMIA LYMPHOMA, V53, P123, DOI 10.3109/10428194.2011.597905; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Tagliabue E, 2010, EXPERT OPIN BIOL TH, V10, P711, DOI 10.1517/14712591003689972; Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605; Wang WD, 1998, P NATL ACAD SCI USA, V95, P492, DOI 10.1073/pnas.95.2.492; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Weichert W, 2009, CANCER LETT, V280, P168, DOI 10.1016/j.canlet.2008.10.047; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Xu Y, 2007, J BIOL CHEM, V282, P37429, DOI 10.1074/jbc.M706039200; Yamamichi N, 2005, ONCOGENE, V24, P5471, DOI 10.1038/sj.onc.1208716; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang XH, 2004, MOL CELL BIOL, V24, P5106, DOI 10.1128/MCB.24.12.5106-5118.2004; Zheng Rena, 2010, Genes Cancer, V1, P1178, DOI 10.1177/1947601911404223	85	38	40	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					653	664		10.1038/onc.2012.613	http://dx.doi.org/10.1038/onc.2012.613			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23524580				2022-12-17	WOS:000331125100013
J	Liu, Y; Raheja, R; Yeh, N; Ciznadija, D; Pedraza, AM; Ozawa, T; Hukkelhoven, E; Erdjument-Bromage, H; Tempst, P; Gauthier, NP; Brennan, C; Holland, EC; Koff, A				Liu, Y.; Raheja, R.; Yeh, N.; Ciznadija, D.; Pedraza, A. M.; Ozawa, T.; Hukkelhoven, E.; Erdjument-Bromage, H.; Tempst, P.; Gauthier, N. P.; Brennan, C.; Holland, E. C.; Koff, A.			TRIM3, a tumor suppressor linked to regulation of p21(Waf1/Cip1)	ONCOGENE			English	Article						glioma; p21; PDGF; stem/progenitor; TRIM3	NEURAL STEM-CELLS; INTEGRATED GENOMIC ANALYSIS; SELF-RENEWAL; CYCLIN D1; ABERRANT EXPRESSION; MALIGNANT GLIOMA; MOUSE MODELS; IN-VIVO; CANCER; DROSOPHILA	The TRIM family of genes is largely studied because of their roles in development, differentiation and host cell antiviral defenses; however, roles in cancer biology are emerging. Loss of heterozygosity of the TRIM3 locus in similar to 20% of human glioblastomas raised the possibility that this NHL-domain containing member of the TRIM gene family might be a mammalian tumor suppressor. Consistent with this, reducing TRIM3 expression increased the incidence of and accelerated the development of platelet-derived growth factor -induced glioma in mice. Furthermore, TRIM3 can bind to the cdk inhibitor p21(WAF1/CIP1). Thus, we conclude that TRIM3 is a tumor suppressor mapping to chromosome 11p15.5 and that it might block tumor growth by sequestering p21 and preventing it from facilitating the accumulation of cyclin D1-cdk4.	[Liu, Y.; Raheja, R.; Yeh, N.; Ciznadija, D.; Hukkelhoven, E.; Erdjument-Bromage, H.; Tempst, P.; Koff, A.] Mem Sloan Kettering Canc Ctr, Programs Mol Biol, New York, NY 10021 USA; [Gauthier, N. P.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Koff, A (corresponding author), Mem Sloan Kettering Canc Ctr, Programs Mol Biol, 1275 York Ave, New York, NY 10021 USA.	a-koff@ski.mskcc.org	Brennan, Cameron/R-7082-2019	Brennan, Cameron/0000-0003-4064-8891; Koff, Andrew/0000-0003-3271-3067; Tempst, Paul/0000-0002-6680-3987; Erdjument-Bromage, Hediye/0000-0003-0224-3594	Memorial Sloan-Kettering Cancer Center Core Grant [P30CA08748]; Brain Tumor Center; Golfers Against Cancer Foundation;  [CA89563]; NATIONAL CANCER INSTITUTE [R01CA089563, P30CA008748] Funding Source: NIH RePORTER	Memorial Sloan-Kettering Cancer Center Core Grant; Brain Tumor Center; Golfers Against Cancer Foundation; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Marta Kovatcheva and other members of the Koff lab, Pengbo Zhou (Cornell University Medical School), John Petrini (MSKCC) and Hakim Djaballah (MSKCC) for comments on this manuscript, and Max Chan Liu (The Browning School) for his assistance with Id1 staining and image acquisition. This work was supported by the Memorial Sloan-Kettering Cancer Center Core Grant (P30CA08748) and grants to Andrew Koff (CA89563). Funding was also provided by the Brain Tumor Center (YL, DC) and the Golfers Against Cancer Foundation (AK).	Aaltomaa S, 1999, PROSTATE, V39, P8; Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Arama E, 2000, ONCOGENE, V19, P3706, DOI 10.1038/sj.onc.1203706; Bae DS, 2001, GYNECOL ONCOL, V81, P341, DOI 10.1006/gyno.2001.6196; Baretton GB, 1999, BRIT J CANCER, V80, P546, DOI 10.1038/sj.bjc.6690390; Barrett LE, 2012, CANCER CELL, V21, P11, DOI 10.1016/j.ccr.2011.11.025; Bello B, 2006, DEVELOPMENT, V133, P2639, DOI 10.1242/dev.02429; Betschinger J, 2006, CELL, V124, P1241, DOI 10.1016/j.cell.2006.01.038; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Boulay JL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-71; Bowman SK, 2008, DEV CELL, V14, P535, DOI 10.1016/j.devcel.2008.03.004; Brennan C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007752; Broxmeyer HE, 2012, ANN NY ACAD SCI, V1266, P151, DOI 10.1111/j.1749-6632.2012.06509.x; Ceccarelli C, 2001, INT J CANCER, V95, P128; Cerami E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008918; Charles N, 2010, CELL STEM CELL, V6, P141, DOI 10.1016/j.stem.2010.01.001; Charles NA, 2010, CELL STEM CELL, V6, P6, DOI 10.1016/j.stem.2009.12.005; Chen J, 2012, CELL, V149, P36, DOI 10.1016/j.cell.2012.03.009; Cheung CC, 2010, P NATL ACAD SCI USA, V107, P11883, DOI 10.1073/pnas.1006529107; Cheung TH, 2001, CANCER LETT, V172, P93, DOI 10.1016/S0304-3835(01)00624-3; Choksi SP, 2006, DEV CELL, V11, P775, DOI 10.1016/j.devcel.2006.09.015; Ciznadija D, 2011, CANCER RES, V71, P6174, DOI 10.1158/0008-5472.CAN-11-1031; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Ferrandina G, 2000, INT J ONCOL, V17, P1231; Gao H, 2004, P NATL ACAD SCI USA, V101, P17204, DOI 10.1073/pnas.0407693101; Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139; Herranz H, 2010, EMBO J, V29, P1688, DOI 10.1038/emboj.2010.69; Hukkelhoven E, 2012, J BIOL CHEM, V287, P38523, DOI 10.1074/jbc.M112.366542; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; James MK, 2008, MOL CELL BIOL, V28, P498, DOI 10.1128/MCB.02171-06; Januschke J, 2008, ONCOGENE, V27, P6994, DOI 10.1038/onc.2008.349; Katz AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032453; Lee CY, 2006, DEV CELL, V10, P441, DOI 10.1016/j.devcel.2006.01.017; Lee J, 2009, EXP MOL MED, V41, P765, DOI 10.3858/emm.2009.41.11.102; Liu Y, 2007, EMBO J, V26, P4683, DOI 10.1038/sj.emboj.7601886; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; Nisole S, 2005, NAT REV MICROBIOL, V3, P799, DOI 10.1038/nrmicro1248; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Reichert H, 2011, RESULTS PROBL CELL D, V53, P529, DOI 10.1007/978-3-642-19065-0_21; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Sarbia M, 2000, Recent Results Cancer Res, V155, P15; Schwamborn JC, 2009, CELL, V136, P913, DOI 10.1016/j.cell.2008.12.024; See WL, 2010, ONCOGENE, V29, P1720, DOI 10.1038/onc.2009.465; See WL, 2010, CELL CYCLE, V9, P1562, DOI 10.4161/cc.9.8.11259; Shih AH, 2004, CANCER RES, V64, P4783, DOI 10.1158/0008-5472.CAN-03-3831; Taylor BS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003179; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Viglietto G, 2002, CELL CYCLE, V1, P394, DOI 10.4161/cc.1.6.263; Vitucci M, 2011, BRIT J CANCER, V104, P545, DOI 10.1038/sj.bjc.6606031; Winters ZE, 2003, BREAST CANCER RES, V5, pR242, DOI 10.1186/bcr654; Wulczyn FG, 2010, ADV EXP MED BIOL, V700, P85, DOI 10.1007/978-1-4419-7823-3_9; Xu XLL, 2009, CELL, V137, P1018, DOI 10.1016/j.cell.2009.03.051; Yan Q, 2005, MOL BIOL CELL, V16, P2470, DOI 10.1091/mbc.E04-11-1014; Yeh N, 2007, MOL CELL BIOL, V27, P5161, DOI 10.1128/MCB.02431-06	55	38	41	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					308	315		10.1038/onc.2012.596	http://dx.doi.org/10.1038/onc.2012.596			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318451	Green Accepted			2022-12-17	WOS:000330214000005
J	Pandolfi, S; Montagnani, V; Penachioni, JY; Vinci, MC; Olivito, B; Borgognoni, L; Stecca, B				Pandolfi, S.; Montagnani, V.; Penachioni, J. Y.; Vinci, M. C.; Olivito, B.; Borgognoni, L.; Stecca, B.			WIP1 phosphatase modulates the Hedgehog signaling by enhancing GLI1 function	ONCOGENE			English	Article						Hedgehog; GLI1; WIP1; melanoma; xenograft; self-renewal; cancer stem cells	BASAL-CELL CARCINOMA; STEM-CELL; WILD-TYPE; PROTEIN PHOSPHATASE; SELF-RENEWAL; IN-VITRO; WIP1-DEPENDENT REGULATION; TUMOR-SUPPRESSOR; POOR-PROGNOSIS; HUMAN HOMOLOG	The Hedgehog-GLI (HH-GLI) signaling plays a critical role in controlling growth and tissue patterning during embryogenesis and is implicated in a variety of human malignancies, including those of the skin. Phosphorylation events have been shown to regulate the activity of the GLI transcription factors, the final effectors of the HH-GLI signaling pathway. Here, we show that WIP1 (or PPM1D), an oncogenic phosphatase amplified/overexpressed in several types of human cancer, is a positive modulator of the HH signaling. Mechanistically, WIP1 enhances the function of GLI1 by increasing its transcriptional activity, nuclear localization and protein stability, but not of GLI2 nor GLI3. We also find that WIP1 and GLI1 are in a complex. Modulation of the transcriptional activity of GLI1 by WIP1 depends on the latter's phosphatase activity and, remarkably, does not require p53, a known WIP1 target. Functionally, we find that WIP1 is required for melanoma and breast cancer cell proliferation and self-renewal in vitro and melanoma xenograft growth induced by activation of the HH signaling. Pharmacological blockade of the HH pathway with the SMOOTHENED antagonist cyclopamine acts synergistically with inhibition of WIP1 in reducing growth of melanoma and breast cancer cells in vitro. Overall, our data uncover a role for WIP1 in modulating the activity of GLI1 and in sustaining cancer cell growth and cancer stem cell self-renewal induced by activation of the HH pathway. These findings open a novel therapeutic approach for human melanomas and, possibly, other cancer types expressing WIP1 and with activated HH pathway.	[Pandolfi, S.; Montagnani, V.; Penachioni, J. Y.; Vinci, M. C.; Stecca, B.] Ist Toscani Tumori CRL ITT, Core Res Lab, Tumor Cell Biol Lab, I-50134 Florence, Italy; [Olivito, B.] Anna Meyer Childrens Hosp, Dept Pediat, Immunol Unit, Florence, Italy; [Borgognoni, L.] Ist Toscani Tumori, SM Annunziata Hosp, Reg Melanoma Referral Ctr, Plast Surg Unit, Florence, Italy	ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; ISPRO Istituto per lo studio, la prevenzione e la rete oncologica	Stecca, B (corresponding author), Ist Toscani Tumori CRL ITT, Core Res Lab, Tumor Cell Biol Lab, Vle Morgagni 50, I-50134 Florence, Italy.	barbara.stecca@ittumori.it	Vinci, Maria Cristina/E-7401-2016; Borgognoni, Lorenzo/X-1981-2019; Stecca, Barbara/J-7209-2016	Vinci, Maria Cristina/0000-0001-6323-147X; Borgognoni, Lorenzo/0000-0002-3571-0366; Stecca, Barbara/0000-0003-1197-1622; OLIVITO, BIAGIO/0000-0002-4479-0708	Associazione Italiana per la Ricerca sul Cancro (AIRC) [9566]; Regional Health Research Program; Fondazione Cassa di Risparmio di Firenze; AIRC fellowship	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Regional Health Research Program; Fondazione Cassa di Risparmio di Firenze(Fondazione Cassa Risparmio Firenze); AIRC fellowship(Fondazione AIRC per la ricerca sul cancro)	We thank G Del Sal, A Ruiz i Altaba, L Luzzatto for helpful comments on the paper and discussion. We are grateful to G Del Sal (Laboratorio Nazionale CIB, Padriciano, Italy) for HCT116 p53wt and p53ko cells, A Ruiz i Altaba (University of Geneva, Geneva, Switzerland), H Sasaki (NCCRI, Tokyo, Japan), RH Medema (University of Utrecht, Utrecht, The Netherlands) for plasmids, G Gerlini (S Maria Annunziata Hospital, Florence, Italy) for help in obtaining samples, E Rovida (University of Florence, Florence, Italy) for assistance with confocal microscopy. This work was supported by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC, 9566), Regional Health Research Program 2009 and Fondazione Cassa di Risparmio di Firenze to BS. SP was supported by AIRC fellowship.	Abe Y, 2008, P NATL ACAD SCI USA, V105, P4838, DOI 10.1073/pnas.0712216105; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Castellino RC, 2008, J NEURO-ONCOL, V86, P245, DOI 10.1007/s11060-007-9470-8; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; Cha H, 2010, CANCER RES, V70, P4112, DOI 10.1158/0008-5472.CAN-09-4244; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Choi J, 2002, MOL CELL BIOL, V22, P1094, DOI 10.1128/MCB.22.4.1094-1105.2002; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Das S, 2009, J BIOL CHEM, V284, P22888, DOI 10.1074/jbc.M109.021949; Demidov ON, 2007, ONCOGENE, V26, P2502, DOI 10.1038/sj.onc.1210032; Demidov ON, 2007, CELL STEM CELL, V1, P180, DOI 10.1016/j.stem.2007.05.020; Dennler S, 2007, CANCER RES, V67, P6981, DOI 10.1158/0008-5472.CAN-07-0491; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Doucette TA, 2012, NEUROSURGERY, V70, P1003, DOI 10.1227/NEU.0b013e31823e5332; Eberl M, 2012, EMBO MOL MED, V4, P218, DOI 10.1002/emmm.201100201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hayashi R, 2011, BIOCHEMISTRY-US, V50, P4537, DOI 10.1021/bi101949t; Hershko T, 2006, J BIOL CHEM, V281, P31309, DOI 10.1074/jbc.M601758200; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Huntzicker EG, 2006, GENE DEV, V20, P276, DOI 10.1101/gad.1380906; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jia H, 2009, DEVELOPMENT, V136, P307, DOI 10.1242/dev.030015; Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010; Jin ZG, 2011, J BIOL CHEM, V286, P36171, DOI 10.1074/jbc.M111.274761; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kasper M, 2006, MOL CELL BIOL, V26, P6283, DOI 10.1128/MCB.02317-05; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Krauss S, 2008, CANCER RES, V68, P4658, DOI 10.1158/0008-5472.CAN-07-6174; Krauss S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007471; Lai K, 2004, BIOPHYS J, V86, P2748, DOI 10.1016/S0006-3495(04)74328-3; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Le Guezennec X, 2012, CELL METAB, V16, P68, DOI 10.1016/j.cmet.2012.06.003; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Liang CH, 2012, BRAIN RES, V1444, P65, DOI 10.1016/j.brainres.2011.12.052; Lindqvist A, 2009, EMBO J, V28, P3196, DOI 10.1038/emboj.2009.246; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Low JA, 2010, J CLIN ONCOL, V28, P5321, DOI 10.1200/JCO.2010.27.9943; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2008, CANCER METAST REV, V27, P123, DOI 10.1007/s10555-008-9127-x; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; Nannenga B, 2006, MOL CARCINOGEN, V45, P594, DOI 10.1002/mc.20195; Ng JMY, 2011, NAT REV CANCER, V11, P493, DOI 10.1038/nrc3079; Nolan-Stevaux O, 2009, GENE DEV, V23, P24, DOI 10.1101/gad.1753809; Pan Y, 2007, J BIOL CHEM, V282, P10846, DOI 10.1074/jbc.M608599200; Parssinen J, 2008, CANCER GENET CYTOGEN, V182, P33, DOI 10.1016/j.cancergencyto.2007.12.013; Peacock CD, 2007, P NATL ACAD SCI USA, V104, P4048, DOI 10.1073/pnas.0611682104; Rayter S, 2008, ONCOGENE, V27, P1036, DOI 10.1038/sj.onc.1210729; Roessler E, 2005, HUM MOL GENET, V14, P2181, DOI 10.1093/hmg/ddi222; Rohatgi R, 2007, NAT CELL BIOL, V9, P1005, DOI 10.1038/ncb435; Rohatgi R, 2007, SCIENCE, V317, P372, DOI 10.1126/science.1139740; Rorick AM, 2007, DEV BIOL, V302, P477, DOI 10.1016/j.ydbio.2006.10.011; Santini R, 2012, STEM CELLS, V30, P1808, DOI 10.1002/stem.1160; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Stecca B, 2010, J MOL CELL BIOL, V2, P84, DOI 10.1093/jmcb/mjp052; Stecca B, 2009, EMBO J, V28, P663, DOI 10.1038/emboj.2009.16; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Teglund S, 2010, BBA-REV CANCER, V1805, P181, DOI 10.1016/j.bbcan.2010.01.003; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608; Varnat F, 2009, EMBO MOL MED, V1, P338, DOI 10.1002/emmm.200900039; Wang Y, 2012, CANCER CELL, V21, P374, DOI 10.1016/j.ccr.2011.12.028; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yamaguchi H, 2006, BIOCHEMISTRY-US, V45, P13193, DOI 10.1021/bi061356b; Zhang XN, 2010, CANCER RES, V70, P7176, DOI 10.1158/0008-5472.CAN-10-0697; Zhu YH, 2009, STEM CELLS, V27, P1433, DOI 10.1002/stem.65	75	38	39	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2013	32	40					4737	4747		10.1038/onc.2012.502	http://dx.doi.org/10.1038/onc.2012.502			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23146903				2022-12-17	WOS:000325274700002
J	Lin, YH; Liao, CJ; Huang, YH; Wu, MH; Chi, HC; Wu, SM; Chen, CY; Tseng, YH; Tsai, CY; Chung, IH; Wu, TI; Tsai, MM; Lin, CD; Lin, KH				Lin, Y-H; Liao, C-J; Huang, Y-H; Wu, M-H; Chi, H-C; Wu, S-M; Chen, C-Y; Tseng, Y-H; Tsai, C-Y; Chung, I-H; Wu, T-I; Tsai, M-M; Lin, C. D.; Lin, K-H			Thyroid hormone receptor represses miR-17 expression to enhance tumor metastasis in human hepatoma cells	ONCOGENE			English	Article						thyroid hormone; microRNA; p-AKT; matrix metalloproteinases-3; hepatocellular carcinoma	BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; NEGATIVE REGULATION; DOWN-REGULATION; CHROMOSOME 13Q; PROLIFERATION; INVASION; GENES; METALLOPROTEINASES; ACTIVATION	MicroRNAs (miRNAs) are thought to control tumor metastasis through direct interactions with target genes. Thyroid hormone (T-3) and its receptor (TR) are involved in cell growth and cancer progression. However, the issue of whether miRNAs participate in T-3/TR-mediated tumor migration is yet to be established. In the current study, we demonstrated that T-3/TR negatively regulates mature miR-17 transcript expression, both in vitro and in vivo. Luciferase reporter and chromatin immunoprecipitation (ChIP) assays localized the regions responding to TR-mediated repression to positions -2234/-2000 of the miR-17 promoter sequence. Overexpression of miR-17 markedly inhibited cell migration and invasion in vitro and in vivo, mediated via suppression of matrix metalloproteinases (MMP)-3. Moreover, p-AKT expression was increased in miR-17-knockdown cells that led to enhanced cell invasion, which was blocked by LY294002. Notably, low miR-17 expression was evident in highly metastatic cells. The cell migration ability was increased by T3, but partially reduced upon miR-17 overexpression. Notably, TR alpha 1 was frequently upregulated in hepatocellular carcinoma (HCC) samples and associated with low overall survival (P = 0.023). miR-17 expression was significantly negatively associated with TRa1 (P = 0.033) and MMP3 (P = 0.043) in HCC specimens. Data from our study suggest that T-3/TR, miR-17, p-AKT and MMP3 activities are interlinked in the regulation of cancer cell metastasis.	[Lin, Y-H; Liao, C-J; Wu, M-H; Chi, H-C; Wu, S-M; Chen, C-Y; Tseng, Y-H; Tsai, C-Y; Chung, I-H; Wu, T-I; Lin, K-H] Chang Gung Univ, Coll Med, Dept Biochem, Tao Yuan 333, Taiwan; [Huang, Y-H] Chang Gung Mem Hosp, Dept Hepatogastroenterol, Liver Res Ctr, Linkou, Taiwan; [Tsai, M-M] Chang Gung Univ Sci & Technol, Dept Nursing, Tao Yuan, Taiwan; [Lin, C. D.] Pacific Union Coll, Premed Program, Angwin, CA USA	Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University of Science & Technology	Lin, KH (corresponding author), Chang Gung Univ, Coll Med, Dept Biochem, 259 Wen Hwa 1 Rd, Tao Yuan 333, Taiwan.	khlin@mail.cgu.edu.tw			Chang-Gung University, Taoyuan, Taiwan [CMRPD 34013, NMRP 140511]; National Science Council of the Republic of China [NSC 94-2320-B-182-052, NSC 98-2312-B-182A-001-MY3]	Chang-Gung University, Taoyuan, Taiwan; National Science Council of the Republic of China(Ministry of Science and Technology, Taiwan)	This work was supported by grants from Chang-Gung University, Taoyuan, Taiwan (CMRPD 34013, NMRP 140511) and from the National Science Council of the Republic of China (NSC 94-2320-B-182-052, NSC 98-2312-B-182A-001-MY3).	Barrera-Hernandez G, 1999, ENDOCRINOLOGY, V140, P5267, DOI 10.1210/en.140.11.5267; Bramhall SR, 1996, BRIT J CANCER, V73, P972, DOI 10.1038/bjc.1996.190; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chang CC, 2013, ORAL ONCOL S, VS1040-8428, P00070; Chen CY, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.011270; Chen RN, 2008, ENDOCRINOLOGY, V149, P3817, DOI 10.1210/en.2007-0989; Cheng S Y, 2000, Rev Endocr Metab Disord, V1, P9, DOI 10.1023/A:1010052101214; Chi HC, 2012, CELL DEATH DIFFER, V19, P1802, DOI 10.1038/cdd.2012.58; Davis FB, 2006, CANCER RES, V66, P7270, DOI 10.1158/0008-5472.CAN-05-4365; Hall LC, 2008, J STEROID BIOCHEM, V109, P57, DOI 10.1016/j.jsbmb.2007.12.008; Huang YH, 2010, J CELL PHYSIOL, V222, P347, DOI 10.1002/jcp.21959; Huang Ya-Hui, 2008, Chang Gung Med J, V31, P325; Kress E, 2010, GASTROENTEROLOGY, V138, P1863, DOI 10.1053/j.gastro.2010.01.041; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Li HL, 2011, BREAST CANCER RES TR, V126, P565, DOI 10.1007/s10549-010-0954-4; Liao CH, 2010, ENDOCR-RELAT CANCER, V17, P99, DOI 10.1677/ERC-09-0050; Liao CJ, 2011, CANCER SCI, V102, P2255, DOI 10.1111/j.1349-7006.2011.02102.x; Lin KH, 2000, ENDOCRINOLOGY, V141, P2540, DOI 10.1210/en.141.7.2540; Lin YH, 2013, ONCOGENE, V32, P3904, DOI 10.1038/onc.2013.5; Lin YW, 1999, EUR J CANCER, V35, P1730, DOI 10.1016/S0959-8049(99)00205-1; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; Nakano K, 2004, BIOCHEM J, V378, P549, DOI 10.1042/BJ20031592; Nomura H, 1996, INT J CANCER, V69, P9, DOI 10.1002/(SICI)1097-0215(19960220)69:1<9::AID-IJC3>3.0.CO;2-8; Okamoto K, 2010, INTERNAL MED, V49, P887, DOI 10.2169/internalmedicine.49.3268; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; Shan SW, 2009, NAT CELL BIOL, V11, P1031, DOI 10.1038/ncb1917; Sze KMF, 2011, HEPATOLOGY, V53, P1558, DOI 10.1002/hep.24232; Thormeyer D, 1999, INT J MOL MED, V4, P351; Tsang YS, 1999, INT J CANCER, V83, P305, DOI 10.1002/(SICI)1097-0215(19991029)83:3<305::AID-IJC3>3.0.CO;2-D; Tsui KH, 2008, PROSTATE, V68, P610, DOI 10.1002/pros.20725; Wu SM, 2011, ONCOGENE, V30, P2057, DOI 10.1038/onc.2010.585; Xu CW, 2010, EUR J CANCER, V46, P2828, DOI 10.1016/j.ejca.2010.06.127; Yang F, 2010, HEPATOLOGY, V51, P1614, DOI 10.1002/hep.23566; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Yu ZR, 2008, J CELL BIOL, V182, P509, DOI 10.1083/jcb.200801079; Yu ZR, 2010, P NATL ACAD SCI USA, V107, P8231, DOI 10.1073/pnas.1002080107; Zhang MJ, 2011, MOL CELL BIOCHEM, V357, P387, DOI 10.1007/s11010-011-0909-z	38	38	39	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4509	4518		10.1038/onc.2013.309	http://dx.doi.org/10.1038/onc.2013.309			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23912452				2022-12-17	WOS:000324831300006
J	Ha, S; Iqbal, NJ; Mita, P; Ruoff, R; Gerald, WL; Lepor, H; Taneja, SS; Lee, P; Melamed, J; Garabedian, MJ; Logan, SK				Ha, S.; Iqbal, N. J.; Mita, P.; Ruoff, R.; Gerald, W. L.; Lepor, H.; Taneja, S. S.; Lee, P.; Melamed, J.; Garabedian, M. J.; Logan, S. K.			Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer	ONCOGENE			English	Article						PIM1; AR; phosphorylation; prostate cancer; hormone refractory	C-MYC; GROWTH-FACTOR; TUMOR-GROWTH; CYCLIN A1; KINASE; PROGRESSION; PROTEIN; CELLS; ACTIVATION; EXPRESSION	Integration of cellular signaling pathways with androgen receptor (AR) signaling can be achieved through phosphorylation of AR by cellular kinases. However, the kinases responsible for phosphorylating the AR at numerous sites and the functional consequences of AR phosphorylation are only partially understood. Bioinformatic analysis revealed AR serine 213 (S213) as a putative substrate for PIM1, a kinase overexpressed in prostate cancer. Therefore, phosphorylation of AR serine 213 by PIM1 was examined using a phosphorylation site-specific antibody. Wild-type PIM1, but not catalytically inactive PIM1, specifically phosphorylated AR but not an AR serine-to-alanine mutant (S213A). In vitro kinase assays confirmed that PIM1 can phosphorylate AR S213 in a ligand-independent manner and cell type-specific phosphorylation was observed in prostate cancer cell lines. Upon PIM1 overexpression, AR phosphorylation was observed in the absence of hormone and was further increased in the presence of hormone in LNCaP, LNCaP-abl and VCaP cells. Moreover, phosphorylation of AR was reduced in the presence of PIM kinase inhibitors. An examination of AR-mediated transcription showed that reporter gene activity was reduced in the presence of PIM1 and wild-type AR, but not S213A mutant AR. Androgen-mediated transcription of endogenous PSA, Nkx3.1 and IGFBP5 was also decreased in the presence of PIM1, whereas IL6, cyclin A1 and caveolin 2 were increased. Immunohistochemical analysis of prostate cancer tissue microarrays showed significant P-AR S213 expression that was associated with hormone refractory prostate cancers, likely identifying cells with catalytically active PIM1. In addition, prostate cancers expressing a high level of P-AR S213 were twice as likely to be from biochemically recurrent cancers. Thus, AR phosphorylation by PIM1 at S213 impacts gene transcription and is highly prevalent in aggressive prostate cancer.	[Ha, S.; Iqbal, N. J.; Mita, P.; Ruoff, R.; Lepor, H.; Taneja, S. S.; Garabedian, M. J.; Logan, S. K.] NYU, Sch Med, Dept Urol, New York, NY 10016 USA; [Ha, S.; Ruoff, R.; Logan, S. K.] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA; [Gerald, W. L.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Lee, P.; Melamed, J.] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; [Garabedian, M. J.] NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA	New York University; New York University; Memorial Sloan Kettering Cancer Center; New York University; New York University	Logan, SK (corresponding author), NYU, Sch Med, Dept Urol, 550 1st Ave,MSB 424, New York, NY 10016 USA.	susan.logan@nyumc.org	Melamed, Jonathan/AAV-3769-2020	Melamed, Jonathan/0000-0003-2844-7990; Logan, Susan/0000-0002-7904-5927; Iqbal, Niloy/0000-0003-0367-2569	New York University School of Medicine Department of Urology at New York University School of Medicine; NIH [R01CA112226, UO1 1U01CA149556-01]; NYU Department of Urology; DOD [PC094786, PC080010]; NATIONAL CANCER INSTITUTE [R01CA112226, U01CA149556] Funding Source: NIH RePORTER	New York University School of Medicine Department of Urology at New York University School of Medicine; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NYU Department of Urology; DOD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge funding from the New York University School of Medicine Department of Urology at New York University School of Medicine. This work was supported by NIH R01CA112226 (SL), funds from the NYU Department of Urology, DOD grant PC094786 for the Prostate Cancer Biorepository Network (PCBN, JM), DOD grant PC080010 (PL) and NIH UO1 1U01CA149556-01(PL).	Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Beharry Z, 2011, P NATL ACAD SCI USA, V108, P528, DOI 10.1073/pnas.1013214108; Bowen C, 2000, CANCER RES, V60, P6111; Chen SY, 2012, J BIOL CHEM, V287, P8571, DOI 10.1074/jbc.M111.325290; Chen WW, 2008, MOL ENDOCRINOL, V22, P1754, DOI 10.1210/me.2007-0219; Chen WW, 2005, MOL CANCER RES, V3, P443, DOI 10.1158/1541-7786.MCR-05-0007; Chun JY, 2009, CLIN CANCER RES, V15, P4815, DOI 10.1158/1078-0432.CCR-09-0640; Cibull TL, 2006, J CLIN PATHOL, V59, P285, DOI 10.1136/jcp.2005.027672; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; CUYPERS HT, 1984, CELL, V37, P141; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Drachenberg DE, 1999, PROSTATE, V41, P127, DOI 10.1002/(SICI)1097-0045(19991001)41:2<127::AID-PROS7>3.0.CO;2-H; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Garraway IP, 2010, PROSTATE, V70, P491, DOI 10.1002/pros.21083; Gould ML, 2010, PROSTATE, V70, P1609, DOI 10.1002/pros.21195; Gstaiger M, 2003, SCIENCE, V302, P1208, DOI 10.1126/science.1088401; Ha S, 2011, ENDOCR-RELAT CANCER, P11; Ha S, 2011, ENDOCR-RELAT CANCER, V18, P245, DOI 10.1530/ERC-10-0204; Hendriksen PJM, 2006, CANCER RES, V66, P5012, DOI 10.1158/0008-5472.CAN-05-3082; Kim J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-248; Kim O, 2004, ONCOGENE, V23, P1838, DOI 10.1038/sj.onc.1207304; Koike N, 2000, FEBS LETT, V467, P17, DOI 10.1016/S0014-5793(00)01105-4; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Michalaki V, 2004, BRIT J CANCER, V90, P2312, DOI 10.1038/sj.bjc.6601814; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Morishita D, 2008, CANCER RES, V68, P5076, DOI 10.1158/0008-5472.CAN-08-0634; Mumenthaler SM, 2009, MOL CANCER THER, V8, P2882, DOI 10.1158/1535-7163.MCT-09-0293; Nwachukwu JC, 2009, CANCER RES, V69, P3140, DOI 10.1158/0008-5472.CAN-08-3738; Payne H, 2011, UROL ONCOL-SEMIN ORI, V29, P593, DOI 10.1016/j.urolonc.2009.11.003; Qin JC, 2012, CELL STEM CELL, V10, P556, DOI 10.1016/j.stem.2012.03.009; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Song H, 2009, ONCOGENE, V28, P3307, DOI 10.1038/onc.2009.181; Su Y, 2011, ONCOGENE, V30, P3907, DOI 10.1038/onc.2011.97; Taneja SS, 2005, J BIOL CHEM, V280, P40916, DOI 10.1074/jbc.M508442200; Thompson J, 2003, LAB INVEST, V83, P1301, DOI 10.1097/01.LAB.0000087585.03162.A3; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; TWILLIE DA, 1995, UROLOGY, V45, P542, DOI 10.1016/S0090-4295(99)80034-X; Valdman A, 2004, PROSTATE, V60, P367, DOI 10.1002/pros.20064; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Wang J, 2010, ONCOGENE, V29, P2477, DOI 10.1038/onc.2010.10; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Ward RD, 2009, BIOFACTORS, V35, P528, DOI 10.1002/biof.66; Wegiel B, 2005, ONCOGENE, V24, P6385, DOI 10.1038/sj.onc.1208795; Wegiel B, 2008, JNCI-J NATL CANCER I, V100, P1022, DOI 10.1093/jnci/djn214; Wen Y, 2000, CANCER RES, V60, P6841; Xia ZP, 2009, J MED CHEM, V52, P74, DOI 10.1021/jm800937p; Xie Y, 2006, ONCOGENE, V25, P70, DOI 10.1038/sj.onc.1209058; Xie Y, 2008, J BIOL CHEM, V283, P3349, DOI 10.1074/jbc.M707773200; Xin L, 2006, P NATL ACAD SCI USA, V103, P7789, DOI 10.1073/pnas.0602567103; Zhou ZX, 2006, CANCER RES, V66, P7889, DOI 10.1158/0008-5472.CAN-06-0486; Zippo A, 2007, NAT CELL BIOL, V9, P932, DOI 10.1038/ncb1618	55	38	41	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					3992	4000		10.1038/onc.2012.412	http://dx.doi.org/10.1038/onc.2012.412			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	22986532	Green Accepted			2022-12-17	WOS:000323748100007
J	Malek, SN				Malek, S. N.			The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia	ONCOGENE			English	Review						CLL; genomic copy number aberrations; gene mutations	TELANGIECTASIA MUTATED GENE; TREATMENT-FREE SURVIVAL; TUMOR-SUPPRESSOR LOCUS; TERM-FOLLOW-UP; CHROMOSOME 13Q14; CLL PATIENTS; DISEASE PROGRESSION; CLONAL EVOLUTION; NOTCH1 MUTATIONS; TP53 MUTATION	Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and remains incurable with conventional chemotherapy treatment approaches. CLL as a disease entity is defined by a relatively parsimonious set of diagnostic criteria and therefore likely constitutes an umbrella term for multiple related illnesses. Of the enduring fundamental biological processes that affect the biology and clinical behavior of CLL, few are as central to the pathogenesis of CLL as recurrent acquired genomic copy number aberrations (aCNA) and recurrent gene mutations. Here, a state-of-the-art overview of the pathological anatomy of the CLL genome is presented, including detailed descriptions of the anatomy of aCNA and gene mutations. Data from SNP array profiling and large-scale sequencing of large CLL cohorts, as well as stimulated karyotyping, are discussed. This review is organized by discussions of the anatomy, underlying pathomechanisms and clinical significance of individual genomic lesions and recurrent gene mutations. Finally, gaps in knowledge regarding the biological and clinical effects of recurrent genomic aberrations or gene mutations on CLL are outlined to provide critical stimuli for future research.	Univ Michigan, Div Hematol & Oncol, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Malek, SN (corresponding author), Univ Michigan, Div Hematol & Oncol, Dept Internal Med, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	smalek@med.umich.edu			NIH; Leukemia and Lymphoma Society of America; Lymphoma Research Foundation; National Institutes of Health [R01 CA136537-01]; Translational Research Program of the Leukemia and Lymphoma Society of America; Scholars in Clinical Research Program of the Leukemia and Lymphoma Society of America; CLL collaborative grant from the Lymphoma Research Foundation; National Institutes of Health through the University of Michigan's Cancer Center Support Grant [5 P30 CA46592]; National Institutes of Health through the University of Michigan's Oncology Research Training Grant [T32 CA 009357-30]; NATIONAL CANCER INSTITUTE [R01CA136537, R01CA171972, P30CA046592, T32CA009357] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia and Lymphoma Society of America(Leukemia and Lymphoma Society); Lymphoma Research Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Translational Research Program of the Leukemia and Lymphoma Society of America; Scholars in Clinical Research Program of the Leukemia and Lymphoma Society of America; CLL collaborative grant from the Lymphoma Research Foundation; National Institutes of Health through the University of Michigan's Cancer Center Support Grant; National Institutes of Health through the University of Michigan's Oncology Research Training Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Dr Malek's work has been funded by the NIH, the Leukemia and Lymphoma Society of America and the Lymphoma Research Foundation. He has received honoraria from Roche and Teva.; This research is supported by the National Institutes of Health through R01 CA136537-01 (SM), the Translational Research Program of the Leukemia and Lymphoma Society of America (SM), the Scholars in Clinical Research Program of the Leukemia and Lymphoma Society of America (SM) and a CLL collaborative grant from the Lymphoma Research Foundation. This research is supported (in part) by the National Institutes of Health through the University of Michigan's Cancer Center Support Grant (5 P30 CA46592) and Oncology Research Training Grant (T32 CA 009357-30). I am grateful for services provided by the microarray core of the University of Michigan Comprehensive Cancer Center.	Augereau A, 2011, BLOOD, V118, P1316, DOI 10.1182/blood-2010-07-295774; Austen B, 2005, BLOOD, V106, P3175, DOI 10.1182/blood-2004-11-4516; Austen B, 2007, J CLIN ONCOL, V25, P5448, DOI 10.1200/JCO.2007.11.2649; Balatti V, 2012, BLOOD, V119, P329, DOI 10.1182/blood-2011-10-386144; Best OG, 2009, LEUKEMIA, V23, P212, DOI 10.1038/leu.2008.260; Braggio E, 2012, LEUKEMIA, V26, P1698, DOI 10.1038/leu.2012.14; Britt-Compton B, 2012, LEUKEMIA, V26, P826, DOI 10.1038/leu.2011.281; Brown JR, 2008, LEUKEMIA, V22, P1966, DOI 10.1038/leu.2008.222; Brown JR, 2012, LEUKEMIA, V26, P1710, DOI 10.1038/leu.2012.33; Brown JR, 2012, CLIN CANCER RES, V18, P3791, DOI 10.1158/1078-0432.CCR-11-2342; Brugat T, 2010, BLOOD, V116, P239, DOI 10.1182/blood-2009-12-257618; Bullrich F, 1996, BLOOD, V88, P3109, DOI 10.1182/blood.V88.8.3109.bloodjournal8883109; Bullrich F, 1999, CANCER RES, V59, P24; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Castro JE, 2009, LEUKEMIA, V23, P1779, DOI 10.1038/leu.2009.133; Cejkova S, 2009, EUR J HAEMATOL, V82, P133, DOI 10.1111/j.1600-0609.2008.01177.x; Dal Bo M, 2011, GENE CHROMOSOME CANC, V50, P633, DOI 10.1002/gcc.20885; Decker S, 2012, BLOOD, V119, P997, DOI 10.1182/blood-2011-06-359075; Del Giudice I, 2012, HAEMATOL-HEMATOL J, V97, P437, DOI 10.3324/haematol.2011.060129; Dicker F, 2009, LEUKEMIA, V23, P117, DOI 10.1038/leu.2008.274; Dicker F, 2006, BLOOD, V108, P3152, DOI 10.1182/blood-2006-02-005322; Dohner H, 1997, LEUKEMIA, V11, pS19; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; Dohner H, 1997, BLOOD, V89, P2516, DOI 10.1182/blood.V89.7.2516; Dreger P, 2010, BLOOD, V116, P2438, DOI 10.1182/blood-2010-03-275420; ELROUBY S, 1993, BLOOD, V82, P3452; Fabbri G, 2011, J EXP MED, V208, P1389, DOI 10.1084/jem.20110921; Fazi C, 2011, BLOOD, V118, P6618, DOI 10.1182/blood-2011-05-357251; Fegan C, 1995, LEUKEMIA, V9, P2003; GAHRTON G, 1980, BLOOD, V56, P640; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Gonzalez D, 2011, J CLIN ONCOL, V29, P2223, DOI 10.1200/JCO.2010.32.0838; Grubor V, 2009, BLOOD, V113, P1294, DOI 10.1182/blood-2008-05-158865; Gunnarsson R, 2010, LEUKEMIA, V24, P211, DOI 10.1038/leu.2009.187; Gunnarsson R, 2011, HAEMATOL-HEMATOL J, V96, P1161, DOI 10.3324/haematol.2010.039768; Haferlach C, 2007, LEUKEMIA, V21, P2442, DOI 10.1038/sj.leu.2404935; Hammarsund M, 2004, FEBS LETT, V556, P75, DOI 10.1016/S0014-5793(03)01371-1; Heerema NA, 2010, CANCER GENET CYTOGEN, V203, P134, DOI 10.1016/j.cancergencyto.2010.07.128; Herling M, 2009, BLOOD, V114, P4675, DOI 10.1182/blood-2009-03-208256; Herman SEM, 2011, BLOOD, V117, P6287, DOI 10.1182/blood-2011-01-328484; Hoellenriegel J, 2011, BLOOD, V118, P3603, DOI 10.1182/blood-2011-05-352492; Huh Y, 2011, AM J CLIN PATHOL, V135, P686, DOI 10.1309/AJCPOEFP3SLX6HXJ; Johnson GG, 2009, CANCER RES, V69, P5210, DOI 10.1158/0008-5472.CAN-09-0627; JULIUSSON G, 1990, NEW ENGL J MED, V323, P720, DOI 10.1056/NEJM199009133231105; Kalachikov S, 1997, GENOMICS, V42, P369, DOI 10.1006/geno.1997.4747; Kanduri M, 2010, BLOOD, V115, P296, DOI 10.1182/blood-2009-07-232868; Kapanadze B, 2000, GENOMICS, V70, P327, DOI 10.1006/geno.2000.6386; Kay NE, 2010, CANCER GENET CYTOGEN, V203, P161, DOI 10.1016/j.cancergencyto.2010.09.003; Kitamura E, 2000, ONCOGENE, V19, P5772, DOI 10.1038/sj.onc.1203978; Klein U, 2010, CANCER CELL, V17, P28, DOI 10.1016/j.ccr.2009.11.019; Knight SJL, 2012, LEUKEMIA, V26, P1564, DOI 10.1038/leu.2012.13; Kujawski L, 2008, BLOOD, V112, P1993, DOI 10.1182/blood-2007-07-099432; Lanasa MC, 2011, LEUKEMIA, V25, P1459, DOI 10.1038/leu.2011.117; Lehmann S, 2008, CANCER-AM CANCER SOC, V112, P1296, DOI 10.1002/cncr.23270; Lia M, 2012, BLOOD, V119, P2981, DOI 10.1182/blood-2011-09-381814; Lin TT, 2010, BLOOD, V116, P1899, DOI 10.1182/blood-2010-02-272104; LIU Y, 1995, BLOOD, V86, P1911, DOI 10.1182/blood.V86.5.1911.bloodjournal8651911; LIU Y, 1993, P NATL ACAD SCI USA, V90, P8697, DOI 10.1073/pnas.90.18.8697; Lopez C, 2012, GENE CHROMOSOME CANC, V51, P881, DOI 10.1002/gcc.21972; Lozanski G, 2012, LEUKEMIA LYMPHOMA, V53, P1743, DOI 10.3109/10428194.2012.668683; Mabuchi H, 2001, CANCER RES, V61, P2870; Malcikova J, 2009, BLOOD, V114, P5307, DOI 10.1182/blood-2009-07-234708; Malek S, ASCO ED BOOK 2010 RE, P263; Martin-Subero J, 2007, LEUKEMIA, V21, P1532, DOI 10.1038/sj.leu.2404695; Mayr C, 2006, BLOOD, V107, P742, DOI 10.1182/blood-2005-05-2093; Migliazza A, 2001, BLOOD, V97, P2098, DOI 10.1182/blood.V97.7.2098; Mohr J, 2011, BLOOD, V117, P1622, DOI 10.1182/blood-2010-08-300160; Mosca L, 2010, CLIN CANCER RES, V16, P5641, DOI 10.1158/1078-0432.CCR-10-0151; Muthusamy N, 2011, CANCER GENET-NY, V204, P77, DOI 10.1016/j.cancergen.2010.12.006; Neilson JR, 1997, LEUKEMIA, V11, P1929, DOI 10.1038/sj.leu.2400819; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Nguyen-Khac F, 2011, AM J BLOOD RES, V1, P13; Ouillette P, 2012, GENES CHROM IN PRESS; Ouillette P, 2008, CANCER RES, V68, P1012, DOI 10.1158/0008-5472.CAN-07-3105; Ouillette P, 2011, CLIN CANCER RES, V17, P6778, DOI 10.1158/1078-0432.CCR-11-0785; Ouillette P, 2011, BLOOD, V118, P3051, DOI 10.1182/blood-2010-12-327858; Ouillette P, 2010, CLIN CANCER RES, V16, P835, DOI 10.1158/1078-0432.CCR-09-2534; Palamarchuk A, 2010, BLOOD, V115, P3916, DOI 10.1182/blood-2009-10-249367; Parikh SA, 2011, BLOOD, V118, P2062, DOI 10.1182/blood-2011-01-329177; Parker H, 2011, LEUKEMIA, V25, P489, DOI 10.1038/leu.2010.288; PETERSON LC, 1992, GENE CHROMOSOME CANC, V4, P273, DOI 10.1002/gcc.2870040402; Pettitt AR, 2012, J CLIN ONCOL, V30, P1647, DOI 10.1200/JCO.2011.35.9695; Pfeifer D, 2007, BLOOD, V109, P1202, DOI 10.1182/blood-2006-07-034256; Ponader S, 2012, BLOOD, V119, P1182, DOI 10.1182/blood-2011-10-386417; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Put N, 2009, GENE CHROMOSOME CANC, V48, P843, DOI 10.1002/gcc.20691; Quesada V, 2012, NAT GENET, V44, P47, DOI 10.1038/ng.1032; Raveche ES, 2007, BLOOD, V109, P5079, DOI 10.1182/blood-2007-02-071225; Rigolin GM, 2012, BLOOD, V119, P2310, DOI 10.1182/blood-2011-11-395269; Roos G, 2008, BLOOD, V111, P2246, DOI 10.1182/blood-2007-05-092759; Rosenwald A, 2004, BLOOD, V104, P1428, DOI 10.1182/blood-2003-09-3236; Rossi D, 2012, BLOOD, V119, P2854, DOI 10.1182/blood-2011-12-395673; Rossi D, 2012, BLOOD, V119, P521, DOI 10.1182/blood-2011-09-379966; Rossi D, 2011, BLOOD, V118, P6904, DOI 10.1182/blood-2011-08-373159; Rossi D, 2009, CLIN CANCER RES, V15, P995, DOI 10.1158/1078-0432.CCR-08-1630; Rossi S, 2010, BLOOD, V116, P945, DOI 10.1182/blood-2010-01-263889; Saddler C, 2008, BLOOD, V111, P1584, DOI 10.1182/blood-2007-09-112698; Saiya-Cork K, 2011, CLIN CANCER RES, V17, P2679, DOI 10.1158/1078-0432.CCR-10-2058; Sampath D, 2012, BLOOD, V119, P1162, DOI 10.1182/blood-2011-05-351510; Schaffner C, 1999, BLOOD, V94, P748, DOI 10.1182/blood.V94.2.748.414k02_748_753; Shanafelt TD, 2008, J CLIN ONCOL, V26, pE5, DOI 10.1200/JCO.2008.16.7874; Shanafelt TD, 2006, J CLIN ONCOL, V24, P4634, DOI 10.1200/JCO.2006.06.9492; Shedden K, 2012, LEUKEMIA, V26, P1108, DOI 10.1038/leu.2011.361; Sorror ML, 2008, J CLIN ONCOL, V26, P4912, DOI 10.1200/JCO.2007.15.4757; Spaner DE, 2012, LEUKEMIA, V26, P1144, DOI 10.1038/leu.2011.329; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; STILGENBAUER S, 1993, BLOOD, V81, P2118; Stilgenbauer S, 2007, HAEMATOLOGICA, V92, P1242, DOI 10.3324/haematol.10720; Stilgenbauer S, 2009, J CLIN ONCOL, V27, P3994, DOI 10.1200/JCO.2008.21.1128; Tam CS, 2009, BLOOD, V114, P957, DOI 10.1182/blood-2009-03-210591; Trbusek M, 2011, J CLIN ONCOL, V29, P2703, DOI 10.1200/JCO.2011.34.7872; Tsimberidou AM, 2009, CANCER-AM CANCER SOC, V115, P373, DOI 10.1002/cncr.23993; UESHIMA Y, 1985, INT J CANCER, V36, P287, DOI 10.1002/ijc.1985.36.3.287; Van Den Neste E, 2007, LEUKEMIA, V21, P1715, DOI 10.1038/sj.leu.2404764; Visone R, 2009, BLOOD, V114, P3872, DOI 10.1182/blood-2009-06-229211; Wang LL, 2011, NEW ENGL J MED, V365, P2497, DOI 10.1056/NEJMoa1109016; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; Zainuddin N, 2011, LEUKEMIA RES, V35, P272, DOI 10.1016/j.leukres.2010.08.023; Zenz T, 2010, LEUKEMIA, V24, P2072, DOI 10.1038/leu.2010.208; Zenz T, 2008, BLOOD, V112, P3322, DOI 10.1182/blood-2008-04-154070; Zenz T, 2010, J CLIN ONCOL, V28, P4473, DOI 10.1200/JCO.2009.27.8762; Zenz T, 2009, BLOOD, V114, P2589, DOI 10.1182/blood-2009-05-224071; Zhang X, 2011, LEUKEMIA, V25, P1908, DOI 10.1038/leu.2011.163	124	38	39	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 6	2013	32	23					2805	2817		10.1038/onc.2012.411	http://dx.doi.org/10.1038/onc.2012.411			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WR	23001040	Green Accepted			2022-12-17	WOS:000320369100001
J	Xu, E; Zhang, J; Chen, X				Xu, E.; Zhang, J.; Chen, X.			MDM2 expression is repressed by the RNA-binding protein RNPC1 via mRNA stability	ONCOGENE			English	Article						RNA-binding proteins; RNPC1; MDM2; mRNA stability	ONCOPROTEIN MDM2; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; UBIQUITIN LIGASE; P53 FAMILY; DEGRADATION; TARGET; INHIBITION; DOMAIN; HUR	The RNA-binding protein (RBP) RNPC1 is a target of the p53 family and forms a feedback regulatory loop with the p53 family proteins. The murine double minute-2 (MDM2) oncogene, a key negative regulator of p53, has a critical role in a variety of fundamental cellular processes. MDM2 expression is found to be regulated via gene amplification, transcription, protein translation and protein stability. In the current study, we reported a novel regulation of MDM2 by RNPC1 via mRNA stability. Specifically, we found that overexpression of RNPC1 decreases, whereas knockdown or knockout of RNPC1 increases, the level of MDM2 transcript and protein independent of p53. To uncover the underlying mechanism, we found that RNPC1 is able to destabilize the MDM2 transcript via binding to multiple AU-/U-rich elements in MDM2 3'untranslated region (3'UTR). Consistent with this, we showed that RNPC1 inhibits expression of exogenous MDM2 from an expression vector as long as the vector contains an AU-/U-rich element from MDM2 3'UTR. Finally, we showed that the RNA-binding activity of RNPC1 is required for binding to MDM2 transcript and consequently, for inhibiting MDM2 expression. Together, we uncover a novel regulation of MDM2 by the RBP RNPC1 via mRNA stability. Oncogene (2013) 32, 2169-2178; doi:10.1038/onc.2012.238; published online 18 June 2012	[Xu, E.; Zhang, J.; Chen, X.] Univ Calif Davis, Dept Surg & Radiol Sci, Comparat Oncol Lab, Davis, CA 95616 USA	University of California System; University of California Davis	Zhang, J (corresponding author), Univ Calif Davis, Dept Surg & Radiol Sci, Comparat Oncol Lab, 2128 Tupper Hall, Davis, CA 95616 USA.	jinzhang@ucdavis.edu; xbchen@ucdavis.edu			NIH [R01 CA076069, R01 CA102188]; NATIONAL CANCER INSTITUTE [R01CA076069, R01CA102188] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported in part by NIH grants R01 CA076069 and R01 CA102188.	BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Bouska A, 2009, TRENDS BIOCHEM SCI, V34, P279, DOI 10.1016/j.tibs.2009.02.006; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; Cho SJ, 2010, NUCLEIC ACIDS RES, V38, P2256, DOI 10.1093/nar/gkp1229; Cho SJ, 2012, J BIOL CHEM, V287, P14535, DOI 10.1074/jbc.M111.326827; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Ghosh M, 2009, J CLIN INVEST, V119, P3530, DOI 10.1172/JCI38263; Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200; Harms KL, 2007, CANCER RES, V67, P3145, DOI 10.1158/0008-5472.CAN-06-4397; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jung YS, 2012, DNA REPAIR, V11, P177, DOI 10.1016/j.dnarep.2011.10.017; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Leveille N, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1519; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lukas J, 2001, CANCER RES, V61, P3212; LUNA RMD, 1995, NATURE, V378, P203; Miyamoto S, 2009, GENES CELLS, V14, P1241, DOI 10.1111/j.1365-2443.2009.01347.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Moumen A, 2007, DEVELOPMENT, V134, P1443, DOI 10.1242/dev.02820; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Peritz T, 2006, NAT PROTOC, V1, P577, DOI 10.1038/nprot.2006.82; Shu LM, 2006, GENE DEV, V20, P2961, DOI 10.1101/gad.1463306; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Xiao JN, 2011, EMBO J, V30, P5021, DOI 10.1038/emboj.2011.463; Xiong L, 2007, J CELL BIOL, V178, P995, DOI 10.1083/jcb.200703044; Xiong X, 2011, ONCOGENE, V30, P1798, DOI 10.1038/onc.2010.569; Yan W, MOL CELL BIOL; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhang J, 2013, ONCOGENE, V32, P61, DOI 10.1038/onc.2012.28; Zhang J, 2011, GENE DEV, V25, P1528, DOI 10.1101/gad.2069311; Zhang J, 2010, P NATL ACAD SCI USA, V107, P9614, DOI 10.1073/pnas.0912594107; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhu Y, 2009, MOL CELL, V35, P316, DOI 10.1016/j.molcel.2009.07.014	46	38	40	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2013	32	17					2169	2178		10.1038/onc.2012.238	http://dx.doi.org/10.1038/onc.2012.238			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22710720	Green Accepted			2022-12-17	WOS:000318062800006
J	Gupta, SK; Oommen, S; Aubry, MC; Williams, BP; Vlahakis, NE				Gupta, S. K.; Oommen, S.; Aubry, M-C; Williams, B. P.; Vlahakis, N. E.			Integrin alpha 9 beta 1 promotes malignant tumor growth and metastasis by potentiating epithelial-mesenchymal transition	ONCOGENE			English	Article						EMT; alpha 9 beta 1 integrin; lung cancer; metastasis; cell migration	UP-REGULATION; CANCER-CELLS; BETA-CATENIN; VEGF-C; SRC; EXPRESSION; MIGRATION; INVASION; GENE	The integrin alpha 9 beta 1 binds a number of extracellular matrix components to mediate cell adhesion, migration and tissue invasion. Although expressed in a variety of normal human cells including endothelium, it is also expressed in cancer cells. We have previously shown that alpha 9 beta 1 binds VEGF-A to facilitate angiogenesis, an important component of the tumor microenvironment. As alpha 9 beta 1 induces accelerated cancer cell migration, we wished to determine what role it played in cancer growth and metastasis. In this study, we show that alpha 9 beta 1 expression induces molecular changes consistent with epithelial-mesenchymal transition. In addition, we found that alpha 9 beta 1 forms a tri-partite protein complex with beta-catenin and E-cadherin, which dissociates following integrin activation and subsequent src and beta-catenin phosphorylation. These findings were consistent in cells in which: alpha 9 beta 1 was exogenously over-expressed, or when its expression was suppressed in cancer cells endogenously expressing alpha 9 beta 1. These in vitro results are biologically significant as alpha 9 beta 1-expressing cancer cells induce greater tumor growth and metastases in mice as compared to the cells without alpha 9 beta 1 expression or when integrin expression is suppressed. Furthermore, integrin alpha 9 beta 1 is expressed in primary human small cell lung cancer and patients having a high expression of alpha 9 beta 1 demonstrated significantly worse long-term survival compared with patients with low alpha 9 beta 1 expression. These findings highlight a novel mechanism of integrin alpha 9 beta 1 function in human cancer. Oncogene (2013) 32, 141 -150; doi:10.1038/onc.2012.41; published online 27 February 2012	[Gupta, S. K.; Oommen, S.; Williams, B. P.; Vlahakis, N. E.] Mayo Clin, Div Pulm & Crit Care Med, Thorac Dis Res Unit, Rochester, MN 55905 USA; [Aubry, M-C] Mayo Clin, Dept Lab Med & Anat Pathol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Vlahakis, NE (corresponding author), Mayo Clin, Div Pulm & Crit Care Med, Thorac Dis Res Unit, 200 1st St SW, Rochester, MN 55905 USA.	vlahakis.nicholas@gene.com			NHLBI [K08HL076455-05]; Mayo Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL076455] Funding Source: NIH RePORTER	NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Mayo Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Drs Dean Sheppard (UCSF, CA), Debabrata Mukhopadhyay and Edward Leof (Mayo Clinic, Rochester, MN, USA) for helpful discussions; Mark A. Schroeder for help with animal studies; Aaron Bungam for the lung tissue registry. This work was supported by NHLBI Research Grant K08HL076455-05 and Mayo Foundation Research Grants to NEV.	Aleshin A, 2010, NEOPLASIA, V12, P599, DOI 10.1593/neo.10328; Allen MD, 2011, J PATHOL, V223, P646, DOI 10.1002/path.2833; Alphonso A, 2009, NEOPLASIA, V11, P1264, DOI 10.1593/neo.91302; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bates RC, 2005, J CLIN INVEST, V115, P339, DOI 10.1172/JCI200523183; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bazigou E, 2009, DEV CELL, V17, P175, DOI 10.1016/j.devcel.2009.06.017; Borok Z, 2009, J CLIN INVEST, V119, P7, DOI 10.1172/JCI38084; Brown MC, 2008, NEURO-ONCOLOGY, V10, P968, DOI 10.1215/15228517-2008-047; Chattopadhyay N, 2003, J CELL BIOL, V163, P1351, DOI 10.1083/jcb.200306067; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Gupta SK, 2009, J CELL SCI, V122, P2043, DOI 10.1242/jcs.041632; HIBI K, 1994, ONCOGENE, V9, P611; Huang XZ, 2000, MOL CELL BIOL, V20, P5208, DOI 10.1128/MCB.20.14.5208-5215.2000; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jung H, 2008, ONCOGENE, V27, P2635, DOI 10.1038/sj.onc.1210914; Kajiya K, 2005, EMBO J, V24, P2885, DOI 10.1038/sj.emboj.7600763; Kim KK, 2009, J CLIN INVEST, V119, P213, DOI 10.1172/JCI36940; Kim S, 2010, CARCINOGENESIS, V31, P597, DOI 10.1093/carcin/bgq024; Kim Y, 2009, J CELL BIOL, V184, P309, DOI 10.1083/jcb.200806067; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lydolph MC, 2009, EXP CELL RES, V315, P3312, DOI 10.1016/j.yexcr.2009.09.022; Maschler S, 2005, ONCOGENE, V24, P2032, DOI 10.1038/sj.onc.1208423; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Nam JS, 2002, CLIN CANCER RES, V8, P2430; Oommen S, 2011, J BIOL CHEM, V286, P1083, DOI 10.1074/jbc.M110.175158; Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552; Rathinam R, 2010, CANCER METAST REV, V29, P223, DOI 10.1007/s10555-010-9211-x; Singh P, 2009, J INVEST DERMATOL, V129, P217, DOI 10.1038/jid.2008.201; Song LX, 2006, CANCER RES, V66, P5542, DOI 10.1158/0008-5472.CAN-05-4620; Takada Y, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-215; Timoshenko AV, 2007, BRIT J CANCER, V97, P1090, DOI 10.1038/sj.bjc.6603993; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; Vlahakis NE, 2005, J BIOL CHEM, V280, P4544, DOI 10.1074/jbc.M412816200; Vlahakis NE, 2007, J BIOL CHEM, V282, P15187, DOI 10.1074/jbc.M609323200; Voulgari A, 2006, BIOCHIM BIOPHYS ACTA, V1796, P75; Wheeler DL, 2009, ONCOLOGIST, V14, P667, DOI 10.1634/theoncologist.2009-0009	38	38	40	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2013	32	2					141	150		10.1038/onc.2012.41	http://dx.doi.org/10.1038/onc.2012.41			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22370635	Green Accepted			2022-12-17	WOS:000314075500002
J	Lee, MH; Na, H; Kim, EJ; Lee, HW; Lee, MO				Lee, M-H; Na, H.; Kim, E-J; Lee, H-W; Lee, M-O			Poly(ADP-ribosyl)ation of p53 induces gene-specific transcriptional repression of MTA1	ONCOGENE			English	Article						MTA1; p53; PARP-1; poly(ADP-ribose)ylation	DNA-DAMAGE RESPONSE; HEPATOCELLULAR-CARCINOMA; COVALENT POLY(ADP-RIBOSYL)ATION; UNMETHYLATED STATE; POLYMERASE PARP; EXPRESSION; BINDING; PROTEIN; METASTASIS; APOPTOSIS	The metastasis-associated protein 1 (MTA1) is overexpressed in various human cancers and is closely connected with aggressive phenotypes; however, little is known about the transcriptional regulation of the MTA1 gene. This study identified the MTA1 gene as a target of p53-mediated transrepression. The MTA1 promoter contains two putative p53 response elements (p53REs), which were repressed by the p53-inducing drug 5-fluorouracil (5-FU). Notably, 5-FU treatment decreased MTA1 expression only in p53 wild-type cells. p53 and histone deacetylases 1/2 were recruited, and acetylation of H3K9 was decreased on the promoter region including the p53REs after 5-FU treatment. Proteomics analysis of the p53 repressor complex, which was pulled down by the MTA1 promoter, revealed that the poly(ADP-ribose) polymerase 1 (PARP-1) was part of the complex. Interestingly, p53 was poly(ADP-ribose)ylated by PARP-1, and the p53-mediated transrepression of the MTA1 gene required poly(ADP-ribose)ylation of p53. In summary, we report a novel function for poly(ADP-ribose)ylation of p53 in the gene-specific regulation of the transcriptional mode of p53 on the promoter of MTA1. Oncogene (2012) 31, 5099-5107; doi:10.1038/onc.2012.2; published online 30 January 2012	[Lee, M-H; Na, H.; Kim, E-J; Lee, M-O] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; [Lee, M-H; Na, H.; Lee, M-O] Seoul Natl Univ, BioMAX Inst, Seoul 151742, South Korea; [Lee, H-W] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biochem, Seoul 120749, South Korea; [Lee, H-W] Yonsei Univ, Lab Anim Res Ctr, Seoul 120749, South Korea	Seoul National University (SNU); Seoul National University (SNU); Yonsei University; Yonsei University	Lee, MO (corresponding author), Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea.	molee@snu.ac.kr	Na, Hyelin/K-7303-2016	Na, Hyelin/0000-0002-9118-5084	NRF [2009-0080757]; SRC/ERC [R11-2007-107-01001-0]	NRF; SRC/ERC(European Research Council (ERC))	This work was supported by grants from the NRF (2009-0080757), and the SRC/ERC (R11-2007-107-01001-0).	Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Denslow SA, 2007, ONCOGENE, V26, P5433, DOI 10.1038/sj.onc.1210611; Esteve PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kai L, 2011, PROSTATE, V71, P268, DOI 10.1002/pros.21240; Kanai M, 2007, NAT CELL BIOL, V9, P1175, DOI 10.1038/ncb1638; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Kraus WL, 2008, CURR OPIN CELL BIOL, V20, P294, DOI 10.1016/j.ceb.2008.03.006; Krishnakumar R, 2010, MOL CELL, V39, P8, DOI 10.1016/j.molcel.2010.06.017; Kumari SR, 1998, CANCER RES, V58, P5075; Lewis BC, 2005, MOL CELL BIOL, V25, P1228, DOI 10.1128/MCB.25.4.1228-1237.2005; Li DQ, 2010, J BIOL CHEM, V285, P19802, DOI 10.1074/jbc.M109.085258; Li DQ, 2010, J BIOL CHEM, V285, P10044, DOI 10.1074/jbc.M109.079095; Li DQ, 2009, J BIOL CHEM, V284, P34545, DOI 10.1074/jbc.M109.056499; Li DQ, 2009, P NATL ACAD SCI USA, V106, P17493, DOI 10.1073/pnas.0908027106; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Lonn P, 2010, MOL CELL, V40, P521, DOI 10.1016/j.molcel.2010.10.029; Lu H, 2011, J BIOL CHEM, V286, P20335, DOI 10.1074/jbc.M110.215632; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Meek DW, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000950; Mehrotra P, 2011, J BIOL CHEM, V286, P1767, DOI 10.1074/jbc.M110.157768; Mendoza-Alvarez H, 2001, J BIOL CHEM, V276, P36425, DOI 10.1074/jbc.M105215200; Moon HE, 2006, ONCOL REP, V16, P929; Morton JP, 2008, AM J PATHOL, V172, P1081, DOI 10.2353/ajpath.2008.070778; Na TY, 2009, HEPATOLOGY, V49, P1122, DOI 10.1002/hep.22740; O'Shaughnessy J, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.1007; Petty RD, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-434; Porta C, 2005, ONCOGENE, V24, P605, DOI 10.1038/sj.onc.1208204; Qian HL, 2005, CLIN EXP METASTAS, V22, P653, DOI 10.1007/s10585-006-9005-2; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Simbulan-Rosenthal CM, 1999, CANCER RES, V59, P2190; Sung YH, 2010, CANCER RES, V70, P10454, DOI 10.1158/0008-5472.CAN-10-0031; Toh Y, 2009, CLIN EXP METASTAS, V26, P215, DOI 10.1007/s10585-008-9233-8; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wang B, 2010, CELL CYCLE, V9, P870, DOI 10.4161/cc.9.5.10825; Wang B, 2009, P NATL ACAD SCI USA, V106, P14373, DOI 10.1073/pnas.0903284106; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; WesierskaGadek J, 1996, BIOCHEM BIOPH RES CO, V224, P96, DOI 10.1006/bbrc.1996.0990; Yap TA, 2011, CA-CANCER J CLIN, V61, P31, DOI 10.3322/caac.20095; Yoo YG, 2008, ONCOGENE, V27, P3405, DOI 10.1038/sj.onc.1211000; Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025; Zampieri M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004717; Zardo G, 1998, J BIOL CHEM, V273, P16517, DOI 10.1074/jbc.273.26.16517	44	38	41	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2012	31	49					5099	5107		10.1038/onc.2012.2	http://dx.doi.org/10.1038/onc.2012.2			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	049RK	22286760				2022-12-17	WOS:000312000900006
J	Fatima, S; Lee, NP; Tsang, FH; Kolligs, FT; Ng, IOL; Poon, RTP; Fan, ST; Luk, JM				Fatima, S.; Lee, N. P.; Tsang, F. H.; Kolligs, F. T.; Ng, I. O. L.; Poon, R. T. P.; Fan, S. T.; Luk, J. M.			Dickkopf 4 (DKK4) acts on Wnt/beta-catenin pathway by influencing beta-catenin in hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; Wnt/beta-catenin signalling; DKK4; tumourigenesis	FREQUENT EPIGENETIC INACTIVATION; LIVER-CANCER; PROGNOSTIC-SIGNIFICANCE; NEGATIVE REGULATOR; FAMILY GENES; TUMOR-GROWTH; COLON-CANCER; EXPRESSION; ANTAGONIST; PHOSPHORYLATION	Deregulation of Wnt/beta-catenin pathway is a hallmark of major gastrointestinal cancers including hepatocellular carcinoma (HCC). The oncogenic role of beta-catenin is well defined but reasons for its accumulation in HCC remain unclear. Dickkopf 4 (DKK4) acts as a negative regulator of Wnt/beta-catenin pathway but its functional role in liver carcinogenesis has not been studied. We investigated the role of DKK4 in beta-catenin regulation in HCC. Reduced expression of DKK4 was found in 47% (38/81) of HCC, as measured by quantitative real time PCR. Ectopic expression of DKK4 in two HCC cell lines, PLC/PRF/5 (PLC) and MHCC97L (97L), attenuated beta-catenin responsive luciferase activity, and decreased both beta-catenin and cyclin D1 protein levels. To study the effect of DKK4 on cell growth and tumourigenicity, two stable HCC cell lines were established from PLC and 97L cells. Functional assays demonstrated that overexpression of DKK4 hampered cell proliferation, reduced colony formation and retarded cell migration. When DKK4-expressing 97L stable cells were used to induce tumour xenografts in nude mice (n = 8), reduction in tumour sizes was observed (P = 0.027). Furthermore, immunohistochemical studies showed that decreased expression of DKK4 was associated with beta-catenin accumulation in HCC tissues. Additionally, inhibition of the proteasome using specific inhibitor in DKK4-expressing 97L stable cells masked the effect of beta-catenin. Our findings suggest a potential tumour suppressive role of DKK4 as well as that of an important regulator of HCC. Oncogene (2012) 31, 4233-4244; doi:10.1038/onc.2011.580; published online 16 January 2012	[Luk, J. M.] pRED China, Roche R& Ctr, Dept Oncol, Shanghai 201203, Peoples R China; [Fatima, S.; Lee, N. P.; Tsang, F. H.; Poon, R. T. P.; Fan, S. T.; Luk, J. M.] Univ Hong Kong, Dept Surg, Pokfulam, Hong Kong, Peoples R China; [Kolligs, F. T.] Univ Munich, Klinikum Grosshadern, Dept Med 2, D-8000 Munich, Germany; [Ng, I. O. L.] Univ Hong Kong, Dept Pathol, Pokfulam, Hong Kong, Peoples R China; [Luk, J. M.] Natl Univ Singapore, Dept Pharmacol, Singapore 117548, Singapore; [Luk, J. M.] Natl Univ Singapore, Dept Surg, Singapore 117548, Singapore; [Luk, J. M.] Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore; [Luk, J. M.] Canc Sci Inst, Singapore, Singapore	University of Hong Kong; University of Munich; University of Hong Kong; National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Luk, JM (corresponding author), pRED China, Roche R& Ctr, Dept Oncol, 720 Cai Lun Rd, Shanghai 201203, Peoples R China.	dr.johnluk@gmail.com	Luk, John/A-4085-2008	Luk, John/0000-0002-6323-7940; Ng, Irene Oi-lin/0000-0001-7532-2029				Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Apte U, 2008, HEPATOLOGY, V47, P288, DOI 10.1002/hep.21973; Baehs S, 2009, CANCER LETT, V276, P152, DOI 10.1016/j.canlet.2008.11.003; Blitzer JT, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-28; Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460; Chen TC, 1998, CANCER LETT, V134, P23, DOI 10.1016/S0304-3835(98)00238-9; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ding Z, 2009, WORLD J GASTROENTERO, V15, P2595, DOI 10.3748/wjg.15.2595; Fatima S, 2011, WORLD J CLIN ONCOL, V2, P311, DOI 10.5306/wjco.v2.i8.311; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Gonzalez FJ, 2006, HEPATOLOGY, V43, P650, DOI 10.1002/hep.21154; Hao K, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-389; Hirata H, 2011, CANCER-AM CANCER SOC, V117, P1649, DOI 10.1002/cncr.25666; Hirata H, 2009, CLIN CANCER RES, V15, P5678, DOI 10.1158/1078-0432.CCR-09-0558; Hu J, 2009, CANCER RES, V69, P6951, DOI 10.1158/0008-5472.CAN-09-0541; Huang H, 1999, AM J PATHOL, V155, P1795, DOI 10.1016/S0002-9440(10)65496-X; Inagawa S, 2002, CLIN CANCER RES, V8, P450; Ishii H, 1999, P NATL ACAD SCI USA, V96, P3928, DOI 10.1073/pnas.96.7.3928; Ito K, 2008, CANCER CELL, V14, P226, DOI 10.1016/j.ccr.2008.08.004; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kemp W, 2005, J GASTROEN HEPATOL, V20, P873, DOI 10.1111/j.1440-1746.2005.03844.x; Krieghoff E, 2006, J CELL SCI, V119, P1453, DOI 10.1242/jcs.02864; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Lee EJ, 2009, INT J CANCER, V124, P287, DOI 10.1002/ijc.23913; Lee NP, 2010, INT J CANCER, V127, P968, DOI 10.1002/ijc.25100; Lee NP, 2009, J PROTEOME RES, V8, P1293, DOI 10.1021/pr800637z; Lee NPY, 2008, PROTEOMICS, V8, P2136, DOI 10.1002/pmic.200700590; Lee NPY, 2006, FEBS LETT, V580, P923, DOI 10.1016/j.febslet.2006.01.019; Liao C, 2000, HEPATOLOGY, V32, P721, DOI 10.1053/jhep.2000.17967; Liao CH, 2011, HEPATOLOGY; Liu AM, 2010, BIOCHEM BIOPH RES CO, V394, P623, DOI 10.1016/j.bbrc.2010.03.036; Liu LX, 2009, HEPATOLOGY, V50, P1453, DOI 10.1002/hep.23143; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lu WJ, 2011, INT J CANCER, V129, P1806, DOI 10.1002/ijc.25857; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Maehata T, 2008, WORLD J GASTROENTERO, V14, P2702, DOI 10.3748/wjg.14.2702; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378-1119(02)01106-X; Matsui A, 2009, CANCER SCI, V100, P1923, DOI 10.1111/j.1349-7006.2009.01272.x; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nakamura T, 2008, J CELL MOL MED, V12, P391, DOI 10.1111/j.1582-4934.2007.00201.x; Nejak-Bowen KN, 2011, SEMIN CANCER BIOL, V21, P44, DOI 10.1016/j.semcancer.2010.12.010; Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054; Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Pendas-Franco N, 2008, ONCOGENE, V27, P4467, DOI 10.1038/onc.2008.88; Pineau P, 1999, ONCOGENE, V18, P3127, DOI 10.1038/sj.onc.1202648; Sakanaka C, 2002, J BIOCHEM, V132, P697, DOI 10.1093/oxfordjournals.jbchem.a003276; Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Shih YL, 2007, INT J CANCER, V121, P1028, DOI 10.1002/ijc.22750; Takagi H, 2008, J GASTROENTEROL, V43, P378, DOI 10.1007/s00535-008-2170-0; Takemaru KI, 2003, NATURE, V422, P905, DOI 10.1038/nature01570; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Tung EKK, 2011, LIVER INT, V31, P1494, DOI 10.1111/j.1478-3231.2011.02597.x; Urakami S, 2006, CLIN CANCER RES, V12, P6989, DOI 10.1158/1078-0432.CCR-06-1194; Wiesman KC, 2010, J CELL COMMUN SIGNAL, V4, P91, DOI 10.1007/s12079-010-0087-x; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Wu YY, 2010, J BIOL CHEM, V285, P34621, DOI 10.1074/jbc.M110.148791; Yamamoto H, 2008, DEV CELL, V15, P37, DOI 10.1016/j.devcel.2008.04.015; Yang B, 2010, WORLD J GASTROENTERO, V16, P755, DOI 10.3748/wjg.v16.i6.755; Yi X, 2008, MOL CELL PROTEOMICS, V7, P315, DOI 10.1074/mcp.M700116-MCP200; Yu B, 2009, J HEPATOL, V50, P948, DOI 10.1016/j.jhep.2008.11.020; Yuan BZ, 1998, CANCER RES, V58, P2196; Yue W, 2008, CARCINOGENESIS, V29, P84, DOI 10.1093/carcin/bgm267; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; Zhang K, 2010, INT J ONCOL, V37, P1495, DOI 10.3892/ijo_00000802; Zhang LH, 2003, J CANCER RES CLIN, V129, P279, DOI 10.1007/s00432-002-0407-5	70	38	41	1	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	38					4233	4244		10.1038/onc.2011.580	http://dx.doi.org/10.1038/onc.2011.580			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008SC	22249261				2022-12-17	WOS:000308975800006
J	Hognas, G; Tuomi, S; Veltel, S; Mattila, E; Murumagi, A; Edgren, H; Kallioniemi, O; Ivaska, J				Hognas, G.; Tuomi, S.; Veltel, S.; Mattila, E.; Murumagi, A.; Edgren, H.; Kallioniemi, O.; Ivaska, J.			Cytokinesis failure due to derailed integrin traffic induces aneuploidy and oncogenic transformation in vitro and in vivo	ONCOGENE			English	Article						integrin traffic; cytokinesis; aneuploidy; cancer	MAMMALIAN-CELLS; CHROMOSOMAL INSTABILITY; TUMORIGENESIS; MICE; CANCER; P53; ENDOCYTOSIS; PROGRESSION; INVASION; MUTATION	Aneuploidy is frequently detected in solid tumors but the mechanisms regulating the generation of aneuploidy and their relevance in cancer initiation remain under debate and are incompletely characterized. Spatial and temporal regulation of integrin traffic is critical for cell migration and cytokinesis. Impaired integrin endocytosis, because of the loss of Rab21 small GTPase or mutations in the integrin beta-subunit cytoplasmic tail, induces failure of cytokinesis in vitro. Here, we describe that repeatedly failed cytokinesis, because of impaired traffic, is sufficient to trigger the generation of aneuploid cells, which display characteristics of oncogenic transformation in vitro and are tumorigenic in vivo. Furthermore, in an in vivo mouse xenograft model, non-transformed cells with impaired integrin traffic formed tumors with a long latency. More detailed investigation of these tumors revealed that the tumor cells were aneuploid. Therefore, abnormal integrin traffic was linked with generation of aneuploidy and cell transformation also in vivo. In human prostate and ovarian cancer samples, downregulation of Rab21 correlates with increased malignancy. Loss-of-function experiments demonstrate that long-term depletion of Rab21 is sufficient to induce chromosome number aberrations in normal human epithelial cells. These data are the first to demonstrate that impaired integrin traffic is sufficient to induce conversion of non-transformed cells to tumorigenic cells in vitro and in vivo. Oncogene (2012) 31, 3597-3606; doi:10.1038/onc.2011.527; published online 28 November 2011	[Hognas, G.; Tuomi, S.; Veltel, S.; Mattila, E.; Ivaska, J.] Univ Turku, VTT Tech Res Ctr Finland, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; [Murumagi, A.; Edgren, H.; Kallioniemi, O.] Univ Helsinki, Inst Mol Med, FIMM, Helsinki, Finland; [Ivaska, J.] Univ Turku, Dept Biochem & Food Chem, FIN-20520 Turku, Finland	University of Turku; VTT Technical Research Center Finland; University of Helsinki; University of Turku	Ivaska, J (corresponding author), Univ Turku, VTT Tech Res Ctr Finland, Turku Ctr Biotechnol, FIN-20520 Turku, Finland.	Johanna.ivaska@vtt.fi	Kallioniemi, Olli P/H-5111-2011	Kallioniemi, Olli P/0000-0002-3231-0332; Ivaska, Johanna/0000-0002-6295-6556; Veltel, Stefan/0000-0002-4925-3776	ERC starting grant; Academy of Finland; Finnish Cancer Organizations; Sigrid Juselius Foundation; Turku Graduate School for Biomedical Sciences; VTT Medical Biotechnology; EMBO LTF; Alexander von Humboldt foundation	ERC starting grant(European Research Council (ERC)); Academy of Finland(Academy of Finland); Finnish Cancer Organizations; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Turku Graduate School for Biomedical Sciences; VTT Medical Biotechnology; EMBO LTF(European Molecular Biology Organization (EMBO)); Alexander von Humboldt foundation(Alexander von Humboldt Foundation)	We thank Dr M Karin for DNA constructs; H Marttila, J Siivonen and L Lahtinen for excellent technical assistance. I Ahonen is thanked for help with the statistical analysis. This research has been supported by ERC starting grant, Academy of Finland, Finnish Cancer Organizations and Sigrid Juselius Foundation. GH is supported by Turku Graduate School for Biomedical Sciences, ST by VTT Medical Biotechnology and SV is supported by EMBO LTF and Alexander von Humboldt foundation. The Central Animal Laboratory of the University of Turku is acknowledged for the animal experiments.	Aszodi A, 2003, GENE DEV, V17, P2465, DOI 10.1101/gad.277003; BENZEEV A, 1981, CELL, V26, P107, DOI 10.1016/0092-8674(81)90038-6; Caswell P, 2008, TRENDS CELL BIOL, V18, P257, DOI 10.1016/j.tcb.2008.03.004; Czuchra A, 2006, J CELL BIOL, V174, P889, DOI 10.1083/jcb.200604060; Evans RD, 2003, J CELL BIOL, V160, P589, DOI 10.1083/jcb.200209016; Ezratty EJ, 2009, J CELL BIOL, V187, P733, DOI 10.1083/jcb.200904054; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; Ivaska J, 2010, CELL TISSUE RES, V339, P111, DOI 10.1007/s00441-009-0857-z; Iwanaga Y, 2007, CANCER RES, V67, P160, DOI 10.1158/0008-5472.CAN-06-3326; Jeganathan K, 2007, J CELL BIOL, V179, P255, DOI 10.1083/jcb.200706015; Kanada M, 2005, MOL BIOL CELL, V16, P3865, DOI 10.1091/mbc.E05-03-0233; Li RH, 2000, P NATL ACAD SCI USA, V97, P3236, DOI 10.1073/pnas.040529797; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Olaharski AJ, 2006, CARCINOGENESIS, V27, P337, DOI 10.1093/carcin/bgi218; Parsons M, 2002, MOL CELL BIOL, V22, P5897, DOI 10.1128/MCB.22.16.5897-5911.2002; Pellinen T, 2008, DEV CELL, V15, P371, DOI 10.1016/j.devcel.2008.08.001; Reverte CG, 2006, J CELL BIOL, V174, P491, DOI 10.1083/jcb.200603069; Rosario CO, 2010, P NATL ACAD SCI USA, V107, P6888, DOI 10.1073/pnas.0910941107; Scita G, 2010, NATURE, V463, P464, DOI 10.1038/nature08910; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Thullberg M, 2007, P NATL ACAD SCI USA, V104, P20338, DOI 10.1073/pnas.0706609105; Torres EM, 2008, GENETICS, V179, P737, DOI 10.1534/genetics.108.090878; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003; Williams BR, 2008, SCIENCE, V322, P703, DOI 10.1126/science.1160058	35	38	38	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	31					3597	3606		10.1038/onc.2011.527	http://dx.doi.org/10.1038/onc.2011.527			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985EG	22120710	Green Published, hybrid			2022-12-17	WOS:000307245600003
J	Muehlich, S; Hampl, V; Khalid, S; Singer, S; Frank, N; Breuhahn, K; Gudermann, T; Prywes, R				Muehlich, S.; Hampl, V.; Khalid, S.; Singer, S.; Frank, N.; Breuhahn, K.; Gudermann, T.; Prywes, R.			The transcriptional coactivators megakaryoblastic leukemia 1/2 mediate the effects of loss of the tumor suppressor deleted in liver cancer 1	ONCOGENE			English	Article						DLC1; MKL1; MKL2; MRTF; Rho; SRF	SERUM RESPONSE FACTOR; TISSUE GROWTH-FACTOR; HEPATOCELLULAR-CARCINOMA; HUMAN HEPATOCARCINOGENESIS; ACTIN CYTOSKELETON; CELL-MIGRATION; TARGET GENES; METASTASIS; SRF; PROGRESSION	Deleted in Liver Cancer 1 (DLC1) is a tumor suppressor whose allele is lost in 50% of liver, breast, lung and 70% of colon cancers. Here, we show that the transcriptional coactivators Megakaryoblastic Leukemia 1 and 2 (MKL1/2) are constitutively localized to the nucleus in hepatocellular and mammary carcinoma cells that lack DLC1. Moreover, DLC1 loss and MKL1 nuclear localization correlate in primary human hepatocellular carcinoma. Nuclear accumulation of MKL1 in DLC1 deficient cancer cells is accomplished by activation of the RhoA/actin signaling pathway and concomitant impairment of MKL1 phosphorylation, which results in constitutive activation of MKL1/2 target genes. We provide evidence that MKL1/2 mediates cancerous transformation in DLC1-deficient hepatocellular and mammary carcinoma cells. Depletion of MKL1/2 suppresses cell migration, cell proliferation and anchorage-independent cell growth induced by DLC1 loss. Oncogene (2012) 31, 3913-3923; doi:10.1038/onc.2011.560; published online 5 December 2011	[Muehlich, S.; Hampl, V.; Khalid, S.; Frank, N.; Gudermann, T.] Univ Munich, Walther Straub Inst Pharmacol & Toxicol, D-80336 Munich, Germany; [Singer, S.; Breuhahn, K.] Univ Heidelberg Hosp, Inst Pathol, Heidelberg, Germany; [Prywes, R.] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	University of Munich; Ruprecht Karls University Heidelberg; Columbia University	Muehlich, S (corresponding author), Univ Munich, Walther Straub Inst Pharmacol & Toxicol, Goethestr 33, D-80336 Munich, Germany.	susanne.muehlich@lrz.uni-muenchen.de		Breuhahn, Kai/0000-0002-2462-1229	German Research Foundation (DFG) [MU 2737/2-1]; National Cancer Institute [CA050329]; NATIONAL CANCER INSTITUTE [R01CA050329] Funding Source: NIH RePORTER	German Research Foundation (DFG)(German Research Foundation (DFG)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Scott Lowe for the DLC1 knockdown hepatocytes and Dr Monilola Olayioye for DLC1 vectors. Breast carcinoma cell lines were kindly provided by Dr Ramon Parsons. This work was funded by grant MU 2737/2-1 from the German Research Foundation (DFG) to SM and grant CA050329 from the National Cancer Institute to RP.	Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; del Pulgar TG, 2005, BIOESSAYS, V27, P602, DOI 10.1002/bies.20238; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Giehl K, 2005, BIOL CHEM, V386, P193, DOI 10.1515/BC.2005.025; Gollob JA, 2006, SEMIN ONCOL, V33, P392, DOI 10.1053/j.seminoncol.2006.04.002; Goodison S, 2005, CANCER RES, V65, P6042, DOI 10.1158/0008-5472.CAN-04-3043; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; Hanna M, 2009, J BIOL CHEM, V284, P23125, DOI 10.1074/jbc.M109.019059; Heering J, 2009, EXP CELL RES, V315, P2505, DOI 10.1016/j.yexcr.2009.05.022; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Knoll B, 2010, BIOL CHEM, V391, P591, DOI 10.1515/BC.2010.061; Knoll B, 2006, NAT NEUROSCI, V9, P195, DOI 10.1038/nn1627; Lahoz A, 2008, GENE DEV, V22, P1724, DOI 10.1101/gad.1691408; Lee SM, 2010, J BIOL CHEM, V285, P22036, DOI 10.1074/jbc.M110.108878; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406; Mazzocca A, 2010, HEPATOLOGY, V51, P523, DOI 10.1002/hep.23285; Medjkane S, 2009, NAT CELL BIOL, V11, P257, DOI 10.1038/ncb1833; Miano JM, 2007, AM J PHYSIOL-CELL PH, V292, pC70, DOI 10.1152/ajpcell.00386.2006; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Morin P, 2009, EUR J CELL BIOL, V88, P495, DOI 10.1016/j.ejcb.2009.04.005; Muehlich S, 2008, MOL CELL BIOL, V28, P6302, DOI 10.1128/MCB.00427-08; Muehlich S, 2007, AM J PHYSIOL-CELL PH, V292, pC1732, DOI 10.1152/ajpcell.00552.2006; Pipes GCT, 2006, GENE DEV, V20, P1545, DOI 10.1101/gad.1428006; Porter KE, 2004, CARDIOVASC RES, V61, P745, DOI 10.1016/j.cardiores.2003.11.032; Prange W, 2003, J PATHOL, V201, P250, DOI 10.1002/path.1448; Selvaraj A, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-13; Singer S, 2007, HEPATOLOGY, V46, P759, DOI 10.1002/hep.21736; Truong H, 2009, CELL ADHES MIGR, V3, P179, DOI 10.4161/cam.3.2.8036; Vartiainen MK, 2007, SCIENCE, V316, P1749, DOI 10.1126/science.1141084; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wong CM, 2005, CANCER RES, V65, P8861, DOI 10.1158/0008-5472.CAN-05-1318; Xie D, 2001, CANCER RES, V61, P8917; Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608; Yuan BZ, 1998, CANCER RES, V58, P2196	37	38	38	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	35					3913	3923		10.1038/onc.2011.560	http://dx.doi.org/10.1038/onc.2011.560			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999VJ	22139079				2022-12-17	WOS:000308342800001
J	Kanno, T; Kamba, T; Yamasaki, T; Shibasaki, N; Saito, R; Terada, N; Toda, Y; Mikami, Y; Inoue, T; Kanematsu, A; Nishiyama, H; Ogawa, O; Nakamura, E				Kanno, T.; Kamba, T.; Yamasaki, T.; Shibasaki, N.; Saito, R.; Terada, N.; Toda, Y.; Mikami, Y.; Inoue, T.; Kanematsu, A.; Nishiyama, H.; Ogawa, O.; Nakamura, E.			JunB promotes cell invasion and angiogenesis in VHL-defective renal cell carcinoma	ONCOGENE			English	Article						renal-cell carcinoma; VHL gene; JunB invasion; angiogenesis	TUMOR-SUPPRESSOR PROTEIN; NF-KAPPA-B; MATRIX METALLOPROTEINASES-2; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; IDENTIFICATION; CANCER; PVHL; PHEOCHROMOCYTOMA; LYMPHOMA	Inactivation of the von Hippel-Lindau (VHL) tumor-suppressor gene causes both hereditary and sporadic clear-cell renal-cell carcinoma (ccRCC). Although the best-characterized function of the VHL protein (pVHL) is regulation of hypoxia-inducible factor-alpha (HIF alpha), pVHL also controls the development of pheochromocytoma through HIF-independent pathways by regulating JunB. However, it is largely unknown how these pathways contribute to the development and progression of ccRCC. In the present study, we confirmed that JunB was upregulated in VHL-defective ccRCC specimens by immunostaining. Short-hairpin RNA (shRNA)-mediated knockdown of JunB in 786-O and A498 VHL null ccRCC cells suppressed their invasiveness. In addition, JunB knockdown significantly repressed tumor growth and microvessel density in xenograft tumor assays. Conversely, forced expression of wild-type, but not dimerization-defective, JunB in a VHL-restored 786-O subclone promoted invasion in vitro and tumor growth and vessel formation in vivo. Quantitative PCR array analysis revealed that JunB regulated multiple genes relating to tumor invasion and angiogenesis such as matrix metalloproteinase-2 (MMP-2), MMP-9 and chemokine (C-C motif) ligand-2 (CCL2) in 786-O cells. JunB knockdown in these cells reduced the proteolytic activity of both MMPs in gelatin zymography and the amount of CCL2 in the culture supernatant. Moreover, shRNA-mediated knockdown of MMP-2 or inhibition of CCL2 activity with a neutralizing antibody repressed xenograft tumor growth and angiogenesis. Collectively, these results suggest that JunB promotes tumor invasiveness and enhances angiogenesis in VHL-defective ccRCCs. Oncogene (2012) 31, 3098-3110; doi: 10.1038/onc.2011.475; published online 24 October 2011	[Nakamura, E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Nakamura, E.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Kanno, T.; Kamba, T.; Yamasaki, T.; Shibasaki, N.; Saito, R.; Terada, N.; Inoue, T.; Kanematsu, A.; Nishiyama, H.; Ogawa, O.] Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto, Japan; [Toda, Y.] Kyoto Univ, Grad Sch Med, Anat Ctr, Kyoto, Japan; [Mikami, Y.] Kyoto Univ, Grad Sch Med, Anat Pathol Lab, Kyoto, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Kyoto University; Kyoto University; Kyoto University	Nakamura, E (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,Mayer 457, Boston, MA 02115 USA.	Nakamura_Eijiro@dfci.harvard.edu	Terada, Naoki/ABD-2387-2020		Ministry of Education, Culture, Sports, Science and Technology, Japan	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr William G Kaelin, Jr, for critical comments and for providing us with the different RCC cell lines. We appreciate all members of Cancer Research Courses for Integrated Research Training at Kyoto University Graduate School of Medicine for helpful advice and discussion. We also thank Tomoko Matsushita, Megumi Kuraguchi and Yuko Fujieda for technical assistance. Grant support: Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Brugarolas J, 2007, NEW ENGL J MED, V356, P185, DOI 10.1056/NEJMe068263; Calzada MJ, 2010, CLIN TRANSL ONCOL, V12, P160, DOI 10.1007/s12094-010-0485-9; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Frew IJ, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.124pe30; Higgins JPT, 2003, AM J PATHOL, V162, P925, DOI 10.1016/S0002-9440(10)63887-4; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; Kaelin WG, 2009, CANCER-AM CANCER SOC, V115, P2262, DOI 10.1002/cncr.24232; Kallakury BVS, 2001, CLIN CANCER RES, V7, P3113; Keeley EC, 2008, ARTERIOSCL THROM VAS, V28, P1928, DOI 10.1161/ATVBAHA.108.162925; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Kurban G, 2008, ONCOGENE, V27, P1004, DOI 10.1038/sj.onc.1210709; Kurban G, 2006, CANCER RES, V66, P1313, DOI 10.1158/0008-5472.CAN-05-2560; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115; Linehan WM, 2007, CLIN CANCER RES, V13, p671S, DOI 10.1158/1078-0432.CCR-06-1870; Linehan WM, 2004, CANCER CELL, V6, P223, DOI 10.1016/j.ccr.2004.09.006; Lu X, 2009, J BIOL CHEM, V284, P29087, DOI 10.1074/jbc.M109.035899; Martin T, 1997, EUR J IMMUNOL, V27, P1091, DOI 10.1002/eji.1830270508; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Morris MR, 2010, ONCOGENE, V29, P2104, DOI 10.1038/onc.2009.493; Nakamura E, 2006, AM J PATHOL, V168, P574, DOI 10.2353/ajpath.2006.050867; Nakamura E, 2006, ENDOCR PATHOL, V17, P97, DOI 10.1385/EP:17:2:97; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; Perez-Gracia JL, 2009, BRIT J CANCER, V101, P1876, DOI 10.1038/sj.bjc.6605409; Piechaczyk M, 2008, BIOCHEM SOC T, V36, P864, DOI 10.1042/BST0360864; Rini BI, 2009, LANCET ONCOL, V10, P992, DOI 10.1016/S1470-2045(09)70240-2; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Roberts AM, 2008, CURR OPIN ONCOL, V20, P83, DOI 10.1097/CCO.0b013e3282f310de; Roy R, 2009, J CLIN ONCOL, V27, P5287, DOI 10.1200/JCO.2009.23.5556; Salcedo R, 2000, BLOOD, V96, P34, DOI 10.1182/blood.V96.1.34.013a49_34_40; Schmidt D, 2007, EMBO J, V26, P710, DOI 10.1038/sj.emboj.7601539; Shaulian E, 2010, CELL SIGNAL, V22, P894, DOI 10.1016/j.cellsig.2009.12.008; Song H, 2006, CANCER RES, V66, P10487, DOI 10.1158/0008-5472.CAN-06-1461; Staber PB, 2007, BLOOD, V110, P3374, DOI 10.1182/blood-2007-02-071258; Struckmann K, 2008, J PATHOL, V214, P464, DOI 10.1002/path.2310; Takahashi M, 2002, INT J UROL, V9, P531, DOI 10.1046/j.1442-2042.2002.00516.x; Terada N, 2010, CANCER RES, V70, P1606, DOI 10.1158/0008-5472.CAN-09-2984; Watanabe M, 2005, CANCER RES, V65, P7628, DOI 10.1158/0008-5472.CAN-05-0925; WEIDNER N, 1995, AM J PATHOL, V147, P9; Woodward ER, 2006, ENDOCR-RELAT CANCER, V13, P415, DOI 10.1677/erc.1.00683; Yang H, 2007, MOL CELL, V28, P15, DOI 10.1016/j.molcel.2007.09.010; Young AC, 2009, CLIN CANCER RES, V15, P7582, DOI 10.1158/1078-0432.CCR-09-2131	48	38	41	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	25					3098	3110		10.1038/onc.2011.475	http://dx.doi.org/10.1038/onc.2011.475			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964OP	22020339	Green Submitted			2022-12-17	WOS:000305705900008
J	Stossi, F; Madak-Erdogan, Z; Katzenellenbogen, BS				Stossi, F.; Madak-Erdogan, Z.; Katzenellenbogen, B. S.			Macrophage-elicited loss of estrogen receptor-alpha in breast cancer cells via involvement of MAPK and c-Jun at the ESR1 genomic locus	ONCOGENE			English	Article						estrogen receptor; macrophages; MAPK; breast cancer; jun	TUMOR-ASSOCIATED MACROPHAGES; TARGET GENES; DNA-BINDING; IN-VITRO; PROGRESSION; POLARIZATION; RESISTANCE; EXPRESSION; PHENOTYPE; DISTINCT	Estrogen receptor-alpha (ER alpha, ESR1) is a pivotal transcriptional regulator of breast cancer physiology and is targeted by endocrine therapies. Loss of ER alpha activity or expression is an indication of endocrine resistance and is associated with increased risk of tumor recurrence and worse prognosis. In this study, we sought to investigate whether elements of the tumor microenvironment, namely macrophages, would impact on ER alpha and we found that macrophage-derived factors caused loss of ER alpha expression in breast cancer cells. Conditioned media from macrophages caused activation of several intracellular pathways in breast cancer cells of which c-Src, protein kinase c and mitogen-activated protein kinase (MAPK) were essential for loss of ER alpha expression. Moreover, a prolonged hyperactivation of MAPK was observed. The activation of this kinase cascade resulted in recruitment of extracellular signal regulated kinase 2 (ERK2) directly to chromatin at the ESR1 gene locus in a process that was dependent upon activation and recruitment of the c-Jun transcription factor. Thus, we identify a novel mechanism for loss of ER alpha expression in breast cancer cells via macrophage activation of kinase cascades in the cancer cells causing transcriptional repression of the ESR1 gene by a direct chromatin action of a c-Jun/ERK2 complex. The findings in this study support an alternative mechanism, not intrinsic to the tumor cell but derived from the crosstalk with the tumor microenvironment, that could lead to endocrine resistance and might be targeted therapeutically to prevent loss of ER alpha expression in breast tumors. Oncogene (2012) 31, 1825-1834; doi: 10.1038/onc.2011.370; published online 22 August 2011	[Stossi, F.; Madak-Erdogan, Z.; Katzenellenbogen, B. S.] Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Katzenellenbogen, BS (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 524 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.	katzenel@illinois.edu		Madak-Erdogan, Zeynep/0000-0003-2607-1643	Breast Cancer Research Foundation; ODS, NIH [P50 AT006268]; NCCAM; NCI; National Center for Complementary & Integrative Health [P50AT006268] Funding Source: NIH RePORTER	Breast Cancer Research Foundation; ODS, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCCAM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by a grant from the Breast Cancer Research Foundation and NIH P50 AT006268 from ODS, NCCAM, and NCI (to BSK).	Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Allavena P, 2008, IMMUNOL REV, V222, P155, DOI 10.1111/j.1600-065X.2008.00607.x; AUWERX J, 1991, EXPERIENTIA, V47, P22, DOI 10.1007/BF02041244; Bayliss J, 2007, CLIN CANCER RES, V13, P7029, DOI 10.1158/1078-0432.CCR-07-0587; Beck AH, 2009, CLIN CANCER RES, V15, P778, DOI 10.1158/1078-0432.CCR-08-1283; Benoit M, 2008, J IMMUNOL, V181, P3733, DOI 10.4049/jimmunol.181.6.3733; Brinkman JA, 2009, J MAMMARY GLAND BIOL, V14, P67, DOI 10.1007/s10911-009-9113-0; Chen JJW, 2005, J CLIN ONCOL, V23, P953, DOI 10.1200/JCO.2005.12.172; Cheung KL, 1997, BREAST CANCER RES TR, V45, P219, DOI 10.1023/A:1005828731462; Chu I, 2007, J CLIN INVEST, V117, P2205, DOI 10.1172/JCI21739; Creighton CJ, 2006, CANCER RES, V66, P3903, DOI 10.1158/0008-5472.CAN-05-4363; Daigneault M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008668; Dumont JA, 1996, CELL GROWTH DIFFER, V7, P351; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Johnston SRD, 1997, ANTI-CANCER DRUG, V8, P911, DOI 10.1097/00001813-199711000-00002; JOHNSTON SRD, 1995, CANCER RES, V55, P3331; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Jordan VC, 2007, J CLIN ONCOL, V25, P5815, DOI 10.1200/JCO.2007.11.3886; Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057; Lawrence MC, 2009, P NATL ACAD SCI USA, V106, P22181, DOI 10.1073/pnas.0912596106; Leek RD, 1999, BRIT J CANCER, V79, P991, DOI 10.1038/sj.bjc.6690158; Leek RD, 1996, CANCER RES, V56, P4625; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Ma JL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-112; Madak-Erdogan Z, 2011, MOL CELL BIOL, V31, P226, DOI 10.1128/MCB.00821-10; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Movahedi K, 2010, CANCER RES, V70, P5728, DOI 10.1158/0008-5472.CAN-09-4672; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Oh AS, 2001, MOL ENDOCRINOL, V15, P1344, DOI 10.1210/me.15.8.1344; Ohri CM, 2009, EUR RESPIR J, V33, P118, DOI 10.1183/09031936.00065708; Pupa SM, 1996, J CLIN ONCOL, V14, P85, DOI 10.1200/JCO.1996.14.1.85; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Redente EF, 2010, AM J PATHOL, V176, P2972, DOI 10.2353/ajpath.2010.090879; Shabo I, 2008, INT J CANCER, V123, P780, DOI 10.1002/ijc.23527; Sharma M, 2010, BREAST CANCER RES TR, V123, P397, DOI 10.1007/s10549-009-0654-0; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004; Sica A, 2008, CANCER LETT, V267, P204, DOI 10.1016/j.canlet.2008.03.028; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; Stossi F, 2004, ENDOCRINOLOGY, V145, P3473, DOI 10.1210/en.2003-1682; Stossi F, 2009, MOL CELL BIOL, V29, P1749, DOI 10.1128/MCB.01476-08; TSUCHIYA S, 1982, CANCER RES, V42, P1530; Watkins SK, 2007, J IMMUNOL, V178, P1357, DOI 10.4049/jimmunol.178.3.1357; Yuan A, 2008, ADV CLIN CHEM, V45, P199, DOI 10.1016/S0065-2423(07)00008-X; Zhu P, 2006, CELL, V124, P615, DOI 10.1016/j.cell.2005.12.032	49	38	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	14					1825	1834		10.1038/onc.2011.370	http://dx.doi.org/10.1038/onc.2011.370			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925TT	21860415	Green Accepted			2022-12-17	WOS:000302785200008
J	Ammoun, S; Schmid, MC; Zhou, L; Ristic, N; Ercolano, E; Hilton, DA; Perks, CM; Hanemann, CO				Ammoun, S.; Schmid, M. C.; Zhou, L.; Ristic, N.; Ercolano, E.; Hilton, D. A.; Perks, C. M.; Hanemann, C. O.			Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival	ONCOGENE			English	Article						human schwannoma; IGFBP-1; PTEN/AKT; Src/FAK; proliferation; adhesion	CELL-PROLIFERATION; SIGNALING PATHWAY; BREAST-CANCER; KINASE; PTEN; ACTIVATION; INTEGRIN; MERLIN; PHOSPHORYLATION; AKT	Merlin is a tumour suppressor involved in the development of a variety of tumours including mesotheliomas. Neurofibromatosis type 2 (NF2), a dominantly inherited tumour disease, is also caused by loss of merlin. NF2 patients suffer from multiple genetically well-defined tumours, schwannomas are most frequent among those. Using our in vitro model for human schwannoma, we found that schwannoma cells display enhanced proliferation because of the overexpression/activation of platelet-derived growth factor receptor and ErbB2/3, increased cell-matrix adhesion because of the overexpression of integrins, and decreased apoptosis. Mechanisms underlying schwannomas basal proliferation and cell-matrix adhesion are not understood. Here, we investigated insulin-like growth factor-binding protein-1 (IGFBP-1), which is expressed and released from central nervous system tumours and strongly overexpressed in schwannoma at the mRNA level. IGFBP-1 acts via beta 1-integrin and focal-adhesion-kinase (FAK), which are strongly overexpressed and basally activated in schwannoma. Using short hairpin RNA knockdown, small inhibitors and recombinant IGFBP-1, we demonstrate that schwannoma cells, in contrast to Schwann cells, release IGFBP-1 that activates the Src/FAK pathway, via integrin beta 1, potentiating schwannoma's proliferation and cell-matrix adhesion. We show that FAK localizes to the nucleus and Src triggers IGFBP-1 production. Further, we observed downregulation of the tumour-suppressor phosphatase and tensin homolog in schwannoma cells leading to increased activity of antiapoptotic AKT. Thus, IGFBP-1/integrin beta 1/Src/FAK pathway has a crucial role in merlin-related tumourigenesis and therefore represents an important therapeutic target in the treatment of merlin-deficient tumours. Oncogene (2012) 31, 1710-1722; doi:10.1038/onc.2011.357; published online 5 September 2011	[Ammoun, S.; Schmid, M. C.; Zhou, L.; Ristic, N.; Ercolano, E.; Hanemann, C. O.] Peninsula Coll Med & Dent, Plymouth PL6 8BU, Devon, England; [Hilton, D. A.] Derriford Hosp, Dept Histopathol, Plymouth PL6 8DH, Devon, England; [Perks, C. M.] Univ Bristol, Dept Clin Sci N Bristol, IGFs & Metab Endocrinol, Bristol, Avon, England	University of Plymouth; Derriford Hospital; University of Bristol	Hanemann, CO (corresponding author), Peninsula Coll Med & Dent, John Bull Bldg,Tamar Sci Pk,Res Way, Plymouth PL6 8BU, Devon, England.	oliver.hanemann@pms.ac.uk	Hanemann, C Oliver/AAV-6257-2020	Hanemann, C Oliver/0000-0002-1951-1025; Perks, Claire/0000-0003-1562-891X	CTF; Northcott Devon Medical Foundation; Peninsula College of Medicine and Dentistry, Plymouth, UK; Action Medical Research [1792] Funding Source: researchfish	CTF; Northcott Devon Medical Foundation; Peninsula College of Medicine and Dentistry, Plymouth, UK; Action Medical Research	This work was supported by the CTF, Northcott Devon Medical Foundation and by Peninsula College of Medicine and Dentistry, Plymouth, UK. Pfizer supplied inhibitor.	Ammoun S, 2008, CANCER RES, V68, P5236, DOI 10.1158/0008-5472.CAN-07-5849; Ammoun S, 2010, NEURO-ONCOLOGY, V12, P834, DOI 10.1093/neuonc/noq012; Ammoun S, 2010, NEUROBIOL DIS, V37, P141, DOI 10.1016/j.nbd.2009.09.017; Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Chaves J, 2011, ANTI-CANCER DRUG, V22, P206, DOI 10.1097/CAD.0b013e32834258a1; Feron M, 2009, AM J PATHOL, V174, P1459, DOI 10.2353/ajpath.2009.080460; Flaiz C, 2007, J NEUROPATH EXP NEUR, V66, P608, DOI 10.1097/nen.0b013e318093e555; Fraenzer JT, 2003, INT J ONCOL, V23, P1493; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hanemann CO, 2006, NEUROPATH APPL NEURO, V32, P605, DOI 10.1111/j.1365-2990.2006.00769.x; Hilton DA, 2009, HISTOPATHOLOGY, V55, P744, DOI 10.1111/j.1365-2559.2009.03440.x; Hiromura M, 2004, J BIOL CHEM, V279, P53407, DOI 10.1074/jbc.M403775200; Houshmandi SS, 2009, MOL CELL BIOL, V29, P1472, DOI 10.1128/MCB.01392-08; JONES JI, 1993, J BIOL CHEM, V268, P1125; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; JONES JI, 1991, P NATL ACAD SCI USA, V88, P7481, DOI 10.1073/pnas.88.17.7481; Kaempchen K, 2003, HUM MOL GENET, V12, P1211, DOI 10.1093/hmg/ddg146; Leu TH, 2002, ONCOGENE, V21, P6992, DOI 10.1038/sj.onc.1205904; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lim ST, 2008, CELL CYCLE, V7, P2306, DOI 10.4161/cc.6367; Lim ST, 2008, MOL CELL, V29, P9, DOI 10.1016/j.molcel.2007.11.031; Lin CH, 2003, J NEUROSCI, V23, P1574; Liu WJ, 2008, ANTICANCER RES, V28, P3613; McClatchey AI, 2009, TRENDS CELL BIOL, V19, P198, DOI 10.1016/j.tcb.2009.02.006; Milner R, 1997, DEV BIOL, V185, P215, DOI 10.1006/dbio.1997.8547; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Morrison H, 2007, CANCER RES, V67, P520, DOI 10.1158/0008-5472.CAN-06-1608; Nagashima T, 2008, ENDOCRINOLOGY, V149, P1227, DOI 10.1210/en.2007-1217; Okada T, 2007, TRENDS CELL BIOL, V17, P222, DOI 10.1016/j.tcb.2007.03.006; Park CH, 2008, BRAIN RES, V1234, P148, DOI 10.1016/j.brainres.2008.07.082; Perks CM, 2007, ONCOGENE, V26, P5966, DOI 10.1038/sj.onc.1210397; Rong R, 2004, P NATL ACAD SCI USA, V101, P18200, DOI 10.1073/pnas.0405971102; Rosenbaum C, 2000, NEUROBIOL DIS, V7, P483, DOI 10.1006/nbdi.2000.0307; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schutt BS, 2004, J MOL ENDOCRINOL, V32, P859, DOI 10.1677/jme.0.0320859; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Utermark T, 2005, BRAIN PATHOL, V15, P17; Utermark T, 2003, BRAIN PATHOL, V13, P352; Wheatcroft SB, 2009, TRENDS ENDOCRIN MET, V20, P153, DOI 10.1016/j.tem.2009.01.002; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Yee D, 2002, SEMIN ONCOL, V29, P86, DOI 10.1053/sonc.2002.34060; Zhang H, 2006, CLIN CANCER RES, V12, P6323, DOI 10.1158/1078-0432.CCR-06-1707; Zumkeller W, 2001, J CLIN PATHOL-MOL PA, V54, P227, DOI 10.1136/mp.54.4.227	46	38	39	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	13					1710	1722		10.1038/onc.2011.357	http://dx.doi.org/10.1038/onc.2011.357			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	918EF	21892205				2022-12-17	WOS:000302231400009
J	Guigon, CJ; Kim, DW; Willingham, MC; Cheng, SY				Guigon, C. J.; Kim, D. W.; Willingham, M. C.; Cheng, S-y			Mutation of thyroid hormone receptor-beta in mice predisposes to the development of mammary tumors	ONCOGENE			English	Article						thyroid hormone receptor; breast cancer; mammary tumors; Pten; mouse models	BREAST-CANCER RISK; C-ERBA-BETA; HEPATOCELLULAR-CARCINOMA; NUCLEAR RECEPTORS; TRANSGENIC MICE; LIGAND-BINDING; MOUSE MODEL; GENE; EXPRESSION; DISEASE	Correlative data suggest that thyroid hormone receptor-beta (TR beta) mutations could increase the risk of mammary tumor development, but unequivocal evidence is still lacking. To explore the role of TR beta mutants in vivo in breast tumor development and progression, we took advantage of a knock-in mouse model harboring a mutation in the Thrb gene encoding TR beta (Thrb(PV) mouse). Although in adult nulliparous females, a single ThrbPV allele did not contribute to mammary gland abnormalities, the presence of two ThrbPV alleles led to mammary hyperplasia in similar to 36% Thrb(PV/PV) mice. The ThrbPV mutation further markedly augmented the risk of mammary hyperplasia in a mouse model with high susceptibility to mammary tumors (Pten(+/-) mouse), as demonstrated by the occurrence of mammary hyperplasia in similar to 60% of Thrb(PV/+) Pten(+/-) and similar to 77% of Thrb(PV/PV) Pten(+/-) mice versus similar to 33% of Thrb(+/+) Pten(+/-) mice. The Thrb(PV) mutation increased the activity of signal transducer and activator of transcription (STAT5) to increase cell proliferation and the expression of the STAT5 target gene encoding beta-casein in the mammary gland. We next sought to understand the molecular mechanism underlying STAT5 overactivation by TR beta PV. Cell-based studies with a breast cancer cell line (T47D cells) showed that thyroid hormone (T3) repressed STAT5 signaling in TR beta-expressing cells through decreasing STAT5-mediated transcription activity and target gene expression, whereas sustained STAT5 signaling was observed in TR beta PV-expressing cells. Collectively, these findings show for the first time that a TR beta mutation promotes the development of mammary hyperplasia via aberrant activation of STAT5, thereby conferring a fertile genetic ground for tumorigenesis. Oncogene (2011) 30, 3381-3390; doi:10.1038/onc.2011.50; published online 14 March 2011	[Guigon, C. J.; Kim, D. W.; Cheng, S-y] NCI, Mol Biol Lab, Ctr Canc Res, Bethesda, MD 20892 USA; [Willingham, M. C.] Wake Forest Univ, Dept Pathol, Winston Salem, NC 27109 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Wake Forest University	Cheng, SY (corresponding author), NCI, Mol Biol Lab, Ctr Canc Res, 37 Convent Dr,Room 5128, Bethesda, MD 20892 USA.	chengs@mail.nih.gov	guigon, celine/L-3518-2017	guigon, celine/0000-0002-4489-4304	Center for Cancer Research, National Cancer Institute, National Institutes of Health; NATIONAL CANCER INSTITUTE [ZIABC011191] Funding Source: NIH RePORTER	Center for Cancer Research, National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr L Fozzatti for her help in mouse dissection, Dr C Lu for taking mouse body pictures, and Drs B Vonderhaar and E Ginsburg for providing T47D cells and helpful technical advice. This research was supported by the Intramural Research Program of Center for Cancer Research, National Cancer Institute, National Institutes of Health.	Agarwal Dwarka P, 2007, J Cancer Res Ther, V3, P172; Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; ALVARADOPISANI AR, 1986, ANTICANCER RES, V6, P1347; Banneau G, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2626; Barash I, 2006, J CELL PHYSIOL, V209, P305, DOI 10.1002/jcp.20771; BARLOW C, 1994, EMBO J, V13, P4241, DOI 10.1002/j.1460-2075.1994.tb06744.x; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; BRINTON LA, 1984, J CHRON DIS, V37, P877, DOI 10.1016/0021-9681(84)90062-6; BRONNEGARD M, 1994, J CLIN ENDOCR METAB, V79, P384, DOI 10.1210/jc.79.2.384; Conde I, 2006, ANN ONCOL, V17, P60, DOI 10.1093/annonc/mdj040; Conzen SD, 2008, MOL ENDOCRINOL, V22, P2215, DOI 10.1210/me.2007-0421; Cotarla I, 2004, INT J CANCER, V108, P665, DOI 10.1002/ijc.11619; Ditsch N, 2010, ANTICANCER RES, V30, P1713; Eilon T, 2007, INT J CANCER, V121, P1892, DOI 10.1002/ijc.22954; Eng C, 2002, ANN NY ACAD SCI, V968, P213, DOI 10.1111/j.1749-6632.2002.tb04337.x; Fang F, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-11; FRANCESCHI S, 1990, EUR J CANCER, V26, P781, DOI 10.1016/0277-5379(90)90151-I; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Giani C, 1996, J CLIN ENDOCR METAB, V81, P990, DOI 10.1210/jc.81.3.990; GOLDMAN MB, 1992, ONCOLOGY-BASEL, V49, P461; Guigon CJ, 2009, ONCOGENE, V28, P509, DOI 10.1038/onc.2008.407; Guigon CJ, 2008, MOL CELL BIOL, V28, P4598, DOI 10.1128/MCB.02192-07; HAYDEN TJ, 1977, J ENDOCRINOL, V75, pP38; HEDLEY AJ, 1981, LANCET, V1, P131; Iavnilovitch E, 2004, INT J CANCER, V112, P607, DOI 10.1002/ijc.20484; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; KALACHE A, 1982, BRIT J SURG, V69, P434, DOI 10.1002/bjs.1800690731; Kaneshige M, 2000, P NATL ACAD SCI USA, V97, P13209, DOI 10.1073/pnas.230285997; Kuijpens JLP, 2005, THYROID, V15, P1253, DOI 10.1089/thy.2005.15.1253; LEMAIRE M, 1986, EUR J CANCER CLIN ON, V22, P301, DOI 10.1016/0277-5379(86)90395-0; Li G, 2002, DEVELOPMENT, V129, P4159; Li Z, 2002, CANCER RES, V62, P1939; Lin KH, 1999, MOL CARCINOGEN, V26, P53, DOI 10.1002/(SICI)1098-2744(199909)26:1<53::AID-MC7>3.0.CO;2-Z; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Manhes C, 2006, J ENDOCRINOL, V190, P271, DOI 10.1677/joe.1.06829; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; MITTRA I, 1974, NATURE, V248, P525, DOI 10.1038/248525a0; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Puzianowska-Kuznicka M, 2002, J CLIN ENDOCR METAB, V87, P1120, DOI 10.1210/jc.87.3.1120; Rhei E, 1997, CANCER RES, V57, P3657; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; Saraiva PP, 2005, BRAZ J MED BIOL RES, V38, P761, DOI 10.1590/S0100-879X2005000500014; Silva JM, 2002, ONCOGENE, V21, P4307, DOI 10.1038/sj.onc.1205534; Simon MS, 2002, CANCER EPIDEM BIOMAR, V11, P1574; SMYTH PPA, 1993, J ENDOCRINOL INVEST, V16, P396, DOI 10.1007/BF03348865; Smyth PPA, 1997, ANN MED, V29, P189, DOI 10.3109/07853899708999335; Stambolic V, 2000, CANCER RES, V60, P3605; Strain JJ, 1997, NUTR CANCER, V27, P48, DOI 10.1080/01635589709514500; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; TAKATANI O, 1989, CANCER RES, V49, P3109; Thormeyer D, 1999, INT J MOL MED, V4, P351; Tosovic A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2587; Turken O, 2003, BREAST CANCER RES, V5, pR110, DOI 10.1186/bcr609; Turkson J, 2004, EXPERT OPIN THER TAR, V8, P409, DOI 10.1517/14728222.8.5.409; Vonderhaar BK, 1999, ENDOCR-RELAT CANCER, V6, P389, DOI 10.1677/erc.0.0060389; WALLIN G, 1992, THYROID, V2, P307, DOI 10.1089/thy.1992.2.307; Wennbo H, 1997, ENDOCRINOLOGY, V138, P4410, DOI 10.1210/en.138.10.4410; Wyszomierski SL, 1999, MOL ENDOCRINOL, V13, P330, DOI 10.1210/me.13.2.330; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607; ZUMOFF B, 1981, ANTICANCER RES, V1, P287	65	38	41	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	30					3381	3390		10.1038/onc.2011.50	http://dx.doi.org/10.1038/onc.2011.50			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	798NO	21399657	Green Accepted			2022-12-17	WOS:000293215700008
J	Hacker, S; Karl, S; Mader, I; Cristofanon, S; Schweitzer, T; Krauss, J; Rutkowski, S; Debatin, KM; Fulda, S				Haecker, S.; Karl, S.; Mader, I.; Cristofanon, S.; Schweitzer, T.; Krauss, J.; Rutkowski, S.; Debatin, K-M; Fulda, S.			Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation	ONCOGENE			English	Article						HDACI; apoptosis; medulloblastoma; mitochondria; chemotherapy	IN-VIVO; KU70 ACETYLATION; PROSTATE-CANCER; EXPRESSION; RESISTANCE; CASPASE-8; THERAPY; TRAIL; SENSITIZATION; SYSTEM	Despite aggressive therapies, the prognosis of children with high-risk medulloblastoma is still poor, thus underscoring the need to develop novel treatment strategies. Here, we report that histone deacetylase inhibitors (HDACI), that is, MS-275, valproic acid or SAHA, provide a novel strategy for sensitization of medulloblastoma to DNA-damaging drugs such as Doxorubicin, VP16 and Cisplatin by promoting p53-dependent, mitochondrial apoptosis. Mechanistic studies reveal that single-agent treatment with MS-275 causes acetylation of the non-histone protein Ku70, an event reported to release Bax from Ku70, whereas DNA-damaging drugs trigger p53 acetylation and accumulation. Combined treatment with MS-275 and Doxorubicin or VP16 cooperates to promote binding of p53 to Bax and p53-dependent Bax activation, resulting in enhanced loss of mitochondrial membrane potential, cytochrome c release and caspase-dependent apoptosis. Overexpression of Bcl-2 almost completely abolishes the MS-275-mediated chemosensitization, underlining the importance of the mitochondrial pathway for inducing apoptosis. Also, MS-275 cooperates with chemotherapeutics to inhibit long-term clonogenic survival. Most importantly, MS-275 increases chemotherapeutic drug-induced apoptosis in primary medulloblastoma samples, and cooperates with Doxorubicin to suppress medulloblastoma growth in an in vivo model, which underscores the clinical relevance of the findings. Thus, HDACI such as MS-275 present a promising approach for chemosensitization of medulloblastoma by enhancing mitochondrial apoptosis in a p53-dependent manner. These findings have important clinical implications for the design of experimental treatment protocols for medulloblastoma. Oncogene (2011) 30, 2275-2281; doi:10.1038/onc.2010.599; published online 17 January 2011	[Cristofanon, S.; Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60528 Frankfurt, Germany; [Haecker, S.; Karl, S.; Mader, I.; Debatin, K-M] Univ Childrens Hosp, Ulm, Germany; [Schweitzer, T.; Krauss, J.] Univ Wurzburg, Dept Neurosurg, Wurzburg, Germany; [Rutkowski, S.] Univ Med Ctr Hamburg Eppendorf, Dept Pediat Hematol & Oncol, Hamburg, Germany	Goethe University Frankfurt; Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Wurzburg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3A, D-60528 Frankfurt, Germany.	simone.fulda@kgu.de	Schweitzer, Tilmann/K-6471-2014; Debatin, Klaus-Michael/J-9704-2014	Fulda, Simone/0000-0002-0459-6417; Debatin, Klaus-Michael/0000-0002-8397-1886	Deutsche Forschungsgemeinschaft [IAP6/18]; European Community	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Community(European Commission)	We thank R Agami (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for kindly providing pRETRO-SUPER vector, CA Schmitt (Berlin, Germany) for providing mouse Bcl-2 vector and A Dittrich for expert technical assistance. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, Else Kroner-Fresenius-Stiftung, IAP6/18 and the European Community (ApopTrain, APO-SYS) (to SF).	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen CS, 2007, CANCER RES, V67, P5318, DOI 10.1158/0008-5472.CAN-06-3996; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Giagkousiklidis S, 2005, CANCER RES, V65, P10502, DOI 10.1158/0008-5472.CAN-05-0866; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; Hacker S, 2009, ONCOGENE, V28, P3097, DOI 10.1038/onc.2009.161; Hess-Stumpp H, 2007, INT J BIOCHEM CELL B, V39, P1388, DOI 10.1016/j.biocel.2007.02.009; Jaboin J, 2002, CANCER RES, V62, P6108; Karl S, 2009, J CELL MOL MED, V13, P4239, DOI 10.1111/j.1582-4934.2009.00888.x; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Kuefer R, 2004, BRIT J CANCER, V90, P535, DOI 10.1038/sj.bjc.6601510; Lee MJ, 2008, CURR OPIN ONCOL, V20, P639, DOI 10.1097/CCO.0b013e3283127095; Rossi A, 2008, CLIN CANCER RES, V14, P971, DOI 10.1158/1078-0432.CCR-07-2072; Rutkowski S, 2007, CLIN CANCER RES, V13, P2651, DOI 10.1158/1078-0432.CCR-06-1779; Subramanian C, 2005, P NATL ACAD SCI USA, V102, P4842, DOI 10.1073/pnas.0408351102; Sykes SM, 2009, J BIOL CHEM, V284, P20197, DOI 10.1074/jbc.M109.026096; Tabori U, 2010, J CLIN ONCOL, V28, P1345, DOI 10.1200/JCO.2009.23.5952; Vogler M, 2008, CANCER RES, V68, P7956, DOI 10.1158/0008-5472.CAN-08-1296; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yamaguchi H, 2009, J BIOL CHEM, V284, P11171, DOI 10.1074/jbc.M809268200	24	38	38	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	19					2275	2281		10.1038/onc.2010.599	http://dx.doi.org/10.1038/onc.2010.599			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	762XD	21562496				2022-12-17	WOS:000290514600010
J	Kucejova, B; Sunny, NE; Nguyen, AD; Hallac, R; Fu, X; Pena-Llopis, S; Mason, RP; DeBerardinis, RJ; Xie, XJ; DeBose-Boyd, R; Kodibagkar, VD; Burgess, SC; Brugarolas, J				Kucejova, B.; Sunny, N. E.; Nguyen, A. D.; Hallac, R.; Fu, X.; Pena-Llopis, S.; Mason, R. P.; DeBerardinis, R. J.; Xie, X-J; DeBose-Boyd, R.; Kodibagkar, V. D.; Burgess, S. C.; Brugarolas, J.			Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic death	ONCOGENE			English	Article						Vhl; Hif; liver steatosis; mitochondrial respiration	LINDAU TUMOR-SUPPRESSOR; RENAL-CELL CARCINOMA; CYTOSOLIC PHOSPHOENOLPYRUVATE CARBOXYKINASE; FATTY-ACID OXIDATION; RETINOID-X-RECEPTOR; HEPATIC GLUCONEOGENESIS; PROLINE HYDROXYLATION; PROLYL HYDROXYLATION; HIF-ALPHA; IN-VIVO	As the ultimate electron acceptor in oxidative phosphorylation, oxygen plays a critical role in metabolism. When oxygen levels drop, heterodimeric hypoxia-inducible factor (Hif) transcription factors become active and facilitate adaptation to hypoxia. Hif regulation by oxygen requires the protein von Hippel-Lindau (pVhl) and pVhl disruption results in constitutive Hif activation. The liver is a critical organ for metabolic homeostasis, and Vhl inactivation in hepatocytes results in a Hif-dependent shortening in life span. While albumin-Cre; Vhl(F/F) mice develop hepatic steatosis and impaired fatty acid oxidation, the variable penetrance and unpredictable life expectancy has made the cause of death elusive. Using a system in which Vhl is acutely disrupted and a combination of ex vivo liver perfusion studies and in vivo oxygen measurements, we demonstrate that Vhl is essential for mitochondrial respiration in vivo. Adenovirus-Cre mediated acute Vhl disruption in the liver caused death within days. Deprived of pVhl, livers accumulated tryglicerides and circulating ketone and glucose levels dropped. The phenotype was reminiscent of inborn defects in fatty acid oxidation and of fasted PPAR alpha-deficient mice and while death was unaffected by pharmacologic PPAR alpha activation, it was delayed by glucose administration. Ex vivo liver perfusion analyses and acylcarnitine profiles showed mitochondrial impairment and a profound inhibition of liver ketone and glucose production. By contrast, other mitochondrial functions, such as ureagenesis, were unaffected. Oxygen consumption studies revealed a marked suppression of mitochondrial respiration, which, as determined by magnetic resonance oximetry in live mice, was accompanied by a corresponding increase in liver pO(2). Importantly, simultaneous inactivation of Hif-1 beta suppressed liver steatosis and rescued the mice from death. These data demonstrate that constitutive Hif activation in mice is sufficient to suppress mitochondrial respiration in vivo and that no other pathway exists in the liver that can allow oxygen utilization when Hif is active precluding thereby metabolic collapse. Oncogene (2011) 30, 2147-2160; doi:10.1038/onc.2010.587; published online 10 January 2011	[Kucejova, B.; Pena-Llopis, S.; Brugarolas, J.] Univ Texas SW Med Ctr Dallas, Dept Dev Biol, Dallas, TX 75390 USA; [Kucejova, B.; Pena-Llopis, S.; Brugarolas, J.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Oncol, Dallas, TX 75390 USA; [Kucejova, B.; Pena-Llopis, S.; Xie, X-J; Brugarolas, J.] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Sunny, N. E.; Fu, X.; Burgess, S. C.] Univ Texas SW Med Ctr Dallas, Adv Imaging Res Ctr, Dallas, TX 75390 USA; [Nguyen, A. D.; DeBose-Boyd, R.] Univ Texas SW Med Ctr Dallas, Dept Mol Genet, Dallas, TX 75390 USA; [Hallac, R.; Mason, R. P.; Kodibagkar, V. D.] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA; [DeBerardinis, R. J.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Xie, X-J] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Brugarolas, J (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Dev Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	james.brugarolas@utsouthwestern.edu	Peña-Llopis, Samuel/ABH-2358-2020; Mason, Ralph/C-8472-2012	Mason, Ralph/0000-0001-7517-3721; Nguyen, Andrew/0000-0002-9492-9472; Hallac, Rami/0000-0001-9025-399X; Pena-Llopis, Samuel/0000-0003-3847-1353; Kucejova, Blanka/0000-0002-5058-330X	American Cancer Society [115739, RO1CA129387]; Generalitat Valenciana (Spain);  [K08NS051843];  [RO1DK078184]; NATIONAL CANCER INSTITUTE [R21CA132096, R01CA139043, R01CA129387, U24CA126608] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK078184] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS051843] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); Generalitat Valenciana (Spain)(Center for Forestry Research & Experimentation (CIEF)); ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Drs Frank J Gonzalez, Volker H Haase, William Y Kim and William G Kaelin Jr for mouse strains and reagents, Dr Michael Brown for discussions, and Dr Jay D Horton for critically reading the manuscript, TianTeng He for help with liver perfusion experiments, and members of the Brugarolas lab for discussions. This work was supported by the following grants to J.B: K08NS051843, American Cancer Society Research Scholar Grant (115739) and RO1CA129387 as well as an RO1DK078184 to S.B. MRI was performed in conjunction with R01CA139043 (R.P.M.) R21CA132096 (V.D.K.) and the UT Southwestern small animal imaging research program U24 CA126608 and P41 RR02584. S.P.-L. was supported in part by a fellowship from the Generalitat Valenciana (Spain). J.B. is a Virginia Murchison Linthicum Scholar in Medical Research at UT Southwestern.	Belanger AJ, 2007, BIOCHEM BIOPH RES CO, V364, P567, DOI 10.1016/j.bbrc.2007.10.062; Bergmeyer H.U., 1974, METHOD ENZYMAT AN, VVol. 3., P1196; Burgess SC, 2004, J BIOL CHEM, V279, P48941, DOI 10.1074/jbc.M407120200; Burgess SC, 2007, CELL METAB, V5, P313, DOI 10.1016/j.cmet.2007.03.004; Burgess SC, 2006, J BIOL CHEM, V281, P19000, DOI 10.1074/jbc.M600050200; Chan SY, 2009, CELL METAB, V10, P273, DOI 10.1016/j.cmet.2009.08.015; Chen SF, 2010, ANGIOGENESIS, V13, P59, DOI 10.1007/s10456-010-9164-2; Chow TFF, 2010, CLIN BIOCHEM, V43, P150, DOI 10.1016/j.clinbiochem.2009.07.020; Ciana P, 2007, MOL ENDOCRINOL, V21, P388, DOI 10.1210/me.2006-0152; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; DOHM GL, 1972, AM J PHYSIOL, V223, P783, DOI 10.1152/ajplegacy.1972.223.4.783; FOLCH J, 1957, J BIOL CHEM, V226, P497; GEBHARD RL, 1987, J LIPID RES, V28, P1177; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1997, P NATL ACAD SCI USA, V94, P9102, DOI 10.1073/pnas.94.17.9102; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Hong SB, 2006, LAB INVEST, V86, P664, DOI 10.1038/labinvest.3700431; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Huss JM, 2001, J BIOL CHEM, V276, P27605, DOI 10.1074/jbc.M100277200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Juan D, 2010, UROLOGY, V75, P835, DOI 10.1016/j.urology.2009.10.033; Jung M, 2009, J CELL MOL MED, V13, P3918, DOI 10.1111/j.1582-4934.2009.00705.x; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kapitsinou PP, 2008, CELL DEATH DIFFER, V15, P650, DOI 10.1038/sj.cdd.4402313; Kasper LH, 2005, EMBO J, V24, P3846, DOI 10.1038/sj.emboj.7600846; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kim WY, 2006, EMBO J, V25, P4650, DOI 10.1038/sj.emboj.7601300; Kuriyama H, 2005, CELL METAB, V1, P41, DOI 10.1016/j.cmet.2004.11.004; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lei L, 2008, MOL CELL BIOL, V28, P3790, DOI 10.1128/MCB.01580-07; Liu HQ, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-51; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Mandard S, 2004, CELL MOL LIFE SCI, V61, P393, DOI 10.1007/s00018-003-3216-3; MASON RP, 1994, ARTIF CELL BLOOD SUB, V22, P1141, DOI 10.3109/10731199409138809; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McDonald JM, 2009, J ANIM SCI, V87, P3105, DOI 10.2527/jas.2009-1935; MILLINGTON DS, 1990, J INHERIT METAB DIS, V13, P321, DOI 10.1007/BF01799385; Nguyen AD, 2007, J BIOL CHEM, V282, P27436, DOI 10.1074/jbc.M704976200; Nickerson ML, 2008, CLIN CANCER RES, V14, P4726, DOI 10.1158/1078-0432.CCR-07-4921; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 2006, NEOPLASIA, V8, P623, DOI 10.1593/neo.06442; Ozer A, 2007, NAT CHEM BIOL, V3, P144, DOI 10.1038/nchembio863; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Park SK, 2007, INT J ONCOL, V30, P341; Peyssonnaux C, 2007, J CLIN INVEST, V117, P1926, DOI 10.1172/JCI31370; Rankin EB, 2008, ONCOGENE, V27, P5354, DOI 10.1038/onc.2008.160; Rankin EB, 2007, J CLIN INVEST, V117, P1068, DOI 10.1172/JCI30117; Rankin EB, 2009, MOL CELL BIOL, V29, P4527, DOI 10.1128/MCB.00200-09; Saudubray JM, 1999, J INHERIT METAB DIS, V22, P488; Simonnet H, 2002, CARCINOGENESIS, V23, P759, DOI 10.1093/carcin/23.5.759; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Taylor CT, 2008, BIOCHEM J, V409, P19, DOI 10.1042/BJ20071249; Tomita S, 2000, MOL ENDOCRINOL, V14, P1674, DOI 10.1210/me.14.10.1674; Tosi MR, 2004, INT J MOL MED, V14, P93; Wakil SJ, 2009, J LIPID RES, V50, pS138, DOI 10.1194/jlr.R800079-JLR200; WILSON CA, 1992, EXP EYE RES, V55, P119, DOI 10.1016/0014-4835(92)90099-E; Wood PA, 1999, CURR OPIN LIPIDOL, V10, P107, DOI 10.1097/00041433-199904000-00004; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zambrano NR, 1999, J UROLOGY, V162, P1246, DOI 10.1016/S0022-5347(05)68259-6; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001	65	38	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	18					2147	2160		10.1038/onc.2010.587	http://dx.doi.org/10.1038/onc.2010.587			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	759ML	21217781	Green Accepted			2022-12-17	WOS:000290249600006
J	Yang, L; Wang, H; Kornblau, SM; Graber, DA; Zhang, N; Matthews, JA; Wang, M; Weber, DM; Thomas, SK; Shah, JJ; Zhang, L; Lu, G; Zhao, M; Muddasani, R; Yoo, SY; Baggerly, KA; Orlowski, RZ				Yang, L.; Wang, H.; Kornblau, S. M.; Graber, D. A.; Zhang, N.; Matthews, J. A.; Wang, M.; Weber, D. M.; Thomas, S. K.; Shah, J. J.; Zhang, L.; Lu, G.; Zhao, M.; Muddasani, R.; Yoo, S-Y; Baggerly, K. A.; Orlowski, R. Z.			Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma	ONCOGENE			English	Article						ZKSCAN3; cyclin D2; multiple myeloma; transcription regulation; pathogenesis	ENDOTHELIAL GROWTH-FACTOR; BONE-MARROW; CANCER PROGRESSION; PRECLINICAL MODELS; C-MAF; CELL; TRANSLOCATION; VEGF; DYSREGULATION; OVEREXPRESSION	Dysregulation of cyclin D2 contributes to the pathogenesis of multiple myeloma, and can occur through translocations that activate MAF/MAFB or MMSET/FGFR3. However, cyclin D2 induction can also be seen in the absence of such translocations, such as in patients with hyperdiploid disease, through unknown mechanisms. In UniGene cluster data-mining and ECgene analysis, we found that zinc-finger with KRAB and SCAN domains 3 (ZKSCAN3), a novel transcription factor, is overrepresented in this malignancy, and three consensus ZKSCAN3 binding sites were found in the cyclin D2 promoter. Analysis of a panel of myeloma cell lines, primary patient samples and datasets from Oncomine and the Multiple Myeloma Genomics Portal (MMGP) revealed expression of ZKSCAN3 messenger RNA (mRNA) in a majority of samples. Studies of cell lines by western blotting, and of primary tissue microarrays by immunohistochemistry, showed ZKSCAN3 protein expression in a majority, and in a manner that paralleled messenger levels in cell lines. ZKSCAN3 overexpression was associated with increased gene copy number or genomic DNA gain/amplification in a subset based on analysis of data from the MMGP, and from fluorescence in situ hybridization studies of cell lines and primary samples. Overexpression of ZKSCAN3 induced cyclin D2 promoter activity in a MAF/MAFB-independent manner, and to an extent that was influenced by the number of consensus ZKSCAN3 binding sites. Moreover, ZKSCAN3 protein expression correlated with cyclin D2 levels in cell lines and primary samples, and its overexpression induced cyclin D2. Conversely, ZKSCAN3 suppression using small hairpin RNAs (shRNAs) reduced cyclin D2 levels, and, importantly, inhibited myeloma cell line proliferation. Finally, ZKSCAN3 was noted to specifically bind to oligonucleotides representing sequences from the cyclin D2 promoter, and to the endogenous promoter itself in myeloma cells. Taken together, the data support the conclusion that ZKSCAN3 induction represents a mechanism by which myeloma cells can induce cyclin D2 dysregulation, and contribute to disease pathogenesis. Oncogene (2011) 30, 1329-1340; doi:10.1038/onc.2010.515; published online 8 November 2010	[Yang, L.] Soochow Univ, Cyrus Tang Hematol Ctr, SIP, Suzhou 215123, Jiangsu, Peoples R China; [Yang, L.; Wang, H.; Matthews, J. A.; Wang, M.; Weber, D. M.; Thomas, S. K.; Shah, J. J.; Orlowski, R. Z.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA; [Wang, H.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Kornblau, S. M.] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA; [Kornblau, S. M.; Graber, D. A.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Zhang, N.; Zhang, L.; Yoo, S-Y; Baggerly, K. A.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Lu, G.; Zhao, M.; Muddasani, R.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Orlowski, R. Z.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Div Canc Med, Houston, TX 77030 USA	Soochow University - China; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Yang, L (corresponding author), Soochow Univ, Cyrus Tang Hematol Ctr, SIP, 199 Renai Rd, Suzhou 215123, Jiangsu, Peoples R China.	yanglin@suda.edu.cn; rorlowsk@mdanderson.org		Muddasani, Ramya/0000-0002-2651-8276; Orlowski, Robert/0000-0002-5723-4129	Leukemia & Lymphoma Society [6096-07]; National Cancer Institute [R01 CA102278]; NATIONAL CANCER INSTITUTE [R01CA102278, P50CA142509, P30CA016672] Funding Source: NIH RePORTER	Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to thank Dr Douglas Boyd for his contributions to the studies of the role of ZKSCAN3 in colon cancer. RZO, a Leukemia & Lymphoma Society Scholar in Clinical Research, would like to acknowledge support from the Leukemia & Lymphoma Society (6096-07) and the National Cancer Institute (R01 CA102278).	Arora T, 1998, J BIOL CHEM, V273, P11799, DOI 10.1074/jbc.273.19.11799; Bergsagel PL, 2005, J CLIN ONCOL, V23, P6333, DOI 10.1200/JCO.2005.05.021; Bergsagel PL, 2005, BLOOD, V106, P296, DOI 10.1182/blood-2005-01-0034; Carrasco DR, 2006, CANCER CELL, V9, P313, DOI 10.1016/j.ccr.2006.03.019; Chang H, 2006, BRIT J HAEMATOL, V135, P486, DOI 10.1111/j.1365-2141.2006.06325.x; Chesi M, 1996, BLOOD, V88, P674, DOI 10.1182/blood.V88.2.674.bloodjournal882674; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; FERTI A, 1984, CANCER GENET CYTOGEN, V12, P247, DOI 10.1016/0165-4608(84)90036-0; Gabrea A, 1999, MOL CELL, V3, P119, DOI 10.1016/S1097-2765(00)80180-X; Gutierrez NC, 2004, BLOOD, V104, P2661, DOI 10.1182/blood-2004-04-1319; Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189; Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535-6108(04)00019-4; Kuhn DJ, 2007, BLOOD, V110, P3281, DOI 10.1182/blood-2007-01-065888; Kumar S, 2003, LEUKEMIA, V17, P2025, DOI 10.1038/sj.leu.2403084; Kyle RA, 2008, BLOOD, V111, P2962, DOI 10.1182/blood-2007-10-078022; Largo C, 2007, HAEMATOLOGICA, V92, P795, DOI 10.3324/haematol.11052; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; Lu G, 2010, CANCER GENET CYTOGEN, V196, P56, DOI 10.1016/j.cancergencyto.2009.08.021; Markovic O, 2008, MED ONCOL, V25, P451, DOI 10.1007/s12032-008-9066-y; Perez-Simon JA, 1998, BLOOD, V91, P3366, DOI 10.1182/blood.V91.9.3366.3366_3366_3371; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; Ria R, 2004, THROMB HAEMOSTASIS, V92, P1438, DOI 10.1160/TH04-06-0334; Santos GC, 2007, J CLIN PATHOL, V60, P1, DOI 10.1136/jcp.2005.034389; Shaughnessy J, 2001, BLOOD, V98, P217, DOI 10.1182/blood.V98.1.217; Voorhees PM, 2007, CLIN CANCER RES, V13, P6469, DOI 10.1158/1078-0432.CCR-07-1293; Yang L, 2008, CANCER RES, V68, P4321, DOI 10.1158/0008-5472.CAN-08-0407; Yang L, 2008, J BIOL CHEM, V283, P35295, DOI 10.1074/jbc.M806965200	29	38	40	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	11					1329	1340		10.1038/onc.2010.515	http://dx.doi.org/10.1038/onc.2010.515			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	736JX	21057542	Green Accepted			2022-12-17	WOS:000288492100007
J	Bengoechea-Alonso, MT; Ericsson, J				Bengoechea-Alonso, M. T.; Ericsson, J.			Tumor suppressor Fbxw7 regulates TGF beta signaling by targeting TGIF1 for degradation	ONCOGENE			English	Article						TGF beta; TGIF; Fbxw7; ubiquitin; tumor suppressor; protein degradation	SMAD TRANSCRIPTIONAL COREPRESSOR; F-BOX PROTEIN; PHOSPHORYLATION-DEPENDENT DEGRADATION; FBW7 UBIQUITIN LIGASE; CYCLIN-E; C-MYC; GROWTH; TRANSDUCTION; SCFFBW7; CANCER	Transforming growth factor-beta (TGF beta) signaling regulates multiple cellular processes, including extracellular matrix production, cell growth, apoptosis and differentiation. Dysfunction of TGF beta signaling has been implicated in various human disorders ranging from vascular diseases to cancer. TGF beta signaling is negatively regulated by the transcriptional repressor TGF beta-induced factor 1 (TGIF1). The tumor suppressor Fbxw7 is the substrate-recognition factor of a ubiquitin ligase that targets multiple proteins for degradation, including c-Myc, cyclin E, c-Jun and Notch. Here, we describe that TGIF1 is targeted for degradation by Fbxw7 in a phosphorylation-dependent manner. Inactivation of Fbxw7 results in the accumulation of phosphorylated TGIF1 molecules and repression of TGF beta-dependent transcription. Cancer cell lines with inactivating mutations in Fbxw7 show enhanced levels of TGIF1 and attenuated TGF beta-dependent signaling. Importantly, inactivation of Fbxw7 attenuates TGF beta-dependent regulation of cell growth and migration. Taken together, our results suggest that Fbxw7 is a novel regulator of TGF beta signaling. Oncogene (2010) 29, 5322-5328; doi: 10.1038/onc.2010.278; published online 12 July 2010	[Bengoechea-Alonso, M. T.; Ericsson, J.] Univ Coll Dublin, UCD Conway Inst, Sch Med & Med Sci, Dublin D4, Ireland	University College Dublin	Ericsson, J (corresponding author), Univ Coll Dublin, UCD Conway Inst, Sch Med & Med Sci, Dublin D4, Ireland.	johan.ericsson@ucd.ie	Ericsson, Johan/AAA-6664-2020	Ericsson, Johan/0000-0003-1186-6574	Ludwig Institute for Cancer Research Ltd.; Science Foundation Ireland [07/SK/B1242b]	Ludwig Institute for Cancer Research Ltd.; Science Foundation Ireland(Science Foundation IrelandEuropean Commission)	We thank Ulla Engstrom for peptide synthesis and antibody purification, and Aris Moustakas, Lars van der Heide and Peter Lonn for plasmids, antibodies and advice. This work was supported by a grant from the Ludwig Institute for Cancer Research Ltd. JE is the recipient of a Science Foundation Ireland Stokes Professorship Award (07/SK/B1242b).	Bartholin L, 2006, MOL CELL BIOL, V26, P990, DOI 10.1128/MCB.26.3.990-1001.2006; Bengoechea-Alonso MT, 2009, J BIOL CHEM, V284, P5885, DOI 10.1074/jbc.M807906200; Faresse N, 2008, EMBO J, V27, P1804, DOI 10.1038/emboj.2008.109; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Lo RS, 2001, EMBO J, V20, P128, DOI 10.1093/emboj/20.1.128; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x; Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338; Onoyama I, 2008, CELL CYCLE, V7, P3307, DOI 10.4161/cc.7.21.6931; Pessah M, 2001, P NATL ACAD SCI USA, V98, P6198, DOI 10.1073/pnas.101579798; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Tetzlaff MT, 2004, P NATL ACAD SCI USA, V101, P3338, DOI 10.1073/pnas.0307875101; Tsunematsu R, 2004, J BIOL CHEM, V279, P9417, DOI 10.1074/jbc.M312337200; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Wotton D, 1999, J BIOL CHEM, V274, P37105, DOI 10.1074/jbc.274.52.37105; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Wotton D, 2001, CELL GROWTH DIFFER, V12, P457; Wu MY, 2009, DEV CELL, V16, P329, DOI 10.1016/j.devcel.2009.02.012; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217	26	38	39	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	38					5322	5328		10.1038/onc.2010.278	http://dx.doi.org/10.1038/onc.2010.278			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	653KE	20622901				2022-12-17	WOS:000282089100010
J	Feng, ZJ; Gao, SB; Wu, Y; Xu, XF; Hua, X; Jin, GH				Feng, Z-J; Gao, S-B; Wu, Y.; Xu, X-F; Hua, X.; Jin, G-H			Lung cancer cell migration is regulated via repressing growth factor PTN/RPTP beta/zeta signaling by menin	ONCOGENE			English	Article						lung cancer; migration; Men1; pleiotrophin; RPTP beta/zeta	FOCAL-ADHESION KINASE; TYROSINE-PHOSPHATASE BETA/ZETA; UP-REGULATION; GENE; PLEIOTROPHIN; INTEGRIN; FAK; METASTASIS; INVASION; PATHWAY	Menin encoded by the multiple endocrine neoplasia type 1 (MEN1) gene is associated with chromatin and the nuclear matrix and exerts multiple biological functions including regulation of cell proliferation and adhesion. Men1 mutations increase the likelihood of lung cancer development in mice. Menin expression is reduced in certain human non-small cell lung cancer cells, and reduction of menin is closely correlated with increased lung cancer metastasis to lymph nodes. However, it is poorly understood whether menin affects migration of lung cancer cells. In this study, we show that meninregulated A549 lung cancer cell migration, which was mediated by growth factor pleiotrophin (PTN) and its cell surface receptor, protein tyrosine phosphatase beta/zeta (RPTP beta/zeta). Ectopic menin expression significantly repressed PTN transcription, but indirectly inhibited RPTP beta/zeta expression through repressing PTN expression. Further studies revealed that menin-regulated cell migration through PTN/RPTP beta/zeta, in conjunction with integrin alpha(v)beta(3), focal adhesion kinase, phosphatidylinositol 3-kinase and phosphorylated extracellular signal regulated kinase 1/2. These findings provide mechanistic insights into the molecular basis for menin/PTN-mediated regulation of A549 lung cancer cell migration. Oncogene (2010) 29, 5416-5426; doi: 10.1038/onc.2010.282; published online 19 July 2010	[Feng, Z-J; Gao, S-B; Wu, Y.; Jin, G-H] Xiamen Univ, Dept Basic Med Sci, Coll Med, Xiamen 361005, Fujian, Peoples R China; [Xu, X-F] Xiamen Second Hosp, Dept Pathol, Xiamen, Fujian, Peoples R China; [Hua, X.] Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA	Xiamen University; University of Pennsylvania	Jin, GH (corresponding author), Xiamen Univ, Dept Basic Med Sci, Coll Med, Daxue Rd 168, Xiamen 361005, Fujian, Peoples R China.	huax@mail.med.upenn.edu; ghjin@xmu.edu.cn		Feng, Zijie/0000-0002-5633-3686	NFSC [30701003]; National Cancer Institute [R01CA113962]; NATIONAL CANCER INSTITUTE [R01CA113962] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK097555] Funding Source: NIH RePORTER	NFSC(National Natural Science Foundation of China (NSFC)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work is supported by an NFSC grant (No. 30701003, GH Jin) and a National Cancer Institute grant (R01CA113962, XH). We appreciate the valuable comments from other members of our laboratories.	Baillat G, 2008, BBA-MOL CELL RES, V1783, P2323, DOI 10.1016/j.bbamcr.2008.08.008; Carelli S, 2006, LUNG CANCER, V53, P263, DOI 10.1016/j.lungcan.2006.06.001; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Chen JS, 2009, HEPATOL RES, V39, P177, DOI 10.1111/j.1872-034X.2008.00449.x; Chen YJ, 2009, J CELL PHYSIOL, V221, P98, DOI 10.1002/jcp.21835; Debelenko LV, 2000, GENE CHROMOSOME CANC, V28, P58, DOI 10.1002/(SICI)1098-2264(200005)28:1<58::AID-GCC7>3.0.CO;2-2; Debelenko LV, 1997, HUM MOL GENET, V6, P2285, DOI 10.1093/hmg/6.13.2285; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Duces A, 2008, MOL CANCER THER, V7, P2817, DOI 10.1158/1535-7163.MCT-08-0301; Gao SB, 2008, ANN ENDOCRINOL-PARIS, V69, P426, DOI 10.1016/j.ando.2008.06.001; Gao SB, 2009, ONCOGENE, V28, P4095, DOI 10.1038/onc.2009.273; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Jager R, 2002, BRIT J CANCER, V86, P858, DOI 10.1038/sj.bjc.6600202; Jin GH, 2007, INT J CANCER, V121, P2539, DOI 10.1002/ijc.22708; Karnik SK, 2005, P NATL ACAD SCI USA, V102, P14659, DOI 10.1073/pnas.0503484102; Klein CA, 2008, SCIENCE, V321, P1785, DOI 10.1126/science.1164853; Lemos MC, 2008, HUM MUTAT, V29, P22, DOI 10.1002/humu.20605; Liu GY, 2008, CELL BIOL INT, V32, P663, DOI 10.1016/j.cellbi.2008.01.292; Lu KV, 2005, J BIOL CHEM, V280, P26953, DOI 10.1074/jbc.M502614200; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; Meng XN, 2009, BRIT J CANCER, V101, P327, DOI 10.1038/sj.bjc.6605154; Mikelis C, 2009, FASEB J, V23, P1459, DOI 10.1096/fj.08-117564; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Molloy T, 2008, CURR OPIN GENET DEV, V18, P35, DOI 10.1016/j.gde.2008.01.019; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Palazzo AF, 2004, SCIENCE, V303, P836, DOI 10.1126/science.1091325; Pannett AAJ, 1999, ENDOCR-RELAT CANCER, V6, P449, DOI 10.1677/erc.0.0060449; Pariser H, 2005, BIOCHEM BIOPH RES CO, V332, P664, DOI 10.1016/j.bbrc.2005.05.007; Pei XH, 2007, CANCER RES, V67, P3162, DOI 10.1158/0008-5472.CAN-06-4517; Perez-Pinera P, 2007, CELL CYCLE, V6, P2877, DOI 10.4161/cc.6.23.5090; Petzmann S, 2001, HUM PATHOL, V32, P333, DOI 10.1053/hupa.2001.22762; Polykratis A, 2005, J BIOL CHEM, V280, P22454, DOI 10.1074/jbc.M414407200; Schnepp RW, 2006, CANCER RES, V66, P5707, DOI 10.1158/0008-5472.CAN-05-4518; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Tamura M, 1999, JNCI-J NATL CANCER I, V91, P1820, DOI 10.1093/jnci/91.21.1820; von Wichert G, 2003, J CELL BIOL, V161, P143, DOI 10.1083/jcb.200211061; Weng TT, 2009, J BIOL CHEM, V284, P28021, DOI 10.1074/jbc.M109.052530; Wu Xinjiang, 2008, Curr Mol Med, V8, P805, DOI 10.2174/156652408786733702; Yan J, 2009, ONCOGENE, V28, P973, DOI 10.1038/onc.2008.435	42	38	44	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	39					5416	5426		10.1038/onc.2010.282	http://dx.doi.org/10.1038/onc.2010.282			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664EZ	20639902	hybrid, Green Published			2022-12-17	WOS:000282944500008
J	Lyngaa, R; Norregaard, K; Kristensen, M; Kubale, V; Rosenkilde, MM; Kledal, TN				Lyngaa, R.; Norregaard, K.; Kristensen, M.; Kubale, V.; Rosenkilde, M. M.; Kledal, T. N.			Cell transformation mediated by the Epstein-Barr virus G protein-coupled receptor BILF1 is dependent on constitutive signaling	ONCOGENE			English	Article						Epstein-Barr virus; cell transformation; G protein-coupled receptor; constitutive activity; signaling; VEGF	SARCOMA-ASSOCIATED HERPESVIRUS; ENDOTHELIAL GROWTH-FACTOR; NF-KAPPA-B; KAPOSIS-SARCOMA; 7-TRANSMEMBRANE RECEPTOR; LYTIC INFECTION; CHEMOKINE; EXPRESSION; GENE; US28	Epstein-Barr virus (EBV) open reading frame BILF1 encodes a seven trans-membrane (TM) G protein-coupled receptor that signals with high constitutive activity through G alpha(i) (Beisser et al., 2005; Paulsen et al., 2005). In this paper, the transforming potential of BILF1 is investigated in vitro in a foci formation assay using retrovirally transduced NIH3T3 cells, as well as in vivo by using nude mice. BILF1 revealed a substantial transforming potential that was dependent on constitutive signaling, as a signaling-deficient mutant completely lost its ability to transform cells in vitro, and an intermediately active triple-mutated receptor possessed an intermediate transforming potential. Furthermore, BILF1 expression induced vascular endothelial growth factor secretion in a constitutively active manner. In nude mice, BILF1 promoted tumor formation in 90% of cases, ORF74 (from Kaposi's sarcoma-associated herpes virus) in 100% of cases, whereas the signaling-deficient receptor resulted in tumor establishment in 40% of cases. These data suggest that BILF1, when expressed during EBV infection, could indeed be involved in the pathogenesis of EBV-associated diseases and malignancies. Furthermore, the correlation between receptor activity and the ability to mediate cell transformation in vitro and tumor formation in vivo supports the idea that inverse agonists for BILF1 could inhibit cell transformation and be relevant therapeutic candidates. Oncogene (2010) 29, 4388-4398; doi: 10.1038/onc.2010.173; published online 14 June 2010	[Lyngaa, R.; Kristensen, M.; Kledal, T. N.] Danish Tech Univ, Lab Cell Biol & Virol, DTU Nanotech, Dept Micro & Nanotechnol, DK-4000 Roskilde, Denmark; [Norregaard, K.; Kubale, V.; Rosenkilde, M. M.] Univ Copenhagen, Mol Pharmacol Lab, Dept Neurosci & Pharmacol, Fac Hlth Sci, Copenhagen, Denmark	Technical University of Denmark; University of Copenhagen	Kledal, TN (corresponding author), Danish Tech Univ, Virol Dept Micro & Nanotechnol, DTU Nanotech, Frederiksborgvej 399,Build 330, DK-4000 Roskilde, Denmark.	tnkl@risoe.dtu.dk		Rosenkilde, Mette Marie/0000-0001-9600-3254				Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Beisser PS, 2005, J VIROL, V79, P441, DOI 10.1128/JVI.79.1.441-449.2005; Beisser PS, 1999, J VIROL, V73, P7218, DOI 10.1128/JVI.73.9.7218-7230.1999; Bodaghi B, 1998, J EXP MED, V188, P855, DOI 10.1084/jem.188.5.855; Burger M, 1999, J IMMUNOL, V163, P2017; Cesarman E, 2000, J EXP MED, V191, P417, DOI 10.1084/jem.191.3.417; DavisPoynter NJ, 1997, J VIROL, V71, P1521, DOI 10.1128/JVI.71.2.1521-1529.1997; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Geras-Raaka E, 1998, BIOCHEM BIOPH RES CO, V253, P725, DOI 10.1006/bbrc.1998.9557; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Ho HH, 2001, J BIOL CHEM, V276, P1376, DOI 10.1074/jbc.M007885200; Hong GK, 2005, J VIROL, V79, P13984, DOI 10.1128/JVI.79.22.13984-13992.2005; Hong GK, 2005, J VIROL, V79, P13993, DOI 10.1128/JVI.79.22.13993-14003.2005; Kieff E, 2007, FIELDS VIROLOGY, P2603; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; Krishna SM, 2006, VIRUS RES, V115, P85, DOI 10.1016/j.virusres.2005.07.010; Maussang D, 2006, P NATL ACAD SCI USA, V103, P13068, DOI 10.1073/pnas.0604433103; McLean KA, 2004, VIROLOGY, V325, P241, DOI 10.1016/j.virol.2004.04.027; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Montone KT, 1996, MODERN PATHOL, V9, P621; Murono S, 2001, P NATL ACAD SCI USA, V98, P6905, DOI 10.1073/pnas.121016998; O'Neil JD, 2008, J GEN VIROL, V89, P2833, DOI 10.1099/vir.0.2008/003392-0; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; Pati S, 2001, J VIROL, V75, P8660, DOI 10.1128/JVI.75.18.8660-8673.2001; Paulsen SJ, 2005, J VIROL, V79, P536, DOI 10.1128/JVI.79.1.536-546.2005; Paydas S, 2008, LEUKEMIA RES, V32, P1424, DOI 10.1016/j.leukres.2008.01.008; Pleskoff O, 2005, FEBS J, V272, P4163, DOI 10.1111/j.1742-4658.2005.04829.x; Rajagopal K, 2005, J CLIN INVEST, V115, P2971, DOI 10.1172/JCI26950; Rosenkilde MM, 2008, BRIT J PHARMACOL, V153, pS154, DOI 10.1038/sj.bjp.0707660; Rosenkilde MM, 2006, J BIOL CHEM, V281, P13199, DOI 10.1074/jbc.M602245200; Rosenkilde MM, 2006, CURR DRUG TARGETS, V7, P103, DOI 10.2174/138945006775270259; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rosenkilde MM, 2005, MOL PHARMACOL, V68, P11, DOI 10.1124/mol.105.011239; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; Sheng W, 2003, J VIROL, V77, P3859, DOI 10.1128/JVI.77.6.3859-3865.2003; Smit MJ, 2002, J VIROL, V76, P1744, DOI 10.1128/JVI.76.4.1744-1752.2002; Sodhi A, 2000, CANCER RES, V60, P4873; Streblow DN, 2003, J BIOL CHEM, V278, P50456, DOI 10.1074/jbc.M307936200; Vieira J, 1998, J VIROL, V72, P8158, DOI 10.1128/JVI.72.10.8158-8165.1998; Vischer HF, 2008, BIOCHEM BIOPH RES CO, V377, P93, DOI 10.1016/j.bbrc.2008.09.082; Waldhoer M, 2002, J VIROL, V76, P8161, DOI 10.1128/JVI.76.16.8161-8168.2002; Walling DM, 2003, J INFECT DIS, V188, P883, DOI 10.1086/378072; Xue SA, 2002, INT J CANCER, V99, P635, DOI 10.1002/ijc.10372; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Zuo JM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000255	47	38	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2010	29	31					4388	4398		10.1038/onc.2010.173	http://dx.doi.org/10.1038/onc.2010.173			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634DG	20543866				2022-12-17	WOS:000280559100003
J	Salmeen, A; Park, BO; Meyer, T				Salmeen, A.; Park, B. O.; Meyer, T.			The NADPH oxidases NOX4 and DUOX2 regulate cell cycle entry via a p53-dependent pathway	ONCOGENE			English	Article						NADPH oxidases; redox signaling; p53; NOX4; DUOX2	SMOOTH-MUSCLE-CELLS; EPIDERMAL-GROWTH-FACTOR; REACTIVE OXYGEN; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTION REPRESSION; RETINOBLASTOMA PROTEIN; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; NAD(P)H OXIDASE	Reactive oxygen species (ROS) are produced in growth factor-signaling pathways leading to cell proliferation, but the mechanisms leading to ROS generation and the targets of ROS signals are not well understood. Using a focused siRNA screen to identify redox-related proteins required for growth factor-induced cell cycle entry, we show that two ROS-generating proteins, the NADPH oxidases NOX4 and DUOX2, are required for platelet-derived growth factor (PDGF) induced retinoblastoma protein (Rb) phosphorylation in normal human fibroblasts. Unexpectedly, NOX4 and DUOX2 knockdown did not inhibit the early signaling pathways leading to cyclin D1 upregulation. However, hours after growth factor stimulation, NOX4 and DUOX2 knockdown reduced ERK1 phosphorylation and increased levels of the tumor suppressor protein p53 and a cell cycle inhibitor protein p21 (Waf1/Cip1) that is transcriptionally regulated by p53. Co-knockdown of NOX4 or DUOX2 with either p53 or with p21 overcame the inhibition of Rb phosphorylation that occurred with NOX4 or DUOX2 knockdown alone. Our results argue that rather than primarily affecting growth factor receptor signaling, NOX4 and DUOX2 regulate cell cycle entry as part of a p53-dependent checkpoint for proliferation. Oncogene (2010) 29, 4473-4484; doi: 10.1038/onc.2010.200; published online 7 June 2010	[Salmeen, A.; Park, B. O.; Meyer, T.] Stanford Univ, Sch Med, Dept Chem & Syst Biol, Clark Ctr W200, Stanford, CA 94305 USA	Stanford University	Salmeen, A (corresponding author), Stanford Univ, Sch Med, Dept Chem & Syst Biol, Clark Ctr W200, 318 Campus Dr, Stanford, CA 94305 USA.	tobias1@stanford.edu		Meyer, Tobias/0000-0003-4339-3804	Burroughs Wellcome Fund; Helen Hay Whitney Foundation/Paul Sigler Agouron Institute; NIH [R33 CA 120732]; NATIONAL CANCER INSTITUTE [R33CA120732] Funding Source: NIH RePORTER	Burroughs Wellcome Fund(Burroughs Wellcome Fund); Helen Hay Whitney Foundation/Paul Sigler Agouron Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Won Do Heo for his assistance with the cell cycle entry assay, Dr Dan Kaplan, Dr Sean Collins and Dr Karlene Cimprich for their critical reading of the article and members of the Meyer lab and Renee Paulsen for helpful discussions. This work was supported by a Career Award in the Biomedical Sciences from the Burroughs Wellcome Fund (AS), by a Helen Hay Whitney Foundation/Paul Sigler Agouron Institute post-doctoral fellowship (AS) and by an NIH grant R33 CA 120732 (TM).	Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Burch PM, 2005, ANTIOXID REDOX SIGN, V7, P741, DOI 10.1089/ars.2005.7.741; Burhans WC, 2009, FREE RADICAL BIO MED, V47, P1282, DOI 10.1016/j.freeradbiomed.2009.05.026; Chambard JC, 2007, BBA-MOL CELL RES, V1773, P1299, DOI 10.1016/j.bbamcr.2006.11.010; Chen K, 2008, J CELL BIOL, V181, P1129, DOI 10.1083/jcb.200709049; Cucoranu I, 2005, CIRC RES, V97, P900, DOI 10.1161/01.RES.0000187457.24338.3D; Hainaut P, 2001, ANTIOXID REDOX SIGN, V3, P611, DOI 10.1089/15230860152542961; Janssen-Heininger YMW, 2008, FREE RADICAL BIO MED, V45, P1, DOI 10.1016/j.freeradbiomed.2008.03.011; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Keyse SM, 2008, CANCER METAST REV, V27, P253, DOI 10.1007/s10555-008-9123-1; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Laurent E, 2008, INT J CANCER, V123, P100, DOI 10.1002/ijc.23423; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Li MX, 2003, J BIOL CHEM, V278, P41059, DOI 10.1074/jbc.M307149200; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Liu YX, 2008, MOL CANCER RES, V6, P624, DOI 10.1158/1541-7786.MCR-07-2019; Mahadev K, 2004, MOL CELL BIOL, V24, P1844, DOI 10.1128/MCB.24.5.1844-1854.2004; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Myers JW, 2003, NAT BIOTECHNOL, V21, P324, DOI 10.1038/nbt792; Park HS, 2005, DIABETES, V54, P3175, DOI 10.2337/diabetes.54.11.3175; Park HS, 2004, MOL CELL BIOL, V24, P4384, DOI 10.1128/MCB.24.10.4384-4394.2004; Petry A, 2006, ANTIOXID REDOX SIGN, V8, P1473, DOI 10.1089/ars.2006.8.1473; Ranjan P, 2006, ANTIOXID REDOX SIGN, V8, P1447, DOI 10.1089/ars.2006.8.1447; Rhee S G, 2000, Sci STKE, V2000, ppe1; Sturrock A, 2006, AM J PHYSIOL-LUNG C, V290, pL661, DOI 10.1152/ajplung.00269.2005; Sturrock A, 2007, AM J PHYSIOL-LUNG C, V292, pL1543, DOI 10.1152/ajplung.00430.2006; Sun XZ, 2003, ANTIOXID REDOX SIGN, V5, P655, DOI 10.1089/152308603770310338; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Velu CS, 2007, BIOCHEMISTRY-US, V46, P7765, DOI 10.1021/bi700425y; Ward JPT, 2008, BBA-BIOENERGETICS, V1777, P1, DOI 10.1016/j.bbabio.2007.10.010; Wilkinson DS, 2008, MOL CELL BIOL, V28, P1988, DOI 10.1128/MCB.01442-07; Wilkinson DS, 2005, MOL CELL BIOL, V25, P1200, DOI 10.1128/MCB.25.3.1200-1212.2005; Winterbourn CC, 2008, FREE RADICAL BIO MED, V45, P549, DOI 10.1016/j.freeradbiomed.2008.05.004; Winterbourn CC, 2008, NAT CHEM BIOL, V4, P278, DOI 10.1038/nchembio.85; Wu GS, 2004, CANCER BIOL THER, V3, P156, DOI 10.4161/cbt.3.2.614; Yamaura M, 2009, CANCER RES, V69, P2647, DOI 10.1158/0008-5472.CAN-08-3745; Yao G, 2008, NAT CELL BIOL, V10, P476, DOI 10.1038/ncb1711; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	43	38	38	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2010	29	31					4473	4484		10.1038/onc.2010.200	http://dx.doi.org/10.1038/onc.2010.200			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634DG	20531308	Green Accepted			2022-12-17	WOS:000280559100010
J	Wu, HH; Cheng, YW; Chang, JT; Wu, TC; Liu, WS; Chen, CY; Lee, H				Wu, H-H; Cheng, Y-W; Chang, J. T.; Wu, T-C; Liu, W-S; Chen, C-Y; Lee, H.			Subcellular localization of apurinic endonuclease 1 promotes lung tumor aggressiveness via NF-kappa B activation	ONCOGENE			English	Article						cytoplasmic Ape1; NF-kappa B; Cox-2; lung tumor metastasis	FACTOR-I; HUMAN-MELANOMA; CANCER; EXPRESSION; APE1/REF-1; P53; APE/REF-1; ALPHA; RESVERATROL; PROGRESSION	Apurinic endonuclease 1 (Ape1) is not only involved in base excision repair, but also activates some transcriptional factors through its redox activity. However, which subcellular localization of Ape1 is involved in the activation of transcriptional factor remains unclear. We first observed that Cox-2 expression was associated with cytoplasmic Ape1 expression in lung tumors and cancer cell lines. We thus hypothesize that nuclear factor (NF)-kappa B is activated by cytoplasmic Ape1 to cause Cox-2 expression. Herein, we generated cytoplasmic and nuclear Ape1 in Ape1-knockdown lung cancer cells by exogenous expression of Ape1 containing various deletions and/or mutations of the nuclear localization sequence. It was observed that cytoplasmic Ape1, but not nuclear Ape1, induced Cox-2 expression through NF-kappa B activation. NF-kappa B activation by cytoplasmic Ape1 was diminished by the Ape1 redox activity inhibitor resveratrol. Cells expressing cytoplasmic Ape1 exhibited tumor progression and metastasis in vitro and in vivo as xenografts, but cells expressing nuclear Ape1 did not. Patients with tumors containing elevated cytoplasmic Ape1 had a poor prognosis and a 3.722-fold risk of tumor recurrence and/or metastasis. Cytoplasmic Ape1 could therefore enhance lung tumor malignancy through NF-kappa B activation, suggesting that combination of cisplatin and specific redox inhibitor could improve chemotherapeutic response in patients with tumors containing elevated cytoplasmic Ape1. Oncogene (2010) 29, 4330-4340; doi:10.1038/onc.2010.178; published online 24 May 2010	[Wu, H-H; Chang, J. T.; Lee, H.] Chung Shan Med Univ, Inst Med & Mol Toxicol, Taichung 402, Taiwan; [Cheng, Y-W; Lee, H.] Chung Shan Med Univ, Inst Med, Taichung 402, Taiwan; [Wu, T-C] Chung Shan Med Univ Hosp, Div Chest Med, Dept Internal Med, Taichung, Taiwan; [Liu, W-S] Chung Shan Med Univ Hosp, Dept Radiat Oncol, Taichung, Taiwan; [Chen, C-Y] China Med Univ Hosp, Dept Surg, Taichung, Taiwan; [Lee, H.] Natl Hlth Res Inst, Div Environm Hlth & Occupat Med, Zhunan, Taiwan	Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University; Chung Shan Medical University Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan; National Health Research Institutes - Taiwan	Lee, H (corresponding author), Chung Shan Med Univ, Inst Med & Mol Toxicol, 110,Sec 1,Jianguo N Rd, Taichung 402, Taiwan.	hlee@nhri.gov.tw	Lee, Huei/B-2664-2010		National Health Research Institute [NHRI96-TD-G-111-006, NHRI97-TD-G-111-006]; National Science Council of Taiwan, ROC [NSC-96-2628-B-040-002-MY3]	National Health Research Institute(National Health Research Institutes - Taiwan); National Science Council of Taiwan, ROC(Ministry of Science and Technology, Taiwan)	This work was jointly supported by grants from the National Health Research Institute (NHRI96-TD-G-111-006; NHRI97-TD-G-111-006) and the National Science Council (NSC-96-2628-B-040-002-MY3) of Taiwan, ROC.	Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Ando K, 2008, NUCLEIC ACIDS RES, V36, P4327, DOI 10.1093/nar/gkn416; Angkeow P, 2002, CELL DEATH DIFFER, V9, P717, DOI 10.1038/sj.cdd.4401025; Athar M, 2007, TOXICOL APPL PHARM, V224, P274, DOI 10.1016/j.taap.2006.12.025; Bapat A, 2009, ANTIOXID REDOX SIGN, V11, P651, DOI [10.1089/ars.2008.2218, 10.1089/ARS.2008.2218]; Bhakat KK, 2009, ANTIOXID REDOX SIGN, V11, P621, DOI [10.1089/ars.2008.2198, 10.1089/ARS.2008.2198]; Busso CS, 2009, ONCOGENE, V28, P1616, DOI 10.1038/onc.2009.5; Chen GA, 2005, P NATL ACAD SCI USA, V102, P12507, DOI 10.1073/pnas.0500397102; CHENG YW, 2004, CANCER RES, V67, P10686; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Dey A, 2008, NAT REV DRUG DISCOV, V7, P1031, DOI 10.1038/nrd2759; Di Maso V, 2007, MOL MED, V13, P89, DOI 10.2119/2006-00084.DiMaso; Fantini D, 2008, FREE RADICAL RES, V42, P20, DOI 10.1080/10715760701765616; Freitas S, 2003, CLIN CANCER RES, V9, P4689; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Jackson EB, 2005, NUCLEIC ACIDS RES, V33, P3303, DOI 10.1093/nar/gki641; Jiang YX, 2001, ONCOGENE, V20, P2254, DOI 10.1038/sj.onc.1204293; Kakolyris S, 1998, HISTOPATHOLOGY, V33, P561; Kakolyris S, 1999, J PATHOL, V189, P351, DOI 10.1002/(SICI)1096-9896(199911)189:3<351::AID-PATH435>3.0.CO;2-1; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kelly JW, 2000, NAT STRUCT BIOL, V7, P824, DOI 10.1038/82815; Liu J, 2006, MOL CANCER RES, V4, P803, DOI 10.1158/1541-7786.MCR-06-0201; Maeda S, 2008, CANCER SCI, V99, P836, DOI 10.1111/j.1349-7006.2008.00763.x; Moore DH, 2000, CLIN CANCER RES, V6, P602; Nishi T, 2002, J BIOL CHEM, V277, P44548, DOI 10.1074/jbc.M202970200; Pines A, 2005, NUCLEIC ACIDS RES, V33, P4379, DOI 10.1093/nar/gki751; Puglisi F, 2002, ONCOL REP, V9, P11; Puglisi F, 2001, ANTICANCER RES, V21, P4041; Qu J, 2007, NUCLEIC ACIDS RES, V35, P2522, DOI 10.1093/nar/gkl1163; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Shimizu N, 2000, NAT BIOTECHNOL, V18, P877, DOI 10.1038/78496; Stathopoulos GT, 2008, MOL CANCER RES, V6, P364, DOI 10.1158/1541-7786.MCR-07-0309; Stathopoulos GT, 2007, P NATL ACAD SCI USA, V104, P18514, DOI 10.1073/pnas.0705316104; Tang XM, 2006, CANCER, V107, P2637, DOI 10.1002/cncr.22315; Tell G, 2009, ANTIOXID REDOX SIGN, V11, P601, DOI 10.1089/ars.2008.2194; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Van Waes C, 2007, CLIN CANCER RES, V13, P1076, DOI 10.1158/1078-0432.CCR-06-2221; Weisz L, 2007, CANCER RES, V67, P2396, DOI 10.1158/0008-5472.CAN-06-2425; Wu C, 2003, J BIOL CHEM, V278, P31980, DOI 10.1074/jbc.M304278200; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Xu Y, 1997, ANTICANCER RES, V17, P3713; Yang S, 2005, MOL CANCER THER, V4, P1923, DOI 10.1158/1535-7163.MCT-05-0229; Yang Z, 2008, MOL CANCER THER, V7, P3751, DOI 10.1158/1535-7163.MCT-08-0562; Zaky A, 2008, NUCLEIC ACIDS RES, V36, P1555, DOI 10.1093/nar/gkm1173	45	38	39	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2010	29	30					4330	4340		10.1038/onc.2010.178	http://dx.doi.org/10.1038/onc.2010.178			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20498636	Bronze			2022-12-17	WOS:000280547900009
J	Tajima, K; Ohashi, R; Sekido, Y; Hida, T; Nara, T; Hashimoto, M; Iwakami, S; Minakata, K; Yae, T; Takahashi, F; Saya, H; Takahashi, K				Tajima, K.; Ohashi, R.; Sekido, Y.; Hida, T.; Nara, T.; Hashimoto, M.; Iwakami, S.; Minakata, K.; Yae, T.; Takahashi, F.; Saya, H.; Takahashi, K.			Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells	ONCOGENE			English	Article						osteopontin; mesothelioma; multidrug resistance; hyaluronan; CD44	MALIGNANT PLEURAL MESOTHELIOMA; RANDOMIZED PHASE-II; LUNG-CANCER CELLS; LEUKEMIA GROUP-B; EPITHELIAL-CELLS; PROGNOSTIC-FACTORS; NONSMALL CELL; TUMOR-CELLS; APOPTOSIS; LINES	Malignant pleural mesothelioma (MPM) is resistant to chemotherapy and thus shows a dismal prognosis. Osteopontin (OPN), a secreted noncollagenous and phosphoprotein, is suggested to be involved in the pathogenesis of MPM. However, the precise role of OPN, especially in the multidrug resistance of MPM, remains to be elucidated. We therefore established stable transfectants (ACC-MESO-1/OPN), which constitutively express OPN, to determine its role in the chemoresistance observed in MPM. The introduction of the OPN gene provides MPM cells with upregulated multidrug resistance through the mechanism of enhanced hyaluronate (HA) binding. The expression of CD44 variant isoforms, which inhibit HA binding, significantly decreased in ACC-MESO-1/OPN cells in comparison to control transfectants. Interestingly, the inhibition of the HA-CD44 interaction abrogated multidrug resistance in the ACC-MESO-1/OPN, thus suggesting the involvement of the surviving signal emanating from the HA-CD44 interaction. An enhanced level of the p-Akt in ACCMESO-1/OPN cells was observed, and was diminished by CD44 siRNA. Inhibition of the Akt phosphorylation increased in number of the cells underwent apoptosis induced by NVB, VP-16 and GEM. Collectively, these results indicate that OPN is strongly involved in multidrug resistance by enhancing the CD44 binding to HA. Oncogene (2010) 29, 1941-1951; doi:10.1038/onc.2009.478; published online 18 January 2010	[Tajima, K.; Ohashi, R.; Minakata, K.; Yae, T.; Takahashi, F.; Takahashi, K.] Juntendo Univ, Sch Med, Dept Resp Med, Bunkyo Ku, Tokyo 1138421, Japan; [Tajima, K.; Ohashi, R.; Minakata, K.; Takahashi, F.; Takahashi, K.] Juntendo Univ, Sch Med, Res Inst Dis Old Ages, Bunkyo Ku, Tokyo 1138421, Japan; [Sekido, Y.; Hida, T.] Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 464, Japan; [Nara, T.; Hashimoto, M.] Juntendo Univ, Sch Med, Dept Mol & Cellular Parasitol, Bunkyo Ku, Tokyo 1138421, Japan; [Iwakami, S.] Juntendo Univ, Shizuoka Hosp, Dept Resp Med, Shizuoka, Japan; [Iwakami, S.] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat,Shinjuku Ku, Tokyo, Japan	Juntendo University; Juntendo University; Aichi Cancer Center; Juntendo University; Juntendo University; Keio University	Tajima, K (corresponding author), Juntendo Univ, Sch Med, Dept Resp Med, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	tajiken@juntendo.ac.jp	Sekido, Yoshitaka/P-9756-2015; Hashimoto, Muneaki/L-6386-2018; Saya, Hideyuki/J-4325-2013	Hashimoto, Muneaki/0000-0001-7215-7558; Saya, Hideyuki/0000-0001-6610-1902; Sekido, Yoshitaka/0000-0002-2428-3848	Ministry of Education, Culture, Sports, Science and Technology of Japan [19590914]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported in part by a Grants-in-Aid for Cancer Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (K.T. No 19590914).	Boutin C, 1998, EUR RESPIR J, V12, P972, DOI 10.1183/09031936.98.12040972; CHAHINIAN AP, 1993, J CLIN ONCOL, V11, P1559, DOI 10.1200/JCO.1993.11.8.1559; Cook AC, 2006, J BIOL CHEM, V281, P24381, DOI 10.1074/jbc.M602694200; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Elliott Tony, 2002, Expert Rev Anticancer Ther, V2, P449, DOI 10.1586/14737140.2.4.449; Ghatak S, 2002, J BIOL CHEM, V277, P38013, DOI 10.1074/jbc.M202404200; Graessmann M, 2007, ONCOGENE, V26, P2840, DOI 10.1038/sj.onc.1210096; Grigoriu BD, 2007, CLIN CANCER RES, V13, P2928, DOI 10.1158/1078-0432.CCR-06-2144; Hazlehurst LA, 2003, ONCOGENE, V22, P7396, DOI 10.1038/sj.onc.1206943; Hughes A, 2002, J CLIN ONCOL, V20, P3533, DOI 10.1200/JCO.2002.10.073; Iida N, 1997, J CELL PHYSIOL, V171, P152, DOI 10.1002/(SICI)1097-4652(199705)171:2<152::AID-JCP5>3.3.CO;2-6; Jackman DM, 2008, CANCER-AM CANCER SOC, V113, P808, DOI 10.1002/cncr.23617; Khan SA, 2005, CLIN EXP METASTAS, V22, P663, DOI 10.1007/s10585-006-9007-0; Kindler HL, 2001, LUNG CANCER-J IASLC, V31, P311, DOI 10.1016/S0169-5002(00)00166-5; Kouniavsky G, 2002, CLIN EXP METASTAS, V19, P55, DOI 10.1023/A:1013880326925; Li Y, 2001, BRIT J CANCER, V85, P600, DOI 10.1054/bjoc.2001.1922; Lokeshwar VB, 1997, CANCER RES, V57, P773; MANZINI VD, 1993, CANCER-AM CANCER SOC, V72, P410, DOI 10.1002/1097-0142(19930715)72:2<410::AID-CNCR2820720216>3.0.CO;2-G; Misra S, 2003, J BIOL CHEM, V278, P25285, DOI 10.1074/jbc.C300173200; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Ohashi R, 2007, CANCER LETT, V252, P225, DOI 10.1016/j.canlet.2006.12.025; Ohashi R, 2009, ANTICANCER RES, V29, P2205; Pass HI, 2005, NEW ENGL J MED, V353, P1564, DOI 10.1056/NEJMoa051185; Rangaswami H, 2006, TRENDS CELL BIOL, V16, P79, DOI 10.1016/j.tcb.2005.12.005; RUFFIE P A, 1991, Current Opinion in Oncology, V3, P328, DOI 10.1097/00001622-199104000-00014; Rusch VW, 1999, ANN THORAC SURG, V68, P1799, DOI 10.1016/S0003-4975(99)01038-3; Russo RIC, 2008, INT J CANCER, V122, P1012, DOI 10.1002/ijc.23122; SAMSON MK, 1987, J CLIN ONCOL, V5, P86, DOI 10.1200/JCO.1987.5.1.86; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Sohara Y, 2001, MOL BIOL CELL, V12, P1859, DOI 10.1091/mbc.12.6.1859; Sugarbaker DJ, 1996, ANN SURG, V224, P288, DOI 10.1097/00000658-199609000-00005; Takahashi F, 2002, INT J CANCER, V98, P707, DOI 10.1002/ijc.10261; Takahashi K, 2003, LUNG CANCER-J IASLC, V41, P145, DOI 10.1016/S0169-5002(03)00224-1; Thylen A, 1997, EUR RESPIR J, V10, P404, DOI 10.1183/09031936.97.10020404; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Uhm JH, 1999, CLIN CANCER RES, V5, P1587; Usami N, 2006, CANCER SCI, V97, P387, DOI 10.1111/j.1349-7006.2006.00184.x; White SC, 2000, ANN ONCOL, V11, P201, DOI 10.1023/A:1008328605413; Zoltan-Jones A, 2003, J BIOL CHEM, V278, P45801, DOI 10.1074/jbc.M308168200	40	38	38	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	13					1941	1951		10.1038/onc.2009.478	http://dx.doi.org/10.1038/onc.2009.478			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20101228				2022-12-17	WOS:000276199600007
J	Guilmeau, S; Flandez, M; Mariadason, JM; Augenlicht, LH				Guilmeau, S.; Flandez, M.; Mariadason, J. M.; Augenlicht, L. H.			Heterogeneity of Jagged1 expression in human and mouse intestinal tumors: implications for targeting Notch signaling	ONCOGENE			English	Article						Jagged1; Notch signaling; colon cancer	PROGENITOR CELLS; CANCER; GENES; LINE; WNT; APC; DIFFERENTIATION; INACTIVATION; REQUIREMENT; SUPPRESSOR	Inhibition of Notch signaling is effective in inhibiting colon tumorigenesis, but targeting specific components of the pathway may provide more effective strategies. Here we show that the expression of Jagged1, a ligand for canonical Notch signaling, was restricted to enteroendocrine cells or undetectable in the mucosa of the human small and large intestine, respectively. In contrast, increased expression characterized half of human colon tumors, although not all tumors with elevated Wnt signaling displayed elevated Jagged1. Increased Jagged1 was also present in intestinal tumors of Apc(1638N/+) and Apc(Min/+) mice, but to a higher level and more frequently in the former, and in 90% of mouse tumors Notch signaling was elevated when Jagged1 was elevated. In the human HT29Cl16E colonic carcinoma cell line, induction of goblet cell differentiation by contact inhibition of growth depended on the loss of Jagged1-mediated Notch activation, with signaling through Notch1 and Notch2 acting redundantly. Therefore, targeting of Jagged1 could be effective in downregulating Notch signaling in a subset of tumors, but may avoid the limiting gastrointestinal toxicity caused by pharmacological inhibition of Notch signaling. Oncogene (2010) 29, 992-1002; doi:10.1038/onc.2009.393; published online 23 November 2009	[Guilmeau, S.; Flandez, M.; Mariadason, J. M.; Augenlicht, L. H.] Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Guilmeau, S (corresponding author), INSERM, Dept Endocrinol Canc & Metab, U567, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	sandra.guilmeau@inserm.fr	Mariadason, John/N-2003-2013; Canet, Marta Flández/E-2681-2019; Guilmeau, Sandra/P-2318-2017	Canet, Marta Flández/0000-0002-9096-2267; Mariadason, John/0000-0001-9123-7684; Guilmeau, Sandra/0000-0002-8260-1218	NCI [RO1 CA114265, U54 CA100926]; Philippe Foundation; NATIONAL CANCER INSTITUTE [R01CA114265, U54CA100926] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Philippe Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank T Sudo (Toray Industries Inc., Kamakura, Japan) for sharing the Hes1 antibody, and Pamela Stanley (Albert Einstein College Medicine, Bronx, NY, USA) for the TP1-Luc plasmid. We are grateful to A Velcich and L Klampfer for helpful comments. This work was supported by NCI Grants RO1 CA114265 and U54 CA100926 to LH Augenlicht, and by the Philippe Foundation.	Akiyoshi T, 2008, GASTROENTEROLOGY, V134, P131, DOI 10.1053/j.gastro.2007.10.008; AUGENLICHT LH, 1987, CANCER RES, V47, P3763; AUGERON C, 1984, CANCER RES, V44, P3961; Estrach S, 2006, DEVELOPMENT, V133, P4427, DOI 10.1242/dev.02644; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Fre S, 2005, NATURE, V435, P964, DOI 10.1038/nature03589; Fre S, 2008, ADV CANCER RES, V100, P85, DOI 10.1016/S0065-230X(08)00003-1; Fre S, 2009, P NATL ACAD SCI USA, V106, P6309, DOI 10.1073/pnas.0900427106; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Ghaleb AM, 2008, MOL CANCER RES, V6, P1920, DOI 10.1158/1541-7786.MCR-08-0224; Guilmeau S, 2008, GASTROENTEROLOGY, V135, P849, DOI 10.1053/j.gastro.2008.05.050; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Katoh M, 2006, INT J MOL MED, V17, P681; LABURTHE M, 1989, AM J PHYSIOL, V256, pG443, DOI 10.1152/ajpgi.1989.256.3.G443; LEVY DB, 1994, CANCER RES, V54, P5953; Martys-Zage JL, 2000, J MOL NEUROSCI, V15, P189, DOI 10.1385/JMN:15:3:189; McCarthy JV, 2005, BIOCHEM SOC T, V33, P568, DOI 10.1042/BST0330568; MERLIN D, 1994, J MEMBRANE BIOL, V137, P137; Milano J, 2004, TOXICOL SCI, V82, P341, DOI 10.1093/toxsci/kfh254; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Ohlstein B, 2006, NATURE, V439, P470, DOI 10.1038/nature04333; Riccio O, 2008, EMBO REP, V9, P377, DOI 10.1038/embor.2008.7; Rodilla V, 2009, P NATL ACAD SCI USA, V106, P6315, DOI 10.1073/pnas.0813221106; Sander GR, 2004, J HISTOCHEM CYTOCHEM, V52, P509, DOI 10.1177/002215540405200409; Shroyer NF, 2007, GASTROENTEROLOGY, V132, P2478, DOI 10.1053/j.gastro.2007.03.047; Smits R, 1997, CARCINOGENESIS, V18, P321, DOI 10.1093/carcin/18.2.321; Stanger BZ, 2005, P NATL ACAD SCI USA, V102, P12443, DOI 10.1073/pnas.0505690102; Strobl LJ, 1997, IMMUNOBIOLOGY, V198, P299, DOI 10.1016/S0171-2985(97)80050-2; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Velcich A, 2005, EXP CELL RES, V304, P28, DOI 10.1016/j.yexcr.2004.10.014; Wheeler JMD, 2002, GUT, V50, P218, DOI 10.1136/gut.50.2.218; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718; Zheng JL, 2000, DEVELOPMENT, V127, P4551	36	38	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					992	1002		10.1038/onc.2009.393	http://dx.doi.org/10.1038/onc.2009.393			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19935714				2022-12-17	WOS:000274604400006
J	Xu, X; Ehdaie, B; Ohara, N; Yoshino, T; Deng, CX				Xu, X.; Ehdaie, B.; Ohara, N.; Yoshino, T.; Deng, C-X			Synergistic action of Smad4 and Pten in suppressing pancreatic ductal adenocarcinoma formation in mice	ONCOGENE			English	Article						AKT; mTOR; Notch1; pancreas cancer; transdifferentiation	SQUAMOUS-CELL CARCINOMA; TUMOR; GENE; CANCER; EXPRESSION; INDUCTION; DISRUPTION; NOTCH; KRAS; PANCREATICODUODENECTOMY	Mutations of SMAD4/DPC4 are found in about 60% of human invasive pancreatic ductal adenocarcinomas (PDACs); yet, the manner in which SMAD4 deficiency enhances tumorigenesis remains elusive. Using a Cre-LoxP approach, we generated a mutant mouse carrying a targeted deletion of Smad4 in the pancreas. We showed that the absence of Smad4 alone did not trigger pancreas tumor formation; however, it increased the expression of an inactivated form of Pten, suggesting a role of Pten in preventing Smad4-/- cells from undergoing malignancy. To investigate this, we disrupted both Pten and Smad4. We showed that Pten deficiency initiated widespread premalignant lesions, and a low tumor incidence that was significantly accelerated by Smad4-deficiency. The absence of Smad4 in a Pten-mutant background enhanced cell proliferation and triggered transdifferentiation from acinar, centroacinar and islet cells, accompanied by activation of Notch1 signaling. We showed that all tumors developed in the Smad4/Pten-mutant pancreas exhibited high levels of pAKT and mTOR, and that about 50 and 83% of human pancreatic cancers examined showed increased pAKT and pmTOR, respectively. Besides the similarity in gene expression, the pAKT and/or pmTOR-positive human PDACs and mouse pancreatic tumors also shared some histopathological similarities. These observations indicate that Smad4/Pten-mutant mice mimic the tumor progression of human pancreatic cancers that are driven by activation of the AKT-mTOR pathway, and uncovered a synergistic action of Smad4 and Pten in repressing pancreatic tumorigenesis. Oncogene (2010) 29, 674-686; doi: 10.1038/onc.2009.375; published online 9 November 2009	[Xu, X.; Ehdaie, B.; Deng, C-X] NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; [Ohara, N.; Yoshino, T.] Okayama Univ, Grad Sch Med & Dent, Dept Pathol, Okayama 7008530, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Okayama University	Deng, CX (corresponding author), NIDDKD, Genet Dev & Dis Branch, NIH, 9000 Rockville Pike,Bldg 10 Rm 9N105, Bethesda, MD 20892 USA.	ChuxiaD@BDG10.NIDDK.NIH.Gov	deng, chuxia/N-6713-2016		National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA	National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Douglas Melton for providing Pdx-Cre mice; Dr Hong Wu for Pten conditional mutant mice; and members of the Deng lab for critically reading the paper. This research was supported by the Intramural Research Program of the National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA.	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Altomare DA, 2003, J CELL BIOCHEM, V88, P470, DOI 10.1002/jcb.10287; Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902; Attri J, 2005, BMC GASTROENTEROL, V5, DOI 10.1186/1471-230X-5-22; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Bardeesy N, 2002, MOL CELL BIOL, V22, P635, DOI 10.1128/MCB.22.2.635-643.2002; Deramaudt T, 2005, BBA-REV CANCER, V1756, P97, DOI 10.1016/j.bbcan.2005.08.003; Ebert MPA, 2002, BRIT J CANCER, V86, P257, DOI 10.1038/sj/bjc/6600031; Farnell MB, 2005, SURGERY, V138, P618, DOI 10.1016/j.surg.2005.06.044; Friedl W, 1999, GENE CHROMOSOME CANC, V25, P403, DOI 10.1002/(SICI)1098-2264(199908)25:4<403::AID-GCC15>3.0.CO;2-P; Gannon M, 2000, GENESIS, V26, P143, DOI 10.1002/(SICI)1526-968X(200002)26:2<143::AID-GENE13>3.0.CO;2-L; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Gu GQ, 2002, DEVELOPMENT, V129, P2447; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 2003, JNCI-J NATL CANCER I, V95, P214, DOI 10.1093/jnci/95.3.214; Hahn SA, 1996, CANCER RES, V56, P490; Hald J, 2003, DEV BIOL, V260, P426, DOI 10.1016/S0012-1606(03)00326-9; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Hruban RH, 2006, CANCER RES, V66, P95, DOI 10.1158/0008-5472.CAN-05-2168; Ijichi H, 2006, GENE DEV, V20, P3147, DOI 10.1101/gad.1475506; Izeradjene K, 2007, CANCER CELL, V11, P229, DOI 10.1016/j.ccr.2007.01.017; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Kang YK, 2002, HUM PATHOL, V33, P877, DOI 10.1053/hupa.2002.127444; Kim BG, 2006, NATURE, V441, P1015, DOI 10.1038/nature04846; Li WM, 2003, DEVELOPMENT, V130, P6143, DOI 10.1242/dev.00820; Maitra A, 2006, BEST PRACT RES CL GA, V20, P211, DOI 10.1016/j.bpg.2005.10.002; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Michl P, 2005, Z GASTROENTEROL, V43, P1133, DOI 10.1055/s-2005-858638; Murtaugh LC, 2003, P NATL ACAD SCI USA, V100, P14920, DOI 10.1073/pnas.2436557100; Peng BL, 2002, CLIN CANCER RES, V8, P3628; Qiao W, 2006, ONCOGENE, V25, P207, DOI 10.1038/sj.onc.1209029; Roy M, 2007, CURR OPIN GENET DEV, V17, P52, DOI 10.1016/j.gde.2006.12.001; Rozenblum E, 1997, CANCER RES, V57, P1731; Sawey ET, 2007, P NATL ACAD SCI USA, V104, P19327, DOI 10.1073/pnas.0705953104; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Semba S, 2003, PANCREAS, V26, P250, DOI 10.1097/00006676-200304000-00008; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stanger BZ, 2005, CANCER CELL, V8, P185, DOI 10.1016/j.ccr.2005.07.015; Suto T, 2002, ANTICANCER RES, V22, P1529; Takaku K, 1999, CANCER RES, V59, P6113; Tamura G, 1996, J PATHOL, V180, P371, DOI 10.1002/(SICI)1096-9896(199612)180:4<371::AID-PATH704>3.0.CO;2-2; Teng Y, 2006, CANCER RES, V66, P6972, DOI 10.1158/0008-5472.CAN-06-0507; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3; WEINSTEIN M, 2006, GENETIC DISRUPTIONS, V5; Xu XL, 2006, J CLIN INVEST, V116, P1843, DOI 10.1172/JCI27282; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yachida S, 2009, ARCH PATHOL LAB MED, V133, P413, DOI 10.1043/1543-2165-133.3.413; Yang LL, 2005, CANCER RES, V65, P8671, DOI 10.1158/0008-5472.CAN-05-0800; Yang X, 2002, GENESIS, V32, P80, DOI 10.1002/gene.10029; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; Yeo CJ, 2002, ANN SURG, V236, P355, DOI 10.1097/00000658-200209000-00012	59	38	40	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2010	29	5					674	686		10.1038/onc.2009.375	http://dx.doi.org/10.1038/onc.2009.375			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	551QI	19901970				2022-12-17	WOS:000274223700005
J	Li, X; Shen, Y; Ichikawa, H; Antes, T; Goldberg, GS				Li, X.; Shen, Y.; Ichikawa, H.; Antes, T.; Goldberg, G. S.			Regulation of miRNA expression by Src and contact normalization: effects on nonanchored cell growth and migration	ONCOGENE			English	Article						Src; contact normalization; cell communication; anchorage independence; migration; cancer	GAP JUNCTIONAL COMMUNICATION; BREAST-CANCER; MICRORNA EXPRESSION; TRANSFORMED-CELLS; HEPATOCELLULAR-CARCINOMA; NONTRANSFORMED CELLS; IN-VIVO; V-CRK; INHIBITION; INVASION	Transformation by the Src tyrosine kinase (Src) promotes nonanchored cell growth and migration. However, non-transformed cells can force Src-transformed cells to assume a normal morphology and phenotype by a process called 'contact normalization'. It has become clear that microRNA (miRNA) can affect tumorigenesis by targeting gene products that direct cell growth and migration. However, the roles of miRNA in Src transformation or contact normalization have not yet been reported. We examined the expression of 95 miRNAs and found 9 of them significantly affected by Src. In this study, we report that miR-218 and miR-224 were most significantly induced by Src, but not affected by contact normalization. In contrast, miR-126 was most significantly suppressed by Src and was induced by contact normalization in transformed cells. Mir-126 targets Crk, a component of the focal adhesion network that participates in events required for tumor cell migration. Accordingly, we show that miR-126 expression correlates inversely with Crk levels, motility and the invasive potential of human mammary carcinoma cells. Moreover, we show that miR-224 expression promotes nonanchored growth of nontransformed cells. These data reveal novel insights into how Src regulates miRNA expression to promote hallmarks of tumor cell growth and invasion, and how nontransformed cells can affect miRNA expression in adjacent tumor cells to inhibit this process. Oncogene (2009) 28, 4272-4283; doi: 10.1038/onc.2009.278; published online 21 September 2009	[Li, X.; Shen, Y.; Goldberg, G. S.] Univ Med & Dent New Jersey, Dept Mol Biol, Stratford, NJ 08084 USA; [Li, X.] Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Stratford, NJ 08084 USA; [Ichikawa, H.] Natl Canc Ctr, Res Inst, Div Genet, Tokyo 104, Japan; [Antes, T.] Syst Biosci SBI, Mountain View, CA USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Cancer Center - Japan	Goldberg, GS (corresponding author), Univ Med & Dent New Jersey, Dept Mol Biol, 2 Med Ctr Dr, Stratford, NJ 08084 USA.	gary.goldberg@umdnj.edu		Antes, Travis/0000-0002-2294-8797	United States National Institutes of Health [CA88805]; Research Foundation of UMDNJ; Marks and Holzman families; Ministry of Education, Culture, Sports, Science and Technology of Japan; NATIONAL CANCER INSTITUTE [R01CA088805] Funding Source: NIH RePORTER	United States National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research Foundation of UMDNJ; Marks and Holzman families; Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Xiaofeng Ye and Reuben Lotan (MD Anderson Cancer Center) for helpful suggestions and for the gifts of cells, and Min Han (UMDNJ) for technical assistance. This study was supported by a grant from the United States National Institutes of Health (CA88805), the Research Foundation of UMDNJ, and the Marks and Holzman families to GSG, and by a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan to HI.	Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Alexander DB, 2004, CANCER RES, V64, P1347, DOI 10.1158/0008-5472.CAN-03-2558; Alexander DB, 2003, CURR MED CHEM, V10, P2045, DOI 10.2174/0929867033456927; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; BIGNAMI M, 1988, ONCOGENE, V2, P509; Blenkiron C, 2007, HUM MOL GENET, V16, pR106, DOI 10.1093/hmg/ddm056; Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Burnham MR, 1996, ONCOGENE, V12, P2467; Caldas C, 2005, NAT MED, V11, P712, DOI 10.1038/nm0705-712; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Crawford M, 2008, BIOCHEM BIOPH RES CO, V373, P607, DOI 10.1016/j.bbrc.2008.06.090; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; DUBIK D, 1987, CANCER RES, V47, P6517; ENOMOTO T, 1984, CANCER RES, V44, P5200; ESINDUY CB, 1995, CARCINOGENESIS, V16, P915, DOI 10.1093/carcin/16.4.915; Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Glick AB, 2005, SEMIN CANCER BIOL, V15, P75, DOI 10.1016/j.semcancer.2004.08.008; GOLDBERG GS, 1994, MOL CARCINOGEN, V11, P106, DOI 10.1002/mc.2940110208; Goldberg GS, 2003, J BIOL CHEM, V278, P46533, DOI 10.1074/jbc.M307526200; Goldberg GS, 2002, J BIOL CHEM, V277, P36725, DOI 10.1074/jbc.M109797200; GOLDBERG GS, 2008, ENCY CANC; Guo CG, 2008, GENE CHROMOSOME CANC, V47, P939, DOI 10.1002/gcc.20596; HENNINGS H, 1990, CANCER RES, V50, P4794; Holst CR, 2003, CANCER RES, V63, P1596; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Jeffrey SS, 2008, NAT BIOTECHNOL, V26, P400, DOI 10.1038/nbt0408-400; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kuhnert F, 2008, DEVELOPMENT, V135, P3989, DOI 10.1242/dev.029736; Ladeiro Y, 2008, HEPATOLOGY, V47, P1955, DOI 10.1002/hep.22256; Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222; Li ZJ, 2008, P NATL ACAD SCI USA, V105, P15535, DOI 10.1073/pnas.0808266105; LIU B, 2009, LUNG CANC IN PRESS, P126; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MARTIN W, 1991, CANCER RES, V51, P5348; Medina PP, 2008, CELL CYCLE, V7, P2485, DOI 10.4161/cc.7.16.6453; MEHTA PP, 1986, CELL, V44, P187, DOI 10.1016/0092-8674(86)90497-6; Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283; NELSON MA, 1992, P NATL ACAD SCI USA, V89, P6398, DOI 10.1073/pnas.89.14.6398; Nikiforova MN, 2008, J CLIN ENDOCR METAB, V93, P1600, DOI 10.1210/jc.2007-2696; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Prueitt RL, 2008, PROSTATE, V68, P1152, DOI 10.1002/pros.20786; Roberts RB, 2002, P NATL ACAD SCI USA, V99, P1521, DOI 10.1073/pnas.032678499; Rodrigues SP, 2005, MOL CANCER RES, V3, P183; Rubin H, 2006, BIOESSAYS, V28, P515, DOI 10.1002/bies.20403; Rubin H, 2008, ADV CANCER RES, V100, P159, DOI 10.1016/S0065-230X(08)00006-7; Rubin H, 2008, P NATL ACAD SCI USA, V105, P6215, DOI 10.1073/pnas.0800747105; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schembri F, 2009, P NATL ACAD SCI USA, V106, P2319, DOI 10.1073/pnas.0806383106; Sethupathy P, 2006, NAT METHODS, V3, P881, DOI 10.1038/NMETH954; Shen YQ, 2006, CANCER RES, V66, P1543, DOI 10.1158/0008-5472.CAN-05-3152; Shin NY, 2004, J BIOL CHEM, V279, P38331, DOI 10.1074/jbc.M404675200; Soncin F, 2003, EMBO J, V22, P5700, DOI 10.1093/emboj/cdg549; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; STOKER MGP, 1966, J CELL SCI, V1, P297; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Vaccariello M, 1999, J INVEST DERMATOL, V113, P384, DOI 10.1046/j.1523-1747.1999.00701.x; Valiunas V, 2005, J PHYSIOL-LONDON, V568, P459, DOI 10.1113/jphysiol.2005.090985; Valiunas V, 2005, BIOCHEM BIOPH RES CO, V333, P174, DOI 10.1016/j.bbrc.2005.05.104; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002; Wang Y, 2008, J BIOL CHEM, V283, P13205, DOI 10.1074/jbc.M707629200; Wang Y, 2009, J CELL MOL MED, V13, P12, DOI 10.1111/j.1582-4934.2008.00510.x; Widschwendter M, 1997, CANCER RES, V57, P4158; Zanette DL, 2007, BRAZ J MED BIOL RES, V40, P1435, DOI 10.1590/S0100-879X2007001100003; Zhang J, 2008, BIOCHEM BIOPH RES CO, V377, P136, DOI 10.1016/j.bbrc.2008.09.089	71	38	40	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2009	28	48					4272	4283		10.1038/onc.2009.278	http://dx.doi.org/10.1038/onc.2009.278			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DS	19767772				2022-12-17	WOS:000272876300005
J	Helmbold, H; Komm, N; Deppert, W; Bohn, W				Helmbold, H.; Koemm, N.; Deppert, W.; Bohn, W.			Rb2/p130 is the dominating pocket protein in the p53-p21 DNA damage response pathway leading to senescence	ONCOGENE			English	Article						Rb2/p130; p53; DNA-damage; senescence	ONCOGENE-INDUCED SENESCENCE; CELLULAR SENESCENCE; FAMILY-MEMBERS; IN-VIVO; ANTICANCER AGENTS; HUMAN FIBROBLASTS; TUMOR-CELLS; S PHASE; GENE; RETINOBLASTOMA	The different pocket proteins are established as negative cell cycle regulators. With regard to the repressor functions of pocket proteins in cellular senescence, studies so far have mainly focused on pRb/p105. Here, we show that in a broad range of wild-type p53-expressing human tumor cells, and in human diploid fibroblasts, Rb2/p130 is the dominating pocket protein in replicative and in accelerated senescence. Senescent cells are arrested at the transition from late G1- to early S-phase, as indicated by the absence of S- and G2-phase cyclins A and B. Expression of cyclin A and entry into S- phase resumed after RNA interference-mediated knockdown of Rb2/p130. Activation of different upstream pathways by overexpression of either p21 or p16 converged on Rb2/p130 accumulation and induced senescence. In contrast, p53- or p21-negative cells treated with DNA-damaging agents failed to accumulate Rb2/p130 and to enter senescence. Our data suggest that Rb2/p130 is a member of the p53-p21 DNA damage signaling cascade, and represents the essential pocket protein family member needed for the induction of any type of senescence. Oncogene (2009) 28, 3456-3467; doi: 10.1038/onc.2009.222; published online 3 August 2009	[Helmbold, H.; Koemm, N.; Deppert, W.; Bohn, W.] Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Dept Tumorvirol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Helmbold, H (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Dept Tumorvirol, Martinistr 52, D-20251 Hamburg, Germany.	heike.helmbold@hpi.uni-hamburg.de			Deutsche Krebshilfe; Freie und Hansestadt Hamburg; Bundesministerium fur Gesundheit	Deutsche Krebshilfe(Deutsche Krebshilfe); Freie und Hansestadt Hamburg; Bundesministerium fur Gesundheit	This work was supported by a grant from Deutsche Krebshilfe (German Cancer Aid) to WB. The Heinrich-Pette-Institute is financially supported by Freie und Hansestadt Hamburg and Bundesministerium fur Gesundheit.	Araki K, 2003, ONCOGENE, V22, P7632, DOI 10.1038/sj.onc.1206840; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Caterina C, 2005, ONCOGENE, V24, P5821, DOI 10.1038/sj.onc.1208880; Chang BD, 1999, CANCER RES, V59, P3761; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Helmbold H, 2006, ONCOGENE, V25, P5257, DOI 10.1038/sj.onc.1209613; Jackson JG, 2006, MOL CELL BIOL, V26, P2501, DOI 10.1128/MCB.26.7.2501-2510.2006; Kapic A, 2006, CELL DEATH DIFFER, V13, P324, DOI 10.1038/sj.cdd.4401756; Khanna KK, 2000, JNCI-J NATL CANCER I, V92, P795, DOI 10.1093/jnci/92.10.795; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; Li Qiang, 2004, Brain Tumor Pathol, V21, P121, DOI 10.1007/BF02482187; Mallette FA, 2007, CELL CYCLE, V6, P1831, DOI 10.4161/cc.6.15.4516; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Psyrri A, 2004, CANCER RES, V64, P3079, DOI 10.1158/0008-5472.CAN-03-3739; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; Susini T, 2001, HUM PATHOL, V32, P360, DOI 10.1053/hupa.2001.23514; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; Takahashi Y, 2000, GENE DEV, V14, P804; te Poele RH, 2002, CANCER RES, V62, P1876; Tosi GM, 2005, ONCOGENE, V24, P5827, DOI 10.1038/sj.onc.1208630; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zhang BY, 2006, P NATL ACAD SCI USA, V103, P437, DOI 10.1073/pnas.0510012103; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	40	38	39	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	39					3456	3467		10.1038/onc.2009.222	http://dx.doi.org/10.1038/onc.2009.222			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	502RR	19648966				2022-12-17	WOS:000270478300003
J	Morioka, Y; Monypenny, J; Matsuzaki, T; Shi, S; Alexander, DB; Kitayama, H; Noda, M				Morioka, Y.; Monypenny, J.; Matsuzaki, T.; Shi, S.; Alexander, D. B.; Kitayama, H.; Noda, M.			The membrane-anchored metalloproteinase regulator RECK stabilizes focal adhesions and anterior-posterior polarity in fibroblasts	ONCOGENE			English	Article						cell adhesion; AP polarity; chemotaxis; MMPs; RAS; fibronectin	CELL-MIGRATION; MATRIX-METALLOPROTEINASE; RHO-GTPASES; FIBRONECTIN; BINDING; PROTEIN; FIBRILLOGENESIS; CYTOSKELETON; CHEMOTAXIS; MOTILITY	Accumulating evidence indicates that Reversion-inducing cysteine-rich protein with Kazal motifs (RECK), a membrane-anchored matrix metalloproteinase regulator, plays crucial roles in mammalian development and tumor suppression. Its mechanisms of action at the single cell level, however, remain largely unknown. In mouse fibroblasts, RECK is abundant around the perinuclear region, membrane ruffles and cell surface. Cells lacking Reck show decreased spreading, ambiguous anterior-posterior (AP) polarity, and increased speed and decreased directional persistence in migration; these characteristics are also found in transformed fibroblasts and fibrosarcoma cells with low RECK expression. RECK-deficient cells fail to form discrete focal adhesions, have increased levels of GTP-bound Rac1 and Cdc42, and a marked decrease in the level of detyrosinated tubulin, a hallmark of stabilized microtubules. RECK-deficient cells also show elevated gelatinolytic activity and decreased fibronectin fibrils. The phenotype of RECK-deficient cells is largely suppressed when the cells are plated on fibronectin-coated substrates. These findings suggest that RECK regulates pericellular extracellular matrix degradation, thereby allowing the cells to form proper cell-substrate adhesions and to maintain AP polarity during migration; this mechanism is compromised in malignant cells.	[Morioka, Y.; Matsuzaki, T.; Shi, S.; Kitayama, H.; Noda, M.] Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto 6068501, Japan; [Monypenny, J.] Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan; [Shi, S.] Harbin Inst Technol, Dept Life Sci & Engn, Harbin 150006, Peoples R China; [Alexander, D. B.] Nagoya City Univ, Grad Sch Med Sci, Dept Mol Toxicol, Mizuho Ku, Nagoya, Aichi, Japan	Kyoto University; Kyoto University; Harbin Institute of Technology; Nagoya City University	Noda, M (corresponding author), Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	mnoda@virus.kyoto-u.ac.jp			JSPS; MEXT	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We are grateful to Dr Susan Creig for the GFP-vinculin expression vector, to Drs Shuh Narumiya, Alicia Arroyo and Motoharu Seiki for critical reading of the paper, and to the anonymous reviewer for suggesting the use of GM130 for analysing cell polarity. We also thank Emi Nishimoto, Takashi Kawai, Aiko Nishimoto and Aki Miyazaki for their technical and secretarial assistance, Akira Omura for his technical advice and So-ichiro Noda for his help in data analysis. This work was supported by JSPS Grant-in-Aid for Creative Scientific Research and MEXT Grant-in-Aid on Priority Areas.	Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Arora PD, 2003, EXP CELL RES, V286, P366, DOI 10.1016/S0014-4827(03)00096-X; Auge F, 2003, BIOORG MED CHEM LETT, V13, P1783, DOI 10.1016/S0960-894X(03)00214-2; COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; Dunn G A, 1983, Agents Actions Suppl, V12, P14; Echizenya M, 2005, ONCOGENE, V24, P5850, DOI 10.1038/sj.onc.1208733; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Kadler KE, 2008, CURR OPIN CELL BIOL, V20, P495, DOI 10.1016/j.ceb.2008.06.008; Kawashima S, 2008, J NEUROCHEM, V104, P376, DOI 10.1111/j.1471-4159.2007.04977.x; Kondo S, 2007, J CELL SCI, V120, P849, DOI 10.1242/jcs.03388; Mao Y, 2005, MATRIX BIOL, V24, P389, DOI 10.1016/j.matbio.2005.06.008; Mellor H, 2004, CURR BIOL, V14, pR434, DOI 10.1016/j.cub.2004.05.038; Miki T, 2007, J BIOL CHEM, V282, P12341, DOI 10.1074/jbc.M610948200; Muraguchi T, 2007, NAT NEUROSCI, V10, P838, DOI 10.1038/nn1922; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; Noda M, 2003, CANCER METAST REV, V22, P167, DOI 10.1023/A:1023043315031; Noda M, 2007, CANCER SCI, V98, P1659, DOI 10.1111/j.1349-7006.2007.00588.x; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Preisinger C, 2004, J CELL BIOL, V164, P1009, DOI 10.1083/jcb.200310061; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Sieg DJ, 1999, J CELL SCI, V112, P2677; Simizu S, 2005, CANCER RES, V65, P7455, DOI 10.1158/0008-5472.CAN-04-4446; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; Takino T, 2006, EXP CELL RES, V312, P1381, DOI 10.1016/j.yexcr.2006.01.008; Wittmann T, 2001, J CELL SCI, V114, P3795; ZICHA D, 1991, J CELL SCI, V99, P769	30	38	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	11					1454	1464		10.1038/onc.2008.486	http://dx.doi.org/10.1038/onc.2008.486			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421JE	19169281	Green Submitted			2022-12-17	WOS:000264354400006
J	Li, S; Szymborski, A; Miron, MJ; Marcellus, R; Binda, O; Lavoie, JN; Branton, PE				Li, S.; Szymborski, A.; Miron, M-J; Marcellus, R.; Binda, O.; Lavoie, J. N.; Branton, P. E.			The adenovirus E4orf4 protein induces growth arrest and mitotic catastrophe in H1299 human lung carcinoma cells	ONCOGENE			English	Article						adenovirus; E4orf4; cell death; growth arrest; mitotic catastrophe; apoptosis	CYCLIN-E OVEREXPRESSION; P53-INDEPENDENT APOPTOSIS; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL CONTROL; TRANSFORMED-CELLS; PHOSPHATASE 2A; DEATH; PROLIFERATION; CANCER; INHIBITION	The human adenovirus E4orf4 protein, when expressed alone, induces p53-independent death in a wide range of cancer cells. Earlier studies by our groups suggested that although in some cases cell death can be associated with some hallmarks of apoptosis, it is not always affected by caspase inhibitors. Thus it is unlikely that E4orf4-induced cell death occurs uniquely through apoptosis. In the present studies using H1299 human lung carcinoma cells as a model system we found that death is induced in the absence of activation of any of the caspases tested, accumulation of reactive oxygen species, or release of cytochrome c from mitochondria. E4orf4 caused a substantial change in cell morphology, including vigorous membrane blebbing, multiple nuclei in many cells and increased cell volume. Most of these characteristics are not typical of apoptosis, but they are of necrosis. FACS analysis and western blotting for cell cycle markers showed that E4orf4-expressing cells became arrested in G(2)/M and also accumulated high levels of cyclin E. The presence of significant numbers of tetraploid and polyploid cells and some cells with micronuclei suggested that E4orf4 appears to induce death in these cells through a process resulting from mitotic catastrophe.	[Li, S.; Szymborski, A.; Miron, M-J; Binda, O.; Branton, P. E.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; [Lavoie, J. N.] Univ Laval, Ctr Rech Cancerol, Hotel Dieu Quebec, Quebec City, PQ, Canada; [Marcellus, R.] Gemin X Biotechnol Inc, Montreal, PQ, Canada; [Branton, P. E.] McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; [Branton, P. E.] McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University; Laval University; McGill University; McGill University	Branton, PE (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg,Room 701,365 Promenade Sir, Montreal, PQ H3G 1Y6, Canada.	philip.branton@mcgill.ca	Binda, Olivier/A-5941-2009	Binda, Olivier/0000-0002-1539-0828; Lavoie, Josee N/0000-0001-6912-1132	Canadian Cancer Society through the National Cancer Institute of Canada; Canadian Institutes of Health Research; Gemin X Biotechnologics Inc	Canadian Cancer Society through the National Cancer Institute of Canada; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Gemin X Biotechnologics Inc	We thank Dennis Takayesu for technical support and Denis Paquette, Helen Chan and Mark Watson from Gemin X Biotechnologies Inc. for making some of the DNA constructs and for help in some experimental protocols. We also thank Eric Massicotte and Nathalie Tessier of Institut des reserches cliniques de Montreal and Ken McDonald at McGill Life Sciences Complex for performing flow cytometry analyses, and Jacynthe Lalibete from the Department of Pharmacology and Therapeutics at McGill University for confocal microscopy study. Gordon Shore provided anti-caspase and anti-actin antibodies. This work was supported by grants from the Canadian Cancer Society through the National Cancer Institute of Canada (PEB, JNL), the Canadian Institutes of Health Research (PEB, JNL), and from Gemin X Biotechnologics Inc (PEB).	BACCHETTI S, 1993, INT J ONCOL, V3, P781; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Blagosklonny MV, 2007, CELL CYCLE, V6, P70, DOI 10.4161/cc.6.1.3682; Blagosklonny MV, 2002, CELL CYCLE, V1, P103, DOI 10.4161/cc.1.2.108; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; Jaattela M, 2002, ANN MED, V34, P480, DOI 10.1080/078538902321012423; Keck JM, 2007, J CELL BIOL, V178, P371, DOI 10.1083/jcb.200703202; Kelekar A, 2005, ANN NY ACAD SCI, V1066, P259, DOI 10.1196/annals.1363.015; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; Kornitzer D, 2001, J CELL BIOL, V154, P331, DOI 10.1083/jcb.200104104; Koutsami MK, 2006, J PATHOL, V209, P512, DOI 10.1002/path.2005; Kroemer G, 2003, BIOCHEM BIOPH RES CO, V304, P433, DOI 10.1016/S0006-291X(03)00614-4; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Lavoie JN, 2000, J CELL BIOL, V150, P1037, DOI 10.1083/jcb.150.5.1037; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Livne A, 2001, J VIROL, V75, P789, DOI 10.1128/JVI.75.2.789-798.2001; Lockshin RA, 2001, NAT REV MOL CELL BIO, V2, P545, DOI 10.1038/35080097; Mansilla S, 2006, CELL CYCLE, V5, P53, DOI 10.4161/cc.5.1.2267; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; Marcellus RC, 2000, J VIROL, V74, P7869, DOI 10.1128/JVI.74.17.7869-7877.2000; Mazumder S, 2004, CURR CANCER DRUG TAR, V4, P65, DOI 10.2174/1568009043481669; Robert A, 2002, J CELL BIOL, V158, P519, DOI 10.1083/jcb.200201106; Roopchand DE, 2001, ONCOGENE, V20, P5279, DOI 10.1038/sj.onc.1204693; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Shtrichman R, 1998, J VIROL, V72, P2975, DOI 10.1128/JVI.72.4.2975-2982.1998; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777; VOJTA PJ, 1995, BBA-REV CANCER, V1242, P29, DOI 10.1016/0304-419X(95)00002-W; Wang XD, 2001, GENE DEV, V15, P2922	37	38	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					390	400		10.1038/onc.2008.393	http://dx.doi.org/10.1038/onc.2008.393			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18955965				2022-12-17	WOS:000262550300007
J	Nehme, R; Conradt, B				Nehme, R.; Conradt, B.			egl-1: a key activator of apoptotic cell death in C-elegans	ONCOGENE			English	Review						BCL-2 family; BH3-only proteins; apoptosis; C. elegans; EGL-1; CED-13	CAENORHABDITIS-ELEGANS; SEX DETERMINATION; MITOCHONDRIAL DYNAMICS; PHYSICAL INTERACTION; TUMOR-SUPPRESSOR; GENETIC-CONTROL; PROTEIN CEH-30; BCL-2 FAMILY; LIN-35 RB; CED-9	Since the discovery of mammalian BIK and BAD in 1995, BH3-only proteins have emerged as key activators of apoptotic cell death in animals as diverse as the nematode, Caenorhabditis elegans, and humans. BH3-only proteins have also emerged as integrators of cell-death signals that determine the life-versus-death decision and that transduce this decision to the central apoptotic machinery through their physical interaction with 'core' BCL-2 family members, such as BCL-2 or BCL- XL. Currently, eight BH3-only proteins have been identified and characterized in mammals, and there is evidence of functional overlap between them. In contrast, only two BH3-only proteins have so far been identified and characterized in C. elegans, EGL-1 and CED-13, and there seems to be only limited functional overlap between them. Combined with the powerful genetic tools available for the analysis of apoptosis in C. elegans, and the ability to study apoptosis at single-cell resolution in this organism, the absence of extensive functional redundancy makes C. elegans an ideal model for studies on BH3-only proteins. In this study, we will review our current understanding of the role and regulation of EGL-1. We will also briefly summarize studies on CED-13, which was identified more recently. Oncogene (2009) 27, S30-S40; doi: 10.1038/onc.2009.41	[Nehme, R.; Conradt, B.] Norris Cotton Canc Ctr, Dept Genet, Dartmouth Med Sch, Hanover, NH 03755 USA	Dartmouth College; Norris Cotton Cancer Center	Conradt, B (corresponding author), Norris Cotton Canc Ctr, Dept Genet, Dartmouth Med Sch, 7400 Remsen Bldg, Hanover, NH 03755 USA.	conradt@dartmouth.edu	Conradt, Barbara/K-2665-2014	Conradt, Barbara/0000-0002-3731-4308	NIH [GM069950, GM076651]; ACS [RSG-06-110-01-CCG]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069950, R01GM076651] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ACS(American Cancer Society); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Angelika Bottger, Eric Lambie and Scott Gerber for comments on the paper and members of the Conradt laboratory for many stimulating discussions. BC is grateful to Bob Horvitz for pointing her towards 'the egl-1 project' and for his encouragement and support, which was critical for the identification of n3082 and for the cloning of egl-1. Research in the Conradt laboratory is funded by the NIH (GM069950, GM076651) and ACS (RSG-06-110-01-CCG).	Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Anderson P, 1995, METHOD CELL BIOL, V48, P31; BOYD JM, 1995, ONCOGENE, V11, P1921; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Conradt B, 1999, CELL, V98, P317, DOI 10.1016/S0092-8674(00)81961-3; Conradt Barbara, 2005, WormBook, P1; del Peso L, 2000, J BIOL CHEM, V275, P27205; del Peso L, 1998, J BIOL CHEM, V273, P33495, DOI 10.1074/jbc.273.50.33495; Delivani P, 2006, MOL CELL, V21, P761, DOI 10.1016/j.molcel.2006.01.034; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Doonan R, 2008, MECH DEVELOP, V125, P883, DOI 10.1016/j.mod.2008.06.002; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, DEVELOPMENT, V112, P591; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Gartner Anton, 2008, WormBook, P1, DOI 10.1895/wormbook.1.145.1; Grote P, 2006, DEV CELL, V11, P561, DOI 10.1016/j.devcel.2006.07.015; Gumienny TL, 1999, DEVELOPMENT, V126, P1011; Han J, 1996, MOL CELL BIOL, V16, P5857; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Harrison MM, 2006, P NATL ACAD SCI USA, V103, P16782, DOI 10.1073/pnas.0608461103; Hatzold J, 2008, PLOS BIOL, V6, P771, DOI 10.1371/journal.pbio.0060084; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Herzig S, 2008, CURR MOL MED, V8, P131, DOI 10.2174/156652408783769625; Hofmann ER, 2002, CURR BIOL, V12, P1908, DOI 10.1016/S0960-9822(02)01262-9; Horvitz HR, 2003, BIOSCIENCE REP, V23, P239, DOI 10.1023/B:BIRE.0000019187.19019.e6; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Irmler M, 1997, FEBS LETT, V406, P189, DOI 10.1016/S0014-5793(97)00271-8; Jagasia R, 2005, NATURE, V433, P754, DOI 10.1038/nature03316; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; Krause M, 1997, DEVELOPMENT, V124, P2179; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Large EE, 2007, TRENDS GENET, V23, P314, DOI 10.1016/j.tig.2007.04.002; Li SG, 2004, J NEUROSCI, V24, P3104, DOI 10.1523/JNEUROSCI.4444-03.2004; Li SG, 2002, DEVELOPMENT, V129, P3523; Li SG, 2006, DEV DYNAM, V235, P2260, DOI 10.1002/dvdy.20858; Liu HR, 2006, DEVELOPMENT, V133, P641, DOI 10.1242/dev.02234; Liu J, 2000, DEVELOPMENT, V127, P5179; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Maurer CW, 2007, DEVELOPMENT, V134, P1357, DOI 10.1242/dev.02818; Metzstein MM, 1999, MOL CELL, V4, P309, DOI 10.1016/S1097-2765(00)80333-0; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Offner N, 2005, DEVELOPMENT, V132, P1807, DOI 10.1242/dev.01712; Park D, 2006, DEVELOPMENT, V133, P4193, DOI 10.1242/dev.02614; Peden E, 2007, GENE DEV, V21, P3195, DOI 10.1101/gad.1607807; Pietsch EC, 2008, ONCOGENE, V27, P6507, DOI 10.1038/onc.2008.315; Reddien PW, 2007, GENETICS, V175, P1719, DOI 10.1534/genetics.106.068148; Rolland S, 2006, CELL DEATH DIFFER, V13, P1281, DOI 10.1038/sj.cdd.4401980; Schertel C, 2007, DEVELOPMENT, V134, P3691, DOI 10.1242/dev.004606; Schumacher B, 2005, CELL DEATH DIFFER, V12, P153, DOI 10.1038/sj.cdd.4401539; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Schwartz HT, 2007, GENE DEV, V21, P3181, DOI 10.1101/gad.1607007; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Stergiou L, 2007, CELL DEATH DIFFER, V14, P1129, DOI 10.1038/sj.cdd.4402115; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Suen DF, 2008, GENE DEV, V22, P1577, DOI 10.1101/gad.1658508; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Thellmann M, 2003, DEVELOPMENT, V130, P4057, DOI 10.1242/dev.00597; TRENT C, 1983, GENETICS, V104, P619; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Woo M, 2003, NAT IMMUNOL, V4, P1016, DOI 10.1038/ni976; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029; Yan N, 2005, NATURE, V437, P831, DOI 10.1038/nature04002; Yan NG, 2004, MOL CELL, V15, P999, DOI 10.1016/j.molcel.2004.08.022; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZARKOWER D, 1993, NUCLEIC ACIDS RES, V21, P3691, DOI 10.1093/nar/21.16.3691; Zarkower D, 2006, WORMBOOK, V1, P1, DOI DOI 10.1895/WORMBOOK.1.84.1	91	38	40	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S30	S40		10.1038/onc.2009.41	http://dx.doi.org/10.1038/onc.2009.41			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641505				2022-12-17	WOS:000268566800003
J	Finkin, S; Aylon, Y; Anzi, S; Oren, M; Shaulian, E				Finkin, S.; Aylon, Y.; Anzi, S.; Oren, M.; Shaulian, E.			Fbw7 regulates the activity of endoreduplication mediators and the p53 pathway to prevent drug-induced polyploidy	ONCOGENE			English	Article						polyploidy; Fbw7; p53; spindle inhibitors	F-BOX PROTEIN; PHOSPHORYLATION-DEPENDENT DEGRADATION; CYCLIN-E; AURORA-A; UBIQUITIN LIGASE; CHROMOSOMAL INSTABILITY; ENDOMETRIAL CANCER; TUMOR SUPPRESSION; OVARIAN-CANCER; C-MYC	Fbw7 is a tumor suppressor that is mutated in numerous cancers. It encodes an E3 ubiquitin ligase, whose ability to decrease the levels of pivotal regulators of cell growth and proliferation underlies its tumor suppressor function. Here, we explore the consequences of Fbw7 inactivation on the outcome of chemotherapeutic treatments. When exposed to spindle toxins such as vinblastine and taxol, Fbw7-deficient cells undergo extensive mitotic slippage and endoreduplication, rendering them polyploid. A combined deregulation of several Fbw7 target proteins is required for this phenotype. Specifically, elevated expression of cyclin E and Aurora A in Fbw7-deficient cells is required for drug-induced polyploidy. However, overexpression of either cyclin E or Aurora A alone is not sufficient for drug-induced polyploidy. In addition, we demonstrate that Fbw7 deficiency limits the ability of p53 to respond to mitotic toxins but not to DNA damage. Furthermore, Fbw7 expression regulates the p53-dependent induction of genes such as Lats2 and p21 in response to vinblastine. Hence, we suggest that Fbw7 serves as a master regulator of the mitotic and tetraploidy checkpoints.	[Finkin, S.; Anzi, S.; Shaulian, E.] Hebrew Univ Jerusalem, Sch Med, Dept Expt Med & Canc Res, Jerusalem, Israel; [Aylon, Y.; Oren, M.] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Weizmann Institute of Science	Shaulian, E (corresponding author), Hebrew Univ Jerusalem, Sch Med, Dept Expt Med & Canc Res, Jerusalem, Israel.	eshaulian@md.huji.ac.il		Oren, Moshe/0000-0003-4311-7172; Shaulian, Eitan/0000-0001-6242-6849	NATIONAL CANCER INSTITUTE [R37CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Aylon Y, 2006, GENE DEV, V20, P2687, DOI 10.1101/gad.1447006; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Cassia R, 2003, J PATHOL, V201, P589, DOI 10.1002/path.1474; Chen SS, 2002, EMBO J, V21, P4491, DOI 10.1093/emboj/cdf409; DEFFIE A, 1995, MOL CELL BIOL, V15, P3926; Di Leonardo A, 1997, CANCER RES, V57, P1013; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; Fujii Y, 2006, CANCER SCI, V97, P729, DOI 10.1111/j.1349-7006.2006.00239.x; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hubalek MM, 2004, ONCOGENE, V23, P4187, DOI 10.1038/sj.onc.1207560; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Kimura T, 2003, CANCER SCI, V94, P431, DOI 10.1111/j.1349-7006.2003.tb01460.x; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kwak EL, 2005, GYNECOL ONCOL, V98, P124, DOI 10.1016/j.ygyno.2005.04.007; Libertini SJ, 2005, CANCER RES, V65, P10700, DOI 10.1158/0008-5472.CAN-05-1666; Liu Q, 2004, J BIOL CHEM, V279, P18210, DOI 10.1074/jbc.M400678200; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Minella AC, 2007, ONCOGENE, V26, P6948, DOI 10.1038/sj.onc.1210518; Minella AC, 2005, CELL CYCLE, V4, P1356, DOI 10.4161/cc.4.10.2058; Minella AC, 2005, P NATL ACAD SCI USA, V102, P9649, DOI 10.1073/pnas.0503677102; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Moberg KH, 2004, CURR BIOL, V14, P965, DOI 10.1016/j.cub.2004.04.040; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Reed SE, 2004, CANCER RES, V64, P795, DOI 10.1158/0008-5472.CAN-03-3417; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Spruck CH, 2002, CANCER RES, V62, P4535; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Takahashi T, 2000, JPN J CANCER RES, V91, P1007, DOI 10.1111/j.1349-7006.2000.tb00878.x; Tanaka T, 1999, CANCER RES, V59, P2041; Toji S, 2004, GENES CELLS, V9, P383, DOI 10.1111/j.1356-9597.2004.00732.x; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2005, J BIOL CHEM, V280, P7654, DOI 10.1074/jbc.M413377200; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217	50	38	40	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4411	4421		10.1038/onc.2008.77	http://dx.doi.org/10.1038/onc.2008.77			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18391985				2022-12-17	WOS:000257881700004
J	Momota, H; Shih, AH; Edgar, M; Holland, E				Momota, H.; Shih, A. H.; Edgar, M. A.; Holland, E. C.			C-Myc and beta-catenin cooperate with loss of p53 to generate multiple members of the primitive neuroectodermal tumor family in mice	ONCOGENE			English	Article						c-Myc; beta-catenin; p53; primitive neuroectodermal tumor; mouse model	CHOROID-PLEXUS TUMORS; LARGE CELL/ANAPLASTIC MEDULLOBLASTOMAS; PEDIATRIC-ONCOLOGY-GROUP; NEURAL PROGENITORS; SONIC HEDGEHOG; ANAPLASTIC MEDULLOBLASTOMA; SOMATIC MUTATIONS; IN-VIVO; EXPRESSION; CELLS	Primitive neuroectodermal tumors ( PNETs) are a family of primary malignant brain tumors that include medulloblastomas. Although genetic models of a subset of medulloblastomas are documented over the past decade, the molecular basis of other subclasses of PNET remains unclear. As elevated c-Myc expression, activation of Wnt/beta-catenin signaling and dysfunction of p53 are seen in human PNETs, we investigated what role these abnormalities have in the formation of PNETs. Incorporating these abnormalities, we generated supratentorial PNET (sPNET) in mice using somatic cell gene transfer. We show that sPNETs arise from GFAP-expressing cells by forced c-Myc expression combined with p53 inactivation. beta-catenin activation promotes tumor progression and induces divergent differentiation. These c-Myc+beta-catenin-induced PNETs are histologically similar to large cell/anaplastic medulloblastomas and can occur in both cerebrum and cerebellum. Furthermore, we have obtained one PNET with marked epithelial differentiation having histological resemblance to choroid plexus carcinoma in this series. Our results in mice suggest that sPNET with varied differentiation and large cell/anaplastic medulloblastomas may be two tumor groups with similar genetic foundations. These data provide insights into the biology and classification of human PNETs and suggest that multiple tumor types or variants can be generated from a fixed set of genetic abnormalities.	[Momota, H.; Shih, A. H.; Holland, E. C.] Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10021 USA; [Edgar, M. A.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Holland, E. C.] Mem Sloan Kettering Canc Ctr, Dept Surg Neusurg & Neurol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Holland, E (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, 1275 York Ave, New York, NY 10021 USA.	hollande@mskcc.org			NATIONAL CANCER INSTITUTE [R01CA099489, R01CA100688] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA099489, R01 CA100688] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADESINA AM, 1994, CANCER RES, V54, P5649; ANWER UE, 1989, ARCH PATHOL LAB MED, V113, P84; Brown HG, 2000, J NEUROPATH EXP NEUR, V59, P857, DOI 10.1093/jnen/59.10.857; Carlotti CG, 2002, ACTA NEUROPATHOL, V103, P1; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Eberhart CG, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-19; Eberhart CG, 2002, CANCER-AM CANCER SOC, V94, P552, DOI 10.1002/cncr.10189; Frank AJ, 2004, MOL BRAIN RES, V121, P137, DOI 10.1016/j.molbrainres.2003.11.016; Fults D, 2002, NEOPLASIA, V4, P32, DOI 10.1038/sj.neo.7900200; Gessl M, 2003, BRAIN PATHOL, V13, P409; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013; Ho YS, 1996, CANCER LETT, V104, P103, DOI 10.1016/0304-3835(96)04238-3; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JANZER RC, 1985, CLIN NEUROPATHOL, V4, P93; Jay V, 1996, ARCH PATHOL LAB MED, V120, P1061; Koch A, 2001, INT J CANCER, V93, P445, DOI 10.1002/ijc.1342; Kratz JE, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-33; Kraus JA, 2002, NEUROPATH APPL NEURO, V28, P325, DOI 10.1046/j.1365-2990.2002.00413.x; Leonard JR, 2001, J NEUROSURG, V95, P82, DOI 10.3171/jns.2001.95.1.0082; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Marino S, 2000, GENE DEV, V14, P994; McCall TD, 2007, CANCER RES, V67, P5179, DOI 10.1158/0008-5472.CAN-06-4177; OHGAKI H, 1993, MOL CARCINOGEN, V8, P74, DOI 10.1002/mc.2940080203; Pauklin S, 2005, BIOCHEM BIOPH RES CO, V334, P386, DOI 10.1016/j.bbrc.2005.06.097; Pillai A, 2004, J NEUROSURG, V100, P1076, DOI 10.3171/jns.2004.100.6.1076; Rao G, 2003, NEOPLASIA, V5, P198, DOI 10.1016/S1476-5586(03)80052-0; Reifenberger J, 1998, J NEUROPATH EXP NEUR, V57, P179; Rostomily RC, 1997, CANCER RES, V57, P3526; Russo C, 1999, CANCER, V86, P331, DOI 10.1002/(SICI)1097-0142(19990715)86:2<331::AID-CNCR18>3.0.CO;2-#; SAYLORS RL, 1991, CANCER RES, V51, P4721; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Shakhova O, 2006, CANCER RES, V66, P5190, DOI 10.1158/0008-5472.CAN-05-3545; Su XH, 2006, MOL CELL BIOL, V26, P1666, DOI 10.1128/MCB.26.5.1666-1678.2006; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vital A, 1998, J NEUROPATH EXP NEUR, V57, P1061, DOI 10.1097/00005072-199811000-00009; Weiner HL, 2002, CANCER RES, V62, P6385; Wetmore C, 2001, CANCER RES, V61, P513; YUASA H, 1993, NEUROSURGERY, V32, P131, DOI 10.1227/00006123-199301000-00021	43	38	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4392	4401		10.1038/onc.2008.81	http://dx.doi.org/10.1038/onc.2008.81			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18372915				2022-12-17	WOS:000257881700002
J	Tseng, RC; Lin, RK; Wen, CK; Tseng, C; Hsu, HS; Hsu, WH; Wang, YC				Tseng, R-C; Lin, R-K; Wen, C-K; Tseng, C.; Hsu, H-S; Hsu, W-H; Wang, Y-C			Epigenetic silencing of AXIN2/betaTrCP and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in lung tumorigenesis	ONCOGENE			English	Article						beta-catenin; AXIN2; betaTrCP; p53; epigenetic alteration; NSCLC	DOWN-REGULATION; EXPRESSION; CANCER; AXIN2; P53; MUTATIONS; ACTIVATION; STABILITY; CARCINOMA; PATHWAY	beta-catenin accumulation is often found in lung tumors, but only a few patients have mutations in beta-catenin gene. In addition, activated p53 downregulates beta-catenin. Therefore, we postulated that alteration of the degradation complex AXIN2 ( axis inhibition protein 2) and betaTrCP (beta-transducin repeat-containing protein) and p53 regulation could result in beta-catenin protein accumulation in lung cancer. Using the immunohistochemical and sequencing analyses, we found that patients with beta-catenin accumulation without mutation were associated with patients with p53 overexpression and low AXIN2 expression (P=0.023 similar to 0.041). Alteration of AXIN2 was associated with poor survival in early stage patients (P=0.016). Low expression of AXIN2 and betaTrCP was significantly associated with promoter hypermethylation and histone deacetylation. Ectopic expression and knockdown of p53, AXIN2 and betaTrCP genes in A549 (p53wild-type) and H1299 (p53 null) lung cancer cell lines showed cooperation between p53 and AXIN2/betaTrCP in the reduction of beta-catenin expression. Our clinical and cell model findings provide new evidence that epigenetic silencing of AXIN2/betaTrCP in the degradation complex and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in non-small cell lung cancer tumorigenesis. In addition, a high level of p53 downregulates the beta-catenin expression, but this effect is attenuated by non-functional AXIN2 or betaTrCP in lung cancer.	[Tseng, R-C; Lin, R-K; Wen, C-K; Wang, Y-C] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan; [Tseng, C.] Natl Tsing Hua Univ, Dept Life Sci, Hsinchu, Taiwan; [Hsu, H-S] Natl Yang Ming Univ, Inst Emergency & Crit Care Med, Taipei Vet Gen Hosp, Dept Surg,Div Thorac Surg, Taipei 112, Taiwan	National Cheng Kung University; National Tsing Hua University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital	Wang, YC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, 1 Univ Rd, Tainan 70101, Taiwan.	ycw5798@mail.ncku.edu.tw	Wang, Yi-Ching/J-8702-2019	Wang, Yi-Ching/0000-0002-7694-2067				Chen RH, 2000, J BIOL CHEM, V275, P17894, DOI 10.1074/jbc.M905336199; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Chung GG, 2004, CANCER, V100, P2084, DOI 10.1002/cncr.20232; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Derks S, 2004, CELL ONCOL, V26, P291; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Hughes TA, 2006, CANCER LETT, V233, P338, DOI 10.1016/j.canlet.2005.03.026; Hughes TA, 2005, EXP CELL RES, V303, P32, DOI 10.1016/j.yexcr.2004.09.014; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kase S, 2000, CLIN CANCER RES, V6, P4789; KASE S, 2000, CLIN CANC RES; Kim CJ, 2007, APMIS, V115, P127, DOI 10.1111/j.1600-0463.2007.apm_562.x; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Koch A, 2005, CLIN CANCER RES, V11, P4295, DOI 10.1158/1078-0432.CCR-04-1162; Koinuma K, 2006, ONCOGENE, V25, P139, DOI 10.1038/sj.onc.1209009; Lee MN, 2007, CLIN CANCER RES, V13, P832, DOI 10.1158/1078-0432.CCR-05-2694; Levina E, 2004, ONCOGENE, V23, P4444, DOI 10.1038/sj.onc.1207587; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Mazieres J, 2005, CANCER LETT, V222, P1, DOI 10.1016/j.canlet.2004.08.040; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Polakis P, 2000, GENE DEV, V14, P1837; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; Tseng RC, 2005, INT J CANCER, V117, P241, DOI 10.1002/ijc.21178; Wang YC, 2005, J CLIN ONCOL, V23, P154, DOI 10.1200/JCO.2005.03.139; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59	32	38	39	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4488	4496		10.1038/onc.2008.83	http://dx.doi.org/10.1038/onc.2008.83			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18372914	Bronze			2022-12-17	WOS:000257881700011
J	Zhang, D; Shimizu, T; Araki, N; Hirota, T; Yoshie, M; Ogawa, K; Nakagata, N; Takeya, M; Saya, H				Zhang, D.; Shimizu, T.; Araki, N.; Hirota, T.; Yoshie, M.; Ogawa, K.; Nakagata, N.; Takeya, M.; Saya, H.			Aurora A overexpression induces cellular senescence in mammary gland hyperplastic tumors developed in p53-deficient mice	ONCOGENE			English	Article						Aurora A; polyploidy; apoptosis; senescence; p16; DNA damage	CENTROSOME AMPLIFICATION; DNA-DAMAGE; MAMMALIAN-CELLS; BREAST-CANCER; ONCOGENIC RAS; KINASE; P53; ACTIVATION; CHECKPOINT; ENRICHMENT	Aurora A mitotic kinase is frequently overexpressed in various human cancers and is widely considered to be an oncoprotein. However, the cellular contexts in which Aurora A induces malignancy in vivo are still unclear. We previously reported a mouse model in which overexpression of human Aurora A in the mammary gland leads to small hyperplastic changes but not malignancy because of the induction of p53-dependent apoptosis. To study the additional factors required for Aurora A-associated tumorigenesis, we generated a new Aurora A overexpression mouse model that lacks p53. We present evidence here that Aurora A overexpression in primary mouse embryonic fibroblasts (MEFs) that lack p53 overrides postmitotic checkpoint and leads to the formation of multinucleated polyploid cells. Induction of Aurora A overexpression in the mammary glands of p53-deficient mice resulted in development of precancerous lesions that were histologically similar to atypical ductal hyperplasia in human mammary tissue and showed increased cellular senescence and p16 expression. We further observed DNA damage in p53-deficient primary MEFs after Aurora A overexpression. Our results suggest that Aurora A overexpression in mammary glands is insufficient for the development of malignant tumors in p53-deficient mice because of the induction of cellular senescence. Both p53 and p16 are critical in preventing mammary gland tumorigenesis in the Aurora A overexpression mouse model.	[Zhang, D.; Shimizu, T.; Araki, N.; Saya, H.] Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto, Japan; [Hirota, T.] Japanese Fdn Canc Res, Inst Canc, Dept Expt Pathol, Tokyo 170, Japan; [Yoshie, M.; Ogawa, K.] Asahikawa Med Coll, Dept Pathol, Asahikawa, Hokkaido 078, Japan; [Nakagata, N.] Kumamoto Univ, Ctr Anim Resources & Dev, Div Reprod Engn, Kumamoto, Japan; [Takeya, M.] Kumamoto Univ, Grad Sch Med Sci, Dept Cell Pathol, Kumamoto, Japan	Kumamoto University; Japanese Foundation for Cancer Research; Asahikawa Medical College; Kumamoto University; Kumamoto University	Saya, H (corresponding author), Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat,Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.	hsaya@a5.keio.jp	Saya, Hideyuki/J-4325-2013	Nakagata, Naomi/0000-0002-5737-9993				Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Fukuda T, 2005, MOL CELL BIOL, V25, P5270, DOI 10.1128/MCB.25.12.5270-5281.2005; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Goepfert TM, 2002, CANCER RES, V62, P4115; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Helmbold H, 2006, ONCOGENE, V25, P5257, DOI 10.1038/sj.onc.1209613; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Howe HL, 2001, J NATL CANCER I, V93, P824, DOI 10.1093/jnci/93.11.824; Jeng YM, 2004, CLIN CANCER RES, V10, P2065, DOI 10.1158/1078-0432.CCR-1057-03; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kunitoku N, 2003, DEV CELL, V5, P853, DOI 10.1016/S1534-5807(03)00364-2; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tanaka T, 1999, CANCER RES, V59, P2041; te Poele RH, 2002, CANCER RES, V62, P1876; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Wang X, 2006, ONCOGENE, V25, P7148, DOI 10.1038/sj.onc.1209707; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Zhang DW, 2004, ONCOGENE, V23, P8720, DOI 10.1038/sj.onc.1208153; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	47	38	40	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4305	4314		10.1038/onc.2008.76	http://dx.doi.org/10.1038/onc.2008.76			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18372918				2022-12-17	WOS:000257691100005
J	Maddika, S; Wiechec, E; Ande, SR; Poon, IK; Fischer, U; Wesselborg, S; Jans, DA; Schulze-Osthoff, K; Los, M				Maddika, S.; Wiechec, E.; Ande, S. R.; Poon, I. K.; Fischer, U.; Wesselborg, S.; Jans, D. A.; Schulze-Osthoff, K.; Los, M.			Interaction with PI3-kinase contributes to the cytotoxic activity of Apoptin	ONCOGENE			English	Article						anticancer drugs; apoptin; apoptosis; PI3-kinase	INDUCED CELL-DEATH; PHOSPHATIDYLINOSITOL 3-KINASE; T-CELLS; APOPTOSIS; ACTIVATION; BINDING; KINASE; PATHWAY; P85	Apoptin, a small protein from the chicken anemia virus, has attracted attention because of its specificity in killing tumor cells. Localization of apoptin in the nucleus of tumor cells has been shown to be vital for proapoptotic activity, however, targeted expression of apoptin in the nucleus of normal cells does not harm the cells, indicating that nuclear localization of apoptin is insufficient for its cytotoxicity. Here, we demonstrate for the first time that apoptin interacts with the SH3 domain of p85, the regulatory subunit of phosphoinositide 3-kinase (PI3-K), through its proline-rich region. Apoptin derivatives devoid of this proline-rich region do not interact with p85, are unable to activate PI3-K, and show impaired apoptosis induction. Moreover, apoptin mutants containing the proline-rich domain are sufficient to elevate PI3-K activity and to induce apoptosis in cancer cells. Downregulation of p85 leads to nuclear exclusion of apoptin and impairs cell death induction, indicating that interaction with the p85 PI3-K subunit essentially contributes to the cytotoxic activity of apoptin.	[Los, M.] BioApplicat Enterprises, Winnipeg, MB R2V 2N6, Canada; [Maddika, S.; Wiechec, E.; Ande, S. R.; Los, M.] Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB, Canada; [Maddika, S.; Ande, S. R.; Los, M.] Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB, Canada; [Wiechec, E.] Univ Aarhus, Inst Human Genet, Aarhus, Denmark; [Poon, I. K.; Jans, D. A.] Monash Univ, Dept Biochem & Mol Biol, Nucl Signaling Lab, Clayton, Vic 3168, Australia; [Fischer, U.; Schulze-Osthoff, K.] Univ Dusseldorf, Inst Mol Med, Dusseldorf, Germany; [Wesselborg, S.] Univ Tubingen, Dept Internal Med 1, Tubingen, Germany; [Los, M.] Univ Manitoba, Manitoba Inst Child Hlth, Winnipeg, MB, Canada; [Los, M.] Univ Manitoba, Dept Human Anat & Cell Biol, Winnipeg, MB, Canada	University of Manitoba; University of Manitoba; Aarhus University; Monash University; Heinrich Heine University Dusseldorf; Eberhard Karls University of Tubingen; University of Manitoba; University of Manitoba	Los, M (corresponding author), BioApplicat Enterprises, Winnipeg, MB R2V 2N6, Canada.	mjelos@gmail.com	Schulze-Osthoff, Klaus/N-9025-2013; Ande, Sudharsana Rao/AAU-6950-2021	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Ande, Sudharsana Rao/0000-0001-8194-2902; Wesselborg, Sebastian/0000-0002-5236-942X; Los, Marek/0000-0001-9518-1411; Poon, Ivan/0000-0002-9119-7173; Jans, David/0000-0001-5115-4745	CIHR [81237, 82359] Funding Source: Medline	CIHR(Canadian Institutes of Health Research (CIHR))		Alvisi G, 2006, DRUG RESIST UPDATE, V9, P40, DOI 10.1016/j.drup.2006.02.003; Burek M, 2006, ONCOGENE, V25, P2213, DOI 10.1038/sj.onc.1209258; Danen-van Oorschot AAAM, 2003, J BIOL CHEM, V278, P27729, DOI 10.1074/jbc.M303114200; Fischer U, 2005, PHARMACOL REV, V57, P187, DOI 10.1124/pr.57.2.6; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Guelen L, 2004, ONCOGENE, V23, P1153, DOI 10.1038/sj.onc.1207224; Janssen K, 2007, ONCOGENE, V26, P1557, DOI 10.1038/sj.onc.1209923; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; Maddika S, 2007, CELL PROLIFERAT, V40, P835, DOI 10.1111/j.1365-2184.2007.00475.x; Maddika S, 2005, J CELL SCI, V118, P4485, DOI 10.1242/jcs.02580; Neri LM, 2002, BBA-MOL CELL BIOL L, V1584, P73, DOI 10.1016/S1388-1981(02)00300-1; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Poon IH, 2005, CANCER RES, V65, P7059, DOI 10.1158/0008-5472.CAN-05-1370; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; Rohn JL, 2002, J BIOL CHEM, V277, P50820, DOI 10.1074/jbc.M208557200; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	19	38	40	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2008	27	21					3060	3065		10.1038/sj.onc.1210958	http://dx.doi.org/10.1038/sj.onc.1210958			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18059340	Green Published, Green Accepted			2022-12-17	WOS:000255681700013
J	Ruddell, A; Kelly-Spratt, KS; Furuya, M; Parghi, SS; Kemp, CJ				Ruddell, A.; Kelly-Spratt, K. S.; Furuya, M.; Parghi, S. S.; Kemp, C. J.			p19/Arf and p53 suppress sentinel lymph node lymphangiogenesis and carcinoma metastasis	ONCOGENE			English	Article						lymph node; lymphangiogenesis; metastasis; p53; p19/Arf	PROMOTES TUMOR-METASTASIS; GROWTH FACTOR-C; VEGF-C; MELANOMA METASTASIS; BREAST-CANCER; SKIN TUMORS; INDUCTION; CELLS; MICE; VASCULATURE	The ability of tumor cells to metastasize is increasingly viewed as an interaction between the primary tumor and host tissues. Deletion of the p19/Arf or p53 tumor suppressor genes accelerates malignant progression and metastatic spread of 7,12-dimethylbenz(a) anthracene (DMBA)/12-O-tetradecanoyl-phorbol-13-acetate (TPA)induced squamous cell carcinomas, providinga model system to address mechanisms of metastasis. Here, we show that benign pre-metastatic papillomas from wildtype mice trigger lymphangiogenesis within draining lymph nodes, whereas there is no growth of primary tumor lymphatic vessels. Lymph node lymphangiogenesis is greatly accelerated in papilloma-bearing p19/Arf- or p53-deficient mice, which coincides with the greater propensity of these tumors to progress to carcinomas and to metastasize. The extent of accumulation of B cells within the tumor-draininglymph nodes of wild-type mice predicted the level of lymph node lymphangiogenesis and metastatic potential. Arf or p53 deficiency strongly accelerated lymph node immune cell accumulation, in a manner that was associated with the extent of lymph node lymphatic sinus growth. This immune cell accumulation and lymph node lymphangiogenesis phenotype identifies host anti-tumor responses that could drive metastatic spread of cancers via the lymphatics.	[Ruddell, A.; Kelly-Spratt, K. S.; Furuya, M.; Parghi, S. S.; Kemp, C. J.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Ruddell, A (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,MS-C2-023,POB 19024, Seattle, WA 98109 USA.	aruddell@fhcrc.org		Ruddell, Alanna/0000-0002-0195-5576	NCI NIH HHS [R01-CA99517, R01-CA68328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA099517, R01CA068328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achen MG, 2006, INT J CANCER, V119, P1755, DOI 10.1002/ijc.21899; Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; Angeli V, 2006, IMMUNITY, V24, P203, DOI 10.1016/j.immuni.2006.01.003; Baldwin ME, 2002, BIOESSAYS, V24, P1030, DOI 10.1002/bies.10173; Brown DM, 2001, IMMUNOLOGY, V102, P486, DOI 10.1046/j.1365-2567.2001.01213.x; BURNS PA, 1991, ONCOGENE, V6, P2363; Cao YH, 2005, NAT REV CANCER, V5, P735, DOI 10.1038/nrc1693; Dadras SS, 2005, MODERN PATHOL, V18, P1232, DOI 10.1038/modpathol.3800410; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FARR A, 1993, J IMMUNOL, V150, P1160; Harrell MI, 2007, AM J PATHOL, V170, P774, DOI 10.2353/ajpath.2007.060761; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Hirakawa S, 2005, J EXP MED, V201, P1089, DOI 10.1084/jem.20041896; Hirakawa S, 2003, AM J PATHOL, V162, P575, DOI 10.1016/S0002-9440(10)63851-5; Hirakawa S, 2007, BLOOD, V109, P1010, DOI 10.1182/blood-2006-05-021758; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; IOACHIM HL, 2002, IOACHIMS LYMPH NODE; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kelly-Spratt KS, 2004, PLOS BIOL, V2, P1138, DOI 10.1371/journal.pbio.0020242; Kemp CJ, 2005, SEMIN CANCER BIOL, V15, P460, DOI 10.1016/j.semcancer.2005.06.003; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kerjaschki D, 2005, J CLIN INVEST, V115, P2316, DOI 10.1172/JCI26354; Krishnan J, 2003, CANCER RES, V63, P713; LEPPINK DM, 1989, TRANSPLANTATION, V48, P874, DOI 10.1097/00007890-198911000-00032; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Nagy JA, 2002, J EXP MED, V196, P1497, DOI 10.1084/jem.20021244; Nathanson SD, 2003, CANCER, V98, P413, DOI 10.1002/cncr.11464; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Roberts N, 2006, CANCER RES, V66, P2650, DOI 10.1158/0008-5472.CAN-05-1843; Ruddell A, 2003, AM J PATHOL, V163, P2233, DOI 10.1016/S0002-9440(10)63581-X; Schacht V, 2005, AM J PATHOL, V166, P913, DOI 10.1016/S0002-9440(10)62311-5; Schacht V, 2003, EMBO J, V22, P3546, DOI 10.1093/emboj/cdg342; Schoppmann SF, 2002, AM J PATHOL, V161, P947, DOI 10.1016/S0002-9440(10)64255-1; Shimizu K, 2004, CANCER SCI, V95, P328, DOI 10.1111/j.1349-7006.2004.tb03211.x; Skelton D, 2001, GENE THER, V8, P1813, DOI 10.1038/sj.gt.3301586; Skobe M, 2001, AM J PATHOL, V159, P893, DOI 10.1016/S0002-9440(10)61765-8; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Stacker SA, 2002, FASEB J, V16, P922, DOI 10.1096/fj.01-0945rev; Van den Eynden GG, 2006, BRIT J CANCER, V95, P1362, DOI 10.1038/sj.bjc.6603443; Wong SY, 2006, CELL CYCLE, V5, P812, DOI 10.4161/cc.5.8.2646	42	38	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	22					3145	3155		10.1038/sj.onc.1210973	http://dx.doi.org/10.1038/sj.onc.1210973			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18059331				2022-12-17	WOS:000255897600007
J	Finckenstein, FG; Shahbazian, V; Davicioni, E; Ren, YX; Anderson, MJ				Finckenstein, F. Graf; Shahbazian, V.; Davicioni, E.; Ren, Y-X; Anderson, M. J.			PAX-FKHR function as pangenes by simultaneously inducing and inhibiting myogenesis	ONCOGENE			English	Article						rhabdomyosarcoma; PAX-FKHR; MyoD; pangene	DNA-BINDING DOMAIN; ALVEOLAR RHABDOMYOSARCOMAS; GENE-EXPRESSION; TRANSCRIPTION FACTOR; CELL-CYCLE; PAX3-FKHR; DIFFERENTIATION; MYOD; PROTEINS; IDENTIFICATION	Alveolar rhabdomyosarcomas (ARMS) escape terminal differentiation despite exhibiting a skeletal muscle phenotype. To understand the role of the ARMS-specific PAX-FKHR proteins in myogenesis, we characterized their regulation of MyoD expression and function. Reporter assays show that PAX-FKHR transactivate MyoD expression through its 258 bp core enhancer. Gel-shift assays confirm that PAX-FKHR bind to core enhancer sequences showing similarity to consensus PAX3/PAX-FKHR-binding sites. We show that while PAX3-FKHR activates the expression of endogenous MyoD and myogenin proteins in transduced NIH3T3 fibroblasts, it inhibits them from terminally differentiating as shown by low myogenin and myosin heavy chain expression, and lack of myotube formation. Attenuation of MyoD transcriptional activity via phosphorylation coupled to the lack of cell cycle arrest is the underlying mechanism for the differentiation block. Lastly, we show that fibroblast growth factor receptor signaling likely mediates the inhibition of differentiation by PAX3-FKHR. In a single experimental system we demonstrate that PAX3-FKHR can simultaneously induce myogenesis while preventing its completion. We propose a model whereby PAX-FKHR commit a yet undefined precursor cell to the myogenic lineage while at the same time inhibit terminal differentiation, thereby contributing to ARMS formation.	[Finckenstein, F. Graf; Shahbazian, V.; Ren, Y-X; Anderson, M. J.] Childrens Hosp Los Angeles, Dept Pathol, Los Angeles, CA 90027 USA; [Davicioni, E.; Anderson, M. J.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA	Children's Hospital Los Angeles; University of Southern California	Anderson, MJ (corresponding author), Childrens Hosp Los Angeles, Saban Res Inst, Dept Pathol & Lab Med, 4650 Sunset Blvd,MS103, Los Angeles, CA 90027 USA.	manderson@chla.usc.edu		Davicioni, Elai/0000-0001-9136-099X				Anderson J, 2001, AM J PATHOL, V159, P1089, DOI 10.1016/S0002-9440(10)61784-1; Anderson MJ, 2001, P NATL ACAD SCI USA, V98, P1589, DOI 10.1073/pnas.98.4.1589; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; Davicioni E, 2006, CANCER RES, V66, P6936, DOI 10.1158/0008-5472.CAN-05-4578; Davis RJ, 1997, P NATL ACAD SCI USA, V94, P8047, DOI 10.1073/pnas.94.15.8047; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GOLDHAMER DJ, 1992, SCIENCE, V256, P538, DOI 10.1126/science.1315077; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Lang D, 2005, NATURE, V433, P884, DOI 10.1038/nature03292; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Liu LN, 1998, CELL GROWTH DIFFER, V9, P699; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Robson EJD, 2006, NAT REV CANCER, V6, P52, DOI 10.1038/nrc1778; SCHMIDT D, 1986, VIRCHOWS ARCH A, V409, P183, DOI 10.1007/BF00708327; TAPSCOTT SJ, 1992, MOL CELL BIOL, V12, P4994, DOI 10.1128/MCB.12.11.4994; Zhang L, 2007, ONCOGENE, V26, P1595, DOI 10.1038/sj.onc.1209958	27	38	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 27	2008	27	14					2004	2014		10.1038/sj.onc.1210835	http://dx.doi.org/10.1038/sj.onc.1210835			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17922034				2022-12-17	WOS:000254359100005
J	Barbetti, V; Gozzini, A; Rovida, E; Morandi, A; Spinelli, E; Fossati, G; Mascagni, P; Lubbert, M; Dello Sbarba, P; Santini, V				Barbetti, V.; Gozzini, A.; Rovida, E.; Morandi, A.; Spinelli, E.; Fossati, G.; Mascagni, P.; Luebbert, M.; Dello Sbarba, P.; Santini, V.			Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells	ONCOGENE			English	Article						AML; AML1/ETO; HDAC inhibitors; gene expression	ACUTE MYELOID-LEUKEMIA; NF-KAPPA-B; TRANSCRIPTION FACTORS; FUSION PARTNER; HEPATOMA-CELLS; RETINOIC ACID; IN-VITRO; APOPTOSIS; TARGET; ACETYLATION	We analysed the in vitro effects of a new hydroxamate derivative, ITF2357, on AML cells. ITF2357 potently induced histone acetylation. ITF2357 0.1 mu M blocked proliferation and induced apoptosis in AML1/ETO-positive Kasumi-1 cells, while AML1/ETO-negative HL60, THP1 and NB4 cell lines were sensitive only to 1 mu M ITF2357. Apoptosis was induced by 0.1 mu M ITF2357 in AML1/ETO-positive primary blasts and U937-A/E cells induced to express AML1/ETO, but not in U937-A/E cells non-expressing AML1/ETO. In Kasumi-1 cells 0.1 mu M ITF2357 induced AML1/ETO degradation through a caspase-dependent mechanism. ITF2357 0.1 mu M also determined DNMT1 efflux from, and p300 influx to, the nucleus. Moreover, 0.1 mu M ITF2357 determined local H4 acetylation and release of DNMT1, HDAC1 and AML1/ETO, paralleled by recruitment of p300 to the IL-3 gene promoter. ITF2357 treatment, however, did not induce re-expression of IL-3 gene. Accordingly, the methylation level of IL-3 promoter, as well as of several other genes, was unmodified. In conclusion, ITF2357 emerged as an antileukaemic agent very potent on AML cells, and on AML1/ETO-positive cells in particular. More relevantly, clearly emerged from our results that ITF2357 could be an ideal agent to treat AML subtypes presenting AML1/ETO fusion protein which determine HDAC involvement in leukaemogenesis.	[Gozzini, A.; Spinelli, E.; Santini, V.] Univ Florence, UF Ematol, AOU Careggi, I-50134 Florence, Italy; [Barbetti, V.; Rovida, E.; Morandi, A.; Dello Sbarba, P.] Univ Florence, Dipartimento Patol Oncol Sperimentali, I-50134 Florence, Italy; [Luebbert, M.] Univ Freiburg, Dept Med, D-7800 Freiburg, Germany; [Fossati, G.; Mascagni, P.] Italfarmaco SpA, Milan, Italy	University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence; University of Freiburg; Italfarmaco	Santini, V (corresponding author), Univ Florence, UF Ematol, AOU Careggi, Viale GB Morgagni 85, I-50134 Florence, Italy.	santini@unifi.it	SANTINI, VALERIA/AAL-3135-2020; Dello Sbarba, Persio/AAX-9887-2020; Rovida, Elisabetta/F-3565-2015	SANTINI, VALERIA/0000-0002-5439-2172; Rovida, Elisabetta/0000-0002-5949-3239; Morandi, Andrea/0000-0002-9222-5332				Alcalay M, 2001, ONCOGENE, V20, P5680, DOI 10.1038/sj.onc.1204642; Altucci L, 2005, CANCER RES, V65, P8754, DOI 10.1158/0008-5472.CAN-04-3569; Armeanu S, 2005, J HEPATOL, V42, P210, DOI 10.1016/j.jhep.2004.10.020; ASOU H, 1991, BLOOD, V77, P2031; Atsumi A, 2006, BIOCHEM BIOPH RES CO, V345, P1471, DOI 10.1016/j.bbrc.2006.05.047; Carta S, 2006, BLOOD, V108, P1618, DOI 10.1182/blood-2006-03-014126; Dai Y, 2005, MOL CELL BIOL, V25, P5429, DOI 10.1128/MCB.25.13.5429-5444.2005; Davie JR, 1997, MOL BIOL REP, V24, P197, DOI 10.1023/A:1006811817247; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; Fazi F, 2005, ONCOGENE, V24, P1820, DOI 10.1038/sj.onc.1208286; Fliegauf M, 2004, ONCOGENE, V23, P9070, DOI 10.1038/sj.onc.1208042; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gozzini A, 2003, CANCER RES, V63, P8955; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; KLISOVIC MI, 2003, LEUKEMIA, V350; Leoni F, 2005, MOL MED, V11, P1, DOI 10.2119/2006-00005.Dinarello; Liu SJ, 2007, J PHARMACOL EXP THER, V321, P953, DOI 10.1124/jpet.106.118406; Liu SJ, 2005, CANCER RES, V65, P1277, DOI 10.1158/0008-5472.CAN-04-4532; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lu Y, 2006, LEUKEMIA, V20, P987, DOI 10.1038/sj.leu.2404218; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mrozek K, 2001, J CLIN ONCOL, V19, P2482, DOI 10.1200/JCO.2001.19.9.2482; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pasqualucci L, 2003, LEUKEMIA LYMPHOMA, V44, pS5, DOI 10.1080/10428190310001621588; Pathil A, 2006, HEPATOLOGY, V43, P425, DOI 10.1002/hep.21054; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; Rahmani M, 2005, CANCER RES, V65, P2422, DOI 10.1158/0008-5472.CAN-04-2440; Santini V, 2007, CURR DRUG METAB, V8, P383, DOI 10.2174/138920007780655397; Tan J, 2006, J BIOL CHEM, V281, P10508, DOI 10.1074/jbc.M512719200; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang L, 2007, CELL DEATH DIFFER, V14, P306, DOI 10.1038/sj.cdd.4401996; Yang G, 2007, ONCOGENE, V26, P91, DOI 10.1038/sj.onc.1209760	33	38	41	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2008	27	12					1767	1778		10.1038/sj.onc.1210820	http://dx.doi.org/10.1038/sj.onc.1210820			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17891169				2022-12-17	WOS:000253962100012
J	Davis, E; Teng, H; Bilican, B; Parker, MI; Liu, B; Carriera, S; Goding, CR; Prince, S				Davis, E.; Teng, H.; Bilican, B.; Parker, M. I.; Liu, B.; Carriera, S.; Goding, C. R.; Prince, S.			Ectopic Tbx2 expression results in polyploidy and cisplatin resistance	ONCOGENE			English	Article						Tbx2; T-box factor; polyploidy; chromosomal instability	CELL-CYCLE; MITOTIC CATASTROPHE; DNA-DAMAGE; SENESCENCE; GENE; P53; REPRESSES; SUBSET; ARREST; DOMAIN	T-box factors play critical roles in embryonic development and have been implicated in cell cycle regulation and cancer. For example, Tbx2 can suppress senescence through a mechanism involving the repression of the cyclin-dependent kinase inhibitors, p19ARF and p21(WAF1/CIP1/SDII), and the Tbx2 gene is deregulated in melanoma, breast and pancreatic cancers. In this study, several transformed human lung. broblast cell lines were shown to downregulate Tbx2. To further investigate the role of Tbx2 in oncogenesis we therefore stably reexpressed Tbx2 in one such cell line. Compared to their parental cells, the resulting Tbx2-expressing cells are larger, with binucleate and lobular nuclei containing double the number of chromosomes. Moreover, these cells had an increase in frequency of several features of genomic instability such as chromosome missegregation, chromosomal rearrangements and polyploidy. While grossly abnormal, these cells still divide and give rise to cells that are resistant to the chemotherapeutic drug cisplatin. Furthermore, this is shown to be neither species nor cell type dependent, as ectopically expressing Tbx2 in a murine melanoma cell line also induce mitotic defects and polyploidy. These results have important implications for our understanding of the role of Tbx2 in tumorigenesis because polyploidy frequently precedes aneuploidy, which is associated with high malignancy and poor prognosis.	[Davis, E.; Prince, S.] Univ Cape Town, Dept Human Biol, Fac Hlth Sci,Div Cell Biol, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, Western Prov, South Africa; [Teng, H.; Parker, M. I.] Univ Cape Town, Fac Hlth Sci, Div Med Biochem, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, Western Prov, South Africa; [Bilican, B.; Liu, B.; Carriera, S.; Goding, C. R.] Marie Curie Res Inst, Signalling & Dev Lab, Surrey, England	University of Cape Town; University of Cape Town	Prince, S (corresponding author), Univ Cape Town, Dept Human Biol, Fac Hlth Sci,Div Cell Biol, Inst Infect Dis & Mol Med, Anzio Rd, ZA-7925 Cape Town, Western Prov, South Africa.	sharon.prince@uct.ac.za	Prince, Sharon/AFU-4911-2022	Prince, Sharon/0000-0002-6975-5255; Goding, Colin/0000-0002-1614-3909; Carreira, Suzanne/0000-0002-5077-5379				Andreassen PR, 2001, CANCER RES, V61, P7660; Baroja A, 1998, LIFE SCI, V62, P2275, DOI 10.1016/S0024-3205(98)00208-2; Bilican B, 2006, EXP CELL RES, V312, P2358, DOI 10.1016/j.yexcr.2006.03.033; Brummelkamp TR, 2002, J BIOL CHEM, V277, P6567, DOI 10.1074/jbc.M110492200; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Butz NV, 2004, GENE, V342, P67, DOI 10.1016/j.gene.2004.07.024; Carlson H, 2002, ONCOGENE, V21, P3827, DOI 10.1038/sj.onc.1205476; Carlson H, 2001, HUM MOL GENET, V10, P2403, DOI 10.1093/hmg/10.21.2403; Danesi R, 2003, PHARMACOL REV, V55, P57, DOI 10.1124/pr.55.1.4; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fan WW, 2004, CANCER RES, V64, P5132, DOI 10.1158/0008-5472.CAN-04-0615; Huang XX, 2005, P NATL ACAD SCI USA, V102, P1065, DOI 10.1073/pnas.0409130102; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jerome-Majewska LA, 2005, DEV DYNAM, V234, P922, DOI 10.1002/dvdy.20575; Lingbeek ME, 2002, J BIOL CHEM, V277, P26120, DOI 10.1074/jbc.M200403200; Mahlamaki EH, 2002, GENE CHROMOSOME CANC, V35, P353, DOI 10.1002/gcc.10122; Naiche LA, 2005, ANNU REV GENET, V39, P219, DOI 10.1146/annurev.genet.39.073003.105925; NAMBA M, 1980, GANN, V71, P300; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Packham EA, 2003, HUM MOL GENET, V12, pR37, DOI 10.1093/hmg/ddg077; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PRIEST JH, 1977, MED CYTOGENETICS CEL, P118; Prince S, 2004, CANCER RES, V64, P1669, DOI 10.1158/0008-5472.CAN-03-3286; Prince S, 2003, PIGM CELL RES, V16, P26, DOI 10.1034/j.1600-0749.2003.00008.x; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; ROTHENBERG M, 1989, JNCI-J NATL CANCER I, V81, P907, DOI 10.1093/jnci/81.12.907; Sinclair CS, 2002, CANCER RES, V62, P3587; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; TENG H, 2007, J CELL BIOCH; Vance KW, 2005, CANCER RES, V65, P2260, DOI 10.1158/0008-5472.CAN-04-3045; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002	31	38	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					976	984		10.1038/sj.onc.1210701	http://dx.doi.org/10.1038/sj.onc.1210701			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700536				2022-12-17	WOS:000252946300009
J	Mohr, A; Buneker, C; Gough, RP; Zwacka, RM				Mohr, A.; Bueneker, C.; Gough, R. P.; Zwacka, R. M.			MnSOD protects colorectal cancer cells from TRAIL-induced apoptosis by inhibition of Smac/DIABLO release	ONCOGENE			English	Article						apoptosis; MnSOD; TRAIL; XIAP; Smac/DIABLO; colon cancer	MANGANESE SUPEROXIDE-DISMUTASE; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; REDOX GENE-THERAPY; PANCREATIC ADENOCARCINOMA; MATRIX METALLOPROTEINASES; ANTIOXIDANT ENZYMES; CONFERS RESISTANCE; OVEREXPRESSION; EXPRESSION	The mitochondrial enzyme manganese superoxide dismutase (MnSOD) has been shown to have two faces with regard to its role in tumor development. On the one side, it is well documented that overexpression of MnSOD slows down cancer cell growth, whereas on the other side MnSOD also has a metastasis-promoting activity. We set out to examine the role of MnSOD in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, thought to be a first-line tumor surveillance mechanism and failure to undergo apoptosis might contribute to metastasis formation. We show that overexpression of MnSOD at moderate levels is able to protect cells from TRAIL-induced apoptosis. While caspase-8 activation and Bid cleavage were not affected by MnSOD, we detected a marked decrease in caspase-3 activation pointing to a mitochondrial resistance mechanism. Indeed, we found that MnSOD-overexpressing cells showed reduced cytochrome c and no Smac/DIABLO release into the cytosol. The resulting lack of X-linked inhibitor of apoptosis (XIAP) inhibition by cytosolic Smac/DIABLO most likely caused the TRAIL resistance as RNAi against XIAP-rescued caspase-3 activity and TRAIL sensitivity. Our results show that reactive oxygen species are involved in TRAIL-induced Smac/DIABLO release and in TRAIL-triggered apoptosis. Hence, high levels of MnSOD, which decompose and neutralize these reactive oxygen species, might contribute to metastasis formation by allowing disseminated tumor cells to escape from TRAIL-mediated tumor surveillance. As part of TRAIL regimens, adjuvant treatment with XIAP inhibitors in the form of Smac/DIABLO mimetics or MnSOD inhibitors might be able to break TRAIL resistance of malignant tumor cells.	[Mohr, A.; Bueneker, C.; Gough, R. P.; Zwacka, R. M.] Natl Univ Ireland Univ Coll Galway, Mol Therapeut Grp, Natl Ctr Biomed Engn Sci, Galway, Ireland; [Bueneker, C.] Univ Ulm, Div Gene Therapy, Ulm, Germany	Ollscoil na Gaillimhe-University of Galway; Ulm University	Mohr, A (corresponding author), Natl Univ Ireland Univ Coll Galway, Mol Therapeut Grp, Natl Ctr Biomed Engn Sci, Univ Rd, Galway, Ireland.	andrea.mohr@nuigalway.ie; ralf.zwacka@nuigalway.ie		Zwacka, Ralf/0000-0003-2821-0387; Mohr, Andrea/0000-0002-4295-0341				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Behrend L, 2005, MOL CELL BIOL, V25, P7758, DOI 10.1128/MCB.25.17.7758-7769.2005; Braeuer SJ, 2006, MOL CANCER RES, V4, P715, DOI 10.1158/1541-7786.MCR-05-0231; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Cullen JJ, 2003, CANCER RES, V63, P1297; Culotta VC, 2006, BBA-MOL CELL RES, V1763, P747, DOI 10.1016/j.bbamcr.2006.05.003; Davis AR, 2001, MOL BIOTECHNOL, V18, P63, DOI 10.1385/MB:18:1:63; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Duiker EW, 2006, EUR J CANCER, V42, P2233, DOI 10.1016/j.ejca.2006.03.018; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Izeradjene K, 2005, CANCER RES, V65, P7436, DOI 10.1158/0008-5472.CAN-04-2628; Izutani R, 1998, J GASTROENTEROL, V33, P816, DOI 10.1007/s005350050181; Janssen AML, 1999, J CANCER RES CLIN, V125, P327, DOI 10.1007/s004320050282; Kahl R, 2004, DRUG METAB REV, V36, P747, DOI 10.1081/DMR-200033488; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Lam EWN, 1997, CANCER RES, V57, P5550; Lee MW, 2002, CANCER LETT, V182, P75; Lewis A, 2005, CLIN EXP METASTAS, V22, P523, DOI 10.1007/s10585-005-4919-7; Li JJ, 1997, CANCER RES, V57, P1991; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Liotta L A, 1990, Semin Cancer Biol, V1, P99; Malafa M, 2000, J SURG RES, V88, P130, DOI 10.1006/jsre.1999.5773; Mantymaa P, 2000, BRIT J HAEMATOL, V108, P574, DOI 10.1046/j.1365-2141.2000.01852.x; Mohr A, 2005, ONCOGENE, V24, P2421, DOI 10.1038/sj.onc.1208432; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nozoe T, 2003, ONCOL REP, V10, P39; Oberley LW, 2005, BIOMED PHARMACOTHER, V59, P143, DOI 10.1016/j.biopha.2005.03.006; Papa S, 2006, CELL DEATH DIFFER, V13, P712, DOI 10.1038/sj.cdd.4401865; Smirnov AS, 2001, CELL DEATH DIFFER, V8, P621, DOI 10.1038/sj.cdd.4400853; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Toh Y, 2000, INT J ONCOL, V17, P107; Toruner M, 2006, J BIOL CHEM, V281, P8686, DOI 10.1074/jbc.M512178200; Vigneswaran N, 2005, INT J ONCOL, V26, P103; Wajant H, 2006, CANC TREAT, V130, P141; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Zhang HJ, 2002, J BIOL CHEM, V277, P20919, DOI 10.1074/jbc.M109801200; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698; Zwacka RM, 1998, HUM GENE THER, V9, P1381, DOI 10.1089/hum.1998.9.9-1381	46	38	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					763	774		10.1038/sj.onc.1210673	http://dx.doi.org/10.1038/sj.onc.1210673			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653087				2022-12-17	WOS:000252884500005
J	Phillips, ER; McKinnon, PJ				Phillips, E. R.; McKinnon, P. J.			DNA double-strand break repair and development	ONCOGENE			English	Review						DNA repair; double-strand breaks; ATM; NHEJ; development	ONCOGENE-INDUCED SENESCENCE; SEVERE COMBINED IMMUNODEFICIENCY; ATM-DEPENDENT PHOSPHORYLATION; EARLY EMBRYONIC LETHALITY; HEMATOPOIETIC STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; HUMAN GENETIC-DISEASE; LEAKY SCID PHENOTYPE; LIGASE IV DEFICIENCY; END-JOINING FACTORS	Normal development of an organism requires the ability to respond to DNA damage. A particularly deleterious lesion is a DNA double-strand break (DSB). The cellular response to DNA DSBs occurs via an integrated sensing and signaling network that maintains genomic stability. The outcomes of defective DNA DSB repair are related to the developmental stage of an organism, and often show striking tissue specificity. Many human diseases are associated with deficiencies in DNA DSB repair and can be characterized by neuropathology, immune deficiency, growth retardation or predisposition to cancer. This review will focus on the requirements of the DNA DSB response that function to maintain homeostasis during mammalian development.	St Jude Childrens Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	McKinnon, PJ (corresponding author), St Jude Childrens Hosp, Dept Genet & Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38105 USA.	peter.mckinnon@stjude.org						Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bassing CH, 2004, DNA REPAIR, V3, P781, DOI 10.1016/j.dnarep.2004.06.001; Bekker-Jensen S, 2005, J CELL BIOL, V170, P201, DOI 10.1083/jcb.200503043; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Bredemeyer AL, 2006, NATURE, V442, P466, DOI 10.1038/nature04866; Brown EJ, 2000, GENE DEV, V14, P397; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Buck D, 2006, EUR J IMMUNOL, V36, P224, DOI 10.1002/eji.200535401; Burma S, 2004, DNA REPAIR, V3, P909, DOI 10.1016/j.dnarep.2004.03.021; Callen E, 2007, CELL, V130, P63, DOI 10.1016/j.cell.2007.06.016; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Cheung AMY, 2004, CANCER RES, V64, P1959, DOI 10.1158/0008-5472.CAN-03-2270; Chong MJ, 2000, P NATL ACAD SCI USA, V97, P889, DOI 10.1073/pnas.97.2.889; Chun HH, 2004, DNA REPAIR, V3, P1187, DOI 10.1016/j.dnarep.2004.04.010; Cleaver JE, 2005, NAT REV CANCER, V5, P564, DOI 10.1038/nrc1652; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Couedel C, 2004, GENE DEV, V18, P1293, DOI 10.1101/gad.1209204; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; D'Andrea AD, 2003, GENE DEV, V17, P1933, DOI 10.1101/gad.1128303; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dibiase SJ, 2000, CANCER RES, V60, P1245; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Difilippantonio S, 2007, J EXP MED, V204, P1003, DOI 10.1084/jem.20070319; Digweed M, 2004, DNA REPAIR, V3, P1207, DOI 10.1016/j.dnarep.2004.03.004; Dornan D, 2006, SCIENCE, V313, P1122, DOI 10.1126/science.1127335; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Frappart PO, 2007, EMBO J, V26, P2732, DOI 10.1038/sj.emboj.7601703; Frappart PO, 2006, NEUROMOL MED, V8, P495, DOI 10.1385/NMM:8:4:495; Frappart PO, 2005, NAT MED, V11, P538, DOI 10.1038/nm1228; Friedberg EC, 2006, DNA REPAIR, V5, P189, DOI 10.1016/j.dnarep.2005.09.009; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Girard PM, 2004, HUM MOL GENET, V13, P2369, DOI 10.1093/hmg/ddh274; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grawunder U, 1998, J BIOL CHEM, V273, P24708, DOI 10.1074/jbc.273.38.24708; Grawunder U, 1998, CURR BIOL, V8, P873, DOI 10.1016/S0960-9822(07)00349-1; Gu YS, 2000, P NATL ACAD SCI USA, V97, P2668, DOI 10.1073/pnas.97.6.2668; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Helleday T, 2007, DNA REPAIR, V6, P923, DOI 10.1016/j.dnarep.2007.02.006; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Heyer WD, 2006, NUCLEIC ACIDS RES, V34, P4115, DOI 10.1093/nar/gkl481; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Holcomb VB, 2006, ONCOGENE, V25, P7159, DOI 10.1038/sj.onc.1209704; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jeggo P, 2002, DNA REPAIR, V1, P771, DOI 10.1016/S1568-7864(02)00096-4; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kennedy RD, 2005, GENE DEV, V19, P2925, DOI 10.1101/gad.1370505; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Kozlov SV, 2006, EMBO J, V25, P3504, DOI 10.1038/sj.emboj.7601231; Lee Y, 2000, GENE DEV, V14, P2576, DOI 10.1101/gad.837100; Lee Y, 2007, NEUROSCIENCE, V145, P1365, DOI 10.1016/j.neuroscience.2006.07.026; Lee Y, 2002, CANCER RES, V62, P6395; Lee Y, 2001, J NEUROSCI, V21, P6687, DOI 10.1523/JNEUROSCI.21-17-06687.2001; Lees-Miller SP, 2003, BIOCHIMIE, V85, P1161, DOI 10.1016/j.biochi.2003.10.011; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; McKinnon PJ, 2007, ANNU REV GENOM HUM G, V8, P37, DOI 10.1146/annurev.genom.7.080505.115648; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; McKinnon PJ, 2004, EMBO REP, V5, P772, DOI 10.1038/sj.embor.7400210; Mills KD, 2004, GENE DEV, V18, P1283, DOI 10.1101/gad.1204304; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Nijnik A, 2007, NATURE, V447, P686, DOI 10.1038/nature05875; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; O'Driscoll M, 2004, DNA REPAIR, V3, P1227, DOI 10.1016/j.dnarep.2004.03.025; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Offit K, 2003, JNCI-J NATL CANCER I, V95, P1548, DOI 10.1093/jnci/djg072; Orii KE, 2006, P NATL ACAD SCI USA, V103, P10017, DOI 10.1073/pnas.0602436103; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Pellegrini M, 2006, NATURE, V443, P222, DOI 10.1038/nature05112; Perrault R, 2004, J CELL BIOCHEM, V92, P781, DOI 10.1002/jcb.20104; Reid S, 2007, NAT GENET, V39, P162, DOI 10.1038/ng1947; Revy P, 2006, CURR OPIN ALLERGY CL, V6, P416, DOI 10.1097/01.all.0000246623.72365.43; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Riballo E, 2001, J BIOL CHEM, V276, P31124, DOI 10.1074/jbc.M103866200; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rooney S, 2003, J EXP MED, V197, P553, DOI 10.1084/jem.20021891; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Rosenthal N, 2007, NAT CELL BIOL, V9, P993, DOI 10.1038/ncb437; Rossi DJ, 2007, NATURE, V447, P725, DOI 10.1038/nature05862; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Sedelnikova OA, 2003, CANCER BIOL THER, V2, P233; Sekiguchi J, 2001, P NATL ACAD SCI USA, V98, P3243, DOI 10.1073/pnas.051632098; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; Shivji MKK, 2004, DNA REPAIR, V3, P835, DOI 10.1016/j.dnarep.2004.03.008; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Stracker TH, 2007, NATURE, V447, P218, DOI 10.1038/nature05740; Stucki M, 2006, DNA REPAIR, V5, P534, DOI 10.1016/j.dnarep.2006.01.012; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Thacker J, 2004, DNA REPAIR, V3, P1081, DOI 10.1016/j.dnarep.2004.04.012; Thacker J, 2003, DNA REPAIR, V2, P655, DOI 10.1016/S1568-7864(03)00062-4; Theunissen JWF, 2003, MOL CELL, V12, P1511, DOI 10.1016/S1097-2765(03)00455-6; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wang HC, 2005, CANCER RES, V65, P4020, DOI 10.1158/0008-5472.CAN-04-3055; Wang JH, 2005, DNA REPAIR, V4, P556, DOI 10.1016/j.dnarep.2005.02.001; Ward I, 2004, CURR TOP DEV BIOL, V63, P1, DOI 10.1016/S0070-2153(04)63001-8; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Williams BR, 2002, CURR BIOL, V12, P648, DOI 10.1016/S0960-9822(02)00763-7; Windhofer F, 2007, INT J RADIAT ONCOL, V68, P1462, DOI 10.1016/j.ijrobp.2007.04.038; Wyman C, 2004, DNA REPAIR, V3, P827, DOI 10.1016/j.dnarep.2004.03.037; Xia B, 2007, NAT GENET, V39, P159, DOI 10.1038/ng1942; Xu Y, 1998, MOL CELL BIOL, V18, P4385, DOI 10.1128/MCB.18.7.4385; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yan CT, 2006, P NATL ACAD SCI USA, V103, P7378, DOI 10.1073/pnas.0601938103; Yoo HY, 2007, J BIOL CHEM, V282, P17501, DOI 10.1074/jbc.M701770200; You ZS, 2005, MOL CELL BIOL, V25, P5363, DOI 10.1128/MCB.25.13.5363-5379.2005; Zhang XS, 2004, MOL CELL BIOL, V24, P9207, DOI 10.1128/MCB.24.20.9207-9220.2004; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	147	38	41	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	2007	26	56					7799	7808		10.1038/sj.onc.1210877	http://dx.doi.org/10.1038/sj.onc.1210877			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066093				2022-12-17	WOS:000251537900011
J	Xu, X; Li, W; Fan, X; Liang, Y; Zhao, M; Zhang, J; Liang, Y; Tong, W; Wang, J; Yang, W; Lu, Y				Xu, X.; Li, W.; Fan, X.; Liang, Y.; Zhao, M.; Zhang, J.; Liang, Y.; Tong, W.; Wang, J.; Yang, W.; Lu, Y.			Identification and characterization of a novel p42.3 gene astumor-s pecific and mitosis phase-dependent expression in gastric cancer	ONCOGENE			English	Article						gastric cancer; p42.3; cell cycle; RNAi	CELL-CYCLE; MOLECULAR-CLONING; PROLIFERATION; CHECKPOINT; PHENOTYPE; PROTEINS	Multiple genetic alterations are attributed to gastric cancer (GC); however, only a few critical genes have been identified so far. In this study, we isolated and characterized a novel gene p42.3, represented as tumor-specific and mitosis phase-dependent expression protein in GC cell line BGC823. Our data showed that the expression of p42.3 was cell cycle-dependent in GC cell lines. Moreover, p42.3 was specifically expressed in primary GC tissues but not in the matched normal mucosa of stomach, and this gene was expressed in diverse embryonic tissues. Furthermore, significant suppression of cell proliferation and tumorigenicity were detected and G(2)/M phase arrest was observed in cell line BGC823 depleted of p42.3 expression by RNAi technique, and we confirmed the expression changes of cyclin B1 and Chk2 following the silence of p42.3. Taken together, we cloned and characterized p42.3 gene that was specifically expressed in GC tumors but not in normal gastric mucosa, and the gene was associated with M-phase regulation. Moreover, p42.3 might be involved in cell proliferation and tumorigenesis; therefore, this gene might have potential applications in the diagnosis or treatment of GC.	Peking Univ, Sch Oncol, Inst Canc Res, Oncol Mol Lab, Beijing 100871, Peoples R China; Chinese Acad Sci, Genom Inst, Beijing, Peoples R China; Tsinghua Univ, Natl Engn Res Ctr Biochip Technol, Sch Med, Beijing 100084, Peoples R China	Peking University; Chinese Academy of Sciences; Tsinghua University	Lu, Y (corresponding author), Peking Univ, Sch Oncol, Inst Canc Res, Oncol Mol Lab, Fu-Cheng rd 52,Hai-Dian Dist, Beijing 100871, Peoples R China.	yongylu@public.bta.net.cn						Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Cobb JA, 2006, NUCLEIC ACIDS RES, V34, P4106, DOI 10.1093/nar/gkl557; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Deng H, 2005, BIOCHEM BIOPH RES CO, V326, P274, DOI 10.1016/j.bbrc.2004.11.027; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Herness EA, 2003, CANCER RES, V63, P329; Ji JF, 2002, ONCOGENE, V21, P6549, DOI 10.1038/sj.onc.1205829; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lu M, 2005, CANCER RES, V65, P6159, DOI 10.1158/0008-5472.CAN-04-4016; Murata T, 2004, GENE EXPR PATTERNS, V5, P171, DOI 10.1016/j.modgep.2004.08.007; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; Pinto-Santini D, 2005, CANCER EPIDEM BIOMAR, V14, P1853, DOI 10.1158/1055-9965.EPI-04-0784; Santamaria-Kisiel L, 2006, BIOCHEM J, V396, P201, DOI 10.1042/BJ20060195; Stock M, 2005, GENE, V360, P1, DOI 10.1016/j.gene.2005.06.026; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Tang ZB, 2004, ONCOL REP, V11, P333; Toyota M, 1999, CANCER RES, V59, P5438; You Wei Cheng, 2005, Chin J Dig Dis, V6, P149; Zeng JZ, 2002, ONCOGENE, V21, P4932, DOI 10.1038/sj.onc.1205652; Zhang PN, 2001, J BIOL CHEM, V276, P19862, DOI 10.1074/jbc.M100597200	25	38	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2007	26	52					7371	7379		10.1038/sj.onc.1210538	http://dx.doi.org/10.1038/sj.onc.1210538			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17525738				2022-12-17	WOS:000250955700009
J	Wickrema, A; Crispino, JD				Wickrema, A.; Crispino, J. D.			Erythroid and megakaryocytic transformation	ONCOGENE			English	Review						AMKL; erythroleukemia; myeloproliferative diseases; GATA1; RUNX1; Fli-1; friend virus	ACUTE MEGAKARYOBLASTIC LEUKEMIA; TRANSCRIPTION FACTOR GATA-1; ACUTE MYELOID-LEUKEMIA; TYROSINE KINASE JAK2; ZINC-FINGER PROTEIN; DOWN-SYNDROME; GENE-EXPRESSION; MYELODYSPLASTIC SYNDROME; AML1/PEBP2-ALPHA-B GENE; ACTIVATING MUTATION	Red blood cells and megakaryocytes arise from a common precursor, the megakaryocyte- erythroid progenitor and share many regulators including the transcription factors GATA- 1 and GFI- 1B and signaling molecules such as JAK2 and STAT5. These lineages also share the distinction of being associated with rare, but aggressive malignancies that have very poor prognoses. In this review, we will briefly summarize features of normal development of red blood cells and megakaryocytes and also highlight events that lead to their leukemic transformation. It is clear that much more work needs to be done to improve our understanding of the unique biology of these leukemias and to pave the way for novel targeted therapeutics.	Northwestern Univ, Div Hematol Oncol, Chicago, IL 60611 USA; Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA	Northwestern University; University of Chicago	Crispino, JD (corresponding author), Northwestern Univ, Div Hematol Oncol, 303 E Sup St,Lurie 5-11, Chicago, IL 60611 USA.	j-crispino@northwestern.edu		Crispino, John/0000-0002-8182-8306	NATIONAL CANCER INSTITUTE [R01CA101774] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA101774, R01 CA101774-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdelhaleem M, 2007, LEUKEMIA, V21, P352, DOI 10.1038/sj.leu.2404503; Al-Ahmari A, 2006, BRIT J HAEMATOL, V133, P646, DOI 10.1111/j.1365-2141.2006.06097.x; Al-Kasim F, 2002, J PEDIAT HEMATOL ONC, V24, P9, DOI 10.1097/00043426-200201000-00004; Andrews NC, 1998, INT J BIOCHEM CELL B, V30, P429, DOI 10.1016/S1357-2725(97)00135-0; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; Barnard DR, 2007, PEDIATR BLOOD CANCER, V49, P17, DOI 10.1002/pbc.20951; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Bernstein J, 2000, LEUKEMIA, V14, P216, DOI 10.1038/sj.leu.2401639; Blair DG, 2000, ONCOGENE, V19, P6472, DOI 10.1038/sj.onc.1204046; Bourquin JP, 2006, P NATL ACAD SCI USA, V103, P3339, DOI 10.1073/pnas.0511150103; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Carpinelli MR, 2004, P NATL ACAD SCI USA, V101, P6553, DOI 10.1073/pnas.0401496101; CARROLL A, 1991, BLOOD, V78, P748; Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; Chang AN, 2002, P NATL ACAD SCI USA, V99, P9237, DOI 10.1073/pnas.142302099; Chen FL, 2000, CURR BIOL, V10, P943, DOI 10.1016/S0960-9822(00)00625-4; Chen Z, 2007, BLOOD, V109, P1451, DOI 10.1182/blood-2006-08-038901; CHUNG SW, 1989, P NATL ACAD SCI USA, V86, P7957, DOI 10.1073/pnas.86.20.7957; Cramer EM, 1997, BLOOD, V89, P2336, DOI 10.1182/blood.V89.7.2336; Crispino JD, 2005, SEMIN CELL DEV BIOL, V16, P137, DOI 10.1016/j.semcdb.2004.11.002; Drexler HG, 2004, LEUKEMIA RES, V28, P1243, DOI 10.1016/j.leukres.2004.03.022; Drissen R, 2005, MOL CELL BIOL, V25, P5205, DOI 10.1128/MCB.25.12.5205-5214.2005; Du KL, 2004, J BIOL CHEM, V279, P17578, DOI 10.1074/jbc.M400961200; Elmaagacli AH, 2007, BRIT J HAEMATOL, V136, P212, DOI 10.1111/j.1365-2141.2006.06407.x; Emambokus N, 2003, EMBO J, V22, P4478, DOI 10.1093/emboj/cdg434; Fang C, 1998, VIROLOGY, V252, P46, DOI 10.1006/viro.1998.9453; Freyssinier JM, 1999, BRIT J HAEMATOL, V106, P912; FRIEND C, 1957, J EXP MED, V105, P307, DOI 10.1084/jem.105.4.307; Frohling S, 2005, J CLIN ONCOL, V23, P6285, DOI 10.1200/JCO.2005.05.010; Gamis AS, 2005, PEDIATR BLOOD CANCER, V44, P13, DOI 10.1002/pbc.20207; Garcon L, 2005, BLOOD, V105, P1448, DOI 10.1182/blood-2003-11-4068; Ge YB, 2004, CANCER RES, V64, P728, DOI 10.1158/0008-5472.CAN-03-2456; Ghinassi B, 2007, BLOOD, V109, P1460, DOI 10.1182/blood-2006-07-030726; Giarratana MC, 2005, NAT BIOTECHNOL, V23, P69, DOI 10.1038/nbt1047; Goerttler PS, 2005, BRIT J HAEMATOL, V129, P138, DOI 10.1111/j.1365-2141.2005.05416.x; Growney JD, 2005, BLOOD, V106, P494, DOI 10.1182/blood-2004-08-3280; Gu TL, 2007, BLOOD, V110, P323, DOI 10.1182/blood-2006-10-052282; HANCOCK V, 1993, BRIT J HAEMATOL, V85, P692, DOI 10.1111/j.1365-2141.1993.tb03210.x; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; ITO E, 1995, BRIT J HAEMATOL, V90, P607, DOI 10.1111/j.1365-2141.1995.tb05591.x; Izraeli S, 2006, HEMATOL ONCOL, V24, P3, DOI 10.1002/hon.758; Jacobs-Helber SM, 2003, BLOOD, V101, P524, DOI 10.1182/blood-2001-11-0084; Jaffe ES, 2001, PATHOLOGY GENETICS T; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Jelinek J, 2005, BLOOD, V106, P3370, DOI 10.1182/blood-2005-05-1800; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Kirito K, 2002, INT J HEMATOL, V75, P51, DOI 10.1007/BF02981979; Kiritoa K, 2006, CURR OPIN HEMATOL, V13, P151, DOI 10.1097/01.moh.0000219660.03657.4b; Kosmider O, 2005, CANCER CELL, V8, P467, DOI 10.1016/j.ccr.2005.11.009; Koury MJ, 2002, CURR OPIN HEMATOL, V9, P93, DOI 10.1097/00062752-200203000-00002; KOURY MJ, 1984, J CELL PHYSIOL, V121, P526, DOI 10.1002/jcp.1041210311; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Kuhl C, 2005, MOL CELL BIOL, V25, P8592, DOI 10.1128/MCB.25.19.8592-8606.2005; Lange B, 2000, BRIT J HAEMATOL, V110, P512, DOI 10.1046/j.1365-2141.2000.02027.x; Lange BJ, 1998, BLOOD, V91, P608; Langebrake C, 2006, HAEMATOLOGICA, V91, P1473; Lannutti BJ, 2006, ONCOGENE, V25, P3316, DOI 10.1038/sj.onc.1209351; Lannutti BJ, 2003, EXP HEMATOL, V31, P1268, DOI 10.1016/j.exphem.2003.09.009; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Li Z, 2005, NAT GENET, V37, P613, DOI 10.1038/ng1566; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; Lulli V, 2006, CELL DEATH DIFFER, V13, P1064, DOI 10.1038/sj.cdd.4401811; Ma XY, 2007, MOL CELL BIOL, V27, P3056, DOI 10.1128/MCB.01339-06; Ma ZG, 2001, NAT GENET, V28, P220, DOI 10.1038/90054; Mahmud DL, 2002, ONCOGENE, V21, P1556, DOI 10.1038/sj.onc.1205230; McLean TW, 1996, BLOOD, V88, P4252; Mercher T, 2001, P NATL ACAD SCI USA, V98, P5776, DOI 10.1073/pnas.101001498; Michiels JJ, 1997, HAEMATOLOGICA, V82, P452; MICHIELS JJ, 2002, SEM VASC MED, V1, P1; Muntean AG, 2005, BLOOD, V106, P1223, DOI 10.1182/blood-2005-02-0551; Muntean AG, 2007, BLOOD, V109, P5199, DOI 10.1182/blood-2006-11-059378; Muntean AG, 2006, LEUKEMIA LYMPHOMA, V47, P986, DOI 10.1080/10428190500485810; Nelson ME, 2006, LEUKEMIA LYMPHOMA, V47, P177, DOI 10.1080/10428190500301348; Ney PA, 2000, BLOOD, V96, P3675, DOI 10.1182/blood.V96.12.3675.h8003675_3675_3680; NUCIFORA G, 1995, BLOOD, V86, P1; Oki Y, 2006, BLOOD, V107, P880, DOI 10.1182/blood-2005-06-2450; Osato M, 2005, CRIT REV EUKAR GENE, V15, P217, DOI 10.1615/CritRevEukarGeneExpr.v15.i3.40; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Osawa M, 2002, BLOOD, V100, P2769, DOI 10.1182/blood-2002-01-0182; Oswald F, 2002, EMBO J, V21, P5417, DOI 10.1093/emboj/cdf549; Pagano L, 2002, LEUKEMIA, V16, P1622, DOI 10.1038/sj.leu.2402618; Pang LY, 2006, BLOOD, V108, P2198, DOI 10.1182/blood-2006-04-019760; Pardanani AD, 2006, BLOOD, V108, P3472, DOI 10.1182/blood-2006-04-018879; Park S, 2002, LEUKEMIA, V16, P1399, DOI 10.1038/sj.leu.2402549; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; Phillips JD, 2007, BLOOD, V109, P2618, DOI 10.1182/blood-2006-06-022848; Pikman Y, 2006, PLOS MED, V3, P1140, DOI 10.1371/journal.pmed.0030270; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Putz G, 2006, ONCOGENE, V25, P929, DOI 10.1038/sj.onc.1209136; Raffel GD, 2007, P NATL ACAD SCI USA, V104, P6001, DOI 10.1073/pnas.0609041104; Rainis L, 2005, CANCER RES, V65, P7596, DOI 10.1158/0008-5472.CAN-05-0147; Raslova H, 2003, BLOOD, V101, P541, DOI 10.1182/blood-2002-05-1553; Raslova H, 2007, BLOOD, V109, P3225, DOI 10.1182/blood-2006-07-037838; Ravid K, 2002, J CELL PHYSIOL, V190, P7, DOI 10.1002/jcp.10035; Rietveld LEG, 2001, ONCOGENE, V20, P3100, DOI 10.1038/sj.onc.1204335; Rosenbauer F, 2007, NAT REV IMMUNOL, V7, P105, DOI 10.1038/nri2024; Rubnitz JE, 2007, CANCER, V109, P157, DOI 10.1002/cncr.22385; Saleque S, 2002, GENE DEV, V16, P301, DOI 10.1101/gad.959102; SAMARUT J, 1982, CELL, V28, P921, DOI 10.1016/0092-8674(82)90071-X; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; SOTIROV N, 1981, J NATL CANCER I, V66, P1143, DOI 10.1093/jnci/66.6.1143; Steensma DP, 2006, LEUKEMIA, V20, P971, DOI 10.1038/sj.leu.2404206; Steensma DP, 2006, BLOOD, V107, P1733, DOI 10.1182/blood-2005-09-3646; Sun W, 2004, BLOOD, V104, P3565, DOI 10.1182/blood-2003-12-4349; Szalai G, 2006, CELL MOL LIFE SCI, V63, P2460, DOI 10.1007/s00018-006-6190-8; Tallman MS, 2000, BLOOD, V96, P2405; Teal HE, 2006, ONCOGENE, V25, P2433, DOI 10.1038/sj.onc.1209288; Tilbrook PA, 2001, CANCER RES, V61, P2453; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tubman VN, 2007, BLOOD, V109, P3297, DOI 10.1182/blood-2006-02-004101; Uddin S, 2004, P NATL ACAD SCI USA, V101, P147, DOI 10.1073/pnas.0307075101; Vannucchi AM, 2002, BLOOD, V100, P1123, DOI 10.1182/blood-2002-06-1913; Vyas P, 1999, BLOOD, V93, P2867; Vyas P, 2007, CURR OPIN PEDIATR, V19, P9, DOI 10.1097/MOP.0b013e328013e7b2; Vyas P, 2006, EARLY HUM DEV, V82, P767, DOI 10.1016/j.earlhumdev.2006.09.016; Walters DK, 2006, CANCER CELL, V10, P65, DOI 10.1016/j.ccr.2006.06.002; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; WICKREMA A, 1992, BLOOD, V80, P1940, DOI 10.1182/blood.V80.8.1940.1940; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; WICKREMA A, 1991, BLOOD, V78, P2269, DOI 10.1182/blood.V78.9.2269.bloodjournal7892269; Wiellette EL, 1999, DEVELOPMENT, V126, P5373; XU Z, 2003, J DISTANCE ED TECHNO, V1, P1; Yamashita N, 2005, BRIT J HAEMATOL, V131, P495, DOI 10.1111/j.1365-2141.2005.05793.x; Yanagida M, 2005, ONCOGENE, V24, P4477, DOI 10.1038/sj.onc.1208675; Zhang MY, 1998, BLOOD, V91, P4136, DOI 10.1182/blood.V91.11.4136.411k26_4136_4144; Zhao RX, 2005, J BIOL CHEM, V280, P22788, DOI 10.1074/jbc.C500138200; Zipursky A, 2003, BRIT J HAEMATOL, V120, P930, DOI 10.1046/j.1365-2141.2003.04229.x	130	38	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	47					6803	6815		10.1038/sj.onc.1210763	http://dx.doi.org/10.1038/sj.onc.1210763			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934487				2022-12-17	WOS:000250147000011
J	Meng, X; Fan, J; Shen, Z				Meng, X.; Fan, J.; Shen, Z.			Roles of BCCIP in chromosome stability and cytokinesis	ONCOGENE			English	Article						cytokinesis; chromosome instability; BRCA2; BCCIP; polyploidy	CENTROSOME AMPLIFICATION; CANCER SUSCEPTIBILITY; PROTEIN; BRCA2; P53; INHIBITION; EXPRESSION; PATHWAYS; ARREST; BREAST	The BRCA2 gene is involved in recombinational DNA repair and cytokinesis. BRCA2 defects are associated with chromosomal abnormalities, which is a hallmark of genomic instability that contributes to tumorigenesis. Here, we show that downregulation of a BRCA2 interacting protein ( BCCIP) in HT1080 cells leads to chromosomal polyploidization, centrosome amplification and abnormal mitotic spindle formation. The BCCIP knockdown cells can enter mitosis and retain spindle checkpoint, but fail to complete cytokinesis. Our data suggest an essential role of BCCIP in the maintenance of genomic integrity.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Radiat Oncol, New Brunswick, NJ 08903 USA; Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; University of New Mexico	Shen, Z (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Radiat Oncol, 195 Little Albany St, New Brunswick, NJ 08903 USA.	shenzh@umdnj.edu		Shen, Zhiyuan/0000-0003-2834-0309; meng, xiangbing/0000-0002-9612-6438	NCI NIH HHS [R01 CA115488, R01 CA115488-04, R01 CA115488-02, R01 CA115488-01, R01 CA115488-03, CA115488] Funding Source: Medline; NIEHS NIH HHS [ES08353, R01 ES008353, R29 ES008353] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA115488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES008353, R01ES008353] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Geddis AE, 2004, BLOOD, V104, P1017, DOI 10.1182/blood-2004-02-0419; Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Liu JM, 2001, ONCOGENE, V20, P336, DOI 10.1038/sj.onc.1204098; Lu HM, 2005, MOL CELL BIOL, V25, P1949, DOI 10.1128/MCB.25.5.1949-1957.2005; Maier D, 1998, ONCOGENE, V16, P3331, DOI 10.1038/sj.onc.1201832; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Meng XB, 2004, CELL CYCLE, V3, P1457, DOI 10.4161/cc.3.11.1213; Meng XB, 2004, CELL CYCLE, V3, P343; Meng XB, 2004, J BIOL CHEM, V279, P6098, DOI 10.1074/jbc.M306794200; Meng XB, 2003, GENE, V302, P139, DOI 10.1016/S0378-1119(02)01098-3; Meng XB, 2007, J BIOL CHEM, V282, P1570, DOI 10.1074/jbc.M607520200; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Merlo A, 2003, NEUROSURG REV, V26, P145, DOI 10.1007/s10143-003-0267-8; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Ono T, 2000, J BIOL CHEM, V275, P31145, DOI 10.1074/jbc.M003031200; Powell SN, 2003, ONCOGENE, V22, P5784, DOI 10.1038/sj.onc.1206678; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; Roversi G, 2006, ONCOGENE, V25, P1571, DOI 10.1038/sj.onc.1209177; Rudkin TM, 2005, TRENDS MOL MED, V11, P145, DOI 10.1016/j.molmed.2005.02.003; SHINMURA K, 2006, ONCOGENE; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3	29	38	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2007	26	43					6253	6260		10.1038/sj.onc.1210460	http://dx.doi.org/10.1038/sj.onc.1210460			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17452982	Green Accepted			2022-12-17	WOS:000249583300001
J	Kim, M; Egan, C; Alain, T; Urbanski, SJ; Lee, PW; Forsyth, PA; Johnston, RN				Kim, M.; Egan, C.; Alain, T.; Urbanski, S. J.; Lee, P. W.; Forsyth, P. A.; Johnston, R. N.			Acquired resistance to reoviral oncolysis in Ras-transformed brosarcoma cells	ONCOGENE			English	Article						reovirus; Ras; oncolysis; resistance	CATHEPSIN-B; PERSISTENT INFECTION; CANCER-THERAPY; INTERFERON; PATHWAY; VIRUS; GENE; MACROPHAGES; ACTIVATION; EXPRESSION	Reovirus shows considerable potential as an oncolytic agent for Ras- activated tumors and is currently in clinical trials. Here we ask whether such tumor cell lines can acquire resistance to reoviral oncolysis. We challenged human HT1080. fibrosarcoma cells that carry a Ras mutation by prolonged exposure to reovirus, thereby yielding highly virus- resistant HTR1 cells. These cells are persistently infected with reovirus, exhibit high Ras activity and retain the original Ras gene mutation, showing that resistance to reovirus can be displayed in cells with active Ras. The HTR1 cells also exhibit reduced cellular cathepsin B activity, which normally contributes to viral entry and activation. Persistently infected HTR1 cells were not tumorigenic in vivo, whereas immunologically cured virus- free HTR1 cells were highly tumorigenic. Thus, acquisition of resistance to reovirus may constrain therapeutic strategies. To determine whether reoviral resistance is associated with a general reduction in apoptotic potential, we challenged the HTR1 cells with apoptotic inducers and E1B- defective adenovirus, resulting in significant apoptosis and cell death following both approaches. Therefore, even if resistance to reoviral oncolysis should arise in tumor cells in vivo, other therapeutic strategies may nevertheless remain effective.	Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Oncol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Pathol, Calgary, AB T2N 4N1, Canada; Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3H 3J5, Canada	University of Calgary; University of Calgary; University of Calgary; Dalhousie University	Johnston, RN (corresponding author), Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Room HMRB 371,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	rnjohnst@ucalgary.ca	Johnston, Randal/B-9247-2009					AHMED R, 1981, CELL, V25, P325, DOI 10.1016/0092-8674(81)90050-7; Baer GS, 1999, J VIROL, V73, P9532, DOI 10.1128/JVI.73.11.9532-9543.1999; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003-9861(92)90290-D; Clarke P, 2001, ONCOGENE, V20, P6910, DOI 10.1038/sj.onc.1204842; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Connolly JL, 2002, J VIROL, V76, P1632, DOI 10.1128/JVI.76.4.1632-1641.2002; Danis C, 1997, VIRUS RES, V51, P139, DOI 10.1016/S0168-1702(97)00088-9; Dermody TS, 1998, CURR TOP MICROBIOL, V233, P1; DERMODY TS, 1995, VIROLOGY, V212, P272, DOI 10.1006/viro.1995.1483; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DUNCAN MR, 1978, J VIROL, V28, P444, DOI 10.1128/JVI.28.2.444-449.1978; Duursma AM, 2003, SEMIN CANCER BIOL, V13, P267, DOI 10.1016/S1044-579X(03)00040-3; Ebert DH, 2004, J BIOL CHEM, V279, P3837, DOI 10.1074/jbc.M310048200; HASHIRO G, 1977, ARCH VIROL, V54, P307, DOI 10.1007/BF01314776; Kominsky DJ, 2002, CELL DEATH DIFFER, V9, P926, DOI 10.1038/sj.cdd.4401045; Langland JO, 2006, VIRUS RES, V119, P100, DOI 10.1016/j.virusres.2005.10.014; Loken SD, 2004, CANCER BIOL THER, V3, P734, DOI 10.4161/cbt.3.8.963; Meusel TR, 2003, J IMMUNOL, V171, P3768, DOI 10.4049/jimmunol.171.7.3768; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAGATA L, 1984, NUCLEIC ACIDS RES, V12, P8699, DOI 10.1093/nar/12.22.8699; Norman KL, 2005, DRUG DISCOV TODAY, V10, P847, DOI 10.1016/S1359-6446(05)03483-5; PATERSON H, 1987, CELL, V51, P803, DOI 10.1016/0092-8674(87)90103-6; Samuel CE, 1998, CURR TOP MICROBIOL, V233, P125; Schotte P, 2001, J BIOL CHEM, V276, P21153, DOI 10.1074/jbc.M102239200; Shiratsuchi A, 2000, J VIROL, V74, P9240, DOI 10.1128/JVI.74.19.9240-9244.2000; SMITH RE, 1969, VIROLOGY, V39, P791, DOI 10.1016/0042-6822(69)90017-8; Steele TA, 2005, EXP BIOL MED, V230, P487; Steele TA, 1996, P SOC EXP BIOL MED, V212, P63; Stewart MJ, 2005, J VIROL, V79, P2979, DOI 10.1128/JVI.79.5.2979-2987.2005; Stoeckel J, 2006, CURR OPIN MOL THER, V8, P249; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; TABER R, 1976, J VIROL, V17, P513, DOI 10.1128/JVI.17.2.513-524.1976; TEODORO JG, 1994, J VIROL, V68, P776, DOI 10.1128/JVI.68.2.776-786.1994; TYLER KL, 2001, LIPPINCOTT FIELDS VI, P1729; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; Yeung MC, 1999, P NATL ACAD SCI USA, V96, P11860, DOI 10.1073/pnas.96.21.11860	38	38	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2007	26	28					4124	4134		10.1038/sj.onc.1210189	http://dx.doi.org/10.1038/sj.onc.1210189			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17213803				2022-12-17	WOS:000247252700008
J	Gaussmann, A; Wenger, T; Eberle, I; Bursen, A; Bracharz, S; Herr, I; Dingermann, T; Marschalek, R				Gaussmann, A.; Wenger, T.; Eberle, I.; Bursen, A.; Bracharz, S.; Herr, I.; Dingermann, T.; Marschalek, R.			Combined effects of the two reciprocal t(4; II) fusion proteins MLL . AF4 and AF4 . MLL confer resistance to apoptosis, cell cycling capacity and growth transformation	ONCOGENE			English	Article						MLL; AF4; acute leukemia; t(4;11) fusion proteins; Nanog	ACUTE LYMPHOBLASTIC-LEUKEMIA; CHILDHOOD ACUTE-LEUKEMIA; CARCINOMA IN-SITU; CHROMOSOMAL REARRANGEMENT; EXPRESSION; MLL-AF4; GENE; PLURIPOTENCY; NANOG; COOPERATION	The reciprocal chromosomal translocation t(4;11) is correlated with infant, childhood, adult and therapy-related high-risk acute leukemia. Here, we investigated the biological effects of MLL (.) AF4, AF4 (.) MLL or the combination of both reciprocal fusion proteins in a conditional in vitro cell culture model system. Several parameters like cell growth, cell cycling capacity, apoptotic behavior and growth transformation were investigated under physiological and stress conditions. Co-transfected cells displayed the highest resistance against apoptotic triggers, cell cycling capacity and loss-of-contact inhibition. These analyses were complemented by gene expression profiling experiments and specific gene signatures were established for each of the three cell lines. Interestingly, co-transfected cells strongly upregulate the homeobox gene Nanog. In combination with Oct4, the Nanog homeoprotein is steering maintenance of pluripotency and self-renewal in embryonic stem cells. Transcription of Nanog and other stem cell factors, like Oct4 and Bmi1, was verified in biopsy material of t(4;11) patient cells which express both reciprocal t(4;11) fusion genes. In conclusion, the presence of both reciprocal MLL fusion proteins confers biological properties known from t(4;11) leukemia, suggesting that each of the two fusion proteins contribute specific properties and, in combination, also synergistic effects to the leukemic phenotype.	Goethe Univ Frankfurt, Bioctr, Inst Pharmaceut Biol, ZAFES, D-60439 Frankfurt, Germany; Heidelberg Univ, Dept Surg, Heidelberg, Germany; German Canc Res Ctr, Heidelberg, Germany	Goethe University Frankfurt; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Marschalek, R (corresponding author), Goethe Univ Frankfurt, Bioctr, Inst Pharmaceut Biol, ZAFES, Max Von Laue Str 9, D-60439 Frankfurt, Germany.	rolf.marschalek@em.uni-frankfurt.de	Marschalek, Rolf/D-3404-2011; Dingermann, Theodor/M-6970-2014	Marschalek, Rolf/0000-0003-4870-3445; Dingermann, Theodor/0000-0002-2788-1085				Almstrup K, 2004, CANCER RES, V64, P4736, DOI 10.1158/0008-5472.CAN-04-0679; Andersson A, 2005, P NATL ACAD SCI USA, V102, P19069, DOI 10.1073/pnas.0506637102; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Booth HAF, 2004, GENOMICS, V84, P229, DOI 10.1016/j.ygeno.2004.02.014; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Bursen A, 2004, ONCOGENE, V23, P6237, DOI 10.1038/sj.onc.1207837; Caslini C, 2004, LEUKEMIA, V18, P1064, DOI 10.1038/sj.leu.2403321; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; CHEN W, 2006, IN RPESS BLOOD  0321; Dordelmann M, 1999, BLOOD, V94, P1209, DOI 10.1182/blood.V94.4.1209.416k05_1209_1217; DOWNING JR, 1994, BLOOD, V83, P330, DOI 10.1182/blood.V83.2.330.bloodjournal832330; FELIX CA, 1995, BLOOD, V85, P3250, DOI 10.1182/blood.V85.11.3250.bloodjournal85113250; GREIL J, 1994, BRIT J HAEMATOL, V86, P275, DOI 10.1111/j.1365-2141.1994.tb04726.x; Guenther MG, 2005, P NATL ACAD SCI USA, V102, P8603, DOI 10.1073/pnas.0503072102; Hoei-Hansen CE, 2005, HISTOPATHOLOGY, V47, P48, DOI 10.1111/j.1365-2559.2005.02182.x; Ivanova N, 2006, NATURE, V442, P533, DOI 10.1038/nature04915; JANSSEN JWG, 1994, BLOOD, V84, P3835, DOI 10.1182/blood.V84.11.3835.bloodjournal84113835; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Kersey JH, 1998, LEUKEMIA, V12, P1561, DOI 10.1038/sj.leu.2401148; LANGE B, 1987, BLOOD, V70, P192; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; LOH YH, 2006, IN PRESS NAT GENET, V5; Metzler M, 2006, ONCOGENE, V25, P3093, DOI 10.1038/sj.onc.1209636; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Mitterbauer-Hohendanner G, 2004, EUR J CLIN INVEST, V34, P12, DOI 10.1111/j.0960-135X.2004.01366.x; PUI CH, 1994, J CLIN ONCOL, V12, P909, DOI 10.1200/JCO.1994.12.5.909; Reichel M, 2001, ONCOGENE, V20, P2900, DOI 10.1038/sj.onc.1204401; Skotheim RI, 2005, CANCER RES, V65, P5588, DOI 10.1158/0008-5472.CAN-05-0153; SO ECW, 2004, ASH ABST, V467; STONG RC, 1985, BLOOD, V65, P21, DOI 10.1182/blood.V65.1.21.21; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Takeda S, 2006, GENE DEV, V20, P2397, DOI 10.1101/gad.1449406; Taranger CK, 2005, MOL BIOL CELL, V16, P5719, DOI 10.1091/mbc.e05-06-0572; Terranova R, 2006, P NATL ACAD SCI USA, V103, P6629, DOI 10.1073/pnas.0507425103; Thomas M, 2005, BLOOD, V106, P3559, DOI 10.1182/blood-2005-03-1283; Xia ZB, 2005, P NATL ACAD SCI USA, V102, P14028, DOI 10.1073/pnas.0506464102; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; Zhang FQ, 2006, M&SOM-MANUF SERV OP, V8, P273, DOI 10.1287/msom.1060.0108	38	38	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2007	26	23					3352	3363		10.1038/sj.onc.1210125	http://dx.doi.org/10.1038/sj.onc.1210125			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17130830				2022-12-17	WOS:000246579600005
J	Zhao, J; Yart, A; Frigerio, S; Perren, A; Schraml, P; Weisstanner, C; Stallmach, T; Krek, W; Moch, H				Zhao, J.; Yart, A.; Frigerio, S.; Perren, A.; Schraml, P.; Weisstanner, C.; Stallmach, T.; Krek, W.; Moch, H.			Sporadic human renal tumors display frequent allelic imbalances and novel mutations of the HRPT2 gene	ONCOGENE			English	Article						LOH; HRPT2 mutation; parafibromin; renal tumor	COMPARATIVE GENOMIC HYBRIDIZATION; HISTOLOGY WILMS-TUMORS; SUPPRESSOR GENE; CELL CARCINOMA; SOMATIC MUTATIONS; PRIMARY HYPERPARATHYROIDISM; PARATHYROID TUMORS; HEREDITARY HYPERPARATHYROIDISM; MET PROTOONCOGENE; HUMAN PAF1	Inactivation of the HRPT2 gene encoding parafibromin was recently linked to the familial hyperparathyroidism-jaw tumor syndrome. Patients with this syndrome carry an increased risk of parathyroid and renal tumors. To determine the relevance of HRPT2 for sporadic renal tumors, clear cell, papillary and chromophobe renal cell carcinomas as well as oncocytomas and Wilms tumors were analysed for HRPT2 gene alterations. Loss of heterozygosity (LOH) of HRPT2 was found in seven of 56 (12.5%) clear cell, three of 14 (21%) papillary, six of 10 (60%) chromophobe renal cell carcinomas, three of eight (38%) oncocytomas and four of 10 (40%) Wilms tumors. In addition, two novel HRPT2 point mutations, causing K34Q and R292K changes in parafibromin, were detected in one clear cell carcinoma and one Wilms tumor, respectively. These tumors displayed LOH of the remaining wild-type allele, but interestingly no von Hippel-Lindau (VHL) mutation. Functional analysis revealed that the K34Q mutant species of parafibromin is, unlike wild-type protein, defective in suppressing cyclin D1 expression in vivo. Taken together, these results suggest that renal cancer-associated mutations in parafibromin occur in the absence of VHL mutation, which in turn may contribute to constitutively elevated cyclin D1 expression and abnormal cell proliferation.	Univ Zurich Hosp, Inst Surg Pathol, Dept Pathol, CH-8091 Zurich, Switzerland; Swiss Fed Inst Technol, Inst Cell Biol, Zurich, Switzerland	University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich	Zhao, J (corresponding author), Univ Zurich Hosp, Inst Surg Pathol, Dept Pathol, Schmelzberger 12, CH-8091 Zurich, Switzerland.	jianming.zhao@usz.ch	Perren, Aurel/N-5979-2019; YART, Armelle/A-5656-2016; Perren, Aurel/A-9383-2018	Perren, Aurel/0000-0002-6819-6092; YART, Armelle/0000-0002-2412-9840; Perren, Aurel/0000-0002-6819-6092; Weisstanner, Christian/0000-0003-2830-1000				Brauch H, 2000, CANCER RES, V60, P1942; Bugert P, 1997, LAB INVEST, V76, P203; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Carling T, 2001, TRENDS ENDOCRIN MET, V12, P53, DOI 10.1016/S1043-2760(00)00345-3; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; Cavaco BM, 2004, J CLIN ENDOCR METAB, V89, P1747, DOI 10.1210/jc.2003-031016; Cavaco BM, 2001, QJM-INT J MED, V94, P213, DOI 10.1093/qjmed/94.4.213; Cetani F, 2004, J CLIN ENDOCR METAB, V89, P5583, DOI 10.1210/jc.2004-0294; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Eble JN, 2004, PATHOLOGY GENETICS T, P359; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; Fuzesi L, 2005, CANCER GENET CYTOGEN, V160, P120, DOI 10.1016/j.cancergencyto.2004.12.010; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1994, HUM MUTAT, V3, P212, DOI 10.1002/humu.1380030307; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GRUNDY PE, 1994, CANCER RES, V54, P2331; Grundy RG, 1998, BRIT J CANCER, V78, P1181, DOI 10.1038/bjc.1998.651; Gstaiger M, 2003, SCIENCE, V302, P1208, DOI 10.1126/science.1088401; Hahn MA, 2005, ONCOGENE, V24, P6241, DOI 10.1038/sj.onc.1208778; Haven CJ, 2000, J CLIN ENDOCR METAB, V85, P1449, DOI 10.1210/jc.85.4.1449; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hing S, 2001, AM J PATHOL, V158, P393, DOI 10.1016/S0002-9440(10)63982-X; Howell VM, 2003, J MED GENET, V40, P657, DOI 10.1136/jmg.40.9.657; JACKSON CE, 1990, SURGERY, V108, P1006; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jiang F, 1998, AM J PATHOL, V153, P1467, DOI 10.1016/S0002-9440(10)65734-3; KAKINUMA A, 1994, INTERNAL MED, V33, P123, DOI 10.2169/internalmedicine.33.123; Khoo SK, 2003, CANCER RES, V63, P4583; Kiuru M, 2002, CANCER RES, V62, P4554; Klamt B, 1998, GENE CHROMOSOME CANC, V22, P287, DOI 10.1002/(SICI)1098-2264(199808)22:4<287::AID-GCC4>3.0.CO;2-R; KOVACS A, 1992, GENE CHROMOSOME CANC, V4, P267, DOI 10.1002/gcc.2870040313; KOVACS G, 1991, GENE CHROMOSOME CANC, V3, P249, DOI 10.1002/gcc.2870030403; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Law MH, 1997, CANCER GENET CYTOGEN, V97, P54, DOI 10.1016/S0165-4608(96)00342-1; Maiti S, 2000, CANCER RES, V60, P6288; MELONI AM, 1992, CANCER GENET CYTOGEN, V61, P108, DOI 10.1016/0165-4608(92)90382-I; Moch H, 1996, CANCER RES, V56, P27; Moch H, 1998, CANCER RES, V58, P2304; Mosimann C, 2006, CELL, V125, P327, DOI 10.1016/j.cell.2006.01.053; Nagy A, 2004, HISTOPATHOLOGY, V44, P542, DOI 10.1111/j.1365-2559.2004.01884.x; Natrajan R, 2006, J PATHOL, V210, P49, DOI 10.1002/path.2021; Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6; Pavlovich CP, 2004, NAT REV CANCER, V4, P381, DOI 10.1038/nrc1364; Perren A, 2004, ENDOCR-RELAT CANCER, V11, P855, DOI 10.1677/erc.1.00841; Presti JC, 1996, GENE CHROMOSOME CANC, V17, P199, DOI 10.1002/(SICI)1098-2264(199612)17:4<199::AID-GCC1>3.0.CO;2-Z; Reutzel D, 2001, CYTOGENET CELL GENET, V93, P221, DOI 10.1159/000056987; Rivera MN, 2005, NAT REV CANCER, V5, P699, DOI 10.1038/nrc1696; Rozenblatt-Rosen O, 2005, MOL CELL BIOL, V25, P612, DOI 10.1128/MCB.25.2.612-620.2005; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Schraml P, 2002, J PATHOL, V196, P186, DOI 10.1002/path.1034; Shattuck TM, 2003, NEW ENGL J MED, V349, P1722, DOI 10.1056/NEJMoa031237; SHUIN T, 1994, CANCER RES, V54, P2852; SPEICHER MR, 1994, AM J PATHOL, V145, P356; SZABO J, 1995, AM J HUM GENET, V56, P944; Teh BT, 1996, J CLIN ENDOCR METAB, V81, P4204, DOI 10.1210/jc.81.12.4204; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; Wang PF, 2005, HORM METAB RES, V37, P380, DOI 10.1055/s-2005-870150; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Woodard GE, 2005, ONCOGENE, V24, P1272, DOI 10.1038/sj.onc.1208274; Yart A, 2005, MOL CELL BIOL, V25, P5052, DOI 10.1128/MCB.25.12.5052-5060.2005	63	38	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2007	26	23					3440	3449		10.1038/sj.onc.1210131	http://dx.doi.org/10.1038/sj.onc.1210131			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17130827				2022-12-17	WOS:000246579600014
J	Thullberg, M; Gad, A; Beeser, A; Chernoff, J; Stromblad, S				Thullberg, M.; Gad, A.; Beeser, A.; Chernoff, J.; Stromblad, S.			The kinase-inhibitory domain of p21-activated kinase 1 (PAK1) inhibits cell cycle progression independent of PAK1 kinase activity	ONCOGENE			English	Article						p21-activated kinase 1 (PAK1); cell cycle; cyclin D1; Rac; GTPase	BREAST-CANCER CELLS; ADAPTER PROTEIN; D1 EXPRESSION; BUDDING-YEAST; ALPHA-PAK; ACTIVATION; PHOSPHORYLATION; CDC42; REVEALS; FAMILY	p21-activated kinase 1 (PAK1) is a mediator of downstream signaling from the small GTPases Rac and Cdc42. In its inactive state, PAK1 forms a homodimer where two kinases inhibit each other in trans. The kinase inhibitory domain ( KID) of one molecule of PAK1 binds to the kinase domain of its counterpart and keeps it inactive. Therefore, the isolated KID of PAK1 has been widely used to specifically inhibit and study PAK function. Here, we show that the isolated KID induced a cell cycle arrest with accumulation of cells in the G1 phase of the cell cycle with an inhibition of cyclin D1 and D2 expression. This cell cycle arrest required the intact KID and was also induced by a mutated KID unable to block PAK1 kinase activity. Furthermore, the KID-induced cell cycle arrest could not be rescued by the expression of a constitutively active PAK1-T423E mutant, concluding that this arrest occurs independently of PAK1 kinase activity. Our results suggest that PAK1 through its KID inhibits cyclin D expression and thereby enforces a cell cycle arrest. Our results also call for serious precaution in the use of KID to study PAK function.	Karolinska Inst, Dept Biosci & Nutr, S-14157 Huddinge, Sweden; Fox Chase Canc Ctr, Tumor Cell Biol Program, Philadelphia, PA 19111 USA; Karolinska Inst, Dept Lab Med, S-14186 Huddinge, Sweden	Karolinska Institutet; Fox Chase Cancer Center; Karolinska Institutet	Thullberg, M (corresponding author), Karolinska Inst, Dept Biosci & Nutr, S-14157 Huddinge, Sweden.	minna.thullberg@ki.se	Gad, Annica/X-8294-2018; Chernoff, Jonathan/I-7631-2014; Gad, Annica/H-8758-2017	Gad, Annica/0000-0002-1098-9129; Chernoff, Jonathan/0000-0002-4803-7836; Gad, Annica/0000-0002-1098-9129; Stromblad, Staffan/0000-0002-1236-6339				Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Bakhiet M, 2001, NAT CELL BIOL, V3, P150, DOI 10.1038/35055057; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Bartek J, 1999, J PATHOL, V187, P95, DOI 10.1002/(SICI)1096-9896(199901)187:1<95::AID-PATH249>3.0.CO;2-#; Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Chi S, 2004, BIOCHEM BIOPH RES CO, V319, P683, DOI 10.1016/j.bbrc.2004.05.042; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Dadke D, 2003, CANCER RES, V63, P8837; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Holly SP, 1999, J CELL BIOL, V147, P845, DOI 10.1083/jcb.147.4.845; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Lee SH, 2001, J BIOL CHEM, V276, P25066, DOI 10.1074/jbc.M010892200; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Leisner TM, 2005, J CELL BIOL, V170, P465, DOI 10.1083/jcb.200502090; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Li WQ, 2001, J BIOL CHEM, V276, P34728, DOI 10.1074/jbc.M103496200; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Nheu T, 2004, CELL CYCLE, V3, P71; Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Schraml P, 2003, AM J PATHOL, V163, P985, DOI 10.1016/S0002-9440(10)63458-X; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Sundberg-Smith LJ, 2005, J BIOL CHEM, V280, P2055, DOI 10.1074/jbc.M406013200; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Thullberg M, 2000, ONCOGENE, V19, P2870, DOI 10.1038/sj.onc.1203579; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Weiss EL, 2000, NAT CELL BIOL, V2, P677, DOI 10.1038/35036300; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035	41	38	40	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1820	1828		10.1038/sj.onc.1209983	http://dx.doi.org/10.1038/sj.onc.1209983			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	17001318				2022-12-17	WOS:000244955600016
J	Kjaer, S; Kurokawa, K; Perrinjaquet, M; Abrescia, C; Ibanez, CF				Kjaer, S.; Kurokawa, K.; Perrinjaquet, M.; Abrescia, C.; Ibanez, C. F.			Self-association of the transmembrane domain of RET underlies oncogenic activation by MEN2A mutations	ONCOGENE			English	Article						GDNF; ret; Hirschsprung; ToxCAT	NEOPLASIA TYPE 2B; ERYTHROPOIETIN RECEPTOR; GXXXG MOTIF; HIRSCHSPRUNGS-DISEASE; DRIVE ASSOCIATION; TRANSFORMING GENE; MEMBRANE-PROTEINS; TYROSINE KINASE; ERBB RECEPTORS; PROTOONCOGENE	In patients with medullary thyroid carcinoma (MTC) and type 2A multiple endocrine neoplasia (MEN2A), mutations of cysteine residues in the extracellular juxta-membrane region of the RET receptor tyrosine kinase cause the formation of covalent receptor dimers linked by intermolecular disulfide bonds between unpaired cysteines, followed by oncogenic activation of the RET kinase. The close proximity to the plasma membrane of the affected cysteine residues prompted us to investigate the possible role of the transmembrane (TM) domain of RET (RET-TM) in receptor-receptor interactions underlying dimer formation. Strong self-association of the RET-TM was observed in a biological membrane. Mutagenesis studies indicated the involvement of the evolutionary conserved residues Ser-649 and Ser-653 in RET-TM oligomerization. Unexpectedly, RET-TM interactions were also abrogated in the A639G/A641R double mutant, first identified in a sporadic case of MTC. In agreement with this, no transforming activity could be detected in full-length RET carrying the A639G and A641R mutations, which remained fully responsive to glial cell-line-derived neurotrophic factor (GDNF) stimulation. When introduced in the context of C634R-a cysteine replacement that is prevalent in MEN2A cases-the A639G/A641R mutations significantly reduced dimer formation and transforming activity in this otherwise highly oncogenic RET variant. These data suggest that a strong propensity to self-association in the RET-TM underlies-and may be required for-dimer formation and oncogenic activation of juxtamembrane cysteine mutants of RET, and explains the close proximity to the plasma membrane of cysteine residues implicated in MEN2A and MTC syndromes.	Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, S-17177 Stockholm, Sweden	Karolinska Institutet	Kjaer, S (corresponding author), Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, Berzelius Vag 35, S-17177 Stockholm, Sweden.	sven.kjaer@cancer.org.uk; carlos.ibanez@neuro.ki.se		Kjaer, Susanne/0000-0002-8347-1398				Abrescia C, 2005, FEBS LETT, V579, P3789, DOI 10.1016/j.febslet.2005.05.075; Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Arighi E, 2004, MOL ENDOCRINOL, V18, P1004, DOI 10.1210/me.2003-0173; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Asai N, 1999, BIOCHEM BIOPH RES CO, V255, P587, DOI 10.1006/bbrc.1999.0237; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bongarzone I, 1998, ONCOGENE, V16, P2295, DOI 10.1038/sj.onc.1201759; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; Cerchia L, 2003, BIOCHEM J, V372, P897, DOI 10.1042/BJ20021530; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; Dawson JP, 2002, J MOL BIOL, V316, P799, DOI 10.1006/jmbi.2001.5353; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; Geneste O, 1999, HUM MOL GENET, V8, P1989, DOI 10.1093/hmg/8.11.1989; Gimm O, 1997, J CLIN ENDOCR METAB, V82, P3902, DOI 10.1210/jc.82.11.3902; Gratkowski H, 2001, P NATL ACAD SCI USA, V98, P880, DOI 10.1073/pnas.98.3.880; Gurezka R, 1999, J BIOL CHEM, V274, P9265, DOI 10.1074/jbc.274.14.9265; Hahn M, 2001, P NATL ACAD SCI USA, V98, P1053, DOI 10.1073/pnas.021558598; Hoppner W, 1997, HUM MOL GENET, V6, P587, DOI 10.1093/hmg/6.4.587; Hoppner W, 1998, HUM MUTAT, pS128; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; Iwashita T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/sj.onc.1202742; Iwashita T, 2001, GASTROENTEROLOGY, V121, P24, DOI 10.1053/gast.2001.25515; Jhiang SM, 1996, THYROID, V6, P115, DOI 10.1089/thy.1996.6.115; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Kalinin VN, 2001, J MOL MED-JMM, V79, P609, DOI 10.1007/s001090100250; Kashuk CS, 2005, P NATL ACAD SCI USA, V102, P8949, DOI 10.1073/pnas.0503259102; Kjaer S, 2003, HUM MOL GENET, V12, P2133, DOI 10.1093/hmg/ddg227; Kubatzky KF, 2005, J BIOL CHEM, V280, P14844, DOI 10.1074/jbc.M411251200; Kubatzky KF, 2001, CURR BIOL, V11, P110, DOI 10.1016/S0960-9822(01)00018-5; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; Li E, 2005, BIOCHEMISTRY-US, V44, P352, DOI 10.1021/bi048480k; Li RH, 2004, J BIOL CHEM, V279, P26666, DOI 10.1074/jbc.M314168200; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Marx SJ, 2005, NAT REV CANCER, V5, P367, DOI 10.1038/nrc1610; Mcclain MS, 2003, J BIOL CHEM, V278, P12101, DOI 10.1074/jbc.M212595200; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Miyauchi A, 1999, JPN J CANCER RES, V90, P1; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; Roy R, 2004, BIOCHEMISTRY-US, V43, P4964, DOI 10.1021/bi0362875; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schneider D, 2004, J MOL BIOL, V343, P799, DOI 10.1016/j.jmb.2004.08.083; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; Senes A, 2004, CURR OPIN STRUC BIOL, V14, P465, DOI 10.1016/j.sbi.2004.07.007; Seubert N, 2003, MOL CELL, V12, P1239, DOI 10.1016/S1097-2765(03)00389-7; Stanley AM, 2005, J MOL BIOL, V347, P759, DOI 10.1016/j.jmb.2005.01.059; Sulistijo ES, 2003, J BIOL CHEM, V278, P51950, DOI 10.1074/jbc.M308429200; Takahashi M, 1999, HUM MUTAT, V13, P331, DOI 10.1002/(SICI)1098-1004(1999)13:4<331::AID-HUMU11>3.3.CO;2-R; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; Vidal M, 2005, CANCER RES, V65, P3538, DOI 10.1158/0008-5472.CAN-04-4561; Young MT, 2003, J BIOL CHEM, V278, P32954, DOI 10.1074/jbc.M302527200; Zhou FX, 2001, P NATL ACAD SCI USA, V98, P2250, DOI 10.1073/pnas.041593698	63	38	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7086	7095		10.1038/sj.onc.1209698	http://dx.doi.org/10.1038/sj.onc.1209698			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16732321				2022-12-17	WOS:000241910500008
J	Gabellini, C; Del Bufalo, D; Zupi, G				Gabellini, C.; Del Bufalo, D.; Zupi, G.			Involvement of RB gene family in tumor angiogenesis	ONCOGENE			English	Review						cancer; angiogenesis; retinoblastoma family proteins	ENDOTHELIAL GROWTH-FACTOR; STIMULATES AXONAL OUTGROWTH; RETINOBLASTOMA PROTEIN; IN-VITRO; BCL-2 OVEREXPRESSION; CELL-PROLIFERATION; FACTOR EXPRESSION; INTERFERON-BETA; UP-REGULATION; THROMBOSPONDIN-1 EXPRESSION	Angiogenesis, the development of new blood vessels from pre-existing vessels, represents a fundamental step in tumor progression and metastatization. The induction of vasculature is required for growth of the tumor mass, to ensure an adequate supply of oxygen and metabolites to the tumor beyond a critical size. Tumor angiogenesis is a highly regulated process that is controlled physiologically by the tumor microenvironment and genetically by alteration of several oncogenes or tumor suppressor genes. W e will focus on recent demonstrations regarding the involvement of the retinoblastoma family proteins ( phosphorylated retinoblastoma (pRb), p107 and pRb2/p130) at different levels of the angiogenic process. pRb and its homologs can regulate the expression of pro-and antiangiogenic factors, such as the vascular endothelial growth factor, through an E2F-dependent mechanism. Moreover, pRb is able to modulate also the transcriptional activity of several angiogenesis-related factors like HIF-1, Id2 and Oct-1. pRb2/p130 is required for both differentiation and mobilization of bone marrow-derived endothelial cell precursors and endothelial sprouting from neighboring vessels. The involvement of the pRb pathway in the angiogenesis process has also been demonstrated by different cellular models expressing viral oncoproteins, like human papilloma virus. Moreover, some natural and synthetic compounds demonstrate their antiangiogenetic activity with a mechanism of action involving pRb. Finally, the possible prognostic value of immunohistochemical evaluation of pRb and/or pRb2/p130 expression can represent a useful tool for the characterization of the angiogenic phenotype of specific tumor histotypes.	Regina Elena Inst Canc Res, Expt Chemotherapy Lab, I-00158 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Zupi, G (corresponding author), Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Via Messi Oro 156, I-00158 Rome, Italy.	zupi@ifo.it	Del Bufalo, Donatella/AAC-1594-2021; Del Bufalo, Donatella/K-8673-2016; Gabellini, Chiara/M-2539-2014	Del Bufalo, Donatella/0000-0002-3148-6096; Del Bufalo, Donatella/0000-0002-3148-6096; Gabellini, Chiara/0000-0002-5544-1570				ABE J, 1994, CANCER RES, V54, P3407; ALBERT DM, 1984, RETINA-J RET VIT DIS, V4, P189, DOI 10.1097/00006982-198400430-00011; Amellem O, 1996, EXP CELL RES, V227, P106, DOI 10.1006/excr.1996.0255; Bale TL, 2002, P NATL ACAD SCI USA, V99, P7734, DOI 10.1073/pnas.102187099; Banerjee D, 2000, CANCER RES, V60, P2365; Bardos JI, 2005, BBA-REV CANCER, V1755, P107, DOI 10.1016/j.bbcan.2005.05.001; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; Beischlag TV, 2004, J BIOL CHEM, V279, P54620, DOI 10.1074/jbc.M410456200; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Biroccio A, 2000, FASEB J, V14, P652, DOI 10.1096/fasebj.14.5.652; Budde A, 2005, ONCOGENE, V24, P1802, DOI 10.1038/sj.onc.1208369; Carmeliet P, 2000, ANN NY ACAD SCI, V902, P249; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; Chang KH, 1997, P NATL ACAD SCI USA, V94, P9040, DOI 10.1073/pnas.94.17.9040; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 2004, CLIN CANCER RES, V10, P3509, DOI 10.1158/1078-0432.CCR-03-0662; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Claudio PP, 2001, CANCER RES, V61, P462; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Danielsen T, 1998, BRIT J CANCER, V78, P1547, DOI 10.1038/bjc.1998.722; Dasgupta P, 2004, MOL CELL BIOL, V24, P9527, DOI 10.1128/MCB.24.21.9527-9541.2004; DelBufalo D, 1997, FASEB J, V11, P947, DOI 10.1096/fasebj.11.12.9337147; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Dhanabal M, 1999, BIOCHEM BIOPH RES CO, V258, P345, DOI 10.1006/bbrc.1999.0595; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Farinelle S, 2000, J PHARMACOL TOXICOL, V43, P15, DOI 10.1016/S1056-8719(00)00080-0; Fels DR, 2005, TRENDS BIOCHEM SCI, V30, P426, DOI 10.1016/j.tibs.2005.06.009; Ferrara N, 2000, RECENT PROG HORM RES, V55, P15; Folkman J, 2003, CURR MOL MED, V3, P643, DOI 10.2174/1566524033479465; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GOHJI K, 1994, INT J CANCER, V58, P380, DOI 10.1002/ijc.2910580313; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hanai J, 2002, J BIOL CHEM, V277, P16464, DOI 10.1074/jbc.M112274200; Harada H, 2003, CANCER LETT, V191, P109, DOI 10.1016/S0304-3835(02)00592-X; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 2000, CURR OPIN CELL BIOL, V12, P685, DOI 10.1016/S0955-0674(00)00152-6; Heffelfinger SC, 2000, PATHOBIOLOGY, V68, P129, DOI 10.1159/000055913; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Howard CM, 1998, J NATL CANCER I, V90, P1451, DOI 10.1093/jnci/90.19.1451; Howard CM, 2000, CANCER RES, V60, P2737; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Iervolino A, 2002, FASEB J, V16, P1453, DOI 10.1096/fj.02-0122fje; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Jones MK, 1999, NAT MED, V5, P1418; Joshi B, 2005, ONCOGENE, V24, P2204, DOI 10.1038/sj.onc.1208206; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; KATO N, 1995, AM J OBSTET GYNECOL, V172, P601, DOI 10.1016/0002-9378(95)90579-0; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Krtolica A, 1996, CANCER RES, V56, P1168; Kvanta A, 1996, EXP EYE RES, V63, P511, DOI 10.1006/exer.1996.0141; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; Lasorella A, 2005, MOL CELL BIOL, V25, P3563, DOI 10.1128/MCB.25.9.3563-3574.2005; Le Buanec H, 1999, BIOMED PHARMACOTHER, V53, P424, DOI 10.1016/S0753-3322(99)80122-X; Li J, 1996, ONCOGENE, V13, P2379; Li WY, 2000, MICROVASC RES, V59, P286, DOI 10.1006/mvre.1999.2221; LUDLOW JW, 1993, ONCOGENE, V8, P331; Ludovini V, 2004, LUNG CANCER, V46, P77, DOI 10.1016/j.lungcan.2004.03.018; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Madigan MC, 1997, ULTRASTRUCT PATHOL, V21, P95, DOI 10.3109/01913129709021310; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Min JK, 2004, CANCER RES, V64, P644, DOI 10.1158/0008-5472.CAN-03-3250; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Miyashita H, 2005, ENDOTHELIUM-J ENDOTH, V12, P163, DOI 10.1080/10623320500227101; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pai Rama, 2000, Molecular Cell Biology Research Communications, V4, P111, DOI 10.1006/mcbr.2000.0260; Pedram A, 1998, J BIOL CHEM, V273, P13966, DOI 10.1074/jbc.273.22.13966; Pedram A, 2001, ENDOCRINOLOGY, V142, P1578, DOI 10.1210/en.142.4.1578; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V176, P633, DOI 10.1016/S0006-291X(05)80231-1; Raffaella R, 2004, EXP CELL RES, V293, P331, DOI 10.1016/j.yexcr.2003.10.014; Rak J, 2000, CANCER RES, V60, P490; Ravi R, 2000, GENE DEV, V14, P34; Sanseverino F, 2006, CANCER BIOL THER, V5, P84, DOI 10.4161/cbt.5.1.2345; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Sherif ZA, 2001, CANCER GENE THER, V8, P771, DOI 10.1038/sj.cgt.7700361; Sheu WHH, 2006, LIFE SCI, V78, P1520, DOI 10.1016/j.lfs.2005.07.046; Singh RK, 1996, J INTERF CYTOK RES, V16, P577, DOI 10.1089/jir.1996.16.577; SINGH RK, 1995, P NATL ACAD SCI USA, V92, P4562, DOI 10.1073/pnas.92.10.4562; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; Suzuma K, 2002, P NATL ACAD SCI USA, V99, P721, DOI 10.1073/pnas.022644499; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Tashiro E, 2003, CANCER RES, V63, P424; Toma JG, 2000, J NEUROSCI, V20, P7648; Tonini T, 2003, ONCOGENE, V22, P6549, DOI 10.1038/sj.onc.1206816; Toussaint-Smith E, 2004, ONCOGENE, V23, P2988, DOI 10.1038/sj.onc.1207442; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trisciuoglio D, 2005, MOL BIOL CELL, V16, P4153, DOI 10.1091/mbc.e04-12-1087; Udagawa T, 2002, FASEB J, V16, P1361, DOI 10.1096/fj.01-0813com; Vidal A, 2005, P NATL ACAD SCI USA, V102, P6890, DOI 10.1073/pnas.0405823102; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Wegiel B, 2005, ONCOGENE, V24, P6385, DOI 10.1038/sj.onc.1208795; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Yu JY, 2001, CIRC RES, V89, P1161, DOI 10.1161/hh2401.101909; Zhai YF, 1999, INT J CANCER, V82, P131, DOI 10.1002/(SICI)1097-0215(19990702)82:1<131::AID-IJC22>3.3.CO;2-F; Zhang HQ, 1999, CELL GROWTH DIFFER, V10, P457; Zhang SY, 2000, CANCER RES, V60, P5972; Zhu YH, 2003, FASEB J, V17, P186, DOI 10.1096/fj.02-0515com; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051	110	38	42	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5326	5332		10.1038/sj.onc.1209631	http://dx.doi.org/10.1038/sj.onc.1209631			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936754				2022-12-17	WOS:000240064100019
J	Schmidt, MHH; Husnjak, K; Szymkiewicz, I; Haglund, K; Dikic, I				Schmidt, M. H. H.; Husnjak, K.; Szymkiewicz, I.; Haglund, K.; Dikic, I.			Cbl escapes Cdc42-mediated inhibition by downregulation of the adaptor molecule beta Pix	ONCOGENE			English	Article						Cbl; Cdc42; beta Pix; ubiquitylation; degradation	RECEPTOR TYROSINE KINASES; NUCLEOTIDE EXCHANGE FACTOR; P21-ACTIVATED KINASES; BINDING PARTNERS; C-CBL; ENDOCYTOSIS; PROTEINS; FAMILY; DEGRADATION; MECHANISMS	The Pix/Cool proteins are involved in the regulation of cell morphology by binding to small Rho GTPases and kinases of the Pak family. Recently, it has been shown that ss Pix/Cool-1 associates with the ubiquitin ligase Cbl, which appears to be a critical step in Cdc42- mediated inhibition of epidermal-growth-factor-receptor(EGFR) ubiquitylation and downregulation. Here we show that the SH3 domain of ss Pix specifically interacts with a proline arginine motif (PxxxPR) present within the ubiquitin ligase Cbl and Pak1 kinase. Owing to targeting of the same sequence, Cbl and Pak1 compete for binding to ss Pix. In this complex, Cbl mediates ubiquitylation and subsequent degradation of ss Pix. Our findings reveal a double feedback loop in which the Cdc42/ss Pix complex blocks Cbl's ability to downregulate EGFR, while Cbl in turn promotes degradation of ss Pix in order to escape this inhibition. Such a relationship provides a mechanism to tune-tune the kinetics of RTK endocytosis and degradation depending on the pool of active Cdc42 and the duration of EGFR signaling.	Univ Frankfurt, Univ Hosp, Inst Biochem 2, Frankfurt, Germany; Rudjer Boskovic Inst, Div Mol Med, Mol Oncol Lab, Zagreb, Croatia	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Rudjer Boskovic Institute	Dikic, I (corresponding author), Univ Frankfurt, Sch Med, Inst Biochem 2, D-60590 Frankfurt, Germany.	ivan.dikic@biochem2.de	Haglund, Kaisa/B-3927-2017; Schmidt, Mirko H. H./ABI-6650-2020; Husnjak, Koraljka/C-3717-2015; Dikic, Ivan/O-4650-2015; Pilecka, Iwona/AAT-9114-2021	Haglund, Kaisa/0000-0002-7946-3299; Schmidt, Mirko H. H./0000-0001-7411-8835; Husnjak, Koraljka/0000-0003-0573-6239; Dikic, Ivan/0000-0001-8156-9511; Pilecka, Iwona/0000-0002-5057-346X				Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Carpino N, 2004, IMMUNITY, V20, P37, DOI 10.1016/S1074-7613(03)00351-0; Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Feng QY, 2004, EMBO J, V23, P3492, DOI 10.1038/sj.emboj.7600331; Feng QY, 2002, J BIOL CHEM, V277, P5644, DOI 10.1074/jbc.M107704200; Feshchenko EA, 2004, ONCOGENE, V23, P4690, DOI 10.1038/sj.onc.1207627; Flanders JA, 2003, FEBS LETT, V550, P119, DOI 10.1016/S0014-5793(03)00853-6; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haglund K, 2005, EMBO REP, V6, P635, DOI 10.1038/sj.embor.7400453; Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1; Jozic D, 2005, NAT STRUCT MOL BIOL, V12, P972, DOI 10.1038/nsmb1000; Kowanetz K, 2004, J BIOL CHEM, V279, P32786, DOI 10.1074/jbc.M403759200; Kowanetz K, 2003, J BIOL CHEM, V278, P39735, DOI 10.1074/jbc.M304541200; Lee J, 2005, EXP CELL RES, V307, P315, DOI 10.1016/j.yexcr.2005.03.028; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Rosenberger G, 2003, HUM MOL GENET, V12, P155, DOI 10.1093/hmg/ddg019; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762; Shin EY, 2002, J BIOL CHEM, V277, P44417, DOI 10.1074/jbc.M203754200; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Szymkiewicz I, 2002, J BIOL CHEM, V277, P39666, DOI 10.1074/jbc.M205535200; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Wu WJ, 2003, CELL, V114, P715, DOI 10.1016/S0092-8674(03)00688-3	26	38	39	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3071	3078		10.1038/sj.onc.1209329	http://dx.doi.org/10.1038/sj.onc.1209329			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407834				2022-12-17	WOS:000237950800012
J	Pouponnot, C; Sii-Felice, K; Hmitou, I; Rocques, N; Lecoin, L; Druillennec, S; Felder-Schmittbuhl, MP; Eychene, A				Pouponnot, C; Sii-Felice, K; Hmitou, I; Rocques, N; Lecoin, L; Druillennec, S; Felder-Schmittbuhl, MP; Eychene, A			Cell context reveals a dual role for Maf in oncogenesis	ONCOGENE			English	Article						AP-1; Jun; transformation; differentiation; tumor suppressor; multiple myeloma	TISSUE-SPECIFIC EXPRESSION; CRYSTALLIN GENE-REGULATION; FACTOR C-MAF; TRANSCRIPTION FACTOR; MULTIPLE-MYELOMA; LENS DIFFERENTIATION; TUMOR-SUPPRESSOR; DISTINCT ROLES; GROWTH-FACTOR; INSULIN GENE	Maf b-Zip transcription factors are involved in both terminal differentiation and oncogenesis. To investigate this apparent contradiction, we used two different primary cell types and performed an extensive analysis of transformation parameters induced by Maf proteins. We show that MafA and c-Maf are potent oncogenes in chicken embryo fibroblasts, while MafB appears weaker. We also provide the first evidence that MafA can confer growth factor independence and promote cell division at low density. Moreover, using MafA as a model, we identified several parameters that are critical for Maf transforming activities. Indeed, MafA ability to induce anchorage-independent cell growth was sensitive to culture conditions. In addition, the transforming activity of MafA was dependent on its phosphorylation state, since mutation on Ser65 impaired its ability to induce growth at low density and anchorage-independent growth. We next examined transforming activity of large Maf proteins in embryonic neuroretina cells, where they are known to induce differentiation. Unlike v-Jun, MafA, MafB and c-Maf did not show oncogenic activity in these cells. Moreover, they counteracted transformation induced by constitutive activation of the Ras/Raf/MEK pathway. Taken together, our results show that Maf proteins could display antagonistic functions in oncogenesis depending on the cellular context, and support a dual role for Maf as both oncogenes and tumor suppressor-like proteins.	Ctr Univ, CNRS, Inst Curie Rech, UMR 146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Pouponnot, C (corresponding author), Ctr Univ, CNRS, Inst Curie Rech, UMR 146, Lab 110, F-91405 Orsay, France.	Celio.Pouponnot@curie.u-psud.fr; Alain.Eychene@curie.u-psud.fr	DRUILLENNEC, Sabine/B-2572-2019; Hmitou, Isabelle/H-8341-2017; Eychene, Alain/M-8838-2017	DRUILLENNEC, Sabine/0000-0003-0237-1465; Hmitou, Isabelle/0000-0001-7320-6075; LECOIN, Laure/0000-0001-5259-4339; Karine, SII FELICE/0000-0002-8695-8652; EYCHENE, Alain/0000-0002-6818-7225				Benkhelifa S, 1998, ONCOGENE, V17, P247, DOI 10.1038/sj.onc.1201898; Benkhelifa S, 2001, MOL CELL BIOL, V21, P4441, DOI 10.1128/MCB.21.14.4441-4452.2001; Blanchi B, 2003, NAT NEUROSCI, V6, P1091, DOI 10.1038/nn1129; Boersma-Vreugdenhil GR, 2004, BRIT J HAEMATOL, V126, P355, DOI 10.1111/j.1365-2141.2004.05050.x; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Chamboredon S, 2003, ONCOGENE, V22, P4047, DOI 10.1038/sj.onc.1206713; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; GOLDE A, 1961, VIROLOGY, V15, P36, DOI 10.1016/0042-6822(61)90074-5; Hale TK, 2000, J BIOL CHEM, V275, P17991, DOI 10.1074/jbc.M000921200; Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood-2004-01-0037; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535-6108(04)00019-4; Hussain S, 1998, CELL GROWTH DIFFER, V9, P677; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kataoka K, 2002, J BIOL CHEM, V277, P49903, DOI 10.1074/jbc.M206796200; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; Kawauchi S, 1999, J BIOL CHEM, V274, P19254, DOI 10.1074/jbc.274.27.19254; Kelly LM, 2000, EMBO J, V19, P1987, DOI 10.1093/emboj/19.9.1987; Kim JI, 1999, P NATL ACAD SCI USA, V96, P3781, DOI 10.1073/pnas.96.7.3781; Kim JI, 1999, IMMUNITY, V10, P745, DOI 10.1016/S1074-7613(00)80073-4; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; KURSCHNER C, 1995, MOL CELL BIOL, V15, P246, DOI 10.1128/MCB.15.1.246; Lecoin L, 2004, GENE EXPR PATTERNS, V4, P35, DOI 10.1016/S1567-133X(03)00152-2; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Manzanares M, 1999, DEVELOPMENT, V126, P759; Matsuoka T, 2004, P NATL ACAD SCI USA, V101, P2930, DOI 10.1073/pnas.0306233101; Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; Nishizawa M, 2003, ONCOGENE, V22, P7882, DOI 10.1038/sj.onc.1206526; Ochi H, 2003, J BIOL CHEM, V278, P537, DOI 10.1074/jbc.M208380200; Ogino H, 1998, SCIENCE, V280, P115, DOI 10.1126/science.280.5360.115; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; Onodera K, 2000, EMBO J, V19, P1335, DOI 10.1093/emboj/19.6.1335; OSTRER H, 1981, DEV BIOL, V86, P403, DOI 10.1016/0012-1606(81)90198-6; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; POUPONNOT C, 1995, MOL CELL BIOL, V15, P5563; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Ring BZ, 2000, DEVELOPMENT, V127, P307; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Sii-Felice K, 2005, FEBS LETT, V579, P3547, DOI 10.1016/j.febslet.2005.04.086; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Swain PK, 2001, J BIOL CHEM, V276, P36824, DOI 10.1074/jbc.M105855200; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vandel L, 1996, MOL CELL BIOL, V16, P1881; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; Watson JEV, 2004, ONCOGENE, V23, P3487, DOI 10.1038/sj.onc.1207474; Yoshida K, 2001, CURR EYE RES, V23, P116, DOI 10.1076/ceyr.23.2.116.5479; Yoshida T, 2002, GENES CELLS, V7, P693, DOI 10.1046/j.1365-2443.2002.00548.x	55	38	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1299	1310		10.1038/sj.onc.1209171	http://dx.doi.org/10.1038/sj.onc.1209171			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247450				2022-12-17	WOS:000235708200003
J	Gross, I; Lhermitte, B; Domon-Dell, C; Duluc, I; Martin, E; Gaiddon, C; Kedinger, M; Freund, JN				Gross, I; Lhermitte, B; Domon-Dell, C; Duluc, I; Martin, E; Gaiddon, C; Kedinger, M; Freund, JN			Phosphorylation of the homeotic tumor suppressor Cdx2 mediates its ubiquitin-dependent proteasome degradation	ONCOGENE			English	Article						Cdx; colon cancer; intestine; CDK2; 4S motif	HOMEOBOX TRANSCRIPTION FACTOR; SUCRASE-ISOMALTASE; MUTANT MICE; INTESTINAL METAPLASIA; CELL DIFFERENTIATION; HOMEODOMAIN PROTEINS; GENE-EXPRESSION; DOWN-REGULATION; BETA-CATENIN; COLON	The Caudal-related homeodomain transcription factor Cdx2 plays a key role in intestinal cell fate determination. Reduction of Cdx2 expression is a feature of many human colon carcinomas and inactivation of one cdx2 allele facilitates the development of invasive adenocarcinoma in the murine colon. Here, we investigated the post-translational regulation of Cdx2. We showed that various forms of Cdx2 coexist in the intestine and colon cancer cell lines, some of them being phosphorylated forms. We found that cyclin-dependent kinase 2 phosphorylated Cdx2 in vitro and in vivo. Using site-specific mutagenesis, we identified serine 281 as a new key residue for Cdx2 phosphorylation. Intriguingly, serine 281 belongs to a conserved motif of four evenly spaced serines (the 4S motif) similar to the one controlling beta-catenin degradation by the proteasome pathway. A nonphosphorylated mutant Cdx2 lacking the 4S motif (4S > A) exhibited reduced polyubiquitination upon proteasome inhibition and increased stability compared to wild-type Cdx2. In addition, we found that this mutant was less efficient to suppress colony formation than wild-type Cdx2. Thus, our data highlight a novel post-translational mechanism controlling Cdx2 degradation via phosphorylation and polyubiquitination, which may be of importance for intestinal development and cancer.	INSERM, Unit 682, F-67200 Strasbourg, France; INSERM, Unit 692, Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Freund, JN (corresponding author), INSERM, Unit 682, 3 Ave Moliere, F-67200 Strasbourg, France.	jean-noel.freund@inserm.u-strasbg.fr	Gross, Isabelle/I-4972-2016; DULUC, Isabelle/AAA-7062-2022; Gaiddon, Christian/F-7321-2012; Domon-Dell, Claire/P-2368-2017; Duluc, Isabelle/O-1972-2017; Gross, Isabelle/P-9859-2019; Freund, Jean-Noel/R-4383-2016	Gross, Isabelle/0000-0002-2783-8773; DULUC, Isabelle/0000-0001-8396-6385; Gaiddon, Christian/0000-0003-4315-3851; Duluc, Isabelle/0000-0001-8396-6385; Gross, Isabelle/0000-0002-2783-8773; Freund, Jean-Noel/0000-0002-0971-3774; DOMON-DELL, Claire/0000-0002-8445-9593				Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Bai YQ, 2003, ONCOGENE, V22, P7942, DOI 10.1038/sj.onc.1206634; Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; BECK F, 1995, DEV DYNAM, V204, P219, DOI 10.1002/aja.1002040302; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; Boulanger J, 2005, J BIOL CHEM, V280, P18095, DOI 10.1074/jbc.M502184200; BOULIKAS T, 1995, CRIT REV EUKAR GENE, V5, P1; Brabletz T, 2004, CANCER RES, V64, P6973, DOI 10.1158/0008-5472.CAN-04-1132; CHANTRET I, 1994, J CELL SCI, V107, P213; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Cillo C, 2001, J CELL PHYSIOL, V188, P161, DOI 10.1002/jcp.1115; Domon-Dell C, 2002, GUT, V50, P525, DOI 10.1136/gut.50.4.525; EE HC, 1995, AM J PATHOL, V147, P586; Fang RX, 2000, GASTROENTEROLOGY, V118, P115, DOI 10.1016/S0016-5085(00)70420-3; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; Gautier-Stein A, 2003, NUCLEIC ACIDS RES, V31, P5238, DOI 10.1093/nar/gkg747; Hinoi T, 2002, GASTROENTEROLOGY, V123, P1565, DOI 10.1053/gast.2002.36598; Houde M, 2001, J BIOL CHEM, V276, P21885, DOI 10.1074/jbc.M100236200; Jaffe L, 1997, GENE DEV, V11, P1327, DOI 10.1101/gad.11.10.1327; Kedinger M, 1998, PHILOS T R SOC B, V353, P847, DOI 10.1098/rstb.1998.0249; Kim S, 2002, GASTROENTEROLOGY, V123, P1163, DOI 10.1053/gast.2002.36043; Lorentz O, 1999, ONCOGENE, V18, P87, DOI 10.1038/sj.onc.1202280; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mutoh H, 2002, BIOCHEM BIOPH RES CO, V294, P470, DOI 10.1016/S0006-291X(02)00480-1; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Park CS, 2004, J BIOL CHEM, V279, P19592, DOI 10.1074/jbc.M314208200; Rings EHHM, 2001, GASTROENTEROLOGY, V121, P1437, DOI 10.1053/gast.2001.29618; Rodolosse A, 1996, BIOCHEM J, V315, P301, DOI 10.1042/bj3150301; Sakaguchi T, 2002, J BIOL CHEM, V277, P21361, DOI 10.1074/jbc.M110261200; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Tamai Y, 1999, CANCER RES, V59, P2965; Taylor JK, 1997, NUCLEIC ACIDS RES, V25, P2293, DOI 10.1093/nar/25.12.2293; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Yamamoto H, 2003, BIOCHEM BIOPH RES CO, V300, P813, DOI 10.1016/S0006-291X(02)02935-2; Zhu ZL, 2002, DEV CELL, V3, P557, DOI 10.1016/S1534-5807(02)00270-8	44	38	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					7955	7963		10.1038/sj.onc.1208945	http://dx.doi.org/10.1038/sj.onc.1208945			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16027724				2022-12-17	WOS:000233656600002
J	Ahtiainen, P; Rulli, SB; Shariatmadari, R; Pelliniemi, LJ; Toppari, J; Poutanen, M; Huhtaniemi, IT				Ahtiainen, P; Rulli, SB; Shariatmadari, R; Pelliniemi, LJ; Toppari, J; Poutanen, M; Huhtaniemi, IT			Fetal but not adult Leydig cells are susceptible to adenoma formation in response to persistently high hCG level: a study on hCG overexpressing transgenic mice	ONCOGENE			English	Article						fetal Leydig cell; adult Leydig cell; tumor; hCG	LUTEINIZING-HORMONE RECEPTOR; HUMAN CHORIONIC-GONADOTROPIN; GENE-EXPRESSION; REPRODUCTIVE-ORGANS; ACTIVATING MUTATION; MOUSE; TESTIS; STEROIDOGENESIS; TUMORIGENESIS; MECHANISMS	We have previously demonstrated that male transgenic (TG) mice overexpressing human chorionic gonadotropin (hCG+) develop reproductive organ defects, but no tumors, in adult age. In this study, the effects of persistently elevated hCG were followed in TG males between day 5 postpartum and adulthood. Leydig cell (LC) adenomas were found in prepubertal mice, most prominently at the age of 10 days, but not in adult age. Serum testosterone concentrations were signifi. cantly increased in TG males at all ages studied. The phenotype of the prepubertal hCG+ males resembled that found in boys upon expression of constitutively activating luteinizing hormone (LH) receptor mutations. The temporal expression patterns of the fetal LC marker gene, thrombospondin 2, and those of adult LCs, hydroxysteroid dehydrogenase-6, delta(5)-3-beta and prostaglandin D synthase, were similar in wild-type and hCG+ males. Hence, the postnatal adenomas resemble functionally fetal LCs, and only these cells are susceptible to hCG-induced tumorigenesis. Our findings demonstrate a novel intriguing difference between the fetal and adult LC populations and provide further insight into the potential tumorigenic effects of gonadotropins.	Univ London Imperial Coll Sci & Technol, Inst Reprod & Dev Biol, London W12 0NN, England; Univ Turku, Dept Physiol, FIN-20520 Turku, Finland; Univ Turku, Turku Grad Sch Biomed Sci, FIN-20520 Turku, Finland; Consejo Nacl Invest Cient & Tecn, Inst Biol & Exot Med, RA-1428 Buenos Aires, DF, Argentina; Univ Turku, Electron Microscopy Lab, FIN-20520 Turku, Finland; Univ Turku, Dept Pediat, FIN-20520 Turku, Finland	Imperial College London; University of Turku; University of Turku; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Turku; University of Turku	Huhtaniemi, IT (corresponding author), Univ London Imperial Coll Sci & Technol, Inst Reprod & Dev Biol, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.	ilpo.huhtaniemi@imperial.ac.uk	Poutanen, Matti/I-1700-2018	Poutanen, Matti/0000-0002-8953-1734	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ariyaratne HBS, 2000, BIOL REPROD, V62, P680, DOI 10.1095/biolreprod62.3.680; CATTANACH BM, 1977, NATURE, V269, P338, DOI 10.1038/269338a0; CHEMES HE, 1996, LEYDIG CELL, P175; CHRISTENSEN AK, 1980, BIOL REPROD, V22, P383; Clegg ED, 1997, REPROD TOXICOL, V11, P107, DOI 10.1016/S0890-6238(96)00203-1; Cook JC, 1999, CRIT REV TOXICOL, V29, P169, DOI 10.1080/10408449991349203; Habert R, 2001, MOL CELL ENDOCRINOL, V179, P47, DOI 10.1016/S0303-7207(01)00461-0; HARDY MP, 1989, ENDOCRINOLOGY, V124, P762, DOI 10.1210/endo-124-2-762; Hirakawa T, 2002, ENDOCRINOLOGY, V143, P1026, DOI 10.1210/en.143.3.1026; HUHTANIEMI I, 1985, J CLIN ENDOCR METAB, V61, P698, DOI 10.1210/jcem-61-4-698; HUHTANIEMI IT, 1985, BIOL REPROD, V32, P721, DOI 10.1095/biolreprod32.4.721; HUHTANIEMI IT, 1982, ENDOCRINOLOGY, V111, P1711, DOI 10.1210/endo-111-5-1711; HUSEBY RA, 1980, CANCER RES, V40, P1006; Kananen K, 1997, ENDOCRINOLOGY, V138, P3521, DOI 10.1210/en.138.8.3521; KENDALL SK, 1995, GENE DEV, V9, P2007, DOI 10.1101/gad.9.16.2007; Keri RA, 2000, P NATL ACAD SCI USA, V97, P383, DOI 10.1073/pnas.97.1.383; KERR JB, 1988, DEVELOPMENT, V103, P535; KORENBROT CC, 1977, BIOL REPROD, V17, P298, DOI 10.1095/biolreprod17.2.298; Kumar TR, 1996, ENDOCRINOLOGY, V137, P4210, DOI 10.1210/en.137.10.4210; KUOPIO T, 1989, BIOL REPROD, V40, P135, DOI 10.1095/biolreprod40.1.135; Li XD, 2001, ENDOCRINOLOGY, V142, P2435, DOI 10.1210/en.142.6.2435; Liu G, 1999, NEW ENGL J MED, V341, P1731, DOI 10.1056/NEJM199912023412304; Ma XP, 2004, P NATL ACAD SCI USA, V101, P17294, DOI 10.1073/pnas.0404743101; Matzuk MM, 2003, BIOL REPROD, V69, P338, DOI 10.1095/biolreprod.102.013953; Mikola M, 2003, ONCOGENE, V22, P3269, DOI 10.1038/sj.onc.1206518; NAVICKIS RJ, 1981, CANCER RES, V41, P1646; O'Shaughnessy PJ, 1998, ENDOCRINOLOGY, V139, P1141, DOI 10.1210/en.139.3.1141; O'Shaughnessy PJ, 2002, BIOL REPROD, V66, P966, DOI 10.1095/biolreprod66.4.966; O'Shaughnessy PJ, 2002, J CELL SCI, V115, P3491; PAKARINEN P, 1990, ENDOCRINOLOGY, V127, P2469, DOI 10.1210/endo-127-5-2469; Parrott JA, 2001, MOL CELL ENDOCRINOL, V172, P213, DOI 10.1016/S0303-7207(00)00340-3; PRAHALADA S, 1994, FUND APPL TOXICOL, V22, P211, DOI 10.1006/faat.1994.1025; Richter-Unruh A, 2002, J CLIN ENDOCR METAB, V87, P1052, DOI 10.1210/jc.87.3.1052; Rulli SB, 2003, ENDOCRINOLOGY, V144, P4980, DOI 10.1210/en.2003-0403; Rulli SB, 2002, ENDOCRINOLOGY, V143, P4084, DOI 10.1210/en.2002-220490; SIMON WE, 1983, J NATL CANCER I, V70, P839; Sundstrom J, 1999, BRIT J CANCER, V80, P149, DOI 10.1038/sj.bjc.6990334; Themmen APN, 2000, ENDOCR REV, V21, P551, DOI 10.1210/er.21.5.551; Wise PM, 1996, SCIENCE, V273, P67, DOI 10.1126/science.273.5271.67; ZHANG FP, 1994, ENDOCRINOLOGY, V134, P2206, DOI 10.1210/en.134.5.2206; Zhang FP, 2001, MOL ENDOCRINOL, V15, P172, DOI 10.1210/me.15.1.172	41	38	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7301	7309		10.1038/sj.onc.1208893	http://dx.doi.org/10.1038/sj.onc.1208893			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16007123	Green Published			2022-12-17	WOS:000233142100006
J	Chaturvedi, V; Sitailo, LA; Qin, JZ; Bodner, B; Denning, MF; Curry, J; Zhang, WG; Brash, D; Nickoloff, BJ				Chaturvedi, V; Sitailo, LA; Qin, JZ; Bodner, B; Denning, MF; Curry, J; Zhang, WG; Brash, D; Nickoloff, BJ			Knockdown of p53 levels in human keratinocytes accelerates Mcl-1 and Bcl-x(L) reduction thereby enhancing UV-light induced apoptosis	ONCOGENE			English	Article						p53; UV-light; keratinocytes; apoptosis; E2F-1; Mcl-1; Bcl-x	C-TERMINAL DOMAIN; SKIN-CANCER; MALIGNANT PROGRESSION; GENE DOSAGE; G2/M ARREST; MUTANT P53; MUTATIONS; PROTEIN; DEATH; BAX	Ultraviolet (UV) light exposure is a common cause of epithelial-derived skin cancers, and the epidermal response to UV-light has been extensively studied using both mouse models and cultured human keratinocytes (KCs). Elimination of cells with UV-induced DNA damage via apoptosis provides a powerful mechanism to minimize retention or expansion of genetically abnormal cells. This cell editing function has largely been ascribed to the biological role of the p53 tumor suppressor gene, as mutations or deletions involving p53 have been linked to skin cancer development. Rather than introducing mutations, or using cells with complete loss of wild-type p53, we used an siRNA-based approach to knockdown, but not eliminate, p53 levels in primary cultures of human KCs followed by UV-irradiation. Surprisingly, when p53 levels were reduced by 50-80% the apoptosis induced by exposure to UV-light was accelerated and markedly enhanced (two- to three-fold) compared to control siRNA treated KCs. The p53 siRNA treated KCs were characterized by elevated E2F-1 levels accompanied by accelerated elimination of the Mcl-1 and Bcl-x(L) antiapoptotic proteins, as well as enhanced Bax oligomerization. Forced overexpression of either Mcl-1 or Bcl-x(L) reduced the UV-light enhanced apoptotic response in p53 siRNA treated KCs. We conclude that p53 not only can provide proapoptotic signals but also regulates a survival pathway influencing Mcl-1 and Bcl-x(L) levels. This overlooked survival function of p53 may explain previous paradoxical responses noted by investigators using p53 heterozygous and knockout mouse models, and opens up the possibility that not all liaisons within the cell involving p53 necessarily represent fatal attractions.	Loyola Univ, Inst Oncol, Med Ctr, Dept Pathol, Maywood, IL 60153 USA; Yale Univ, Sch Med, Dept Radiat Oncol, New Haven, CT 06520 USA	Loyola University Chicago; Yale University	Nickoloff, BJ (corresponding author), Loyola Univ, Inst Oncol, Med Ctr, Dept Pathol, Bldg 112,Room 301,2160 S 1st Ave, Maywood, IL 60153 USA.	bnickol@lumc.edu		Zhang, Wengeng/0000-0002-1000-4692	NATIONAL CANCER INSTITUTE [R01CA083784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047814, R01AR047307] Funding Source: NIH RePORTER; NCI NIH HHS [CA 83784] Funding Source: Medline; NIAMS NIH HHS [AR 47814, AR 47307] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Bolshakov S, 2003, CLIN CANCER RES, V9, P228; Bowden GT, 2004, NAT REV CANCER, V4, P23, DOI 10.1038/nrc1253; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Campisi J, 2004, NAT MED, V10, P231, DOI 10.1038/nm0304-231; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; Chaturvedi V, 2004, J INVEST DERMATOL, V123, P1200, DOI 10.1111/j.0022-202X.2004.23514.x; Chaturvedi V, 2001, J DERMATOL SCI, V26, P67, DOI 10.1016/S0923-1811(00)00157-2; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Friedler A, 2002, P NATL ACAD SCI USA, V99, P937, DOI 10.1073/pnas.241629998; Greenhalgh DA, 1996, CANCER RES, V56, P4413; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hawkins DS, 1996, CANCER RES, V56, P892; Honeycutt KA, 2004, J INVEST DERM SYMP P, V9, P261, DOI 10.1111/j.1087-0024.2004.09312.x; Iglesias-Serret D, 2003, ARCH BIOCHEM BIOPHYS, V417, P141, DOI 10.1016/S0003-9861(03)00345-X; Jackson S, 2000, GENE DEV, V14, P3065, DOI 10.1101/gad.182100; Jiang WD, 1999, ONCOGENE, V18, P4247, DOI 10.1038/sj.onc.1202789; Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Knezevic D, 2004, CELL CYCLE, V3, P729; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Leffell DJ, 1996, SCI AM, V275, P52, DOI 10.1038/scientificamerican0796-52; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maeda T, 2002, J INVEST DERMATOL, V119, P22, DOI 10.1046/j.1523-1747.2002.01781.x; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; McKay BC, 2000, MOL BIOL CELL, V11, P2543, DOI 10.1091/mbc.11.8.2543; McKay Bruce C., 1999, Neoplasia (New York), V1, P276, DOI 10.1038/sj.neo.7900028; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; NELSON MA, 1994, CANCER LETT, V85, P23, DOI 10.1016/0304-3835(94)90234-8; Nickoloff BJ, 2002, J INVEST DERM SYMP P, V7, P27, DOI 10.1046/j.1523-1747.2002.19633.x; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Ouhtit A, 1998, J NATL CANCER I, V90, P523, DOI 10.1093/jnci/90.7.523; Perfettini JL, 2004, NAT CELL BIOL, V6, P386, DOI 10.1038/ncb0504-386; Qin JZ, 2004, J CELL PHYSIOL, V200, P155, DOI 10.1002/jcp.20017; Qin JZ, 2002, ONCOGENE, V21, P2991, DOI 10.1038/sj.onc.1205404; Rambhatla L., 2001, J BIOMED BIOTECHNOL, V1, P28, DOI DOI 10.1155/S1110724301000079; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sitailo LA, 2004, J INVEST DERMATOL, V123, P434, DOI 10.1111/j.0022-202X.2004.23403.x; Tsai KY, 2004, AM J MED GENET C, V131C, P82, DOI 10.1002/ajmg.c.30037; Tudor D, 2004, J INVEST DERM SYMP P, V9, P208, DOI 10.1111/j.1087-0024.2004.09310.x; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; van Oosten M, 2005, DNA REPAIR, V4, P81, DOI 10.1016/j.dnarep.2004.08.008; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Wang Y, 2004, CANCER CELL, V5, P501, DOI 10.1016/S1535-6108(04)00113-8; WEINBERG WC, 1994, CANCER RES, V54, P5584; Zhang WG, 2005, CARCINOGENESIS, V26, P249, DOI 10.1093/carcin/bgh300; Zhao RB, 2000, GENE DEV, V14, P981; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	66	38	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5299	5312		10.1038/sj.onc.1208650	http://dx.doi.org/10.1038/sj.onc.1208650			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	15940268				2022-12-17	WOS:000231158500004
J	Kuninaka, S; Nomura, M; Hirota, T; Iida, SI; Hara, T; Honda, S; Kunitoku, N; Sasayama, T; Arima, Y; Marumoto, T; Koja, K; Yonehara, S; Saya, H				Kuninaka, S; Nomura, M; Hirota, T; Iida, SI; Hara, T; Honda, S; Kunitoku, N; Sasayama, T; Arima, Y; Marumoto, T; Koja, K; Yonehara, S; Saya, H			The tumor suppressor WARTS activates the Omi/HtrA2-dependent pathway of cell death	ONCOGENE			English	Article						mitotic kinases; mitochondria; apoptosis; PDZ domain; IAPs; caspases; cancer	SERINE-PROTEASE OMI/HTRA2; ANTI-APOPTOTIC PROTEIN; PROMOTES APOPTOSIS; HUMAN HOMOLOG; MITOTIC APPARATUS; CASPASE ACTIVITY; MAMMALIAN-CELLS; IAP PROTEINS; CYCLE EXIT; DROSOPHILA	Drosophila tumor suppressor WARTS (Wts) is an evolutionally conserved serine/threonine kinase and participates in a signaling complex that regulates both proliferation and apoptosis to ensure the proper size and shape of the fly. Human counterparts of this complex have been found to be frequently downregulated or mutated in cancers. WARTS, a human homolog of Wts, is also known as tumor suppressor and mitotic regulator, but its molecular implications in tumorigenesis are still obscure. Here, we show that WARTS binds via its C-terminus to the PDZ domain of a proapoptotic serine protease Omi/HtrA2. Depletion of WARTS inhibited Omi/HtrA2-mediated cell death, whereas overexpression of WARTS promoted this process. Furthermore, WARTS can enhance the protease activity of Omi/HtrA2 both in vivo and in vitro. Activation of Omi/HtrA2-mediated cell death is thus a potential mechanism for the tumor suppressive activity of WARTS.	Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan; Univ Ryukyus, Sch Med, Dept Surg 2, Okinawa 9030215, Japan; Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan	Kumamoto University; University of the Ryukyus; Kyoto University	Saya, H (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Kuninaka, Shinji/J-7158-2013; Arima, Yoshimi/J-8057-2013; Saya, Hideyuki/J-4325-2013	Sasayama, Takashi/0000-0002-5593-9045				Abrams JM, 2002, CELL, V110, P403, DOI 10.1016/S0092-8674(02)00904-2; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cilenti L, 2004, J BIOL CHEM, V279, P50295, DOI 10.1074/jbc.M406006200; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hisaoka M, 2002, LAB INVEST, V82, P1427, DOI 10.1097/01.LAB.0000032381.68634.CA; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Iida S, 2004, ONCOGENE, V23, P5266, DOI 10.1038/sj.onc.1207623; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Makino K, 1997, ONCOGENE, V14, P2425, DOI 10.1038/sj.onc.1201087; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Martins LM, 2003, J BIOL CHEM, V278, P49417, DOI 10.1074/jbc.M308659200; Morisaki T, 2002, FEBS LETT, V529, P319, DOI 10.1016/S0014-5793(02)03360-4; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Schmitt CA, 1999, J PATHOL, V187, P127; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; Suzuki Y, 2004, CELL DEATH DIFFER, V11, P208, DOI 10.1038/sj.cdd.4401343; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Trencia A, 2004, J BIOL CHEM, V279, P46566, DOI 10.1074/jbc.M406317200; Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wang XD, 2001, GENE DEV, V15, P2922; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; XU TA, 1995, DEVELOPMENT, V121, P1053; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Yang XL, 2004, NAT CELL BIOL, V6, P609, DOI 10.1038/ncb1140; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793	51	38	40	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5287	5298		10.1038/sj.onc.1208682	http://dx.doi.org/10.1038/sj.onc.1208682			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007220				2022-12-17	WOS:000231158500003
J	Maina, EN; Morris, MR; Zatyka, M; Raval, RR; Banks, RE; Richards, FM; Johnson, CM; Maher, ER				Maina, EN; Morris, MR; Zatyka, M; Raval, RR; Banks, RE; Richards, FM; Johnson, CM; Maher, ER			Identification of novel VHL target genes and relationship to hypoxic response pathways	ONCOGENE			English	Article						VHL; HIF gene expression; microarray hypoxia; renal cell carcinoma	LINDAU TUMOR-SUPPRESSOR; RENAL-CELL CARCINOMA; ENDOTHELIAL GROWTH-FACTOR; BECKWITH-WIEDEMANN-SYNDROME; FACTOR MESSENGER-RNA; OVARIAN-CANCER CELLS; INDUCIBLE FACTOR; TISSUE FACTOR; PROSTATE-CANCER; CLINICAL-FEATURES	Upregulation of hypoxia-inducible factors HIF-1 and HIF-2 is frequent in human cancers and may result from tissue hypoxia or genetic mechanisms, in particular the inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene (TSG). Tumours with VHL inactivation are highly vascular, but it is unclear to what extent HIF-dependent and HIF-independent mechanisms account for pVHL tumour suppressor activity. As the identification of novel pVHL targets might provide insights into pVHL tumour suppressor activity, we performed gene expression microarray analysis in VHL-wild-type and VHL-null renal cell carcinoma (RCC) cell lines. We identified 30 differentially regulated pVHL targets ( 26 of which were 'novel') and the results of microarray analysis were confirmed in all 11 novel targets further analysed by real-time RT-PCR or Western blotting. Furthermore, nine of 11 targets were dysregulated in the majority of a series of primary clear cell RCC with VHL inactivation. Three of the nine targets had been identified previously as candidate TSGs (DOC-2/DAB2, CDKN1C and SPARC) and all were upregulated by wild-type pVHL. The significance for pVHL function of two further genes upregulated by wild-type pVHL was initially unclear, but re-expression of GNG4 ( G protein gamma-4 subunit/ guanine nucleotide-binding protein-4) and MLC2 ( myosin light chain) in a RCC cell line suppressed tumour cell growth. pVHL regulation of CDKN1C, SPARC and GNG4 was not mimicked by hypoxia, whereas for six of 11 novel targets analysed ( including DOC-2/DAB2 and MLC2) the effects of pVHL inactivation and hypoxia were similar. For GPR56 there was evidence of a tissue-specific hypoxia response. Such a phenomenon might, in part, explain organ-specific tumorigenesis in VHL disease. These provide insights into mechanisms of pVHL tumour suppressor function and identify novel hypoxia-responsive targets that might be implicated in tumorigenesis both VHL disease and in other cancers with HIF upregulation.	Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Sch Med, Canc Res UK Res Grp, Birmingham B15 2TT, W Midlands, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; St James Univ Hosp, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England; Pfizer Global R&D, Discovery Biol, Sandwich CT13 9NJ, Kent, England	University of Birmingham; University of Birmingham; University of Oxford; Wellcome Centre for Human Genetics; Cancer Research UK; Saint James's University Hospital; University of Leeds; Pfizer	Maher, ER (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	e.r.maher@bham.ac.uk	Morris, Mark/C-6413-2008; MAHER, EAMONN R/A-9507-2008; Zatyka, Malgorzata/D-9340-2017	MAHER, EAMONN R/0000-0002-6226-6918; Zatyka, Malgorzata/0000-0003-3427-1653; Morris, Mark/0000-0002-0700-355X; Johnson, Claire/0000-0003-4428-3594; Banks, Rosamonde/0000-0002-0042-8715				Agathanggelou A, 2003, CANCER RES, V63, P5344; Baba M, 2003, ONCOGENE, V22, P2728, DOI 10.1038/sj.onc.1206373; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Chlenski A, 2002, CANCER RES, V62, P7357; Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; FOSTER K, 1994, BRIT J CANCER, V69, P230, DOI 10.1038/bjc.1994.44; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Guan M, 2002, MOL BIOTECHNOL, V20, P123, DOI 10.1385/MB:20:2:123; HASSELAAR P, 1992, J CELL BIOCHEM, V49, P272, DOI 10.1002/jcb.240490310; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Horiuchi A, 2002, ANTICANCER RES, V22, P2697; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Ivanov S, 2001, AM J PATHOL, V158, P905, DOI 10.1016/S0002-9440(10)64038-2; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jiang YD, 2003, MOL CANCER RES, V1, P453; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kalyanaraman S, 1998, GENOMICS, V49, P147, DOI 10.1006/geno.1998.5223; Kikuchi T, 2002, ONCOGENE, V21, P2741, DOI 10.1038/sj.onc.1205376; Kleeff J, 2002, DIS COLON RECTUM, V45, P1242, DOI 10.1007/s10350-004-6399-2; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; Knebelmann B, 1998, CANCER RES, V58, P226; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Kumar J, 2003, J HIGH ENERGY PHYS; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; Kuroda N, 2003, HISTOL HISTOPATHOL, V18, P487, DOI 10.14670/HH-18.487; Lam WWK, 1999, J MED GENET, V36, P518; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Li YH, 2002, BLOOD, V100, P2572, DOI 10.1182/blood-2001-11-0026; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Mack FA, 2003, CANCER CELL, V3, P75, DOI 10.1016/S1535-6108(02)00240-4; Maher ER, 2000, J CLIN INVEST, V105, P247, DOI 10.1172/JCI9340; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Michl P, 2001, GASTROENTEROLOGY, V121, P678, DOI 10.1053/gast.2001.27124; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Morrissey C, 2001, CANCER RES, V61, P7277; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Ohta S, 2002, ANTICANCER RES, V22, P2991; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341; Schwahn DJ, 1998, ONCOGENE, V17, P1173, DOI 10.1038/sj.onc.1202038; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tseng CP, 1999, J BIOL CHEM, V274, P31981, DOI 10.1074/jbc.274.45.31981; Turner A, 2003, BIOCHEM J, V370, P403, DOI 10.1042/BJ20021360; Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200; Wykoff CC, 2004, BRIT J CANCER, V90, P1235, DOI 10.1038/sj.bjc.6601657; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4; Zatyka M, 2002, CANCER RES, V62, P3803; Zimmer M, 2004, MOL CANCER RES, V2, P89	68	38	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4549	4558		10.1038/sj.onc.1208649	http://dx.doi.org/10.1038/sj.onc.1208649			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15824735				2022-12-17	WOS:000230157100008
J	Zhang, XM; Podsypanina, K; Huang, SX; Mohsin, SK; Chamness, GC; Hatsell, S; Cowin, P; Schiff, R; Li, Y				Zhang, XM; Podsypanina, K; Huang, SX; Mohsin, SK; Chamness, GC; Hatsell, S; Cowin, P; Schiff, R; Li, Y			Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations	ONCOGENE			English	Article						estrogen receptor; breast cancer; Wnt; mouse model	HUMAN-BREAST-CANCER; HUMAN ENDOTHELIAL-CELLS; IN-VIVO; PATHWAY ACTIVATION; HORMONE DEPENDENCE; NEU PROTOONCOGENE; GLAND HYPERPLASIA; PROGENITOR CELLS; BETA-CATENIN; STEM-CELLS	The majority (75%) of human breast cancers express estrogen receptor (ER). Although ER-positive tumors usually respond to antiestrogen therapies, 30% of them do not. It is not known what controls the ER status of breast cancers or their responsiveness to antihormone interventions. In this report, we document that transgenic (TG) expression of Wnt-1 in mice induces ER-positive tumors. Loss of Pten or gain of Ras mutations during the evolution of tumors in Wnt-1 TG mice has no effect on the expression of ER, but overexpression of Neu or loss of p53 leads to ER-negative tumors. Thus, our results provide compelling evidence that expression of ER in breast cancer may be influenced by specific genetic changes that promote cancer progression. These findings constitute a first step to explore the molecular mechanisms leading to ER-positive or ER-negative mammary tumors. In addition, we find that ER-positive tumors arising in Wnt-1 TG mice are refractory to both ovariectomy and the ER antagonist tamoxifen, but lose ER expression with tamoxifen, suggesting that antiestrogen selects for ER-negative tumor cells and that the ER-positive cell fraction is dispensable for growth of these tumors. This is a first report of a mouse model of antiestrogen-resistant ER-positive breast cancers, and could provide a powerful tool to study the molecular mechanisms that control antiestrogen resistance.	Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA; Mem Sloan Kettering Canc Ctr, Cell Biol & Genet Program, Varmus Lab, New York, NY 10021 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Dermatol, New York, NY 10016 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Memorial Sloan Kettering Cancer Center; New York University; New York University; Baylor College of Medicine	Li, Y (corresponding author), Baylor Coll Med, Breast Ctr, 1 Baylor Plaza,N1210-03, Houston, TX 77030 USA.	liyi@breastcenter.tmc.edu	Li, Yi/A-7635-2009	Li, Yi/0000-0002-9976-518X; Hatsell, Sarah/0000-0003-1103-6087; Cowin, Pamela/0000-0002-1827-1154; li, yi/0000-0002-3875-3513	NATIONAL CANCER INSTITUTE [P01CA094060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047429] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA94060-02] Funding Source: Medline; NIGMS NIH HHS [GM47429] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allred DC, 2004, BREAST CANCER RES, V6, P240, DOI 10.1186/bcr938; Alonso L, 2003, GENE DEV, V17, P1189, DOI 10.1101/gad.1086903; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Barbareschi M, 1996, HUM PATHOL, V27, P1149, DOI 10.1016/S0046-8177(96)90307-X; Bocchinfuso WP, 1999, CANCER RES, V59, P1869; Braun BS, 2004, P NATL ACAD SCI USA, V101, P597, DOI 10.1073/pnas.0307203101; Brennan KR, 2004, J MAMMARY GLAND BIOL, V9, P119, DOI 10.1023/B:JOMG.0000037157.94207.33; Cheng GJ, 2004, P NATL ACAD SCI USA, V101, P3739, DOI 10.1073/pnas.0307864100; Chu EY, 2004, DEVELOPMENT, V131, P4819, DOI 10.1242/dev.01347; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; Clarke RB, 1997, CANCER RES, V57, P4987; Cui XS, 2000, ONCOGENE, V19, P5988, DOI 10.1038/sj.onc.1203993; Cunha GR, 1996, J MAMMARY GLAND BIOL, V1, P21, DOI 10.1007/BF02096300; Dai C, 2003, CANCER J, V9, P72, DOI 10.1097/00130404-200303000-00002; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Dontu G, 2004, TRENDS ENDOCRIN MET, V15, P193, DOI 10.1016/j.tem.2004.05.011; Faridi J, 2003, CLIN CANCER RES, V9, P2933; Figtree GA, 2003, CIRCULATION, V107, P120, DOI 10.1161/01.CIR.0000043805.11780.F5; Garcia JM, 1999, BREAST CANCER RES TR, V57, P237, DOI 10.1023/A:1006273516976; Gasco M, 2002, BREAST CANCER RES, V4, P70, DOI 10.1186/bcr426; Gattelli A, 2004, CANCER RES, V64, P5193, DOI 10.1158/0008-5472.CAN-03-3992; Giamarchi C, 2002, BBA-GENE STRUCT EXPR, V1578, P12, DOI 10.1016/S0167-4781(02)00480-3; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hatsell S, 2003, J MAMMARY GLAND BIOL, V8, P145, DOI 10.1023/A:1025944723047; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KEMLER R, 1981, J EMBRYOL EXP MORPH, V64, P45; Klopocki E, 2004, INT J ONCOL, V25, P641; Konecny G, 2003, J NATL CANCER I, V95, P142, DOI 10.1093/jnci/95.2.142; Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200; LE GP, 1994, J BIOL CHEM, V269, P4458; Li L, 2003, P NATL ACAD SCI USA, V100, P4807, DOI 10.1073/PNAS.0831079100; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Li Y, 2001, BMC Mol Biol, V2, P2, DOI 10.1186/1471-2199-2-2; Lin SCJ, 2004, CANCER RES, V64, P3525, DOI 10.1158/0008-5472.CAN-03-3524; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; MATSUZAWA A, 1986, INT REV CYTOL, V103, P303, DOI 10.1016/S0074-7696(08)60839-6; MCGUIRE WL, 1991, MOL ENDOCRINOL, V5, P1571, DOI 10.1210/mend-5-11-1571; Medina D, 2003, CANCER RES, V63, P1067; Medina D, 2002, FASEB J, V16, P881, DOI 10.1096/fj.01-0885fje; MEDINA D, 1980, CANCER RES, V40, P368; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Michalides R, 2004, CANCER CELL, V5, P597, DOI 10.1016/j.ccr.2004.05.016; Milovanovic T, 2004, INT J ONCOL, V25, P1337; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Podsypanina K, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-24; Rose-Hellekant TA, 2003, ONCOGENE, V22, P4664, DOI 10.1038/sj.onc.1206619; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shi W, 2003, INT J CANCER, V104, P195, DOI 10.1002/ijc.10909; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; SUKUMAR S, 1988, SCIENCE, V240, P524, DOI 10.1126/science.3282307; Swope DL, 2002, GENE, V294, P239, DOI 10.1016/S0378-1119(02)00796-5; Tilli MT, 2003, AM J PATHOL, V163, P1713, DOI 10.1016/S0002-9440(10)63529-8; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Trowbridge JM, 1997, P NATL ACAD SCI USA, V94, P10132, DOI 10.1073/pnas.94.19.10132; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; Wu KD, 2002, CANCER RES, V62, P6376; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	77	38	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4220	4231		10.1038/sj.onc.1208597	http://dx.doi.org/10.1038/sj.onc.1208597			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15824740				2022-12-17	WOS:000229815300006
J	Naishiro, Y; Yamada, T; Idogawa, M; Honda, K; Takada, M; Kondo, T; Imai, K; Hirohashi, S				Naishiro, Y; Yamada, T; Idogawa, M; Honda, K; Takada, M; Kondo, T; Imai, K; Hirohashi, S			Morphological and transcriptional responses of untransformed intestinal epithelial cells to an oncogenic beta-catenin protein	ONCOGENE			English	Article						IEC6; beta-catenin; colorectal carcinogenesis; IGFBP2; clusterin	FACTOR-BINDING PROTEIN-2; COLORECTAL-CANCER; GENE-EXPRESSION; TUMOR-FORMATION; IGF-I; GROWTH; MICE; POLYPOSIS; DIFFERENTIATION; NEOPLASIA	Aberrant transactivation of a certain set of target genes by the beta-catenin and T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription factor complexes has been implicated in the process of intestinal epithelial cells entering early colorectal carcinogenesis. A rat intestinal epithelial cell line IEC6 became elongated, extended protrusions at cell periphery, and increased stress fibers and focal contacts upon the induction of beta-catenin protein stabilized by deletion of the N-terminal glycogen synthase kinase-3 beta (GSK beta) phosphorylation sites (beta-catenin Delta N89). We used the GeneChip(TM) oligonucleotide microarray system to examine approximately 24 000 genes and identified 13 genes whose expression was altered during the course of this morphological transformation. Those genes included known negative regulators of the Wnt signaling pathway, Sfrp4 and Axin2; extracellular matrix and related molecule, Hxb and Crtl1; cell adhesion and cytoskeletal proteins, Podxl, Igaf4, and Itab6; and molecules involved in the insulin and insulin-like growth factor (IGF) signaling pathways, Enpp1, Igfbp2, and Sgk. We report the finding that insulin-like growth factor-binding protein-2 (IGFBP2) is a direct target gene of the beta-catenin and TCF/LEF complexes. The IGFBP2 protein interacts with integrins. Disruption of the multigene network system regulating cell adhesion and cytoskeleton may be crucial in the initiation of colorectal carcinogenesis.	Natl Canc Ctr, Res Inst, Chemotherapy Div, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Canc Proteom Project, Chuo Ku, Tokyo 1040045, Japan; Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan	National Cancer Center - Japan; National Cancer Center - Japan; Sapporo Medical University	Yamada, T (corresponding author), Natl Canc Ctr, Res Inst, Chemotherapy Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	tyamada@ncc.go.jp	Kondo, Tadashi/I-4819-2019; Idogawa, Masashi/B-5208-2008	Kondo, Tadashi/0000-0001-6405-7792; Idogawa, Masashi/0000-0002-8507-1726				Barbara PD, 2003, CELL MOL LIFE SCI, V60, P1322, DOI 10.1007/s00018-003-2289-3; BROWN AL, 1990, MOL ENDOCRINOL, V4, P2039, DOI 10.1210/mend-4-12-2039; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Chen XD, 2003, P NATL ACAD SCI USA, V100, P9530, DOI 10.1073/pnas.1233633100; CORKINS MR, 1995, BIOCHEM BIOPH RES CO, V211, P707, DOI 10.1006/bbrc.1995.1870; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Fuller GN, 1999, CANCER RES, V59, P4228; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He TC, 1997, BIOESSAYS, V19, P551, DOI 10.1002/bies.950190705; Hoeflich A, 2001, CANCER RES, V61, P8601; Inomata M, 1996, CANCER RES, V56, P2213; Kayahara T, 2003, FEBS LETT, V535, P131, DOI 10.1016/S0014-5793(02)03896-6; KEDINGER M, 1986, DEV BIOL, V113, P474, DOI 10.1016/0012-1606(86)90183-1; Kikuchi A, 2003, CANCER SCI, V94, P225, DOI 10.1111/j.1349-7006.2003.tb01424.x; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Maiti S, 2000, CANCER RES, V60, P6288; Miraki-Moud F, 2001, CLIN ENDOCRINOL, V54, P499, DOI 10.1046/j.1365-2265.2001.01221.x; Mishra L, 1998, GROWTH HORM IGF RES, V8, P473, DOI 10.1016/S1096-6374(98)80300-6; Muller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630; Oshima H, 1997, CANCER RES, V57, P1644; Palmer RE, 2001, CURR BIOL, V11, P1805, DOI 10.1016/S0960-9822(01)00560-7; Pereira JJ, 2004, CANCER RES, V64, P977, DOI 10.1158/0008-5472.CAN-03-3056; Polakis P, 1999, ADV EXP MED BIOL, V470, P23; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Schutt BS, 2004, J MOL ENDOCRINOL, V32, P859, DOI 10.1677/jme.0.0320859; Schwartz DR, 2002, CANCER RES, V62, P4722; Seike M, 2003, CANCER RES, V63, P4641; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; Soubeyran P, 2001, ONCOGENE, V20, P4180, DOI 10.1038/sj.onc.1204551; Sparks AB, 1998, CANCER RES, V58, P1130; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Suh ER, 2001, AM J PHYSIOL-GASTR L, V280, pG149, DOI 10.1152/ajpgi.2001.280.1.G149; Suzuki Y, 2004, NUCLEIC ACIDS RES, V32, pD78, DOI 10.1093/nar/gkh076; Takeda T, 2001, J CLIN INVEST, V108, P289, DOI 10.1172/JCI12539; Theodosiou NA, 2003, DEV BIOL, V259, P258, DOI 10.1016/S0012-1606(03)00185-4; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wang H, 2003, CANCER RES, V63, P4315; Yamada T, 2003, CANCER RES, V63, P895; Yamada T, 2000, CANCER RES, V60, P4761; ZHANG Y, 1995, AM J PHYSIOL-ENDOC M, V269, pE804, DOI 10.1152/ajpendo.1995.269.5.E804	47	38	39	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 28	2005	24	19					3141	3153		10.1038/sj.onc.1208517	http://dx.doi.org/10.1038/sj.onc.1208517			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735679				2022-12-17	WOS:000228728100008
J	Liang, H; Samanta, S; Nagarajan, L				Liang, H; Samanta, S; Nagarajan, L			SSBP2, a candidate tumor suppressor gene, induces growth arrest and differentiation of myeloid leukemia cells	ONCOGENE			English	Article						AML; leukemia; suppressor; SSBP2	BINDING PROTEIN LDB1; EXPRESSION; LINES; OVEREXPRESSION; REPRESSION; MUTATIONS; REVEALS; CLONING; TARGET; TAL1	Acute myelogenous leukemia (AML) is the most common leukemia in adults with clonal proliferation of myeloid stem cells. Two or more cooperating mechanisms, namely block in differentiation, enhanced proliferation and resistance to programmed cell death, underlie this neoplastic transformation. Nonrandom, complete and partial deletions of chromosome 5 are common anomalies in AML. Using positional cloning strategies, we characterized an evolutionarily conserved candidate myeloid leukemia suppressor gene encoding sequence-specific single-stranded DNA binding protein 2 ( SSBP2) from chromosome 5q13.3, a locus that is frequently deleted in AML. Recent studies in Drosophila and Xenopus demonstrate a pivotal role for SSBPs in embryonic differentiation. In mammals, SSBP2 is one of three highly related and ubiquitously expressed genes. Here, we identify frequent loss of SSBP2 protein expression in human AML cell lines using highly specific antibodies. Furthermore, inducible expression of SSBP2 in the AML cell line U937 leads to loss of clonogenicity, G1 arrest and partial differentiation. Remarkably, inducible expression of SSBP2 is accompanied by downregulation of C-MYC expression. Our findings are consistent with human SSBP2 being a novel regulator of hematopoietic growth and differentiation, whose loss confers a block in differentiation advantage to myeloid leukemic cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Nagarajan, L (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holocombe Blvd,Box 45, Houston, TX 77030 USA.	lnagaraj@mdanderson.org			NCI NIH HHS [CA16672] Funding Source: Medline; NHLBI NIH HHS [HL074449] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074449] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bayarsaihan D, 1998, BIOCHEM J, V331, P447, DOI 10.1042/bj3310447; BI SC, 1992, LEUKEMIA, V6, P839; Boer J, 1998, MOL CELL BIOL, V18, P1236, DOI 10.1128/MCB.18.3.1236; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Cantor AB, 2001, CURR OPIN GENET DEV, V11, P513, DOI 10.1016/S0959-437X(00)00226-4; Caslini C, 2000, P NATL ACAD SCI USA, V97, P2797, DOI 10.1073/pnas.040574897; Castro P, 2002, GENOMICS, V80, P78, DOI 10.1006/geno.2002.6805; Castro PD, 2000, BLOOD, V95, P2138, DOI 10.1182/blood.V95.6.2138; Chen L, 2002, P NATL ACAD SCI USA, V99, P14320, DOI 10.1073/pnas.212532399; Dong WF, 1997, DNA CELL BIOL, V16, P671, DOI 10.1089/dna.1997.16.671; Emes RD, 2001, HUM MOL GENET, V10, P2813, DOI 10.1093/hmg/10.24.2813; Fleckenstein DS, 2002, LEUKEMIA RES, V26, P207, DOI 10.1016/S0145-2126(01)00107-2; Grand CL, 2004, P NATL ACAD SCI USA, V101, P6140, DOI 10.1073/pnas.0400460101; Hu QH, 2000, J BIOL CHEM, V275, P4435, DOI 10.1074/jbc.275.6.4435; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; Qian ZJ, 2002, P NATL ACAD SCI USA, V99, P14925, DOI 10.1073/pnas.222491799; Rizzo MG, 1998, BRIT J CANCER, V77, P1429, DOI 10.1038/bjc.1998.236; Suzuki H, 2001, GENOME RES, V11, P1758, DOI 10.1101/gr.180101; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; van Meyel DJ, 2003, DEVELOPMENT, V130, P1915, DOI 10.1242/dev.00389; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Xu ZX, 2003, MOL CELL BIOL, V23, P7585, DOI 10.1128/MCB.23.21.7585-7599.2003	23	38	39	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2625	2634		10.1038/sj.onc.1208167	http://dx.doi.org/10.1038/sj.onc.1208167			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15782145				2022-12-17	WOS:000228356700004
J	Steiner, FA; Hong, JA; Fischette, MR; Beer, DG; Guo, ZS; Chen, GA; Weiser, TS; Kassis, ES; Nguyen, DM; Lee, S; Trepel, JB; Schrump, DS				Steiner, FA; Hong, JA; Fischette, MR; Beer, DG; Guo, ZS; Chen, GA; Weiser, TS; Kassis, ES; Nguyen, DM; Lee, S; Trepel, JB; Schrump, DS			Sequential 5-Aza 2 '-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells	ONCOGENE			English	Article						TFPI-2; 5-aza 2 '-deoxycytidine; depsipeptide FK228; lung cancer; esophageal cancer	HISTONE DEACETYLASE INHIBITORS; SERINE-PROTEASE INHIBITOR; HUMAN GLIOMA-CELLS; FACTOR VIIA; DNA METHYLATION; IN-VITRO; DEMETHYLASE ACTIVITY; CARCINOMA-CELLS; UP-REGULATION; GENE	cDNA arrays were used to examine gene induction in CALU-6 and H460 lung cancer cells mediated by sequential 5-aza 2-deoxycytidine (DAC)/depsipeptide FK228 (DP) exposure in order to identify translational end points for clinical trials evaluating these agents. In both cell lines, sequential DAC/DP treatment induced expression of tissue factor pathway inhibitor-2 (TFPI-2), an inhibitor of Factor VII: tissue factor signal transduetion known to diminish the malignant phenotype of cancer cells. TFPI-2 expression was diminished or absent in 16 of 32 cell lines established from thoracic malignancies. Sequential DAC/DP treatment induced TFPI-2 in cancer cells deficient for TFPI-2 expression in the basal state. Promoter methylation coincided with loss of TFPI-2 expression in a number of cancer tines. TFPI-2 promoter methylation was observed in one of five pulmonary adenocarcinomas, and seven of seven esophageal adenocarcinomas, but not corresponding normal tissues. DP enhanced acetylation of TFPI-2-associated histones in CALU-6 cells. DP or PDBU, alone, induced TFPI-2 expression in cancer cells deficient for TFPI-2 expression in the absence of promoter methylation. In these cells, DP-mediated TFPI-2 induction was abrogated by calphostin. Induction of TFPI-2 by distinct, yet cooperative mechanisms involving chromatin remodeling and PKC signaling strengthens the preclinical rationale for sequential administration of DNA demethylating agents and HDAC inhibitors in cancer patients. Furthermore, induction of TFPI-2 may be a useful surrogate marker of treatment response in individuals receiving sequential DAC/DP infusions.	NCI, Thorac Oncol Sect, Surg Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; Univ Michigan, Ctr Med, Thorac Surg Sect, Ann Arbor, MI USA; NCI, Med Oncol Clin Res Unit, Ctr Canc Res, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Schrump, DS (corresponding author), NCI, Thorac Oncol Sect, Surg Branch, Ctr Canc Res,NIH, Bldg 10,Room 4-3942,10 Ctr Dr MSC1201, Bethesda, MD 20892 USA.	david_schrump@nih.gov	Chen, Guoan/J-9140-2018; Guo, Zong Sheng/H-3098-2019	Chen, Guoan/0000-0001-5608-6761; Guo, Zong Sheng/0000-0002-4624-9907	NATIONAL CANCER INSTITUTE [Z01SC010093, Z01BC010519, ZIASC010093, Z01SC006743, ZICSC006743] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe K, 1999, P NATL ACAD SCI USA, V96, P8663, DOI 10.1073/pnas.96.15.8663; Annunziato AT, 2000, GENE EXPRESSION, V9, P37; Attwood JT, 2002, CELL MOL LIFE SCI, V59, P241, DOI 10.1007/s00018-002-8420-z; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Bender CM, 1998, CANCER RES, V58, P95; Brinkmann H, 2001, J BIOL CHEM, V276, P22491, DOI 10.1074/jbc.M100206200; Bromberg ME, 1999, THROMB HAEMOSTASIS, V82, P88; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; Chand HS, 2004, BLOOD, V103, P1069, DOI 10.1182/blood-2003-06-1930; Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957; Detich N, 2003, J BIOL CHEM, V278, P27586, DOI 10.1074/jbc.M303740200; Fahrner JA, 2002, CANCER RES, V62, P7213; Folkman J, 1996, NAT MED, V2, P167, DOI 10.1038/nm0296-167; Han JW, 2001, J BIOL CHEM, V276, P42084, DOI 10.1074/jbc.M106688200; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Herman MP, 2001, J CLIN INVEST, V107, P1117, DOI 10.1172/JCI10403; Hjortoe GM, 2004, BLOOD, V103, P3029, DOI 10.1182/blood-2003-10-3417; Izumi H, 2000, FEBS LETT, V481, P31, DOI 10.1016/S0014-5793(00)01902-5; Jin MS, 2001, GYNECOL ONCOL, V83, P325, DOI 10.1006/gyno.2001.6394; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kamei S, 2001, BBA-GENE STRUCT EXPR, V1517, P430, DOI 10.1016/S0167-4781(00)00298-0; Kast C, 2003, J BIOL CHEM, V278, P6787, DOI 10.1074/jbc.M210935200; Kazama Y, 2000, THROMB HAEMOSTASIS, V83, P141; Kim YB, 2000, J ANTIBIOT, V53, P1191, DOI 10.7164/antibiotics.53.1191; Konduri SD, 2003, ONCOGENE, V22, P4509, DOI 10.1038/sj.onc.1206695; Konduri SD, 2003, INT J ONCOL, V22, P1277; Konduri SD, 2002, ONCOGENE, V21, P921, DOI 10.1038/sj.onc.1204983; Konduri SD, 2001, INT J ONCOL, V18, P127; Konduri SD, 2000, CLIN EXP METASTAS, V18, P303, DOI 10.1023/A:1011085820250; Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Lakka SS, 2000, CLIN EXP METASTAS, V18, P239, DOI 10.1023/A:1006755223357; LEHMAN TA, 1991, CANCER RES, V51, P4090; Liu YY, 1999, ARCH BIOCHEM BIOPHYS, V370, P112, DOI 10.1006/abbi.1999.1371; Markl IDC, 2001, CANCER RES, V61, P5875; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Mueller BM, 1998, J CLIN INVEST, V101, P1372, DOI 10.1172/JCI930; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; MUKHOPADHYAY T, 1991, CANCER RES, V51, P1744; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Neaud V, 2000, J BIOL CHEM, V275, P35565, DOI 10.1074/jbc.M006101200; Nguyen DM, 2004, CLIN CANCER RES, V10, P1813, DOI 10.1158/1078-0432.CCR-0901-3; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; Rao CN, 2000, BIOCHEM BIOPH RES CO, V276, P1286, DOI 10.1006/bbrc.2000.3611; Rao CN, 1996, ARCH BIOCHEM BIOPHYS, V335, P82, DOI 10.1006/abbi.1996.0484; Rao CN, 2003, INT J ONCOL, V22, P843; Rao CN, 1999, BIOCHEM BIOPH RES CO, V255, P94, DOI 10.1006/bbrc.1999.0153; Rao CN, 1998, INT J CANCER, V76, P749, DOI 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y; Rao CN, 2001, CLIN CANCER RES, V7, P570; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Sandor V, 2000, BRIT J CANCER, V83, P817, DOI 10.1054/bjoc.2000.1327; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Sato M, 2002, ONCOGENE, V21, P4822, DOI 10.1038/sj.onc.1205581; SHAPIRO GI, 1995, CANCER RES, V55, P6200; Shinoda E, 1999, J BIOL CHEM, V274, P5379, DOI 10.1074/jbc.274.9.5379; Siegbahn A, 2000, BLOOD, V96, P3452, DOI 10.1182/blood.V96.10.3452.h8003452_3452_3458; Sorensen BB, 1999, J BIOL CHEM, V274, P21349, DOI 10.1074/jbc.274.30.21349; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Tasiou A, 2001, INT J ONCOL, V19, P591; Ueki T, 2002, ONCOGENE, V21, P2114, DOI 10.1038/sj.onc.1205275; Vairapandi M, 2004, J CELL BIOCHEM, V91, P572, DOI 10.1002/jcb.10749; Versteeg HH, 2000, J BIOL CHEM, V275, P28750, DOI 10.1074/jbc.M907635199; Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Weiser TS, 2001, ANN THORAC SURG, V71, P295, DOI 10.1016/S0003-4975(00)02421-8; Weiser TS, 2001, J IMMUNOTHER, V24, P151, DOI 10.1097/00002371-200103000-00010; Wojtukiewicz MZ, 2003, THROMB HAEMOSTASIS, V90, P140; Yu XD, 2002, J NATL CANCER I, V94, P504; ZACHARSKI LR, 1987, CANCER, V60, P2675, DOI 10.1002/1097-0142(19871201)60:11<2675::AID-CNCR2820601117>3.0.CO;2-C; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697; Zhu WG, 2001, CANCER RES, V61, P1327	75	38	47	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 31	2005	24	14					2386	2397		10.1038/sj.onc.1208376	http://dx.doi.org/10.1038/sj.onc.1208376			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735751				2022-12-17	WOS:000227877400011
J	Guo, Y; Harwalkar, J; Stacey, DW; Hitomi, M				Guo, Y; Harwalkar, J; Stacey, DW; Hitomi, M			Destabilization of cyclin D1 message plays a critical role in cell cycle exit upon mitogen withdrawal	ONCOGENE			English	Article						cyclin D1; cell cycle; message stability; single-cell analysis; mitogenic signaling	SMOOTH-MUSCLE-CELLS; BREAST-CANCER CELLS; MESSENGER-RNA; TRANSCRIPTIONAL REGULATION; SIGNALING PATHWAY; RESTRICTION POINT; DEPENDENT KINASES; PROMOTER ACTIVITY; HUMAN FIBROBLASTS; GENE-EXPRESSION	Cyclin D1 is critical for entry into, continuation of, and exit from the cell division cycle. Mitogen stimulation of quiescent cells induces cyclin D1 expression in a transcription-dependent manner. In actively cycling cells, on the other hand, fluctuation of cyclin D1 protein levels through the cell cycle is post-transcriptionally regulated. Cyclin D1 is expressed at low levels during S phase to allow efficient DNA synthesis, and induced to high levels in G2 phase through Ras activity to commit the cells to continuing cell cycle progression. Once induced in G2 phase, cyclin D1 expression becomes Ras independent through the next G1 phase, where it promotes G1/S transition. When mitogenic signaling is abrogated, however, cyclin D1 fails to increase during G2 phase and the cell becomes arrested in the next G1 phase. In this way, the expression levels of cyclin D1 in G2 phase determine the fate of the next cell cycle. Despite its importance of the mechanism of cyclin D1 suppression upon mitogen withdrawal is unknown. Using both quantitative fluorescence microscopy and biochemical analyses, we have found that, upon serum deprivation, cyclin D1 mRNA is downmodulated without any decline in its rate of transcription. Furthermore, cyclin D1 mRNA half-life becomes shorter when serum is removed. These results demonstrate that cyclin D1 message destabilization plays a critical role in cyclin D1 suppression during G2 phase of serum-deprived cultures, and therefore in the withdrawal from the cell cycle.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hitomi, M (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, NC2-150,9500 Euclid Ave, Cleveland, OH 44195 USA.	hitomim@ccf.org			NCI NIH HHS [CA92194] Funding Source: Medline; NIGMS NIH HHS [GM52271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; ALBRECHT JH, 1993, AM J PHYSIOL, V265, P857; Amanatullah DF, 2001, METHOD ENZYMOL, V333, P116; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Blagosklonny MV, 2002, CELL CYCLE, V1, P103, DOI 10.4161/cc.1.2.108; Briata P, 2003, MOL CELL, V12, P1201, DOI 10.1016/S1097-2765(03)00407-6; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Ciarmatori S, 2001, MOL CELL BIOL, V21, P5806, DOI 10.1128/MCB.21.17.5806-5814.2001; Connell-Crowley L, 1998, CURR BIOL, V8, P65, DOI 10.1016/S0960-9822(98)70021-1; DELISLE AJ, 1983, MOL CELL BIOL, V3, P1920, DOI 10.1128/MCB.3.11.1920; Dufourny B, 2000, J ENDOCRINOL, V166, P329, DOI 10.1677/joe.0.1660329; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gouble A, 2002, CANCER RES, V62, P1489; Guo Y, 2002, ONCOGENE, V21, P7545, DOI 10.1038/sj.onc.1205907; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; Hitomi M, 2001, FEBS LETT, V490, P123, DOI 10.1016/S0014-5793(01)02115-9; Hitomi M, 1999, CURR BIOL, V9, P1075, DOI 10.1016/S0960-9822(99)80476-X; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Miyakawa Y, 2001, BIOCHEM BIOPH RES CO, V284, P71, DOI 10.1006/bbrc.2001.4950; Musa NL, 1999, AM J RESP CELL MOL, V20, P352, DOI 10.1165/ajrcmb.20.2.3160; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; RICKLES R, 1982, P NATL ACAD SCI-BIOL, V79, P749, DOI 10.1073/pnas.79.3.749; RIMOKH R, 1994, BLOOD, V83, P3689; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Sa G, 2002, CELL CYCLE, V1, P50, DOI 10.4161/cc.1.1.100; SHERR CJ, 1992, CIBA F SYMP, V170, P209; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Stacey D W, 1981, Methods Enzymol, V79, P76; Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5; Topisirovic I, 2003, MOL CELL BIOL, V23, P8992, DOI 10.1128/MCB.23.24.8992-9002.2003; Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Winston JT, 1996, ONCOGENE, V12, P127	59	38	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1032	1042		10.1038/sj.onc.1208299	http://dx.doi.org/10.1038/sj.onc.1208299			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592507				2022-12-17	WOS:000226749200009
J	Yang, LC; Leung, ACC; Ko, JMY; Lo, PHY; Tang, JCO; Srivastava, G; Oshimura, M; Stanbridge, EJ; Daigo, Y; Nakamura, Y; Tang, CMC; Lau, KW; Law, S; Lung, ML				Yang, LC; Leung, ACC; Ko, JMY; Lo, PHY; Tang, JCO; Srivastava, G; Oshimura, M; Stanbridge, EJ; Daigo, Y; Nakamura, Y; Tang, CMC; Lau, KW; Law, S; Lung, ML			Tumor suppressive role of a 2.4Mb 9q33-q34 critical region and DEC1 in esophageal squamous cell carcinoma	ONCOGENE			English	Article						chromosome 9; deleted in esophageal cancer 1; tumor suppressor gene; esophageal carcinoma; microcell-mediated chromosome transfer	COMPARATIVE GENOMIC HYBRIDIZATION; NASOPHARYNGEAL CARCINOMA; HOMOZYGOUS DELETION; CHROMOSOME TRANSFER; FUNCTIONAL EVIDENCE; GENETIC ALTERATIONS; BLADDER-CANCER; ALLELE LOSS; LINES; HETEROZYGOSITY	The key genes involved in the development of esophageal squamous cell carcinoma (ESCC) remain to be elucidated. Previous studies indicate extensive genomic alterations occur on chromosome 9 in ESCC. Using a monochromosome transfer approach, this study provides functional evidence and narrows down the critical region (CR) responsible for chromosome 9 tumor suppressing activity to a 2.4 Mb region mapping to 9q33 - q34 between markers D9S1798 and D9S61. Interestingly, a high prevalence of allelic loss in this CR is also observed in primary ESCC tumors by microsatellite typing. Allelic loss is found in 30/ 34 (88%) tumors and the loss of heterozygosity (LOH) frequency ranges from 67 to 86%. Absent to low expression of a 9q32 candidate tumor suppressor gene (TSG), DEC1 ( deleted in esophageal cancer 1), is detected in four Asian ESCC cell lines. Stably expressing DEC1 transfectants provide functional evidence for inhibition of tumor growth in nude mice and DEC1 expression is decreased in tumor segregants arising after long-term selection in vivo. There is 74% LOH in the DEC1 region of ESCC primary tumors. This study provides the first functional evidence for the presence of critical tumor suppressive regions on 9q33 - q34. DEC1 is a candidate TSG that may be involved in ESCC development.	Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Hong Kong, Peoples R China; Tottori Univ, Dept Biomed Sci, Tottori 680, Japan; Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab, Tokyo, Japan; Tuen Mun Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Tuen Mun Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; University of Hong Kong; Hong Kong Polytechnic University; Tottori University; University of California System; University of California Irvine; University of Tokyo; Tuen Mun Hospital; Tuen Mun Hospital; University of Hong Kong	Lung, ML (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Hong Kong, Peoples R China.	bomaria@ust.hk	Tang, Johnny Cheuk-on/W-7214-2019; Tang, Johnny C. O./M-9639-2014; Ko, Josephine/U-2972-2019; Law, Simon/C-4324-2009; Lung, Maria Li/C-4495-2009	Tang, Johnny Cheuk-on/0000-0002-4261-3206; Tang, Johnny C. O./0000-0002-4261-3206; Ko, Josephine/0000-0002-7997-331X; Law, Simon/0000-0002-6518-5806; Daigo, Yataro/0000-0002-0915-3025; Lung, Maria Li/0000-0003-2559-3626				AOKI T, 1994, GENE CHROMOSOME CANC, V10, P177, DOI 10.1002/gcc.2870100305; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Cheng Y, 2000, GENE CHROMOSOME CANC, V28, P82, DOI 10.1002/(SICI)1098-2264(200005)28:1<82::AID-GCC10>3.0.CO;2-8; Chow LSN, 2004, INT J CANCER, V109, P839, DOI 10.1002/ijc.20079; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; Gorgoulis VG, 1998, MOL MED, V4, P807, DOI 10.1007/BF03401773; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; Grady B, 2001, J UROLOGY, V166, P1088, DOI 10.1016/S0022-5347(05)65927-7; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; He CD, 1999, CHINESE MED J-PEKING, V112, P497; Holmberg E, 1996, BRIT J CANCER, V74, P246, DOI 10.1038/bjc.1996.345; HU CP, 1984, J NATL CANCER I, V72, P577; Hu YC, 2002, CANCER GENET CYTOGEN, V135, P120, DOI 10.1016/S0165-4608(01)00580-5; HUANG Y, 1992, CANCER RES, V52, P6525; Jagasia AA, 1996, CANCER LETT, V105, P91, DOI 10.1016/0304-3835(96)04274-7; Karkera JD, 2000, CLIN CANCER RES, V6, P3565; Kwong FM, 2004, CANCER LETT, V208, P207, DOI 10.1016/j.canlet.2003.11.017; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Marshall B, 1997, CANCER GENET CYTOGEN, V96, P134, DOI 10.1016/S0165-4608(96)00300-7; Miura K, 1996, CANCER RES, V56, P1629; MORI T, 1994, HUM MOL GENET, V3, P1969, DOI 10.1093/hmg/3.11.1969; Murakami Y, 2002, ONCOGENE, V21, P6936, DOI 10.1038/sj.onc.1205825; Muzeau F, 1997, INT J CANCER, V72, P27, DOI 10.1002/(SICI)1097-0215(19970703)72:1<27::AID-IJC3>3.0.CO;2-6; Naidoo R, 1999, DIAGN MOL PATHOL, V8, P131, DOI 10.1097/00019606-199909000-00005; Nishiwaki T, 2000, GENE CHROMOSOME CANC, V27, P169, DOI 10.1002/(SICI)1098-2264(200002)27:2<169::AID-GCC8>3.3.CO;2-D; Nishiyama H, 1999, GENE CHROMOSOME CANC, V26, P171, DOI 10.1002/(SICI)1098-2264(199910)26:2<171::AID-GCC10>3.3.CO;2-2; Pack SD, 1999, GENE CHROMOSOME CANC, V25, P160, DOI 10.1002/(SICI)1098-2264(199906)25:2<160::AID-GCC12>3.0.CO;2-U; Parker WL, 2003, J BONE MINER RES, V18, P289, DOI 10.1359/jbmr.2003.18.2.289; Parris CN, 1999, CANCER RES, V59, P516; Qin P, 2004, J CELL BIOCHEM, V92, P147, DOI 10.1002/jcb.20057; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; SAMPSON JR, 1995, J MED GENET, V32, P848, DOI 10.1136/jmg.32.11.848; SAXON PJ, 1985, MOL CELL BIOL, V5, P140, DOI 10.1128/MCB.5.1.140; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; STANBRIDGE EJ, 1978, P NATL ACAD SCI USA, V75, P1466, DOI 10.1073/pnas.75.3.1466; Tada K, 2000, CANCER GENET CYTOGEN, V117, P108, DOI 10.1016/S0165-4608(99)00160-0; Takahashi K., 1990, JPN J ORAL MAXILLOFA, V36, P307; Tang JCO, 2001, CANCER GENET CYTOGEN, V124, P36, DOI 10.1016/S0165-4608(00)00317-4; Wang L, 1996, ONCOGENE, V12, P699; Wiest JS, 1997, CANCER RES, V57, P1; Wu Q, 1996, INT J CANCER, V65, P840, DOI 10.1002/(SICI)1097-0215(19960315)65:6<840::AID-IJC22>3.0.CO;2-6; YAMADA H, 1990, ONCOGENE, V5, P1141; Yang LC, 2004, CANCER LETT, V203, P71, DOI 10.1016/j.canlet.2003.09.027; Yen CC, 2003, INT J ONCOL, V23, P871; Yen CC, 2001, CANCER, V92, P2769, DOI 10.1002/1097-0142(20011201)92:11<2769::AID-CNCR10118>3.0.CO;2-M	45	38	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					697	705		10.1038/sj.onc.1208179	http://dx.doi.org/10.1038/sj.onc.1208179			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580306				2022-12-17	WOS:000226420400017
J	Petitjean, A; Cavard, C; Shi, H; Tribollet, V; Hainaut, P; de Fromentel, CC				Petitjean, A; Cavard, C; Shi, H; Tribollet, V; Hainaut, P; de Fromentel, CC			The expression of TA and Delta Np63 are regulated by different mechanisms in liver cells	ONCOGENE			English	Article						p63; TP53 family; DNA-damage; liver; HCC; topoisomerase inhibitor	KINASE C-ABL; DNA-DAMAGE; HEPATOCELLULAR-CARCINOMA; APOPTOTIC RESPONSE; P53 PROTEIN; P73; P63; FAMILY; GENE; CANCER	The TP63 gene, a member of the TP53 gene family, encodes several isoforms with (TAp63) or without (DeltaNp63) transactivating properties. Whereas the role of p63 in the normal development of squamous epithelia is well established, its function in other cell types remains to be elucidated. Here, we have analysed the expression of TA and DeltaNp63 isoforms in liver cells, by using both primary hepatocytes from wild type and p53-null mice and three human hepatocellular carcinoma (HCC) cell lines, according to the transformation state and the TP53 status of the cells. We observed the expression of DeltaNp63 isoforms only in a p53-null context. On the other hand, the expression of TAp63 isoforms was restricted to the HCC cell lines, whatever the TP53 status. We then studied the expression of TP63 upon genotoxic treatment. When treated with UVB or H2O2, hepatocytes did not exhibit any change in p63 mRNA level. At the opposite, upon treatment with topoisomerase II inhibitors ( doxorubicin or etoposide), the expression of TAp63 isoforms was clearly induced, independently of the TP53 status of cells. The same treatment did not induce any variation in the expression of DeltaNp63 isoforms, both at mRNA and protein levels. In HCC cell lines, doxorubicin or etoposide treatment also resulted in an increase of TAp63 transcripts only. This increase was accompanied by an increase in the intracellular level of TAp63 alpha protein. In parallel, we observed an upregulation of some p53-target genes related to cell cycle regulation, such as WAF1/CIP1, PIG3, 14-3-3sigma or GADD45, independently of the TP53 status of cells. In conclusion, we report for the first time that TA and DeltaNp63 alpha proteins are present in liver cells. Furthermore, our results suggest that p63 may partially substitute for wild-type p53, in counteracting uncontrolled liver cell proliferation in response to certain forms of DNA-damage.	Ctr Leon Berard, INSERM, U590, Unite Oncogenese & Progress Tumorale, F-69008 Lyon, France; Int Agcy Res Canc, F-69372 Lyon 08, France; Inst Cochin Genet Mol, CNRS, UMR 8104, INSERM,U567, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; World Health Organization; International Agency for Research on Cancer (IARC); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	de Fromentel, CC (corresponding author), Ctr Leon Berard, INSERM, U590, Unite Oncogenese & Progress Tumorale, 28 Rue Laennec, F-69008 Lyon, France.	carondef@lyon.fnclcc.fr	Hainaut, Pierre/B-6018-2012; de Fromentel, Claude Caron/Y-9715-2019	Hainaut, Pierre/0000-0002-1303-1610; de Fromentel, Claude Caron/0000-0001-7566-3958				Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; Bruix J, 2002, HEPATOLOGY, V35, P519, DOI 10.1053/jhep.2002.32089; Chou YY, 1997, J GASTROEN HEPATOL, V12, P569, DOI 10.1111/j.1440-1746.1997.tb00487.x; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Courtois S, 2004, ONCOGENE, V23, P631, DOI 10.1038/sj.onc.1206929; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Gillet R, 2000, ONCOGENE, V19, P3498, DOI 10.1038/sj.onc.1203671; Gong JG, 1999, NATURE, V399, P806; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; Hortobagyi GN, 1997, DRUGS, V54, P1, DOI 10.2165/00003495-199700544-00003; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Katoh I, 2000, ONCOGENE, V19, P3126, DOI 10.1038/sj.onc.1203644; Lee TKW, 2002, CANCER CHEMOTH PHARM, V49, P78, DOI 10.1007/s00280-001-0376-4; Levrero M, 2000, J CELL SCI, V113, P1661; Liefer KM, 2000, CANCER RES, V60, P4016; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; Mueller H, 1996, ANTICANCER RES, V16, P3845; Okada Y, 2002, EXP CELL RES, V276, P194, DOI 10.1006/excr.2002.5535; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; Sayan AE, 2001, ONCOGENE, V20, P5111, DOI 10.1038/sj.onc.1204669; Shen HM, 1996, MUTAT RES-REV GENET, V366, P23, DOI 10.1016/S0165-1110(96)90005-6; Staib F, 2003, HUM MUTAT, V21, P201, DOI 10.1002/humu.10176; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; van Bokhoven H, 2002, TRENDS MOL MED, V8, P133, DOI 10.1016/S1471-4914(01)02260-2; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhu HM, 2002, CELL CYCLE, V1, P59, DOI 10.4161/cc.1.1.101	37	38	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					512	519		10.1038/sj.onc.1208215	http://dx.doi.org/10.1038/sj.onc.1208215			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15543231				2022-12-17	WOS:000226279700021
J	Kim, CJ; Cho, YG; Park, CH; Jeong, SW; Nam, SW; Kim, SY; Lee, SH; Yoo, NJ; Lee, JY; Park, WS				Kim, CJ; Cho, YG; Park, CH; Jeong, SW; Nam, SW; Kim, SY; Lee, SH; Yoo, NJ; Lee, JY; Park, WS			Inactivating mutations of the Siah-1 gene in gastric cancer	ONCOGENE			English	Article						stomach; beta-catenin; p53; cyclin D1; expression	BETA-CATENIN; TUMOR SUPPRESSION; POLYPOSIS-COLI; HUMAN HOMOLOG; SINA GENE; P53; APOPTOSIS; ABSENTIA; PATHWAY; PROTEIN	Siah-1 is the mammalian homolog of Drosophila seven in absentia (sina) and has been identified as a p53-inducible gene. Siah-1 can induce cell cycle arrests, tumor suppression, and apoptosis through a novel beta-catenin degradation pathway. To determine whether genetic alterations of Siah-1 gene are involved in the development and/or progression of gastric cancer, we searched for mutation of the Siah-1 gene in 95 gastric cancers by single-strand conformational polymorphism and sequencing. The effect of Siah-1 on beta-catenin degradation was further examined in wild- and mutant-type Siah-1-transfected HEK 293T cells. We found two missense mutations of the Siah-1 gene. The cases with Siah-1 mutation showed nuclear translocation and cytoplasmic staining of beta-catenin. Interestingly, two mutants of Siah-1 stabilized cytoplasmic levels of beta-catenin, even after treatment of adriamycin. Furthermore, both mutants failed to suppress cyclin D1 expression and to induce apoptosis. These data suggest that inactivating mutations of the Siah-1 may contribute to the development of gastric cancer through beta-catenin stabilization and apoptosis block.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Surg, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Biochem, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Park, WS (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.	wonsang@catholic.ac.kr	Yoo, Nam Jin/GNM-9060-2022					Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; DELLA NG, 1993, DEVELOPMENT, V117, P1333; Fiucci G, 2004, P NATL ACAD SCI USA, V101, P3510, DOI 10.1073/pnas.0400177101; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Hu G, 1999, MOL CELL BIOL, V19, P724; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; NAKATSURU S, 1992, HUM MOL GENET, V1, P559, DOI 10.1093/hmg/1.8.559; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; Park WS, 1999, CANCER RES, V59, P4257; Park WS, 2000, APMIS, V108, P195, DOI 10.1034/j.1600-0463.2000.d01-44.x; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; Shtutman Michael, 2002, Cancer Research, V62, P5947; SIVAK MV, 1984, GASTROINTEST ENDOSC, V30, P102, DOI 10.1016/S0016-5107(84)72333-9; SUH CI, 2000, J KOREAN CANC ASS, V32, P827; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884	25	38	41	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8591	8596		10.1038/sj.onc.1208113	http://dx.doi.org/10.1038/sj.onc.1208113			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467739				2022-12-17	WOS:000224988800004
J	Huang, H; Okamoto, Y; Yokoo, H; Heppner, FL; Vital, A; Fevre-Montange, M; Jouvet, A; Yonekawa, Y; Lazaridis, EN; Kleihues, P; Ohgaki, H				Huang, H; Okamoto, Y; Yokoo, H; Heppner, FL; Vital, A; Fevre-Montange, M; Jouvet, A; Yonekawa, Y; Lazaridis, EN; Kleihues, P; Ohgaki, H			Gene expression profiling and subgroup identification of oligodendrogliomas	ONCOGENE			English	Article						oligodendroglioma; low-grade astrocytoma; cDNA array; LOH 1p; LOH 19q; TP53 mutations	CELL-CYCLE; MICROARRAY; SURVIVAL; RECEPTOR; GLIOMAS; MARKER; GRADE; OLIG2; JUND; 19Q	The histological diagnosis of low-grade astrocytomas and oligodendrogliomas (WHO grade II) is often challenging, particularly in cases that show both astrocytic and oligodendroglial differentiation. We carried out gene expression profiling on 17 oligodendrogliomas (93% with LOH 1p and/or 19q) and 15 low-grade astrocytomas (71% with a TP53 mutation), using a cDNA array containing 1176 cancer-related genes. In oligodendrogliomas, 40 genes showed on average higher expression (at least a two-fold increase) than in astrocytomas, including DES, TDGF1, TGF-beta, GABA-BR1A, Histone H4, CDKN1A, PCDH43, Rho7 and Jun-D, while 39 genes were expressed at lower levels (at least a two-fold decrease), including JNK2, ITGB4, JNK3A2, RhoC, IFI-56K, AAD14 and EGFR. Immunohistochemistry revealed nuclear staining of Jun-D in oligodendrogliomas, in contrast to the inummoreactivity of cytoplasm and cell processes in low-grade astrocytomas. Partial least-squares analysis of the 79 genes at least two-fold differentially expressed between oligodendrogliomas and low-grade astrocytomas demonstrated perfect separation of oligodendrogliomas from low-grade astrocytomas and normal cerebral white matter. Clustering analysis based on the entire gene set divided the 17 subjects with oligodendrogliomas into two subgroups with significantly different survival (log-rank test, P = 0.0305; survival to 5-years, 80 vs 0%, P = 0.048). These results demonstrate that oligodendrogliomas and low-grade astrocytomas differ in their gene expression profiles, and that there are subgroups of oligodendroglioma with distinct expression profiles related to clinical outcome.	Int Agcy Res Canc, F-69372 Lyon 08, France; Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; Victor Segalen Univ, Dept Neuropathol, F-33076 Bordeaux, France; Neurol & Neurosurg Hosp, Dept Neuropathol, F-69394 Lyon, France; Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland	World Health Organization; International Agency for Research on Cancer (IARC); University of Zurich; University Zurich Hospital; UDICE-French Research Universities; Universite de Bordeaux; CHU Lyon; University of Zurich; University Zurich Hospital	Ohgaki, H (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	ohgaki@iarc.fr	Heppner, Frank/ABH-8393-2020	Heppner, Frank/0000-0001-9816-8917				Azzarelli BN, 2003, J NEUROPATH EXP NEUR, V62, P544; Blumcke I, 2001, J NEUROPATH EXP NEUR, V60, P984; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; DURAND JF, 2001, GUIDE UTILISATION RE; Fuller GN, 1999, CANCER RES, V59, P4228; Grifa A, 1998, BIOCHEM BIOPH RES CO, V250, P240, DOI 10.1006/bbrc.1998.9296; Gunthert AR, 2002, BIOCHEM BIOPH RES CO, V294, P11, DOI 10.1016/S0006-291X(02)00427-8; Gutmann DH, 2002, CANCER RES, V62, P2085; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Huang HT, 2000, CANCER RES, V60, P6868; Ino Y, 2001, CLIN CANCER RES, V7, P839; KLEIHUES P, 2000, DIFFUSE ASTROCYTOMA, P22; Li T, 2002, J BIOL CHEM, V277, P32668, DOI 10.1074/jbc.M203519200; Ligon KL, 2003, J NEUROPATH EXP NEUR, V62, P544; Lu QR, 2001, P NATL ACAD SCI USA, V98, P10851, DOI 10.1073/pnas.181340798; Marie Y, 2001, LANCET, V358, P298, DOI 10.1016/S0140-6736(01)05499-X; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; Miettinen HE, 2001, J NEURO-ONCOL, V55, P29, DOI 10.1023/A:1012961918848; Mukasa A, 2002, ONCOGENE, V21, P3961, DOI 10.1038/sj.onc.1205495; Nguyen DV, 2002, BIOINFORMATICS, V18, P39, DOI 10.1093/bioinformatics/18.1.39; Nigro JM, 2001, AM J PATHOL, V158, P1253, DOI 10.1016/S0002-9440(10)64076-X; Nutt CL, 2003, CANCER RES, V63, P1602; OBATA S, 1995, J CELL SCI, V108, P3765; Ohnishi A, 2003, J NEUROPATH EXP NEUR, V62, P1052, DOI 10.1093/jnen/62.10.1052; Perry JR, 2001, CURR OPIN NEUROL, V14, P705, DOI 10.1097/00019052-200112000-00005; Peters HC, 1998, NEUROGENETICS, V2, P47, DOI 10.1007/s100480050051; REIFENBERGER G, 2000, OLIGODENDROGLIOMA PA, P56; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; Rickman DS, 2001, CANCER RES, V61, P6885; Sallinen SL, 2000, CANCER RES, V60, P6617; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; Schafer J.L., 1997, ANAL INCOMPLETE MULT, DOI 10.1201/9781439821862; Smith JS, 2000, J CLIN ONCOL, V18, P636, DOI 10.1200/JCO.2000.18.3.636; Tanwar MK, 2002, CANCER RES, V62, P4364; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wagner EF, 2001, ONCOGENE, V20, P2334, DOI 10.1038/sj.onc.1204416; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; Watanabe T, 2002, ACTA NEUROPATHOL, V103, P267, DOI 10.1007/s004010100464; Watson MA, 2001, CANCER RES, V61, P1825; Zerbini LF, 2003, CANCER RES, V63, P2206	40	38	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					6012	6022		10.1038/sj.onc.1207781	http://dx.doi.org/10.1038/sj.onc.1207781			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208679	Bronze			2022-12-17	WOS:000222941100017
J	Finzer, P; Krueger, A; Stohr, M; Brenner, D; Soto, U; Kuntzen, C; Krammer, PH; Rosl, F				Finzer, P; Krueger, A; Stohr, M; Brenner, D; Soto, U; Kuntzen, C; Krammer, PH; Rosl, F			HDAC inhibitors trigger apoptosis in HPV-positive cells by inducing the E2F-p73 pathway	ONCOGENE			English	Article						human papillomavirus; cervical carcinoma cells; HDAC inhibitors	CERVICAL-CARCINOMA CELLS; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; CD95 APO-1/FAS; GENE-EXPRESSION; E2F; INDUCTION; P53; DEGRADATION; CANCER	Histone deacetylase (HDAC) inhibitors induce an intrinsic type of apoptosis in human papillomavirus (HPV)-positive cells by disrupting the mitochondrial transmembrane potential (DeltaPsi(m)). Loss of DeltaPsi(m) was only detected in E7, but not in E6 oncogene-expressing cells. HDAC inhibition led to a time-dependent degradation of the pocket proteins pRb, p107 and p130, releasing 'free' E2F-1 following initial G1 arrest. Inhibition of proteasomal proteolysis, but not of caspase activity rescued pRb from degradation and functionally restored its inhibitory effect on the cyclin E gene, known to be suppressedby pRb-E2F-1 in conjunction with HDAC1. Using siRNA targeted against p53, E2F-1 still triggered apoptosis by inducing the E2F-responsive proapoptotic alpha- and beta-isoforms of p73. These data may determine future therapeutic strategies in which HDAC inhibitors can effectively eliminate HPV-positive cells by an apoptotic route that does not rely on the reactivation of the 'classical' p53 pathway through a preceding shut-off of viral gene expression.	Deutsch Krebsforschungszentrum, Forschungsschewerpunkt Angew Tumorvirol, Abt Virale Transformat Mech, D-69120 Heidelberg, Germany; Abt Immungenet, D-69120 Heidelberg, Germany; Forschungsschwerpunkt Zytometrie, D-69120 Heidelberg, Germany; Univ Munich, Klinikum Grosshadern, D-8000 Munich, Germany; Dana Farber Canc Inst, Boston, MA 02115 USA	Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich; Harvard University; Dana-Farber Cancer Institute	Finzer, P (corresponding author), Deutsch Krebsforschungszentrum, Forschungsschewerpunkt Angew Tumorvirol, Abt Virale Transformat Mech, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	p.finzer@dkfz.de	Krueger, Andreas/B-9427-2009	Krueger, Andreas/0000-0001-7873-7334; Brenner, Dirk/0000-0001-8979-1045				Aguilar-Lemarroy A, 2001, INT J CANCER, V93, P823, DOI 10.1002/ijc.1405; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bernard HU, 2002, ANTIVIR THER, V7, P219; Boutillier AL, 2000, ONCOGENE, V19, P2171, DOI 10.1038/sj.onc.1203532; Boyer SN, 1996, CANCER RES, V56, P4620; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; DEAN PN, 1974, J CELL BIOL, V60, P523, DOI 10.1083/jcb.60.2.523; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Eichhorst ST, 2000, MOL CELL BIOL, V20, P7826, DOI 10.1128/MCB.20.20.7826-7837.2000; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Finzer P, 2003, J CANCER RES CLIN, V129, P107, DOI 10.1007/s00432-003-0416-z; Finzer P, 2002, VIROLOGY, V304, P265, DOI 10.1006/viro.2002.1667; Finzer P, 2001, ONCOGENE, V20, P4768, DOI 10.1038/sj.onc.1204652; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Gomez-Manzano C, 2001, CANCER RES, V61, P6693; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Griffiths DJ, 1997, J VIROL, V71, P2866, DOI 10.1128/JVI.71.4.2866-2872.1997; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hwang SG, 2002, J BIOL CHEM, V277, P2923, DOI 10.1074/jbc.M109113200; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Lin KI, 1998, CELL DEATH DIFFER, V5, P577, DOI 10.1038/sj.cdd.4400384; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nees M, 2001, J VIROL, V75, P4283, DOI 10.1128/JVI.75.9.4283-4296.2001; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Re D, 2000, EXP HEMATOL, V28, P31, DOI 10.1016/S0301-472X(99)00125-3; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Rosato RR, 2003, CANCER RES, V63, P3637; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Soto U, 1999, ONCOGENE, V18, P3187, DOI 10.1038/sj.onc.1202765; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; STOHR M, 1978, STAIN TECHNOL, V53, P205; Tan XQ, 1997, J BIOL CHEM, V272, P9613; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Wang QM, 2000, CLIN CANCER RES, V6, P2951; Wharton W, 2000, J BIOL CHEM, V275, P33981, DOI 10.1074/jbc.M005600200; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	73	38	38	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4807	4817		10.1038/sj.onc.1207620	http://dx.doi.org/10.1038/sj.onc.1207620			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15077164				2022-12-17	WOS:000222104200001
J	Espert, L; Rey, C; Gonzalez, L; Degols, G; Chelbi-Alix, MK; Mechti, N; Gongora, C				Espert, L; Rey, C; Gonzalez, L; Degols, G; Chelbi-Alix, MK; Mechti, N; Gongora, C			The exonuclease ISG20 is directly induced by synthetic dsRNA via NF-kappa B and IRF1 activation	ONCOGENE			English	Article						ISG20; dsRNA; NF-kappa B; IRF1; transcription; interferon	DOUBLE-STRANDED-RNA; REGULATORY FACTOR-I; PROTEIN-KINASE-R; GENE-EXPRESSION; NUCLEAR-MATRIX; VIRUS; APOPTOSIS; INDUCTION; PATHWAY; STRESS	Many interferon (IFN)-stimulated genes are also induced by double-stranded RNA (dsRNA), a component closely associated with the IFN system in the context of virus-host interactions. Recently, we demonstrated that the IFN-induced 3' --> 5' exonuclease ISG20 possesses antiviral activities against RNA viruses. Here we show that ISG20 induction by synthetic dsRNA (pIpC) is stronger and faster than its induction by IFN. Two families of transcription factors are implicated in the transcriptional activation of ISG20 by dsRNA. Initially, the NF-kappaB factors p50 and p65 bind and activate the kappaB element of the Isg20 promoter. This is followed by IRFI binding to the ISRE. As pIpC often induces protein movements in the cells, we questioned whether it could influence ISG20 localization. Interestingly and contrary to IFN, dsRNA induces a nuclear matrix enrichment of the ISG20 protein. dsRNA induction of ISG20 via NF-kappaB and its antiviral activity led us to suggest that ISG20 could participate in the cellular response to virus infection.	CNRS, UMR 5160, EFS, F-34094 Montpellier 5, France; Inst Andre Lwoff, CNRS, UPR 9045, F-94801 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Gongora, C (corresponding author), CNRS, UMR 5160, EFS, 240 Ave Emile Jeanbrau, F-34094 Montpellier 5, France.	celine.gongora@ibph.pharma.univ.montp1.fr	Espert, Lucile/ABF-5614-2021	GONGORA, Celine/0000-0001-9034-4031				Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; BANDYOPADHYAY SK, 1995, J BIOL CHEM, V270, P19624, DOI 10.1074/jbc.270.33.19624; Behr M, 2001, J INTERF CYTOK RES, V21, P981, DOI 10.1089/107999001753289596; Blair LA, 2002, J BIOL CHEM, V277, P359, DOI 10.1074/jbc.M109819200; Deppert W, 2000, CRIT REV EUKAR GENE, V10, P45; DiazGuerra M, 1997, VIROLOGY, V236, P354, DOI 10.1006/viro.1997.8719; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Espert L, 2003, J BIOL CHEM, V278, P16151, DOI 10.1074/jbc.M209628200; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Geiss G, 2001, J BIOL CHEM, V276, P30178, DOI 10.1074/jbc.C100137200; Gongora C, 2000, NUCLEIC ACIDS RES, V28, P2333, DOI 10.1093/nar/28.12.2333; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Hummer BT, 2001, J VIROL, V75, P7774, DOI 10.1128/JVI.75.16.7774-7777.2001; Iordanov MS, 2001, MOL CELL BIOL, V21, P61, DOI 10.1128/MCB.21.1.61-72.2001; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693; Kehoe KE, 2001, J IMMUNOL, V167, P2496, DOI 10.4049/jimmunol.167.5.2496; Mori K, 2001, MOL CELL ENDOCRINOL, V184, P77, DOI 10.1016/S0303-7207(01)00641-4; Nguyen LH, 2001, BIOCHEMISTRY-US, V40, P7174, DOI 10.1021/bi010141t; Okorokov AL, 2002, ONCOGENE, V21, P356, DOI 10.1038/sj.onc.1205112; Peters KL, 2002, P NATL ACAD SCI USA, V99, P6322, DOI 10.1073/pnas.092133199; Roti JLR, 1997, CRIT REV EUKAR GENE, V7, P343, DOI 10.1615/CritRevEukarGeneExpr.v7.i4.30; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Saura M, 1999, J MOL BIOL, V289, P459, DOI 10.1006/jmbi.1999.2752; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; TEN RM, 1993, CR ACAD SCI III-VIE, V316, P496; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	31	38	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4636	4640		10.1038/sj.onc.1207586	http://dx.doi.org/10.1038/sj.onc.1207586			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064705				2022-12-17	WOS:000221799000013
J	Mayhew, CN; Perkin, LM; Zhang, XP; Sage, J; Jacks, T; Knudsen, ES				Mayhew, CN; Perkin, LM; Zhang, XP; Sage, J; Jacks, T; Knudsen, ES			Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents	ONCOGENE			English	Article						cell cycle checkpoints; chemotherapeutics; immortalization; thymidylate synthase; retinoblastoma tumor suppressor	RETINOBLASTOMA TUMOR-SUPPRESSOR; CELL-CYCLE ARREST; LARGE T-ANTIGEN; DNA-DAMAGE; FUNCTIONAL INACTIVATION; THYMIDYLATE SYNTHETASE; GENE-EXPRESSION; G(1) ARREST; P53; PROTEIN	The retinoblastoma (RB) tumor suppressor has been proposed to function as a key mediator of cell cycle checkpoints induced by chemotherapeutic agents. However, these prior studies have relied on embryonic fibroblasts harboring chronic loss of RB, a condition under which compensation of RB functions is known to occur. Here we utilized primary adult. broblasts derived from mice harboring loxP sites flanking exon 3 of the Rb gene to delineate the action of RB in the chemotherapeutic response. In this system we find that targeted disruption of Rb leads to little overt change in cell cycle distribution. However, these cells exhibited deregulation of RB/E2F target genes and became aneuploid following culture in the absence of RB. When challenged with both DNA damaging and antimetabolite chemotherapeutics, RB was required for primary adult cells to undergo DNA damage checkpoint responses and loss of RB resulted in enhanced aneuploidy following challenge. In contrast, following spontaneous immortalization and the loss of functional p53 signaling, the antimetabolite 5-fluorouracil (5-FU) failed to induce arrest despite the presence of RB. In these immortal cultures RB/E2F targets were deregulated in a complex, gene-specific manner and RB was required for the checkpoint response to camptothecin (CPT). Mechanistic analyses of the checkpoint responses in primary cells indicated that loss of RB leads to increased p53 signaling and decreased viability following both CPT and 5-FU treatment. However, the mechanism through which these agents act to facilitate cell cycle inhibition through RB were distinct. These studies underscore the critical role of RB in DNA-damage checkpoint signaling and demonstrate that RB mediates chemotherapeutic-induced cell cycle inhibition in adult. broblasts by distinct mechanisms.	Univ Cincinnati, Coll Med, Dept Cell Biol, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA; MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	University System of Ohio; University of Cincinnati; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Knudsen, ES (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA.	erik.knudsen@uc.edu	Mayhew, Christopher N/AGB-4929-2022		NATIONAL CANCER INSTITUTE [T32CA059268] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA 59268] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Angus SP, 2002, J BIOL CHEM, V277, P44376, DOI 10.1074/jbc.M205911200; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Avni D, 2003, MOL CELL, V12, P735, DOI 10.1016/S1097-2765(03)00355-1; Balsitis SJ, 2003, MOL CELL BIOL, V23, P9094, DOI 10.1128/MCB.23.24.9094-9103.2003; Banerjee D, 2002, BBA-MOL BASIS DIS, V1587, P164, DOI 10.1016/S0925-4439(02)00079-0; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bartkova J, 1997, Prog Cell Cycle Res, V3, P211; Berkovich E, 2003, ONCOGENE, V22, P161, DOI 10.1038/sj.onc.1206144; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Leonardo A, 1997, CANCER RES, V57, P1013; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EL DW, 1993, CELL, V75, P817; Flatt PM, 2000, DRUG METAB REV, V32, P283, DOI 10.1081/DMR-100102335; Guo N, 2000, J BIOL CHEM, V275, P1715, DOI 10.1074/jbc.275.3.1715; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lan ZD, 2002, J BIOL CHEM, V277, P8372, DOI 10.1074/jbc.M108906200; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lentini L, 2002, NEOPLASIA, V4, P380, DOI 10.1038/sj.neo.7900256; LI WW, 1995, P NATL ACAD SCI USA, V92, P10436, DOI 10.1073/pnas.92.22.10436; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Longley DB, 2002, CANCER RES, V62, P2644; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MacPherson D, 2003, MOL CELL BIOL, V23, P1044, DOI 10.1128/MCB.23.3.1044-1053.2003; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Markey MP, 2002, CANCER RES, V62, P6587; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MUDRAK I, 1994, MOL CELL BIOL, V14, P1886, DOI 10.1128/MCB.14.3.1886; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; Peters GJ, 2002, BBA-MOL BASIS DIS, V1587, P194, DOI 10.1016/S0925-4439(02)00082-0; Philips A, 1998, ONCOGENE, V16, P1373, DOI 10.1038/sj.onc.1201655; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; RITTLING SR, 1992, ONCOGENE, V7, P935; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; SANTI DV, 1974, BIOCHEMISTRY-US, V13, P471, DOI 10.1021/bi00700a012; Siddiqui H, 2003, MOL CELL BIOL, V23, P7719, DOI 10.1128/MCB.23.21.7719-7731.2003; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMITH ML, 1994, EXP CELL RES, V215, P386, DOI 10.1006/excr.1994.1356; SOMMER H, 1974, BIOCHEM BIOPH RES CO, V57, P689, DOI 10.1016/0006-291X(74)90601-9; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; Stewart ZA, 2001, CHEM RES TOXICOL, V14, P243, DOI 10.1021/tx000199t; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338; Zheng L, 2002, ADV CANCER RES, V85, P13, DOI 10.1016/S0065-230X(02)85002-3	77	38	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4107	4120		10.1038/sj.onc.1207503	http://dx.doi.org/10.1038/sj.onc.1207503			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064736				2022-12-17	WOS:000221520200009
J	Bader, AG; Vogt, PK				Bader, AG; Vogt, PK			An essential role for protein synthesis in oncogenic cellular transformation	ONCOGENE			English	Review						P3k; Akt; translation; TOR; TSC; Rheb; Raptor; YB-1	NF-KAPPA-B; RNA-ASSOCIATED PROTEIN; CAP-BINDING PROTEIN; REPRESSOR PHAS-I; P70 S6 KINASE; MESSENGER-RNA; MAMMALIAN TARGET; TUBEROUS-SCLEROSIS; PHOSPHOINOSITIDE 3-KINASE; TRANSCRIPTION FACTOR	The induction and maintenance of oncogenic transformation requires interference with the controls that regulate translation and transcription. The PI 3-kinase pathway, which shows gain of function in numerous and diverse human cancers, generates signals that have a positive effect on the initiation of protein synthesis. Here we review the components of the PI 3-kinase signaling pathway and the mRNA-binding protein YB-1, exploring their roles in protein synthesis and oncogenic cell transformation.	Scripps Res Inst, Dept Mol & Expt Med, Div Oncovirol, La Jolla, CA 92037 USA	Scripps Research Institute	Bader, AG (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Oncovirol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	andreas@scripps.edu	Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500				Abraham RT, 2003, CURR TOP MICROBIOL, V279, P299; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; Bacus SS, 2002, ONCOGENE, V21, P3532, DOI 10.1038/sj.onc.1205438; Bader AG, 2003, P NATL ACAD SCI USA, V100, P12384, DOI 10.1073/pnas.2135336100; BARRIEUX A, 1976, BIOCHEMISTRY-US, V15, P3523, DOI 10.1021/bi00661a020; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; BLOBEL G, 1972, BIOCHEM BIOPH RES CO, V47, P88, DOI 10.1016/S0006-291X(72)80014-7; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; DEL PL, 1997, SCIENCE, V278, P687; Depowski PL, 2001, MODERN PATHOL, V14, P672, DOI 10.1038/modpathol.3880371; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Dilling MB, 2002, J BIOL CHEM, V277, P13907, DOI 10.1074/jbc.M110782200; DILLING MB, 1994, CANCER RES, V54, P903; Dudkin L, 2001, CLIN CANCER RES, V7, P1758; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Elit Laurie, 2002, Curr Opin Investig Drugs, V3, P1249; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; Evdokimova VM, 1999, INT J BIOCHEM CELL B, V31, P139, DOI 10.1016/S1357-2725(98)00137-X; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Geoerger B, 2001, CANCER RES, V61, P1527; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Hamilton GS, 1998, J MED CHEM, V41, P5119, DOI 10.1021/jm980307x; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; HESKETH R, 1997, FACTSBOOK SER, P3; Houghton PJ, 2003, CURR TOP MICROBIOL, V279, P339; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Ito T, 2003, CURR TOP MICROBIOL, V274, P1; Izumi H, 2001, NUCLEIC ACIDS RES, V29, P1200, DOI 10.1093/nar/29.5.1200; Jaeschke A, 2003, CURR TOP MICROBIOL, V279, P283; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Katsani KR, 2003, CURR TOP MICROBIOL, V274, P113; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liao YD, 2003, INT J CANCER, V107, P676, DOI 10.1002/ijc.11471; Liu ET, 2003, CURR OPIN GENET DEV, V13, P97, DOI 10.1016/S0959-437X(03)00008-X; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; MINICH WB, 1992, BIOCHIMIE, V74, P477, DOI 10.1016/0300-9084(92)90088-V; Miralem T, 2003, MOL CELL BIOL, V23, P579, DOI 10.1128/MCB.23.2.579-593.2003; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; MONTAGNE J, 2001, SCI STKE, pPE36; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Nekrasov MP, 2003, J BIOL CHEM, V278, P13936, DOI 10.1074/jbc.M209145200; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Ozes ON, 1999, NATURE, V401, P82; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Proud CG, 2003, CURR TOP MICROBIOL, V279, P215; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; Russo G, 2003, ONCOGENE, V22, P6497, DOI 10.1038/sj.onc.1206865; Samuels Y., 2004, SCIENCE; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Sekulic A, 2000, CANCER RES, V60, P3504; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; VEZINA C, 1975, J ANTIBIOT, V28, P721, DOI 10.7164/antibiotics.28.721; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999; Zhang YF, 2003, ONCOGENE, V22, P2782, DOI 10.1038/sj.onc.1206357; Zimmer SG, 2000, ANTICANCER RES, V20, P1343; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	110	38	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2004	23	18					3145	3150		10.1038/sj.onc.1207550	http://dx.doi.org/10.1038/sj.onc.1207550			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094764				2022-12-17	WOS:000220879700003
J	Kobayashi, K; Nishioka, M; Kohno, T; Nakamoto, M; Maeshima, A; Aoyagi, K; Sasaki, H; Takenoshita, S; Sugimura, H; Yokota, J				Kobayashi, K; Nishioka, M; Kohno, T; Nakamoto, M; Maeshima, A; Aoyagi, K; Sasaki, H; Takenoshita, S; Sugimura, H; Yokota, J			Identification of genes whose expression is upregulated in lung adenocarcinoma cells in comparison with type II alveolar cells and bronchiolar epithelial cells in vivo	ONCOGENE			English	Article						lung adenocarcinoma; type II alveolar cells; bronchiolar epithelial cells; laser capture microdissection; cDNA microarray	LASER CAPTURE MICRODISSECTION; MATRIX METALLOPROTEINASES; DIFFERENTIAL EXPRESSION; TISSUE LOCALIZATION; MESSENGER-RNA; MICROARRAY ANALYSIS; DNA TOPOISOMERASES; TUMOR-CELLS; CARCINOMAS; CANCER	To identify genes whose expression is upregulated in lung adenocarcinoma (AdC) cells in comparison with noncancerous peripheral lung epithelial cells, type II alveolar cells and bronchiolar epithelial cells, as well as AdC cells, were isolated by laser capture microdissection, and subjected to cDNA microarray analysis of 637 human cancer-related genes. Each of the component cells was obtained from several different individuals and analysed independently. As a comparison, two lung AdC cell lines and two primarily cultured normal lung epithelial cell lines were also subjected to cDNA microarray analysis. Four genes, TOP2A, MMP15, MX2 and KOC1, were commonly upregulated in microdissected AdC cells in comparison with microdissected epithelial cells. Hierarchical clustering analysis revealed that differences in gene-expression profiles were more evident between cultured and uncultured cells than between cancerous and noncancerous cells. To further identify the common molecular targets of AdC cells in vivo, quantitative real-time RT-PCR was performed against the four genes upregulated by cDNA microarray analysis. The TOP2A, MMP15, MX2 and KOC1 genes were overexpressed in 10/10 (100%), 8/10 (80%), 5/10 (50%) and 3/10 (30%) microdissected AdC cell samples, respectively, in comparison with any of nine independently microdissected noncancerous epithelial cell samples. The TOP2A gene was commonly overexpressed in lung AdC cells, as previously reported. In addition, the MMP15 and MX2 genes were identified, for the first time, as being commonly overexpressed in lung AdC cells. These results strongly indicate that the MMP15 and MX2 genes could be novel markers for molecular diagnosis and therapy of lung AdC.	Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan; Fukushima Med Univ, Sch Med, Dept Surg 2, Fukushima 9601295, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Genet, Chuo Ku, Tokyo 1040045, Japan; Hamamatsu Univ Sch Med, Dept Pathol 1, Shizuoka 4313192, Japan	National Cancer Center - Japan; Fukushima Medical University; National Cancer Center - Japan; National Cancer Center - Japan; Hamamatsu University School of Medicine	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.	jyokota@gan2.ncc.go.jp						Aoyagi K, 2003, BIOCHEM BIOPH RES CO, V300, P915, DOI 10.1016/S0006-291X(02)02967-4; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Crnogorac-Jurcevic Tatjana, 2002, Methods Mol Biol, V193, P197; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Giaccone G, 1995, BBA-GENE STRUCT EXPR, V1264, P337, DOI 10.1016/0167-4781(95)00171-9; Goodwin LO, 2001, ANN CLIN LAB SCI, V31, P369; JENSEN SM, 1994, INT J CANCER, V58, P629, DOI 10.1002/ijc.2910580503; Kitagawa Y, 1998, J UROLOGY, V160, P1540, DOI 10.1016/S0022-5347(01)62609-0; McDoniels-Silvers AL, 2002, NEOPLASIA, V4, P141, DOI 10.1038/sj.neo.7900217; Melen K, 1996, J BIOL CHEM, V271, P23478, DOI 10.1074/jbc.271.38.23478; Mirski SEL, 2000, LAB INVEST, V80, P787, DOI 10.1038/labinvest.3780083; Miura K, 2002, CANCER RES, V62, P3244; MuellerPillasch F, 1997, ONCOGENE, V14, P2729, DOI 10.1038/sj.onc.1201110; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; Nawrocki B, 1997, INT J CANCER, V72, P556, DOI 10.1002/(SICI)1097-0215(19970807)72:4<556::AID-IJC2>3.3.CO;2-#; PHELPS DS, 1988, AM REV RESPIR DIS, V137, P939, DOI 10.1164/ajrccm/137.4.939; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; POLLETE M, 1996, VIRCHOWS ARCH, V428, P29; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sobin LH, 2002, TNM CLASSIFICATION M, P97; Sugita M, 2002, CANCER RES, V62, P3971; Syahruddin E, 1998, JPN J CANCER RES, V89, P855, DOI 10.1111/j.1349-7006.1998.tb00640.x; TOKURAKU M, 1995, INT J CANCER, V64, P355, DOI 10.1002/ijc.2910640513; Travis WD, 1999, WHO HISTOLOGICAL TYP; Ueno H, 1997, CANCER RES, V57, P2055; Vaarala MH, 2000, LAB INVEST, V80, P1259, DOI 10.1038/labinvest.3780134; Virtanen C, 2002, P NATL ACAD SCI USA, V99, P12357, DOI 10.1073/pnas.192240599; Wang T, 2003, BRIT J CANCER, V88, P887, DOI 10.1038/sj.bjc.6600806; Wang T, 2000, ONCOGENE, V19, P1519, DOI 10.1038/sj.onc.1203457; Wang TT, 2001, ONCOGENE, V20, P7699, DOI 10.1038/sj.onc.1204939; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; Wikman H, 2002, ONCOGENE, V21, P5804, DOI 10.1038/sj.onc.1205726; Yoshimi I, 2003, JPN J CLIN ONCOL, V33, P98, DOI 10.1093/jjco/hyg019	36	38	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	2004	23	17					3089	3096		10.1038/sj.onc.1207433	http://dx.doi.org/10.1038/sj.onc.1207433			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14755238				2022-12-17	WOS:000220845200013
J	Castellone, MD; Celetti, A; Guarino, V; Cirafici, AM; Basolo, F; Giannini, R; Medico, E; Kruhoffer, M; Orntoft, TF; Curcio, F; Fusco, A; Melillo, RM; Santoro, M				Castellone, MD; Celetti, A; Guarino, V; Cirafici, AM; Basolo, F; Giannini, R; Medico, E; Kruhoffer, M; Orntoft, TF; Curcio, F; Fusco, A; Melillo, RM; Santoro, M			Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells	ONCOGENE			English	Article						kinase; carcinoma; motility; Ras; tyrosine; thyroid	TYROSINE KINASE; IN-VITRO; RET; CD44; ACTIVATION; RECEPTOR; CANCER; LINE; IDENTIFICATION; ONCOPROTEIN	Papillary thyroid carcinomas are characterized by rearrangements of the RET receptor tyrosine kinase generating RET/ PTC oncogenes. Here we show that osteopontin ( OPN), a secreted glycoprotein, is a major RET/ PTC- induced transcriptional target in PC Cl 3 thyroid follicular cells. OPN upregulation depended on the integrity of the RET/ PTC kinase and tyrosines Y1015 and Y1062, two major RET/ PTC autophosphorylation sites. RET/ PT C also induced a strong overexpression of CD44, a cell surface signalling receptor for OPN. Upregulation of CD44 was dependent on RET/ PTC Y1062, as well. Constitutive OPN overexpression or treatment with exogenous recombinant OPN sharply increased proliferation, Matrigel invasion and spreading in collagen gels of RET/ PTC- transformed PC Cl 3 cells. These effects were impaired by the treatment of PC Cl 3- RET/ PTC cells with OPN- and CD44- blocking antibodies. Thus, RET/ PTC signalling triggers an autocrine loop involving OPN and CD44 that sustains proliferation and invasion of transfomed PC Cl 3 thyrocytes.	Univ Naples Federico II, Fac Med, Dipartimento Biol & Patol Cellulare & Mol, CNR,Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Dipartimento Oncol, Pisa, Italy; Univ Turin, Inst Canc Res & Treatment IRCC, Div Mol Oncol, Candiolo, TO, Italy; Aarhus Univ Hosp, Dept Clin Biochem, Mol Diagnost Lab, DK-8000 Aarhus, Denmark; Univ Udine, Dipartimento Patol & Med Sperimentale & Clin, I-33100 Udine, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Aarhus University; University of Udine	Santoro, M (corresponding author), Univ Naples Federico II, Fac Med, Dipartimento Biol & Patol Cellulare & Mol, CNR,Ist Endocrinol & Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.	masantor@unina.it	Celetti, Angela/AAY-7172-2020; Giannini, Riccardo/K-4223-2013; Curcio, Francesco/K-4669-2014; Basolo, Fulvio/AAC-2727-2019; Giannini, Riccardo/Q-6087-2019; melillo, rosa marina/O-5255-2015; Medico, Enzo/AAC-3185-2021	Giannini, Riccardo/0000-0001-9740-0219; Basolo, Fulvio/0000-0003-1657-5020; Giannini, Riccardo/0000-0001-9740-0219; Medico, Enzo/0000-0002-3917-2438; MELILLO, Rosa Marina/0000-0002-9233-5275; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037; CURCIO, Francesco/0000-0002-9070-4807; Fusco, Alfredo/0000-0003-3332-5197				Andreozzi F, 2003, ONCOGENE, V22, P2942, DOI 10.1038/sj.onc.1206475; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Bartolazzi A, 2001, LANCET, V357, P1644, DOI 10.1016/S0140-6736(00)04817-0; Basolo F, 2002, INT J CANCER, V97, P608, DOI 10.1002/ijc.10116; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Buckwalter TLF, 2002, ONCOGENE, V21, P8166, DOI 10.1038/sj.onc.1205938; Carlomagno F, 2002, CANCER RES, V62, P7284; Castellone MD, 2003, ONCOGENE, V22, P246, DOI 10.1038/sj.onc.1206112; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; CHANG PL, 1993, CANCER RES, V53, P2217; CURCIO F, 1994, P NATL ACAD SCI USA, V91, P9004, DOI 10.1073/pnas.91.19.9004; ERMAK G, 1995, CANCER RES, V55, P4594; Fagin JA, 2002, ENDOCRINOLOGY, V143, P2025, DOI 10.1210/en.143.6.2025; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; Iwashita T, 1996, ONCOGENE, V12, P481; Kamikura DM, 2000, MOL CELL BIOL, V20, P3482, DOI 10.1128/MCB.20.10.3482-3496.2000; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; Lin YH, 2000, MOL CELL BIOL, V20, P2734, DOI 10.1128/MCB.20.8.2734-2742.2000; Lin YH, 2001, J BIOL CHEM, V276, P46024, DOI 10.1074/jbc.M105132200; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Medico E, 2001, CANCER RES, V61, P5861; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Mercalli E, 2001, ONCOGENE, V20, P3475, DOI 10.1038/sj.onc.1204462; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; Santoro M, 1996, ONCOGENE, V12, P1821; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Weiss JM, 2001, J EXP MED, V194, P1219, DOI 10.1084/jem.194.9.1219; YUE TL, 1994, EXP CELL RES, V214, P459, DOI 10.1006/excr.1994.1282; Zhang GX, 2003, MOL CELL BIOL, V23, P6507, DOI 10.1128/MCB.23.18.6507-6519.2003	39	38	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2188	2196		10.1038/sj.onc.1207322	http://dx.doi.org/10.1038/sj.onc.1207322			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14981541				2022-12-17	WOS:000220280900008
J	Levchenko, T; Bratt, A; Arbiser, JL; Holmgren, L				Levchenko, T; Bratt, A; Arbiser, JL; Holmgren, L			Angiomotin expression promotes hemangioendothelioma invasion	ONCOGENE			English	Article						angiostatin; angiomotin; angiogenesis; motility	ENDOTHELIAL-CELL MIGRATION; TRACTIONAL FORCES; TUMOR INVASION; ANGIOGENESIS; PROTEIN; PROTEOLYSIS; ANGIOSTATIN; MECHANISMS; GROWTH	Angiomotin was identified by its ability to bind angiostatin and has been shown to mediate its activity in vitro. The family of angiomotin-like protein consists of three members that have coiled-coil domains and conserved c-terminal PDZ-binding motifs. We show here that expression of angiomotin in mouse aortic endothelial (MAE) cells results in stabilization of tubes in the Matrigel assay. Control tubes start to regress after 72 h, whereas MAE-angiomotin ( MAE Amot) tubes were stable for over 30 days. In contrast, cells expressing a functional mutant lacking the PDZ protein interaction motif did not migrate and form tubes. Cells from the established tubes invaded into the solidified matrigel. We therefore tested whether angiomotin promotes endothelial invasion. In microcarrier-based invasion in vitro assay, angiomotin-expressing cells invaded collagen matrix and formed tube-like branches. This was confirmed in vivo as injection of MAE-Amot cells promoted tumor growth and invasion into surrounding muscle tissue. Injection of cells transfected with the functional mutant resulted in establishment of noninvasive tumors surrounded by a capsule of fibrous tissue. These tumors remained in constant size or dormant over 3 weeks. Zymogel analysis of the transfected cells did not reveal any differences in proteolytic activity. However, time-lapse photography showed a significant increase in random motility in MAE-Amot cells. We conclude that angiomotin may promote angiogenesis by both stimulating invasion as well as stabilizing established tubes.	Karolinska Inst, Ctr Canc, Dept Oncol Pathol, S-17176 Stockholm, Sweden; Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA	Karolinska Institutet; Emory University	Holmgren, L (corresponding author), Karolinska Hosp, CCK,R8-03, S-17176 Stockholm, Sweden.	lars.holmgren@cck.ki.se		Tegnebratt, Tetyana/0000-0003-4298-2295	NIAMS NIH HHS [AR42687, AR02030, AR44947] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR044947, P30AR042687] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Auerbach R, 2003, CLIN CHEM, V49, P32, DOI 10.1373/49.1.32; Ballestrem C, 2000, MOL BIOL CELL, V11, P2999, DOI 10.1091/mbc.11.9.2999; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; Bratt A, 2002, GENE, V298, P69, DOI 10.1016/S0378-1119(02)00928-9; Edwards DR, 1998, NATURE, V394, P527, DOI 10.1038/28961; Eriksson K, 2003, FEBS LETT, V536, P19, DOI 10.1016/S0014-5793(03)00003-6; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Holmgren L, 1996, CANCER METAST REV, V15, P241, DOI 10.1007/BF00437478; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; Lawler J, 2002, J CELL MOL MED, V6, P1, DOI 10.1111/j.1582-4934.2002.tb00307.x; Levchenko T, 2003, J CELL SCI, V116, P3803, DOI 10.1242/jcs.00694; LIOTTA LA, 1984, AM J PATHOL, V117, P339; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; NEHLS V, 1995, MICROVASC RES, V50, P311, DOI 10.1006/mvre.1995.1061; Nyberg P, 2003, J BIOL CHEM, V278, P22404, DOI 10.1074/jbc.M210325200; Parker KK, 2002, FASEB J, V16, DOI 10.1096/fj.02-0038com; Pepper MS, 1996, ENZYME PROTEIN, V49, P138, DOI 10.1159/000468622; Pintucci Giuseppe, 1996, Seminars in Thrombosis and Hemostasis, V22, P517, DOI 10.1055/s-2007-999054; Serini G, 2003, EMBO J, V22, P1771, DOI 10.1093/emboj/cdg176; Staff AC, 2001, SCAND J CLIN LAB INV, V61, P257, DOI 10.1080/00365510152378978; Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247; Vouret-Craviari V, 1998, MOL BIOL CELL, V9, P2639, DOI 10.1091/mbc.9.9.2639; Wang N, 2002, CELL MOTIL CYTOSKEL, V52, P97, DOI 10.1002/cm.10037; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F	24	38	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1469	1473		10.1038/sj.onc.1207264	http://dx.doi.org/10.1038/sj.onc.1207264			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14730344				2022-12-17	WOS:000189035800014
J	Luoh, SW; Venkatesan, N; Tripathi, R				Luoh, SW; Venkatesan, N; Tripathi, R			Overexpression of the amplified Pip4k2 beta gene from 17q11-12 in breast cancer cells confers proliferation advantage	ONCOGENE			English	Article						tumor biology; breast cancer; gene amplification; gene expression; HER-2/Neu	IN-SITU HYBRIDIZATION; PHOSPHATIDYLINOSITOL PHOSPHATE KINASES; GROWTH-FACTOR RECEPTOR; HER-2/NEU GENE; N-MYC; INOSITIDE PHOSPHORYLATION; AMPLIFICATION STATUS; 11Q13 AMPLIFICATION; PUTATIVE ONCOGENE; PROGNOSTIC-FACTOR	Gene amplification is common in solid tumors and is associated with adverse prognosis, disease progression, and development of drug resistance. A small segment from chromosome 17q11-12 containing the HER-2/Neu gene is amplified in about 25% of breast cancer. HER-2/Neu amplification is associated with adverse prognosis and may predict response to chemotherapy and hormonal manipulation. Moreover, HER-2/Neu amplification may select patients for anti-HER-2/Neu-based therapy with Herceptin. We and others recently described a common sequence element from the HER-2/Neu region that was amplified in breast cancer cells. In addition, most, if not all, of the amplified genes from this region display overexpression. This raises the intriguing possibility that genes immediately adjacent to HER-2/Neu may influence the biological behavior of breast cancer carrying HER-2/ Neu amplification and serve as rational targets for therapy. By extracting sequence information from public databases, we have constructed a contig in bacterial artificial chromosomes (BACs) that extends from HER-2/ Neu to a phosphotidylinositol phosphate kinase (PIPK), Pip4k2beta from 17q11 - 12. Although a role of PI-3-kinase and AKT in cancer biology has been previously described, PIPK has not been previously implicated. We show that Pip4k2b, initially known as Pip5k2beta, is amplified in a subset of breast cancer cell lines and primary breast cancer samples that carry HER-2/ Neu amplification. Out of eight breast cancer cell lines with HER-2/ Neu amplification, three have concomitant amplification of the Pip4k2beta gene - UACC-812, BT-474 and ZR-75-30. Similarly, two out of four primary breast tumors with HER-2/ Neu amplification carry Pip4k2b gene amplification. Intriguingly, one tumor displays an increase in the gene copy number of Pip4k2b that is significantly more than that of HER-2/ Neu. Moreover, dual color FISH reveals that amplified Pip4k2b gene may exist in a distinct structure from that of HER-2/ Neu in ZR-75-30 cell line. These studies suggest that Pip4k2b may reside on an amplification maximum distinct from that of HER-2/Neu and serve as an independent target for amplification and selective retention. Pip4k2beta amplification is associated with overexpression at the RNA and protein level in breast cancer cell lines. Stable expression of Pip4k2b in breast cancer cell lines with and without HER-2/Neu amplification increases cell proliferation and anchorage-independent growth. The above observations implicate Pip4k2b in the development and/or progression of breast cancer. Our study suggests that Pip4k2b may be a distinct target for gene amplification and selective retention from 17q11-12.	Univ Calif Los Angeles, Med Ctr, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA; Cincinnati Vet Affairs Med Ctr, Cincinnati, OH 45220 USA; Univ Cincinnati, Coll Med, Dept Med, Div Hematol & Oncol, Cincinnati, OH 45267 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati	Luoh, SW (corresponding author), Oregon Hlth Sci Univ, Portland VA Med Ctr, RAD 47,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.							AMLER LC, 1989, MOL CELL BIOL, V9, P4903, DOI 10.1128/MCB.9.11.4903; Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Arneson LS, 1999, J BIOL CHEM, V274, P17794, DOI 10.1074/jbc.274.25.17794; Barlund M, 2000, CANCER RES, V60, P5340; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Brien TP, 2000, HUM PATHOL, V31, P35, DOI 10.1016/S0046-8177(00)80195-1; Bringuier PP, 1996, ONCOGENE, V12, P1747; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Ishikawa T, 1997, AM J PATHOL, V151, P761; Kauraniemi P, 2001, CANCER RES, V61, P8235; Kunz J, 2000, MOL CELL, V5, P1, DOI 10.1016/S1097-2765(00)80398-6; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; Luoh SW, 2002, CANCER GENET CYTOGEN, V136, P43, DOI 10.1016/S0165-4608(01)00657-4; Massion PP, 2002, CANCER RES, V62, P3636; McEwen RK, 1999, J BIOL CHEM, V274, P33905, DOI 10.1074/jbc.274.48.33905; Mejillano M, 2001, J BIOL CHEM, V276, P1865, DOI 10.1074/jbc.M007271200; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; Nakajima M, 1999, CANCER, V85, P1894; Nessling M, 1998, GENE CHROMOSOME CANC, V23, P307, DOI 10.1002/(SICI)1098-2264(199812)23:4<307::AID-GCC5>3.0.CO;2-#; Paik SM, 1998, JNCI-J NATL CANCER I, V90, P1361, DOI 10.1093/jnci/90.18.1361; Pauletti G, 2000, J CLIN ONCOL, V18, P3651, DOI 10.1200/JCO.2000.18.21.3651; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PRESS MF, 1994, CANCER RES, V54, P5675; PRESS MF, 1993, CANCER RES, V53, P4960; PROCTOR AJ, 1991, ONCOGENE, V6, P789; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; RAVDIN PM, 1995, GENE, V159, P19, DOI 10.1016/0378-1119(94)00866-Q; ROELOFS H, 1993, GENE CHROMOSOME CANC, V7, P74, DOI 10.1002/gcc.2870070203; Rolitsky CD, 1999, INT J GYNECOL PATHOL, V18, P138, DOI 10.1097/00004347-199904000-00007; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; Ross JS, 1997, HUM PATHOL, V28, P827, DOI 10.1016/S0046-8177(97)90157-X; Rozenvayn N, 2001, J BIOL CHEM, V276, P22410, DOI 10.1074/jbc.M008184200; Rubie H, 1997, J CLIN ONCOL, V15, P1171, DOI 10.1200/JCO.1997.15.3.1171; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SZEPETOWSKI P, 1992, ONCOGENE, V7, P751; SZEPETOWSKI P, 1993, GENOMICS, V16, P745, DOI 10.1006/geno.1993.1257; THEILLET C, 1990, ONCOGENE, V5, P147; Thor AD, 1998, JNCI-J NATL CANCER I, V90, P1346, DOI 10.1093/jnci/90.18.1346; Tolias KF, 1998, J BIOL CHEM, V273, P18040, DOI 10.1074/jbc.273.29.18040; Walch AK, 2000, MODERN PATHOL, V13, P814, DOI 10.1038/modpathol.3880143; Wu GJ, 2000, CANCER RES, V60, P5371; Wu GJ, 2001, CANCER RES, V61, P4951; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	67	38	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	2004	23	7					1354	1363		10.1038/sj.onc.1207251	http://dx.doi.org/10.1038/sj.onc.1207251			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14691457				2022-12-17	WOS:000189035800003
J	Vega, A; Salas, A; Gamborino, E; Sobrido, MJ; Macaulay, V; Carracedo, A				Vega, A; Salas, A; Gamborino, E; Sobrido, MJ; Macaulay, V; Carracedo, A			MtDNA mutations in tumors of the central nervous system reflect the neutral evolution of mtDNA in populations	ONCOGENE			English	Article						mtDNA; CNS tumors; neutral evolution; instability; hotspots	MITOCHONDRIAL-DNA MUTATIONS; MICROSATELLITE INSTABILITY; SOMATIC MUTATIONS; CONTROL REGION; CANCER; CARCINOMA; GENOME; HETEROPLASMY; FREQUENCY; SEQUENCES	Mitochondrial DNA ( mtDNA) instability has been observed in different types of cancer, including colorectal, breast, and gastric cancer. The relationship between the occurrence of such alteration and the nuclear microsatellite instability (nMI) status of the neoplastic cells remains controversial. In an attempt to clarify this issue, we sequenced the first and second mtDNA hypervariable regions, and typed the mitochondrial ( CA)(n) dinucleotide polymorphism in 69 patients with primary tumors of the central nervous system (CNS), previously screened for nMI. Tumor samples showed 27 D-loop sequence changes (39.1%) compared to the corresponding blood samples. Microsatellite homoplasmic allele mutations were detected in four cases (5.8%). We did not find significant associations of the mtDNA instability status with clinicopathological parameters including sex, age, tumor size, and duration of clinical course. Neither did we find any association between mtDNA and nuclear instabilities, indicating that, at least in CNS tumors, they respond to different DNA repair mechanisms. We have also compiled the mtDNA instabilities previously reported by other authors for several types of tumors, comparing them to mtDNA polymorphisms in human populations. Most of the tumor-associated changes are common human polymorphisms and mutational hotspots. To explain the molecular behavior of mtDNA instability in tumors, we propose a model also common to other biological situations.	Univ Santiago de Compostela, Fac Med, Unidad Genet Forense, Galica, Spain; Univ Santiago de Compostela, Hosp Clin Univ, Unidad Mol Med, Galica, Spain; Univ Santiago de Compostela, Hosp Clin Univ, Serv Cirugia, Galica, Spain; Hosp San Rafael, La Coruna, Galica, Spain; Univ Oxford, Dept Stat, Oxford OX1 3TG, England; Univ Glasgow, Dept Stat, Glasgow, Lanark, Scotland	Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; University of Oxford; University of Glasgow	Salas, A (corresponding author), Univ Santiago de Compostela, Fac Med, Unidad Genet Forense, Galica, Spain.	apimlase@usc.es	Salas, Antonio/E-3977-2012; Carracedo, Angel/D-4257-2012	Salas, Antonio/0000-0002-2336-702X; Carracedo, Angel/0000-0003-1085-8986				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; BANDELT HJ, 1995, GENETICS, V141, P743; Bandelt HJ, 1999, MOL BIOL EVOL, V16, P37, DOI 10.1093/oxfordjournals.molbev.a026036; Bandelt HJ, 2002, AM J HUM GENET, V71, P1150, DOI 10.1086/344397; Bodenteich Angelika, 1992, Human Molecular Genetics, V1, P140, DOI 10.1093/hmg/1.2.140-a; Chinnery PF, 2002, LANCET, V360, P1323, DOI 10.1016/S0140-6736(02)11310-9; Coller HA, 2001, NAT GENET, V28, P147, DOI 10.1038/88859; DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T; FIELD JK, 1995, BRIT J CANCER, V71, P1065, DOI 10.1038/bjc.1995.205; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Forster L, 2002, P NATL ACAD SCI USA, V99, P13950, DOI 10.1073/pnas.202400499; GALL K, 1993, INT J EXP PATHOL, V74, P333; Habano W, 1998, ONCOGENE, V17, P1931, DOI 10.1038/sj.onc.1202112; Habano W, 2000, GASTROENTEROLOGY, V118, P835, DOI 10.1016/S0016-5085(00)70169-7; Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933; Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Khrapko K, 1997, P NATL ACAD SCI USA, V94, P13798, DOI 10.1073/pnas.94.25.13798; KIARIS H, 1995, BRIT J CANCER, V72, P123, DOI 10.1038/bjc.1995.287; Kirches E, 1999, GENE CHROMOSOME CANC, V26, P80, DOI 10.1002/(SICI)1098-2264(199909)26:1<80::AID-GCC11>3.0.CO;2-4; Maca-Meyer N, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-13; Malyarchuk BA, 2002, HUM GENET, V111, P46, DOI 10.1007/s00439-002-0740-4; Maximo V, 2000, GASTROENTEROLOGY, V119, P1808, DOI 10.1016/S0016-5085(00)70044-8; Meyer S, 1999, GENETICS, V152, P1103; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Richards M, 2000, AM J HUM GENET, V67, P1251, DOI 10.1016/S0002-9297(07)62954-1; Richards M, 2001, AM J HUM GENET, V68, P1315, DOI 10.1086/320615; RISINGER JI, 1993, CANCER RES, V53, P5100; Salas A, 2002, AM J HUM GENET, V71, P1082, DOI 10.1086/344348; Salas A, 2001, INT J LEGAL MED, V114, P186, DOI 10.1007/s004140000164; Sobrido MJ, 2000, J NEUROL NEUROSUR PS, V69, P369, DOI 10.1136/jnnp.69.3.369; Stoneking M, 2000, AM J HUM GENET, V67, P1029, DOI 10.1086/303092; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TULLY G, 2003, UNPUB FORENSIC SCI I; Vega A, 2001, CANCER, V92, P2920, DOI 10.1002/1097-0142(20011201)92:11<2920::AID-CNCR10110>3.3.CO;2-J; YEE CJ, 1994, CANCER RES, V54, P1641	37	38	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1314	1320		10.1038/sj.onc.1207214	http://dx.doi.org/10.1038/sj.onc.1207214			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647457				2022-12-17	WOS:000188892200017
J	Stewart, RA; Li, DM; Huang, H; Xu, T				Stewart, RA; Li, DM; Huang, H; Xu, T			A genetic screen for modifiers of the lats tumor suppressor gene identifies C-terminal Src kinase as a regulator of cell proliferation in Drosophila	ONCOGENE			English	Article						CSK; LATS; SRC; tissue size; cell proliferation; genetic modifier	PROTEIN-TYROSINE KINASE; FOCAL ADHESION KINASE; BREAST-CANCER CELLS; FAMILY KINASES; NEGATIVE REGULATION; EYE DEVELOPMENT; HUMAN HOMOLOG; MICE LACKING; CSK; GROWTH	Disrupting mechanisms that control cell proliferation, cell size and apoptosis can cause changes in animal and tissue size and contribute to diseases such as cancer. The LATS family of serine/threonine kinases control tissue size by regulating cell proliferation and function as tumor suppressor genes in both Drosophila and mammals. In order to understand the role of lats in size regulation, we performed a genetic modifier screen in Drosophila to identify components of the lats signaling pathway. Mutations in the Drosophila homolog of C-terminal Src kinase (dcsk) were identified as dominant modifiers of both lats gain-of-function and loss-of-function phenotypes. Homozygous dcsk mutants have enlarged tissue phenotypes similar to lats and FACS and immunohistochemistry analysis of these tissues revealed that dcsk also regulates cell proliferation during development. Animals having mutations in both dcsk and lats display cell overproliferation phenotypes more severe than either mutant alone, demonstrating these genes function together in vivo to regulate cell numbers. Furthermore, homozygous dcsk phenotypes can be partially suppressed by overexpression of lats, indicating that lats is a downstream mediator of dcsk function in vivo. Finally, we show that dCSK phosphorylates LATS in vitro at a conserved C-terminal tyrosine residue, which is critical for normal LATS function in vivo. Taken together, these results demonstrate a role for dCSK in regulating cell numbers during development by inhibiting cell proliferation and suggest that lats is one of the mediators of the dcsk phenotype.	Howard Hughes Med Inst, Dept Genet, New Haven, CT 06536 USA; Boyer Ctr Mol Med, Dept Genet, New Haven, CT 06536 USA; Yale Univ, Dept Genet, Sch Med, New Haven, CT 06536 USA	Howard Hughes Medical Institute; Yale University	Xu, T (corresponding author), Howard Hughes Med Inst, Dept Genet, 295 Congress Ave,POB 9812, New Haven, CT 06536 USA.		Stewart, Rodney/ABA-6757-2020	Stewart, Rodney/0000-0003-1220-1830	NATIONAL CANCER INSTITUTE [R01CA069408] Funding Source: NIH RePORTER; NCI NIH HHS [CA69408] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; BOUGERET C, 1993, ONCOGENE, V8, P1241; Bougeret C, 2001, J BIOL CHEM, V276, P33711, DOI 10.1074/jbc.M104209200; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Cam WR, 2001, CANCER, V92, P61, DOI 10.1002/1097-0142(20010701)92:1<61::AID-CNCR1292>3.0.CO;2-D; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Cooper JA, 1996, CELL GROWTH DIFFER, V7, P1435; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dodson GS, 1998, DEVELOPMENT, V125, P2883; Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Guarnieri DJ, 1998, MOL CELL, V1, P831, DOI 10.1016/S1097-2765(00)80082-9; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HAY BA, 1994, DEVELOPMENT, V120, P2121; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; Huang H, 1999, DEVELOPMENT, V126, P5365; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Li G, 2002, DEVELOPMENT, V129, P4159; Lowry WE, 2002, DEV CELL, V2, P733, DOI 10.1016/S1534-5807(02)00175-2; Lu XY, 1999, DEV BIOL, V208, P233, DOI 10.1006/dbio.1999.9196; Masaki T, 1999, HEPATOLOGY, V29, P379, DOI 10.1002/hep.510290239; McCartney BM, 2000, DEVELOPMENT, V127, P1315; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; OKADA M, 1991, J BIOL CHEM, V266, P24249; Oldham S, 2000, PHILOS T R SOC B, V355, P945, DOI 10.1098/rstb.2000.0630; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; Rubin GM, 1997, COLD SPRING HARB SYM, V62, P347; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Ruzzene M, 1997, EUR J BIOCHEM, V246, P433, DOI 10.1111/j.1432-1033.1997.t01-1-00433.x; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; Spradling AC, 1999, GENETICS, V153, P135; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Stamenovic D, 1999, J THEOR BIOL, V201, P63, DOI 10.1006/jtbi.1999.1014; Takahashi F, 1996, GENE DEV, V10, P1645, DOI 10.1101/gad.10.13.1645; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Theodosiou NA, 1998, DEVELOPMENT, V125, P3411; Thomas BI, 1999, TRENDS GENET, V15, P184, DOI 10.1016/S0168-9525(99)01720-5; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; Treisman JE, 1998, CURR TOP DEV BIOL, V39, P119, DOI 10.1016/S0070-2153(08)60454-8; Tremblay L, 1996, INT J CANCER, V68, P164, DOI 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W; Wolff Tanya, 1993, P1277; Xia H, 2002, ONCOGENE, V21, P1233, DOI 10.1038/sj.onc.1205174; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; XU TA, 1995, DEVELOPMENT, V121, P1053; Yang XL, 2001, ONCOGENE, V20, P6516, DOI 10.1038/sj.onc.1204817; Zavitz KH, 1997, CURR OPIN CELL BIOL, V9, P773, DOI 10.1016/S0955-0674(97)80077-4; Zrihan-Licht S, 1998, J BIOL CHEM, V273, P4065, DOI 10.1074/jbc.273.7.4065	68	38	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2003	22	41					6436	6444		10.1038/sj.onc.1206820	http://dx.doi.org/10.1038/sj.onc.1206820			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508523				2022-12-17	WOS:000185535300013
J	Matsuzawa-Watanabe, Y; Inoue, J; Semba, K				Matsuzawa-Watanabe, Y; Inoue, J; Semba, K			Transcriptional activity of testis-determining factor SRY is modulated by the Wilms' tumor 1 gene product, WT1	ONCOGENE			English	Article						tumor-suppressor gene; transcription factor; gonad; sex determination	SEX-DETERMINING REGION; DNA-BINDING; SUPPRESSOR GENE; EXPRESSION; PROTEIN; CHROMOSOME; VARIANTS; SEQUENCE; SOX9	The Wilms' tumor 1 (WT1) and sex-determining region of the Y chromosome (SRY) genes are essential for development of the mammalian gonads and mutations in these genes are associated with gonadal dysgenesis in humans. The SRY gene encodes a transcription factor with one high-mobility group (HMG) box as a DNA-binding domain. WT1 encodes a transcription factor that contains four contiguous C2H2-type zinc-finger motifs as a DNA/RNA binding or protein-protein interaction domain. Here we report that WT1 binds to and acts synergistically with SRY to activate transcription from a promoter containing SRY-binding sites. This interaction is mediated by the WT1 zinc-finger domain and the SRY HMG box. WT1 mutants associated with Denys-Drash syndrome (DDS), which is characterized by Wilms' tumor, pseudohermaphroditism, and nephropathy, fail to interact with SRY. Wildtype WT1 is recruited to SRY-binding sites in an SRY-dependent manner, whereas DDS mutants are not recruited as efficiently. These results suggest that WT1 forms a complex with SRY to regulate transcription and that this WT1-SRY interaction is important in testis development.	Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Semba, K (corresponding author), Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	ksemba@ims.u-tokyo.ac.jp						ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DUBIN RA, 1994, MOL ENDOCRINOL, V8, P1182, DOI 10.1210/me.8.9.1182; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HACKER A, 1995, DEVELOPMENT, V121, P1603; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; Hanley NA, 2000, MECH DEVELOP, V91, P403, DOI 10.1016/S0925-4773(99)00307-X; Hanley NA, 1999, MECH DEVELOP, V87, P175, DOI 10.1016/S0925-4773(99)00123-9; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; Hossain A, 2001, J BIOL CHEM, V276, P16817, DOI 10.1074/jbc.M009056200; KENT J, 1995, ONCOGENE, V11, P1781; Kim J, 1999, MOL CELL BIOL, V19, P2289; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; Koopman P, 1999, CELL MOL LIFE SCI, V55, P839; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; McElreavey K, 1999, AM J MED GENET, V89, P176, DOI 10.1002/(SICI)1096-8628(19991229)89:4<176::AID-AJMG2>3.0.CO;2-B; Moore AW, 1999, DEVELOPMENT, V126, P1845; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; Osaki E, 1999, NUCLEIC ACIDS RES, V27, P2503, DOI 10.1093/nar/27.12.2503; Patek CE, 1999, P NATL ACAD SCI USA, V96, P2931, DOI 10.1073/pnas.96.6.2931; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Sakamoto Y, 1997, ONCOGENE, V15, P2001, DOI 10.1038/sj.onc.1201391; Scharnhorst V, 2001, GENE, V273, P141, DOI 10.1016/S0378-1119(01)00593-5; Semba K, 1996, GENE, V175, P167, DOI 10.1016/0378-1119(96)00143-6; Shimamura R, 1997, CLIN CANCER RES, V3, P2571; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Wagner KD, 2002, FASEB J, V16, P1117, DOI 10.1096/fj.01-0986fje; Wagner KD, 2002, EMBO J, V21, P1398, DOI 10.1093/emboj/21.6.1398	38	38	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					7900	7904		10.1038/sj.onc.1206717	http://dx.doi.org/10.1038/sj.onc.1206717			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970737				2022-12-17	WOS:000185388200004
J	Nishizawa, M; Kataoka, K; Vogt, PK				Nishizawa, M; Kataoka, K; Vogt, PK			MafA has strong cell transforming ability but is a weak transactivator	ONCOGENE			English	Article						oncogenic transformation; transcriptional; activation; regulatable construct	BZIP TRANSCRIPTION FACTOR; FACTOR C-MAF; V-MAF; ESTROGEN-RECEPTOR; FACTOR NF-E2; GENE; JUN; ONCOGENE; DIFFERENTIATION; FAMILY	The maf oncogene of the avian oncogenic retrovirus AS42 encodes a nuclear bZip protein, v-Maf, that recognizes sequences related to the AP-1 target site. The corresponding cellular protein, c-Maf belongs to a family of related bZip proteins together with MafA and MafB. In this paper, we compare the transactivation and cell transforming abilities of MafA and MafB along with two forms of the c-Maf protein. These proteins induce cellular transformation when expressed in chicken embryo fibroblasts. In reporter assays, MafA is a much less effective transactivator than the other Maf proteins, but unexpectedly shows the strongest activity in cell transformation. Chimeras of MafA and MOB correlate the strong cell transforming ability of MafA with its DNA-binding domain. The DNA-binding domain of MafA is also correlated with weak transactivation. Additional mutagenesis experiments show that transactivation and transformation by MafA are also controlled by phosphorylation of two conserved serine residues in the transactivation domain. Finally, we constructed MafA-estrogen receptor fusion molecules that show tightly hormone-dependent cell transforming ability. These regulatable constructs permit a kinetic characterization of target gene responses and facilitate discrimination between direct and indirect targets.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Tokyo Inst Technol, Frontier Collaborat Res Ctr, Midori Ku, Yokohama, Kanagawa 2268503, Japan	Scripps Research Institute; Tokyo Institute of Technology	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, BCC239,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NCI NIH HHS [CA78230, CA42564, CA79616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564, R01CA079616, R01CA078230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Benkhelifa S, 1998, ONCOGENE, V17, P247, DOI 10.1038/sj.onc.1201898; Benkhelifa S, 2001, MOL CELL BIOL, V21, P4441, DOI 10.1128/MCB.21.14.4441-4452.2001; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; Hanamura I, 2001, JPN J CANCER RES, V92, P638, DOI 10.1111/j.1349-7006.2001.tb01142.x; Ho IC, 2002, CELL, V109, pS109, DOI 10.1016/S0092-8674(02)00705-5; Ho IC, 1998, J EXP MED, V188, P1859, DOI 10.1084/jem.188.10.1859; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kataoka K, 2001, J BIOL CHEM, V276, P36849, DOI 10.1074/jbc.M102234200; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KAWAI S, 1992, VIROLOGY, V188, P778, DOI 10.1016/0042-6822(92)90532-T; Kawauchi S, 1999, J BIOL CHEM, V274, P19254, DOI 10.1074/jbc.274.27.19254; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kim JI, 1999, P NATL ACAD SCI USA, V96, P3781, DOI 10.1073/pnas.96.7.3781; Kim JI, 1999, IMMUNITY, V10, P745, DOI 10.1016/S1074-7613(00)80073-4; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; NISHIZAWA M, 2003, IN PRESS ONCOGENE; Ogino H, 1998, SCIENCE, V280, P115, DOI 10.1126/science.280.5360.115; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; Ring BZ, 2000, DEVELOPMENT, V127, P307; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Sharon-Friling R, 1998, MOL CELL BIOL, V18, P2067, DOI 10.1128/MCB.18.4.2067; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198	38	38	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7882	7890		10.1038/sj.onc.1206526	http://dx.doi.org/10.1038/sj.onc.1206526			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970735				2022-12-17	WOS:000185388200002
J	Kain, KH; Gooch, S; Klemke, RL				Kain, KH; Gooch, S; Klemke, RL			Cytoplasmic c-Abl provides a molecular 'rheostat' controlling carcinoma cell survival and invasion	ONCOGENE			English	Article						c-Abl kinase; Crk; invasion; survival; metastasis	FOCAL ADHESION KINASE; PROTEIN-TYROSINE KINASE; EPIDERMAL-GROWTH-FACTOR; ADAPTER PROTEIN; DNA-DAMAGE; APOPTOTIC RESPONSE; INDUCED ACTIVATION; FACTOR RECEPTOR; F-ACTIN; IN-VIVO	Tumor cell metastasis involves the coordinated activation of migration and survival mechanisms necessary for cell invasion of foreign tissues. Here, we report that cytoplasmic c-Abl tyrosine kinase determines whether a cell invades the ECM or commits suicide. c-Abl phosphorylates the cytoskeleton-associated adaptor protein, Crk, at tyrosine 221, causing disassociation of Crk from the Crk-associated substrate (CAS) and disassembly of Crk/CAS complexes. c-Abl-induced disruption of Crk/CAS complexes inhibits cell migration and promotes apoptosis in normal cells, and is deregulated in highly invasive carcinoma cells. c-Abl-mediated disassembly of Crk/CAS complexes and induction of death occur via disruption of the cytoskeleton, which is distinct from nuclear c-Abl-induced apoptosis in response to DNA-damaging agents. Inhibition of c-Abl kinase activity or Crk binding to Abl's polyproline region prevents Crk phosphorylation and apoptosis, leading to increased cell survival and invasion of the extracellular matrix. Together, these data illustrate that c-Abl prevents aberrant motility and survival through Crk 221 phosphorylation and modulation of Crk/CAS complexes, and that deregulation of this pathway contributes to cell metastasis.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Klemke, RL (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd,SP 231, La Jolla, CA 92037 USA.	klemke@scripps.edu			NATIONAL CANCER INSTITUTE [R29CA078493, R01CA097022] Funding Source: NIH RePORTER; NCI NIH HHS [CA97022, CA78493] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Echarri A, 2001, CURR BIOL, V11, P1759, DOI 10.1016/S0960-9822(01)00538-3; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; Fan PD, 2000, MOL CELL BIOL, V20, P7591, DOI 10.1128/MCB.20.20.7591-7601.2000; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Gong JG, 1999, NATURE, V399, P806; Hashimoto Y, 1998, J BIOL CHEM, V273, P17186, DOI 10.1074/jbc.273.27.17186; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Ito Y, 2001, MOL CELL BIOL, V21, P6233, DOI 10.1128/MCB.21.18.6233-6242.2001; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; MATSUDA M, 1993, J BIOL CHEM, V268, P4441; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Mills JC, 1999, J CELL BIOL, V146, P703, DOI 10.1083/jcb.146.4.703; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Smith JJ, 2002, MOL CELL BIOL, V22, P1412, DOI 10.1128/MCB.22.5.1412-1423.2002; Smith JM, 2002, FRONT BIOSCI, V7, pD31; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Ting AY, 2001, P NATL ACAD SCI USA, V98, P15003, DOI 10.1073/pnas.211564598; Tosello-Trampont AC, 2001, J BIOL CHEM, V276, P13797, DOI 10.1074/jbc.M011238200; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Wang BL, 1996, ONCOGENE, V13, P1379; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Woodring PJ, 2002, J CELL BIOL, V156, P879, DOI 10.1083/jcb.200110014; Woodring PJ, 2001, J BIOL CHEM, V276, P27104, DOI 10.1074/jbc.M100559200; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	52	38	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6071	6080		10.1038/sj.onc.1206930	http://dx.doi.org/10.1038/sj.onc.1206930			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955086				2022-12-17	WOS:000185137800016
J	Ng, CC; Arakawa, H; Fukuda, S; Kondoh, H; Nakamura, Y				Ng, CC; Arakawa, H; Fukuda, S; Kondoh, H; Nakamura, Y			p53RFP, a p53-inducible RING-finger protein, regulates the stability of p21(WAF1)	ONCOGENE			English	Article						p53RFP; p53-inducible gene; IBR domain	CYCLIN-DEPENDENT KINASES; P53-DEPENDENT APOPTOSIS; UBIQUITIN LIGASE; BINDING-SITE; HUMAN CANCER; PROTEASOME; DEGRADATION; GENES; PATHWAY; P21	The mechanisms by which p53 prevents development of cancer are much more complicated than previously thought. Under normal conditions, p53 is involved in cell-cycle arrest, apoptosis, DNA repair, and inhibition of angiogenesis; it also promotes degradation of proteins through transcriptional regulation of certain target genes. Here we report the isolation of a novel transcriptional target of p53, designated p53RFP (p53-inducible RING-finger protein), whose product has E3 ubiquitin ligase activity. Its expression was negatively correlated to that of p21(WAF1) protein; p53RFP is likely to play a role in the regulation of this protein, probably through interaction with, and ubiquitination of, p21(WAF1). p53RFP appears to represent the second known example, the first being MDM2, of an E3 ubiquitin ligase as a p53 target. Our results further suggest that p53 might regulate the stability of p21(WAF1) through transcriptional regulation of p53RFP, and this feature may represent a novel mechanism for a p53-dependent cell-cycle checkpoint.	Univ Tokyo, Mol Med Lab, Ctr Human Genet, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan	University of Tokyo; Osaka University	Nakamura, Y (corresponding author), Univ Tokyo, Mol Med Lab, Ctr Human Genet, Inst Med Sci,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	NG, CHING CHING/B-9221-2010; Arakawa, Hirofumi/L-3459-2013	Arakawa, Hirofumi/0000-0001-6077-0638				Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fukuchi K, 1999, BBA-MOL CELL RES, V1451, P206, DOI 10.1016/S0167-4889(99)00081-6; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Marin I, 2002, MOL BIOL EVOL, V19, P2039, DOI 10.1093/oxfordjournals.molbev.a004029; Matsuda N, 2001, J CELL SCI, V114, P1949; Mimnaugh EG, 1999, ELECTROPHORESIS, V20, P418, DOI 10.1002/(SICI)1522-2683(19990201)20:2<418::AID-ELPS418>3.0.CO;2-N; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Rousseau D, 1999, ONCOGENE, V18, P4313, DOI 10.1038/sj.onc.1202686; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zhao RB, 2000, GENE DEV, V14, P981	27	38	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4449	4458		10.1038/sj.onc.1206586	http://dx.doi.org/10.1038/sj.onc.1206586			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853982				2022-12-17	WOS:000183978900015
J	Matteucci, E; Modora, S; Simone, M; Desiderio, MA				Matteucci, E; Modora, S; Simone, M; Desiderio, MA			Hepatocyte growth factor induces apoptosis through the extrinsic pathway in hepatoma cells: favouring role of hypoxia-inducible factor-1 deficiency	ONCOGENE			English	Article						hepatocyte growth factor; apoptosis; hypoxia-inducible factor-1; ornithine decarboxylase; caspases	ORNITHINE-DECARBOXYLASE; TRANSDUCTION PATHWAYS; FACTOR PROTECTS; HEPG2 HEPATOMA; FACTOR 1-ALPHA; CYTOCHROME-C; RECEPTOR; DEATH; INVOLVEMENT; SURVIVAL	Two hepatocarcinoma cell lines, the Hepa-1 wild-type (c1c7) and the beta-subunit mutated (c4) lacking hypoxia-inducible factor-1 (HIF-1) activity, were differentially susceptible to apoptosis by hepatocyte growth factor (HGF). The c4 cells were 40% apoptotic 48 h after HGF treatment. On the contrary, the wild-type c1c7 cells showed modest signs of apoptosis only at 72 h. The revertant vT{2} cells, consisting of c4 cells stably transfected with HIF-1b expression vector, behaved as the parental cells. To understand the mechanisms of this different sensitivity, we examined a panel of genes involved in apoptosis: ornithine decarboxylase, c-Myc and p53 protein levels progressively decreased while JNK1, caspase 8 and 3 activities persistently increased in c4 cells undergoing apoptosis. Distinct time-related events in c1c7 cells were the transient activations of JNK1 and caspase 8 followed by the accumulation of ODC and c-Myc proteins. The proapoptotic effect of HGF in c4 hepatocarcinoma cells seems to be related to HIF-1 deficiency with loss of cytoprotective and signalling functions. This may contribute to the triggering of the extrinsic pathway consisting in caspase 8 activation, which in turn causes BID cleavage and cytochrome c release. The effector caspase 3 is also activated.	Univ Milan, Sch Med, Inst Gen Pathol, I-20133 Milan, Italy; Mario Negri Inst Pharmacol Res, Dept Oncol, Flow Cytometry Unit, I-20157 Milan, Italy	University of Milan; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Desiderio, MA (corresponding author), Univ Milan, Sch Med, Inst Gen Pathol, Via L Mangiagalli 31, I-20133 Milan, Italy.	a.desiderio@unimi.it	Desiderio, Maria Alfonsina/M-8870-2016	Desiderio, Maria Alfonsina/0000-0002-9894-9462				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Akakura N, 2001, CANCER RES, V61, P6548; Alfranca A, 2002, MOL CELL BIOL, V22, P12, DOI 10.1128/MCB.22.1.12-22.2002; Arakaki N, 1999, J BIOL CHEM, V274, P13541, DOI 10.1074/jbc.274.19.13541; Baek JH, 2000, ONCOGENE, V19, P4621, DOI 10.1038/sj.onc.1203814; Bendinelli P, 1996, FEBS LETT, V398, P193, DOI 10.1016/S0014-5793(96)01228-8; Bowers DC, 2000, CANCER RES, V60, P4277; Chen CY, 2001, CELL GROWTH DIFFER, V12, P297; Conner EA, 1997, BIOCHEM BIOPH RES CO, V236, P396, DOI 10.1006/bbrc.1997.6938; DESIDERIO MA, 1995, CELL GROWTH DIFFER, V6, P505; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; Grassilli E, 1998, BIOCHEM BIOPH RES CO, V250, P293, DOI 10.1006/bbrc.1998.9291; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Katoh O, 1998, CANCER RES, V58, P5565; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; Maggiora P, 1997, J CELL PHYSIOL, V173, P183, DOI 10.1002/(SICI)1097-4652(199711)173:2<183::AID-JCP18>3.3.CO;2-Y; Mar PK, 1995, MOL CARCINOGEN, V14, P240, DOI 10.1002/mc.2940140404; Matteucci E, 2001, J CELL PHYSIOL, V186, P387, DOI 10.1002/1097-4652(2000)9999:9999<000::AID-JCP1033>3.0.CO;2-8; Minet E, 2001, FREE RADICAL BIO MED, V31, P847, DOI 10.1016/S0891-5849(01)00657-8; Murakami Y, 2000, BIOCHEM BIOPH RES CO, V267, P1, DOI 10.1006/bbrc.1999.1706; Noguchi K, 2001, BIOCHEM BIOPH RES CO, V281, P1313, DOI 10.1006/bbrc.2001.4498; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt T, 1999, CELL DEATH DIFFER, V6, P873, DOI 10.1038/sj.cdd.4400562; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Semenza GL, 2000, GENE DEV, V14, P1983; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Suzuki H, 2001, ONCOGENE, V20, P5779, DOI 10.1038/sj.onc.1204742; Tacchini L, 2000, EXP CELL RES, V256, P272, DOI 10.1006/excr.2000.4824; Tacchini L, 2001, CARCINOGENESIS, V22, P1363, DOI 10.1093/carcin/22.9.1363; Thomas T, 2001, CELL MOL LIFE SCI, V58, P244, DOI 10.1007/PL00000852; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; Williams KJ, 2002, ONCOGENE, V21, P282, DOI 10.1038/sj.onc.1205047; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	46	38	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2003	22	26					4062	4073		10.1038/sj.onc.1206519	http://dx.doi.org/10.1038/sj.onc.1206519			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821940				2022-12-17	WOS:000183707600009
J	Perucho, M				Perucho, M			Tumors with microsatellite instability: many mutations, targets and paradoxes	ONCOGENE			English	Editorial Material							SHORT MONONUCLEOTIDE REPEATS; MISMATCH REPAIR; MUTATOR PHENOTYPE; GASTROINTESTINAL CANCER; FRAMESHIFT MUTATIONS; SOMATIC MUTATIONS; COLORECTAL-CANCER; COLON-CANCER; GENE; SEQUENCES		Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Perucho, M (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, 11099 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Perucho, Manuel/0000-0002-2169-2662				Duval A, 2002, CANCER RES, V62, P1609; Duval A, 2002, ONCOGENE, V21, P8062, DOI 10.1038/sj.onc.1206013; Duval A, 2002, CANCER RES, V62, P2447; Gil J, 1999, CANCER RES, V59, P2034; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KIM HG, 1994, AM J PATHOL, V145, P148; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Perucho M, 1999, CANCER RES, V59, P249; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Souza RF, 1999, ONCOGENE, V18, P4063, DOI 10.1038/sj.onc.1202768; Suzuki K, 2002, CANCER RES, V62, P1961; WOERNER SM, IN PRESS ONCOGENE; Yamamoto H, 2000, CELL DEATH DIFFER, V7, P238, DOI 10.1038/sj.cdd.4400651; Yamamoto H, 1997, CANCER RES, V57, P4420; Zhang L, 2001, CANCER RES, V61, P3801	18	38	42	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 17	2003	22	15					2223	2225		10.1038/sj.onc.1206580	http://dx.doi.org/10.1038/sj.onc.1206580			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700658	Bronze			2022-12-17	WOS:000182231500001
J	Wang, B; Wei, DY; Crum, VE; Richardson, EL; Xiong, HH; Luo, Y; Huang, S; Abbruzzese, JL; Xie, KP				Wang, B; Wei, DY; Crum, VE; Richardson, EL; Xiong, HH; Luo, Y; Huang, S; Abbruzzese, JL; Xie, KP			A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis	ONCOGENE			English	Article						nitric oxide; angiogenesis; metastasis; tumor; pancreas	SYNTHASE-II GENE; EXPRESSION; CELLS; ADENOCARCINOMA; ANGIOGENESIS; APOPTOSIS; DISRUPTION; BIOLOGY; ABILITY; MICE	In the present study, a model system for studying the role of nitric oxide (NO) in tumor growth and metastasis was reported. Incubation of Panc02 murine pancreatic adenocarcinoma cells in vitro with cytokines and interferon led to heterogeneous expression of NO synthase 11 (NOS 11) protein. Clonal sublines expressing different levels of NOS 11 were then established using a limited dilution technique. After orthotopical implantation into the pancreas of syngeneic C57BL/6 mice, clones with a low level of NOS 11 expression produced tumors in pancreas, metastasized to the liver, and formed ascites, whereas those having a high level of NOS 11 expression did not. Liver-metastasis variants having low to high metastatic ability were also established using in vivo/in vitro passage. Compared with parental Panc02 cells exhibiting a high level of NOS 11 expression, these variants had a decreased level of NOS 11 expression. Furthermore, the heterogeneous Panc02 cells were injected intravenously into a large number of syngeneic mice. Variants that metastasized to the liver, lung, skin, peritoneum, ovary, and lymph nodes were established. All of the metastatic variants exhibited a lower level of NOS 11 expression than the parental Panc02 cell line did. However, the phenotypes of NOS 11 induction and metastatic ability were unstable. Multiple in vitrolin vivo selection led to stable low NOS 11 expression and high metastatic potential. Finally, to further confirm the role of NOS 11 expression derived from tumor cells in metastasis, poorly metastatic Panc02-H0 and highly metastatic Panc02-H7 cells were injected into the pancreas of syngeneic NOS II-/- mice, and groups of mice received i.p. injections of either phosphate-buffered saline or L-N-6-(I-iminoethyl) lysine. Inhibition of NOS 11 activity in vivo significantly promoted distant liver metastasis. Collectively, these data show that NOS 11 expression is highly heterogeneous and dynamically regulated, which can directly influence tumor growth and metastasis.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Xie, KP (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Box 426,1515 Holcombe Blvd, Houston, TX 77030 USA.	kepxie@mail.mdanderson.org			NCI NIH HHS [1R01-CA093829] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093829] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambs S, 1998, NAT MED, V4, P1371, DOI 10.1038/3957; Ambs S, 1997, FASEB J, V11, P443, DOI 10.1096/fasebj.11.6.9194524; Ambs S, 1998, CANCER RES, V58, P334; COBBS CS, 1995, CANCER RES, V55, P727; CORBETT TH, 1984, CANCER RES, V44, P717; DiNapoli MR, 1996, J EXP MED, V183, P1323, DOI 10.1084/jem.183.4.1323; DONG ZY, 1994, CANCER RES, V54, P789; FIDLER IJ, 1987, CURR PROB SURG, V24, P137, DOI 10.1016/0011-3840(87)90002-5; Fukumura D, 1998, CANCER METAST REV, V17, P77, DOI 10.1023/A:1005908805527; Gansauge S, 1998, CELL GROWTH DIFFER, V9, P611; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; JUANG SH, 1998, CANCER BIOTHERAPY, V12, P167; Jurasz P, 2001, CANCER RES, V61, P376; Kong G, 2001, INT J PANCREATOL, V29, P133, DOI 10.1385/IJGC:29:3:133; Lala PK, 2001, LANCET ONCOL, V2, P149, DOI 10.1016/S1470-2045(00)00256-4; Lala PK, 1998, CANCER METAST REV, V17, P91, DOI 10.1023/A:1005960822365; Martinez A, 2001, Med Sci Monit, V7, P646; Moncada S, 1999, J ROY SOC MED, V92, P164, DOI 10.1177/014107689909200402; Moochhala S, 1996, CARCINOGENESIS, V17, P1171, DOI 10.1093/carcin/17.5.1171; MOORE WM, 1994, J MED CHEM, V37, P3886, DOI 10.1021/jm00049a007; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Nussler AK, 1998, LANGENBECK ARCH SURG, V383, P474, DOI 10.1007/s004230050163; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RADOMSKI MW, 1991, CANCER RES, V51, P6073; Shi Q, 2000, CANCER RES, V60, P2579; Shi Q, 1999, CANCER RES, V59, P2072; THOMSEN LL, 1994, BRIT J CANCER, V72, P41; Wang BL, 2001, INT J PANCREATOL, V29, P37, DOI 10.1385/IJGC:29:1:37; Wang BL, 2001, ONCOGENE, V20, P6930, DOI 10.1038/sj.onc.1204871; Wang BL, 2001, INT J CANCER, V91, P607, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1109>3.0.CO;2-D; Wang BL, 2001, CANCER RES, V61, P71; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; XIE K, 2003, IN PRESS FREE RAD BI; XIE K, 1997, CLIN CANCER RES, V3, P2189; Xie KP, 1997, J NATL CANCER I, V89, P421, DOI 10.1093/jnci/89.6.421; XIE KP, 1995, CANCER RES, V55, P3123; Xie KP, 1997, ONCOGENE, V15, P771, DOI 10.1038/sj.onc.1201239; Xie KP, 2001, INT J PANCREATOL, V29, P25, DOI 10.1385/IJGC:29:1:25; XIE KP, 1993, INT J ONCOL, V3, P1043; Xie KP, 1998, CANCER METAST REV, V17, P55, DOI 10.1023/A:1005956721457; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333	43	38	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1771	1782		10.1038/sj.onc.1206386	http://dx.doi.org/10.1038/sj.onc.1206386			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660813				2022-12-17	WOS:000181678200004
J	Castellone, MD; Cirafici, AM; De Vita, G; De Falco, V; Malorni, L; Tallini, G; Fagin, JA; Fusco, A; Melillo, RM; Santoro, M				Castellone, MD; Cirafici, AM; De Vita, G; De Falco, V; Malorni, L; Tallini, G; Fagin, JA; Fusco, A; Melillo, RM; Santoro, M			Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes	ONCOGENE			English	Article						kinase; carcinoma; survival; ras; tyrosine; thyroid; oncogene; TUNEL	EPIDERMAL GROWTH-FACTOR; PAPILLARY CARCINOMAS; RET PROTOONCOGENE; PATHWAY; REARRANGEMENTS; PROLIFERATION; ONCOPROTEIN; ACTIVATION; RECEPTOR; KINASES	RET gene rearrangements, which generate chimeric RET/ PTC oncogenes, are early events in the evolution of thyroid papillary carcinomas. Expression of RET/PTC oncogenes promotes neoplastic transformation of cultured thyroid cells and of thyroid glands in transgenic mice. Notwithstanding these oncogenic effects, we have found that the expression of two RET/PTC oncogenes (H4-RET and RFG-RET) induces apoptosis of rat thyroid PC CL 3 cells. Promotion of thyroid cell death depends on the kinase activity of RET/PTC and on the phosphorylation of a tyrosine residue (tyrosine 1062) that maps in the carboxy-terminus of the RET protein. Tyrosine 1062 is essential for RET/PTC-mediated activation of the Ras/ ERK pathway. Inhibition of Ras/ERK by a dominant negative Ras or by the MEKI inhibitor, PD98059, obstructed RET/PTC-mediated apoptosis. We also show that signals transmitted by tyrosine 1062 mediate proapoptotic events like Bcl-2 down regulation and Bax upregulation, and that adoptive overexpression of Bcl-2 overcomes RET/PTC-induced apoptosis. Thus, gene rearrangements that generate RET/PTC oncogenes subvert RET function by converting it into a chronically active kinase that is constitutively phosphorylated on tyrosine 1062. In turn, Y1062 phosphorylation transmits not only mitogenic but also proapoptotic signals to thyroid cells.	Univ Naples Federico II, Ist Endocrinol & Oncol Sperimentale, CNR, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Yale Univ, Dept Pathol, New Haven, CT 06520 USA; Univ Cincinnati, Coll Med, Div Endocrinol, Cincinnati, OH 45267 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; Yale University; University System of Ohio; University of Cincinnati	Santoro, M (corresponding author), Univ Naples Federico II, Ist Endocrinol & Oncol Sperimentale, CNR, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.		melillo, rosa marina/O-5255-2015; DE FALCO, VALENTINA/C-2061-2015; Malorni, Luca/J-1973-2019; De Vita, Gabriella/H-4422-2011; Tallini, Giovanni/F-7850-2013	DE FALCO, VALENTINA/0000-0002-8972-7921; Malorni, Luca/0000-0002-4297-2997; De Vita, Gabriella/0000-0002-7302-1174; Tallini, Giovanni/0000-0003-0113-6682; MELILLO, Rosa Marina/0000-0002-9233-5275; Fusco, Alfredo/0000-0003-3332-5197; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037				Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Cheng GJ, 2001, ONCOGENE, V20, P7334, DOI 10.1038/sj.onc.1204928; Corvi R, 2001, LAB INVEST, V81, P1639, DOI 10.1038/labinvest.3780377; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DREMIER S, 1994, ENDOCRINOLOGY, V135, P135, DOI 10.1210/en.135.1.135; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gimm O, 2001, CANCER LETT, V163, P143, DOI 10.1016/S0304-3835(00)00697-2; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; LAMY F, 1993, J BIOL CHEM, V268, P8398; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Mercalli E, 2001, ONCOGENE, V20, P3475, DOI 10.1038/sj.onc.1204462; Monaco C, 2001, ONCOGENE, V20, P599, DOI 10.1038/sj.onc.1204127; Pierotti MA, 2001, CANCER LETT, V166, P1, DOI 10.1016/S0304-3835(01)00439-6; ROGER PP, 1982, FEBS LETT, V144, P209, DOI 10.1016/0014-5793(82)80639-X; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1994, ONCOGENE, V9, P509; Shirokawa JM, 2000, MOL ENDOCRINOL, V14, P1725, DOI 10.1210/me.14.11.1725; Sugg SL, 1998, J CLIN ENDOCR METAB, V83, P4116, DOI 10.1210/jc.83.11.4116; Tong Q, 1997, J BIOL CHEM, V272, P9043; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	30	38	38	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					246	255		10.1038/sj.onc.1206112	http://dx.doi.org/10.1038/sj.onc.1206112			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527893				2022-12-17	WOS:000180322400009
J	Delhommeau, FO; Thierry, A; Feneux, D; Lauret, E; Leclercq, E; Courtier, MH; Sainteny, F; Vainchenker, W; Bennaceur-Griscelli, A				Delhommeau, FO; Thierry, A; Feneux, D; Lauret, E; Leclercq, E; Courtier, MH; Sainteny, F; Vainchenker, W; Bennaceur-Griscelli, A			Telomere dysfunction and telomerase reactivation in human leukemia cell lines after telomerase inhibition by the expression of a dominant-negative hTERT mutant	ONCOGENE			English	Article						telomere; telomerase; leukemia; retrovirus; cell death; therapy	REVERSE-TRANSCRIPTASE GENE; HUMAN TUMOR-CELLS; IONIZING-RADIATION; CATALYTIC SUBUNIT; HUMAN-CHROMOSOMES; TTAGGG REPEATS; LIFE-SPAN; LENGTH; APOPTOSIS; ENDS	As activation of telomerase represents a key step in the malignant transformation process, experimental models to develop anti-telomerase drugs provide a rational basis for anticancer strategies. We analysed the short and longterm efficacy of a stably expressed dominant-negative mutant (DN) of the telomerase catalytic unit (hTERT) in UT-7 and U937 human leukemia cell lines by using an IRES-e-GFP retrovirus. As expected, telomerase inactivation resulted in drastic telomere shortening, cytogenetic instability and cell growth inhibition in all e-GFP positive DN clones after 15-35 days of culture. However, despite this initial response, 50% of e-GFP positive DN clones with short telomeres escaped from crisis after 35 days of culture and recovered a proliferation rate similar to the control cells. This rescue was associated with a telomerase reactivation inducing telomere lengthening. We identified two pathways, one involving the loss of the DN transgene expression and the other the transcriptional up-regulation of endogenous hTERT with persistence of the DN transgene expression. Although this second mechanism appears to be a very rare event (one clone), these findings suggest that genomic instability induced by short telomeres after telomerase inhibition might enhance the probability of activation or selection of telomere maintenance mechanisms dependent on hTERT transcription.	Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France; Hop Bicetre, Serv Hematol & Cytogenet, F-94270 Le Kremlin Bicetre, France; Inst Gustave Roussy, Dept Clin Biol, Serv Hematol Biol, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Bennaceur-Griscelli, A (corresponding author), Inst Gustave Roussy, INSERM, U362, PR-1,39-53 Rue Camille Desmoulins, F-94805 Villejuif, France.	abenna@igr.fr	LAURET, Evelyne/P-4929-2017	LAURET, Evelyne/0000-0003-4643-6857; bennaceur griscelli, annelise/0000-0002-3557-4499; Vainchenker, William/0000-0003-4705-202X; Delhommeau, Francois/0000-0002-4915-0734				Arai K, 2002, J BIOL CHEM, V277, P8538, DOI 10.1074/jbc.M111068200; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Bryce LA, 2000, NEOPLASIA, V2, P197, DOI 10.1038/sj.neo.7900092; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; di Fagagna FD, 1999, NAT GENET, V23, P76; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Goytisolo FA, 2000, J EXP MED, V192, P1625, DOI 10.1084/jem.192.11.1625; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Hou M, 2001, CLIN CHEM, V47, P519; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; KOMATSU N, 1991, CANCER RES, V51, P341; Kondo Y, 1998, ONCOGENE, V16, P2243, DOI 10.1038/sj.onc.1201754; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Lee KH, 2001, P NATL ACAD SCI USA, V98, P3381, DOI 10.1073/pnas.051629198; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Morin GB, 1997, EXP GERONTOL, V32, P375, DOI 10.1016/S0531-5565(96)00164-7; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Pendino F, 2002, LEUKEMIA, V16, P826, DOI 10.1038/sj.leu.2402470; Pendino F, 2001, P NATL ACAD SCI USA, V98, P6662, DOI 10.1073/pnas.111464998; Raymond E, 1996, CURR OPIN BIOTECH, V7, P583, DOI 10.1016/S0958-1669(96)80068-1; Riou JF, 2002, P NATL ACAD SCI USA, V99, P2672, DOI 10.1073/pnas.052698099; Sachsinger J, 2001, CANCER RES, V61, P5580; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wright WE, 1996, DEV GENET, V18, P173; Zhang AJ, 2000, CANCER RES, V60, P6230; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	51	38	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2002	21	54					8262	8271		10.1038/sj.onc.1206054	http://dx.doi.org/10.1038/sj.onc.1206054			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447689				2022-12-17	WOS:000179323900004
J	Saez, C; Pereda, T; Borrero, JJ; Espina, A; Romero, F; Tortolero, M; Pintor-Toro, JA; Segura, DI; Japon, MA				Saez, C; Pereda, T; Borrero, JJ; Espina, A; Romero, F; Tortolero, M; Pintor-Toro, JA; Segura, DI; Japon, MA			Expression of hpttg proto-oneogene in lymphoid neoplasias	ONCOGENE			English	Article						hpttg proto-oncogene; B-cell lymphoma; T-cell; lymphoma; Hodgkin's disease; immunohistochemistry	TUMOR-TRANSFORMING GENE; TRANSCRIPTIONAL ACTIVATION FUNCTION; STRAND BREAK REPAIR; PITUITARY-ADENOMAS; CELL LYMPHOMA; HUMAN CANCERS; PTTG; CHECKPOINT; MYC; IDENTIFICATION	Pituitary tumor-transforming gene (pttg) is a distinct proto-oncogene which is expressed in certain normal tissues with high proliferation rate and in a variety of tumors. PTTG is the vertebrate analog of yeast securins Pds1 and Cut2 with a key role in the regulation of sister chromatid separation during mitosis. Impairment of PTTG regulated functions is expected to lead to chromosomal instability and aneuploidy. Human pttg (hpttg) is abundantly expressed in Jurkat T lymphoblastic lymphoma cells but not in normal peripheral blood leukocytes. To obtain additional data on the potential role of hpttg in lymphomagenesis we selected 150 cases of lymphoid tumors for the assessment of hpttg expression in tumor tissues. Immunohistochemical studies on formalin-fixed, paraffin-em bedded tissues revealed hPTTG in 38.8% of B-cell lymphomas, 70.2% of T-cell lymphomas, and 73.1% of Hodgkin's lymphomas. Among B-cell lymphomas, the most frequently immunostained tumors were plasma cell tumors, diffuse large cell lymphomas, and follicle center cell lymphomas. In Hodgkin's disease, immunoreactivity was mainly noted in Reed-Sternberg cells. In conclusion, the frequent overexpression of hpttg in many histological subtypes of lymphoma suggests the involvement of this protooncogene in lymphomagenesis.	Hosp Univ Virgen Rocio, Dept Pathol, Seville 41013, Spain; CSIC, Inst Recursos Nat & Agrobiol, E-41080 Seville, Spain; Univ Seville, Dept Microbiol, Fac Biol, Seville 41080, Spain	Virgen del Rocio University Hospital; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS); University of Sevilla	Japon, MA (corresponding author), Hosp Univ Virgen Rocio, Dept Pathol, Avenida Manuel Siurot SN, Seville 41013, Spain.		IBIS, TUMORIGENESIS/P-3506-2015; Tortolero, Maria/K-5744-2014; Romero, Francisco/K-2101-2014; Japón, Miguel A/L-2555-2017; Espina Zambrano, Águeda Gema/AAB-2657-2021; Sáez, Carmen/B-9468-2015; Pintor-Toro, Jose/L-4737-2014	Tortolero, Maria/0000-0003-1797-9940; Romero, Francisco/0000-0002-9588-6881; Japón, Miguel A/0000-0002-5980-5044; Espina Zambrano, Águeda Gema/0000-0003-1962-0990; Sáez, Carmen/0000-0002-8600-0508; Borrero, Juan Jose/0000-0003-4776-1061; Pintor-Toro, Jose/0000-0002-9060-5243				Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chien WW, 2000, J BIOL CHEM, V275, P19422, DOI 10.1074/jbc.M910105199; Cohen-Fix O, 1997, P NATL ACAD SCI USA, V94, P14361, DOI 10.1073/pnas.94.26.14361; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Davies J, 1999, ONCOGENE, V18, P3643, DOI 10.1038/sj.onc.1202956; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Hardwick KG, 1998, TRENDS GENET, V14, P1, DOI 10.1016/S0168-9525(97)01340-1; HARRIS NL, 1994, BLOOD, V84, P1361; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Hecht JL, 2000, J CLIN ONCOL, V18, P3707, DOI 10.1200/JCO.2000.18.21.3707; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; LANDANYI M, 1991, BLOOD, V77, P1057; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Pei L, 2001, J BIOL CHEM, V276, P8484, DOI 10.1074/jbc.M009654200; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Ramos-Morales F, 2000, ONCOGENE, V19, P403, DOI 10.1038/sj.onc.1203320; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Romero F, 2001, NUCLEIC ACIDS RES, V29, P1300, DOI 10.1093/nar/29.6.1300; Saez C, 1999, ONCOGENE, V18, P5473, DOI 10.1038/sj.onc.1202914; Strausberg RL, 1997, NAT GENET, V15, P415, DOI 10.1038/ng0497supp-415; Werner CA, 1997, AM J PATHOL, V151, P335; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	30	38	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2002	21	53					8173	8177		10.1038/sj.onc.1205954	http://dx.doi.org/10.1038/sj.onc.1205954			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444553				2022-12-17	WOS:000179231400011
J	Alavanja, MCR				Alavanja, MCR			Biologic damage resulting from exposure to tobacco smoke and from radon: implication for preventive interventions	ONCOGENE			English	Review						lung cancer; radon; smoking; pathologic mechanism	OXIDATIVE DNA-DAMAGE; LUNG-CANCER RISK; S-TRANSFERASE M1; SISTER-CHROMATID EXCHANGES; P53 MUTATION HOTSPOT; ALPHA-PARTICLES; MAMMALIAN-CELLS; CIGARETTE-SMOKE; FREE-RADICALS; UNITED-STATES	Cigarette smoking and residential radon are, respectively, the first and second leading cause of lung cancer in the United States today. Of the approximately 157000 lung deaths occurring in 2000, approximately 90% can be attributed to cigarette smoking and 30% 4 the lung cancer deaths among non-smokers can be attributed to residential radon exposure. Although dwarfed by cigarette related lung cancer, lung cancer among lifetime non-smokers is a leading cause of death in the United States, and many other countries, accounting for approximately 16000 deaths per year in the US. Laboratory studies and epidemiological investigations, particularly those conducted in the past decade, are yielding evidence that tobacco smoke and radon may share important elements of lung cancer's pathologic mechanism(s). Lung cancer prevention among smokers, ex-smokers and lifetime nonsmokers can be enhanced as we learn more about the etiologic mechanism(s) of lung cancer resulting from these and other exposures including diet, non-malignant respiratory diseases, occupational exposures, and susceptibility-gene. In this article we review both laboratory and epidemiologic data that gives insight into the biologic damage done to the lung from these exposures.	NCI, Div Canc Epidemiol & Genet, Rockville, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Alavanja, MCR (corresponding author), NCI, Div Canc Epidemiol & Genet, 6120 Execut Blvd,Room 8000, Rockville, MD 20892 USA.	alavanjm@mail.nih.gov			NATIONAL CANCER INSTITUTE [Z01CP010123] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams GED, 1986, INTRO CELLULAR MOL B, P154; ALAVANJA MCR, 1992, AM J EPIDEMIOL, V136, P623, DOI 10.1093/oxfordjournals.aje.a116542; ALAVANJA MCR, 1995, CANCER CAUSE CONTROL, V6, P209, DOI 10.1007/BF00051792; Albanes D, 1999, AM J CLIN NUTR, V69, p1345S; AMES BN, 1989, FREE RADICAL RES COM, V7, P121, DOI 10.3109/10715768909087933; ARUOMA OI, 1991, BIOCHEM J, V273, P601, DOI 10.1042/bj2730601; Asami S, 1996, CANCER RES, V56, P2546; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Azzam EI, 2000, CANCER RES, V60, P2623; Bartsch H, 1996, MUTAT RES-REV GENET, V340, P67, DOI 10.1016/S0165-1110(96)90040-8; BARTSCH H, 1995, PHARMACOGENETICS, V5, pS84, DOI 10.1097/00008571-199512001-00007; BARTSCH H, 1995, LANCET, V346, P121, DOI 10.1016/S0140-6736(95)92144-3; Bartsch H, 1997, EUR J CANCER PREV, V6, P529, DOI 10.1097/00008469-199712000-00007; Bartsch H, 1996, ENVIRON HEALTH PERSP, V104, P569, DOI 10.2307/3432825; BARTSCH H, 1991, MUTAT RES, V250, P103, DOI 10.1016/0027-5107(91)90167-M; BENDICH A, 1994, PURE APPL CHEM, V66, P1017, DOI 10.1351/pac199466051017; BESSHO T, 1993, J BIOL CHEM, V268, P19416; BLOT WJ, 1996, CANC EPIDEMIOLOGY PR, P637; BREIMER LH, 1991, FREE RADICAL RES COM, V14, P159, DOI 10.3109/10715769109088945; Brenner DJ, 2001, RADIAT RES, V155, P402, DOI 10.1667/0033-7587(2001)155[0402:TBEIRO]2.0.CO;2; BROOKS AL, 1990, INT J RADIAT BIOL, V58, P799, DOI 10.1080/09553009014552181; BYERS T, 1992, ANNU REV NUTR, V12, P139, DOI 10.1146/annurev.nu.12.070192.001035; CANDELORA EC, 1992, NUTR CANCER, V17, P263, DOI 10.1080/01635589209514195; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; CHAMULITRAT W, 1991, ARCH BIOCHEM BIOPHYS, V290, P153, DOI 10.1016/0003-9861(91)90601-E; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHUNG FL, 1992, CANC CHEMOPREVENTION; CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003; CUETO R, 1994, VIB SPECTROSC, V7, P97, DOI 10.1016/0924-2031(94)85045-3; Cujic M, 2021, INT J BIOMETEOROL, V65, P69, DOI 10.1007/s00484-020-01860-w; DEGAN P, 1995, CARCINOGENESIS, V16, P735, DOI 10.1093/carcin/16.4.735; DEKOK TMCM, 1994, CARCINOGENESIS, V15, P1399, DOI 10.1093/carcin/15.7.1399; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Deshpande A, 1996, RADIAT RES, V145, P260, DOI 10.2307/3578980; DI MASCIO P, 1989, ARCH BIOCHEM BIOPHYS, V274, P532, DOI 10.1016/0003-9861(89)90467-0; DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M; EMERIT I, 1995, FREE RADICAL BIO MED, V18, P985, DOI 10.1016/0891-5849(94)00220-E; EVANS MD, 1991, CHEM-BIOL INTERACT, V79, P151, DOI 10.1016/0009-2797(91)90079-M; EVANS MD, 1994, AM J PHYSIOL, V266, pL593, DOI 10.1152/ajplung.1994.266.6.L593; Fahey JW, 1999, FOOD CHEM TOXICOL, V37, P973, DOI 10.1016/S0278-6915(99)00082-4; Feskanich D, 2000, JNCI-J NATL CANCER I, V92, P1812, DOI 10.1093/jnci/92.22.1812; Fraga CG, 1996, MUTAT RES-FUND MOL M, V351, P199, DOI 10.1016/0027-5107(95)00251-0; Garcia-Closas R, 1998, NUTR CANCER, V32, P154, DOI 10.1080/01635589809514734; GRINBERGFUNES RA, 1994, CARCINOGENESIS, V15, P2449, DOI 10.1093/carcin/15.11.2449; HECHT SS, 1995, CANCER EPIDEM BIOMAR, V4, P877; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Hecht SS, 1999, J NUTR, V129, p768S, DOI 10.1093/jn/129.3.768S; Hei TK, 1998, P NATL ACAD SCI USA, V95, P8103, DOI 10.1073/pnas.95.14.8103; Hei TK, 1997, P NATL ACAD SCI USA, V94, P3765, DOI 10.1073/pnas.94.8.3765; HICKMAN AW, 1994, CANCER RES, V54, P5797; HIGINBOTHAM KG, 1992, CANCER RES, V52, P4727; Hoffmann D, 1997, J TOXICOL ENV HEALTH, V50, P307, DOI 10.1080/009841097160393; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1997, CARCINOGENESIS, V18, P511, DOI 10.1093/carcin/18.3.511; Houlston RS, 1999, CANCER EPIDEM BIOMAR, V8, P675; Hussain SP, 1998, CANCER RES, V58, P4023; HUSSAIN SP, 1994, ONCOGENE, V9, P2277; *IARC, 1986, IARC MON EV CARC RIS, V38, P389; Jansen MCJF, 2001, INT J CANCER, V92, P913, DOI 10.1002/ijc.1278; JEFFREY AM, 1976, J AM CHEM SOC, V98, P5714, DOI 10.1021/ja00434a060; JONAS SK, 1992, FREE RADICAL RES COM, V17, P407, DOI 10.3109/10715769209083145; KALRA J, 1991, INT J EXP PATHOL, V72, P1; KENNEDY A, 1997, CARCINOGENESIS, V8, P683; Kennedy CH, 1996, CARCINOGENESIS, V17, P1671, DOI 10.1093/carcin/17.8.1671; Ketterer B, 1998, FREE RADICAL RES, V28, P647, DOI 10.3109/10715769809065820; Knekt P, 1999, J NATL CANCER I, V91, P182, DOI 10.1093/jnci/91.2.182; KOLM RH, 1995, BIOCHEM J, V311, P453, DOI 10.1042/bj3110453; Kriek E, 1998, MUTAT RES-FUND MOL M, V400, P215, DOI 10.1016/S0027-5107(98)00065-7; KRINSKY NI, 1993, ANNU REV NUTR, V13, P561, DOI 10.1146/annurev.nutr.13.1.561; KUCHINO Y, 1987, NATURE, V327, P77, DOI 10.1038/327077a0; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LEANDERSON P, 1992, CHEM-BIOL INTERACT, V81, P197, DOI 10.1016/0009-2797(92)90034-I; Lehnert BE, 1997, CANCER RES, V57, P2164; LEMARCHAND L, 1993, CANCER EPIDEM BIOMAR, V2, P183; Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0; Little MP, 2001, RADIAT RES, V156, P695, DOI 10.1667/0033-7587(2001)156[0695:TBEICC]2.0.CO;2; Loft S, 1996, J MOL MED, V74, P297, DOI 10.1007/s001090050031; LOFT S, 1994, FASEB J, V8, P534, DOI 10.1096/fasebj.8.8.8181672; LOFT S, 1992, CARCINOGENESIS, V13, P2241, DOI 10.1093/carcin/13.12.2241; LOFT S, 1995, TRANSPLANTATION, V59, P16, DOI 10.1097/00007890-199501150-00004; London SJ, 2000, LANCET, V356, P724, DOI 10.1016/S0140-6736(00)02631-3; Lubin JH, 1994, RADON LUNG CANC RISK; MAYNE ST, 1994, J NATL CANCER I, V86, P33, DOI 10.1093/jnci/86.1.33; MCDONALD JW, 1995, CANCER EPIDEM BIOMAR, V4, P791; Michaud DS, 2000, AM J CLIN NUTR, V72, P990; Mooney LA, 1997, CARCINOGENESIS, V18, P503, DOI 10.1093/carcin/18.3.503; MOONEY LA, 1995, CANCER EPIDEM BIOMAR, V4, P627; Mortensen A, 1997, FREE RADICAL RES, V27, P229, DOI 10.3109/10715769709097855; Nagasawa H, 1999, RADIAT RES, V152, P552, DOI 10.2307/3580153; NAGASAWA H, 1992, CANCER RES, V52, P6394; National Research Council, 1999, REP COMM BIOL EFF IO; Nyberg F, 1998, INT J CANCER, V78, P430, DOI 10.1002/(SICI)1097-0215(19981109)78:4&lt;430::AID-IJC7&gt;3.0.CO;2-V; OSBORNE MR, 1976, INT J CANCER, V18, P362, DOI 10.1002/ijc.2910180315; Prieme H, 1998, CARCINOGENESIS, V19, P347, DOI 10.1093/carcin/19.2.347; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; PRYOR WA, 1983, ENVIRON HEALTH PERSP, V47, P345, DOI 10.1289/ehp.8347345; Pryor WA, 1997, ENVIRON HEALTH PERSP, V105, P875, DOI 10.2307/3433297; RILEY PA, 1994, INT J RADIAT BIOL, V65, P27, DOI 10.1080/09553009414550041; ROOTS R, 1972, INT J RADIAT BIOL RE, V21, P329, DOI 10.1080/09553007214550401; Rossman TG, 1998, MUTAT RES-FUND MOL M, V402, P103, DOI 10.1016/S0027-5107(97)00287-X; Slater T. F., 1972, FREE RADICAL MECH TI; Speizer FE, 1999, CANCER CAUSE CONTROL, V10, P475, DOI 10.1023/A:1008931526525; Spitz MR, 2000, CANCER EPIDEM BIOMAR, V9, P1017; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P427, DOI 10.1007/BF00054304; STONE KK, 1994, ENVIRON HEALTH PERSP, V102, P173, DOI 10.2307/3432235; Surgeon General, 1988, HLTH CONS SMOK NIC A; TAYLOR JA, 1994, LANCET, V343, P86, DOI 10.1016/S0140-6736(94)90818-4; TEEBOR GW, 1988, INT J RADIAT BIOL, V54, P131, DOI 10.1080/09553008814551591; TINKLER JH, 1995, NAT MED, V1, P98; U.S. Department of Health and Human Services, 2001, WOM SMOK REP SURG GE; United Nations Scientific Committee on the Effects of Atomic Radiation, 2000, UNSCEAR 2000 REPORT; US Department of Health and Human Services [Internet], 1990, HLTH BEN SMOK CESS R; VAHAKANGAS K, 1985, CARCINOGENESIS, V6, P1109, DOI 10.1093/carcin/6.8.1109; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2; Van Lieshout EMM, 1998, ONCOL REP, V5, P959; van Poppel G, 1999, ADV EXP MED BIOL, V472, P159; Verhagen H, 1997, CANCER LETT, V114, P127, DOI 10.1016/S0304-3835(97)04641-7; Verhoeven DTH, 1996, CANCER EPIDEM BIOMAR, V5, P733; VONSONNTAG C, 1994, INT J RADIAT BIOL, V65, P19, DOI 10.1080/09553009414550031; Voorrips LE, 2000, CANCER CAUSE CONTROL, V11, P101, DOI 10.1023/A:1008906706084; Wei YH, 1998, P SOC EXP BIOL MED, V217, P53; WESTRA WH, 1993, CANCER-AM CANCER SOC, V72, P432, DOI 10.1002/1097-0142(19930715)72:2<432::AID-CNCR2820720219>3.0.CO;2-#; Williams JA, 2001, CARCINOGENESIS, V22, P209, DOI 10.1093/carcin/22.2.209; WU AH, 1995, AM J EPIDEMIOL, V141, P1023, DOI 10.1093/oxfordjournals.aje.a117366; Wu LJ, 1999, P NATL ACAD SCI USA, V96, P4959, DOI 10.1073/pnas.96.9.4959; Yarborough A, 1996, CANCER RES, V56, P683; Yngveson A, 1999, CANCER EPIDEM BIOMAR, V8, P433; Yu R, 1998, CANCER RES, V58, P402; ZHANG LX, 1992, CANCER RES, V52, P5702; Zhao B, 2001, CANCER EPIDEM BIOMAR, V10, P1063; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797; Ziegler RG, 1996, J NATL CANCER I, V88, P612, DOI 10.1093/jnci/88.9.612; Ziegler RG, 1996, CANCER CAUSE CONTROL, V7, P157, DOI 10.1007/BF00115646	134	38	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7365	7375		10.1038/sj.onc.1205798	http://dx.doi.org/10.1038/sj.onc.1205798			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379879				2022-12-17	WOS:000178618000009
J	Brownson, RC; Figgs, LW; Caisley, LE				Brownson, RC; Figgs, LW; Caisley, LE			Epidemiology of environmental tobacco smoke exposure	ONCOGENE			English	Article						environmental tobacco smoke; lung neoplasms; socioeconomic level; tobacco smoke pollution	LUNG-CANCER RISK; PASSIVE SMOKING; NONSMOKING WOMEN; PUBLICATION BIAS; GENETIC SUSCEPTIBILITY; INVOLUNTARY SMOKING; LIFETIME EXPOSURE; HEALTH; POPULATION; GSTM1	The health hazards due to exposure to environmental tobacco smoke (ETS) are increasingly established. ETS contains thousands of chemicals including 43 known carcinogens. One of the most important known health effects of ETS exposure is lung cancer in non-smokers, based on epidemiologic evidence and knowledge of the uptake and metabolism of ETS. Epidemiologic studies need to carefully take into account confounding and potential errors in exposure assessment. More research is needed to understand the genetic factors that influence ETS-induced lung cancer. Studies of the patterns of ETS exposure suggest higher rates of exposure in people employed as blue collar workers, in service occupations, earning lower incomes, and among the less educated. Certain racial/ethnic groups (e.g. Blacks, American Indians) may be at higher risk of ETS exposure. Despite substantial progress in protecting individuals from ETS exposure, additional efforts are needed in improving and enforcing policies to reduce exposure.	St Louis Univ, Sch Publ Hlth, Salus Ctr, Dept Community Hlth, St Louis, MO 63104 USA; St Louis Univ, Sch Publ Hlth, Salus Ctr, Prevent Res Ctr, St Louis, MO 63104 USA	Saint Louis University; Saint Louis University	Brownson, RC (corresponding author), St Louis Univ, Sch Publ Hlth, Salus Ctr, Dept Community Hlth, 3545 Lafayette Ave, St Louis, MO 63104 USA.	brownson@slu.edu						AKIBA S, 1986, CANCER RES, V46, P4804; Bartsch H, 2000, CANCER EPIDEM BIOMAR, V9, P3; BAST RC, 2000, CANC MED; Bennett WP, 1999, JNCI-J NATL CANCER I, V91, P2009, DOI 10.1093/jnci/91.23.2009; Benowitz NL, 1996, EPIDEMIOL REV, V18, P188, DOI 10.1093/oxfordjournals.epirev.a017925; BERO LA, 1994, JAMA-J AM MED ASSOC, V272, P133, DOI 10.1001/jama.272.2.133; Boffetta P, 1998, J NATL CANCER I, V90, P1440, DOI 10.1093/jnci/90.19.1440; Brenneman MA, 2000, MUTAT RES-DNA REPAIR, V459, P89, DOI 10.1016/S0921-8777(00)00002-1; Brownson RC, 1998, EPIDEMIOL REV, V20, P218, DOI 10.1093/oxfordjournals.epirev.a017982; Brownson RC, 1997, ANNU REV PUBL HEALTH, V18, P163, DOI 10.1146/annurev.publhealth.18.1.163; BROWNSON RC, 1993, INT J EPIDEMIOL, V22, P804, DOI 10.1093/ije/22.5.804; BROWNSON RC, 1992, AM J PUBLIC HEALTH, V82, P1525, DOI 10.2105/AJPH.82.11.1525; BUTLER TL, 1988, RELATIONSHIP PASSIVE; *CA EPA, 1997, HLTH EFF EXP ENV TOB; Cardenas VM, 1997, CANCER CAUSE CONTROL, V8, P57, DOI 10.1023/A:1018483121625; CDC, NAT REP HUM EXP ENV; CORREA P, 1983, LANCET, V2, P595; COULTAS DB, 1989, AM J EPIDEMIOL, V130, P338, DOI 10.1093/oxfordjournals.aje.a115340; CUMMINGS KM, 1989, AM J EPIDEMIOL, V130, P122, DOI 10.1093/oxfordjournals.aje.a115303; Curtin F, 1998, AM J EPIDEMIOL, V148, P1040; Divine KK, 2001, MUTAT RES-DNA REPAIR, V461, P273, DOI 10.1016/S0921-8777(00)00059-8; Dresler CM, 2000, LUNG CANCER-J IASLC, V30, P153, DOI 10.1016/S0169-5002(00)00163-X; ERIKSEN MP, 1988, ANNU REV PUBL HEALTH, V9, P47, DOI 10.1146/annurev.pu.09.050188.000403; Fontenot J. P., 1991, PROF ANIM SCI, V7, P1; Gao Y, 1999, MUTAT RES-GEN TOX EN, V444, P441, DOI 10.1016/S1383-5718(99)00092-3; GARFINKEL L, 1985, J NATL CANCER I, V75, P463; Gealy R, 1999, CANCER EPIDEM BIOMAR, V8, P297; Gerlach K K, 1997, Tob Control, V6, P199; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; Hackshaw AK, 1997, BMJ-BRIT MED J, V315, P980, DOI 10.1136/bmj.315.7114.980; HAMMOND SK, 1993, J NATL CANCER I, V85, P474, DOI 10.1093/jnci/85.6.474; HAMMOND SK, 1995, JAMA-J AM MED ASSOC, V274, P956, DOI 10.1001/jama.274.12.956; HECHT SS, 1993, NEW ENGL J MED, V329, P1543, DOI 10.1056/NEJM199311183292105; HIRAYAMA T, 1984, PREV MED, V13, P680, DOI 10.1016/S0091-7435(84)80017-1; HOLE DJ, 1989, BRIT MED J, V299, P423, DOI 10.1136/bmj.299.6696.423; Hou SM, 2001, CANCER EPIDEM BIOMAR, V10, P133; HUMBLE CG, 1987, AM J PUBLIC HEALTH, V77, P598, DOI 10.2105/AJPH.77.5.598; JANERICH DT, 1990, NEW ENGL J MED, V323, P632, DOI 10.1056/NEJM199009063231003; JINOT J, 1994, J CLIN EPIDEMIOL, V47, P339, DOI 10.1016/0895-4356(94)90154-6; Jockel KH, 1998, EPIDEMIOLOGY, V9, P672; Johnson KC, 2001, INT J CANCER, V93, P902, DOI 10.1002/ijc.1416; KABAT GC, 1984, CANCER, V53, P1214, DOI 10.1002/1097-0142(19840301)53:5<1214::AID-CNCR2820530532>3.0.CO;2-8; KABAT GC, 1995, AM J EPIDEMIOL, V142, P141, DOI 10.1093/oxfordjournals.aje.a117612; KALANDIDI A, 1990, CANCER CAUSE CONTROL, V1, P15, DOI 10.1007/BF00053179; Kawachi I, 1996, AM J EPIDEMIOL, V144, P909; KOLONEL LN, 1977, AM J EPIDEMIOL, V106, P476, DOI 10.1093/oxfordjournals.aje.a112494; KOO LC, 1987, INT J CANCER, V39, P162, DOI 10.1002/ijc.2910390207; Kreuzer M, 2000, AM J EPIDEMIOL, V151, P241, DOI 10.1093/oxfordjournals.aje.a010199; LAM TH, 1987, BRIT J CANCER, V56, P673, DOI 10.1038/bjc.1987.264; Lee CH, 2000, INT J EPIDEMIOL, V29, P224, DOI 10.1093/ije/29.2.224; LEE PN, 1986, BRIT J CANCER, V54, P97, DOI 10.1038/bjc.1986.157; LEFCOE NM, 1983, CHEST, V84, P90, DOI 10.1378/chest.84.1.90; LEMARCHAND L, 1991, CANCER CAUSE CONTROL, V2, P11, DOI 10.1007/BF00052356; LERCHEN ML, 1986, AM J EPIDEMIOL, V123, P481, DOI 10.1093/oxfordjournals.aje.a114263; Liotta L, 2000, NAT REV GENET, V1, P48, DOI 10.1038/35049567; Liu G, 2001, CANCER RES, V61, P8718; MACLURE M, 1989, AM J PUBLIC HEALTH, V79, P1381, DOI 10.2105/AJPH.79.10.1381; Malats N, 2000, CANCER EPIDEM BIOMAR, V9, P827; MATANOSKI G, 1995, AM J EPIDEMIOL, V142, P149, DOI 10.1093/oxfordjournals.aje.a117613; McLaughlin J K, 1990, Epidemiology, V1, P408, DOI 10.1097/00001648-199009000-00013; *NAT HLTH MED RES, 1997, HLTH EFF PASS SMOK; NRC (National Research Council), 1986, ENV TOB SMOK MEAS EX; Nyberg F, 1998, EPIDEMIOLOGY, V9, P301, DOI 10.1097/00001648-199805000-00015; Nyberg F, 1997, EPIDEMIOLOGY, V8, P304, DOI 10.1097/00001648-199705000-00013; ONEILL I, 1987, ENV CARCINOGENS METH, V9; PERSHAGEN G, 1987, AM J EPIDEMIOL, V125, P17, DOI 10.1093/oxfordjournals.aje.a114504; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233, DOI 10.1001/jama.275.16.1233; PRON GE, 1988, AM J EPIDEMIOL, V127, P267, DOI 10.1093/oxfordjournals.aje.a114802; QING L, 1993, AM J EPIDEMIOL, V137, P145, DOI 10.1093/oxfordjournals.aje.a116654; Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576; Rapiti E, 1999, LUNG CANCER-J IASLC, V23, P183, DOI 10.1016/S0169-5002(99)00013-6; Ratnasinghe D, 2001, CANCER EPIDEM BIOMAR, V10, P119; REPACE JL, 1993, NICOTINE ADDICTION P, P129; RIBOLI E, 1990, CANCER CAUSE CONTROL, V1, P243, DOI 10.1007/BF00117476; SCHOTTENFELD D, 1997, CANC EPIDEMIOLOGY PR; SHIMIZU H, 1988, TOHOKU J EXP MED, V154, P389, DOI 10.1620/tjem.154.389; SIDNEY S, 1989, AM J EPIDEMIOL, V129, P1305, DOI 10.1093/oxfordjournals.aje.a115250; SIEGEL M, 1993, JAMA-J AM MED ASSOC, V270, P490, DOI 10.1001/jama.270.4.490; STAMATAKIS KA, 2002, J WOMENS HLTH GENDER; STOCKWELL HG, 1992, J NATL CANCER I, V84, P1417, DOI 10.1093/jnci/84.18.1417; Stucker I, 1999, INT J EPIDEMIOL, V28, P829, DOI 10.1093/ije/28.5.829; SVENSSON C, 1989, ACTA ONCOL, V28, P623, DOI 10.3109/02841868909092282; US Department of Health and Human Services, 1986, HLTH CONS INV SMOK R; *USEPA, 1992, RESP HLTH EFF PASS S; Vahakangas KH, 2001, CANCER RES, V61, P4350; VANDENBROUCKE JP, 1988, BRIT MED J, V296, P391, DOI 10.1136/bmj.296.6619.391; Vine M. F., 1990, BIOL MARKERS EPIDEMI, P196; Wang JS, 1999, BIOTECHNOL BIOENG, V62, P402, DOI 10.1002/(SICI)1097-0290(19990220)62:4<402::AID-BIT3>3.3.CO;2-M; Wang LD, 2000, INT J CANCER, V88, P139, DOI 10.1002/1097-0215(20001001)88:1&lt;139::AID-IJC22&gt;3.0.CO;2-L; WELLS AJ, 1988, BRIT MED J, V296, P1128, DOI 10.1136/bmj.296.6629.1128-a; Whitlock G, 1998, TOB CONTROL, V7, P276, DOI 10.1136/tc.7.3.276; WU AH, 1985, JNCI-J NATL CANCER I, V74, P747; Zaridze D, 1998, INT J CANCER, V75, P335, DOI 10.1002/(SICI)1097-0215(19980130)75:3<335::AID-IJC1>3.0.CO;2-3; Zhong LJ, 1999, CANCER CAUSE CONTROL, V10, P607, DOI 10.1023/A:1008962025001	94	38	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7341	7348		10.1038/sj.onc.1205809	http://dx.doi.org/10.1038/sj.onc.1205809			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379877				2022-12-17	WOS:000178618000007
J	Rubin, H				Rubin, H			Selective clonal expansion and microenvironmental permissiveness in tobacco carcinogenesis	ONCOGENE			English	Review						cigarette smoke; initiation; promotion; co-carcinogenesis	TUMOR-PROMOTING AGENTS; POLYCYCLIC AROMATIC-HYDROCARBONS; MOUSE SKIN; PULMONARY METASTASES; OPTICAL ENANTIOMERS; CIGARETTE-SMOKE; PHORBOL ESTERS; NEOPLASTIC TRANSFORMATION; EPIDERMAL HYPERPLASIA; COCARCINOGENIC ACTION	Historically our knowledge about the direct carcinogenic activity of cigarette smoke and its constituents grew from painting experiments on the skin of mice to produce papillomas and carcinomas. The neutral fraction of cigarette smoke condensate had most of the carcinogenic activity in this test and was rich in carcinogenic polycyclic aromatic hydrocarbons (PAHs), the most abundant by far being BP. However, the concentration of BP in the condensate was only about 2% the amount of pure BP required to cause skin tumors. In other fractions there were non-carcinogenic constituents that promoted tumor formation when applied repeatedly to mouse skin that had been initiated by a single subcarcinogenic application of BP. There were also constituents of cigarette smoke that acted as cocarcinogens when applied simultaneously with repeated applications of BP. BP was effective as an initiator at lower concentrations than as a complete carcinogen, and some non-carcinogenic PAHs in the condensate were also active initiators. It was concluded from these studies that cigarette smoke condensate is primarily a tumor-promoting and co-carcinogenic agent with weak activity as a complete carcinogen. A major effect of promoters, and possibly of co-carcinogens, is a diffuse hyperplasia which includes selective expansion of clones carrying endogenous mutations and/or mutations induced by PAHs and other carcinogens such as NNK. The induced mutations as well as damaged cells would occur throughout the exposed region and, along with the hyperplasia, increase the permissiveness of the cellular microenvironment for neoplastic expression of any potential tumor cell in its midst. Since neither the promoters nor co-carcinogens in tobacco smoke are known to interact directly with DNA, their effects can be considered epigenetic processes that act upon genetically altered cells. Examples are cited from studies of experimental skin carcinogenesis, smoking-induced histopathological changes in human lung and spontaneous transformation in cell culture to illustrate the genetic and epigenetic interactions of neoplastic development in general and their significance for smoking-induced lung cancer in particular. Certain dietary modifications that appear to be effective in moderating the promotional phase of animal and human carcinogenesis are suggested for trial in managing lung cancer.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Rubin, H (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	hrubin@uclink4.berkeley.edu			NATIONAL LIBRARY OF MEDICINE [G13LM007483] Funding Source: NIH RePORTER	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		AARONSON SA, 1968, SCIENCE, V162, P1024, DOI 10.1126/science.162.3857.1024; ALDAZ CM, 1985, CANCER RES, V45, P2753; AMES BN, 1973, P NATL ACAD SCI USA, V70, P2281, DOI 10.1073/pnas.70.8.2281; Andersson DI, 1998, SCIENCE, V282, P1133, DOI 10.1126/science.282.5391.1133; ARMUTH V, 1972, CANCER RES, V32, P2259; AUERBACH O, 1961, NEW ENGL J MED, V265, P253, DOI 10.1056/NEJM196108102650601; AUERBACH O, 1962, NEW ENGL J MED, V267, P119, DOI 10.1056/NEJM196207192670302; AUERBACH O, 1970, ARCH ENVIRON HEALTH, V21, P754, DOI 10.1080/00039896.1970.10667329; AUERBACH O, 1956, CANCER, V9, P76, DOI 10.1002/1097-0142(195601/02)9:1<76::AID-CNCR2820090106>3.0.CO;2-D; Berenblum I, 1941, CANCER RES, V1, P44; Berenblum I, 1941, CANCER RES, V1, P807; BERENBLUM I, 1949, BRIT J CANCER, V3, P384, DOI 10.1038/bjc.1949.42; BERENBLUM I, 1947, BRIT J CANCER, V1, P379, DOI 10.1038/bjc.1947.35; BERENBLUM I, 1947, BRIT J CANCER, V1, P383, DOI 10.1038/bjc.1947.36; BERENBLUM I, 1974, CARCINOGENESIS BIOL; BERRY DL, 1978, CANCER RES, V38, P2301; Biesele JJ, 1943, J NATL CANCER I, V4, P373; BOUTWELL RK, 1964, PROG EXP TUMOR RES, V4, P207; BRAND KG, 1976, CANCER RES, V36, P3681; BROOKES P, 1964, NATURE, V202, P781, DOI 10.1038/202781a0; BROWN JM, 1973, BRIT J RADIOL, V46, P613, DOI 10.1259/0007-1285-46-548-613; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BUENING MK, 1978, P NATL ACAD SCI USA, V75, P5358, DOI 10.1073/pnas.75.11.5358; Burczynski ME, 2000, CANCER RES, V60, P908; BURDETTE WJ, 1955, CANCER RES, V15, P201; BURKHART F, 1997, NY TIMES        0116; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; Cairns J., 1978, CANC SCI SOC; CAIRNS J, 1991, GENETICS, V154, P1427; CARMEL RJ, 1977, CANCER RES, V37, P145; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Chen JX, 1998, CANCER RES, V58, P2070; CHENG SC, 1988, CARCINOGENESIS, V9, P1721, DOI 10.1093/carcin/9.9.1721; Chow M, 1999, P NATL ACAD SCI USA, V96, P2093, DOI 10.1073/pnas.96.5.2093; Chow M, 2000, CANCER RES, V60, P6510; COOK J. W., 1937, AMER JOUR CANCER, V29, P219; Cook JW, 1933, J CHEM SOC, P395, DOI 10.1039/jr9330000395; CRAMER W., 1942, JOUR NATION CANCER INST, V2, P369; CRAMER W., 1942, JOUR NATION CANCER INST, V2, P379; DAVIES D F, 1960, J Chronic Dis, V11, P579, DOI 10.1016/0021-9681(60)90059-X; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Denissenko MF, 1997, P NATL ACAD SCI USA, V94, P3893, DOI 10.1073/pnas.94.8.3893; DOLL R, 1952, BMJ-BRIT MED J, V2, P1271, DOI 10.1136/bmj.2.4797.1271; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; Dolle MET, 2000, P NATL ACAD SCI USA, V97, P8403, DOI 10.1073/pnas.97.15.8403; DRUCKREY H., 1963, ZEIT KREBSFORSCH, V65, P465, DOI 10.1007/BF00525755; DZARLIEVAPETRUSEVSKA RT, 1985, CARCINOGENESIS, V6, P1447, DOI 10.1093/carcin/6.10.1447; Elsasser WM, 1998, REFLECTIONS THEORY O; ESSENBERG JM, 1952, SCIENCE, V116, P561, DOI 10.1126/science.116.3021.561; FRANKFURT OS, 1973, JNCI-J NATL CANCER I, V51, P1861, DOI 10.1093/jnci/51.6.1861; FRANKFURT OS, 1972, JNCI-J NATL CANCER I, V49, P131; Friedewald WF, 1944, J EXP MED, V80, P101, DOI 10.1084/jem.80.2.101; FURSTENBERGER G, 1981, P NATL ACAD SCI-BIOL, V78, P7722, DOI 10.1073/pnas.78.12.7722; FURSTENBERGER G, 1985, SCIENCE, V230, P76, DOI 10.1126/science.3929385; FURSTENBERGER G, 1983, SCIENCE, V220, P89, DOI 10.1126/science.6828884; FURTH J, 1953, CANCER RES, V13, P477; GELLHORN A, 1958, CANCER RES, V18, P510; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; Hastings PJ, 2000, CELL, V103, P723, DOI 10.1016/S0092-8674(00)00176-8; Hayward SW, 2001, CANCER RES, V61, P8135; HECHT SS, 1988, CARCINOGENESIS, V9, P875, DOI 10.1093/carcin/9.6.875; HECHT SS, 1981, J NATL CANCER I, V66, P163; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; HECKER E, 1968, CANCER RES, V28, P2338; HENNINGS H, 1983, NATURE, V304, P67, DOI 10.1038/304067a0; HIEGER I, 1962, BRIT J CANCER, V16, P716, DOI 10.1038/bjc.1962.83; HIEGER I, 1936, AM J CANC, V28, P522; HOLLIDAY R, 1994, DEV GENET, V15, P453, DOI 10.1002/dvg.1020150602; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; HUBERMAN E, 1974, INT J CANCER, V13, P326, DOI 10.1002/ijc.2910130308; Hussain SP, 2001, CANCER RES, V61, P6350; IVERSEN OH, 1985, VIRCHOWS ARCH B, V49, P129, DOI 10.1007/BF02912091; KAINA B, 1989, TERATOGEN CARCIN MUT, V9, P331, DOI 10.1002/tcm.1770090602; KAPITULNIK J, 1978, CANCER RES, V38, P354; KATO R, 1969, HEREDITAS-GENETISK A, V61, P1; KATO R, 1968, HEREDITAS-GENETISK A, V59, P120; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KENNAWAY E. L., 1930, BRIT MED JOUR, V1, P1044; Krawczak M, 1998, MUTAGENESIS, V13, P319, DOI 10.1093/mutage/13.4.319; KRAWCZAK M, 1995, HUM MUTAT, V5, P48, DOI 10.1002/humu.1380050107; LANKAS GR, 1977, MUTAT RES, V45, P153, DOI 10.1016/0027-5107(77)90053-7; LEE LW, 1989, AM J PATHOL, V135, P63; LEUCHTENBERGER C, 1974, ONCOLOGY-BASEL, V29, P122, DOI 10.1159/000224894; LEVIN W, 1977, CANCER RES, V37, P2721; LEVIN W, 1977, CANCER RES, V37, P3356; Levin W, 1978, POLYCYCLIC HYDROCARB, P189; MACKAY W, 1992, CARCINOGENESIS, V13, P1415, DOI 10.1093/carcin/13.8.1415; MacKenzie I, 1941, J EXP MED, V73, P391, DOI 10.1084/jem.73.3.391; MARX JL, 1978, SCIENCE, V201, P515, DOI 10.1126/science.307276; Melendez-Colon VJ, 1999, CARCINOGENESIS, V20, P1885, DOI 10.1093/carcin/20.10.1885; MILAS L, 1984, CANC INVASTION METAS; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; Mottram JC, 1944, J PATHOL BACTERIOL, V56, P181, DOI 10.1002/path.1700560207; NEWBOLD RF, 1979, INT J CANCER, V24, P203, DOI 10.1002/ijc.2910240212; Olumi AF, 1999, CANCER RES, V59, P5002; PARKINSON EK, 1985, BRIT J CANCER, V52, P479, DOI 10.1038/bjc.1985.219; Peacock PR, 1938, BRIT J EXP PATHOL, V19, P315; PELLING JC, 1982, CARCINOGENESIS, V3, P1135, DOI 10.1093/carcin/3.10.1135; PELLING JC, 1984, CANCER RES, V44, P1081; PETRUSEVSKA RT, 1988, CARCINOGENESIS, V9, P1207, DOI 10.1093/carcin/9.7.1207; PHILLIPS DH, 1983, NATURE, V303, P468, DOI 10.1038/303468a0; Pullinger BD, 1940, J PATHOL BACTERIOL, V50, P463, DOI 10.1002/path.1700500308; Pullinger BD, 1941, J PATHOL BACTERIOL, V53, P287, DOI 10.1002/path.1700530213; RAICK AN, 1972, CANCER RES, V32, P1562; Ralston SL, 1995, CARCINOGENESIS, V16, P2899, DOI 10.1093/carcin/16.12.2899; REDDY AL, 1983, NATURE, V304, P69, DOI 10.1038/304069a0; Rodin SN, 2000, P NATL ACAD SCI USA, V97, P12244, DOI 10.1073/pnas.180320897; RODIN SN, 2002, IN PRESS MUTATION RE; ROE FJC, 1955, BRIT J CANCER, V9, P177, DOI 10.1038/bjc.1955.14; ROE FJC, 1959, BRIT J CANCER, V13, P623, DOI 10.1038/bjc.1959.68; ROSE DP, 1986, CANCER-AM CANCER SOC, V58, P2363, DOI 10.1002/1097-0142(19861201)58:11<2363::AID-CNCR2820581102>3.0.CO;2-#; Rosenberg SM, 1998, GENETICS, V148, P1559; Rous P, 1941, J EXP MED, V73, P365, DOI 10.1084/jem.73.3.365; RUBIN H, 1995, P NATL ACAD SCI USA, V92, P4843, DOI 10.1073/pnas.92.11.4843; RUBIN H, 1989, P NATL ACAD SCI USA, V86, P1860, DOI 10.1073/pnas.86.6.1860; RUBIN H, 1960, VIROLOGY, V10, P29, DOI 10.1016/0042-6822(60)90004-0; Rubin H, 2001, CARCINOGENESIS, V22, P1903, DOI 10.1093/carcin/22.12.1903; Rubin H, 2001, ADV CANCER RES, V83, P159, DOI 10.1016/S0065-230X(01)83006-2; Rubin H, 2001, CANCER RES, V61, P799; RUBIN H, 1994, P NATL ACAD SCI USA, V91, P1039, DOI 10.1073/pnas.91.3.1039; RUBIN H, 1992, P NATL ACAD SCI USA, V89, P977, DOI 10.1073/pnas.89.3.977; RUBIN H, 1994, P NATL ACAD SCI USA, V91, P12076, DOI 10.1073/pnas.91.25.12076; RUBIN H, 1975, P NATL ACAD SCI USA, V72, P3551, DOI 10.1073/pnas.72.9.3551; RUGGERI B, 1993, P NATL ACAD SCI USA, V90, P1013, DOI 10.1073/pnas.90.3.1013; SALAMAN MH, 1953, BRIT J CANCER, V7, P472, DOI 10.1038/bjc.1953.49; SETALA K, 1959, J NATL CANCER I, V23, P925; SHUBIK P, 1950, CANCER RES, V10, P13; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SIMS P, 1974, NATURE, V252, P326, DOI 10.1038/252326a0; SISSKIN EF, 1982, CARCINOGENESIS, V3, P403, DOI 10.1093/carcin/3.4.403; Slaga T J, 1982, Carcinog Compr Surv, V7, P19; SLAGA TJ, 1980, P NATL ACAD SCI-BIOL, V77, P3659, DOI 10.1073/pnas.77.6.3659; SLAGA TJ, 1979, CANCER RES, V39, P67; STOKER M, 1964, VIROLOGY, V24, P165, DOI 10.1016/0042-6822(64)90099-6; TANNENBAUM A, 1959, PHYSIOPATHOLOGY CANC, P517; TERZAGHIHOWE M, 1987, CARCINOGENESIS, V8, P145, DOI 10.1093/carcin/8.1.145; Thun MJ, 1997, JNCI-J NATL CANCER I, V89, P1580, DOI 10.1093/jnci/89.21.1580; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; VANDUURE.BL, 1970, J NATL CANCER I, V44, P1167; VANDUURE.BL, 1973, JNCI-J NATL CANCER I, V51, P703; VANDUUREN BL, 1976, JNCI-J NATL CANCER I, V56, P1237, DOI 10.1093/jnci/56.6.1237; VANDUUREN BL, 1966, JNCI-J NATL CANCER I, V37, P519; VANDUUREN BL, 1971, JNCI-J NATL CANCER I, V47, P235; VANDUUREN BL, 1975, CANCER RES, V35, P502; VANDUUREN BL, 1980, BANBURY REPORT, V3, P105; Waddington CH, 2012, INT J EPIDEMIOL, V41, P10, DOI 10.1093/ije/dyr184; WEINSTEIN IB, 1976, SCIENCE, V193, P592, DOI 10.1126/science.959820; WEISS RA, 1970, EXP CELL RES, V63, P1, DOI 10.1016/0014-4827(70)90326-5; WITHERS HR, 1973, CANCER RES, V33, P1931; WYNDER E L, 1961, Acta Med Scand Suppl, V369, P63; WYNDER EL, 1957, CANCER, V10, P1193, DOI 10.1002/1097-0142(195711/12)10:6<1193::AID-CNCR2820100616>3.0.CO;2-Y; WYNDER EL, 1957, J NATL CANCER I, V19, P361, DOI 10.1093/jnci/19.3.361; WYNDER EL, 1959, CANCER, V12, P1079, DOI 10.1002/1097-0142(195911/12)12:6<1079::AID-CNCR2820120604>3.0.CO;2-I; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P329, DOI 10.1001/jama.1950.02910390001001; WYNDER EL, 1953, CANCER RES, V13, P855; WYNDER EL, 1961, CANCER, V14, P1306, DOI 10.1002/1097-0142(196111/12)14:6<1306::AID-CNCR2820140621>3.0.CO;2-T; WYNDER EL, 1969, CANCER, V24, P289, DOI 10.1002/1097-0142(196908)24:2<289::AID-CNCR2820240212>3.0.CO;2-8; WYNDER EL, 1958, CANCER-AM CANCER SOC, V11, P1140, DOI 10.1002/1097-0142(195811/12)11:6<1140::AID-CNCR2820110609>3.0.CO;2-Z; WYNDER EL, 1957, CANCER-AM CANCER SOC, V10, P255, DOI 10.1002/1097-0142(195703/04)10:2<255::AID-CNCR2820100208>3.0.CO;2-H; YANG NC, 1961, SCIENCE, V134, P386, DOI 10.1126/science.134.3476.386; YAO A, 1994, P NATL ACAD SCI USA, V91, P7712, DOI 10.1073/pnas.91.16.7712; YUSPA SH, 1982, CANCER RES, V42, P2344; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0; YUSPA SH, 1981, NATURE, V293, P72, DOI 10.1038/293072a0; Zhang WG, 2001, P NATL ACAD SCI USA, V98, P13948, DOI 10.1073/pnas.241353198	165	38	38	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7392	7411		10.1038/sj.onc.1205800	http://dx.doi.org/10.1038/sj.onc.1205800			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379881	Bronze			2022-12-17	WOS:000178618000011
J	Lee, DCW; Chan, KW; Chan, SY				Lee, DCW; Chan, KW; Chan, SY			RET receptor tyrosine kinase isoforms in kidney function and disease	ONCOGENE			English	Article						RET; GDNF; kidney; mIMCD3; polycystic kidney disease	URETERAL BUD DEVELOPMENT; ENTERIC NERVOUS-SYSTEM; CELL-LINE; NEUROTROPHIC FACTOR; MOUSE KIDNEY; PROTOONCOGENE; EXPRESSION; GDNF; BINDING; EMBRYOGENESIS	The RET proto-oncogene encodes two major isoforms, RET9 and RET51, which differ at the carboxyl-terminal. Loss-of-function mutations in RET result in gut aganglionosis while gain of function mutations result in cancer syndromes. From studies on transgenic mice, RET9 is important for early development of the kidney and the enteric nervous system. Little is known about the function of RET isoforms in later life. Here we report the expression of RET isoforms and its signalling complex, GDNF and GFRalpha1, in foetal and adult human kidneys. We found their expression in both the developing and the adult renal collecting system. We further show that only RET51 but not RET9 could promote the survival and tubulogenesis of mIMCD3 (mouse inner medullary collecting duct) cells in collagen gel. Our results agree with the hypothesis that RET51 signalling is related to differentiation events in later kidney organogenesis. In addition, it may also have a function in the adult kidney. We further extend our study by showing increased RET and GDNF expression in collecting duct cysts of polycystic kidney patients. This suggests that GDNF/RET signalling may contribute to proliferation of the collecting duct epithelium in an autocrine/paracrine manner.	Univ Hong Kong, Queen Mary Hosp, Dept Paediat, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Ctr Human Dev & Birth Defects, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Chan, SY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Paediat, Hong Kong, Hong Kong, Peoples R China.			Chan, Siu Yuen/0000-0001-7262-1293				Anders J, 2001, J BIOL CHEM, V276, P35808, DOI 10.1074/jbc.M104968200; Batourina E, 2001, NAT GENET, V27, P74, DOI 10.1038/83792; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Brenner BM, 1996, BRENNER RECTORS KIDN; Chan SY, 1998, ONCOGENE, V17, P661, DOI 10.1038/sj.onc.1201970; de Graaff E, 2001, GENE DEV, V15, P2433, DOI 10.1101/gad.205001; Edery P, 1997, BIOESSAYS, V19, P389, DOI 10.1002/bies.950190506; Fisher CE, 2001, DEVELOPMENT, V128, P4329; Grimm L, 1998, HUM MOL GENET, V7, P1873, DOI 10.1093/hmg/7.12.1873; Hellmich HL, 1996, MECH DEVELOP, V54, P95, DOI 10.1016/0925-4773(95)00464-5; HOLTHOFER H, 1981, LAB INVEST, V45, P391; Ishiguro Y, 1999, ENDOCRINOLOGY, V140, P3992, DOI 10.1210/en.140.9.3992; Ivanchuk SM, 1998, ONCOGENE, V16, P991, DOI 10.1038/sj.onc.1201622; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Lanoix J, 1996, ONCOGENE, V13, P1153; Lee DCW, 1998, J UROLOGY, V159, P291, DOI 10.1016/S0022-5347(01)64084-9; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; O'Rourke DA, 1999, AM J PHYSIOL-RENAL, V276, pF581, DOI 10.1152/ajprenal.1999.276.4.F581; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Pollack AL, 1998, DEV BIOL, V204, P64, DOI 10.1006/dbio.1998.9091; Poteryaev D, 1999, FEBS LETT, V463, P63, DOI 10.1016/S0014-5793(99)01590-2; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; Reynolds L, 2001, ONCOGENE, V20, P3986, DOI 10.1038/sj.onc.1204434; Sainio K, 1997, DEVELOPMENT, V124, P4077; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; Srinivas S, 1999, DEVELOPMENT, V126, P1375; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; Taraviras S, 1999, DEVELOPMENT, V126, P2785; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885	36	38	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	2002	21	36					5582	5592		10.1038/sj.onc.1205741	http://dx.doi.org/10.1038/sj.onc.1205741			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165857				2022-12-17	WOS:000177442000008
J	Larminat, F; Germanier, M; Papouli, E; Defais, M				Larminat, F; Germanier, M; Papouli, E; Defais, M			Deficiency in BRCA2 leads to increase in non-conservative homologous recombination	ONCOGENE			English	Article						BRCA2; homologous recombination; DNA repair; DNA interstrand crosslink; Rad51; single-strand annealing	STRAND BREAK REPAIR; INTERSTRAND CROSS-LINKS; HAMSTER CELL MUTANTS; MAMMALIAN-CELLS; DNA-REPAIR; RAD51 RECOMBINATION; CHROMOSOMAL BREAKS; IONIZING-RADIATION; VERTEBRATE CELLS; PROTEIN	The BRCA2 tumor suppressor has been implicated in the maintenance of genomic integrity through a function in cellular responses to DNA damage. The BRCA2 protein directly associates with Rad51, that is essential for repair of double-strand breaks (DSBs) by homologous recombination (HR). In this report, we study the BRCA2-defective Chinese hamster cell mutant V-C8 for its ability to perform homology-directed repair (HDR) between repeated sequences. V-C8 cells were recently shown to be defective in Rad51 foci formation in response to DNA damage. Strikingly, we find that these BRCA2 mutant cells exhibit a strong stimulation of HDR activity compared to the V79 parental cells, which harbor a wild-type BRCA2. Furthermore, molecular characterization of the HDR products shows that loss of BRCA2 in V-C8 cells leads to significant reduction in Rad51-dependent gene conversion but strong enhancement of Rad51-independent single-strand annealing (SSA) events frequency. These data imply that, when HDR by conservative gene conversion is impaired, DSBs usually repaired by this pathway are instead resolved by other non-conservative HDR subpathways. Therefore, high chromosomal instability in BRCA2-deficient cells presumably results from enhancement of error-prone repair mechanisms, such as SSA.	CNRS, Inst Pharmacol & Biol Struct, UMR 5089, F-31077 Toulouse 4, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Larminat, F (corresponding author), CNRS, Inst Pharmacol & Biol Struct, UMR 5089, 205 Route Narbonne, F-31077 Toulouse 4, France.							Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; OVERKAMP WJI, 1993, SOMAT CELL MOLEC GEN, V19, P431, DOI 10.1007/BF01233248; Papouli E, 2000, BIOCHEM PHARMACOL, V59, P1101, DOI 10.1016/S0006-2952(00)00234-3; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; VERHAEGH GWCT, 1995, MUTAT RES-DNA REPAIR, V337, P119, DOI 10.1016/0921-8777(95)00017-E; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; Yu VPCC, 2000, GENE DEV, V14, P1400; Yuan SSF, 1999, CANCER RES, V59, P3547; ZDZIENICKA MZ, 1990, SOMAT CELL MOLEC GEN, V16, P575, DOI 10.1007/BF01233098; ZHANG LH, 1992, J MOL BIOL, V223, P627, DOI 10.1016/0022-2836(92)90979-T	31	38	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5188	5192		10.1038/sj.onc.1205659	http://dx.doi.org/10.1038/sj.onc.1205659			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140769				2022-12-17	WOS:000176975900017
J	Kawamata, N; Sakajiri, S; Sugimoto, K; Isobe, Y; Kobayashi, H; Oshimi, K				Kawamata, N; Sakajiri, S; Sugimoto, K; Isobe, Y; Kobayashi, H; Oshimi, K			A novel chromosomal translocation t(1;14)(q25;q32) in pre-B acute lymphoblastic leukemia involves the LIM homeodomain protein gene, Lhx4	ONCOGENE			English	Article						inverse PCR; transcriptional factor; immunoglobulin heavy chain gene; RT-PCR; reporter gene assay	CHRONIC MYELOGENOUS LEUKEMIA; TRANSCRIPTION FACTORS; MOLECULAR-CLONING; HOMEOBOX GENES; HOX GENE; EXPRESSION; ACTIVATION; LYMPHOMAS; LOCUS; HLH-2	Chromosome 1q21-25 is one of the hotspots of chromosomal abnormalities including translocations and duplications in hematological malignancies. This would suggest that oncogene(s) reside in this region. We have cloned the junctional sequence of t(1;14)(q25;q32) in preB acute lymphoblastic leukemia cells by an inverse PCR method. A novel sequence was fused to the joining region of the immunoglobulin heavy chain gene. We confirmed this rearrangement by Southern blot analysis, genomic PCR and fluorescence in situ hybridization. We found a coding sequence which is homologous to the mouse Lhx4 cDNA sequence 17 kb from the breakpoint. The human Lhx4 gene encodes 390 amino-acids, including one tandem pair of LIM domains and one homeodomain. The human Lhx4 gene consists of six exons. Lhx4 protein is very homologous to human Lhx3 protein except in the N-terminal region. The transcripts of the Lhx4 gene were not detected in adult multiple tissues analysed by Northern blotting, but were detected in the leukemic cells carrying t(1;14)(q25;q32) by reverse-transcription PCR. The protein expression of Lhx4 in these leukemic cells was confirmed by Western blot analysis. Lhx4 activated the reporter gene carrying the mouse alpha-glycoprotein subunit promoter region, which is regulated by Lhx3. LIM protein and homeodomain protein genes are frequently involved in translocations of hematological malignancies. The Lhx4 gene is deregulated in the leukemic cells and Lhx4 protein may play an important role, possibly as an activator, in leukemogenesis.	Juntendo Univ, Sch Med, Dept Med, Div Hematol,Bunkyo Ku, Tokyo 1138421, Japan; Saitama Canc Ctr, Dept Med, Div Hematol, Ina, Saitama 3620806, Japan	Juntendo University	Kawamata, N (corresponding author), Juntendo Univ, Sch Med, Dept Med, Div Hematol,Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.			Sugimoto, Keiji/0000-0001-9835-5405				Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Buske C, 2000, INT J HEMATOL, V71, P301; Dawid IB, 2001, NEURON, V30, P301, DOI 10.1016/S0896-6273(01)00307-5; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; De Vita VT, 2001, CANC PRINCIPLES PRAC; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; Jin L, 1998, ENDOCR PATHOL, V9, P169, DOI 10.1007/BF02782609; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; KOBAYASHI H, 1994, BLOOD, V84, P3473; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; Liu YB, 2002, BRAIN RES, V928, P147, DOI 10.1016/S0006-8993(01)03243-7; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Machinis K, 2001, AM J HUM GENET, V69, P961, DOI 10.1086/323764; MIKI T, 1994, BLOOD, V83, P217; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Nowell PC, 1997, CANCER GENET CYTOGEN, V94, P13, DOI 10.1016/S0165-4608(96)00227-0; Popescu NC, 1997, CANCER GENET CYTOGEN, V93, P10, DOI 10.1016/S0165-4608(96)00262-2; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; Sharma K, 1998, CELL, V95, P817, DOI 10.1016/S0092-8674(00)81704-3; Sheng HZ, 1997, SCIENCE, V278, P1809, DOI 10.1126/science.278.5344.1809; Sloop KW, 1999, MOL ENDOCRINOL, V13, P2212, DOI 10.1210/me.13.12.2212; Sloop KW, 2001, J BIOL CHEM, V276, P36311, DOI 10.1074/jbc.M103888200; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Thor S, 1999, NATURE, V397, P76, DOI 10.1038/16275; Willis TG, 1997, BLOOD, V90, P2456; Willis TG, 2000, BLOOD, V96, P808, DOI 10.1182/blood.V96.3.808.015k30_808_822; Wu HK, 1997, BIOCHEM BIOPH RES CO, V234, P742, DOI 10.1006/bbrc.1997.6592; Wu HK, 1996, ONCOGENE, V12, P1205	35	38	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4983	4991		10.1038/sj.onc.1205628	http://dx.doi.org/10.1038/sj.onc.1205628			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118377				2022-12-17	WOS:000176874800013
J	Yu, CY; Wang, LH; Khaletskiy, A; Farrar, WL; Larner, A; Colburn, NH; Li, JH				Yu, CY; Wang, LH; Khaletskiy, A; Farrar, WL; Larner, A; Colburn, NH; Li, JH			STAT3 activation is required for interleukin-6 induced transformation in tumor-promotion sensitive mouse skin epithelial cells	ONCOGENE			English	Article						transcription factor; STAT3; transformation response; matrix metalloproteinase; mouse skin cells	NF-KAPPA-B; EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER CELLS; TRANSCRIPTION FACTORS; MATRIX METALLOPROTEINASES; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; TRANSGENIC MICE; PROTEIN-KINASE; AP-1	STAT3, a member of signal transducers and activators of transcription (STATs) originally discovered as mediators in cytokine signaling pathways, plays an active role in oncogenesis. However, the function of STAT3 in signaling multistage carcinogenesis, especially in transformation of tumor-promotion sensitive epithelial cells has not been elucidated. The present study demonstrates that STAT3 is activated in interleukin-6 induced transformation in mouse skin epithelial cells. DNA binding and transcriptional activities of STAT3 were significantly increased by interleukin-6. This induced anchorage-independent transformation in tumor-promotion sensitive JB6 mouse skin P+ cells but not in the resistant variant P- cells. Two forms of dominant negative STAT3 (mutant of transcriptional domain, mF, or DNA-binding domain, mD) were stably transfected into P+ cells. Activation of STAT3 was abolished and importantly, interleukin-6 induced anchorage-independent growth was absent in both mutant STAT3 transfectants. To determine the genes targeted by STAT3, three matrix metalloproteinase proteins linked with carcinogenesis of epithelial cells were analysed. Both basal and interleukin-6 induced expression of collagenase I and stromelysin I, but not gelatinase A, were inhibited in the mutant STAT3 transfectants. Furthermore, transfection of a wild type STAT3 restored STAT3 transactivation and response to interleukin-6 induced transformation in mutant STAT3 transfectants, which up-regulated collagenase I and stromelysin I as well. Together, these results provide the first evidence that STAT3 activation is required in the progression of multistage carcinogenesis of mouse skin epithelial cells, and matrix metalloproteinases are actively involved in STAT3-mediated cell transformation.	City Hope Natl Med Ctr, Beckman Res Inst, Div Radiat Oncol, Duarte, CA 91010 USA; NCI, Expt Immunol Lab, NIH, Frederick, MD 21702 USA; NCI, Cytokine Mol Mech Sect, Mol Immunoregulat Lab, NIH, Frederick, MD 21702 USA; NCI, Lab Basic Res, NIH, Frederick, MD 21702 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44106 USA	City of Hope; Beckman Research Institute of City of Hope; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cleveland Clinic Foundation	Li, JH (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Radiat Oncol, Halper S Bldg,H115,1500 Duarte Rd, Duarte, CA 91010 USA.			Li, Jian Jian/0000-0003-3694-9675; Yu, Cheng-Rong/0000-0001-7246-0362				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; Balmain A, 2000, CARCINOGENESIS, V21, P371, DOI 10.1093/carcin/21.3.371; Beetz A, 2000, INT J RADIAT BIOL, V76, P1443, DOI 10.1080/09553000050176207; BENEDETTI FD, 1990, MOL CELL BIOL CYTOKI, V1, P275; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Besser D, 1999, MOL CELL BIOL, V19, P1401; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BROWN K, 1995, CANCER METAST REV, V14, P113, DOI 10.1007/BF00665795; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1996, RECENT PROG HORM RES, V51, P391; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Demoulin JB, 2000, CANCER RES, V60, P3971; Dokter WHA, 1996, LEUKEMIA, V10, P1308; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; FINBLOOM DS, 1995, CELL SIGNAL, V7, P739, DOI 10.1016/0898-6568(95)02004-7; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Huang CS, 1996, MOL CELL BIOL, V16, P6427; IGLESIAS M, 1995, AM J PATHOL, V146, P944; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; KAWANO M, 1989, CANCER SURV, V8, P905; Korzus E, 1997, J BIOL CHEM, V272, P1188, DOI 10.1074/jbc.272.2.1188; Larner A, 1996, BIOTHERAPY, V8, P175, DOI 10.1007/BF01877202; Li JJ, 1996, CANCER RES, V56, P483; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Li JJ, 1997, CANCER RES, V57, P3569; LI JJ, 1995, ONCOGENE, V10, P1989; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; Li ZK, 2001, RADIAT RES, V155, P543, DOI 10.1667/0033-7587(2001)155[0543:EGAIMH]2.0.CO;2; Lochter A, 1998, ANN NY ACAD SCI, V857, P180, DOI 10.1111/j.1749-6632.1998.tb10116.x; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MATRISIAN LM, 1994, ANN NY ACAD SCI, V732, P42, DOI 10.1111/j.1749-6632.1994.tb24723.x; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; SIU X, 1999, BLOOD, V93, P2525; Stancato LF, 1996, J BIOL CHEM, V271, P4134; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; Takeda K, 1998, J IMMUNOL, V161, P4652; TOSATO G, 1988, SCIENCE, V239, P502, DOI 10.1126/science.2829354; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VAN SJ, 1990, ANNU REV IMMUNOL, V8, P253; Vincenti MP, 1998, MOL CARCINOGEN, V21, P194, DOI 10.1002/(SICI)1098-2744(199803)21:3<194::AID-MC7>3.0.CO;2-M; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; Xia CL, 1997, INT J BIOCHEM CELL B, V29, P1525, DOI 10.1016/S1357-2725(97)00083-6; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu CR, 1998, J LEUKOCYTE BIOL, V64, P245, DOI 10.1002/jlb.64.2.245; Yu CR, 1996, J IMMUNOL, V157, P126; Yu CR, 1999, J IMMUNOL, V162, P2785; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	67	38	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					3949	3960		10.1038/sj.onc.1205499	http://dx.doi.org/10.1038/sj.onc.1205499			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037677				2022-12-17	WOS:000175869900001
J	Yuan, LWC; Giordano, A				Yuan, LWC; Giordano, A			Acetyltransferase machinery conserved in p300/CBP-family proteins	ONCOGENE			English	Article						p300; CBP; PCAT; histone/protein acetyltransferase; protein domains; protein structure	MULTIPLE SEQUENCE ALIGNMENT; TRANSCRIPTIONAL COACTIVATOR; DROSOPHILA CBP; DNA-BINDING; P300; ACETYLATION; CBP/P300; ACTIVATION; CHROMATIN; GENE	CREB-binding protein (CBP) and p300 are highly, conserved and functionally related transcription coactivators and histone/protein acetyltransferases. They are, tumor suppressors, participate in a wide variety of physiological events, and serve as integrators among different signal transduction pathways. In this study, 11 distinct proteins that have a high degree of homology with the amino acid sequence of p300 have been identified in current protein databases. All of these, 11 proteins belong to either animal or plant multicellular organisms (higher eucaryotes). Conservation of p300/ CBP domains among these proteins was examined further by sequence alignment and pattern search. The domains of p300/CBP that are required for the HAT function, including PHD, putative CoA-binding, and ZZ domains, are conserved in all of these 11 proteins. This observation is consistent with the previous functional assays and indicates that they are a family of acetyltransferases, i.e. p300/CBP acetyltransferases (PCAT). TAZ domains (TAZ1 and/or TAZ2) of PCAT proteins may allow them to participate in transcription regulation by either directly recruiting transcription factors, acetylating them subsequently, or directing targeted acetylation of nucleosomal histones.	Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA	Jefferson University; Boston University	Giordano, A (corresponding author), Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA.	agiordan@lac.jci.tju.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Akimaru H, 1997, NAT GENET, V17, P211, DOI 10.1038/ng1097-211; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bordoli L, 2001, NUCLEIC ACIDS RES, V29, P589, DOI 10.1093/nar/29.3.589; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Clements A, 1999, EMBO J, V18, P3521, DOI 10.1093/emboj/18.13.3521; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Deng LW, 2000, VIROLOGY, V277, P278, DOI 10.1006/viro.2000.0593; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; ECKNER R, 1994, COLD SPRING HARB SYM, V59, P85, DOI 10.1101/SQB.1994.059.01.012; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Giles RH, 1997, GENOMICS, V42, P96, DOI 10.1006/geno.1997.4699; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Goodman RH, 2000, GENE DEV, V14, P1553; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karplus K, 1998, BIOINFORMATICS, V14, P846, DOI 10.1093/bioinformatics/14.10.846; KOKEN MHM, 1995, CR ACAD SCI III-VIE, V318, P733; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P11, DOI 10.1016/0968-0004(96)80878-4; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Radhakrishnan I, 1999, J MOL BIOL, V287, P859, DOI 10.1006/jmbi.1999.2658; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Shi Y, 1998, GENE DEV, V12, P943, DOI 10.1101/gad.12.7.943; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Yuan YP, 1998, BIOINFORMATICS, V14, P285, DOI 10.1093/bioinformatics/14.3.285; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	54	38	42	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2253	2260		10.1038/sj.onc.1205283	http://dx.doi.org/10.1038/sj.onc.1205283			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948408				2022-12-17	WOS:000174555300014
J	Haier, J; Nicolson, GL				Haier, J; Nicolson, GL			PTEN regulates tumor cell adhesion of colon carcinoma cells under dynamic conditions of fluid flow	ONCOGENE			English	Article						PTEN; cell adhesion; colon carcinoma; shear stress; laminar flow; focal adhesion kinase	EXTRACELLULAR-MATRIX COMPONENTS; PROTEIN-TYROSINE PHOSPHATASES; FOCAL ADHESION; JUVENILE POLYPOSIS; SIGNAL-TRANSDUCTION; COWDEN-DISEASE; SUPPRESSOR; GENE; INTEGRIN; MUTATIONS	The regulation of integrin-mediated cell adhesion and its stabilization involves different phosphorylation and dephosphorylation events. Focal adhesion kinase (FAK) has been recently found to be a substrate of the dual-specific phosphatase PTEN in glioma cells, where it appears to be involved in regulation of cell spreading and migration as part of focal adhesions. We have investigated the role of PTEN in cell adhesion of HT-29 human colon carcinoma cells under static and hydrodynamic conditions of fluid flow. PTEN coprecipitated with FAK and paxillin dependent on the formation of adhesions to collagens. This corresponded with an adhesion-dependent increase in Tyr-phosphatase activity of PTEN. Using preparations of native FAK and PTEN from HT-29 cells in a specific Tyr-phosphatase assay FAK was identified as substrate for this dephosphorylation. If expression of PTEN was reduced using antisense oligonucleotides cell adhesion under dynamic conditions of laminar flow, but not under static conditions was significantly increased. In addition, cell spreading was increased in cells with reduced PTEN expression. We conclude that PTEN appears to be involved in the regulation of integrin-mediated adhesion through dephosphorylation of FAK. This phosphatase might play a role as a negative regulator for the formation of stable HT-29 cell adhesion to extracellular matrix.	Inst Mol Med, Huntington Beach, CA 92649 USA; Univ Hosp Muenster, Dept Surg, Mol Biol Lab, D-48149 Munster, Germany	University of Munster	Haier, J (corresponding author), Inst Mol Med, 15162 Triton Lane, Huntington Beach, CA 92649 USA.	haier@uni-muenster.de						Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Besson A, 1999, EUR J BIOCHEM, V263, P605, DOI 10.1046/j.1432-1327.1999.00542.x; Cairns P, 1997, CANCER RES, V57, P4997; Chang JG, 1999, EUR J CANCER, V35, P647, DOI 10.1016/S0959-8049(98)00411-0; CHEN YP, 1994, J BIOL CHEM, V269, P18307; Chi SG, 1998, GASTROENTEROLOGY, V115, P1084, DOI 10.1016/S0016-5085(98)70078-2; Cool D E, 1993, Semin Cell Biol, V4, P443, DOI 10.1006/scel.1993.1052; Dahia PLM, 1997, CANCER RES, V57, P4710; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Garcia JM, 1999, BREAST CANCER RES TR, V57, P237, DOI 10.1023/A:1006273516976; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Ghosh AK, 1999, GENE, V235, P85, DOI 10.1016/S0378-1119(99)00206-1; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Guanti G, 2000, HUM MOL GENET, V9, P283, DOI 10.1093/hmg/9.2.283; Haier J, 1999, INT J COLORECTAL DIS, V14, P119, DOI 10.1007/s003840050196; Haier J, 1999, CLIN EXP METASTAS, V17, P377, DOI 10.1023/A:1006658414040; Haier J, 1999, CLIN EXP METASTAS, V17, P713, DOI 10.1023/A:1006754829564; Haier J, 2000, J CANCER RES CLIN, V126, P699, DOI 10.1007/s004320000161; Haier J, 1999, BRIT J CANCER, V80, P1867, DOI 10.1038/sj.bjc.6690614; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Li DM, 1997, CANCER RES, V57, P2124; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Maier D, 1999, CANCER RES, V59, P5479; Manes S, 1999, MOL CELL BIOL, V19, P3125; Marsh DJ, 1997, CANCER RES, V57, P5017; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Olschwang S, 1998, NAT GENET, V18, P12, DOI 10.1038/ng0198-12; Pesche S, 1998, ONCOGENE, V16, P2879, DOI 10.1038/sj.onc.1202081; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rasheed BKA, 1997, CANCER RES, V57, P4187; Resnick N, 1997, ADV EXP MED BIOL, V430, P155; Retta SF, 1996, EXP CELL RES, V229, P307, DOI 10.1006/excr.1996.0376; Risinger JI, 1997, CANCER RES, V57, P4736; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TAKAGI J, 1995, CELL STRUCT FUNCT, V20, P403, DOI 10.1247/csf.20.403; Tamura M, 1999, JNCI-J NATL CANCER I, V91, P1820, DOI 10.1093/jnci/91.21.1820; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tsuchiya KD, 1998, GENE CHROMOSOME CANC, V21, P113, DOI 10.1002/(SICI)1098-2264(199802)21:2<113::AID-GCC6>3.0.CO;2-3; Wang XD, 2000, J IMMUNOL, V164, P1934, DOI 10.4049/jimmunol.164.4.1934; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yano Y, 1996, AM J PHYSIOL-CELL PH, V271, pC635, DOI 10.1152/ajpcell.1996.271.2.C635; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	62	38	50	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1450	1460		10.1038/sj.onc.1205213	http://dx.doi.org/10.1038/sj.onc.1205213			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857088				2022-12-17	WOS:000173861000015
J	Saavedra, AP; Tsygankova, OM; Prendergast, GV; Dworet, JH; Cheng, G; Meinkoth, JL				Saavedra, AP; Tsygankova, OM; Prendergast, GV; Dworet, JH; Cheng, G; Meinkoth, JL			Role of cAMP, PKA and Rap1A in thyroid follicular cell survival	ONCOGENE			English	Article						thyroid; apoptosis; PKA; cAMP; Rap1	DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; MEDIATED APOPTOSIS; SIGNALING PATHWAYS; PHOSPHORYLATION; ACTIVATION; INHIBITION; GROWTH; RAS; MONOPHOSPHATE	Cyclic AMP (cAMP) rescues cells from apoptosis stimulated by diverse insults. We examined the role of cAMP as a survival factor, and the signaling pathways through which cAMP affords protection. Rat thyroid cells were selected for these studies given the predominant role of cAMP in thyrotropin (TSH)-stimulated proliferation and as an oncogene in thyroid cells. Wistar rat thyroid (WRT) cells perished via apoptosis following sodium nitroprusside (SNP) treatment. Elevations in cAMP following treatment with forskolin, 8BrcAMP or IBMX rescued cells from SNP-induced cell death. Notably, TSH prevented apoptosis, implicating an important role for this hormone as a survival factor. Cyclic AMP activates multiple signaling pathways including those mediated through PKA, PI3K, p70S6k and the Ras-related small G protein, Rap1. Intriguingly, multiple pathways modulate thyroid cell survival. Interference with cAMP-stimulated p70S6k, but not PI3K, activity abrogated cell survival. Treatment with PKA inhibitors was sufficient to stimulate apoptosis in hormone-deprived cells and markedly enhanced cell death in response to SNP. Cells expressing an activated Rap1A mutant exhibited an enhanced sensitivity to SNP-induced apoptosis, while those expressing dominant negative Rap1A were resistant to SNP-initiated cell death. Together, these findings establish an important role for PKA and Rap1 in the control of thyroid cell survival.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Meinkoth, JL (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.	meinkoth@pharm.med.upenn.edu	Meinkoth, Judy L/G-2900-2010		NIDDK NIH HHS [R01 DK02494, K 02 DK 55757] Funding Source: Medline; NINDS NIH HHS [5-F31-NS09883] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS009883] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Arscott PL, 1997, ENDOCRINOLOGY, V138, P5019, DOI 10.1210/en.138.11.5019; Banke TG, 2000, J NEUROSCI, V20, P89, DOI 10.1523/JNEUROSCI.20-01-00089.2000; BRANDI ML, 1987, MOL CELL ENDOCRINOL, V54, P91, DOI 10.1016/0303-7207(87)90142-0; Bretz JD, 1999, J BIOL CHEM, V274, P23627, DOI 10.1074/jbc.274.33.23627; BUBIS J, 1988, J BIOL CHEM, V263, P9668; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Cass LA, 1998, ENDOCRINOLOGY, V139, P1991, DOI 10.1210/en.139.4.1991; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Cheng GJ, 2001, ONCOGENE, V20, P7334, DOI 10.1038/sj.onc.1204928; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; DANIEL V, 1973, P NATL ACAD SCI USA, V70, P76, DOI 10.1073/pnas.70.1.76; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dremier S, 2000, BIOCHEM BIOPH RES CO, V267, P7, DOI 10.1006/bbrc.1999.1919; DREMIER S, 1994, BIOCHEM BIOPH RES CO, V200, P52, DOI 10.1006/bbrc.1994.1412; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; FINDIK D, 1995, J CELL BIOCHEM, V57, P12, DOI 10.1002/jcb.240570103; Fladmark KE, 1997, BIOCHEM BIOPH RES CO, V232, P20, DOI 10.1006/bbrc.1997.6214; GEIER A, 1995, J CELL PHYSIOL, V163, P570, DOI 10.1002/jcp.1041630318; Gire V, 2000, ONCOGENE, V19, P2269, DOI 10.1038/sj.onc.1203544; Gu CH, 2000, J BIOL CHEM, V275, P20726, DOI 10.1074/jbc.M000152200; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Jun CD, 1998, CELL IMMUNOL, V183, P13, DOI 10.1006/cimm.1997.1232; Kawakami A, 1996, ENDOCRINOLOGY, V137, P3163, DOI 10.1210/en.137.8.3163; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kupperman E, 1996, ENDOCRINOLOGY, V137, P96, DOI 10.1210/en.137.1.96; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Li X, 1999, ENDOCRINOLOGY, V140, P5962, DOI 10.1210/en.140.12.5962; LINTIG FCV, 2000, ONCOGENE, V19, P4029; MAENHAUT C, 1991, BIOCHIMIE, V73, P29, DOI 10.1016/0300-9084(91)90070-H; MALY FE, 1994, J BIOL CHEM, V269, P18743; Medina DL, 2000, EUR J ENDOCRINOL, V143, P161, DOI 10.1530/eje.0.1430161; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Motohashi S, 1996, LIFE SCI, V59, pPL227, DOI 10.1016/0024-3205(96)00437-7; Myklebust JH, 1999, J CELL PHYSIOL, V180, P71; Niwa M, 1999, EUR J PHARMACOL, V371, P59, DOI 10.1016/S0014-2999(99)00145-4; NOBES CD, 1995, EUR J NEUROSCI, V7, P344, DOI 10.1111/j.1460-9568.1995.tb01069.x; Ottonello L, 1998, EXP HEMATOL, V26, P895; Parvathenani LK, 1998, J BIOL CHEM, V273, P6736, DOI 10.1074/jbc.273.12.6736; Polte T, 1998, BIOCHEM BIOPH RES CO, V251, P460, DOI 10.1006/bbrc.1998.9486; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Somers JP, 1999, MOL ENDOCRINOL, V13, P1364, DOI 10.1210/me.13.8.1364; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Villone G, 1997, CELL GROWTH DIFFER, V8, P1181; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WALKER C, 1983, J IMMUNOL, V130, P1770; Walton M, 1999, J NEUROCHEM, V73, P1836; Webster CRL, 1998, HEPATOLOGY, V27, P1324, DOI 10.1002/hep.510270519; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; WynfordThomas D, 1997, HORM RES, V47, P145, DOI 10.1159/000185458; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yao R, 1996, ONCOGENE, V13, P343; Zanassi P, 2001, J BIOL CHEM, V276, P11487, DOI 10.1074/jbc.M007631200	62	38	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2002	21	5					778	788		10.1038/sj.onc.1205123	http://dx.doi.org/10.1038/sj.onc.1205123			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850806				2022-12-17	WOS:000173427000009
J	Koch, CA; Huang, SC; Moley, JF; Azumi, N; Chrousos, GP; Gagel, RF; Zhuang, ZP; Pacak, K; Vortmeyer, AO				Koch, CA; Huang, SC; Moley, JF; Azumi, N; Chrousos, GP; Gagel, RF; Zhuang, ZP; Pacak, K; Vortmeyer, AO			Allelic imbalance of the mutant and wild-type RET allele in MEN 2A-associated medullary thyroid carcinoma	ONCOGENE			English	Article						RET; MEN 2; medullary thyroid carcinoma; allelic imbalance	NONRANDOM DUPLICATION; PROTOONCOGENE	Germline mutations of the RET proto-oncogene are responsible for the familial tumor syndrome called multiple endocrine neoplasia type 2 (MEN 2) that includes medullary thyroid carcinoma (MTC). Although inherited mutations of RET lead to tumor formation in patients with MEN 2, it is not understood why only selected cells develop into tumors. We have recently shown that duplication of the mutated RET allele or loss of the wild-type allele might represent mechanisms of tumorigenesis in patients with MEN 2A-related pheochromocytoma. We now analysed 19 DNA samples of MTC (15 of which were non-microdissected, four of which were microdissected) from patients with MEN 2A. Using polymorphic marker and phosphorimage densitometry analyses, we found allelic imbalance of the mutated and wild-type RET allele in six of 19 DNA MTC samples. Of note, two of the four microdissected tumor DNA samples showed allelic imbalance of RET, whereas only four of the 15 non-microdissected MTC samples did. These results underscore the significance of microdissection in the analysis of tumor DNA. In our study, some of the non-microdissected tumor DNA samples may have failed to display allelic imbalance of RET, because of contamination of tumor DNA with nonneoplastic. DNA or noninformative microsatellite marker analysis. Taken together, our results suggest allelic imbalance between mutated and wild-type RET as a possible mechanism for tumor formation in some patients with MEN 2A-related MTC.	NINDS, Mol Pathogenesis Unit, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; NICHD, Pediat & Reprod Endocrinol Branch, NIH, Bethesda, MD USA; Washington Univ, Sch Med, Dept Surg, St Louis, MO USA; Georgetown Univ, Washington, DC USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Washington University (WUSTL); Georgetown University; University of Texas System; UTMD Anderson Cancer Center	Koch, CA (corresponding author), NINDS, Mol Pathogenesis Unit, Surg Neurol Branch, NIH, Bldg 10,Rm 9D42, Bethesda, MD 20892 USA.	kochc@exchange.nih.gov	Koch, Christian A/A-4699-2008	Koch, Christian A/0000-0003-3127-5739; Koch, Christian/0000-0003-0678-1242	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002991] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; Cinti R, 2000, CYTOGENET CELL GENET, V88, P56, DOI 10.1159/000015485; Eng C, 1996, NEW ENGL J MED, V335, P943, DOI 10.1056/NEJM199609263351307; Huang SC, 2000, CANCER RES, V60, P6223; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; Ponder BAJ, 1999, CANCER RES, V59, p1736S; Zhuang Z, 1998, Cell Vis, V5, P43; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727; ZHUANG ZP, 1995, AM J PATHOL, V146, P620	11	38	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2001	20	53					7809	7811		10.1038/sj.onc.1204991	http://dx.doi.org/10.1038/sj.onc.1204991			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753660				2022-12-17	WOS:000172161700013
J	Werner, S; Beer, HD; Mauch, C; Luscher, B; Werner, S				Werner, S; Beer, HD; Mauch, C; Luscher, B; Werner, S			The Mad1 transcription factor is a novel target of activin and TGF-beta action in keratinocytes: possible role of Mad1 in wound repair and psoriasis	ONCOGENE			English	Article						Mad; Myc; wound; epidermis; keratinocyte; psoriasis	GROWTH-FACTOR-BETA; TRANSGENIC MICE REVEALS; MYC ANTAGONIST MAD1; C-MYC; EPIDERMAL DIFFERENTIATION; TERMINAL DIFFERENTIATION; HISTONE DEACETYLASE; MYC/MAX/MAD NETWORK; NUCLEOTIDE-SEQUENCE; CELL-LINE	Activin A, a member of the transforming growth factor beta (TGF-beta) superfamily, affects keratinocyte proliferation and differentiation in vitro and in vivo. However, little is known about the mechanisms of activin action in keratinocytes, and its target genes have not been identified. In this study, we demonstrate that activin A and TGF-beta1 directly induce the expression and activity of Mad1, an antagonist of the c-Myc transcription factor, in the human HaCaT keratinocyte cell line. Expression and activity of Mad1 was strongly induced by both factors in keratinocytes, although the intensity of induction was different for activin A and TGF-beta1. To determine a possible role of activin and TGF-beta1 in the regulation of mad1 expression in vivo, we analysed its expression during cutaneous wound repair when high levels of these factors are present. Expression of mad1 mRNA and protein, but not of other mad genes, increased significantly after skin injury, particularly in polymorphonuclear leukocytes and in suprabasal keratinocytes of the hyperproliferative epithelium. Elevated levels of mad1 mRNA were also detected in the hyperthickened epidermis of psoriatic patients. Since Mad1 regulates proliferation and/or differentiation of various cell types, our results suggest that this transcription factor mediates at least in the part the anti-mitotic and/or differentiation-inducing activities of TGF-beta and activin in keratinocytes.	ETH Zurich Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland; Univ Cologne, Dept Dermatol & Venerol, D-50924 Cologne, Germany; Hannover Med Sch, Inst Mol Biol, D-30623 Hannover, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Cologne; Hannover Medical School	Werner, S (corresponding author), ETH Zurich Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland.	Sabine.werner@cell.biol.ethz.ch	; Luscher, Bernhard/A-7330-2011	Werner, Sabine/0000-0001-7397-8710; Beer, Hans-Dietmar/0000-0002-8085-713X; Luscher, Bernhard/0000-0002-9622-8709				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARK RAF, 1996, MOL BIOL WOUND REPAI, P195; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Frank S, 1996, J BIOL CHEM, V271, P10188, DOI 10.1074/jbc.271.17.10188; Gandarillas A, 2000, EXP GERONTOL, V35, P53, DOI 10.1016/S0531-5565(99)00088-1; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; Gehring S, 2000, J BIOL CHEM, V275, P10413, DOI 10.1074/jbc.275.14.10413; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; Hubner G, 1996, DEV BIOL, V173, P490, DOI 10.1006/dbio.1996.0042; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Larsson LG, 1997, ONCOGENE, V15, P737, DOI 10.1038/sj.onc.1201390; LARSSON LG, 1994, ONCOGENE, V9, P1247; Lymboussaki A, 1996, BRIT J CANCER, V73, P1347, DOI 10.1038/bjc.1996.257; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; MASSAGUE J, 1990, ANN REV CELL BIOL, V6, P1; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Munz B, 1999, EMBO J, V18, P5205, DOI 10.1093/emboj/18.19.5205; Munz B, 1997, J INVEST DERMATOL, V108, P307, DOI 10.1111/1523-1747.ep12286470; OKane S, 1997, INT J BIOCHEM CELL B, V29, P63, DOI 10.1016/S1357-2725(96)00120-3; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; Queva C, 1999, CELL GROWTH DIFFER, V10, P785; Queva C, 2001, MOL CELL BIOL, V21, P703, DOI 10.1128/MCB.21.3.703-712.2001; ROBERTS AB, 1996, MOL CELLULAR BIOL WO, P275; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; Seishima M, 1999, J INVEST DERMATOL, V112, P432, DOI 10.1046/j.1523-1747.1999.00558.x; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; Shimizu A, 1998, GENES CELLS, V3, P125, DOI 10.1046/j.1365-2443.1998.00174.x; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; Wang XJ, 1999, P NATL ACAD SCI USA, V96, P8483, DOI 10.1073/pnas.96.15.8483; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; WERNER S, 1994, J INVEST DERMATOL, V103, P469, DOI 10.1111/1523-1747.ep12395564; Werner S, 2000, EXP CELL RES, V254, P80, DOI 10.1006/excr.1999.4726; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; Yin XY, 1999, ONCOGENE, V18, P6621, DOI 10.1038/sj.onc.1203097; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	51	38	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7494	7504		10.1038/sj.onc.1204937	http://dx.doi.org/10.1038/sj.onc.1204937			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709721				2022-12-17	WOS:000171976900006
J	Cabeza-Arvelaiz, Y; Thompson, TC; Sepulveda, JL; Chinault, AC				Cabeza-Arvelaiz, Y; Thompson, TC; Sepulveda, JL; Chinault, AC			LAPSER1: a novel candidate tumor suppressor gene from 10q24.3	ONCOGENE			English	Article						prostate cancer; tumor suppressor; LZTS1; LAPSER1	HUMAN PROSTATE-CANCER; FREQUENT INACTIVATION; ALLELIC LOSS; CELL-LINES; PTEN/MMAC1; CARCINOMAS; REGIONS; 8P22; PTEN; EXPRESSION	Numerous LOH and mutation analysis studies in different tumor tissues, including prostate, indicate that there are multiple tumor suppressor genes (TSGs) present within the human chromosome 8p21-22 and 10q23-24 regions. Recently, we showed that LZTS1 (or FEZ1), a putative TSG located on 8p22, has the potential to function as a cell growth modulator. We report here the cloning, gene organization, cDNA sequence characterization and expression analysis of LAPSER1, an LZTS1-related gene. This gene maps within a subregion of human chromosome 10q24.3 that has been reported to be deleted in various cancers, including prostate tumors, as frequently as the neighboring PTEN locus. The complete LAPSER1 cDNA sequence encodes a predicted protein containing various domains resembling those typically found in transcription factors (P-Box, Q-rich and multiple leucine zippers). LAPSER1 is expressed at the highest levels in normal prostate and testis, where multiple isoforms are seen, some of which are either undetectable or differentially expressed in some prostate tumor tissues and cell lines. Over-expression of LAPSER1 cDNA strongly inhibited cell growth and colony-forming efficiencies of most cancer cells assessed. Together these data suggest that LAPSER1 is another gene involved in the regulation of cell growth whose loss of function may contribute to the development of cancer.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Urol, Houston, TX 77030 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA	Baylor College of Medicine; Baylor College of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Chinault, AC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P50CA058204] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA58204] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bova GS, 1996, GENOMICS, V35, P46, DOI 10.1006/geno.1996.0321; Cabeza-Arvelaiz Y, 2001, ONCOGENE, V20, P4169, DOI 10.1038/sj.onc.1204539; CABEZAARVELAIZ Y, 1993, DNA CELL BIOL, V12, P881, DOI 10.1089/dna.1993.12.881; Cairns P, 1997, CANCER RES, V57, P4997; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; Chiariello E, 1998, ONCOGENE, V16, P541, DOI 10.1038/sj.onc.1201689; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dong JT, 1998, ONCOGENE, V17, P1979, DOI 10.1038/sj.onc.1202119; Feilotter HE, 1998, ONCOGENE, V16, P1743, DOI 10.1038/sj.onc.1200205; Foulkes NS, 1996, BBA-REV CANCER, V1288, pF101, DOI 10.1016/S0304-419X(96)00025-X; FUJIWARA Y, 1995, ONCOGENE, V10, P891; Gotoh A, 1997, J UROLOGY, V158, P636, DOI 10.1016/S0022-5347(01)64574-9; GRAY IC, 1995, CANCER RES, V55, P4800; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; ICHIKAWA T, 1994, CANCER RES, V54, P2299; Ishii H, 1999, P NATL ACAD SCI USA, V96, P3928, DOI 10.1073/pnas.96.7.3928; Ittmann M, 1996, CANCER RES, V56, P2143; KAGAN J, 1995, ONCOGENE, V11, P2121; KAHN T, 1994, CANCER RES, V54, P1305; Kim SK, 1998, ONCOGENE, V17, P1749, DOI 10.1038/sj.onc.1202073; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAMPARIELLO F, 1994, CYTOMETRY, V15, P294, DOI 10.1002/cyto.990150404; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MacGrogan D, 1996, GENOMICS, V35, P55, DOI 10.1006/geno.1996.0322; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Murakami YS, 1996, CANCER RES, V56, P2157; Narahara K, 1997, J MED GENET, V34, P213, DOI 10.1136/jmg.34.3.213; Orikasa K, 1998, J HUM GENET, V43, P228, DOI 10.1007/s100380050078; Petersen S, 1998, ONCOGENE, V17, P449, DOI 10.1038/sj.onc.1201949; PIRROTTA V, 1987, EMBO J, V6, P791, DOI 10.1002/j.1460-2075.1987.tb04821.x; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Teng DHF, 1997, CANCER RES, V57, P5221; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; Yeh JJ, 1999, GENE CHROMOSOME CANC, V26, P322, DOI 10.1002/(SICI)1098-2264(199912)26:4<322::AID-GCC6>3.0.CO;2-#; Yokomizo A, 1998, INT J ONCOL, V13, P101	41	38	40	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6707	6717		10.1038/sj.onc.1204866	http://dx.doi.org/10.1038/sj.onc.1204866			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709705				2022-12-17	WOS:000171551600007
J	Soubeyran, P; Haglund, K; Garcia, S; Barth, BU; Iovanna, J; Dikic, I				Soubeyran, P; Haglund, K; Garcia, S; Barth, BU; Iovanna, J; Dikic, I			Homeobox gene Cdx1 regulates Ras, Rho and PI3 kinase pathways leading to transformation and tumorigenesis of intestinal epithelial cells	ONCOGENE			English	Article						transformation; intestinal epithelial cells; Cdx1; Ras; PI3 kinase	PROTEIN EXPRESSION; COLORECTAL-CANCER; DOWN-REGULATION; DIFFERENTIATION; ACTIVATION; INHIBITION; ELEMENT; HOMOLOG	The Cdx1 homeobox gene encodes for an intestine-specific transcription factor involved in the control of proliferation and differentiation of epithelial cells. Although it has been indicated that Cdx1 may act as a proto-oncogene in cultured fibroblasts, its direct role in the regulation of intestinal tumorigenesis has not been demonstrated. Here we show that expression of Cdx1 in an intestinal epithelial cell line (IEC-6) induces anchorage-independent growth in soft agar and promotes the formation of adenocarcinoma in vivo, The phenotype of Cdx1-induced tumors was exacerbated when IEC-6/ Cdx1 cells were injected together with matrigel containing mitogens and extracellular matrix components. These changes were correlated with an increase in the GTP-bound form of Ras, modulation of Cdc42 and Rho-A activities, and accumulation of phosphatidyl inositol 3 (PI3) kinase products. Moreover, combined inhibition of Ras/Rho and PI3 kinase signaling by syntethic inhibitors blocked colony formation of IEC-6/Cdx1 cells in soft agar, Taken together, these results demonstrate a direct involvement of Cdx1, and its collaboration with Ras, Rho and PI3 kinase pathways, in transformation and tumorigenesis of intestinal epithelial cells.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; INSERM, Lab Physiol & Pathol Digest, U315, F-13009 Marseille, France; Hop Nord Marseille, F-13915 Marseille, France	Ludwig Institute for Cancer Research; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Dikic, I (corresponding author), Ludwig Inst Canc Res, Box 595,Husargatan 3, S-75124 Uppsala, Sweden.	Ivan.Dikic@licr.uu.se	Soubeyran, Philippe/P-1758-2018; Iovanna, Juan/M-9805-2017; Dikic, Ivan/O-4650-2015; Haglund, Kaisa/B-3927-2017	Iovanna, Juan/0000-0003-1822-2237; Dikic, Ivan/0000-0001-8156-9511; Haglund, Kaisa/0000-0002-7946-3299; Soubeyran, Philippe/0000-0002-5876-3217				Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; [Anonymous], 1988, LAB ANIM-UK, V22, P195; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; Bell E, 1999, SCIENCE, V284, P2168, DOI 10.1126/science.284.5423.2168; Bijl JJ, 1997, AM J PATHOL, V151, P1067; Blaukat A, 2000, MOL CELL BIOL, V20, P6837, DOI 10.1128/MCB.20.18.6837-6848.2000; Chariot A, 1999, ONCOGENE, V18, P4007, DOI 10.1038/sj.onc.1202776; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Duluc I, 1997, J CELL SCI, V110, P1317; EE HC, 1995, AM J PATHOL, V147, P586; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Isaacs HV, 1998, EMBO J, V17, P3413, DOI 10.1093/emboj/17.12.3413; JAMES R, 1994, J BIOL CHEM, V269, P15229; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KNITTEL T, 1995, DEVELOPMENT, V121, P1077; Lorentz O, 1999, ONCOGENE, V18, P87, DOI 10.1038/sj.onc.1202280; Lorentz O, 1999, J BIOL CHEM, V274, P7196, DOI 10.1074/jbc.274.11.7196; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; MAULBECKER CC, 1993, CELL GROWTH DIFFER, V4, P431; PERKINS AC, 1993, EMBO J, V12, P3835, DOI 10.1002/j.1460-2075.1993.tb06062.x; Prendergast GC, 2000, CURR OPIN CELL BIOL, V12, P166, DOI 10.1016/S0955-0674(99)00072-1; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Ren P, 2000, AM J PATHOL, V156, P621, DOI 10.1016/S0002-9440(10)64766-9; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Suh E, 1996, MOL CELL BIOL, V16, P619; Wicking C, 1998, ONCOGENE, V17, P657, DOI 10.1038/sj.onc.1201971	34	38	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2001	20	31					4180	4187		10.1038/sj.onc.1204551	http://dx.doi.org/10.1038/sj.onc.1204551			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464284				2022-12-17	WOS:000169857200008
J	Reynolds, L; Jones, K; Winton, DJ; Cranston, A; Houghton, C; Howard, L; Ponder, BAJ; Smith, DP				Reynolds, L; Jones, K; Winton, DJ; Cranston, A; Houghton, C; Howard, L; Ponder, BAJ; Smith, DP			C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET	ONCOGENE			English	Article						RET; multiple endocrine neoplasia; MEN2A; receptor tyrosine kinase; transgenic mice	MULTIPLE ENDOCRINE NEOPLASIA; TYROSINE KINASE DOMAIN; PAPILLARY CARCINOMAS; MOLECULAR CHARACTERIZATION; MEDULLARY CARCINOMA; RET/PTC1 ONCOGENE; PROTOONCOGENE; MUTATIONS; ACTIVATION; GDNF	Gain-of-function mutations in the gene encoding the receptor tyrosine kinase RET have been identified as the aetiological factor for multiple endocrine neoplasia type 2A (MEN2A). MEN2A is a dominantly-inherited cancer predisposition syndrome characterized by medullary thyroid carcinoma, a tumour of the calcitonin-producing thyroid C-cells. There are three isoforms of RET: RET9, RET43 and RET51, and although in vitro evidence suggests they vary in cellular transformation activities, little is known about their function in tumorigenesis in vivo. To address this, we used RET51 cDNA to construct mice in which the most frequent MEN2A mutation, Cys-634-Arg, was expressed under the control of the human calcitonin promoter (CT-2A mice), These mice developed C-cell tumours resembling human MTC and follicular tumours resembling human papillary thyroid carcinoma (PTC) depending on the founder line examined, One founder line developed compound MTC/PTC at low frequency (8%) and pancreatic cystadenocarcinoma, CT-2A mice also displayed a developmental defect in thyroid follicular structure, in which much of the thyroid was occupied by large irregular cystic follicles thought to be derived from the ultimobranchial body, a developmental precursor of the thyroid gland, The CT-2A mice will provide a suitable model to further study the effects of the MEN 2A RET mutation in vivo.	Univ Cambridge, Cambridge Inst Med Res, CRC, Dept Oncol, Cambridge CB2 2XY, England	University of Cambridge	Ponder, BAJ (corresponding author), Univ Cambridge, Cambridge Inst Med Res, CRC, Dept Oncol, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.							Acton DS, 2000, ONCOGENE, V19, P3121, DOI 10.1038/sj.onc.1203648; Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; Borrello MG, 1995, ONCOGENE, V11, P2419; Bunone G, 2000, CANCER RES, V60, P2845; CAILLOU B, 1991, P53; DECKER RA, 1993, SURGERY, V114, P1059; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; FABBRO D, 1994, CANCER RES, V54, P4744; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HARACH HR, 1994, DIS THYROID, P341; HOFSTRA RMW, 1994, NATURE, V367, P275; Jhiang SM, 1996, THYROID, V6, P115, DOI 10.1089/thy.1996.6.115; Johnston D, 1998, ONCOGENE, V16, P167, DOI 10.1038/sj.onc.1201478; KOVACS CS, 1994, CANCER-AM CANCER SOC, V74, P928, DOI 10.1002/1097-0142(19940801)74:3<928::AID-CNCR2820740321>3.0.CO;2-E; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEDOUARIN N, 1970, CR ACAD SCI D NAT, V270, P2857; LJUNGBERG O, 1983, CANCER, V52, P1053, DOI 10.1002/1097-0142(19830915)52:6<1053::AID-CNCR2820520621>3.0.CO;2-Q; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Manley NR, 1998, DEV BIOL, V195, P1, DOI 10.1006/dbio.1997.8827; MANLEY NR, 1995, DEVELOPMENT, V121, P1989; Marshall GM, 1997, CANCER RES, V57, P5399; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MYERS SM, 1995, ONCOGENE, V11, P2039; OISHI S, 1995, ENDOCR J, V42, P527, DOI 10.1507/endocrj.42.527; Okada Y, 1999, INT J CANCER, V81, P67, DOI 10.1002/(SICI)1097-0215(19990331)81:1<67::AID-IJC13>3.0.CO;2-V; Orlandi F, 2001, J ENDOCRINOL INVEST, V24, P51, DOI 10.1007/BF03343809; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Peleg S, 1989, Henry Ford Hosp Med J, V37, P194; Ponder BAJ, 1996, ADV CANCER RES, V70, P179, DOI 10.1016/S0065-230X(08)60875-1; Portella G, 1996, ONCOGENE, V13, P2021; Powell DJ, 1998, CANCER RES, V58, P5523; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROSSEL M, 1995, HUM GENET, V95, P403; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; SAAD MF, 1984, MEDICINE, V63, P319, DOI 10.1097/00005792-198411000-00001; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SANTORO M, 1994, ONCOGENE, V9, P509; Santoro M, 1996, ONCOGENE, V12, P1821; Santoro W, 1999, J ENDOCRINOL INVEST, V22, P811, DOI 10.1007/BF03343650; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TRUPP M, 1996, NATURE, V381, P789; WETZEL BK, 1969, ENDOCRINOLOGY, V84, P563, DOI 10.1210/endo-84-3-563; WOLLMAN SH, 1978, ANAT REC, V191, P111, DOI 10.1002/ar.1091910110	56	38	39	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					3986	3994		10.1038/sj.onc.1204434	http://dx.doi.org/10.1038/sj.onc.1204434			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494127				2022-12-17	WOS:000169681500007
J	de Bruijn, DRH; dos Santos, NR; Thijssen, J; Balemans, M; Debernardi, S; Linder, B; Young, BD; van Kessel, AG				de Bruijn, DRH; dos Santos, NR; Thijssen, J; Balemans, M; Debernardi, S; Linder, B; Young, BD; van Kessel, AG			The synovial sarcoma associated protein SYT interacts with the acute leukemia associated protein AF10	ONCOGENE			English	Article						synovial sarcoma; SYT; yeast two hybrid; protein-protein interactions; AF10; acute leukemia	KRUPPEL-ASSOCIATED BOX; RING FINGER; TRANSCRIPTIONAL REPRESSION; T(10-11) TRANSLOCATION; DROSOPHILA-TRITHORAX; SET DOMAIN; GENE; SSX; MOTIF; FUSION	As a result of the synovial sarcoma associated t(X;18) translocation, the human SYT gene on chromosome 18 is fused to either the SSX1 or the SSX2 gene on the X chromosome. Although preliminary evidence indicates that the (fusion) proteins encoded by these genes may play a role in transcriptional regulation, little is known about their exact function. We set out to isolate interacting proteins through yeast two hybrid screening of a human cDNA library using SYT as a bait. Of the positive clones isolated, two were found to correspond to the acute leukemia t(10;11) associated AF10 gene, a fusion partner of MLL, Confirmation of these results was obtained via co-immunoprecipitation of endogenous and exogenous, epitope-tagged, SYT and AF10 proteins from cell line extracts and colocalization of epitope-tagged SYT and AF10 proteins in transfected cells. Subsequent sequential mutation analysis revealed a highly specific interaction of N-terminal SYT fragments with C-terminal AF10 fragments, The N-terminal interaction domain of the SYT protein was also found to be present in several SYT orthologs and homologs, The C-terminal interaction domain of AF10 is located outside known functional domains. Based on these results, a model is proposed in which the SYT and AF10 proteins act in concert as bipartite transcription factors. This model has implications for the molecular mechanisms underlying the development of both human synovial sarcomas and acute leukemias.	Univ Nijmegen Hosp, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands; St Bartholomews Hosp, Imperial Canc Res Fund, Med Oncol Unit, London EC1A 7BE, England	Radboud University Nijmegen; Cancer Research UK; University of London; Queen Mary University London	de Bruijn, DRH (corresponding author), Univ Nijmegen Hosp, Dept Human Genet, POB 9101, NL-6500 HB Nijmegen, Netherlands.		van Kessel, Ad Geurts/A-2810-2010; dos Santos, Nuno Rodrigues/F-4411-2012; de Bruijn, D.R.H./L-4233-2015	dos Santos, Nuno Rodrigues/0000-0001-7347-2592; 				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; CHAPLIN T, 1995, BLOOD, V86, P2073, DOI 10.1182/blood.V86.6.2073.bloodjournal8662073; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; deBruijn DRH, 1996, ONCOGENE, V13, P643; DEBRUIJN DRH, 1994, DIFFERENTIATION, V58, P141; DEBRUIJN DRH, 2001, IN PRESS CYTOGENET C; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; deLeeuw B, 1996, CYTOGENET CELL GENET, V73, P179, DOI 10.1159/000134334; DELEEUW B, 1994, CANCER GENET CYTOGEN, V73, P89, DOI 10.1016/0165-4608(94)90191-0; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; dos Santos NR, 2000, EXP CELL RES, V256, P192, DOI 10.1006/excr.2000.4813; dos Santos NR, 2000, CANCER RES, V60, P1654; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; EPSTEIN H, 1992, BIOESSAYS, V14, P411, DOI 10.1002/bies.950140612; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; KANAZAWA S, 1988, MOL CELL BIOL, V8, P664, DOI 10.1128/MCB.8.2.664; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Linder B, 2000, J MOL BIOL, V299, P369, DOI 10.1006/jmbi.2000.3766; Linder B, 1998, BBA-GENE STRUCT EXPR, V1443, P285, DOI 10.1016/S0167-4781(98)00226-7; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SINGH PB, 1994, J CELL SCI, V107, P2653; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; STASSEN MJ, 1995, MECH DEVELOP, V52, P209, DOI 10.1016/0925-4773(95)00402-M; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Tripoulas N, 1996, GENETICS, V143, P913; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; vanKessel AG, 1997, CANCER GENET CYTOGEN, V95, P67, DOI 10.1016/S0165-4608(96)00241-5; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514	51	38	41	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3281	3289		10.1038/sj.onc.1204419	http://dx.doi.org/10.1038/sj.onc.1204419			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423977				2022-12-17	WOS:000169163500011
J	Shah, V; Bharadwaj, S; Kaibuchi, K; Prasad, GL				Shah, V; Bharadwaj, S; Kaibuchi, K; Prasad, GL			Cytoskeletal organization in tropomyosin-mediated reversion of ras-transformation: Evidence for Rho kinase pathway	ONCOGENE			English	Article						tropomyosin; cytoskeleton; Rho kinase	SERUM RESPONSE FACTOR; BINDING PROTEIN-RHO; ACTIN CYTOSKELETON; FOCAL ADHESIONS; GELSOLIN EXPRESSION; NONMUSCLE CALDESMON; STRESS FIBERS; ONCOGENIC RAS; CELLS; SUPPRESSION	Tropomyosin (TM) family of cytoskeletal proteins is implicated in stabilizing actin microfilaments. Many TM isoforms, including tropomyosin-1 (TM1), are downregulated in transformed cells. Previously we demonstrated that TM1 is a suppressor of the malignant transformation, and that TM1 reorganizes microfilaments in the transformed cells, To investigate how TM1 induces microfilament organization in transformed cells, we utilized uas-transformed NIH3T3 (DT) cells, and those transduced to express TM1, and/or TM2, Enhanced expression of TM1 alone, but not TM2, results in re-emergence of microfilaments; TM1, together with TM2 remarkably improves microfilament architecture. TM1 induced cytoskeletal reorganization involves an enhanced expression of caldesmon, but not vinculin, alpha -actinin, or gelsolin, In addition, TM1-induced cytoskeletal reorganization and the revertant phenotype appears to involve re-activation of RhoA controlled pathways in DT cells. RhoA expression, which is suppressed in DT cells, is significantly increased in TM1-expressing cells, without detectable changes in the expression of Pac or Cdc42, Furthermore, expression of a dominant negative Rho kinase, or treatment with Y-27632 disassembled microfilaments in normal NIH3T3 and in TM1 expressing cells. These data suggest that reactivation of Rho kinase directed pathways are critical for TM1-mediated microfilament assemblies.	Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Wistar Inst Anat & Cell Biol, Philadelphia, PA USA; Nara Inst Sci & Technol, Ikoma, Japan	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; The Wistar Institute; Nara Institute of Science & Technology	Prasad, GL (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.							Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Asch HL, 1999, BREAST CANCER RES TR, V55, P179; Ayscough KR, 1998, CURR OPIN CELL BIOL, V10, P102, DOI 10.1016/S0955-0674(98)80092-6; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; Braverman RH, 1996, ONCOGENE, V13, P537; BUTTON E, 1995, CELL MOTIL CYTOSKEL, V30, P247, DOI 10.1002/cm.970300402; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; COOPER HL, 1987, CANCER RES, V47, P4493; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Helfman DM, 1999, MOL BIOL CELL, V10, P3097, DOI 10.1091/mbc.10.10.3097; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; Huber PAJ, 1997, INT J BIOCHEM CELL B, V29, P1047, DOI 10.1016/S1357-2725(97)00004-6; ISHIKAWA R, 1989, J BIOL CHEM, V264, P16764; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; Ishikawa R, 1998, J BIOL CHEM, V273, P26991, DOI 10.1074/jbc.273.41.26991; Izawa I, 1998, ONCOGENE, V17, P2863, DOI 10.1038/sj.onc.1202213; JANCSO A, 1991, J BIOL CHEM, V266, P5891; JANMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111, DOI 10.1016/0955-0674(95)80052-2; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KUMAR A, 1993, INDIAN J HETEROCY CH, V3, P1; LEAVITT J, 1986, MOL CELL BIOL, V6, P2721, DOI 10.1128/MCB.6.7.2721; Lin SK, 1997, MOLECULES, V2, P1, DOI 10.3390/jan97p1; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; Mielnicki LM, 1999, EXP CELL RES, V249, P161, DOI 10.1006/excr.1999.4461; Momiyama T, 1998, BIOCHEM BIOPH RES CO, V242, P429, DOI 10.1006/bbrc.1997.7959; Montaner S, 1999, J BIOL CHEM, V274, P8506, DOI 10.1074/jbc.274.13.8506; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V26, P248, DOI 10.1002/cm.970260308; NOVY RE, 1991, J BIOL CHEM, V266, P16917; PITTENGER MF, 1995, J CELL SCI, V108, P3253; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; PRASAD GL, 1994, EUR J BIOCHEM, V224, P1, DOI 10.1111/j.1432-1033.1994.tb19988.x; Prasad GL, 1999, ONCOGENE, V18, P2027, DOI 10.1038/sj.onc.1202264; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; PRASAD GL, 1991, BIOCHEM BIOPH RES CO, V177, P1068, DOI 10.1016/0006-291X(91)90647-P; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Shah V, 1998, SOMAT CELL MOLEC GEN, V24, P273, DOI 10.1023/B:SCAM.0000007130.08611.fc; Spencer JA, 1999, ONCOGENE, V18, P7319, DOI 10.1038/sj.onc.1203121; Treisman R, 1998, COLD SPRING HARB SYM, V63, P643, DOI 10.1101/sqb.1998.63.643; WARREN KS, 1995, J CELL BIOL, V129, P697, DOI 10.1083/jcb.129.3.697; Warren KS, 1996, CELL MOTIL CYTOSKEL, V34, P215, DOI 10.1002/(SICI)1097-0169(1996)34:3<215::AID-CM5>3.0.CO;2-8; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	56	38	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2001	20	17					2112	2121		10.1038/sj.onc.1204291	http://dx.doi.org/10.1038/sj.onc.1204291			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360195				2022-12-17	WOS:000168116700006
J	Milligan, L; Antoine, E; Bisbal, C; Weber, M; Brunel, C; Forne, T; Cathala, G				Milligan, L; Antoine, E; Bisbal, C; Weber, M; Brunel, C; Forne, T; Cathala, G			H19 gene expression is up-regulated exclusively by stabilization of the RNA during muscle cell differentiation	ONCOGENE			English	Article						H19; parental imprinting; post-transcriptional regulation; muscle cell differentiation	TUMOR-SUPPRESSOR GENE; MYC MESSENGER-RNA; FACTOR-II GENE; IMPRINTED GENES; ALPHA-FETOPROTEIN; IGF2 EXPRESSION; WILMS-TUMOR; METHYLATION; DELETION; TRANSCRIPTION	H19 is a paternally imprinted gene whose expression produces a 2.4 kb RNA in most tissues during development and in mammalian myoblastic cell lines upon differentiation. Deletion of the active maternal allele of H19 and its flanking regions in the mouse leads to biallelic methylation and loss of imprinting of the neighbouring Igf2 gene, The function of H19 RNA remains unknown and, although polysome-associated, the absence of a conserved open reading frame suggests that it does not encode a protein product. We describe a novel post-transcriptional regulation of H19 gene expression which,in spite of this lack of coding capacity, is dependent on translational activity. We show that stabilization of the RNA is solely responsible for its accumulation during in vitro muscle cell differentiation, This conclusion is based on the finding that inhibition of protein synthesis results in a dramatic destabilization of H19 RNA in proliferating mouse C2C12 myoblastic cells but not in differentiated cells, and on run-on experiments which showed that the rate of transcription of H19 RNA remains constant during muscle cell differentiation. This mechanism could also be involved in H19 gene expression during mouse development in addition to its transcriptional activation which we have shown to occur.	Univ Montpellier 2, Inst Genet Mol, UMR 5535 CNRS, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Cathala, G (corresponding author), Univ Montpellier 2, Inst Genet Mol, UMR 5535 CNRS, IFR 24,1919 Route de Mende, F-34293 Montpellier 5, France.		Bisbal, Catherine/I-6984-2016; Forne, Thierry/D-3718-2013; Weber, Michael/P-1914-2016	Bisbal, Catherine/0000-0003-1086-020X; Forne, Thierry/0000-0002-9179-1551; Weber, Michael/0000-0003-3484-5821; Milligan, Laura/0000-0001-6985-3034				Ainscough JFX, 1997, DEVELOPMENT, V124, P3621; Barlow DP, 1997, EMBO J, V16, P6899, DOI 10.1093/emboj/16.23.6899; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BIRAN H, 1994, TUMOR BIOL, V15, P123, DOI 10.1159/000217882; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Cui HM, 1997, CANCER RES, V57, P4469; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DEPONTIZILLI L, 1988, P NATL ACAD SCI USA, V85, P1389, DOI 10.1073/pnas.85.5.1389; Dugimont T, 1998, ONCOGENE, V16, P2395, DOI 10.1038/sj.onc.1201742; EVERSOLECIRE P, 1995, CELL GROWTH DIFFER, V6, P337; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Forne T, 1997, P NATL ACAD SCI USA, V94, P10243, DOI 10.1073/pnas.94.19.10243; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hayashida T, 1997, J BIOCHEM-TOKYO, V122, P901; Hibi K, 1996, CANCER RES, V56, P480; Hurst LD, 1999, TRENDS GENET, V15, P134, DOI 10.1016/S0168-9525(99)01696-0; Jones BK, 1998, GENE DEV, V12, P2200, DOI 10.1101/gad.12.14.2200; Joubel A, 1996, CELL MOL BIOL, V42, P1159; Jouvenot Y, 1999, CURR BIOL, V9, P1199, DOI 10.1016/S0960-9822(00)80026-3; Juan V, 2000, NUCLEIC ACIDS RES, V28, P1221, DOI 10.1093/nar/28.5.1221; Junien C, 1992, CURR OPIN GENET DEV, V2, P431, DOI 10.1016/S0959-437X(05)80154-6; KIM DK, 1994, J CLIN INVEST, V93, P355, DOI 10.1172/JCI116967; Ladomery M, 1997, BIOESSAYS, V19, P903, DOI 10.1002/bies.950191010; LEIBOVITCH MP, 1991, BIOCHEM BIOPH RES CO, V180, P1241, DOI 10.1016/S0006-291X(05)81329-4; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LI XR, 1995, ONCOGENE, V11, P221; Li YM, 1998, J BIOL CHEM, V273, P28247, DOI 10.1074/jbc.273.43.28247; LustigYariv O, 1997, ONCOGENE, V15, P169, DOI 10.1038/sj.onc.1201175; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; RAYNAL F, 1984, FEBS LETT, V167, P263, DOI 10.1016/0014-5793(84)80139-8; Reik W, 1998, CURR OPIN GENET DEV, V8, P154, DOI 10.1016/S0959-437X(98)80136-6; REIK W, 1994, HUM MOL GENET, V3, P1297, DOI 10.1093/hmg/3.8.1297; Ripoche MA, 1997, GENE DEV, V11, P1596, DOI 10.1101/gad.11.12.1596; SINGER C, 1995, CANCER RES, V55, P2448; Smith CM, 1998, MOL CELL BIOL, V18, P6897, DOI 10.1128/MCB.18.12.6897; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Tilghman SM, 1999, CELL, V96, P185, DOI 10.1016/S0092-8674(00)80559-0; Tremblay KD, 1997, MOL CELL BIOL, V17, P4322, DOI 10.1128/MCB.17.8.4322; VACHER J, 1992, MOL CELL BIOL, V12, P856, DOI 10.1128/MCB.12.2.856; Verkerk AJMH, 1997, ONCOGENE, V14, P95, DOI 10.1038/sj.onc.1200802; WISDOM R, 1990, J BIOL CHEM, V265, P19015; Yeilding NM, 1998, J BIOL CHEM, V273, P15749, DOI 10.1074/jbc.273.25.15749; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707; Yun K, 1996, AM J PATHOL, V148, P1081	52	38	39	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5810	5816		10.1038/sj.onc.1203965	http://dx.doi.org/10.1038/sj.onc.1203965			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126368				2022-12-17	WOS:000165477700013
J	Kawabe, S; Roth, JA; Wilson, DR; Meyn, RE				Kawabe, S; Roth, JA; Wilson, DR; Meyn, RE			Adenovirus-mediated p16(INK4a) gene expression radiosensitizes non-small cell lung cancer cells in a p53-dependent manner	ONCOGENE			English	Article						apoptosis; adenovirus, p16(INK4a); p53; radiation; lung cancer	RETINOBLASTOMA-PROTEIN; P53; INHIBITION; RB; APOPTOSIS	We examined the influence of adenovirus-mediated wildtype p16(INK4n) (Ad/p16) expression on the radiation sensitivity of NSCLC cell lines, all of which lacked constitutive p16(INK4n) but each of which varied in p53 status: A549 (- p16(INK4n)/+pRb/wt-p53), H322 (- p16(INK4n)/ + pRb/mt-p53), and H1299 (- p16(INK4a)/ +pRb/deleted-p53). The in vitro clonogenic survival results indicate that Ad/p16 enhanced the radiosensitivity of A549 but not H322 or H1299. Further analysis indicated that the apoptosis induced by combination therapy using Ad/p16 plus irradiation was dependent on the endogenous p53 status of the cancer cells. We performed Western blotting to analyst the p53 protein expression of A549 cells treated with either Ad/p16 or Ad/Luc. Endogenous p53 protein levels were higher in A549 cells transfected with Ad/p16 than in those transfected with Ad/Luc. Furthermore, when wt-p53 protein expression was restored in H1299 using Ad/ p53, Ad/p16 stabilized p53 protein expression and radiosensitized the cells. These results suggest that Ad/ p16-induccd stabilization of p53 protein may play an important role in Ad/p16 mediated radiosensitization by enhancing or restoring apoptosis properties. Thus, Ad/p16 plus radiation in combination may be a useful gene therapy strategy for tumors that have wt-p53 but nonfunctional p16(INK4n).	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Introgen Therapeut Inc, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Meyn, RE (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Box 066,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P30CA016672, P01CA006294, P01CA078778] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA06294, CA16672, P01 CA78778] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FANG X, 1998, INT J ONCOL, V12, P665; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Gallardo D, 1996, CANCER RES, V56, P4891; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; JIN X, 1996, ONCOGENE, V12, P103; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; Kratzke RA, 1996, CANCER RES, V56, P3415; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; McPake CR, 1999, CANCER RES, V59, P4247; Miyakoshi J, 1997, JPN J CANCER RES, V88, P34, DOI 10.1111/j.1349-7006.1997.tb00298.x; MUKHOPADHYAY T, 1993, CANCER RES, V53, P4362; NEVINS JR, 1992, SCIENCE, V258, P424; Nishio M, 1996, J CLIN ONCOL, V14, P497, DOI 10.1200/JCO.1996.14.2.497; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shim J, 2000, J BIOL CHEM, V275, P14107, DOI 10.1074/jbc.275.19.14107; Spitz FR, 1996, CLIN CANCER RES, V2, P1665; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yap DBS, 1999, ONCOGENE, V18, P7681, DOI 10.1038/sj.onc.1202954	27	38	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2000	19	47					5359	5366		10.1038/sj.onc.1203935	http://dx.doi.org/10.1038/sj.onc.1203935			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103937				2022-12-17	WOS:000165302300007
J	Finzer, P; Soto, U; Delius, H; Patzelt, A; Coy, JF; Poustka, A; zur Hausen, H; Rosl, F				Finzer, P; Soto, U; Delius, H; Patzelt, A; Coy, JF; Poustka, A; zur Hausen, H; Rosl, F			Differential transcriptional regulation of the monocyte-chemoattractant protein-1 (MCP-1) gene in tumorigenic and non-tumorigenic HPV 18 positive cells: The role of the chromatin structure and AP-1 composition	ONCOGENE			English	Article						chemokines; human papillomaviruses; cervical cancer; somatic cell hybrids; tumorigenicity	NF-KAPPA-B; CERVICAL INTRAEPITHELIAL NEOPLASIA; HUMAN PAPILLOMAVIRUS INFECTION; JE GENE; HELA-CELLS; HYBRIDS; ALPHA; EXPRESSION; GROWTH; DNA	The expression of the monocyte-chemoattractant-protein-1 (MCP-1) is closely linked with a non-tumorigenic phenotype in somatic cell hybrids made between the human papillomavirus type 18 (HPV 18) positive cervical carcinoma cell line HeLa and normal human fibroblasts, In contrast, MCP-1 transcription is absent in tumorigenic segregants derived from the same hybrids or in parental HeLa cells. Selectivity of MCP-1 transcription, which is regulated at the le, el of initiation of transcription, is mainly based on differences in the location and extension of DNAse I-hypersensitive regions (DHSR) at both ends of the gene, While TNF-alpha only moderately increases the sensitivity of pre-existing 5'-DHSRs, a 3'-end DHSR became strongly induced exclusively in non-malignant hybrids, DNA sequencing showed that the 3'-DHSR coincides with an additional AP-1 site located approximately 600 bp downstream of the polyadenylation site. Analyses of AP-1 composition revealed that MCP-1 is only expressed in those cells where jun-family members were mainly heterodimerized with the fos-related protein fra-1. In contrast, in tumorigenic cells the 1:1 ratio between jun and fra-1 is disturbed and the MCP-1 gene is no longer expressed. Hence, alterations in the heterodimerization pattern of AP-1 and its selective accessibility to opened chromatin may represent a novel regulatory pathway in the regulation of chemokines in malignant and non-malignant HPV-positive cells.	Deutsch Krebsforschungszentrum, Forschungsschwerpunkt Angew Tumorvirol, D-69120 Heidelberg, Germany; Forschungsschwerpunkt Genomforsch & Bioinformat, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Rosl, F (corresponding author), Deutsch Krebsforschungszentrum, Forschungsschwerpunkt Angew Tumorvirol, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.							ALTMANN A, 1994, INTERVIROLOGY, V37, P180, DOI 10.1159/000150376; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BIRAGYN A, 1995, J IMMUNOL, V155, P674; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; KENNY MK, 1988, J BIOL CHEM, V263, P9809; KLEINE K, 1995, MOL CARCINOGEN, V14, P179, DOI 10.1002/mc.2940140307; Kleine-Lowinski K, 1999, INT J CANCER, V82, P6, DOI 10.1002/(SICI)1097-0215(19990702)82:1<6::AID-IJC2>3.0.CO;2-3; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Maehama T, 1998, INT J CANCER, V76, P639, DOI 10.1002/(SICI)1097-0215(19980529)76:5<639::AID-IJC5>3.0.CO;2-R; Majewski S., 1996, PAPILLOMAVIRUS REPOR, V7, P143; MEHRABIAN M, 1991, GENOMICS, V9, P200, DOI 10.1016/0888-7543(91)90239-B; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; Ozbun MA, 1996, J VIROL, V70, P5437, DOI 10.1128/JVI.70.8.5437-5446.1996; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; Rosl F, 1999, CONT CANC RES, P207; ROSL F, 1994, J VIROL, V68, P2142; ROSL F, 1989, MOL CARCINOGEN, V2, P72, DOI 10.1002/mc.2940020205; Soto U, 1999, ONCOGENE, V18, P3187, DOI 10.1038/sj.onc.1202765; SOTO U, 2000, IN PRESS INT J CANC; SPINILLO A, 1993, GYNECOL ONCOL, V48, P210, DOI 10.1006/gyno.1993.1035; STANBRIDGE EJ, 1984, CANCER SURV, V3, P335; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TAY SK, 1987, BRIT J OBSTET GYNAEC, V94, P1094, DOI 10.1111/j.1471-0528.1987.tb02296.x; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; UEDA A, 1994, J IMMUNOL, V153, P2052; Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092; Wingender E, 1997, NUCLEIC ACIDS RES, V25, P265, DOI 10.1093/nar/25.1.265; ZURHAUSEN H, 1994, COLD SPRING HARB SYM, V59, P623, DOI 10.1101/SQB.1994.059.01.071	38	38	41	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2000	19	29					3235	3244		10.1038/sj.onc.1203643	http://dx.doi.org/10.1038/sj.onc.1203643			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918580				2022-12-17	WOS:000088019300002
J	Bearss, DJ; Subler, MA; Hundley, JE; Troyer, DA; Salinas, RA; Windle, JJ				Bearss, DJ; Subler, MA; Hundley, JE; Troyer, DA; Salinas, RA; Windle, JJ			Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors	ONCOGENE			English	Article						p53; MMTV-ras; MMTV-myc; doxorubicin; paclitaxel; apoptosis	PROGRAMMED CELL-DEATH; C-MYC; GROWTH ARREST; CANCER-THERAPY; INDUCED APOPTOSIS; MICE DEFICIENT; HA-RAS; P53; TAXOL; TUMORIGENESIS	Several transgenic mouse tumor models were utilized to explore how specific genetic alterations affect the tumor cell response to chemotherapeutic agents in vivo. Specifically, MMTV-ras transgenic mice were interbred to p53 knock-out mice to create a model for assessing the role of p53 in chemotherapeutic responses. In addition, MMTV-ras tumors were compared to MMTV-myc and MMTV-ras/myc tumors. Mice of each genotype reproducibly develop mammary and/or salivary tumors, but tumor growth dynamics vary considerably between genotypes, MMTV-ras/p53(-/-) tumors exhibit higher S phase fractions than MMTV-ras/p53(+/+) tumors, although both tumor types display very low apoptosis levels. In contrast, MMTV-myc tumors exhibit both high S phase fractions and spontaneous apoptosis levels. Tumor-bearing mice of each genotype mere treated with either doxorubicin or paclitaxel, and effects on overall tumor growth, cell cycle distribution and apoptosis were evaluated. Surprisingly, neither agent efficiently induced apoptosis in any of the tumor models, including those with wildtype p53. Rather, tumor responses were mediated primarily by changes in cell cycle distribution. However, the spontaneous apoptosis levels did serve as a predictor of tumor growth response, in that only those tumors with high pretreatment apoptosis levels underwent significant regression following treatment with either agent.	Canc Therapy & Res Ctr, Inst Drug Dev, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA	Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Windle, JJ (corresponding author), Canc Therapy & Res Ctr, Inst Drug Dev, 8122 Datapoint Dr,Suite 700, San Antonio, TX 78229 USA.		Bearss, David/Q-9141-2019	Windle, Jolene/0000-0001-6690-385X; Bearss, David/0000-0002-4458-826X; Bearss, David/0000-0002-4280-5670	NATIONAL CANCER INSTITUTE [P30CA054174] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA54174] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; BHALLA K, 1993, LEUKEMIA, V7, P563; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARDIFF RD, 1991, AM J PATHOL, V139, P495; CARDIFF RD, 1995, CANCER LETT, V90, P13, DOI 10.1016/0304-3835(94)03672-6; CARDIFF RD, 1993, CANCER SURV, V16, P97; Chabner B., 1993, CANC PRINCIPLES PRAC, P325; DARZYNKIEWICZ Z, 1994, J CELL BIOCHEM, V56, P1; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Dorr R.T., 1994, CANC CHEMOTHERAPY HD; El-Deiry Wafik S., 1997, Current Opinion in Oncology, V9, P79; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FAN SJ, 1994, CANCER RES, V54, P5824; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; Hundley JE, 1997, CANCER RES, V57, P600; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Lanni JS, 1997, P NATL ACAD SCI USA, V94, P9679, DOI 10.1073/pnas.94.18.9679; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MANFREDI JJ, 1984, PHARMACOL THERAPEUT, V25, P83, DOI 10.1016/0163-7258(84)90025-1; MILAS L, 1995, CANCER CHEMOTH PHARM, V35, P297, DOI 10.1007/BF00689448; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NOOTER K, 1995, BRIT J CANCER, V71, P556, DOI 10.1038/bjc.1995.109; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; SHAO ZM, 1995, ONCOGENE, V11, P493; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; YonishRouach E, 1996, EXPERIENTIA, V52, P1001, DOI 10.1007/BF01920109	43	38	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1114	1122		10.1038/sj.onc.1203275	http://dx.doi.org/10.1038/sj.onc.1203275			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713698				2022-12-17	WOS:000085796400020
J	Dumont, E; Fuchs, KP; Bommer, G; Christoph, B; Kremmer, E; Kempkes, B				Dumont, E; Fuchs, KP; Bommer, G; Christoph, B; Kremmer, E; Kempkes, B			Neoplastic transformation by Notch is independent of transcriptional activation by RBP-J signalling	ONCOGENE			English	Article						notch; transactivation domain; RBP-J; EBNA2; E1A; neoplastic transformation	EPSTEIN-BARR-VIRUS; J-KAPPA; CHROMOSOMAL LOCUS; PROMOTER ANALYSIS; ANKYRIN REPEATS; GENE; PATHWAY; DOMAIN; TRANSDUCTION; SEQUENCES	Signalling through the transmembrane receptor Notch is triggered by ligand binding, which induces the proteolytic cleavage of the Notch protein. This cleavage generates an intracellular fragment of the Notch protein (Notch-IC), which translocates into the nucleus and modifies transcription of target genes through its association with the RBP-J protein, Thus, the isolated Notch-IC protein represents the constitutively activated receptor. We have performed a deletion analysis of Notch IC in order to identify the transferable transactivation domain of Notch-IC and the minimal domain of Notch-TC required for RBP-J dependent transactivational activation. Functionally, Notch-IC has been Linked to cell fate decision in development and oncogenesis in vivo. In vitro, Notch-IC can cooperate in neoplastic transformation of baby rat kidney cells with the adenoviral E1A protein. We have defined the minimal domain of Notch-IC required for E1A cotransformation. This domain, consisting of the ankyrin repeats of Notch-IC only, can neither activate RBP-J dependent transcription nor does it carry a transactivation domain. Therefore, the ankyrin repeat domain of Notch-IC might trigger novel pathways relevant for transformation but unrelated to RBP-J signalling.	GSF Forschungszentrum Umwelt & Gesundheit, Inst Klin Mol Biol & Tumorgenet, D-81377 Munich, Germany; GSF Forschungszentrum Umwelt & Gesundheit, Inst Mol Immunol, D-81377 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Kempkes, B (corresponding author), GSF Forschungszentrum Umwelt & Gesundheit, Inst Klin Mol Biol & Tumorgenet, Marchioninistr 25, D-81377 Munich, Germany.		Kempkes, Bettina/B-3322-2013; Bommer, Guido/A-8425-2011	Bommer, Guido/0000-0001-6898-4884				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 1997, J BIOL CHEM, V272, P11336; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; delaPompa J, 1997, DEVELOPMENT, V124, P1139; DOU SB, 1994, MOL CELL BIOL, V14, P3310, DOI 10.1128/MCB.14.5.3310; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Jehn BM, 1999, J IMMUNOL, V162, P635; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Kieff E., 1996, FIELDS VIROLOGY, P2343; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; KUNZLER M, 1994, EMBO J, V13, P641, DOI 10.1002/j.1460-2075.1994.tb06302.x; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; Minoguchi S, 1997, MOL CELL BIOL, V17, P2679, DOI 10.1128/MCB.17.5.2679; Nishimura M, 1998, GENOMICS, V49, P69, DOI 10.1006/geno.1998.5213; Nofziger D, 1999, DEVELOPMENT, V126, P1689; OKA C, 1995, DEVELOPMENT, V121, P3291; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; RABSON M, 1982, J VIROL, V44, P834, DOI 10.1128/JVI.44.3.834-844.1982; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shawber C, 1996, DEVELOPMENT, V122, P3765; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; TAKEBAYASHI K, 1995, J BIOL CHEM, V270, P1342, DOI 10.1074/jbc.270.3.1342; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; vonBoehmer H, 1997, CURR BIOL, V7, pR308, DOI 10.1016/S0960-9822(06)00145-X; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	35	38	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2000	19	4					556	561		10.1038/sj.onc.1203352	http://dx.doi.org/10.1038/sj.onc.1203352			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698525				2022-12-17	WOS:000085104200009
J	Spencer, JA; Misra, RP				Spencer, JA; Misra, RP			Expression of the SRF gene occurs through a Ras/Sp/SRF-mediated-mechanism in response to serum growth signals	ONCOGENE			English	Article						gene regulation; signal transduction; Sp1; SRF	C-FOS; TRANSCRIPTIONAL ACTIVATION; LYSOPHOSPHATIDIC ACID; BINDING; PROMOTER; ELEMENTS; CALCIUM; SEQUENCES; PATHWAYS; UPSTREAM	Serum Response Factor (SRF) plays a central role in the transcriptional response of mammalian cells to a variety of extracellular signals. It is a key regulator of many cellular early response genes which are believed to be involved in cell growth, differentiation, and development, The mechanism by which SRF activates transcription in response to mitogenic agents has been extensively studied, however, less is known about regulation of the SRF gene itself. Previously, we identified distinct regulatory elements in the SRF promoter that play a role in activation, including an ETS domain binding site, an overlapping Sp1/Egr-1 binding site, and two SRF binding sites, We further showed that serum induces the SRF gene by a mechanism that requires an intact SRF binding site, also termed a CArG box, In the present study we demonstrate that in response to stimulation by cells by lysophosphatidic acid (LPA) or whole serum, the SRF promoter is upregulated by a bipartite pathway that requires both an Spl factor binding site and the CArG motifs for maximal stimulation, The CArG box-dependent component of this pathway is targeted by Rho mediated signals, and the Spl binding site dependent component is targeted by Ras mediated signals.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Misra, RP (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.				NIGMS NIH HHS [R55 GM/OD51856] Funding Source: Medline; NINDS NIH HHS [R29 NS36256] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM051856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS036256] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; Chen BK, 1997, BBA-LIPID LIPID MET, V1344, P270, DOI 10.1016/S0005-2760(96)00151-8; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; FUJII M, 1994, J VIROL, V68, P7275, DOI 10.1128/JVI.68.11.7275-7283.1994; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; Hanlon M, 1999, J BIOL CHEM, V274, P14224, DOI 10.1074/jbc.274.20.14224; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; LATINKIC BV, 1991, NUCLEIC ACIDS RES, V19, P3261, DOI 10.1093/nar/19.12.3261; LATINKIC BV, 1994, J BIOL CHEM, V269, P23163; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; MISRA RP, 1994, J BIOL CHEM, V269, P25483; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; MOOLENAAR WH, 1992, COLD SPRING HARB SYM, V57, P163, DOI 10.1101/SQB.1992.057.01.021; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; Spencer JA, 1996, J BIOL CHEM, V271, P16535, DOI 10.1074/jbc.271.28.16535; Spencer JA, 1999, MOL CELL BIOL, V19, P3977; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1990, CANCER BIOL, V1, P47; Treisman R, 1992, CURR OPIN GENET DEV, V2, P221, DOI 10.1016/S0959-437X(05)80277-1; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474	39	38	38	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	1999	18	51					7319	7327		10.1038/sj.onc.1203121	http://dx.doi.org/10.1038/sj.onc.1203121			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602487				2022-12-17	WOS:000084119400017
J	Deka, J; Herter, P; Sprenger-Haussels, M; Koosch, S; Franz, D; Muller, KM; Kuhnen, C; Hoffmann, I; Muller, O				Deka, J; Herter, P; Sprenger-Haussels, M; Koosch, S; Franz, D; Muller, KM; Kuhnen, C; Hoffmann, I; Muller, O			The APC protein binds to A/T rich DNA sequences	ONCOGENE			English	Article						Adenomatous Polyposis Coli; DNA binding protein; S(T)PXX sequence motif	TUMOR-SUPPRESSOR PROTEIN; POLYPOSIS-COLI PROTEIN; BETA-CATENIN; FUNCTIONAL INTERACTION; CELL-MIGRATION; ASSOCIATION; GSK3-BETA; NUCLEAR; SITES; AXIN	The tumor suppressor protein APC (Adenomatous Polyposis Coil) is localized in the cytosol and in the nucleus. In this study, we demonstrate that the nuclear APC protein le, el is high in cells in the basal crypt region of the normal colorectal epithelium, Strikingly; the APC protein staining resembles the staining pattern of a nuclear proliferation marker. As a first step tow ards a possible role of the nuclear APC protein, we provide data showing the direct interaction of the nuclear APC protein with DNA. A nuclear APC isoform precipitates with matrix-immobilized DNA. Vice versa, the immunoprecipitation of APC from nuclear lysates results in coprecipitation of genomic DNA, Using recombinant APC fragments ne mapped three DNA binding domains: one within the beta-catenin binding and regulatory domain, and two in the carboxyterminal third of the APC protein. All these three domains contain clusters of repetitive S(T)PXX sequence motifs that were described to mediate the DNA interaction of many other DNA binding proteins. In analogy to S(T)PSS proteins, the APC protein binds preferentially to A/T rich DNA sequences rather than to a single DNA sequence motif.	Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44227 Dortmund, Germany; Inst Berufsgenossenschaftl Kliniken Bergmannsheil, Bochum, Germany	Max Planck Society	Muller, O (corresponding author), Max Planck Inst Mol Physiol, Abt Strukturelle Biol, Otto Hahn Str 11, D-44227 Dortmund, Germany.		Herter, Peter/L-7415-2013	Herter, Peter/0000-0001-7437-2200				Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BERMAN J, 1987, METHOD ENZYMOL, V155, P528; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CHURCHILL MEA, 1989, EMBO J, V8, P4189, DOI 10.1002/j.1460-2075.1989.tb08604.x; Deka J, 1998, EUR J BIOCHEM, V253, P591, DOI 10.1046/j.1432-1327.1998.2530591.x; dePater S, 1996, NUCLEIC ACIDS RES, V24, P4624, DOI 10.1093/nar/24.23.4624; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; HEINEN CD, 1995, CANCER RES, V55, P4797; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; MIYASHIRO I, 1995, ONCOGENE, V11, P89; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Pyles RB, 1998, ONCOGENE, V16, P77, DOI 10.1038/sj.onc.1201505; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Stevens A, 1992, HISTOLOGY; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588	28	38	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	1999	18	41					5654	5661		10.1038/sj.onc.1202944	http://dx.doi.org/10.1038/sj.onc.1202944			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523845				2022-12-17	WOS:000083016500006
J	Gewirtz, AM				Gewirtz, AM			Myb targeted therapeutics for the treatment of human malignancies	ONCOGENE			English	Article						Myb; proto-oncogene; antisense; antibody; therapeutics; gene therapy	MUSCLE CELL-PROLIFERATION; ABL ANTISENSE OLIGODEOXYNUCLEOTIDES; MYELOGENOUS LEUKEMIA-CELLS; NORMAL HUMAN HEMATOPOIESIS; CHRONIC MYELOID-LEUKEMIA; C-KIT LIGAND; BCR-ABL; MESSENGER-RNA; IN-VITRO; V-MYB	For the past several years, we have been engaged in developing a therapeutically effective strategy for disrupting gene function with reverse complementary, or so called 'antisense', oligodeoxynucleotides (ODN), This pursuit has focused on finding appropriate diseases in which to apply this approach, and suitable gene targets. Of the genes that we have targeted for disruption using the antisense ODN strategy (Clevenger et al,, 1995; Gewirtz and Calabretta, 1988; Ratajczak ef al,, 1992c; Small et al,, 1994) one that has been of particular interest, and one where therapeutically motivated disruptions are now in clinical trial, is the myb gene (reviewed in Lyon et al,, 1994), These trials involve treatment of human leukemias. These diseases are a logical choice for developing oncogene targeted therapies because of easy access to tissues, and the abundance of knowledge about the cell and molecular biology of these diseases. Nevertheless, as will be touched on below, other malignancies have also been examined as models for Myb targeted therapy with some surprisingly encouraging results. Finally, while we have focused our efforts on the ODN strategy, I will allude briefly to other strategies for disrupting Myb function with therapeutic intent.	Univ Penn, Sch Med, Dept Internal Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Inst Human Gene Therapy, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Gewirtz, AM (corresponding author), Univ Penn, Sch Med, Dept Internal Med, Room 712 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.				NATIONAL CANCER INSTITUTE [R01CA066731, P01CA072765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK052558] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA72765, R01CA66731] Funding Source: Medline; NIDDK NIH HHS [P01DK52558-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; Azrin MA, 1997, CATHETER CARDIO DIAG, V41, P232, DOI 10.1002/(SICI)1097-0304(199707)41:3<232::AID-CCD2>3.0.CO;2-7; BARLETTA C, 1987, SCIENCE, V235, P1064, DOI 10.1126/science.3469751; BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1993, BLOOD, V81, P2898; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BROWN KE, 1992, J BIOL CHEM, V267, P4625; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CALABRETTA B, 1991, P NATL ACAD SCI USA, V88, P2351, DOI 10.1073/pnas.88.6.2351; CALABRETTA B, 1991, Critical Reviews in Oncogenesis, V2, P187; CARACCIOLO D, 1990, J CLIN INVEST, V85, P55, DOI 10.1172/JCI114433; CARSON WE, 1994, P NATL ACAD SCI USA, V91, P7553, DOI 10.1073/pnas.91.16.7553; Castier Y, 1998, J CARDIOVASC SURG, V39, P1; Chasty R, 1996, LEUKEMIA RES, V20, P391, DOI 10.1016/0145-2126(95)00124-7; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CLEVENGER CV, 1995, J BIOL CHEM, V270, P13246, DOI 10.1074/jbc.270.22.13246; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; deFabritiis P, 1997, LEUKEMIA, V11, P811, DOI 10.1038/sj.leu.2400664; DEFABRITIIS P, 1995, LEUKEMIA, V9, P662; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; Eckstein F, 1996, BIOCHEM SOC T, V24, P601, DOI 10.1042/bst0240601; Gewirtz A. M., 1996, Blood, V88, p270A; Gewirtz AM, 1998, BLOOD, V92, P712, DOI 10.1182/blood.V92.3.712.415a32_712_736; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GILES RV, 1995, BLOOD, V86, P744, DOI 10.1182/blood.V86.2.744.bloodjournal862744; Graf T, 1998, CURR BIOL, V8, pR353, DOI 10.1016/S0960-9822(98)70220-9; Gunther EJ, 1996, PHOTOCHEM PHOTOBIOL, V63, P207, DOI 10.1111/j.1751-1097.1996.tb03015.x; HIJIYA N, 1994, P NATL ACAD SCI USA, V91, P4499, DOI 10.1073/pnas.91.10.4499; James H A, 1997, Methods Mol Biol, V74, P1; Jarvis TC, 1996, RNA, V2, P419; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; Kasono K, 1998, BIOCHEM BIOPH RES CO, V251, P124, DOI 10.1006/bbrc.1998.9259; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; KU DH, 1993, J BIOL CHEM, V268, P2255; Kypreos KE, 1998, CELL GROWTH DIFFER, V9, P723; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; MELOTTI P, 1994, J BIOL CHEM, V269, P25303; Melotti P, 1996, P NATL ACAD SCI USA, V93, P5313, DOI 10.1073/pnas.93.11.5313; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAYAMA K, 1993, INT IMMUNOL, V5, P817, DOI 10.1093/intimm/5.8.817; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Pitsch RJ, 1996, J VASC SURG, V23, P783, DOI 10.1016/S0741-5214(96)70240-9; PRESS RD, 1994, MOL CELL BIOL, V14, P2278, DOI 10.1128/MCB.14.4.2278; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P1710, DOI 10.1073/pnas.89.5.1710; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P11823, DOI 10.1073/pnas.89.24.11823; RATAJCZAK MZ, 1992, BLOOD, V79, P1956; ROSENBERG RD, 1993, THROMB HAEMOSTASIS, V70, P10; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SIMONS M, 1995, AM J PHYSIOL-CELL PH, V268, pC856, DOI 10.1152/ajpcell.1995.268.4.C856; SIMONS M, 1993, J BIOL CHEM, V268, P627; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SMALL D, 1994, P NATL ACAD SCI USA, V91, P459, DOI 10.1073/pnas.91.2.459; SULLENGER BA, 1995, APPL BIOCHEM BIOTECH, V54, P57, DOI 10.1007/BF02787911; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Thompson MA, 1998, CANCER RES, V58, P5168; Tomita A, 1998, LEUKEMIA, V12, P1422, DOI 10.1038/sj.leu.2401113; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731; TRAVALI S, 1991, ONCOGENE, V6, P887; Vandenbark GR, 1996, CELL GROWTH DIFFER, V7, P1383; VORBRUEGGEN G, 1994, NUCLEIC ACIDS RES, V22, P2466, DOI 10.1093/nar/22.13.2466; Wagner RW, 1997, MOL MED TODAY, V3, P31, DOI 10.1016/S1357-4310(96)10053-8; Wu AG, 1995, LEUKEMIA LYMPHOMA, V20, P67, DOI 10.3109/10428199509054755; YU H, 1993, BLOOD, V81, P373	73	38	39	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 13	1999	18	19					3056	3062		10.1038/sj.onc.1202785	http://dx.doi.org/10.1038/sj.onc.1202785			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378701				2022-12-17	WOS:000080387800015
J	Weston, K				Weston, K			Reassessing the role of C-MYB in tumorigenesis	ONCOGENE			English	Article						myb; myc; pim-1; transformation; tumorigenesis	E-MU-MYC; T-CELL LYMPHOMAS; TRANSGENIC MICE; MYELOID CELLS; PIM-1 KINASE; B-CELL; V-MYB; ERYTHROPOIETIN RECEPTOR; COOPERATING ONCOGENES; INHIBITS APOPTOSIS	Hematopoietic tumors in both humans and mice frequently up-regulate expression of the c-myb gene, but it is unclear whether this is a cause or a consequence of the leukemic state. Recent results placing super-activation of the c-Myb protein at the bottom of a kinase-activated signal transduction pathway indicate that it may be a downstream effector of transformation induced by other oncogenes, The relationship between c-Myb and the serine-threonine kinase pim-l, its immediate activator, is discussed, together with the possibility that c-Myb, like pim-l, may be able to synergize with c-Myc to induce tumors.	Inst Canc Res, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Weston, K (corresponding author), Inst Canc Res, CRC, Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.							Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Allen JD, 1996, SEMIN CANCER BIOL, V7, P299, DOI 10.1006/scbi.1996.0038; Allen JD, 1997, ONCOGENE, V15, P1133, DOI 10.1038/sj.onc.1201288; AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; AZIZ N, 1993, ONCOGENE, V8, P2259; Badiani PA, 1996, ONCOGENE, V13, P2205; BAER MR, 1992, BLOOD, V79, P1319; Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; CUYPERS HT, 1984, CELL, V37, P141; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DOMEN J, 1993, LEUKEMIA, V7, pS108; DOMEN J, 1993, BLOOD, V82, P1445; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Feldman BJ, 1997, ONCOGENE, V15, P2735, DOI 10.1038/sj.onc.1201670; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Gewirtz AM, 1998, BLOOD, V92, P712, DOI 10.1182/blood.V92.3.712.415a32_712_736; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; JIANG X, 1994, MAMM GENOME, V5, P142, DOI 10.1007/BF00352344; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; Kung H J, 1991, Curr Top Microbiol Immunol, V171, P1; LAIRD PW, 1993, NUCLEIC ACIDS RES, V21, P4750, DOI 10.1093/nar/21.20.4750; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Lilly M, 1997, CANCER RES, V57, P5348; LILLY M, 1992, ONCOGENE, V7, P727; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; MOROY T, 1991, ONCOGENE, V6, P1941; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUSHINSKI JF, 1983, SCIENCE, V220, P795, DOI 10.1126/science.6687762; NESS SA, 1999, IN PRESS ONCOGENE; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Rohwer F, 1996, J IMMUNOL, V157, P643; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SCHIRM S, 1990, J VIROL, V64, P767, DOI 10.1128/JVI.64.2.767-773.1990; Schmidt T, 1998, EMBO J, V17, P5349, DOI 10.1093/emboj/17.18.5349; SHINTO Y, 1995, ONCOGENE, V11, P1729; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; VILLENEUVE L, 1993, J VIROL, V67, P5733, DOI 10.1128/JVI.67.10.5733-5739.1993; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; Wolff L, 1996, CRIT REV ONCOGENESIS, V7, P245, DOI 10.1615/CritRevOncog.v7.i3-4.60	57	38	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 13	1999	18	19					3034	3038		10.1038/sj.onc.1202728	http://dx.doi.org/10.1038/sj.onc.1202728			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378698				2022-12-17	WOS:000080387800012
J	Frenkel, J; Sherman, D; Fein, A; Schwartz, D; Almog, N; Kapon, A; Goldfinger, N; Rotter, V				Frenkel, J; Sherman, D; Fein, A; Schwartz, D; Almog, N; Kapon, A; Goldfinger, N; Rotter, V			Accentuated apoptosis in normally developing p53 knockout mouse embryos following genotoxic stress	ONCOGENE			English	Article						p53-dependent and independent apoptosis; embryogenesis	WILD-TYPE P53; RADIATION-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; TRANSGENIC MICE; P53-DEFICIENT MICE; DNA-DAMAGE; MDM2-DEFICIENT MICE; IONIZING-RADIATION; GAMMA-IRRADIATION; IN-VIVO	In order to identify the alternative pathways which may substitute for the p53 function during embryogenesis, we have focused our studies on p53-/- normally developing mouse embryos that survived a genotoxic stress. We assumed that under these conditions p53-independent pathways, which physiologically control genomic stability, are enhanced. We found that while p53+/+ mouse embryos elicited, as expected, a p53-dependent apoptosis, p53-/- normally developing mice exhibited an accentuated p53-independent apoptotic response. The p53-dependent apoptosis detected in p53+/+ embryos, was an immediate reaction mostly detected in the brain, whereas the p53-independent apoptosis was a delayed reaction with a prominent pattern observed in epithelial cells of most organs in the p53-deficient mice only. These results suggest that in the absence of p53-dependent apoptosis, which is a fast response to damaged DNA, p53-independent apoptotic pathways, with slower kinetics, are turned on to secure genome stability.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Assaf Harofeh Med Ctr, Dept Obstet & Gynecol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Embryol & Teratol, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.							Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; CHANDRASEKARAN K, 1981, P NATL ACAD SCI-BIOL, V78, P6953, DOI 10.1073/pnas.78.11.6953; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Godley LA, 1996, GENE DEV, V10, P836, DOI 10.1101/gad.10.7.836; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1991, CANCER RES, V51, P6304; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LOUIS JM, 1988, BIOCHIM BIOPHYS ACTA, V950, P395, DOI 10.1016/0167-4781(88)90136-4; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUNA RMD, 1995, NATURE, V378, P203; MacCallum DE, 1996, ONCOGENE, V13, P2575; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; MERRITT AJ, 1994, CANCER RES, V54, P614; MORA PT, 1980, NATURE, V288, P722, DOI 10.1038/288722a0; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Peled A, 1996, CANCER RES, V56, P2148; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SCHMID P, 1991, DEVELOPMENT, V113, P857; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TIMME TL, 1994, BIOTECHNIQUES, V17, P461; WRIDE MA, 1994, INT J DEV BIOL, V38, P673; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHUANG SM, 1995, CANCER RES, V55, P486	46	38	38	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2901	2907		10.1038/sj.onc.1202518	http://dx.doi.org/10.1038/sj.onc.1202518			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362261				2022-12-17	WOS:000080125100013
J	Sunwoo, JB; Sun, PC; Gupta, VK; Schmidt, AP; El-Mofty, S; Scholnick, SB				Sunwoo, JB; Sun, PC; Gupta, VK; Schmidt, AP; El-Mofty, S; Scholnick, SB			Localization of a putative tumor suppressor gene in the sub-telomeric region of chromosome 8p	ONCOGENE			English	Article						deletion mapping; 8p23; squamous cell carcinoma; tumor suppressor gene	SQUAMOUS-CELL CARCINOMAS; ARM 8P; SUPRAGLOTTIC LARYNX; ALLELIC IMBALANCE; FREQUENT LOSS; CANCER; DELETION; LOCI; HEAD; 3P	Several regions of chromsome arm 8p are frequently deleted in a variety of human malignancies including those of the prostate, head and neck, lung, and colon, suggesting that there is more than one tumor suppressor gene on this chromosome arm. Both laryngeal and oral squamous cell carcinomas exhibit three distinct and nonoverlapping regions of deletion on 8p, We have further refined the localization of the putative suppressor in 8p23 by using eight microsatellite loci to create a high resolution deletion map of 150 squamous cell carcinomas of the larynx and oral cavity, These new data demonstrate that there are two distinct classes of deletion within this relatively small region of the chromosome and suggest two possible locations for the gene within the D8S264 to D8S1788 interval. We also determined that there is little difference between the allelic loss frequencies of microsatellites mapping near the telomeric ends of other chromosome arms and loci mapping to more centromere proximal regions of the same arm. These data suggest that the high allelic loss frequencies seen at 8p23 loci are not the result of a generalized instability of chromosome ends and are instead consistent with the activation of a specific suppressor gene.	Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Scholnick, SB (corresponding author), Washington Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, St Louis, MO 63110 USA.			Sunwoo, John/0000-0002-8393-4196	NATIONAL CANCER INSTITUTE [R01CA058473] Funding Source: NIH RePORTER; NCI NIH HHS [CA58473] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAIRNS P, 1994, CANCER RES, V54, P1422; FUJIWARA Y, 1993, CANCER RES, V53, P1172; Gotta M, 1996, EXPERIENTIA, V52, P1136, DOI 10.1007/BF01952113; Gustafson CE, 1996, CANCER RES, V56, P5238; Leach RJ, 1996, CYTOGENET CELL GENET, V75, P71, DOI 10.1159/000134460; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MACOSKA JA, 1995, CANCER RES, V55, P5390; MAESTRO R, 1993, CANCER RES, V53, P5775; Ranta S, 1996, GENOME RES, V6, P351, DOI 10.1101/gr.6.5.351; SCHOLNICK SB, 1994, CANCER, V73, P2472, DOI 10.1002/1097-0142(19940515)73:10<2472::AID-CNCR2820731005>3.0.CO;2-B; Scholnick SB, 1996, J NATL CANCER I, V88, P1676, DOI 10.1093/jnci/88.22.1676; Scholnick SB, 1998, OTOLARYNG HEAD NECK, V118, P363, DOI 10.1016/S0194-5998(98)70316-X; Spanknebel KA, 1997, AM J HUM GENET, V61, pA83; Sunwoo JB, 1996, GENE CHROMOSOME CANC, V16, P164, DOI 10.1002/(SICI)1098-2264(199607)16:3<164::AID-GCC2>3.0.CO;2-X; Tanaka K, 1996, ONCOGENE, V12, P405; Washburn J., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P515; Wu CL, 1997, GENE CHROMOSOME CANC, V20, P347, DOI 10.1002/(SICI)1098-2264(199712)20:4<347::AID-GCC5>3.0.CO;2-1; YAREMKO ML, 1994, GENE CHROMOSOME CANC, V10, P1, DOI 10.1002/gcc.2870100102; YOO GH, 1994, CANCER RES, V54, P4603	19	38	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2651	2655		10.1038/sj.onc.1202838	http://dx.doi.org/10.1038/sj.onc.1202838			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353609				2022-12-17	WOS:000079907100013
J	Sweetser, DA; Froelick, GJ; Matsumoto, AM; Kafer, KE; Marck, B; Palmiter, RD; Kapur, RP				Sweetser, DA; Froelick, GJ; Matsumoto, AM; Kafer, KE; Marck, B; Palmiter, RD; Kapur, RP			Ganglioneuromas and renal anomalies are induced by activated RETMEN2B in transgenic mice	ONCOGENE			English	Article						ganglioneuroma; ret proto-oncogene; multiple endocrine neoplasia; renal agenesis; neuroblastoma; transgenic; autonomic nervous system	MEDULLARY-THYROID CARCINOMA; TYROSINE KINASE DOMAIN; ENTERIC NERVOUS-SYSTEM; NEOPLASIA TYPE 2B; RET PROTOONCOGENE; CELL-LINE; C-RET; SYMPATHOADRENAL LINEAGE; SYMPATHETIC NEUROBLASTS; KIDNEY DEVELOPMENT	Multiple endocrine neoplasia type 2B (MEN2B) is an autosomal dominant syndrome characterized by the development of medullary thyroid carcinoma, pheochromocytomas, musculoskeletal anomalies and mucosal ganglioneuromas, MEN2B is caused by a specific mutation (Met918 --> Thr) in the RET receptor tyrosine kinase, Different mutations of RET lead to other conditions including MEN2A, familial medullary thyroid carcinoma and intestinal aganglionosis (Hirschsprung disease). Transgenic mice were created using the dopamine beta-hydroxylase promoter to direct expression of RETMEN2B the developing sympathetic and enteric nervous systems and the adrenal medulla, D beta H-RETMEN2B transgenic mice developed benign neuroglial tumors, histologically identical to human ganglioneuromas, in their sympathetic nervous systems and adrenal glands. The enteric nervous system was not affected. The neoplasms in D beta H-RETMEN2B mice were similar to benign neuroglial tumors induced in transgenic mice by activated Ras expression under control of the same promoter, Levels of phoshorylated MAP kinase were not increased in the RETMEN2B-induced neurolgial proliferations, suggesting that alternative pathways may play a role in the pathogenesis of these lesions, Transgenic mice with the highest levels of D beta H-RETMEN2B expression, unexpectedly developed renal malformations analogous to those reported with loss of function mutations in the Ret gene.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98105 USA; Univ Washington, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Med Ctr, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98108 USA; Univ Washington, Sch Med, Populat Ctr Res Reprod, Seattle, WA 98108 USA; VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System	Sweetser, DA (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,C1-169, Seattle, WA 98105 USA.		Matsumoto, Alvin/AAH-6096-2020; Sweetser, David/ABB-9347-2021	Sweetser, David/0000-0002-1621-3284	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD012629] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009351] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052530] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA09351] Funding Source: Medline; NICHD NIH HHS [HD12629] Funding Source: Medline; NIDDK NIH HHS [R01DK52530] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; BALJET B, 1975, STAIN TECHNOL, V50, P31, DOI 10.3109/10520297509117028; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; Borrello MG, 1995, ONCOGENE, V11, P2419; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BRODEUR GM, 1997, PRINCIPLES PRACTICE; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; Califano D, 1996, P NATL ACAD SCI USA, V93, P7933, DOI 10.1073/pnas.93.15.7933; CARLSON KM, 1993, DEVELOPMENT, V119, P1005; CARNAHAN JF, 1991, DEV BIOL, V148, P552, DOI 10.1016/0012-1606(91)90273-6; DALESSIO A, 1995, CELL GROWTH DIFFER, V6, P1387; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; Durbec PL, 1996, DEVELOPMENT, V122, P349; Edery P, 1997, BIOESSAYS, V19, P389, DOI 10.1002/bies.950190506; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ForssPetter S, 1997, J NEUROSCI RES, V50, P829, DOI 10.1002/(SICI)1097-4547(19971201)50:5<829::AID-JNR19>3.0.CO;2-W; HEINICKE EA, 1987, J NEUROSCI METH, V21, P45, DOI 10.1016/0165-0270(87)90101-4; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; IKEDA I, 1990, ONCOGENE, V5, P1291; IKUNO N, 1995, PATHOL RES PRACT, V191, P92, DOI 10.1016/S0344-0338(11)80558-3; Iwashita T, 1996, ONCOGENE, V12, P481; JHIANG SM, 1992, ONCOGENE, V7, P1331; KAPUR RP, 1992, DEVELOPMENT, V116, P167; KAPUR RP, 1991, NEURON, V7, P717, DOI 10.1016/0896-6273(91)90275-5; Kusafuka T, 1996, PEDIATR SURG INT, V12, P11, DOI 10.1007/BF01194794; Lechner MS, 1997, MECH DEVELOP, V62, P105, DOI 10.1016/S0925-4773(97)00667-9; Liu ZZ, 1996, DEV BIOL, V178, P133, DOI 10.1006/dbio.1996.0204; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Rizzo C, 1996, J BIOL CHEM, V271, P29497, DOI 10.1074/jbc.271.46.29497; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Sweetser DA, 1997, ONCOGENE, V15, P2783, DOI 10.1038/sj.onc.1201452; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TSUZUKI T, 1995, ONCOGENE, V10, P191; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; WAJJWALKU W, 1992, JPN J CANCER RES, V83, P671, DOI 10.1111/j.1349-7006.1992.tb01963.x; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619	54	38	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					877	886		10.1038/sj.onc.1202376	http://dx.doi.org/10.1038/sj.onc.1202376			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023663				2022-12-17	WOS:000078510600004
J	Voorhoeve, PM; Watson, RJ; Farlie, PG; Bernards, R; Lam, EWF				Voorhoeve, PM; Watson, RJ; Farlie, PG; Bernards, R; Lam, EWF			Rapid dephosphorylation of p107 following UV irradiation	ONCOGENE			English	Article						E2F; p107; G1 arrest; PP2A; UV response	RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; THREONINE PROTEIN PHOSPHATASES; CELL-CYCLE CONTROL; GROWTH SUPPRESSION; IN-VIVO; SUSCEPTIBILITY GENE; CATALYTIC SUBUNIT; CANCER CELL; FAMILY	In response to UV irradiation, mouse NIH3T3 fibroblasts transiently arrest predominantly in the G1 phase of the cell cycle. Here, we investigate the role of the retinoblastoma-related pocket proteins in this biological process. We report here that UV induces an increase in p107/E2F complexes, shown previously to be repressors of E2F-dependent transcriptional activity. Several lines of evidence indicate that the increase of p107/E2F complexes following UV irradiation is a consequence of rapid dephosphorylation of p107. First, UV-mediated p107 dephosphorylation could be abolished by pretreatment of NIH3T3 fibroblasts with the serine/threonine phosphatase inhibitors calyculin A and okadaic acid. Second, alteration of protein phosphatase 2A holoenzyme composition by over-expression of specific B subunits interfered with UV-mediated dephosphorylation of p107, Consistent with this, p107 could be dephosphorylated in vitro with PP2A, Moreover, dephosphorylation of p107 was shown to be independent of the activity of p53 and p21, as it occurred also in UV-treated p53-null as well as p21-null mouse fibroblasts. We observed a close correlation between the UV dosages required for G1 cell cycle arrest and p107 dephosphorylation. Our data suggest a model in which UV radiation-induced cell cycle arrest depends, at least in part, on the induction of a PP2A-like phosphatase that acts on p107.	Imperial Coll Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Imperial Coll Sch Med, Dept Med Microbiol, London W2 1PG, England; Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands	Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; Netherlands Cancer Institute	Lam, EWF (corresponding author), Imperial Coll Sch Med, Ludwig Inst Canc Res, Norfolk Pl, London W2 1PG, England.		Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576; Bernards, Rene/0000-0001-8677-3423				BACHRACH U, 1975, P NATL ACAD SCI USA, V72, P3087, DOI 10.1073/pnas.72.8.3087; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CIMENT G, 1978, SCIENCE, V202, P765, DOI 10.1126/science.213832; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HATAKEYAMA M, 1994, COLD SPRING HARB SYM, V59, P1; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HONKANAN RE, 1994, TOXICON, V32, P339, DOI 10.1016/0041-0101(94)90086-8; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KATO J, 1993, GENE DEV, V7, P331; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MAYOL X, 1995, ONCOGENE, V11, P801; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Nelson DA, 1997, ONCOGENE, V14, P2407, DOI 10.1038/sj.onc.1201081; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; NEVINS JR, 1992, SCIENCE, V258, P424; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; RONAI ZA, 1990, CELL BIOL TOXICOL, V6, P105, DOI 10.1007/BF00135030; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STONE SR, 1988, NUCLEIC ACIDS RES, V16, P11365, DOI 10.1093/nar/16.23.11365; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; van der Eb A J, 1980, Methods Enzymol, V65, P826; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.biochem.54.1.425; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; WU CL, 1995, MOL CELL BIOL, V15, P2536; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZHANG YH, 1995, ONCOGENE, V10, P2085; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZHU LG, 1995, MOL CELL BIOL, V15, P3552	66	38	39	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					679	688		10.1038/sj.onc.1202289	http://dx.doi.org/10.1038/sj.onc.1202289			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989818	Green Published			2022-12-17	WOS:000078394400013
J	Liu, ML; Von Lintig, FC; Liyanage, M; Shibata, MA; Jorcyk, CL; Ried, T; Boss, GR; Green, JE				Liu, ML; Von Lintig, FC; Liyanage, M; Shibata, MA; Jorcyk, CL; Ried, T; Boss, GR; Green, JE			Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice	ONCOGENE			English	Article						CGH; Ki-ras; gene amplification; MAP kinase; mammary gland tumor; transgenic mice; Ras-bound GTP and GDP	LARGE T-ANTIGEN; HUMAN-BREAST CARCINOMAS; C-MYC; ONCOGENE AMPLIFICATION; PROTO-ONCOGENE; GENE; CELLS; EXPRESSION; CANCER; TUMORIGENESIS	We have previously documented that transgenic mice expressing SV40 Tag regulated by the rat prostatic steroid-binding protein C3(1) 5'-flanking region display multistage mammary tumorigenesis. To delineate genetic changes associated with mammary tumor progression, comparative genomic hybridization (CGH) was performed. CGH revealed a consistent gain of the telomeric region of chromosome 6, This region contains the Ki-ras proto-oncogene, Analyses of genomic DNA by Southern blot demonstrated up to 40-fold amplification of the Ki-ras gene. Ki-ras amplification was detected in 12, 46 and 68% of tumors from 4, 5 and 6 month old mice, respectively, whereas no amplifications were found in any preneoplastic mammary tissues. Tumors bearing Ki-ras gene amplification exhibited high levels of Ki-ras RNA and protein, The over-expressed Ki-Ras protein in these tumors appeared functionally active as indicated by the elevated MAP kinase activity, These data demonstrate that while Ki-ras amplification might not be an early event, there is a strong association between Ki-ras amplification and over-expression and mammary tumor progression in this model. This study also shows that CGH is a powerful and useful technique for identifying chromosomal copy number changes during tumor progression, and that this model may provide a predictable in vivo system for studying gene amplification.	NCI, Div Basic Sci, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; NIH, Natl Human Genome Res Inst, Bethesda, MD USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of California System; University of California San Diego	Green, JE (corresponding author), NCI, Div Basic Sci, Lab Cell Regulat & Carcinogenesis, Bldg 41 Room C619, Bethesda, MD 20892 USA.		Shibata, Masa-Aki/L-1624-2019	Shibata, Masa-Aki/0000-0002-3350-7305; Boss, Gerry/0000-0002-9758-8714				ALDAZ CM, 1993, CANCER RES, V53, P5339; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CHRISTOFORI G, 1994, SEMIN CANCER BIOL, V5, P3; CZERNIAK B, 1989, CANCER, V63, P2008, DOI 10.1002/1097-0142(19890515)63:10<2008::AID-CNCR2820631024>3.0.CO;2-D; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GARCIA I, 1989, CANCER RES, V49, P6675; Guha A, 1996, ONCOGENE, V12, P507; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; Jenkins RB, 1997, CANCER RES, V57, P524; Jones KA, 1995, CANCER SURV, V25, P315; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MATIN A, 1993, CELL GROWTH DIFFER, V4, P1051; PROSPERI MT, 1990, CANCER LETT, V51, P169, DOI 10.1016/0304-3835(90)90053-Z; RIED T, 1995, CANCER RES, V55, P5415; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; SHEKHAR PVM, 1994, INVAS METAST, V14, P27; Shibata MA, 1996, CANCER RES, V56, P2998; Shibata MA, 1996, CANCER RES, V56, P4894; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; THEILLET C, 1986, CANCER RES, V46, P4776; VARLEY JM, 1987, ONCOGENE, V1, P423; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	33	38	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2403	2411		10.1038/sj.onc.1202456	http://dx.doi.org/10.1038/sj.onc.1202456			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811472				2022-12-17	WOS:000076723300015
J	Lounis, H; Mes-Masson, AM; Dion, F; Bradley, WEC; Seymour, RJ; Provencher, D; Tonin, PN				Lounis, H; Mes-Masson, AM; Dion, F; Bradley, WEC; Seymour, RJ; Provencher, D; Tonin, PN			Mapping of chromosome 3p deletions in human epithelial ovarian tumors	ONCOGENE			English	Article						ovarian; chromosome 3p; loss of heterozygosity; tumor suppressor	SUPPRESSOR GENE; RECEPTOR GENE; HUMAN GENOME; CELL-LINES; FHIT GENE; LOW-GRADE; CANCER; CARCINOMAS; MAP; IDENTIFICATION	Epithelial ovarian tumors frequently display deletions on the short arm of chromosome 3 suggesting the existence of tumor suppressor genes within the deleted regions. We have recently established a primary tissue culture system as a model to investigate the genetic events associated with ovarian cancer. The frequencies of loss of heterozygosity (LOH) at 16 loci representative of chromosome 3p in 33 tumor biopsies and 47 ovarian primary cultures derived from unselected ovarian cancers were examined, This repertoire also included benign and borderline tumors as well as malignant ovarian ascites, LOH was observed in 25 (31%) samples for at least one marker: 21 of 58 malignant, two of 12 borderline and two of 10 benign specimens, Chromosome 3p loss was not restricted to ovarian tumors of high grade and stage. LOH was observed in both cultured and non cultured tumors and ascites, A spontaneously immortalized cell line derived from a malignant ovarian ascites, OV-90, displayed LOH of the majority of markers suggesting loss of one homolog of chromosome 3p, The pattern of deletion displayed by these 25 samples enabled the determination of at least two distinct regions of overlapping deletions on chromosome 3p extending from D3S1270 to D3S1597 and from D3S1293 to D3S1283, In addition, a region proximal to D3S1300 was deleted in a subset of samples. Although loss of loci overlapping these three regions (Regions I, II and III) were observed in malignant and benign tumors, in borderline tumors loss was observed of markers representative of Region III only. While RAR beta is presently included in Region II, the minimal regions of deletion exclude VHL, TGFBR2, PTPasey and FHIT as candidate tumor suppressors in ovarian tumorigenesis.	CHUM Campus Notre Dame, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Obstet Gynecol, Montreal, PQ H3C 3J2, Canada; McGill Univ, Montreal Gen Hosp, Res Inst, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Obstet & Gynecol, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3G 1A4, Canada	Universite de Montreal; Universite de Montreal; McGill University; McGill University; McGill University; McGill University	Mes-Masson, AM (corresponding author), CHUM Campus Notre Dame, Inst Canc Montreal, 1560 Rue Sherbrooke Est, Montreal, PQ H2L 4M1, Canada.			Mes-Masson, Anne-Marie/0000-0002-6498-266X				Aebi S, 1996, CANCER RES, V56, P3087; BUICK RN, 1985, CANCER RES, V45, P3668; Cheng PC, 1996, J NATL CANCER I, V88, P510, DOI 10.1093/jnci/88.8.510; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; DODSON MK, 1993, CANCER RES, V53, P4456; EHLEN T, 1990, ONCOGENE, V5, P219; Foster K, 1995, EUR J CANCER, V31A, P2392, DOI 10.1016/0959-8049(95)00437-8; Hendricks DT, 1997, CANCER RES, V57, P2112; HOULE B, 1994, CANCER RES, V54, P365; JONES MH, 1992, ONCOGENE, V7, P1631; KRUK PA, 1990, LAB INVEST, V63, P132; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LAFORGIA S, 1993, CANCER RES, V53, P3118; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LATIF F, 1993, CANCER RES, V53, P861; LOUNIS H, 1994, EXP CELL RES, V215, P303, DOI 10.1006/excr.1994.1346; MANNING A, 1998, UNPUB MOL CARCINOGEN; MATHEW S, 1994, GENOMICS, V20, P114, DOI 10.1006/geno.1994.1134; MATTEI MG, 1991, GENOMICS, V10, P1061, DOI 10.1016/0888-7543(91)90199-O; Nakashima R, 1996, ONCOL REP, V3, P887; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PARSONS R, 1995, CANCER RES, V55, P5548; PEJOVIC T, 1992, GENE CHROMOSOME CANC, V4, P58, DOI 10.1002/gcc.2870040108; Phillips NJ, 1996, CANCER RES, V56, P606; RIMESSI P, 1994, ONCOGENE, V9, P3467; Schuler GD, 1996, SCIENCE, V274, P547; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Sun HS, 1996, MAMM GENOME, V7, P128, DOI 10.1007/s003359900032; SUN LZ, 1994, J BIOL CHEM, V269, P26449; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WANG JC, 1998, UNPUB CANC GENET CYT; WARY KK, 1993, CANCER RES, V53, P1498; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V11, P91, DOI 10.1016/0165-4608(84)90102-X; WHITMAN G, 1993, NORMAL OVARIAN DEV F; Yonescu R, 1996, CANCER GENET CYTOGEN, V87, P167, DOI 10.1016/0165-4608(95)00241-3; ZHENG JP, 1991, CANCER RES, V51, P4045	37	38	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 5	1998	17	18					2359	2365		10.1038/sj.onc.1202152	http://dx.doi.org/10.1038/sj.onc.1202152			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811467				2022-12-17	WOS:000076723300010
J	Gupta, RW; Mayer, BJ				Gupta, RW; Mayer, BJ			Dominant-negative mutants of the SH2/SH3 adapters Nck and Grb2 inhibit MAP kinase activation and mesoderm-specific gene induction by eFGF in Xenopus	ONCOGENE			English	Article						SH2/SH3 adapters; MAPK; FGF; mesoderm induction	FIBROBLAST GROWTH-FACTOR; PC12 CELL-DIFFERENTIATION; SRC HOMOLOGY-3 DOMAINS; PROTEIN-KINASE; FGF-RECEPTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASES; POINT MUTATION; SH3 DOMAINS; PATHWAY	The SH2/SH3 adapters Nck, Grb2 and Crk promote the assembly of signaling complexes by binding to tyrosine phosphorylated proteins using their SH2 domains and to proline-rich sequences on effector molecules using their SH3 domains. FGF, which activates a receptor tyrosine kinase, induces mesoderm formation in Xenopus embryos through activation of the Ras/Raf/MAPK signaling pathway. We present evidence that dominant-negative mutants of Nck and Grb2, but not Crk1, can inhibit mesoderm-specific gene induction by eFGF in Xenopus animal cap explants. We also show that dominant-negative mutants of Grb2 and Nck can inhibit eFGF-induced Erk1 activation in Xenopus animal caps, and that targeting the first two SH3 domains of Nck to the membrane can activate Erk1 in the absence of eFGF.. Furthermore, combinations of the dominant-negative Grb2 mutants with the inhibitory Nck mutant synergistically inhibited Erk1 activation by eFGF in Xenopus animal caps, suggesting that the dominant-negative Nck and Grb2 mutants inhibit Erk1 activation by binding to different proteins. By contrast only Grb2 mutants could inhibit eFGF-induced Erk1 activation in human 293 cells, demonstrating diversity in the specific mechanisms of signaling from FGF to MAP kinases in different cells.	Harvard Med Sch, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Mayer, BJ (corresponding author), Harvard Med Sch, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.							CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FELLER SM, 1995, ONCOGENE, V10, P1465; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HU G, 1995, MOL CELL BIOL, V15, P1169; HUGHES DA, 1993, NATURE, V364, P349, DOI 10.1038/364349a0; ISAACS HV, 1992, DEVELOPMENT, V114, P711; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; Kitamura T, 1996, BIOCHEM BIOPH RES CO, V219, P509, DOI 10.1006/bbrc.1996.0264; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LABONNE C, 1995, DEVELOPMENT, V121, P1475; LALLEMAIN G, 1992, MOL CELL BIOL, V12, P2222, DOI 10.1128/MCB.12.5.2222; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MUSLIN AJ, 1994, MOL CELL BIOL, V14, P3006, DOI 10.1128/MCB.14.5.3006; NAKEILNY S, 1992, EMBO J, V11, P2123; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Okada S, 1996, J BIOL CHEM, V271, P25533, DOI 10.1074/jbc.271.41.25533; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Rockow S, 1996, ONCOGENE, V12, P2351; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; RYAN PJ, 1994, DEV BIOL, V166, P101, DOI 10.1006/dbio.1994.1299; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SPENCER DM, 1995, P NATL ACAD SCI USA, V92, P9805, DOI 10.1073/pnas.92.21.9805; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; Tanaka M, 1997, P NATL ACAD SCI USA, V94, P4493, DOI 10.1073/pnas.94.9.4493; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VIZE PD, 1991, METHOD CELL BIOL, V36, P367; Ward CW, 1996, J BIOL CHEM, V271, P5603, DOI 10.1074/jbc.271.10.5603; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0	61	38	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	1998	17	17					2155	2165		10.1038/sj.onc.1202158	http://dx.doi.org/10.1038/sj.onc.1202158			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811447				2022-12-17	WOS:000076698200002
J	Salvat, C; Jariel-Encontre, I; Acquaviva, C; Omura, S; Piechaczyk, M				Salvat, C; Jariel-Encontre, I; Acquaviva, C; Omura, S; Piechaczyk, M			Differential directing of c-Fos and c-Jun proteins to the proteasome in serum-stimulated mouse embryo fibroblasts	ONCOGENE			English	Article						c-Fos; c-Jun; ubiquitin; proteasome; stimulation for growth	UBIQUITIN-ACTIVATING ENZYME; TEMPERATURE-SENSITIVE MUTANTS; CELL-CYCLE; TRANSCRIPTION FACTORS; V-FOS; MICROBIAL METABOLITE; G0-TO-G1 TRANSITION; NEUROBLASTOMA-CELLS; DNA-SYNTHESIS; TS85 CELLS	c-Fos and c-Jun proteins are highly unstable transcription factors that heterodimerize within the AP-1 transcription complex. Their accumulation is transilently induced at the beginning of the G(0)-to-S phase transition in quiescent cells stimulated for growth. To address the mechanisms responsible for rapid clearance of c-Fos and c-Jun proteins under these experimental conditions, we have used the ts20 mouse embryo fibroblasts which express a thermosensitive mutant of the E1 enzyme of the ubiquitin pathway. The use of cell-permeant protease inhibitors indicates that both proteins are degraded by the proteasome and excludes any major contribution for calpains and lysosomes during the G(0)-to-S phase transition. Synchronisation of ts20 cells at the non permissive temperature blocks the degradation of c-Jun, indicating that this process is E1-dependent. In contrast, c-Fos is broken down according to an apparently E1-independent pathway in ts20 cells, although a role for ubiquitinylation in this process cannot be formally ruled out. Interestingly, c-Jun is highly unstable in c-Fos-null mouse embryo fibroblasts stimulated for growth. Taken together, these observations show that in vivo during a G(0)-to-S phase transition (i) the precise mechanisms triggering c-Fos and c-Jun directing to the proteasome are not identical, (ii) the presence of c-Fos is not an absolute prerequisite for the degradation of c-Jun and (iii) the degradation of c-Jun is not required for that of c-Fos.	CNRS, UMR5535, Inst Med Genet, F-34293 Montpellier 05, France; Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, Tokyo 108, Japan; Kitasato Univ, Kitasato Inst, Biol Funct Res Ctr, Minato Ku, Tokyo 108, Japan	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Kitasato University; Kitasato University	Piechaczyk, M (corresponding author), CNRS, UMR5535, Inst Med Genet, 1919 Route Mende, F-34293 Montpellier 05, France.		Acquaviva, Claire/N-4306-2017; PIECHACZYK, Marc/E-7896-2013	Acquaviva, Claire/0000-0002-0227-9813; PIECHACZYK, Marc/0000-0003-1367-2597				Angel P. E., 1994, FOS JUN FAMILIES TRA; Aniento F, 1996, FEBS LETT, V390, P47, DOI 10.1016/0014-5793(96)00625-4; Carillo S, 1996, BIOCHEM J, V313, P245, DOI 10.1042/bj3130245; CARILLO S, 1994, ONCOGENE, V9, P1679; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Curran T, 1988, ONCOGENE HDB, P307; DEVERAUX Q, 1990, J BIOL CHEM, V265, P6323; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fuchs SY, 1996, ONCOGENE, V13, P1531; HARLOW E, 1988, ANTIBODIES; HATFIELD PM, 1992, J BIOL CHEM, V267, P14799; HermidaMatsumoto ML, 1996, J BIOL CHEM, V271, P4930; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; HOPSUHAVU VK, 1997, PROTEOLYSIS CELL FUN; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; JENNISSEN HP, 1995, EUR J BIOCHEM, V231, P1; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KAY GF, 1991, NATURE, V354, P486, DOI 10.1038/354486a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; KULKA RG, 1988, J BIOL CHEM, V263, P15726; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Mils V, 1997, ONCOGENE, V14, P1555, DOI 10.1038/sj.onc.1200991; MITCHELL MJ, 1991, NATURE, V354, P483, DOI 10.1038/354483a0; MORI M, 1993, J BIOL CHEM, V268, P16803; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; OMURA S, 1991, J ANTIBIOT, V44, P117, DOI 10.7164/antibiotics.44.117; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; RABOY B, 1986, EMBO J, V5, P863, DOI 10.1002/j.1460-2075.1986.tb04296.x; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; ROUX P, 1994, C FOS C JUN FAMILIES, P87; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; SLATER ML, 1976, CELL, V7, P289, DOI 10.1016/0092-8674(76)90028-3; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; Steff AM, 1997, BIOCHEM J, V323, P685, DOI 10.1042/bj3230685; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Wang WL, 1996, P NATL ACAD SCI USA, V93, P8236, DOI 10.1073/pnas.93.16.8236; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WATT F, 1993, NUCLEIC ACIDS RES, V21, P5092, DOI 10.1093/nar/21.22.5092; ZENG GC, 1984, MOL CELL BIOL, V4, P1815, DOI 10.1128/MCB.4.9.1815; Zhang WL, 1997, ONCOGENE, V14, P255, DOI 10.1038/sj.onc.1200841	64	38	38	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					327	337		10.1038/sj.onc.1201922	http://dx.doi.org/10.1038/sj.onc.1201922			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690514				2022-12-17	WOS:000074947500007
J	Watson, RH; Neville, PJ; Roy, WJ; Hitchcock, A; Campbell, IG				Watson, RH; Neville, PJ; Roy, WJ; Hitchcock, A; Campbell, IG			Loss of heterozygosity on chromosomes 7p, 7q, 9p and 11q is an early event in ovarian tumorigenesis	ONCOGENE			English	Article						loss of heterozygosity; tumour suppressor gene; ovarian cancer	LOW-GRADE; CANCER; CARCINOMAS; MUTATION; TUMORS; DELETION; FREQUENT; PROTEIN; REGIONS; BENIGN	Forty early stage malignant and seven borderline ovarian tumours mere analysed for loss of heterozygosity (LOH) on chromosomes 6, 7, 9, 11 and 7, LOH involving at least one locus was observed in 32 (80%) early stage and six (86%) borderline tumours, Frequent LOH in the early stage tumours was detected on chromosome arms 7p (31%), 7q (50%), 9p (42%) and 11q (34%) suggesting that these chromosomes harbour tumour suppressor genes which are inactivated early in tumorigenesis, Borderline tumours exhibited a similar pattern of LOH to that observed in the early stage malignant tumours, indicating that the development of both malignant and borderline forms may involve inactivation of the same set of tumour suppressor genes. Together with our previous investigation of benign ovarian tumours this data supports the theory that malignant ovarian tumours may arise from benign and borderline precursors.	Princess Anne Hosp, Southampton SO16 5YA, Hants, England; Southampton Gen Hosp, Dept Histopathol, Southampton SO16 6YD, Hants, England	University of Southampton	Watson, RH (corresponding author), Princess Anne Hosp, Level F,Coxford Rd, Southampton SO16 5YA, Hants, England.		campbell, Ian G/F-6006-2011	Campbell, Ian/0000-0002-7773-4155				CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; CAMPBELL IG, 1995, INT J CANCER, V63, P222, DOI 10.1002/ijc.2910630213; CHAMPENE MH, 1995, GENE CHROMOSOME CANC, V4, P304; CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; CLIBY W, 1993, CANCER RES, V53, P2393; Davis M, 1996, CANCER RES, V56, P741; Devlin J, 1996, BRIT J CANCER, V73, P420, DOI 10.1038/bjc.1996.75; DODSON MK, 1993, CANCER RES, V53, P4456; Edelson MI, 1997, ONCOGENE, V14, P2979, DOI 10.1038/sj.onc.1201271; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOULKES WD, 1995, BRIT J CANCER, V72, P883, DOI 10.1038/bjc.1995.428; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; GALLION HH, 1992, GYNECOL ONCOL, V47, P137, DOI 10.1016/0090-8258(92)90096-2; ISHWAD CS, 1995, GENE CHROMOSOME CANC, V14, P51, DOI 10.1002/gcc.2870140109; Kerr J, 1996, ONCOGENE, V13, P1815; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; Lane RP, 1996, GENOMICS, V35, P456, DOI 10.1006/geno.1996.0385; Latil A, 1995, CLIN CANCER RES, V1, P1385; Li DW, 1996, CARCINOGENESIS, V17, P1751, DOI 10.1093/carcin/17.8.1751; MILNER BJ, 1993, CANCER RES, V53, P2128; MULLENBACH R, 1989, TRENDS GENET, V5, P391; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; OSBORNE RJ, 1994, BRIT J CANCER, V69, P429, DOI 10.1038/bjc.1994.79; Roy WJ, 1997, ONCOGENE, V15, P2031, DOI 10.1038/sj.onc.1201372; SAITO S, 1992, CANCER RES, V52, P5815; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; Skomedal H, 1997, J PATHOL, V181, P158; TIBLETTI MG, 1996, CANCER RES, V56, P4493; Turkmen B, 1997, ELECTROPHORESIS, V18, P686, DOI 10.1002/elps.1150180505; Werness BA, 1997, HUM PATHOL, V28, P626, DOI 10.1016/S0046-8177(97)90087-3; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZHENG JP, 1995, J NATL CANCER I, V87, P1146, DOI 10.1093/jnci/87.15.1146; ZHENG JP, 1993, CANCER RES, V53, P4138	33	38	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					207	212		10.1038/sj.onc.1201945	http://dx.doi.org/10.1038/sj.onc.1201945			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674705				2022-12-17	WOS:000074706700009
J	Schafer, H; Trauzold, A; Sebens, T; Deppert, W; Folsch, UR; Schmidt, WE				Schafer, H; Trauzold, A; Sebens, T; Deppert, W; Folsch, UR; Schmidt, WE			The proliferation-associated early response gene p22/PRG1 is a novel p53 target gene	ONCOGENE			English	Article						early response gene; tumor suppressor; transcription factor; growth control	WILD-TYPE P53; NUCLEAR ANTIGEN PROMOTER; TUMOR-SUPPRESSOR P53; CARCINOMA CELL-LINE; ADENYLATE-CYCLASE; DNA-BINDING; MUTANT P53; GROWTH ARREST; BAX GENE; APOPTOSIS	The novel early response gene p22/PRG1 is linked to cell cycle entry and the induction of proliferation in various cell types although its exact function is still unknown. The p22/PRG1 promoter region contains a 20 bp sequence matching the consensus binding motif for the tumor suppressor protein p53, Gel shift assays demonstrated that p53 specifically binds to an oligonucleotide derived from the p53 binding site of the p22/PRG1 promoter. Chloramphenicol acetyltransferase (CAT) reporter gene assays confirmed that this site confers p53-dependent transcriptional activity to the p22/PRG1 promoter. In Hela cells, p22/PRG1 promoter constructs induced CAT expression only when cotransfected with an expression plasmid for wild-type, but not for mutant p53, Similarly, CAT expression was inducible at the permissive (31 degrees C) but not at the non-permissive temperature (39 degrees C) in the rat embryo fibroblast-derived cell line clone-6 that expresses a temperature-sensitive mutant p53, Conversion of this mutant p53 to a functional p53 at the permissive temperature was accompanied by a significant increase of endogenous p22/PRG1 mRNA level in this cell line. gamma-irradiation of rat splenocytes or doxorubicin-treatment of Hela cells increased p53 levels followed by transcriptional activation of p22/PRG1 and p21/Waf1 in parallel. Our data demonstrate that p22/PRG1 transcription is induced by p53 during p53-dependent cell cycle arrest and apoptosis, Therefore, p22/PRG1 represents a novel target for transcriptional activation by p53.	Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, D-24105 Kiel, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-2000 Hamburg, Germany	University of Kiel; Heinrich Pette Institute; University of Hamburg	Schmidt, WE (corresponding author), Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, Schittenhelmstr 12, D-24105 Kiel, Germany.		Trauzold, Anna/P-4398-2014; Schäfer, Heiner/C-1055-2011					ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BAE IS, 1995, CANCER RES, V55, P2387; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; BUSCAIL L, 1992, GASTROENTEROLOGY, V103, P1002, DOI 10.1016/0016-5085(92)90035-W; CHARLES CH, 1993, ONCOGENE, V8, P797; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1988, ONCOGENE, V3, P313; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GISH WR, 1987, J VIROL, V61, P2864, DOI 10.1128/JVI.61.9.2864-2876.1987; Hecker D, 1996, ONCOGENE, V12, P953; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Knippschild U, 1996, ONCOGENE, V12, P1755; Kondratyev AD, 1996, CANCER RES, V56, P1498; KRUISBEEK AM, 1993, CURRENT PROTOCOLS IM, V1; LING YH, 1993, CANCER RES, V53, P1845; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Martinez JD, 1997, ONCOGENE, V14, P2511, DOI 10.1038/sj.onc.1201095; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Molinari M, 1996, ONCOGENE, V13, P2077; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; OLSON DC, 1994, CELL GROWTH DIFFER, V5, P61; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; SAITO Y, 1995, ONCOGENE, V11, P1013; Schafer H, 1996, CANCER RES, V56, P2641; Schafer H, 1996, BIOCHEM BIOPH RES CO, V221, P111, DOI 10.1006/bbrc.1996.0554; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6148; SEKI H, 1994, EUR J IMMUNOL, V24, P2914, DOI 10.1002/eji.1830241150; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TISHLER RB, 1993, CANCER RES, V53, P2212; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZERRAHN J, 1992, ONCOGENE, V7, P1371	48	38	38	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 14	1998	16	19					2479	2487		10.1038/sj.onc.1201788	http://dx.doi.org/10.1038/sj.onc.1201788			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627114				2022-12-17	WOS:000073672300006
J	Maheswaran, S; Englert, C; Lee, SB; Ezzel, RM; Settleman, J; Haber, DA				Maheswaran, S; Englert, C; Lee, SB; Ezzel, RM; Settleman, J; Haber, DA			E1B 55K sequesters WT1 along with p53 within a cytoplasmic body in adenovirus-transformed kidney cells	ONCOGENE			English	Article						Wilms tumor; WT1; adenovirus; E1B 55K; sequestation; nuclear body	WILMS-TUMOR GENE; TRANSCRIPTIONAL REPRESSION; T-ANTIGEN; PROTEIN; APOPTOSIS; LOCALIZATION; ASSOCIATION; COMPLEX; DOMAIN; INHIBITION	WT1 encodes a tumor suppressor that is expressed in cells of the developing kidney and is inactivated in Wilms tumor, a pediatric kidney cancer. The adenovirus E1B 55K gene product contributes to the transformation of primary baby rat kidney (BRK) cells by binding and inactivating the product of the p53 tumor suppressor. We have previously demonstrated that WT1 and p53 are present within a protein complex in vivo. We non show that WT1 is physically associated with E1B 55K in adenovirus-transformed cells, an interaction that is mediated by the first two zinc fingers of WT1. Immunodepletion of p53 abrogates the coimmunoprecipitation of E1B 55K and WT1, consistent with the presence of a trimeric protein complex containing these three proteins. In the presence of E1B 55K, WT1 which is normally localized in the nucleus, is retained within a very high molecular weight complex and sequestered in the characteristic perinuclear cytoplasmic body that contains E1B 55K and p53, Expression of E1B 55K in osteosarcoma cells that undergo apoptosis following expression of WT1 inhibits WT1-mediated cell death. We conclude that E1B 55K may target WT1 along with p53, resulting in the functional inactivation of both tumor suppressor gene products by this viral oncoprotein.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Surg Res Unit, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University	Haber, DA (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA.			Lee, Sean/0000-0001-6211-3498; Englert, Christoph/0000-0002-5931-3189	NATIONAL CANCER INSTITUTE [R01CA058596, R37CA058596] Funding Source: NIH RePORTER; NCI NIH HHS [CA58596] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRAITHWAITE AW, 1989, J VIROL, V63, P1792, DOI 10.1128/JVI.63.4.1792-1799.1989; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; GESSLER M, 1990, NATURE, V343, P744; HABER DA, 1992, P NATL ACAD SCI USA, V89, P6010, DOI 10.1073/pnas.89.13.6010; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HASTIE ND, 1994, ANNU REV GENET, V28, P523; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; Jones N C, 1990, Semin Cancer Biol, V1, P425; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; Menke AL, 1996, ONCOGENE, V12, P537; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; STILLMAN B, 1986, CANCER SURV, V5, P389; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANDENHEUVEL SJL, 1993, J VIROL, V67, P5226, DOI 10.1128/JVI.67.9.5226-5234.1993; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	34	38	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2041	2050		10.1038/sj.onc.1201741	http://dx.doi.org/10.1038/sj.onc.1201741			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572485				2022-12-17	WOS:000073177200002
J	Muller, C; Dusseau, C; Calsou, P; Salles, B				Muller, C; Dusseau, C; Calsou, P; Salles, B			Human normal peripheral blood B-lymphocytes are deficient in DNA-dependent protein kinase activity due to the expression of a variant form of the Ku86 protein	ONCOGENE			English	Article						DNA-PK; Ku autoantigen; B-lymphocytes; V(D)J recombination	STRAND-BREAK-REPAIR; V(D)J RECOMBINATION; CATALYTIC SUBUNIT; SCID MUTATION; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; MAMMALIAN-CELLS; AUTOANTIGEN KU; BINDING; DEFECTS	The heterodimeric Ku protein, which comprises a 86 kDa (Ku86) amd a 70 kDa (Ku70) subunits, is an abundant nuclear DNA-binding protein which binds in vitro to DNA termini without sequence specificity, Ku is the DNA-targeting component of the large catalytic sub-unit of the DNA-dependent protein kinase complex (DNA-PKcs), that plays a critical role in mammalian double-strand break repair and lymphoid V(D)J recombination, By using electrophoretic mobility shift assays, we demonstrated that in addition to the major Ku.DNA complex usually detected in cell line extracts, a second complex with faster electrophoretic mobility was observed in normal peripheral blood lymphocytes (PBL) extracts, The presence of this faster migrating complex was restricted to B cells among the circulating lymphocyte population, Western blot analysis revealed that B cells express a variant form of the Ku86 protein with an apparent molecular weight of 69 kDa, and not the 86 kDa- full-length protein, Although the heterodimer Ku70/variant-Ku86 binds to DNA-ends, this altered form of the Ku heterodimer has a decreased ability to recruit the catalytic component of the complex, DNA-PKcs, which contributes to an absence of detectable DIVA-PK activity in B cells, These data provide a molecular basis for the increased sensitivity of B cells to ionizing radiation and identify a new mechanism of regulation of DNA-PK activity that operates in vivo.	CNRS, Inst Pharmacol & Biol Struct, UPR 9062, F-31077 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Salles, B (corresponding author), CNRS, Inst Pharmacol & Biol Struct, UPR 9062, 205 Route Narbonne, F-31077 Toulouse, France.		MULLER, Catherine/M-2185-2018; MULLER, Catherine/E-2060-2011; salles, bernard/B-8531-2008; calsou, patrick/AAB-5123-2020	Calsou, Patrick/0000-0001-7951-9806				AJMANI AK, 1995, J EXP MED, V181, P2049, DOI 10.1084/jem.181.6.2049; ANDERSON CW, 1994, J PROTEIN CHEM, V13, P500; BARRET JM, 1995, CARCINOGENESIS, V16, P1611, DOI 10.1093/carcin/16.7.1611; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; CAO QP, 1994, BIOCHEMISTRY-US, V33, P8548, DOI 10.1021/bi00194a021; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; Danska JS, 1996, MOL CELL BIOL, V16, P5507; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; FALZON M, 1993, J BIOL CHEM, V268, P10546; Finnie NJ, 1996, PHILOS T ROY SOC B, V351, P173, DOI 10.1098/rstb.1996.0014; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FRANCOEUR AM, 1986, J IMMUNOL, V136, P1648; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; GUIDOS CJ, 1996, GENE DEV, V10, P1054; Han ZY, 1996, J BIOL CHEM, V271, P14098, DOI 10.1074/jbc.271.24.14098; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Jongmans W, 1996, ONCOGENE, V13, P1133; KISHI H, 1983, J IMMUNOL, V131, P1961; KU GS, 1983, J IMMUNOL, V131, P2444; MAYER PJ, 1986, MUTAT RES, V166, P275, DOI 10.1016/0167-8817(86)90027-1; MCMILLAN TJ, 1994, INT J RADIAT BIOL, V65, P49, DOI 10.1080/09553009414550071; MINORI T, 1986, J BIOL CHEM, V261, P10375; MINORI T, 1981, J CLIN INVEST, V68, P611; MULLER C, 1994, INT J CANCER, V56, P749, DOI 10.1002/ijc.2910560523; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; PROSSER JS, 1976, INT J RADIAT BIOL, V30, P459, DOI 10.1080/09553007614551271; PRUSEK W, 1979, ARCH IMMUNOL THER EX, V27, P59; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SCHWARTZ JL, 1980, ENVIRON MUTAGEN, V2, P473, DOI 10.1002/em.2860020406; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; WANG JS, 1993, MOL BIOL REP, V18, P15, DOI 10.1007/BF01006891; WANG JS, 1994, FEBS LETT, V351, P219, DOI 10.1016/0014-5793(94)00863-9; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7; Wu XT, 1996, MOL CELL BIOL, V16, P5186; YANEVA M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P181, DOI 10.1016/0167-4781(91)90099-8; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2; ZHU C, 1996, CELL, V876, P379	47	38	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1553	1560		10.1038/sj.onc.1201676	http://dx.doi.org/10.1038/sj.onc.1201676			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569022				2022-12-17	WOS:000072743200005
J	Philips, A; Huet, X; Plet, A; Le Cam, L; Vie, A; Blanchard, JM				Philips, A; Huet, X; Plet, A; Le Cam, L; Vie, A; Blanchard, JM			The retinoblastoma protein is essential for cyclin A repression in quiescent cells	ONCOGENE			English	Article						cyclin A; transcription; pocket proteins	A GENE-TRANSCRIPTION; DNA-REPLICATION; ADENOVIRUS E1A; EXPRESSION; P107; E2F; RB; FIBROBLASTS; CDK2; P130	Cyclin A is a positive regulatory component of kinases required for the progression through S phase and for the transition between the G2 and M phases of the cell division cycle. Previous studies have demonstrated that the promoter of its gene is under transcriptional repression in quiescent cells. Whereas the DNA sequences mediating this effect have been clearly delineated, the nature of the proteins acting in trans is still debated, Indirect observations suggest the involvement of proteins related to the retinoblastoma tumor suppressor protein (pRb), However, the precise role of these proteins has been difficult to assess, since most experiments designed to analyse their function have been carried out in transformed cell lines, Nevertheless, a current model has emerged whereby the role of the p130 protein would be restricted to resting and early G1 cells and p107, absent in quiescent cells, would be involved later in the control of the G1/S transition, whilst pRb mould be effective throughout the cell cycle, We show here that cyclin A transcriptional inhibition is relieved in primary fibroblasts from pRb(-/-) embryos and not in fibroblasts from p130(-/-), p107(-/-) or even p130(-/-)/p107(-/-) double mutant embryos, This suggests a unique role for pRb in controlling the extinction of specific genes in GO, providing thus the first example of non-overlapping functions achieved by the different pocket proteins.	Inst Mol Genet, CNRS, UMR 5535, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Blanchard, JM (corresponding author), Inst Mol Genet, CNRS, UMR 5535, 1919 Route Mende, F-34293 Montpellier 5, France.		PHILIPS, Alexandre/AAB-6047-2020; Le Cam, Laurent/O-1408-2016	LE CAM, Laurent/0000-0003-0325-878X				BARLAT I, 1995, ONCOGENE, V11, P1309; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; BUCHOU T, 1993, ONCOGENE, V8, P1765; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Cress WD, 1996, CURR TOP MICROBIOL, V208, P63; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FOTEDAR R, 1991, COLD SH Q B, V56, P325; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HEICHMAN KA, 1994, CELL, V79, P556; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HERBER B, 1994, ONCOGENE, V9, P1295; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Huet X, 1996, MOL CELL BIOL, V16, P3789; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAYOL X, 1993, ONCOGENE, V8, P2561; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PAGANO M, 1992, EMBO J, V88, P1039; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Plet A, 1997, ONCOGENE, V14, P2575, DOI 10.1038/sj.onc.1201103; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SARDET C, 1997, ONCOGENES TRANSCRIPT, V2; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zerfass K, 1996, J VIROL, V70, P2637, DOI 10.1128/JVI.70.4.2637-2642.1996; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	47	38	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1373	1381		10.1038/sj.onc.1201655	http://dx.doi.org/10.1038/sj.onc.1201655			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525736				2022-12-17	WOS:000072572400001
J	Albertoni, M; Daub, DM; Arden, KC; Viars, CS; Powell, C; Van Meir, EG				Albertoni, M; Daub, DM; Arden, KC; Viars, CS; Powell, C; Van Meir, EG			Genetic instability leads to loss of both p53 alleles in a human glioblastoma	ONCOGENE			English	Article						glioma; brain tumour; PCR diagnosis; p53	WILD-TYPE P53; CELL-CYCLE; HUMAN CANCERS; EXPRESSION; AMPLIFICATION; LINES; DNA; CHECKPOINT; CYTOMETRY; MUTATIONS	Little is known about the relationship between genetic recombination mechanisms and loss of tumour suppressor genes in solid tumours. Here, we demonstrate deletion and truncation of both p53 alleles in a primary human glioblastoma and a derived cell line as the combined result of a t(17;20) reciprocal translocation and a 1.1 Mbp genomic deletion on chromosome 17p, starting in intron 4 of the p53 gene and ending at the telomeric CA-repeat marker D17S960. These results (i) suggest that genetic instability can lead to loss of tumour suppressor function in solid cancers, (ii) provide mapping of one such recombination event at the nucleotide level, and (iii) establish the orientation of the p53 gene on chromosome 17 as: centromere 5'-3'-telomere.	CHU Vaudois BH19 109, Dept Neurosurg, Lab Tumour Biol & Genet, CH-1011 Lausanne, Switzerland; Ludwig Inst Canc Res, San Diego, CA 92093 USA; LabCorp, Mol Biol & Pathol, Res Triangle Pk, NC 27709 USA	Ludwig Institute for Cancer Research	Van Meir, EG (corresponding author), CHU Vaudois BH19 109, Dept Neurosurg, Lab Tumour Biol & Genet, CH-1011 Lausanne, Switzerland.			Van Meir, Erwin G./0000-0003-2444-7707				BERMINGHAM JR, 1995, GENOMICS, V29, P70, DOI 10.1006/geno.1995.1216; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BOUFFLER SD, 1995, CANCER RES, V55, P3883; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Di Leonardo A, 1997, CANCER RES, V57, P1013; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LICHTER P, 1990, P NATL ACAD SCI USA, V87, P6634, DOI 10.1073/pnas.87.17.6634; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOEB LA, 1991, CANCER RES, V51, P3075; LUZI P, 1994, CYTOMETRY, V18, P79, DOI 10.1002/cyto.990180205; MAKOSWALES M, 1995, NAT MED, V1, P570; Marchevsky A, 1996, CYTOMETRY, V26, P101; MCPHERSON MJ, 1991, PCR PRACTICAL APPROA, P137; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MEYN MS, 1994, INT J RADIAT BIOL, V66, P141; MILLER CW, 1990, CANCER RES, V50, P7950; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PELTOMAKI P, 1993, CANCER RES, V53, P5853; POGRIBNY IP, 1995, CANCER RES, V55, P1894; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; STUDER A, 1985, ACTA NEUROPATHOL, V66, P208, DOI 10.1007/BF00688585; VAN MEIR EG, 1995, P NATL ACAD SCI USA, V92, P1008, DOI 10.1073/pnas.92.4.1008; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; VAN MEIR EG, 1994, CANCER RES, V54, P649; VANMEYEL DJ, 1994, JNCI-J NATL CANCER I, V86, P1011, DOI 10.1093/jnci/86.13.1011; VONDEIMLING A, 1992, CANCER RES, V52, P2987; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	33	38	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					321	326		10.1038/sj.onc.1201544	http://dx.doi.org/10.1038/sj.onc.1201544			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467957				2022-12-17	WOS:000071582100004
J	Su, YA; Lee, MM; Hutter, CM; Meltzer, PS				Su, YA; Lee, MM; Hutter, CM; Meltzer, PS			Characterization of a highly conserved gene (OS4) amplified with CDK4 in human sarcomas	ONCOGENE			English	Article						neoplasm; genetics; chromosome 12q; homogeneously staining region	HUMAN-MALIGNANT GLIOMAS; SOFT-TISSUE SARCOMAS; HUMAN CANCERS; AMPLIFICATION; MDM2; REGION; DNA; SAS; MICRODISSECTION; AMPLICONS	Amplification and overexpression of genes involved in growth control occur frequently in human Here, we report characterization of the fun length OS4 cDNA derived from 12q13-q15 (Su et al., Proc. Natl. Acad. Sci. USA, 91: 9121-9125, 1994), a region frequently amplified in sarcomas and brain tumors. This cDNA consists of 4833 base pairs (bp) encoding an open reading frame (ORF) of 283 amino acids, The ORF predicts a water-soluble acidic (pi 5.50) polypeptide with a molecular weight of 31 759. Database searches revealed highly significant similarity between OS4 and eight proteins predicted from genomic sequences of Caenorhabditis elegans, Schizosaccaharomyces pombe, and Saccharomyces cerevisiae. Thus, OS4 defines a novel evolutionarily conserved gene superfamily. Northern and database analyses revealed OS4 transcripts in numerous human tissues demonstrating its ubiquitous expression. We also observed overexpression of OS4 in three cancer cell lines with amplification of this gene. Furthermore, we detected OS4 amplification in 5/5 primary sarcomas with known amplification of the closely linked marker CDK4. These results demonstrate that the highly conserved OS4 gene is frequently included in the 22q13-q15 amplicon and may contribute to the development of a subset of sarcomas.	NATL HUMAN GENOME RES INST, NIH, CANC GENET LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; BROWN T, 1993, CURRENT PROTOCOLS MO; Elkahloun AG, 1996, GENE CHROMOSOME CANC, V17, P205, DOI 10.1002/(SICI)1098-2264(199612)17:4<205::AID-GCC2>3.3.CO;2-#; ELKAHLOUN AG, 1997, IN PRESS GENOMICS; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Gracia E, 1996, HUM MOL GENET, V5, P595, DOI 10.1093/hmg/5.5.595; JANKOWSKI SA, 1994, ONCOGENE, V9, P1205; KHATIB ZA, 1993, CANCER RES, V53, P5535; LEACH FS, 1993, CANCER RES, V53, P2231; MELTZER PS, 1991, CELL GROWTH DIFFER, V2, P495; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PONTEN J, 1967, INT J CANCER, V2, P434, DOI 10.1002/ijc.2910020505; Reifenberger G, 1996, CANCER RES, V56, P5141; REIFENBERGER G, 1994, CANCER RES, V54, P4299; RHIM JS, 1975, INT J CANCER, V15, P23, DOI 10.1002/ijc.2910150104; ROBERTS WM, 1989, CANCER RES, V49, P5407; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SMITH SH, 1992, CANCER RES, V52, P3746; Su YA, 1996, MOL CARCINOGEN, V15, P270, DOI 10.1002/(SICI)1098-2744(199604)15:4<270::AID-MC4>3.0.CO;2-K; SU YA, 1994, P NATL ACAD SCI USA, V91, P9121, DOI 10.1073/pnas.91.19.9121	23	38	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	1997	15	11					1289	1294		10.1038/sj.onc.1201294	http://dx.doi.org/10.1038/sj.onc.1201294			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315096				2022-12-17	WOS:A1997XV84500006
J	Ruchaud, S; Seite, P; Foulkes, NS; SassoneCorsi, P; Lanotte, M				Ruchaud, S; Seite, P; Foulkes, NS; SassoneCorsi, P; Lanotte, M			The transcriptional repressor ICER and cAMP-induced programmed cell death	ONCOGENE			English	Article						apoptosis; leukaemia; cAMP-signalling; transcription factors; CREM; ICER	LONG-TERM DESENSITIZATION; DNA FRAGMENTATION; RETINOIC ACID; CREM GENE; RESPONSIVE-ELEMENT; CYCLIC-NUCLEOTIDES; CHOLERA-TOXIN; KINASE-I; APOPTOSIS; EXPRESSION	The cAMP pathway plays a central role in the response to hormonal signals for cell proliferation, differentiation and apoptosis, In IPC-81 leukaemia cells, activation of the cAMP pathway by prostaglandin E1 treatment, or other cAMP-elevating agents, induces apoptosis within 4-6 h. Inhibition of mRNA or protein synthesis during the first 2h of cAMP induction protects cells from apoptosis, suggesting a requirement for early gene expression. cAMP-dependent protein kinase phosphorylates a class of nuclear factors and thereby regulates the transcription of a specific set of genes. Here we show that CREM (cAMP Responsive Element Modulator) expression is induced rapidly upon prostaglandin E1 treatment of IPC-81 cells. The induced transcripts correspond to the early product ICER (Inducible cAMP Early Repressor), ICER expression remains elevated until the burst of cell death, Protein synthesis inhibitors which prevent cAMP-induced apoptosis also block de novo ICER synthesis, Transfected IPC-81 cell lines, constitutively expressing high level of ICER are resistant to cAMP-induced cell death, In these transfected cells, cAMP fails to upregulate the ICER transcripts demonstrating that ICER exerts strongly its repressor function on CRE-containing genes. That an early expression of ICER blocks apoptosis, suggests that gene repression by endogenous ICER in IPC-81 is unsufficient or occurs too late to protect cells against death. ICER transfected cells rescued from cAMP-induced apoptosis are growth arrested, It shows for the first time that CREM activation directly participates to the decision of the cell to die. ICER, by sequentially repressing distinct sets of CRE-containing genes could modulate cell fate.	HOP ST LOUIS,CTR G HAYEM,INSERM U301,F-75010 PARIS,FRANCE; INST GENET BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)			Ruchaud, Sandrine/AAJ-2179-2021; Foulkes, Nicholas S/K-7003-2013	Foulkes, Nicholas S/0000-0002-1794-9891; Seite, Paule/0000-0002-7809-7610				Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BRAUMANN TJ, 1995, J CHROMATOGR, V350, P105; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DOWD DR, 1992, MOL CELL BIOL, V12, P3600, DOI 10.1128/MCB.12.8.3600; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; DUPREZ E, 1993, J BIOL CHEM, V268, P8332; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; FRIEDMAN DL, 1976, PHYSIOL REV, V56, P652, DOI 10.1152/physrev.1976.56.4.652; GIANNI M, 1995, BLOOD, V85, P3619, DOI 10.1182/blood.V85.12.3619.bloodjournal85123619; GJERTSEN BT, 1995, BBA-MOL CELL RES, V1269, P187, DOI 10.1016/0167-4889(95)00117-B; Green DR, 1996, CELL DEATH DIFFER, V3, P339; GROUL DJ, 1993, MOL ENDOCRINOL, V7, P104; HAWLEY RG, 1994, GENE THER, V1, P136; HAYARI Y, 1985, EUR J IMMUNOL, V15, P43, DOI 10.1002/eji.1830150109; HITTELMAN KJ, 1973, PROSTAGLANDINS, P151; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOMNA V, 1978, BIOCHEM BIOPH RES CO, V82, P1246; HOUGE G, 1995, MOL CELL BIOL, V15, P2051; HOUGE G, 1993, FEBS LETT, V315, P16, DOI 10.1016/0014-5793(93)81123-H; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; KIZAKI H, 1989, J IMMUNOL, V143, P1790; KIZAKI H, 1990, J BIOL CHEM, V265, P5280; LALLI E, 1995, P NATL ACAD SCI USA, V92, P9633, DOI 10.1073/pnas.92.21.9633; LANOTTE M, 1986, LEUKEMIA RES, V10, P1319, DOI 10.1016/0145-2126(86)90340-1; LANOTTE M, 1986, EXP HEMATOL, V14, P724; LANOTTE M, 1991, J CELL PHYSIOL, V146, P73, DOI 10.1002/jcp.1041460110; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; McConkey D J, 1992, Semin Immunol, V4, P371; MCCONKEY DJ, 1993, FASEB J, V7, P580, DOI 10.1096/fasebj.7.6.8386120; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONACO L, 1995, P NATL ACAD SCI USA, V92, P10673, DOI 10.1073/pnas.92.23.10673; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORI K, 1989, BIOCHEM BIOPH RES CO, V162, P1535, DOI 10.1016/0006-291X(89)90849-8; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OLSSON IL, 1982, CANCER RES, V42, P3922; POTTEN CS, 1988, CELL, V53, P676; PRATT RM, 1975, P NATL ACAD SCI USA, V72, P874, DOI 10.1073/pnas.72.3.874; ROSSI GB, 1980, BLOOD, V56, P74; Rowan S, 1997, LEUKEMIA, V11, P457, DOI 10.1038/sj.leu.2400626; Ruchaud S., 1995, Cellular Pharmacology, V2, P127; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; SASSONECORSI P, 1994, EMBO J, V13, P4717, DOI 10.1002/j.1460-2075.1994.tb06797.x; SONNENBURG WK, 1988, J BIOL CHEM, V263, P6155; SPAULDING SW, 1993, ENDOCR REV, V14, P632, DOI 10.1210/er.14.5.632; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUSUKI K, 1990, BIOCHEM BIOPH RES CO, V171, P827; TAETLE R, 1980, CANCER RES, V40, P1223; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.biochem.59.1.971; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TORTORA G, 1988, BLOOD, V71, P230; VINTERMYR OK, 1993, EXP CELL RES, V206, P157, DOI 10.1006/excr.1993.1132; WEILERGUETTLER H, 1992, P NATL ACAD SCI USA, V89, P2155, DOI 10.1073/pnas.89.6.2155; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILLIAMS GT, 1987, GENE, V53, P121, DOI 10.1016/0378-1119(87)90099-0; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40	70	38	39	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					827	836		10.1038/sj.onc.1201248	http://dx.doi.org/10.1038/sj.onc.1201248			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266969				2022-12-17	WOS:A1997XQ11700009
J	Knoepfler, PS; Kamps, MP				Knoepfler, PS; Kamps, MP			The highest affinity DNA element bound by Pbx complexes in t(1;19) leukemic cells fails to mediate cooperative DNA-binding or cooperative transactivation by E2a-Pbx1 and class I Hox proteins - Evidence for selective targetting of E2a-Pbx1 to a subset of Pbx-recognition elements	ONCOGENE			English	Article						Pbx; E2a-Pbx1; Hox; t(1;19) pre-B ALL	EMBRYONAL CARCINOMA-CELLS; HUMAN PROTOONCOGENE PBX1; HOMEOBOX GENES; RETINOIC ACID; PRE-B; TRANSLOCATION PROTEIN; TRANSCRIPTION FACTOR; HOMEODOMAIN; MOTIF; EXTRADENTICLE	Oncoprotein E2a-Pbx1 contains the N-terminal transactivation domains of E2a and the majority of the homeodomain protein, Pbx1, Using recombinant proteins, both Pbx1 and E2a-Pbx1 heterodimerize with Hox proteins on bipartite elements, Pbx1 binding a 5' TGAT core and Class I Hox proteins binding adjacent 3' TAAT, TTAT, or TGAT cores. In contrast to these in vitro results, nuclear extracts from E2a-Pbx1-transformed cells assemble an abundant Pbx-containing complex on TGATTGAT that excludes E2a-Pbx1, suggesting that an uncharacterized in vivo partner discriminates between E2a-Pbx1 and Pbx proteins, distinguishing it from Hox proteins. Here, we describe the DNA-binding properties of this complex, and identify TGATTGAC (PCE; Pbx Consensus Element) as its optimal recognition motif. In vitro, the PCE fails to bind heterodimers of Class I Hox proteins plus either Pbx1 or E2a-Pbx1. Likewise, in vivo, the PCE fails to mediate cooperative transactivation by E2a-Pbx1 plus Class I Hox proteins. Thus, the PCE binds a Pbx dimer partner that behaves unlike Class I Hox proteins, Competition analysis indicates that the Pbx-containing complex that binds the PCE also binds the TGATTGAT Pbx-Hox element and binds promoter elements required for tissue-specific expression of a number of cellular genes. Thus, different Pbx partners dictate targetting of Pbx heterodimers to related DNA motifs that differ in the sequence of their 3' half-sites, and E2a-Pbx1 heterodimerizes with only a subset of Pbx partners, restricting its potential DNA targets.			Knoepfler, PS (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT PATHOL,9500 GILMAN DR,LA JOLLA,CA 92093, USA.			Knoepfler, Paul/0000-0001-5444-334X	NATIONAL CANCER INSTITUTE [P01CA050528, R01CA056876] Funding Source: NIH RePORTER; NCI NIH HHS [CA56876, 2 PO1 CA50528] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; JOHNSON FB, 1995, P NATL ACAD SCI USA, V92, P739, DOI 10.1073/pnas.92.3.739; KAGAWA N, 1994, J BIOL CHEM, V269, P18716; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAMPS MP, 1991, GENE DEV, V5, P353; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Knoepfler PS, 1996, NUCLEIC ACIDS RES, V24, P2288, DOI 10.1093/nar/24.12.2288; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KNOEPFLER PS, 1997, IN PRESS MECH DEV; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Lu Q, 1996, MOL CELL BIOL, V16, P1632; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; LU QA, 1995, MOL CELL BIOL, V15, P3786; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PEERS B, 1995, MOL CELL BIOL, V15, P7091; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; ROBERTS VJ, 1995, MECH DEVELOP, V51, P193, DOI 10.1016/0925-4773(95)00364-9; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SPOEREL NA, 1993, J MOL BIOL, V230, P151, DOI 10.1006/jmbi.1993.1132; TANG SQ, 1995, NUCLEIC ACIDS RES, V23, P1928, DOI 10.1093/nar/23.11.1928; VALLEJO M, 1992, J BIOL CHEM, V267, P12868; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; ZWARTKRUIS F, 1993, EXP CELL RES, V205, P422, DOI 10.1006/excr.1993.1108	44	38	39	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2521	2531		10.1038/sj.onc.1201097	http://dx.doi.org/10.1038/sj.onc.1201097			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191052				2022-12-17	WOS:A1997XA94900004
J	Kalikin, LM; Frank, TS; SvobodaNewman, SM; Wetzel, JC; Cooney, KA; Petty, EM				Kalikin, LM; Frank, TS; SvobodaNewman, SM; Wetzel, JC; Cooney, KA; Petty, EM			A region of interstitial 17q25 allelic loss in ovarian tumors coincides with a defined region of loss in breast tumors	ONCOGENE			English	Article						loss of heterozygosity; ovarian; breast; prostate; tumor suppressor; chromosome 17q25	CANCER; CHROMOSOME-17Q; MUTATIONS; DELETION; DISTAL; LOCUS; GENE	Chromosomal regions of allelic imbalance in tumors are predicted to define the general location of tumor suppressor genes, We previously localized a putative breast tumor suppressor gene to a 3 cM region on 17q25 by deletion mapping of microsatellite markers in breast tumors, To determine if the same 17q25 region of loss is important in the genesis of other tumor types, 32 ovarian tumors and 24 prostate tumors, as well as 33 additional breast tumors, were analysed with 17q25 polymorphic microsatellite markers, While no significant loss was observed in prostate tumors, greater than half of ovarian tumors exhibited loss coincident with the candidate region previously defined in breast tumors. These results suggest that one or more novel tumor suppressor genes exist on 17q25 within a concordant region of interstitial loss defined in both breast and ovarian neoplasms.	UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT SURG, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Cooney, Kathleen/0000-0003-3831-6943	NATIONAL CANCER INSTITUTE [K08CA066613, F32CA071166, P50CA069568] Funding Source: NIH RePORTER; NCI NIH HHS [F32CA71166-01, P50CA69568, K08CA66613-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARASON A, 1993, AM J HUM GENET, V52, P711; Cooney KA, 1996, CANCER RES, V56, P1142; Cooney KA, 1996, CANCER RES, V56, P4150; ECCLES DM, 1992, ONCOGENE, V7, P2069; Fasman KH, 1996, NUCLEIC ACIDS RES, V24, P57, DOI 10.1093/nar/24.1.57; Foster JW, 1996, GENOMICS, V33, P185, DOI 10.1006/geno.1996.0182; Frank TS, 1996, DIAGN MOL PATHOL, V5, P220, DOI 10.1097/00019606-199609000-00012; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GODWIN AK, 1994, AM J HUM GENET, V55, P666; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HANSEN MF, 1987, CANCER RES, V47, P5518; JACOBS IJ, 1993, CANCER RES, V53, P1218; Kalikin LM, 1996, GENE CHROMOSOME CANC, V17, P64, DOI 10.1002/(SICI)1098-2264(199609)17:1<64::AID-GCC10>3.3.CO;2-1; KIRCHWEGER R, 1994, INT J CANCER, V56, P193, DOI 10.1002/ijc.2910560208; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; Merajver SD, 1995, CLIN CANCER RES, V1, P539; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P689, DOI 10.1093/nar/19.3.689; Schultz DC, 1996, CANCER RES, V56, P1997; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; SKUSE GR, 1995, LANCET, V345, P902, DOI 10.1016/S0140-6736(95)90015-2; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; Thorlacius S, 1996, NAT GENET, V13, P117, DOI 10.1038/ng0596-117; Wertheim I, 1996, ONCOGENE, V12, P2147	24	38	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	1997	14	16					1991	1994		10.1038/sj.onc.1201013	http://dx.doi.org/10.1038/sj.onc.1201013			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150366				2022-12-17	WOS:A1997WV80400012
J	Taglienti, CA; Wysk, M; Davis, RJ				Taglienti, CA; Wysk, M; Davis, RJ			Molecular cloning of the epidermal growth factor-stimulated protein kinase p56 KKIAMRE	ONCOGENE			English	Article						EGF; MAP kinase; signal transduction	SIGNAL-TRANSDUCTION PATHWAY; CELL-CYCLE CONTROL; MAP KINASE; C-MYC; CAENORHABDITIS-ELEGANS; PHOSPHORYLATION SITES; ACTIVATION DOMAIN; ESCHERICHIA-COLI; XENOPUS-OOCYTES; HUMAN HOMOLOG	A 56 kDa protein kinase was molecularly cloned from human fetal brain. This protein kinase (p56 KKIAMRE) shares homology with p42 KKIALRE (Meyerson et al., 1992) and is related to the proline-directed protein kinase group of signal transducing enzymes. The p56 KKIAMRE and p42 KKIALRE protein kinases exhibit mutually exclusive expression in reproductive tissues; p56 KKIAMRE in testis and p42 KKIALRE in ovary. p56 KKIAMRE and p42 KKIALRE may therefore contribute to signal transduction within these highly differentiated tissues. p56 KKIAMRE and p42 KKIALRE are activated by treatment of cells with epidermal growth factor (EGF). Although p56 KKIAMRE and p42 KKIALRE contain the MAP kinase dual phosphorylation motif Thr-Xaa-Tyr (Thr-Asp-Tyr), phosphorylation on Thr and Tyr within this motif is not required for EGF-stimulated protein kinase activity.	UNIV MASSACHUSETTS, SCH MED, PROGRAM MOL MED, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, SCH MED, DEPT MOL GENET & MICROBIOL, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOL BIOL, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester					NCI NIH HHS [CA65861, CA58396] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065861, R01CA058396] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ASHWORTH A, 1992, ONCOGENE, V7, P2555; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CHOI KY, 1994, CELL, V78, P499; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ELION EA, 1995, TRENDS CELL BIOL, V5, P322, DOI 10.1016/S0962-8924(00)89055-8; FUKUDA M, 1994, J BIOL CHEM, V269, P33097; GASKINS C, 1994, MOL CELL BIOL, V14, P6996, DOI 10.1128/MCB.14.10.6996; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GUPTA S, 1994, FEBS LETT, V353, P281, DOI 10.1016/0014-5793(94)01052-8; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KOLAND JG, 1990, BIOCHEM BIOPH RES CO, V166, P90, DOI 10.1016/0006-291X(90)91915-F; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KOSAKO H, 1994, J CELL SCI, P115; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LACKNER MR, 1994, GENE DEV, V8, P160, DOI 10.1101/gad.8.2.160; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEUNG PCK, 1992, ENDOCR REV, V13, P476, DOI 10.1210/er.13.3.476; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; MALDONADO F, 1988, NUCLEIC ACIDS RES, V16, P8189, DOI 10.1093/nar/16.16.8189; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RON D, 1992, BIOTECHNIQUES, V13, P866; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHULTZ J, 1995, CURR OPIN GENET DEV, V5, P31, DOI 10.1016/S0959-437X(95)90050-0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WU Y, 1994, GENE DEV, V8, P147, DOI 10.1101/gad.8.2.147; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202	63	38	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 19	1996	13	12					2563	2574						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000130				2022-12-17	WOS:A1996VZ65400006
J	Byrne, JL; Paterson, HF; Marshall, CJ				Byrne, JL; Paterson, HF; Marshall, CJ			p21Ras activation by the guanine nucleotide exchange factor Sos, requires the Sos/Grb2 interaction and a second ligand-dependent signal involving the Sos N-terminus	ONCOGENE			English	Article						hSos; Grb2; p21Ras; signal transduction	NERVE GROWTH-FACTOR; GRB2 ADAPTER PROTEIN; PC12 CELLS; KINASE ACTIVATION; RAS; MEMBRANE; DIFFERENTIATION; MICROINJECTION; TRANSDUCTION; SEVENLESS	It has been suggested that a key event in growth factor-induced p21Ras activation by the guanine nucleotide exchange factor Sos, is the recruitment of Sos to the plasma membrane by its interaction with the adaptor protein Grb2. However, other evidence argues that the sub cellular localisation of Sos is independent of Grb2, and that the Sos/Grb2 interaction can be dispensed with for p21Ras activation. To clarify the role of the Sos/Grb2 interaction in ligand-stimulated p21Ras activation, we have utilised the observation that overexpression of the Sos C-terminal domain can effectively inhibit p21Ras-dependent signalling in three different mammalian systems. We have shown that concurrent expression of Grb2, but not SH2 or SH3 domain mutants of Grb2, or the alternative adaptor protein Nck, can rescue this inhibitory effect: of the C-terminus. This shows that the Grb2/Sos interaction is required to mediate growth factor-dependent activation of p21Ras, and requires the presence of intact SH2 and SH3 domains of Grb2. This approach was also used for a functional analysis of Sos which revealed that growth factor dependent signals are transmitted through both the N-terminal and C-terminal domains.	INST CANC RES,CHESTER BEATTY LABS,CANC RES CAMPAIGN,CTR CELL & MOL BIOL,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK				Byrne, Jenny/0000-0002-9381-1851				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HU Q, 1995, MOL CELL BIOL, V88, P189; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PRONK GJ, 1993, J BIOL CHEM, V268; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294	39	38	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2055	2065						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950972				2022-12-17	WOS:A1996VV14500002
J	Malkowicz, SB; Tomaszewski, JE; Linnenbach, AJ; Cangiano, TA; Maruta, Y; McGarvey, TW				Malkowicz, SB; Tomaszewski, JE; Linnenbach, AJ; Cangiano, TA; Maruta, Y; McGarvey, TW			Novel p21(WAF1/CIP1) mutations in superficial and invasive transitional cell carcinomas	ONCOGENE			English	Article						cell cycle; bladder carcinoma; p21(WAF1/CIP1) gene	CYCLIN-DEPENDENT KINASES; HUMAN BLADDER-CANCER; P53 GENE; P53-INDEPENDENT EXPRESSION; TUMOR SUPPRESSION; OVARIAN-CANCER; INHIBITOR P21; WAF1/CIP1; ALLELOTYPE; INDUCTION	Alterations in the p53 gene are a predominant component in the development of transitional cell carcinoma (TCC), but the particular pathways distal to p53 alterations which contribute to urothelial transformation are not defined, Here, the p21(WAF1/CIP1) gene, a p53 inducible and p53 independent gene product, was studied in TCC, p21(WAF1/CIP1) expression was measured by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) from five cell lines and 28 tumor specimens (14 superficial, 14 muscle invasive), This was expressed as a ratio of the gene product to L7, a ribosomal housekeeping gene, In addition, exons 4 through 8 of the p53 gene as well as exon 2 of the p21(WAF1/CIP1) gene were assayed for mutations by polymerase chain reaction/ single stranded conformation polymorphism analysis (PCR/SSCP), Candidate mutations were verified by sequencing, p21(WAF1/CIP1)/L7 expression was significantly decreased in invasive lesions compared to superficial lesions (P<0.002), p53 mutations were detected by PCR/SSCP in seven tumors [25%] (one superficial, six invasive) and p21(WAF1/CIP1)/L7 expression was significantly decreased in all tumors that had p53 mutations (P<0.007), PCR/SSCP analysis of exon 2 in p21(WAF1/CIP1) detected band in tumor specimens (two superficial, two invasive), which sequencing and comparison to autologous normal matched DNA revealed as novel mutations.	VET ADM MED CTR,PHILADELPHIA,PA 19104; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	US Department of Veterans Affairs; Veterans Health Administration (VHA); The Wistar Institute	Malkowicz, SB (corresponding author), UNIV PENN,MED CTR,DEPT PATHOL,DEPT SURG,DIV UROL,1 RHOADS,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.							AKAMA Y, 1995, P AM ASSOC CANC RES, V36, pA193; BARBOULE N, 1995, INT J CANCER, V63, P611, DOI 10.1002/ijc.2910630502; BHATIA K, 1995, CANCER RES, V55, P1431; CHEN YQ, 1995, CANCER RES, V55, P4536; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLIBY W, 1993, CANCER RES, V53, P2393; CORDONCARDO C, 1992, J NATL CANCER I, V84, P1251, DOI 10.1093/jnci/84.16.1251; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DIGIUSEPPE JA, 1995, AM J PATHOL, V147, P884; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ESRIG D, 1993, AM J PATHOL, V143, P1389; GAO X, 1995, ONCOGENE, V11, P1395; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; Hayashi K, 1991, PCR Methods Appl, V1, P34; Horikoshi T, 1993, Methods Mol Biol, V15, P177, DOI 10.1385/0-89603-244-2:177; JIANG HP, 1994, ONCOGENE, V9, P3397; JUNG JM, 1995, ONCOGENE, V11, P2021; KAWASAKI T, 1994, CANCER LETT, V82, P113, DOI 10.1016/0304-3835(94)90154-6; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIANES P, 1994, J NATL CANCER I, V86, P1325, DOI 10.1093/jnci/86.17.1325; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1251; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; MICHIELI P, 1994, CANCER RES, V54, P3391; Michieli P, 1996, ONCOGENE, V12, P775; MORITA R, 1991, CANCER RES, V51, P820; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; Ozcelik H, 1995, CLIN CANCER RES, V1, P907; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; RUPPERT JM, 1993, CANCER RES, V53, P5093; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SATO T, 1991, CANCER RES, V51, P5118; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SPRUCK CH, 1994, CANCER RES, V54, P784; VIDAL MJ, 1995, P AM ASS RES, V36, pA1138; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WATANABE H, 1995, BBA-GENE STRUCT EXPR, V1263, P275, DOI 10.1016/0167-4781(95)00110-3; WILLIAMSON MP, 1994, GENE CHROMOSOME CANC, V9, P108, DOI 10.1002/gcc.2870090206	43	38	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1831	1837						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934528				2022-12-17	WOS:A1996VR79500001
J	Knecht, H; McQuain, C; Martin, J; Rothenberger, S; Drexler, HG; Berger, C; Bachmann, E; Kittler, ELW; Odermatt, BF; Quesenberry, PJ				Knecht, H; McQuain, C; Martin, J; Rothenberger, S; Drexler, HG; Berger, C; Bachmann, E; Kittler, ELW; Odermatt, BF; Quesenberry, PJ			Expression of the LMP1 oncoprotein in the EBV negative Hodgkin's disease cell line L-428 is associated with Reed-Sternberg cell morphology	ONCOGENE			English	Article						LMP1; oncoprotein; Reed-Sternberg cells; giant cells; NF-kappa B; L-428 cell line; 293 cells	EPSTEIN-BARR-VIRUS; LATENT MEMBRANE-PROTEIN; NF-KAPPA-B; NASOPHARYNGEAL CARCINOMA; ONCOGENE; GENE; ACTIVATION; DOMAIN; DNA; MEMBRANE-PROTEIN-1	The latent membrane protein 1 (LMP1) oncogene is one of the major proteins synthesized by the Epstein-Barr virus (EBV) and is expressed in Reed-Sternberg (RS) cells of EBV-associated Hodgkin's disease (HD), We have studied the effect of this oncoprotein on the formation of RS cells in the EBV-negative HD cell lines L-428 and KM-H2 as well as on the formation of multinucleated cells in the mononuclear human embryonic kidney cell line 293. LMP1 prototype (B95-8) and its naturally occurring carboxy terminal 30 base pair deletion variant LMP1-del were transfected into the cell lines and cytocentrifuge preparations were analysed after 24, 48, 72, 144, 216, and 240 h. While no oncoprotein expression was seen in the KM-H2 cell lines, expression of LMP1 and LMP1-del was observed in the L-428 and 293 cell lines, In the HD cell line L-428 oncoprotein expression was infrequent but when observed was very strong and preferentially associated with multinucleated RS cell morphology (71% of LMP1 positive cells), This is in contrast with the untransfected or transfected but not expressing cells where intermediate mononuclear elements predominated over multinucleated RS cells (< 3%), Frequent oncoprotein expression was observed in the 293 cells and again was associated with multinuclearity, These LMP1 expressing 293 giant cells showed strong expression of ICAM-1 (CD54), not detectable in the untransfected cells, In the LMP1-del transfectants giant cells with more than four nuclei were frequently observed, However, giant cells were much less frequent in 293 cells transfected with the amino terminal deletion variant of LMP1 or the lytic form of LMP1, known to induce low NF-kappa B activation compared to the LMP1 prototype, Therefore, LMP1 mediated NF-kappa B activation appears to be involved in polycaria formation, The strong association of LMP1 expression with multinuclearity in a genetically unstable condition - the L-428 and 293 cells show multiple chromosomal abnormalities - suggests that this oncoprotein including its naturally occurring carboxy terminal deletion variant promote the formation of multinuclear cells, in particular of RS cells in EBV-associated HD.	PURDUE UNIV,DEPT PHARMACOL,W LAFAYETTE,IN 47907; UNIV LAUSANNE,INST PHARMACOL,LAUSANNE,SWITZERLAND; GERMAN COLLECT MICROORGANISMS & CELL CULTURES,BRAUNSCHWEIG,GERMANY; INST PATHOL,LAB IMMUNOHISTOCHEM,ZURICH,SWITZERLAND	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Lausanne; Leibniz Institut fur Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ)	Knecht, H (corresponding author), UNIV MASSACHUSETTS,MED CTR,CTR CANC,LINK LABS,DIV HEMATOL ONCOL,55 LAKE AVE N,WORCESTER,MA 01655, USA.			Rothenberger, Sylvia/0000-0001-8633-2994	NATIONAL CANCER INSTITUTE [R29CA064610] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64610] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAICHWAL VR, 1987, J VIROL, V61, P866, DOI 10.1128/JVI.61.3.866-875.1987; Bankier A T, 1983, Mol Biol Med, V1, P425; BROUSSET P, 1992, LAB INVEST, V67, P457; CHEN ML, 1992, ONCOGENE, V7, P2131; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DIEHL V, 1995, NEW ENGL J MED, V332, P461, DOI 10.1056/NEJM199502163320709; DREXLER HG, 1994, LEUKEMIA LYMPHOMA, V3, P201; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HALUSKA FG, 1994, BLOOD, V84, P1005, DOI 10.1182/blood.V84.4.1005.bloodjournal8441005; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; HUEN DS, 1995, ONCOGENE, V10, P549; JOSKE D, 1993, BLOOD REV, V7, P215, DOI 10.1016/0268-960X(93)90008-R; KAMESAKI H, 1986, BLOOD, V68, P285; KAZAZI F, 1994, J GEN VIROL, V75, P2795, DOI 10.1099/0022-1317-75-10-2795; KNECHT H, 1995, ONCOGENE, V10, P523; KNECHT H, 1993, BLOOD, V82, P2937; KNECHT H, 1993, ACTA HAEMATOL-BASEL, V90, P167; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PENG M, 1992, ONCOGENE, V7, P1775; PENGPILON M, 1995, J GEN VIROL, V76, P767, DOI 10.1099/0022-1317-76-4-767; Rothenberger S., 1995, Blood, V86, p741A; SCHAADT M, 1979, BLUT, V38, P185, DOI 10.1007/BF01007965; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WEBERMATTHIESEN K, 1995, BLOOD, V86, P1464, DOI 10.1182/blood.V86.4.1464.bloodjournal8641464; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B	38	38	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					947	953						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806684				2022-12-17	WOS:A1996VG76600008
J	Rosenberger, SF; Bowden, GT				Rosenberger, SF; Bowden, GT			Okadaic acid stimulated TRE binding activity in a papilloma producing mouse keratinocyte cell line involves increased AP-1 expression	ONCOGENE			English	Article						okadaic acid; tumor promotion; AP-1; TRE binding; mouse keratinocytes	TUMOR PROMOTER; PROTEIN PHOSPHATASES; GENE-EXPRESSION; C-JUN; PHORBOL ESTERS; FOS; ACTIVATION; INDUCTION; ONCOGENE; PHOSPHORYLATION	The effects of the non-phorbol ester type tumor promoter okadaic acid, a serine-threonine phosphatase inhibitor, on activator protein 1 (AP-1) DNA binding activity were studied in papilloma producing 308 mouse keratinocytes. Okadaic acid increased AP-1 binding to a consensus TPA responsive element (TRE) within 2 h; maximum stimulation was observed at 6 h followed by a gradual decrease to basal levels within 24 h, Jun B, Jun D and Fos B proteins were identified as the major components of the AP-1 complex binding to the TRE element at 6 h, Inhibition of transcription with actinomycin D and inhibition of protein synthesis with cycloheximide abrogated the okadaic acid effect on AP-1 DNA binding, indicating that transcription and translation are required for okadaic acid increased TRE binding activity, Northern and Western blot analyses revealed a correlation between increased AP-1 binding activity and accumulation of jun B, jun D and fos B mRNAs and proteins, These data suggest increased AP-1 expression as principal mechanism of okadaic acid stimulated AP-1 activation in the mouse keratinocytes studied.			Rosenberger, SF (corresponding author), UNIV ARIZONA,HLTH SCI CTR,DEPT RADIAT ONCOL,1501 N CAMPBELL AVE,TUCSON,AZ 85724, USA.				NATIONAL CANCER INSTITUTE [R01CA040584] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40584] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BERNSTEIN LR, 1992, MOL CARCINOGEN, V6, P221, DOI 10.1002/mc.2940060308; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BROOKS JW, 1995, MOL IMMUNOL, V32, P779, DOI 10.1016/0161-5890(95)00055-J; CARTER R, 1994, ONCOGENE, V9, P2675; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COFFER P, 1994, ONCOGENE, V9, P911; COSENZA SC, 1994, J CELL BIOCHEM, V55, P503, DOI 10.1002/jcb.240550410; DATTA R, 1991, CELL GROWTH DIFFER, V2, P43; DICKINSON JA, 1995, CELL IMMUNOL, V165, P92, DOI 10.1006/cimm.1995.1191; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DOMANN FE, 1994, MOL CARCINOGEN, V9, P61, DOI 10.1002/mc.2940090202; DONG ZG, 1995, INT J ONCOL, V7, P359; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; GROVERBARDWICK A, 1994, CARCINOGENESIS, V15, P1667, DOI 10.1093/carcin/15.8.1667; GRUDA MC, 1994, ONCOGENE, V9, P2537; HABY C, 1994, BIOCHEM PHARMACOL, V48, P819, DOI 10.1016/0006-2952(94)90061-2; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HOLLADAY K, 1992, MOL CARCINOGEN, V5, P16, DOI 10.1002/mc.2940050106; HONKANEN RE, 1991, J BIOL CHEM, V266, P6614; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KIM SJ, 1990, CELL REGUL, V1, P269, DOI 10.1091/mbc.1.3.269; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEE JS, 1994, J BIOL CHEM, V269, P2887; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MONTECLARO FS, 1993, P NATL ACAD SCI USA, V90, P6726, DOI 10.1073/pnas.90.14.6726; MURATA M, 1982, B JPN SOC SCI FISH, V48, P549; NAKAMURA T, 1991, CELL GROWTH DIFFER, V2, P267; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PAI SR, 1994, ANTICANCER RES, V14, P985; REZZONICO R, 1995, ONCOGENE, V11, P1069; RIECKMANN P, 1992, BIOCHEM BIOPH RES CO, V187, P51, DOI 10.1016/S0006-291X(05)81457-3; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSA T, 1989, BIOCHEM BIOPH RES CO, V159, P939, DOI 10.1016/0006-291X(89)92199-2; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SMITH MJ, 1992, BLOOD, V79, P2107; STRICKLAND JE, 1988, CANCER RES, V48, P165; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; TANGUAY DA, 1994, CELL IMMUNOL, V158, P281, DOI 10.1006/cimm.1994.1276; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WESTERMARCK J, 1994, CELL GROWTH DIFFER, V5, P1205; WU WS, 1992, ONCOGENE, V7, P2287; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; YOZA BK, 1992, CELL GROWTH DIFFER, V3, P677	56	38	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2301	2308						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649769				2022-12-17	WOS:A1996UQ22000006
J	Pollock, RE; Lang, AQ; Luo, JX; ElNaggar, AK; Yu, DH				Pollock, RE; Lang, AQ; Luo, JX; ElNaggar, AK; Yu, DH			Soft tissue sarcoma metastasis from clonal expansion of p53 mutated tumor cells	ONCOGENE			English	Article						sarcoma; p53 suppressor gene; clonal heterogeneity; metastasis; loss of heterozygosity	MUTATIONS; GENE; BONE	Although soft tissue sarcoma has a high incidence of p53 mutations, it is not clear if such alterations facilitate tumor growth and metastasis. In this study, fresh autologous normal lymphocytes, normal muscle, primary and metastatic sarcoma tissues from a single synovial sarcoma patient were examined for p53-related alterations that potentially associated with sarcoma tumor development and metastasis. Normal tissues contain two wild-type p53 alleles. Primary sarcoma had one chromosome 17p p53 allelic deletion without apparent p53 mutation in the other allele. However, metastatic tumor had deletion of one p53 allele with an exon 5 codon 135 missense mutation in the other allele. This p53 gene point mutation in the metastasis was associated with the production of mutated p53 protein. A small clone of cells harboring the identical p53 gene point mutation was identified in the primary tumor using mutant allele specific PCR amplification, albeit at levels much less than in the metastatic sarcoma. This single patient example indicate that soft tissue sarcoma metastasis can develop from clonal expansion of primary tumor cells bearing p53 mutations.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Pollock, RE (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT SURG ONCOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.			Yu, Dihua/0000-0001-6231-9381	NATIONAL CANCER INSTITUTE [R29CA060488, R01CA060488, R01CA067802] Funding Source: NIH RePORTER; NCI NIH HHS [CA60488, CA67802] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVEGARD TA, 1989, J CLIN ONCOL, V7, P1845, DOI 10.1200/JCO.1989.7.12.1845; BEAHRS OH, 1992, MANUAL STAGING CANCE; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DROBNJAK M, 1994, J NATL CANCER I, V86, P549, DOI 10.1093/jnci/86.7.549; FELIX CA, 1992, CANCER RES, V52, P2243; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HU GY, 1992, BRIT J HAEMATOL, V81, P489, DOI 10.1111/j.1365-2141.1992.tb02979.x; KOMURO H, 1993, CANCER RES, V53, P5284; LATRES E, 1994, AM J PATHOL, V145, P345; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PINKEL D, 1986, COLD SPRING HARB SYM, V51, P151, DOI 10.1101/SQB.1986.051.01.018; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; TAKEDA S, 1993, HUM MUTAT, V2, P112, DOI 10.1002/humu.1380020209; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; WADAYAMA B, 1993, BRIT J CANCER, V68, P1134, DOI 10.1038/bjc.1993.493; YANG JC, 1993, CANC PRINCIPLES PRAC, P1436; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499	22	38	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					2035	2039						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649865				2022-12-17	WOS:A1996UK49800023
J	Rose, FV; Barnea, ER				Rose, FV; Barnea, ER			Response of human ovarian carcinoma cell lines to antiprogestin mifepristone	ONCOGENE			English	Article						ovarian cancer; antiprogestin; progesterone receptor; mifepristone; cell cycle	BREAST-CANCER; PROGESTERONE; ENDOMETRIAL; ESTROGEN; SURVIVAL; PHASE; PROLIFERATION; TAMOXIFEN; RECEPTORS; KINETICS	The effects of antiprogestin mifepristone (MF) on the growth, progesterone receptor expression and cell cycle kinetics of several human ovarian epithelial carcinoma (OEC) cell lines were evaluated. MF, a synthetic antiprogestin, has been shown to have some antiproliferative activity in breast tumors and in the endometrium, but its efficacy in ovarian carcinomas has not been explored previously. Continuous exposure of OEC cells to MF resulted in a dose- and time-dependent growth inhibition, as determined by MTT assay. Growth inhibition was apparent by day three following addition of MF to cultures in vitro. All cell lines used in this study expressed a progesterone receptor (PR). MF down regulated PR expression on these cells. Changes in the cell cycle kinetics of OEC cells exposed to MF correlated with the observed antiproliferative effects. MF blocked cells in a G(0)/G(1) phase of the cell cycle and thus reduced the number of cells in the S phase. The efficacy of MF was compared with that of taxol and tamoxifen in the same human OEC cell lines. Continuous exposure of OEC cells to tamoxifen resulted in a varied cytostatic response and a transient change in the cell cycle. Taxol inhibited growth of some but not all of the cell lines. These results indicate that PR-positive human OEC cells are sensitive to MF in vitro and that MF may be an active agent against ovarian epithelial tumors.			Rose, FV (corresponding author), UNIV MED & DENT NEW JERSEY,COOPER HOSP,ROBERT WOOD JOHNSON MED SCH,UNIV MED CTR,CAMDEN,NJ 08103, USA.		Barnea, Eytan/AAC-9910-2021; Barnea, Eytan/AAK-9467-2021	Barnea, Eytan/0000-0003-4677-4370				AHLGREN JD, 1993, J CLIN ONCOL, V11, P1957, DOI 10.1200/JCO.1993.11.10.1957; BAKKER GH, 1990, J STEROID BIOCHEM, V37, P789, DOI 10.1016/0960-0760(90)90421-G; BERTAGNA X, 1994, J CLIN ENDOCR METAB, V78, P375, DOI 10.1210/jc.78.2.375; BRENNER RM, 1994, HUM REPROD, V9, P82, DOI 10.1093/humrep/9.suppl_1.82; DREICER R, 1992, CANCER INVEST, V10, P27, DOI 10.3109/07357909209032786; GALTIERDEREURE F, 1992, J CLIN ENDOCR METAB, V75, P1497, DOI 10.1210/jc.75.6.1497; GEISINGER KR, 1990, CANCER, V65, P1055, DOI 10.1002/1097-0142(19900301)65:5<1055::AID-CNCR2820650502>3.0.CO;2-9; GHOSH D, 1992, HUM REPROD, V7, P1048, DOI 10.1093/oxfordjournals.humrep.a137792; GRAHAM ML, 1989, CANCER RES, V49, P3934; HORWITZ KB, 1992, ENDOCR REV, V13, P146, DOI 10.1210/er.13.2.146; KALLIONIEMI OP, 1988, CANCER, V61, P334, DOI 10.1002/1097-0142(19880115)61:2<334::AID-CNCR2820610224>3.0.CO;2-M; KAUPPILA A, 1984, ACTA OBSTET GYN SCAN, V63, P441, DOI 10.3109/00016348409156700; KLEMI PJ, 1989, OBSTET GYNECOL, V74, P200; KRIGMAN H, 1994, CLIN OBSTET GYNECOL, V37, P475, DOI 10.1097/00003081-199406000-00021; LEBEAU MC, 1994, HUM REPROD, V9, P437, DOI 10.1093/oxfordjournals.humrep.a138524; MAENTAUSTA O, 1993, J CLIN ENDOCR METAB, V77, P913, DOI 10.1210/jc.77.4.913; Milas Luka, 1994, In Vivo (Attiki), V8, P665; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NICOLETTI MI, 1993, ANN ONCOL, V4, P151, DOI 10.1093/oxfordjournals.annonc.a058419; NORDEEN SK, 1993, MOL ENDOCRINOL, V7, P731, DOI 10.1210/me.7.6.731; OZOLS RF, 1991, CANCER TREAT REV, V18, P77, DOI 10.1016/0305-7372(91)90027-W; RAO BR, 1991, ENDOCR REV, V12, P14, DOI 10.1210/edrv-12-1-14; REDDEL RR, 1987, CANCER RES, V47, P5323; ROTELLO RJ, 1992, AM J PATHOL, V140, P449; SATYASWAROOP P, 1992, PRINCIPLES PRACTICE, P151; SAUSVILLE E, 1992, PRINCIPLES PRACTICE, P47; SLOTMAN BJ, 1990, CANCER, V66, P740, DOI 10.1002/1097-0142(19900815)66:4<740::AID-CNCR2820660423>3.0.CO;2-H; THOMPSON MA, 1993, ADV EXP MED BIOL, V330, P155; WOODS LK, 1979, CANCER RES, V39, P4449	29	38	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					999	1003						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649817				2022-12-17	WOS:A1996UA88400007
J	Wyllie, FS; Haughton, MF; Bond, JA; Rowson, JM; Jones, CJ; WynfordThomas, D				Wyllie, FS; Haughton, MF; Bond, JA; Rowson, JM; Jones, CJ; WynfordThomas, D			S phase cell-cycle arrest following DNA damage is independent of the p53/p21(WAF1) signalling pathway	ONCOGENE			English	Article						p53; p21(WAF-1); SDI1; CIP1; S phase; checkpoint	ATAXIA-TELANGIECTASIA; P53; REPLICATION; PROTEIN; CHECKPOINT; BLEOMYCIN; KINASES; CANCER	It is now likely that the cyclin-kinase inhibitor, p21(WAF1/SDI1), is,key effector of p53-mediated cell-cycle arrest at the G(1)/S checkpoint following DNA damage. More recently, however, in vitro data has suggested that this pathway may also mediate the acute inhibition of DNA synthesis seen in cells already in S phase. Here we address this question in an intact cell system using normal human diploid fibroblasts in which p53 function is manipulated by expression mutant (ala(143)) introduced vector. Induction of DNA strand breaks in normal control fibroblasts by exposure to bleomycin led as expected to G(1)/S cell cycle arrest, induction of p21(WAF1) and a rapid reduction in the rate of DNA synthesis in cells already in S phase. Stable expression of mutant p53 abrogated the G(1)/S (but not the G(1)/M) cell cycle checkpoint and abolished the induction of p21(WAF1), but had no significant effect on the inhibition of DNA replication in S phase nuclei. We conclude that, despite the in vitro evidence for inhibitory activity on PCNA/polymerase delta, p21(WAF1) induction does not appear to be essential for the acute inhibition of DNA synthesis in the intact cell following strand-break damage in S phase.	UNIV WALES COLL MED,DEPT PATHOL,CRC THYROID TUMOUR BIOL GRP,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University				Jones, Christopher/0000-0002-5447-8187				BOND JA, 1994, ONCOGENE, V9, P1885; CANMAN CE, 1994, CANCER RES, V54, P5054; CLEAVER JE, 1992, RADIAT RES, V131, P338, DOI 10.2307/3578425; CRAMER P, 1981, NATURE, V291, P671, DOI 10.1038/291671a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAMB JR, 1989, INT J RADIAT BIOL, V56, P125, DOI 10.1080/09553008914551271; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI R, 1994, ONCOGENE, V9, P2261; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PINES J, 1994, NATURE, V369, P520, DOI 10.1038/369520a0; POVIRK LF, 1991, MUTAT RES, V257, P127, DOI 10.1016/0165-1110(91)90022-N; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WALTERS RA, 1975, BIOCHEM BIOPH RES CO, V65, P265, DOI 10.1016/S0006-291X(75)80088-X; WRIGHT PA, 1991, ONCOGENE, V6, P1693; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; WYLLIE FS, 1995, ONCOGENE, V10, P49; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	32	38	38	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1077	1082						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649799				2022-12-17	WOS:A1996UA88400016
J	Abe, S; Yagi, T; Ishiyama, S; Hiroe, M; Marumo, F; Ikawa, Y				Abe, S; Yagi, T; Ishiyama, S; Hiroe, M; Marumo, F; Ikawa, Y			Molecular cloning of a novel serine/threonine kinase, MRK, possibly involved in cardiac development	ONCOGENE			English	Article						serine/threonine protein kinase; cardiac development	FIBROBLAST GROWTH-FACTOR; POLYMERASE CHAIN-REACTION; PROTEIN-KINASE; PHOSPHORYLATION SITES; REGULATORY PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; ENDOTHELIAL-CELLS; PHORBOL ESTERS; P34CDC2 KINASE; MAP KINASE	We have isolated a novel member of putative serine/threonine kinase from a rat heart cDNA library using polymerase chain reaction methods, The novel kinase is transcribed as 2.6 kb mRNA encoding for a protein of 629 amino acids with the long C-terminal non-catalytic portion, Amino acids analysis revealed that the N-terminal catalytic domain is 87% identical to the male-germ cell associated kinase (MAK), a cdc2-related serine/threonine kinase found to promote meiosis during spermatogenesis, Therefore, we designated this novel kinase as the MAK-related kinase (MRK), MRK protein, with a molecular weight of 66 kD, was shown to phosphorylate itself and the exogenous substrates, histone H1 and myelin basic protein, In addition, phosphoamino acid analysis confirmed the serine/threonine-specific protein kinase activity of MRK, Although MRK was ubiquitous in adult rat tissues, the expression of MRK protein in embryos was restricted primarily to embryonic myocardium during early organogenesis, This finding suggests that MRK may be a participant in cardiac development.	RIKEN,INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN; TOKYO MED & DENT UNIV,SCH MED,DEPT INTERNAL MED 2,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,SCH MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN	RIKEN; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)								AKHURST RJ, 1990, DEVELOPMENT, V108, P645; BARNETT JV, 1994, DEV DYNAM, V199, P12, DOI 10.1002/aja.1001990103; BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V64, P573; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CONSIGLI SA, 1991, J CELL PHYSIOL, V146, P379, DOI 10.1002/jcp.1041460307; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEWEILENMANN CM, 1987, BASIC RES CARDIOL, V82, P507; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DUMONT DJ, 1992, ONCOGENE, V7, P1471; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ENGELMANN GL, 1994, CELL MOL BIOL RES, V40, P93; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8993; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; JIN Y, 1994, J MOL CELL CARDIOL, V26, P1449, DOI 10.1006/jmcc.1994.1164; JINNO A, 1993, MOL CELL BIOL, V13, P4146, DOI 10.1128/MCB.13.7.4146; JOUANNOT P, 1975, AM J PHYSIOL, V229, P355, DOI 10.1152/ajplegacy.1975.229.2.355; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KORHONEN J, 1994, ONCOGENE, V9, P395; KRANIAS EG, 1982, NATURE, V298, P182, DOI 10.1038/298182a0; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; Maniatis T, 1989, DECONTAMINATION DILU; MARCELLE C, 1992, ONCOGENE, V7, P2479; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; MUSLIN AJ, 1991, DEVELOPMENT, V112, P1095; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; OELRICHS RB, 1993, ONCOGENE, V8, P11; ORR UA, 1992, DEVELOPMENT, V115, P289; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RAZ V, 1991, ONCOGENE, V6, P753; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SHIGETA H, 1992, ENDOCR J, V40, P641; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; TORRES L, 1991, MOL MICROBIOL, V5, P2845, DOI 10.1111/j.1365-2958.1991.tb01993.x; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WU Y, 1994, EMBO J, V8, P147; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069; YOSHIDA A, 1992, FEBS LETT, V309, P343, DOI 10.1016/0014-5793(92)80804-P	52	38	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2187	2195						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570168				2022-12-17	WOS:A1995TK70200001
J	Koegl, M; Courtneidge, SA; SupertiFurga, G				Koegl, M; Courtneidge, SA; SupertiFurga, G			Structural requirements for the efficient regulation of the Src protein tyrosine kinase by Csk	ONCOGENE			English	Article						Src protein tyrosine kinase; Csk protein tyrosine kinase; SH2 domain; SH3 domain; autophosphorylation site; schizosaccharomyces pomte	C-SRC; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; AUTOPHOSPHORYLATION SITE; TRANSFORMING PROTEIN; CELL-TRANSFORMATION; FAMILY KINASES; SARCOMA-VIRUS; PP60C-SRC; PHOSPHORYLATION	Protein tyrosine kinases of the Src family are negatively regulated by phosphorylation in the C-terminal tail of the molecule, A different protein tyrosine kinase, Csk, is largely responsible for this regulation, The phosphorylated tail of c-Src engages with the SH2 domain in a conformation that is associated with low kinase activity and which involves stabilization by the SH3 domain, Inducible expression of c-Src in fission yeast is lethal unless Csk is coexpressed, Using this assay we present evidence that Src regulation by C-terminal phosphorylation does not require the myristylation signal or the unique domain at the N-terminus of the Src protein, Mutagenesis of the SH3 and SH2 domains of Csk show that neither are necessary in yeast or in vitro for efficient regulation of Src, Mutation of Tyr416 of Src, a site of autophosphorylation common to most protein tyrosine kinases, abolished the ability of Src to arrest growth of S. pombe and dramatically reduces the ability to phosphorylate endogenous proteins, Tyr416 had the same effect on a shorter form of Src consisting of the kinase domain only, indicating that the mutation affects a property intrinsic to the catalytic domain, The residual activity of full-length Src mutated at Tyr416 is efficiently repressed by Csk action, suggesting that regulation by C-terminal phosphorylation does not act by preventing phosphorylation at Tyr416.	EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAMME, D-69012 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)			Superti-Furga, Giulio/F-4755-2015; Superti-Furga, Giulio/AAE-5681-2019	Superti-Furga, Giulio/0000-0002-0570-1768; 				BAGRODIA S, 1993, MOL CELL BIOL, V13, P1464, DOI 10.1128/MCB.13.3.1464; BEACH D, 1985, CURR GENET, V10, P297, DOI 10.1007/BF00365626; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; BORCHERT TV, 1994, FEBS LETT, V341, P79, DOI 10.1016/0014-5793(94)80244-0; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; BRUGGE JS, 1987, MOL CELL BIOL, V7, P2180, DOI 10.1128/MCB.7.6.2180; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FLORIO M, 1994, MOL BIOL CELL, V5, P283, DOI 10.1091/mbc.5.3.283; HARVEY R, 1989, MOL CELL BIOL, V9, P3647, DOI 10.1128/MCB.9.9.3647; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KNIGHTON DR, 1993, P NATL ACAD SCI USA, V90, P5001, DOI 10.1073/pnas.90.11.5001; KOEGL M, 1994, BIOCHEM J, V302, P737, DOI 10.1042/bj3020737; KOEGL M, 1992, SEMIN VIROL, V2, P375; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIU XQ, 1993, ONCOGENE, V8, P1119; MARIN O, 1991, J BIOL CHEM, V266, P17798; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1988, J BIOCHEM-TOKYO, V104, P297, DOI 10.1093/oxfordjournals.jbchem.a122461; OKADA M, 1993, J BIOL CHEM, V268, P18070; OKADA M, 1988, BIOCHEM BIOPH RES CO, V154, P796, DOI 10.1016/0006-291X(88)90210-0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PARTANEN J, 1991, ONCOGENE, V6, P2013; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; RUDD CE, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239, DOI 10.1016/0304-419X(93)90007-Y; RUZZENE M, 1994, J BIOL CHEM, V269, P15885; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SNYDER MA, 1983, CELL, V32, P891, DOI 10.1016/0092-8674(83)90074-0; SNYDER MA, 1984, VIROLOGY, V136, P375, DOI 10.1016/0042-6822(84)90174-0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STOVER DR, 1994, J BIOL CHEM, V269, P26885; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	72	38	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2317	2329						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570183				2022-12-17	WOS:A1995TK70200016
J	SUEN, KL; BUSTELO, XR; BARBACID, M				SUEN, KL; BUSTELO, XR; BARBACID, M			LACK OF EVIDENCE FOR THE ACTIVATION OF THE RAS RAF MITOGENIC PATHWAY BY 14-3-3-PROTEINS IN MAMMALIAN-CELLS	ONCOGENE			English	Article						RAS PROTEINS; RAF KINASE; MEK; MAP KINASE; SIGNAL TRANSDUCTION	TYROSINE 3-MONOOXYGENASE; KINASE-C; TRANSFORMATION; IDENTIFICATION; FAMILY; DNA	We have isolated cDNA clones encoding the rodent 14-3-3 zeta and epsilon isoforms by screening bacteriophage expression libraries vith a probe derived from the carboxy-terminus of the Vav oncoprotein. These isoforms, however, did not recognize the full length Vav protein under physiological conditions. In agreement with previous studies (see D Morrison, Science 266, 56-57, 1994), these 14-3-3 proteins bound very efficiently to Raf. The interaction between 14-3-3 zeta and Raf involves the central region of 14-3-3 zeta which includes a motif related to annexins. 14-3-3 zeta binds to Raf independently of Ras and forms stable ternary complexes with these two molecules. In contrast to published reports, we have observed that the catalytic activity of Raf was not activated in Raf/14-3-3 zeta immunocomplexes. Likewise, purified preparations of 14-3-3 zeta had no effect on the kinase activity of Raf immunoprecipitates. In addition, Ras activated Raf regardless of whether it was bound or not to 14-3-3 zeta. Finally, overexpression of 14-3-3 zeta cDNA clones in NIH3T3 cells did not result in detectable morphologic transformation even when co-transfected with plasmids encoding Raf and/or Ras proteins. These observations argue against a critical regulatory role of the 14-3-3 proteins in the Raf mitogenic pathway.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC ONCOL,PRINCETON,NJ 08543	Bristol-Myers Squibb			Bustelo, Xose R./A-9526-2010	Bustelo, Xose R./0000-0001-9398-6072				AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHEN FS, 1994, FEBS LETT, V347, P128, DOI 10.1016/0014-5793(94)00520-6; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUADRADO A, 1993, ONCOGENE, V8, P2443; DU XP, 1994, J BIOL CHEM, V269, P18287; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; ICHIMURA T, 1987, FEBS LETT, V219, P79, DOI 10.1016/0014-5793(87)81194-8; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; KAPLAN DR, 1989, BIOCHIM BIOPHYS ACTA, V948, P345, DOI 10.1016/0304-419X(89)90006-1; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LOEB LA, 1986, J BIOL CHEM, V262, P10467; LU GH, 1992, P NATL ACAD SCI USA, V89, P11490, DOI 10.1073/pnas.89.23.11490; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; RAPP UR, 1991, ONCOGENE, V6, P495; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; ROBINSON K, 1994, BIOCHEM J, V239, P853; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAKAHASHI N, 1991, J MOL BIOL, V217, P125; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; YAMAUCHI T, 1981, BIOCHEM BIOPH RES CO, V100, P807, DOI 10.1016/S0006-291X(81)80246-X	39	38	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					825	831						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675443				2022-12-17	WOS:A1995RU79800002
J	FUJITA, M; SHIKU, H				FUJITA, M; SHIKU, H			DIFFERENCES IN SENSITIVITY TO INDUCTION OF APOPTOSIS AMONG RAT FIBROBLAST CELLS TRANSFORMED BY HTLV-I TAX GENE OR CELLULAR NUCLEAR ONCOGENES	ONCOGENE			English	Article						HTLV-I; TAX; C-MYC; C-FOS; APOPTOSIS; RAT-1	VIRUS TYPE-I; LONG TERMINAL REPEAT; NF-KAPPA-B; LEUKEMIA-VIRUS; C-FOS; TRANSCRIPTIONAL ACTIVATOR; NEOPLASTIC TRANSFORMATION; EXPRESSION; PROTEIN; MYC	The tax gene of human T lymphotropic virus type I has been implicated in the genesis of adult T cell leukemia (ATL), It has been reported that expression of tax induces neoplastic transformation in the rat fibroblast cell line Rat-1, and that co-expression with the ras gene can transform rat embryo fibroblasts. Possible activation of cellular oncogenes including c-myc and c-fos by tax has been implicated in these tax functions, In this study, comparative analysis of biological properties of tax and cellular nuclear oncogenes c-myc and c-fos was performed in Rat-1 cells, While all three oncogenes could transform Rat-1 cells, significant differences in the sensitivity to induction of apoptosis were observed between cells transformed with each oncogene, Induction of apoptosis by serum starvation was observed in tax-transfected Rat-1 cells but to a lesser extent than that in those transfected with c-myc or c-fos, In contrast, exposure to a DNA-damaging agent, etoposide, resulted in enhanced apoptotic death only in c-myc-transfected Rat-1 cells, Our findings indicate that the pathways for apoptosis induction may not be identical among these three oncogenes, and that the relatively low apoptosis-inducing activity and sufficient transforming capacity of tax might be associated with transformation of T cells and the low susceptibility of the transformed T cells (ATL cells) to chemotherapeutic agents.	NAGASAKI UNIV,SCH MED,DEPT ONCOL,NAGASAKI 852,JAPAN	Nagasaki University				Fujita, Masatoshi/0000-0001-6617-2452				BHALLA K, 1993, BLOOD, V82, P3133; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJITA M, 1994, BLOOD, V84, P2591, DOI 10.1182/blood.V84.8.2591.bloodjournal8482591; FUJITA M, 1993, FEBS LETT, V322, P15, DOI 10.1016/0014-5793(93)81101-5; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIRAI H, 1992, ONCOGENE, V7, P1737; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MILLER AD, 1984, CELL, V36, P51; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NAKAMURA M, 1989, J BIOL CHEM, V264, P20189; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; SAKURAI M, 1992, INT J CANCER, V52, P323, DOI 10.1002/ijc.2910520228; Sambrook J., 1989, MOL CLONING; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TSUDA H, 1993, JPN J CANCER RES, V84, P431, DOI 10.1111/j.1349-7006.1993.tb00154.x; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; 1991, LEUKEMIA RES, V15, P81	45	38	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					15	20						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624122				2022-12-17	WOS:A1995RJ29500003
J	SONOBE, MH; YOSHIDA, T; MURAKAMI, M; KAMEDA, T; IBA, H				SONOBE, MH; YOSHIDA, T; MURAKAMI, M; KAMEDA, T; IBA, H			FRA-2 PROMOTER CAN RESPOND TO SERUM-STIMULATION THROUGH AP-1 COMPLEXES	ONCOGENE			English	Article						TRANSCRIPTION; AUTOREGULATION; FRA-2; AP-1; SERUM-STIMULATION	C-FOS; ANTISENSE RNA; JUN PROTEINS; GENE FAMILY; CELLS; DNA; EXPRESSION; ONCOGENE; GROWTH; TRANSCRIPTION	fra-2 (fos-related antigen-2) expression is detected at a basal level even in growth-arrested chicken embryo fibroblasts (CEF), but upon serum-stimulation high levels of its transcripts are transiently observed. This induction is delayed and prolonged compared to that of c-fos. Transient expression experiments in CEF using a series of constructs of chicken fra-2 promoter region linked to the CAT reporter gene indicated previously that serum response element (SRE) is not required for full serum inducibility. In this report, we show that constructs in which the CRE-Like sequence and both AP-1 binding sites are disrupted lack serum inducibility, suggesting that either of these enhancers is important in serum induction of fra-2. In growth-arrested CEF, small amounts of Fra-2/c-Jun complex bind to the AP-1 consensus sequences in fra-2 promoter, while a significant part of the enhanced AP-1 binding activity after 60-120 min of serum stimulation is attributable to c-Fos/c-Jun heterodimer. At later times Fra-2/c-Jun again becomes the main complex. Transient expression assays in F9 cells indicated that c-Fos/c-Jun heterodimers have strong stimulatory effects on fra-2 promoter activity, while Fra-2/c-Jun complex has lower transcriptional activity than that of c-Jun homodimer. These results suggest that c-Fos (induced at earlier times) and c-Jun proteins are at least partly responsible for serum-induced expression of fra-2.	UNIV TOKYO,INST MED SCI,DEPT TUMOR VIRUS RES,MINATO KU,TOKYO 108,JAPAN	University of Tokyo			Sonobe, Martha/I-2877-2015					CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FOLETTA VC, 1994, ONCOGENE, V9, P3305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OKUNO H, 1993, ONCOGENE, V8, P695; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RUNKEL L, 1991, MOL CELL BIOL, V11, P1270, DOI 10.1128/MCB.11.3.1270; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; Treisman R, 1990, Semin Cancer Biol, V1, P47; VANBEVEREN C, 1983, CELL, V27, P1241; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; WEBSTER KA, 1990, MOL CELL BIOL, V10, P2402, DOI 10.1128/MCB.10.5.2402; YANISCHPERRON C, 1985, GENE, V4, P103; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	38	38	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					689	696						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862446				2022-12-17	WOS:A1995QH61200008
J	SOULIER, J; MADANI, A; CACHEUX, V; ROSENZWAJG, M; SIGAUX, F; STERN, MH				SOULIER, J; MADANI, A; CACHEUX, V; ROSENZWAJG, M; SIGAUX, F; STERN, MH			THE MTCP-1 C6.1B GENE ENCODES FOR A CYTOPLASMIC 8-KD PROTEIN OVEREXPRESSED IN T-CELL LEUKEMIA BEARING A T(X,14)-TRANSLOCATION	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; ATAXIA-TELANGIECTASIA; CHROMOSOME; ABNORMALITIES	The t(X;14)(q28;q11.2) translocation is associated with mature T-cell proliferations. Recently this translocation has been shown to implicate the MTCP-1/c6.1B gene on chromosome Xq28, leading to aberrant or overexpressed MTCP-1 transcripts. The potential coding role of this gene was made uncertain by the lack of a long open reading frame in its major transcripts. However, a short 204 bases open reading frame is potentially coding for a 68 amino-acid protein. Here, we show that this open reading frame sequence and the deduced product are well conserved in mouse. A 8 kD protein (p8), which corresponds to the predicted molecular weight was revealed in transient transfectants and in cell lines by Western blotting, using a rabbit antiserum. This product was absent in lymphoblastoid cell lines with deletions of the MTCP-1/c6.1B locus. A dramatic overexpression of p8 was found in leukemic cells from a patient with a t(X;14). This small protein was localized in the cytoplasm by immunofluorescence. In conclusion, MTCP-1 encodes for a cytoplasmic 8 kD product. Its potential role in leukemogenesis is supported by its overexpression in leukemia with t(X;14), but its function remains unknown.	HOP ST LOUIS,HEMATOL MOLEC LAB,F-75475 PARIS 10,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite			Stern, Marc-Henri/A-2728-2011; Rosenzwajg, Michelle/AAF-6276-2019	Stern, Marc-Henri/0000-0002-8100-2272; Rosenzwajg, Michelle/0000-0001-5312-6203				BEATTY DW, 1986, S AFR MED J, V69, P115; CANKI N, 1983, ZDRAV VESTN, V52, P567; DALLAPICCOLA B, 1984, INT J CANCER, V34, P171, DOI 10.1002/ijc.2910340206; FISCH P, 1993, ONCOGENE, V8, P3271; GOYNS MH, 1993, LEUKEMIA, V7, P848; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KENWRICK S, 1992, HUM MOL GENET, V1, P179, DOI 10.1093/hmg/1.3.179; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Sambrook J., 1989, MOL CLONING LAB MANU; SMITH DB, 1992, CURRENT PROTOCOLS MO; STERN MH, 1989, BLOOD, V73, P1285; STERN MH, 1993, ONCOGENE, V8, P2475; STERN MH, 1993, CAUSES CONSEQUENCES, P165; TAYLOR AMR, 1981, INT J CANCER, V27, P311, DOI 10.1002/ijc.2910270309; TAYLOR AMR, 1992, LEUKEMIA, V6, P961; THICK J, 1994, LEUKEMIA, V8, P564; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WITZIG TE, 1986, AM J HEMATOL, V21, P139, DOI 10.1002/ajh.2830210204	18	38	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3565	3570						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970717				2022-12-17	WOS:A1994PT39200019
J	KARAGIANNI, N; TSAWDAROGLOU, N				KARAGIANNI, N; TSAWDAROGLOU, N			THE C-FOS SERUM RESPONSE ELEMENT (SRE) CONFERS NEGATIVE RESPONSE TO GLUCOCORTICOIDS	ONCOGENE			English	Article							HORMONE REGULATORY ELEMENT; MAMMARY-TUMOR VIRUS; DNA-BINDING DOMAIN; NUCLEOSOME STRUCTURE; GENE-EXPRESSION; PROTEIN COMPLEX; TERNARY COMPLEX; PROLACTIN GENE; GROWTH-FACTOR; RECEPTOR	Ligand activated Glucocorticoid Receptor (GR), specifically inhibited the serum induced c-fos promoter activation in NIH3T3 fibroblasts. The negative control was mediated by the c-fos SRE and correlated with the relative abundance of active GR. Serum activated SRE was repressed 3-4-fold by glucocorticoids irrespective of the promoter context (heterologous or authentic). The suppressing ability of GR was absolutely dependent on its DNA binding domain (DBD), since deletion of this region left the serum induction unimpaired. The methylation interference pattern of GR revealed two distinct binding sites within the SRE and identified the GR contact bases, important also for binding and function of SRE targeted transcription factors, such as the Serum Response Factor (SRF) and the p62 Ternary Complex Factor (TCF). We conclude that GR binds to c-fos SRE and inhibits c-fos promoter activation by antagonizing the function of positive transcription factors targeting to overlapping or identical sites. Since the c-fos SRE is activated by multiple mitogenic signalling pathways, inactivation by GR could explain, at least in part, the growth inhibitory response of fibroblasts to glucocorticoid hormones.	NATL HELLEN RES FDN, INST BIOL RES & BIOTECHNOL, GR-11635 ATHENS, GREECE	National Hellenic Research Foundation								ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOULDEN A, 1990, VIROLOGY, V174, P204, DOI 10.1016/0042-6822(90)90069-4; CADEPOND F, 1992, EXP CELL RES, V201, P99, DOI 10.1016/0014-4827(92)90352-9; CAIRNS W, 1991, J BIOL CHEM, V266, P11221; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; CHEN TA, 1990, J MOL BIOL, V212, P481, DOI 10.1016/0022-2836(90)90327-I; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DROUIN J, 1989, MOL CELL BIOL, V9, P5305, DOI 10.1128/MCB.9.12.5305; DURANT S, 1986, ENDOCR REV, V7, P254, DOI 10.1210/edrv-7-3-254; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAGOT D, 1991, ENDOCRINOLOGY, V129, P1033, DOI 10.1210/endo-129-2-1033; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HOECK W, 1992, J STEROID BIOCHEM, V41, P283, DOI 10.1016/0960-0760(92)90353-K; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LEE H, 1991, FEBS LETT, V280, P134, DOI 10.1016/0014-5793(91)80221-N; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; METZ R, 1991, ONCOGENE, V6, P2165; MILLER AD, 1984, CELL, V36, P51; ORO AE, 1988, CELL, V55, P1109, DOI 10.1016/0092-8674(88)90255-3; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; TOURAY M, 1991, ONCOGENE, V6, P1227; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TRESIMAN R, 1990, CANCER BIOL, V1, P47; TRUSS M, 1991, MOL CELL BIOL, V11, P3247, DOI 10.1128/MCB.11.6.3247; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	53	38	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1994	9	8					2327	2334						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036015				2022-12-17	WOS:A1994NX62900026
J	DANIEL, J; BUSH, J; CARDELLI, J; SPIEGELMAN, GB; WEEKS, G				DANIEL, J; BUSH, J; CARDELLI, J; SPIEGELMAN, GB; WEEKS, G			ISOLATION OF 2 NOVEL RAS GENES IN DICTYOSTELIUM-DISCOIDEUM - EVIDENCE FOR A COMPLEX, DEVELOPMENTALLY-REGULATED RAS GENE SUBFAMILY	ONCOGENE			English	Article							GTP-BINDING PROTEIN; VULVAR INDUCTION; PLASMA-MEMBRANE; AMINO-ACIDS; CELL-LINE; P21 RAS; ONCOGENE; GAP; ACTIVATION; DOMAIN	In Dictyostelium discoideum, three ras genes (rasD, rasG and rasB) and one uas-related gene (rap1) have been previously isolated and characterized, and the deduced amino acid sequence of their predicted protein products share at least 50% sequence identity with the human H-Ras protein. We have now cloned and characterized two additional members of the ras gene subfamily in Dictyostelium, rasC and rasS. These genes are developmentally regulated and unlike the previously isolated Dictyostelium ras genes, maximum levels of their transcripts were detected during aggregation, suggesting that the encoded proteins have distinct functions during aggregation. The rasC cDNA encodes a 189 amino acid protein that is 65% identical to the Dictyostelium RasD and RasG proteins and 56% identical to the human H-Ras protein. The predicted 194 amino acid gene product encoded by rasS is 60% identical to the Dictyostelium RasD and RasG proteins and 54% identical to the human H-Ras protein. Whereas RasD, RasG, RasB and Rap1 are totally conserved in their putative effector domains relative to H-Ras, RasC and RasS have single amino acid substitutions in their effector domains, consistent with the idea that they have unique functions. In RasC, aspartic acid-38 has been replaced by asparagine (D38N), and in RasS, isoleucine-36 has been replaced by leucine (I36L). In addition, both proteins have several differences in the effector-proximal domain, a domain which is believed to play a role in Ras target activation. In RasC, there is a single conservative amino acid change in the canonical sequence of the binding site for the Ras-specific monoclonal antibody Y13-259, and consequently, RasC is less immunoreactive with the antibody than either of the Dictyostelium RasD or RasG proteins. In contrast, RasS, which has three substitutions in the Y13-259 binding site, does not react with the Y13-259 antibody.	UNIV BRITISH COLUMBIA,DEPT MICROBIOL,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER V6T 1Z3,BC,CANADA; LOUISIANA STATE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,SHREVEPORT,LA 71130	University of British Columbia; University of British Columbia; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOKOCH GM, 1993, BIOCHEM J, V289, P17, DOI 10.1042/bj2890017; BONNER JT, 1947, J EXP ZOOL, V106, P1, DOI 10.1002/jez.1401060102; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DANIEL J, 1993, ONCOGENE, V8, P1041; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; KRISTENSEN T, 1987, NUCLEIC ACIDS RES, V15, P5507, DOI 10.1093/nar/15.14.5507; LACAL JC, 1986, MOL CELL BIOL, V6, P1002, DOI 10.1128/MCB.6.4.1002; LOOMIS WF, 1982, DEV DICTYOSTELIUM DI; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; Maniatis T., 1982, MOL CLONING; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MOZER B, 1985, MOL CELL BIOL, V5, P885, DOI 10.1128/MCB.5.4.885; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OHMSTEDE CA, 1990, P NATL ACAD SCI USA, V87, P6527, DOI 10.1073/pnas.87.17.6527; PAWSON T, 1985, MOL CELL BIOL, V5, P33, DOI 10.1128/MCB.5.1.33; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; REYMOND CD, 1986, NATURE, V323, P340, DOI 10.1038/323340a0; REYMOND CD, 1984, CELL, V39, P141, DOI 10.1016/0092-8674(84)90199-5; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBBINS SM, 1990, NUCLEIC ACIDS RES, V18, P5265, DOI 10.1093/nar/18.17.5265; ROBBINS SM, 1989, P NATL ACAD SCI USA, V86, P938, DOI 10.1073/pnas.86.3.938; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHEJTER ED, 1985, EMBO J, V4, P407, DOI 10.1002/j.1460-2075.1985.tb03643.x; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4724; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SRIVASTAVA SK, 1989, MOL CELL BIOL, V9, P1779, DOI 10.1128/MCB.9.4.1779; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; THIERY R, 1992, BIOCHEM CELL BIOL, V70, P1193, DOI 10.1139/o92-165; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	54	38	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					501	508						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290260				2022-12-17	WOS:A1994MW24800017
J	FELIX, CA; BROWN, DL; MITSUDOMI, T; IKAGAKI, N; WONG, A; WASSERMAN, R; WOMER, RB; BIEGEL, JA				FELIX, CA; BROWN, DL; MITSUDOMI, T; IKAGAKI, N; WONG, A; WASSERMAN, R; WOMER, RB; BIEGEL, JA			POLYMORPHISM AT CODON-36 OF THE P53 GENE	ONCOGENE			English	Note							CELL LUNG-CANCER; TP53; MUTATIONS; P53-GENE; REGION	A polymorphism at codon 36 in exon 4 of the p53 gene was identified by single strand conformation polymorphism (SSCP) analysis and direct sequencing of genomic DNA PCR products. The polymorphic allele, present in the heterozygous state in genomic DNAs of four of 100 individuals (4%), changes the codon 36 CCG to CCA, eliminates a FinI restriction site and creates a BccI site. Including this polymorphism there are four known polymorphisms in the p53 coding sequence.	CHILDRENS HOSP PHILADELPHIA,DEPT PEDIAT,DIV GENET,PHILADELPHIA,PA 19104; UNIV OCCUPAT & ENVIRONM HLTH,SCH MED,DEPT SURG 2,KITAKYUSHU,FUKUOKA 807,JAPAN; THOMAS JEFFERSON UNIV,CANC RES CTR,PHILADELPHIA,PA 19107	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Occupational & Environmental Health - Japan; Jefferson University	FELIX, CA (corresponding author), CHILDRENS HOSP PHILADELPHIA,DEPT PEDIAT,DIV ONCOL,PHILADELPHIA,PA 19104, USA.			Mitsudomi, Tetsuya/0000-0001-9860-8505	NATIONAL CANCER INSTITUTE [R01CA046274, P01CA047983] Funding Source: NIH RePORTER; NCI NIH HHS [P0-1 CA 47983, CA 46274] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHUJA HG, 1990, ONCOGENE, V5, P1409; ARA S, 1990, NUCLEIC ACIDS RES, V18, P4961, DOI 10.1093/nar/18.16.4961; CARBONE D, 1991, ONCOGENE, V6, P1691; CHIBA I, 1990, ONCOGENE, V5, P1603; CHUMAKOV PM, 1991, NUCLEIC ACIDS RES, V19, P6969, DOI 10.1093/nar/19.24.6969-a; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DELACALLE O, 1990, NUCLEIC ACIDS RES, V18, P206, DOI 10.1093/nar/18.1.206-a; DELACALLEMARTIN O, 1990, NUCLEIC ACIDS RES, V18, P4963, DOI 10.1093/nar/18.16.4963; FELIX CA, 1993, ONCOGENE, V8, P1203; FELIX CA, 1992, J CLIN INVEST, V90, P653, DOI 10.1172/JCI115907; FELIX CA, 1992, CANCER RES, V52, P2243; FELIX CA, 1992, J CLIN INVEST, V89, P649; MAZARS GR, 1992, ONCOGENE, V7, P781; MITSUDOMI T, 1992, ONCOGENE, V7, P171; PERILONGO G, 1993, LEUKEMIA, V7, P912; PROSSER J, 1991, NUCLEIC ACIDS RES, V19, P4799, DOI 10.1093/nar/19.17.4799-a; WILLEMS PMW, 1992, NUCLEIC ACIDS RES, V20, P1172, DOI 10.1093/nar/20.5.1172-a	17	38	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					327	328						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302598				2022-12-17	WOS:A1994MW24700041
J	AZIZ, N; WU, J; DUBENDORFF, JW; LIPSICK, JS; STURGILL, TW; BENDER, TP				AZIZ, N; WU, J; DUBENDORFF, JW; LIPSICK, JS; STURGILL, TW; BENDER, TP			C-MYB AND V-MYB ARE DIFFERENTIALLY PHOSPHORYLATED BY P42MAPK IN-VITRO	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; NERVE GROWTH-FACTOR; MICROTUBULE-ASSOCIATED PROTEIN-2; AVIAN-MYELOBLASTOSIS VIRUS; COLONY-STIMULATING FACTOR; SERINE-THREONINE KINASE; LONG TERMINAL REPEAT; MYELIN BASIC-PROTEIN; DNA-BINDING ACTIVITY; MAP KINASE	The product of the c-myb proto-oncogene is a highly conserved transcription factor that has been shown to function as both a transactivator and repressor. The v-myb oncogenes of E26 leukemia virus and avian myeloblastosis virus (AMV) encode proteins truncated at both the amino and carboxy termini, deleting portions of the DNA-binding and negative regulatory domains present in c-Myb. Similar truncations of c-Myb alter its function, suggesting that the viral proteins lack important regulatory sequences. Interestingly, eight potential sites of phosphorylation by proline-directed protein kinases conserved between the avian, murine and human Myb proteins are clustered in or near the negative regulatory domain of c-Myb. The majority of these sites are deleted in both the E26 and AMV viral proteins. In this paper we show that one proline-directed protein kinase, p42mapk, phosphorylates bacterially synthesized avian and murine c-Myb but not AMV v-Myb in vitro. We find that p42mapk phosphorylates c-Myb on serine and threonine, but not on tyrosine. Furthermore, deletion analysis indicates that the sites of phosphorylation map to the C-terminal negative regulatory domain. We speculate that the inability of v-Myb to be phosphorylated by p42mapk may contribute to its oncogenic properties.	SUNY, DEPT MICROBIOL, STONY BROOK, NY 11794 USA; UNIV VIRGINIA, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, DEPT INTERNAL MED, CHARLOTTESVILLE, VA 22908 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College; University of Virginia; University of Virginia			Wu, Jie/R-2404-2019	Wu, Jie/0000-0002-2864-1606; Aziz, Natasha/0000-0001-8195-1446	NCI NIH HHS [CA 40042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; ADDISON C, 1990, ONCOGENE, V5, P423; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BADING H, 1989, ONCOGENE, V4, P33; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOSSELUT R, 1992, VIROLOGY, V186, P764, DOI 10.1016/0042-6822(92)90044-P; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DASGUPTA P, 1992, J VIROL, V66, P270, DOI 10.1128/JVI.66.1.270-276.1992; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; Johnson R A, 1979, Adv Cyclic Nucleotide Res, V10, P135; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KENNEY SC, 1992, MOL CELL BIOL, V12, P136, DOI 10.1128/MCB.12.1.136; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LALLEMAIN G, 1991, CELL REGUL, V2, P675, DOI 10.1091/mbc.2.8.675; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NEL AE, 1990, J IMMUNOL, V144, P2683; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OKUDA K, 1992, BLOOD, V79, P2880; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PETER M, 1992, EUR J BIOCHEM, V205, P287, DOI 10.1111/j.1432-1033.1992.tb16779.x; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAMSAY RG, 1991, ONCOGENE, V6, P1875; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; RUSHLOW KE, 1982, SCIENCE, V216, P1421, DOI 10.1126/science.6283631; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SETH A, 1991, J BIOL CHEM, V266, P23521; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOBERGRASSER U, 1992, ONCOGENE, V7, P589; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TSAO H, 1990, J BIOL CHEM, V265, P15471; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3; ZOBEL A, 1992, BIOCHEM BIOPH RES CO, V186, P715, DOI 10.1016/0006-291X(92)90805-U	84	38	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2259	2265						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336948				2022-12-17	WOS:A1993LP17100028
J	VOUSDEN, KH; VOJTESEK, B; FISHER, C; LANE, D				VOUSDEN, KH; VOJTESEK, B; FISHER, C; LANE, D			HPV-16 E7 OR ADENOVIRUS E1A CAN OVERCOME THE GROWTH ARREST OF CELLS IMMORTALIZED WITH A TEMPERATURE-SENSITIVE P53	ONCOGENE			English	Note							HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; WILD-TYPE P53; SV40 LARGE T; CERVICAL-CARCINOMA; MUTANT P53; MUTATIONAL ANALYSIS; CYCLE REGULATION; SIMIAN VIRUS-40; PROTEIN-KINASE	Rat embryo fibroblasts immortalized with a temperature-sensitive p53 mutant and ras rapidly stop proliferating at 33-degrees-C. Expression of the viral oncoproteins human papillomavirus type 16 (HPV-16) E7 or adenovirus E1A efficiently overcame this growth arrest, although cells rescued by E7 or EIA displayed no detectable changes in p53 expression. Co-transfection of HPV-16 E6, which binds and directs the degradation of human p53, affected neither growth of the cells at 33-degrees-C nor the amount or conformation of the p53 protein, possibly reflecting an inability of E6 to interact with mouse p53 in rodent cells. Our results suggest either that the temperature-sensitive p53 failed to regain full wild-type suppressor activity at 33-degrees-C or that E7 and E1A can modulate wild-type p53 growth-suppressor activity without altering the conformation or stability of the protein.	UNIV DUNDEE,DEPT BIOCHEM,CANC RES CAMPAIGN LABS,CELL TRANSFORMAT RES GRP,DUNDEE DD1 4HN,SCOTLAND	University of Dundee	VOUSDEN, KH (corresponding author), ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,NORFOLK PL,LONDON W2 1PG,ENGLAND.		Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BARTEK J, 1990, ONCOGENE, V5, P893; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN TM, 1992, ONCOGENE, V7, P1541; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1991, ONCOGENE, V6, P873; CROOK T, 1991, ONCOGENE, V6, P1251; DAVIES R, 1993, IN PRESS J VIROL; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; INOUE H, 1992, VIROLOGY, V187, P343, DOI 10.1016/0042-6822(92)90325-J; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KLEINBERGER T, 1991, P NATL ACAD SCI USA, V88, P11143, DOI 10.1073/pnas.88.24.11143; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHAELMICHALOVITZ D, 1991, J VIROL, V65, P4160, DOI 10.1128/JVI.65.8.4160-4168.1991; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; MORRIS JDH, 1993, ONCOGENE, V8, P893; MUNGER K, 1989, J VIROL, V63, P4417; PAGANO M, 1992, ONCOGENE, V7, P1681; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SANTHANAM J, 1992, P NATL ACAD SCI USA, V88, P7605; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHEFFNER M, 1990, CELL, V63, P1129; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TOMMASINO M, 1993, ONCOGENE, V8, P195; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOUSDEN KH, 1989, ONCOGENE, V4, P153; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	89	38	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1697	1702						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389035				2022-12-17	WOS:A1993LE06400036
J	PUISIEUX, A; PONCHEL, F; OZTURK, M				PUISIEUX, A; PONCHEL, F; OZTURK, M			P53 AS A GROWTH SUPPRESSOR GENE IN HBV-RELATED HEPATOCELLULAR-CARCINOMA CELLS	ONCOGENE			English	Note							ANTIGEN; MUTATION; PROTEIN; ALLELES; LIVER	Mutations of the p53 detected in human hepatocellular carcinomas suggest that its inactivation is a critical step in hepatocellular carcinogenesis. In order to test whether the expression of p53 is compatible with the transformed phenotype of hepatoma cells, we transfected Hep 3B cell line with p53 expression vectors. This cell line, which contains integrated hepatitis B virus sequences, is a good model to study whether the wild-type p53 can function as a tumour suppressor gene in virus-related hepatocellular carcinoma. Wild-type and mutant p53 (Ala143)-expression vectors containing a neo(R) gene were used. The number of antibiotic-resistant colonies was six times lower after transfection with wild-type p53 vector as compared to the mutant vector. As measured by a specific radioimmunoassay, six of eight (75%) colonies randomly selected after mutant p53 transfections expressed the transfected mutant p53 protein. In contrast, out of eight colonies from wild-type p53-transfections, none expressed detectable p53 protein. The absence of p53 protein was due to the selective deletion of transfected wild-type p53 cDNA sequences. These studies demonstrate that the growth of hepatocellular carcinoma cells is not compatible with the expression of wild-type p53. Therefore, p53 should be considered as a tumour suppressor gene in hepatocytes.	CTR LEON BERARD,ONCOL MOLEC LAB,F-69373 LYON,FRANCE; MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA	UNICANCER; Centre Leon Berard; Harvard University; Massachusetts General Hospital			OZTURK, MEHMET/AAS-7241-2021; ozturk, mehmet/G-3330-2014	OZTURK, MEHMET/0000-0002-6092-9706; PUISIEUX, Alain/0000-0002-9938-3798	NATIONAL CANCER INSTITUTE [R01CA054567, R29CA049832] Funding Source: NIH RePORTER; NCI NIH HHS [CA-49832, CA-54567] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ASUBEL FM, 1991, CURRENT PROTOCOLS MO; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CASEY G, 1991, ONCOGENE, V6, P1791; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HOSONO S, 1991, ONCOGENE, V6, P237; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; ISAACS WB, 1991, CANCER RES, V51, P4716; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MORGAN RA, 1990, HUM GENE THER, V1, P135, DOI 10.1089/hum.1990.1.2-135; MURAKAMI Y, 1991, CANCER RES, V51, P5520; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; PUISIEUX A, 1991, CANCER RES, V51, P6185; ROBINSON WS, 1990, J MED VIROL, V31, P18, DOI 10.1002/jmv.1890310106; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	21	38	38	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					487	490						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381223				2022-12-17	WOS:A1993KN00600028
J	EYCHENE, A; BARNIER, JV; APIOU, F; DUTRILLAUX, B; CALOTHY, G				EYCHENE, A; BARNIER, JV; APIOU, F; DUTRILLAUX, B; CALOTHY, G			CHROMOSOMAL ASSIGNMENT OF 2 HUMAN B-RAF(RMIL) PROTOONCOGENE LOCI - B-RAF-1 ENCODING THE P94(BRAF RMIL) AND B-RAF-2, A PROCESSED PSEUDOGENE	ONCOGENE			English	Note							RAF FAMILY; C-MIL; B-RAF; KINASE; TRANSDUCTION; EXPRESSION; RETROVIRUS; SEQUENCE; GENES; VIRUS	The B-raf gene is the human homolog of the avian c-Rmil proto-oncogene encoding a 94-kDa serine/threonine kinase detected in avian cells. We have previously shown that this protein contains amino-terminal sequences not found in other proteins of the mil/raf gene family. These sequences are encoded by three exons in the avian genome. We report that these three exons are conserved in the human B-raf gene and that they encode an amino acid sequence similar to that of the avian c-Rmil gene, indicating that in both avian and mammalian species the product of the B-raf/c-Rmil gene is a 94-kDa protein. We also identified two human B-raf loci: B-raf-1, located on chromosome 7q34, which encodes the functional B-raf/Rmil gene product, and B-raf-2, an inactive processed pseudogene located on chromosome Xq13.	CTR UNIV ORSAY,INST CURIE,CNRS,URA 1443,F-91405 ORSAY,FRANCE; INST CURIE,CNRS,URA 620,F-75231 PARIS 05,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Eychene, Alain/M-8838-2017	EYCHENE, Alain/0000-0002-6818-7225				BONNER T, 1984, SCIENCE, V223, P71, DOI 10.1126/science.6691137; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; EYCHENE A, 1989, NUCLEIC ACIDS RES, V17, P1250, DOI 10.1093/nar/17.3.1250; EYCHENE A, 1992, IN PRESS ONCOGENE; FELDER MP, 1991, J VIROL, V65, P3633, DOI 10.1128/JVI.65.7.3633-3640.1991; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; LEMIEUX N, 1992, IN PRESS CYTOGENET C; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; Maniatis T, 1989, DECONTAMINATION DILU; MARX M, 1988, EMBO J, V7, P3369, DOI 10.1002/j.1460-2075.1988.tb03209.x; RAPP UR, 1991, ONCOGENE, V6, P495; REEVES BR, 1989, ONCOGENE, V4, P373; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; STORM SM, 1990, ONCOGENE, V5, P345; VANIN EF, 1984, BIOCHIM BIOPHYS ACTA, V782, P231, DOI 10.1016/0167-4781(84)90057-5; VIEGASPEQUIGNOT E, 1978, ANN GENET-PARIS, V21, P122	19	38	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1657	1660						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630826				2022-12-17	WOS:A1992JE81300025
J	BURKE, LC; BYBEE, A; THOMAS, NSB				BURKE, LC; BYBEE, A; THOMAS, NSB			THE RETINOBLASTOMA PROTEIN IS PARTIALLY PHOSPHORYLATED DURING EARLY G1 IN CYCLING CELLS BUT NOT IN G1 CELLS ARRESTED WITH ALPHA-INTERFERON	ONCOGENE			English	Note							SUSCEPTIBILITY GENE-PRODUCT; EXPRESSION; MITOSIS; KINASE; RB	The retinoblastoma protein (pRB) is thought to act as a tumour suppressor which is inactivated by phosphorylation. In quiescent (G0) cells pRB exists in a hypophosphorylated form (pRB110), but proliferating cells in G1 contain a significant proportion of phosphorylated pRB (pRB112-114). Studies of synchronized or elutriated cells have suggested that the phosphorylated forms of pRB disappear as cells pass from G2/M to G0/G1 and that pRB is phosphorylated again to pRB114 at the G1/S border. In this study we used two-parameter flow cytometry and cell sorting to isolate cycling cells in early and late G1 (G1A and G1B), and we show that partially phosphorylated pRB is present in cycling human lymphoid cells even in G1A. These G1A cells contain intermediate forms of pRB which become further phosphorylated to pRB112-114 as cells pass into G1B. Therefore pRB is at least partially phosphorylated from early G1 onwards. Cell cycle arrest by alpha-interferon (alpha-IFN) results in an accumulation of cells in both G1A and G1B, and these cells contain mainly pRB110. Since pRB110 is thought to prevent cell proliferation, the cytostatic effect of alpha-IFN may therefore occur by preventing the initial phosphorylation of pRB during or prior to G1A.	UNIV COLL & MIDDLESEX SCH MED,DEPT HAEMATOL,MOLEC BIOL LAB,98 CHENIES MEWS,LONDON WC1E 6HX,ENGLAND	University of London; University College London								BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DARZYNKIEWICZ Z, 1982, J CELL PHYSIOL, V113, P465, DOI 10.1002/jcp.1041130316; DARZYNKIEWICZ Z, 1980, CYTOMETRY, V1, P98, DOI 10.1002/cyto.990010203; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V64, P521; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; PARDEE AB, 1987, CANCER RES, V47, P1488; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SILVERMAN RH, 1982, EUR J BIOCHEM, V126, P333; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; THOMAS NSB, 1991, ONCOGENE, V6, P317; THOMAS NSB, 1989, J BIOL CHEM, V264, P13697; XU HJ, 1989, ONCOGENE, V4, P807; Zetterberg A, 1990, CURR OPIN CELL BIOL, V2, P296, DOI 10.1016/0955-0674(90)90022-7	30	38	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					783	788						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565475				2022-12-17	WOS:A1992HQ68200024
J	SITHANANDAM, G; DRUCK, T; CANNIZZARO, LA; LEUZZI, G; HUEBNER, K; RAPP, UR				SITHANANDAM, G; DRUCK, T; CANNIZZARO, LA; LEUZZI, G; HUEBNER, K; RAPP, UR			B-RAF AND A B-RAF PSEUDOGENE ARE LOCATED ON 7Q IN MAN	ONCOGENE			English	Note							COMPLETE CODING SEQUENCE; GAUCHER DISEASE; HUMAN HOMOLOGS; X-CHROMOSOME; MIL ONCOGENE; A-RAF; C-RAF; V-RAF; GENE; FAMILY	The B-raf gene was lozalized to human chromosome region 7p11-7qter by Southern blot analysis of its segregation in a panel of rodent-human hybrids, using a B-raf cDNA clone. Chromosomal in situ hybridization refined the localization to 7q33-36. Analysis of genomic B-raf clones identified a B-raf pseudogene in addition to the active gene. Based on the chromosomal mapping data we conclude that the pseudogene is located near the active gene.	NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; PRI DYNCORP,FREDERICK CANC RES & DEV CTR,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702; TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NCI NIH HHS [N01-CO-74102] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUER SR, 1988, IMMUNOGENETICS, V28, P328, DOI 10.1007/BF00364231; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BLEEKERWAGEMAKERS LM, 1985, HUM GENET, V71, P211, DOI 10.1007/BF00284575; BONNER T, 1984, SCIENCE, V223, P71, DOI 10.1126/science.6691137; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CANNIZZARO LA, 1990, GENOMICS, V6, P197, DOI 10.1016/0888-7543(90)90557-B; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; GINNS EI, 1985, P NATL ACAD SCI USA, V82, P7101, DOI 10.1073/pnas.82.20.7101; GRECO A, 1989, GENOMICS, V4, P240, DOI 10.1016/0888-7543(89)90326-1; GUSELLA JF, 1986, COLD SPRING HARB SYM, V51, P359, DOI 10.1101/SQB.1986.051.01.043; HUEBNER K, 1988, ONCOGENE, V3, P449; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; KIECHLESCHWARZ M, 1991, CANCER GENET CYTOGEN, V53, P125, DOI 10.1016/0165-4608(91)90124-D; KNOWLES BB, 1977, J EXP MED, V145, P314, DOI 10.1084/jem.145.2.314; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KWAN S-P, 1988, Genomics, V3, P39, DOI 10.1016/0888-7543(88)90156-5; MAHER ER, 1991, GENOMICS, V10, P957, DOI 10.1016/0888-7543(91)90185-H; MARI O, 1991, J BIOL CHEM, V266, P23753; MARK GE, 1984, SCIENCE, V224, P285, DOI 10.1126/science.6324342; MIHALY A, 1990, NEUROSCI LETT, V116, P45, DOI 10.1016/0304-3940(90)90384-L; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MOLDERS H, 1985, EMBO J, V4, P693, DOI 10.1002/j.1460-2075.1985.tb03685.x; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORRISON DK, 1989, CELL, V58, P648; RAPP UR, 1985, RECENT RES CANCER, V99, P221; RAPP UR, 1991, ONCOGENE, V6, P495; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SHAFITZAGARDO B, 1981, AM J HUM GENET, V33, P564; SHULTZ AM, 1988, ONCOGENE, V2, P187; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; STORM SM, 1990, ONCOGENE, V5, P345; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; ZIMRAN A, 1990, J CLIN INVEST, V85, P219, DOI 10.1172/JCI114415	39	38	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					795	799						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565476				2022-12-17	WOS:A1992HQ68200026
J	WADA, RK; SEEGER, RC; REYNOLDS, CP; ALLOGGIAMENTO, T; YAMASHIRO, JM; RULAND, C; BLACK, AC; ROSENBLATT, JD				WADA, RK; SEEGER, RC; REYNOLDS, CP; ALLOGGIAMENTO, T; YAMASHIRO, JM; RULAND, C; BLACK, AC; ROSENBLATT, JD			CELL TYPE-SPECIFIC EXPRESSION AND NEGATIVE REGULATION BY RETINOIC ACID OF THE HUMAN N-MYC PROMOTER IN NEUROBLASTOMA-CELLS	ONCOGENE			English	Article							HUMAN NEURO-BLASTOMA; DIHYDROFOLATE-REDUCTASE PROMOTER; SV40 EARLY PROMOTER; C-MYC; NUCLEOTIDE-SEQUENCE; PROTO-ONCOGENE; GENE; TRANSCRIPTION; UPSTREAM; ELEMENTS	Expression of the N-myc oncogene is an important determinant of tumor behavior in human neuroblastoma. To study the regulation of N-myc, we have subcloned fragments of the 5' flanking region of the human N-myc gene upstream of the chloramphenicol acetyl transferase (CAT) reporter gene, and assayed for promoter activity in transient transfections into neuroblastoma and other cell lines. Upstream sequences were found to possess promoter activity to within 121 bp of the major cap site (-121). Negative regulatory elements were identified in regions approximately 2 kb and 500 bp upstream from the major cap site, as well as 150-1000 bp downstream. promoter constructs containing downstream elements from bp +150 to +1000 were active in N-myc-expressing neuroblastoma cell lines, but not in non-expressing Epstein-Barr virus (EBV)-transformed 729-6 B-cell or HeLa cell lines, while those lacking this element were active in all cell types tested. All tested constructs retaining promoter activity showed decreased activity in parallel with the down-regulation of endogenous N-myc in response to treatment of transfected cells with retinoic acid. These studies suggest that N-myc regulation may be controlled at different levels, and provide a basis for further characterization of N-myc regulation in neuroblastoma.	UNIV CALIF LOS ANGELES,SCH MED,GWYNNE HAZEN CHERRY MEM LAB,LOS ANGELES,CA 90024; UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,SCH MED,DEPT PEDIAT,DIV HEMATOL ONCOL,LOS ANGELES,CA 90027; UNIV CALIF LOS ANGELES,SCH MED,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Children's Hospital Los Angeles; University of Southern California; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	WADA, RK (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,DIV HEMATOL ONCOL,10833 LE CONTE AVE,LOS ANGELES,CA 90024, USA.			Reynolds, C. Patrick/0000-0002-2827-8536	NATIONAL CANCER INSTITUTE [R55CA044904, R01CA044904, R01CA022794] Funding Source: NIH RePORTER; NCI NIH HHS [CA 22794, CA44904] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABISS LE, 1990, MOL CELL BIOL, V10, P6700, DOI 10.1128/MCB.10.12.6700; BATY D, 1984, NUCLEIC ACIDS RES, V12, P915, DOI 10.1093/nar/12.2.915; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; COHN SL, 1990, ONCOGENE, V5, P1821; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; EVERETT RD, 1983, NUCLEIC ACIDS RES, V11, P2447, DOI 10.1093/nar/11.8.2447; EVERSON TC, 1964, ANN NY ACAD SCI, V114, P721; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; GHOSH PK, 1981, J VIROL, V40, P224, DOI 10.1128/JVI.40.1.224-240.1981; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRADY EF, 1987, CANCER RES, V47, P2931; HILLER S, 1991, ONCOGENE, V6, P969; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MCWILLIAMS NB, 1986, MED PEDIATR ONCOL, V14, P41, DOI 10.1002/mpo.2950140110; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MITCHELL PJ, 1986, MOL CELL BIOL, V6, P425, DOI 10.1128/MCB.6.2.425; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; NISEN PD, 1988, J NATL CANCER I, V80, P1633, DOI 10.1093/jnci/80.20.1633; ROSEN N, 1986, CANCER RES, V46, P4139; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Seeger R C, 1988, Prog Clin Biol Res, V271, P41; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIDELL N, 1984, EXP CELL RES, V155, P305, DOI 10.1016/0014-4827(84)90795-X; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPINELLI W, 1982, CANCER RES, V42, P5067; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; THIELE CJ, 1988, ONCOGENE, V3, P281; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THIELE CJ, 1988, EXP CELL BIOL, V56, P321; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VIGNERON M, 1984, EMBO J, V3, P2373, DOI 10.1002/j.1460-2075.1984.tb02142.x; Wada R K, 1988, Prog Clin Biol Res, V271, P57; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WHARIN L, 1991, INT J CANCER, V48, P136; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x; ZIMMERMAN K, 1990, MOL CELL BIOL, V10, P2096, DOI 10.1128/MCB.10.5.2096; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	47	38	38	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					711	717						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565467				2022-12-17	WOS:A1992HQ68200013
J	MCDONNELL, PC; KUMAR, S; RABSON, AB; GELINAS, C				MCDONNELL, PC; KUMAR, S; RABSON, AB; GELINAS, C			TRANSCRIPTIONAL ACTIVITY OF REL FAMILY PROTEINS	ONCOGENE			English	Article							NF-KAPPA-B; LONG TERMINAL REPEAT; AVIAN RETICULOENDOTHELIOSIS VIRUS; TRANSFORMED LYMPHOID-CELLS; V-REL; CYTOPLASMIC PROTEIN; CELLULAR PROTEINS; ONCOGENE ENCODES; BINDING PROTEINS; MAMMALIAN-CELLS	Our studies originally demonstrated that the v-rel oncoprotein repressed gene expression in chicken lymphoid cells, while it activated transcription in rodent fibroblasts. Here we report that the c-rel protein can activate expression of genes linked to kappa-B motifs when low levels of endogenous kappa-B-binding activity are present. In contrast v-rel, and to a lesser extent c-rel, inhibit NF-kappa-B-mediated activation of the human immunodeficiency virus long terminal repeat (HIV LTR) in phorbol ester-stimulated HeLa cells. Competition assays show that v-rel competitively inhibits both NF-kappa-B and c-rel-mediated transcriptional activation. Analysis of mutant HIV LTR-chloramphenicol acetyltransferase (CAT) constructs in which all Sp1 or both NF-kappa-B elements have been deleted shows that NF-kappa-B motifs are required for rel-mediated effects on gene expression. Transforming v-rel mutants compete efficiently with phorbol ester-activated kappa-B factors, whereas a transformation-defective mutant of v-rel is impaired in this activity. Taken together, these results strengthen the hypothesis that v-rel functions as a dominant interfering member of rel family proteins. These results also suggest that the ability of v- and c-rel to activate or repress gene expression in specific cells may result from their capacity to compete with endogenous rel family proteins whose expression and/or activity are cell-specific.	CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MOLEC GENET & MICROBIOL,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center								BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BHAT GV, 1990, ONCOGENE, V5, P625; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; EMBRETSON JE, 1987, J VIROL, V61, P3454, DOI 10.1128/JVI.61.11.3454-3462.1987; FRANKLIN RB, 1974, INTERVIROLOGY, V3, P342, DOI 10.1159/000149771; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HANNINK M, 1990, ONCOGENE, V5, P1843; HARRICH D, 1989, J VIROL, V63, P2585, DOI 10.1128/JVI.63.6.2585-2591.1989; HERZOG NK, 1986, J VIROL, V57, P371, DOI 10.1128/JVI.57.1.371-375.1986; INOUE JI, 1991, P NATL ACAD SCI USA, V8, P3715; INOUYE S, 1987, SYNTHESIS APPLICATIO, P181; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAO KR, 1991, P NATL ACAD SCI USA, V88, P2697, DOI 10.1073/pnas.88.7.2697; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOO HM, 1991, J VIROL, V65, P4769, DOI 10.1128/JVI.65.9.4769-4776.1991; LEONARD J, 1989, J VIROL, V63, P4919, DOI 10.1128/JVI.63.11.4919-4924.1989; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MORRISON LE, 1989, ONCOGENE, V4, P677; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PARROTT C, 1991, J VIROL, V65, P1414, DOI 10.1128/JVI.65.3.1414-1419.1991; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; ROSS EK, 1991, J VIROL, V65, P4350, DOI 10.1128/JVI.65.8.4350-4358.1991; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; THEILEN GH, 1966, J NATL CANCER I, V37, P731; WALRO DS, 1987, VIROLOGY, V160, P433, DOI 10.1016/0042-6822(87)90015-8; YAMAGUCHI Y, 1989, J VIROL, V63, P1040, DOI 10.1128/JVI.63.3.1040-1048.1989	47	38	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					163	170						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741161				2022-12-17	WOS:A1992HC22700022
J	MEDCALF, EA; TAKAHASHI, T; CHIBA, I; MINNA, J; MILNER, J				MEDCALF, EA; TAKAHASHI, T; CHIBA, I; MINNA, J; MILNER, J			TEMPERATURE-SENSITIVE MUTANTS OF P53 ASSOCIATED WITH HUMAN CARCINOMA OF THE LUNG	ONCOGENE			English	Article							TUMOR SUPPRESSOR PROTEIN; MONOCLONAL-ANTIBODIES; SIMIAN VIRUS-40; IMMUNOLOGICAL VARIANTS; GENE; TRANSFORMATION; ANTIGEN; CANCER; EXPRESSION; ONCOGENE	We have compared the effects of specific point mutations on the tertiary and quaternary structure of the human p53 protein. Eight mutants, each derived from primary resected tissues of lung carcinomas, were expressed in vitro under strictly defined conditions, such that the only known variant was the point mutation present in each p53 mRNA. All the mutations were located in highly conserved domains. The tertiary structure of each mutant protein was investigated by reactivity with anti-p53 monoclonal antibodies directed against conformation-dependent epitopes. Quaternary structure was examined by gel filtration. Although all the mutant proteins exhibited abnormal tertiary structures, their quaternary structures appeared similar to wild type, the one exception being p53-tyr135, which contains tyrosine in place of cysteine at residue 135. The conformational phenotype of mutant human p53 was found to be dependent upon (i) the locus of the mutation and (ii) the nature of the amino acid substitution: two different substitutions at residue 273 yielded two mutants with differing structural properties. We have discovered three mutants of human p53 that are temperature sensitive for conformation; one is mutated at codon 273, a 'hotspot' for p53 mutation in human cancer.	UNIV CAMBRIDGE,DEPT PATHOL,DIV VIROL,TENNIS COURT RD,CAMBRIDGE CB2 1QP,ENGLAND; USN HOSP,NCI,MED ONCOL BRANCH,BETHESDA,MD 20814	University of Cambridge; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy			Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001				BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIBA I, 1990, ONCOGENE, V5, P1603; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1990, EMBO J, V9, P1591; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MALKIN D, 1990, SCIENCE, V250, P1222; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1990, ONCOGENE, V5, P1683; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; MILNER J, 1991, CELL, V65, P1; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6567; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	32	38	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					71	76						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741167				2022-12-17	WOS:A1992HC22700010
J	TARAKHOVSKY, A; ZAICHUK, T; PRASSOLOV, V; BUTENKO, ZA				TARAKHOVSKY, A; ZAICHUK, T; PRASSOLOV, V; BUTENKO, ZA			A 25-KDA POLYPEPTIDE IS THE LIGAND FOR P185NEU AND IS SECRETED BY ACTIVATED MACROPHAGES	ONCOGENE			English	Article							GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE-ACTIVITY; NEU PROTO-ONCOGENE; POINT MUTATION; EGF RECEPTOR; HUMAN-BREAST; C-ERBB-2 ONCOGENE; TUMOR-ANTIGEN; GENE; EXPRESSION	Medium conditioned by mouse peritoneal macrophages, activated by muramyl dipeptide (MDP), was used as a possible source of p185neu-specific ligand. MDP-activated macrophage-conditioned medium (MDP-CM) was shown to induce p185neu down-regulation in NEU-expressing NIH3T3 cells in a dose-dependent and temperature-sensitive manner. To exclude the possibility of an indirect action of proteins/metabolites present in MDP-CM on p185neu turnover, a ligand-trapping approach was used. Secreted NEU protein possessing only the extracellular domain but lacking transmembrane and protein kinase domains was expressed in HeLa cells and then purified from conditioned medium, using affinity chromatography on WGA-Sepharose. Co-incubation of the truncated, soluble NEU protein preparation with MDP-CM abolished MDP-CM-induced p185neu down-regulation and reduced self-phosphorylation. It is concluded that a putative p185neu-specific ligand is produced by macrophages activated by MDP. Using MDP-CM, the presence of a 25 kDa polypeptide, distinct from EGF, PDGF, FGF, IGF, TGF-alpha and TGF-beta and TNF-alpha, could be demonstrated by decorating a Western blot with soluble NEU and anti-NEU antibodies. Thus, a 25kDa (non-reduced) p185neu ligand has been described.	ACAD SCI UKSSR,INST ONCOL PROBLEMS,DEPT LEUKEMIAGENESIS,KIEV,UKRAINE,USSR; ACAD SCI USSR,INST MOLEC BIOL,MOSCOW V-71,USSR	National Academy of Sciences Ukraine								AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; ALAN A, 1981, MOL CELL BIOCHEM, V41, P27; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; BAHR GM, 1986, FASEB J, V45, P2541; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BERGER MS, 1988, CANCER RES, V48, P1238; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1988, ONCOGENE, V2, P273; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; JALANKO A, 1988, BIOCHIM BIOPHYS ACTA, V949, P206, DOI 10.1016/0167-4781(88)90084-X; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; Maniatis T., 1982, MOL CLONING; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PRASSOLOV VS, 1988, P ACAD SCI USSR, V300, P1498; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TALBOT PJ, 1984, J IMMUNOL METHODS, V73, P177, DOI 10.1016/0022-1759(84)90043-7; TARAKHOVSKY AM, 1990, ONCOGENE, V5, P405; TARAKHOVSKYA, 1990, ONCOGENES GROWTH CON, P207; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WEBER W, 1984, SCIENCE, V224, P294, DOI 10.1126/science.6324343; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WIEDERMANN CJ, 1988, J IMMUNOL, V137, P3928; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179; ZHOU DJ, 1987, CANCER RES, V47, P6123	59	38	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2187	2196						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1685016				2022-12-17	WOS:A1991GX73500003
J	GROSSI, M; CALCONI, A; TATO, F				GROSSI, M; CALCONI, A; TATO, F			V-JUN ONCOGENE PREVENTS TERMINAL DIFFERENTIATION AND SUPPRESSES MUSCLE-SPECIFIC GENE-EXPRESSION IN ASV-17-INFECTED MUSCLE-CELLS	ONCOGENE			English	Article							MYOGENIC CELLS; DNA-BINDING; ENHANCER BINDING; PROTO-ONCOGENE; C-JUN; MYOBLASTS; MYC; PROTEINS; AP-1; FOS	Infection of replicating quail myoblasts with avian sarcoma virus 17 (ASV-17) results in the inhibition of terminal differentiation into multinucleated myotubes and in the acquisition of anchorage-independent proliferation. Expression of v-jun, the ASV-17 oncogene, concomitantly leads to the accumulation of the gag-jun polyprotein P65 in the nucleus and to the lack of expression of typical differentiation-specific genes such as myosin heavy chain (MHC) and alpha-actinin. Surprisingly, expression of desmin, the muscle-specific subunit of intermediate filaments, is conserved in ASV-17-transformed myoblasts. Analysis of clonal strains of transformed myoblasts suggests that (i) suppression of morphological and biochemical differentiation depends on the absence of muscle-specific gene transcripts; (ii) inhibition of muscle differentiation by v-jun does not depend on the transcriptional silencing of MyoD, a muscle-specific regulatory gene; (iii) expression of desmin is compatible with proliferation of ASV-17-transformed cells and is independent of v-jun and MyoD levels of expression. The present data suggest that nuclear localization of v-jun prevents terminal differentiation in myoblasts and selectively down-regulates muscle-specific genes in terminally differentiated myotubes. In this respect, the behaviour of v-jun is quite different from that of v-myc, thus suggesting that these two oncogenes, although both encoding nuclear proteins, may have different mechanisms of action.	UNIV ROME LA SAPIENZA,DIPARTIMENTO BIOL CELLULARE & SVILUPPO,SEZ SCI MICROBIOL,I-00185 ROME,ITALY	Sapienza University Rome			Grossi, Milena/D-2955-2009					ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; CAPETANAKI YG, 1984, COLD SPRING HARB SYM, P415; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; GROSSI M, 1989, PATHOLOGY GENE EXPRE, P313; HASTINGS KEM, 1982, MUSCLE DEV MOL CELLU, P215; HILL CS, 1986, J CELL BIOL, V103, P2185, DOI 10.1083/jcb.103.6.2185; HOLTZER H, 1975, Q REV BIOPHYS, V8, P523, DOI 10.1017/S0033583500001980; KAUFMAN SJ, 1988, P NATL ACAD SCI USA, V85, P9606, DOI 10.1073/pnas.85.24.9606; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SCHNEIDER MD, 1988, MOL NEUROBIOL, V2, P1, DOI 10.1007/BF02935631; SU HY, 1991, ONCOGENE, V6, P1759; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TATO F, 1983, DIFFERENTIATION, V24, P131, DOI 10.1111/j.1432-0436.1983.tb01312.x; VOGEL Z, 1972, P NATL ACAD SCI USA, V69, P3180, DOI 10.1073/pnas.69.11.3180; VOGT PK, 1988, ONCOGENE, V3, P3; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198	30	38	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1767	1773						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923502				2022-12-17	WOS:A1991GX11800007
J	PRIBYL, LJ; WATSON, DK; SCHULZ, RA; PAPAS, TS				PRIBYL, LJ; WATSON, DK; SCHULZ, RA; PAPAS, TS			D-ELG, A MEMBER OF THE DROSOPHILA-ETS GENE FAMILY - SEQUENCE, EXPRESSION AND EVOLUTIONARY COMPARISON	ONCOGENE			English	Article								We have cloned a cDNA from the Drosophila elg gene, a new member of the ets family of genes. The D-elg gene is located at 97D on chromosome 3R and is expressed as a 2.0 kb RNA in the embryos, pupae and adults, with no detectable expression in third instar larvae. D-elg expression is observed in all cells of early stage embryos, prior to transcriptional activation of the zygotic genome, and is maintained throughout embryogenesis with no regional localization. The cDNA encodes a predicted protein of 15.4 kD that has an 86 amino acid sequence with 72% similarity to the carboxy terminal region of the Drosophila ets-2 gene. Comparison with all known ets genes allows us to define a minimal region required for assignment to the ets gene family.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT BIOCHEM & MOLEC BIOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	PRIBYL, LJ (corresponding author), NCI, MOLEC ONCOL LAB, FREDERICK, MD 21702 USA.							ANGERER LM, 1987, METHOD ENZYMOL, V152, P649; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BISHOP JG, 1988, GENE DEV, V2, P567, DOI 10.1101/gad.2.5.567; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHEN JH, 1990, ONCOGENE RES, V5, P277; CHEN JH, 1988, ONCOGENE RES, V2, P371; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HOFFMANN FM, 1989, CURR TOP MICROBIOL, V147, P1; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; JANKNECHT R, 1989, NUCLEIC ACIDS RES, V17, P4455, DOI 10.1093/nar/17.12.4455; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; LINDSLEY DL, 1967, CARNEGIE I WASHINGTO, V627, P1; Maniatis T., 1982, MOL CLONING; Maxam A M, 1980, Methods Enzymol, V65, P499; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; Pardue M L, 1975, Methods Cell Biol, V10, P1, DOI 10.1016/S0091-679X(08)60727-X; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; POGNONEC P, 1989, ONCOGENE, V4, P691; PRIBYL LJ, 1988, DEV BIOL, V127, P45, DOI 10.1016/0012-1606(88)90187-X; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; SAINT R, 1988, NATURE, V334, P151, DOI 10.1038/334151a0; SCHULZ RA, 1989, DEV BIOL, V131, P515, DOI 10.1016/S0012-1606(89)80022-3; SCHULZ RA, 1991, DEV BIOL, V143, P206, DOI 10.1016/0012-1606(91)90068-E; SETH A, 1990, ONCOGENE, V5, P1761; SHILO BZ, 1987, TRENDS GENET, V3, P69, DOI 10.1016/0168-9525(87)90178-8; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1990, ADV AP BIOT, V6, P221; WATSON DK, 1988, VIROLOGY, V164, P99, DOI 10.1016/0042-6822(88)90624-1; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1988, VIROLOGY, V167, P1, DOI 10.1016/0042-6822(88)90047-5; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WATSON DK, 1986, P NATL ACAD SCI USA, V83, P1792, DOI 10.1073/pnas.83.6.1792; WATSON DK, 1990, ONCOGENESIS, P207	44	38	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1991	6	7					1175	1183						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1713660				2022-12-17	WOS:A1991GV26000012
J	CARBONE, A; GUSELLA, GL; RADZIOCH, D; VARESIO, L				CARBONE, A; GUSELLA, GL; RADZIOCH, D; VARESIO, L			HUMAN HARVEY-RAS IS BIOCHEMICALLY DIFFERENT FROM KIRSTEN-RAS OR N-RAS	ONCOGENE			English	Article							PROTEIN KINASE-C; SERUM-RESPONSE ELEMENT; GROWTH-FACTOR; PHORBOL ESTER; ADENYLATE-CYCLASE; FOS EXPRESSION; TRANSFORMED FIBROBLASTS; ONCOGENE PRODUCT; NIH/3T3 CELLS; P21 PROTEINS	The biochemical effects of the human H-, N- and K-ras oncogenes were studied. We analysed the induction of c-fos mRNA and protein by the protein kinase C (PKC) activator 12-O-tetradecanoyl-phorbol-13-acetate (TPA) in exponentially growing NIH3T3 fibroblasts transformed by transfection with ras oncogenes. We found that H-ras has the unique ability to inhibit c-fos induction by TPA. In contrast, normal c-fos expression was induced by TPA in fibroblasts transformed by N- or K-ras or by the ras-unrelated oncogenes dbl and trk. The inhibition of c-fos induction by H-ras was not due to alteration in the binding of TPA to the transformed cells or to the selection of idiosyncratic clones. These results provide clear evidence that H-ras is functionally different from K- or N-ras.	NCI,FREDERICK CANC RES & DEV CTR,MOLEC IMMUNOREGULAT LAB,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702; UNIV CATTOLICA DEL SACRO CUORE,IST ANAT PATOL,I-00168 ROME,ITALY; NCI,FREDERICK CANC RES & DEV CTR,INC DYN CORP,PROGRAM RESOURCES,FREDERICK,MD 21702; MCGILL UNIV,MONTREAL GEN HOSP,DEPT MED,MONTREAL H3G 1A4,QUEBEC,CANADA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Catholic University of the Sacred Heart; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; McGill University	VARESIO, L (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,MOLEC IMMUNOREGULAT LAB,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702, USA.		varesio, luigi/J-8261-2016	varesio, luigi/0000-0001-5659-2218; CARBONE, Arnaldo/0000-0001-9695-5837; Radzioch, Danuta/0000-0002-1601-2757	NCI NIH HHS [N01-CO-74102] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLESTER R, 1987, J BIOL CHEM, V262, P2688; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BECKNER SK, 1985, NATURE, V317, P71, DOI 10.1038/317071a0; BENJAMIN CW, 1987, P NATL ACAD SCI USA, V84, P546, DOI 10.1073/pnas.84.2.546; BRANDTRAUF PW, 1988, P NATL ACAD SCI USA, V85, P5869, DOI 10.1073/pnas.85.16.5869; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLETTA G, 1987, ONCOGENE RES, V1, P459; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GARTE SJ, 1985, BIOCHEM BIOPH RES CO, V133, P702, DOI 10.1016/0006-291X(85)90961-1; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GIARDINA SL, 1987, ANAL BIOCHEM, V161, P109, DOI 10.1016/0003-2697(87)90659-2; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LACAL JC, 1986, CELL, V44, P609, DOI 10.1016/0092-8674(86)90270-9; LEVINSON AD, 1986, TRENDS GENET, V2, P81, DOI 10.1016/0168-9525(86)90184-8; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; LOWY DR, 1986, CANCER SURV, V5, P275; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PREISS J, 1986, J BIOL CHEM, V261, P8597; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; SUZUKI H, 1989, EXP CELL RES, V184, P524, DOI 10.1016/0014-4827(89)90350-9; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TARPLEY WG, 1986, P NATL ACAD SCI USA, V83, P3703, DOI 10.1073/pnas.83.11.3703; TEMELES GL, 1985, NATURE, V313, P700, DOI 10.1038/313700a0; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	42	38	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					731	737						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1905005				2022-12-17	WOS:A1991GT82500007
J	POGNONEC, P; BOULUKOS, KE; BOSSELUT, R; BOYER, C; SCHMITTVERHULST, AM; GHYSDAEL, J				POGNONEC, P; BOULUKOS, KE; BOSSELUT, R; BOYER, C; SCHMITTVERHULST, AM; GHYSDAEL, J			IDENTIFICATION OF A ETS1 VARIANT PROTEIN UNAFFECTED IN ITS CHROMATIN AND INVITRO DNA-BINDING CAPACITIES BY T-CELL ANTIGEN RECEPTOR TRIGGERING AND INTRACELLULAR CALCIUM RISES	ONCOGENE			English	Article									INST PASTEUR,CNRS,UA 041160,INSERM,U186,1 RUE CALMETTE,F-59019 LILLE,FRANCE; CNRS,INSERM,CTR IMMUNOL,F-13288 MARSEILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			GHYSDAEL, Jacques/F-3377-2013	Schmitt-Verhulst, Anne-Marie/0000-0002-1296-2739				ALBERT F, 1982, IMMUNOGENETICS, V16, P533, DOI 10.1007/BF00372022; ALBERT F, 1984, IMMUNOGENETICS, V19, P279, DOI 10.1007/BF00345401; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN JH, 1988, ONCOGENE RES, V2, P371; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; FUJIWARA S, 1988, ONCOGENE, V2, P99; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GEGONNE A, 1987, VIROLOGY, V156, P177, DOI 10.1016/0042-6822(87)90450-8; GEGONNE A, 1987, MOL CELL BIOL, V7, P806, DOI 10.1128/MCB.7.2.806; GHYSDAEL J, 1986, EMBO J, V5, P2251, DOI 10.1002/j.1460-2075.1986.tb04492.x; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; HUA C, 1986, J IMMUNOL, V136, P1927; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; PINK JR, 1983, MOL IMMUNOL, V20, P491, DOI 10.1016/0161-5890(83)90030-5; POGNONEC P, 1988, ARCH INT PHYSIOL BIO, V96, pB51; POGNONEC P, 1989, ONCOGENE, V4, P691; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; SITKOVSKY MV, 1984, P NATL ACAD SCI-BIOL, V81, P1519, DOI 10.1073/pnas.81.5.1519; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2	30	38	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					603	610						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	2183162				2022-12-17	WOS:A1990DB85300022
J	STARNAUD, R; CRAIG, J; MCBURNEY, MW; PAPKOFF, J				STARNAUD, R; CRAIG, J; MCBURNEY, MW; PAPKOFF, J			THE INT-1 PROTO-ONCOGENE IS TRANSCRIPTIONALLY ACTIVATED DURING NEUROECTODERMAL DIFFERENTIATION OF P19 MOUSE EMBRYONAL CARCINOMA-CELLS	ONCOGENE			English	Article									UNIV OTTAWA,DEPT MED,451 SMYTH RD,OTTAWA K1H 8M5,ONTARIO,CANADA; SYNTEX INC,CANC & DEV BIOL,PALO ALTO,CA 94304	University of Ottawa; Syntex Corporation								AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BELL JC, 1986, MOL CELL BIOL, V6, P617, DOI 10.1128/MCB.6.2.617; BENDER W, 1987, CELL, V50, P519, DOI 10.1016/0092-8674(87)90023-7; BOER PH, 1987, MOL CELL BIOL, V7, P3107, DOI 10.1128/MCB.7.9.3107; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; EDWARDS MKS, 1983, DEV BIOL, V98, P187, DOI 10.1016/0012-1606(83)90348-2; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KEMLER R, 1981, J EMBRYOL EXP MORPH, V64, P45; LAZARUS P, 1988, ONCOGENE, V3, P517; LEMISCHKA IR, 1981, J MOL BIOL, V151, P101, DOI 10.1016/0022-2836(81)90223-0; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1987, ONCOGENE, V1, P243; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; PAPKOFF J, 1989, IN PRESS MOL CELL BI; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PATERNO GD, 1989, UNPUB; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SCHUURING E, 1989, MOL CELL BIOL, V9, P1357, DOI 10.1128/MCB.9.3.1357; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; STAINES WA, 1987, NEUROSCIENCE, V23, P571, DOI 10.1016/0306-4522(87)90077-7; STARNAUD R, 1988, ONCOGENE, V3, P553; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; UZVOLGYI E, 1988, P NATL ACAD SCI USA, V85, P3034, DOI 10.1073/pnas.85.9.3034; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; ZAMBONI L, 1967, J CELL BIOL, V35, pA148	41	38	38	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1077	1080						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2674852				2022-12-17	WOS:A1989AM53100004
J	GRAZIANI, G; RON, D; EVA, A; SRIVASTAVA, SK				GRAZIANI, G; RON, D; EVA, A; SRIVASTAVA, SK			THE HUMAN DBL-PROTO-ONCOGENE PRODUCT IS A CYTOPLASMIC PHOSPHOPROTEIN WHICH IS ASSOCIATED WITH THE CYTOSKELETAL MATRIX	ONCOGENE			English	Article									NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,ROOM 1E24,BETHESDA,MD 20892; GEORGETOWN UNIV,CTR CANC,WASHINGTON,DC 20007	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University			Eva, Alessandra/J-8268-2016; Graziani, Grazia/G-5747-2012	Eva, Alessandra/0000-0003-2949-078X; Graziani, Grazia/0000-0002-0221-768X	NATIONAL CANCER INSTITUTE [R29CA046455] Funding Source: NIH RePORTER; NCI NIH HHS [CA-46455] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARVUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BENZEEV A, 1979, CELL, V17, P859, DOI 10.1016/0092-8674(79)90326-X; BOSS MA, 1981, J VIROL, V40, P472, DOI 10.1128/JVI.40.2.472-481.1981; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1987, ONCOGENE, V1, P355; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; FRANKE WW, 1978, EXP CELL RES, V116, P429, DOI 10.1016/0014-4827(78)90466-4; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAY AJ, 1974, VIROLOGY, V60, P398, DOI 10.1016/0042-6822(74)90335-3; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; MANGER R, 1986, J VIROL, V59, P66, DOI 10.1128/JVI.59.1.66-72.1986; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; RADKE K, 1983, J CELL BIOL, V97, P1601, DOI 10.1083/jcb.97.5.1601; ROBBINS KC, 1985, EMBO J, V4, P1783, DOI 10.1002/j.1460-2075.1985.tb03851.x; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; SCHATZMAN RC, 1986, MOL CELL BIOL, V6, P1329, DOI 10.1128/MCB.6.4.1329; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SINGER SJ, 1974, ANNU REV BIOCHEM, V43, P805, DOI 10.1146/annurev.bi.43.070174.004105; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P38, DOI 10.1073/pnas.82.1.38; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; STOLZENBACH F, 1966, METHOD ENZYMOL, V9, P278; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG LH, 1988, VIRUS RES, V9, P159; WIDNELL CC, 1968, P NATL ACAD SCI USA, V61, P1050, DOI 10.1073/pnas.61.3.1050; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0	32	38	39	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					823	829						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2666904				2022-12-17	WOS:A1989AE58400002
J	MITCHELL, CD; COWELL, JK				MITCHELL, CD; COWELL, JK			PREDISPOSITION TO RETINOBLASTOMA DUE TO A TRANSLOCATION WITHIN THE 4.7R LOCUS	ONCOGENE			English	Article											MITCHELL, CD (corresponding author), INST CHILD HLTH,DEPT HAEMATOL & ONCOL,IMPERIAL CANC RES FUND,MOLEC GENET LAB,30 GUILDFORD ST,LONDON WC1,ENGLAND.			Cowell, John/0000-0002-2079-5950				BLANQUET V, 1987, HUM GENET, V76, P102; BOOKSTEIN R, 1988, P NATL ACAD SCI USA, V85, P221; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; COWELL JK, 1980, J NATL CANCER I, V65, P955; COWELL JK, 1986, HUM GENET, V72, P164; COWELL JK, 1987, CANCER GENET CYTOGEN, V27, P27, DOI 10.1016/0165-4608(87)90256-1; COWELL JK, 1986, HUMAN CYTOGENETICS P, P202; COWELL JK, 1987, BRIT J CANCER, V555, P661; DAVISON EV, 1979, CLIN GENET, V15, P505; DRYJA TP, 1984, NEW ENGL J MED, V310, P550, DOI 10.1056/NEJM198403013100902; DUNN J, COMMUNICATION; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YT, 1987, SCIENCE, V36, P1657; GODDARD AD, 1988, MOL CELL BIOL, V8, P2082, DOI 10.1128/MCB.8.5.2082; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARNDEN D, 1984, ADV CANCER RES, V41, P185, DOI 10.1016/S0065-230X(08)60017-2; LALANDE M, 1984, CANCER GENET CYTOGEN, V13, P283, DOI 10.1016/0165-4608(84)90073-6; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; Maniatis T., 1982, MOL CLONING; MITCHELL CD, 1988, IN PRESS HUMAN GENET; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPARKES RS, 1983, SCIENCE, V219, P971, DOI 10.1126/science.6823558; SQUIRE J, 1985, HUM GENET, V70, P291, DOI 10.1007/BF00295364; TURLEAU C, 1983, ANN GENET-PARIS, V26, P158; TURLEAU C, 1985, CANCER GENET CYTOGEN, V16, P321, DOI 10.1016/0165-4608(85)90240-7; VOGEL F, 1979, HUM GENET, V52, P1; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x	32	38	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1989	4	2					253	257						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2927947				2022-12-17	WOS:A1989U567500019
J	KING, CR; BORRELLO, I; PORTER, L; COMOGLIO, P; SCHLESSINGER, J				KING, CR; BORRELLO, I; PORTER, L; COMOGLIO, P; SCHLESSINGER, J			LIGAND-INDEPENDENT TYROSINE PHOSPHORYLATION OF EGF RECEPTOR AND THE ERBB-2/NEU PROTO-ONCOGENE PRODUCT IS INDUCED BY HYPEROSMOTIC SHOCK	ONCOGENE			English	Article									RORER BIOTECHNOL,KING OF PRUSSIA,PA 19406; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; UNIV TURIN,DIPARTIMENTO SCI BIOMED & ONCOL UMAMA,I-10126 TURIN,ITALY	Weizmann Institute of Science; University of Turin				Comoglio, Paolo/0000-0002-7056-5328; Porter, Laura/0000-0002-4068-1950				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; COCHET C, 1988, J BIOL CHEM, V263, P3290; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; EVELOFF JL, 1987, AM J PHYSIOL, V252, pF1, DOI 10.1152/ajprenal.1987.252.1.F1; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; GECK P, 1985, ANN NY ACAD SCI, V456, P166, DOI 10.1111/j.1749-6632.1985.tb14862.x; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KADOWAKI T, 1987, BIOCHEM BIOPH RES CO, V144, P699, DOI 10.1016/S0006-291X(87)80021-9; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1985, NUCLEIC ACIDS RES, V13, P8477, DOI 10.1093/nar/13.23.8477; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; LIN CR, 1984, SCIENCE, V224, P843, DOI 10.1126/science.6326261; LIVNEH E, 1987, EMBO J, V6, P2669, DOI 10.1002/j.1460-2075.1987.tb02558.x; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; SCHLESSINGER J, 1983, CRC CR REV BIOCH MOL, V14, P93, DOI 10.3109/10409238309102791; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2069; SCHULDINER S, 1982, P NATL ACAD SCI-BIOL, V79, P7778, DOI 10.1073/pnas.79.24.7778; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; TAL M, 1988, CANCER RES, V48, P1517; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1985, J BIOL CHEM, V260, P315; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YOKOTA J, 1986, LANCET, V1, P765; ZIPPEL R, 1986, BIOCHIM BIOPHYS ACTA, V881, P54, DOI 10.1016/0304-4165(86)90096-6	35	38	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					13	18						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2464783				2022-12-17	WOS:A1989U567400002
J	KATZIR, N; ARMAN, E; COHEN, D; GIVOL, D; RECHAVI, G				KATZIR, N; ARMAN, E; COHEN, D; GIVOL, D; RECHAVI, G			COMMON ORIGIN OF TRANSMISSIBLE VENEREAL TUMORS (TVT) IN DOGS	ONCOGENE			English	Article									BEN GURION UNIV NEGEV,DEPT IMMUNOL,IL-84120 BEERSHEBA,ISRAEL; CHAIM SHEBA MED CTR,INST HEMATOL,IL-52621 TEL HASHOMER,ISRAEL; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Ben Gurion University; Chaim Sheba Medical Center; Weizmann Institute of Science								BALTIMORE D, 1985, CELL, V40, P481, DOI 10.1016/0092-8674(85)90190-4; COHEN D, 1985, ADV CANCER RES, V43, P75, DOI 10.1016/S0065-230X(08)60943-4; HATTORI M, 1985, NUCLEIC ACIDS RES, V13, P7813, DOI 10.1093/nar/13.21.7813; KATZIR N, 1985, P NATL ACAD SCI USA, V82, P1054, DOI 10.1073/pnas.82.4.1054; MANIATIS T, 1982, MOL CLONING LABORATO; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Nowinsky M., 1876, ZENTRALBL MED WISS, V14, P790; POTTER SS, 1984, P NATL ACAD SCI-BIOL, V81, P1012, DOI 10.1073/pnas.81.4.1012; ROGERS JH, 1985, INT REV CYTOL, V93, P231; SINGER MF, 1982, CELL, V28, P433, DOI 10.1016/0092-8674(82)90194-5; Sticker A., 1906, Z KREBSFORSCH, V4, P227	11	38	38	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	4					445	448						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	K7483	3330787				2022-12-17	WOS:A1987K748300015
J	Jia, YF; Ding, XM; Zhou, LH; Zhang, L; Yang, XC				Jia, Yuefeng; Ding, Xuemei; Zhou, Lihua; Zhang, Li; Yang, Xuecheng			Mesenchymal stem cells-derived exosomal microRNA-139-5p restrains tumorigenesis in bladder cancer by targeting PRC1	ONCOGENE			English	Article							IN-VITRO; GROWTH; MIR-139-5P; CYCLE	microRNAs (miRNAs) can be delivered to tumor cells where they exert their function via mesenchymal stem cells (MSCs)-derived exosomes. This study investigated exosomal transfer of miR-139-5p to bladder cancer cells and their role in the regulation of tumorigenesis. The dysregulation of polycomb repressor complex 1 (PRC1) in bladder cancer was characterized by RNA quantification, and its functional significance in bladder cancer cells was identified by loss-of-function experiments. We predicted the miR-139-5p that could play a role in regulating PRC1, which was further verified using dual-luciferase reporter gene assay. Next, we altered the expression of miR-139-5p and PRC1 in bladder cancer cells to identify their functions in cancer progression. Bladder cancer cells were co-cultured with exosomes isolated from human umbilical cord mesenchymal stem cells (hUCMSCs) over-expressing miR-139-5p. The intercellular transfer of miR-139-5p along with in vitro and in vivo functions was determined using gain- and loss-of-function approaches. Our results revealed that PRC1 levels were increased in bladder cancer tissues and cells, and silencing PRC1 appeared to impede the cell proliferation, migration, and invasion potentials. In addition, miR-139-5p was observed to be down-regulated in bladder cancer, which targeted PRC1 and reduced its expression, hereby resulting in ameliorated tumorigenic characteristics of bladder cancer cells in vitro. Furthermore, we noted that miR-139-5p from hUCMSCs-derived exosomes could be transferred into bladder cancer cells to down-regulate the PRC1 expression. Moreover, hUCMSCs-derived exosomal miR-139-5p conferred a suppressive role on bladder cancer development in vitro and in vivo. These data together supported the tumor-inhibiting role of MSCs-derived exosomal miR-139-5p in bladder cancer, highlighting a promising therapeutic strategy.	[Jia, Yuefeng; Yang, Xuecheng] Qingdao Univ, Affiliated Hosp, Dept Urol, Qingdao 266003, Peoples R China; [Ding, Xuemei; Zhang, Li] Qingdao Univ, Affiliated Hosp, Dept Surg, Qingdao 266003, Peoples R China; [Zhou, Lihua] Qingdao Univ, Affiliated Hosp, Dept Pharm, Qingdao 266003, Peoples R China	Qingdao University; Qingdao University; Qingdao University	Yang, XC (corresponding author), Qingdao Univ, Affiliated Hosp, Dept Urol, Qingdao 266003, Peoples R China.	m18661805062@163.com						Alzahrani FA, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/8058979; Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010; Chen Y, 2018, AM J PHYSIOL-CELL PH, V315, pC225, DOI 10.1152/ajpcell.00283.2017; Cosenza S, 2018, THERANOSTICS, V8, P1399, DOI 10.7150/thno.21072; Dai SP, 2015, BIOCHEM BIOPH RES CO, V467, P204, DOI 10.1016/j.bbrc.2015.10.006; De Faveri LE, 2015, TRANSL ONCOL, V8, P387, DOI 10.1016/j.tranon.2015.08.002; Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715; Di Meo A, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0644-5; He CJ, 2018, THERANOSTICS, V8, P237, DOI 10.7150/thno.21945; Jiang C, 2018, J CELL BIOCHEM, V119, P6429, DOI 10.1002/jcb.26610; Kamat AM, 2016, LANCET, V388, P2796, DOI 10.1016/S0140-6736(16)30512-8; Keller S, 2009, CANCER LETT, V278, P73, DOI 10.1016/j.canlet.2008.12.028; Kluth LA, 2015, EUR UROL, V68, P238, DOI 10.1016/j.eururo.2015.01.032; Li JB, 2014, CHEM SOC REV, V43, P506, DOI 10.1039/c3cs60312a; Li ZH, 2014, NAT REV DRUG DISCOV, V13, P622, DOI 10.1038/nrd4359; Liang W, 2013, MOL CELL BIOCHEM, V382, P283, DOI 10.1007/s11010-013-1745-0; Liu PF, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0021-9; Luo HB, 2015, J HUAZHONG U SCI-MED, V35, P730, DOI 10.1007/s11596-015-1498-y; Luo HB, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317718414; Milane L, 2015, J CONTROL RELEASE, V219, P278, DOI 10.1016/j.jconrel.2015.06.029; Pakravan K, 2017, CELL ONCOL, V40, P457, DOI 10.1007/s13402-017-0335-7; Sanli O, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.22; Shang S, 2019, CANCER MED-US, V8, P7728, DOI 10.1002/cam4.2633; Sun Q, 2018, ONCOL LETT, V16, P793, DOI 10.3892/ol.2018.8773; Tang H, 2019, DIGEST LIVER DIS, V51, P1314, DOI 10.1016/j.dld.2019.02.012; Wang B, 2018, INT J NANOMED, V13, P5257, DOI 10.2147/IJN.S167880; Wang K, 2017, J CELL MOL MED, V21, P3730, DOI 10.1111/jcmm.13282; Xu W, 2015, INT J CLIN EXP PATHO, V8, P3864; Xu XD, 2014, ASIAN PAC J CANCER P, V15, P3471, DOI 10.7314/APJCP.2014.15.8.3471; Yonemori M, 2016, CANCER SCI, V107, P1233, DOI 10.1111/cas.13002; Yoshino H, 2013, NAT REV UROL, V10, P396, DOI 10.1038/nrurol.2013.113; Zhan P, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0682-z; Zhang B, 2017, J CELL MOL MED, V21, P1329, DOI 10.1111/jcmm.13063; Zhang LJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-124; Zhu S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02863-3	35	37	38	2	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					246	261		10.1038/s41388-020-01486-7	http://dx.doi.org/10.1038/s41388-020-01486-7		OCT 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33122828				2022-12-17	WOS:000582827800005
J	Llanos, S; Megias, D; Blanco-Aparicio, C; Hernandez-Encinas, E; Rovira, M; Pietrocola, F; Serrano, M				Llanos, Susana; Megias, Diego; Blanco-Aparicio, Carmen; Hernandez-Encinas, Elena; Rovira, Miguel; Pietrocola, Federico; Serrano, Manuel			Lysosomal trapping of palbociclib and its functional implications	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; INDUCED SENESCENCE; DRUGS; RESISTANCE; RADIATION; HEAD; PROLIFERATION; SENSITIVITY; INHIBITION; MECHANISMS	Palbociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) approved for the treatment of some cancers. The main mechanism of action of palbociclib is to induce cell cycle arrest and senescence on responsive cells. Here, we report that palbociclib concentrates in intracellular acidic vesicles, where it can be readily observed due to its intrinsic fluorescence, and it is released from these vesicles upon dilution or washing out of the extracellular medium. This reversible storage of drugs into acidic vesicles is generally known as lysosomal trapping and, based on this, we uncover novel properties of palbociclib. In particular, a short exposure of cells to palbociclib is sufficient to produce a stable cell-cycle arrest and long-term senescence. Moreover, after washing out the drug, palbociclib-treated cells release the drug to the medium and this conditioned medium is active on susceptible cells. Interestingly, cancer cells resistant to palbociclib also accumulate and release the drug producing paracrine senescence on susceptible cells. Finally, other lysosomotropic drugs, such as chloroquine, interfere with the accumulation of palbociclib into lysosomes, thereby reducing the minimal dose of palbociclib required for cell-cycle arrest and senescence. In summary, lysosomal trapping explains the prolonged temporal activity of palbociclib, the paracrine activity of exposed cells, and the cooperation with lysosomotropic drugs. These are important features that may help to improve the therapeutic dosing and efficacy of palbociclib. Finally, two other clinically approved CDK4/6 inhibitors, ribociclib and abemaciclib, present a similar behavior as palbociclib, suggesting that lysosomal trapping is a property common to all three clinically-approved CDK4/6 inhibitors.	[Llanos, Susana; Megias, Diego; Blanco-Aparicio, Carmen; Hernandez-Encinas, Elena; Serrano, Manuel] Spanish Natl Canc Res Ctr CNIO, Madrid, Spain; [Rovira, Miguel; Pietrocola, Federico; Serrano, Manuel] BIST, Inst Res Biomed IRB Barcelona, Barcelona, Spain; [Serrano, Manuel] Catalan Inst Res & Adv Studies ICREA, Barcelona, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; ICREA	Llanos, S; Serrano, M (corresponding author), Spanish Natl Canc Res Ctr CNIO, Madrid, Spain.; Serrano, M (corresponding author), BIST, Inst Res Biomed IRB Barcelona, Barcelona, Spain.; Serrano, M (corresponding author), Catalan Inst Res & Adv Studies ICREA, Barcelona, Spain.	sllanos@cnio.es; manuel.serrano@irbbarcelona.org	, Susana/AAA-9282-2019; Megías, Diego/L-6008-2014; Blanco-Aparicio, Carmen/I-3162-2015; Serrano, Manuel/H-2634-2015; Pietrocola, Federico/AAW-9621-2020	Blanco-Aparicio, Carmen/0000-0002-3249-6595; Serrano, Manuel/0000-0001-7177-9312; Pietrocola, Federico/0000-0002-2930-234X; Llanos, Susana/0000-0002-8555-9326; Rovira, Miguel/0000-0002-1391-8465; Megias, Diego/0000-0003-0755-0518	"la Caixa"-Severo Ochoa PhD scholarship; EMBO Long-Term Postdoctoral Fellowship [ALTF 358-2017]; CNIO; IRB; Spanish Ministry of Economy (MINECO, SAF); European Research Council (ERC); Botin Foundation; Banco Santander (Santander Universities Global Division); "la Caixa" Foundation; MINECO	"la Caixa"-Severo Ochoa PhD scholarship; EMBO Long-Term Postdoctoral Fellowship(European Molecular Biology Organization (EMBO)); CNIO; IRB; Spanish Ministry of Economy (MINECO, SAF); European Research Council (ERC)(European Research Council (ERC)European Commission); Botin Foundation; Banco Santander (Santander Universities Global Division); "la Caixa" Foundation(La Caixa Foundation); MINECO(Spanish Government)	M.R. was holder of a "la Caixa"-Severo Ochoa PhD scholarship. F.P. is supported by EMBO Long-Term Postdoctoral Fellowship (ALTF 358-2017). Work in the laboratory of M.S. was funded by the CNIO and the IRB, and by grants from the Spanish Ministry of Economy (MINECO, SAF), the European Research Council (ERC Advanced Grant), the Botin Foundation and Banco Santander (Santander Universities Global Division), and by "la Caixa" Foundation. CNIO and IRB Barcelona are recipients of a Severo Ochoa Award of Excellence from the MINECO. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acosta JC, 2012, TRENDS CELL BIOL, V22, P211, DOI 10.1016/j.tcb.2011.11.006; Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; Beaver JA, 2015, CLIN CANCER RES, V21, P4760, DOI 10.1158/1078-0432.CCR-15-1185; Chen F, 2017, ANTI-CANCER AGENT ME, V17, P1; Chen L, 2017, BRIT J PHARMACOL, V174, P2427, DOI 10.1111/bph.13836; Daniel WA, 2003, PROG NEURO-PSYCHOPH, V27, P65, DOI 10.1016/S0278-5846(02)00317-2; Daniel WA, 1997, PHARMACOL TOXICOL, V80, P62, DOI 10.1111/j.1600-0773.1997.tb00285.x; Daniel WA, 1999, EUR NEUROPSYCHOPHARM, V9, P483, DOI 10.1016/S0924-977X(99)00034-6; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Freund A, 2010, TRENDS MOL MED, V16, P238, DOI 10.1016/j.molmed.2010.03.003; Goel S, 2017, NATURE, V548, P471, DOI 10.1038/nature23465; Goldman SDB, 2009, BIOANALYSIS, V1, P1445, DOI 10.4155/BIO.09.128; GRENMAN R, 1991, CANCER, V67, P2741, DOI 10.1002/1097-0142(19910601)67:11<2741::AID-CNCR2820671105>3.0.CO;2-S; Hay T, 2009, DRUG METAB DISPOS, V37, P1864, DOI 10.1124/dmd.109.027888; Hernandez-Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001; Herranz N, 2015, NAT CELL BIOL, V17, P1205, DOI 10.1038/ncb3225; Kazmi F, 2013, DRUG METAB DISPOS, V41, P897, DOI 10.1124/dmd.112.050054; Knas M, 2012, FOLIA HISTOCHEM CYTO, V50, P220, DOI 10.5603/FHC.2012.0031; Kurz DJ, 2000, J CELL SCI, V113, P3613; Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195; Leontieva OV, 2015, ONCOTARGET, V6, P23238, DOI 10.18632/oncotarget.4836; Leontieva OV, 2013, CELL CYCLE, V12, P3063, DOI 10.4161/cc.26130; LI WW, 1995, P NATL ACAD SCI USA, V92, P10436, DOI 10.1073/pnas.92.22.10436; MACINTYRE AC, 1988, BIOPHARM DRUG DISPOS, V9, P513, DOI 10.1002/bod.2510090602; Massaro RR, 2017, PHARMACOL RES, V119, P242, DOI 10.1016/j.phrs.2017.02.013; Miettinen TP, 2018, EMBO J, V37, DOI 10.15252/embj.201798359; Mok CC, 2017, EXPERT REV CLIN IMMU, V13, P35, DOI 10.1080/1744666X.2016.1212659; Munoz-Espin D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823; Murayama N, 2006, J PHARM SCI-US, V95, P1763, DOI 10.1002/jps.20530; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Ndolo RA, 2010, J PHARMACOL EXP THER, V333, P120, DOI 10.1124/jpet.109.160226; Palmgren JJ, 2006, EUR J PHARM BIOPHARM, V64, P369, DOI 10.1016/j.ejpb.2006.06.005; PEKKOLAHEINO K, 1994, ARCH OTOLARYNGOL, V120, P750; PEKKOLAHEINO K, 1995, J CANCER RES CLIN, V121, P452, DOI 10.1007/BF01218360; Pierzynska-Mach A, 2014, CYTOM PART A, V85A, P729, DOI 10.1002/cyto.a.22495; Purvis JE, 2012, SCIENCE, V336, P1440, DOI 10.1126/science.1218351; Robinson TJW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078641; Servomaa K, 1996, CELL PROLIFERAT, V29, P219, DOI 10.1046/j.1365-2184.1996.01009.x; Valenzuela CA, 2017, EXP CELL RES, V360, P390, DOI 10.1016/j.yexcr.2017.09.031; VanArsdale T, 2015, CLIN CANCER RES, V21, P2905, DOI 10.1158/1078-0432.CCR-14-0816; Verhaegen M, 2012, ONCOGENE, V31, P828, DOI 10.1038/onc.2011.277; Vijayaraghavan S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15916; Wang HZ, 2017, NATURE, V546, P426, DOI 10.1038/nature22797; Zhitomirsky B, 2016, DRUG RESIST UPDATE, V24, P23, DOI 10.1016/j.drup.2015.11.004; 2009, METHOD ENZYMOL, V452, P181, DOI DOI 10.1016/S0076-6879(08)03612-4; 2012, EXPERT OPIN DRUG MET, V8, P943, DOI DOI 10.1517/17425255.2012.691165	49	37	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3886	3902		10.1038/s41388-019-0695-8	http://dx.doi.org/10.1038/s41388-019-0695-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30692638	Green Published, hybrid			2022-12-17	WOS:000468035600009
J	Das, S; Bar-Sagi, D				Das, Shipra; Bar-Sagi, Dafna			BTK signaling drives CD1d(hi)CD5(+) regulatory B-cell differentiation to promote pancreatic carcinogenesis	ONCOGENE			English	Article							BRUTONS TYROSINE KINASE; T-CELLS; AUTOIMMUNITY; INHIBITION; CANCER; TUMOR; ACTIVATION; EXPRESSION	The immune microenvironment of pancreatic ductal adenocarcinoma (PDA) is comprised of a heterogeneous population of cells that are critical for disease evolution. Prominent among these are the specialized CD1d(hi)CD5(+) regulatory B (B-reg) cells that exert a pro-tumorigenic role by promoting tumor cell proliferation. Dissecting the molecular pathways regulating this immune sub-population can thus be valuable for uncovering potential therapeutic targets. Here, we investigate Bruton's tyrosine kinase (BTK), a key B-cell kinase, as a potential regulator of CD1d(hi)CD5(+) B-reg differentiation in the pancreatic tumor microenvironment. Treatment of cytokine-induced B cells in vitro with the high specificity BTK inhibitor Tirabrutinib inhibited CD1d(hi)CD5(+) B-reg differentiation and production of IL-10 and IL-35, essential mediators of B-reg immunosuppressive functions. The BTK signaling pathway was also found to be active in vivo in PanIN-associated regulatory B cells. Tirabrutinib treatment of mice bearing orthotopic Kras(G12D)-pancreatic lesions severely compromised stromal accumulation of the CD1d(hi)CD5(+) B-reg population. This was accompanied by an increase in stromal CD8(+)IFN gamma(+) cytotoxic T cells and significant attenuation of tumor cell proliferation and PanIN growth. Our results uncover a novel role for BTK in regulating CD1d(hi)CD5(+) B-reg differentiation and emphasize its potential as a therapeutic target for pancreatic cancer.	[Das, Shipra; Bar-Sagi, Dafna] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA	New York University	Bar-Sagi, D (corresponding author), NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA.	dafna.bar-sagi@nyulangone.org		Bar-Sagi, Dafna/0000-0003-2597-8948	National Institutes of Health/National Cancer Institute [P30CA016087]; Gilead Sciences, Inc., Foster City, CA, USA; NIH/NCI [CA210263]; Lustgarten Foundation Pancreatic Cancer Convergence Dream Team grant [SU2C-AACR-DT14-14]; NATIONAL CANCER INSTITUTE [R35CA210263, P30CA016087] Funding Source: NIH RePORTER	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Gilead Sciences, Inc., Foster City, CA, USA(Gilead Sciences); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Lustgarten Foundation Pancreatic Cancer Convergence Dream Team grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank L.J. Taylor for help with article preparation and members of the Bar-Sagi lab for valuable discussions and comments. The authors also thank NYU Langone's Cytometry and Cell Sorting Laboratory, which is supported in part by grant P30CA016087 from the National Institutes of Health/National Cancer Institute, for providing cell sorting/flow cytometry technologies. This work was supported in part by Gilead Sciences, Inc., Foster City, CA, USA, by NIH/NCI grant CA210263 (D.B.-S.) and by the Lustgarten Foundation Pancreatic Cancer Convergence Dream Team grant SU2C-AACR-DT14-14 (to D.B.-S.). Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research.	Brunner C, 2002, IMMUNOBIOLOGY, V206, P432, DOI 10.1078/0171-2985-00192; Burger JA, 2018, NAT REV CANCER, V18, P148, DOI 10.1038/nrc.2017.121; Corneth OBJ, 2016, J IMMUNOL, V197, P58, DOI 10.4049/jimmunol.1600208; De Monte L, 2011, J EXP MED, V208, P469, DOI 10.1084/jem.20101876; Delitto D, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1820-x; DiLillo DJ, 2010, ANN NY ACAD SCI, V1183, P38, DOI 10.1111/j.1749-6632.2009.05137.x; Doyle SL, 2007, J BIOL CHEM, V282, P36953, DOI 10.1074/jbc.M707682200; Egwuagu CE, 2015, CRIT REV IMMUNOL, V35, P49, DOI 10.1615/CritRevImmunol.2015012558; Granville CA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005061; Gunderson AJ, 2016, CANCER DISCOV, V6, P270, DOI 10.1158/2159-8290.CD-15-0827; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hiraoka N, 2006, CLIN CANCER RES, V12, P5423, DOI 10.1158/1078-0432.CCR-06-0369; Isaza-Correa JM, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0057-5; Jefferies CA, 2003, J BIOL CHEM, V278, P26258, DOI 10.1074/jbc.M301484200; Kurahara H, 2011, J SURG RES, V167, pE211, DOI 10.1016/j.jss.2009.05.026; Lee KE, 2016, CANCER DISCOV, V6, P256, DOI 10.1158/2159-8290.CD-15-0822; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; McAllister F, 2014, CANCER CELL, V25, P621, DOI 10.1016/j.ccr.2014.03.014; Mielgo A, 2013, BMB REP, V46, P131, DOI 10.5483/BMBRep.2013.46.3.036; Mohamed AJ, 2009, IMMUNOL REV, V228, P58, DOI 10.1111/j.1600-065X.2008.00741.x; Ochi A, 2012, J EXP MED, V209, P1671, DOI 10.1084/jem.20111706; Petro JB, 2001, J BIOL CHEM, V276, P1715, DOI 10.1074/jbc.M009137200; Ponader S, 2014, J CLIN ONCOL, V32, P1830, DOI 10.1200/JCO.2013.53.1046; Pylayeva-Gupta Y, 2016, CLIN CANCER RES, V22, P4973, DOI 10.1158/1078-0432.CCR-16-0743; Pylayeva-Gupta Y, 2016, CANCER DISCOV, V6, P247, DOI 10.1158/2159-8290.CD-15-0843; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Rahib L, 2016, JAMA ONCOL, V2, P1209, DOI 10.1001/jamaoncol.2016.0585; Rishi A, 2015, SEMIN ONCOL, V42, P28, DOI 10.1053/j.seminoncol.2014.12.004; Rosser EC, 2014, NAT MED, V20, P1334, DOI 10.1038/nm.3680; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Schmidt NW, 2006, J IMMUNOL, V177, P7203, DOI 10.4049/jimmunol.177.10.7203; Schwartz M, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0145-x; Stromnes IM, 2014, CARCINOGENESIS, V35, P1451, DOI 10.1093/carcin/bgu115; Tai YT, 2012, BLOOD, V120, P1877, DOI 10.1182/blood-2011-12-396853; Unek T, 2013, HEPATO-GASTROENTEROL, V60, P2085, DOI 10.5754/hge.13421; Vonderheide RH, 2013, CURR OPIN IMMUNOL, V25, P200, DOI 10.1016/j.coi.2013.01.006; Zdanov S, 2016, CANCER IMMUNOL RES, V4, P354, DOI 10.1158/2326-6066.CIR-15-0241; Zhang JJ, 2018, CANCERS, V10, DOI 10.3390/cancers10020039; Zhang YQ, 2014, CANCER IMMUNOL RES, V2, P423, DOI 10.1158/2326-6066.CIR-14-0016-T; Zhu ZH, 2014, CANCER DISCOV, V4, P452, DOI 10.1158/2159-8290.CD-13-0646	40	37	40	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3316	3324		10.1038/s41388-018-0668-3	http://dx.doi.org/10.1038/s41388-018-0668-3			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30635655	Green Accepted			2022-12-17	WOS:000465557200015
J	Cui, TT; Bell, EH; McElroy, J; Becker, AP; Gulati, PM; Geurts, M; Mladkova, N; Gray, A; Liu, K; Yang, LL; Liu, ZY; Fleming, JL; Haque, SJ; Barnholtz-Sloan, JS; Ligon, KL; Beroukhim, R; Robe, P; Chakravarti, A				Cui, Tiantian; Bell, Erica H.; McElroy, Joseph; Becker, Aline Paixao; Gulati, Pooja Manchanda; Geurts, Marjolein; Mladkova, Nikol; Gray, Ashley; Liu, Kevin; Yang, Linlin; Liu, Ziyan; Fleming, Jessica L.; Haque, S. Jaharul; Barnholtz-Sloan, Jill S.; Ligon, Keith L.; Beroukhim, Rameen; Robe, Pierre; Chakravarti, Arnab			miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma	ONCOGENE			English	Article							ORGAN SIZE CONTROL; MICRORNA EXPRESSION; HIPPO PATHWAY; PROLIFERATION; CANCER; YAP; TUMORIGENICITY; TEMOZOLOMIDE; HOMEOSTASIS; APOPTOSIS	Glioblastomas (GBMs) are the most aggressive primary brain tumors, with an average survival of less than 15 months. Therefore, there is a critical need to develop novel therapeutic strategies for GBM. This study aimed to assess the prognostic value of miR-4516 and investigate its oncogenic functions and the underlying cellular and molecular mechanisms in GBM. To determine the correlation between miR-4516 expression and overall survival of patients with GBM, total RNAs were isolated from 268 FFPE tumor samples, miR expression was assayed (simultaneously) using the nCounter human miRNA v3a assay followed by univariable and multivariable survival analyses. Further, in vitro and in vivo studies were conducted to define the role of miR-4516 in GBM tumorigenesis and the underlying molecular mechanisms. Upon multivariable analysis, miR-4516 was correlated with poor prognosis in GBM patients (HR = 1.49, 95%CI: 1.12-1.99, P = 0.01). Interestingly, the significance of miR-4516 was retained including MGMT methylation status. Overexpression of miR-4516 significantly enhanced cell proliferation and invasion of GBM cells both in vitro and in vivo. While conducting downstream targeting studies, we found that the tumor-promoting function of miR-4516, in part, was mediated by direct targeting of PTPN14 (protein tyrosine phosphatase, non-receptor type 14) which, in turn, regulated the Hippo pathway in GBM. Taken together, our data suggest that miR-4516 represents an independent negative prognostic factor in GBM patients and acts as a novel oncogene in GBM, which regulates the PTPN14/Hippo pathway. Thus, this newly identified miR-4516 may serve as a new potential therapeutic target for GBM treatment.	[Cui, Tiantian; Bell, Erica H.; Becker, Aline Paixao; Gulati, Pooja Manchanda; Yang, Linlin; Liu, Ziyan; Fleming, Jessica L.; Haque, S. Jaharul; Chakravarti, Arnab] Arthur G James Hosp, Dept Radiat Oncol, Ohio State Comprehens Canc Ctr, Columbus, OH 43210 USA; [McElroy, Joseph] Ohio State Univ, Dept Biomed Informat, Ctr Biostat, Columbus, OH 43210 USA; [Geurts, Marjolein; Robe, Pierre] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Neurol & Neurosurg, Utrecht, Netherlands; [Mladkova, Nikol] Columbia Univ, Dept Internal Med, Div Nephrol, New York, NY 10032 USA; [Gray, Ashley] Ohio State Univ, Columbus, OH 43210 USA; [Liu, Kevin] Ohio State Univ, Coll Med, Columbus, OH 43210 USA; [Barnholtz-Sloan, Jill S.] Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH USA; [Ligon, Keith L.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Ligon, Keith L.; Beroukhim, Rameen] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Beroukhim, Rameen] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Utrecht University; Utrecht University Medical Center; Columbia University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Case Western Reserve University; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute	Chakravarti, A (corresponding author), Arthur G James Hosp, Dept Radiat Oncol, Ohio State Comprehens Canc Ctr, Columbus, OH 43210 USA.	Chakravarti.7@osu.edu	Geurts, Marjolein/AAP-4148-2020; Becker, Aline/AAD-2209-2021; Barnholtz-Sloan, Jill/A-4817-2011	Barnholtz-Sloan, Jill/0000-0001-6190-9304	National Cancer Institute [R01CA169368, R01CA11522358, R01CA1145128, R01CA108633, R01CA188228, 1RC2CA148190, U10CA180850-01]; Brain Tumor Funders Collaborative Grant; Ohio State University Comprehensive Cancer Center Award; NATIONAL CANCER INSTITUTE [R01CA188228, R01CA169368, P30CA016058, UG1CA233331, U10CA180850] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Brain Tumor Funders Collaborative Grant; Ohio State University Comprehensive Cancer Center Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Cancer Institute [R01CA169368 (to A.C.), R01CA11522358 (to A.C.), R01CA1145128 (to A.C.), R01CA108633 (to A.C.), R01CA188228 (to A.C., R.B., K.L., and J.B.), 1RC2CA148190 (to A.C.), and U10CA180850-01 (to A.C.)]; A Brain Tumor Funders Collaborative Grant (to A.C.); Ohio State University Comprehensive Cancer Center Award (to A.C.).	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Bady P, 2012, ACTA NEUROPATHOL, V124, P547, DOI 10.1007/s00401-012-1016-2; Bell EH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118745; Belle L, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005547; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Borrelli N, 2017, MODERN PATHOL, V30, P39, DOI [10.1038/nnodpathol.2016.157, 10.1038/modpathol.2016.157]; Chang WH, 2016, TUMOR BIOL, V37, P14813, DOI 10.1007/s13277-016-5295-4; Chowdhari S, 2014, J CELL PHYSIOL, V229, P1630, DOI 10.1002/jcp.24608; Cui TT, 2015, ONCOTARGET, V6, P10060, DOI 10.18632/oncotarget.3542; Cui TT, 2012, CARCINOGENESIS, V33, P2326, DOI 10.1093/carcin/bgs273; Du WZ, 2015, NEURO-ONCOLOGY, V17, P243, DOI 10.1093/neuonc/nou217; Fortin JP, 2017, BIOINFORMATICS, V33, P558, DOI 10.1093/bioinformatics/btw691; Garzon R, 2006, TRENDS MOL MED, V12, P580, DOI 10.1016/j.molmed.2006.10.006; Han CH, 2014, MOL CANCER RES, V12, P784, DOI 10.1158/1541-7786.MCR-13-0638; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hsu SD, 2011, NUCLEIC ACIDS RES, V39, pD163, DOI 10.1093/nar/gkq1107; Laczmanska I, 2011, ACTA BIOCHIM POL, V58, P467; Lenos K, 2012, CANCER RES, V72, P4074, DOI 10.1158/0008-5472.CAN-12-0215; Li SW, 2017, NEURO-ONCOLOGY, V19, P55, DOI 10.1093/neuonc/now129; Liu X, 2013, ONCOGENE, V32, P1266, DOI 10.1038/onc.2012.147; Losman JA, 2013, GENE DEV, V27, P836, DOI 10.1101/gad.217406.113; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Maksimovic J, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r44; McNamara Mairead G, 2013, Cancers (Basel), V5, P1103, DOI 10.3390/cancers5031103; Michaloglou C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061916; Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI [10.1093/neuonc/nov189, 10.1093/neuonc/noaa200, 10.1093/neuonc/noab200]; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Team RC, 2016, R LANG ENV STAT COMP; Varelas X, 2014, DEVELOPMENT, V141, P1614, DOI 10.1242/dev.102376; Wang LJ, 2015, ONCOTARGET, V6, P5932, DOI 10.18632/oncotarget.3465; Wang WQ, 2012, GENE DEV, V26, P1959, DOI 10.1101/gad.192955.112; Wilson KE, 2014, J BIOL CHEM, V289, P23693, DOI 10.1074/jbc.M113.534701; Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104; Xia HP, 2013, NEURO-ONCOLOGY, V15, P413, DOI 10.1093/neuonc/nos296; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zougman A, 2013, EUR J CANCER, V49, P531, DOI 10.1016/j.ejca.2012.07.031	41	37	37	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					2923	2936		10.1038/s41388-018-0601-9	http://dx.doi.org/10.1038/s41388-018-0601-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30559405	Green Accepted			2022-12-17	WOS:000465167600004
J	Zhao, LJ; Wang, W; Xu, L; Yi, T; Zhao, X; Wei, YQ; Vermeulen, L; Goel, A; Zhou, ST; Wang, X				Zhao, Linjie; Wang, Wei; Xu, Lian; Yi, Tao; Zhao, Xia; Wei, Yuquan; Vermeulen, Louis; Goel, Ajay; Zhou, Shengtao; Wang, Xin			Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer	ONCOGENE			English	Article							MOLECULAR SUBTYPES; EARLY RELAPSE; EXPRESSION; PROGRESSION; TRANSITION; SIGNATURE; DISTINCT; CARCINOMA; APOPTOSIS; TARGETS	Ovarian cancer is a heterogeneous malignancy that poses tremendous clinical challenge. Based on unsupervised classification of whole-genome gene expression profiles, four molecular subtypes of ovarian cancer were recently identified. However, single-driver molecular events specific to these subtypes have not been clearly elucidated. We aim to characterize the regulatory mechanisms underlying the poor prognosis mesenchymal subtype of ovarian cancer using a systems biology approach, involving a variety of molecular modalities including gene and microRNA expression profiles. miR-508-3p emerged as the most powerful determinant that regulates a cascade of dysregulated genes in the mesenchymal subtype, including core genes involved in epithelial-mesenchymal transition (EMT) program. Moreover, miR-508-3p down-regulation, due to promoter hypermethylation, was directly correlated with metastatic behaviors in vitro and in vivo. Taken together, our multidimensional network analysis identified miR-508-3p as a master regulator that defines the mesenchymal subtype and provides a novel prognostic biomarker to improve management of this disease.	[Zhao, Linjie; Yi, Tao; Zhao, Xia; Wei, Yuquan; Zhou, Shengtao] Sichuan Univ, Key Lab Birth Defects & Related Dis Women & Child, Dept Obstet & Gynecol, Chengdu, Sichuan, Peoples R China; [Zhao, Linjie; Yi, Tao; Zhao, Xia; Wei, Yuquan; Zhou, Shengtao] Sichuan Univ, State Key Lab Biotherapy, West China Second Univ Hosp, Chengdu, Sichuan, Peoples R China; [Zhao, Linjie; Yi, Tao; Zhao, Xia; Wei, Yuquan; Zhou, Shengtao] Collaborat Innovat Ctr, Chengdu, Sichuan, Peoples R China; [Wang, Wei; Wang, Xin] City Univ Hong Kong, Dept Biomed Sci, Kowloon Tong, Hong Kong, Peoples R China; [Xu, Lian] Sichuan Univ, Dept Pathol, West China Second Univ Hosp, Chengdu, Sichuan, Peoples R China; [Vermeulen, Louis] Univ Amsterdam, Ctr Expt Mol Med, Acad Med Ctr, Lab Expt Oncol & Radiobiol LEXOR, NL-1105 AZ Amsterdam, Netherlands; [Goel, Ajay] Baylor Univ, Med Ctr, Ctr Gastrointestinal Res, Dallas, TX USA; [Goel, Ajay] Baylor Univ, Med Ctr, Ctr Translat Genom & Oncol, Baylor Scott & White Res Inst, Dallas, TX USA; [Goel, Ajay] Baylor Univ, Med Ctr, Charles A Sammons Canc Ctr, Dallas, TX USA; [Wang, Xin] City Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China	Sichuan University; Sichuan University; City University of Hong Kong; Sichuan University; University of Amsterdam; Academic Medical Center Amsterdam; Baylor University; Baylor University Medical Center; Baylor Health Care System; Baylor University; Baylor University Medical Center; Baylor University; Baylor University Medical Center; City University of Hong Kong	Zhou, ST (corresponding author), Sichuan Univ, Key Lab Birth Defects & Related Dis Women & Child, Dept Obstet & Gynecol, Chengdu, Sichuan, Peoples R China.; Zhou, ST (corresponding author), Sichuan Univ, State Key Lab Biotherapy, West China Second Univ Hosp, Chengdu, Sichuan, Peoples R China.; Zhou, ST (corresponding author), Collaborat Innovat Ctr, Chengdu, Sichuan, Peoples R China.; Wang, X (corresponding author), City Univ Hong Kong, Dept Biomed Sci, Kowloon Tong, Hong Kong, Peoples R China.; Wang, X (corresponding author), City Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China.	taotaovip2005@163.com; xin.wang@cityu.edu.hk	Wang, Xin/A-1130-2012	Wang, Xin/0000-0002-5122-2418; Zhou, Shengtao/0000-0001-8322-5536; Vermeulen, Louis/0000-0002-6066-789X	National Natural Science Foundation of China [81822034, 81773119, 81402396]; National Key Research and Development Program of China [2018YFA0109200, 2017YFA0106800]; Sichuan Science-Technology Soft Sciences Project [2016ZR0086]; West China Second Hospital, Sichuan University [KS021]; Research Grants Council of the Hong Kong Special Administrative Region, China [CityU 21101115, 11102317, 11103718]; Science Technology and Innovation Committee of Shenzhen Municipality [JCYJ20170307091256048]; Shenzhen Research Institute, City University of Hong Kong	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Sichuan Science-Technology Soft Sciences Project; West China Second Hospital, Sichuan University; Research Grants Council of the Hong Kong Special Administrative Region, China(Hong Kong Research Grants Council); Science Technology and Innovation Committee of Shenzhen Municipality; Shenzhen Research Institute, City University of Hong Kong(City University of Hong Kong)	This work was supported by grants from the National Natural Science Foundation of China (grant#81822034, grant #81773119, and grant #81402396), National Key Research and Development Program of China (2018YFA0109200 and 2017YFA0106800), Sichuan Science-Technology Soft Sciences Project (grant #2016ZR0086), Direct Scientific Research Grants from West China Second Hospital, Sichuan University (grant #KS021) awarded to Shengtao Zhou and a grant from the Research Grants Council of the Hong Kong Special Administrative Region, China (Project No. CityU 21101115, 11102317, 11103718), as well as a grant from The Science Technology and Innovation Committee of Shenzhen Municipality (JCYJ20170307091256048) awarded to Xin Wang, and partially supported by the Shenzhen Research Institute, City University of Hong Kong.	Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Bagnoli M, 2016, LANCET ONCOL, V17, P1137, DOI 10.1016/S1470-2045(16)30108-5; Bagnoli M, 2011, ONCOTARGET, V2, P1265, DOI 10.18632/oncotarget.401; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bilyk O, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00145; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bonome T, 2008, CANCER RES, V68, P5478, DOI 10.1158/0008-5472.CAN-07-6595; Bowtell DD, 2015, NAT REV CANCER, V15, P668, DOI 10.1038/nrc4019; Cairo S, 2008, CANCER CELL, V14, P471, DOI 10.1016/j.ccr.2008.11.002; Ceppi P, 2014, ONCOGENE, V33, P269, DOI 10.1038/onc.2013.55; Chaisaingmongkol J, 2017, CANCER CELL, V32, P57, DOI 10.1016/j.ccell.2017.05.009; Chan CK, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160275; De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174; Di Stefano V, 2016, AM J PATHOL, V186, P2473, DOI 10.1016/j.ajpath.2016.05.019; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Fletcher MNC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3464; Floor S, 2011, ONCOGENE, V30, P4609, DOI 10.1038/onc.2011.184; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Huang TT, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0493-7; Jiang JW, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.36; Karnezis AN, 2017, NAT REV CANCER, V17, P65, DOI 10.1038/nrc.2016.113; Konecny GE, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju249; Kossai M, 2018, PATHOBIOLOGY, V85, P41, DOI 10.1159/000479006; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lin CY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5620; Liu N, 2017, ONCOTARGET, V8, P60015, DOI 10.18632/oncotarget.9623; Martin M., 2011, EMBNET J, V17, P10, DOI 10.14806/ej.17.1.200; Mateescu B, 2011, NAT MED, V17, P1627, DOI 10.1038/nm.2512; Matulonis UA, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.61; Nam EJ, 2016, ONCOTARGET, V7, P70524, DOI 10.18632/oncotarget.12045; Northcott PA, 2017, NATURE, V547, P311, DOI 10.1038/nature22973; Pan YH, 2017, ONCOTARGET, V8, P17406, DOI 10.18632/oncotarget.15921; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Sean D, 2007, BIOINFORMATICS, V23, P1846, DOI 10.1093/bioinformatics/btm254; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tan TZ, 2013, EMBO MOL MED, V5, P1051, DOI 10.1002/emmm.201201823; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Vang S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058226; Wang X, 2011, BIOINFORMATICS, V27, P879, DOI 10.1093/bioinformatics/btr028; Way GP, 2016, G3-GENES GENOM GENET, V6, P4097, DOI 10.1534/g3.116.033514; Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104; Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020; Yu XT, 2013, TUMOR BIOL, V34, P3501, DOI 10.1007/s13277-013-0928-3; Yu Y, 2013, CELL, V152, P248, DOI 10.1016/j.cell.2012.12.006; Zhai QN, 2012, BIOCHEM BIOPH RES CO, V419, P621, DOI 10.1016/j.bbrc.2012.02.060; Zhao L, 2017, ONCOGENE, V36, P3384, DOI 10.1038/onc.2016.487; Zhao LJ, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1412-6; Zhao LJ, 2017, CANCER RES, V77, P1369, DOI 10.1158/0008-5472.CAN-16-1615; Zhao LJ, 2013, HUM REPROD, V28, P1324, DOI 10.1093/humrep/det042; Zhao M, 2015, SCI REP-UK, V5, DOI 10.1038/srep11459; Zhou ST, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M112.017988; Zhou ST, 2012, CANCER LETT, V318, P14, DOI 10.1016/j.canlet.2011.10.038	55	37	37	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2305	2319		10.1038/s41388-018-0577-5	http://dx.doi.org/10.1038/s41388-018-0577-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30478449	Green Published, hybrid			2022-12-17	WOS:000462588000006
J	Wang, E; Sorolla, A; Cunningham, PT; Bogdawa, HM; Beck, S; Golden, E; Dewhurst, RE; Florez, L; Cruickshank, MN; Hoffmann, K; Hopkins, RM; Kim, J; Woo, AJ; Watt, PM; Blancafort, P				Wang, Edina; Sorolla, Anabel; Cunningham, Paula T.; Bogdawa, Heique M.; Beck, Samuel; Golden, Emily; Dewhurst, Robert E.; Florez, Laura; Cruickshank, Mark N.; Hoffmann, Katrin; Hopkins, Richard M.; Kim, Jonghwan; Woo, Andrew J.; Watt, Paul M.; Blancafort, Pilar			Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers	ONCOGENE			English	Article							BET BROMODOMAIN INHIBITORS; C-MYC; TRANSCRIPTION FACTOR; RESISTANCE; OMOMYC; MAX; CHEMOTHERAPY; ACTIVATION; EFFICACY; PROTEIN	Overexpression of MYC oncogene is highly prevalent in many malignancies such as aggressive triple-negative breast cancers (TNBCs) and it is associated with very poor outcome. Despite decades of research, attempts to effectively inhibit MYC, particularly with small molecules, still remain challenging due to the featureless nature of its protein structure. Herein, we describe the engineering of the dominant-negative MYC peptide (OmoMYC) linked to a functional penetrating 'Phylomer' peptide (FPPa) as a therapeutic strategy to inhibit MYC in TNBC. We found FPPa-OmoMYC to be a potent inducer of apoptosis (with IC50 from 1-2 mu M) in TNBC cells with negligible effects in non-tumorigenic cells. Transcriptome analysis of FPPa-OmoMYC-treated cells indicated that the fusion protein inhibited MYC-dependent networks, inducing dynamic changes in transcriptional, metabolic, and apoptotic processes. We demonstrated the efficacy of FPPa-OmoMYC in inhibiting breast cancer growth when injected orthotopically in TNBC allografts. Lastly, we identified strong pharmacological synergisms between FPPa-OmoMYC and chemotherapeutic agents. This study highlights a novel therapeutic approach to target highly aggressive and chemoresistant MYC-activated cancers.	[Wang, Edina; Sorolla, Anabel; Golden, Emily; Woo, Andrew J.; Blancafort, Pilar] QEII Med Ctr, Harry Perkins Inst Med Res, Nedlands, WA, Australia; [Wang, Edina; Sorolla, Anabel; Golden, Emily; Woo, Andrew J.; Blancafort, Pilar] Univ Western Australia, Ctr Med Res, Crawley, WA 6009, Australia; [Wang, Edina; Sorolla, Anabel; Golden, Emily; Blancafort, Pilar] Univ Western Australia, Sch Human Sci, Crawley, WA 6009, Australia; [Cunningham, Paula T.; Bogdawa, Heique M.; Dewhurst, Robert E.; Florez, Laura; Hoffmann, Katrin; Hopkins, Richard M.; Watt, Paul M.] Phylog Pty Ltd, Subiaco, WA 6008, Australia; [Cunningham, Paula T.; Bogdawa, Heique M.; Dewhurst, Robert E.; Florez, Laura; Cruickshank, Mark N.; Hoffmann, Katrin; Watt, Paul M.] Univ Western Australia, Telethon Kids Inst, Subiaco, WA 6008, Australia; [Beck, Samuel; Kim, Jonghwan] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA; [Beck, Samuel] Kathryn W Davis Ctr Regenerat Biol & Med, MDI Biol Lab, Salsbury Cove, ME 04672 USA	Harry Perkins Institute of Medical Research; University of Western Australia; University of Western Australia; University of Western Australia; Telethon Kids Institute; University of Western Australia; University of Texas System; University of Texas Austin	Blancafort, P (corresponding author), QEII Med Ctr, Harry Perkins Inst Med Res, Nedlands, WA, Australia.; Blancafort, P (corresponding author), Univ Western Australia, Ctr Med Res, Crawley, WA 6009, Australia.; Blancafort, P (corresponding author), Univ Western Australia, Sch Human Sci, Crawley, WA 6009, Australia.; Watt, PM (corresponding author), Phylog Pty Ltd, Subiaco, WA 6008, Australia.; Watt, PM (corresponding author), Univ Western Australia, Telethon Kids Inst, Subiaco, WA 6008, Australia.	paul.watt@telethonkids.org.au; pilar.blancafort@uwa.edu.au	Wang, Edina/AAC-5455-2019; Sorolla, Anabel/E-2546-2012; Kim, Jonghwan/AAR-2815-2021	Sorolla, Anabel/0000-0001-8238-8763; Kim, Jonghwan/0000-0002-9919-9843; Cruickshank, Mark/0000-0002-1869-1175; Blancafort, Pilar/0000-0002-3881-7396; Dewhurst, Robert/0000-0001-8441-4427; Wang, Edina/0000-0002-9652-3513; Beck, Samuel/0000-0002-0184-8367; Golden, Emily/0000-0001-6386-201X; Woo, Andrew/0000-0003-1198-6373	ARC Future Fellowship [FT130101767]; CCWA Research Fellowship; NHMRC [APP1069308]; NIH [R01CA170370, R01DA036906]; NCBF [NC-14-024]; RPHMRF; CCWA;  [R01GM112722]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM104318, R01GM112722] Funding Source: NIH RePORTER	ARC Future Fellowship(Australian Research Council); CCWA Research Fellowship; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCBF; RPHMRF; CCWA(Cancer Council Western Australia); ; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the following grants awarded to PB: the ARC Future Fellowship FT130101767, the CCWA Research Fellowship, NHMRC grant APP1069308, NIH grants R01CA170370, R01DA036906, and the NCBF NC-14-024. JK is supported by R01GM112722. AJW is supported by the RPHMRF and the CCWA. AS is supported by NCBF. We would like to acknowledge the Centre for Microscopy, Characterisation & Analysis, the FACS facility and the AGFR at Harry Perkins Institute.	Annibali D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5632; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Beltran AS, 2014, ONCOGENE, V33, P4767, DOI 10.1038/onc.2013.422; Berg T, 2002, P NATL ACAD SCI USA, V99, P3830, DOI 10.1073/pnas.062036999; Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Bid HK, 2016, MOL CANCER THER, V15, P1018, DOI 10.1158/1535-7163.MCT-15-0567; Bidwell GL, 2006, BIOCHEM PHARMACOL, V71, P248, DOI 10.1016/j.bcp.2005.10.041; Bidwell GL, 2005, MOL CANCER THER, V4, P1076, DOI 10.1158/1535-7163.MCT-04-0253; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Camarda R, 2016, NAT MED, V22, P427, DOI 10.1038/nm.4055; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cinar M, 2015, LEUKEMIA RES, V39, P730, DOI 10.1016/j.leukres.2015.04.003; Clausen DM, 2010, J PHARMACOL EXP THER, V335, P715, DOI 10.1124/jpet.110.170555; Dang CV, 2017, NAT REV CANCER, V17, P502, DOI 10.1038/nrc.2017.36; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Delmore JE, 2016, CELL, V146, P904; DeMichele A, 2015, CLIN CANCER RES, V21, P995, DOI 10.1158/1078-0432.CCR-14-2258; Dickler MN, 2008, CLIN CANCER RES, V14, P7878, DOI 10.1158/1078-0432.CCR-08-0141; Fletcher S, 2015, BBA-GENE REGUL MECH, V1849, P525, DOI 10.1016/j.bbagrm.2014.03.005; Galardi S, 2016, EMBO REP, V17, P1872, DOI 10.15252/embr.201541489; Gebhardt A, 2006, J CELL BIOL, V172, P139, DOI 10.1083/jcb.200506057; Giorello L, 1998, CANCER RES, V58, P3654; Green AR, 2016, BRIT J CANCER, V114, P917, DOI 10.1038/bjc.2016.46; Grushko TA, 2004, CLIN CANCER RES, V10, P499, DOI 10.1158/1078-0432.CCR-0976-03; Guo JX, 2009, CANCER CHEMOTH PHARM, V63, P615, DOI 10.1007/s00280-008-0774-y; Hart JR, 2014, P NATL ACAD SCI USA, V111, P12556, DOI 10.1073/pnas.1319488111; HENDERSON IC, 1989, J CLIN ONCOL, V7, P560, DOI 10.1200/JCO.1989.7.5.560; Horiuchi D, 2012, J EXP MED, V209, P679, DOI 10.1084/jem.20111512; HSU B, 1995, ONCOGENE, V11, P175; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Jung LA, 2017, ONCOGENE, V36, P1911, DOI 10.1038/onc.2016.354; Kurimchak AM, 2016, CELL REP, V16, P1273, DOI 10.1016/j.celrep.2016.06.091; Lee KM, 2017, CELL METAB, V26, P633, DOI 10.1016/j.cmet.2017.09.009; Leonetti C, 1999, CLIN CANCER RES, V5, P2588; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Pereira CBL, 2017, CLIN BREAST CANCER, V17, P188, DOI 10.1016/j.clbc.2016.12.005; Liu TZ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13923; Lorenzin F, 2016, ELIFE, V5, DOI 10.7554/eLife.15161; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Milech N, 2015, SCI REP-UK, V5, DOI 10.1038/srep18329; Milech Nadia, 2012, Methods Mol Biol, V899, P43, DOI 10.1007/978-1-61779-921-1_3; Miller TW, 2011, CLIN CANCER RES, V17, P2024, DOI 10.1158/1078-0432.CCR-10-2567; Mongiardi MP, 2015, SCI REP-UK, V5, DOI 10.1038/srep15494; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Palaskas N, 2011, CANCER RES, V71, P5164, DOI 10.1158/0008-5472.CAN-10-4633; Pan XN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105381; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Roberts PJ, 2012, CLIN CANCER RES, V18, P5290, DOI 10.1158/1078-0432.CCR-12-0563; Savino M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022284; Sharma P, 2017, CLIN CANCER RES, V23, P649, DOI 10.1158/1078-0432.CCR-16-0162; Shen LL, 2015, P NATL ACAD SCI USA, V112, P5425, DOI 10.1073/pnas.1501555112; Shi XR, 2016, P NATL ACAD SCI USA, V113, pE4558, DOI 10.1073/pnas.1608319113; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508; Sorolla A, 2016, NANOSCALE, V8, P9343, DOI 10.1039/c5nr08331a; Soucek L, 2004, CELL DEATH DIFFER, V11, P1038, DOI 10.1038/sj.cdd.4401443; Soucek L, 2002, CANCER RES, V62, P3507; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112; Stellas D, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju320; Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006; Stuhlmiller TJ, 2015, CELL REP, V11, P390, DOI 10.1016/j.celrep.2015.03.037; Wang HB, 2007, MOL CANCER THER, V6, P2399, DOI 10.1158/1535-7163.MCT-07-0005; Watt PM, 2017, CURR OPIN CHEM BIOL, V38, P127, DOI 10.1016/j.cbpa.2017.03.016; Watt PM, 2009, FUTURE MED CHEM, V1, P257, DOI [10.4155/fmc.09.28, 10.4155/FMC.09.28]; Watt PM, 2006, NAT BIOTECHNOL, V24, P177, DOI 10.1038/nbt1190; Whitfield JR, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00010; Wolfer A, 2010, P NATL ACAD SCI USA, V107, P3698, DOI 10.1073/pnas.0914203107; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	74	37	38	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					140	150		10.1038/s41388-018-0421-y	http://dx.doi.org/10.1038/s41388-018-0421-y			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30076412	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000454775900010
J	Liu, J; Zhang, Z; Li, XW; Chen, J; Wang, GD; Tian, ZH; Qian, MR; Chen, ZQ; Guo, H; Tang, GB; Huang, WJ; Tian, DA; Wang, DW; Nie, YZ; Fan, DM; Wu, KC; Xia, LM				Liu, Jian; Zhang, Zhe; Li, Xiaowei; Chen, Jie; Wang, Guodong; Tian, Zuhong; Qian, Meirui; Chen, Zhangqian; Guo, Hao; Tang, Guangbo; Huang, Wenjie; Tian, Dean; Wang, Daowen; Nie, Yongzhan; Fan, Daiming; Wu, Kaichun; Xia, Limin			Forkhead box Cl promotes colorectal cancer metastasis through transactivating ITGA7 and FGFR4 expression	ONCOGENE			English	Article							FIBROBLAST-GROWTH-FACTOR; TO-MESENCHYMAL TRANSITION; INDICATES POOR-PROGNOSIS; TUMOR-METASTASIS; FOXC1; CARCINOMA; GENE; OVEREXPRESSION; INHIBITION; MUTATION	Metastatic colorectal cancer (CRC) is one of the most common causes of cancer death worldwide; however, the molecular mechanism underlying CRC metastasis remains unknown. Using an integrated approach, we identified forkhead box C1 (FOXC1) as a novel regulator of CRC metastasis. Elevated expression of FOXC1 is significantly correlated with metastasis, recurrence and reduced survival. FOXC1 overexpression promotes CRC invasion and lung metastasis, whereas FOXC1 knockdown has the opposite effect. In addition, FOXC1 directly binds its target genes integrin ea (ITGA7) and fibroblast growth factor receptor 4 (FGFR4) and activates their expression. Genetic epistasis analysis confirmed that ITGA7 and FGFR4 act downstream of FOXC1. Furthermore, pharmaceutical inhibition of FGFR4 can reverse CRC metastasis mediated by FOXC1 overexpression. These results suggest that FOXC1 is a prognostic biomarker in CRC patients and targeting the FGFR4 signaling pathway may provide a promising strategy for the treatment of FOXC1-driven CRC metastasis.	[Liu, Jian; Zhang, Zhe; Li, Xiaowei; Chen, Jie; Wang, Guodong; Tian, Zuhong; Qian, Meirui; Chen, Zhangqian; Guo, Hao; Tang, Guangbo; Huang, Wenjie; Nie, Yongzhan; Fan, Daiming; Wu, Kaichun; Xia, Limin] Fourth Mil Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China; [Liu, Jian; Zhang, Zhe; Li, Xiaowei; Chen, Jie; Wang, Guodong; Tian, Zuhong; Qian, Meirui; Chen, Zhangqian; Guo, Hao; Tang, Guangbo; Huang, Wenjie; Nie, Yongzhan; Fan, Daiming; Wu, Kaichun; Xia, Limin] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian, Shaanxi, Peoples R China; [Huang, Wenjie; Tian, Dean; Wang, Daowen; Xia, Limin] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Gastroenterol, Wuhan 430030, Hubei, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Huazhong University of Science & Technology	Wu, KC; Xia, LM (corresponding author), Fourth Mil Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China.; Wu, KC; Xia, LM (corresponding author), Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian, Shaanxi, Peoples R China.; Xia, LM (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Gastroenterol, Wuhan 430030, Hubei, Peoples R China.	kaicwu@fmmu.edu.cn; xialimin@fmmu.edu.cn			National Natural Science Foundation of China [81522031, 81772623, 81627807, 81421003]; National Center for Clinical Research of Digestive Diseases [2015BAI13B07]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Center for Clinical Research of Digestive Diseases	This study was supported by the National Natural Science Foundation of China (Nos. 81522031, 81772623, 81627807, and 81421003) and the National Center for Clinical Research of Digestive Diseases (2015BAI13B07).	Babina IS, 2017, NAT REV CANCER, V17, P318, DOI 10.1038/nrc.2017.8; Benayoun BA, 2011, TRENDS GENET, V27, P224, DOI 10.1016/j.tig.2011.03.003; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Chung TKH, 2012, INT J CANCER, V130, P1036, DOI 10.1002/ijc.26060; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; El-Shami K, 2015, CA-CANCER J CLIN, V65, P427, DOI 10.3322/caac.21286; Haas TL, 2017, CELL STEM CELL, V21, P35, DOI 10.1016/j.stem.2017.04.009; Hagel M, 2015, CANCER DISCOV, V5, P424, DOI 10.1158/2159-8290.CD-14-1029; Han BC, 2018, ONCOGENE, V37, P1399, DOI 10.1038/s41388-017-0021-2; Hannenhalli S, 2009, NAT REV GENET, V10, P233, DOI 10.1038/nrg2523; Honkanen RA, 2003, AM J OPHTHALMOL, V135, P368, DOI 10.1016/S0002-9394(02)02061-5; Huang L, 2017, AM J TRANSL RES, V9, P1297; Huang WJ, 2015, GASTROENTEROLOGY, V149, P1053, DOI 10.1053/j.gastro.2015.05.058; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jensen TW, 2015, JNCI-J NATL CANCER I, V107, P1; Li CS, 2014, BIOMARKERS, V19, P81, DOI 10.3109/1354750X.2013.876555; Liu R, 2013, CANCER RES, V73, P5926, DOI 10.1158/0008-5472.CAN-12-4718; MCNUTT NS, 1981, LAB INVEST, V44, P309; Ming XY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13568; Mortemousque B, 2004, ARCH OPHTHALMOL-CHIC, V122, P1527, DOI 10.1001/archopht.122.10.1527; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Packer LM, 2015, CANCER DISCOV, V5, P355, DOI 10.1158/2159-8290.CD-15-0246; Pai R, 2008, CANCER RES, V68, P5086, DOI 10.1158/0008-5472.CAN-07-2325; Sizemore ST, 2012, J BIOL CHEM, V287, P24631, DOI 10.1074/jbc.M112.375865; Somerville TDD, 2015, CANCER CELL, V28, P329, DOI 10.1016/j.ccell.2015.07.017; Su Y, 2014, INT J MOL MED, V34, P842, DOI 10.3892/ijmm.2014.1819; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Turkington RC, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.10; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Wang L, 2013, TUMOR BIOL, V34, P853, DOI 10.1007/s13277-012-0617-7; Xia LM, 2017, CANCER CELL, V31, P653, DOI 10.1016/j.ccell.2017.04.005; Xia LM, 2014, HEPATOLOGY, V59, P958, DOI 10.1002/hep.26735; Xia LM, 2013, HEPATOLOGY, V57, P610, DOI 10.1002/hep.26029; Xia LM, 2012, J HEPATOL, V57, P600, DOI 10.1016/j.jhep.2012.04.020; Xie MH, 1999, CYTOKINE, V11, P729, DOI 10.1006/cyto.1999.0485; Xu Y, 2014, HISTOPATHOLOGY, V64, P963, DOI 10.1111/his.12347; Yao CC, 1996, J BIOL CHEM, V271, P25598, DOI 10.1074/jbc.271.41.25598; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522	38	37	38	0	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2018	37	41					5477	5491		10.1038/s41388-018-0355-4	http://dx.doi.org/10.1038/s41388-018-0355-4			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GW5QO	29884889				2022-12-17	WOS:000446991200001
J	Li, WL; Ng, JMK; Wong, CC; Ng, EKW; Yu, J				Li, Weilin; Ng, Jennifer Mun-Kar; Wong, Chi Chun; Ng, Enders Kwok Wai; Yu, Jun			Molecular alterations of cancer cell and tumour microenvironment in metastatic gastric cancer	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; LYMPH-NODE METASTASIS; ENDOTHELIAL GROWTH-FACTOR; POOR-PROGNOSIS; STEM-CELLS; PERITONEAL DISSEMINATION; IN-VIVO; MATRIX METALLOPROTEINASES; HELICOBACTER-PYLORI; GENE-EXPRESSION	The term metastasis is widely used to describe the endpoint of the process by which tumour cells spread from the primary location to an anatomically distant site. Achieving successful dissemination is dependent not only on the molecular alterations of the cancer cells themselves, but also on the microenvironment through which they encounter. Here, we reviewed the molecular alterations of metastatic gastric cancer (GC) as it reflects a large proportion of GC patients currently seen in clinic. We hope that further exploration and understanding of the multistep metastatic cascade will yield novel therapeutic targets that will lead to better patient outcomes.	[Li, Weilin; Ng, Enders Kwok Wai] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; [Li, Weilin; Ng, Jennifer Mun-Kar; Wong, Chi Chun; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong	Ng, EKW (corresponding author), Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China.	endersng@surgery.cuhk.edu.hk; junyu@cuhk.edu.hk	Li, Weilin/ABG-9032-2021; Wong, Chi Chun/C-4636-2016; Yu, Jun/D-8569-2015; Ng, Enders Kwok-wai/E-8276-2016	Yu, Jun/0000-0001-5008-2153; Ng, Enders Kwok-wai/0000-0001-7219-5810	RGC/GRF Hong Kong [14114615, 14101917, 14111216, 14106145]; National Natural Science Foundation of China (NSFC) [81772501, 81502064]; HMRF Hong Kong [03140856]; Vice-Chancellor's Discretionary Fund CUHK; Shenzhen Virtual University Park Support Scheme; CUHK direct grant	RGC/GRF Hong Kong(Hong Kong Research Grants Council); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); HMRF Hong Kong; Vice-Chancellor's Discretionary Fund CUHK; Shenzhen Virtual University Park Support Scheme; CUHK direct grant(Chinese University of Hong Kong)	This project was supported by research funds from RGC/GRF Hong Kong (14114615, 14101917, 14111216, 14106145); National Natural Science Foundation of China (NSFC) (81772501, 81502064); HMRF Hong Kong (03140856); Vice-Chancellor's Discretionary Fund CUHK; Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute; CUHK direct grant.	Abe A, 2017, GASTRIC CANCER, V20, P92, DOI 10.1007/s10120-015-0584-y; Achen MG, 2005, CANCER CELL, V7, P121, DOI 10.1016/j.ccr.2005.01.017; Aihara R, 2005, BRIT J SURG, V92, P454, DOI 10.1002/bjs.4868; Al-Batran SE, 2012, ANN ONCOL, V23, P1699, DOI 10.1093/annonc/mdr552; Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480; Arigami T, 2009, INT J ONCOL, V35, P19, DOI 10.3892/ijo_00000308; Arita T, 2016, ONCOTARGET, V7, P56855, DOI 10.18632/oncotarget.10869; Baba K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11769-x; Bae IH, 2006, CANCER RES, V66, P4991, DOI 10.1158/0008-5472.CAN-05-4254; Bebb JR, 2003, GUT, V52, P1408, DOI 10.1136/gut.52.10.1408; Berger L, 2016, STEM CELLS, V34, P1011, DOI 10.1002/stem.2269; Bie QL, 2017, ONCOTARGET, V8, P18914, DOI 10.18632/oncotarget.14835; Boulay A, 2001, CANCER RES, V61, P2189; Busuttil RA, 2014, CLIN CANCER RES, V20, P2761, DOI 10.1158/1078-0432.CCR-13-3049; Calcagno DQ, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-141; Camerer E, 2004, BLOOD, V104, P397, DOI 10.1182/blood-2004-02-0434; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chang Q, 2015, ONCOTARGET, V6, P42838, DOI 10.18632/oncotarget.5814; Chen DH, 2018, J CELL MOL MED, V22, P797, DOI 10.1111/jcmm.13357; Chen FZ, 2013, ONCOL REP, V30, P2705, DOI 10.3892/or.2013.2704; Chen JT, 2015, INT J CLIN EXP PATHO, V8, P10922; Chen YS, 2014, CARCINOGENESIS, V35, P442, DOI 10.1093/carcin/bgt311; Chen Y, 2011, INT J CANCER, V129, P1586, DOI 10.1002/ijc.25831; Cho HJ, 2014, INT J CANCER, V135, P1553, DOI 10.1002/ijc.28801; Cho HJ, 2014, ONCOTARGET, V5, P1554, DOI 10.18632/oncotarget.1733; Cho HJ, 2009, CLIN CANCER RES, V15, P2612, DOI 10.1158/1078-0432.CCR-08-2192; Cho SJ, 2015, INT J CANCER, V136, P810, DOI 10.1002/ijc.29056; Chu DK, 2011, INT J CANCER, V129, P887, DOI 10.1002/ijc.25734; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cui YH, 2016, ONCOTARGET, V7, P34356, DOI 10.18632/oncotarget.8879; Deng G, 2017, FEBS LETT, V591, P2167, DOI 10.1002/1873-3468.12722; Deng JH, 2012, CANCER CELL, V21, P642, DOI 10.1016/j.ccr.2012.03.039; Deng J, 2016, ONCOTARGET, V7, P10037, DOI 10.18632/oncotarget.7048; Dong WJ, 2016, INT J CANCER, V138, P1680, DOI 10.1002/ijc.29899; Dong YC, 2015, GENE, V563, P29, DOI 10.1016/j.gene.2015.03.003; Du C, 2010, CANCER RES, V70, P7810, DOI 10.1158/0008-5472.CAN-09-4481; Duan JJ, 2016, ONCOTARGET, V7, P44522, DOI 10.18632/oncotarget.9936; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Eto K, 2015, INT J CANCER, V136, P1537, DOI 10.1002/ijc.29168; Ferlay J, 2015, INT J CANCER, V136, P86; Ferro A, 2014, EUR J CANCER, V50, P1330, DOI 10.1016/j.ejca.2014.01.029; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Fong MY, 2015, NAT CELL BIOL, V17, P183, DOI 10.1038/ncb3094; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Fukushima M, 2012, NEUROL MED-CHIR, V52, P751, DOI 10.2176/nmc.52.751; Galaup A, 2006, P NATL ACAD SCI USA, V103, P18721, DOI 10.1073/pnas.0609025103; Gan L, 2018, ONCOGENE, V37, P744, DOI 10.1038/onc.2017.363; Ge XX, 2016, ONCOTARGET, V7, P24466, DOI 10.18632/oncotarget.8228; Ghilardi G, 2001, CLIN CANCER RES, V7, P2344; Gong JH, 2015, TUMOR BIOL, V36, P7831, DOI 10.1007/s13277-015-3510-3; Guo B, 2014, MOL CANCER RES, V12, P313, DOI 10.1158/1541-7786.MCR-13-0507; Guo WW, 2016, CARCINOGENESIS, V37, P397, DOI 10.1093/carcin/bgw013; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Han FJ, 2016, ONCOTARGET, V7, P38626, DOI 10.18632/oncotarget.9573; Han JY, 2014, INT J ONCOL, V45, P291, DOI 10.3892/ijo.2014.2401; Hayakawa Y, 2015, CANCER CELL, V28, P800, DOI 10.1016/j.ccell.2015.10.003; He BY, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.253; He CY, 2017, ONCOTARGET, V8, P46818, DOI 10.18632/oncotarget.17473; Honda M, 1996, GUT, V39, P444, DOI 10.1136/gut.39.3.444; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Hou FT, 2012, MED ONCOL, V29, P2691, DOI 10.1007/s12032-011-0127-2; Hou JJ, 2016, CANCER LETT, V376, P22, DOI 10.1016/j.canlet.2016.02.015; Hsu KW, 2014, CARCINOGENESIS, V35, P208, DOI 10.1093/carcin/bgt285; Huang J, 2014, ONCOGENE, V33, P2737, DOI 10.1038/onc.2013.238; Huang J, 2015, ONCOTARGET, V6, P1652, DOI 10.18632/oncotarget.2936; Huang N, 2015, ONCOTARGET, V6, P15222, DOI 10.18632/oncotarget.3835; Huang TT, 2015, ONCOTARGET, V6, P18012, DOI 10.18632/oncotarget.4000; Iida T, 2014, ONCOL REP, V31, P605, DOI 10.3892/or.2013.2911; Iwasa S, 2009, ANTICANCER RES, V29, P4751; Jia BQ, 2012, TUMOR BIOL, V33, P919, DOI 10.1007/s13277-012-0317-3; Jiang YX, 2017, ONCOGENE, V36, P1256, DOI 10.1038/onc.2016.291; Jung H, 2008, ONCOGENE, V27, P2635, DOI 10.1038/sj.onc.1210914; Kabashima A, 2000, CLIN CANCER RES, V6, P3581; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Karaman S, 2014, J CLIN INVEST, V124, P922, DOI 10.1172/JCI71606; Karpanen T, 2008, ANNU REV PATHOL-MECH, V3, P367, DOI 10.1146/annurev.pathol.3.121806.151515; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim HP, 2014, ONCOGENE, V33, P3334, DOI 10.1038/onc.2013.285; Kim HK, 2003, EUR J CANCER, V39, P184, DOI 10.1016/S0959-8049(02)00596-8; Koh YJ, 2010, CANCER CELL, V18, P171, DOI 10.1016/j.ccr.2010.07.001; Kou YB, 2013, INT J IMMUNOPATH PH, V26, P361, DOI 10.1177/039463201302600209; Kubben FJGM, 2007, EUR J CANCER, V43, P1869, DOI 10.1016/j.ejca.2007.05.013; Kung JTY, 2013, GENETICS, V193, P651, DOI 10.1534/genetics.112.146704; Kurashige J, 2015, CARCINOGENESIS, V36, P133, DOI 10.1093/carcin/bgu232; Kurashige J, 2012, ANN SURG ONCOL, V19, pS656, DOI 10.1245/s10434-012-2217-6; Labelle M, 2011, CANCER CELL, V20, P576, DOI 10.1016/j.ccr.2011.09.009; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee SH, 2015, ONCOTARGET, V6, P33269, DOI 10.18632/oncotarget.5037; Lei C, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.493; Li HM, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-136; Li H, 2016, CANCER LETT, V370, P39, DOI 10.1016/j.canlet.2015.10.006; Li J, 2015, ONCOTARGET, V6, P8323, DOI 10.18632/oncotarget.3200; Li JH, 2012, J CANCER RES CLIN, V138, P763, DOI 10.1007/s00432-012-1154-x; Li JJ, 2017, FASEB J, V31, P3774, DOI 10.1096/fj.201601140RR; Li MR, 2017, BMC GASTROENTEROL, V17, DOI 10.1186/s12876-017-0616-7; Li P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066782; Li RX, 2014, MOL CELL BIOCHEM, V396, P295, DOI 10.1007/s11010-014-2164-6; Li WJ, 2011, BIOCHEM BIOPH RES CO, V416, P372, DOI 10.1016/j.bbrc.2011.11.045; Lian DN, 2018, CANCER BIOMARK, V21, P151, DOI 10.3233/CBM-170462; Lian L, 2015, CANCER BIOMARK, V15, P899, DOI 10.3233/CBM-150534; Liang XM, 2015, ONCOTARGET, V6, P17661, DOI 10.18632/oncotarget.3756; Lin BR, 2007, MOL CANCER RES, V5, P1111, DOI 10.1158/1541-7786.MCR-06-0289; Ling ZQ, 2014, ANN ONCOL, V25, P1363, DOI 10.1093/annonc/mdu168; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; Liotta LA, 2004, NATURE, V430, P973, DOI 10.1038/430973a; Liu F, 2018, CANCER SCI, V109, P65, DOI 10.1111/cas.13429; Liu JK, 2017, INT J ONCOL, V50, P356, DOI 10.3892/ijo.2016.3807; Liu XY, 2015, ONCOTARGET, V6, P25418, DOI 10.18632/oncotarget.4456; Liu YW, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.150; Liu ZF, 2014, J CELL MOL MED, V18, P610, DOI 10.1111/jcmm.12209; Lowy AM, 2006, CANCER RES, V66, P4734, DOI 10.1158/0008-5472.CAN-05-4268; Ma HY, 2015, ONCOTARGET, V6, P24348, DOI 10.18632/oncotarget.4484; Maehara Y, 2000, SURGERY, V128, P408, DOI 10.1067/msy.2000.107265; Malladi S, 2016, CELL, V165, P45, DOI 10.1016/j.cell.2016.02.025; Marchet A, 2007, ANN SURG, V245, P543, DOI 10.1097/01.sla.0000250423.43436.e1; Mariotti S, 2016, ONCOTARGET, V7, P1808, DOI 10.18632/oncotarget.6577; Martinho O, 2013, ONCOL REP, V29, P690, DOI 10.3892/or.2012.2179; Mashino K, 2002, CANCER RES, V62, P2937; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Mi YS, 2017, CANCER LETT, V389, P11, DOI 10.1016/j.canlet.2016.12.033; Mikami J, 2016, GASTRIC CANCER, V19, P817, DOI 10.1007/s10120-015-0556-2; Mochizuki Y, 2004, CLIN EXP METASTAS, V21, P39, DOI 10.1023/B:CLIN.0000017181.01474.35; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Mura G, 2016, J CANC METASTASIS TR, V2, P365, DOI DOI 10.20517/2394-4722.2016.19; Nakayama T, 2011, ONCOL REP, V25, P929, DOI 10.3892/or.2011.1176; Nieswandt B, 1999, CANCER RES, V59, P1295; Nishimura S, 2001, CANCER RES, V61, P7009; Noh HS, 2016, ONCOTARGET, V7, P4632, DOI 10.18632/oncotarget.6728; Ock CY, 2017, GASTRIC CANCER, V20, P254, DOI 10.1007/s10120-016-0613-5; Olmeda D, 2017, NATURE, V546, P676, DOI 10.1038/nature22977; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Palumbo JS, 2005, BLOOD, V105, P178, DOI 10.1182/blood-2004-06-2272; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; Peng Y, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.225; Peng ZH, 2006, CLIN CANCER RES, V12, P6386, DOI 10.1158/1078-0432.CCR-05-2359; Peruzzi D, 2009, CLIN CANCER RES, V15, P4104, DOI 10.1158/1078-0432.CCR-08-3226; Poola I, 2005, NAT MED, V11, P481, DOI 10.1038/nm1243; Qi M, 2018, ONCOGENE, V37, P1075, DOI 10.1038/onc.2017.380; Qiao JL, 2016, ONCOTARGET, V7, P46088, DOI 10.18632/oncotarget.10024; Qiao SS, 2015, BIOCHEM J, V469, P469, DOI 10.1042/BJ20150253; Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020; Ren G, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-67; Ren YH, 2014, ONCOTARGET, V5, P7093, DOI 10.18632/oncotarget.2197; Riihimaki M, 2016, ONCOTARGET, V7, P52307, DOI 10.18632/oncotarget.10740; Rothwell PM, 2012, LANCET, V379, P1591, DOI 10.1016/S0140-6736(12)60209-8; Ruivo CF, 2017, CANCER RES, V77, P6480, DOI 10.1158/0008-5472.CAN-17-0994; Sadeghi B, 2000, CANCER-AM CANCER SOC, V88, P358, DOI 10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.3.CO;2-F; Sakimura S, 2015, ANN SURG ONCOL, V22, pS1436, DOI 10.1245/s10434-015-4418-2; Scheel C, 2007, CANCER RES, V67, P11476, DOI 10.1158/0008-5472.CAN-07-1653; Schumacher D, 2014, PURINERG SIGNAL, V10, P730; Sentani K, 2014, GASTRIC CANCER, V17, P412, DOI 10.1007/s10120-013-0302-6; Sha SM, 2013, DIGEST LIVER DIS, V45, P422, DOI 10.1016/j.dld.2012.12.004; Shi M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-269; Shi ZD, 2013, CANCER RES, V73, P5519, DOI 10.1158/0008-5472.CAN-13-0280; Shibata W, 2013, GUT, V62, P192, DOI 10.1136/gutjnl-2011-301824; Song GY, 2017, ONCOTARGET, V8, P45725, DOI 10.18632/oncotarget.17392; Sood AK, 2006, CLIN CANCER RES, V12, P369, DOI 10.1158/1078-0432.CCR-05-1698; Speak AO, 2017, NAT PROTOC, V12, P2465, DOI 10.1038/nprot.2017.118; Stanger BZ, 2013, CANCER CELL, V24, P9, DOI 10.1016/j.ccr.2013.06.009; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Sun TT, 2016, CANCER DISCOV, V6, P784, DOI 10.1158/2159-8290.CD-15-0921; Sun YT, 2015, TRENDS PHARMACOL SCI, V36, P349, DOI 10.1016/j.tips.2015.04.001; Tammela T, 2010, CELL, V140, P460, DOI 10.1016/j.cell.2010.01.045; Tang B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074527; Tang Y, 2008, CLIN CANCER RES, V14, P2870, DOI 10.1158/1078-0432.CCR-07-4042; Taniguchi S, 2001, CANCER RES, V61, P7627; Tao YM, 2017, ONCOTARGET, V8, P88870, DOI 10.18632/oncotarget.21488; Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsai CY, 2014, CLIN CANCER RES, V20, P2276, DOI 10.1158/1078-0432.CCR-13-1221; Turajlic S, 2016, SCIENCE, V352, P169, DOI 10.1126/science.aaf2784; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; van der Weyden L, 2017, NATURE, V541, P233, DOI 10.1038/nature20792; Wang HQ, 2017, ENDOCR-RELAT CANCER, V24, P565, DOI 10.1530/ERC-17-0058; Wang Jian-Jun, 2015, Asian Pac J Cancer Prev, V16, P4203; Wang L, 2015, ONCOTARGET, V6, P11492, DOI 10.18632/oncotarget.3416; Wang YD, 2007, WORLD J GASTROENTERO, V13, P6269, DOI 10.3748/wjg.13.6269; Watanabe M, 2014, J GASTROINTEST SURG, V18, P481, DOI 10.1007/s11605-013-2407-y; Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537; Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987; Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909; Wu CY, 2007, EUR J CANCER, V43, P799, DOI 10.1016/j.ejca.2006.10.022; Wu CY, 2007, CLIN CANCER RES, V13, P2054, DOI 10.1158/1078-0432.CCR-06-2299; Wu JY, 2006, CANCER RES, V66, P5111, DOI 10.1158/0008-5472.CAN-06-0383; Wu LJ, 2014, INT J CLIN EXP PATHO, V7, P1140; Wu LJ, 2016, TUMOR BIOL, V37, P12169, DOI 10.1007/s13277-016-5071-5; Wu SM, 2016, J PINEAL RES, V60, P142, DOI 10.1111/jpi.12295; Wu WD, 2015, CELL PHYSIOL BIOCHEM, V35, P1764, DOI 10.1159/000373988; Wu XY, 2017, ONCOTARGET, V8, P20741, DOI 10.18632/oncotarget.15119; Xia JL, 2016, CANCER LETT, V381, P31, DOI 10.1016/j.canlet.2016.07.014; Xiang XJ, 2015, CELL PHYSIOL BIOCHEM, V36, P1382, DOI 10.1159/000430304; Xu L, 2017, CANCER LETT, V393, P76, DOI 10.1016/j.canlet.2017.02.014; Xu SH, 2017, ONCOTARGET, V8, P12705, DOI 10.18632/oncotarget.6194; Xu SH, 2015, J PATHOL, V236, P175, DOI 10.1002/path.4515; Yan HB, 2014, CARCINOGENESIS, V35, P867, DOI 10.1093/carcin/bgt398; Yan L, 2017, TUMOR BIOL, V39; Yanaka Y, 2015, CARCINOGENESIS, V36, P1363, DOI 10.1093/carcin/bgv106; Yang B, 2014, CLIN TRANSL ONCOL, V16, P374, DOI 10.1007/s12094-013-1081-6; Yang EV, 2006, CANCER RES, V66, P10357, DOI 10.1158/0008-5472.CAN-06-2496; Yang L, 2017, ONCOTARGET, V8, P68180, DOI 10.18632/oncotarget.19254; Yang SW, 2017, ONCOTARGET, V8, P9535, DOI 10.18632/oncotarget.14484; Yang T, 2016, ONCOTARGET, V7, P18085, DOI 10.18632/oncotarget.7634; Yang Y, 2017, ONCOTARGET, V8, P8057, DOI 10.18632/oncotarget.14074; Yang YH, 2008, CLIN CANCER RES, V14, P74, DOI 10.1158/1078-0432.CCR-07-1179; Ye JX, 2017, MOL ONCOL, V11, P1208, DOI 10.1002/1878-0261.12089; Yi J, 2008, NEOPLASIA, V10, P41, DOI 10.1593/neo.07754; Yokobori T, 2009, CANCER RES, V69, P3788, DOI 10.1158/0008-5472.CAN-08-2846; Yonemura Y, 2001, CLIN CANCER RES, V7, P1647; Yoo YA, 2011, CANCER RES, V71, P7061, DOI 10.1158/0008-5472.CAN-11-1338; Yu S, 2016, ONCOTARGET, V7, P34773, DOI 10.18632/oncotarget.8977; Yu WW, 2017, ONCOTARGET, V8, P39280, DOI 10.18632/oncotarget.16849; Yuan WQ, 2016, ONCOTARGET, V7, P29507, DOI 10.18632/oncotarget.8789; Zarrabi K, 2011, J BIOL CHEM, V286, P33167, DOI 10.1074/jbc.M111.256644; Zhang BG, 2014, ONCOTARGET, V5, P10584, DOI 10.18632/oncotarget.2513; Zhang HY, 2018, CANCER SCI, V109, P629, DOI 10.1111/cas.13488; Zhang HY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15016; Zhang H, 2018, ANN SURG, V267, P311, DOI 10.1097/SLA.0000000000002058; Zhang JP, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0467-9; Zhang L, 2014, ONCOGENE, V33, P5491, DOI 10.1038/onc.2013.495; Zhang YJ, 2015, ONCOTARGET, V6, P7244, DOI 10.18632/oncotarget.3133; Zhao L, 2018, CELL BIOL INT, V42, P294, DOI 10.1002/cbin.10894; Zhao L, 2013, CLIN CANCER RES, V19, P6419, DOI 10.1158/1078-0432.CCR-13-0254; Zhao X, 2014, CELL DEATH DIFFER, V21, P1900, DOI 10.1038/cdd.2014.109; Zhao X, 2013, ONCOGENE, V32, P1363, DOI 10.1038/onc.2012.156; Zhao ZS, 2010, CLIN CANCER RES, V16, P260, DOI 10.1158/1078-0432.CCR-09-1247; Zheng HC, 2006, ANTICANCER RES, V26, P3579; Zhong HJ, 2011, INT J HYPERTHER, V27, P604, DOI 10.3109/02656736.2011.564598; Zhong J, 2016, WORLD J GASTROENTERO, V22, P2434, DOI 10.3748/wjg.v22.i8.2434; Zhou Q, 2017, ONCOGENE, V36, P1873, DOI 10.1038/onc.2016.352; Zhou Q, 2016, CELL PHYSIOL BIOCHEM, V39, P453, DOI 10.1159/000445638; Zhou XY, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0145-6; Zhu HY, 2015, INT J MOL MED, V35, P798, DOI 10.3892/ijmm.2015.2069; Zhu Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.263; Zuo QF, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.297	241	37	38	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2018	37	36					4903	4920		10.1038/s41388-018-0341-x	http://dx.doi.org/10.1038/s41388-018-0341-x			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS6QR	29795331	hybrid, Green Published			2022-12-17	WOS:000443823600001
J	Guarnieri, AL; Towers, CG; Drasin, DJ; Oliphant, MUJ; Andrysik, Z; Hotz, TJ; Vartuli, RL; Linklater, ES; Pandey, A; Khanal, S; Espinosa, JM; Ford, HL				Guarnieri, A. L.; Towers, C. G.; Drasin, D. J.; Oliphant, M. U. J.; Andrysik, Z.; Hotz, T. J.; Vartuli, R. L.; Linklater, E. S.; Pandey, A.; Khanal, S.; Espinosa, J. M.; Ford, H. L.			The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L	ONCOGENE			English	Article							CANCER STEM-CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; DOWN-REGULATION; GASTRIC-CANCER; HEPATOCELLULAR-CARCINOMA; THERAPEUTIC IMPLICATIONS; SIGNALING PATHWAY; MICRORNA CLUSTER; LUNG-CANCER; IN-VITRO	Tumor-initiating cells (TIC) represent a subset of tumor cells with increased self-renewal capability. TICs display resistance to frontline cancer treatment and retain the ability to repopulate a tumor after therapy, leading to cancer relapse. NOTCH signaling has been identified as an important driver of the TIC population, yet mechanisms governing regulation of this pathway in cancer remain to be fully elucidated. Here we identify a novel mechanism of NOTCH regulation and TIC induction in breast cancer via the miR-106b-25 miRNA cluster. We show that the miR-106b-25 cluster upregulates NOTCH1 in multiple breast cancer cell lines, representing both estrogen receptor (ER+) and triple negative breast cancer (TNBC) through direct repression of the E3 ubiquitin ligase, NEDD4L. We further show that upregulation of NOTCH1 is necessary for TIC induction downstream of miR-106b-25 in both ER + and TNBC breast cancer cells, and that re-expression of NEDD4L is sufficient to reverse miR106b-25-mediated NOTCH1 upregulation and TIC induction. Importantly, we demonstrate a significant positive correlation between miR-106b-25 and NOTCH1 protein, yet a significant inverse correlation between miR-106b-25 and NEDD4L mRNA in human breast cancer, suggesting a critical role for the miR106b-25/NEDD4L/ NOTCH1 axis in the disease. Further, we show for the first time that NEDD4L expression alone is significantly associated with a better relapse-free prognosis for breast cancer patients. These data expand our knowledge of the mechanisms underlying NOTCH activation and TIC induction in breast cancer, and may provide new avenues for the development of therapies targeting this resistant subset of tumor cells.	[Guarnieri, A. L.; Towers, C. G.; Drasin, D. J.; Vartuli, R. L.; Linklater, E. S.; Ford, H. L.] Univ Colorado, Program Mol Biol, Anschutz Med Campus, Aurora, CO 80045 USA; [Guarnieri, A. L.; Towers, C. G.; Oliphant, M. U. J.; Andrysik, Z.; Hotz, T. J.; Vartuli, R. L.; Pandey, A.; Khanal, S.; Espinosa, J. M.; Ford, H. L.] Univ Colorado, Dept Pharmacol, Anschutz Med Campus, Aurora, CO 80045 USA; [Oliphant, M. U. J.; Ford, H. L.] Univ Colorado, Integrated Physiol Program, Anschutz Med Campus, Aurora, CO 80045 USA; [Andrysik, Z.; Espinosa, J. M.] Univ Colorado, Linda Crnic Inst Syndrome, Anschutz Med Campus, Aurora, CO 80045 USA; [Espinosa, J. M.] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Boulder	Ford, HL (corresponding author), Univ Colorado, Program Mol Biol, Anschutz Med Campus, Aurora, CO 80045 USA.; Ford, HL (corresponding author), Univ Colorado, Dept Pharmacol, Anschutz Med Campus, Aurora, CO 80045 USA.; Ford, HL (corresponding author), Univ Colorado, Integrated Physiol Program, Anschutz Med Campus, Aurora, CO 80045 USA.	Heide.Ford@ucdenver.edu			METAvivor Foundation; Department of Defense Breast Cancer Research Program [W81XWH-10-1-0296]; Ruth L. Kirschstein National Service Research Award (F32) [1F32CA199716-01]; Ruth L. Kirschstein National Service Research Award (F31) [5F31CA210622-02]; NCI [F99 CA223023]; NIH-RO1 Diversity Supplement [R01-CA157790]; UNCF/MERCK Graduate Fellowship; T32 Cancer Biology training grant [CA190216-1 A1]; UC Denver AMC Molecular Biology Program T32 training grant [T32 GM008730];  [R01CA095277];  [R01CA117907]; NATIONAL CANCER INSTITUTE [F31CA210622, F99CA223023, R01CA157790, R01CA095277, R01CA117907, T32CA190216, F32CA199716, P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008730] Funding Source: NIH RePORTER	METAvivor Foundation; Department of Defense Breast Cancer Research Program(United States Department of Defense); Ruth L. Kirschstein National Service Research Award (F32); Ruth L. Kirschstein National Service Research Award (F31); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH-RO1 Diversity Supplement; UNCF/MERCK Graduate Fellowship; T32 Cancer Biology training grant; UC Denver AMC Molecular Biology Program T32 training grant; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Paul Jedlicka for the generous gift of mice for limiting dilution experiments. We also want to thank the University of Colorado Cancer center flow cytometry shared resource for performing flow cytometry experiments needed for this work (P30CA046934), the Functional Genomics Facility for shRNA constructs, and The Cancer Genome Atlas (TCGA) for use of their breast cancer patient data set. This work was supported by R01CA095277 (HLF), R01CA117907 (JME), the METAvivor Foundation (HLF), the Department of Defense Breast Cancer Research Program W81XWH-10-1-0296 (ALG), the Ruth L. Kirschstein National Service Research Award (F32) 1F32CA199716-01 (ALG), the Ruth L. Kirschstein National Service Research Award (F31) 5F31CA210622-02 (MUJO), the NCI fellow transition award F99 CA223023 (MUJO), UC Denver AMC Molecular Biology Program T32 training grant T32 GM008730 (CGT), NIH-RO1 Diversity Supplement to R01-CA157790 (CGT), the UNCF/MERCK Graduate Fellowship (CGT), and the T32 Cancer Biology training grant CA190216-1 A1 (CGT).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Pires BRB, 2016, ANTICANCER RES, V36, P5681, DOI 10.21873/anticanres.11151; Brett JO, 2011, AGING-US, V3, P108, DOI 10.18632/aging.100285; Brooks MD, 2015, CELL STEM CELL, V17, P260, DOI 10.1016/j.stem.2015.08.014; Capaccione KM, 2013, CARCINOGENESIS, V34, P1420, DOI 10.1093/carcin/bgt127; Chastagner P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002735; Chen S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165776; Choi N, 2015, ONCOTARGET, V6, P23533, DOI 10.18632/oncotarget.4372; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Espinoza I, 2013, CANCER LETT, V341, P41, DOI 10.1016/j.canlet.2013.08.027; Espinoza I, 2013, PHARMACOL THERAPEUT, V139, P95, DOI 10.1016/j.pharmthera.2013.02.003; Farabaugh SM, 2012, ONCOGENE, V31, P552, DOI 10.1038/onc.2011.259; Gao S, 2009, MOL CELL, V36, P457, DOI 10.1016/j.molcel.2009.09.043; Geling A, 2002, EMBO REP, V3, P688, DOI 10.1093/embo-reports/kvf124; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Goel P, 2015, GENE, V557, P1, DOI 10.1016/j.gene.2014.11.051; Gong C, 2015, ONCOGENE, V34, P84, DOI 10.1038/onc.2013.525; Gravgaard KH, 2012, BREAST CANCER RES TR, V134, P207, DOI 10.1007/s10549-012-1969-9; Guo SC, 2011, BBA-REV CANCER, V1815, P197, DOI 10.1016/j.bbcan.2010.12.002; Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302; Hu CY, 2006, AM J PATHOL, V168, P973, DOI 10.2353/ajpath.2006.050416; Kan T, 2009, GASTROENTEROLOGY, V136, P1689, DOI 10.1053/j.gastro.2009.02.002; Koch U, 2013, DEVELOPMENT, V140, P689, DOI 10.1242/dev.080614; Kolch W, 2015, NAT REV CANCER, V15, P515, DOI 10.1038/nrc3983; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Li C, 2015, THORAC CANCER, V6, P524, DOI 10.1111/1759-7714.12242; Li Y, 2009, CANCER SCI, V100, P1234, DOI 10.1111/j.1349-7006.2009.01164.x; Liu S, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002537; Liu YL, 2016, SCI REP-UK, V6, DOI 10.1038/srep28329; Lo Sardo F, 2017, CARCINOGENESIS, V38, P64, DOI 10.1093/carcin/bgw110; Mazaleyrat SL, 2003, DEV BIOL, V255, P363, DOI 10.1016/S0012-1606(02)00086-6; Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815; Ni XJ, 2014, CANCER SCI, V105, P18, DOI 10.1111/cas.12309; Ntziachristos P, 2014, CANCER CELL, V25, P318, DOI 10.1016/j.ccr.2014.02.018; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Poliseno L, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000594; Pursglove SE, 2005, INT J BIOCHEM CELL B, V37, P2472, DOI 10.1016/j.biocel.2005.06.013; Qian S, 2008, BIOCHEM BIOPH RES CO, V377, P668, DOI 10.1016/j.bbrc.2008.10.052; Qu MH, 2016, TUMOR BIOL, V37, P5645, DOI 10.1007/s13277-015-4328-8; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sakata T, 2004, CURR BIOL, V14, P2228, DOI 10.1016/j.cub.2004.12.028; Sansone P, 2007, STEM CELLS, V25, P807, DOI 10.1634/stemcells.2006-0442; Schrijver WAME, 2017, ONCOTARGET, V8, P3111, DOI 10.18632/oncotarget.13623; Shyamasundar S, 2016, INT J ONCOL, V49, P2629, DOI 10.3892/ijo.2016.3761; Smith AL, 2012, ONCOGENE, V31, P5162, DOI 10.1038/onc.2012.11; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Wang ZW, 2009, CANCER LETT, V279, P8, DOI 10.1016/j.canlet.2008.09.030; Xu X, 2016, SCI REP-UK, V6, DOI 10.1038/srep31267; Yang F, 2017, CELL MOL LIFE SCI, V74, P951, DOI 10.1007/s00018-016-2334-7; Yau WL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057882; Yen CS, 2016, WORLD J GASTROENTERO, V22, P5183, DOI 10.3748/wjg.v22.i22.5183; Yu D, 2014, LAB INVEST, V94, P1370, DOI 10.1038/labinvest.2014.125; Zhang RP, 2016, TUMOR BIOL, V37, P10507, DOI 10.1007/s13277-016-4937-x	53	37	38	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2018	37	28					3879	3893		10.1038/s41388-018-0239-7	http://dx.doi.org/10.1038/s41388-018-0239-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM8HR	29662198	Green Accepted			2022-12-17	WOS:000438465600009
J	Araiza-Olivera, D; Feng, Y; Semenova, G; Prudnikova, TY; Rhodes, J; Chernoff, J				Araiza-Olivera, D.; Feng, Y.; Semenova, G.; Prudnikova, T. Y.; Rhodes, J.; Chernoff, J.			Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors	ONCOGENE			English	Article							ZEBRAFISH; MUTATIONS; RAC1; GTPASE; RAS; P21-ACTIVATED-KINASE-1; PROGRESSION	Activating mutations in the RAC1 gene have recently been discovered as driver events in malignant melanoma. Expression of this gene is associated with melanocyte proliferation, and melanoma cells bearing this mutation are insensitive to BRAF inhibitors such as vemurafenib and dabrafenib, and also may evade immune surveillance due to enhanced expression of PD-L1. Activating mutations in RAC1 are of special interest, as small-molecule inhibitors for the RAC effector p21-activated kinase (PAK) are in late-stage clinical development and might impede oncogenic signaling from mutant RAC1. In this work, we explore the effects of PAK inhibition on RAC1(P29S) signaling in zebrafish embryonic development, in the proliferation, survival and motility of RAC1(P29S)-mutant human melanoma cells, and on tumor formation and progression from such cells in mice. We report that RAC1(P29S) evokes a Rasopathy-like phenotype on zebrafish development that can be blocked by inhibitors of PAK or MEK. We also found and that RAC1-mutant human melanoma cells are resistant to clinical inhibitors of BRAF but are uniquely sensitive to PAK inhibitors. These data suggest that suppressing the PAK pathway might be of therapeutic benefit in this type of melanoma.	[Araiza-Olivera, D.; Feng, Y.; Semenova, G.; Prudnikova, T. Y.; Chernoff, J.] Fox Chase Canc Ctr, Canc Biol Program, 333 Cottman Ave W451, Philadelphia, PA 19111 USA; [Semenova, G.] Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow, Russia; [Rhodes, J.] Fox Chase Canc Ctr, Blood Cell Dev Funct Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Araiza-Olivera, D.] Univ Nacl Autonoma Mexico, Inst Quim, Mexico City, DF, Mexico	Fox Chase Cancer Center; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Fox Chase Cancer Center; Universidad Nacional Autonoma de Mexico	Chernoff, J (corresponding author), Fox Chase Canc Ctr, Canc Biol Program, 333 Cottman Ave W451, Philadelphia, PA 19111 USA.	Jonathan.Chernoff@fccc.edu	Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NIH CORE Grant [P30CA006927];  [R01CA227184]; NATIONAL CANCER INSTITUTE [R01CA142928, P30CA006927] Funding Source: NIH RePORTER	NIH CORE Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Ruth Halaban and Meenhard Herlyn for providing melanoma cell lines, and Dr Rebecca Burdine for Tg(cmlc2:EGFP) zebrafish, Genentech for providing Frax-1036 and the Fox Chase Cancer Center Animal Facility for assistance with zebrafish experiments. This work was supported by R01CA227184 (JC), NIH CORE Grant P30CA006927, and an appropriation from the state of Pennsylvania to the Fox Chase Cancer Center.	Anastasaki C, 2012, DIS MODEL MECH, V5, P546, DOI 10.1242/dmm.008672; Anastasaki C, 2009, HUM MOL GENET, V18, P2543, DOI 10.1093/hmg/ddp186; Chow HY, 2012, CANCER RES, V72, P5966, DOI 10.1158/0008-5472.CAN-12-2246; Davis MJ, 2013, P NATL ACAD SCI USA, V110, P912, DOI 10.1073/pnas.1220895110; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Fritsch R, 2013, CELL, V153, P1050, DOI 10.1016/j.cell.2013.04.031; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Grzmil M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000959; Vu HL, 2015, PIGM CELL MELANOMA R, V28, P590, DOI 10.1111/pcmr.12392; Halaban R, 2016, J INVEST DERMATOL, V136, P1755, DOI 10.1016/j.jid.2016.05.095; Halaban R, 2015, CLIN THER, V37, P682, DOI 10.1016/j.clinthera.2014.10.027; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Jindal GA, 2015, DIS MODEL MECH, V8, P769, DOI 10.1242/dmm.020339; Kawazu M, 2013, P NATL ACAD SCI USA, V110, P3029, DOI 10.1073/pnas.1216141110; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Li A, 2011, DEV CELL, V21, P722, DOI 10.1016/j.devcel.2011.07.008; Lightcap CM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006025; Limame R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046536; Lindsay CR, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1560; Link V, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-1; Ong CC, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0564-5; Ong CC, 2013, JNCI-J NATL CANCER I, V105, P606, DOI 10.1093/jnci/djt054; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645; Rhodes J, 2009, MOL CELL BIOL, V29, P5911, DOI 10.1128/MCB.00558-09; Semenova G, 2017, BIOCHEM SOC T, V45, P79, DOI 10.1042/BST20160134; Shin JT, 2005, NUCLEIC ACIDS RES, V33, P5437, DOI 10.1093/nar/gki853; Watson IR, 2014, CANCER RES, V74, P4845, DOI 10.1158/0008-5472.CAN-14-1232-T	30	37	37	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					944	952		10.1038/onc.2017.400	http://dx.doi.org/10.1038/onc.2017.400			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059171	Green Accepted			2022-12-17	WOS:000425281800011
J	Sodi, VL; Bacigalupa, ZA; Ferrer, CM; Lee, JV; Gocal, WA; Mukhopadhyay, D; Wellen, KE; Ivan, M; Reginato, MJ				Sodi, V. L.; Bacigalupa, Z. A.; Ferrer, C. M.; Lee, J. V.; Gocal, W. A.; Mukhopadhyay, D.; Wellen, K. E.; Ivan, M.; Reginato, M. J.			Nutrient sensor O-GlcNAc transferase controls cancer lipid metabolism via SREBP-1 regulation	ONCOGENE			English	Article							BETA-N-ACETYLGLUCOSAMINE; C-MYC; PROSTATE-CANCER; BREAST-CANCER; TRANSCRIPTION FACTORS; GLCNACYLATION; CELLS; AMPK; LIPOGENESIS; METASTASIS	Elevated O-GlcNAcylation is associated with disease states such as diabetes and cancer. O-GlcNAc transferase (OGT) is elevated in multiple cancers and inhibition of this enzyme genetically or pharmacologically inhibits oncogenesis. Here we show that O-GlcNAcylation modulates lipid metabolism in cancer cells. OGT regulates expression of the master lipid regulator the transcription factor sterol regulatory element binding protein 1 (SREBP-1) and its transcriptional targets both in cancer and lipogenic tissue. OGT regulates SREBP-1 protein expression via AMP-activated protein kinase (AMPK). SREBP-1 is critical for OGT-mediated regulation of cell survival and of lipid synthesis, as overexpression of SREBP-1 rescues lipogenic defects associated with OGT suppression, and tumor growth in vitro and in vivo. These results unravel a previously unidentified link between O-GlcNAcylation, lipid metabolism and the regulation of SREBP-1 in cancer and suggests a crucial role for O-GlcNAc signaling in transducing nutritional state to regulate lipid metabolism.	[Sodi, V. L.; Bacigalupa, Z. A.; Ferrer, C. M.; Gocal, W. A.; Mukhopadhyay, D.; Reginato, M. J.] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, 245 N 15th Street, Philadelphia, PA 19102 USA; [Lee, J. V.] Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Perelman Sch Med, Philadelphia, PA 19104 USA; [Ivan, M.] Indiana Univ, Dept Med, Indianapolis, IN USA	Drexel University; University of Pennsylvania; Pennsylvania Medicine; Indiana University System; Indiana University-Purdue University Indianapolis	Reginato, MJ (corresponding author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, 245 N 15th Street, Philadelphia, PA 19102 USA.	Mauricio.Reginato@drexelmed.edu		Gocal, Wiktoria/0000-0001-8894-8047	NCI [CA192868, CA183574, CA155413]; NATIONAL CANCER INSTITUTE [R01CA155413, F31CA183574, F31CA192868] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Nicholas Xerri for technical support and Mignon Keaton for help in analyzing LC-MS metabolite data. This work was supported by NCI grants CA192868 (to VLS), CA183574 (to CMF) and CA155413 (to MJR).	Anderson SM, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1653; Baenke F, 2013, DIS MODEL MECH, V6, P1353, DOI 10.1242/dmm.011338; Beckner ME, 2010, INT J CANCER, V126, P2282, DOI 10.1002/ijc.24918; Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124; Busino L, 2012, NAT CELL BIOL, V14, P375, DOI 10.1038/ncb2463; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; Caldwell SA, 2010, ONCOGENE, V29, P2831, DOI 10.1038/onc.2010.41; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; Eberle D, 2004, BIOCHIMIE, V86, P839, DOI 10.1016/j.biochi.2004.09.018; Ferrer CM, 2017, ONCOGENE, V36, P559, DOI 10.1038/onc.2016.228; Ferrer CM, 2016, J MOL BIOL, V428, P3282, DOI 10.1016/j.jmb.2016.05.028; Ferrer CM, 2014, MOL CELL, V54, P820, DOI 10.1016/j.molcel.2014.04.026; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hardiville S, 2014, CELL METAB, V20, P208, DOI 10.1016/j.cmet.2014.07.014; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Horton JD, 2002, COLD SPRING HARB SYM, V67, P491, DOI 10.1101/sqb.2002.67.491; Itkonen HM, 2013, CANCER RES, V73, P5277, DOI 10.1158/0008-5472.CAN-13-0549; Jones SF, 2015, CLIN CANCER RES, V21, P5434, DOI 10.1158/1078-0432.CCR-15-0126; Kawauchi K, 2009, P NATL ACAD SCI USA, V106, P3431, DOI 10.1073/pnas.0813210106; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Li WH, 2012, CELL CYCLE, V11, P2348, DOI 10.4161/cc.20811; Li XY, 2016, ONCOTARGET, V7, P12869, DOI 10.18632/oncotarget.7331; Li Y, 2011, CELL METAB, V13, P376, DOI 10.1016/j.cmet.2011.03.009; Lopez-Ibanez J, 2016, NUCLEIC ACIDS RES, V44, pW201, DOI 10.1093/nar/gkw253; Luo ZJ, 2010, FUTURE ONCOL, V6, P457, DOI [10.2217/fon.09.174, 10.2217/FON.09.174]; Lynch TP, 2012, J BIOL CHEM, V287, P11070, DOI 10.1074/jbc.M111.302547; McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899; O'Donnell N, 2004, MOL CELL BIOL, V24, P1680, DOI 10.1128/MCB.24.4.1680-1690.2004; Ozcan S, 2010, BBA-GENE REGUL MECH, V1799, P353, DOI 10.1016/j.bbagrm.2010.02.005; Rohrig F, 2016, NAT REV CANCER, V16, P732, DOI 10.1038/nrc.2016.89; Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x; Shaw Reuben J, 2012, F1000 Biol Rep, V4, P2, DOI 10.3410/B4-2; Sodi VL, 2015, MOL CANCER RES, V13, P923, DOI 10.1158/1541-7786.MCR-14-0536; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Varki A., 1999, ESSENTIALS GLYCOBIOL; Walker AK, 2011, CELL, V147, P840, DOI 10.1016/j.cell.2011.09.045; Wellen KE, 2010, MOL CELL, V40, P323, DOI 10.1016/j.molcel.2010.10.004; Zadra G, 2015, MOL CANCER RES, V13, P1059, DOI 10.1158/1541-7786.MCR-15-0068	41	37	42	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					924	934		10.1038/onc.2017.395	http://dx.doi.org/10.1038/onc.2017.395			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059153	Green Submitted, Green Accepted			2022-12-17	WOS:000425281800009
J	Govaere, O; Petz, M; Wouters, J; Vandewynckel, YP; Scott, EJ; Topal, B; Nevens, F; Verslype, C; Anstee, QM; Van Vlierberghe, H; Mikulits, W; Roskams, T				Govaere, O.; Petz, M.; Wouters, J.; Vandewynckel, Y-P; Scott, E. J.; Topal, B.; Nevens, F.; Verslype, C.; Anstee, Q. M.; Van Vlierberghe, H.; Mikulits, W.; Roskams, T.			The PDGFR alpha-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma	ONCOGENE			English	Article							IRES-MEDIATED TRANSLATION; POOR-PROGNOSIS; EXPRESSION; CYTOKERATIN-19; ANGIOGENESIS; DIAGNOSIS; MARKER; B1; LA	Human hepatocellular carcinomas (HCCs) expressing the biliary/hepatic progenitor cell marker keratin 19 (K19) have been linked with a poor prognosis and exhibit an increase in platelet-derived growth factor receptor a (PDGFR alpha) and laminin beta 1 (LAMB1) expression. PDGFR alpha has been reported to induce de novo synthesis of LAMB1 protein in a Sjogren syndrome antigen B (La/SSB)-dependent manner in a murine metastasis model. However, the role of this cascade in human HCC remains unclear. This study focused on the functional role of the PDGFR alpha-La/SSB-LAMB1 pathway and its molecular link to K19 expression in human HCC. In surgical HCC specimens from a cohort of 136 patients, PDGFR alpha expression correlated with K19 expression, microvascular invasion and metastatic spread. In addition, PDGFR alpha expression in pre-operative needle biopsy specimens predicted poor overall survival during a 5-year follow-up period. Consecutive histological staining demonstrated that the signaling components of the PDGFR alpha-La/SSB-LAMB1 pathway were strongly expressed at the invasive front. K19-positive HCC cells displayed high levels of alpha 2 beta 1 integrin (ITG) receptor, both in vitro and in vivo. In vitro activation of PDGFR alpha signaling triggered the translocation of nuclear La/SSB into the cytoplasm, enhanced the protein synthesis of LAMB1 by activating its internal ribosome entry site, which in turn led to increased secretion of laminin-111. This effect was abrogated by the PDGFR alpha-specific inhibitor crenolanib. Importantly LAMB1 stimulated ITG-dependent focal adhesion kinase/Src proto-oncogene non-receptor tyrosine kinase signaling. It also promoted the ITG-specific downstream target Rho-associated coiled-coil containing protein kinase 2, induced K19 expression in an autocrine manner, invadopodia formation and cell invasion. Finally, we showed that the knockdown of LAMB1 or K19 in subcutaneous xenograft mouse models resulted in significant loss of cells invading the surrounding stromal tissue and reduced HepG2 colonization into lung and liver after tail vein injection. The PDGFR alpha-LAMB1 pathway supports tumor progression at the invasive front of human HCC through K19 expression.	[Govaere, O.; Wouters, J.; Roskams, T.] Katholieke Univ Leuven, Dept Imaging & Pathol, Leuven, Belgium; [Govaere, O.; Wouters, J.; Topal, B.; Nevens, F.; Verslype, C.; Roskams, T.] Univ Hosp Leuven, Leuven, Belgium; [Govaere, O.; Scott, E. J.; Anstee, Q. M.] Newcastle Univ, Med Sch, Liver Res Grp, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England; [Petz, M.; Mikulits, W.] Med Univ Vienna, Comprehens Canc Ctr, Inst Canc Res, Dept Med 1, Borschke Gasse 8A, A-1090 Vienna, Austria; [Vandewynckel, Y-P; Van Vlierberghe, H.] Univ Ghent, Dept Hepatol & Gastroenterol, Ghent, Belgium; [Topal, B.] Katholieke Univ Leuven, Dept Abdominal Surg, Leuven, Belgium; [Nevens, F.; Verslype, C.] Katholieke Univ Leuven, Dept Hematol, Leuven, Belgium	KU Leuven; KU Leuven; University Hospital Leuven; Newcastle University - UK; Medical University of Vienna; Ghent University; KU Leuven; KU Leuven	Mikulits, W (corresponding author), Med Univ Vienna, Comprehens Canc Ctr, Inst Canc Res, Dept Med 1, Borschke Gasse 8A, A-1090 Vienna, Austria.; Govaere, O (corresponding author), Med Sch, Inst Cellular Med, Liver Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	olivier.govaere@ncl.ac.uk; wolfgang.mikulits@meduniwien.ac.at	Wouters, Jasper/AAK-8597-2020; Govaere, Olivier/R-9372-2019; Topal, Baki/AAH-9019-2021; Anstee, Quentin M./L-2981-2013; Mikulits, Wolfgang/AAH-4043-2021; Scott, Emma/AAG-1311-2019	Wouters, Jasper/0000-0002-7129-2990; Govaere, Olivier/0000-0002-4426-6930; Topal, Baki/0000-0002-2687-7535; Anstee, Quentin M./0000-0002-9518-0088; Scott, Emma/0000-0002-5358-5132; Mikulits, Wolfgang/0000-0003-4612-7106; Roskams, Tania/0000-0002-2816-1530; Verslype, Chris/0000-0003-3857-466X; Van Vlierberghe, Hans/0000-0003-0647-9238	Belgian Federal Science Policy Office, Interuniversity Attraction Poles program [P7/83-HEPRO]; Austrian Science Fund, FWF [T597-B13, P25356]; Belgian Kom op tegen Kanker; Medical Research Council [1681148] Funding Source: researchfish	Belgian Federal Science Policy Office, Interuniversity Attraction Poles program; Austrian Science Fund, FWF(Austrian Science Fund (FWF)); Belgian Kom op tegen Kanker; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Belgian Federal Science Policy Office, Interuniversity Attraction Poles program-P7/83-HEPRO (to OG), Austrian Science Fund, FWF, T597-B13 (to MP) and P25356 (to WM) and the Belgian Kom op tegen Kanker (to JW). We thank Kathleen Van den Eynde and the Fibrosis Lab, Newcastle University, UK for their indispensible technical support.	Bruix J, 2014, GUT, V63, P844, DOI 10.1136/gutjnl-2013-306627; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Coulon S, 2011, LIVER INT, V31, P146, DOI 10.1111/j.1478-3231.2010.02369.x; Desmet VJ, 2011, VIRCHOWS ARCH, V458, P251, DOI 10.1007/s00428-011-1048-3; Dhanasekaran R, 2016, J HEPATOL, V64, P736, DOI 10.1016/j.jhep.2015.09.008; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI 10.1016/j.ejca.2011.12.021; Fernandez M, 2009, J HEPATOL, V50, P604, DOI 10.1016/j.jhep.2008.12.011; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giannelli G, 2014, GUT, V63, P1668, DOI 10.1136/gutjnl-2014-307323; Govaere O, 2016, J HEPATOL, V64, P609, DOI 10.1016/j.jhep.2015.11.011; Govaere O, 2014, GUT, V63, P674, DOI 10.1136/gutjnl-2012-304351; Guldiken N, 2016, J HEPATOL, V65, P552, DOI 10.1016/j.jhep.2016.04.024; Heinrich MC, 2012, CLIN CANCER RES, V18, P4375, DOI 10.1158/1078-0432.CCR-12-0625; Hoshida Y, 2008, NEW ENGL J MED, V359, P1995, DOI 10.1056/NEJMoa0804525; Hoshida Y, 2009, CANCER RES, V69, P7385, DOI 10.1158/0008-5472.CAN-09-1089; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kikuchi A, 2015, GENE EXPRESSION, V16, P109, DOI 10.3727/105221615X14181438356210; Kim H, 2011, HEPATOLOGY, V54, P1707, DOI 10.1002/hep.24559; Kojiro M, 2009, HEPATOLOGY, V49, P658, DOI 10.1002/hep.22709; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Llovet JM, 2006, GASTROENTEROLOGY, V131, P1758, DOI 10.1053/j.gastro.2006.09.014; Martin K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12502; Mu X, 2015, J CLIN INVEST, V125, P3891, DOI 10.1172/JCI77995; Patarroyo M, 2002, SEMIN CANCER BIOL, V12, P197, DOI 10.1016/S1044-579X(02)00023-8; Petz M, 2012, NUCLEIC ACIDS RES, V40, P9738, DOI 10.1093/nar/gks760; Petz M, 2012, NUCLEIC ACIDS RES, V40, P290, DOI 10.1093/nar/gkr717; Suzuki Keiko, 2010, BMC Res Notes, V3, P294, DOI 10.1186/1756-0500-3-294; Tsuchiya K, 2011, ONCOLOGY-BASEL, V80, P278, DOI 10.1159/000328448; Uenishi T, 2003, CANCER SCI, V94, P851, DOI 10.1111/j.1349-7006.2003.tb01366.x; van Zijl F, 2009, ONCOGENE, V28, P4022, DOI 10.1038/onc.2009.253; Villanueva A, 2010, ANNU REV MED, V61, P317, DOI 10.1146/annurev.med.080608.100623; Wei T, 2014, ONCOTARGET, V5, P10307, DOI 10.18632/oncotarget.2537; Wong CCL, 2009, HEPATOLOGY, V49, P1583, DOI 10.1002/hep.22836; Yang XR, 2008, CLIN CANCER RES, V14, P3850, DOI 10.1158/1078-0432.CCR-07-4338; Yimlamai D, 2014, CELL, V157, P1324, DOI 10.1016/j.cell.2014.03.060; Zhuang PY, 2008, CANCER-AM CANCER SOC, V112, P2740, DOI 10.1002/cncr.23488	38	37	38	4	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6605	6616		10.1038/onc.2017.260	http://dx.doi.org/10.1038/onc.2017.260			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28783171	Green Published, hybrid			2022-12-17	WOS:000416049200009
J	Otsubo, K; Goto, H; Nishio, M; Kawamura, K; Yanagi, S; Nishie, W; Sasaki, T; Maehama, T; Nishina, H; Mimori, K; Nakano, T; Shimizu, H; Mak, TW; Nakao, K; Nakanishi, Y; Suzuki, A				Otsubo, K.; Goto, H.; Nishio, M.; Kawamura, K.; Yanagi, S.; Nishie, W.; Sasaki, T.; Maehama, T.; Nishina, H.; Mimori, K.; Nakano, T.; Shimizu, H.; Mak, T. W.; Nakao, K.; Nakanishi, Y.; Suzuki, A.			MOB1-YAP1/TAZ-NKX2.1 axis controls bronchioalveolar cell differentiation, adhesion and tumour formation	ONCOGENE			English	Article							BULLOUS-PEMPHIGOID ANTIGEN; STEM-CELLS; TRANSCRIPTIONAL COACTIVATOR; HIPPO PATHWAY; CO-REPRESSOR; LUNG STEM; TAZ; EXPRESSION; PROTEIN; GENE	Mps One Binder Kinase Activator (MOB) 1A/1B are core components of the Hippo pathway. These proteins, which coactivate LArge Tumour Suppressor homologue kinases, are also tumour suppressors. To investigate MOB1A/B's roles in normal physiology and lung cancer, we generated doxycycline (Dox)-inducible, bronchioalveolar epithelium-specific, null mutations of MOB1A/B in mice (SPC-rtTA/(tetO) 7-Cre/Mob1a flox/flox/Mob1b(-/-); termed luMob1DKO mice). Most mutants (70%) receiving Dox in utero (luMob1DKO (E6.5-18.5) mice) died of hypoxia within 1 h post-birth. Their alveolar epithelial cells showed increased proliferation, impaired YAP1/TAZ-dependent differentiation and decreased surfactant protein production, all features characteristic of human respiratory distress syndrome. Intriguingly, mutant mice that received Dox postnatally (luMob1DKO (P21-41) mice) did not develop spontaneous lung adenocarcinomas, and urethane treatment-induced lung tumour formation was decreased (rather than increased). Lungs of luMob1DKO (P21-41) mice exhibited increased detachment of bronchiolar epithelial cells and decreased numbers of the bronchioalveolar stem cells thought to initiate lung adenocarcinomas. YAP1/TAZ-NKX2.1-dependent expression of collagen XVII, a key hemidesmosome component, was also reduced. Thus, a MOB1-YAP1/TAZ-NKX2.1 axis is essential for normal lung homeostasis and expression of the collagen XVII protein necessary for alveolar stem cell maintenance in the lung niche.	[Otsubo, K.; Goto, H.; Nishio, M.; Suzuki, A.] Med Inst Bioregulat, Div Canc Genet, Fukuoka, Japan; [Otsubo, K.; Nakanishi, Y.] Kyushu Univ, Grad Sch Med Sci, Res Inst Dis Chest, Fukuoka, Japan; [Nishio, M.; Suzuki, A.] Kobe Univ, Grad Sch Med, Div Mol & Cellular Biol, Kobe, Hyogo, Japan; [Kawamura, K.] Waseda Univ, Fac Sci & Engn, Tokyo, Japan; [Yanagi, S.] Miyazaki Univ, Fac Med, Dept Internal Med, Div Neurol Respirol Endocrinol & Metab, Kiyotake, Miyazaki, Japan; [Nishie, W.; Shimizu, H.] Hokkaido Univ, Grad Sch Med, Dept Dermatol, Sapporo, Hokkaido, Japan; [Sasaki, T.] Akita Univ, Grad Sch Med, Dept Med Biol, Akita, Japan; [Maehama, T.] Natl Inst Infect Dis, Dept Biochem & Cell Biol, Tokyo, Japan; [Nishina, H.] Tokyo Med & Dent Univ, Grad Sch Med, Dept Dev & Regenerat Biol, Tokyo, Japan; [Mimori, K.] Kyushu Univ, Beppu Hosp, Dept Surg, Beppu, Oita, Japan; [Nakano, T.] Osaka Univ, Med Sch, Dept Pathol, Suita, Osaka, Japan; [Nakano, T.] Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka, Japan; [Mak, T. W.; Nakao, K.] Univ Hlth Network, Campbell Family Inst Canc Res, Toronto, ON, Canada; [Nakao, K.] Kyoto Univ, Grad Sch Med, Med Innovat Ctr, Kyoto, Japan	Kyushu University; Kobe University; Waseda University; University of Miyazaki; Hokkaido University; Akita University; National Institute of Infectious Diseases (NIID); Tokyo Medical & Dental University (TMDU); Kyushu University; Osaka University; Osaka University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Kyoto University	Suzuki, A (corresponding author), Kobe Univ, Grad Sch Med, Div Mol Cellular Biol, Chuo Ku, Kusunoki Cho 7-5-1, Kobe, Hyogo 6500017, Japan.	suzuki@med.kobe-u.ac.jp	Maehama, Tomohiko/AAX-8926-2020; Suzuki, Akira/GYD-6697-2022; Maehama, Tomohiko/HGB-4896-2022	Suzuki, Akira/0000-0002-5950-8808; Maehama, Tomohiko/0000-0002-9685-2317	MEXT [26860214, 24240120]; JSPS [26860214, 24240120]; Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University; P-DIRECT [11088019]; AMED [16770279]; Uehara Memorial Foundation; Grants-in-Aid for Scientific Research [17H03982, 15K19026] Funding Source: KAKEN	MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University; P-DIRECT; AMED(Japan Agency for Medical Research and Development (AMED)); Uehara Memorial Foundation(Uehara Memorial Foundation); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are grateful to Dr Jeffrey A Whitsett (Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, USA) for giving us SPC-rtTA/(tetO)<INF>7</INF>-Cre mice, and to A Fujimoto, M Kamihashi and M Suzuki (all of Kyushu Univ.), S Maegawa, J Utsumi, F Ishikawa, M Seiki and T Noda (all of AMED), for expert technical assistance and helpful discussions. This work was supported by MEXT and JSPS (grants 26860214 to MN, 24240120 to AS and HG); the Cooperative Research Project Program of the Medical Institute of Bioregulation, Kyushu University; P-DIRECT (grants 11088019 to AS); AMED (grants 16770279 to AS and HG); and the Uehara Memorial Foundation (to AS).	Chen HY, 2015, J CLIN ONCOL, V33, P2303, DOI 10.1200/JCO.2014.59.3590; Chung C, 2013, P NATL ACAD SCI USA, V110, P7732, DOI 10.1073/pnas.1220603110; Coleman CM, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-51; Corti M, 1996, AM J RESP CELL MOL, V14, P309, DOI 10.1165/ajrcmb.14.4.8600933; Debbabi H, 2005, AM J PHYSIOL-LUNG C, V289, pL274, DOI 10.1152/ajplung.00004.2005; Demello DE, 2002, IN VITRO CELL DEV-AN, V38, P154; Dovey JS, 2008, P NATL ACAD SCI USA, V105, P11857, DOI 10.1073/pnas.0803574105; Driscoll Barbara, 2012, Methods Mol Biol, V879, P109, DOI 10.1007/978-1-61779-815-3_7; Giangreco A, 2007, AM J RESP CRIT CARE, V175, P547, DOI 10.1164/rccm.200607-984PP; Horio Y, 1996, MOL CARCINOGEN, V17, P217, DOI 10.1002/(SICI)1098-2744(199612)17:4<217::AID-MC5>3.0.CO;2-A; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim M, 2015, CELL REP, V11, P270, DOI 10.1016/j.celrep.2015.03.015; Lange AW, 2015, J MOL CELL BIOL, V7, P35, DOI 10.1093/jmcb/mju046; Lin CW, 2015, DEV BIOL, V403, P101, DOI 10.1016/j.ydbio.2015.04.014; Makita R, 2008, AM J PHYSIOL-RENAL, V294, pF542, DOI 10.1152/ajprenal.00201.2007; MALKINSON AM, 1983, J NATL CANCER I, V70, P931; Matsumura H, 2016, SCIENCE, V351, DOI 10.1126/science.aad4395; MCGRATH JA, 1995, NAT GENET, V11, P83, DOI 10.1038/ng0995-83; Mitani A, 2009, AM J RESP CRIT CARE, V180, P326, DOI 10.1164/rccm.200812-1827OC; Nakayama H, 2001, JPN CIRC J, V65, P783, DOI 10.1253/jcj.65.783; Nishie W, 2007, NAT MED, V13, P378, DOI 10.1038/nm1496; Nishio M, 2016, P NATL ACAD SCI USA, V113, pE71, DOI 10.1073/pnas.1517188113; Nishio M, 2013, CANCER SCI, V104, P1271, DOI 10.1111/cas.12227; Nishio M, 2012, J CLIN INVEST, V122, P4505, DOI 10.1172/JCI63735; NISHIZAWA Y, 1993, J BIOCHEM-TOKYO, V113, P493, DOI 10.1093/oxfordjournals.jbchem.a124072; Park KS, 2004, J BIOL CHEM, V279, P17384, DOI 10.1074/jbc.M312569200; Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499; Powell AM, 2005, CLIN EXP DERMATOL, V30, P682, DOI 10.1111/j.1365-2230.2005.01937.x; Sasaki H, 2007, CLIN LUNG CANCER, V8, P273, DOI 10.3816/CLC.2007.n.006; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Tanimura S, 2011, CELL STEM CELL, V8, P177, DOI 10.1016/j.stem.2010.11.029; Valencia-Sama I, 2015, J BIOL CHEM, V290, P16906, DOI 10.1074/jbc.M115.642363; Ventura JJ, 2007, NAT GENET, V39, P750, DOI 10.1038/ng2037; Wan HJ, 2005, J BIOL CHEM, V280, P13809, DOI 10.1074/jbc.M414122200; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925-4773(99)00325-1; Westcott PMK, 2015, NATURE, V517, P489, DOI 10.1038/nature13898; Whitsett JA, 2004, HUM MOL GENET, V13, pR207, DOI 10.1093/hmg/ddh252; Whitsett JA, 2010, ANNU REV MED, V61, P105, DOI 10.1146/annurev.med.60.041807.123500; WIKENHEISER KA, 1992, CANCER RES, V52, P5342; Xie M, 2012, J THORAC ONCOL, V7, P799, DOI 10.1097/JTO.0b013e318248240b; Yamada M, 2005, J HISTOCHEM CYTOCHEM, V53, P735, DOI 10.1369/jhc.4A6483.2005; Yanagi S, 2007, J CLIN INVEST, V117, P2929, DOI 10.1172/JCI31854; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhou Z, 2011, ONCOGENE, V30, P2181, DOI 10.1038/onc.2010.606	49	37	41	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4201	4211		10.1038/onc.2017.58	http://dx.doi.org/10.1038/onc.2017.58			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28346423	Green Accepted			2022-12-17	WOS:000405835800011
J	Shang, Y; He, J; Wang, Y; Feng, Q; Zhang, Y; Guo, J; Li, J; Li, S; Wang, Y; Yan, G; Ren, F; Shi, Y; Xu, J; Zeps, N; Zhai, Y; He, D; Chang, Z				Shang, Y.; He, J.; Wang, Y.; Feng, Q.; Zhang, Y.; Guo, J.; Li, J.; Li, S.; Wang, Y.; Yan, G.; Ren, F.; Shi, Y.; Xu, J.; Zeps, N.; Zhai, Y.; He, D.; Chang, Z.			CHIP/Stub1 regulates the Warburg effect by promoting degradation of PKM2 in ovarian carcinoma	ONCOGENE			English	Article							PYRUVATE-KINASE M2; UBIQUITIN LIGASE; CELL-METABOLISM; CHIP; GLYCOLYSIS; ISOFORM; IDENTIFICATION; TARGET; ROLES	Tumor cells preferentially adopt aerobic glycolysis for their energy supply, a phenomenon known as the Warburg effect. It remains a matter of debate as to how the Warburg effect is regulated during tumor progression. Here, we show that CHIP (carboxyl terminus of Hsc70-interacting protein), a U-box E3 ligase, suppresses tumor progression in ovarian carcinomas by inhibiting aerobic glycolysis. While CHIP is downregulated in ovarian carcinoma, induced expression of CHIP results in significant inhibition of the tumor growth examined by in vitro and in vivo experiments. Reciprocally, depletion of CHIP leads to promotion of tumor growth. By a SiLAD proteomics analysis, we identified pyruvate kinase isoenzyme M2 (PKM2), a critical regulator of glycolysis in tumors, as a target that CHIP mediated for degradation. Accordingly, we show that CHIP regulates PKM2 protein stability and thereafter the energy metabolic processes. Depletion or knockout of CHIP increased the glycolytic products in both tumor and mouse embryonic fibroblast cells. Simultaneously, we observed that CHIP expression inversely correlated with PKM2 levels in human ovarian carcinomas. This study reveals a mechanism that the Warburg effect is regulated by CHIP through its function as an E3 ligase, which mediates the degradation of PKM2 during tumor progression. Our findings shed new light into understanding of ovarian carcinomas and may provide a new therapeutic strategy for ovarian cancer.	[Shang, Y.; He, J.; Yan, G.; Zhai, Y.; He, D.] Beijing Normal Univ, Coll Life Sci, Dept Cell Biol, Minist Educ,Key Lab Cell Proliferat & Regulat Bio, Beijing, Peoples R China; [Shang, Y.; Wang, Y.; Zhang, Y.; Guo, J.; Li, J.; Li, S.; Wang, Y.; Ren, F.; Chang, Z.] Tsinghua Univ, Sch Med, Dept Basic Med Sci, State Key Lab Membrane Biol, Beijing, Peoples R China; [Feng, Q.] Zhengzhou Univ, Affiliated Hosp 3, Dept Gynecol & Obstet, Zhengzhou, Peoples R China; [Shi, Y.] Penn State Univ, Dept Cellular & Mol Physiol, Coll Med, Hershey, PA USA; [Xu, J.] Univ Western Australia, Sch Pathol & Lab Med, M504, Crawley, WA, Australia; [Zeps, N.] Univ Western Australia, Sch Surg, M509, Crawley, WA, Australia; [Zeps, N.] St John God HealthCare, Bendat Family Comprehens Canc Ctr, Subiaco, WA, Australia	Beijing Normal University; Tsinghua University; Zhengzhou University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Western Australia; University of Western Australia; St John of God Health Care	Shang, Y; Chang, Z (corresponding author), Tsinghua Univ, Sch Med, New Med Sci Bldg A307, Beijing 100084, Peoples R China.	shangyu@bnu.edu.cn; zhijiec@tsinghua.edu.cn	Chang, Zhijie/AAH-8109-2019; Zeps, Nikolajs/AAF-3186-2021; Zhang, Yanquan/D-5615-2017	Zeps, Nikolajs/0000-0002-6404-6839; Zhang, Yanquan/0000-0003-3527-9972; Xu, Jiake/0000-0003-2021-8309	Ministry of Science and Technology, China [2016YFA0500300, 2011CB910502, 2011CB915504]; NSFC [81672715, 81301701, 81572729, 81402293, 81230044]	Ministry of Science and Technology, China(Ministry of Science and Technology, China); NSFC(National Natural Science Foundation of China (NSFC))	We thank Dr Deyin Guo for providing PKM2 constructs (Wuhan University, China), and Dr Beihua Kong for providing HEY and A278O cells (Shandong University, China). We also thank Dr Suneng Fu and Yilie Liao for their technical support on the extracellular acidification rate and oxygen consumption rate experiment. We thank Dr Suozhu Sun (The Second Artillery General Hospital, China) for his help with the pathological analyses on the tumor samples. This work was supported by Grants from Ministry of Science and Technology, China (2016YFA0500300, 2011CB910502 and 2011CB915504) and NSFC (81672715, 81301701, 81572729, 81402293 and 81230044) in China.	Altenberg B, 2004, GENOMICS, V84, P1014, DOI 10.1016/j.ygeno.2004.08.010; Chaneton B, 2012, TRENDS BIOCHEM SCI, V37, P309, DOI 10.1016/j.tibs.2012.04.003; Chao CCK, 2015, CLIN CHIM ACTA, V438, P139, DOI 10.1016/j.cca.2014.08.015; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Dayton TL, 2016, GENE DEV, V30, P1020, DOI 10.1101/gad.278549.116; Goldberg MS, 2012, J EXP MED, V209, P217, DOI 10.1084/jem.20111487; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hosios AM, 2015, MOL CELL, V59, P850, DOI 10.1016/j.molcel.2015.07.013; Hou J, 2017, ONCOGENE, V36, P1134, DOI 10.1038/onc.2016.280; Huang LQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092949; Israelsen WJ, 2015, SEMIN CELL DEV BIOL, V43, P43, DOI 10.1016/j.semcdb.2015.08.004; Israelsen WJ, 2013, CELL, V155, P397, DOI 10.1016/j.cell.2013.09.025; Kajiro M, 2009, NAT CELL BIOL, V11, P312, DOI 10.1038/ncb1839; Kefas B, 2010, NEURO-ONCOLOGY, V12, P1102, DOI 10.1093/neuonc/noq080; Kundrat L, 2010, J MOL BIOL, V395, P587, DOI 10.1016/j.jmb.2009.11.017; Li RF, 2007, J MOL BIOL, V374, P777, DOI 10.1016/j.jmb.2007.09.082; Li XN, 2008, J CELL BIOL, V181, P959, DOI 10.1083/jcb.200711044; Li ZW, 2014, BBA-REV CANCER, V1846, P285, DOI 10.1016/j.bbcan.2014.07.008; Liu AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086872; Liu K, 2016, J BIOL CHEM, V291, P10307, DOI 10.1074/jbc.M115.703066; Lu DD, 2012, CANCER CELL, V21, P92, DOI 10.1016/j.ccr.2011.12.016; Luo WB, 2012, TRENDS ENDOCRIN MET, V23, P560, DOI 10.1016/j.tem.2012.06.010; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Paul I, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/918183; Poersch A, 2013, MOL CANCER THER, V12, DOI 10.1158/1535-7163.TARG-13-A138; Shang Y, 2014, CELL SIGNAL, V26, P1098, DOI 10.1016/j.cellsig.2014.01.030; Shang Y, 2009, BIOCHEM BIOPH RES CO, V386, P242, DOI 10.1016/j.bbrc.2009.06.043; Sun C, 2014, J CANCER RES CLIN, V140, P189, DOI 10.1007/s00432-013-1571-5; Sun QA, 2011, P NATL ACAD SCI USA, V108, P4129, DOI 10.1073/pnas.1014769108; Viana R, 2015, BMC BIOCHEM, V16, DOI 10.1186/s12858-015-0053-6; Wang YH, 2014, CELL, V158, P1309, DOI 10.1016/j.cell.2014.07.048; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wong N, 2015, CANCER LETT, V356, P184, DOI 10.1016/j.canlet.2014.01.031; Xin H, 2005, J BIOL CHEM, V280, P20842, DOI 10.1074/jbc.M412275200; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Yu ZH, 2013, J BIOL CHEM, V288, P35406, DOI 10.1074/jbc.M113.508226; Zhang Z, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002991	37	37	44	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4191	4200		10.1038/onc.2017.31	http://dx.doi.org/10.1038/onc.2017.31			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28346425				2022-12-17	WOS:000405835800010
J	Werden, SJ; Sphyris, N; Sarkar, TR; Paranjape, AN; LaBaff, AM; Taube, JH; Hollier, BG; Ramirez-Pena, EQ; Soundararajan, R; den Hollander, P; Powell, E; Echeverria, GV; Miura, N; Chang, JT; Piwnica-Worms, H; Rosen, JM; Mani, SA				Werden, S. J.; Sphyris, N.; Sarkar, T. R.; Paranjape, A. N.; LaBaff, A. M.; Taube, J. H.; Hollier, B. G.; Ramirez-Pena, E. Q.; Soundararajan, R.; den Hollander, P.; Powell, E.; Echeverria, G. V.; Miura, N.; Chang, J. T.; Piwnica-Worms, H.; Rosen, J. M.; Mani, S. A.			Phosphorylation of serine 367 of FOXC2 by p38 regulates ZEB1 and breast cancer metastasis, without impacting primary tumor growth	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ACTIVATED PROTEIN-KINASE; STEM-CELLS; SIGNALING PATHWAYS; MIR-200 FAMILY; INVASION; EMT; EXPRESSION; PLASTICITY; INSIGHTS	Metastatic competence is contingent upon the aberrant activation of a latent embryonic program, known as the epithelial-mesenchymal transition (EMT), which bestows stem cell properties as well as migratory and invasive capabilities upon differentiated tumor cells. We recently identified the transcription factor FOXC2 as a downstream effector of multiple EMT programs, independent of the EMT-inducing stimulus, and as a key player linking EMT, stem cell traits and metastatic competence in breast cancer. As such, FOXC2 could serve as a potential therapeutic target to attenuate metastasis. However, as FOXC2 is a transcription factor, it is difficult to target by conventional means such as small-molecule inhibitors. Herein, we identify the serine/threonine-specific kinase p38 as a druggable upstream regulator of FOXC2 stability and function that elicits phosphorylation of FOXC2 at serine 367 (S367). Using an orthotopic syngeneic mouse tumor model, we make the striking observation that inhibition of p38-FOXC2 signaling selectively attenuates metastasis without impacting primary tumor growth. In this model, circulating tumor cell numbers are significantly reduced in mice treated with the p38 inhibitor SB203580, relative to vehicle-treated counterparts. Accordingly, genetic or pharmacological inhibition of p38 decreases FOXC2 protein levels, reverts the EMT phenotype and compromises stem cell attributes in vitro. We also identify the EMT-regulator ZEB1-known to directly repress E-cadherin/CDH1-as a downstream target of FOXC2, critically dependent on its activation by p38. Consistent with the notion that activation of the p38-FOXC2 signaling axis represents a critical juncture in the acquisition of metastatic competence, the phosphomimetic FOXC2(S367E) mutant is refractory to p38 inhibition both in vitro and in vivo, whereas the non-phosphorylatable FOXC2(S367A) mutant fails to elicit EMT and upregulate ZEB1. Collectively, our data demonstrate that FOXC2 regulates EMT, stem cell traits, ZEB1 expression and metastasis in a p38-dependent manner, and attest to the potential utility of p38 inhibitors as antimetastatic agents.	[Werden, S. J.; Sphyris, N.; Sarkar, T. R.; Paranjape, A. N.; Taube, J. H.; Hollier, B. G.; Ramirez-Pena, E. Q.; Soundararajan, R.; den Hollander, P.; Mani, S. A.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, 2130 W Holcombe Blvd, Houston, TX 77030 USA; [LaBaff, A. M.] Univ Texas MD Anderson Canc Ctr, Mol & Cellular Oncol, Houston, TX 77030 USA; [Powell, E.; Echeverria, G. V.; Piwnica-Worms, H.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Miura, N.] Hamamatsu Univ, Sch Med, Dept Biochem, Hamamatsu, Shizuoka, Japan; [Chang, J. T.] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Rosen, J. M.] Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; [Rosen, J. M.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Mani, S. A.] Univ Texas MD Anderson Canc Ctr, Metastasis Res Ctr, Houston, TX 77030 USA; [Mani, S. A.] Univ Texas MD Anderson Canc Ctr, Ctr Stem Cell & Dev Biol, Houston, TX 77030 USA; [Taube, J. H.] Baylor Univ, Waco, TX 76798 USA; [Hollier, B. G.] Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Brisbane, Qld 4102, Australia	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Hamamatsu University School of Medicine; University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor University; Queensland University of Technology (QUT)	Mani, SA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, 2130 W Holcombe Blvd, Houston, TX 77030 USA.	smani@mdanderson.org	Mani, Sendurai A./A-7244-2009; Paranjape, Anurag N./P-1255-2018; SPHYRIS, NATHALIE/GQY-6349-2022	Mani, Sendurai A./0000-0002-5918-4276; Paranjape, Anurag N./0000-0001-6119-0766; Taube, Joseph/0000-0002-3636-5189; Ramirez-Pena, Esmeralda/0000-0002-5200-7488; Echeverria, Gloria/0000-0002-3772-9298; Sphyris, Nathalie/0000-0003-1860-1958	National Institute of Health [5RO1CA155243]; Cancer Prevention and Research Institute of Texas [RP-130485]; Cancer Center Support Grant from the National Cancer Institute [5P30CA016672]; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA155243] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas; Cancer Center Support Grant from the National Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Dr Mike Lewis, Dr Patricia Thompson and Dr Jody Vykoukal for helpful discussions. We particularly thank Dr Jonathan Kurie, Dr Robert Weinberg and Dr Mien-Chie Hung for critically reading the manuscript. This research was supported by grants from the National Institute of Health (5RO1CA155243) and the Cancer Prevention and Research Institute of Texas (RP-130485). SAM is an American Cancer Society M Patricia Alexander Research Scholar (121958-RSG-12-102-01-DDC). SJW received a Susan G Komen Breast Cancer Foundation Postdoctoral Fellowship. Flow cytometry, animal imaging and histopathology were in part funded by the Cancer Center Support Grant from the National Cancer Institute (5P30CA016672).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alspach E, 2014, CANCER DISCOV, V4, P716, DOI 10.1158/2159-8290.CD-13-0743; Aomatsu K, 2012, INVEST OPHTH VIS SCI, V53, P751, DOI 10.1167/iovs.11-8222; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Barrantes ID, 2012, BIOCHEM SOC T, V40, P79, DOI 10.1042/BST20110676; Blanco MA, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2831; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Donnelly SM, 2014, CURR MED CHEM, V21, P501; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Emerling BM, 2005, MOL CELL BIOL, V25, P4853, DOI 10.1128/MCB.25.12.4853-4862.2005; Fehm T, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1869; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Gutierrez MC, 2005, J CLIN ONCOL, V23, P2469, DOI 10.1200/JCO.2005.01.172; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hollier BG, 2013, CANCER RES, V73, P1981, DOI 10.1158/0008-5472.CAN-12-2962; Huang S, 2000, J BIOL CHEM, V275, P12266, DOI 10.1074/jbc.275.16.12266; Kawano H, 2003, J AM SOC NEPHROL, V14, P584, DOI 10.1097/01.ASN.0000050415.97942.2F; Kopper F, 2014, CELL CYCLE, V13, P884, DOI 10.4161/cc.28292; Kumar S, 1999, BIOCHEM BIOPH RES CO, V263, P825, DOI 10.1006/bbrc.1999.1454; Kume T, 2012, J ONCOL, V2012, DOI 10.1155/2012/204593; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Malinowsky K, 2012, TRANSL ONCOL, V5, P98, DOI 10.1593/tlo.11268; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Pantel K, 1999, JNCI-J NATL CANCER I, V91, P1113, DOI 10.1093/jnci/91.13.1113; Pulaski B A, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2002s39; Sarkar TR, 2015, ONCOGENE, V34, P2958, DOI 10.1038/onc.2014.245; Steeg PS, 2008, NAT CLIN PRACT ONCOL, V5, P206, DOI 10.1038/ncponc1066; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Taube JH, 2013, SCI REP-UK, V3, DOI 10.1038/srep02687; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Vecchi M, 2008, ONCOGENE, V27, P2148, DOI 10.1038/sj.onc.1210858; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Yan CL, 2010, AM J PATHOL, V176, P2247, DOI 10.2353/ajpath.2010.090048; Yoshizuka N, 2012, MOL CELL BIOL, V32, P606, DOI 10.1128/MCB.06301-11	45	37	42	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					5977	5988		10.1038/onc.2016.203	http://dx.doi.org/10.1038/onc.2016.203			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	27292262	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000388509400005
J	Bhatt, S; Stender, JD; Joshi, S; Wu, G; Katzenellenbogen, BS				Bhatt, S.; Stender, J. D.; Joshi, S.; Wu, G.; Katzenellenbogen, B. S.			OCT-4: a novel estrogen receptor-alpha collaborator that promotes tamoxifen resistance in breast cancer cells	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; GENE-EXPRESSION; STEM-CELLS; PROSTATE CARCINOGENESIS; MOLECULAR DETERMINANTS; ENDOCRINE RESISTANCE; ER-ALPHA; PHOSPHORYLATION; TRANSCRIPTION; THERAPY	Tamoxifen has shown great success in the treatment of breast cancer; however, long-term treatment can lead to acquired tamoxifen (TOT) resistance and relapse. TOT classically antagonizes estradiol (E2) -dependent breast cancer cell growth, but exerts partial agonist/antagonist behavior on gene expression. Although both E2 and TOT treatment of breast cancer cells results in recruitment of the estrogen receptor (ER) to common and distinct genomic sites, the mechanisms and proteins underlying TOT preferential recruitment of the ER remains poorly defined. To this end, we performed in silico motif-enrichment analyses within the ER-binding peaks in response to E2 or TOT, to identify factors that would specifically recruit ER to genomic binding sites in the presence of TOT as compared to E2. Intriguingly, we found Nkx3-1 and Oct-transcription factor homodimer motifs to be enriched in TOT preferential binding sites and confirmed the critical role of Oct-3/4 (aka Oct-4) in directing ER recruitment to TOT preferential genomic binding sites, by chromatin immunoprecipitation (ChIP) analyses. Further investigation revealed Oct-4 expression to be basally repressed by Nkx3-1 in MCF-7 cells and TOT treatment appeared to elevate Nkx3-1 degradation through a p38MAPK-dependent phosphorylation of the E3 ligase, Skp2 at serine-64 residue, as observed by quantitative mass-spectrometry analyses. Consistently, Oct-4 upon induction by phospho-Ser64-Skp2-mediated proteasomal degradation of Nkx3-1, participated in ER transcriptional complexes along with p38MAPK and Skp2 in a tamoxifen-dependent manner leading to TOT-dependent gene activation and cell proliferation of the TOT-resistant MCF-7-tam(r) breast cancer cells. Notably, Oct-4 levels were highly elevated in MCF-7-tam(r) cells, and appeared critical for their TOT sensitivity in cell proliferation assays. Furthermore, overexpression of Oct-4 enhanced tumor growth in the presence of tamoxifen in mice in vivo. Collectively, our work presents a novel mechanism for tamoxifen-specific gene activation by ER, secondary to its TOT preferential recruitment to genomic sites by specific activation of Oct-4, a phenomenon that appears to underlie tamoxifen resistance in breast cancer cells and in xenograft tumor models, and could be useful in designing therapeutic interventions to improve treatment outcome.	[Bhatt, S.; Stender, J. D.] Univ Illinois, Dept Biochem, Urbana, IL USA; [Joshi, S.] Agilent Technol, Cedar Creek, TX USA; [Wu, G.] Harvard Med Sch, Joslin Diabet Ctr, Res Div, Boston, MA USA; [Katzenellenbogen, B. S.] Univ Illinois, Mol & Integrat Physiol, Urbana, IL USA	University of Illinois System; University of Illinois Urbana-Champaign; Agilent Technologies; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; University of Illinois System; University of Illinois Urbana-Champaign	Katzenellenbogen, BS (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 524 Burrill Hall,407 South Goodwin Ave, Urbana, IL 61801 USA.	katzenel@illinois.edu			NIH [5RO1 CA18119]; Breast Cancer Research Foundation; Juvenile Diabetes Research Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation)	We thank Dr Peter Yau, Biotechnology Core, UIUC, for contributions to the mass-spectrometry analyses. This work was supported by grants from the NIH 5RO1 CA18119 (BSK), The Breast Cancer Research Foundation (BSK) and Juvenile Diabetes Research Foundation (GW). SB conceived of, designed and executed the study, performed experiments, data analyses and interpretation and wrote the manuscript. JDS conceived the study, performed computational analysis and contributed to experimental data. GW and SJ contributed to experimental data. BSK conceived and designed the study, performed data analyses and interpretation and wrote the manuscript.	Allgood VE, 1997, BIOCHEMISTRY-US, V36, P224, DOI 10.1021/bi961125c; Bayliss J, 2007, CLIN CANCER RES, V13, P7029, DOI 10.1158/1078-0432.CCR-07-0587; Beelen K, 2012, NAT REV CLIN ONCOL, V9, P529, DOI 10.1038/nrclinonc.2012.121; Bergamaschi A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2913; Bhatt S, 2012, MOL CELL BIOL, V32, P1928, DOI 10.1128/MCB.06561-11; Bianco S, 2012, TRANSCR-AUSTIN, V3, P165, DOI 10.4161/trns.20496; Bowen C, 2000, CANCER RES, V60, P6111; Brueggemeier RW, 2005, ENDOCR REV, V26, P331, DOI 10.1210/er.2004-0015; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Connor CE, 2001, CANCER RES, V61, P2917; Coser KR, 2009, P NATL ACAD SCI USA, V106, P14536, DOI 10.1073/pnas.0907560106; de Leeuw R, 2013, ONCOGENE, V32, P3543, DOI 10.1038/onc.2012.361; Frasor J, 2004, CANCER RES, V64, P1522, DOI 10.1158/0008-5472.CAN-03-3326; Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497; Gidekel S, 2003, CANCER CELL, V4, P361, DOI 10.1016/S1535-6108(03)00270-8; Green KA, 2007, NAT REV CANCER, V7, P713, DOI 10.1038/nrc2211; Gutierrez MC, 2005, J CLIN ONCOL, V23, P2469, DOI 10.1200/JCO.2005.01.172; Herman ME, 1996, J STEROID BIOCHEM, V59, P121, DOI 10.1016/S0960-0760(96)00114-8; Holmes KA, 2008, CANCER RES, V68, P7380, DOI 10.1158/0008-5472.CAN-08-0133; Hoskins JM, 2009, NAT REV CANCER, V9, P576, DOI 10.1038/nrc2683; Huber-Keener KJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041333; Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001; JAIYESIMI IA, 1995, J CLIN ONCOL, V13, P513, DOI 10.1200/JCO.1995.13.2.513; Jin TR, 1999, INT J CANCER, V81, P104, DOI 10.1002/(SICI)1097-0215(19990331)81:1<104::AID-IJC18>3.0.CO;2-Q; Jordan VC, 2007, J CLIN ONCOL, V25, P5815, DOI 10.1200/JCO.2007.11.3886; Katzenellenbogen BS, 2002, SCIENCE, V295, P2380, DOI 10.1126/science.1070442; Katzenellenbogen BS, 2004, SEMIN ONCOL, V31, P28, DOI 10.1053/j.seminoncol.2004.01.004; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P2884, DOI 10.1073/pnas.042688999; Kim MJ, 2002, CANCER RES, V62, P2999; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Lupien M, 2009, ENDOCR-RELAT CANCER, V16, P381, DOI 10.1677/ERC-09-0038; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Monk M, 2001, ONCOGENE, V20, P8085, DOI 10.1038/sj.onc.1205088; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Ogawa S, 2005, CELL, V122, P707, DOI 10.1016/j.cell.2005.06.029; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271; Ramos-Mejia V, 2005, DEV DYNAM, V232, P180, DOI 10.1002/dvdy.20211; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Tai MH, 2005, CARCINOGENESIS, V26, P495, DOI 10.1093/carcin/bgh321; Wang LH, 2006, CANCER CELL, V10, P487, DOI 10.1016/j.ccr.2006.09.015; Welboren WJ, 2009, ENDOCR-RELAT CANCER, V16, P1073, DOI 10.1677/ERC-09-0086; Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88	51	37	38	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5722	5734		10.1038/onc.2016.105	http://dx.doi.org/10.1038/onc.2016.105			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27065334				2022-12-17	WOS:000386998400004
J	Hobbs, RP; Batazzi, AS; Han, MC; Coulombe, PA				Hobbs, R. P.; Batazzi, A. S.; Han, M. C.; Coulombe, P. A.			Loss of Keratin 17 induces tissue-specific cytokine polarization and cellular differentiation in HPV16-driven cervical tumorigenesis in vivo	ONCOGENE			English	Article							ATYPICAL SQUAMOUS-CELLS; INTRAEPITHELIAL NEOPLASIA; UNDETERMINED SIGNIFICANCE; DIAGNOSTIC-VALUE; GENE-EXPRESSION; RESERVE CELLS; MARKER; CYTOKERATIN-17; CANCER; CARCINOMA	Despite preventive human papilloma virus (HPV) vaccination efforts, cervical cancer remains a leading cause of death in women worldwide. Development of therapeutic approaches for cervical cancer are hampered by a lack of mechanistic insight during tumorigenesis. The cytoskeletal protein Keratin 17 (KRT17;K17) is robustly expressed in a broad array of carcinomas, including in cervical tumors, where it has both diagnostic and prognostic value. In this study, we have established multiple functional roles for K17 in the promotion of cervical tumorigenesis in vivo using the established HPV16(tg) mouse model for cervical squamous cell carcinoma. In HPV16tg/+;Krt17(-/-)relative to HPV16(tg/+) reference female mice, onset of cervical lesions is delayed and closely paralleled by marked reductions in hyperplasia, dysplasia and vascularization. In addition, loss of Krt17 is associated with a cytokine polarization and recruitment of effector immune cells to lesion-prone cervical epithelia. Further, we observed marked enhancement of terminal differentiation in HPV16(tg/+); Krt17(-/-)cervical epithelium accompanied by a stimulation and expansion in the expression of p63, a known basal/reserve cell marker in this tissue. Altogether, the data suggest that the loss of Krt17 may foster an overall protective environment for lesion-prone cervical tissue. In addition to providing new insights into the immunomodulatory and cellular mechanisms of cervical tumorigenesis, these findings may help guide the development of future therapies including vaccines.	[Hobbs, R. P.; Batazzi, A. S.; Han, M. C.; Coulombe, P. A.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, 615 North Wolfe St, Baltimore, MD 21205 USA; [Coulombe, P. A.] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; [Coulombe, P. A.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Coulombe, P. A.] Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD 21205 USA; [Coulombe, P. A.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canccr Ctr, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Coulombe, PA (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, 615 North Wolfe St, Baltimore, MD 21205 USA.	coulombe@jhu.edu			NIH [CA160255, AR44232]; NIH training grant from the National Institutes of Health [CA009110]; NATIONAL CANCER INSTITUTE [R01CA160255, T32CA009110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044232] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH training grant from the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank members of the Coulombe laboratory for support, Dr Michelle Kerns for critical reading of the manuscript and Drs Janice Evans, Hyo Lee and TC Wu for advice and assistance. These studies were supported by NIH research grants CA160255 and AR44232 (to PAC) and NIH training grant CA009110 (to RH) from the National Institutes of Health.	Arbeit JM, 1996, P NATL ACAD SCI USA, V93, P2930, DOI 10.1073/pnas.93.7.2930; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Chen Y, 2011, ONCOLOGY-BASEL, V80, P333, DOI 10.1159/000329098; Chung BM, 2015, J CELL BIOL, V208, P613, DOI 10.1083/jcb.201408026; Chung SH, 2010, TRENDS ENDOCRIN MET, V21, P504, DOI 10.1016/j.tem.2010.03.005; Cohen-Kerem R, 2004, ANN OTO RHINOL LARYN, V113, P821, DOI 10.1177/000348940411301008; DePianto D, 2010, NAT GENET, V42, P910, DOI 10.1038/ng.665; Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214; Escobar-Hoyos LF, 2015, CANCER RES, V75, P3650, DOI 10.1158/0008-5472.CAN-15-0293; Escobar-Hoyos LF, 2014, MODERN PATHOL, V27, P621, DOI 10.1038/modpathol.2013.166; Feng DQ, 2009, ONCOL REP, V22, P1129, DOI 10.3892/or_00000545; Freeman AK, 2011, SEMIN CELL DEV BIOL, V22, P681, DOI 10.1016/j.semcdb.2011.08.009; Helt AM, 2002, J VIROL, V76, P10559, DOI 10.1128/JVI.76.20.10559-10568.2002; Herfs M, 2013, J PATHOL, V229, P460, DOI 10.1002/path.4110; Hobbs RP, 2015, NAT GENET, V47, P933, DOI 10.1038/ng.3355; Hopman AHN, 2006, J PATHOL, V210, P412, DOI 10.1002/path.2070; Hopman AHN, 2004, J PATHOL, V202, P23, DOI 10.1002/path.1490; Ide M, 2012, ANN SURG ONCOL, V19, P3506, DOI 10.1245/s10434-012-2437-9; Kim S, 2006, NATURE, V441, P362, DOI 10.1038/nature04659; Lee BN, 2004, CLIN DIAGN LAB IMMUN, V11, P239, DOI 10.1128/CDLI.11.2.239-244.2004; Martens J, 1999, CANCER CYTOPATHOL, V87, P87, DOI 10.1002/(SICI)1097-0142(19990425)87:2<87::AID-CNCR8>3.0.CO;2-L; Martens JE, 2004, ANTICANCER RES, V24, P771; Martens JE, 2009, INT J GYNECOL PATHOL, V28, P381, DOI 10.1097/PGP.0b013e31819932f8; McGowan KM, 1998, J CELL BIOL, V143, P469, DOI 10.1083/jcb.143.2.469; Melero I, 2014, NAT REV CLIN ONCOL, V11, P509, DOI 10.1038/nrclinonc.2014.111; Mighty KK, 2014, RECENT RESULTS CANC, V193, P135, DOI 10.1007/978-3-642-38965-8_8; MITCHELL MF, 1994, CANCER EPIDEM BIOMAR, V3, P619; Patterson AL, 2013, CELL CYCLE, V12, P2888, DOI 10.4161/cc.25917; Plummer M, 2007, J INFECT DIS, V195, P1582, DOI 10.1086/516784; Rodriguez R, 2008, INT J GYNECOL PATHOL, V27, P108, DOI 10.1097/pgp.0b013e31804216b8; Romano RA, 2012, DEVELOPMENT, V139, P772, DOI 10.1242/dev.071191; Sankar S, 2013, MOL CELL BIOL, V33, P4448, DOI 10.1128/MCB.00241-13; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; SMEDTS F, 1992, AM J PATHOL, V140, P601; Sun B, 2015, INT J CLIN EXP PATHO, V8, P1783; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Toyoshima T, 2008, J CANCER RES CLIN, V134, P515, DOI 10.1007/s00432-007-0308-8; Van de Putte G, 2003, GYNECOL ONCOL, V89, P140, DOI 10.1016/S0090-8258(03)00010-6; van de Rijn M, 2002, AM J PATHOL, V161, P1991, DOI 10.1016/S0002-9440(10)64476-8; Wang YF, 2013, TUMOR BIOL, V34, P1685, DOI 10.1007/s13277-013-0703-5	41	37	37	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5653	5662		10.1038/onc.2016.102	http://dx.doi.org/10.1038/onc.2016.102			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	27065324	Green Accepted			2022-12-17	WOS:000386998300008
J	Kitadate, A; Ikeda, S; Teshima, K; Ito, M; Toyota, I; Hasunuma, N; Takahashi, N; Miyagaki, T; Sugaya, M; Tagawa, H				Kitadate, A.; Ikeda, S.; Teshima, K.; Ito, M.; Toyota, I.; Hasunuma, N.; Takahashi, N.; Miyagaki, T.; Sugaya, M.; Tagawa, H.			MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITOR; ONCOGENE-INDUCED SENESCENCE; TUMOR-SUPPRESSOR GENES; MYCOSIS-FUNGOIDES; MANTLE CELL; CANCER; P53; EXPRESSION; SAHA; VORINOSTAT	Multiple sequential genetic and epigenetic alterations underlie cancer development and progression. Overcoming cellular senescence is an early step in cancer pathogenesis. Here, we demonstrate that a noncoding regulatory RNA, microRNA-16 (miR-16), has the potential to induce cellular senescence. First, we examined the expression of miR-16 in primary cutaneous T-cell lymphoma (CTCL) and other non-Hodgkin T/natural killer (NK)-cell lymphomas and found that miR-16 was downregulated than that in the corresponding normal cells. Notably, miR-16 expression was reduced as the primary CTCL progressed from the early stage to the advanced stage. Next, we transduced CTCL cells with miR-16 to examine whether this miRNA exhibited tumor-suppressive effects in CTCL cells. In CTCL cells expressing wild-type p53, forced expression of miR-16 enhanced p21 expression via downregulation of the polycomb group protein Bmi1, thereby inducing cellular senescence. Alternatively, in CTCL cells lacking functional p53, miR-16 induced compensatory apoptosis. The miR-16 transfection significantly decreased senescent cells and increased apoptotic cells in p21-knockdown CTCL cells expressing wild-type p53, suggesting that the presence or absence of p21 may be the most important condition in the senescence-apoptosis switch in CTCL lymphomagenesis. Furthermore, we found that the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) restored the expression of miR-16 and its essential targets, induced senescence in CTCL cells expressing wild-type p53 and promoted apoptosis in cells with nonfunctional p53. Moreover, we found that other T/NK-cell lymphoma cell lines showed similar tumor-suppressive effects in response to miR-16 and SAHA and that these effects were dependent on p53 status. These results suggested that epigenetic silencing of miR-16 may be a key step during lymphoma development. Elucidation of the essential targets of miR-16 and SAHA provides a basis for the clinical application of SAHA in the treatment of CTCL and other non-Hodgkin T/NK-cell lymphomas.	[Kitadate, A.; Ikeda, S.; Teshima, K.; Ito, M.; Toyota, I.; Takahashi, N.; Tagawa, H.] Akita Univ, Grad Sch Med, Dept Hematol Nephrol & Rheumatol, 1-1-1 Hondo, Akita 0108543, Japan; [Hasunuma, N.] Akita Univ, Dept Dermatol, Akita, Japan; [Miyagaki, T.; Sugaya, M.] Univ Tokyo, Dept Dermatol, Tokyo, Japan	Akita University; Akita University; University of Tokyo	Tagawa, H (corresponding author), Akita Univ, Grad Sch Med, Dept Hematol Nephrol & Rheumatol, 1-1-1 Hondo, Akita 0108543, Japan.	htagawa0279jp@yahoo.co.jp	Miyagaki, Tomomitsu/AFP-0003-2022; Kitadate, Akihiro/AAD-7306-2020; 菅谷, 誠/GWC-3786-2022	Kitadate, Akihiro/0000-0003-3218-2446	JSPS KAKENHI [25461405]; Uehara Memorial Foundation	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Uehara Memorial Foundation(Uehara Memorial Foundation)	We wish to express our appreciation to Mr J Yamashita for his outstanding technical assistance. This work was supported by JSPS KAKENHI Grant Number 25461405 (Grant-in-Aid for Scientific Research (to HT)) and a Grant from the Uehara Memorial Foundation.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Al-Yacoub N, 2012, J INVEST DERMATOL, V132, P2263, DOI 10.1038/jid.2012.125; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bhattacharya R, 2009, CANCER RES, V69, P9090, DOI 10.1158/0008-5472.CAN-09-2552; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Brueckner B, 2005, CANCER RES, V65, P6305, DOI 10.1158/0008-5472.CAN-04-2957; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Cui YX, 2009, BLOOD, V113, P5217, DOI 10.1182/blood-2008-06-160168; Duvic M, 2007, BLOOD, V109, P31, DOI 10.1182/blood-2006-06-025999; Fasano CA, 2007, CELL STEM CELL, V1, P87, DOI 10.1016/j.stem.2007.04.001; Gallardo F, 2004, HAEMATOLOGICA, V89, P1401; Heider U, 2009, EUR J HAEMATOL, V82, P440, DOI 10.1111/j.1600-0609.2009.01239.x; Hu XW, 2014, CANCER CELL, V26, P344, DOI 10.1016/j.ccr.2014.07.009; Ito M, 2014, BLOOD, V123, P1499, DOI 10.1182/blood-2013-09-527739; Janicke RU, 2007, CELL CYCLE, V6, P407; Jaffe ES, 2008, WORLD HLTH ORG CLASS, P269; Johmura Y, 2014, MOL CELL, V55, P73, DOI 10.1016/j.molcel.2014.05.003; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Krenning L, 2014, MOL CELL, V55, P59, DOI 10.1016/j.molcel.2014.05.007; Laharanne E, 2010, MODERN PATHOL, V23, P547, DOI 10.1038/modpathol.2009.196; Ling X, 2014, CANCER RES, V74, P7487, DOI 10.1158/0008-5472.CAN-14-0683; Linsley PS, 2007, MOL CELL BIOL, V27, P2240, DOI 10.1128/MCB.02005-06; Litvinov IV, 2014, CLIN CANCER RES, V20, P3799, DOI 10.1158/1078-0432.CCR-14-0307; Liu Q, 2008, NUCLEIC ACIDS RES, V36, P5391, DOI 10.1093/nar/gkn522; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Manfe V, 2012, J INVEST DERMATOL, V132, P1487, DOI 10.1038/jid.2012.10; Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272; McGregor JM, 1999, J INVEST DERMATOL, V112, P317, DOI 10.1046/j.1523-1747.1999.00507.x; Miyagaki T, 2011, CLIN CANCER RES, V17, P7529, DOI 10.1158/1078-0432.CCR-11-1192; Munoz-Espin D, 2013, CELL, V155, P1104, DOI 10.1016/j.cell.2013.10.019; Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434; Polytarchou C, 2012, P NATL ACAD SCI USA, V109, P14470, DOI 10.1073/pnas.1212811109; Ralfkiaer E, 2008, WHO CLASSIFICATION T, P296; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Sampath D, 2012, BLOOD, V119, P1162, DOI 10.1182/blood-2011-05-351510; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Storer M, 2013, CELL, V155, P1119, DOI 10.1016/j.cell.2013.10.041; Teshima K, 2014, ONCOGENE, V33, P2191, DOI 10.1038/onc.2013.177; TOSCA A, 1991, ANTICANCER RES, V11, P1433; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; van Doorn R, 2005, J CLIN ONCOL, V23, P3886, DOI 10.1200/JCO.2005.11.353; Watanabe A, 2011, LEUKEMIA, V25, P1324, DOI 10.1038/leu.2011.81; Weinberg RA, 2007, BIOL CANC; Willemze R, 2005, BLOOD, V105, P3768, DOI 10.1182/blood-2004-09-3502; Zhang CL, 2007, HUM PATHOL, V38, P995, DOI 10.1016/j.humpath.2006.10.021; Zhang CL, 2005, J INVEST DERMATOL, V125, P1045, DOI 10.1111/j.0022-202X.2005.23925.x; Zhang X, 2012, ONCOGENE, V31, P3002, DOI 10.1038/onc.2011.470	50	37	39	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3692	3704		10.1038/onc.2015.435	http://dx.doi.org/10.1038/onc.2015.435			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26640145				2022-12-17	WOS:000379622800008
J	Ferreira, HJ; Heyn, H; Vizoso, M; Moutinho, C; Vidal, E; Gomez, A; Martinez-Cardus, A; Simo-Riudalbas, L; Moran, S; Jost, E; Esteller, M				Ferreira, H. J.; Heyn, H.; Vizoso, M.; Moutinho, C.; Vidal, E.; Gomez, A.; Martinez-Cardus, A.; Simo-Riudalbas, L.; Moran, S.; Jost, E.; Esteller, M.			DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia	ONCOGENE			English	Article							AML; GENES; CELL; HOX; METHYLATION; EXPRESSION; TARGETS	Close to half of de novo acute myeloid leukemia (AML) cases do not exhibit any cytogenetic aberrations. In this regard, distortion of the DNA methylation setting and the presence of mutations in epigenetic modifier genes can also be molecular drivers of the disease. In recent years, somatic missense mutations of the DNA methyltransferase 3A (DNMT3A) have been reported in similar to 20% of AML patients; however, no obvious critical downstream gene has been identified that could explain the role of DNMT3A in the natural history of AML. Herein, using whole-genome bisulfite sequencing and DNA methylation microarrays, we have identified a key gene undergoing promoter hypomethylation-associated transcriptional reactivation in DNMT3 mutant patients, the leukemogenic HOX cofactor MEIS1. Our results indicate that, in the absence of mixed lineage leukemia fusions, an alternative pathway for engaging an oncogenic MEIS1-dependent transcriptional program can be mediated by DNMT3A mutations.	[Ferreira, H. J.; Heyn, H.; Vizoso, M.; Moutinho, C.; Vidal, E.; Gomez, A.; Martinez-Cardus, A.; Simo-Riudalbas, L.; Moran, S.; Esteller, M.] Bellvitge Biomed Res Inst IDIBELL, PEBC, Barcelona, Catalonia, Spain; [Jost, E.] Rhein Westfal TH Aachen, Fac Med, Dept Hematol Oncol Hemostaseol & Stem Cell Transp, Aachen, Germany; [Esteller, M.] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Catalonia, Spain; [Esteller, M.] ICREA, Barcelona, Catalonia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); RWTH Aachen University; University of Barcelona; ICREA	Esteller, M (corresponding author), Hosp Duran & Reynals, Bellvitge Biomed Res Inst IDIBELL, PEBC, 3rd Floor,Avda Gran Via Km 2-7, Barcelona 08908, Catalonia, Spain.	mesteller@idibell.cat	Esteller, Manel/L-5956-2014; Moran, Sebastian/G-5293-2013; Martinez, Anna/AAA-4939-2020; Vidal, Enrique/R-5593-2019; Gomez Moruno, Antonio/H-7574-2015	Esteller, Manel/0000-0003-4490-6093; Moran, Sebastian/0000-0003-4192-8983; Vidal, Enrique/0000-0002-4217-1807; Heyn, Holger/0000-0002-3276-1889; Ferreira, Humberto/0000-0003-0834-2956; Gomez Moruno, Antonio/0000-0001-5308-981X; Martinez Cardus, Anna/0000-0002-3937-8794; Vizoso, Miguel/0000-0002-9992-2851	European Community [HEALTH-F5-011-282510-BLUEPRINT]; Cellex Foundation; MINECO Project [SAF2011-22803]; AGAUR [2014SGR633]; Health and Science Departments of the Catalan government (Generalitat de Catalunya); Program in Experimental Biology and Biomedicine, University of Coimbra, Portugal; ERC [268626-EPINORC]; ICREA Funding Source: Custom	European Community(European Commission); Cellex Foundation(Foundation CELLEX); MINECO Project(Spanish Government); AGAUR(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); Health and Science Departments of the Catalan government (Generalitat de Catalunya); Program in Experimental Biology and Biomedicine, University of Coimbra, Portugal; ERC(European Research Council (ERC)European Commission); ICREA(ICREA)	This work was supported by the European Community's Seventh Framework Program (FP7/2007-2013) under grant agreements HEALTH-F5-011-282510-BLUEPRINT and ERC no. 268626-EPINORC project; the Cellex Foundation; the MINECO Project no. SAF2011-22803 and AGAUR 2014SGR633 grants; and the Health and Science Departments of the Catalan government (Generalitat de Catalunya). HJF was supported by the Program in Experimental Biology and Biomedicine, University of Coimbra, Portugal and ME is an ICREA Research Professor.	Grimwade D, 2010, BLOOD, V116, P354, DOI 10.1182/blood-2009-11-254441; Hajkova H, 2012, LEUKEMIA RES, V36, P1128, DOI 10.1016/j.leukres.2012.05.012; Heuser M, 2011, CANCER CELL, V20, P39, DOI 10.1016/j.ccr.2011.06.020; Hollink IHIM, 2012, LEUKEMIA, V26, P371, DOI 10.1038/leu.2011.210; Im AP, 2014, LEUKEMIA, V28, P1774, DOI 10.1038/leu.2014.124; Kohlmann A, 2005, LEUKEMIA, V19, P953, DOI 10.1038/sj.leu.2403746; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; Pineault N, 2002, EXP HEMATOL, V30, P49, DOI 10.1016/S0301-472X(01)00757-3; Qu Y, 2014, EPIGENETICS-US, V9, P1108, DOI 10.4161/epi.29315; Roller A, 2013, LEUKEMIA, V27, P1573, DOI 10.1038/leu.2013.65; Russler-Germain DA, 2014, CANCER CELL, V25, P442, DOI 10.1016/j.ccr.2014.02.010; Wong P, 2007, GENE DEV, V21, P2762, DOI 10.1101/gad.1602107; Yan XJ, 2011, NAT GENET, V43, P309, DOI 10.1038/ng.788; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004	15	37	39	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					3079	3082		10.1038/onc.2015.359	http://dx.doi.org/10.1038/onc.2015.359			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26434589	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000377474500013
J	Weekes, D; Kashima, TG; Zandueta, C; Perurena, N; Thomas, DP; Sunters, A; Vuillier, C; Bozec, A; El-Emir, E; Miletich, I; Patino-Garcia, A; Lecanda, F; Grigoriadis, AE				Weekes, D.; Kashima, T. G.; Zandueta, C.; Perurena, N.; Thomas, D. P.; Sunters, A.; Vuillier, C.; Bozec, A.; El-Emir, E.; Miletich, I.; Patino-Garcia, A.; Lecanda, F.; Grigoriadis, A. E.			Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTORS; C-FOS PROTOONCOGENE; NUCLEAR TRANSLOCATION; GENE-EXPRESSION; TRANSGENIC MICE; BONE; DIFFERENTIATION; CANCER; OVEREXPRESSION; OSTEOBLASTS	Osteosarcoma is the most common primary malignancy of the skeleton and is prevalent in children and adolescents. Survival rates are poor and have remained stagnant owing to chemoresistance and the high propensity to form lung metastases. In this study, we used in vivo transgenic models of c-fos oncogene-induced osteosarcoma and chondrosarcoma in addition to c-Fos-inducible systems in vitro to investigate downstream signalling pathways that regulate osteosarcoma growth and metastasis. Fgfr1 (fibroblast growth factor receptor 1) was identified as a novel c-Fos/activator protein-1(AP-1)-regulated gene. Induction of c-Fos in vitro in osteoblasts and chondroblasts caused an increase in Fgfr1 RNA and FGFR1 protein expression levels that resulted in increased and sustained activation of mitogen-activated protein kinases (MAPKs), morphological transformation and increased anchorage-independent growth in response to FGF2 ligand treatment. High levels of FGFR1 protein and activated pFRS2 alpha signalling were observed in murine and human osteosarcomas. Pharmacological inhibition of FGFR1 signalling blocked MAPK activation and colony growth of osteosarcoma cells in vitro. Orthotopic injection in vivo of FGFR1-silenced osteosarcoma cells caused a marked twofold to fivefold decrease in spontaneous lung metastases. Similarly, inhibition of FGFR signalling in vivo with the small-molecule inhibitor AZD4547 markedly reduced the number and size of metastatic nodules. Thus deregulated FGFR signalling has an important role in osteoblast transformation and osteosarcoma formation and regulates the development of lung metastases. Our findings support the development of anti-FGFR inhibitors as potential antimetastatic therapy.	[Weekes, D.; Kashima, T. G.; Thomas, D. P.; Sunters, A.; Vuillier, C.; El-Emir, E.; Miletich, I.; Grigoriadis, A. E.] Kings Coll London, Dept Craniofacial Dev & Stem Cell Biol, London SE1 9RT, England; [Zandueta, C.; Perurena, N.; Lecanda, F.] Univ Navarra, Ctr Appl Med Res CIMA, Div Oncol, Adhes & Metastasis Lab, E-31080 Pamplona, Spain; [Bozec, A.] Univ Klinikum Erlangen, Dept Rheumatol & Immunol, Erlangen, Germany; [Patino-Garcia, A.] Univ Navarra, Ctr Appl Med Res CIMA, Lab Pediat, E-31080 Pamplona, Spain; [Patino-Garcia, A.; Lecanda, F.] Navarra Inst Hlth Res, IdiSNA, Pamplona, Spain; [Weekes, D.] Kings Coll London, Breakthrough Breast Canc Unit, London SE1 9RT, England; [Sunters, A.] Univ London Royal Vet Coll, London, England	University of London; King's College London; University of Navarra; University of Erlangen Nuremberg; University of Navarra; University of London; King's College London; University of London; University of London Royal Veterinary College	Grigoriadis, AE (corresponding author), Kings Coll London, Guys Hosp, Dept Craniofacial Dev & Stem Cell Biol, Tower Floor 27, London SE1 9RT, England.	agi.grigoriadis@kcl.ac.uk	Bozec, Aline/M-6942-2015; Patiño-Garcia, Ana/I-4299-2012	Bozec, Aline/0000-0001-8174-2118; Patiño-Garcia, Ana/0000-0002-4066-8203; Miletich, Isabelle/0000-0003-2817-7492; Perurena, Naiara/0000-0003-0874-3389; Zandueta Pascual, Carolina/0000-0002-7931-8649; Weekes, Daniel/0000-0001-8083-7617	Bone Cancer Research Trust, UK [BCRT04/07, BCRT09/08]; Wellcome Trust [059344]; Arthritis Research UK [G0538]; Medical Research Council [G78/4785]; 'UTE project FIMA' agreement; Cancer Research Thematic Network of the Health Institute Carlos III [RTICC RD06/0020/0066]; Spanish Ministry of Science and Innovation; European Regional Development Fund (ERDF); AECC grant	Bone Cancer Research Trust, UK; Wellcome Trust(Wellcome Trust); Arthritis Research UK(Versus Arthritis); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); 'UTE project FIMA' agreement; Cancer Research Thematic Network of the Health Institute Carlos III; Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); European Regional Development Fund (ERDF)(European Commission); AECC grant	This manuscript is dedicated to the memory of Dr Takeshi G Kashima, friend and colleague, without whom this work would not progress. We thank Dr M Albert Basson (KCL, London, UK), Dr Ozge Uluckan (CNIO, Madrid, Spain) and Dr Latifa Bakiri (CNIO, Madrid, Spain) for helpful comments and critical reading of the manuscript and Professor Larry J Suva (UAMS, Little Rock, AR, USA) for the microCT analysis. This work was supported in part by: Bone Cancer Research Trust, UK (BCRT04/07; BCRT09/08), Wellcome Trust (059344), Arthritis Research UK (G0538) and Medical Research Council (G78/4785) to AEG; 'UTE project FIMA' agreement, The Cancer Research Thematic Network of the Health Institute Carlos III (RTICC RD06/0020/0066), Spanish Ministry of Science and Innovation and European Regional Development Fund (ERDF) 'Una manera de hacer Europa' and AECC grant to FL. FL is an investigator from the I3 Program.	Amary MF, 2014, CANCER MED-US, V3, P980, DOI 10.1002/cam4.268; Ando Kosei, 2012, Sarcoma, V2012, P523432, DOI 10.1155/2012/523432; Behr B, 2010, BONE, V47, P281, DOI 10.1016/j.bone.2010.05.008; Bodo M, 2002, MOL MED, V8, P393, DOI 10.1007/BF03402020; Bozec A, 2010, J CELL BIOL, V190, P1093, DOI 10.1083/jcb.201002111; Brooks AN, 2012, CLIN CANCER RES, V18, P1855, DOI 10.1158/1078-0432.CCR-11-0699; Carter EP, 2015, TRENDS CELL BIOL, V25, P221, DOI 10.1016/j.tcb.2014.11.003; Chen Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098293; Dailey L, 2005, CYTOKINE GROWTH F R, V16, P233, DOI 10.1016/j.cytogfr.2005.01.007; David JP, 2005, J CLIN INVEST, V115, P664, DOI 10.1172/JCI200522877; Durchdewald M, 2008, CANCER RES, V68, P6877, DOI 10.1158/0008-5472.CAN-08-0299; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; FERRACINI R, 1995, ONCOGENE, V10, P739; Franchi A, 1998, VIRCHOWS ARCH, V432, P515, DOI 10.1007/s004280050199; Fujiwara M, 2011, TUMOR BIOL, V32, P611, DOI 10.1007/s13277-011-0160-y; Gavine PR, 2012, CANCER RES, V72, P2045, DOI 10.1158/0008-5472.CAN-11-3034; Greulich H, 2011, TRENDS MOL MED, V17, P283, DOI 10.1016/j.molmed.2011.01.012; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; Grose R, 2007, EMBO J, V26, P1268, DOI 10.1038/sj.emboj.7601583; Guagnano V, 2012, CANCER DISCOV, V2, P1118, DOI 10.1158/2159-8290.CD-12-0210; Hajihosseini MK, 2004, DEVELOPMENT, V131, P325, DOI 10.1242/dev.00940; Jamil N, 2010, INT J EXP PATHOL, V91, P387, DOI 10.1111/j.1365-2613.2010.00749.x; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838; Kashima T, 2003, INT J CANCER, V104, P147, DOI 10.1002/ijc.10931; Kashimaa TG, 2009, HUM PATHOL, V40, P226, DOI 10.1016/j.humpath.2008.07.008; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kunita A, 2011, AM J PATHOL, V179, P1041, DOI 10.1016/j.ajpath.2011.04.027; LADANYI M, 1993, DIAGN MOL PATHOL, V2, P163, DOI 10.1097/00019606-199303000-00024; Marie PJ, 2005, J CELL BIOCHEM, V96, P888, DOI 10.1002/jcb.20582; Marshall ME, 2011, CLIN CANCER RES, V17, P5016, DOI 10.1158/1078-0432.CCR-11-0050; Mills IG, 2012, SEMIN CELL DEV BIOL, V23, P165, DOI 10.1016/j.semcdb.2011.09.004; Miraoui H, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3146re9; Ng AJM, 2012, CLIN SARCOMA RES, V2, DOI 10.1186/2045-3329-2-19; Ohbayashi N, 2002, GENE DEV, V16, P870, DOI 10.1101/gad.965702; Ornitz DM, 2005, CYTOKINE GROWTH F R, V16, P205, DOI 10.1016/j.cytogfr.2005.02.003; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; Raucci A, 2008, J CELL PHYSIOL, V215, P442, DOI 10.1002/jcp.21323; Sabbieti MG, 2005, CELL TISSUE RES, V319, P267, DOI 10.1007/s00441-004-0981-8; Shimizu T, 2010, ONCOGENE, V29, P5687, DOI 10.1038/onc.2010.312; Shimizu T, 2012, MOL CANCER RES, V10, P454, DOI 10.1158/1541-7786.MCR-11-0347; Sorensen V, 2006, BIOESSAYS, V28, P504, DOI 10.1002/bies.20405; Sunters A, 2004, J BIOL CHEM, V279, P9882, DOI 10.1074/jbc.M310184200; Sunters A, 1998, DEV GENET, V22, P386, DOI 10.1002/(SICI)1520-6408(1998)22:4<386::AID-DVG8>3.0.CO;2-2; Thomas DP, 2000, J CELL SCI, V113, P439; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Vicent S, 2008, CANCER RES, V68, P2275, DOI 10.1158/0008-5472.CAN-07-6493; WANG ZQ, 1995, CANCER RES, V55, P6244; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; Wilkie AOM, 2005, CYTOKINE GROWTH F R, V16, P187, DOI 10.1016/j.cytogfr.2005.03.001; WU JX, 1990, ONCOGENE, V5, P989; Yaguchi Y, 2009, DEV DYNAM, V238, P2058, DOI 10.1002/dvdy.22013; Zenz R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2338	53	37	37	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2852	2861		10.1038/onc.2015.344	http://dx.doi.org/10.1038/onc.2015.344			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26387545	Green Accepted			2022-12-17	WOS:000377473700005
J	Satheesha, S; Manzella, G; Bovay, A; Casanova, EA; Bode, PK; Belle, R; Feuchtgruber, S; Jaaks, P; Dogan, N; Koscielniak, E; Schafer, BW				Satheesha, S.; Manzella, G.; Bovay, A.; Casanova, E. A.; Bode, P. K.; Belle, R.; Feuchtgruber, S.; Jaaks, P.; Dogan, N.; Koscielniak, E.; Schafer, B. W.			Targeting hedgehog signaling reduces self-renewal in embryonal rhabdomyosarcoma	ONCOGENE			English	Article							STEM-CELLS; TUMOR-CELL; PATHWAY; GROWTH; GLI; REQUIREMENT; EXPRESSION; MODEL; RAS	Current treatment regimens for rhabdomyosarcoma (RMS), the most common pediatric soft tissue cancer, rely on conventional chemotherapy, and although they show clinical benefit, there is a significant risk of adverse side effects and secondary tumors later in life. Therefore, identifying and targeting sub-populations with higher tumorigenic potential and self-renewing capacity would offer improved patient management strategies. Hedgehog signaling has been linked to the development of embryonal RMS (ERMS) through mouse genetics and rare human syndromes. However, activating mutations in this pathway in sporadic RMS are rare and therefore the contribution of hedgehog signaling to oncogenesis remains unclear. Here, we show by genetic loss-and gain-of-function experiments and the use of clinically relevant small molecule modulators that hedgehog signaling is important for controlling self-renewal of a subpopulation of RMS cells in vitro and tumor initiation in vivo. In addition, hedgehog activity altered chemoresistance, motility and differentiation status. The core stem cell gene NANOG was determined to be important for ERMS self-renewal, possibly acting downstream of hedgehog signaling. Crucially, evaluating the presence of a subpopulation of tumor-propagating cells in patient biopsies identified by GLI1 and NANOG expression had prognostic significance. Hence, this work identifies novel functional aspects of hedgehog signaling in ERMS, redefines the rationale for its targeting as means to control ERMS self-renewal and underscores the importance of studying functional tumor heterogeneity in pediatric cancers.	[Satheesha, S.; Manzella, G.; Bovay, A.; Casanova, E. A.; Bode, P. K.; Belle, R.; Jaaks, P.; Dogan, N.; Schafer, B. W.] Univ Childrens Hosp, Dept Oncol, Steinwiessstr 75, CH-8032 Zurich, Switzerland; [Satheesha, S.; Manzella, G.; Bovay, A.; Casanova, E. A.; Bode, P. K.; Belle, R.; Jaaks, P.; Dogan, N.; Schafer, B. W.] Univ Childrens Hosp, Childrens Res Ctr, Steinwiessstr 75, CH-8032 Zurich, Switzerland; [Bode, P. K.] Univ Zurich Hosp, Inst Surg Pathol, CH-8091 Zurich, Switzerland; [Feuchtgruber, S.; Koscielniak, E.] Klinikum Stuttgart, Olgahosp, Dept Oncol Hematol Immunol, Stuttgart, Germany	University Children's Hospital Zurich; University Children's Hospital Zurich; University of Zurich; University Zurich Hospital; General Hospital of N. Ionia Agia Olga; Klinikum Stuttgart	Schafer, BW (corresponding author), Univ Childrens Hosp, Dept Oncol, Steinwiessstr 75, CH-8032 Zurich, Switzerland.; Schafer, BW (corresponding author), Univ Childrens Hosp, Childrens Res Ctr, Steinwiessstr 75, CH-8032 Zurich, Switzerland.	Beat.Schaefer@kispi.uzh.ch		Schafer, Beat/0000-0001-5988-2915; Rappaz, Sampoorna/0000-0002-7330-7586; Bode, Peter/0000-0002-9633-4042; Bovay, Amandine/0000-0001-6947-9812	Swiss National Science Fund [31003A-138460]; Sciex [F-80016-02-01]; Cancer League Canton Zurich	Swiss National Science Fund(Swiss National Science Foundation (SNSF)); Sciex; Cancer League Canton Zurich	We highly appreciate St Jude's Children's Research Hospital for providing the ERMS PDX samples, Swiss Pediatric Oncology Group (SPOG) for providing ERMS patient tumor samples and the German Soft tissue sarcoma study group (CWS) for providing the TMA sections and performing the clinical data analysis. We are also grateful to Silvia Behnke (Sophistolab AG) and the technicians at the Institute of Surgical Pathology (University Hospital Zurich) for their excellent service. The work was supported by grants from Swiss National Science Fund (31003A-138460), Sciex (F-80016-02-01) and Cancer League Canton Zurich.	Amakye D, 2013, NAT MED, V19, P1410, DOI 10.1038/nm.3389; Annavarapu SR, 2013, LAB INVEST, V93, P1090, DOI 10.1038/labinvest.2013.97; Belyea Brian, 2012, Sarcoma, V2012, P406239, DOI 10.1155/2012/406239; Brack AS, 2008, CELL STEM CELL, V2, P50, DOI 10.1016/j.stem.2007.10.006; Buckingham M, 2007, ANNU REV CELL DEV BI, V23, P645, DOI 10.1146/annurev.cellbio.23.090506.123438; Chen EY, 2014, P NATL ACAD SCI USA, V111, P5349, DOI 10.1073/pnas.1317731111; Chen X, 2013, CANCER CELL, V24, P710, DOI 10.1016/j.ccr.2013.11.002; Ehnman M, 2013, CANCER RES, V73, P2139, DOI 10.1158/0008-5472.CAN-12-1646; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gage PJ, 2005, INVEST OPHTH VIS SCI, V46, P4200, DOI 10.1167/iovs.05-0691; Hawkins DS, 2014, CURR OPIN PEDIATR, V26, P50, DOI 10.1097/MOP.0000000000000041; Hirotsu M, 2009, BRIT J CANCER, V101, P2030, DOI 10.1038/sj.bjc.6605407; Hui CC, 2011, ANNU REV CELL DEV BI, V27, P513, DOI 10.1146/annurev-cellbio-092910-154048; Ignatius MS, 2012, CANCER CELL, V21, P680, DOI 10.1016/j.ccr.2012.03.043; Kuang S, 2008, CELL STEM CELL, V2, P22, DOI 10.1016/j.stem.2007.12.012; Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007; Liu P, 2010, DEV DYNAM, V239, P2161, DOI 10.1002/dvdy.22347; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; Merchant AA, 2010, CLIN CANCER RES, V16, P3130, DOI 10.1158/1078-0432.CCR-09-2846; Nitzki F, 2011, ONCOGENE, V30, P4428, DOI 10.1038/onc.2011.157; Paulson V, 2011, GENE CHROMOSOME CANC, V50, P397, DOI 10.1002/gcc.20864; Po A, 2010, EMBO J, V29, P2646, DOI 10.1038/emboj.2010.131; Pressey JG, 2013, PEDIATR BLOOD CANCER, V60, P45, DOI 10.1002/pbc.24117; Pressey JG, 2011, PEDIATR BLOOD CANCER, V57, P930, DOI 10.1002/pbc.23174; Raimondi L, 2012, CELL DEATH DIFFER, V19, P871, DOI 10.1038/cdd.2011.171; Rajurkar M, 2014, ONCOGENE, V33, P5370, DOI 10.1038/onc.2013.480; Satheesha S, 2014, STEM CELLS CANC STEM, V11, P111; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Stecca B, 2009, EMBO J, V28, P663, DOI 10.1038/emboj.2009.16; Theunissen TW, 2011, PHILOS T R SOC B, V366, P2222, DOI 10.1098/rstb.2011.0003; Vermeulen L, 2012, LANCET ONCOL, V13, pE83, DOI 10.1016/S1470-2045(11)70257-1; Vidal SJ, 2014, ONCOGENE, V33, P4451, DOI 10.1038/onc.2013.411; von Maltzahn J, 2012, TRENDS CELL BIOL, V22, P602, DOI 10.1016/j.tcb.2012.07.008; Voronova A, 2013, J BIOL CHEM, V288, P4389, DOI 10.1074/jbc.M112.400184; Wachtel M, 2006, J CLIN ONCOL, V24, P816, DOI 10.1200/JCO.2005.03.4934; Walter D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019506; Wang ML, 2013, ONCOTARGETS THER, V6, P1207, DOI 10.2147/OTT.S38114; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137; Zibat A, 2010, ONCOGENE, V29, P6323, DOI 10.1038/onc.2010.368	40	37	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2020	2030		10.1038/onc.2015.267	http://dx.doi.org/10.1038/onc.2015.267			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26189795	hybrid, Green Published			2022-12-17	WOS:000374505600002
J	Subbaiah, VK; Zhang, Y; Rajagopalan, D; Abdullah, LN; Yeo-Teh, NSL; Tomaic, V; Banks, L; Myers, MP; Chow, EK; Jha, S				Subbaiah, V. K.; Zhang, Y.; Rajagopalan, D.; Abdullah, L. N.; Yeo-Teh, N. S. L.; Tomaic, V.; Banks, L.; Myers, M. P.; Chow, E. K.; Jha, S.			E3 ligase EDD1/UBR5 is utilized by the HPV E6 oncogene to destabilize tumor suppressor TIP60	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; HISTONE ACETYLTRANSFERASE; EDD; ACETYLATION; PROTEIN; GENE; DEGRADATION; INHIBITION; CHROMATIN; COMPLEX	Tat-interacting protein of 60 kDa (TIP60) is an essential lysine acetyltransferase implicated in transcription, DNA damage response and apoptosis. TIP60 protein expression is reduced in cancers. In cervical cancers, human papillomavirus (HPV) E6 oncogene targets cellular p53, Bak and some of the PDZ domain-containing proteins for proteasome-mediated degradation through E6AP ligase. Recently, E6 oncogene from high-risk and low-risk categories was also shown to target TIP60. However, the molecular mechanisms and whether destabilization of TIP60 contributes to HPV E6-mediated transformation remain unanswered. Our proteomic analyses revealed EDD1 (E3 identified by differential display), an E3 ligase generally overexpressed in cancers as a novel interacting partner of TIP60. By investigating protein turnover and ubiquitination assays, we show that EDD1 negatively regulates TIP60's stability through the proteasome pathway. Strikingly, HPV E6 uses this function of EDD1 to destabilize TIP60. Colony-formation assays and soft agar assays show that gain of function of TIP60 or depletion of EDD1 in HPV-positive cervical cancer cells significantly inhibits cell growth in vitro. This phenotype is strongly supported by the in-vivo studies where re-activation of TIP60 in cervical cancer cells dramatically reduces tumor formation. In summary, we have discovered a novel ligase through which E6 destabilizes TIP60. Currently, in the absence of an effective therapeutic vaccine for malignant cervical cancers, cervical cancer still remains to be a major disease burden. Hence, our studies implying a distinct tumor suppressor role for TIP60 in cervical cancers show that reactivation of TIP60 could be of therapeutic value.	[Subbaiah, V. K.; Zhang, Y.; Rajagopalan, D.; Abdullah, L. N.; Yeo-Teh, N. S. L.; Chow, E. K.; Jha, S.] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore; [Rajagopalan, D.; Jha, S.] Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore; [Yeo-Teh, N. S. L.] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 117548, Singapore; [Tomaic, V.; Banks, L.; Myers, M. P.] Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy; [Chow, E. K.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore 117595, Singapore	National University of Singapore; National University of Singapore; National University of Singapore; International Center for Genetic Engineering & Biotechnology (ICGEB); National University of Singapore	Jha, S (corresponding author), Ctr Translat Med, 14 Med Dr,MD6-13-02J, Singapore 117599, Singapore.	csisjha@nus.edu.sg	Jha, Sudhakar/S-3550-2019; , Subbaiah/AAB-9747-2021; Jha, Sudhakar/B-2308-2009	Jha, Sudhakar/0000-0002-5093-4843; Yeo-Teh, Nicole/0000-0002-9153-9663; Krishna, Vanitha/0000-0002-0444-531X; Chow, Edward/0000-0002-3075-1898	National Research Foundation Singapore; Singapore Ministry of Education under its Research Centers of Excellence initiative to the Cancer Science Institute of Singapore [R-713-006-014-271]; National Medical Research Council (NMRC) [CBRG-NIG BNIG11nov001]; Ministry of Education Academic Research Fund (MOE AcRF); National Research Foundation Cancer Science Institute of Singapore RCE Main Grant; National Medical Research Council (NMRC CBRG-NIG) [BNIG12nov017]	National Research Foundation Singapore(National Research Foundation, Singapore); Singapore Ministry of Education under its Research Centers of Excellence initiative to the Cancer Science Institute of Singapore(Ministry of Education, Singapore); National Medical Research Council (NMRC)(National Medical Research Council, Singapore); Ministry of Education Academic Research Fund (MOE AcRF); National Research Foundation Cancer Science Institute of Singapore RCE Main Grant(National Research Foundation, Singapore); National Medical Research Council (NMRC CBRG-NIG)(National Medical Research Council, Singapore)	We thank the members of the Jha laboratory for helpful discussion and comments. We thank Drs Neerja Karnani (Singapore Institute for Clinical Science, A*STAR), Daniel G Tenen (Cancer Science Institute of Singapore) and Yoshiaki Ito (Cancer Science Institute of Singapore) for their comments on the manuscript. We thank Drs Shojiro Kitajima for soft agar assays, Amit Kumar Pandey for real-time PCR and Tan Boon Toh for tumor quantification analysis. SJ was supported by grants from the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centers of Excellence initiative to the Cancer Science Institute of Singapore (R-713-006-014-271), National Medical Research Council (NMRC CBRG-NIG BNIG11nov001) and Ministry of Education Academic Research Fund (MOE AcRF Tier 1 T1-2012 Oct-04). EKC was supported by grants from the National Research Foundation Cancer Science Institute of Singapore RCE Main Grant, National Medical Research Council (NMRC CBRG-NIG BNIG12nov017) and Ministry of Education Academic Research Fund (MOE AcRF Tier 1 T1-2012 Oct-11).	Alpsoy A, 2014, BIOMED PHARMACOTHER, V68, P351, DOI 10.1016/j.biopha.2013.09.007; Awasthi S, 2005, MOL CELL BIOL, V25, P6178, DOI 10.1128/MCB.25.14.6178-6198.2005; Bradley A, 2014, CARCINOGENESIS, V35, P1100, DOI 10.1093/carcin/bgt489; Callaghan MJ, 1998, ONCOGENE, V17, P3479, DOI 10.1038/sj.onc.1202249; Chou SW, 2009, ANTIMICROB AGENTS CH, V53, P81, DOI 10.1128/AAC.01177-08; Col E, 2005, EMBO J, V24, P2634, DOI 10.1038/sj.emboj.7600734; Eblen ST, 2003, J BIOL CHEM, V278, P14926, DOI 10.1074/jbc.M300485200; Fazzio TG, 2008, CELL, V134, P162, DOI 10.1016/j.cell.2008.05.031; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Gorrini C, 2007, NATURE, V448, P1063, DOI 10.1038/nature06055; Gupta A, 2013, ONCOGENE, V32, P5017, DOI 10.1038/onc.2012.534; Hay-Koren A, 2011, MOL BIOL CELL, V22, P399, DOI 10.1091/mbc.E10-05-0440; Henderson MJ, 2006, J BIOL CHEM, V281, P39990, DOI 10.1074/jbc.M602818200; Henderson MJ, 2002, J BIOL CHEM, V277, P26468, DOI 10.1074/jbc.M203527200; Honda Y, 2002, J BIOL CHEM, V277, P3599, DOI 10.1074/jbc.M104347200; Hu YF, 2009, DEV DYNAM, V238, P2912, DOI 10.1002/dvdy.22110; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P5249, DOI 10.1073/pnas.92.11.5249-a; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jha S, 2008, MOL CELL BIOL, V28, P2690, DOI 10.1128/MCB.01983-07; Jha S, 2010, MOL CELL, V38, P700, DOI 10.1016/j.molcel.2010.05.020; Jha S, 2009, MOL CELL, V34, P521, DOI 10.1016/j.molcel.2009.05.016; Kaidi A, 2013, NATURE, V498, DOI 10.1038/nature12201; Kimura A, 1998, GENES CELLS, V3, P789, DOI 10.1046/j.1365-2443.1998.00229.x; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Lee MT, 2013, J BIOL CHEM, V288, P25038, DOI 10.1074/jbc.M113.476952; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; Li RF, 2011, CELL HOST MICROBE, V10, P390, DOI 10.1016/j.chom.2011.08.013; Mahajan MA, 2014, MOL CELL ENDOCRINOL, V382, P159, DOI 10.1016/j.mce.2013.09.021; MANSFIELD E, 1994, DEV BIOL, V165, P507, DOI 10.1006/dbio.1994.1271; Metzger MB, 2012, J CELL SCI, V125, P531, DOI 10.1242/jcs.091777; Mori Y, 2002, CANCER RES, V62, P3641; Ohshima R, 2007, GENES CELLS, V12, P1339, DOI 10.1111/j.1365-2443.2007.01138.x; Reitsma JM, 2011, CELL HOST MICROBE, V9, P103, DOI 10.1016/j.chom.2011.01.006; Sapountzi V, 2006, INT J BIOCHEM CELL B, V38, P1496, DOI 10.1016/j.biocel.2006.03.003; Sho T, 2011, BBA-MOL CELL RES, V1813, P1245, DOI 10.1016/j.bbamcr.2011.03.018; Squatrito M, 2006, TRENDS CELL BIOL, V16, P433, DOI 10.1016/j.tcb.2006.07.007; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Subbaiah VK, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002543; Sun YL, 2007, MOL CELL BIOL, V27, P8502, DOI 10.1128/MCB.01382-07; Sun YL, 2010, CELL CYCLE, V9, P930, DOI 10.4161/cc.9.5.10931; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Tomaic V, 2011, J VIROL, V85, P3120, DOI 10.1128/JVI.02004-10; Utley RT, 2003, CURR TOP MICROBIOL, V274, P203; Zheng H, 2013, MOL CELL, V50, P699, DOI 10.1016/j.molcel.2013.04.013	46	37	40	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2062	2074		10.1038/onc.2015.268	http://dx.doi.org/10.1038/onc.2015.268			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26234678				2022-12-17	WOS:000374505600006
J	Goswami, MT; Reka, AK; Kurapati, H; Kaza, V; Chen, J; Standiford, TJ; Keshamouni, VG				Goswami, M. T.; Reka, A. K.; Kurapati, H.; Kaza, V.; Chen, J.; Standiford, T. J.; Keshamouni, V. G.			Regulation of complement-dependent cytotoxicity by TGF-beta-induced epithelial-mesenchymal transition	ONCOGENE			English	Article							TUMOR-CELLS; CANCER; EXPRESSION; PROTEINS; CD59; NEUTRALIZATION; MODULATION; RESISTANCE; PREDICTS; SURVIVAL	The process of epithelial-mesenchymal transition (EMT), in addition to being an initiating event for tumor metastasis, is implicated in conferring several clinically relevant properties to disseminating cancer cells. These include stem cell-like properties, resistance to targeted therapies and ability to evade immune surveillance. Enrichment analysis of gene expression changes during transforming growth factor-beta (TGF-beta)-induced EMT in lung cancer cells identified complement cascade as one of the significantly enriched pathway. Further analysis of the genes in the complement pathway revealed an increase in the expression of complement inhibitors and a decrease in the expression of proteins essential for complement activity. In this study, we tested whether EMT confers resistance to complement-dependent cytotoxicity (CDC) in lung cancer cells and promotes tumor progression. CD59 is a potent inhibitor of membrane attack complex that mediates complement-dependent cell lysis. We observed a significant increase in the CD59 expression on the surface of cells after TGF-beta-induced EMT. Furthermore, CD59 knockdown restored susceptibility of cells undergoing EMT to cetuximab-mediated CDC. TGF-beta-induced CD59 expression during EMT is dependent on Smad3 but not on Smad2. Chromatin immunoprecipitation analysis confirmed that Smad3 directly binds to the CD59 promoter. Stable knockdown of CD59 in A549 cells inhibited experimental metastasis. These results demonstrate that TGF-beta-induced EMT and CD59 expression confers an immune-evasive mechanism to disseminating tumor cells facilitating tumor progression. Together, our data demonstrates that CD59 inhibition may serve as an adjuvant to enhance the efficacy of antibody-mediated therapies, as well as to inhibit metastasis in lung cancer.	[Goswami, M. T.; Reka, A. K.; Kurapati, H.; Kaza, V.; Chen, J.; Standiford, T. J.; Keshamouni, V. G.] Univ Michigan, Med Ctr, Dept Internal Med, Div Pulm & Crit Care Med, 4062 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Keshamouni, VG (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Pulm & Crit Care Med, 4062 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	vkeshamo@med.umich.edu		Keshamouni, Venkateshwar/0000-0003-1947-791X	NIH/NCI [CA132571-01]; Elizabeth A Crary Fund; NIH/NHLBI [HL097564]; NATIONAL CANCER INSTITUTE [R01CA132571] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL123515, R01HL097564] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Elizabeth A Crary Fund; NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This research is funded by an NIH/NCI (CA132571-01) grant and the Elizabeth A Crary Fund to VGK and NIH/NHLBI HL097564 to TJS.	Corrales L, 2012, J IMMUNOL, V189, P4674, DOI 10.4049/jimmunol.1201654; Cragg MS, 2000, CELL DEATH DIFFER, V7, P48, DOI 10.1038/sj.cdd.4400627; Donin N, 2003, CLIN EXP IMMUNOL, V131, P254, DOI 10.1046/j.1365-2249.2003.02066.x; Fishelson Z, 2003, MOL IMMUNOL, V40, P109, DOI 10.1016/S0161-5890(03)00112-3; Ge XW, 2011, CLIN CANCER RES, V17, P6702, DOI 10.1158/1078-0432.CCR-11-0647; Hsu YF, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-139; Hu WG, 2011, CANCER RES, V71, P2298, DOI 10.1158/0008-5472.CAN-10-3016; Jurianz K, 1999, IMMUNOPHARMACOLOGY, V42, P209, DOI 10.1016/S0162-3109(99)00006-5; Jurianz K, 1999, MOL IMMUNOL, V36, P929, DOI 10.1016/S0161-5890(99)00115-7; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Keshamouni VG, 2009, J PROTEOME RES, V8, P35, DOI 10.1021/pr8006478; Keshamouni VG, 2006, J PROTEOME RES, V5, P1143, DOI 10.1021/pr050455t; Kim DD, 2006, CLIN IMMUNOL, V118, P127, DOI 10.1016/j.clim.2005.10.014; Kim WS, 1999, ANTICANCER RES, V19, P301; Kohler BA, 2011, JNCI-J NATL CANCER I, V103, P714, DOI 10.1093/jnci/djr077; Kong FM, 1999, CANCER-AM CANCER SOC, V86, P1712, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1712::AID-CNCR12>3.0.CO;2-V; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Markiewski MM, 2008, NAT IMMUNOL, V9, P1225, DOI 10.1038/ni.1655; Markiewski MM, 2009, TRENDS IMMUNOL, V30, P286, DOI 10.1016/j.it.2009.04.002; Masszi A, 2004, AM J PATHOL, V165, P1955, DOI 10.1016/S0002-9440(10)63247-6; NISHIOKA K, 1976, ANN NY ACAD SCI, V276, P303, DOI 10.1111/j.1749-6632.1976.tb41656.x; Pasch MC, 1999, EUR J IMMUNOL, V29, P100, DOI 10.1002/(SICI)1521-4141(199901)29:01<100::AID-IMMU100>3.3.CO;2-I; Reka AK, 2014, CARCINOGENESIS, V35, P1292, DOI 10.1093/carcin/bgu041; Reka AK, 2011, J THORAC ONCOL, V6, P1784, DOI 10.1097/JTO.0b013e31822adfb0; Reka AK, 2010, MOL CANCER THER, V9, P3221, DOI 10.1158/1535-7163.MCT-10-0570; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thomson S, 2005, CANCER RES, V65, P9455, DOI 10.1158/0008-5472.CAN-05-1058; Varsano S, 1998, CLIN EXP IMMUNOL, V113, P173; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Watson NFS, 2006, CANCER IMMUNOL IMMUN, V55, P973, DOI 10.1007/s00262-005-0055-0; Xu CL, 2005, PROSTATE, V62, P224, DOI 10.1002/pros.20134; Yan J, 2008, ADV EXP MED BIOL, V632, P159, DOI 10.1007/978-0-387-78952-1_12; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zavadil J, 2008, CANCER RES, V68, P9574, DOI 10.1158/0008-5472.CAN-08-2316; Zhao WP, 2009, ONCOL REP, V21, P1405, DOI 10.3892/or_00000368	38	37	39	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1888	1898		10.1038/onc.2015.258	http://dx.doi.org/10.1038/onc.2015.258			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26148233	Green Accepted			2022-12-17	WOS:000374010300002
J	Boudjadi, S; Carrier, JC; Groulx, JF; Beaulieu, JF				Boudjadi, S.; Carrier, J. C.; Groulx, J-F; Beaulieu, J-F			Integrin alpha 1 beta 1 expression is controlled by c-MYC in colorectal cancer cells	ONCOGENE			English	Article							TRANSCRIPTIONAL REGULATION; EPITHELIAL-CELLS; GENE-EXPRESSION; DNA-BINDING; MAX; APOPTOSIS; PROLIFERATION; CARCINOMA; INVASION; SUBUNIT	The alpha 1 beta 1 collagen receptor is only present in a few epithelial cell types. In the intestine, it is specifically expressed in proliferating crypt cells. This integrin has been reported to be involved in various cancers where it mediates the downstream activation of the Ras/ERK proliferative pathway. We have recently shown that integrin alpha 1 beta 1 is present in two-thirds of colon adenocarcinomas, but the mechanism by which ITGA1 expression is regulated is not known. DNA methylation, involved in ITGA1 repression during megakaryocyte differentiation, is not the mechanism of ITGA1 regulation in colorectal cancer cells. Our in silico analysis of the ITGA1 promoter revealed two response elements for MYC, an oncogenic factor known to regulate cancer cell proliferation, invasion and migration. In situ, the expressions of both MYC and ITGA1 are localized in the lower crypt of the normal colon and correlate in 72% of the 65 analyzed colorectal cancers. MYC pharmacological inhibition or downregulation of expression with short hairpin RNA in HT29, T84 and SW480 cells resulted in reduced ITGA1 expression at both the transcript and protein levels. Chromatin immunoprecipitation assays revealed that MYC was bound to the chromatin region of the ITGA1 proximal promoter, whereas MYC overexpression enhanced ITGA1 promoter activity that was reduced with MAD co-transfection or by the disruption of the response elements. We concluded that MYC is a key regulating factor for the control of ITGA1 expression.	[Boudjadi, S.; Carrier, J. C.; Groulx, J-F; Beaulieu, J-F] Univ Sherbrooke, Lab Intestinal Physiopathol, Dept Anat & Cell Biol, Sherbrooke, PQ J1K 2R1, Canada; [Boudjadi, S.; Carrier, J. C.] Univ Sherbrooke, Dept Med, Fac Med & Hlth Sci, Sherbrooke, PQ J1K 2R1, Canada	University of Sherbrooke; University of Sherbrooke	Beaulieu, JF (corresponding author), Fac Med & Sci Sante, Dept Anat & Biol Cellulaire, Aile 4,Local 9425,3001,12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	Jean-Francois.Beaulieu@USherbrooke.ca			Canadian Institute of Health Research Grants [MOP-97836, MOP-123415]; Canadian Research Chair in Intestinal Physiopathology; Fonds de la Recherche en Sante du Quebec; Fonds de la Recherche du Quebec-Sante (FRQS)	Canadian Institute of Health Research Grants(Canadian Institutes of Health Research (CIHR)); Canadian Research Chair in Intestinal Physiopathology; Fonds de la Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec); Fonds de la Recherche du Quebec-Sante (FRQS)	We thank Elizabeth Herring for technical support and reviewing the manuscript, Eric Tremblay for virus production, Dr Marie-Pierre Garand of the Biostatistics Facility of the Centre de Recherche du CHUS for assistance in statistical analyses and Dr Andrea Quaroni (Cornell University, Ithaca) for the gift of Caco-2/15 cells. This work was supported by the Canadian Institute of Health Research Grants MOP-97836 and MOP-123415 (to J-FB). J-FB is the recipient of the Canadian Research Chair in Intestinal Physiopathology. JCC is a scholar of the Fonds de la Recherche du Quebec-Sante (FRQS). J-FB and JCC are members of the Fonds de la Recherche en Sante du Quebec-funded Centre de Recherche of the Centre Hospitalier Universitaire de Sherbrooke.	Abair TD, 2008, BLOOD, V112, P3242, DOI 10.1182/blood-2007-12-126433; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Barczyk M, 2010, CELL TISSUE RES, V339, P269, DOI 10.1007/s00441-009-0834-6; Basora N, 1998, INT J CANCER, V75, P738, DOI 10.1002/(SICI)1097-0215(19980302)75:5<738::AID-IJC12>3.0.CO;2-2; Beaulieu Jean-Francois, 2010, World J Gastrointest Pathophysiol, V1, P3, DOI 10.4291/wjgp.v1.i1.3; BEAULIEU JF, 1992, J CELL SCI, V102, P427; Beausejour M, 2012, APOPTOSIS, V17, P566, DOI 10.1007/s10495-012-0713-6; Belaguli NS, 2010, NEOPLASIA, V12, P856, DOI 10.1593/neo.10224; Benoit YD, 2010, BIOCHEM BIOPH RES CO, V399, P434, DOI 10.1016/j.bbrc.2010.07.107; Bettess MD, 2005, MOL CELL BIOL, V25, P7868, DOI 10.1128/MCB.25.17.7868-7878.2005; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boudjadi S, 2013, BIOMARK RES, V1, DOI 10.1186/2050-7771-1-16; Boudjadi S, 2013, AM J PATHOL, V183, P266, DOI 10.1016/j.ajpath.2013.03.021; Bustin SA, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-74; Cheli Y, 2007, BBA-GENE STRUCT EXPR, V1769, P546, DOI 10.1016/j.bbaexp.2007.06.004; Chen YH, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-246; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dydensborg AB, 2006, AM J PHYSIOL-GASTR L, V290, pG1067, DOI 10.1152/ajpgi.00234.2005; Dydensborg AB, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-223; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fujimoto H, 2001, GENES CELLS, V6, P337, DOI 10.1046/j.1365-2443.2001.00428.x; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Giancotti FG, 2000, NAT CELL BIOL, V2, pE13, DOI 10.1038/71397; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Groulx JF, 2014, CARCINOGENESIS, V35, P1217, DOI 10.1093/carcin/bgu006; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Huang MJ, 2006, EXP HEMATOL, V34, P1480, DOI 10.1016/j.exphem.2006.06.019; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lin CP, 2007, ANTI-CANCER DRUG, V18, P161, DOI 10.1097/CAD.0b013e3280109424; Lochter A, 1999, MOL BIOL CELL, V10, P271, DOI 10.1091/mbc.10.2.271; Macias-Perez I, 2008, CANCER RES, V68, P6127, DOI 10.1158/0008-5472.CAN-08-1395; Mo H, 2006, P NATL ACAD SCI USA, V103, P6344, DOI 10.1073/pnas.0601418103; Ni HH, 2005, ONCOGENE, V24, P6820, DOI 10.1038/sj.onc.1208848; Nishida W, 2002, J BIOL CHEM, V277, P7308, DOI 10.1074/jbc.M111824200; Obata H, 1997, J BIOL CHEM, V272, P26643, DOI 10.1074/jbc.272.42.26643; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Park S, 2004, BBA-GEN SUBJECTS, V1670, P217, DOI 10.1016/j.bbagen.2003.12.007; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Sabo A, 2014, NATURE, V511, P488, DOI 10.1038/nature13537; SIKORA K, 1987, CANCER-AM CANCER SOC, V59, P1289, DOI 10.1002/1097-0142(19870401)59:7<1289::AID-CNCR2820590710>3.0.CO;2-O; Suzuki H, 2010, CARCINOGENESIS, V31, P342, DOI 10.1093/carcin/bgp179; Tanaka N, 2008, INT J ONCOL, V33, P815, DOI 10.3892/ijo_00000069; Vachon Pierre H, 2011, J Signal Transduct, V2011, P738137, DOI 10.1155/2011/738137; van Golen CM, 2003, ONCOGENE, V22, P2664, DOI 10.1038/sj.onc.1206362; Van Slambrouck S, 2007, INT J ONCOL, V31, P1501; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Yang CQ, 2003, CANCER RES, V63, P8312; Yang HP, 2009, HEPATOLOGY, V49, P860, DOI 10.1002/hep.22720; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641	55	37	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1671	1678		10.1038/onc.2015.231	http://dx.doi.org/10.1038/onc.2015.231			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26096932	hybrid, Green Published			2022-12-17	WOS:000373064200006
J	Whang, YM; Park, SI; Trenary, IA; Egnatchik, RA; Fessel, JP; Kaufman, JM; Carbone, DP; Young, JD				Whang, Y. M.; Park, S. I.; Trenary, I. A.; Egnatchik, R. A.; Fessel, J. P.; Kaufman, J. M.; Carbone, D. P.; Young, J. D.			LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR RECEPTOR MUTATIONS; GENE-MUTATIONS; GROWTH; AMPK; APOPTOSIS; CHEMOTHERAPY; METABOLISM; INHIBITION; GEFITINIB	The tumor suppressor serine/threonine kinase 11 (STK11 or LKB1) is mutated in 20-30% of patients with non-small-cell lung cancer (NSCLC). Loss of LKB1-adenosine monophosphate-activated protein kinase (AMPK) signaling confers sensitivity to metabolic inhibition or stress-induced mitochondrial insults. We tested the hypothesis that loss of LKB1 sensitizes NSCLC cells to energetic stress induced by treatment with erlotinib. LKB1-deficient cells exhibited enhanced sensitivity to erlotinib in vitro and in vivo that was associated with alterations in energy metabolism and mitochondrial dysfunction. Loss of LKB1 expression altered the cellular response to erlotinib treatment, resulting in impaired ATP homeostasis and an increase in reactive oxygen species. Furthermore, erlotinib selectively blocked mammalian target of rapamycin signaling, inhibited cell growth and activated apoptosis in LKB1-deficient cells. Erlotinib treatment also induced AMPK activation despite loss of LKB1 expression, which was partially reduced by the application of a calcium/calmodulin-dependent protein kinase kinase 2 inhibitor (STO-609) or calcium chelator (BAPTA-AM). These findings may have significant implications for the design of novel NSCLC treatments that target dysregulated metabolic and signaling pathways in LKB1-deficient tumors.	[Whang, Y. M.; Trenary, I. A.; Egnatchik, R. A.; Young, J. D.] Vanderbilt Univ, Dept Biomol & Chem Engn, PMB 351604, Nashville, TN 37235 USA; [Park, S. I.] Vanderbilt Univ, Dept Med, Div Clin Pharmacol, Ctr Bone Biol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Fessel, J. P.] Vanderbilt Univ, Dept Med, Div Allergy Pulm & Crit Care Med, 221 Kirkland Hall, Nashville, TN 37235 USA; [Kaufman, J. M.] Vanderbilt Univ, Dept Canc Biol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Carbone, D. P.] Ohio State Univ, Med Ctr, Dept Internal Med, Columbus, OH 43210 USA; [Young, J. D.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University System of Ohio; Ohio State University; Vanderbilt University	Young, JD (corresponding author), Vanderbilt Univ, Dept Biomol & Chem Engn, PMB 351604, Nashville, TN 37235 USA.	j.d.young@vanderbilt.edu	Young, Jamey/A-5857-2012; Park, Serk In/D-2840-2011	Park, Serk In/0000-0001-8643-5096; Fessel, Joshua/0000-0003-0797-7693	NIH [P50 CA090949, K08 HL121174]; DOD [W81XWH-12-1-0383]; NSF [CBET-1105991]; Uniting Against Lung Cancer; Div Of Chem, Bioeng, Env, & Transp Sys [1105991] Funding Source: National Science Foundation; NATIONAL CANCER INSTITUTE [U10CA180850, P50CA090949] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL121174] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); NSF(National Science Foundation (NSF)); Uniting Against Lung Cancer; Div Of Chem, Bioeng, Env, & Transp Sys(National Science Foundation (NSF)NSF - Directorate for Engineering (ENG)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by NIH P50 CA090949, DOD W81XWH-12-1-0383, NSF CBET-1105991, and by an award from Uniting Against Lung Cancer. Dr Joshua P. Fessel was also supported by NIH K08 HL121174. The authors thank Dr Changki Lee for his assistance with the animal experiments.	Cappuzzo F, 2010, LANCET ONCOL, V11, P521, DOI 10.1016/S1470-2045(10)70112-1; Carretero J, 2007, ONCOGENE, V26, P1616, DOI 10.1038/sj.onc.1209951; Deng J, 2007, CANCER RES, V67, P11867, DOI 10.1158/0008-5472.CAN-07-1961; Eimer S, 2011, CANCER BIOL THER, V11, P1017, DOI 10.4161/cbt.11.12.15693; Faber AC, 2009, P NATL ACAD SCI USA, V106, P19503, DOI 10.1073/pnas.0905056106; Faubert B, 2014, P NATL ACAD SCI USA, V111, P2554, DOI 10.1073/pnas.1312570111; Garassino MC, 2011, J CLIN ONCOL, V29, P3835, DOI 10.1200/JCO.2011.36.7847; Gowans GJ, 2013, CELL METAB, V18, P556, DOI 10.1016/j.cmet.2013.08.019; Grassian AR, 2011, GENE DEV, V25, P1716, DOI 10.1101/gad.16771811; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kaufman JM, 2014, J THORAC ONCOL, V9, P794, DOI 10.1097/JTO.0000000000000173; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Ling YH, 2008, MOL PHARMACOL, V74, P793, DOI 10.1124/mol.107.044396; Liu Y, 2013, CANCER DISCOV, V3, P870, DOI 10.1158/2159-8290.CD-13-0015; Mahoney CL, 2009, BRIT J CANCER, V100, P370, DOI 10.1038/sj.bjc.6604886; Matsumoto S, 2007, ONCOGENE, V26, P5911, DOI 10.1038/sj.onc.1210418; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Murphy TA, 2013, BIOTECHNOL BIOENG, V110, P1748, DOI 10.1002/bit.24836; Nakada D, 2010, NATURE, V468, P653, DOI 10.1038/nature09571; Oakhill JS, 2011, SCIENCE, V332, P1433, DOI 10.1126/science.1200094; Oakhill JS, 2010, P NATL ACAD SCI USA, V107, P19237, DOI 10.1073/pnas.1009705107; Onozato R, 2007, CANCER SCI, V98, P1747, DOI 10.1111/j.1349-7006.2007.00585.x; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Park SI, 2013, CANCER RES, V73, P6574, DOI 10.1158/0008-5472.CAN-12-4692; RAPP E, 1988, J CLIN ONCOL, V6, P633, DOI 10.1200/JCO.1988.6.4.633; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sanders MJ, 2007, BIOCHEM J, V403, P139, DOI 10.1042/BJ20061520; Shackelford DB, 2013, CANCER CELL, V23, P143, DOI 10.1016/j.ccr.2012.12.008; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Tracy S, 2004, CANCER RES, V64, P7241, DOI 10.1158/0008-5472.CAN-04-1905; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; Van Schaeybroeck S, 2006, MOL CANCER THER, V5, P1154, DOI 10.1158/1535-7163.MCT-05-0446; West L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031906; Whang YM, 2005, CANCER RES, V65, P3682, DOI 10.1158/0008-5472.CAN-04-2792; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Zannetti A, 2008, CLIN CANCER RES, V14, P5209, DOI 10.1158/1078-0432.CCR-08-0374	44	37	38	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					856	866		10.1038/onc.2015.140	http://dx.doi.org/10.1038/onc.2015.140			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	26119936	Green Accepted			2022-12-17	WOS:000370332200006
J	Aschacher, T; Wolf, B; Enzmann, F; Kienzl, P; Messner, B; Sampl, S; Svoboda, M; Mechtcheriakova, D; Holzmann, K; Bergmann, M				Aschacher, T.; Wolf, B.; Enzmann, F.; Kienzl, P.; Messner, B.; Sampl, S.; Svoboda, M.; Mechtcheriakova, D.; Holzmann, K.; Bergmann, M.			LINE-1 induces hTERT and ensures telomere maintenance in tumour cell lines	ONCOGENE			English	Article							REVERSE-TRANSCRIPTASE INHIBITORS; EMBRYONIC STEM-CELLS; DNA-DAMAGE-RESPONSE; C-MYC; MAMMALIAN TELOMERES; CATALYTIC SUBUNIT; CANCER-CELLS; CHROMOSOME INSTABILITY; L1 RETROTRANSPOSITION; TERMINAL TRANSFERASE	A hallmark of cancer cells is an activated telomere maintenance mechanism, which allows prolonged survival of the malignant cells. In more than 80% of tumours, telomeres are elongated by the enzyme telomerase, which adds de novo telomere repeats to the ends of chromosomes. Cancer cells are also characterized by expression of active LINE-1 elements (L1s, long interspersed nuclear elements-1). L1 elements are abundant retrotransposons in the eukaryotic genome that are primarily known for facilitating aberrant recombination. Using L1-knockdown (KD), we show for the first time that L1 is critical for telomere maintenance in telomerase-positive tumour cells. The reduced length of telomeres in the L1-KD-treated cells correlated with an increased rate of telomere dysfunction foci, a reduced expression of shelterin proteins and an increased rate of anaphase bridges. The decreased telomere length was associated with a decreased telomerase activity and decreased telomerase mRNA level; the latter was increased upon L1 overexpression. L1-KD also led to a decrease in mRNA and protein expression of cMyc and KLF-4, two main transcription factors of telomerase and altered mRNA levels of other stem-cell-associated proteins such as CD44 and hMyb, as well as a corresponding reduced growth of spheroids. The KD of KLF-4 or cMyc decreased the level of L1-ORF1 mRNA, suggesting a specific reciprocal regulation with L1. Thus, our findings contribute to the understanding of L1 as a pathogenicity factor in cancer cells. As L1 is only expressed in pathophysiological conditions, L1 now appears to be target in the rational treatment of telomerase-positive cancer.	[Aschacher, T.; Messner, B.] Med Univ Vienna, Dept Surg, Cardiac Surg Res Labs, A-1090 Vienna, Austria; [Wolf, B.; Enzmann, F.; Kienzl, P.; Bergmann, M.] Med Univ Vienna, Dept Surg, Surg Res Labs, A-1090 Vienna, Austria; [Sampl, S.; Holzmann, K.] Inst Canc Res, Dept Med 1, Vienna, Austria; [Svoboda, M.; Mechtcheriakova, D.] Med Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria; [Mechtcheriakova, D.; Holzmann, K.; Bergmann, M.] Comprehens Canc Ctr Vienna, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna	Bergmann, M (corresponding author), Med Univ Vienna, Dept Surg, Surg Res Labs, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	michael.bergmann@meduniwien.ac.at	Bergmann, Michael/GZK-7700-2022; Messner, Barbara/GLS-8150-2022; Enzmann, Florian K/U-6884-2019; Holzmann, Klaus/I-4437-2019	Messner, Barbara/0000-0001-8331-6497; Enzmann, Florian K/0000-0002-7200-4145; Holzmann, Klaus/0000-0003-4077-3377; Mechtcheriakova, Diana/0000-0002-8737-3592; Bergmann, Michael/0000-0001-8529-1166; Wolf, Brigitte/0000-0003-2120-5614; Kienzl, Philip/0000-0002-0114-6904	Medical Scientific Fund of the Mayor of Vienna [10091]	Medical Scientific Fund of the Mayor of Vienna	We want to thank Roger Reddel and Bert Vogelstein for providing cell lines, Silvia Bacchetti for adenovirus expressing hTERT, Satoru Kyo for hTERT promoter constructs. Furthermore, we appreciate the critical discussion with members of the Surgical Research Laboratories of the Medical University of Vienna, as well as with Igor Bondarev, Roger Reddel, Berthold Streubl and Wolfgang Kostler. Further, we appreciate the critical reading of the manuscript by Walter Berger and Christine Brostjan. SS and KH were supported by the Medical Scientific Fund of the Mayor of Vienna #10091.	Ahmad K, 1999, GENETICS, V151, P1041; Aoki Y, 2012, GENOME MED, V4, DOI 10.1186/gm402; Aschacher T, 2012, NEOPLASIA, V14, P44, DOI 10.1593/neo.11426; Atsumi Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023432; Babushok DV, 2007, HUM MUTAT, V28, P527, DOI 10.1002/humu.20486; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Bailey SM, 2006, NUCLEIC ACIDS RES, V34, P2408, DOI 10.1093/nar/gkl303; Beck CR, 2011, ANNU REV GENOM HUM G, V12, P187, DOI 10.1146/annurev-genom-082509-141802; Belancio VP, 2010, NUCLEIC ACIDS RES, V38, P3909, DOI 10.1093/nar/gkq132; Belgnaoui SM, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-13; BLACKBURN EH, 1989, GENOME, V31, P553, DOI 10.1139/g89-104; BLACKBURN EH, 1991, TRENDS BIOCHEM SCI, V16, P378, DOI 10.1016/0968-0004(91)90155-O; Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Cesare AJ, 2013, MOL CELL, V51, P141, DOI 10.1016/j.molcel.2013.06.006; Chen JM, 2005, HUM GENET, V117, P411, DOI 10.1007/s00439-005-1321-0; Choi KH, 2011, NUCLEIC ACIDS RES, V39, P9206, DOI 10.1093/nar/gkr665; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Dai LX, 2011, BMC BIOCHEM, V12, DOI 10.1186/1471-2091-12-18; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; de Lange T, 2010, COLD SH Q B, V75, P167, DOI 10.1101/sqb.2010.75.017; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dikmen ZG, 2005, CANCER RES, V65, P7866, DOI 10.1158/0008-5472.CAN-05-1215; Ergun S, 2004, J BIOL CHEM, V279, P27753, DOI 10.1074/jbc.M312985200; Fang JL, 2009, TOXICOL SCI, V111, P120, DOI 10.1093/toxsci/kfp136; Farkash EA, 2006, NUCLEIC ACIDS RES, V34, P1196, DOI 10.1093/nar/gkj522; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Fumagalli M, 2012, NAT CELL BIOL, V14, P355, DOI 10.1038/ncb2466; Garcia-Perez JL, 2007, HUM MOL GENET, V16, P1569, DOI 10.1093/hmg/ddm105; Goytisolo FA, 2001, MOL CELL BIOL, V21, P3642, DOI 10.1128/MCB.21.11.3642-3651.2001; Grandjenette C, 2014, NEOPLASIA, V16, P511, DOI 10.1016/j.neo.2014.05.009; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Grusch Michael, 2009, V515, P125, DOI 10.1007/978-1-59745-559-6_8; Guiducci C, 2001, EXP CELL RES, V265, P304, DOI 10.1006/excr.2001.5189; Han JS, 2005, BIOESSAYS, V27, P775, DOI 10.1002/bies.20257; Hao Huang, 2008, J Exp Clin Cancer Res, V27, P27, DOI 10.1186/1756-9966-27-27; Hao LY, 2004, J BIOL CHEM, V279, P45148, DOI 10.1074/jbc.M403924200; Haoudi A, 2004, J BIOMED BIOTECHNOL, P185, DOI 10.1155/S1110724304403131; Harley CB, 2008, NAT REV CANCER, V8, P167, DOI 10.1038/nrc2275; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hochreiter AE, 2006, CLIN CANCER RES, V12, P3184, DOI 10.1158/1078-0432.CCR-05-2760; Hu XY, 2009, NUCLEOS NUCLEOT NUCL, V28, P1, DOI 10.1080/15257770802581633; Kano H, 2009, GENE DEV, V23, P1303, DOI 10.1101/gad.1803909; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kolosha VO, 2003, J BIOL CHEM, V278, P8112, DOI 10.1074/jbc.M210487200; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lewis KA, 2012, STRUCTURE, V20, P28, DOI 10.1016/j.str.2011.10.017; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Martinez P, 2011, NAT REV CANCER, V11, P161, DOI 10.1038/nrc3025; Montoya-Durango DE, 2009, MUTAT RES-FUND MOL M, V665, P20, DOI 10.1016/j.mrfmmm.2009.02.011; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Morrish TA, 2002, NAT GENET, V31, P159, DOI 10.1038/ng898; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Ohka F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023332; Oricchio E, 2007, ONCOGENE, V26, P4226, DOI 10.1038/sj.onc.1210214; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Qian YQ, 2014, CELL IMMUNOL, V289, P63, DOI 10.1016/j.cellimm.2014.03.009; Rodic N, 2014, AM J PATHOL, V184, P1280, DOI 10.1016/j.ajpath.2014.01.007; Sampl S, 2012, TRANSL ONCOL, V5, P56, DOI 10.1593/tlo.11202; Schneider-Stock R, 2003, J PATHOL, V199, P517, DOI 10.1002/path.1315; Sciamanna E, 2005, ONCOGENE, V24, P3923, DOI 10.1038/sj.onc.1208562; Sciamanna I, 2013, ONCOTARGET, V4, P2271, DOI 10.18632/oncotarget.1403; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; Sinibaldi-Vallebona Paola, 2011, Cancers (Basel), V3, P1141, DOI 10.3390/cancers3011141; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Takakura M, 1999, CANCER RES, V59, P551; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Verdun RE, 2007, NATURE, V447, P924, DOI 10.1038/nature05976; Vitullo P, 2012, MOL REPROD DEV, V79, P118, DOI 10.1002/mrd.22003; Wallace NA, 2008, GENE, V419, P75, DOI 10.1016/j.gene.2008.04.013; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Wissing S, 2012, HUM MOL GENET, V21, P208, DOI 10.1093/hmg/ddr455; Wong CW, 2010, STEM CELLS, V28, P1510, DOI 10.1002/stem.477; Xi LH, 2014, NUCLEIC ACIDS RES, V42, P8565, DOI 10.1093/nar/gku560	81	37	39	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2016	35	1					94	104		10.1038/onc.2015.65	http://dx.doi.org/10.1038/onc.2015.65			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DA4ZT	25798839				2022-12-17	WOS:000367812400009
J	Pazarentzos, E; Bivona, TG				Pazarentzos, E.; Bivona, T. G.			Adaptive stress signaling in targeted cancer therapy resistance	ONCOGENE			English	Review							CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; NEGATIVE BREAST-CANCER; ANTI-EGFR THERAPY; ACQUIRED-RESISTANCE; COLORECTAL-CANCER; MEK INHIBITION; ANDROGEN RECEPTOR; PROSTATE-CANCER; BRAF(V600E) INHIBITION	The identification of specific genetic alterations that drive the initiation and progression of cancer and the development of targeted drugs that act against these driver alterations has revolutionized the treatment of many human cancers. Although substantial progress has been achieved with the use of such targeted cancer therapies, resistance remains a major challenge that limits the overall clinical impact. Hence, despite progress, new strategies are needed to enhance response and eliminate resistance to targeted cancer therapies in order to achieve durable or curative responses in patients. To date, efforts to characterize mechanisms of resistance have primarily focused on molecular events that mediate primary or secondary resistance in patients. Less is known about the initial molecular response and adaptation that may occur in tumor cells early upon exposure to a targeted agent. Although understudied, emerging evidence indicates that the early adaptive changes by which tumor cells respond to the stress of a targeted therapy may be crucial for tumo r cell survival during treatment and the development of resistance. Here we review recent data illuminating the molecular architecture underlying adaptive stress signaling in tumor cells. We highlight how leveraging this knowledge could catalyze novel strategies to minimize or eliminate targeted therapy resistance, thereby unleashing the full potential of targeted therapies to transform many cancers from lethal to chronic or curable conditions.	[Pazarentzos, E.; Bivona, T. G.] Univ Calif San Francisco, Div Hematol Oncol, Dept Med, San Francisco, CA 94158 USA; [Pazarentzos, E.; Bivona, T. G.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Bivona, TG (corresponding author), Univ Calif San Francisco, Div Hematol Oncol, Dept Med, 600 16th St Genentech Hall,N212D, San Francisco, CA 94158 USA.	Trever.Bivona@ucsf.edu		Pazarentzos, Evangelos/0000-0002-5453-1646	NIH [NIH R01 CA169338]; Howard Hughes Medical Institute; Doris Duke Charitable Foundation; Searle Scholars Program; California Institute for Quantitative Biosciences; QB3@UCSF; NATIONAL CANCER INSTITUTE [K08CA154787, DP2CA174497, R01CA169338] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); Searle Scholars Program; California Institute for Quantitative Biosciences; QB3@UCSF; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Bivona lab for critical review and thoughtful comments on the manuscript. We are grateful to the following funding sources: NIH Director's New Innovator Award, NIH R01 CA169338, Howard Hughes Medical Institute, Doris Duke Charitable Foundation, Searle Scholars Program, California Institute for Quantitative Biosciences, QB3@UCSF (to TGB).	Ahmed KM, 2008, ONCOGENE, V27, P6738, DOI 10.1038/onc.2008.265; Akhavan D, 2013, CANCER DISCOV, V3, P534, DOI 10.1158/2159-8290.CD-12-0502; Aparicio A, 2011, CANCER DISCOV, V1, P466, DOI 10.1158/2159-8290.CD-11-0259; Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Bailey ST, 2014, MOL CANCER RES, V12, P408, DOI 10.1158/1541-7786.MCR-13-0206-T; Baker NM, 2013, NATURE, V497, P577, DOI 10.1038/nature12248; Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chandarlapaty S, 2012, CANCER DISCOV, V2, P311, DOI 10.1158/2159-8290.CD-12-0018; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598; Chen XF, 2002, CANCER RES, V62, P1213; Chen YJ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3575; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219; Ducker GS, 2014, ONCOGENE, V33, P1590, DOI 10.1038/onc.2013.92; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Duru N, 2014, J CANCER RES CLIN, V140, P1, DOI 10.1007/s00432-013-1494-1; Duru N, 2012, CLIN CANCER RES, V18, P6634, DOI 10.1158/1078-0432.CCR-12-1436; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Flanigan SA, 2013, CLIN CANCER RES, V19, P6219, DOI 10.1158/1078-0432.CCR-13-0145; Fox EM, 2011, CANCER RES, V71, P6773, DOI 10.1158/0008-5472.CAN-11-1295; Garraway LA, 2012, CANCER DISCOV, V2, P214, DOI 10.1158/2159-8290.CD-12-0012; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Glickman MS, 2012, CELL, V148, P1089, DOI 10.1016/j.cell.2012.02.015; Godin-Heymann N, 2008, MOL CANCER THER, V7, P874, DOI 10.1158/1535-7163.MCT-07-2387; Goltsov A, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00013; Haber DA, 2011, CELL, V145, P19, DOI 10.1016/j.cell.2011.03.026; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Huang PH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.287re6; Ishiguro Y, 2013, ONCOTARGET, V4, P550, DOI 10.18632/oncotarget.939; Kaplon J, 2013, NATURE, V498, P109, DOI 10.1038/nature12154; Kirouac DC, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004008; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Lee HJ, 2014, CANCER CELL, V26, P207, DOI 10.1016/j.ccr.2014.05.019; Li X, 2008, CELL SIGNAL, V20, P2145, DOI 10.1016/j.cellsig.2008.08.006; Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011; Lovly CM, 2014, CLIN CANCER RES, V20, P2249, DOI 10.1158/1078-0432.CCR-13-1610; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; McDonagh CF, 2012, MOL CANCER THER, V11, P582, DOI 10.1158/1535-7163.MCT-11-0820; Miller TW, 2011, J CLIN ONCOL, V29, P4452, DOI 10.1200/JCO.2010.34.4879; Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Moreno-Sanchez R, 2007, FEBS J, V274, P1393, DOI 10.1111/j.1742-4658.2007.05686.x; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Papa S, 2012, ADV EXP MED BIOL, V942, P3, DOI 10.1007/978-94-007-2869-1_1; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Saez-Ayala M, 2013, CANCER CELL, V24, P105, DOI 10.1016/j.ccr.2013.05.009; Scaltriti M, 2009, ONCOGENE, V28, P803, DOI 10.1038/onc.2008.432; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schweizer L, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-4; Sequist LV, 2013, J CLIN ONCOL, V31, P3327, DOI 10.1200/JCO.2012.44.2806; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Shi Y, 2005, INT J INF TECH DECIS, V4, P1; Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Turke AB, 2012, CANCER RES, V72, P3228, DOI 10.1158/0008-5472.CAN-11-3747; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Watanabe S, 2013, LUNG CANCER, V82, P370, DOI 10.1016/j.lungcan.2013.06.003; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wetterskog D, 2014, ONCOGENE, V33, P966, DOI 10.1038/onc.2013.41; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330; Zhao YJ, 2014, NAT REV CLIN ONCOL, V11, P385, DOI 10.1038/nrclinonc.2014.83; Zimmermann G, 2013, NATURE, V497, P638, DOI 10.1038/nature12205	81	37	37	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2015	34	45					5599	5606		10.1038/onc.2015.26	http://dx.doi.org/10.1038/onc.2015.26			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GA	25703329	Green Accepted, Green Submitted			2022-12-17	WOS:000364594300001
J	Labbe, DP; Zadra, G; Ebot, EM; Mucci, LA; Kantoff, PW; Loda, M; Brown, M				Labbe, D. P.; Zadra, G.; Ebot, E. M.; Mucci, L. A.; Kantoff, P. W.; Loda, M.; Brown, M.			Role of diet in prostate cancer: the epigenetic link	ONCOGENE			English	Review							GROWTH-FACTOR-I; TUMOR-SUPPRESSOR GENES; DNA HYPOMETHYLATION; HISTONE ACETYLATION; CELLULAR-METABOLISM; METHYLATION STATUS; ENERGY-BALANCE; LIFE-STYLE; BODY-MASS; FAT DIET	Diet is hypothesized to be a critical environmentally related risk factor for prostate cancer (PCa) development, and specific diets and dietary components can also affect PCa progression; however, the mechanisms underlying these associations remain elusive. As for a maturing organism, PCa's epigenome is plastic and evolves from the pre-neoplastic to the metastatic stage. In particular, epigenetic remodeling relies on substrates or cofactors obtained from the diet. Here we review the evidence that bridges dietary modulation to alterations in the prostate epigenome. We propose that such diet-related effects offer a mechanistic link between the impact of different diets and the course of PCa development and progression.	[Labbe, D. P.; Zadra, G.; Kantoff, P. W.; Loda, M.; Brown, M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Labbe, D. P.; Brown, M.] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02115 USA; [Zadra, G.; Loda, M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02215 USA; [Ebot, E. M.; Mucci, L. A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA; [Mucci, L. A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Brown, M (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,D730, Boston, MA 02215 USA.	myles_brown@dfci.harvard.edu	Brown, Myles/AAX-5332-2021; Labbé, David P./C-2702-2009; Brown, Myles/B-6906-2008	Brown, Myles/0000-0002-8213-1658; Labbé, David P./0000-0001-8864-8765; Kantoff, Philip/0000-0001-7275-0597	Canadian Institute of Health Research (CIHR) Fellowship; National Cancer Institute [1P01CA163227, P50CA090381]; NATIONAL CANCER INSTITUTE [P01CA163227, P50CA090381] Funding Source: NIH RePORTER	Canadian Institute of Health Research (CIHR) Fellowship(Canadian Institutes of Health Research (CIHR)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Edward L Giovannucci, Thomas Westerling, Luz E Tavera-Mendoza and Sonal Jhaveri for the critical review of this manuscript. DPL is a recipient of a Canadian Institute of Health Research (CIHR) Fellowship. LAM was a Young Investigator of the Prostate Cancer Foundation. This work was supported by grants from the National Cancer Institute (1P01CA163227 to MB and P50CA090381 to MB and PWK).	Anzo M, 2008, CANCER RES, V68, P3342, DOI 10.1158/0008-5472.CAN-07-3165; Aronson WJ, 2010, J UROLOGY, V183, P345, DOI 10.1016/j.juro.2009.08.104; Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Berquin IM, 2007, J CLIN INVEST, V117, P1866, DOI 10.1172/JCI31494; Bert SA, 2013, CANCER CELL, V23, P9, DOI 10.1016/j.ccr.2012.11.006; Bhusari S, 2011, PROSTATE, V71, P1621, DOI 10.1002/pros.21379; Bianco-Miotto T, 2010, CANCER EPIDEM BIOMAR, V19, P2611, DOI 10.1158/1055-9965.EPI-10-0555; Bistulfi G, 2011, CANCER PREV RES, V4, P1825, DOI 10.1158/1940-6207.CAPR-11-0140; Blando J, 2011, CANCER PREV RES, V4, P2002, DOI 10.1158/1940-6207.CAPR-11-0182; Boyd LK, 2012, NAT REV UROL, V9, P652, DOI 10.1038/nrurol.2012.185; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brooks JD, 1998, CANCER EPIDEM BIOMAR, V7, P531; Bungard D, 2010, SCIENCE, V329, P1201, DOI 10.1126/science.1191241; Buschemeyer WC, 2007, EUR UROL, V52, P331, DOI 10.1016/j.eururo.2007.04.069; Cai L, 2011, MOL CELL, V42, P426, DOI 10.1016/j.molcel.2011.05.004; Canto C, 2012, CELL METAB, V15, P838, DOI 10.1016/j.cmet.2012.04.022; Cao Y, 2011, CANCER PREV RES, V4, P486, DOI 10.1158/1940-6207.CAPR-10-0229; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chan JM, 2005, J CLIN ONCOL, V23, P8152, DOI 10.1200/JCO.2005.03.1492; Chen D, 2008, GENE DEV, V22, P1753, DOI 10.1101/gad.1650608; Cooney Craig A, 2002, J Nutr, V132, p2393S, DOI 10.1093/jn/132.8.2393S; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dang CV, 2010, CANCER RES, V70, P859, DOI 10.1158/0008-5472.CAN-09-3556; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Dobosy JR, 2008, PROSTATE, V68, P1187, DOI 10.1002/pros.20782; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Ellinger J, 2010, PROSTATE, V70, P61, DOI 10.1002/pros.21038; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Etminan M, 2004, CANCER EPIDEM BIOMAR, V13, P340; FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Fujiki R, 2011, NATURE, V480, P557, DOI 10.1038/nature10656; Galdieri L, 2012, J BIOL CHEM, V287, P23865, DOI 10.1074/jbc.M112.380519; Gao X, 2005, JNCI-J NATL CANCER I, V97, P1768, DOI 10.1093/jnci/dji402; Giovannucci E, 2007, INT J CANCER, V121, P1571, DOI 10.1002/ijc.22788; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111; Hallows WC, 2006, P NATL ACAD SCI USA, V103, P10230, DOI 10.1073/pnas.0604392103; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Huffman DM, 2007, CANCER RES, V67, P417, DOI 10.1158/0008-5472.CAN-06-1244; Hurst R, 2012, AM J CLIN NUTR, V96, P111, DOI 10.3945/ajcn.111.033373; Irshad S, 2013, CANCER METAST REV, V32, P109, DOI 10.1007/s10555-012-9409-1; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Jackson MD, 2013, GENES NUTR, V8, P199, DOI 10.1007/s12263-012-0321-7; James SJ, 1997, CARCINOGENESIS, V18, P287, DOI 10.1093/carcin/18.2.287; Jarrard DF, 1995, CLIN CANCER RES, V1, P1471; Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437; Jeronimo C, 2004, CLIN CANCER RES, V10, P8472, DOI 10.1158/1078-0432.CCR-04-0894; Ji HK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026057; Kaelin WG, 2013, CELL, V153, P56, DOI 10.1016/j.cell.2013.03.004; Kalaany NY, 2009, NATURE, V458, P725, DOI 10.1038/nature07782; Kee K, 2004, J BIOL CHEM, V279, P40076, DOI 10.1074/jbc.M406002200; Kikuno N, 2008, INT J CANCER, V123, P552, DOI 10.1002/ijc.23590; Knock E, 2006, CANCER RES, V66, P10349, DOI 10.1158/0008-5472.CAN-06-2477; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Kobayashi N, 2008, CANCER RES, V68, P3066, DOI 10.1158/0008-5472.CAN-07-5616; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kushi LH, 2012, CA-CANCER J CLIN, V62, P30, DOI 10.3322/caac.20140; Lippman SM, 2009, JAMA-J AM MED ASSOC, V301, P39, DOI 10.1001/jama.2008.864; Llaverias G, 2010, AM J PATHOL, V177, P3180, DOI 10.2353/ajpath.2010.100568; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Lu C, 2012, CELL METAB, V16, P9, DOI 10.1016/j.cmet.2012.06.001; Ma J, 2008, LANCET ONCOL, V9, P1039, DOI 10.1016/S1470-2045(08)70235-3; Majeed N, 2005, ONCOGENE, V24, P4736, DOI 10.1038/sj.onc.1208572; Majid S, 2008, CANCER RES, V68, P2736, DOI 10.1158/0008-5472.CAN-07-2290; Malvezzi M, 2014, ANN ONCOL, V25, P1650, DOI 10.1093/annonc/mdu138; McDunn JE, 2013, PROSTATE, V73, P1547, DOI 10.1002/pros.22704; Morrish F, 2010, J BIOL CHEM, V285, P36267, DOI 10.1074/jbc.M110.141606; Moyer VA, 2012, ANN INTERN MED, V157, P120, DOI 10.7326/0003-4819-157-2-201207170-00459; Narita S, 2008, PROSTATE, V68, P321, DOI 10.1002/pros.20681; Nimptsch K, 2011, INT J CANCER, V128, P660, DOI 10.1002/ijc.25381; Ogishima T, 2005, CLIN CANCER RES, V11, P1028; Ornish D, 2008, P NATL ACAD SCI USA, V105, P8369, DOI 10.1073/pnas.0803080105; Osterhues A, 2013, CRIT REV FOOD SCI, V53, P1180, DOI 10.1080/10408398.2011.575966; Pakneshan P, 2003, FASEB J, V17, P1081, DOI 10.1096/fj.02-0973com; Palmer J, 2008, PROSTATE, V68, P345, DOI 10.1002/pros.20692; Pandey M, 2012, MOL CARCINOGEN, V51, P952, DOI 10.1002/mc.20866; PEGG AE, 1970, BIOCHEM J, V117, P17, DOI 10.1042/bj1170017; Pelton K, 2012, CURR OPIN PHARMACOL, V12, P751, DOI 10.1016/j.coph.2012.07.006; Perry AS, 2007, BRIT J CANCER, V96, P1587, DOI 10.1038/sj.bjc.6603767; Perry AS, 2010, NAT REV UROL, V7, P668, DOI 10.1038/nrurol.2010.185; Poirier LA, 2001, CANCER EPIDEM BIOMAR, V10, P649; Pommier AJC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003483; Priolo C, 2014, CANCER RES, V74, P7198, DOI 10.1158/0008-5472.CAN-14-1490; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rous P, 1914, J EXP MED, V20, P433, DOI 10.1084/jem.20.5.433; Rycyna KJ, 2013, UROLOGY, V82, P1197, DOI 10.1016/j.urology.2013.07.012; Santourlidis S, 1999, PROSTATE, V39, P166; Saraon P, 2014, PROSTATE, V74, P372, DOI 10.1002/pros.22758; Schaid DJ, 2004, HUM MOL GENET, V13, pR103, DOI 10.1093/hmg/ddh072; Schulz WA, 2002, GENE CHROMOSOME CANC, V35, P58, DOI 10.1002/gcc.10092; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Severi G, 2006, CANCER EPIDEM BIOMAR, V15, P1137, DOI 10.1158/1055-9965.EPI-05-0823; Shabbeer S, 2012, CANCER PREV RES, V5, P229, DOI 10.1158/1940-6207.CAPR-11-0357; SHIMIZU H, 1991, BRIT J CANCER, V63, P963, DOI 10.1038/bjc.1991.210; Shukeir N, 2006, CANCER RES, V66, P9202, DOI 10.1158/0008-5472.CAN-06-1954; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sinclair KD, 2007, P NATL ACAD SCI USA, V104, P19351, DOI 10.1073/pnas.0707258104; Supic G, 2013, NUTR CANCER, V65, P781, DOI 10.1080/01635581.2013.805794; Sutherland BW, 2008, CANCER RES, V68, P3495, DOI 10.1158/0008-5472.CAN-07-6531; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Timp W, 2013, NAT REV CANCER, V13, P497, DOI 10.1038/nrc3486; Tio M, 2014, PROSTATE CANCER P D, V17, P213, DOI 10.1038/pcan.2014.16; Trottier G, 2010, NAT REV UROL, V7, P21, DOI 10.1038/nrurol.2009.234; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Valdes-Mora F, 2015, ONCOGENE, V34, P1609, DOI 10.1038/onc.2014.111; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vardi A, 2010, IN VIVO, V24, P393; Venkateswaran V, 2007, J NATL CANCER I, V99, P1793, DOI 10.1093/jnci/djm231; Venkateswaran V, 2010, NAT REV UROL, V7, P442, DOI 10.1038/nrurol.2010.102; Wang ZH, 2005, ENDOCRINOLOGY, V146, P5188, DOI 10.1210/en.2005-0607; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Waterland RA, 2007, FASEB J, V21, P3380, DOI 10.1096/fj.07-8229com; WCRF/AICR, 2007, FOOD NUTR PHYS ACT P, P517; Wellen KE, 2012, NAT REV MOL CELL BIO, V13, P270, DOI 10.1038/nrm3305; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Wilson KM, 2012, ASIAN J ANDROL, V14, P365, DOI 10.1038/aja.2011.142; Wolff GL, 1999, PHYSIOL GENOMICS, V1, P151, DOI 10.1152/physiolgenomics.1999.1.3.151; Wolff GL, 1998, FASEB J, V12, P949, DOI 10.1096/fasebj.12.11.949; Xu W, 2014, ONCOGENE, V33, P2279, DOI 10.1038/onc.2013.163; Yegnasubramanian S, 2008, CANCER RES, V68, P8954, DOI 10.1158/0008-5472.CAN-07-6088; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Yue SH, 2014, CELL METAB, V19, P393, DOI 10.1016/j.cmet.2014.01.019; Zadra G, 2014, EMBO MOL MED, V6, P519, DOI 10.1002/emmm.201302734; Zadra G, 2013, BBA-MOL CELL BIOL L, V1831, P1518, DOI 10.1016/j.bbalip.2013.03.010; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689	131	37	37	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4683	4691		10.1038/onc.2014.422	http://dx.doi.org/10.1038/onc.2014.422			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	25531313	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000360931500002
J	Hasegawa, Y; Takahashi, M; Ariki, S; Asakawa, D; Tajiri, M; Wada, Y; Yamaguchi, Y; Nishitani, C; Takamiya, R; Saito, A; Uehara, Y; Hashimoto, J; Kurimura, Y; Takahashi, H; Kuroki, Y				Hasegawa, Y.; Takahashi, M.; Ariki, S.; Asakawa, D.; Tajiri, M.; Wada, Y.; Yamaguchi, Y.; Nishitani, C.; Takamiya, R.; Saito, A.; Uehara, Y.; Hashimoto, J.; Kurimura, Y.; Takahashi, H.; Kuroki, Y.			Surfactant protein D suppresses lung cancer progression by downregulation of epidermal growth factor signalling (vol 34, pg 838, 2014)	ONCOGENE			English	Correction													Asakawa, Daiki/M-9393-2019; Yamaguchi, Yoshiki/N-5246-2015; Ariki, Shigeru/E-3861-2014; Asakawa, Daiki/L-7798-2016; Saito, Atsushi/M-7382-2018; Takahashi, Motoko/I-3154-2013	Asakawa, Daiki/0000-0002-9357-8420; Yamaguchi, Yoshiki/0000-0003-0100-5439; Ariki, Shigeru/0000-0001-5838-499X; Asakawa, Daiki/0000-0002-9357-8420; Saito, Atsushi/0000-0003-3430-884X; Takahashi, Motoko/0000-0002-2112-6142; Uehara, Yasuaki/0000-0002-6439-2715; Takamiya, Rina/0000-0002-5947-488X				Hasegawa Y, 2015, ONCOGENE, V34, P838, DOI [10.1038/onc.2014.20, 10.1038/onc.2015.266]	1	37	39	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4285	4286		10.1038/onc.2015.266	http://dx.doi.org/10.1038/onc.2015.266			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	26250851	Bronze			2022-12-17	WOS:000359199800015
J	Ho, PWM; Goradia, A; Russell, MR; Chalk, AM; Milley, KM; Baker, EK; Danks, JA; Slavin, JL; Walia, M; Crimeen-Irwin, B; Dickins, RA; Martin, TJ; Walkley, CR				Ho, P. W. M.; Goradia, A.; Russell, M. R.; Chalk, A. M.; Milley, K. M.; Baker, E. K.; Danks, J. A.; Slavin, J. L.; Walia, M.; Crimeen-Irwin, B.; Dickins, R. A.; Martin, T. J.; Walkley, C. R.			Knockdown of PTHR1 in osteosarcoma cells decreases invasion and growth and increases tumor differentiation in vivo	ONCOGENE			English	Article							HORMONE-RELATED PROTEIN; SMOOTH-MUSCLE-CELLS; PARATHYROID-HORMONE; BONE-FORMATION; PTH/PTHRP RECEPTOR; ANGIOTENSIN-II; RAT; EXPRESSION; LOCALIZATION; OSTEOBLAST	Osteosarcoma (OS) is the most common cancer of bone. Parathyroid hormone (PTH) regulates calcium homeostasis and bone development, while the paracrine/autocrine PTH-related protein (PTHrP) has central roles in endochondral bone formation and bone remodeling. Using a murine OS model, we found that OS cells express PTHrP and the common PTH/PTHrP receptor (PTHR1). To investigate the role of PTHR1 signaling in OS cell behavior, we used shRNA to reduce PTHR1 expression. This only mildly inhibited proliferation in vitro, but markedly reduced invasion through collagen and reduced expression of RANK ligand (RANKL). Administration of PTH(1-34) did not stimulate OS proliferation in vivo but, strikingly, PTHR1 knockdown resulted in a profound growth inhibition and increased differentiation/mineralization of the tumors. Treatment with neutralizing antibody to PTHrP did not recapitulate the knockdown of PTHR1. Consistent with this lack of activity, PTHrP was predominantly intracellular in OS cells. Knockdown of PTHR1 resulted in increased expression of late osteoblast differentiation genes and upregulation of Wnt antagonists. RANKL production was reduced in knockdown tumors, providing for reduced homotypic signaling through the receptor, RANK. Loss of PTHR1 resulted in the coordinated loss of gene signatures associated with the polycomb repressive complex 2 (PRC2). Using Ezh2 inhibitors, we demonstrate that the increased expression of osteoblast maturation markers is in part mediated by the loss of PRC2 activity. Collectively these results demonstrate that PTHR1 signaling is important in maintaining OS proliferation and undifferentiated state. This is in part mediated by intracellular PTHrP and through regulation of the OS epigenome.	[Ho, P. W. M.; Goradia, A.; Russell, M. R.; Chalk, A. M.; Baker, E. K.; Walia, M.; Crimeen-Irwin, B.; Martin, T. J.; Walkley, C. R.] Univ Melbourne, St Vincents Hosp, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; [Ho, P. W. M.; Goradia, A.; Russell, M. R.; Chalk, A. M.; Baker, E. K.; Walia, M.; Crimeen-Irwin, B.; Martin, T. J.; Walkley, C. R.] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia; [Milley, K. M.; Danks, J. A.] RMIT Univ, Sch Med Sci, Bundoora, Vic, Australia; [Slavin, J. L.] St Vincents Hosp, Dept Pathol, Fitzroy, Vic 3065, Australia; [Dickins, R. A.] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Mol Med, Parkville, Vic 3050, Australia	St Vincent's Hospital Melbourne; St. Vincent's Institute of Medical Research; University of Melbourne; St Vincent's Hospital Melbourne; University of Melbourne; Royal Melbourne Institute of Technology (RMIT); St Vincent's Hospital Melbourne; Royal Melbourne Hospital; Walter & Eliza Hall Institute	Walkley, CR (corresponding author), St Vincents Inst, Stem Cell Regulat Unit, 9 Princes St, Fitzroy, Vic 3065, Australia.	jmartin@svi.edu.au; cwalkley@svi.edu.au	Walkley, Carl/AAO-6021-2020; Dickins, Ross A/K-2852-2012; Milley, Kristi/ADF-2413-2022; Chalk, Alistair/B-3019-2008	Walkley, Carl/0000-0002-4784-9031; Dickins, Ross A/0000-0003-4112-5304; Milley, Kristi/0000-0002-3615-4648; Chalk, Alistair/0000-0002-9630-6236	National Health and Medical Research Council of Australia (NHMRC); Cancer Council of Victoria; NHMRC Career Development Award; Cure Cancer Australia Foundation Fellowship; Victorian State Government	National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); NHMRC Career Development Award(National Health and Medical Research Council (NHMRC) of Australia); Cure Cancer Australia Foundation Fellowship; Victorian State Government	We thank the SVH BioResources Centre; P Kocovski and S Taylor for technical assistance, L Purton and J Heierhorst for comments and discussion. This work was supported by grants from the National Health and Medical Research Council of Australia (NHMRC; to CRW and CRW/TJM); Cancer Council of Victoria (to CRW and EKB); NHMRC Career Development Award (CRW); Cure Cancer Australia Foundation Fellowship (EKB); in part by the Victorian State Government Operational Infrastructure Support Program (to St. Vincent's Institute). CRW is the Philip Desbrow Senior Research Fellow of the Leukaemia Foundation. The authors thank Chugai Pharmaceutical Company for providing the alpha-PTHrP neutralizing antibody; The Structural Genomics Consortium for generously providing GSK343 and UNC1999.	Akiyama T, 2010, CLIN EXP METASTAS, V27, P207, DOI 10.1007/s10585-010-9319-y; Allan EH, 2003, J CELL BIOCHEM, V90, P158, DOI 10.1002/jcb.10614; Allan EH, 2008, J BONE MINER RES, V23, P1170, DOI 10.1359/JBMR.080324; Allison Daniel C., 2012, Sarcoma, V2012, P704872, DOI 10.1155/2012/704872; Andrews EB, 2012, J BONE MINER RES, V27, P2429, DOI 10.1002/jbmr.1768; Beristain AG, 2012, J CELL SCI, V125, P943, DOI 10.1242/jcs.094029; DANKS JA, 1989, J BONE MINER RES, V4, P273; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; Gardella TJ, 2001, TRENDS ENDOCRIN MET, V12, P210, DOI 10.1016/S1043-2760(01)00409-X; Gopalakrishnan R, 2005, CELLS TISSUES ORGANS, V181, P166, DOI 10.1159/000091378; Gorlick R, 2013, PEDIATR BLOOD CANCER, V60, P1009, DOI 10.1002/pbc.24429; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; INGLETON PM, 1977, LAB ANIM SCI, V27, P748; Janeway KA, 2010, LANCET ONCOL, V11, P670, DOI 10.1016/S1470-2045(10)70062-0; Jans DA, 1997, FEBS LETT, V410, P368, DOI 10.1016/S0014-5793(97)00622-4; JIANG BB, 1995, MINER ELECTROL METAB, V21, P157; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524; Keller H, 2005, BONE, V37, P148, DOI 10.1016/j.bone.2005.03.018; Kuijjer ML, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-245; Kuijjer ML, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-66; Lam MHC, 1997, J CELL PHYSIOL, V173, P433, DOI 10.1002/(SICI)1097-4652(199712)173:3<433::AID-JCP16>3.0.CO;2-C; Lamoureux F, 2007, CANCER RES, V67, P7308, DOI 10.1158/0008-5472.CAN-06-4130; Liu YQ, 2012, J CLIN INVEST, V122, P3101, DOI 10.1172/JCI61209; Maeda S, 1996, ENDOCRINOLOGY, V137, P3154, DOI 10.1210/en.137.8.3154; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; MARTIN TJ, 1976, NATURE, V260, P436, DOI 10.1038/260436a0; Martin TJ, 2005, J CLIN INVEST, V115, P2322, DOI 10.1172/JCI26239; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; McCauley LK, 2012, J BONE MINER RES, V27, P1231, DOI 10.1002/jbmr.1617; Miao DS, 2002, J CLIN INVEST, V109, P1173, DOI 10.1172/JCI200214817; Molyneux SD, 2010, J CLIN INVEST, V120, P3310, DOI 10.1172/JCI42391; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Mutsaers AJ, 2013, BONE, V55, P166, DOI 10.1016/j.bone.2013.02.016; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; OKANO K, 1994, ENDOCRINOLOGY, V135, P1093, DOI 10.1210/en.135.3.1093; Onuma E, 2004, ANTICANCER RES, V24, P2665; PIROLA CJ, 1993, J BIOL CHEM, V268, P1987; Premsrirut PK, 2011, CELL, V145, P145, DOI 10.1016/j.cell.2011.03.012; Takiguchi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054009; Tashjian AH, 2008, J BONE MINER RES, V23, P803, DOI 10.1359/JBMR.080208; Thompson DL, 2002, J BONE MINER RES, V17, P311, DOI 10.1359/jbmr.2002.17.2.311; Vargas MA, 2003, ENDOCRINOLOGY, V144, P4876, DOI 10.1210/en.2003-0253; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Watson PH, 2000, J BONE MINER RES, V15, P1033, DOI 10.1359/jbmr.2000.15.6.1033; Yang R, 2007, INT J CANCER, V121, P943, DOI 10.1002/ijc.22749	46	37	37	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2922	2933		10.1038/onc.2014.217	http://dx.doi.org/10.1038/onc.2014.217			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25043296				2022-12-17	WOS:000355324300011
J	Hasegawa, Y; Takahashi, M; Ariki, S; Asakawa, D; Tajiri, M; Wada, Y; Yamaguchi, Y; Nishitani, C; Takamiya, R; Saito, A; Uehara, Y; Hashimoto, J; Kurimura, Y; Takahashi, H; Kuroki, Y				Hasegawa, Y.; Takahashi, M.; Ariki, S.; Asakawa, D.; Tajiri, M.; Wada, Y.; Yamaguchi, Y.; Nishitani, C.; Takamiya, R.; Saito, A.; Uehara, Y.; Hashimoto, J.; Kurimura, Y.; Takahashi, H.; Kuroki, Y.			Surfactant protein D suppresses lung cancer progression by downregulation of epidermal growth factor signaling	ONCOGENE			English	Article							CARBOHYDRATE-RECOGNITION DOMAIN; IDIOPATHIC PULMONARY FIBROSIS; FACTOR RECEPTOR; TYROSINE KINASE; D BINDS; NEGATIVE COOPERATIVITY; EXTRACELLULAR DOMAINS; ALVEOLAR MACROPHAGES; MYCOBACTERIUM-AVIUM; GM3 BINDING	Surfactant protein D (SP-D) is a member of the collectin family that has an important role in maintaining pulmonary homeostasis. In this study, we demonstrated that SP-D inhibited the proliferation, migration and invasion of A549 human lung adenocarcinoma cells. We found that SP-D suppressed epidermal growth factor (EGF) signaling in A549 cells, H441 human lung adenocarcinoma cells and human EGF receptor (EGFR) stable expression CHO-K1 cells. A binding study using I-125-EGF demonstrated that SP-D downregulated the binding of EGF to EGFR. A ligand blot indicated that SP-D bound to EGFR, and a lectin blot suggested that EGFR in A549 cells had both high-mannose type and complex type N-glycans. We purified the recombinant extracellular domain of EGFR (soluble EGFR=soluble EGFR (sEGFR)), and demonstrated that SP-D directly bound to sEGFR in a Ca2+-dependent manner. The binding of SP-D to sEGFR was suppressed by EDTA, mannose or N-glycopeptidase F treatment. Mass spectrometric analysis indicated that N-glycans in domain III of EGFR were of a high-type. These data suggest that SP-D reduces EGF binding to EGFR through the interaction between the carbohydrate recognition domain of SP-D and N-glycans of EGFR, and downregulates EGF signaling. Our finding suggests the novel type of regulation system of EGF signaling involving lectin-to-carbohydrate interaction and downregulation of ligand binding.	[Hasegawa, Y.; Takahashi, M.; Ariki, S.; Nishitani, C.; Takamiya, R.; Saito, A.; Uehara, Y.; Hashimoto, J.; Kurimura, Y.; Kuroki, Y.] Sapporo Med Univ, Sch Med, Dept Biochem, Sapporo, Hokkaido 0608556, Japan; [Hasegawa, Y.; Saito, A.; Uehara, Y.; Takahashi, H.] Sapporo Med Univ, Sch Med, Dept Resp Med & Allergol, Sapporo, Hokkaido 0608556, Japan; [Asakawa, D.; Tajiri, M.; Wada, Y.] Osaka Med Ctr, Dept Mol Med, Osaka, Japan; [Asakawa, D.; Tajiri, M.; Wada, Y.] Res Inst Maternal & Child Hlth, Osaka, Japan; [Yamaguchi, Y.] RIKEN, Max Planck Joint Res Ctr, Syst Glycobiol Res Grp, Wako, Saitama, Japan; [Hashimoto, J.; Kurimura, Y.] Sapporo Med Univ, Sch Med, Dept Urol, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University; Sapporo Medical University; Osaka Medical Center for Cancer & Cardiovascular Diseases; RIKEN; Sapporo Medical University	Takahashi, M (corresponding author), Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, South 1 West 17, Sapporo, Hokkaido 0608556, Japan.	takam@sapmed.ac.jp	Asakawa, Daiki/M-9393-2019; Yamaguchi, Yoshiki/N-5246-2015; Ariki, Shigeru/E-3861-2014; Asakawa, Daiki/L-7798-2016; Saito, Atsushi/M-7382-2018; Takahashi, Motoko/I-3154-2013	Asakawa, Daiki/0000-0002-9357-8420; Yamaguchi, Yoshiki/0000-0003-0100-5439; Ariki, Shigeru/0000-0001-5838-499X; Asakawa, Daiki/0000-0002-9357-8420; Saito, Atsushi/0000-0003-3430-884X; Takahashi, Motoko/0000-0002-2112-6142; Uehara, Yasuaki/0000-0002-6439-2715; Takamiya, Rina/0000-0002-5947-488X	Japan Society for the Promotion of Science; Takeda Science Foundation; Suhara Foundation	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Takeda Science Foundation(Takeda Science Foundation (TSF)); Suhara Foundation	This work was supported in part by a Grant-in-Aid for Science Research from the Japan Society for the Promotion of Science, grants from the Takeda Science Foundation and from the Suhara Foundation.	Alvarado D, 2010, CELL, V142, P568, DOI 10.1016/j.cell.2010.07.015; Ariki S, 2011, J IMMUNOL, V187, P2586, DOI 10.4049/jimmunol.1100024; Aubry MC, 2002, MAYO CLIN PROC, V77, P763, DOI 10.4065/77.8.763; BASTACKY J, 1995, J APPL PHYSIOL, V79, P1615, DOI 10.1152/jappl.1995.79.5.1615; BETZ C, 1995, CANCER RES, V55, P4283; BREMER EG, 1986, J BIOL CHEM, V261, P2434; Dawson JP, 2007, STRUCTURE, V15, P942, DOI 10.1016/j.str.2007.06.013; HONDA Y, 1995, AM J RESP CRIT CARE, V152, P1860, DOI 10.1164/ajrccm.152.6.8520747; Hrustanovic G, 2013, CANCER BIOL THER, V14, P304, DOI 10.4161/cbt.23627; Hubbard R, 2000, AM J RESP CRIT CARE, V161, P5, DOI 10.1164/ajrccm.161.1.9906062; Ishii T, 2012, COPD, V9, P409, DOI 10.3109/15412555.2012.676110; Kawashima N, 2009, J BIOL CHEM, V284, P6147, DOI 10.1074/jbc.M808171200; Kingma PS, 2006, CURR OPIN PHARMACOL, V6, P277, DOI 10.1016/j.coph.2006.02.003; Kudo K, 2004, J IMMUNOL, V172, P7592, DOI 10.4049/jimmunol.172.12.7592; Kuroki Y, 2007, CELL MICROBIOL, V9, P1871, DOI 10.1111/j.1462-5822.2007.00953.x; Lin ZW, 2007, INT J ONCOL, V31, P181; Macdonald JL, 2008, P NATL ACAD SCI USA, V105, P112, DOI 10.1073/pnas.0707080105; Mason RJ, 2000, AM J PATHOL, V156, P175, DOI 10.1016/S0002-9440(10)64717-7; Nagae H, 1997, CLIN CHIM ACTA, V266, P157, DOI 10.1016/S0009-8981(97)00124-1; Nie XM, 2008, BIOCHEMISTRY-US, V47, P12878, DOI 10.1021/bi8010175; Ohya M, 2006, BIOCHEMISTRY-US, V45, P8657, DOI 10.1021/bi060176z; Oxnard GR, 2011, CLIN CANCER RES, V17, P5530, DOI 10.1158/1078-0432.CCR-10-2571; Park J, 2001, EUR RESPIR J, V17, P1216, DOI 10.1183/09031936.01.99055301; Partridge EA, 2004, SCIENCE, V306, P120, DOI 10.1126/science.1102109; Qi Zhi-li, 2002, Ai Zheng, V21, P772; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532, DOI 10.1152/jappl.1986.60.2.532; Restrepo CI, 1999, AM J RESP CELL MOL, V21, P576, DOI 10.1165/ajrcmb.21.5.3334; Sahly H, 2002, J IMMUNOL, V169, P3267, DOI 10.4049/jimmunol.169.6.3267; Sato Y, 2001, J BIOL CHEM, V276, P11956, DOI 10.1074/jbc.M008551200; Sawada K, 2010, J BIOL CHEM, V285, P8434, DOI 10.1074/jbc.M109.074765; Sin DD, 2008, CHEST, V134, P582, DOI 10.1378/chest.08-0600; Smith KD, 1996, GROWTH FACTORS, V13, P121, DOI 10.3109/08977199609034572; SODERQUIST AM, 1984, J BIOL CHEM, V259, P2586; Tajiri M, 2005, GLYCOBIOLOGY, V15, P1332, DOI 10.1093/glycob/cwj019; Tajiri M, 2009, J PROTEOME RES, V8, P688, DOI 10.1021/pr800727w; Takahashi H, 1996, RESPIRATION, V63, P390; Takahashi M, 2013, J BIOL CHEM, V288, P32910, DOI 10.1074/jbc.M113.491902; Tino MJ, 1999, AM J PHYSIOL-LUNG C, V276, pL164, DOI 10.1152/ajplung.1999.276.1.L164; Tsuda T, 2000, J BIOL CHEM, V275, P21988, DOI 10.1074/jbc.M003400200; Wada Y, 2004, ANAL CHEM, V76, P6560, DOI 10.1021/ac049062o; Wang XQ, 2001, GLYCOBIOLOGY, V11, P515, DOI 10.1093/glycob/11.7.515; Whitsett JA, 2002, NEW ENGL J MED, V347, P2141, DOI 10.1056/NEJMra022387; Wright JR, 2005, NAT REV IMMUNOL, V5, P58, DOI 10.1038/nri1528; Wright JR, 1997, PHYSIOL REV, V77, P931, DOI 10.1152/physrev.1997.77.4.931; Wu HX, 2003, J CLIN INVEST, V111, P1589, DOI 10.1172/JCI200316889; Yamazoe M, 2008, J BIOL CHEM, V283, P35878, DOI 10.1074/jbc.M807268200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yoon SJ, 2006, P NATL ACAD SCI USA, V103, P18987, DOI 10.1073/pnas.0609281103; Zhang F, 2004, CHEST, V125, p109S, DOI 10.1378/chest.125.5_suppl.109S	49	37	39	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					838	845		10.1038/onc.2014.20	http://dx.doi.org/10.1038/onc.2014.20			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	26250851				2022-12-17	WOS:000349472000004
J	Jagadeeshan, S; Krishnamoorthy, YR; Singhal, M; Subramanian, A; Mavuluri, J; Lakshmi, A; Roshini, A; Baskar, G; Ravi, M; Joseph, LD; Sadasivan, K; Krishnan, A; Nair, AS; Venkatraman, G; Rayala, SK				Jagadeeshan, S.; Krishnamoorthy, Y. R.; Singhal, M.; Subramanian, A.; Mavuluri, J.; Lakshmi, A.; Roshini, A.; Baskar, G.; Ravi, M.; Joseph, L. D.; Sadasivan, K.; Krishnan, A.; Nair, A. S.; Venkatraman, G.; Rayala, S. K.			Transcriptional regulation of fibronectin by p21-activated kinase-1 modulates pancreatic tumorigenesis	ONCOGENE			English	Article						Pak1; fibronectin; PDAC; NF-kappa B-p65; KRAS intact model	NF-KAPPA-B; DUCTAL ADENOCARCINOMA; CANCER; EXPRESSION; PAK1; PATHWAY; RAS; LOCALIZATION; TARGETS; BIOLOGY	Pancreatic ductal adenocarcinoma (PDAC) is the eighth largest cause of cancer-related mortality across the world, with a median 5-year survival rate of less than 3.5%. This is partly because the molecules and the molecular mechanisms that contribute to PDAC are not well understood. Our goal is to understand the role of p21-activated kinase 1 (Pak1) signaling axis in the progression of PDAC. Pak1, a serine/threonine kinase, is a well-known regulator of cytoskeletal remodeling, cell motility, cell proliferation and cell survival. Recent reports suggest that Pak1 by itself can have an oncogenic role in a wide variety of cancers. In this study, we analyzed the expression of Pak1 in human pancreatic cancer tissues and found that Pak1 levels are significantly upregulated in PDAC samples as compared with adjacent normals. Further, to study the functional role of Pak1 in pancreatic cancer model systems, we developed stable overexpression and lentiviral short hairpin RNA-mediated knockdown (KD) clones of Pak1 and studied the changes in transforming properties of the cells. We also observed that Pak1 KD clones failed to form tumors in nude mice. By adopting a quantitative PCR array-based approach, we identified fibronectin, a component of the extracellular matrix and a mesenchymal marker, as a transcriptional target of Pak1 signaling. The underlying molecular mechanism of Pak1-mediated transformation includes its nuclear import and recruitment to the fibronectin promoter via interaction with nuclear factor-kappa B (NF-kappa B)-p65 complex. To our knowledge, this is the first study illustrating Pak1-NF-kappa B-p65-mediated fibronectin regulation as a potent tumor-promoting mechanism in KRAS intact model.	[Jagadeeshan, S.; Krishnamoorthy, Y. R.; Singhal, M.; Subramanian, A.; Mavuluri, J.; Lakshmi, A.; Roshini, A.; Rayala, S. K.] IIT Madras, Dept Biotechnol, Chennai 600036, Tamil Nadu, India; [Baskar, G.; Ravi, M.] Sri Ramachandra Univ, Dept Human Genet, Chennai 600116, Tamil Nadu, India; [Joseph, L. D.] Sri Ramachandra Univ, Dept Pathol, Chennai 600116, Tamil Nadu, India; [Sadasivan, K.] Govt Med Coll, Dept Plast & Reconstruct Surg, Thiruvananthapuram, Kerala, India; [Nair, A. S.] RGCB, Thiruvananthapuram 695014, Kerala, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Madras; Sri Ramachandra Institute of Higher Education & Research; Sri Ramachandra Institute of Higher Education & Research; Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Rayala, SK (corresponding author), IIT Madras, Dept Biotechnol, Chennai 600036, Tamil Nadu, India.	sasha@rgcb.res.in; ganeshv@sriramachandra.edu.in; rayala@iitm.ac.in	Krishnan, Anand/H-1314-2016; Singhal, Mahak/V-4017-2019; Mavuluri, Jayadev/AAW-6724-2021; JAGADEESHAN, SANKAR/S-8384-2019; Venkatraman, Ganesh/AAB-1467-2020; Joseph, Leena Dennis/AAS-9420-2020; Arivazhagan, Lakshmi/AAD-8613-2020	Singhal, Mahak/0000-0002-7303-9585; JAGADEESHAN, SANKAR/0000-0002-3778-8757; Venkatraman, Ganesh/0000-0003-0179-9785; Arivazhagan, Lakshmi/0000-0002-3713-442X; Muralikrishnan, Anirudh Subramanian/0000-0001-7102-9968; Rayala, Suresh/0000-0003-4394-4450	Department of Biotechnology (DBT), Government of India [BT/PR13559/Med/30/283/2010]; Indian Institute of Technology Madras (IITM)	Department of Biotechnology (DBT), Government of India(Department of Biotechnology (DBT) India); Indian Institute of Technology Madras (IITM)	We thank Silpa for help in mutagenesis and cloning and Swarnalatha for help with Pak1 lentiviral clones. Thanks to Sekar Sathiya, Rohan Prasad, Hemadev and the entire team of the Centre for Toxicology and Developmental Research (CEFT), Sri Ramachandra University, Chennai, for help with animal experiments. We thank the Department of Biotechnology (DBT), Government of India for the financial support to SKR (grant no.: BT/PR13559/Med/30/283/2010) and Indian Institute of Technology Madras (IITM) for all other facilities.	ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Arias-Romero LE, 2008, BIOL CELL, V100, P97, DOI 10.1042/BC20070109; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Costello E, 2012, NAT REV GASTRO HEPAT, V9, P435, DOI 10.1038/nrgastro.2012.119; Crnogorac-Jurcevic T, 2001, ONCOGENE, V20, P7437, DOI 10.1038/sj.onc.1204935; Falasca M, 2011, ANTI-CANCER AGENT ME, V11, P455, DOI 10.2174/187152011795677382; Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; He H, 2008, BBA-MOL CELL RES, V1783, P1943, DOI 10.1016/j.bbamcr.2008.04.016; Hidalgo M, 2012, CLIN CANCER RES, V18, P4249, DOI 10.1158/1078-0432.CCR-12-1327; Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kichina JV, 2010, EXPERT OPIN THER TAR, V14, P703, DOI 10.1517/14728222.2010.492779; Kimmelman AC, 2008, P NATL ACAD SCI USA, V105, P19372, DOI 10.1073/pnas.0809966105; Krautz C, 2011, ANTI-CANCER AGENT ME, V11, P411, DOI 10.2174/187152011795677409; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Linder S, 2001, HEPATO-GASTROENTEROL, V48, P1321; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Mao Y, 2005, J CELL SCI, V118, P4427, DOI 10.1242/jcs.02566; Menard RE, 2003, CELL SIGNAL, V15, P1099, DOI 10.1016/S0898-6568(03)00087-1; Morris JP, 2010, NAT REV CANCER, V10, P683, DOI 10.1038/nrc2899; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Ong CC, 2011, ONCOTARGET, V2, P491; Ong CC, 2011, P NATL ACAD SCI USA, V108, P7177, DOI 10.1073/pnas.1103350108; Sanchez-Solana B, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.404061; Singh RR, 2005, J BIOL CHEM, V280, P18130, DOI 10.1074/jbc.M412607200; Stanisavljevic J, 2011, J CELL SCI, V124, P4159, DOI 10.1242/jcs.078824; Ungefroren H, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-67; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; World Cancer Research Fund/ American Institute for Cancer Research, 2012, CONT UPD PROJ SUMM F; Wu R, 2010, INT J CANCER, V127, P2230, DOI 10.1002/ijc.25226; Ye Diana Zi, 2012, Cell Logist, V2, P105; Yeh JJ, 2007, EXPERT OPIN THER TAR, V11, P673, DOI 10.1517/14728222.11.5.673	34	37	38	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					455	464		10.1038/onc.2013.576	http://dx.doi.org/10.1038/onc.2013.576			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24561527				2022-12-17	WOS:000348451300006
J	Li, L; Puliyappadam, V; Chakraborty, S; Rehman, A; Vemireddy, V; Saha, D; Souza, RF; Hatanpaa, KJ; Koduru, P; Burma, S; Boothman, DA; Habib, AA				Li, L.; Puliyappadam, V. T.; Chakraborty, S.; Rehman, A.; Vemireddy, V.; Saha, D.; Souza, R. F.; Hatanpaa, K. J.; Koduru, P.; Burma, S.; Boothman, D. A.; Habib, A. A.			EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma	ONCOGENE			English	Article						EGFRvIII; glioblastoma; EGFR wild type; Met; antagonistic interaction; temozolomide	GROWTH-FACTOR RECEPTOR; C-MET; SIGNALING NETWORKS; AUTOCRINE LOOP; BRAIN-TUMORS; CELLS; GLIOMA; EXPRESSION; CANCER; RADIORESISTANCE	Epidermal growth factor receptor (EGFR)vIII is the most common EGFR mutant found in glioblastoma (GBM). EGFRvIII does not bind ligand, is highly oncogenic and is usually coexpressed with EGFR wild type (EGFRwt). EGFRvIII activates Met, and Met contributes to EGFRvIII-mediated oncogenicity and resistance to treatment. Here, we report that addition of EGF results in a rapid loss of EGFRvIII-driven Met phosphorylation in glioma cells. Met is associated with EGFRvIII in a physical complex. Addition of EGF results in a dissociation of the EGFRvIII-Met complex with a concomitant loss of Met phosphorylation. Consistent with the abrogation of Met activation, addition of EGF results in the inhibition of EGFRvIII-mediated resistance to chemotherapy. Thus, our study suggests that ligand in the milieu of EGFRvIII-expressing GBM cells is likely to influence the EGFRvIII-Met interaction and resistance to treatment, and highlights a novel antagonistic interaction between EGFRwt and EGFRvIII in glioma cells.	[Li, L.; Puliyappadam, V. T.; Chakraborty, S.; Rehman, A.; Vemireddy, V.; Habib, A. A.] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75216 USA; [Saha, D.; Burma, S.; Boothman, D. A.] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75216 USA; [Souza, R. F.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75216 USA; [Souza, R. F.] Univ Texas SW Med Ctr Dallas, Esophagal Dis Ctr, Dallas, TX 75216 USA; [Hatanpaa, K. J.; Koduru, P.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75216 USA; [Boothman, D. A.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75216 USA; [Boothman, D. A.; Habib, A. A.] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75216 USA; [Habib, A. A.] VA North Texas Hlth Care Syst, Dallas, TX USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA North Texas Health Care System	Habib, AA (corresponding author), Univ Texas SW Med Ctr Dallas, North Texas VA Hlth care Syst, Dept Neurol, Mail Code 151,4500 South Lancaster Rd, Dallas, TX 75235 USA.	Amyn.Habib@UTSouthwestern.edu	Boothman, David/Q-7776-2019		NIH [RO1N5062080, RO1 CA139217]; National Institutes of Health [RO1 CA149461, R01-DK63621, R01-CA134571]; National Aeronautics and Space Administration [NNX13AI13G]; Cancer Prevention and Research Institute of Texas [RP100644]; Office of Medical Research, Departments of Veterans Affairs (RFS); NATIONAL CANCER INSTITUTE [R01CA134571, P30CA142543, R01CA139217, R01CA149461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS062080] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Aeronautics and Space Administration(National Aeronautics & Space Administration (NASA)); Cancer Prevention and Research Institute of Texas; Office of Medical Research, Departments of Veterans Affairs (RFS); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported in part by NIH grant RO1N5062080 to AAH and by RO1 CA139217 to DAB. SB is supported by grants from the National Institutes of Health (RO1 CA149461), National Aeronautics and Space Administration (NNX13AI13G) and the Cancer Prevention and Research Institute of Texas (RP100644). This work was also supported by the Office of Medical Research, Departments of Veterans Affairs (RFS) and the National Institutes of Health (R01-DK63621, R01-CA134571 to RFS).	Abounader R, 2001, FASEB J, V15, P108, DOI 10.1096/fj.01-0421fje; Biernat W, 2004, BRAIN PATHOL, V14, P131, DOI 10.1111/j.1750-3639.2004.tb00045.x; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chumbalkar V, 2011, J PROTEOME RES, V10, P1343, DOI 10.1021/pr101075e; Dulak AM, 2011, ONCOGENE, V30, P3625, DOI 10.1038/onc.2011.84; Eder JP, 2009, CLIN CANCER RES, V15, P2207, DOI 10.1158/1078-0432.CCR-08-1306; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Garnett J, 2013, NEOPLASIA, V15, P73, DOI 10.1593/neo.121536; Hatanpaa KJ, 2010, NEOPLASIA, V12, P675, DOI 10.1593/neo.10688; Heimberger AB, 2005, CLIN CANCER RES, V11, P1462, DOI 10.1158/1078-0432.CCR-04-1737; Huang PH, 2007, P NATL ACAD SCI USA, V104, P12867, DOI 10.1073/pnas.0705158104; Huang PH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.287re6; Hwang Y, 2011, MOL CANCER RES, V9, P1199, DOI 10.1158/1541-7786.MCR-11-0229; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Jiwani AJ, 2011, PROTEOME SCI, V9, DOI 10.1186/1477-5956-9-53; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; Karpel-Massler G, 2009, MOL CANCER RES, V7, P1000, DOI 10.1158/1541-7786.MCR-08-0479; Li B, 2004, ONCOGENE, V23, P4594, DOI 10.1038/sj.onc.1207602; Li L, 2014, ONCOGENE, V33, P4253, DOI 10.1038/onc.2013.400; Lorimer IAJ, 2002, CURR CANCER DRUG TAR, V2, P91, DOI 10.2174/1568009023333926; Luwor RB, 2004, ONCOGENE, V23, P6095, DOI 10.1038/sj.onc.1207870; Mishima K, 1998, ACTA NEUROPATHOL, V96, P322, DOI 10.1007/s004010050901; Nishikawa Ryo, 2004, Brain Tumor Pathol, V21, P53, DOI 10.1007/BF02484510; Pedersen MW, 2001, ANN ONCOL, V12, P745, DOI 10.1023/A:1011177318162; Puliyappadamba VT, 2013, CELL REP, V4, P764, DOI 10.1016/j.celrep.2013.07.025; Ramnarain DB, 2006, CANCER RES, V66, P867, DOI 10.1158/0008-5472.CAN-05-2753; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tang P, 1997, J NEURO-ONCOL, V35, P303, DOI 10.1023/A:1005824802617; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Xu L, 2010, ONCOGENE, V29, P2616, DOI 10.1038/onc.2010.16; Zhang Y, 2013, CLIN CANCER RES, V19, P1433, DOI 10.1158/1078-0432.CCR-12-2832; Zou HY, 2007, CANCER RES, V67, P4408, DOI 10.1158/0008-5472.CAN-06-4443	33	37	38	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					129	134		10.1038/onc.2013.534	http://dx.doi.org/10.1038/onc.2013.534			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24362532	Green Accepted			2022-12-17	WOS:000349740100012
J	Tsai, CH; Teng, CH; Tu, YT; Cheng, TS; Wu, SR; Ko, CJ; Shyu, HY; Lan, SW; Huang, HP; Tzeng, SF; Johnson, MD; Lin, CY; Hsiao, PW; Lee, MS				Tsai, C-H; Teng, C-H; Tu, Y-T; Cheng, T-S; Wu, S-R; Ko, C-J; Shyu, H-Y; Lan, S-W; Huang, H-P; Tzeng, S-F; Johnson, M. D.; Lin, C-Y; Hsiao, P-W; Lee, M-S			HAI-2 suppresses the invasive growth and metastasis of prostate cancer through regulation of matriptase	ONCOGENE			English	Article						prostate cancer; hepatocyte growth factor activator inhibitor-2; cancer cell invasion; tumorigenicity; metastasis	SERINE-PROTEASE INHIBITOR; FACTOR ACTIVATOR INHIBITOR-1; HUMAN BREAST-CANCER; CELL-SURFACE; PLACENTAL DEVELOPMENT; ZYMOGEN ACTIVATION; EPITHELIAL-CELLS; TUMOR-GROWTH; IN-VITRO; HEPATOCYTE	Dysregulation of cell surface proteolysis has been strongly implicated in tumorigenicity and metastasis. In this study, we delineated the role of hepatocyte growth factor activator inhibitor-2 (HAI-2) in prostate cancer (PCa) cell migration, invasion, tumorigenicity and metastasis using a human PCa progression model (103E, N1, and N2 cells) and xenograft models. N1 and N2 cells were established through serial intraprostatic propagation of 103E human PCa cells and isolation of the metastatic cells from nearby lymph nodes. The invasion capability of these cells was revealed to gradually increase throughout the serial isolations (103E < N1 < N2). In this series of cells, the expression of HAI-2 but not HAI-1 was significantly decreased throughout the progression and occurred in parallel with increased activation of matriptase. The expression level and activity of matriptase increased whereas the HAI-2 protein level decreased over the course of orthotopic tumor growth in mice, which was consistent with the immunohistochemical profiles of matriptase and HAI-2 in archival PCa specimens. Knockdown of matriptase reduced the PCa cell invasion induced by HAI-2 knockdown. HAI-2 overexpression or matriptase silencing in N2 cells downregulated matriptase activity and significantly decreased tumorigenicity and metastatic capability in orthotopically xenografted mice. These results suggest that during the progression of human PCa, matriptase activity is primarily controlled by HAI-2 expression. The imbalance between HAI-2 and matriptase expression led to matriptase activation, thereby increasing cell migration, invasion, tumorigenicity and metastasis.	[Tsai, C-H; Tzeng, S-F; Hsiao, P-W] Acad Sinica, Agr Biotechnol Res Ctr, Taipei 115, Taiwan; [Teng, C-H; Tu, Y-T; Cheng, T-S; Wu, S-R; Ko, C-J; Shyu, H-Y; Lan, S-W; Lee, M-S] Natl Taiwan Univ, Coll Med, Dept Biochem & Mol Biol, Taipei 10764, Taiwan; [Shyu, H-Y] Minist Justice, Invest Bur, Taipei, Taiwan; [Huang, H-P] Natl Taiwan Univ, Coll Med, Grad Inst Med Genom & Prote, Taipei 10764, Taiwan; [Johnson, M. D.; Lin, C-Y] Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA	Academia Sinica - Taiwan; National Taiwan University; National Taiwan University; Georgetown University	Hsiao, PW (corresponding author), Acad Sinica, Agr Biotechnol Res Ctr, 128 Acad Rd,Sect 2, Taipei 115, Taiwan.	pwhsiao@gate.sinica.edu.tw; mslee2006@ntu.edu.tw	Ko, Chun-Jung/AAA-6187-2022; Hsiao, Pei-Wen/V-5653-2018	johnson, Michael/0000-0001-6260-7586; LEE, MING-SHYUE/0000-0002-8673-5088; HUANG, HSIANG-PO/0000-0002-3382-305X; Hsiao, Pei-Wen/0000-0002-3589-6754; LEE, MING-SHYUE/0000-0002-5884-4535; Ko, Chun-Jung/0000-0001-6565-7060	Taiwan National Health Research Institutes [NHRI-EX101-9909BC, NHRI-EX102-9909BC]; Taiwan National Science Council [NSC 97-2320-B-002-052-MY3, NSC 100-2628-B-002-004-MY4, NSC 101-2324-B-002-015, NSC 98-2320-B-001-018-MY3]; National Taiwan University [98R0305]; National Taiwan University Cutting-Edge Steering Research Project [10R71602C4]; Postdoctoral Fellowship from the Aim for Top University Program, National Taiwan University; Agricultural Biotechnology Research Center and Academia Sinica; NATIONAL CANCER INSTITUTE [P30CA051008, R01CA123223] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000101] Funding Source: NIH RePORTER	Taiwan National Health Research Institutes; Taiwan National Science Council(Ministry of Science and Technology, Taiwan); National Taiwan University(National Taiwan University); National Taiwan University Cutting-Edge Steering Research Project; Postdoctoral Fellowship from the Aim for Top University Program, National Taiwan University; Agricultural Biotechnology Research Center and Academia Sinica; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This study was supported by Taiwan National Health Research Institutes Grants NHRI-EX101-9909BC and NHRI-EX102-9909BC, Taiwan National Science Council Grants NSC 97-2320-B-002-052-MY3, NSC 100-2628-B-002-004-MY4 and NSC 101-2324-B-002-015, the Frontier and Innovative Research Grant of National Taiwan University 98R0305 and National Taiwan University Cutting-Edge Steering Research Project 10R71602C4 to M-S Lee; Postdoctoral Fellowship from the Aim for Top University Program, National Taiwan University, to T-S Cheng; and grants from the National Science Council, Taiwan (NSC 98-2320-B-001-018-MY3), financial and instrumental support from the Agricultural Biotechnology Research Center and Academia Sinica awarded to P-W Hsiao. We are also grateful to Miranda Loney (Editor, ABRC) for critical suggestions editing this article.	Antalis TM, 2010, BIOCHEM J, V428, P325, DOI 10.1042/BJ20100046; Bergum C, 2010, PROSTATE, V70, P1422, DOI 10.1002/pros.21177; Chen CJ, 2011, AM J PHYSIOL-CELL PH, V300, pC406, DOI 10.1152/ajpcell.00403.2010; Cheng TS, 2013, CANCER PREV RES, V6, P495, DOI 10.1158/1940-6207.CAPR-12-0293-T; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Fukai K, 2003, CANCER RES, V63, P8674; Heinz-Erian P, 2009, AM J HUM GENET, V84, P188, DOI 10.1016/j.ajhg.2009.01.004; Huang HP, 2012, HEPATOLOGY, V55, P161, DOI 10.1002/hep.24657; Jin XL, 2006, CANCER SCI, V97, P1327, DOI 10.1111/j.1349-7006.2006.00328.x; Kang JY, 2003, CANCER RES, V63, P1101; Kawaguchi T, 1997, J BIOL CHEM, V272, P27558, DOI 10.1074/jbc.272.44.27558; Kirchhofer D, 2005, FEBS LETT, V579, P1945, DOI 10.1016/j.febslet.2005.01.085; Kongkham PN, 2008, CANCER RES, V68, P9945, DOI 10.1158/0008-5472.CAN-08-2169; Lee MS, 2007, AM J PHYSIOL-CELL PH, V293, pC95, DOI 10.1152/ajpcell.00611.2006; Lee MS, 2005, AM J PHYSIOL-CELL PH, V288, pC932, DOI 10.1152/ajpcell.00497.2004; Lee MS, 2006, J CANC MOL, V2, P183; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lin CY, 2008, FRONT BIOSCI-LANDMRK, V13, P621, DOI 10.2741/2707; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; List K, 2006, MOL MED, V12, P1, DOI 10.2119/2006-00022.List; Marlor CW, 1997, J BIOL CHEM, V272, P12202, DOI 10.1074/jbc.272.18.12202; Morris MR, 2005, CANCER RES, V65, P4598, DOI 10.1158/0008-5472.CAN-04-3371; Muller-Pillasch F, 1998, BBA-GENE STRUCT EXPR, V1395, P88, DOI 10.1016/S0167-4781(97)00129-2; Nagakawa O, 2005, EUR UROL, V48, P686, DOI 10.1016/j.eururo.2005.05.020; Netzel-Arnett S, 2003, CANCER METAST REV, V22, P237, DOI 10.1023/A:1023003616848; Oberst M, 2001, AM J PATHOL, V158, P1301, DOI 10.1016/S0002-9440(10)64081-3; Oberst MD, 2003, J BIOL CHEM, V278, P26773, DOI 10.1074/jbc.M304282200; Oberst MD, 2003, J HISTOCHEM CYTOCHEM, V51, P1017, DOI 10.1177/002215540305100805; Parr C, 2004, CLIN CANCER RES, V10, P202, DOI 10.1158/1078-0432.CCR-0553-3; Parr C, 2006, INT J CANCER, V119, P1176, DOI 10.1002/ijc.21881; Saleem M, 2006, CANCER EPIDEM BIOMAR, V15, P217, DOI 10.1158/1055-9965.EPI-05-0737; Satomi S, 2001, BIOCHEM BIOPH RES CO, V287, P995, DOI 10.1006/bbrc.2001.5686; SHI YE, 1993, CANCER RES, V53, P1409; Szabo R, 2007, ONCOGENE, V26, P1546, DOI 10.1038/sj.onc.1209966; Szabo R, 2011, ONCOGENE, V30, P2003, DOI 10.1038/onc.2010.586; Szabo R, 2008, J BIOL CHEM, V283, P29495, DOI 10.1074/jbc.M801970200; Szabo R, 2009, DEVELOPMENT, V136, P2653, DOI 10.1242/dev.038430; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tsai CH, 2009, CLIN CANCER RES, V15, P5435, DOI 10.1158/1078-0432.CCR-09-0298; Uhland K, 2006, CELL MOL LIFE SCI, V63, P2968, DOI 10.1007/s00018-006-6298-x; Weiss L, 2000, Cancer Metastasis Rev, V19, pI; Wu SR, 2010, AM J PATHOL, V177, P3145, DOI 10.2353/ajpath.2010.100228	46	37	38	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2014	33	38					4643	4652		10.1038/onc.2013.412	http://dx.doi.org/10.1038/onc.2013.412			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3VX	24121274	Green Accepted			2022-12-17	WOS:000342007200003
J	Kosari, F; Ida, C; Aubry, MC; Yang, L; Kovtun, IV; Klein, JLS; Li, Y; Erdogan, S; Tomaszek, S; Murphy, SJ; Bolette, LC; Kolbert, CP; Yang, P; Wigle, DA; Vasmatzis, G				Kosari, F.; Ida, C. M.; Aubry, M-C; Yang, L.; Kovtun, I. V.; Klein, J. L. S.; Li, Y.; Erdogan, S.; Tomaszek, S. C.; Murphy, S. J.; Bolette, L. C.; Kolbert, C. P.; Yang, P.; Wigle, D. A.; Vasmatzis, G.			ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation	ONCOGENE			English	Article						prognostic biomarker; MASH1; lung cancer; neuroendocrine; microarray	MEDULLARY-THYROID CANCER; ACHAETE-SCUTE HOMOLOG-1; GENE-EXPRESSION; CIGARETTE-SMOKING; CELLS; MICE; PROTOONCOGENE; FEATURES; SUBTYPE; FUSIONS	ASCL1 is an important regulatory transcription factor in pulmonary neuroendocrine (NE) cell development, but its value as a biomarker of NE differentiation in lung adenocarcinoma (AD) and as a potential prognostic biomarker remains unclear. We examined ASCL1 expression in lung cancer samples of varied histologic subtype, clinical outcome and smoking status and compared with expression of traditional NE markers. ASCL1 mRNA expression was found almost exclusively in smokers with AD, in contrast to nonsmokers and other lung cancer subtypes. ASCL1 protein expression by immunohistochemical (IHC) analysis correlated best with synaptophysin compared with chromogranin and CD56/NCAM. Analysis of a compendium of 367 microarray-based gene expression profiles in stage I lung adenocarcinomas identified significantly higher expression levels of the RET oncogene in ASCL1-positive tumors (ASCL1(+)) compared with ASCL1(-) tumors (q-value < 10(-9)). High levels of RET expression in ASCL1(+) but not in ASCL1(-) tumors was associated with significantly shorter overall survival (OS) in stage 1 (P = 0.007) and in all AD (P = 0.037). RET protein expression by IHC had an association with OS in the context of ASCL1 expression. In silico gene set analysis and in vitro experiments by ASCL1 shRNA in AD cells with high endogenous expression of ASCL1 and RET implicated ASCL1 as a potential upstream regulator of the RET oncogene. Also, silencing ASCL1 in AD cells markedly reduced cell growth and motility. These results suggest that ASCL1 and RET expression defines a clinically relevant subgroup of similar to 10% of AD characterized by NE differentiation.	[Kosari, F.; Klein, J. L. S.; Murphy, S. J.; Vasmatzis, G.] Mayo Clin, Dept Mol Med, Rochester, MN 55905 USA; [Ida, C. M.; Aubry, M-C; Yang, L.; Erdogan, S.; Bolette, L. C.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA; [Kovtun, I. V.] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; [Li, Y.; Yang, P.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA; [Tomaszek, S. C.; Wigle, D. A.] Mayo Clin, Dept Surg & Adv Genom Technol Ctr, Rochester, MN 55905 USA; [Kolbert, C. P.] Mayo Clin, Adv Genom Technol Ctr, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Vasmatzis, G (corresponding author), Mayo Clin, Lab Med & Pathol, 200 First Str SW, Rochester, MN 55905 USA.	vasmatzis.george@mayo.edu	Kovtun, Irina/ABA-8484-2020		Waterman Biomarker Discovery grant; Mayo Clinic Center for Individualized Medicine; NATIONAL CANCER INSTITUTE [P30CA015083] Funding Source: NIH RePORTER	Waterman Biomarker Discovery grant; Mayo Clinic Center for Individualized Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a Waterman Biomarker Discovery grant and by the Mayo Clinic Center for Individualized Medicine.	Arighi E, 2005, CYTOKINE GROWTH F R, V16, P441, DOI 10.1016/j.cytogfr.2005.05.010; Boldrini L, 2009, ONCOL REP, V22, P683, DOI 10.3892/or_00000488; Borges M, 1997, NATURE, V386, P852, DOI 10.1038/386852a0; Bryant CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011712; Burton MD, 1997, J AUTONOM NERV SYST, V63, P137, DOI 10.1016/S0165-1838(97)00002-7; Chen H, 1996, SURGERY, V120, P168, DOI 10.1016/S0039-6060(96)80284-4; Dauger S, 2001, PHYSIOL GENOMICS, V7, P149, DOI 10.1152/physiolgenomics.00056.2001; Dauger S, 1999, PEDIATR RES, V46, P535, DOI 10.1203/00006450-199911000-00008; Freedman ND, 2008, LANCET ONCOL, V9, P649, DOI 10.1016/S1470-2045(08)70154-2; Fujiwara T, 2012, LUNG CANCER, V75, P119, DOI 10.1016/j.lungcan.2011.05.028; Huber K, 2005, DEV BIOL, V279, P501, DOI 10.1016/j.ydbio.2005.01.007; Huber K, 2002, DEVELOPMENT, V129, P4729; Ionescu DN, 2007, AM J SURG PATHOL, V31, P26, DOI 10.1097/01.pas.0000213319.04919.97; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Kang HC, 2004, CLIN CANCER RES, V10, P272, DOI 10.1158/1078-0432.CCR-1025-3; Khuder SA, 2001, LUNG CANCER, V31, P139, DOI 10.1016/S0169-5002(00)00181-1; Kohno T, 2012, NAT MED, V18, P375, DOI 10.1038/nm.2644; Kouvaraki MA, 2005, THYROID, V15, P531, DOI 10.1089/thy.2005.15.531; Landi MT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001651; Linnoila RI, 2000, CANCER RES, V60, P4005; Lo LC, 1998, DEVELOPMENT, V125, P609; Lodish MB, 2008, EXPERT REV ANTICANC, V8, P625, DOI 10.1586/14737140.8.4.625; Marsh DJ, 2011, ADV OTO-RHINO-LARYNG, V70, P84, DOI 10.1159/000322479; Massion PP, 2008, AM J RESP CRIT CARE, V178, P1164, DOI 10.1164/rccm.200801-142OC; Osada H, 2005, CANCER RES, V65, P10680, DOI 10.1158/0008-5472.CAN-05-1404; Osada H, 2008, CANCER RES, V68, P1647, DOI 10.1158/0008-5472.CAN-07-5039; Poulsen TT, 2008, CANCER GENE THER, V15, P563, DOI 10.1038/cgt.2008.24; Powell CA, 2003, AM J RESP CELL MOL, V29, P157, DOI 10.1165/rcmb.2002-0183RC; Rheinbay E, 2013, CELL REP, V3, P1567, DOI 10.1016/j.celrep.2013.04.021; Shaw AT, 2009, J CLIN ONCOL, V27, P4247, DOI 10.1200/JCO.2009.22.6993; Shoba T, 2002, NEUROSCI LETT, V318, P129, DOI 10.1016/S0304-3940(01)02491-0; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Takahashi T, 2010, ANN SURG ONCOL, V17, P889, DOI 10.1245/s10434-009-0808-7; Travis WD., 2004, TRAVIS WB WHO CLASSI; Wang R, 2012, J CLIN ONCOL, V30, P4352, DOI 10.1200/JCO.2012.44.1477	35	37	38	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3776	3783		10.1038/onc.2013.359	http://dx.doi.org/10.1038/onc.2013.359			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	24037524	Green Accepted			2022-12-17	WOS:000339394100003
J	Albinet, V; Bats, ML; Huwiler, A; Rochaix, P; Chevreau, C; Segui, B; Levade, T; Andrieu-Abadie, N				Albinet, V.; Bats, M-L; Huwiler, A.; Rochaix, P.; Chevreau, C.; Segui, B.; Levade, T.; Andrieu-Abadie, N.			Dual role of sphingosine kinase-1 in promoting the differentiation of dermal fibroblasts and the dissemination of melanoma cells	ONCOGENE			English	Article						dermal fibroblasts; melanoma; migration; sphingosine-1-phosphate; Sphk1(-/-) mice	STROMAL FIBROBLASTS; TUMOR-DEVELOPMENT; SPHINGOSINE-1-PHOSPHATE; INVASION; RECEPTOR; GROWTH; ANGIOGENESIS; SPHINGOLIPIDS; 1-PHOSPHATE; EXPRESSION	Despite progress in the understanding of the biology and genetics of melanoma, no effective treatment against this cancer is available. The adjacent microenvironment has an important role in melanoma progression. Defining the molecular signals that control the bidirectional dialog between malignant cells and the surrounding stroma is crucial for efficient targeted therapy. Our study aimed at defining the role of sphingosine-1-phosphate (S1P) in melanoma-stroma interactions. Transcriptomic analysis of human melanoma cell lines showed increased expression of sphingosine kinase-1 (SPHK1), the enzyme that produces S1P, as compared with normal melanocytes. Such an increase was also observed by immunohistochemistry in melanoma specimens as compared with nevi, and occurred downstream of ERK activation because of BRAF or NRAS mutations. Importantly, migration of melanoma cells was not affected by changes in SPHK1 activity in tumor cells, but was stimulated by comparable modifications of S1P-metabolizing enzymes in cocultured dermal fibroblasts. Reciprocally, incubation of fibroblasts with the conditioned medium from SPHK1-expressing melanoma cells resulted in their differentiation to myofibroblasts, increased production of matrix metalloproteinases and enhanced SPHK1 expression and activity. In vivo tumorigenesis experiments showed that the lack of S1P in the microenvironment prevented the development of orthotopically injected melanoma cells. Finally, local tumor growth and dissemination were enhanced more efficiently by coinjection of wild-type skin fibroblasts than by fibroblasts from Sphk1(-/-) mice. This report is the first to document that SPHK1/S1P modulates the communication between melanoma cells and dermal fibroblasts. Altogether, our findings highlight SPHK1 as a potential therapeutic target in melanoma progression.	[Albinet, V.; Bats, M-L; Segui, B.; Levade, T.; Andrieu-Abadie, N.] Ctr Rech Cancerol Toulouse, Equipe Labellisee Ligue Canc 2013, INSERM, UMR1037, Toulouse, France; [Albinet, V.; Bats, M-L; Segui, B.; Levade, T.; Andrieu-Abadie, N.] Univ Toulouse 3, F-31062 Toulouse, France; [Huwiler, A.] Univ Bern, Inst Pharmacol, Bern, Switzerland; [Rochaix, P.] Serv Anat & Cytol Pathol, Toulouse, France; [Chevreau, C.] Inst Claudius Regaud, Dept Med Oncol, Toulouse, France; [Levade, T.] CHU, Lab Biochim Metab, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Bern; UNICANCER; Institut Claudius Regaud; CHU de Toulouse	Andrieu-Abadie, N (corresponding author), CHU Rangueil, Ctr Rech Cancerol Toulouse, Equipe Labellisee Ligue Canc 2013, Inserm,UMR1037, BP84225, F-31432 Toulouse, France.	nathalie.andrieu@inserm.fr	Levade, Thierry/O-8948-2014; Rochaix, Philippe/O-4710-2014; Ségui, Bruno/O-8957-2014; Chevreau, Christine/A-5565-2015; Andrieu-Abadie, Nathalie/N-6793-2013	Rochaix, Philippe/0000-0001-6238-1599; Ségui, Bruno/0000-0002-6119-1889; Andrieu-Abadie, Nathalie/0000-0003-2698-1970; Bats, Marie-Lise/0000-0002-8359-4662	INSERM; Paul Sabatier University; Ligue Nationale Contre le Cancer; Association pour la Recherche sur le Cancer	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Paul Sabatier University; Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council)	We thank Drs D Bennett (London, UK), R Marais (London, UK), SM Pitson (Adelaide, SA, Australia) and H Tsao (Boston, MA, USA) for providing cells and vectors, Drs G Fabrias and J Casas for mass spectrometry analysis, and C David, C Fourreau and C Nevoit for technical support. The financial support by INSERM, Paul Sabatier University and Ligue Nationale Contre le Cancer is gratefully acknowledged. VA is a recipient of a fellowship from Association pour la Recherche sur le Cancer.	Arikawa K, 2003, J BIOL CHEM, V278, P32841, DOI 10.1074/jbc.M305024200; Asnacios A, 2008, J CLIN ONCOL, V26, P963, DOI 10.1200/JCO.2007.12.7431; Beacham DA, 2005, SEMIN CANCER BIOL, V15, P329, DOI 10.1016/j.semcancer.2005.05.003; Bektas M, 2005, ONCOGENE, V24, P178, DOI 10.1038/sj.onc.1208019; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; Caballero S, 2009, EXP EYE RES, V88, P367, DOI 10.1016/j.exer.2008.07.012; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; Colie S, 2009, CANCER RES, V69, P9346, DOI 10.1158/0008-5472.CAN-09-2198; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Deng JH, 2012, CANCER CELL, V21, P642, DOI 10.1016/j.ccr.2012.03.039; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Flach EH, 2011, MOL PHARMACEUT, V8, P2039, DOI 10.1021/mp200421k; French KJ, 2003, CANCER RES, V63, P5962; Gault CR, 2012, J BIOL CHEM, V287, P31794, DOI 10.1074/jbc.M112.385765; Geller AC, 2007, J AM ACAD DERMATOL, V57, P555, DOI 10.1016/j.jaad.2007.06.032; Gellings Lowe N, 2009, CARDIOVASC RES, V82, P303, DOI 10.1093/cvr/cvp056; Hofmann UB, 2005, BIOCHIMIE, V87, P307, DOI 10.1016/j.biochi.2005.01.013; Huwiler A, 2008, BIOCHEM PHARMACOL, V75, P1893, DOI 10.1016/j.bcp.2007.12.018; Jolly PS, 2005, BLOOD, V105, P4736, DOI 10.1182/blood-2004-12-4686; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Keller CD, 2007, AM J PATHOL, V170, P281, DOI 10.2353/ajpath.2007.060485; Kono Y, 2007, AM J RESP CELL MOL, V37, P395, DOI 10.1165/rcmb.2007-0065OC; Kunz-Schughart LA, 2002, HISTOL HISTOPATHOL, V17, P599, DOI 10.14670/HH-17.599; LaMontagne K, 2006, CANCER RES, V66, P221, DOI 10.1158/0008-5472.CAN-05-2001; Lavieu Gregory, 2008, V445, P159, DOI 10.1007/978-1-59745-157-4_11; Li CY, 2011, J HEPATOL, V54, P1205, DOI 10.1016/j.jhep.2010.08.028; Li G, 2003, ONCOGENE, V22, P3162, DOI 10.1038/sj.onc.1206455; Liu SQ, 2012, INT J COLORECTAL DIS, V27, P1569, DOI 10.1007/s00384-012-1510-y; Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003; Madhunapantula SV, 2012, PIGM CELL MELANOMA R, V25, DOI 10.1111/j.1755-148X.2012.00970.x; Mitra P, 2007, METHOD ENZYMOL, V434, P257, DOI 10.1016/S0076-6879(07)34014-7; Platz A, 2008, MOL ONCOL, V1, P395, DOI 10.1016/j.molonc.2007.12.003; Ponnusamy S, 2012, EMBO MOL MED, V4, P761, DOI 10.1002/emmm.201200244; Pushparaj PN, 2009, J IMMUNOL, V183, P221, DOI 10.4049/jimmunol.0803430; Pyne NJ, 2012, BIOCHIM BIOPHYS ACTA, V1831, P228; Rebecca VW, 2012, MELANOMA RES, V22, P114, DOI 10.1097/CMR.0b013e328351fa4d; Rolin J, 2011, CANCER MICROENVIRON, V4, P393, DOI 10.1007/s12307-011-0088-1; Ruiter D, 2002, LANCET ONCOL, V3, P35, DOI 10.1016/S1470-2045(01)00620-9; Schwalm S, 2013, BBA-MOL CELL BIOL L, V1831, P239, DOI 10.1016/j.bbalip.2012.07.022; Shimoda M, 2010, SEMIN CELL DEV BIOL, V21, P19, DOI 10.1016/j.semcdb.2009.10.002; Sly W S, 1979, Methods Enzymol, V58, P444; Smalley KSM, 2005, EXPERT REV ANTICANC, V5, P1069, DOI 10.1586/14737140.5.6.1069; Takuwa Y, 2012, BIOCHIM BIOPHYS ACTA, V1831, P185; Urata Yoshiko, 2005, Kobe Journal of Medical Sciences, V51, P17; Vasseur S, 2002, EMBO REP, V3, P165, DOI 10.1093/embo-reports/kvf023; Visentin B, 2006, CANCER CELL, V9, P225, DOI 10.1016/j.ccr.2006.02.023; Watterson KR, 2007, WOUND REPAIR REGEN, V15, P607, DOI 10.1111/j.1524-475X.2007.00292.x; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Yamaguchi H, 2003, BIOCHEM J, V374, P715, DOI 10.1042/BJ20030381; Yamanaka M, 2004, J BIOL CHEM, V279, P53994, DOI 10.1074/jbc.M410144200; Yin M, 2012, AM J PATHOL, V181, P2202, DOI 10.1016/j.ajpath.2012.08.027; Youm JK, 2008, J DERMATOL SCI, V51, P89, DOI 10.1016/j.jdermsci.2008.03.002	53	37	45	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3364	3373		10.1038/onc.2013.303	http://dx.doi.org/10.1038/onc.2013.303			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23893239				2022-12-17	WOS:000338779300003
J	Taulli, R; Foglizzo, V; Morena, D; Coda, DM; Ala, U; Bersani, F; Maestro, N; Ponzetto, C				Taulli, R.; Foglizzo, V.; Morena, D.; Coda, D. M.; Ala, U.; Bersani, F.; Maestro, N.; Ponzetto, C.			Failure to downregulate the BAF53a subunit of the SWI/SNF chromatin remodeling complex contributes to the differentiation block in rhabdomyosarcoma	ONCOGENE			English	Article						BAF53a; chromatin remodeling; miR-206; rhabdomyosarcoma; differentiation therapy	TERMINAL DIFFERENTIATION; EXPRESSION; MIR-206; GENE; MYOD; PROLIFERATION; GROWTH; TRANSCRIPTION; INHIBITION; INDUCTION	Rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in children and young adults, is characterized by a partially differentiated myogenic phenotype. We have previously shown that the blocking of tumor growth and resumption of differentiation can be achieved by re-expression of miR-206, a muscle-enriched microRNA missing in RMS. In this work, we focused on BAF53a, one of the genes downregulated in miR-206-expressing RMS cells, which codes for a subunit of the SWI/SNF chromatin remodeling complex. Here we show that the BAF53a transcript is significantly higher in primary RMS tumors than in normal muscle, and is a direct target of miR-206. Sustained expression of BAF53a interferes with differentiation in myogenic cells, whereas its silencing in RMS cells increases expression of myogenic markers and inhibits proliferation and anchorage-independent growth. Accordingly, BAF53a silencing also impairs embryonal RMS and alveolar RMS tumor growth, inducing their morphological and biochemical differentiation. These results indicate that failure to downregulate the BAF53a subunit may contribute to the pathogenesis of RMS, and suggest that BAF53a may represent a novel therapeutic target for this tumor.	[Taulli, R.; Foglizzo, V.; Morena, D.; Coda, D. M.; Bersani, F.; Maestro, N.; Ponzetto, C.] Univ Turin, Sch Med, Dept Oncol, I-10126 Turin, Italy; [Taulli, R.; Foglizzo, V.; Morena, D.; Coda, D. M.; Bersani, F.; Maestro, N.; Ponzetto, C.] Ctr Expt Res & Med Studies, CERMS, Turin, Italy; [Ala, U.] Univ Turin, Dept Mol Biotechnol & Hlth Sci, I-10126 Turin, Italy	University of Turin; University of Turin	Ponzetto, C (corresponding author), Univ Turin, Dept Oncol, Corso Massimo dAzeglio 52, I-10126 Turin, Italy.	carola.ponzetto@unito.it	Maestro, Nicola/AAA-6097-2020; Ala, Ugo/K-2029-2016; TAULLI, Riccardo/J-7347-2018	Maestro, Nicola/0000-0001-7909-3737; Ala, Ugo/0000-0001-5408-6397; TAULLI, Riccardo/0000-0003-1277-6263; Bersani, Francesca/0000-0002-0343-7078; Foglizzo, Valentina/0000-0001-5059-3279	Regione Piemonte (IMMONC Project); Italian Association for Cancer Research (AIRC); International Foundation of Research in Experimental Medicine (FIRMS)	Regione Piemonte (IMMONC Project)(Regione Piemonte); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); International Foundation of Research in Experimental Medicine (FIRMS)	We are grateful to Janet Shipley and Zoe Walters of the Molecular Cytogenetics Team (The Institute of Cancer Research, Sutton, Surrey, UK), for indicating the appropriate RMS databanks, to PL Puri (Sanford-Burnham, San Diego) for providing reagents and feedback, to Elisa DeLuca for technical help with the confocal microscope and to Rosella Rota and Giorgia Bracaglia for providing the human myoblasts samples and for helpful suggestions. This work was supported by funding from the Regione Piemonte (IMMONC Project) and the Italian Association for Cancer Research (AIRC). The support of the International Foundation of Research in Experimental Medicine (FIRMS) is gratefully acknowledged.	Bao XM, 2013, CELL STEM CELL, V12, P193, DOI 10.1016/j.stem.2012.12.014; Belyea Brian, 2012, Sarcoma, V2012, P406239, DOI 10.1155/2012/406239; BOUCHE M, 1993, EXP CELL RES, V208, P209, DOI 10.1006/excr.1993.1239; Boutet SC, 2012, CELL STEM CELL, V10, P327, DOI 10.1016/j.stem.2012.01.017; Chen JF, 2010, J CELL BIOL, V190, P867, DOI 10.1083/jcb.200911036; Coutinho P, 2012, SOC MUSCLE BIOL FRON; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Forcales SV, 2012, EMBO J, V31, P301, DOI 10.1038/emboj.2011.391; Goljanek-Whysall K, 2012, J CELL SCI, V125, P3590, DOI 10.1242/jcs.101758; Ho L, 2010, NATURE, V463, P474, DOI 10.1038/nature08911; Kim HK, 2006, J CELL BIOL, V174, P677, DOI 10.1083/jcb.200603008; Krasteva V, 2012, BLOOD, V120, P4720, DOI 10.1182/blood-2012-04-427047; MacQuarrie KL, 2012, SKELET MUSCLE, V2, DOI 10.1186/2044-5040-2-7; Mallappa C, 2010, MOL CELL BIOL, V30, P3176, DOI 10.1128/MCB.00214-10; McDowell HP, 2003, ARCH DIS CHILD, V88, P354, DOI 10.1136/adc.88.4.354; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Meyer WH, 2004, CANCER TREAT REV, V30, P269, DOI 10.1016/j.ctrv.2003.11.001; Missiaglia E, 2010, BRIT J CANCER, V102, P1769, DOI 10.1038/sj.bjc.6605684; Ohfuchi E, 2002, BIOSCI BIOTECH BIOCH, V66, P1740, DOI 10.1271/bbb.66.1740; Ohkawa Y, 2007, J BIOL CHEM, V282, P6564, DOI 10.1074/jbc.M608898200; Olave I, 2002, GENE DEV, V16, P2509, DOI 10.1101/gad.992102; Puri PL, 2000, GENE DEV, V14, P574; Raimondi L, 2012, CELL DEATH DIFFER, V19, P871, DOI 10.1038/cdd.2011.171; Raney R B, 2001, Sarcoma, V5, P9, DOI 10.1080/13577140120048890; Rao PK, 2010, FASEB J, V24, P3427, DOI 10.1096/fj.09-150698; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Ricaud S, 2003, ONCOGENE, V22, P8221, DOI 10.1038/sj.onc.1207177; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; Roma J, 2011, CLIN CANCER RES, V17, P505, DOI 10.1158/1078-0432.CCR-10-0166; Rosenberg MI, 2006, J CELL BIOL, V175, P77, DOI 10.1083/jcb.200603039; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Taulli R, 2006, CANCER RES, V66, P4742, DOI 10.1158/0008-5472.CAN-05-4292; Taulli R, 2010, CELL CYCLE, V9, P918, DOI 10.4161/cc.9.5.10864; Taulli R, 2009, J CLIN INVEST, V119, P2366, DOI 10.1172/JCI38075; Walters ZS, 2013, ONCOGENE, V1, P10; Wang H, 2008, CANCER CELL, V14, P369, DOI 10.1016/j.ccr.2008.10.006; Williamson D, 2010, J CLIN ONCOL, V28, P2151, DOI 10.1200/JCO.2009.26.3814; Wu JI, 2007, NEURON, V56, P94, DOI 10.1016/j.neuron.2007.08.021; Wu JI, 2012, ACTA BIOCH BIOPH SIN, V44, P54, DOI 10.1093/abbs/gmr099; Xia SJ, 2005, EUR J CANCER, V41, P2513, DOI 10.1016/j.ejca.2005.08.003; Yan D, 2009, J BIOL CHEM, V284, P29596, DOI 10.1074/jbc.M109.020511; Yang ZH, 2009, GENE DEV, V23, P694, DOI 10.1101/gad.1765109; Yoo AS, 2009, NATURE, V460, P642, DOI 10.1038/nature08139; Zhang L, 2013, CANCER LETT, V332, P94, DOI 10.1016/j.canlet.2013.01.023; Zhou J, 2013, BIOCHEM BIOPH RES CO, V13, P364	49	37	38	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2354	2362		10.1038/onc.2013.188	http://dx.doi.org/10.1038/onc.2013.188			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23728344				2022-12-17	WOS:000335451800008
J	Bosco-Clement, G; Zhang, F; Chen, Z; Zhou, HM; Li, H; Mikami, I; Hirata, T; Yagui-Beltran, A; Lui, N; Do, HT; Cheng, T; Tseng, HH; Choi, H; Fang, LT; Kim, IJ; Yue, D; Wang, C; Zheng, Q; Fujii, N; Mann, M; Jablons, DM; He, B				Bosco-Clement, G.; Zhang, F.; Chen, Z.; Zhou, H-M; Li, H.; Mikami, I.; Hirata, T.; Yagui-Beltran, A.; Lui, N.; Do, H. T.; Cheng, T.; Tseng, H-H; Choi, H.; Fang, L-T; Kim, I-J; Yue, D.; Wang, C.; Zheng, Q.; Fujii, N.; Mann, M.; Jablons, D. M.; He, B.			Targeting Gli transcription activation by small molecule suppresses tumor growth	ONCOGENE			English	Article						cancer; targeted therapy; Gli; TAF9; Hedgehog pathway	HEDGEHOG PATHWAY INHIBITOR; SIGNALING PATHWAY; CANCER; MEDULLOBLASTOMA; MEDIATORS; PROMOTER; EMX2; P53	Targeted inhibition of Hedgehog signaling at the cell membrane has been associated with anticancer activity in preclinical and early clinical studies. Hedgehog signaling involves activation of Gli transcription factors that can also be induced by alternative pathways. In this study, we identified an interaction between Gli proteins and a transcription coactivator TBP-associated factor 9 (TAF9), and validated its functional relevance in regulating Gli transactivation. We also describe a novel, synthetic small molecule, FN1-8, that efficiently interferes with Gli/TAF9 interaction and downregulate Gli/TAF9-dependent transcriptional activity. More importantly, FN1-8 suppresses cancer cell proliferation in vitro and inhibits tumor growth in vivo. Our results suggest that blocking Gli transactivation, an important control point of multiple oncogenic pathways, may be an effective anticancer strategy.	[Bosco-Clement, G.; Zhang, F.; Chen, Z.; Li, H.; Mikami, I.; Hirata, T.; Yagui-Beltran, A.; Lui, N.; Do, H. T.; Cheng, T.; Tseng, H-H; Choi, H.; Fang, L-T; Kim, I-J; Yue, D.; Zheng, Q.; Jablons, D. M.; He, B.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Surg, Thorac Oncol Program, San Francisco, CA 94115 USA; [Zhang, F.] Tsinghua Univ, Grad Sch Shenzhen, Div Life & Hlth Sci, Shenzhen 518057, Peoples R China; [Chen, Z.; Zhou, H-M] Tsinghua Univ, Sch Life Sci, Beijing 100084, Peoples R China; [Mikami, I.; Hirata, T.] Nippon Med Sch, Dept Surg, Div Thorac Surg, Tokyo 113, Japan; [Yue, D.; Wang, C.] Tianjin Med Univ, Canc Inst & Hosp, Dept Lung Canc, Tianjin, Peoples R China; [Zheng, Q.] Peking Univ, Canc Hosp & Inst, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing 100871, Peoples R China; [Fujii, N.] St Jude Childrens Res Hosp, Dept Chem Biol & Therapeut, Memphis, TN 38105 USA; [Mann, M.] Univ Calif San Francisco, Dept Surg, Div Cardiothorac Surg, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Tsinghua University; University Town of Shenzhen; Tsinghua Shenzhen International Graduate School; Tsinghua University; Nippon Medical School; Tianjin Medical University; Peking University; St Jude Children's Research Hospital; University of California System; University of California San Francisco	He, B (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Surg, Thorac Oncol Program, San Francisco, CA 94115 USA.	david.jablons@ucsfmedctr.org; biao.he@ucsfmedctr.org	Tseng, Hsin-Hui Katty/AAG-1941-2019; Fang, Li Tai/ABA-6638-2021; Fujii, Naoaki/I-6423-2013	Fang, Li Tai/0000-0003-3201-5162; 	Joan's Legacy: Uniting Against Lung Cancer Research Grant; NIH/NCI [R01CA125030, R01CA132566]; Eileen D Ludwig Endowed for Thoracic Oncology Research; Bonnie J Addario Lung Cancer Foundation; Kazan, McClain, Abrams, Fernandez, Lyons, Greenwood, Harley and Oberman Foundation; Honeywell Foundation; Barbara Isackson Lung Cancer Research Fund; NATIONAL CANCER INSTITUTE [R01CA132566, R01CA125030] Funding Source: NIH RePORTER	Joan's Legacy: Uniting Against Lung Cancer Research Grant; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Eileen D Ludwig Endowed for Thoracic Oncology Research; Bonnie J Addario Lung Cancer Foundation; Kazan, McClain, Abrams, Fernandez, Lyons, Greenwood, Harley and Oberman Foundation; Honeywell Foundation; Barbara Isackson Lung Cancer Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Joan's Legacy: Uniting Against Lung Cancer Research Grant, NIH/NCI Grant R01CA125030, and the Eileen D Ludwig Endowed for Thoracic Oncology Research (to BH); NIH/NCI Grant R01CA132566, the Bonnie J Addario Lung Cancer Foundation, the Kazan, McClain, Abrams, Fernandez, Lyons, Greenwood, Harley and Oberman Foundation, Honeywell Foundation and the Barbara Isackson Lung Cancer Research Fund (to DMJ).	Arai MA, 2011, ORG BIOMOL CHEM, V9, P1133, DOI 10.1039/c0ob00677g; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Choi Y, 2000, J BIOL CHEM, V275, P15912, DOI 10.1074/jbc.275.21.15912; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Dennler S, 2007, CANCER RES, V67, P6981, DOI 10.1158/0008-5472.CAN-07-0491; Dennler S, 2009, J BIOL CHEM, V284, P31523, DOI 10.1074/jbc.M109.059964; di Magliano MP, 2006, GENE DEV, V20, P3161, DOI 10.1101/gad.1470806; Dijkgraaf GJP, 2011, CANCER RES, V71, P435, DOI 10.1158/0008-5472.CAN-10-2876; FALGOUT B, 1988, J VIROL, V62, P622, DOI 10.1128/JVI.62.2.622-625.1988; Feldmann G, 2007, CANCER RES, V67, P2187, DOI 10.1158/0008-5472.CAN-06-3281; Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302; He B, 2010, US Patent No, Patent No. 7714014; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Hosoya T, 2008, CHEMBIOCHEM, V9, P1082, DOI 10.1002/cbic.200700511; Huangfu D, 2006, DEVELOPMENT, V133, P3, DOI 10.1242/dev.02169; Hyman JM, 2009, P NATL ACAD SCI USA, V106, P14132, DOI 10.1073/pnas.0907134106; Ji ZY, 2007, J BIOL CHEM, V282, P14048, DOI 10.1074/jbc.M611089200; Jung DJ, 2006, DRUG DISCOV TODAY, V11, P452, DOI 10.1016/j.drudis.2006.03.011; Kalderon D, 2000, CELL, V103, P371, DOI 10.1016/S0092-8674(00)00129-X; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Lauth M, 2007, CELL CYCLE, V6, P2458, DOI 10.4161/cc.6.20.4808; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; LoRusso PM, 2011, CLIN CANCER RES, V17, P2502, DOI 10.1158/1078-0432.CCR-10-2745; Low JA, 2010, J CLIN ONCOL, V28, P5321, DOI 10.1200/JCO.2010.27.9943; Merchant AA, 2010, CLIN CANCER RES, V16, P3130, DOI 10.1158/1078-0432.CCR-09-2846; Mullor JL, 2001, CURR BIOL, V11, P769, DOI 10.1016/S0960-9822(01)00229-9; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Okamoto J, 2010, ONCOGENE, V29, P5969, DOI 10.1038/onc.2010.330; Okamoto J, 2011, CLIN LUNG CANCER, V12, P237, DOI 10.1016/j.cllc.2011.03.025; Raz DJ, 2008, CLIN CANCER RES, V14, P5565, DOI 10.1158/1078-0432.CCR-08-0544; Reguart N, 2004, BIOCHEM BIOPH RES CO, V323, P229, DOI 10.1016/j.bbrc.2004.08.075; Rifai Y, 2011, BIOORG MED CHEM LETT, V21, P718, DOI 10.1016/j.bmcl.2010.11.126; Riobo NA, 2006, P NATL ACAD SCI USA, V103, P4505, DOI 10.1073/pnas.0504337103; Riobo NA, 2006, CANCER RES, V66, P839, DOI 10.1158/0008-5472.CAN-05-2539; Rovnak J, 2006, J VIROL, V80, P12041, DOI 10.1128/JVI.01425-06; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Ruiz i Altaba A, 2007, TRENDS CELL BIOL, V17, P438, DOI 10.1016/j.tcb.2007.06.007; Scales SJ, 2009, TRENDS PHARMACOL SCI, V30, P303, DOI 10.1016/j.tips.2009.03.007; Schnidar H, 2009, CANCER RES, V69, P1284, DOI 10.1158/0008-5472.CAN-08-2331; Shao HS, 2005, MOL CELL BIOL, V25, P206, DOI 10.1128/MCB.25.1.206-219.2005; Shimogawa H, 2004, J AM CHEM SOC, V126, P3461, DOI 10.1021/ja038855+; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Yang L, 2010, ONCOGENE, V29, P469, DOI 10.1038/onc.2009.392; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275; Yauch RL, 2009, SCIENCE, V326, P572, DOI 10.1126/science.1179386; Yoon JW, 1998, J BIOL CHEM, V273, P3496, DOI 10.1074/jbc.273.6.3496	51	37	38	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2087	2097		10.1038/onc.2013.164	http://dx.doi.org/10.1038/onc.2013.164			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23686308	Green Accepted, Green Submitted			2022-12-17	WOS:000334599100008
J	Sun, MM; Li, JF; Guo, LL; Xiao, HT; Dong, L; Wang, F; Huang, FB; Cao, D; Qin, T; Yin, XH; Li, JM; Wang, SL				Sun, M. M.; Li, J. F.; Guo, L. L.; Xiao, H. T.; Dong, L.; Wang, F.; Huang, F. B.; Cao, D.; Qin, T.; Yin, X. H.; Li, J. M.; Wang, S. L.			TGF-beta 1 suppression of microRNA-450b-5p expression: a novel mechanism for blocking myogenic differentiation of rhabdomyosarcoma	ONCOGENE			English	Article						rhabdomyosarcoma; TGF-beta 1; miR-450b-5p; differentiation	TGF-BETA; MUSCLE DIFFERENTIATION; CELL-PROLIFERATION; SKELETAL-MUSCLE; GROWTH; CANCER; SMAD3; TRANSFORMING-GROWTH-FACTOR-BETA-1; QUANTIFICATION; TRANSCRIPTION	Transforming growth factor beta 1 (TGF-beta 1) is the most potent inhibitor of myogenic differentiation (MyoD) of rhabdomyosarcoma (RMS); however, the underlying mechanisms of this inhibition remain unclear. In this study, we identified novel TGF-beta 1-related microRNAs (miRNAs); among these, miR-450b-5p is significantly regulated by TGF-beta 1. We provide evidence that TGF-beta 1 exerts it function by suppressing miR-450b-5p. Both in cultured cells and tumor implants, miR-450b-5p significantly arrested the growth of RMS and promoted its MyoD. Utilizing a bioinformatics approach, we identified miR-450b-5p target mRNAs. Among these candidates, only the expression of ecto-NOX disulfide-thiol exchanger 2 (ENOX2) and paired box 9 (PAX9) was augmented by miR-450b-5p knockdown examined by western blot; the engineered inhibition antagonized TGF-beta 1-mediated differentiation inhibition. Furthermore, we found that the Smad3 and Smad4 pathways, but not Smad2, are the principal mediator of TGF-beta 1 suppression of miR-450b-5p. Taken together, these results suggest that disrupting the TGF-beta 1 suppression of miR-450b-5p, or knockdown of ENOX2 and PAX9, are effective approaches in inducing RMS MyoD.	[Sun, M. M.; Qin, T.; Yin, X. H.] Soochow Univ, Sch Med, Dept Anat, Suzhou 215123, Peoples R China; [Li, J. F.] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Pathol, Hangzhou 310003, Zhejiang, Peoples R China; [Guo, L. L.; Dong, L.; Wang, F.; Huang, F. B.; Cao, D.; Li, J. M.; Wang, S. L.] Soochow Univ, Sch Med, Dept Pathol, Suzhou 215123, Peoples R China; [Xiao, H. T.] Sichuan Univ, West China Hosp, Dept Burn & Plast Surg, Chengdu 610064, Peoples R China	Soochow University - China; Zhejiang University; Soochow University - China; Sichuan University	Wang, SL (corresponding author), Soochow Univ, Sch Med, Dept Pathol, Suzhou 215123, Peoples R China.	jianmingli@suda.edu.cn; wangsoly112@hotmail.com			Chinese Nature Science Foundation [81072186, 81272738]; Jiangsu Provincial Nature Science Foundation [SBK20110743]; Jiangsu Provincial Higher Institution Nature Science Foundation [10KJB320018]; Suzhou Applied Basic Research Programs [SYS201207]; Jiangsu Overseas Research and Training Program for University Prominent Young and Middle-aged Teachers and Presidents	Chinese Nature Science Foundation; Jiangsu Provincial Nature Science Foundation; Jiangsu Provincial Higher Institution Nature Science Foundation; Suzhou Applied Basic Research Programs; Jiangsu Overseas Research and Training Program for University Prominent Young and Middle-aged Teachers and Presidents	We would like to thank the West China Hospital of Sichuan University for providing us with the tumor specimens. This work was supported partially by the Chinese Nature Science Foundation (81072186, 81272738), Jiangsu Provincial Nature Science Foundation (SBK20110743), Jiangsu Provincial Higher Institution Nature Science Foundation (10KJB320018), Suzhou Applied Basic Research Programs (SYS201207), and Sponsorship of Jiangsu Overseas Research and Training Program for University Prominent Young and Middle-aged Teachers and Presidents.	Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bouche M, 2000, FASEB J, V14, P1147, DOI 10.1096/fasebj.14.9.1147; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Ge XJ, 2011, CELL RES, V21, P1591, DOI 10.1038/cr.2011.72; Guo H, 2007, CHINESE MED J-PEKING, V120, P515, DOI 10.1097/00029330-200703020-00016; Hatley ME, 2012, CANCER CELL, V22, P536, DOI 10.1016/j.ccr.2012.09.004; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Li Y, 2004, AM J PATHOL, V164, P1007, DOI 10.1016/S0002-9440(10)63188-4; Liu D, 2004, EMBO J, V23, P1557, DOI 10.1038/sj.emboj.7600179; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Liu NC, 2012, J AGR FOOD CHEM, V60, P2758, DOI 10.1021/jf204869w; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mishra PJ, 2009, J CLIN INVEST, V119, P2119, DOI 10.1172/JCI40107; Rodrigo I, 2003, DEVELOPMENT, V130, P473, DOI 10.1242/dev.00240; Schmittgen TD, 2008, METHODS, V44, P31, DOI 10.1016/j.ymeth.2007.09.006; Sebire NJ, 2003, J CLIN PATHOL, V56, P412, DOI 10.1136/jcp.56.6.412; Segev H, 2004, STEM CELLS, V22, P265, DOI 10.1634/stemcells.22-3-265; Shoji Y, 1996, J CLIN PATHOL, V49, P134, DOI 10.1136/jcp.49.2.134; Sun Q, 2008, NUCLEIC ACIDS RES, V36, P2690, DOI 10.1093/nar/gkn032; Suzuki HI, 2011, J BIOCHEM, V149, P15, DOI 10.1093/jb/mvq113; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Wang B, 2010, ONCOGENE, V29, P1787, DOI 10.1038/onc.2009.468; Wang SL, 2010, CANCER SCI, V101, P1108, DOI 10.1111/j.1349-7006.2010.01512.x; Wang SL, 2009, CANCER GENET CYTOGEN, V190, P8, DOI 10.1016/j.cancergencyto.2008.10.013; Wang V, 2009, BIODRUGS, V23, P15, DOI 10.2165/00063030-200923010-00002; Wurdinger T, 2007, PHARMACOGENOMICS J, V7, P297, DOI 10.1038/sj.tpj.6500429; Yamagata K, 2009, MOL CELL, V36, P340, DOI 10.1016/j.molcel.2009.08.017; Yang ZH, 2009, GENE DEV, V23, P694, DOI 10.1101/gad.1765109; Ye L, 2005, CHINESE MED J-PEKING, V118, P678; Zeng ZM, 2012, EXP CELL RES, V318, P1759, DOI 10.1016/j.yexcr.2012.04.021	35	37	40	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2075	2086		10.1038/onc.2013.165	http://dx.doi.org/10.1038/onc.2013.165			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23665678				2022-12-17	WOS:000334599100007
J	Tempe, D; Vives, E; Brockly, F; Brooks, H; De Rossi, S; Piechaczyk, M; Bossis, G				Tempe, D.; Vives, E.; Brockly, F.; Brooks, H.; De Rossi, S.; Piechaczyk, M.; Bossis, G.			SUMOylation of the inducible (c-Fos:c-Jun)/AP-1 transcription complex occurs on target promoters to limit transcriptional activation	ONCOGENE			English	Article						AP-1; SUMO; transcription; c-Fos	JUN PROTEINS; SUMO; AP-1; SPECIFICITY; PATHWAY; GENES	The inducible proto-oncogenic (c-Fos:c-Jun)/AP-1 transcription complex binds 12-O-tetradecanoylphorbol 13-acetate (TPA)-responsive elements (TRE) in its target genes. It is tightly controlled at multiple levels to avoid the deleterious effects of its inappropriate activation. In particular, SUMOylation represses its transactivation capacity in transient reporter assays using constitutively expressed proteins. This led to the presumption that (c-Fos:c-Jun)/AP-1 SUMOylation would be required to turn-off transcription of its target genes, as proposed for various transcription factors. Instead, thanks to the generation of an antibody specific for SUMO-modified c-Fos, we provide here direct evidence that SUMOylated c-Fos is present on a stably integrated reporter TPA-inducible promoter at the onset of transcriptional activation and colocalizes with RNA polymerase II within chromatin. Interestingly, (c-Fos:c-Jun)/AP-1 SUMOylation limits reporter gene induction, as well as the appearance of active transcription-specific histone marks on its promoter. Moreover, non-SUMOylatable mutant (c-Fos:c-Jun)/AP-1 dimers accumulate to higher levels on their target promoter, suggesting that SUMOylation might facilitate the release of (c-Fos:c-Jun)/AP-1 from promoters. Finally, activation of GADD153, an AP-1 target gene, is also associated with a rapid increase in SUMOylation at the level of its TRE and c-Fos SUMOylation dampens its induction by TPA. Taken together, our data suggest that SUMOylation could serve to buffer transcriptional activation of AP-1 target genes.	[Tempe, D.; Brockly, F.; Brooks, H.; Piechaczyk, M.; Bossis, G.] CNRS, UMR 5535, Inst Genet Mol Montpellier, Equipe Labellisee Ligue Canc, Montpellier 5, France; [Tempe, D.; Brockly, F.; Brooks, H.; Piechaczyk, M.; Bossis, G.] Univ Montpellier 2, Montpellier, France; [Tempe, D.; Brockly, F.; Brooks, H.; Piechaczyk, M.; Bossis, G.] Univ Montpellier I, Montpellier, France; [Vives, E.] IRCM, Montpellier, France; [Vives, E.] Univ Montpellier I, INSERM, U896, Montpellier, France; [Vives, E.] CRLC Val dAurelle Paul Lamarque, Montpellier, France; [De Rossi, S.] BIOCAMPUS Montpellier, Montpellier RIO Imaging, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Universite de Montpellier	Piechaczyk, M (corresponding author), CNRS, UMR 5535, Inst Genet Mol Montpellier, Equipe Labellisee Ligue Canc, 1919 Route Mende, Montpellier 5, France.	marc.piechaczyk@igmm.cnrs.fr; guillaume.bossis@igmm.cnrs.fr	Bossis, Guillaume/C-7172-2012; VIVES, Eric/AAG-6569-2020; PIECHACZYK, Marc/E-7896-2013	PIECHACZYK, Marc/0000-0003-1367-2597; VIVES, Eric/0000-0001-5391-9641; bossis, guillaume/0000-0002-3349-8250	CNRS; Association pour la Recherche sur le Cancer (ARC); Agence Nationale de la Recherche [BLAN08-3_310119]	CNRS(Centre National de la Recherche Scientifique (CNRS)); Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Agence Nationale de la Recherche(French National Research Agency (ANR))	We are grateful to Drs R Hipskind, I Jariel-Encontre, T Salem and G Moquet-Torcy for fruitful discussions and critical reading of the manuscript. MP's laboratory is an 'Equipe Labellisee of the French Ligue Nationale contre le Cancer. This work was also supported by the CNRS, the Association pour la Recherche sur le Cancer (ARC), and the Agence Nationale de la Recherche (BLAN08-3_310119).	Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Barry J, 2011, INT J BIOCHEM CELL B, V43, P37, DOI 10.1016/j.biocel.2010.09.022; Bettermann K, 2012, CANCER LETT, V316, P113, DOI 10.1016/j.canlet.2011.10.036; Bossis G, 2005, MOL CELL BIOL, V25, P6964, DOI 10.1128/MCB.25.16.6964-6979.2005; Bossis G, 2006, MOL CELL, V21, P349, DOI 10.1016/j.molcel.2005.12.019; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fluhmann B, 1998, MOL CELL ENDOCRINOL, V139, P89, DOI 10.1016/S0303-7207(98)00070-7; Garcia-Dominguez M, 2009, BBA-GENE REGUL MECH, V1789, P451, DOI 10.1016/j.bbagrm.2009.07.001; Gareau JR, 2010, NAT REV MOL CELL BIO, V11, P861, DOI 10.1038/nrm3011; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Glatter T, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2008.75; Golebiowski F, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000282; Gomard T, 2010, PLOS ONE, V5, pA178, DOI 10.1371/journal.pone.0009585; Guo BQ, 2011, NUCLEIC ACIDS RES, V39, P6403, DOI 10.1093/nar/gkr267; Guyton KZ, 1996, BIOCH J 2, V314; Harper CV, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000607; Jakobs A, 2007, NAT METHODS, V4, P245, DOI 10.1038/NMETH1006; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kubota Y, 2011, NAT CELL BIOL, V13, P282, DOI 10.1038/ncb2169; Liu HW, 2012, NUCLEIC ACIDS RES, V40, P10172, DOI 10.1093/nar/gks819; Lyst MJ, 2007, BIOCHEM SOC T, V35, P1389, DOI 10.1042/BST0351389; Maison C, 2011, NAT GENET, V43, P220, DOI 10.1038/ng.765; Malnou CE, 2010, J BIOL CHEM, V285, P6552, DOI 10.1074/jbc.M109.032680; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Rosonina E, 2012, GENE DEV, V26, P350, DOI 10.1101/gad.184689.111; Rosonina E, 2010, GENE DEV, V24, P1242, DOI 10.1101/gad.1917910; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Tempe D, 2008, BIOCHEM SOC T, V36, P874, DOI 10.1042/BST0360874; Ubeda M, 1999, MOL CELL BIOL, V19, P7589	33	37	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					921	927		10.1038/onc.2013.4	http://dx.doi.org/10.1038/onc.2013.4			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23396363				2022-12-17	WOS:000331626900013
J	Can, G; Akpinar, B; Baran, Y; Zhivotovsky, B; Olsson, M				Can, G.; Akpinar, B.; Baran, Y.; Zhivotovsky, B.; Olsson, M.			5-Fluorouracil signaling through a calcium-calmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells	ONCOGENE			English	Article						apoptosis; 5-fluorouracil; calcium; calmodulin; p53; DR5	DNA-DAMAGE; CANCER-CELLS; RIBOSOME BIOGENESIS; C-FLIP; CHECKPOINT; PROTEIN; AGENTS; DEATH; PHOSPHORYLATION; CHEMOTHERAPY	5-Fluorouracil (5-FU) is an anti-metabolite that is in clinical use for treatment of several cancers. In cells, it is converted into three distinct fluoro-based nucleotide analogs, which interfere with DNA synthesis and repair, leading to genome impairment and, eventually, apoptotic cell death. Current knowledge states that in certain cell types, 5-FU-induced stress is signaling through a p53-dependent induction of tumor necrosis factor-receptor oligomerization required for death-inducing signaling complex formation and caspase-8 activation. Here we establish a role of calcium (Ca2+) as a messenger for p53 activation in response to 5-FU. Using a combination of pharmacological and genetic approaches, we show that treatment of colon carcinoma cells stimulates entry of extracellular Ca2+ through long lasting-type plasma membrane channels, which further directs posttranslational phosphorylation of at least three p53 serine residues (S15, S33 and S37) by means of calmodulin (CaM) activity. Obstructing this pathway by the Ca2+-chelator BAPTA (1,2-bis(o-aminophenoxy) ethane-N, N, N', N'-tetraacetic acid) or by inhibitors of CaM efficiently reduces 5-FU-induced caspase activities and subsequent cell death. Moreover, ectopic expression of p53 S15A in HCT116 p53(-/-) cells confirmed the importance of a Ca2+-CaM-p53 axis in 5-FU-induced extrinsic apoptosis. The fact that a widely used therapeutic drug, such as 5-FU, is operating via this pathway could provide new therapeutic intervention points, or specify new combinatorial treatment regimes.	[Can, G.; Akpinar, B.; Zhivotovsky, B.; Olsson, M.] Karolinska Inst, Inst Environm Med, Div Toxicol, SE-17177 Stockholm, Sweden; [Baran, Y.] Izmir Inst Technol, Dept Mol Biol & Genet, Canc Genet & Mol Hematol Lab, Izmir, Turkey	Karolinska Institutet; Izmir Institute of Technology	Zhivotovsky, B (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol, SE-17177 Stockholm, Sweden.	Boris.Zhivotovsky@ki.se	Olsson, Magnus/E-3140-2012; Can, Geylani/B-6667-2012; Zhivotovsky, Boris/A-4346-2014; Can, Geylani/M-5538-2019	Olsson, Magnus/0000-0002-6370-8423; Can, Geylani/0000-0002-1716-7830; Zhivotovsky, Boris/0000-0002-2238-3482; Can, Geylani/0000-0002-1716-7830	Swedish Science Foundation; Swedish and Stockholm Cancer Societies; Swedish Childhood Cancer Foundation; EC-FP-6 (Chemores); EC-FP-7 (APO-SYS)	Swedish Science Foundation; Swedish and Stockholm Cancer Societies; Swedish Childhood Cancer Foundation(European Commission); EC-FP-6 (Chemores); EC-FP-7 (APO-SYS)(European CommissionEuropean Commission Joint Research Centre)	We thank Professors Bert Vogelstein, Peter H Krammer, Ladislav Andera, Moshe Oren and Dr Inna Lavrik for their contribution of cells, antibodies and vectors. This study was supported by grants from the Swedish Science Foundation, the Swedish and Stockholm Cancer Societies, the Swedish Childhood Cancer Foundation and the EC-FP-6 (Chemores) and EC-FP-7 (APO-SYS). MO is a fellow of the Swedish Society of Medical Research.	Abdulghani J, 2010, EXPERT OPIN THER TAR, V14, P1091, DOI 10.1517/14728222.2010.519701; Bagnoli M, 2010, INT J BIOCHEM CELL B, V42, P210, DOI 10.1016/j.biocel.2009.11.015; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823; Borralho PM, 2007, BBA-MOL BASIS DIS, V1772, P40, DOI 10.1016/j.bbadis.2006.09.005; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Burger K, 2010, J BIOL CHEM, V285, P12416, DOI 10.1074/jbc.M109.074211; Coutinho I, 2009, FEBS LETT, V583, P3582, DOI 10.1016/j.febslet.2009.10.030; Craig AL, 2007, MOL CELL BIOL, V27, P3542, DOI 10.1128/MCB.01595-06; de la Cruz-Morcillo MA, 2012, ONCOGENE, V31, P1073, DOI 10.1038/onc.2011.321; Derheimer FA, 2007, P NATL ACAD SCI USA, V104, P12778, DOI 10.1073/pnas.0705317104; Galligan L, 2005, MOL CANCER THER, V4, P2026, DOI 10.1158/1535-7163.MCT-05-0262; GLAZER RI, 1982, MOL PHARMACOL, V21, P468; Harr MW, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a005579; Henry RE, 2012, EMBO J, V31, P1266, DOI 10.1038/emboj.2011.498; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; Kim HD, 2011, ONCOGENE, V30, P3317, DOI 10.1038/onc.2011.47; KUFE DW, 1981, J BIOL CHEM, V256, P9802; Kumar S K, 2001, Curr Oncol Rep, V3, P94, DOI 10.1007/s11912-001-0007-6; Lamprecht SA, 2003, NAT REV CANCER, V3, P601, DOI 10.1038/nrc1144; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Li Y, 2010, MOL CANCER THER, V9, P113, DOI 10.1158/1535-7163.MCT-08-1189; Longley DB, 2006, ONCOGENE, V25, P838, DOI 10.1038/sj.onc.1209122; Longley DB, 2004, CLIN CANCER RES, V10, P3562, DOI 10.1158/1078-0432.CCR-03-0532; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; MacLaine NJ, 2011, CELL CYCLE, V10, P916, DOI 10.4161/cc.10.6.15076; Matuo R, 2009, J APPL TOXICOL, V29, P308, DOI 10.1002/jat.1411; Naka T, 2002, CANCER RES, V62, P5800; Oberle C, 2010, CELL DEATH DIFFER, V17, P1167, DOI 10.1038/cdd.2009.214; OConnor PM, 1997, CANCER RES, V57, P4285; Olsson M, 2011, CELL DEATH DIFFER, V18, P1441, DOI 10.1038/cdd.2011.30; Olsson M, 2009, ONCOGENE, V28, P1949, DOI 10.1038/onc.2009.36; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Perraud A, 2011, ONCOL REP, V26, P1091, DOI 10.3892/or.2011.1404; Pinton P, 2008, ONCOGENE, V27, P6407, DOI 10.1038/onc.2008.308; Pospisilova S, 2004, BIOCHEM J, V378, P939, DOI 10.1042/BJ20030662; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Seiple L, 2006, NUCLEIC ACIDS RES, V34, P140, DOI 10.1093/nar/gkj430; Stagni V, 2010, CARCINOGENESIS, V31, P1956, DOI 10.1093/carcin/bgq193; Takeda K, 2004, EMBO REP, V5, P161, DOI 10.1038/sj.embor.7400072; Wang SL, 2004, CANCER RES, V64, P6666, DOI 10.1158/0008-5472.CAN-04-1734	43	37	39	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2013	32	38					4529	4538		10.1038/onc.2012.467	http://dx.doi.org/10.1038/onc.2012.467			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23108402	Green Published			2022-12-17	WOS:000324831300008
J	Ben-Shmuel, A; Shvab, A; Gavert, N; Brabletz, T; Ben-Ze'ev, A				Ben-Shmuel, A.; Shvab, A.; Gavert, N.; Brabletz, T.; Ben-Ze'ev, A.			Global analysis of L1-transcriptomes identified IGFBP-2 as a target of ezrin and NF-kappa B signaling that promotes colon cancer progression	ONCOGENE			English	Article						L1; IGFBP-2; ezrin; NF-kappa B; CRC	FACTOR-BINDING PROTEIN-2; I IGF-I; THERAPEUTIC TARGET; ERM PROTEINS; INSULIN; EXPRESSION; SERUM; L1; BIOMARKER; RECEPTOR	L1, a neuronal cell adhesion receptor of the immunoglobulin-like protein family is expressed in invading colorectal cancer (CRC) cells as a target gene of Wnt/beta-catenin signaling. Overexpression of L1 in CRC cells enhances cell motility and proliferation, and confers liver metastasis. We recently identified ezrin and the I kappa B-NF-kappa B pathway as essential for the biological properties conferred by L1 in CRC cells. Here, we studied the underlying molecular mechanisms and found that L1 enhances ezrin phosphorylation, via Rho-associated protein kinase (ROCK), and is required for L1-ezrin co-localization at the juxtamembrane domain and for enhancing cell motility. Global transcriptomes from L1-expressing CRC cells were compared with transcriptomes from the same cells expressing small hairpin RNA (shRNA) to ezrin. Among the genes whose expression was elevated by L1 and ezrin we identified insulin-like growth factor-binding protein 2 (IGFBP-2) and showed that its increased expression is mediated by an NF-kappa B-mediated transactivation of the IGFBP-2 gene promoter. Expression of a constitutively activated mutant ezrin (Ezrin567D) could also increase IGFBP-2 levels in CRC cells. Overexpression of IGFBP-2 in CRC cells lacking L1-enhanced cell proliferation (in the absence of serum), cell motility, tumorigenesis and induced liver metastasis, similar to L1 overexpression. Suppression of endogenous IGFBP-2 in L1-transfected cells inhibited these properties conferred by L1. We detected IGFBP-2 in a unique organization at the bottom of human colonic crypts in normal mucosa and at increased levels throughout human CRC tissue samples co-localizing with the phosphorylated p65 subunit of NF-kappa B. Finally, we found that IGFBP-2 and L1 can form a molecular complex suggesting that L1-mediated signaling by the L1-ezrin-NF-kappa B pathway, that induces IGFBP-2 expression, has an important role in CRC progression.	[Ben-Shmuel, A.; Shvab, A.; Gavert, N.; Ben-Ze'ev, A.] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; [Brabletz, T.] Univ Freiburg, Dept Visceral Surg, D-79106 Freiburg, Germany	Weizmann Institute of Science; University of Freiburg	Ben-Ze'ev, A (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	avri.ben-zeev@weizmann.ac.il		Gavert, Nancy/0000-0003-1639-4684; ben-ze'ev, avri/0000-0001-6113-3921	Israel Science Foundation (ISF); Israel Cancer Research Fund (ICRF)	Israel Science Foundation (ISF)(Israel Science Foundation); Israel Cancer Research Fund (ICRF)	We thank Drs M Arpin, M Pollak, W Zhang and V Lemmon for providing reagents. This study was supported by grants from the Israel Science Foundation (ISF) and from Israel Cancer Research Fund (ICRF). AB-Z is the incumbent of the Lunenfeld-Kunin Professorial chair of genetics.	Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; Bulut G, 2012, ONCOGENE, V31, P269, DOI 10.1038/onc.2011.245; Busund LTR, 2004, VIRCHOWS ARCH, V444, P142, DOI 10.1007/s00428-003-0931-y; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; COHEN P, 1993, J CLIN ENDOCR METAB, V76, P1031, DOI 10.1210/jc.76.4.1031; Conacci-Sorrell ME, 2002, GENE DEV, V16, P2058, DOI 10.1101/gad.227502; Degenhardt T, 2006, J BIOL CHEM, V281, P39607, DOI 10.1074/jbc.M605623200; ELATIQ F, 1994, INT J CANCER, V57, P491, DOI 10.1002/ijc.2910570409; Elmlinger MW, 2001, ENDOCRINOLOGY, V142, P1652, DOI 10.1210/en.142.4.1652; Fievet B, 2007, BBA-MOL CELL RES, V1773, P653, DOI 10.1016/j.bbamcr.2006.06.013; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Gautreau A, 2002, J CELL BIOL, V10, P193; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Gavert N, 2008, EXPERT OPIN BIOL TH, V8, P1749, DOI 10.1517/14712598.8.11.1749 ; Gavert N, 2007, CANCER RES, V67, P7703, DOI 10.1158/0008-5472.CAN-07-0991; Gavert N, 2011, MOL CANCER RES, V9, P14, DOI 10.1158/1541-7786.MCR-10-0406; Gavert N, 2010, J CELL SCI, V123, P2134, DOI 10.1242/jcs.069542; HLAVIN ML, 1991, GENOMICS, V11, P416, DOI 10.1016/0888-7543(91)90150-D; Hoeflich A, 2001, CANCER RES, V61, P8601; Hortsch M, 2000, MOL CELL NEUROSCI, V15, P1, DOI 10.1006/mcne.1999.0809; Kaaks R, 2000, JNCI-J NATL CANCER I, V92, P1592, DOI 10.1093/jnci/92.19.1592; KARASIK A, 1994, J CLIN ENDOCR METAB, V78, P271, DOI 10.1210/jc.78.2.271; Langsrud O, 2007, J APPL STAT, V34, P1275, DOI 10.1080/02664760701594246; Liou JM, 2010, J CLIN ENDOCR METAB, V95, P1717, DOI 10.1210/jc.2009-2668; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Mendes KN, 2010, INT J ONCOL, V37, P143, DOI 10.3892/ijo_00000662; Mishra L, 1998, GROWTH HORM IGF RES, V8, P473, DOI 10.1016/S1096-6374(98)80300-6; Miyako K, 2009, MOL ENDOCRINOL, V23, P169, DOI 10.1210/me.2008-0168; Moore LM, 2009, P NATL ACAD SCI USA, V106, P16675, DOI 10.1073/pnas.0900807106; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Pollak M, 2012, CLIN CANCER RES, V18, P40, DOI 10.1158/1078-0432.CCR-11-0998; Ren L, 2009, ONCOGENE, V28, P792, DOI 10.1038/onc.2008.437; Renehan AG, 2000, J CLIN ENDOCR METAB, V85, P3402, DOI 10.1210/jc.85.9.3402; Schutt BS, 2004, J MOL ENDOCRINOL, V32, P859, DOI 10.1677/jme.0.0320859; So AI, 2008, CLIN CANCER RES, V14, P6944, DOI 10.1158/1078-0432.CCR-08-0408; Tang FQ, 2009, J BIOL CHEM, V284, P27456, DOI 10.1074/jbc.M109.033795; Wang GK, 2006, J BIOL CHEM, V281, P14085, DOI 10.1074/jbc.M513686200	40	37	40	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2013	32	27					3220	3230		10.1038/onc.2012.340	http://dx.doi.org/10.1038/onc.2012.340			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	176JZ	22869145				2022-12-17	WOS:000321301600002
J	Chung, S; Yao, J; Suyama, K; Bajaj, S; Qian, X; Loudig, OD; Eugenin, EA; Phillips, GR; Hazan, RB				Chung, S.; Yao, J.; Suyama, K.; Bajaj, S.; Qian, X.; Loudig, O. D.; Eugenin, E. A.; Phillips, G. R.; Hazan, R. B.			N-cadherin regulates mammary tumor cell migration through Akt3 suppression	ONCOGENE			English	Article						adhesion; motility; Akt isoforms; Akt3; breast cancer	BREAST-CANCER; FGF-RECEPTOR; SIGNALING PATHWAY; METASTASIS; ACTIVATION; EXPRESSION; PROGRESSION; PROLIFERATION; ISOFORMS; PROTEIN	N-cadherin is a cell-cell adhesion molecule that plays a role in breast cancer metastasis. Here, we show that in vivo expression of N-cadherin in the PyMT mouse model, which enhances mammary tumor metastasis, results in selective inhibition of Akt3 expression and phosphorylation. Similarly, exogenous expression of N-cadherin in PyMT or MCF-7 mammary tumor cells enhanced cell motility and caused a dramatic reduction in Akt3 expression and phosphorylation. Moreover, knockdown of Akt3 in PyMT tumor cells increased cell motility and disrupted mammary morphogenesis, but had no effect on cell proliferation. Conversely, overexpression of wild-type Akt3 in PyMT-N-cadherin cells inhibited cell motility promoted by N-cadherin. Taken altogether, these findings demonstrate that N-cadherin suppresses Akt3 to promote cell motility and highlight the intricate regulation of Akt isoforms by N-cadherin during metastasis. Oncogene (2013) 32, 422-430; doi:10.1038/onc.2012.65; published online 12 March 2012	[Chung, S.; Yao, J.; Suyama, K.; Bajaj, S.; Qian, X.; Loudig, O. D.; Eugenin, E. A.; Hazan, R. B.] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; [Phillips, G. R.] Mt Sinai Sch Med, Dept Neurosci, New York, NY USA	Yeshiva University; Albert Einstein College of Medicine; Icahn School of Medicine at Mount Sinai	Hazan, RB (corresponding author), Albert Einstein Coll Med, Dept Pathol, F529S,1300 Morris Pk Ave, Bronx, NY 10461 USA.	Rachel.hazan@einstein.yu.edu	qian, xia/L-1616-2013; Qian, Xia/D-8255-2014		National Cancer Institute [1R01 CA135061-01A1]; NIH; Breast Cancer Research Foundation; Training Program in Cellular and Molecular Biology and Genetics [T32 GM007491]; NATIONAL CANCER INSTITUTE [R01CA090872, R01CA135061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH096625, K01MH076679] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; Training Program in Cellular and Molecular Biology and Genetics; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This study was supported by grants from National Cancer Institute (Grant 1R01 CA135061-01A1) the NIH and Breast Cancer Research Foundation (to RB Hazan). Su Chung was partly supported by the Training Program in Cellular and Molecular Biology and Genetics (T32 GM007491).	Agiostratidou G, 2007, J MAMMARY GLAND BIOL, V12, P127, DOI 10.1007/s10911-007-9044-6; Agiostratidou G, 2009, CANCER RES, V69, P5030, DOI 10.1158/0008-5472.CAN-08-4007; Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Cavallaro Ugo, 2004, Curr Opin Investig Drugs, V5, P1274; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chin YR, 2010, MOL CELL, V38, P333, DOI 10.1016/j.molcel.2010.02.031; Chin YR, 2009, CELL SIGNAL, V21, P470, DOI 10.1016/j.cellsig.2008.11.015; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Dillon RL, 2010, CANCER RES, V70, P4260, DOI 10.1158/0008-5472.CAN-10-0266; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; Hulit J, 2007, CANCER RES, V67, P3106, DOI 10.1158/0008-5472.CAN-06-3401; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; Nagi C, 2005, BREAST CANCER RES TR, V94, P225, DOI 10.1007/s10549-005-7727-5; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Nogueira C, 2010, ONCOGENE, V29, P6222, DOI 10.1038/onc.2010.349; Roccaro AM, 2009, BLOOD, V113, P6669, DOI 10.1182/blood-2009-01-198408; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Toker A, 2006, CANCER RES, V66, P3963, DOI 10.1158/0008-5472.CAN-06-0743; Wheelock MJ, 2003, CURR OPIN CELL BIOL, V15, P509, DOI 10.1016/S0955-0674(03)00101-7; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135	27	37	38	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2013	32	4					422	430		10.1038/onc.2012.65	http://dx.doi.org/10.1038/onc.2012.65			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22410780	Green Accepted			2022-12-17	WOS:000315551300003
J	Psallidas, I; Stathopoulos, GT; Maniatis, NA; Magkouta, S; Moschos, C; Karabela, SP; Kollintza, A; Simoes, DCM; Kardara, M; Vassiliou, S; Papiris, SA; Roussos, C; Kalomenidis, I				Psallidas, I.; Stathopoulos, G. T.; Maniatis, N. A.; Magkouta, S.; Moschos, C.; Karabela, S. P.; Kollintza, A.; Simoes, D. C. M.; Kardara, M.; Vassiliou, S.; Papiris, S. A.; Roussos, C.; Kalomenidis, I.			Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion	ONCOGENE			English	Article						osteopontin; pleural effusion; cancer; inflammation; angiogenesis	TUMOR PROGRESSION; OSTEOPONTIN ISOFORMS; LUNG-CANCER; IN-VIVO; MACROPHAGES; METASTASIS; INFLAMMATION; INVASION; GROWTH; CELLS	Secreted phosphoprotein-1 (SPP1) promotes cancer cell survival and regulates tumor-associated angiogenesis and inflammation, both central to the pathogenesis of malignant pleural effusion (MPE). Here, we examined the impact of tumor- and host-derived SPP1 in MPE formation and explored the mechanisms by which the cytokine exerts its effects. We used a syngeneic murine model of lung adenocarcinoma-induced MPE. To dissect the effects of tumor- versus host-derived SPP1, we intrapleurally injected wild-type and SPP1-knockout C57/BL/6 mice with either wild-type or SPP1-deficient syngeneic lung cancer cells. We demonstrated that both tumor- and host-derived SPP1 promoted pleural fluid accumulation and tumor dissemination in a synergistic manner (P<0.001). SPP1 of host origin elicited macrophage recruitment into the cancer-affected pleural cavity and boosted tumor angiogenesis, whereas tumor-derived SPP1 curtailed cancer cell apoptosis in vivo. Moreover, the cytokine directly promoted vascular hyper-permeability independently of vascular endothelial growth factor. In addition, SPP1 of tumor and host origin differentially affected the expression of proinflammatory and angiogenic mediators in the tumor microenvironment. These results suggest that SPP1 of tumor and host origin impact distinct aspects of MPE pathobiology to synergistically promote pleural fluid formation and pleural tumor progression. SPP1 may present an attractive target of therapeutic interventions for patients with MPE. Oncogene (2013) 32, 528-535; doi:10.1038/onc.2012.57; published online 27 February 2012	[Psallidas, I.; Stathopoulos, G. T.; Maniatis, N. A.; Magkouta, S.; Moschos, C.; Karabela, S. P.; Kollintza, A.; Simoes, D. C. M.; Kardara, M.; Papiris, S. A.; Roussos, C.; Kalomenidis, I.] Evangelismos Med Ctr, Athens Med Sch, Dept Crit Care & Pulm Serv 1, Marianthi Simou Lab, Athens, Greece; [Psallidas, I.; Moschos, C.; Papiris, S. A.; Kalomenidis, I.] Attikon Hosp, Athens Med Sch, Dept Pulm Med 2, Haidari, Greece; [Stathopoulos, G. T.] Univ Patras, Sch Med, Dept Physiol, Rion, Greece; [Vassiliou, S.] Euaggelismos Hosp, Dept Hematol & Lymphomas, Athens, Greece	Evangelismos Hospital; National & Kapodistrian University of Athens; University Hospital Attikon; University of Patras	Psallidas, I (corresponding author), Athens Med Sch, Dept Crit Care & Pulm Serv 1, Marianthi Simou Lab, 3 Ploutarhou St, Athens 10675, Greece.	jpsallidas@med.uoa.gr	Stathopoulos, Georgios/AAE-6884-2020; PAPIRIS, SPYROS/AAD-1825-2020; Stathopoulos, Georgios/D-6576-2013; Kalomenidis, Ioannis/AAD-7521-2019	Stathopoulos, Georgios/0000-0002-9215-6461; Psallidas, Ioannis/0000-0001-7284-0111; Simoes, Davina Camargo Madeira/0000-0002-7262-1784	'Thorax' Foundation (Athens, Greece); GlaxoSmithKline [12 000]	'Thorax' Foundation (Athens, Greece); GlaxoSmithKline(GlaxoSmithKline)	We thank Dr A Marantidou and Z Kollia for professional veterinarian and animal care assistance, respectively. We also thank L Liaw (Maine Medical Center Research Institute) for permission to use the Spp1 +1+ and Spp1-/- mice. This work was supported by the 'Thorax' Foundation (Athens, Greece) and by a research grant by GlaxoSmithKline (funding 12 000 to IP). GlaxoSmithKline had no involvement in study design, collection, analysis and interpretation of data, writing of the report and in the decision to submit the report for publication. IP and IK had full control of all of the data in this study and take complete responsibility for the integrity of the data and the accuracy of the data analysis.	Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029; Bourassa B, 2004, CELL IMMUNOL, V227, P1, DOI 10.1016/j.cellimm.2004.01.001; Burdo TH, 2007, J LEUKOCYTE BIOL, V81, P1504, DOI 10.1189/jlb.1106711; Burgers JA, 2008, EUR RESPIR J, V32, P1321, DOI 10.1183/09031936.00165607; Chakraborty G, 2008, CANCER RES, V68, P152, DOI 10.1158/0008-5472.CAN-07-2126; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Crawford HC, 1998, CANCER RES, V58, P5206; Cui R, 2009, LUNG CANCER, V63, P368, DOI 10.1016/j.lungcan.2008.06.020; Dai J, 2009, ONCOGENE, V28, P3412, DOI 10.1038/onc.2009.189; Dai JX, 2010, CANCER IMMUNOL IMMUN, V59, P355, DOI 10.1007/s00262-009-0754-z; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Dickson PV, 2007, CLIN CANCER RES, V13, P3942, DOI 10.1158/1078-0432.CCR-07-0278; Du XL, 2009, GYNECOL ONCOL, V115, P371, DOI 10.1016/j.ygyno.2009.08.029; Ivanov SV, 2009, BIOCHEM BIOPH RES CO, V382, P514, DOI 10.1016/j.bbrc.2009.03.042; Kalomenidis I, 2011, RESPIROLOGY, V16, P1020, DOI 10.1111/j.1440-1843.2011.02023.x; Krump-Konvalinkova V, 2001, LAB INVEST, V81, P1717, DOI 10.1038/labinvest.3780385; Liaw L, 1998, J CLIN INVEST, V101, P1468; Mason CK, 2008, MOL CANCER THER, V7, P548, DOI 10.1158/1535-7163.MCT-07-2251; Moschos C, 2009, RESPIROLOGY, V14, P716, DOI 10.1111/j.1440-1843.2009.01536.x; Moschos C, 2009, NEOPLASIA, V11, P298, DOI 10.1593/neo.81480; Nemoto H, 2001, J BONE MINER RES, V16, P652, DOI 10.1359/jbmr.2001.16.4.652; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Psallidas I, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-56; Rangaswami H, 2006, TRENDS CELL BIOL, V16, P79, DOI 10.1016/j.tcb.2005.12.005; Rittling SR, 2002, J BIOL CHEM, V277, P9175, DOI 10.1074/jbc.M109028200; Roberts ME, 2010, THORAX, V65, P32, DOI 10.1136/thx.2010.136994; Rodrigues LR, 2007, CANCER EPIDEM BIOMAR, V16, P1087, DOI 10.1158/1055-9965.EPI-06-1008; Shevde LA, 2010, CURR MOL MED, V10, P71, DOI 10.2174/156652410791065381; Shinohara ML, 2008, P NATL ACAD SCI USA, V105, P7235, DOI 10.1073/pnas.0802301105; Sica A., 2010, Experimental Oncology, V32, P153; Stathopoulos GT, 2008, JNCI-J NATL CANCER I, V100, P1464, DOI 10.1093/jnci/djn325; Stathopoulos GT, 2008, AM J RESP CRIT CARE, V178, P50, DOI 10.1164/rccm.200710-1513OC; Stathopoulos GT, 2007, CANCER RES, V67, P9825, DOI 10.1158/0008-5472.CAN-07-1064; Stathopoulos GT, 2010, AM J RESP CRIT CARE, V182, P1273, DOI 10.1164/rccm.201001-0001OC; Stathopoulos GT, 2006, AM J RESP CELL MOL, V34, P142, DOI 10.1165/rcmb.2005-0130OC; Van Meter MEM, 2011, J GEN INTERN MED, V26, P70, DOI 10.1007/s11606-010-1472-0; Wai PY, 2006, SURGERY, V140, P132, DOI 10.1016/j.surg.2006.02.005; Wai PY, 2005, CARCINOGENESIS, V26, P741, DOI 10.1093/carcin/bgi027; Xanthou G, 2007, NAT MED, V13, P570, DOI 10.1038/nm1580; Yamamoto Y, 1998, INFECT IMMUN, V56, P370; Yano S, 2000, AM J PATHOL, V157, P1893, DOI 10.1016/S0002-9440(10)64828-6; Zhao W, 2010, J BIOL CHEM, V285, P20452, DOI 10.1074/jbc.M110.110312	42	37	37	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2013	32	4					528	535		10.1038/onc.2012.57	http://dx.doi.org/10.1038/onc.2012.57			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22370646				2022-12-17	WOS:000315551300013
J	Schafer, H; Struck, B; Feldmann, EM; Bergmann, F; Grage-Griebenow, E; Geismann, C; Ehlers, S; Altevogt, P; Sebens, S				Schaefer, H.; Struck, B.; Feldmann, E-M; Bergmann, F.; Grage-Griebenow, E.; Geismann, C.; Ehlers, S.; Altevogt, P.; Sebens, S.			TGF-beta 1-dependent L1CAM expression has an essential role in macrophage-induced apoptosis resistance and cell migration of human intestinal epithelial cells	ONCOGENE			English	Article						colon cancer; inflammatory bowel disease; CD171; cellular microenvironment	INFLAMMATORY-BOWEL-DISEASE; PANCREATIC DUCTAL ADENOCARCINOMA; OVARIAN-CARCINOMA CELLS; ULCERATIVE-COLITIS; TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; COLONIC MACROPHAGES; PROTEASOME ACTIVITY; ADHESION MOLECULE; UP-REGULATION	Patients with chronic inflammatory bowel disease (IBD) have an increased risk to develop colorectal cancer (CRC) particularly after long duration of the disease. Chronic inflammation of the intestinal mucosa is characterized by a marked enrichment of immune cells such as macrophages as well as by high expression of cytokines and growth factors including transforming growth factor-beta 1 (TGF-beta 1). The adhesion molecule L1CAM mediates chemoresistance and migration of tumor cells and is elevated in CRC tissues being associated with metastatic spread and poor prognosis for the patients. In this study, we examine the role of TGF-beta 1-induced L1CAM expression and macrophages in malignant transformation of intestinal epithelial cells. We demonstrate that TGF-beta 1 stimulation leads to a Slug-dependent upregulation of L1CAM expression already in the colonic intestinal epithelial cell line NCM460 thereby enhancing cell motility and apoptosis resistance. Accordingly, NCM460 cells acquired a migratory and apoptosis-resistant phenotype if transfected with L1CAM. Immunohistochemistry of colonic biopsies revealed considerable L1CAM expression in intestinal epithelial cells in tissues from IBD patients but not in normal colonic tissues. Moreover, L1CAM expression increased with duration of disease being associated with the presence of CD33+ macrophages. Coculture with macrophages generated from monocyte colony-stimulating factor (MCSF)-treated monocytes led to the upregulation of Slug and L1CAM in NCM460 cells thereby elevating cell motility and apoptosis resistance. Pharmacological inhibition of TGF-beta 1 signalling abolished expression of Slug and L1CAM in cocultured NCM460 cells resulting in decreased cell migration and apoptosis resistance. In conclusion, these data provide new insights into the mechanisms by which IBD promotes malignant transformation of intestinal epithelial cells and underscore the role of L1CAM and macrophages in this scenario. Oncogene (2013) 32, 180-189; doi:10.1038/onc.2012.44; published online 20 February 2012	[Schaefer, H.; Struck, B.; Feldmann, E-M; Grage-Griebenow, E.; Geismann, C.] UKSH, Lab Mol Gastroenterol & Hepatol, Dept Internal Med 1, D-24105 Kiel, Germany; [Struck, B.; Feldmann, E-M; Grage-Griebenow, E.; Geismann, C.; Sebens, S.] UKSH, Inst Expt Med, Dept Internal Med 1, D-24105 Kiel, Germany; [Bergmann, F.] Heidelberg Univ, Dept Pathol, Heidelberg, Germany; [Ehlers, S.] Forschungszentrum, Dept Mol Infect Biol, Borstel, Germany; [Altevogt, P.] German Canc Res Ctr, Dept Translat Immunol D015, Heidelberg, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Sebens, S (corresponding author), UKSH, Inst Expt Med, Dept Internal Med 1, Campus Kiel,Arnold Heller Str 3,Haus 6, D-24105 Kiel, Germany.	mueerkoe@1med.uni-kiel.de	Schäfer, Heiner/C-1055-2011; Geismann, Claudia/AAX-8158-2021; Sebens, Susanne/C-1222-2010; Ehlers, Stefan/B-4075-2010	Geismann, Claudia/0000-0003-0640-9256; 	German Research Society DFG [Scha677/9-1, SE-1831/2-1]; German Cluster of Excellence 'Inflammation at Interfaces'	German Research Society DFG(German Research Foundation (DFG)); German Cluster of Excellence 'Inflammation at Interfaces'	Excellent technical assistance by Dagmar Leisner, Erika Kuhlenhauser, Christina Trabandt and Maike Witt-Ramdohr, statistical advice by Jurgen Hedderich and funding by the German Research Society DFG (Scha677/9-1 and SE-1831/2-1) as well as the German Cluster of Excellence 'Inflammation at Interfaces' are acknowledged.	Arlt A, 2009, ONCOGENE, V28, P3983, DOI 10.1038/onc.2009.264; Arlt MJE, 2006, CANCER RES, V66, P936, DOI 10.1158/0008-5472.CAN-05-1818; Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P975, DOI 10.1053/gast.1996.v110.pm8613031; Bergmann F, 2010, ONCOL REP, V24, P909, DOI 10.3892/or_00000936; Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z; BULL DM, 1977, J CLIN INVEST, V59, P966, DOI 10.1172/JCI108719; Clovel T, 2007, INFLAMM BOWEL DIS, V13, P1153, DOI 10.1002/ibd.20174; Ellenrieder V, 2002, J GASTROINTEST CANC, V31, P61, DOI 10.1385/IJGC:31:1-3:61; Ellenrieder V, 2001, CANCER RES, V61, P4222; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Gavert N, 2007, CANCER RES, V67, P7703, DOI 10.1158/0008-5472.CAN-07-0991; Gavert N, 2011, MOL CANCER RES, V9, P14, DOI 10.1158/1541-7786.MCR-10-0406; Geismann C, 2011, INT J ONCOL, V38, P257, DOI 10.3892/ijo_00000846; Geismann C, 2009, CANCER RES, V69, P4517, DOI 10.1158/0008-5472.CAN-08-3493; GOLDER JP, 1983, GASTROENTEROLOGY, V84, P795; Grage-Griebenow E, 2001, EUR J IMMUNOL, V31, P48; Herszenyi L, 2007, DIGEST DIS, V25, P267, DOI 10.1159/000103898; Hosui A, 2009, J EXP MED, V206, P819, DOI 10.1084/jem.20080003; Huszar M, 2006, HUM PATHOL, V37, P1000, DOI 10.1016/j.humpath.2006.03.014; Huszar M, 2010, J PATHOL, V220, P551, DOI 10.1002/path.2673; Kaifi JT, 2007, MODERN PATHOL, V20, P1183, DOI 10.1038/modpathol.3800955; Kamada N, 2005, J IMMUNOL, V175, P6900, DOI 10.4049/jimmunol.175.10.6900; Krausgruber T, 2011, NAT IMMUNOL, V12, P231, DOI 10.1038/ni.1990; Lawrance IC, 2001, INFLAMM BOWEL DIS, V7, P16, DOI 10.1097/00054725-200102000-00003; Matsumoto S, 2010, J IMMUNOL, V184, P1543, DOI 10.4049/jimmunol.0801217; Min JK, 2010, CLIN CANCER RES, V16, P3571, DOI 10.1158/1078-0432.CCR-09-3075; Moyer MP, 1996, IN VITRO CELL DEV-AN, V32, P315; Muerkoster S, 2004, CANCER RES, V64, P1331, DOI 10.1158/0008-5472.CAN-03-1860; Rahimi R, 2002, MED SCI MONITOR, V13, pPI13; Rezaie A, 2006, ANN NY ACAD SCI, V1091, P110, DOI 10.1196/annals.1378.060; Roessner A, 2008, PATHOL RES PRACT, V204, P511, DOI 10.1016/j.prp.2008.04.011; Rogler G, 1998, CLIN EXP IMMUNOL, V112, P205; Rogler G, 1997, EUR J GASTROEN HEPAT, V9, P893, DOI 10.1097/00042737-199709000-00013; Schiechl G, 2011, J CLIN INVEST, V121, P1692, DOI 10.1172/JCI42540; Schniewind B, 2007, ONCOGENE, V26, P4850, DOI 10.1038/sj.onc.1210272; Sebens S, 2011, J BIOL CHEM, V286, P40911, DOI 10.1074/jbc.M111.274902; Smith PD, 2001, J IMMUNOL, V167, P2651, DOI 10.4049/jimmunol.167.5.2651; Smith PD, 2005, IMMUNOL REV, V206, P149, DOI 10.1111/j.0105-2896.2005.00288.x; Smythies LE, 2005, J CLIN INVEST, V115, P66, DOI 10.1172/JCI200519229; Stadnicki A, 2009, INT IMMUNOPHARMACOL, V9, P761, DOI 10.1016/j.intimp.2009.02.014; Stoeck A, 2007, GYNECOL ONCOL, V104, P461, DOI 10.1016/j.ygyno.2006.08.038; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Verreck FAW, 2006, J LEUKOCYTE BIOL, V79, P285, DOI 10.1189/jlb.0105015; Wiercinska-Drapalo A, 2001, CYTOKINE, V14, P343, DOI 10.1006/cyto.2001.0901; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005; Xie JL, 2008, WORLD J GASTROENTERO, V14, P378, DOI 10.3748/wjg.14.378; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927	47	37	37	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2013	32	2					180	189		10.1038/onc.2012.44	http://dx.doi.org/10.1038/onc.2012.44			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22349829				2022-12-17	WOS:000314075500006
J	Li, X; Lu, Y; Liang, K; Hsu, JM; Albarracin, C; Mills, GB; Hung, MC; Fan, Z				Li, X.; Lu, Y.; Liang, K.; Hsu, J-M; Albarracin, C.; Mills, G. B.; Hung, M-C; Fan, Z.			Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR	ONCOGENE			English	Article						EGFR; Brk; Cbl; Src; breast cancer	EPIDERMAL-GROWTH-FACTOR; BREAST-TUMOR KINASE; MAMMARY EPITHELIAL-CELLS; PROTEIN-TYROSINE KINASE; FACTOR RECEPTOR; THERAPEUTIC TARGET; CANCER CELLS; DOWN-REGULATION; BRK; EXPRESSION	Epidermal growth factor receptor (EGFR)-mediated cell signaling is critical for mammary epithelial cell growth and survival; however, targeting EGFR has shown no or only minimal therapeutic benefit in patients with breast cancer. Here, we report a novel regulatory mechanism of EGFR signaling that may explain the low response rates. We found that breast tumor kinase (Brk)/protein-tyrosine kinase 6 (PTK6), a nonreceptor protein-tyrosine kinase highly expressed in most human breast tumors, interacted with EGFR and sustained ligand-induced EGFR signaling. We demonstrate that Brk inhibits ligand-induced EGFR degradation through uncoupling activated EGFR from casitas B-lineage lymphoma-mediated EGFR ubiquitination. In addition, upon activation by EGFR, Brk directly phosphorylated Y845 in the EGFR kinase domain, thereby further potentiating EGFR kinase activity. Experimental elevation of Brk conferred resistance of breast cancer cells to cetuximab (an EGFR-blocking antibody)-induced inhibition of cell signaling and proliferation, whereas knockdown of Brk sensitized the cells to cetuximab by inducing apoptosis. Our findings reveal a previously unknown role of Brk in EGFR-targeted therapy. Oncogene (2012) 31, 4372-4383; doi:10.1038/onc.2011.608; published online 9 January 2012	[Li, X.; Lu, Y.; Liang, K.; Fan, Z.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Hsu, J-M; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Albarracin, C.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.	zfan@mdanderson.org	Hsu, Jung-Mao/AAP-8045-2020; Hung, Mien-Chie/ABD-5911-2021; Hsu, Jung-Mao/AAC-9527-2019	Hung, Mien-Chie/0000-0003-4317-4740; 	US Congressionally Directed Medical Research Programs of the Department of Defense [W81XWH-06-1-0544, W81XWH-07-1-0526]; Breast Cancer Research Foundation; National Institutes of Health [5R01CA129036]; MD Anderson's NIH Cancer Center Support Grant [CA016672]; NATIONAL CANCER INSTITUTE [R01CA129036, P30CA016672] Funding Source: NIH RePORTER	US Congressionally Directed Medical Research Programs of the Department of Defense; Breast Cancer Research Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MD Anderson's NIH Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Mark R Crompton (University of London) for providing the Brk DNA constructs, Dr Steven P Ethier (Karmanos Cancer Institute) for the SUM series of cell lines and Stephanie Deming (Department of Scientific Publications, MD Anderson Cancer Center) for editing the manuscript. This work was supported in part by grants from the US Congressionally Directed Medical Research Programs of the Department of Defense (W81XWH-06-1-0544 and W81XWH-07-1-0526), the Breast Cancer Research Foundation and the National Institutes of Health (5R01CA129036) and MD Anderson's NIH Cancer Center Support Grant (CA016672).	Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Born M, 2005, J PATHOL, V205, P592, DOI 10.1002/path.1720; Chen HY, 2004, MOL CELL BIOL, V24, P10558, DOI 10.1128/MCB.24.24.10558-10572.2004; Corkery B, 2009, ANN ONCOL, V20, P862, DOI 10.1093/annonc/mdn710; Easty DJ, 1997, INT J CANCER, V71, P1061, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1061::AID-IJC24>3.0.CO;2-F; Eck SM, 2009, MOL CANCER RES, V7, P1033, DOI 10.1158/1541-7786.MCR-09-0015; Forozan F, 1999, BRIT J CANCER, V81, P1328, DOI 10.1038/sj.bjc.6695007; Grovdal LM, 2004, EXP CELL RES, V300, P388, DOI 10.1016/j.yexcr.2004.07.003; Harvey AJ, 2004, ANTI-CANCER DRUG, V15, P107, DOI 10.1097/01.cad.0000113339.62364.b5; Harvey AJ, 2003, ONCOGENE, V22, P5006, DOI 10.1038/sj.onc.1206577; Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258; Huang F, 2007, P NATL ACAD SCI USA, V104, P16904, DOI 10.1073/pnas.0707416104; Irie HY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011729; Kamalati T, 2000, ONCOGENE, V19, P5471, DOI 10.1038/sj.onc.1203931; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; Kang SA, 2010, J BIOL CHEM, V285, P26013, DOI 10.1074/jbc.M109.088971; LEE ST, 1993, ONCOGENE, V8, P3403; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Li XQ, 2008, MOL CANCER THER, V7, P1207, DOI 10.1158/1535-7163.MCT-07-2187; Liu L, 2006, ONCOGENE, V25, P4904, DOI 10.1038/sj.onc.1209501; Llor X, 1999, CLIN CANCER RES, V5, P1767; Lu Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015823; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Normanno N, 2005, FRONT BIOSCI-LANDMRK, V10, P2611, DOI 10.2741/1725; Ostrander JH, 2007, CANCER RES, V67, P4199, DOI 10.1158/0008-5472.CAN-06-3409; Polo S, 2004, CURR OPIN CELL BIOL, V16, P156, DOI 10.1016/j.ceb.2004.02.003; Qiu HQ, 2005, ONCOGENE, V24, P5656, DOI 10.1038/sj.onc.1208721; Qiu HQ, 2004, ONCOGENE, V23, P2216, DOI 10.1038/sj.onc.1207339; Qiu HQ, 2002, J BIOL CHEM, V277, P34634, DOI 10.1074/jbc.M203877200; Rimawi MF, 2010, CANCER-AM CANCER SOC, V116, P1234, DOI 10.1002/cncr.24816; SAINSBURY JRC, 1985, LANCET, V1, P364; Sartor CI, 1997, CANCER RES, V57, P978; Serfas MS, 2003, ONCOL RES, V13, P409; Shen CH, 2008, CANCER RES, V68, P7779, DOI 10.1158/0008-5472.CAN-08-0997; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; TAKETANI Y, 1983, P NATL ACAD SCI-BIOL, V80, P2647, DOI 10.1073/pnas.80.9.2647; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Weaver AM, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1794; Xiang B, 2008, P NATL ACAD SCI USA, V105, P12463, DOI 10.1073/pnas.0805009105; Yamaoka T, 2011, AM J PHYSIOL-GASTR L, V301, pG368, DOI 10.1152/ajpgi.00327.2010; Zhang P, 2005, J BIOL CHEM, V280, P1982, DOI 10.1074/jbc.M412038200	44	37	37	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	40					4372	4383		10.1038/onc.2011.608	http://dx.doi.org/10.1038/onc.2011.608			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017LL	22231447	Green Accepted			2022-12-17	WOS:000309591300004
J	Camus, S; Quevedo, C; Menendez, S; Paramonov, I; Stouten, PFW; Janssen, RAJ; Rueb, S; He, S; Snaar-Jagalska, BE; Laricchia-Robbio, L; Belmonte, JCI				Camus, S.; Quevedo, C.; Menendez, S.; Paramonov, I.; Stouten, P. F. W.; Janssen, R. A. J.; Rueb, S.; He, S.; Snaar-Jagalska, B. E.; Laricchia-Robbio, L.; Belmonte, J. C. Izpisua			Identification of phosphorylase kinase as a novel therapeutic target through high-throughput screening for anti-angiogenesis compounds in zebrafish	ONCOGENE			English	Article						phosphorylase kinase; PhK; angiogenesis; zebrafish; cancer	ANTIANGIOGENIC COMPOUNDS; CLINICAL RESISTANCE; GENE AMPLIFICATION; CANCER; GROWTH; METHOTREXATE	Angiogenesis is essential for development and tumor progression. With the aim of identifying new compound inhibitors of the angiogenesis process, we used an established enhanced green fluorescent protein-transgenic zebrafish line to develop an automated assay that enables high-throughput screening of compound libraries in a whole-organism setting. Using this system, we have identified novel kinase inhibitor compounds that show anti-angiogenic properties in both zebrafish in-vivo system and in human endothelial cell in-vitro angiogenesis models. Furthermore, we have determined the kinase target of these compounds and have identified and validated a previously uncharacterized involvement of phosphorylase kinase subunit G1 (PhKG1) in angiogenesis in vivo. In addition, we have found that PhKG1 is upregulated in human tumor samples and that aberrations in gene copy number of PhK subunits are a common feature of human tumors. Our results provide a novel insight into the angiogenesis process, as well as identify new potential targets for anti-angiogenic therapies. Oncogene (2012) 31, 4333-4342; doi:10.1038/onc.2011.594; published online 19 December 2011	[Belmonte, J. C. Izpisua] Salk Inst Biol Studies, La Jolla, CA 92037 USA; [Camus, S.; Menendez, S.; Paramonov, I.; Laricchia-Robbio, L.; Belmonte, J. C. Izpisua] Ctr Regenerat Med Barcelona, Barcelona, Spain; [Quevedo, C.] Biobide SL, San Sebastian, Spain; [Stouten, P. F. W.] Galapagos NV, Mechelen, Belgium; [Janssen, R. A. J.] Galapagos BV, Leiden, Netherlands; [Rueb, S.; He, S.; Snaar-Jagalska, B. E.] Leiden Univ, Inst Biol, Leiden, Netherlands	Salk Institute; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Centro de Medicina Regenerativa de Barcelona; University of Barcelona; Galapagos NV; Galapagos NV; Leiden University; Leiden University - Excl LUMC	Belmonte, JCI (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	belmonte@salk.edu		Stouten, Pieter/0000-0002-5203-2202; Menendez, Sergio/0000-0002-7929-8641	European Community [HEALTH-F2-2008-201439]; MICINN; Fundacion Cellex	European Community(European Commission); MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish GovernmentEuropean Commission); Fundacion Cellex(Foundation CELLEX)	We would like to thank Cornel Catana of Galapagos for molecular modeling efforts and acknowledge the support and intellectual contribution of the Scientific Director of Biobide, Carles Callol. This project was financially supported by the European Community under the FP7 ZF-Cancer project (HEALTH-F2-2008-201439), MICINN and Fundacion Cellex.	Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; CARMAN MD, 1984, J CLIN ONCOL, V2, P16, DOI 10.1200/JCO.1984.2.1.16; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cascante M, 2010, BIOCHEM SOC T, V38, P1302, DOI 10.1042/BST0381302; Edmunds SC, 2002, INVEST OPHTH VIS SCI, V43, P2845; Eilken HM, 2010, CURR OPIN CELL BIOL, V22, P617, DOI 10.1016/j.ceb.2010.08.010; Faucherre A, 2008, ONCOGENE, V27, P1079, DOI 10.1038/sj.onc.1210730; FERGUSON PJ, 1991, J OTOLARYNGOL, V20, P130; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; GOKER E, 1995, BLOOD, V86, P677, DOI 10.1182/blood.V86.2.677.bloodjournal862677; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; Graves D, 1999, PHARMACOL THERAPEUT, V82, P143, DOI 10.1016/S0163-7258(98)00049-7; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Isogai S, 2001, DEV BIOL, V230, P278, DOI 10.1006/dbio.2000.9995; Kidd KR, 2003, BRIT J PHARMACOL, V140, P585, DOI 10.1038/sj.bjp.0705496; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lane DP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001222; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Letamendia A, PLOS ONE UNPUB; Liang D, 2001, MECH DEVELOP, V108, P29, DOI 10.1016/S0925-4773(01)00468-3; Lyons MS, 1998, DEV DYNAM, V212, P133, DOI 10.1002/(SICI)1097-0177(199805)212:1<133::AID-AJA12>3.0.CO;2-8; Marshall KE, 2010, DEV DYNAM, V239, P3000, DOI 10.1002/dvdy.22437; Parng C, 2002, ASSAY DRUG DEV TECHN, V1, P41, DOI 10.1089/154065802761001293; Pownall ME, 1996, DEVELOPMENT, V122, P3881; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Tran TC, 2007, CANCER RES, V67, P11386, DOI 10.1158/0008-5472.CAN-07-3126; Vizan P, 2009, CARCINOGENESIS, V30, P946, DOI 10.1093/carcin/bgp083; Wang CY, 2010, EUR UROL, V58, P418, DOI 10.1016/j.eururo.2010.05.024	29	37	40	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	39					4333	4342		10.1038/onc.2011.594	http://dx.doi.org/10.1038/onc.2011.594			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	016LP	22179836				2022-12-17	WOS:000309520200007
J	Tessema, M; Yingling, CM; Thomas, CL; Klinge, DM; Bernauer, AM; Liu, Y; Dacic, S; Siegfried, JM; Dahlberg, SE; Schiller, JH; Belinsky, SA				Tessema, M.; Yingling, C. M.; Thomas, C. L.; Klinge, D. M.; Bernauer, A. M.; Liu, Y.; Dacic, S.; Siegfried, J. M.; Dahlberg, S. E.; Schiller, J. H.; Belinsky, S. A.			SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15	ONCOGENE			English	Article						NSCLC; camptothecin; SULF-2; topotecan	ORAL TOPOTECAN; PHASE-II; PROMOTER METHYLATION; ANTITUMOR-ACTIVITY; EXPRESSION; GROWTH; EGFR; RESISTANCE; GENES; ADENOCARCINOMAS	The heparan sulfate 6-O-endosulfatase (SULF2) promotes growth and metastasis of solid tumors. We recently identified that cytosine methylation of the SULF2 promoter is associated with better survival of resected lung adenocarcinoma patients, and now also demonstrates a marginal improvement in survival of advanced non-small cell lung cancer (NSCLC) patients receiving standard chemotherapy (hazard ratio = 0.63, P = 0.07). Subsequent studies focused on investigating the effect of methylation on SULF2 expression and its genome-wide impact. The genes and pathways modulated by epigenetic inactivation of SULF2 and the effects on sensitivity to chemotherapy were characterized in vitro and in vivo. Silencing SULF2 through small interfering RNA or methylation primarily increased expression of interferon-inducible genes including ISG15, a marker for increased sensitivity to topoisomerase-1 inhibitors such as camptothecin (CPT). NSCLC cell lines with methylated SULF2 (SULF2M) express 60-fold higher ISG15 compared with SULF2 unmethylated (SULF2U) NSCLC cell lines and normal human bronchial epithelial cells. In vitro, SULF2M and high ISG15 (ISG15H)-expressing NSCLC cell lines were 134-fold more sensitive to CPT than SULF2U and low ISG15 (ISG15L)-expressing cell lines. Topotecan, a soluble analog of CPT and FDA-approved anticancer drug, dramatically arrested the growth of SULF2M-ISG15H, but not SULF2U-ISG15L lung tumors in nude mice (P<0.002). Similarly, high ISG15 expression that is comparable to the topotecan (TPT)-sensitive NSCLC cell lines was found in tumors from 25% of NSCLC patients compared with normal lung, indicating a potential to identify and target the most sensitive NSCLC subpopulation for personalized TPT therapy. Oncogene (2012) 31, 4107-4116; doi: 10.1038/onc.2011.577; published online 12 December 2011	[Tessema, M.; Yingling, C. M.; Thomas, C. L.; Klinge, D. M.; Bernauer, A. M.; Liu, Y.; Belinsky, S. A.] LRRI, Lovelace Resp Res Inst, Lung Canc Program, Albuquerque, NM 87108 USA; [Dacic, S.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA; [Siegfried, J. M.] Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA; [Dahlberg, S. E.] Dana Farber Canc Inst, Dept Biostat & Comput Biol, Boston, MA 02115 USA; [Schiller, J. H.] Univ Texas SW, Dept Internal Med, Dallas, TX USA	Lovelace Respiratory Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Dana-Farber Cancer Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas	Belinsky, SA (corresponding author), LRRI, Lovelace Resp Res Inst, Lung Canc Program, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108 USA.	sbelinsk@LRRI.org	Dahlberg, Suzanne/L-2622-2019	Dahlberg, Suzanne/0000-0001-5139-831X	NIH [R01 ES008801, CA089551, P50 CA090440]; NATIONAL CANCER INSTITUTE [U24CA114737, R01CA089551, P50CA090440, U10CA023318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008801] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This study was supported by NIH grants R01 ES008801 and CA089551 to SAB, and P50 CA090440 to JMS.	Andersen JB, 2006, BRIT J CANCER, V94, P1465, DOI 10.1038/sj.bjc.6603099; Bishop JR, 2007, NATURE, V446, P1030, DOI 10.1038/nature05817; Desai SD, 2006, CANCER RES, V66, P921, DOI 10.1158/0008-5472.CAN-05-1123; Desai SD, 2008, MOL CANCER THER, V7, P1430, DOI 10.1158/1535-7163.MCT-07-2345; Duan ZF, 2004, MOL CANCER THER, V3, P833; Gonzalez EE, 2011, INVEST NEW DRUG, V29, P1459, DOI 10.1007/s10637-010-9442-2; Helfrich BA, 2006, CLIN CANCER RES, V12, P7117, DOI 10.1158/1078-0432.CCR-06-0760; Johansson FK, 2005, ONCOGENE, V24, P3896, DOI 10.1038/sj.onc.1208553; Jones S, 2008, CLIN LUNG CANCER, V9, P154, DOI 10.3816/CLC.2008.n.023; Kalikaki A, 2008, BRIT J CANCER, V99, P923, DOI 10.1038/sj.bjc.6604629; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Lai JP, 2008, HEPATOLOGY, V47, P1211, DOI 10.1002/hep.22202; Lai JP, 2010, HEPATOLOGY, V52, P1680, DOI 10.1002/hep.23848; Lemjabbar-Alaoui H, 2010, ONCOGENE, V29, P635, DOI 10.1038/onc.2009.365; Lin CP, 2008, J BIOL CHEM, V283, P21074, DOI 10.1074/jbc.M803493200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LORTAT-JACOB H, 1991, J CLIN INVEST, V87, P878, DOI 10.1172/JCI115093; McGuire WP, 2000, J CLIN ONCOL, V18, P1062, DOI 10.1200/JCO.2000.18.5.1062; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; Monk BJ, 2009, J CLIN ONCOL, V27, P4649, DOI 10.1200/JCO.2009.21.8909; Morimoto-Tomita M, 2005, NEOPLASIA, V7, P1001, DOI 10.1593/neo.05496; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Nawroth R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000392; O'Brien M, 2007, ONCOLOGIST, V12, P1194, DOI 10.1634/theoncologist.12-10-1194; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Ramlau R, 2006, J CLIN ONCOL, V24, P2800, DOI 10.1200/JCO.2005.03.6491; Sugaya N, 2008, J BIOL CHEM, V283, P10366, DOI 10.1074/jbc.M705948200; Tessema M, 2010, ONCOGENE, V29, P5159, DOI 10.1038/onc.2010.255; Tessema M, 2008, CANCER RES, V68, P1707, DOI 10.1158/0008-5472.CAN-07-6325; Tessema M, 2009, CARCINOGENESIS, V30, P1132, DOI 10.1093/carcin/bgp114; Uchimura Kenji, 2006, BMC Biochem, V7, P2, DOI 10.1186/1471-2091-7-2; Weitz JJ, 2000, LUNG CANCER-J IASLC, V28, P157, DOI 10.1016/S0169-5002(99)00128-2; White SC, 2000, CLIN CANCER RES, V6, P868	34	37	40	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	37					4107	4116		10.1038/onc.2011.577	http://dx.doi.org/10.1038/onc.2011.577			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NR	22158045	Green Accepted			2022-12-17	WOS:000308688900003
J	Ding, Y; Ding, J; Wu, K; Wen, W; Liu, C; Yan, HX; Chen, C; Wang, S; Tang, H; Gao, CK; Guo, LN; Cao, D; Li, Z; Feng, GS; Wang, HY; Xu, ZF				Ding, Y.; Ding, J.; Wu, K.; Wen, W.; Liu, C.; Yan, H-X; Chen, C.; Wang, S.; Tang, H.; Gao, C-K; Guo, L-N; Cao, D.; Li, Z.; Feng, G-S; Wang, H-Y; Xu, Z-F			Cross-talk between endothelial cells and tumor via delta-like ligand4/Notch/PTEN signaling inhibits lung cancer growth	ONCOGENE			English	Article						lung cancer; vascular endothelial cells; delta-like ligand 4; Notch; PTEN	UP-REGULATION; THERAPEUTIC IMPLICATIONS; NOTCH; ANGIOGENESIS; DLL4; ACTIVATION; PATHWAY; PTEN; PROLIFERATION; EXPRESSION	Lung cancer is a leading cause of cancer death in many countries. Notch signaling has been demonstrated to frequently participate in the process of lung carcinogenesis. Delta-like ligand 4 (Dll4) is a vascular-specific ligand of Notch, and has a critical role in the angiogenesis of numerous cancers. However, the role of Dll4 in the crosstalk between endothelial cells (ECs) and tumor cells remains obscure. Herein, our study revealed that Dll4-expressing ECs (EC-Dll4) significantly suppressed the proliferation of neighboring non-small cell lung cancer (NSCLC) cells and attenuated the growth of NSCLC xenograft in nude mice. On the contrary, silencing endothelial Dll4 by its specific interference RNA reversed these effects of Dll4 on NSCLC cell proliferation and tumor formation. Furthermore, activation of Notch1, but not Notch2 or Notch3, was enhanced in NSCLC cells cultured with EC-Dll4, as well as in xenografts induced by a mixture of NSCLC cells and EC-Dll4. Interference of Notch1 significantly attenuated Dll4-mediated suppression of NSCLC cell proliferations, indicating that Dll4/Notch1 signaling negatively modulates the NSCLC growth. Moreover, PTEN expression in NSCLC cells was increased by EC-Dll4 or rhDll4 (recombinant human-Dll4 protein), and the induction was impaired by Notch1 interference suggesting that Dll4 could upregulate PTEN expression by Notch1. Taken together, we conclude that the cross-talk between ECs and NSCLC cells by Dll4/Notch1/PTEN signaling pathway inhibits the growth of NSCLC. Oncogene (2012) 31, 2899-2906; doi:10.1038/onc.2011.467; published online 17 October 2011	[Ding, Y.; Wang, S.; Tang, H.; Gao, C-K; Xu, Z-F] Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Thorac & Cardiovasc Surg, Shanghai 200003, Peoples R China; [Ding, J.; Wu, K.; Wen, W.; Liu, C.; Yan, H-X; Chen, C.; Guo, L-N; Cao, D.; Li, Z.; Wang, H-Y] Second Mil Med Univ, Eastern Hepatobiliary Surg Inst, Int Cooperat Lab Signal Transduct, Shanghai 200438, Peoples R China; [Feng, G-S] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Feng, G-S] Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA	Naval Medical University; Naval Medical University; University of California System; University of California San Diego; University of California System; University of California San Diego	Xu, ZF (corresponding author), Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Thorac & Cardiovasc Surg, 415 Fengyang Rd, Shanghai 200003, Peoples R China.	hywangk@vip.sina.com; xu_zhi_fei@yahoo.com.cn	ding, jin/GVT-5062-2022		National Natural Science Foundation of China [30972965, 31071236, 30800576]; Shanghai Pujiang program	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Pujiang program(Shanghai Pujiang Program)	This work was supported by grants from the National Natural Science Foundation of China (30972965, 31071236 and 30800576) and the Shanghai Pujiang program.	Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025; Chen YB, 2007, CANCER RES, V67, P7954, DOI 10.1158/0008-5472.CAN-07-1229; Collins BJ, 2004, SEMIN CANCER BIOL, V14, P357, DOI 10.1016/j.semcancer.2004.04.015; Deftos ML, 2000, CURR OPIN IMMUNOL, V12, P166, DOI 10.1016/S0952-7915(99)00067-9; Detterbeck FC, 2009, CHEST, V136, P260, DOI 10.1378/chest.08-0978; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Fortini ME, 2009, DEV CELL, V16, P633, DOI 10.1016/j.devcel.2009.03.010; Graziani I, 2008, CANCER RES, V68, P9678, DOI 10.1158/0008-5472.CAN-08-0969; Haruki N, 2005, CANCER RES, V65, P3555, DOI 10.1158/0008-5472.CAN-04-3132; Hofmann JJ, 2007, GENE EXPR PATTERNS, V7, P461, DOI 10.1016/j.modgep.2006.11.002; Indraccolo S, 2009, CANCER RES, V69, P1314, DOI 10.1158/0008-5472.CAN-08-2791; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Konishi J, 2007, CANCER RES, V67, P8051, DOI 10.1158/0008-5472.CAN-07-1022; Kunnimalaiyaan M, 2005, AM J PHYSIOL-GASTR L, V289, pG636, DOI 10.1152/ajpgi.00146.2005; Kunnimalaiyaan M, 2007, ONCOLOGIST, V12, P535, DOI 10.1634/theoncologist.12-5-535; Li JL, 2007, CANCER RES, V67, P11244, DOI 10.1158/0008-5472.CAN-07-0969; Lobov IB, 2007, P NATL ACAD SCI USA, V104, P3219, DOI 10.1073/pnas.0611206104; Mailhos C, 2001, DIFFERENTIATION, V69, P135, DOI 10.1046/j.1432-0436.2001.690207.x; Meurette O, 2009, CANCER RES, V69, P5015, DOI 10.1158/0008-5472.CAN-08-3478; Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355; Nor JE, 2001, CANCER RES, V61, P2183; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Patel NS, 2005, CANCER RES, V65, P8690, DOI 10.1158/0008-5472.CAN-05-1208; Phng LK, 2009, DEV CELL, V16, P196, DOI 10.1016/j.devcel.2009.01.015; Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Scehnet JS, 2007, BLOOD, V109, P4753, DOI 10.1182/blood-2006-12-063933; Segarra M, 2008, BLOOD, V112, P1904, DOI 10.1182/blood-2007-11-126045; Wen W, 2010, CANCER RES, V70, P2010, DOI 10.1158/0008-5472.CAN-08-4910; Whelan JT, 2007, CELL CYCLE, V6, P80, DOI 10.4161/cc.6.1.3648; Williams CK, 2006, BLOOD, V107, P931, DOI 10.1182/blood-2005-03-1000; Winer E, 2009, J CLIN ONCOL, V27, P812, DOI 10.1200/JCO.2008.21.2134; Yan MH, 2007, CLIN CANCER RES, V13, P7243, DOI 10.1158/1078-0432.CCR-07-1393; Yan MH, 2010, NATURE, V463, pE6, DOI 10.1038/nature08751; Yin Y, 2008, ONCOGENE, V27, P5443, DOI 10.1038/onc.2008.241; Zeng QH, 2005, CANCER CELL, V8, P13, DOI 10.1016/j.ccr.2005.06.004	37	37	40	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	23					2899	2906		10.1038/onc.2011.467	http://dx.doi.org/10.1038/onc.2011.467			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958YW	22002304				2022-12-17	WOS:000305277900009
J	Rao, VH; Kandel, A; Lynch, D; Pena, Z; Marwaha, N; Deng, C; Watson, P; Hansen, LA				Rao, V. H.; Kandel, A.; Lynch, D.; Pena, Z.; Marwaha, N.; Deng, C.; Watson, P.; Hansen, L. A.			A positive feedback loop between HER2 and ADAM12 in human head and neck cancer cells increases migration and invasion	ONCOGENE			English	Article						HER2; ADAM12; head and neck cancer; oral cancer; migration; invasion	GROWTH-FACTOR-RECEPTOR; HUMAN-BREAST-CANCER; GENE-EXPRESSION; PROTEIN EXPRESSION; FAMILY-MEMBERS; CARCINOMA; OVEREXPRESSION; AMPLIFICATION; ERBB2; EGFR	Increased activation of epidermal growth factor receptor (EGFR) family members such as HER2/Erbb2 can result in more aggressive disease, resistance to chemotherapy and reduced survival of head and neck squamous cell carcinoma (HNSCC) patients. In order to identify mechanisms through which these receptor tyrosine kinases accelerate tumor progression, the regulation of metalloprotease expression by EGFR family members was investigated in 11 squamous cell carcinoma (SCC) cell lines. HER2 expression was significantly correlated with ADAM12 (A Disintegrin And Metalloprotease 12) expression in these cell lines and was co-expressed in human head and neck cancers. Inhibition of HER2 or EGFR decreased ADAM12 transcripts whereas HER2 transfection upregulated ADAM12 expression. To understand the molecular mechanisms underlying HER2 regulation of ADAM12, we investigated the signaling pathways directing ADAM12 production in SCC cells. Inhibition of phosphatidyl inositol-3-kinase or mammalian target of rapamycin decreased ADAM12 transcripts in HER2-expressing SCC cells, whereas transfection with AKT increased ADAM12 mRNA. Experiments utilizing ADAM12 transfection or siRNA targeting of ADAM12 revealed that the protease increased both the migration and invasiveness of oral SCC cells. Surprisingly, ADAM12 also increased HER2 message, protein levels and activity through an Ets1-dependent mechanism. Collectively, these results reveal a novel positive activation loop between ADAM12 and HER2 that may contribute to HNSCC progression. Oncogene (2012) 31, 2888-2898; doi:10.1038/onc.2011.460; published online 10 October 2011	[Rao, V. H.; Kandel, A.; Lynch, D.; Pena, Z.; Marwaha, N.; Hansen, L. A.] Creighton Univ, Sch Med, Dept Biomed Sci, Omaha, NE 68178 USA; [Deng, C.] Creighton Univ, Sch Med, Dept Pathol, Omaha, NE 68178 USA; [Watson, P.] Creighton Univ, Sch Med, Dept Prevent Hlth, Omaha, NE 68178 USA	Creighton University; Creighton University; Creighton University	Hansen, LA (corresponding author), Creighton Univ, Sch Med, Dept Biomed Sci, 2500 Calif Plaza,Criss 2,Room 431, Omaha, NE 68178 USA.	LHansen@creighton.edu			NIH; Nebraska Cancer and Smoking-Related Diseases Research Program; Dobleman Institute for Head and Neck Cancer Research; National Institutes of Health [1RO1ES015585]; State of Nebraska [LB595]; Dobleman Head and Neck Cancer Institute; National Center for Research Resources, National Institutes of Health [1CO6RR17417-01, G20RR024001]; NATIONAL CENTER FOR RESEARCH RESOURCES [G20RR024001, C06RR017417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015585] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nebraska Cancer and Smoking-Related Diseases Research Program; Dobleman Institute for Head and Neck Cancer Research; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); State of Nebraska; Dobleman Head and Neck Cancer Institute; National Center for Research Resources, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Dr Hansen's work has been funded by the NIH, the Nebraska Cancer and Smoking-Related Diseases Research Program and the Dobleman Institute for Head and Neck Cancer Research. The other authors declare no conflict of interest.; The cell lines used in this study were gifts from Drs Greg Oakley (University of Nebraska, Lincoln) and Thomas Carey (University of Michigan). We also thank Drs U. Wewer and C. Frohlich (University of Copenhagen, Denmark) for the gifts of ADAM12 plasmids. This research was supported by the National Institutes of Health (1RO1ES015585), the State of Nebraska LB595 and The Dobleman Head and Neck Cancer Institute. This investigation was conducted in a facility constructed with support from Research Facilities Improvement Program Grant Numbers 1CO6RR17417-01 and G20RR024001 from the National Center for Research Resources, National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health.	Akervall J, 2004, ACTA OTO-LARYNGOL, V124, P851, DOI 10.1080/00016480410017323; Ang KK, 2002, CANCER RES, V62, P7350; Arora S, 2005, CLIN CANCER RES, V11, P2272, DOI 10.1158/1078-0432.CCR-04-0572; Brenner JC, 2010, HEAD NECK-J SCI SPEC, V32, P417, DOI 10.1002/hed.21198; Brunner K, 2010, ANAL QUANT CYTOL, V32, P78; Carl-McGrath S, 2005, INT J ONCOL, V26, P17; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chin D, 2006, EXPERT REV ANTICANC, V6, P1111, DOI 10.1586/14737140.6.7.1111; Coutant A, 2005, J HEPATOL, V43, P1038; El-Abaseri TB, 2006, CARCINOGENESIS, V27, P225, DOI 10.1093/carcin/bgi220; Erjala K, 2006, CLIN CANCER RES, V12, P4103, DOI 10.1158/1078-0432.CCR-05-2404; Ettl T, 2008, HISTOPATHOLOGY, V53, P567, DOI 10.1111/j.1365-2559.2008.03159.x; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; GRENMAN R, 1991, CANCER, V67, P2741, DOI 10.1002/1097-0142(19910601)67:11<2741::AID-CNCR2820671105>3.0.CO;2-S; Hanawa M, 2006, INT J CANCER, V118, P1173, DOI 10.1002/ijc.21454; Hudson LG, 2009, FUTURE ONCOL, V5, P323, DOI 10.2217/FON.09.10; Ibrahim SO, 1997, ANTICANCER RES, V17, P4539; Jacobsen J, 2009, CURR PHARM DESIGN, V15, P2300, DOI 10.2174/138161209788682389; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kawaguchi N, 2003, J CELL SCI, V116, P3893, DOI 10.1242/jcs.00699; Kodama T, 2004, AM J PATHOL, V165, P1743, DOI 10.1016/S0002-9440(10)63429-3; Kong A, 2006, CANCER RES, V66, P2834, DOI 10.1158/0008-5472.CAN-05-2994; Kornberg LJ, 2005, LARYNGOSCOPE, V115, P690, DOI 10.1097/01.mlg.0000161333.67977.93; Kveiborg M, 2005, CANCER RES, V65, P4754, DOI 10.1158/0008-5472.CAN-05-0262; Kveiborg M, 2008, INT J BIOCHEM CELL B, V40, P1685, DOI 10.1016/j.biocel.2008.01.025; Le Pabic H, 2003, HEPATOLOGY, V37, P1056, DOI 10.1053/jhep.2003.50205; Lendeckel U, 2005, J CANCER RES CLIN, V131, P41, DOI 10.1007/s00432-004-0619-y; Liu F, 2001, EUR J BIOCHEM, V268, P3501, DOI 10.1046/j.1432-1327.2001.02254.x; Madson JG, 2006, AM J PATHOL, V169, P1402, DOI 10.2353/ajpath.2006.060082; Madson JG, 2009, AM J PATHOL, V174, P2357, DOI 10.2353/ajpath.2009.080638; Markowski J, 2009, J PHYSIOL PHARMACOL, V60, P57; Mino N, 2009, J SURG ONCOL, V100, P267, DOI 10.1002/jso.21313; Moon C, 2010, EXP BIOL MED, V235, P907, DOI 10.1258/ebm.2009.009181; O-Charoenrat P, 2000, INT J CANCER, V86, P307, DOI 10.1002/(SICI)1097-0215(20000501)86:3<307::AID-IJC2>3.0.CO;2-I; Ou CC, 2008, CARCINOGENESIS, V29, P299, DOI 10.1093/carcin/bgm263; Pande P, 1999, J PATHOL, V189, P40, DOI 10.1002/(SICI)1096-9896(199909)189:1<40::AID-PATH405>3.0.CO;2-#; Pande P, 2001, CANCER DETECT PREV, V25, P496; Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571; Ragin CCR, 2007, J DENT RES, V86, P104, DOI 10.1177/154405910708600202; Rocks N, 2006, BRIT J CANCER, V94, P724, DOI 10.1038/sj.bjc.6602990; Roepman P, 2005, NAT GENET, V37, P182, DOI 10.1038/ng1502; Rohatgi N, 2005, ORAL ONCOL, V41, P806, DOI 10.1016/j.oraloncology.2005.04.010; Roy R, 2004, J BIOL CHEM, V279, P51323, DOI 10.1074/jbc.M409565200; Sato-Kuwabara Y, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-6; Scott GK, 2000, ONCOGENE, V19, P6490, DOI 10.1038/sj.onc.1204041; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Shirakihara T, 2007, MOL BIOL CELL, V18, P3533, DOI 10.1091/mbc.E07-03-0249; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Squire JA, 2002, HEAD NECK-J SCI SPEC, V24, P874, DOI 10.1002/hed.10122; Thodeti CK, 2005, EXP CELL RES, V309, P438, DOI 10.1016/j.yexcr.2005.06.020; Worsham MJ, 1999, J CLIN PATHOL-MOL PA, V52, P42, DOI 10.1136/mp.52.1.42; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294	52	37	38	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	23					2888	2898		10.1038/onc.2011.460	http://dx.doi.org/10.1038/onc.2011.460			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958YW	21986939	Green Accepted			2022-12-17	WOS:000305277900008
J	Vasseur, S; Afzal, S; Tomasini, R; Guillaumond, F; Tardivel-Lacombe, J; Mak, TW; Iovanna, JL				Vasseur, S.; Afzal, S.; Tomasini, R.; Guillaumond, F.; Tardivel-Lacombe, J.; Mak, T. W.; Iovanna, J. L.			Consequences of DJ-1 upregulation following p53 loss and cell transformation	ONCOGENE			English	Article						DJ-1; p53; transformation; Akt; ROS	DNA-DAMAGE RESPONSE; TUMOR-SUPPRESSOR; ANTIOXIDANT FUNCTION; PROTEIN; APOPTOSIS; PATHWAY; IDENTIFICATION; INHIBITION; EXPRESSION; ONCOGENE	p53 is a tumor suppressor that responds to various stress signals by initiating cell-cycle arrest, senescence and apoptosis. Mutations of the p53 gene are found in over 50% of human tumors, highlighting the importance of p53 in tumor suppression. Numerous studies have reported on the interactions between p53, IGF-1-AKT and mTOR pathways as potentially explaining some of the tumor suppressive activities of p53. To further understand the basis of these interactions, we analyzed the involvement of DJ-1, an oncogene known to drive AKT-mediated cell survival, in the p53-AKT axis. In this study, we show that DJ-1 and p53 are tightly 'linked': p53 prevents the accumulation of DJ-1 protein, whereas loss of p53 leads to stabilization and enhancement of DJ-1 expression. Interestingly, this increase in DJ-1 level is only observed when p53 loss is accompanied by transformation of cells. Moreover, DJ-1 seems to be required for the enhanced activation of AKT observed in p53-deficient cells. Such observation confers a new property to DJ-1 associated to transforming-process to its oncogenic ability to drive AKT activation. We also show that DJ-1 is necessary for p53 activation following oxidative stress, suggesting the existence of a finely regulated loop between these two proteins in transformed cells. Finally, we demonstrate that in the absence of p53, DJ-1 is stabilized by ROS accumulation, and surprisingly seems to be required for this high intracellular ROS production. These data offer new insights into the regulation of DJ-1 and suggest that DJ-1 is a target of p53. Importantly, our study highlights that during transformation, DJ-1 is having a key role in the p53-regulated AKT pathway and p53-driven oxidative-stress response. Oncogene (2012) 31, 664-670; doi:10.1038/onc.2011.268; published online 4 July 2011	[Vasseur, S.; Afzal, S.; Mak, T. W.] Univ Hlth Network, Ontario Canc Inst, Campbell Family Canc Res Inst, Toronto, ON M5G 2C1, Canada; [Vasseur, S.; Tomasini, R.; Guillaumond, F.; Tardivel-Lacombe, J.; Iovanna, J. L.] Inst Natl Sante & Rech Med, U624, F-13288 Marseille 9, France	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Institut National de la Sante et de la Recherche Medicale (Inserm)	Mak, TW (corresponding author), Univ Hlth Network, Ontario Canc Inst, Campbell Family Canc Res Inst, Toronto, ON M5G 2C1, Canada.	tmak@uhnresearch.ca; juan.iovanna@inserm.fr	Guillaumond, Fabienne/E-8265-2017; Iovanna, Juan/M-9805-2017; tomasini, richard/F-1130-2017; vasseur, sophie/O-9803-2017	Guillaumond, Fabienne/0000-0001-7456-7315; Iovanna, Juan/0000-0003-1822-2237; tomasini, richard/0000-0003-0869-0811; vasseur, sophie/0000-0002-2339-8854	Institute National de la Sante et de la Recherche Medicale France; Fondation Sante, Sport et developpement durable; Canadian Institute of Health Research; 'Ligue Contre le Cancer', France; 'Institut National du Cancer (INCa)', France	Institute National de la Sante et de la Recherche Medicale France; Fondation Sante, Sport et developpement durable; Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); 'Ligue Contre le Cancer', France; 'Institut National du Cancer (INCa)', France(Institut National du Cancer (INCA) France)	We thank P Spoto and K Sari for technical assistance. S Vasseur, R Tomasini, and J Tardivel-Lacombe were supported by Institute National de la Sante et de la Recherche Medicale France. F Guillaumond was supported by the 'Fondation Sante, Sport et developpement durable'. S Vasseur and S Afzal were supported by the Canadian Institute of Health Research. This work was also supported by grants from the 'Ligue Contre le Cancer', France and the 'Institut National du Cancer (INCa)', France.	Aleyasin H, 2010, P NATL ACAD SCI USA, V107, P3186, DOI 10.1073/pnas.0914876107; Cano CE, 2009, CANCER RES, V69, P219, DOI 10.1158/0008-5472.CAN-08-2320; Dong PX, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-103; Fan J, 2008, FEBS LETT, V582, P1151, DOI 10.1016/j.febslet.2008.03.003; Feng ZH, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001057; Giaime E, 2010, CELL DEATH DIFFER, V17, P158, DOI 10.1038/cdd.2009.116; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Guzman JN, 2010, NATURE, V468, P696, DOI 10.1038/nature09536; Hao LY, 2010, P NATL ACAD SCI USA, V107, P9747, DOI 10.1073/pnas.0911175107; Hinkle DA, 2011, NEUROPATHOLOGY, V31, P29, DOI 10.1111/j.1440-1789.2010.01124.x; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Kahle PJ, 2009, FREE RADICAL BIO MED, V47, P1354, DOI 10.1016/j.freeradbiomed.2009.08.003; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Marcondes AM, 2010, BLOOD, V115, P1993, DOI 10.1182/blood-2009-08-236992; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Nister M, 2005, ONCOGENE, V24, P3563, DOI 10.1038/sj.onc.1208354; Rahman-Roblick R, 2008, ONCOGENE, V27, P4854, DOI 10.1038/onc.2008.124; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Shenkman M, 2007, BIOCHEM J, V404, P509, DOI 10.1042/BJ20061854; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Vasseur S, 2002, EMBO REP, V3, P165, DOI 10.1093/embo-reports/kvf023; Vasseur S, 2009, P NATL ACAD SCI USA, V106, P1111, DOI 10.1073/pnas.0812745106; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Waak J, 2009, J BIOL CHEM, V284, P14245, DOI 10.1074/jbc.M806902200; Wilhelm MT, 2010, GENE DEV, V24, P549, DOI 10.1101/gad.1873910; You H, 2004, P NATL ACAD SCI USA, V101, P14057, DOI 10.1073/pnas.0406286101; Zhan H, 2010, J BIOL CHEM, V285, P29662, DOI 10.1074/jbc.M110.125138	28	37	41	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	5					664	670		10.1038/onc.2011.268	http://dx.doi.org/10.1038/onc.2011.268			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21725356				2022-12-17	WOS:000300221800012
J	Saji, M; Narahara, K; McCarty, SK; Vasko, VV; La Perle, KM; Porter, K; Jarjoura, D; Lu, C; Cheng, SY; Ringel, MD				Saji, M.; Narahara, K.; McCarty, S. K.; Vasko, V. V.; La Perle, K. M.; Porter, K.; Jarjoura, D.; Lu, C.; Cheng, S-Y; Ringel, M. D.			Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer	ONCOGENE			English	Article						PI3 kinase; thyroid hormone receptor beta; thyrotropin; p27; gelsolin	EPITHELIAL-MESENCHYMAL TRANSITION; MOUSE MODEL; CELL-MIGRATION; BREAST-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE; DISTINCT ROLES; BETA-RECEPTOR; P27(KIP1); GROWTH; MICE	Akt activation is common in progressive thyroid cancer. In breast cancer, Akt1 induces primary cancer growth, but is reported to inhibit metastasis in vivo in several model systems. In contrast, clinical and in vitro studies suggest a metastasis-promoting role for Akt1 in thyroid cancer. The goal of this study was to determine the functional role of Akt1 in thyroid cancer growth and metastatic progression in vivo using thyroid hormone receptor (TR) beta(PV/PV) knock-in (PV) mice, which develop metastatic thyroid cancer. We crossed Akt1(-/-) and PV mice and compared tumor development, local progression, metastasis and histology in TR beta(PV/PV)/Akt1(+/+) (PVPV-Akt1WT) and TR beta(PV/PV)/Akt1(-/-) (PVPV-Akt1KO) mice. Mice were killed at 3, 6, 9, 12 and 15 months; necropsy was performed and serum thyroid stimulating hormone (TSH) was measured. Thyroid hyperplasia occurred in both groups beginning at 3 months; the thyroid size was greater in the PVPV-Akt1WT mice (P<0.001). In comparison with PVPV-Akt1WT mice, thyroid cancer development was delayed in the PVPV-Akt1KO mice (P = 0.003) and the degree of tumor invasiveness was reduced. The PVPV-Akt1WT mice displayed pulmonary metastases at 12 and 15 months of age, by contrast PVPV-Akt1KO mice did not develop distant metastases at 15 months of age. Despite continued expression of Akt2 or Akt3, pAkt levels were decreased and there was evidence of reduced Akt effect on p27 in the PVPV-Akt1KO thyroids. TSH levels were similarly elevated in PV mice regardless of Akt1 expression. In conclusion, thyroid cancer development and progression in TR beta(PV/PV) mice are Akt1-dependent, consistent with a tumor progression-promoting role in this murine thyroid cancer model. Oncogene (2011) 30, 4307-4315; doi: 10.1038/onc.2011.136; published online 2 May 2011	[Saji, M.; Narahara, K.; McCarty, S. K.; Ringel, M. D.] Ohio State Univ, Coll Med, Div Endocrinol, Columbus, OH 43210 USA; [Saji, M.; Narahara, K.; McCarty, S. K.; Ringel, M. D.] Ohio State Univ, Coll Med, Div Diabet, Columbus, OH 43210 USA; [Saji, M.; Narahara, K.; McCarty, S. K.; Ringel, M. D.] Ohio State Univ, Coll Med, Div Metab, Columbus, OH 43210 USA; [Saji, M.; Narahara, K.; McCarty, S. K.; Porter, K.; Jarjoura, D.; Ringel, M. D.] Arthur G James Comprehens Canc Ctr, Columbus, OH USA; [Ringel, M. D.] Ohio State Univ, Coll Med, Div Oncol, Columbus, OH 43210 USA; [Porter, K.; Jarjoura, D.] Ohio State Univ, Coll Med, Ctr Biostat, Columbus, OH 43210 USA; [Vasko, V. V.] Uniformed Serv Univ Hlth Sci, Dept Pediat, Bethesda, MD 20814 USA; [La Perle, K. M.] Ohio State Univ, Coll Vet Med, Columbus, OH 43210 USA; [Lu, C.; Cheng, S-Y] NCI, NIH, Bethesda, MD 20892 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Uniformed Services University of the Health Sciences - USA; University System of Ohio; Ohio State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ringel, MD (corresponding author), Ohio State Univ, Coll Med, Div Endocrinol, 445D McCampbell Hall,1581 Dodd Dr, Columbus, OH 43210 USA.	matthew.ringel@osumc.edu	La Perle, Krista Marie DuBray/B-3099-2015; Saji, Motoyasu/E-4007-2011	Ringel, Matthew/0000-0001-8672-3266	NIH [P01CA124570, R01CA102572]; NATIONAL CANCER INSTITUTE [R01CA102572, P01CA124570] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funding for the work is from NIH grants (P01CA124570 and R01CA102572) to MDR. We appreciate the technical assistance of Michael Ostrowski, John Thompson and Jun Liu.	Chellaiah MA, 2001, J BIOL CHEM, V276, P47434, DOI 10.1074/jbc.M107494200; Chen J, 2010, BLOOD, V115, P4237, DOI 10.1182/blood-2009-11-255323; Chen ML, 2006, GENE DEV, V20, P1569, DOI 10.1101/gad.1395006; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Coulonval K, 2000, BIOCHEM J, V348, P351, DOI 10.1042/0264-6021:3480351; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Dillon RL, 2010, CANCER RES, V70, P4260, DOI 10.1158/0008-5472.CAN-10-0266; Dillon RL, 2009, CANCER RES, V69, P5057, DOI 10.1158/0008-5472.CAN-08-4287; Fernandez-Hernando C, 2009, ARTERIOSCL THROM VAS, V29, P2033, DOI 10.1161/ATVBAHA.109.196394; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Furuya F, 2006, P NATL ACAD SCI USA, V103, P1780, DOI 10.1073/pnas.0510849103; Furuya F, 2007, CARCINOGENESIS, V28, P2451, DOI 10.1093/carcin/bgm174; Gonzalez E, 2009, P NATL ACAD SCI USA, V106, P7004, DOI 10.1073/pnas.0901933106; Guigon CJ, 2010, CARCINOGENESIS, V31, P1284, DOI 10.1093/carcin/bgq059; Heron-Milhavet L, 2006, MOL CELL BIOL, V26, P8267, DOI 10.1128/MCB.00201-06; Hutchinson JN, 2004, CANCER RES, V64, P3171, DOI 10.1158/0008-5472.CAN-03-3465; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Kaneshige M, 2000, P NATL ACAD SCI USA, V97, P13209, DOI 10.1073/pnas.230285997; Kim CS, 2007, ENDOCRINOLOGY, V148, P1306, DOI 10.1210/en.2006-0923; Kim CS, 2009, THYROID, V19, P1317, DOI 10.1089/thy.2009.1609; Kim CS, 2005, ENDOCRINOLOGY, V146, P4456, DOI 10.1210/en.2005-0172; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; Larreaa MD, 2009, P NATL ACAD SCI USA, V106, P9268, DOI 10.1073/pnas.0805057106; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liu H, 2006, P NATL ACAD SCI USA, V103, P4134, DOI 10.1073/pnas.0511342103; Lu CX, 2010, ENDOCRINOLOGY, V151, P1929, DOI 10.1210/en.2009-1017; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; Meng Q, 2006, CELL SIGNAL, V18, P2262, DOI 10.1016/j.cellsig.2006.05.019; Mielnicki LM, 1999, EXP CELL RES, V249, P161, DOI 10.1006/excr.1999.4461; Ni XG, 2008, MOL MED, V14, P582, DOI 10.2119/2008-00020.Ni; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Pohlenz J, 1999, THYROID, V9, P1265, DOI 10.1089/thy.1999.9.1265; Ricarte-Filho JC, 2009, CANCER RES, V69, P4885, DOI 10.1158/0008-5472.CAN-09-0727; Ringel MD, 2001, CANCER RES, V61, P6105; Saito J, 2001, THYROID, V11, P339, DOI 10.1089/10507250152039073; Saji M, 2005, BIOCHEM BIOPH RES CO, V332, P167, DOI 10.1016/j.bbrc.2005.04.109; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Stambolic V, 2006, TRENDS CELL BIOL, V16, P461, DOI 10.1016/j.tcb.2006.07.001; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Tanaka H, 2006, INT J CANCER, V118, P1680, DOI 10.1002/ijc.21559; Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486; Vasko V, 2004, J MED GENET, V41, P161, DOI 10.1136/jmg.2003.015339; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wu FY, 2006, CANCER RES, V66, P2162, DOI 10.1158/0008-5472.CAN-05-3304; Ying H, 2003, CARCINOGENESIS, V24, P1467, DOI 10.1093/carcin/bgg111; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Zhou GL, 2006, J BIOL CHEM, V281, P36443, DOI 10.1074/jbc.M600788200	50	37	37	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	42					4307	4315		10.1038/onc.2011.136	http://dx.doi.org/10.1038/onc.2011.136			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HP	21532616	Green Accepted			2022-12-17	WOS:000296356400002
J	Boulay, PL; Schlienger, S; Lewis-Saravalli, S; Vitale, N; Ferbeyre, G; Claing, A				Boulay, P-L; Schlienger, S.; Lewis-Saravalli, S.; Vitale, N.; Ferbeyre, G.; Claing, A.			ARF1 controls proliferation of breast cancer cells by regulating the retinoblastoma protein	ONCOGENE			English	Article						ADP-ribosylation factor; breast cancer; cell cycle; proliferation; retinoblastoma protein	ADP-RIBOSYLATION FACTOR; CELLULAR SENESCENCE; CYCLIN D1; IN-VIVO; TUMOR SUPPRESSION; ONCOGENIC RAS; ACTIVATION; PATHWAY; GENE; INHIBITION	The ADP-ribosylation factors (ARFs) 1 and 6 are small GTP-binding proteins, highly expressed and activated in several breast cancer cell lines and are associated with enhanced migration and invasiveness. In this study, we report that ARF1 has a critical role in cell proliferation. Depletion of this GTPase or expression of a dominant negative form, which both resulted in diminished ARF1 activity, led to sustained cell-growth arrest. This cellular response was associated with the induction of senescent markers in highly invasive breast cancer cells as well as in control mammary epithelial cells by a mechanism regulating retinoblastoma protein (pRB) function. When examining the role of ARF1, we found that this GTPase was highly activated in normal proliferative conditions, and that a limited amount could be found in the nucleus, associated with the chromatin of MDA-MB-231 cells. However, when cells were arrested in the G(0)/G(1) phase or transfected with a dominant negative form of ARF1, the total level of activated ARF1 was markedly reduced and the GTPase significantly enriched in the chromatin. Using biochemical approaches, we demonstrated that the GDP-bound form of ARF1 directly interacted with pRB, but not other members of this family of proteins. In addition, depletion of ARF1 or expression of ARF1T(31)N resulted in the constitutive association of pRB and E2F1, thereby stabilizing the interaction of E2F1 as well as pRB at endogenous sites of target gene promoters, preventing expression of E2F target genes, such as cyclin D1, Mcm6 and E2F1, important for cell-cycle progression. These novel findings provide direct physiological and molecular evidence for the role of ARF1 in controlling cell proliferation, dependent on its ability to regulate pRB/E2F1 activity and gene expression for enhanced proliferation and breast cancer progression. Oncogene (2011) 30, 3846-3861; doi:10.1038/onc.2011.100; published online 11 April 2011	[Boulay, P-L; Schlienger, S.; Lewis-Saravalli, S.; Claing, A.] Univ Montreal, Fac Med, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada; [Ferbeyre, G.; Claing, A.] Univ Montreal, Fac Med, Dept Biochem, Montreal, PQ H3C 3J7, Canada; [Vitale, N.] Univ Strasbourg, Inst Neurosci Cellulaires & Integrat, CNRS, Unite Propre Rech 3212, Strasbourg, France	Universite de Montreal; Universite de Montreal; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Claing, A (corresponding author), Univ Montreal, Fac Med, Dept Pharmacol, POB 6128, Montreal, PQ H3C 3J7, Canada.	audrey.claing@umontreal.ca	Ferbeyre, Gerardo/A-1569-2010; Vitale, Nicolas/G-5967-2014	Vitale, Nicolas/0000-0002-4752-4907; Ferbeyre, Gerardo/0000-0002-2146-618X	Canadian Institutes of Health Research (CIHR) [MOP-79470]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	We would like to thank Dr Tony Kouzarides (The Gurdon Institute, University of Cambridge, UK) for GST-pRB. We thank Raphaelle Lambert from genomic platform of IRIC (Montreal, Canada). We are grateful to Dr Christian Beausejour (University of Montreal, Montreal, Canada) for reagents and helpful discussion. We thank Dr Stephane A Laporte (McGill University, Montreal, Canada) for the use of his confocal microscope and Dr Denis de Blois and Julie-Emilie Huot-Marchand (University of Montreal, Montreal, Canada) for the use of their photo-microscopy plateform. We thank Dr Veronique Bourdeau (University of Montreal, Montreal, Canada) for helpful discussion and critical reading of the paper. This work was supported by the Canadian Institutes of Health Research (CIHR) grant MOP-79470 to AC. PLB is the recipient of a Frederick Banting and Charles Best PhD Research Award from the CIHR. AC is the recipient of a New Investigator Award from the CIHR.	Altan-Bonnet N, 2003, P NATL ACAD SCI USA, V100, P13314, DOI 10.1073/pnas.2234055100; Azab AK, 2009, BLOOD, V114, P619, DOI 10.1182/blood-2009-01-199281; Bartholomew JN, 2009, CANCER RES, V69, P2878, DOI 10.1158/0008-5472.CAN-08-2857; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Boulay PL, 2008, J BIOL CHEM, V283, P36425, DOI 10.1074/jbc.M803603200; Boyer SN, 1996, CANCER RES, V56, P4620; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Cohen LA, 2007, MOL BIOL CELL, V18, P2244, DOI 10.1091/mbc.E06-11-0998; Cotton M, 2007, MOL BIOL CELL, V18, P501, DOI 10.1091/mbc.E06-06-0567; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DIMRI GP, 1994, COLD SPRING HARB SYM, V59, P67, DOI 10.1101/SQB.1994.059.01.010; Dubois T, 2003, BIOCHEM BIOPH RES CO, V301, P502, DOI 10.1016/S0006-291X(02)03010-3; Dunphy JL, 2007, TRAFFIC, V8, P661, DOI 10.1111/j.1600-0854.2007.00561.x; DURO D, 1995, ONCOGENE, V11, P21; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Hafner M, 2006, NATURE, V444, P941, DOI 10.1038/nature05415; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Houndolo T, 2005, J BIOL CHEM, V280, P5598, DOI 10.1074/jbc.M411456200; Hui R, 2000, CLIN CANCER RES, V6, P2777; Larreaa MD, 2009, P NATL ACAD SCI USA, V106, P9268, DOI 10.1073/pnas.0805057106; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lin CY, 2002, J CELL SCI, V115, P4433, DOI 10.1242/jcs.00123; Mallette FA, 2007, CELL CYCLE, V6, P1831, DOI 10.4161/cc.6.15.4516; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Miller CL, 2007, MOL CELL PROTEOMICS, V6, P1027, DOI 10.1074/mcp.M700056-MCP200; Mitchell R, 2003, J BIOL CHEM, V278, P33818, DOI 10.1074/jbc.M305825200; Motti ML, 2005, AM J PATHOL, V166, P737, DOI 10.1016/S0002-9440(10)62295-X; Mythreye K, 2009, P NATL ACAD SCI USA, V106, P8221, DOI 10.1073/pnas.0812879106; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Narita Y, 2002, CANCER RES, V62, P6764; NEVINS JR, 1991, COLD SH Q B, V56, P157; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1999, ONCOGENE, V18, P2299, DOI 10.1038/sj.onc.1202544; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Padilla PI, 2008, P NATL ACAD SCI USA, V105, P3357, DOI 10.1073/pnas.0712387105; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Roninson IB, 2003, J CELL BIOCHEM, V88, P83, DOI 10.1002/jcb.10320; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SOULE HD, 1990, CANCER RES, V50, P6075; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; Sullivan R, 2008, MOL CANCER THER, V7, P1961, DOI 10.1158/1535-7163.MCT-08-0198; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; Takahashi Y, 2000, GENE DEV, V14, P804; Takano Y, 1999, J CANCER RES CLIN, V125, P505, DOI 10.1007/s004320050309; Tonic I, 2010, J BIOL CHEM, V285, P23790, DOI 10.1074/jbc.M110.104372; Vernier M, 2011, GENE DEV, V25, P41, DOI 10.1101/gad.1975111; Viaud J, 2007, P NATL ACAD SCI USA, V104, P10370, DOI 10.1073/pnas.0700773104; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu D, 2009, ONCOGENE, V28, P2219, DOI 10.1038/onc.2009.96; YAGATA H, 2011, BREAST CANC; Yakes FM, 2002, CANCER RES, V62, P4132; Yudin D, 2009, J CELL SCI, V122, P587, DOI 10.1242/jcs.015289; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	62	37	37	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	36					3846	3861		10.1038/onc.2011.100	http://dx.doi.org/10.1038/onc.2011.100			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	817PV	21478909				2022-12-17	WOS:000294687200003
J	Chen, LP; Lai, YD; Li, DC; Zhu, XN; Yang, P; Li, WX; Zhu, W; Zhao, J; Li, XD; Xiao, YM; Zhang, Y; Xing, XM; Wang, Q; Zhang, B; Lin, YC; Zeng, JL; Zhang, SX; Liu, CX; Li, ZF; Zeng, XW; Lin, ZN; Zhuang, ZX; Chen, W				Chen, L-P; Lai, Y-D; Li, D-C; Zhu, X-N; Yang, P.; Li, W-X; Zhu, W.; Zhao, J.; Li, X-D; Xiao, Y-M; Zhang, Y.; Xing, X-M; Wang, Q.; Zhang, B.; Lin, Y-C; Zeng, J-L; Zhang, S-X; Liu, C-X; Li, Z-F; Zeng, X-W; Lin, Z-N; Zhuang, Z-X; Chen, W.			alpha 4 is highly expressed in carcinogen-transformed human cells and primary human cancers	ONCOGENE			English	Article						alpha 4; protein phosphatase 2A; cell transformation; human cancers	PROTEIN PHOSPHATASE 2A; SENSITIVE SIGNAL-TRANSDUCTION; TUMOR-SUPPRESSOR PP2A; CATALYTIC SUBUNIT; UBIQUITIN LIGASE; BINDING PROTEIN; OPITZ-SYNDROME; A-ALPHA; TARGETS; GROWTH	A regulator of the protein phosphatase 2A (PP2A), alpha 4, has been implicated in a variety of functions that regulate many cellular processes. To explore the role of alpha 4 in human cell transformation and tumorigenesis, we show that alpha 4 is highly expressed in human cells transformed by chemical carcinogens including benzo(a) pyrene, aflatoxin B(1), N-methyl-N'-nitro- N-nitrosoguanidine, nickel sulfate and in several hepatic and lung cancer cell lines. In addition, overexpression of a4 was detected in 87.5% (74/80) of primary hepatocellular carcinomas, 84.0% (21/25) of primary lung cancers and 81.8% (9/11) of primary breast cancers, indicating that a4 is ubiquitously highly expressed in human cancer. Functional studies revealed that elevated alpha 4 expression results in an increase in cell proliferation, promotion of cell survival and decreased PP2A-attributable activity. Importantly, ectopic expression of alpha 4 permits non-transformed human embryonic kidney cells (HEKTER) and L02R cells to form tumors in immunodeficient mice. Furthermore, we show that the highly expressed alpha 4 in transformed cells or human tumors is not regulated by DNA hypomethylation. A microRNA, miR-34b, that suppresses the expression of alpha 4 through specific binding to the 3'-untranslated region of alpha 4 is downregulated in transformed or human lung tumors. Taken together, these observations identify that alpha 4 possesses an oncogenic function. Reduction of PP2A activity due to an enhanced alpha 4-PP2A interaction contributes directly to chemical carcinogen-induced tumorigenesis. Oncogene (2011) 30, 2943-2953; doi:10.1038/onc.2011.20; published online 21 February 2011	[Chen, L-P; Lai, Y-D; Li, D-C; Zhu, X-N; Yang, P.; Li, W-X; Xiao, Y-M; Xing, X-M; Wang, Q.; Zhang, B.; Lin, Y-C; Zeng, J-L; Zhang, S-X; Liu, C-X; Li, Z-F; Zeng, X-W; Lin, Z-N; Zhuang, Z-X; Chen, W.] Sun Yat Sen Univ, Sch Publ Hlth, Guangdong Prov Key Lab Food Nutr & Hlth, Dept Toxicol,Fac Prevent Med, Guangzhou 510080, Guangdong, Peoples R China; [Lai, Y-D] Guangzhou Med Coll, Inst Chem Carcinogenesis, Guangzhou, Guangdong, Peoples R China; [Li, W-X; Zhu, W.] Guangzhou Ctr Dis Control, Unit Toxicol, Guangzhou, Guangdong, Peoples R China; [Zhao, J.] Guangzhou Med Univ, Affiliated Canc Hosp, Dept Thorac Surg, Guangzhou, Guangdong, Peoples R China; [Li, X-D] Sun Yat Sen Univ, Ctr Canc, Dept Thorac Surg, Guangzhou 510275, Guangdong, Peoples R China; [Zhang, Y.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, Guangzhou 510275, Guangdong, Peoples R China; [Zhuang, Z-X] Shenzhen Ctr Dis Control & Prevent, Dept Toxicol, Shenzhen, Peoples R China	Sun Yat Sen University; Guangzhou Medical University; Guangzhou Medical University; Sun Yat Sen University; Sun Yat Sen University; Shenzhen Center for Disease Control & Prevention (SZCDC)	Chen, W (corresponding author), Sun Yat Sen Univ, Sch Publ Hlth, Guangdong Prov Key Lab Food Nutr & Hlth, Dept Toxicol,Fac Prevent Med, 74 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.	chenwen@mail.sysu.edu.cn	ZHANG, BO/K-4561-2013; li, wenxue/K-7505-2014	ZHANG, BO/0000-0002-6352-1757; li, wenxue/0000-0002-0346-5300	NSFC [30925029, 30630055, 30800930, 30771832, 30901211]; National Key Basic Research and Development Program [2010CB912803]; National High Technology Research and Development Key Program of China [2008AA062504]; Ministry of Health of China [200902006]; Fundamental Research Funds for the Central Universities [10ykjc05, 10lgzd10]; Guangdong Province Universities and Colleges Pearl River	NSFC(National Natural Science Foundation of China (NSFC)); National Key Basic Research and Development Program(National Basic Research Program of China); National High Technology Research and Development Key Program of China(National High Technology Research and Development Program of China); Ministry of Health of China; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Guangdong Province Universities and Colleges Pearl River	We thank Dr Richard Possemato for critical reading of the manuscript. This work was supported by a Distinguished Young Scholar of NSFC (30925029), Key Program of NSFC (30630055) and NSFC (30800930, 30771832, 30901211), National Key Basic Research and Development Program (2010CB912803), National High Technology Research and Development Key Program of China (2008AA062504), Ministry of Health of China (200902006), the Fundamental Research Funds for the Central Universities (10ykjc05 and 10lgzd10) and Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme GDUPS (2010).	Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Bielinski VA, 2007, EXP CELL RES, V313, P3117, DOI 10.1016/j.yexcr.2007.05.008; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2005, CANCER RES, V65, P8183, DOI 10.1158/0008-5472.CAN-05-1103; Colella S, 2001, INT J CANCER, V93, P798, DOI 10.1002/ijc.1423; Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585; Smetana JHC, 2006, BBA-PROTEINS PROTEOM, V1764, P724, DOI 10.1016/j.bbapap.2006.01.018; Deichmann M, 2001, MELANOMA RES, V11, P577, DOI 10.1097/00008390-200112000-00004; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Dowling RJO, 2010, BBA-PROTEINS PROTEOM, V1804, P433, DOI 10.1016/j.bbapap.2009.12.001; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Gibbons James J, 2009, Semin Oncol, V36 Suppl 3, pS3, DOI 10.1053/j.seminoncol.2009.10.011; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; Inui S, 1998, BLOOD, V92, P539, DOI 10.1182/blood.V92.2.539.414k23_539_546; Irigaray P, 2010, CARCINOGENESIS, V31, P135, DOI 10.1093/carcin/bgp252; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Ji WD, 2008, CARCINOGENESIS, V29, P1267, DOI 10.1093/carcin/bgn012; Kong M, 2004, SCIENCE, V306, P695, DOI 10.1126/science.1100537; Kong M, 2007, J BIOL CHEM, V282, P29712, DOI 10.1074/jbc.M703159200; Kong M, 2009, MOL CELL, V36, P51, DOI 10.1016/j.molcel.2009.09.025; Liu J, 2001, P NATL ACAD SCI USA, V98, P6650, DOI 10.1073/pnas.111154698; Ma Ru-lin, 2008, Zhonghua Yufang Yixue Zazhi, V42, P395; McConnell JL, 2010, BIOCHEMISTRY-US, V49, P1713, DOI 10.1021/bi901837h; McDonald WJ, 2010, J CELL BIOCHEM, V110, P1123, DOI 10.1002/jcb.22624; Meric-Bernstam F, 2009, J CLIN ONCOL, V27, P2278, DOI 10.1200/JCO.2008.20.0766; Mumby M, 2007, CELL, V130, P21, DOI 10.1016/j.cell.2007.06.034; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Onda M, 1997, GENOMICS, V46, P373, DOI 10.1006/geno.1997.5048; Pang YQ, 2008, TOXICOL APPL PHARM, V232, P478, DOI 10.1016/j.taap.2008.08.009; Pigazzi M, 2009, CANCER RES, V69, P2471, DOI 10.1158/0008-5472.CAN-08-3404; Prickett TD, 2007, MOL CELL BIOL, V27, P4217, DOI 10.1128/MCB.00067-07; Sablina AA, 2007, CELL, V129, P969, DOI 10.1016/j.cell.2007.03.047; Shouse GP, 2010, ONCOGENE, V29, P3933, DOI 10.1038/onc.2010.161; Trockenbacher A, 2001, NAT GENET, V29, P287, DOI 10.1038/ng762; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Wang B, 2008, CELL RES, V18, P974, DOI 10.1038/cr.2008.274; Westermarck J, 2008, TRENDS MOL MED, V14, P152, DOI 10.1016/j.molmed.2008.02.001; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang J, 2007, BIOCHEMISTRY-US, V46, P8807, DOI 10.1021/bi7007118; Yorimitsu T, 2009, AUTOPHAGY, V5, P616, DOI 10.4161/auto.5.5.8091; Zhang YY, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000438	44	37	41	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	26					2943	2953		10.1038/onc.2011.20	http://dx.doi.org/10.1038/onc.2011.20			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	785QZ	21339737				2022-12-17	WOS:000292245100005
J	Kochert, K; Ullrich, K; Kreher, S; Aster, JC; Kitagawa, M; Johrens, K; Anagnostopoulos, I; Jundt, F; Lamprecht, B; Zimber-Strobl, U; Stein, H; Janz, M; Dorken, B; Mathas, S				Koechert, K.; Ullrich, K.; Kreher, S.; Aster, J. C.; Kitagawa, M.; Joehrens, K.; Anagnostopoulos, I.; Jundt, F.; Lamprecht, B.; Zimber-Strobl, U.; Stein, H.; Janz, M.; Doerken, B.; Mathas, S.			High-level expression of Mastermind-like 2 contributes to aberrant activation of the NOTCH signaling pathway in human lymphomas	ONCOGENE			English	Article						Mastermind-like; NOTCH; lymphoma; Hodgkin	ACUTE LYMPHOBLASTIC-LEUKEMIA; CLASSICAL HODGKIN LYMPHOMA; TRANSCRIPTION FACTOR E2A; NEOPLASTIC B-CELLS; STERNBERG CELLS; HUMAN HOMOLOG; COMPLEX; COACTIVATORS; RESISTANCE; INHIBITION	Inappropriate activation of the NOTCH signaling pathway, for example, by activating mutations, contributes to the pathogenesis of various human malignancies. Here, we demonstrate that aberrant expression of an essential NOTCH coactivator of the Mastermind-like (MAML) family provides an alternative mechanism to activate NOTCH signaling in human lymphoma cells. We detected high-level MAML2 expression in several B cell-derived lymphoma types, including classical Hodgkin lymphoma (cHL) cells, relative to normal B cells. Inhibition of MAML-protein activity by a dominant negative form of MAML or by small hairpin RNAs targeting MAML2 in cHL cells resulted in downregulation of the NOTCH target genes HES7 and HEY1, which we identified as overexpressed in cHL cells, and in reduced proliferation. Furthermore, a NOTCH gene-expression signature in cHL cells confirmed their cell-autonomous NOTCH activity. Finally, in line with the essential role of MAML proteins for assembly and activity of the NOTCH transcriptional complex (NTC), we show that MAML-derived small-peptide constructs block NOTCH activity and disrupt NTC formation in vitro. These data strongly suggest direct targeting of the NTC as treatment strategy for NOTCH-dependent malignancies. Oncogene (2011) 30, 1831-1840; doi:10.1038/onc.2010.544; published online 29 November 2010	[Koechert, K.; Ullrich, K.; Kreher, S.; Jundt, F.; Lamprecht, B.; Janz, M.; Doerken, B.; Mathas, S.] Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; [Koechert, K.; Ullrich, K.; Kreher, S.; Jundt, F.; Lamprecht, B.; Janz, M.; Doerken, B.; Mathas, S.] Charite, CVK, D-13125 Berlin, Germany; [Aster, J. C.; Stein, H.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Kitagawa, M.] Chiba Univ, Grad Sch Med, Dept Mol & Tumor Pathol, Chiba, Japan; [Joehrens, K.; Anagnostopoulos, I.] Charite, Inst Pathol, D-13125 Berlin, Germany; [Zimber-Strobl, U.] German Res Ctr Environm Hlth, Helmholtz Ctr Munich, Dept Gene Vectors, Munich, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Harvard University; Brigham & Women's Hospital; Chiba University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Mathas, S (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.	stephan.mathas@charite.de	Zimber-Strobl, Ursula/M-4618-2014; Jundt, Franziska/E-9748-2014; Mathas, Stephan/I-5589-2015	Zimber-Strobl, Ursula/0000-0002-9765-5251; Jundt, Franziska/0000-0002-8661-7110; Kochert, Karl/0000-0002-5548-2022; Kitagawa, Motoo/0000-0003-1036-840X; Janz, Martin/0000-0002-1127-0044	Deutsche Forschungsgemeinschaft; Berliner Krebsgesellschaft; Wilhelm Sander-Stiftung	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Berliner Krebsgesellschaft; Wilhelm Sander-Stiftung	We thank Caroline Gartner (Berlin), Melanie Manzke (Berlin) and Simone Kressmann (Berlin) for outstanding technical assistance, and Peter Rahn (Berlin) for cell sorting. We thank Raphael Kopan (Washington) for the Hes1-pGL2 reporter construct, Lizi Wu (Gainesville, Florida) for the MAML3 expression construct, Karin Zimmermann (Berlin) and Ulf Leser (Berlin) for helpful suggestions in regard to gene set analysis, and Ariane Buchal and Benedikt Sedlmaier (both Berlin, Germany) for providing human tonsil material. This work was supported in part by grants from the Deutsche Forschungsgemeinschaft, the Berliner Krebsgesellschaft and the Wilhelm Sander-Stiftung.	Bessho Y, 2001, GENES CELLS, V6, P175, DOI 10.1046/j.1365-2443.2001.00409.x; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Del Bianco C, 2008, J MOL BIOL, V376, P131, DOI 10.1016/j.jmb.2007.11.061; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Janz M, 2006, BLOOD, V107, P2536, DOI 10.1182/blood-2005-07-2694; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; Jin BF, 2010, J BIOL CHEM, V285, P14356, DOI 10.1074/jbc.M109.078865; Jundt F, 2008, LEUKEMIA, V22, P1587, DOI 10.1038/leu.2008.101; Jundt F, 2004, BLOOD, V103, P3511, DOI 10.1182/blood-2003-07-2254; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Kapp U, 1999, J EXP MED, V189, P1939, DOI 10.1084/jem.189.12.1939; Koch U, 2007, CELL MOL LIFE SCI, V64, P2746, DOI 10.1007/s00018-007-7164-1; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Lee SY, 2009, CANCER SCI, V100, P920, DOI 10.1111/j.1349-7006.2009.01130.x; Li XY, 2008, J EXP MED, V205, P2851, DOI 10.1084/jem.20081561; Lietz A, 2007, BRIT J HAEMATOL, V137, P342, DOI 10.1111/j.1365-2141.2007.06583.x; Lin SE, 2002, J BIOL CHEM, V277, P50612, DOI 10.1074/jbc.M209529200; Lubman OY, 2007, J MOL BIOL, V365, P577, DOI 10.1016/j.jmb.2006.09.071; Maillard I, 2004, BLOOD, V104, P1696, DOI 10.1182/blood-2004-02-0514; Mathas S, 2006, NAT IMMUNOL, V7, P207, DOI 10.1038/ni1285; McElhinny AS, 2008, ONCOGENE, V27, P5138, DOI 10.1038/onc.2008.228; Moellering RE, 2009, NATURE, V462, P182, DOI 10.1038/nature08543; Murre C, 2005, NAT IMMUNOL, V6, P1079, DOI 10.1038/ni1260; Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037; Nam Y, 2003, J BIOL CHEM, V278, P21232, DOI 10.1074/jbc.M301567200; Nie L, 2003, EMBO J, V22, P5780, DOI 10.1093/emboj/cdg567; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Oyama T, 2007, P NATL ACAD SCI USA, V104, P9764, DOI 10.1073/pnas.0700240104; Rosati E, 2009, BLOOD, V113, P856, DOI 10.1182/blood-2008-02-139725; STANELLE J, 2010, BLOOD, DOI DOI 10.1182/BLOOD2010-01-265827; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wilson JJ, 2006, CELL, V124, P985, DOI 10.1016/j.cell.2006.01.035; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Wu L, 2007, BLOOD, V110, P3618, DOI 10.1182/blood-2007-06-097030; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644	41	37	38	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	15					1831	1840		10.1038/onc.2010.544	http://dx.doi.org/10.1038/onc.2010.544			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM	21119597				2022-12-17	WOS:000289512200010
J	Hagner, PR; Mazan-Mamczarz, K; Dai, B; Balzer, EM; Corl, S; Martin, SS; Zhao, XF; Gartenhaus, RB				Hagner, P. R.; Mazan-Mamczarz, K.; Dai, B.; Balzer, E. M.; Corl, S.; Martin, S. S.; Zhao, X. F.; Gartenhaus, R. B.			Ribosomal protein S6 is highly expressed in non-Hodgkin lymphoma and associates with mRNA containing a 5 ' terminal oligopyrimidine tract	ONCOGENE			English	Article						RPS6; diffuse large B-cell lymphoma; 5 ' terminal oligopyrimidine; p53	TRANSLATIONAL CONTROL; P53 EXPRESSION; PHOSPHORYLATION; GENE; PATHWAY; CANCER; TRANSDUCTION; ACTIVATION; INDUCTION; CARCINOMA	The molecular mechanism(s) linking tumorigenesis and morphological alterations in the nucleolus are presently coming into focus. The nucleolus is the cellular organelle in which the formation of ribosomal subunits occurs. Ribosomal biogenesis occurs through the transcription of ribosomal RNA (rRNA), rRNA processing and production of ribosomal proteins. An error in any of these processes may lead to deregulated cellular translation, evident in multiple cancers and 'ribosomopathies'. Deregulated protein synthesis may be achieved through the overexpression of ribosomal proteins as seen in primary leukemic blasts with elevated levels of ribosomal proteins S11 and S14. In this study, we demonstrate that ribosomal protein S6 (RPS6) is highly expressed in primary diffuse large B-cell lymphoma (DLBCL) samples. Genetic modulation of RPS6 protein levels with specifically targeted short hairpin RNA (shRNA) lentiviruses led to a decrease in the actively proliferating population of cells compared with control shRNA. Low-dose rapamycin treatments have been shown to affect the translation of 5' terminal oligopyrimidine (5' TOP) tract mRNA, which encodes the translational machinery, implicating RPS6 in 5' TOP translation. Recently, it was shown that disruption of 40S ribosomal biogenesis through specific small inhibitory RNA knockdown of RPS6 defined RPS6 as a critical regulator of 5' TOP translation. For the first time, we show that RPS6 associates with multiple mRNAs containing a 5' TOP tract. These findings expand our understanding of the mechanism(s) involved in ribosomal biogenesis and deregulated protein synthesis in DLBCL. Oncogene (2011) 30, 1531-1541; doi: 10.1038/onc.2010.533; published online 22 November 2010	[Hagner, P. R.; Mazan-Mamczarz, K.; Dai, B.; Balzer, E. M.; Corl, S.; Martin, S. S.; Zhao, X. F.; Gartenhaus, R. B.] Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, Dept Med, Baltimore, MD 21201 USA; [Hagner, P. R.] Harvard Univ, Sch Med, Dept Biochem & Mol Pharmacol, Boston, MA USA; [Gartenhaus, R. B.] Vet Adm Med Ctr, Baltimore, MD 21218 USA	University System of Maryland; University of Maryland Baltimore; Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Gartenhaus, RB (corresponding author), Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Canc Ctr, Dept Med, 9-011 BRB,655 W Baltimore St,22 S Greene St, Baltimore, MD 21201 USA.	rgartenhaus@som.umaryland.edu			Department of Veterans Affairs; National Institutes of Health [R01AA017972]; NATIONAL CANCER INSTITUTE [P30CA134274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA017972] Funding Source: NIH RePORTER	Department of Veterans Affairs(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	The WT-RPS16-hGH and Cm5-RPS16-hGH constructs that contain the coding region of hGH fused to the first 29 nucleotides of the RPS16 5' untranslated region (WT-RPS16-hGH) or to the mutant in which five of the eight pyrimidines within the 5' TOP have been mutated to purines (Cm5) were kindly provided by the laboratories of Dr Oded Meyuhas and Dr George Thomas, This work was funded in part by a Merit Review Award from the Department of Veterans Affairs (RBG) and R01AA017972 from the National Institutes of Health (RBG).	Avni D, 1997, NUCLEIC ACIDS RES, V25, P995, DOI 10.1093/nar/25.5.995; Badis G, 2004, MOL CELL, V15, P5, DOI 10.1016/j.molcel.2004.06.028; Dai BJ, 2006, CANCER RES, V66, P8058, DOI 10.1158/0008-5472.CAN-06-1364; Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951; Espinosa L, 1997, BBA-GENE STRUCT EXPR, V1354, P58, DOI 10.1016/S0167-4781(97)00124-3; Fatica A, 2002, CURR OPIN CELL BIOL, V14, P313, DOI 10.1016/S0955-0674(02)00336-8; FERRARI S, 1990, CANCER RES, V50, P5825; Fewell SW, 1999, MOL CELL BIOL, V19, P826; FRANCO R, 1990, J BIOL CHEM, V265, P4321; FRIGERIO JM, 1995, BBA-GENE STRUCT EXPR, V1262, P64, DOI 10.1016/0167-4781(95)00045-I; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Galban S, 2003, MOL CELL BIOL, V23, P7083, DOI 10.1128/MCB.23.20.7083-7095.2003; Ganapathi KA, 2008, BRIT J HAEMATOL, V141, P376, DOI 10.1111/j.1365-2141.2008.07095.x; GROSS T, 1988, CURR GENET, V13, P57, DOI 10.1007/BF00365757; Iadevaia V, 2008, RNA, V14, P1730, DOI 10.1261/rna.1037108; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Kapasi P, 2007, MOL CELL, V25, P113, DOI 10.1016/j.molcel.2006.11.028; Koduru PRK, 1997, BLOOD, V90, P4078, DOI 10.1182/blood.V90.10.4078; Kondoh N, 2001, ANTICANCER RES, V21, P2429; Law PTW, 1996, BBA-GENE STRUCT EXPR, V1305, P105, DOI 10.1016/0167-4781(95)00224-3; Lee-Fruman KK, 1999, ONCOGENE, V18, P5108, DOI 10.1038/sj.onc.1202894; Lerner RS, 2003, RNA, V9, P1123, DOI 10.1261/rna.5610403; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; Mazan-Mamczarz K, 2008, ONCOGENE, V27, P6151, DOI 10.1038/onc.2008.215; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Mitrovich QM, 2000, GENE DEV, V14, P2173, DOI 10.1101/gad.819900; Nakamura JL, 2008, CANCER RES, V68, P6516, DOI 10.1158/0008-5472.CAN-07-6188; NYGARD O, 1990, EUR J BIOCHEM, V191, P1, DOI 10.1111/j.1432-1033.1990.tb19087.x; Ofir-Rosenfeld Y, 2008, MOL CELL, V32, P180, DOI 10.1016/j.molcel.2008.08.031; Patursky-Polischuk I, 2009, MOL CELL BIOL, V29, P640, DOI 10.1128/MCB.00980-08; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Perry RP, 2007, GENE, V401, P1, DOI 10.1016/j.gene.2007.07.007; Pianese G., 1896, BEITR PATHOL ANAT AL, V142, P1; Reinert LS, 2006, CANCER RES, V66, P8994, DOI 10.1158/0008-5472.CAN-06-1999; ROMMENS JM, 1995, GENOMICS, V28, P530, DOI 10.1006/geno.1995.1185; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Ruvinsky I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005618; Sanchez-Beato M, 2003, BLOOD, V101, P1220, DOI 10.1182/blood-2002-07-2009; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Vladimirov SN, 1996, EUR J BIOCHEM, V239, P144, DOI 10.1111/j.1432-1033.1996.0144u.x; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; WATSON KL, 1992, P NATL ACAD SCI USA, V89, P11302, DOI 10.1073/pnas.89.23.11302	47	37	38	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	13					1531	1541		10.1038/onc.2010.533	http://dx.doi.org/10.1038/onc.2010.533			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	743DU	21102526	Green Accepted			2022-12-17	WOS:000288998300004
J	Sugano, G; Bernard-Pierrot, I; Lae, M; Battail, C; Allory, Y; Stransky, N; Krumeich, S; Lepage, ML; Maille, P; Donnadieu, MH; Abbou, CC; Benhamou, S; Lebret, T; Sastre-Garau, X; Amigorena, S; Radvanyi, F; Thery, C				Sugano, G.; Bernard-Pierrot, I.; Lae, M.; Battail, C.; Allory, Y.; Stransky, N.; Krumeich, S.; Lepage, M-L; Maille, P.; Donnadieu, M-H; Abbou, C. C.; Benhamou, S.; Lebret, T.; Sastre-Garau, X.; Amigorena, S.; Radvanyi, F.; Thery, C.			Milk fat globule-epidermal growth factor-factor VIII (MFGE8)/lactadherin promotes bladder tumor development	ONCOGENE			English	Article						MFGE8; lactadherin; bladder carcinoma; tumor microenvironment; immune response	DISCOIDIN-DOMAIN PROTEIN; APOPTOTIC CELLS; EGF REPEAT; LACTADHERIN; CANCER; CARCINOGENESIS; MOUSE; PROGRESSION; MODEL; MICE	Milk fat globule-epidermal growth factor-factor VIII (MFGE8), also called lactadherin or SED1, is a secreted integrin-binding protein that promotes elimination of apoptotic cells by phagocytes leading to tolerogenic immune responses, and vascular endothelial growth factor (VEGF)induced angiogenesis: two important processes for cancer development. Here, by transcriptomic analysis of 228 biopsies of bladder carcinomas, we observed overexpression of MFGE8 during tumor development, correlated with expression of genes involved in cell adhesion or migration and in immune responses, but not in VEGF-mediated angiogenesis. To test whether MFGE8 expression was instrumental in bladder tumor development, or a simple consequence of this development, we used genetic ablation in a mouse model of carcinogen-induced bladder carcinoma. We showed that Mfge8 was also upregulated in mouse carcinoma, and that in its absence, Mfge8-deficient animals developed less advanced tumors. Angiogenesis was similar in carcinogen-treated Mfge8-expressing or -deficient bladders, thus ruling out a major role of the proangiogenic function of Mfge8 for its protumoral role. By contrast, the tumor-promoting role of Mfge8 was not observed anymore in mice devoid of adaptive immune system, and human tumors overexpressing MFGE8 where invaded with macrophages and regulatory T cells, thus suggesting that MFGE8/lactadherin favors development of bladder tumors at least partly by an immune system-dependent mechanism. Our observations suggest future use of MFGE8-inhibiting molecules as therapies of bladder carcinomas, and of a limited number of other human cancers, in which our analysis of public databases also revealed overexpression of MFGE8. Oncogene (2011) 30, 642-653; doi:10.1038/onc.2010.446; published online 18 October 2010	[Sugano, G.; Krumeich, S.; Amigorena, S.; Thery, C.] Inst Curie, Res Ctr, INSERM, U932, F-75248 Paris 05, France; [Bernard-Pierrot, I.; Battail, C.; Stransky, N.; Lepage, M-L; Radvanyi, F.] CNRS, UMR144, Paris, France; [Lae, M.; Amigorena, S.] Inst Curie Hosp, Dept Tumor Biol, Paris, France; [Allory, Y.; Abbou, C. C.] Hop Henri Mondor, INSERM, U955, F-94010 Creteil, France; [Allory, Y.; Abbou, C. C.] AP HP Henri Mondor Albert Chenevier Grp, Dept Urol, Creteil, France; [Allory, Y.; Maille, P.] AP HP Henri Mondor Albert Chenevier Grp, Dept Pathol, Creteil, France; [Donnadieu, M-H] Inst Curie Hosp, Dept Translat Res, Paris, France; [Abbou, C. C.] Univ Paris 12, Fac Med, Creteil, France; [Benhamou, S.] INSERM, U946, Fdn Jean Dausset, CEPH, Paris, France; [Benhamou, S.] Inst Gustave Roussy, CNRS, FRE 2939, Villejuif, France; [Lebret, T.] Hop Foch, Dept Urol, Suresnes, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Foundation Jean Dausset-CEPH; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Hospital Foch	Thery, C (corresponding author), Inst Curie, Res Ctr, INSERM, U932, 26 Rue Ulm, F-75248 Paris 05, France.	clotilde.thery@curie.fr	thery, clotilde/F-6373-2013; Benhamou, Simone/ABD-2590-2020; Benhamou, Simone/K-6554-2015	thery, clotilde/0000-0001-8294-6884; Radvanyi, Francois/0000-0002-5696-6424; Sastre-Garau, Xavier/0000-0001-5992-2083; Amigorena, Sebastian/0000-0001-8583-8416; Sugano, Gael/0000-0002-9520-7375; Battail, Christophe/0000-0001-6849-7824; BENHAMOU, Simone/0000-0001-5853-8047	Association pour la Recherche Contre le Cancer; La Ligue Nationale Contre le Cancer (FR: equipe labellisee); program 'Carte d'Identite des Tumeurs', initiated, developed; Ligue Nationale Contre le Cancer; Fondation de France 'Impulsion' program (CT)	Association pour la Recherche Contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); La Ligue Nationale Contre le Cancer (FR: equipe labellisee); program 'Carte d'Identite des Tumeurs', initiated, developed; Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Fondation de France 'Impulsion' program (CT)	We thank Drs A-C Baglin and Y Denoux (Tumorotheque, Service d'Anatomie et Cytologie Pathologiques, CMC Foch, Suresnes, France), Dr M-J Terrier-Lacombe (Service de Pathologie, Institut Gustave Roussy, Villejuif, France), and Professor K Leroy (Plateforme de Ressources Biologiques, Pole de Recherche Clinique, APHP, Hopital Henri Mondor, Creteil, France) for providing tumor samples. Microbiochips SAS (Paris, France) performed and analyzed antibody microarray hybridizations. This work would not have been possible without the expertise of the Animal Facility and of the Nikon Imaging Center at Institut Curie. We thank S Barrafato and F Valenty (mouse histology), K Zemplenyi (ultrasound analyses), E Chapeaublanc (preparation of Supplementary tables), B Asselain and A Savignoni (statistics) for their help, and V Soumelis, H Kitamura and JW Pollard for critical reading of the manuscript. This work was supported by grants from Association pour la Recherche Contre le Cancer and Fondation de France 'Impulsion' program (CT), La Ligue Nationale Contre le Cancer (FR: equipe labellisee), and the program 'Carte d'Identite des Tumeurs', initiated, developed and funded by Ligue Nationale Contre le Cancer. GS was a fellow from Ministere de la Recherche et des Technologies.	Ait-Oufella H, 2007, CIRCULATION, V115, P2168, DOI 10.1161/CIRCULATIONAHA.106.662080; Andersen MH, 2000, BIOCHEMISTRY-US, V39, P6200, DOI 10.1021/bi992221r; Atabai K, 2005, MOL BIOL CELL, V16, P5528, DOI 10.1091/mbc.E05-02-0128; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; BECCI PJ, 1981, CANCER RES, V41, P927; Bu HF, 2007, J CLIN INVEST, V117, P3673, DOI 10.1172/JCI31841; CERIANI RL, 1982, P NATL ACAD SCI-BIOL, V79, P5420, DOI 10.1073/pnas.79.17.5420; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; de Visser KE, 2005, CANCER CELL, V7, P411, DOI 10.1016/j.ccr.2005.04.014; deMedina SGD, 1997, ONCOGENE, V14, P323, DOI 10.1038/sj.onc.1200830; Draghici S, 2007, GENOME RES, V17, P1537, DOI 10.1101/gr.6202607; Eble J, 2004, WHO CLASSIFICATION T; Ensslin MA, 2003, CELL, V114, P405, DOI 10.1016/S0092-8674(03)00643-3; Ensslin MA, 2007, P NATL ACAD SCI USA, V104, P2715, DOI 10.1073/pnas.0610296104; Fens MHAM, 2008, BLOOD, V111, P4542, DOI 10.1182/blood-2007-06-094763; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hanayama R, 2005, P NATL ACAD SCI USA, V102, P16886, DOI 10.1073/pnas.0508599102; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; Jinushi M, 2008, CANCER RES, V68, P8889, DOI 10.1158/0008-5472.CAN-08-2147; Jinushi M, 2007, J CLIN INVEST, V117, P1902, DOI 10.1172/JCI30966; Komura H, 2009, J IMMUNOL, V182, P581, DOI 10.4049/jimmunol.182.1.581; LAROCCA D, 1991, CANCER RES, V51, P4994; MCCORMICK DL, 1981, CARCINOGENESIS, V2, P251, DOI 10.1093/carcin/2.3.251; Nandrot EF, 2007, P NATL ACAD SCI USA, V104, P12005, DOI 10.1073/pnas.0704756104; Neutzner M, 2007, CANCER RES, V67, P6777, DOI 10.1158/0008-5472.CAN-07-0165; Oshima K, 2002, EUR J BIOCHEM, V269, P1209, DOI 10.1046/j.1432-1033.2002.02758.x; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Saint F, 2001, BJU INT, V88, P602, DOI 10.1046/j.1464-410X.2001.02394.x; Sharma P, 2007, SEMIN ONCOL, V34, P165, DOI 10.1053/j.seminoncol.2006.12.004; Shi JL, 2004, BBA-BIOMEMBRANES, V1667, P82, DOI 10.1016/j.bbamem.2004.09.006; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Silvestre JS, 2005, NAT MED, V11, P499, DOI 10.1038/nm1233; Stransky N, 2006, NAT GENET, V38, P1386, DOI 10.1038/ng1923; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; Taylor MR, 1997, DNA CELL BIOL, V16, P861, DOI 10.1089/dna.1997.16.861; Veron P, 2005, BLOOD CELL MOL DIS, V35, P81, DOI 10.1016/j.bcmd.2005.05.001; Williams PD, 2008, NEOPLASIA, V10, P838, DOI 10.1593/neo.08432; Xu L, 2008, MOL CANCER RES, V6, P760, DOI 10.1158/1541-7786.MCR-07-0344	39	37	37	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	6					642	653		10.1038/onc.2010.446	http://dx.doi.org/10.1038/onc.2010.446			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	719GY	20956946				2022-12-17	WOS:000287192000002
J	Wheeler, DS; Barrick, SR; Grubisha, MJ; Brufsky, AM; Friedman, PA; Romero, G				Wheeler, D. S.; Barrick, S. R.; Grubisha, M. J.; Brufsky, A. M.; Friedman, P. A.; Romero, G.			Direct interaction between NHERF1 and Frizzled regulates beta-catenin signaling	ONCOGENE			English	Article						NHERF1; EBP50; breast cancer; Wnt; Frizzled; beta-catenin	PROTEIN-COUPLED-RECEPTORS; HUMAN BREAST-CANCER; CYCLIN D1; EXPRESSION; CELLS; RECOGNITION; ASSOCIATION; ENDOCYTOSIS; PROGNOSIS; MECHANISM	Although Wnt-Frizzled (Fzd) signaling is critical in the pathophysiology of carcinomas, its role in human breast cancer has been difficult to establish. We show here that the adaptor protein Na+/H+ exchange regulatory factor1 (NHERF1), a protein abundantly expressed in normal mammary epithelium, regulates Wnt signaling, maintaining low levels of beta-catenin activation. NHERF1's effects are mediated by direct interactions between one of its PSD-95/drosophila discs large/ZO-1 (PDZ) domains and the C-terminus of a subset of Fzd receptors. Loss of NHERF1 in breast cancer cell lines enhances canonical Wnt signaling and Wnt-dependent cell proliferation. Furthermore, the mammary glands of NHERF1-knockout mice exhibit increased mammary duct density accompanied by increased proliferation and beta-catenin activity. Finally, we demonstrate a negative correlation between NHERF1 expression and nuclear beta-catenin in human breast carcinomas. Taken together, these results provide a novel insight into the regulation of Wnt signaling in normal and neoplastic breast tissues, and identify NHERF1 as an important regulator of the pathogenesis of breast tumors. Oncogene (2011) 30, 32-42; doi: 10.1038/onc.2010.389; published online 30 August 2010	[Wheeler, D. S.; Barrick, S. R.; Grubisha, M. J.; Friedman, P. A.; Romero, G.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Lab GPCR Biol, Pittsburgh, PA 15261 USA; [Wheeler, D. S.; Grubisha, M. J.] Univ Pittsburgh, Sch Med, Med Scientist Training Program, Pittsburgh, PA 15261 USA; [Brufsky, A. M.; Friedman, P. A.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15261 USA; [Brufsky, A. M.; Romero, G.] Univ Pittsburgh, Sch Med, Univ Pittsburgh Canc Inst, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Romero, G (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Lab GPCR Biol, E1355 BST, Pittsburgh, PA 15261 USA.	ggr@pitt.edu	Barrick, Stacey/J-1595-2015; Brufsky, Adam/AAE-7470-2020	Barrick, Stacey/0000-0002-4837-3741; Brufsky, Adam/0000-0001-8080-7960	National Institutes of Health [DK083211, DK079864, DK54171]; Office of the Senior Vice Chancellor for the Health Sciences of the University of Pittsburgh; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK079864, F30DK083211, R01DK054171, R01DK069998] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Office of the Senior Vice Chancellor for the Health Sciences of the University of Pittsburgh(University of Pittsburgh); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants DK083211 (DSW), DK079864 (GR) and DK54171 (PAF) from the National Institutes of Health. We also acknowledge support from the Office of the Senior Vice Chancellor for the Health Sciences of the University of Pittsburgh (GR).	Ayyanan A, 2006, P NATL ACAD SCI USA, V103, P3799, DOI 10.1073/pnas.0600065103; Bates IR, 2006, BIOPHYS J, V91, P1046, DOI 10.1529/biophysj.106.084830; Cardone RA, 2007, MOL BIOL CELL, V18, P1768, DOI 10.1091/mbc.E06-07-0617; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; Dai JL, 2004, ONCOGENE, V23, P8681, DOI 10.1038/sj.onc.1207962; Dolled-Filhart M, 2006, CANCER RES, V66, P5487, DOI 10.1158/0008-5472.CAN-06-0100; Ediger TR, 1999, ENDOCRINOLOGY, V140, P2976, DOI 10.1210/en.140.7.2976; Ellis MJ, 2009, JAMA-J AM MED ASSOC, V302, P774, DOI 10.1001/jama.2009.1204; Fantozzi A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1530; Garrido JL, 2009, MOL ENDOCRINOL, V23, P2048, DOI 10.1210/me.2008-0436; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; Karthikeyan S, 2001, J MOL BIOL, V308, P963, DOI 10.1006/jmbi.2001.4634; Koo TH, 2002, ONCOGENE, V21, P4080, DOI 10.1038/sj.onc.1205514; Kreimann EL, 2007, ONCOGENE, V26, P5290, DOI 10.1038/sj.onc.1210336; Laura RP, 2002, EXP CELL RES, V275, P155, DOI 10.1006/excr.2002.5475; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Luyten A, 2008, MOL BIOL CELL, V19, P1594, DOI 10.1091/mbc.E07-08-0832; Mangia A, 2009, HISTOPATHOLOGY, V55, P600, DOI 10.1111/j.1365-2559.2009.03424.x; Pan Y, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1846; Pan Y, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1616; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Song J, 2007, HISTOPATHOLOGY, V51, P40, DOI 10.1111/j.1365-2559.2007.02730.x; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stemmer-Rachamimov AO, 2001, AM J PATHOL, V158, P57, DOI 10.1016/S0002-9440(10)63944-2; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Umekita Y, 2002, INT J CANCER, V98, P415, DOI 10.1002/ijc.10151; Wang B, 2007, J BIOL CHEM, V282, P36214, DOI 10.1074/jbc.M707263200; Wawrzak D, 2009, ADV ENZYME REGUL, V49, P98, DOI 10.1016/j.advenzreg.2009.01.002; Weinman EJ, 2006, ANNU REV PHYSIOL, V68, P491, DOI 10.1146/annurev.physiol.68.040104.131050; Wheeler D, 2007, J BIOL CHEM, V282, P25076, DOI 10.1074/jbc.M701544200; Yao R, 2004, ONCOGENE, V23, P6023, DOI 10.1038/sj.onc.1207817; Yu A, 2007, DEV CELL, V12, P129, DOI 10.1016/j.devcel.2006.10.015	32	37	40	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					32	42		10.1038/onc.2010.389	http://dx.doi.org/10.1038/onc.2010.389			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20802536	Green Accepted			2022-12-17	WOS:000285959300003
J	Xiao, Y; Ye, Y; Zou, X; Jones, S; Yearsley, K; Shetuni, B; Tellez, J; Barsky, SH				Xiao, Y.; Ye, Y.; Zou, X.; Jones, S.; Yearsley, K.; Shetuni, B.; Tellez, J.; Barsky, S. H.			The lymphovascular embolus of inflammatory breast cancer exhibits a Notch 3 addiction	ONCOGENE			English	Article						inflammatory breast cancer; lymphovascular emboli; Notch 3 signaling; gamma-secretase inhibitors; Notch 3 siRNA; apoptosis	STEM-CELLS; IN-VITRO; E-CADHERIN; C-MYC; MAMMARY; EXPRESSION; GENE; ACTIVATION; PATHWAY; DIFFERENTIATION	Inflammatory breast carcinoma (IBC) is characterized by exaggerated lymphovascular invasion (LVI), recapitulated in our human xenograft, MARY-X. This model exhibited lymphovascular emboli in vivo and corresponding spheroids in vitro. Owing to the morphological and gene profile resemblance of these spheroids to embryonal blastocysts, we wondered whether they might exhibit embryonic stem cell signaling. Specifically we investigated Notch and observed selective Notch 3 activation by expression profiling, reverse transcriptase- and real-time PCR, western blot and immunofluorescence in vitro, and immunohistochemistry in vivo. Notch 3 intracellular domain (N3icd) and six target genes, HES-5, HEY-1, c-Myc, Deltex-1, NRARP and PBX1, markedly increased in MARY-X. In addition, a significant percentage of MARY-X cells expressed aldehyde dehydrogenase (ALDH), a stem cell marker. Only the ALDH(+) cells were capable of secondary spheroidgenesis, tumorigenicity and self-renewal. Inhibiting Notch 3 activation in vitro with gamma-secretase inhibitors (GSIs) or small interfering RNA resulted in a downregulation of Notch target genes, including CD133, and an induction of caspase 3-mediated apoptosis. Transfection of N3icd but not Notch 1 intracellular domain into normal human mammary epithelial cells resulted in increased expression of Notch target genes and induction of spheroidgenesis. GSI in vivo resulted in inhibitory but diffusion-limited effects on Notch 3 signaling, resulting in xenograft growth reduction. The lymphovascular emboli of human IBC exhibited dual N3icd and ALDH1 immunoreactivities independently of molecular subtype. This Notch 3 addiction of lymphovascular emboli might be exploited in future therapeutic strategies. Oncogene (2011) 30, 287-300; doi:10.1038/onc.2010.405; published online 13 September 2010	[Ye, Y.; Tellez, J.; Barsky, S. H.] Univ Nevada, Sch Med, Dept Pathol, Reno, NV 89557 USA; [Xiao, Y.; Zou, X.; Jones, S.; Yearsley, K.; Shetuni, B.] Ohio State Univ, Coll Med, Dept Pathol, Columbus, OH 43210 USA; [Barsky, S. H.] Nevada Canc Inst, Las Vegas, NV USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; University System of Ohio; Ohio State University; University of California System; University of California San Diego	Barsky, SH (corresponding author), Univ Nevada, Sch Med, Dept Pathol, 1 Manville Med Bldg, Reno, NV 89557 USA.	sbarsky@medicine.nevada.edu	zou, Xianghong/E-4374-2011		American Airlines-Susan G Komen for the Cure [KGO81287]; Department of Defense [BC990959, BC024258, BC053405]; Strategic Initiative, at Ohio State; Donald A Senhauser Endowment; NATIONAL CANCER INSTITUTE [R01CA113579] Funding Source: NIH RePORTER	American Airlines-Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); Department of Defense(United States Department of Defense); Strategic Initiative, at Ohio State; Donald A Senhauser Endowment; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the American Airlines-Susan G Komen for the Cure Promise Grant KGO81287, Department of Defense Breast Cancer Research Program Grants BC990959, BC024258, BC053405, the Strategic Initiative Grant Program at Ohio State and The Donald A Senhauser Endowment. Figures 1a, b, c and 2e were, in part, reprinted from Am J Pathol 2008, 173: 561-574 with permission from the American Society For Investigative Pathology.	Alpaugh ML, 1999, CANCER RES, V59, P5079; Alpaugh ML, 2002, AM J PATHOL, V161, P619, DOI 10.1016/S0002-9440(10)64217-4; Alpaugh ML, 2002, HUM GENE THER, V13, P1245, DOI 10.1089/104303402320139023; Alpaugh ML, 2002, ONCOGENE, V21, P3631, DOI 10.1038/sj.onc.1205389; Androutsellis-Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940; Ayyanan A, 2006, P NATL ACAD SCI USA, V103, P3799, DOI 10.1073/pnas.0600065103; Barsky SH, 2003, EXP MOL PATHOL, V74, P113, DOI 10.1016/S0014-4800(03)00011-X; Bellavia D, 2008, ONCOGENE, V27, P5092, DOI 10.1038/onc.2008.230; Bertucci F, 2005, CANCER RES, V65, P2170, DOI 10.1158/0008-5472.CAN-04-4115; Bertucci F, 2006, CANCER RES, V66, P4636, DOI 10.1158/0008-5472.CAN-06-0031; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Callahan R, 2004, J MAMMARY GLAND BIOL, V9, P145, DOI 10.1023/B:JOMG.0000037159.63644.81; Cariati M, 2005, SURG ONCOL, V14, P133, DOI 10.1016/j.suronc.2005.07.004; Chiba S, 2006, STEM CELLS, V24, P2437, DOI 10.1634/stemcells.2005-0661; Clark AT, 2004, STEM CELLS, V22, P169, DOI 10.1634/stemcells.22-2-169; Cuevas IC, 2005, CANCER RES, V65, P5070, DOI 10.1158/0008-5472.CAN-05-0240; Curry CL, 2005, ONCOGENE, V24, P6333, DOI 10.1038/sj.onc.1208783; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Farnie G, 2007, JNCI-J NATL CANCER I, V99, P616, DOI 10.1093/jnci/djk133; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Giraldez AJ, 2002, MECH DEVELOP, V115, P101, DOI 10.1016/S0925-4773(02)00124-7; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Gordon WR, 2007, NAT STRUCT MOL BIOL, V14, P295, DOI 10.1038/nsmb1227; Haruki N, 2005, CANCER RES, V65, P3555, DOI 10.1158/0008-5472.CAN-04-3132; Hu CY, 2006, AM J PATHOL, V168, P973, DOI 10.2353/ajpath.2006.050416; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Klinakis A, 2006, P NATL ACAD SCI USA, V103, P9262, DOI 10.1073/pnas.0603371103; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Krzywinski M, 2004, NUCLEIC ACIDS RES, V32, P3651, DOI 10.1093/nar/gkh700; Kubota H, 2003, P NATL ACAD SCI USA, V100, P6487, DOI 10.1073/pnas.0631767100; Leong KG, 2007, J EXP MED, V204, P2935, DOI 10.1084/jem.20071082; Leong KG, 2006, BLOOD, V107, P2223, DOI 10.1182/blood-2005-08-3329; Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5; PALANGIE T, 1994, EUR J CANCER, V30A, P921, DOI 10.1016/0959-8049(94)90115-5; Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103; Park JT, 2008, CANCER RES, V68, P8852, DOI 10.1158/0008-5472.CAN-08-0517; Park JT, 2006, CANCER RES, V66, P6312, DOI 10.1158/0008-5472.CAN-05-3610; POLITI K, 2006, SEMIN CANCER BIOL, V14, P341; Purow BW, 2005, CANCER RES, V65, P2353, DOI 10.1158/0008-5472.CAN-04-1890; RACHEL E, 2001, CURR BIOL, V11, P514; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rizzo P, 2008, ONCOGENE, V27, P5124, DOI 10.1038/onc.2008.226; Sanchez-Irizarry C, 2004, MOL CELL BIOL, V24, P9265, DOI 10.1128/MCB.24.21.9265-9273.2004; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Sansone P, 2007, STEM CELLS, V25, P807, DOI 10.1634/stemcells.2006-0442; Santagata S, 2004, CANCER RES, V64, P6854, DOI 10.1158/0008-5472.CAN-04-2500; SHEILA K, 2004, NATURE, V432, P396; Shih IM, 2007, CANCER RES, V67, P1879, DOI 10.1158/0008-5472.CAN-06-3958; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Sternlicht MD, 1996, IN VITRO CELL DEV-AN, V32, P550; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Sun YP, 2005, ONCOGENE, V24, P5365, DOI 10.1038/sj.onc.1208528; Tomlinson JS, 2001, CANCER RES, V61, P5231; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Xiao Y, 2008, AM J PATHOL, V173, P561, DOI 10.2353/ajpath.2008.071214; Yamaguchi N, 2008, CANCER RES, V68, P1881, DOI 10.1158/0008-5472.CAN-07-1597; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	65	37	39	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					287	300		10.1038/onc.2010.405	http://dx.doi.org/10.1038/onc.2010.405			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20838375				2022-12-17	WOS:000286418800004
J	Ocak, S; Yamashita, H; Udyavar, AR; Miller, AN; Gonzalez, AL; Zou, Y; Jiang, A; Yi, Y; Shyr, Y; Estrada, L; Quaranta, V; Massion, PP				Ocak, S.; Yamashita, H.; Udyavar, A. R.; Miller, A. N.; Gonzalez, A. L.; Zou, Y.; Jiang, A.; Yi, Y.; Shyr, Y.; Estrada, L.; Quaranta, V.; Massion, P. P.			DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway	ONCOGENE			English	Article						array CGH; copy number alterations; pathway analysis; FAK; adhesion; spreading	COMPARATIVE GENOMIC HYBRIDIZATION; GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; KINASE INHIBITOR; GENE-EXPRESSION; CARCINOMAS; PROTEIN; OVEREXPRESSION; SIGNATURES; TUMORS	Small-cell lung cancer (SCLC) is the most aggressive subtype of lung cancer in its clinical behavior, with a 5-year overall survival as low as 5%. Despite years of research in the field, molecular determinants of SCLC behavior are still poorly understood, and this deficiency has translated into an absence of specific diagnostics and targeted therapeutics. We hypothesized that tumor DNA copy number alterations would allow the identification of molecular pathways involved in SCLC progression. Array comparative genomic hybridization was performed on DNA extracted from 46 formalin-fixed paraffin-embedded SCLC tissue specimens. Genomic profiling of tumor and sex-matched control DNA allowed the identification of 70 regions of copy number gain and 55 regions of copy number loss. Using molecular pathway analysis, we found a strong enrichment in these regions of copy number alterations for 11 genes associated with the focal adhesion pathway. We verified these findings at the genomic, gene expression and protein level. Focal Adhesion Kinase (FAK), one of the central genes represented in this pathway, was commonly expressed in SCLC tumors and constitutively phosphorylated in SCLC cell lines. Those were poorly adherent to most substrates but not to laminin-322. Inhibition of FAK phosphorylation at Tyr(397) by a small-molecule inhibitor, PF-573,228, induced a dose-dependent decrease of adhesion and an increase of spreading in SCLC cell lines on laminin-322. Cells that tended to spread also showed a decrease in focal adhesions, as demonstrated by a decreased vinculin expression. These results support the concept that pathway analysis of genes in regions of copy number alterations may uncover molecular mechanisms of disease progression and demonstrate a new role of FAK and associated adhesion pathways in SCLC. Further investigations of FAK at the functional level may lead to a better understanding of SCLC progression and may have therapeutic implications. Oncogene (2010) 29, 6331-6342; doi:10.1038/onc.2010.362; published online 30 August 2010	[Massion, P. P.] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; [Yamashita, H.; Udyavar, A. R.; Estrada, L.; Quaranta, V.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA; [Gonzalez, A. L.] Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA; [Jiang, A.; Shyr, Y.] Vanderbilt Univ, Canc Biostat Ctr, Nashville, TN 37232 USA; [Yi, Y.] Vanderbilt Univ, Div Med Genet, Nashville, TN 37232 USA; [Miller, A. N.; Massion, P. P.] Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Massion, PP (corresponding author), Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Div Allergy Pulm & Crit Care Med, 2220 Pierce Ave,Preston Res Bldg 640, Nashville, TN 37232 USA.	pierre.massion@vanderbilt.edu	Quaranta, Vito/G-6512-2016; Wang, Weili/D-1546-2011	Quaranta, Vito/0000-0001-7491-8672; Estrada, Lourdes/0000-0002-3645-4456; Yamashita, Hironobu/0000-0003-2587-7100; Jiang, Aixiang/0000-0002-6153-7595	Cancer Center Support [5P30 CA068485]; Department of Veterans Affairs; IASLC; Universite Catholique de Louvain (Bourse Clinicien-Chercheur), Belgium; NATIONAL CANCER INSTITUTE [U54CA113007, P30CA068485] Funding Source: NIH RePORTER	Cancer Center Support; Department of Veterans Affairs(US Department of Veterans Affairs); IASLC; Universite Catholique de Louvain (Bourse Clinicien-Chercheur), Belgium; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Kathy Taylor, Director of the Research Institute at St Thomas Health Services, Nashville, TN, for sharing archived SCLC tissue blocks; Dr Coe for providing array CGH data (Coe et al., 2006); and Vanderbilt's Immunohistochemistry Core (supported by a Cancer Center Support Grant 5P30 CA068485) for their contribution. We also thank Steven K Hanks, Alissa M Weaver and Donna J Webb for their useful input in the interpretation of the paper. This work was supported by a Merit Review grant from the Department of Veterans Affairs. Dr Ocak was supported by an IASLC Young Investigator Fellowship Award and by a grant from Universite Catholique de Louvain (Bourse Clinicien-Chercheur), Belgium.	Balsara BR, 2002, ONCOGENE, V21, P6877, DOI 10.1038/sj.onc.1205836; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Cappuzzo F, 2005, JNCI-J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112; Coe BP, 2006, BRIT J CANCER, V94, P1927, DOI 10.1038/sj.bjc.6603167; Cooper S, 2006, RESPIROLOGY, V11, P241, DOI 10.1111/j.1440-1843.2006.00850.x; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Gallia GL, 2006, MOL CANCER RES, V4, P709, DOI 10.1158/1541-7786.MCR-06-0172; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069; Jackman DM, 2005, LANCET, V366, P1385, DOI 10.1016/S0140-6736(05)67569-1; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kim YH, 2006, ONCOGENE, V25, P130, DOI 10.1038/sj.onc.1208997; Kirov SA, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-72; LEVIN NA, 1994, CANCER RES, V54, P5086; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; Massion PP, 2008, AM J RESP CRIT CARE, V178, P1164, DOI 10.1164/rccm.200801-142OC; Massion PP, 2003, CANCER RES, V63, P7113; Massion PP, 2002, CANCER RES, V62, P3636; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; MIURA I, 1992, CANCER RES, V52, P1322; Olejniczak ET, 2007, MOL CANCER RES, V5, P331, DOI 10.1158/1541-7786.MCR-06-0367; Osada H, 2008, CANCER RES, V68, P1647, DOI 10.1158/0008-5472.CAN-07-5039; OWENS LV, 1995, CANCER RES, V55, P2752; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Peng WX, 2005, CANCER SCI, V96, P661, DOI 10.1111/j.1349-7006.2005.00092.x; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Qian J, 2009, MOL CANCER THER, V8, P101, DOI 10.1158/1535-7163.MCT-08-0973; RIED T, 1994, CANCER RES, V54, P1801; Roberts WG, 2008, CANCER RES, V68, P1935, DOI 10.1158/0008-5472.CAN-07-5155; Rozengurt E, 2007, J CELL PHYSIOL, V213, P589, DOI 10.1002/jcp.21246; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shi Q, 2007, MOL CARCINOGEN, V46, P488, DOI 10.1002/mc.20297; SIDHU GS, 1979, AM J PATHOL, V96, P5; Siesser PMF, 2006, CLIN CANCER RES, V12, P3233, DOI 10.1158/1078-0432.CCR-06-0456; Slack-Davis JK, 2007, J BIOL CHEM, V282, P14845, DOI 10.1074/jbc.M606695200; SOZZI G, 1987, CANCER GENET CYTOGEN, V27, P45, DOI 10.1016/0165-4608(87)90259-7; Taniwaki M, 2006, INT J ONCOL, V29, P567; Tanno S, 2004, LUNG CANCER, V46, P11, DOI 10.1016/j.lungcan.2004.03.006; Ullmann R, 1998, HUM PATHOL, V29, P1145, DOI 10.1016/S0046-8177(98)90428-2; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475; Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603	46	37	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2010	29	48					6331	6342		10.1038/onc.2010.362	http://dx.doi.org/10.1038/onc.2010.362			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	688SW	20802517	Green Accepted			2022-12-17	WOS:000284874700004
J	Pan, J; Nakade, K; Huang, YC; Zhu, ZW; Masuzaki, S; Hasegawa, H; Murata, T; Yoshiki, A; Yamaguchi, N; Lee, CH; Yang, WC; Tsai, EM; Obata, Y; Yokoyama, KK				Pan, J.; Nakade, K.; Huang, Y-C; Zhu, Z-W; Masuzaki, S.; Hasegawa, H.; Murata, T.; Yoshiki, A.; Yamaguchi, N.; Lee, C-H; Yang, W-C; Tsai, E-M; Obata, Y.; Yokoyama, K. K.			Suppression of cell-cycle progression by Jun dimerization protein-2 (JDP2) involves downregulation of cyclin-A2	ONCOGENE			English	Article						cyclin-A2; cell proliferation; JDP2; epidermal thickness; cell-cycle arrest	INSERTIONAL MUTAGENESIS; AP-1 REPRESSOR; TRANSCRIPTION FACTOR; DIFFERENTIATION; IDENTIFICATION; TRANSFORMATION; FIBROBLASTS; ACTIVATION; INHIBITORS; DISTINCT	We report here a novel role for Jun dimerization protein-2 (JDP2) as a regulator of the progression of normal cells through the cell cycle. To determine the role of JDP2 in vivo, we generated Jdp2-knockout (Jdp2KO) mice by targeting exon-1 to disrupt the site of initiation of transcription. The epidermal thickening of skin from the Jdp2KO mice after treatment with 12-O-tetradecanoyl-phorbol 13-acetate (TPA) proceeded more rapidly than that of control mice, and more proliferating cells were found at the epidermis. Fibroblasts derived from embryos of Jdp2KO mice proliferated faster and formed more colonies than fibroblasts from wild-type mice. JDP2 was recruited to the promoter of the gene for cyclin-A2 (ccna2) at the AP-1 site. Cells lacking Jdp2 had elevated levels of cyclin-A2 mRNA. Furthermore, reintroduction of JDP2 resulted in the repression of transcription of ccna2 and of cell-cycle progression. Thus, transcription of the gene for cyclin-A2 appears to be a direct target of JDP2 in the suppression of cell proliferation. Oncogene (2010) 29, 6245-6256; doi:10.1038/onc.2010.355; published online 30 August 2010	[Huang, Y-C; Lee, C-H; Tsai, E-M; Yokoyama, K. K.] Kaohsiung Med Univ, Grad Inst Med, Ctr Excellence Environm Med, Kaohsiung 807, Taiwan; [Pan, J.; Nakade, K.; Masuzaki, S.; Murata, T.; Yoshiki, A.; Obata, Y.; Yokoyama, K. K.] RIKEN BioResource Ctr, Ibaraki, Japan; [Pan, J.; Zhu, Z-W] Zhejiang Acad Agr Sci, Inst Anim Husb & Vet, Hangzhou, Zhejiang, Peoples R China; [Hasegawa, H.; Yamaguchi, N.] Chiba Univ, Grad Sch Pharmaceut Sci, Dept Mol & Cell Biol, Chiba, Japan; [Lee, C-H] Kaohsiung Municipal Hsiaokang Hosp, Kaohsiung, Taiwan; [Yang, W-C] Acad Sinica, Agr Biotechnol Res Ctr, Taipei 115, Taiwan; [Yokoyama, K. K.] Univ Tokyo, Grad Sch Med, Dept Mol Prevent Med, Tokyo, Japan	Kaohsiung Medical University; RIKEN; Zhejiang Academy of Agricultural Sciences; Chiba University; Kaohsiung Medical University; Kaohsiung Municipal Siao-Gang Hospital; Academia Sinica - Taiwan; University of Tokyo	Yokoyama, KK (corresponding author), Kaohsiung Med Univ, Grad Inst Med, Ctr Excellence Environm Med, Kaohsiung 807, Taiwan.	kazu@kmu.edu.tw	Lee, Chih-Hung/AAJ-5551-2020; Obata, Yuichi/A-5300-2016; Lee, Chih-Hung/B-4081-2010; Yoshiki, Atsushi/O-6162-2019; Yang, Wen-Chin/D-3441-2015	Lee, Chih-Hung/0000-0001-9804-3874; Obata, Yuichi/0000-0003-1839-4709; Yoshiki, Atsushi/0000-0002-9450-5151; Yang, Wen-Chin/0000-0001-6410-2581	RIKEN; Ministry of Education, Culture, Sports, Science and Technology of Japan; Kaohsiung Medical University, Taiwan [KMU-EM-99-3]	RIKEN; Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Kaohsiung Medical University, Taiwan	We thank S Itohara, C Jin, R Chiu, K Itakura, T Kondo, S Takahashi, P Kourilsky and G Gachelin for discussion, and L-H Lee, M Hirose and K Inabe for technical support. This work was supported by grants from the RIKEN Bioresource Project (to AY, YO and KKY), the Ministry of Education, Culture, Sports, Science and Technology of Japan (to KN, NY and KKY) and Kaohsiung Medical University, Taiwan (KMU-EM-99-3, to KKY, C-HL and ET).	Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Bitton-Worms K, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-54; Blazek E, 2003, ONCOGENE, V22, P2151, DOI 10.1038/sj.onc.1206312; Broder YC, 1998, CURR BIOL, V8, P1121, DOI 10.1016/S0960-9822(98)70467-1; Caldon CE, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-2; Chaudhry HW, 2004, J BIOL CHEM, V279, P35858, DOI 10.1074/jbc.M404975200; Cherasse Y, 2008, FEBS LETT, V582, P1537, DOI 10.1016/j.febslet.2008.03.050; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; GRANA X, 1995, ONCOGENE, V11, P211; Heinrich R, 2004, J BIOL CHEM, V279, P5708, DOI 10.1074/jbc.M307608200; Hwang HC, 2002, P NATL ACAD SCI USA, V99, P11293, DOI 10.1073/pnas.162356099; Jin CY, 2006, NAT STRUCT MOL BIOL, V13, P331, DOI 10.1038/nsmb1063; Jin CY, 2002, MOL CELL BIOL, V22, P4815, DOI 10.1128/MCB.22.13.4815-4826.2002; Jin CY, 2001, FEBS LETT, V489, P34, DOI 10.1016/S0014-5793(00)02387-5; Kalaszczynska I, 2009, CELL, V138, P352, DOI 10.1016/j.cell.2009.04.062; Kawaida R, 2003, J EXP MED, V197, P1029, DOI 10.1084/jem.20021321; Lerdrup M, 2005, BBA-MOL CELL RES, V1745, P29, DOI 10.1016/j.bbamcr.2005.06.008; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Mateo F, 2009, ONCOGENE, V28, P2654, DOI 10.1038/onc.2009.127; Nakade K, 2007, CELL DEATH DIFFER, V14, P1398, DOI 10.1038/sj.cdd.4402129; Nakade K, 2009, J BIOL CHEM, V284, P10808, DOI 10.1074/jbc.M808333200; Nakamura Y, 1998, CANCER RES, V58, P4832; Ostrovsky O, 2002, J BIOL CHEM, V277, P40043, DOI 10.1074/jbc.M205494200; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Piu F, 2001, MOL CELL BIOL, V21, P3012, DOI 10.1128/MCB.21.9.3012-3024.2001; Polager S, 2009, NAT REV CANCER, V9, P738, DOI 10.1038/nrc2718; Polisetty N, 2008, MOL VIS, V14, P431; Rasmussen MH, 2009, NUCLEIC ACIDS RES, V37, P4657, DOI 10.1093/nar/gkp469; Rasmussen MH, 2005, VIROLOGY, V337, P353, DOI 10.1016/j.virol.2005.04.027; Satyanarayana A, 2009, ONCOGENE, V28, P2925, DOI 10.1038/onc.2009.170; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stewart M, 2007, CANCER RES, V67, P5126, DOI 10.1158/0008-5472.CAN-07-0433; Sweeney C, 1996, DEVELOPMENT, V122, P53; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Weidenfeld-Baranboim K, 2008, NUCLEIC ACIDS RES, V36, P3608, DOI 10.1093/nar/gkn268; Weidenfeld-Baranboim K, 2009, NUCLEIC ACIDS RES, V37, P2194, DOI 10.1093/nar/gkp083	36	37	38	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	47					6245	6256		10.1038/onc.2010.355	http://dx.doi.org/10.1038/onc.2010.355			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	685CG	20802531	hybrid, Green Published			2022-12-17	WOS:000284601700006
J	Alessio, N; Squillaro, T; Cipollaro, M; Bagella, L; Giordano, A; Galderisi, U				Alessio, N.; Squillaro, T.; Cipollaro, M.; Bagella, L.; Giordano, A.; Galderisi, U.			The BRG1 ATPase of chromatin remodeling complexes is involved in modulation of mesenchymal stem cell senescence through RB-P53 pathways	ONCOGENE			English	Article						stem cells; senescence; apoptosis; p53; retinoblastoma; chromatin	RETINOBLASTOMA PROTEIN; STROMAL CELLS; DNA-REPAIR; TUMOR-SUPPRESSOR; GROWTH ARREST; P53; DIFFERENTIATION; APOPTOSIS; BINDING; GENE	We focused our attention on brahma-related gene 1 (BRG1), the ATPase subunit of the SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeling complex, and analyzed its role in mesenchymal stem cell (MSC) biology. We hypothesized that deviation from the correct concentration of these proteins, which act at the highest level of gene regulation, may be deleterious for cells. We wanted to know what would happen if a cell had to cope with altered regulation of gene expression, either by upregulation or downregulation of BRG1. We assumed that cells would try to restore homeostasis or, alternatively, that the event could trigger senescence/apoptosis phenomena. To this end, in MSCs, we silenced BRG1gene. Knockdown of BRG1 expression induced a significant increase in senescent cells and decrease in apoptotic cells. It is interesting that BRG1 downregulation also induced an increase in heterochromatin. At the molecular level, these phenomena were associated with activation of retinoblastoma-like protein 2 (RB2)/P130-and P53-related pathways. Senescence was accompanied by reduced expression of some stemness-related genes. This is consistent with our previous research, which showed that BRG1 upregulation by ectopic expression also induced senescence processes. Together, these data suggest that BRG1 belongs to a class of genes whose expression is tightly regulated; hence, subtle alterations in BRG1 activity seem to negatively affect mechanisms regulating chromatin status and, in turn, impair cellular physiology. Oncogene (2010) 29, 5452-5463; doi:10.1038/onc.2010.285; published online 9 August 2010	[Cipollaro, M.; Galderisi, U.] Univ Naples 2, Biotechnol & Mol Biol Sect, Dept Expt Med, I-80138 Naples, Italy; [Alessio, N.; Squillaro, T.; Bagella, L.; Giordano, A.; Galderisi, U.] Temple Univ, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; [Alessio, N.; Bagella, L.] Univ Sassari, Dept Biomed Sci, Div Biochem & Biophys, I-07100 Sassari, Italy; [Squillaro, T.] Univ Siena, I-53100 Siena, Italy; [Giordano, A.] Univ Siena, Human Pathol & Oncol Dept, I-53100 Siena, Italy; [Giordano, A.] Human Hlth Fdn, Spoleto, Italy	Universita della Campania Vanvitelli; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Sassari; University of Siena; University of Siena	Galderisi, U (corresponding author), Univ Naples 2, Biotechnol & Mol Biol Sect, Dept Expt Med, Via Costantinopoli 16, I-80138 Naples, Italy.	umberto.galderisi@unina2.it	Alessio, Nicola/K-2119-2018; Giordano, Antonio/F-1927-2010	Alessio, Nicola/0000-0002-5019-2130; Giordano, Antonio/0000-0002-5959-016X; Cipollaro, Marilena/0000-0003-4350-4324; GALDERISI, Umberto/0000-0003-0909-7403; BAGELLA, Luigi/0000-0003-2815-037X	SHRO	SHRO	This work was partially supported by SHRO funds to UG and AG. We thank Maria Rosaria Cipollaro for technical assistance. We thank Dr Francesca Pentimalli for helpful discussion.; Author contributions: Tiziana Squillaro: conception and design, performed experiments; Nicola Alessio: conception and design, performed experiments; Marilena Cipollaro: assembly of data, data analysis and interpretation; Luigi Bagella: provision of study material, data analysis and interpretation and financial support; Antonio Giordano: conception and design, data analysis and interpretation and financial support; Umberto Galderisi: conception and design, data analysis and interpretation, paper writing and financial support.	Alves H, 2009, J CELL MOL MED; Beyer Nardi N, 2006, HANDB EXP PHARM, V174, P249; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Diggle CP, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng083; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Dornan D, 2003, MOL CELL BIOL, V23, P8846, DOI 10.1128/MCB.23.23.8846-8861.2003; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Felsani A, 2006, ONCOGENE, V25, P5277, DOI 10.1038/sj.onc.1209621; Fotedar R, 2004, CELL CYCLE, V3, P134; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Galderisi U, 2006, ONCOGENE, V25, P5250, DOI 10.1038/sj.onc.1209736; Galderisi U, 1999, J CELL BIOCHEM, V73, P97, DOI 10.1002/(SICI)1097-4644(19990401)73:1<97::AID-JCB11>3.0.CO;2-M; Giorgio M, 2007, NAT REV MOL CELL BIO, V8, p722A; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Hendricks KB, 2004, MOL CELL BIOL, V24, P362, DOI 10.1128/MCB.24.1.362-376.2004; Hill R, 2008, CELL CYCLE, V7, P2535; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Kang H, 2004, MOL CELL BIOL, V24, P1188, DOI 10.1128/MCB.24.3.1188-1199.2004; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kholodenko BN, 2000, EUR J BIOCHEM, V267, P1583, DOI 10.1046/j.1432-1327.2000.01197.x; Kidder BL, 2009, STEM CELLS, V27, P317, DOI 10.1634/stemcells.2008-0710; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355; Marsden VS, 2006, BLOOD, V107, P1872, DOI 10.1182/blood-2005-05-2160; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Matoba R, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000026; Matsumoto S, 2006, DEV BIOL, V289, P372, DOI 10.1016/j.ydbio.2005.10.044; Mikkers H, 2005, EMBO J, V24, P2715, DOI 10.1038/sj.emboj.7600749; Morales M, 2005, GENE DEV, V19, P3043, DOI 10.1101/gad.1373705; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; MULLERSIEBURG CE, 1995, STEM CELLS, V13, P477, DOI 10.1002/stem.5530130505; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Naidu SR, 2009, ONCOGENE, V28, P2492, DOI 10.1038/onc.2009.121; Napolitano MA, 2007, J CELL SCI, V120, P2904, DOI 10.1242/jcs.004002; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Oberdoerffer P, 2007, NAT REV MOL CELL BIO, V8, P692, DOI 10.1038/nrm2238; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Rajagopalan S, 2008, NUCLEIC ACIDS RES, V36, P5983, DOI 10.1093/nar/gkn598; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Ronen A, 2001, ENVIRON MOL MUTAGEN, V37, P241, DOI 10.1002/em.1033; Saha A, 2006, NAT REV MOL CELL BIO, V7, P437, DOI 10.1038/nrm1945; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sethe S, 2006, AGEING RES REV, V5, P91, DOI 10.1016/j.arr.2005.10.001; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Trotter Kevin W, 2008, Nucl Recept Signal, V6, pe004, DOI 10.1621/nrs.06004; von Zglinicki T, 2001, EXP GERONTOL, V36, P1049, DOI 10.1016/S0531-5565(01)00111-5; WANG HGH, 1995, J VIROL, V69, P7917, DOI 10.1128/JVI.69.12.7917-7924.1995; WANG HGH, 1993, J VIROL, V67, P4804, DOI 10.1128/JVI.67.8.4804-4813.1993; Wesierska-Gadek J, 2005, CELL MOL BIOL LETT, V10, P439; Yu K, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000129; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	67	37	40	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	40					5452	5463		10.1038/onc.2010.285	http://dx.doi.org/10.1038/onc.2010.285			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FM	20697355				2022-12-17	WOS:000282945800003
J	Krndija, D; Schmid, H; Eismann, JL; Lother, U; Adler, G; Oswald, F; Seufferlein, T; von Wichert, G				Krndija, D.; Schmid, H.; Eismann, J-L; Lother, U.; Adler, G.; Oswald, F.; Seufferlein, T.; von Wichert, G.			Substrate stiffness and the receptor-type tyrosine-protein phosphatase alpha regulate spreading of colon cancer cells through cytoskeletal contractility	ONCOGENE			English	Article						spreading; force; colon cancer; tyrosine-phosphatase; contractility; invasion	SRC-FAMILY KINASES; RPTP-ALPHA; MECHANICAL FORCE; LEADING-EDGE; PTP-ALPHA; FIBROBLASTS; EXPRESSION; ADHESION; MATRIX; ACTIVATION	Microenvironmental clues are critical to cell behavior. One of the key elements of migration is the generation and response to forces. Up to now, there is no definitive concept on how the generation and responses to cellular forces influence cancer-cell behavior. Here, we show that expression of receptor-type tyrosine-protein phosphatase alpha (RPTP alpha) in human SW480 colon cancer cells sets a threshold for the response to matrix forces by changing cellular contractility. This can be explained as an RPTP alpha-mediated increase in contractility with a consecutive increase in number and size of adhesion sites and stress fibers. These effects are mediated through myosin light chain kinase and largely independent of Rho/Rho-kinase (ROCK) signaling. In addition, we report that RPTPa influences spreading on low-rigidity surfaces, binding of collagen-coated beads and expression of RPTPa is required for invasion into the chorioallantoic membrane. These data suggest that force-responsive proteins such as RPTPa can influence cancer-cell behavior and identify potential targets for cancer therapy. Oncogene (2010) 29, 2724-2738; doi:10.1038/onc.2010.25; published online 8 March 2010	[Krndija, D.; Schmid, H.; Eismann, J-L; Lother, U.; Adler, G.; Oswald, F.; Seufferlein, T.; von Wichert, G.] Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Baden Wuerttemb, Germany	Ulm University	von Wichert, G (corresponding author), Univ Ulm, Dept Internal Med 1, Albert Einstein Allee 23, D-89081 Ulm, Baden Wuerttemb, Germany.	goetz.wichert@uniklinik-ulm.de	Krndija, Denis/AAR-5918-2020; Seufferlein, Thomas TW/P-7147-2018; Oswald, Franz/AAO-9584-2020	Krndija, Denis/0000-0001-8686-7542; 	DFG; Deutsche Krebshilfe	DFG(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe)	This work was supported by the DFG to GvW and FO and the Deutsche Krebshilfe to GvW and TS.	Ardini E, 2000, ONCOGENE, V19, P4979, DOI 10.1038/sj.onc.1203869; Balaban NQ, 2001, NAT CELL BIOL, V3, P466, DOI 10.1038/35074532; Benoliel AM, 2003, ANTICANCER RES, V23, P4891; Berndt A, 1999, HISTOCHEM CELL BIOL, V111, P399, DOI 10.1007/s004180050373; Bodrikov V, 2005, J CELL BIOL, V168, P127, DOI 10.1083/jcb.200405073; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Han B, 2004, J BIOL CHEM, V279, P54793, DOI 10.1074/jbc.M406880200; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; HARRIS AK, 1981, NATURE, V290, P249, DOI 10.1038/290249a0; Ingber DE, 2003, ANN MED, V35, P564, DOI 10.1080/07853890310016333; Jiang GY, 2006, BIOPHYS J, V90, P1804, DOI 10.1529/biophysj.105.072462; Kostic A, 2006, MOL BIOL CELL, V17, P2684, DOI 10.1091/mbc.E05-12-1161; Kunzi-Rapp K, 2001, J UROLOGY, V166, P1502, DOI 10.1016/S0022-5347(05)65820-X; Lee W, 1996, J CELL PHYSIOL, V168, P695, DOI 10.1002/(SICI)1097-4652(199609)168:3<695::AID-JCP22>3.0.CO;2-X; Munevar S, 2001, BIOPHYS J, V80, P1744, DOI 10.1016/S0006-3495(01)76145-0; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Petrone A, 2000, J CELL SCI, V113, P2345; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Sawada Y, 2006, CELL, V127, P1015, DOI 10.1016/j.cell.2006.09.044; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; TABITI K, 1995, CANCER LETT, V93, P239, DOI 10.1016/0304-3835(95)03816-F; Thamilselvan V, 2004, GASTROENTEROLOGY, V126, P8, DOI 10.1053/j.gastro.2003.10.078; Totsukawa G, 2004, J CELL BIOL, V164, P427, DOI 10.1083/jcb.200306172; von Wichert G, 2003, J CELL BIOL, V161, P143, DOI 10.1083/jcb.200211061; Wang YL, 1998, METHOD ENZYMOL, V298, P489, DOI 10.1016/S0076-6879(98)98041-7; Wang YX, 2005, NATURE, V434, P1040, DOI 10.1038/nature03469; Wells RG, 2008, HEPATOLOGY, V47, P1394, DOI 10.1002/hep.22193; Wozniak MA, 2003, J CELL BIOL, V163, P583, DOI 10.1083/jcb.200305010; Wu CW, 2006, CANCER LETT, V242, P95, DOI 10.1016/j.canlet.2005.10.046; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	34	37	38	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	2010	29	18					2724	2738		10.1038/onc.2010.25	http://dx.doi.org/10.1038/onc.2010.25			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20208566				2022-12-17	WOS:000277354600012
J	Cooper, SJ; Zou, H; LeGrand, SN; Marlow, LA; von Roemeling, CA; Radisky, DC; Wu, KJ; Hampel, N; Margulis, V; Tun, HW; Blobe, GC; Wood, CG; Copland, JA				Cooper, S. J.; Zou, H.; LeGrand, S. N.; Marlow, L. A.; von Roemeling, C. A.; Radisky, D. C.; Wu, K. J.; Hampel, N.; Margulis, V.; Tun, H. W.; Blobe, G. C.; Wood, C. G.; Copland, J. A.			Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma	ONCOGENE			English	Article						transcriptional regulation; GATA3; type III transforming growth factor-beta receptor; methylation; clear cell renal cell carcinoma	TGF-BETA; BETAGLYCAN EXPRESSION; CANCER; GENE; DIFFERENTIATION; INVASIVENESS; INHIBITION; MOTILITY	Loss of transforming growth factor-beta receptor III (TbRIII) correlates with loss of transforming growth factor-beta (TGF-beta) responsiveness and suggests a role for dysregulated TGF-beta signaling in clear cell renal cell carcinoma (ccRCC) progression and metastasis. Here we identify that for all stages of ccRCC TbRIII expression is downregulated in patient-matched tissue samples and cell lines. We find that this loss of expression is not due to methylation of the gene and we define GATA3 as the first transcriptional factor to positively regulate TbRIII expression in human cells. We localize GATA3's binding to a 10-bp region of the TbRIII proximal promoter. We demonstrate that GATA3 mRNA is downregulated in all stages, of ccRCC, mechanistically show that GATA3 is methylated in ccRCC patient tumor tissues as well as cell lines, and that inhibiting GATA3 expression in normal renal epithelial cells downregulates TbRIII mRNA and protein expression. These data support a sequential model whereby loss of GATA3 expression through epigenetic silencing decreases TbRIII expression during ccRCC progression. Oncogene (2010) 29, 2905-2915; doi:10.1038/onc.2010.64; published online 8 March 2010	[Copland, J. A.] Mayo Clin, Dept Canc Biol, Mayo Clin Comprehens Canc Ctr, Coll Med, Jacksonville, FL 32224 USA; [Zou, H.] Mayo Clin Rochester, Dept Gastroenterol & Hepatol, Rochester, MN USA; [Wu, K. J.] Mayo Clin, Dept Pathol, Jacksonville, FL 32224 USA; [Hampel, N.; Blobe, G. C.] Duke Univ, Med Ctr, Dept Med & Pharmacol, Durham, NC 27710 USA; [Hampel, N.; Blobe, G. C.] Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA; [Margulis, V.; Wood, C. G.] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA; [Tun, H. W.] Mayo Clin, Dept Hematol & Oncol, Jacksonville, FL 32224 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Duke University; Duke University; University of Texas System; UTMD Anderson Cancer Center; Mayo Clinic	Copland, JA (corresponding author), Mayo Clin, Dept Canc Biol, Mayo Clin Comprehens Canc Ctr, Coll Med, 4500 San Pablo Rd,Griffin Bld Rm 309, Jacksonville, FL 32224 USA.	copland.john@mayo.edu	Radisky, Derek/B-6569-2018; Blobe, Gerard/AAJ-5945-2020; Hempel, Nadine/F-1700-2014	Radisky, Derek/0000-0002-1962-8784; Blobe, Gerard/0000-0002-4274-8901; Hempel, Nadine/0000-0002-5574-8783; Marlow, Laura/0000-0002-4726-9889; von Roemeling, Christina/0000-0002-3754-5544	NIH [CA104505, 3RO1CA104505-05S1, CA106307]; Dr Ellis and Dona Brunton Rare Cancer Research Fund; NATIONAL CANCER INSTITUTE [R01CA106307, R01CA104505] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dr Ellis and Dona Brunton Rare Cancer Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Holly Hammond for her close editing of the manuscript. We also thank Tam How, Brandy Edenfield and Gregory Kennedy for their technical support. This work was funded in part by NIH Grant CA104505 (JAC and CGW), 3RO1CA104505-05S1 (JAC), Dr Ellis and Dona Brunton Rare Cancer Research Fund ( JAC), NIH Grant CA106307 (GCB) and a generous gift from Susan A Olde, OBE.	Chakravarthy D, 1999, INT J ONCOL, V15, P187; Cooper S, 2005, MOL CARCINOGEN, V43, P108, DOI 10.1002/mc.20101; Copland JA, 2006, ONCOGENE, V25, P2304, DOI 10.1038/sj.onc.1209267; Copland JA, 2003, ONCOGENE, V22, P8053, DOI 10.1038/sj.onc.1206835; Dong M, 2007, J CLIN INVEST, V117, P206, DOI 10.1172/JCI29293; Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047; Finger EC, 2008, CARCINOGENESIS, V29, P528, DOI 10.1093/carcin/bgm289; Florio P, 2005, EUR J ENDOCRINOL, V152, P277, DOI 10.1530/eje.1.01849; Gordon KJ, 2008, CARCINOGENESIS, V29, P252, DOI 10.1093/carcin/bgm249; Grote D, 2006, DEVELOPMENT, V133, P53, DOI 10.1242/dev.02184; Gulbinas A, 2006, J HISTOCHEM CYTOCHEM, V54, P161, DOI 10.1369/jhc.5A6626.2005; Gumz ML, 2007, CLIN CANCER RES, V13, P4740, DOI 10.1158/1078-0432.CCR-07-0143; Hempel N, 2008, CARCINOGENESIS, V29, P905, DOI 10.1093/carcin/bgn049; Hempel N, 2007, CANCER RES, V67, P5231, DOI 10.1158/0008-5472.CAN-07-0035; Ho IC, 2007, CELL MOL IMMUNOL, V4, P15; Kouros-Mehr H, 2008, CURR OPIN CELL BIOL, V20, P164, DOI 10.1016/j.ceb.2008.02.003; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; LABASTIE MC, 1995, KIDNEY INT, V47, P1597, DOI 10.1038/ki.1995.223; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lopez-Casillas F, 2003, J BIOL CHEM, V278, P382, DOI 10.1074/jbc.M208520200; Margulis V, 2008, CLIN CANCER RES, V14, P5722, DOI 10.1158/1078-0432.CCR-08-0546; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; McCarthy TL, 2007, MOL ENDOCRINOL, V21, P2713, DOI 10.1210/me.2007-0210; Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495; Motzer RJ, 1999, J CLIN ONCOL, V17, P2530, DOI 10.1200/JCO.1999.17.8.2530; Mythreye K, 2009, P NATL ACAD SCI USA, V106, P8221, DOI 10.1073/pnas.0812879106; Pantuck AJ, 2001, J UROLOGY, V166, P1611, DOI 10.1016/S0022-5347(05)65640-6; Sharifi N, 2007, PROSTATE, V67, P301, DOI 10.1002/pros.20526; Stenvers KL, 2003, MOL CELL BIOL, V23, P4371, DOI 10.1128/MCB.23.12.4371-4385.2003; Tavares TS, 2008, CANCER BIOL THER, V7, P1607, DOI 10.4161/cbt.7.10.6584; Turley RS, 2007, CANCER RES, V67, P1090, DOI 10.1158/0008-5472.CAN-06-3117; Van Esch H, 2000, NATURE, V406, P419, DOI 10.1038/35019088; Wood CG, 2007, CLIN CANCER RES, V13, p697S, DOI 10.1158/1078-0432.CCR-06-2109; You HJ, 2009, CARCINOGENESIS, V30, P1281, DOI 10.1093/carcin/bgp071	35	37	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	20					2905	2915		10.1038/onc.2010.64	http://dx.doi.org/10.1038/onc.2010.64			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20208565	Green Accepted			2022-12-17	WOS:000277890400002
J	Boidot, R; Vegran, F; Jacob, D; Chevrier, S; Cadouot, M; Feron, O; Solary, E; Lizard-Nacol, S				Boidot, R.; Vegran, F.; Jacob, D.; Chevrier, S.; Cadouot, M.; Feron, O.; Solary, E.; Lizard-Nacol, S.			The transcription factor GATA-1 is overexpressed in breast carcinomas and contributes to survivin upregulation via a promoter polymorphism	ONCOGENE			English	Article						GATA-1; survivin promoter polymorphism; breast carcinoma	SPLICE VARIANTS; GENE-EXPRESSION; CANCER; ERYTHROPOIETIN; PHOSPHORYLATION; DIFFERENTIATION; REQUIREMENTS; ACTIVATION; APOPTOSIS; CLEAVAGE	Expression of survivin, a member of the inhibitor of apoptosis protein family, is elevated in human cancers and considered as a new therapeutic target. Mechanism upregulating survivin expression in tumour cells is poorly understood. In this study, we show that breast cancer patients harbouring a polymorphism G235A in the survivin promoter present a higher level of survivin expression. This polymorphism creates a binding site for the transcription factor GATA-1 inducing a second GATA-1-binding site in survivin promoter. At the mRNA level, GATA-1 was present in breast carcinomas and adjacent normal tissues, whereas the protein was only detected in carcinomas by western blot and immunohistochemistry. Transfection of wild-type and different constitutively active GATA-1 mutants (serine 26, 178 or 310) showed that only phospho-serine 26 GATA-1 was able to increase survivin expression. This increase was higher in G235A than in G235G cell lines. Phospho-serine 26 GATA-1 bound directly survivin promoter, with a stronger interaction in G235A than in G235G polymorphism indicating that both GATA-1-binding sites are functional. These data identify GATA-1 as a key feature in tumour aggressiveness by enhancing survivin expression and delineate its targeting as a possible new therapeutic strategy in breast carcinomas. Oncogene (2010) 29, 2577-2584; doi:10.1038/onc.2009.525; published online 25 January 2010	[Boidot, R.; Vegran, F.; Jacob, D.; Chevrier, S.; Cadouot, M.; Lizard-Nacol, S.] Ctr Georges Francois Leclerc, Mol Genet Lab, F-21034 Dijon, France; [Solary, E.] UMR INSERM, U866, IFR 100, Dijon, France	UNICANCER; Centre Georges-Francois Leclerc; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Lizard-Nacol, S (corresponding author), Ctr Georges Francois Leclerc, Mol Genet Lab, 1 Rue Prof Marion, F-21034 Dijon, France.	SLizard@dijon.fnclcc.fr	VEGRAN, Frederique/O-9986-2018; VEGRAN, Frédérique/H-4792-2017; FERON, Olivier/AAM-6395-2020	VEGRAN, Frederique/0000-0002-4377-1441; FERON, Olivier/0000-0001-5360-0286; Solary, Eric/0000-0002-8629-1341	Conseil Regional de Bourgogne; Association pour la Recherche contre le Cancer	Conseil Regional de Bourgogne(Region Bourgogne-Franche-Comte); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer)	This work was supported by the Conseil Regional de Bourgogne and the Association pour la Recherche contre le Cancer. We thank Dr Laurent Arnould (as Pathologist) for the validation of GATA-1 immunohistochemical staining.	Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Altieri Dario C, 2003, Prog Cell Cycle Res, V5, P447; Altieri DC, 2005, IMMUNITY, V22, P534, DOI 10.1016/j.immuni.2005.05.001; Altieri DC, 1999, LAB INVEST, V79, P1327; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Boidot R, 2008, GENE CHROMOSOME CANC, V47, P299, DOI 10.1002/gcc.20533; Boidot R, 2009, INT J MOL MED, V23, P285, DOI 10.3892/ijmm_00000129; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; Connell CM, 2008, CANCER RES, V68, P7923, DOI 10.1158/0008-5472.CAN-08-0817; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; De Gobbi M, 2006, SCIENCE, V312, P1215, DOI 10.1126/science.1126431; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; Kadri Z, 2005, MOL CELL BIOL, V25, P7412, DOI 10.1128/MCB.25.17.7412-7422.2005; Leung CG, 2007, J EXP MED, V204, P1603, DOI 10.1084/jem.20062395; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li FZ, 1999, CANCER RES, V59, P3143; Nasu S, 2002, ANTICANCER RES, V22, P1839; O'Driscoll L, 2003, CURR CANCER DRUG TAR, V3, P131, DOI 10.2174/1568009033482038; Obexer P, 2009, MOL BIOL CELL, V20, P2041, DOI 10.1091/mbc.E08-07-0699; Perez-Stable CM, 2000, MOL CELL ENDOCRINOL, V167, P43, DOI 10.1016/S0303-7207(00)00300-2; Phillips TM, 2007, NEOPLASIA, V9, P1122, DOI 10.1593/neo.07694; Ribeil JA, 2007, NATURE, V445, P102, DOI 10.1038/nature05378; Richter M, 2003, AM J PHYSIOL-LUNG C, V285, pL719, DOI 10.1152/ajplung.00406.2002; Ryan B, 2005, BRIT J CANCER, V92, P120, DOI 10.1038/sj.bjc.6602314; Sebastian S, 2002, MOL ENDOCRINOL, V16, P2243, DOI 10.1210/me.2002-0123; Towatari M, 2004, HEMATOL J, V5, P262, DOI 10.1038/sj.thj.6200345; Vegran F, 2007, ONCOGENE, V26, P290, DOI 10.1038/sj.onc.1209784; Vegran F, 2005, INT J ONCOL, V27, P1151; Wu YH, 2008, ACTA BIOCHIM POL, V55, P673; Xia F, 2006, CANCER RES, V66, P3392, DOI 10.1158/0008-5472.CAN-05-4537; Xu Y, 2004, DNA CELL BIOL, V23, P527, DOI 10.1089/dna.2004.23.527; Yu YL, 2005, J BIOL CHEM, V280, P29533, DOI 10.1074/jbc.M506514200; Zhao W, 2006, BLOOD, V107, P907, DOI 10.1182/blood-2005-06-2516; Zhen HN, 2007, INT J ONCOL, V31, P1111; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	38	37	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	17					2577	2584		10.1038/onc.2009.525	http://dx.doi.org/10.1038/onc.2009.525			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20101202				2022-12-17	WOS:000277169400012
J	Komiya, T; Coxon, A; Park, Y; Chen, WD; Zajac-Kaye, M; Meltzer, P; Karpova, T; Kaye, FJ				Komiya, T.; Coxon, A.; Park, Y.; Chen, W-D; Zajac-Kaye, M.; Meltzer, P.; Karpova, T.; Kaye, F. J.			Enhanced activity of the CREB co-activator Crtc1 in LKB1 null lung cancer	ONCOGENE			English	Article						Crtc1; LKB1; lung cancer; Mect1/Torc1; NR4A2	SENSITIVE COINCIDENCE DETECTOR; PEUTZ-JEGHERS-SYNDROME; MUCOEPIDERMOID CARCINOMA; SALIVARY-GLAND; MAMMALIAN-CELLS; WARTHINS TUMORS; GENE-EXPRESSION; RECEPTOR NR4A2; FUSION; ACTIVATION	Activation of Crtc1 (also known as Mect1/Torc1) by a t(11; 19) chromosomal rearrangement underlies the etiology of malignant salivary gland tumors. As LKB1 is a target for mutational inactivation in lung cancer and was recently shown to regulate hepatic Crtc2/CREB transcriptional activity in mice, we now present evidence suggesting disruption of an LKB1/Crtc pathway in cancer. Although Crtc1 is preferentially expressed in adult brain tissues, we observed elevated levels of steady-state Crtc1 in thoracic tumors. In addition, we show that somatic loss of LKB1 is associated with underphosphorylation of endogenous Crtc1, enhanced Crtc1 nuclear localization and enhanced expression of the Crtc prototypic target gene, NR4A2/Nurr1. Inhibition of NR4A2 was associated with growth suppression of LKB1 null tumors, but showed little effect on LKB1-wildtype cells. These data strengthen the role of dysregulated Crtc as a bona. de cancer gene, present a new element to the complex LKB1 tumorigenic axis, and suggest that Crtc genes may be aberrantly activated in a wider range of common adult malignancies. Oncogene (2010) 29, 1672-1680; doi:10.1038/onc.2009.453; published online 14 December 2009	[Komiya, T.; Coxon, A.; Park, Y.; Chen, W-D; Meltzer, P.; Kaye, F. J.] NCI, Genet Branch, Bethesda, MD 20892 USA; [Komiya, T.; Coxon, A.; Park, Y.; Chen, W-D; Zajac-Kaye, M.; Meltzer, P.; Karpova, T.; Kaye, F. J.] Natl Naval Med Ctr, Bethesda, MD USA; [Zajac-Kaye, M.] NCI, Med Oncol Branch, Bethesda, MD 20892 USA; [Karpova, T.] NCI, Lab Receptor Biol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kaye, FJ (corresponding author), Univ Florida Coll, Canc Genet Res Ctr, Dept Med, Rm 364,1376 Mowry Rd, Gainesville, FL 32610 USA.	fkaye@ufl.edu	kaye, frederic/E-2437-2011; CHEN, WEI-DONG/F-4521-2014	CHEN, WEI-DONG/0000-0003-2264-5515; Karpova, Tatiana/0000-0001-6025-2128	Intramural NIH HHS [Z01 SC007256-20] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIASC007256, ZIABC011091, Z01SC007256] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achcar RDD, 2009, HUM PATHOL, V40, P854, DOI 10.1016/j.humpath.2008.11.007; Behboudi A, 2005, GENE CHROMOSOME CANC, V43, P202, DOI 10.1002/gcc.20168; Bittinger MA, 2004, CURR BIOL, V14, P2156, DOI 10.1016/j.cub.2004.11.002; Camelo-Piragua SI, 2009, HUM PATHOL, V40, P887, DOI 10.1016/j.humpath.2008.11.004; Carling D, 2006, TRENDS MOL MED, V12, P144, DOI 10.1016/j.molmed.2006.02.003; Cheng HL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000369; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Coxon A, 2005, CANCER RES, V65, P7137, DOI 10.1158/0008-5472.CAN-05-1125; Dentin R, 2007, NATURE, V449, P366, DOI 10.1038/nature06128; Enlund F, 2004, EXP CELL RES, V292, P21, DOI 10.1016/j.yexcr.2003.09.007; Fu A, 2008, CELL CYCLE, V7, P3823, DOI 10.4161/cc.7.24.7241; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342; Holla VR, 2006, J BIOL CHEM, V281, P2676, DOI 10.1074/jbc.M507752200; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Huang X, 2008, BIOCHEM J, V412, P211, DOI 10.1042/BJ20080557; Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Katajisto P, 2007, BBA-REV CANCER, V1775, P63, DOI 10.1016/j.bbcan.2006.08.003; Katoh Y, 2006, FEBS J, V273, P2730, DOI 10.1111/j.1742-4658.2006.05291.x; Kaye FJ, 2006, CLIN CANCER RES, V12, P3878, DOI 10.1158/1078-0432.CCR-06-0791; Kaye FJ, 2009, MOL CANCER THER, V8, P1399, DOI 10.1158/1535-7163.MCT-09-0135; Kazakov DV, 2007, AM J DERMATOPATH, V29, P457, DOI 10.1097/DAD.0b013e318156d76f; Ke N, 2004, CANCER RES, V64, P8208, DOI 10.1158/0008-5472.CAN-04-2134; Komiya T, 2006, ONCOGENE, V25, P6128, DOI 10.1038/sj.onc.1209627; Kovacs KA, 2007, P NATL ACAD SCI USA, V104, P4700, DOI 10.1073/pnas.0607524104; Lennerz JKM, 2009, AM J SURG PATHOL, V33, P835, DOI 10.1097/PAS.0b013e318190cf5b; Li QX, 2006, HISTOL HISTOPATHOL, V21, P533, DOI 10.14670/HH-21.533; Li SA, 2009, J NEUROSCI, V29, P2334, DOI 10.1523/JNEUROSCI.2296-08.2009; Li XL, 2009, CARCINOGENESIS, V30, P1606, DOI 10.1093/carcin/bgp161; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Pei LM, 2006, NAT MED, V12, P1048, DOI 10.1038/nm1471; Ravnskjaer K, 2007, EMBO J, V26, P2880, DOI 10.1038/sj.emboj.7601715; Sanchez-Cespedes M, 2007, ONCOGENE, V26, P7825, DOI 10.1038/sj.onc.1210594; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015; Shah U, 2008, CANCER RES, V68, P3562, DOI 10.1158/0008-5472.CAN-07-6620; Shaw RJ, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.286pe55; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tirado Y, 2007, GENE CHROMOSOME CANC, V46, P708, DOI 10.1002/gcc.20458; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Wallen-Mackenzie A, 2003, GENE DEV, V17, P3036, DOI 10.1101/gad.276003; Wang B, 2008, CELL METAB, V7, P434, DOI 10.1016/j.cmet.2008.02.010; Wu LZ, 2005, EMBO J, V24, P2391, DOI 10.1038/sj.emboj.7600719; Zhou Y, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000016	48	37	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	2010	29	11					1672	1680		10.1038/onc.2009.453	http://dx.doi.org/10.1038/onc.2009.453			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	20010869	Green Accepted			2022-12-17	WOS:000275694700012
J	Kelly-Spratt, KS; Philipp-Staheli, J; Gurley, KE; Hoon-Kim, K; Knoblaugh, S; Kemp, CJ				Kelly-Spratt, K. S.; Philipp-Staheli, J.; Gurley, K. E.; Hoon-Kim, K.; Knoblaugh, S.; Kemp, C. J.			Inhibition of PI-3K restores nuclear p27(Kip1) expression in a mouse model of Kras-driven lung cancer	ONCOGENE			English	Article						kras; p27; Akt; lung cancer; tumor suppressor	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; TUMOR SUPPRESSION; BREAST-CANCER; MICE LACKING; P53 RESTORATION; P27; PHOSPHORYLATION; GROWTH; DEGRADATION	Reduced expression of the CDK inhibitor p27(Kip1) (p27) in human lung cancer correlates with tumor aggressiveness and poor prognosis. However, the regulation of p27 expression and the role of p27 during lung cancer are poorly understood. Urethane-induced lung tumors in mice frequently harbor mutations in the Kras oncogene, and in this study, we use this model to address the regulation of p27 during tumorigenesis. The Ras effector Akt is known to regulate p27 mRNA abundance by phosphorylating and inactivating the FOXO transcription factors. Phosphorylated Akt and FOXO proteins were both increased in lung tumors, correlating with a reduction in p27 mRNA transcript. Akt also directly phosphorylates p27 and regulates its nuclear/cytoplasmic localization. Tumors showed a reduced nuclear/cytoplasmic ratio of p27 protein, together with an increase in phosphorylated Thr197 p27 in the cytoplasmic pool. Treatment of lung tumor-bearing mice with the phosphoinositol-3 kinase inhibitor LY294002 induced a rapid decrease in phosphorylated Akt and phosphorylated p27, concomitant with an increase in nuclear p27. Germline p27 deficiency accelerated both the growth and malignant progression of urethane-induced lung tumors, and did so in a cell autonomous manner, confirming a causal role of p27 in tumor suppression. These results show that p27 is a potent barrier to the growth and malignant progression of Kras-initiated lung tumors. Further, the reduction of nuclear p27 in tumors is mediated by oncogene signaling pathways, which can be reversed by pharmacological agents. Oncogene (2009) 28, 3652-3662; doi:10.1038/onc.2009.226; published online 3 August 2009	[Kemp, C. J.] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Kemp, CJ (corresponding author), Fred Hutchinson Canc Res Ctr, Div Human Biol, C1-015,1100 Fairview Ave N, Seattle, WA 98109 USA.	cjkemp@fhcrc.org			NIH [T32 CA8046, R01]; ACS; NATIONAL CANCER INSTITUTE [R01CA099517] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ACS(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by a NIH T32 CA8046 Interdisciplinary Training Grant in Cancer Research (KSK-S), and an ACS Research Scholar Award and a NIH R01 Research Grant (CJK).	Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2006, GENE DEV, V20, P47, DOI 10.1101/gad.1384406; Besson A, 2004, NAT REV CANCER, V4, P948, DOI 10.1038/nrc1501; Blain SW, 2002, NAT MED, V8, P1076, DOI 10.1038/nm1002-1076; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; Catzavelos C, 1999, CANCER RES, V59, P684; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Fujita N, 2003, J BIOL CHEM, V278, P49254, DOI 10.1074/jbc.M306614200; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Inui N, 2003, BIOCHEM BIOPH RES CO, V303, P978, DOI 10.1016/S0006-291X(03)00469-8; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; KAWAMATA N, 1995, CANCER RES, V55, P2266; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kossatz U, 2006, EMBO J, V25, P5159, DOI 10.1038/sj.emboj.7601388; Kotake Y, 2005, J BIOL CHEM, V280, P1095, DOI 10.1074/jbc.M406117200; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Malkinson AM, 2001, LUNG CANCER, V32, P265, DOI 10.1016/S0169-5002(00)00232-4; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Motti ML, 2005, AM J PATHOL, V166, P737, DOI 10.1016/S0002-9440(10)62295-X; Motti ML, 2004, CELL CYCLE, V3, P1074; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Philipp-Staheli J, 2004, ONCOGENE, V23, P905, DOI 10.1038/sj.onc.1207220; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Sa G, 2004, EXP CELL RES, V300, P427, DOI 10.1016/j.yexcr.2004.07.032; Schiappacassi M, 2008, MOL CANCER THER, V7, P1164, DOI 10.1158/1535-7163.MCT-07-2154; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shaffer DR, 2005, P NATL ACAD SCI USA, V102, P210, DOI 10.1073/pnas.0407362102; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Shin I, 2005, J BIOL CHEM, V280, P6055, DOI 10.1074/jbc.M412367200; Singhal S, 2005, CLIN CANCER RES, V11, P3974, DOI 10.1158/1078-0432.CCR-04-2661; Susaki E, 2007, CELL CYCLE, V6, P3015, DOI 10.4161/cc.6.24.5087; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tong W, 1998, CELL GROWTH DIFFER, V9, P787; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; Yuan YH, 2007, CANCER RES, V67, P8032, DOI 10.1158/0008-5472.CAN-07-0083; Zindy F, 1999, P NATL ACAD SCI USA, V96, P13462, DOI 10.1073/pnas.96.23.13462	55	37	37	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	2009	28	41					3652	3662		10.1038/onc.2009.226	http://dx.doi.org/10.1038/onc.2009.226			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KJ	19648963	Green Accepted			2022-12-17	WOS:000270851800006
J	Zhu, C; Qin, YR; Xie, D; Chua, DTT; Fung, JM; Chen, L; Fu, L; Hu, L; Guan, XY				Zhu, C.; Qin, Y-R; Xie, D.; Chua, D. T. T.; Fung, J. M.; Chen, L.; Fu, L.; Hu, L.; Guan, X-Y			Characterization of tumor suppressive function of P300/CBP-associated factor at frequently deleted region 3p24 in esophageal squamous cell carcinoma	ONCOGENE			English	Article						esophageal squamous cell carcinoma; PCAF; tumor suppressor gene; loss of heterozygosity; methylation	COMPARATIVE GENOMIC HYBRIDIZATION; CHROMOSOMAL-ABERRATIONS; CYCLIN D1; GENE; EXPRESSION; PCAF; HYPERMETHYLATION; REVEALS; CANCER; BETA	Deletion of 3p is one of the most frequent genetic alterations in many tumors, including esophageal squamous cell carcinoma (ESCC). In our recent study, deletion of 3p24 was frequently detected in ESCC and one candidate tumor suppressor gene (TSG), p300/CBP-associated factor ( PCAF), was identified within the region. In this study, downregulation of PCAF was detected in 23/40 (57.5%) of primary ESCCs and 4/9 (44.4%) of the ESCC cell lines. A further study found that downregulation of PCAF was also associated with hypermethylation of the promoter region of PCAF gene. Methylation-specific PCR found that promoter methylation was detected in 28/40 (70%) of primary ESCCs and 5/9 (55.6%) of ESCC cell lines. In addition, the expression of PCAF could be reactivated in ESCC cell line KYSE510 after demethylation treatment with 5-aza-dC. Functional studies showed that PCAF was able to suppress tumorigenicity of ESCC cells both in vitro and in vivo, including foci formation, colony formation in soft agar and tumor formation in nude mice. Molecular study found that the tumor suppressive mechanism of PCAF was associated with its role in cell cycle arrest at the G1/S checkpoint by the downregulation of CDK2 and upregulation of p21(waf1/Cip1), Smad4, Rb and p27(Kip1). In conclusion, PCAF might be the target TSG responsible for the 3p24 deletion event, which has an important role in the development and progression of ESCC. Oncogene ( 2009) 28, 2821-2828; doi:10.1038/onc.2009.137; published online 15 June 2009	[Zhu, C.; Chua, D. T. T.; Fung, J. M.; Chen, L.; Fu, L.; Hu, L.; Guan, X-Y] Univ Hong Kong, Dept Clin Oncol, Pokfulam, Hong Kong, Peoples R China; [Qin, Y-R] Zhengzhou Univ, Dept Clin Oncol, Affiliated Hosp 1, Zhengzhou, Peoples R China; [Xie, D.; Guan, X-Y] Sun Yat Sen Univ, State Key Lab Oncol So China, Guangzhou, Peoples R China; [Xie, D.; Guan, X-Y] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China	University of Hong Kong; Zhengzhou University; Sun Yat Sen University; Sun Yat Sen University	Guan, XY (corresponding author), Univ Hong Kong, Dept Clin Oncol, Room L10-56,Lab Block,21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	xyguan@hkucc.hku.hk	Fu, Li/F-7182-2010; Chen, Leilei/F-7668-2011; Guan, Xin-Yuan/A-3639-2009	Fu, Li/0000-0003-2643-6278; Guan, Xin-Yuan/0000-0002-4485-6017	Research Grant Council Central Allocation [HKUST 2/06C]; Sun Yat-Sen University 'Hundred Talents Program' [85000-3171311]; Major State Basic Research Program of China [2006CB910104]; National Natural Science Foundation of China [30772475]	Research Grant Council Central Allocation; Sun Yat-Sen University 'Hundred Talents Program'; Major State Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by Research Grant Council Central Allocation ( HKUST 2/06C), Sun Yat-Sen University 'Hundred Talents Program' (85000-3171311), a grant from the Major State Basic Research Program of China (2006CB910104) and a grant from the National Natural Science Foundation of China ( 30772475).	ATADJA P, 1995, EXP CELL RES, V217, P205, DOI 10.1006/excr.1995.1080; Cao ZA, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-11; Carnero A, 1998, CURR TOP MICROBIOL, V227, P43; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chiao PJ, 1999, ANN NY ACAD SCI, V880, P31, DOI 10.1111/j.1749-6632.1999.tb09507.x; de Jong JS, 1998, J CLIN PATHOL-MOL PA, V51, P30, DOI 10.1136/mp.51.1.30; Forbes S, 2006, BRIT J CANCER, V94, P318, DOI 10.1038/sj.bjc.6602928; Fu L, 2007, CANCER RES, V67, P10720, DOI 10.1158/0008-5472.CAN-07-2411; Guan XY, 2001, CANCER RES, V61, P3806; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kuroki T, 2003, CANCER RES, V63, P3724; Kwong D, 2004, HUM PATHOL, V35, P309, DOI 10.1016/j.humpath.2003.10.020; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Offner FA, 2000, PATHOLOGE, V21, P349, DOI 10.1007/s002920000414; OGASAWARA S, 1995, CANCER RES, V55, P891; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Pack SD, 1999, GENE CHROMOSOME CANC, V25, P160, DOI 10.1002/(SICI)1098-2264(199906)25:2<160::AID-GCC12>3.0.CO;2-U; Qin YR, 2008, INT J CANCER, V123, P826, DOI 10.1002/ijc.23577; Schiltz RL, 2000, BBA-REV CANCER, V1470, pM37, DOI 10.1016/S0304-419X(99)00037-2; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Tanaka H, 1996, INT J CANCER, V65, P372, DOI 10.1002/(SICI)1097-0215(19960126)65:3<372::AID-IJC16>3.3.CO;2-3; Ullmannova V, 2003, LEUKEMIA RES, V27, P1115, DOI 10.1016/S0145-2126(03)00103-6; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang X, 2008, ONCOGENE, V27, P1894, DOI 10.1038/sj.onc.1210821; Watts GS, 2004, NEOPLASIA, V6, P187, DOI 10.1593/neo.03292; Xie D, 2003, INT J CANCER, V107, P896, DOI 10.1002/ijc.11514; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yen CC, 2001, CANCER, V92, P2769, DOI 10.1002/1097-0142(20011201)92:11<2769::AID-CNCR10118>3.0.CO;2-M; Zhang CS, 2007, J CLIN PATHOL, V60, P1249, DOI 10.1136/jcp.2006.044099; Zhao LY, 2003, ONCOGENE, V22, P8316, DOI 10.1038/sj.onc.1206916	31	37	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28	31					2821	2828		10.1038/onc.2009.137	http://dx.doi.org/10.1038/onc.2009.137			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479TS	19525977				2022-12-17	WOS:000268684400005
J	Ancot, F; Foveau, B; Lefebvre, J; Leroy, C; Tulasne, D				Ancot, F.; Foveau, B.; Lefebvre, J.; Leroy, C.; Tulasne, D.			Proteolytic cleavages give receptor tyrosine kinases the gift of ubiquity	ONCOGENE			English	Review						receptor tyrosine kinase; cleavages; caspase; metalloprotease; gamma-secretase; signalling	GROWTH-FACTOR RECEPTOR; ALPHA-CONVERTING ENZYME; ANAPLASTIC LYMPHOMA KINASE; HUMAN ENDOTHELIAL-CELLS; C-KIT RECEPTOR; GAMMA-SECRETASE; DOWN-REGULATION; INTRACELLULAR DOMAIN; DEPENDENCE RECEPTOR; ECTODOMAIN CLEAVAGE	Receptor tyrosine kinases (RTK) constitute a large family of membrane receptors which, in response to their respective ligand, transmit information into cells. RTK regulate multiple biological responses, and their deregulation is often associated with tumourigenesis. The intracellular signalling pathways initiated by full-length membrane RTK are studied extensively, but many RTK fragments showing unexpected cellular localization have been observed. These fragments are generated by proteolytic cleavages, catalyzed notably by caspases, membrane metalloproteases or gamma-secretase. Interestingly, these cleavages, in addition to regulating membrane receptor levels, generate active fragments that can regulate biological processes, such as transcription or the survival/apoptosis balance. Thus, proteolytic cleavages release RTK from the membrane and extend their functions. Furthermore, the RTK proteolysis are involved in regulating cell transformation, which highlights their potential as attractive targets for therapeutic strategies. Oncogene (2009) 28, 2185-2195; doi: 10.1038/onc.2009.88; published online 4 May 2009	[Ancot, F.; Foveau, B.; Lefebvre, J.; Leroy, C.; Tulasne, D.] Univ Lille 2, Univ Lille 1, CNRS, Inst Biol Lille,Inst Pasteur Lille,UMR 8161, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Tulasne, D (corresponding author), Univ Lille 2, Univ Lille 1, CNRS, Inst Biol Lille,Inst Pasteur Lille,UMR 8161, BP 447, F-59021 Lille, France.	david.tulasne@ibl.fr	Tulasne, David/AAR-5287-2020; Tulasne, David/A-8705-2008	Tulasne, David/0000-0002-6764-7242; 	CNRS; Institut Pasteur de Lille, and INSERM; Ligue contre le Cancer, comite Nord; Association pour la Recherche sur le Cancer; Fondation Recherche Medicale, Comite Nord-Pas de Calais; Agence Nationale de la Recherche, Young Investigator Program; Institut Pasteur/Region Nord-Pas de Calais' fellowship; French Research and Technology Minister	CNRS(Centre National de la Recherche Scientifique (CNRS)); Institut Pasteur de Lille, and INSERM; Ligue contre le Cancer, comite Nord(Ligue nationale contre le cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Fondation Recherche Medicale, Comite Nord-Pas de Calais; Agence Nationale de la Recherche, Young Investigator Program(French National Research Agency (ANR)); Institut Pasteur/Region Nord-Pas de Calais' fellowship(Region Hauts-de-France); French Research and Technology Minister	This work was supported by the CNRS, the Institut Pasteur de Lille, and INSERM, and by grants from the 'Ligue contre le Cancer, comite Nord', the 'Association pour la Recherche sur le Cancer', the 'Fondation Recherche Medicale, Comite Nord-Pas de Calais' and 'Agence Nationale de la Recherche, Young Investigator Program'. BF was supported by a 'Institut Pasteur/Region Nord-Pas de Calais' fellowship and FA and JL by grants from the French Research and Technology Minister.	Allouche M, 2007, CELL CYCLE, V6, P1533, DOI 10.4161/cc.6.13.4433; Amit I, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100195; Arasada RR, 2005, J BIOL CHEM, V280, P30783, DOI 10.1074/jbc.M506057200; Athauda G, 2006, CLIN CANCER RES, V12, P4154, DOI 10.1158/1078-0432.CCR-06-0250; Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Bae SS, 2001, FEBS LETT, V491, P16, DOI 10.1016/S0014-5793(01)02167-6; Benoit V, 2004, CANCER RES, V64, P2684, DOI 10.1158/0008-5472.CAN-03-2914; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Bredesen DE, 2005, CELL DEATH DIFFER, V12, P1031, DOI 10.1038/sj.cdd.4401680; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; Canibano C, 2007, EMBO J, V26, P2015, DOI 10.1038/sj.emboj.7601636; Chen-Konak L, 2003, FASEB J, V17, P2121, DOI 10.1096/fj.02-1151fje; Cheng QC, 2003, J BIOL CHEM, V278, P38421, DOI 10.1074/jbc.M302111200; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; Christianson TA, 1998, CANCER RES, V58, P5123; Codony-Servat J, 1999, CANCER RES, V59, P1196; CREPALDI T, 1994, J BIOL CHEM, V269, P1750; Cruz AC, 2004, J BIOL CHEM, V279, P5612, DOI 10.1074/jbc.M312323200; Dahlen DD, 2001, LEUKEMIA RES, V25, P413, DOI 10.1016/S0145-2126(00)00122-3; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Diaz-Rodriguez E, 1999, EUR J NEUROSCI, V11, P1421, DOI 10.1046/j.1460-9568.1999.00552.x; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Findley CM, 2007, ARTERIOSCL THROM VAS, V27, P2619, DOI 10.1161/ATVBAHA.107.150482; Foveau B, 2007, CELL DEATH DIFFER, V14, P752, DOI 10.1038/sj.cdd.4402080; Foveau B, 2009, MOL BIOL CELL, V20, P2495, DOI 10.1091/mbc.E08-09-0969; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P9774, DOI 10.1021/bi0494976; Furne C, 2009, BBA-MOL CELL RES, V1793, P231, DOI 10.1016/j.bbamcr.2008.09.009; GALVANI AP, 1995, BIOCHEM PHARMACOL, V50, P959, DOI 10.1016/0006-2952(95)00219-P; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; He YY, 2006, ONCOGENE, V25, P1521, DOI 10.1038/sj.onc.1209184; He YY, 2003, J BIOL CHEM, V278, P42457, DOI 10.1074/jbc.M303376200; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Kasuga K, 2007, BIOCHEM BIOPH RES CO, V360, P90, DOI 10.1016/j.bbrc.2007.06.022; Kolibaba KS, 1997, BBA-REV CANCER, V1333, pF217, DOI 10.1016/S0304-419X(97)00022-X; Kong-Beltran M, 2004, CANCER CELL, V6, P75, DOI 10.1016/j.ccr.2004.06.013; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Kopitz C, 2007, CANCER RES, V67, P8615, DOI 10.1158/0008-5472.CAN-07-0232; LEV S, 1992, J BIOL CHEM, V267, P10866; Linggi B, 2006, ONCOGENE, V25, P160, DOI 10.1038/sj.onc.1209003; Linggi B, 2006, J BIOL CHEM, V281, P25373, DOI 10.1074/jbc.M603998200; Litterst C, 2007, J BIOL CHEM, V282, P16155, DOI 10.1074/jbc.M611449200; Liu XD, 2006, CANCER BIOL THER, V5, P648, DOI 10.4161/cbt.5.6.2707; Luthi AU, 2007, CELL DEATH DIFFER, V14, P641, DOI 10.1038/sj.cdd.4402103; Lyu J, 2008, DEV CELL, V15, P773, DOI 10.1016/j.devcel.2008.10.004; Maina F, 1999, NAT NEUROSCI, V2, P213, DOI 10.1038/6310; Marron MB, 2007, J BIOL CHEM, V282, P30509, DOI 10.1074/jbc.M702535200; Mateos S, 2003, ONCOGENE, V22, P740, DOI 10.1038/sj.onc.1206213; McCarthy MJ, 1999, LAB INVEST, V79, P889; McElroy B, 2007, BIOCHEM BIOPH RES CO, V358, P1136, DOI 10.1016/j.bbrc.2007.05.062; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Migliore C, 2008, EUR J CANCER, V44, P641, DOI 10.1016/j.ejca.2008.01.022; Molina MA, 2001, CANCER RES, V61, P4744; Mourali J, 2006, MOL CELL BIOL, V26, P6209, DOI 10.1128/MCB.01515-05; Nagy P, 2005, CANCER RES, V65, P473; Naresh A, 2006, CANCER RES, V66, P6412, DOI 10.1158/0008-5472.CAN-05-2368; Nath D, 2001, J CELL SCI, V114, P1213; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Parks AL, 2007, TRENDS GENET, V23, P140, DOI 10.1016/j.tig.2007.01.008; Perez-Torres M, 2008, EXP CELL RES, V314, P2907, DOI 10.1016/j.yexcr.2008.07.013; Petrelli A, 2006, P NATL ACAD SCI USA, V103, P5090, DOI 10.1073/pnas.0508156103; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Rovida E, 2001, J IMMUNOL, V166, P1583, DOI 10.4049/jimmunol.166.3.1583; Runeberg-Roos P, 2007, ANN MED, V39, P572, DOI 10.1080/07853890701646256; Saez R, 2006, CLIN CANCER RES, V12, P424, DOI 10.1158/1078-0432.CCR-05-1807; Sanderson MP, 2008, J CELL BIOCHEM, V103, P1783, DOI 10.1002/jcb.21569; Sardi SP, 2006, CELL, V127, P185, DOI 10.1016/j.cell.2006.07.037; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schlessinger J, 2006, CELL, V127, P45, DOI 10.1016/j.cell.2006.09.013; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; Slack BE, 2006, J CELL BIOCHEM, V98, P672, DOI 10.1002/jcb.20812; Strohecker AM, 2008, J BIOL CHEM, V283, P18269, DOI 10.1074/jbc.M802156200; Swendeman S, 2008, CIRC RES, V103, P916, DOI 10.1161/CIRCRESAHA.108.184416; Tauszig-Delamasure S, 2007, P NATL ACAD SCI USA, V104, P13361, DOI 10.1073/pnas.0701243104; Tikhomirov O, 2005, ONCOGENE, V24, P3906, DOI 10.1038/sj.onc.1208534; Tousseyn Thomas, 2006, Birth Defects Research, V78, P24, DOI 10.1002/bdrc.20066; Tulasne D, 2004, MOL CELL BIOL, V24, P10328, DOI 10.1128/MCB.24.23.10328-10339.2004; TURNER AM, 1995, BLOOD, V85, P2052, DOI 10.1182/blood.V85.8.2052.bloodjournal8582052; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; Vidal GA, 2007, ONCOGENE, V26, P462, DOI 10.1038/sj.onc.1209794; Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200; Wajih N, 2002, CIRC RES, V90, P46, DOI 10.1161/hh0102.102756; Warri AM, 1996, EUR J CANCER, V32A, P134, DOI 10.1016/0959-8049(95)00550-1; Wilhelmsen K, 2004, MOL CELL BIOL, V24, P454, DOI 10.1128/MCB.24.1.454-464.2004; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Wilquet V, 2004, CURR OPIN NEUROBIOL, V14, P582, DOI 10.1016/j.conb.2004.08.001; Witters L, 2008, CANCER RES, V68, P7083, DOI 10.1158/0008-5472.CAN-08-0739; Xia WL, 2004, ONCOGENE, V23, P646, DOI 10.1038/sj.onc.1207166; Yabkowitz R, 1999, BLOOD, V93, P1969, DOI 10.1182/blood.V93.6.1969.406k14_1969_1979; Yabkowitz R, 1997, BLOOD, V90, P706, DOI 10.1182/blood.V90.2.706.706_706_715; YEE NS, 1993, J BIOL CHEM, V268, P14189; YEE NS, 1994, J BIOL CHEM, V269, P31991; Zhuang SG, 2003, ONCOGENE, V22, P4413, DOI 10.1038/sj.onc.1206604	102	37	38	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	22					2185	2195		10.1038/onc.2009.88	http://dx.doi.org/10.1038/onc.2009.88			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453VF	19421148				2022-12-17	WOS:000266640300001
J	Tanaka, K; Okamoto, S; Ishikawa, Y; Tamura, H; Hara, T				Tanaka, K.; Okamoto, S.; Ishikawa, Y.; Tamura, H.; Hara, T.			DDX1 is required for testicular tumorigenesis, partially through the transcriptional activation of 12p stem cell genes	ONCOGENE			English	Article						DDX1; germ cell tumor; testis; cyclin-D2	MESSENGER-RNA EXPRESSION; DEAD-BOX PROTEINS; CD9 EXPRESSION; CYCLIN D2; TUMORS; PROLIFERATION; NEUROBLASTOMA; TESTIS; MOUSE; DIFFERENTIATION	Cytogenetic analysis has identified 12p gain as the most frequent abnormality in human testicular germ cell tumors (TGCTs). It has been suggested that amplification and overexpression of stem cell-associated genes, including cyclin-D2, on the human chromosome 12p region are involved in germ cell tumorigenesis. By subtractive cDNA analysis, we identified Ddx1, a member of the DEAD-box protein family, as a gene predominantly expressed in the primordial germ cells of mouse embryos. Knockdown of Ddx1 in a mouse spermatogonia-derived cell line, GC-1spg, by short interference RNA repressed the expression of cyclin-D2, CD9 and GDF3 genes. In the mouse cyclin-D2 gene, a genomic DNA region between -348 and -329 was responsible for transcriptional activation by DDX1 based on reporter and gel shift assays. Similarly, DDX1 knockdown in the human TGCT cell line NEC8 repressed the expression of stem cell-associated genes localized on chromosome 12p13.3, including cyclin-D2, CD9 and NANOG. DDX1-knocked-down TGCT cells could not form solid tumors in nude mice. Furthermore, in situ hybridization revealed that DDX1 mRNA was produced in both seminoma and nonseminoma types of human TGCT samples. We conclude that DDX1 is a critical factor for testicular tumorigenesis. Oncogene (2009) 28, 2142-2151; doi: 10.1038/onc.2009.89; published online 27 April 2009	[Hara, T.] Tokyo Metropolitan Org Med Res, Stem Cell Project Grp, Tokyo Metropolitan Inst Med Sci, Setagaya Ku, Tokyo 1568506, Japan; [Ishikawa, Y.] Tokyo Metropolitan Org Med Res, Core Technol & Res Ctr, Tokyo Metropolitan Inst Med Sci, Tokyo 1568506, Japan	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science	Hara, T (corresponding author), Tokyo Metropolitan Org Med Res, Stem Cell Project Grp, Tokyo Metropolitan Inst Med Sci, Setagaya Ku, 2-1-6 Kamikitazawa, Tokyo 1568506, Japan.	tanaka-ky@igakuken.or.jp; hara-tk@igakuken.or.jp	Okamoto, Shiki/X-7274-2018	Okamoto, Shiki/0000-0002-2802-0527	Ministry of Education, Culture, Sports, Science, and Technology of Japan	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Y Futamata (Nippon Becton Dickinson) for help in the cell sorting experiments. We extend our thanks to all laboratory members for their technical assistance and valuable advice. The anti-SSEA-1 antibody (MC-480) developed by Dr D Solter and Dr BB Knowles was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and was maintained by the University of Iowa, Department of Biological Sciences, Iowa City, IA 52242. This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.	ATKIN NB, 1982, LANCET, V2, P1349; Beumer TL, 2000, BIOL REPROD, V63, P1893, DOI 10.1095/biolreprod63.6.1893; Biermann Katharina, 2007, Cancer Genomics & Proteomics, V4, P359; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; Chaganti RSK, 2000, CANCER RES, V60, P1475; Chaganti RSK, 1998, APMIS, V106, P80, DOI 10.1111/j.1699-0463.1998.tb01322.x; De Rooij DG, 1998, INT J EXP PATHOL, V79, P67, DOI 10.1046/j.1365-2613.1998.00057.x; DEVALOIR T, 1991, P NATL ACAD SCI USA, V88, P2113, DOI 10.1073/pnas.88.6.2113; Fujino RS, 2006, MOL ENDOCRINOL, V20, P904, DOI 10.1210/me.2005-0423; Godbout R, 1998, J BIOL CHEM, V273, P21161, DOI 10.1074/jbc.273.33.21161; GODBOUT R, 1993, P NATL ACAD SCI USA, V90, P7578, DOI 10.1073/pnas.90.16.7578; Hori H, 2004, J SURG RES, V117, P208, DOI 10.1016/j.jss.2004.01.014; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891-2905.2001; Kanatsu-Shinohara M, 2004, BIOL REPROD, V70, P70, DOI 10.1095/biolreprod.103.020867; Kawashima M, 2002, J HISTOCHEM CYTOCHEM, V50, P1195, DOI 10.1177/002215540205000906; Korkola JE, 2006, CANCER RES, V66, P820, DOI 10.1158/0008-5472.CAN-05-2445; Kubota H, 2003, P NATL ACAD SCI USA, V100, P6487, DOI 10.1073/pnas.0631767100; Kubota H, 2004, BIOL REPROD, V71, P722, DOI 10.1095/biolreprod.104.029207; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Linder P, 2006, NUCLEIC ACIDS RES, V34, P4168, DOI 10.1093/nar/gkl468; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; MOTOYAMA T, 1987, ACTA PATHOL JAPON, V37, P431; Nakayama H, 1996, DEV GROWTH DIFFER, V38, P141, DOI 10.1046/j.1440-169X.1996.t01-1-00003.x; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; RODRIGUEZ E, 1992, GENE CHROMOSOME CANC, V5, P21, DOI 10.1002/gcc.2870050104; Rosenberg C, 2000, ONCOGENE, V19, P5858, DOI 10.1038/sj.onc.1203950; SHUIN T, 1994, CANCER, V73, P1721, DOI 10.1002/1097-0142(19940315)73:6<1721::AID-CNCR2820730628>3.0.CO;2-W; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100; SQUIRE JA, 1995, ONCOGENE, V10, P1417; Summersgill B, 2001, BRIT J CANCER, V85, P213, DOI 10.1054/bjoc.2001.1889; Sunden Y, 2007, MICROBIOL IMMUNOL, V51, P339, DOI 10.1111/j.1348-0421.2007.tb03907.x; Tanaka K, 2002, DEV BIOL, V246, P466, DOI 10.1006/dbio.2002.0671; Watsuji T, 1997, BIOCHEM BIOPH RES CO, V234, P769, DOI 10.1006/bbrc.1997.6705; Weber A, 2004, J CLIN ONCOL, V22, P2681, DOI 10.1200/JCO.2004.07.192	37	37	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2009	28	21					2142	2151		10.1038/onc.2009.89	http://dx.doi.org/10.1038/onc.2009.89			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	451DQ	19398953				2022-12-17	WOS:000266451300003
J	Mourskaia, AA; Dong, Z; Ng, S; Banville, M; Zwaagstra, JC; O'Connor-McCourt, MD; Siegel, PM				Mourskaia, A. A.; Dong, Z.; Ng, S.; Banville, M.; Zwaagstra, J. C.; O'Connor-McCourt, M. D.; Siegel, P. M.			Transforming growth factor-beta 1 is the predominant isoform required for breast cancer cell outgrowth in bone	ONCOGENE			English	Article						TGF-beta isoforms; breast cancer; ligand trap; bone microenvironment	HORMONE-RELATED PROTEIN; TUMOR-SUPPRESSOR; I RECEPTOR; SKELETAL METASTASIS; BETA; EXPRESSION; SMAD; MECHANISMS; VIVO	Transforming growth factor (TGF)-beta signaling is a potent modulator of the invasive and metastatic behavior of breast cancer cells. Indeed, breast tumor responsiveness to TGF-beta is important for the development of osteolytic bone metastases. However, the specific TGF-beta isoforms that promote breast cancer outgrowth in bone is unknown. We demonstrate that expression of a TGF-beta ligand trap, which neutralizes TGF-beta 1 and TGF-beta 3, in MDA-MB-231 breast cancer cells diminished their outgrowth in bone and reduced the severity of osteolytic lesion formation when compared with controls. We further show that a reduction or loss of TGF-beta 1 expression within the bone microenvironment of TGF-beta 1+/- and TGF-beta 1-/- mice significantly reduced the incidence of breast tumor outgrowth compared with wild-type animals. Interestingly, those tumors capable of growing within the tibiae of TGF-beta 1-deficient mice had upregulated expression of all three TGF-b isoforms. Finally, breast cancer cells expressing the TGF-b ligand trap showed a pronounced reduction in their ability to form osteolytic lesions when injected into the tibiae of TGF-beta 1-/- mice. Thus, our studies show that both host- and tumor-derived TGF-beta expression plays a critical role during the establishment and outgrowth of breast cancer cells in bone.	[Mourskaia, A. A.; Dong, Z.; Zwaagstra, J. C.; Siegel, P. M.] McGill Univ, Dept Med, Montreal, PQ H3A 1A4, Canada; [Ng, S.; O'Connor-McCourt, M. D.; Siegel, P. M.] McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 1A4, Canada; [Banville, M.; Zwaagstra, J. C.; O'Connor-McCourt, M. D.] Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; [O'Connor-McCourt, M. D.; Siegel, P. M.] McGill Univ, Dept Biochem, Montreal, PQ H3A 1A4, Canada	McGill University; McGill University; National Research Council Canada; McGill University	Siegel, PM (corresponding author), McGill Univ, Dept Med, 740 Dr Penfield Ave,Room 2201, Montreal, PQ H3A 1A4, Canada.	peter.siegel@mcgill.ca						Bandyopadhyay A, 2006, CANCER RES, V66, P6714, DOI 10.1158/0008-5472.CAN-05-3565; Baselga J, 2008, BIOMARKERS, V13, P217, DOI 10.1080/13547500701676019 ; Broussau S, 2008, MOL THER, V16, P500, DOI 10.1038/sj.mt.6300383; Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931; De Crescenzo G, 2006, J MOL BIOL, V355, P47, DOI 10.1016/j.jmb.2005.10.022; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; del Re E, 2004, J BIOL CHEM, V279, P22765, DOI 10.1074/jbc.M401350200; Ehata S, 2007, CANCER SCI, V98, P127, DOI 10.1111/j.1349-7006.2006.00357.x; Engle SJ, 1999, CANCER RES, V59, P3379; Geiser AG, 1998, BONE, V23, P87, DOI 10.1016/S8756-3282(98)00078-7; Groppe J, 2008, MOL CELL, V29, P157, DOI 10.1016/j.molcel.2007.11.039; Hering S, 2001, EXP CLIN ENDOCR DIAB, V109, P107, DOI 10.1055/s-2001-14830; Hering S, 2001, EXP CLIN ENDOCR DIAB, V109, P217, DOI 10.1055/s-2001-15109; Hess KR, 2006, CANCER, V106, P1624, DOI 10.1002/cncr.21778; Janssens K, 2005, ENDOCR REV, V26, P743, DOI 10.1210/er.2004-0001; Kakonen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Komesli S, 1998, EUR J BIOCHEM, V254, P505, DOI 10.1046/j.1432-1327.1998.2540505.x; Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911-005-5399-8; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Liao JH, 2006, CANCER METAST REV, V25, P559, DOI 10.1007/s10555-006-9033-z; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MANOLAGAS SC, 1995, BONE, V17, pS63, DOI 10.1016/8756-3282(95)00180-L; Mastro AM, 2003, CLIN EXP METASTAS, V20, P275, DOI 10.1023/A:1022995403081; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Mourskaia AA, 2007, ANTI-CANCER AGENT ME, V7, P504, DOI 10.2174/187152007781668689; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Northey JJ, 2008, MOL CELL BIOL, V28, P3162, DOI 10.1128/MCB.01734-07; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rose AAN, 2006, B CANCER, V93, P931; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sotiriou C, 2001, CANCER LETT, V169, P87, DOI 10.1016/S0304-3835(01)00524-9; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486; Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070	41	37	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2009	28	7					1005	1015		10.1038/onc.2008.454	http://dx.doi.org/10.1038/onc.2008.454			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	408TH	19079339	Green Published			2022-12-17	WOS:000263457400007
J	Wilson, TR; McEwan, M; McLaughlin, K; Le Clorennec, C; Allen, WL; Fennell, DA; Johnston, PG; Longley, DB				Wilson, T. R.; McEwan, M.; McLaughlin, K.; Le Clorennec, C.; Allen, W. L.; Fennell, D. A.; Johnston, P. G.; Longley, D. B.			Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells	ONCOGENE			English	Article						FLIP; Bax; XIAP; colorectal cancer; caspase 3	X-LINKED INHIBITOR; RECEPTOR-INDUCED APOPTOSIS; C-FLIP; CASPASE-9 INHIBITOR; PROGNOSTIC MARKER; DEATH RECEPTORS; EXPRESSION; TRAIL; TUMOR; PROTEIN	Death receptors can directly(type I cells) or indirectly induce apoptosis by activating mitochondrial-regulated apoptosis (type II cells). The level of caspase 8 activation is thought to determine whether a cell is type I or II, with type II cells less efficient at activating this caspase following death receptor activation. FLICE-inhibitory protein (FLIP) blocks death receptor-mediated apoptosis by inhibiting caspase 8 activation; therefore, we assessed whether silencing FLIP could convert type II cells into type I. FLIP silencing-induced caspase 8 activation in Bax wild-type and null HCT116 colorectal cancer cells; however, complete caspase 3 processing and apoptosis were only observed in Bax wild-type cells. Bax-null cells were also more resistant to chemotherapy and tumor necrosis factor-related apoptosis inducing ligand and, unlike the Bax wild-type cells, were not sensitized to these agents by FLIP silencing. Further analyses indicated that release of second mitochondrial activator of caspases from mitochondria and subsequent inhibition of X-linked inhibitor of apoptosis protein ( XIAP) was required to induce full caspase 3 processing and apoptosis following FLIP silencing. These results indicate that silencing FLIP does not necessarily by pass the requirement for mitochondrial involvement in type II cells. Furthermore, targeting FLIP and XIAP may represent a therapeutic strategy for the treatment of colorectal tumors with defects in mitochondrial-regulated apoptosis.	[Wilson, T. R.; McEwan, M.; McLaughlin, K.; Le Clorennec, C.; Allen, W. L.; Fennell, D. A.; Johnston, P. G.; Longley, D. B.] Queens Univ Belfast, Drug Resistance Lab, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland	Queens University Belfast	Longley, DB (corresponding author), Queens Univ Belfast, Drug Resistance Lab, Ctr Canc Res & Cell Biol, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	d.longley@qub.ac.uk	Wilson, Timothy R/F-8210-2012; McEwan, Miranda V/A-6900-2012	McLaughlin, Kirsty/0000-0002-3584-4911	Cancer Research UK, the Medical Research Council; Ulster Cancer Foundation; Medical Research Council [G0400302] Funding Source: researchfish; MRC [G0400302] Funding Source: UKRI	Cancer Research UK, the Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)Cancer Research UK); Ulster Cancer Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was supported by: Cancer Research UK, the Medical Research Council and the Ulster Cancer Foundation.	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Arango D, 2004, BRIT J CANCER, V91, P1931, DOI 10.1038/sj.bjc.6602215; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Berger AB, 2006, CELL RES, V16, P961, DOI 10.1038/sj.cr.7310112; Bratton SB, 2003, CELL DEATH DIFFER, V10, P4, DOI 10.1038/sj.cdd.4401176; Broaddus VC, 2005, J BIOL CHEM, V280, P12486, DOI 10.1074/jbc.M408190200; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; Dean EJ, 2007, EXPERT OPIN THER TAR, V11, P1459, DOI 10.1517/14728222.11.11.1459; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ekert PG, 2001, CELL DEATH DIFFER, V8, P662, DOI 10.1038/sj.cdd.4400895; Ferreira CG, 2001, CLIN CANCER RES, V7, P2468; Galligan L, 2005, MOL CANCER THER, V4, P2026, DOI 10.1158/1535-7163.MCT-05-0262; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Han J, 2004, LEUKEMIA, V18, P1671, DOI 10.1038/sj.leu.2403496; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Hyer ML, 2005, CANCER RES, V65, P4799, DOI 10.1158/0008-5472.CAN-04-3319; Jansson A, 2002, J CLIN ONCOL, V20, P811, DOI 10.1200/JCO.20.3.811; Jonsson G, 2003, ANTICANCER RES, V23, P1213; Kang SY, 2007, CLIN CANCER RES, V13, P4146, DOI 10.1158/1078-0432.CCR-06-3063; Kim SH, 2004, J BIOL CHEM, V279, P40044, DOI 10.1074/jbc.M404541200; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Krajewska M, 2003, CLIN CANCER RES, V9, P4914; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LaCasse EC, 2006, CLIN CANCER RES, V12, P5231, DOI 10.1158/1078-0432.CCR-06-0608; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li M, 2007, CHINESE MED J-PEKING, V120, P469, DOI 10.1097/00029330-200703020-00007; Longley DB, 2006, ONCOGENE, V25, P838, DOI 10.1038/sj.onc.1209122; Mathas S, 2004, J EXP MED, V199, P1041, DOI 10.1084/jem.20031080; Mizutani Y, 2007, INT J ONCOL, V30, P919; Ozoren N, 2000, CANCER RES, V60, P6259; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Ryu BK, 2001, J PATHOL, V194, P15, DOI 10.1002/path.835; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schimmer AD, 2003, CANCER RES, V63, P1242; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Tamm I, 2004, HEMATOL J, V5, P489, DOI 10.1038/sj.thj.6200549; Theodorakis P, 2002, CANCER RES, V62, P3373; Valnet-Rabier MB, 2005, BRIT J HAEMATOL, V128, P767, DOI 10.1111/j.1365-2141.2005.05378.x; Verdine GL, 2007, CLIN CANCER RES, V13, P7264, DOI 10.1158/1078-0432.CCR-07-2184; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; Wang SL, 2003, P NATL ACAD SCI USA, V100, P15095, DOI 10.1073/pnas.2435285100; Wang XD, 2001, GENE DEV, V15, P2922; Werner AB, 2002, J BIOL CHEM, V277, P40760, DOI 10.1074/jbc.M204351200; Wilson TR, 2007, CANCER RES, V67, P5754, DOI 10.1158/0008-5472.CAN-06-3585; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhou XD, 2004, CLIN SCI, V106, P397, DOI 10.1042/CS20030238; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	54	37	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					63	72		10.1038/onc.2008.366	http://dx.doi.org/10.1038/onc.2008.366			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18820704				2022-12-17	WOS:000262294100007
J	Feres, KJ; Ischenko, I; Hayman, MJ				Feres, K. J.; Ischenko, I.; Hayman, M. J.			The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells	ONCOGENE			English	Article						RON; MSP; c-Src; breast cancer; cell spreading; survival	EPIDERMAL-GROWTH-FACTOR; MACROPHAGE-STIMULATING PROTEIN; C-SRC; CANCER CELLS; MESENCHYMAL TRANSITION; TUMOR-CELLS; MET FAMILY; ACTIVATION; PHOSPHORYLATION; OVEREXPRESSION	The recepteur d'origine nantais (RON) is a receptor tyrosine kinase (RTK) in the scatter factor family, which includes the c-Met receptor. RON exhibits increased expression in a significant number of human breast cancer tissues as well as in many established breast cancer cell lines. Recent studies have indicated that in addition to ligand-dependent signaling events, RON also promotes signals in the absence of its only known ligand, MSP, when expressed in epithelial cells. In this study, we found that when expressed in MCF-10A breast epithelial cells, RON exhibits both MSP-dependent and MSP-independent signaling, which lead to distinct biological outcomes. In the absence of MSP, RON signaling promotes cell survival, increased cell spreading and enhanced migration in response to other growth factors. However, both RON-mediated proliferation and migration require the addition of MSP in MCF-10A cells. Both MSP-dependent and MSP-independent signaling by RON are mediated in part by Src family kinases. These data suggest that RON has two alternative modes of signaling that can contribute to oncogenic behavior in normal breast epithelial cells.	[Feres, K. J.; Ischenko, I.; Hayman, M. J.] SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hayman, MJ (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Life Sci Bldg, Stony Brook, NY 11794 USA.	mhayman@ms.cc.sunysb.edu			NCI [CA28146]; Beauty Foundation; Long Island League to Abolish Cancer (LILAC); NIH [T32-CA009176]; NATIONAL CANCER INSTITUTE [T32CA009176, P01CA028146] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Beauty Foundation; Long Island League to Abolish Cancer (LILAC); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Roger Daly and Joan S. Brugge for providing the MCF-10A/ecoR cell line, James Keller for RT-PCR assistance, Dr W Todd Miller for the DN-Src construct, Kyeisha Hodge for generating the K114M mutant and Dr Edward Chan for various reagents used throughout this study. We also thank members of our laboratory plus Dr Mina Bissell for helpful discussions. The studies were funded by NCI grant CA28146, the Walk for Beauty Foundation and Long Island League to Abolish Cancer (LILAC) to MJH. KJF was supported by NIH T32-CA009176.	Bezerra JA, 1998, J CLIN INVEST, V101, P1175, DOI 10.1172/JCI1744; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Chen YQ, 2000, EXP CELL RES, V261, P229, DOI 10.1006/excr.2000.5012; Cote M, 2007, BIOCHEM BIOPH RES CO, V360, P219, DOI 10.1016/j.bbrc.2007.06.033; Danilkovitch A, 2000, MOL CELL BIOL, V20, P2218, DOI 10.1128/MCB.20.6.2218-2227.2000; Danilkovitch-Miagkova A, 2000, J BIOL CHEM, V275, P14783, DOI 10.1074/jbc.C000028200; Danilkovitch-Miagkova A, 2003, CURR CANCER DRUG TAR, V3, P31, DOI 10.2174/1568009033333745; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Emaduddin M, 2008, P NATL ACAD SCI USA, V105, P2358, DOI 10.1073/pnas.0712176105; Hofmann C, 2007, GASTROENTEROLOGY, V132, P587, DOI 10.1053/j.gastro.2006.11.017; Hsu PY, 2006, J UROLOGY, V176, P2262, DOI 10.1016/j.juro.2006.07.048; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Ishizawar RC, 2004, J BIOL CHEM, V279, P23773, DOI 10.1074/jbc.M312368200; Kang HG, 2007, CANCER RES, V67, P3094, DOI 10.1158/0008-5472.CAN-06-3259; Lee WY, 2005, CLIN CANCER RES, V11, P2222, DOI 10.1158/1078-0432.CCR-04-1761; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Montesano R, 1998, CELL GROWTH DIFFER, V9, P355; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Muller EJ, 2008, J INVEST DERMATOL, V128, P501, DOI 10.1038/sj.jid.5701248; Muraoka RS, 1999, ENDOCRINOLOGY, V140, P187, DOI 10.1210/en.140.1.187; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; O'Toole JM, 2006, CANCER RES, V66, P9162, DOI 10.1158/0008-5472.CAN-06-0283; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Petrenko O, 1999, IMMUNITY, V10, P691, DOI 10.1016/S1074-7613(00)80068-0; Riggins RB, 2006, CANCER RES, V66, P7007, DOI 10.1158/0008-5472.CAN-05-3952; RONSIN C, 1993, ONCOGENE, V8, P1195; Santoro MM, 2003, DEV CELL, V5, P257, DOI 10.1016/S1534-5807(03)00201-6; Stahl S, 1997, J CELL SCI, V110, P55; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Tagliaferri P, 2005, CURR DRUG TARGETS, V6, P289, DOI 10.2174/1389450053765897; Thomas RM, 2007, CANCER RES, V67, P6075, DOI 10.1158/0008-5472.CAN-06-4128; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Van Slambrouck S, 2007, INT J ONCOL, V31, P1501; Wang D, 2004, ONCOGENE, V23, P1668, DOI 10.1038/sj.onc.1207282; Wang MH, 2003, CARCINOGENESIS, V24, P1291, DOI 10.1093/carcin/bgg089; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; Wei X, 2005, J BIOL CHEM, V280, P35098, DOI 10.1074/jbc.M505737200; Weiss FU, 1997, CURR OPIN GENET DEV, V7, P80, DOI 10.1016/S0959-437X(97)80113-X; Welm AL, 2007, P NATL ACAD SCI USA, V104, P7570, DOI 10.1073/pnas.0702095104; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; Wu WD, 2002, J BIOL CHEM, V277, P24252, DOI 10.1074/jbc.M200437200; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Yamamoto N, 2006, J CELL SCI, V119, P4623, DOI 10.1242/jcs.03236; Yokoyama N, 2005, J BIOL CHEM, V280, P8893, DOI 10.1074/jbc.M412623200; Zalcenstein A, 2006, ONCOGENE, V25, P359, DOI 10.1038/sj.onc.1209061; Zinser GM, 2006, CANCER RES, V66, P11967, DOI 10.1158/0008-5472.CAN-06-2473	48	37	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					279	288		10.1038/onc.2008.383	http://dx.doi.org/10.1038/onc.2008.383			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18836480	Green Accepted			2022-12-17	WOS:000262501100011
J	Burgess, A; Labbe, JC; Vigneron, S; Bonneaud, N; Strub, JM; Van Dorsselaer, A; Lorca, T; Castro, A				Burgess, A.; Labbe, J. -C; Vigneron, S.; Bonneaud, N.; Strub, J. M.; Van Dorsselaer, A.; Lorca, T.; Castro, A.			Chfr interacts and colocalizes with TCTP to the mitotic spindle	ONCOGENE			English	Article						checkpoint; cancer; Chfr; prophase; spindle; TCTP	CONTROLLED TUMOR PROTEIN; CHECKPOINT PROTEIN; STRESS CHECKPOINT; CELL-CYCLE; GENE; HYPERMETHYLATION; MITOSIS; DELAYS; LIGASE; GROWTH	Chfr is a checkpoint protein that plays an important function in cell cycle progression and tumor suppression, although its exact role and regulation are unclear. Previous studies have utilized overexpression of Chfr to determine the signaling pathway of this protein in vivo. In this study, we demonstrate, by using three different antibodies against Chfr, that the endogenous and highly overexpressed ectopic Chfr protein is localized and regulated differently in cells. Endogenous and lowly expressed ectopic Chfr are cytoplasmic and localize to the spindle during mitosis. Higher expression of ectopic Chfr correlates with a shift in the localization of this protein to the nucleus/PML bodies, and with a block of cell proliferation. In addition, endogenous and lowly expressed ectopic Chfr is stable throughout the cell cycle, whereas when highly expressed, ectopic Chfr is actively degraded during S-G2/M phases in an autoubiquitination and proteasome-dependent manner. A two-hybrid screen identified TCTP as a possible Chfr-interacting partner. Biochemical analysis with the endogenous proteins confirmed this interaction and identified beta-tubulin as an additional partner for Chfr, supporting the mitotic spindle localization of Chfr. The Chfr-TCTP interaction was stable throughout the cell cycle, but it could be diminished by the complete depolymerization of the microtubules, providing a possible mechanism where Chfr could be the sensor that detects microtubule disruption and then activates the prophase checkpoint.	[Burgess, A.; Labbe, J. -C; Lorca, T.; Castro, A.] Univ Montpellier 2, Ctr Rech Biochim Macromol, CNRS, UMR Labellisee Ligue Natl Canc 5237,IFR 122, Montpellier, France; [Burgess, A.; Labbe, J. -C; Vigneron, S.; Lorca, T.; Castro, A.] Univ Montpellier I, Ctr Rech Biochim Macromol, CNRS, UMR Labellisee Ligue Natl Canc 5237,IFR 122, Montpellier, France; [Bonneaud, N.] CNRS, IGH, UPR14142, Montpellier, France; [Strub, J. M.] Inst Pluridisciplinaire Hubert Curien, UMR7178, Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3)	Lorca, T (corresponding author), Univ Montpellier, Ctr Rech Biochim Macromol, CNRS, 1919 Route Mende, F-34293 Montpellier, France.	thierry.lorca@crbm.cnrs.fr; anna.castro@crbm.cnrs.fr	CASTRO, ANNA/F-4350-2010; Burgess, Andrew/C-7952-2009; labbe, jean-claude/B-2277-2009; Burgess, Andrew/H-3339-2019	CASTRO, ANNA/0000-0002-3655-1352; Burgess, Andrew/0000-0003-4536-9226; Burgess, Andrew/0000-0003-4536-9226; Strub, Jean-Marc/0000-0001-6224-3428; Lorca, Thierry/0000-0003-2007-8924	Ligue Nationale Contre le Cancer (Equipe Labellisee)	Ligue Nationale Contre le Cancer (Equipe Labellisee)(Ligue nationale contre le cancer)	We thank Julian Cau from the Montpellier RIO Imaging facility (CRBM). We also acknowledge J Casanova, JM Donnay and JC Mazur for their technical support. This work was supported by the Ligue Nationale Contre le Cancer (Equipe Labellisee). AB is a Ligue Nationale Contre le Cancer fellow.	Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Bothos J, 2003, ONCOGENE, V22, P7101, DOI 10.1038/sj.onc.1206831; Burgess A, 2006, J BIOL CHEM, V281, P9987, DOI 10.1074/jbc.M512714200; Chaturvedi P, 2002, CANCER RES, V62, P1797; CHEUNG H, 2003, P NATL ACAD SCI USA, V100, P7818; Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47; Daniels MJ, 2004, NAT STRUCT MOL BIOL, V11, P1114, DOI 10.1038/nsmb837; Erson AE, 2004, MOL CARCINOGEN, V39, P26, DOI 10.1002/mc.10161; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gachet Y, 1999, J CELL SCI, V112, P1257; Hsu YC, 2007, NATURE, V445, P785, DOI 10.1038/nature05528; Jung J, 2004, J BIOL CHEM, V279, P49868, DOI 10.1074/jbc.M400895200; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Liu H, 2005, MOL CELL BIOL, V25, P3117, DOI 10.1128/MCB.25.8.3117-3126.2005; Loring GL, 2008, CELL CYCLE, V7, P96, DOI 10.4161/cc.7.1.5113; Mariatos G, 2003, CANCER RES, V63, P7185; Matsusaka T, 2004, J CELL BIOL, V166, P507, DOI 10.1083/jcb.200401139; Mikhailov A, 2005, CELL CYCLE, V4, P57, DOI 10.4161/cc.4.1.1357; Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402; MURRAY AW, 1991, SCI AM, V264, P56, DOI 10.1038/scientificamerican0391-56; Privette LM, 2007, CANCER RES, V67, P6064, DOI 10.1158/0008-5472.CAN-06-4109; Rieder CL, 2000, CURR BIOL, V10, P1067, DOI 10.1016/S0960-9822(00)00678-3; Satoh A, 2003, CANCER RES, V63, P8606; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Tuynder M, 2004, P NATL ACAD SCI USA, V101, P15364, DOI 10.1073/pnas.0406776101; Tuynder M, 2002, P NATL ACAD SCI USA, V99, P14976, DOI 10.1073/pnas.222470799; Uzbekov R, 1998, EXP CELL RES, V242, P60, DOI 10.1006/excr.1998.4097; Yang Y, 2005, ONCOGENE, V24, P4778, DOI 10.1038/sj.onc.1208666; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538	31	37	41	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2008	27	42					5554	5566		10.1038/onc.2008.167	http://dx.doi.org/10.1038/onc.2008.167			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KX	18504434	Green Submitted			2022-12-17	WOS:000259280800002
J	Bheda, A; Creek, KE; Pirisi, L				Bheda, A.; Creek, K. E.; Pirisi, L.			Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes	ONCOGENE			English	Article						p53; EGFR promoter; HPV16; human keratinocytes; YY1; Sp1	TRANSCRIPTION FACTOR YY1; CERVICAL-CANCER; GENE; IDENTIFICATION; ACTIVATION; EXPRESSION; REGULATOR; BINDING; SP1; E6	Overexpression of the epidermal growth factor receptor (EGFR) in human papillomavirus type 16-immortalized human keratinocytes (HKc) is caused by the viral oncoprotein E6, which targets p53 for degradation. We have previously observed that expression of p53 RNAi in normal HKc is associated with an increase in EGFR mRNA and protein. We now report that p53 RNAi induces EGFR promoter activityup to approximately 10-fold in normal HKc, and this effect does not require intact p53 binding sites on the EGFR promoter. Exogenous wildtype p53 inhibits the EGFR promoter at low levels, and activates it at higher concentrations. Yin Yang 1 (YY1), which negatively regulates p53, induces EGFR promoter activity, and this effect is augmented by p53 RNAi. Intact p53 binding sites on the EGFR promoter are not required for activation by YY1. In addition, Sp1 and YY1 synergistically induce the EGFR promoter in normal HKc, indicating that Sp1 may recruit YY1 as a coactivator. Wild-type p53 suppressed Sp1- and YY1-mediated induction of the EGFR promoter. We conclude that acute loss of p53 in normal HKc induces EGFR expression by a mechanism that involves YY1 and Sp1 and does not require p53 binding to the EGFR promoter.	[Pirisi, L.] Univ S Carolina, Sch Med, S Carolina Canc Ctr, Dept Pathol Microbiol & Immunol,Basic Sci Labs, Columbia, SC 29203 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Pirisi, L (corresponding author), Univ S Carolina, Sch Med, S Carolina Canc Ctr, Dept Pathol Microbiol & Immunol,Basic Sci Labs, 14 Richland Med Pk,Suite 500, Columbia, SC 29203 USA.	pirisi@med.sc.edu			NATIONAL CANCER INSTITUTE [R01CA089502, P20CA096427] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [P20MD001770] Funding Source: NIH RePORTER; NCI NIH HHS [P20 CA096427-03, R01 CA089502, P20CA096427, P20 CA096427, R01CA89502, R01 CA089502-05] Funding Source: Medline; NIMHD NIH HHS [P20 MD001770, P20 MD001770-030002] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))		Ai WD, 2000, J VIROL, V74, P5198, DOI 10.1128/JVI.74.11.5198-5205.2000; Akerman GS, 2001, CANCER RES, V61, P3837; Arteaga CL, 2002, ONCOLOGIST, V7, P31; Baldwin A, 2004, J VIROL, V78, P3953, DOI 10.1128/JVI.78.8.3953-3964.2004; DEB SP, 1994, ONCOGENE, V9, P1341; Dykxhoorn DM, 2005, ANNU REV MED, V56, P401, DOI 10.1146/annurev.med.56.082103.104606; Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; HALEY J, 1987, ONCOGENE RES, V1, P375; Hu GY, 1997, JNCI-J NATL CANCER I, V89, P1271, DOI 10.1093/jnci/89.17.1271; Innocente SA, 2005, FEBS LETT, V579, P1001, DOI 10.1016/j.febslet.2004.12.073; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; Johnson AC, 2000, MOL MED, V6, P17, DOI 10.1007/BF03401931; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; Kawada H, 2005, J INVEST DERMATOL, V124, P1206, DOI 10.1111/j.0022-202X.2005.23748.x; Kilic G, 1999, EUR J GYNAECOL ONCOL, V20, P167; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Mathur SP, 2001, AM J REPROD IMMUNOL, V46, P280, DOI 10.1034/j.1600-0897.2001.d01-14.x; PIRISI L, 1988, CARCINOGENESIS, V9, P1573, DOI 10.1093/carcin/9.9.1573; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; Sheikh MS, 1997, ONCOGENE, V15, P1095, DOI 10.1038/sj.onc.1201264; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Wang X, 2006, J CELL BIOL, V172, P409, DOI 10.1083/jcb.200510002; XU J, 1993, J BIOL CHEM, V268, P16065; Yakovleva T, 2004, BIOCHEM BIOPH RES CO, V318, P615, DOI 10.1016/j.bbrc.2004.04.065; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhao RB, 2000, GENE DEV, V14, P981; ZYZAK LL, 1994, CELL GROWTH DIFFER, V5, P537	32	37	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4315	4323		10.1038/onc.2008.65	http://dx.doi.org/10.1038/onc.2008.65			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18391986	Green Accepted			2022-12-17	WOS:000257691100006
J	Jiao, W; Lin, HM; Datta, J; Braunschweig, T; Chung, JY; Hewitt, SM; Rane, SG				Jiao, W.; Lin, H-M; Datta, J.; Braunschweig, T.; Chung, J-Y; Hewitt, S. M.; Rane, S. G.			Aberrant nucleocytoplasmic localization of the retinoblastoma tumor suppressor protein in human cancer correlates with moderate/poor tumor differentiation	ONCOGENE			English	Article						RB; CDK; cancer; export; localization; differentiation	RING-FINGER DOMAIN; CELL-CYCLE; NUCLEAR EXPORT; BREAST-CANCER; GENE-PRODUCT; PHOSPHORYLATION; CDK4; EXPRESSION; MELANOMA; MECHANISM	Inactivation of the retinoblastoma (RB) tumor suppressor pathway, via elevated cyclin-dependent kinase (CDK) activity, is observed in majority of human cancers. Since CDK deregulation is evident in most cancer cells, pharmacological CDK inhibition has become an attractive therapeutic strategy in oncology. We recently showed that an oncogenic CDK4R24C mutation alters the subcellular localization of the normally nuclear RB phosphoprotein. Here, using 71 human cancer cell lines and over 300 primary human cancer tissues, we investigated whether changes in RB subcellular localization occur during human cancer progression. We uncover that diverse human cancers and their derived cell lines, particularly those with poor tumor differentiation, display significant cytoplasmic mislocalization of ordinarily nuclear RB. The nucleocytoplasmically distributed RB was derived via CDK-dependent and Exportin1-mediated nuclear export. Indeed, cytoplasmically mislocalized RB could be efficiently confined to the nucleus by pharmacologically reducing CDK activity or by inhibiting the Exportin1-mediated nuclear export pathway. Our observations uncover a post-translational CDK-dependent mechanism of RB inactivation and suggest that cytoplasmically localized RB may harbor a tumor promoting function. We propose that RB inactivation, via aberrant nucleocytoplasmic transport, may disrupt normal cell differentiation programs and accelerate the cancer process. These results are evidence that tumor cells modulate the protein transport machinery thereby making the protein transport process a viable therapeutic target.	[Lin, H-M; Rane, S. G.] NIDDKD, Diabet Branch, NIH, Bethesda, MD 20892 USA; [Jiao, W.; Lin, H-M; Datta, J.; Rane, S. G.] Lab Cell Regulat & Carcinogenesis, Bethesda, MD USA; [Braunschweig, T.; Chung, J-Y; Hewitt, S. M.] NCI, Pathol Lab, Tissue Array Res Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rane, SG (corresponding author), NIDDKD, Diabet Branch, NIH, CRC 5-5940,9000 Rockville Pike, Bethesda, MD 20892 USA.	ranes@mail.nih.gov	Chung, Joon-Yong/J-9177-2017; Braunschweig, Till/AAO-5725-2020	Chung, Joon-Yong/0000-0001-5041-5982; Braunschweig, Till/0000-0001-9166-2912; Datta, Jashodeep/0000-0003-2869-1571; Hewitt, Stephen/0000-0001-8283-1788	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZICBC010923, Z01BC010923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK055107, ZIADK055107] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alkarain A, 2004, J MAMMARY GLAND BIOL, V9, P67, DOI 10.1023/B:JOMG.0000023589.00994.5e; Blain SW, 2002, NAT MED, V8, P1076, DOI 10.1038/nm1002-1076; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Braunschweig T, 2005, EXPERT REV PROTEOMIC, V2, P325, DOI 10.1586/14789450.2.3.325; Camphausen K, 2004, MOL CANCER THER, V3, P409; Chestukhin A, 2002, MOL CELL BIOL, V22, P453, DOI 10.1128/MCB.22.2.453-468.2002; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Goodrich DW, 2006, ONCOGENE, V25, P5233, DOI 10.1038/sj.onc.1209616; Haluska FG, 1998, J CLIN ONCOL, V16, P670, DOI 10.1200/JCO.1998.16.2.670; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Jiao W, 2006, J BIOL CHEM, V281, P38098, DOI 10.1074/jbc.M605271200; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kastan MB, 2003, CELL, V112, P1, DOI 10.1016/S0092-8674(02)01281-3; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; Khidr L, 2006, ONCOGENE, V25, P5210, DOI 10.1038/sj.onc.1209612; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; Lu S, 1997, CANCER RES, V57, P4511; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; NORK TM, 1994, INVEST OPHTH VIS SCI, V35, P2682; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; PAULL KD, 1989, J NATL CANCER I, V81, P1088, DOI 10.1093/jnci/81.14.1088; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Schwartz GK, 2005, J CLIN ONCOL, V23, P9408, DOI 10.1200/JCO.2005.01.5594; Sedlacek HH, 2001, CRIT REV ONCOL HEMAT, V38, P139, DOI 10.1016/S1040-8428(00)00124-4; Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; STOKKE T, 1993, EXP CELL RES, V204, P147, DOI 10.1006/excr.1993.1019; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; WEINSTEIN JN, 1992, SCIENCE, V258, P447, DOI 10.1126/science.1411538; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331; Yen A, 1997, EUR J CELL BIOL, V72, P159; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588; Ziegler E. C., 2005, SCI STKE, pre6, DOI DOI 10.1126/STKE.2842005RE6; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	52	37	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	22					3156	3164		10.1038/sj.onc.1210970	http://dx.doi.org/10.1038/sj.onc.1210970			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18071317				2022-12-17	WOS:000255897600008
J	Muerkoster, SS; Rausch, AV; Isberner, A; Minkenberg, J; Blaszczuk, E; Witt, M; Folsch, UR; Schmitz, F; Schafer, H; Arlt, A				Mueerkoester, S. Sebens; Rausch, A. V.; Isberner, A.; Minkenberg, J.; Blaszczuk, E.; Witt, M.; Foelsch, U. R.; Schmitz, F.; Schaefer, H.; Arlt, A.			The apoptosis-inducing effect of gastrin on colorectal cancer cells relates to an increased IEX-1 expression mediating NF-kappa B inhibition	ONCOGENE			English	Article						early-response gene; gastrin receptor; loss of function mutation; apoptosis; colon cancer	EARLY-RESPONSE GENE; GLYCINE-EXTENDED GASTRIN; COLON-CANCER; CARCINOMA CELLS; TRANSGENIC MICE; MOUSE MODEL; CRYPT FOCI; IN-VIVO; PROGASTRIN; RECEPTORS	Addressing the puzzling role of amidated gastrin(17) ( G17) and the gastrin/ CCKB/ CCK2 receptor in colorectal carcinogenesis, we analysed potential candidate genes involved in G17-dependent NF-kappa B inhibition and apoptosis. The colorectal carcinoma cell line Colo320 over-expressing the wild-type CCK2 receptor ( Colo320wt) underwent G17-induced apoptosis along with suppressed NF-kappa B activation and decreased expression of the antiapoptotic NF-kappa B target genes cIAP1 and cIAP2, whereas G17 was without effect on Colo320 cells expressing a CCK2 receptor bearing a loss of function mutation ( Colo320mut). Gene microarray analysis revealed an elevated expression of the stress response gene IEX-1 in G17-treated Colo320wt but not Colo320mut cells. Quantitative real-time PCR and conventional RT-PCR confirmed this G17-dependent increase of IEX-1 expression in Colo320wt cells. If these cells were subjected to IEX-1 knockdown by small interfering RNA transfection, the apoptosis-inducing effect of G17 was abolished. Moreover, tumor necrosis factor alpha (TNF alpha)- or 5-FU-induced apoptosis that is greatly enhanced by G17 treatment in Colo320wt cells was prevented if IEX-1 expression was repressed. Under these conditions of blocked IEX-1 expression, the NF-kappa B activity remained unaffected by G17, in particular in Colo320wt cells co-treated with TNF alpha and also the suppressive effect of G17 on cIAP1 and cIAP2 expression was not observed anymore if IEX-1 expression was blocked. Conversely, IEX-1 overexpression in Colo320mut cells caused an increase of basal and TNF alpha- or 5-FU-induced apoptosis, an effect not further triggered by G17 treatment. Using a xenograft tumor model in severe combined immune deficiency mice, we could show that experimental systemic hypergastrinemia induced by the administration of omeprazole led to enhanced apoptosis as well as to a marked increase of IEX-1 expression in Colo320wt tumors, but not in Colo320mut tumors. These observations indicate that the proapoptotic effect of G17 on human colon cancer cells expressing the wild-type CCK2 receptor is mediated by IEX-1, which modulates NF-kappa B-dependent antiapoptotic protection and thereby exerts tumor-suppressive potential.	[Mueerkoester, S. Sebens; Rausch, A. V.; Isberner, A.; Minkenberg, J.; Blaszczuk, E.; Witt, M.; Foelsch, U. R.; Schmitz, F.; Schaefer, H.; Arlt, A.] Univ Hosp Schleswig Holstein, Dept Med 1, Lab Mol Gastroenterol & Hepatol, D-24105 Kiel, Germany; [Schmitz, F.] Klinikum Hildesheim, Dept Med 2, Hildesheim, Germany	University of Kiel; Schleswig Holstein University Hospital	Schafer, H (corresponding author), Univ Hosp Schleswig Holstein, Dept Med 1, Lab Mol Gastroenterol & Hepatol, Campus Kiel,Schittenhelmstr 12, D-24105 Kiel, Germany.	hschaef@1med.uni-kiel.de	Arlt, Alexander/G-7308-2019; Schmitz, Frank/ABB-6798-2021; Schäfer, Heiner/C-1055-2011; Sebens, Susanne/C-1222-2010	Arlt, Alexander/0000-0002-6160-1059; 				Ahmed S, 2004, FEBS LETT, V556, P199, DOI 10.1016/S0014-5793(03)01408-X; Aly A, 2004, BBA-REV CANCER, V1704, P1, DOI 10.1016/j.bbcan.2004.01.004; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Arlt A, 2003, ONCOGENE, V22, P3343, DOI 10.1038/sj.onc.1206524; Arlt A, 2007, BIOCHEM J, V402, P367, DOI 10.1042/BJ20061072; Baldwin GS, 1998, GUT, V42, P581, DOI 10.1136/gut.42.4.581; Clerc P, 1997, INT J CANCER, V72, P931, DOI 10.1002/(SICI)1097-0215(19970917)72:6<931::AID-IJC2>3.0.CO;2-Q; Cobb S, 2004, CANCER-AM CANCER SOC, V100, P1311, DOI 10.1002/cncr.20094; Cobb S, 2002, GASTROENTEROLOGY, V123, P516, DOI 10.1053/gast.2002.34754; Copps J, 2007, PEPTIDES, V28, P632, DOI 10.1016/j.peptides.2006.10.008; Corcoran JA, 2006, J VIROL, V80, P9720, DOI 10.1128/JVI.01216-06; Dilley WG, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-9; Dockray GJ, 1996, PHYSIOL REV, V76, P767, DOI 10.1152/physrev.1996.76.3.767; Grobe O, 2001, FEBS LETT, V494, P196, DOI 10.1016/S0014-5793(01)02344-4; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hu YH, 2004, CANCER RES, V64, P7748, DOI 10.1158/0008-5472.CAN-04-1827; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Koh TJ, 1999, J CLIN INVEST, V103, P1119, DOI 10.1172/JCI4910; Kondratyev AD, 1996, CANCER RES, V56, P1498; Muerkoster S, 2005, GASTROENTEROLOGY, V129, P952, DOI 10.1053/j.gastro.2005.06.059; Nambiar PR, 2004, CANCER RES, V64, P6394, DOI 10.1158/0008-5472.CAN-04-0933; Osawa Y, 2003, J IMMUNOL, V170, P4053, DOI 10.4049/jimmunol.170.8.4053; Perkins ND, 2006, CELL DEATH DIFFER, V13, P759, DOI 10.1038/sj.cdd.4401838; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; PINSON DM, 1995, GASTROENTEROLOGY, V108, P1068, DOI 10.1016/0016-5085(95)90204-X; Rooman I, 2001, GASTROENTEROLOGY, V121, P940, DOI 10.1053/gast.2001.27998; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; Schafer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131; Schafer H, 1996, CANCER RES, V56, P2641; Schilling D, 2001, ONCOGENE, V20, P7992, DOI 10.1038/sj.onc.1204965; Schmidt WE, 2004, GASTROENTEROLOGY, V126, P606, DOI 10.1053/j.gastro.2003.12.017; Schmitz F, 2001, EUR J CLIN INVEST, V31, P812, DOI 10.1046/j.1365-2362.2001.00870.x; Shen L, 2006, J BIOL CHEM, V281, P15304, DOI 10.1074/jbc.M600054200; Siddheshwar RK, 2001, GUT, V48, P47, DOI 10.1136/gut.48.1.47; Singh P, 2007, ONCOGENE, V26, P425, DOI 10.1038/sj.onc.1209798; Singh P, 2000, AM J PHYSIOL-GASTR L, V278, pG390, DOI 10.1152/ajpgi.2000.278.3.G390; Till A, 2005, J BIOL CHEM, V280, P5994, DOI 10.1074/jbc.M411541200; Watson SA, 2001, CANCER RES, V61, P625; Wu MX, 2003, APOPTOSIS, V8, P11, DOI 10.1023/A:1021688600370; Yu HG, 2005, CELL SIGNAL, V17, P1505, DOI 10.1016/j.cellsig.2005.03.009	40	37	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1122	1134		10.1038/sj.onc.1210728	http://dx.doi.org/10.1038/sj.onc.1210728			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17704804				2022-12-17	WOS:000253136700012
J	Rainey, MD; Black, EJ; Zachos, G; Gillespie, DAF				Rainey, M. D.; Black, E. J.; Zachos, G.; Gillespie, D. A. F.			Chk2 is required for optimal mitotic delay in response to irradiation-induced DNA damage incurred in G(2) phase	ONCOGENE			English	Article						Chk1; Chk2; DNA damage; G(2)/M checkpoint; mitosis; genome stability	IONIZING-RADIATION; TUMOR-SUPPRESSOR; CHECKPOINT KINASE; CELLS; ACTIVATION; ATM; CANCER; PHOSPHORYLATION; TUMORIGENESIS; INHIBITION	Whether Chk2 contributes to DNA damage- induced arrest in G(2) has been controversial. To investigate this issue further, we generated Chk2-deficient DT40 B-lymphoma cells by gene targeting and compared their cell cycle response to ionizing radiation (IR) with wildtype (WT) and isogenic Chk1-deficient counterparts. After moderate doses of IR (4 Gy), we find that Chk2(-/-) cells which are in G(1) or S phase at the time of irradiation arrest efficiently in G(2). In contrast, Chk2-/- cells which are in G(2) when DNA damage is incurred exhibit an impaired mitotic delay compared to WT, with the result that cells enter mitosis with damaged DNA as judged by the presence of numerous gamma-H2AX foci on condensed chromosomes. Impaired G(2) delay as the result of Chk2 deficiency can be detected at very low doses of radiation (0.1 Gy), and may allow division with spontaneous DNA damage, since a higher proportion of mitotic Chk2-/- cells bear spontaneous gamma-H2AX foci and damaged chromosomes during unperturbed growth compared to WT. The contribution of Chk2 to G(2)/M delay is epistatic to that of Chk1, since Chk1-/- cells exhibit no measurable mitotic delay at any radiation dose tested. We suggest that this function of Chk2 could contribute to tumour suppression, since cell division with low levels of spontaneous damage is likely to promote genetic instability and thus carcinogenesis.	[Gillespie, D. A. F.] Univ Glasgow, Fac Biomed & Life Sci, Glasgow G61 1BD, Lanark, Scotland; [Rainey, M. D.; Black, E. J.; Zachos, G.; Gillespie, D. A. F.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	University of Glasgow; Beatson Institute	Gillespie, DAF (corresponding author), Univ Glasgow, Fac Biomed & Life Sci, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	d.gillespie@beatson.gla.ac.uk	Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544; Rainey, Michael/0000-0001-9777-873X				Ahn JY, 2000, CANCER RES, V60, P5934; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Cao L, 2006, EMBO J, V25, P2167, DOI 10.1038/sj.emboj.7601115; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Lukas C, 2001, CANCER RES, V61, P4990; Mailand N, 2006, MOL CELL, V23, P307, DOI 10.1016/j.molcel.2006.06.016; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McGowan CH, 2002, BIOESSAYS, V24, P502, DOI 10.1002/bies.10101; Miller CW, 2002, GENE CHROMOSOME CANC, V33, P17, DOI 10.1002/gcc.1207; Nevanlinna H, 2006, ONCOGENE, V25, P5912, DOI 10.1038/sj.onc.1209877; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shiromizu T, 2006, GENES CELLS, V11, P477, DOI 10.1111/j.1365-2443.2006.00955.x; Skoufias DA, 2004, MOL CELL, V15, P977, DOI 10.1016/j.molcel.2004.08.018; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Takao N, 1999, ONCOGENE, V18, P7002, DOI 10.1038/sj.onc.1203172; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Yu Q, 2001, FEBS LETT, V505, P7, DOI 10.1016/S0014-5793(01)02756-9; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060	28	37	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2008	27	7					896	906		10.1038/sj.onc.1210702	http://dx.doi.org/10.1038/sj.onc.1210702			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17684483				2022-12-17	WOS:000252946300002
J	Suzuki, E; Imoto, I; Pimkhaokham, A; Nakagawa, T; Kamata, N; Kozaki, K; Amagasa, T; Inazawa, J				Suzuki, E.; Imoto, I.; Pimkhaokham, A.; Nakagawa, T.; Kamata, N.; Kozaki, K-i; Amagasa, T.; Inazawa, J.			PRTFDC1, a possible tumor-suppressor gene, is frequently silenced in oral squamous-cell carcinomas by aberrant promoter hypermethylation	ONCOGENE			English	Article						array-CGH; oral squamous-cell carcinoma; PRTFDC1; homozygous deletion; methylation	EPIGENETIC MECHANISMS; CANCER; METHYLATION; INACTIVATION; ABERRATIONS; EXPRESSION	Array-based comparative genomic hybridization (array-CGH) has good potential for the high-throughput identification of genetic aberrations in cell genomes. In the course of a program to screen a panel of oral squamous-cell carcinoma (OSCC), cell lines for genomic copy-number aberrations by array-CGH using our in-house arrays, we identified a 3-Mb homozygous deletion at 10p12 in 1 of 18 cell lines (5.6%). Among seven genes located within this region, expression of PRTFDC1 mRNA was not detected in 50% (9/18) or decreased in 5.6% (1/18) of OSCC cell lines, but detected in normal oral epithelia and restored in gene-silenced OSCC cells without its homozygous loss after treatment with 5-aza-2 '-deoxycytidine. Among 17 cell lines without a homozygous deletion, the hypermethylation of the PRTFDC1 CpG island, which showed promoter activity, was observed in all nine cell lines with no or reduced PRTFDC1 expression (52.9%). Methylation of this CpG island was also observed in primary OSCC tissues (8/47, 17.0%). In addition, restoration of PRTFDC1 in OSCC cells lacking its expression inhibited cell growth in colony-formation assays, whereas knockdown of PRTFDC1 expression in OSCC cells expressing the gene promoted cell growth. These results suggest that epigenetic silencing of PRTFDC1 by hypermethylation of the CpG island leads to a loss of PRTFDC1 function, which might be involved in squamous cell oral carcinogenesis.	[Suzuki, E.; Imoto, I.; Pimkhaokham, A.; Nakagawa, T.; Kozaki, K-i; Inazawa, J.] Tokyo Med & Dent Univ, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan; [Suzuki, E.; Imoto, I.; Pimkhaokham, A.; Nakagawa, T.; Kozaki, K-i; Inazawa, J.] Tokyo Med & Dent Univ, Sch Biomed Sci, Tokyo 1138510, Japan; [Suzuki, E.; Amagasa, T.] Tokyo Med & Dent Univ, Grad Sch, Dept Maxillofacial Surg, Tokyo 1138510, Japan; [Imoto, I.; Kozaki, K-i; Inazawa, J.] Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo 1138510, Japan; [Imoto, I.; Kozaki, K-i; Inazawa, J.] Japan Sci & Technol Corp, CREST, Saitama, Japan; [Pimkhaokham, A.] Chulalongkorn Univ, Fac Dent, Dept Oral & Maxillofacial Surg, Bangkok, Thailand; [Kamata, N.] Hiroshima Univ, Div Cervico Gnathostomatol, Dept Oral & Maxillofacial Surg, Grad Sch Biomed Sci,Minami Ku, Hiroshima, Japan; [Inazawa, J.] Tokyo Med & Dent Univ, Century Ctr Excellence Program Mol Destruct & Rec, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Chulalongkorn University; Hiroshima University; Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	Imoto, Issei/AAD-5799-2020; imoto, Issei/D-8065-2012; Pimkhaokham, Atiphan/AAQ-4177-2021; Kozaki, Ken-ichi/M-6281-2014	Kozaki, Ken-ichi/0000-0003-3286-819X; Pimkhaokham, Atiphan/0000-0002-0170-243X				Akanuma D, 1999, ORAL ONCOL, V35, P476, DOI 10.1016/S1368-8375(99)00020-2; Baldwin C, 2005, CANCER RES, V65, P7561, DOI 10.1158/0008-5472.CAN-05-1513; Brinkman BMN, 2006, CURR OPIN ONCOL, V18, P228, DOI 10.1097/01.cco.0000219250.15041.f8; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Fujimoto R., 2004, J JPN ORAL MUCO MEMB, V8, P1, DOI [10.6014/jjomm1995.8.1, DOI 10.6014/jjomm1995.8.1]; Ha PK, 2006, LANCET ONCOL, V7, P77, DOI 10.1016/S1470-2045(05)70540-4; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hermsen MAJA, 1997, ORAL ONCOL, V33, P414, DOI 10.1016/S0964-1955(97)00031-6; Imoto I, 2006, CANCER RES, V66, P4617, DOI 10.1158/0008-5472.CAN-05-4437; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Izumi H, 2005, HUM MOL GENET, V14, P997, DOI 10.1093/hmg/ddi092; Jin C, 2006, CANCER GENET CYTOGEN, V164, P44, DOI 10.1016/j.cancergencyto.2005.06.008; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kolb A, 2003, BIOCHEM BIOPH RES CO, V306, P1099, DOI 10.1016/S0006-291X(03)01104-5; Kusumoto Y, 2004, J PERIODONTOL, V75, P370, DOI 10.1902/jop.2004.75.3.370; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Misawa A, 2005, CANCER RES, V65, P10233, DOI 10.1158/0008-5472.CAN-05-1073; Nagpal JK, 2003, ORAL ONCOL, V39, P213, DOI 10.1016/S1368-8375(02)00162-8; Nakagawachi T, 2003, ONCOGENE, V22, P8835, DOI 10.1038/sj.onc.1207183; Nicklas JA, 2006, ENVIRON MOL MUTAGEN, V47, P212, DOI 10.1002/em.20187; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Saigusa K, 2007, ONCOGENE, V26, P1110, DOI 10.1038/sj.onc.1210148; Scully C, 2000, ORAL ONCOL, V36, P256, DOI 10.1016/S1368-8375(00)00007-5; Shaw R, 2006, INT J ORAL MAX SURG, V35, P101, DOI 10.1016/j.ijom.2005.06.014; Snijders AM, 2005, ONCOGENE, V24, P4232, DOI 10.1038/sj.onc.1208601; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; Takada H, 2006, ONCOGENE, V25, P6554, DOI 10.1038/sj.onc.1209657; Takada H, 2005, ONCOGENE, V24, P8051, DOI 10.1038/sj.onc.1208952; Takada H, 2005, CANCER SCI, V96, P100, DOI 10.1111/j.1349-7006.2005.00016.x; Wolff E, 1998, ORAL ONCOL, V34, P186, DOI 10.1016/S1368-8375(97)00079-1; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532	33	37	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2007	26	57					7921	7932		10.1038/sj.onc.1210589	http://dx.doi.org/10.1038/sj.onc.1210589			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599052				2022-12-17	WOS:000252163500011
J	Bellanger, S; de Gramont, A; Sobczak-Thepot, J				Bellanger, S.; de Gramont, A.; Sobczak-Thepot, J.			Cyclin B2 suppresses mitotic failure and DNA re-replication in human somatic cells knocked down for both cyclins B1 and B2	ONCOGENE			English	Article						cyclin; mitosis; RNA interference; replication; cell cycle	DEPENDENT KINASES; MAMMALIAN-CELLS; GEMININ BINDING; TUMOR-CELLS; IN-VITRO; PHOSPHORYLATION; MITOSIS; B1; LOCALIZATION; INHIBITOR	Cyclin-dependent kinase 1 (CDK1) plays a crucial role in establishing metaphase and has also been shown to prevent DNA re-replication. Cyclins B1 and B2 are two known activators of CDK1 operating during mitosis in human cells. Little is known about the specific roles of each of these cyclins in CDK1 activation, but cyclin B2 is thought to play a minor role and to be unable to replace cyclin B1 for mitosis completion. In our study, we found that severe reduction by separate RNA interference of either cyclin B1 or cyclin B2 protein levels results in little or no alteration of the cell cycle and, more specifically, of mitosis progression. In contrast, simultaneous depletion of both B-type cyclins leads to massive accumulation of 4N cells, mitotic failure, premature mitosis exit and DNA re-replication. These defects can be corrected by the ectopic expression of a cyclin B2 resistant to the short hairpin RNA. Altogether, these data show that, in cycling human cells, cyclin B2 can compensate for the downregulation of cyclin B1 during mitosis. They also clearly implicate cyclins B1 and B2 as crucial activators of CDK1 in its biological function of DNA re-replication prevention.	Univ Paris 06, CNRS, UMR 7098, Biochim Cellulaire Lab, F-75005 Paris, France; Inst Med Biol, Singapore 138673, Singapore; NIH, NIDDK, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Sobczak-Thepot, J (corresponding author), Univ Paris 06, CNRS, UMR 7098, Biochim Cellulaire Lab, F-75005 Paris, France.	Joelle.Sobczak-Thepot@snv.jussieu.fr		Sobczak, Joelle/0000-0001-7180-2789				Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Brandeis M, 1998, P NATL ACAD SCI USA, V95, P4344, DOI 10.1073/pnas.95.8.4344; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; DESSEV G, 1991, J CELL BIOL, V112, P523, DOI 10.1083/jcb.112.4.523; Draviam VM, 2001, J CELL BIOL, V152, P945, DOI 10.1083/jcb.152.5.945; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; Gong DQ, 2007, CURR BIOL, V17, P85, DOI 10.1016/j.cub.2006.11.066; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Itzhaki JE, 1997, NAT GENET, V15, P258, DOI 10.1038/ng0397-258; JACK DB, 1995, MOL MED TODAY, V1, P2; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Lee YM, 2006, CELL CYCLE, V5, P2110, DOI 10.4161/cc.5.18.3218; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; Li CJ, 2004, MOL CELL BIOL, V24, P5875, DOI 10.1128/MCB.24.13.5875-5886.2004; Liu EB, 2004, J BIOL CHEM, V279, P17283, DOI 10.1074/jbc.C300549200; Machida YJ, 2007, GENE DEV, V21, P184, DOI 10.1101/gad.1495007; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Niiya F, 2005, J BIOL CHEM, V280, P36502, DOI 10.1074/jbc.M508007200; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; Seong YS, 2003, CANCER RES, V63, P7384; Sugimoto N, 2004, J BIOL CHEM, V279, P19691, DOI 10.1074/jbc.M313175200; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yuan J, 2006, ONCOGENE, V25, P1753, DOI 10.1038/sj.onc.1209202; Yuan JP, 2004, ONCOGENE, V23, P5843, DOI 10.1038/sj.onc.1207757; Zhou Y, 2002, NUCLEIC ACIDS RES, V30, P1664, DOI 10.1093/nar/30.7.1664; Zhu WG, 2004, MOL CELL BIOL, V24, P7140, DOI 10.1128/MCB.24.16.7140-7150.2004	36	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2007	26	51					7175	7184		10.1038/sj.onc.1210539	http://dx.doi.org/10.1038/sj.onc.1210539			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17533373				2022-12-17	WOS:000250955600001
J	Gutzman, JH; Rugowski, DE; Nikolai, SE; Schuler, LA				Gutzman, J. H.; Rugowski, D. E.; Nikolai, S. E.; Schuler, L. A.			Stat5 activation inhibits prolactin-induced AP-1 activity: distinct prolactin-initiated signals in tumorigenesis dependent on cell context	ONCOGENE			English	Article						prolactin; breast cancer; AP-1; Stat5	BREAST-CANCER CELLS; C-FOS; TRANSCRIPTION FACTORS; MAMMARY-GLAND; CYCLIN D1; TRANSDUCER; EXPRESSION; PROTEIN-1; INVASION; JUN	The essential role of prolactin (PRL) in normal mammary gland growth and differentiation has implicated this hormone in the development and progression of breast cancer. Although Stat5 is the best-characterized mediator of PRL signals, PRL also activates multiple other signals, whose roles in normal and pathologic processes are not well understood. We have shown that PRL stimulates activating protein-1 (AP-1) activity in breast cancer cells, and can cooperate with estradiol in this pathway. AP-1 modulates many processes critical for carcinogenesis, including cell proliferation, survival, transformation, invasion and angiogenesis, and is elevated in many neoplasms, including breast tumors. Here, we investigated the relationship between PRL signals to AP-1 and Stat5. We found that PRL activation of Stat5a and Stat5b, but not Stat1 or Stat3, reduced PRL signals to AP-1, without altering estradiol-induced AP-1 activity. The truncation mutant, Stat5/Delta 53C, but not Stat5Y699F, was an effective inhibitor, consistent with a requirement for Stat5 dimerization and nuclear accumulation, but not its C-terminal transactivation activity. The association of Stat5 with AP-1 proteins suggests that this underlies the inhibition. Predictably, the ability of PRL to activate Stat5 and AP-1 was inversely related in mammary cell lines. Further, reduction of Stat5 protein with siRNA in T47D cells, which contain elevated Stat5, increased PRL-induced AP-1 signals, transcripts for the AP-1 target, matrix metalloproteinase-2 and associated invasive behavior. This study points to the importance of cell context in determining the spectrum of PRL-induced actions, which is critical for understanding the contributions of PRL to breast cancer.	Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA; Univ Wisconsin, Mol & Environm Toxicol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Schuler, LA (corresponding author), Univ Wisconsin, Dept Comparat Biosci, 2015 Linden Dr, Madison, WI 53706 USA.	schulerl@svm.vetmed.wisc.edu	Gutzman, Jennifer/AAA-9058-2020	Gutzman, Jennifer/0000-0002-7725-6923	NATIONAL CANCER INSTITUTE [R01CA078312] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA78312, R01 CA078312] Funding Source: Medline; NIDDK NIH HHS [DK07623] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bjornstrom L, 2002, MOL ENDOCRINOL, V16, P2202, DOI 10.1210/me.2002-0072; BLAND KI, 1995, ANN SURG, V221, P706, DOI 10.1097/00000658-199506000-00010; Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Buettner R, 2002, CLIN CANCER RES, V8, P945; Cao JS, 2004, ENDOCRINOLOGY, V145, P1739, DOI 10.1210/en.2003-0752; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Cotarla I, 2004, INT J CANCER, V108, P665, DOI 10.1002/ijc.11619; DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Faulds MH, 2001, MOL ENDOCRINOL, V15, P1929, DOI 10.1210/me.15.11.1929; Gee JMW, 2000, INT J CANCER, V89, P177, DOI 10.1002/(SICI)1097-0215(20000320)89:2<177::AID-IJC13>3.0.CO;2-0; Goffin V, 2005, ENDOCR REV, V26, P400, DOI 10.1210/er.2004-0016; Gutzman JH, 2005, MOL ENDOCRINOL, V19, P1765, DOI 10.1210/me.2004-0339; Gutzman JH, 2004, MOL ENDOCRINOL, V18, P3064, DOI 10.1210/me.2004-0187; Hennighausen L, 2005, NAT REV MOL CELL BIO, V6, P715, DOI 10.1038/nrm1714; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Humphreys RC, 1999, CELL GROWTH DIFFER, V10, P685; Iavnilovitch E, 2002, MOL CANCER RES, V1, P32; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Keely PJ, 2001, METHODS ENZYMOL, V333, P256; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Luo GY, 2000, MOL ENDOCRINOL, V14, P114, DOI 10.1210/me.14.1.114; Milde-Langosch K, 2000, INT J CANCER, V87, P468, DOI 10.1002/1097-0215(20000815)87:4<468::AID-IJC2>3.0.CO;2-R; Milde-Langosch K, 2004, BREAST CANCER RES TR, V86, P139, DOI 10.1023/B:BREA.0000032982.49024.71; Nakamura T, 2002, J BIOL CHEM, V277, P6254, DOI 10.1074/jbc.M109878200; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046; Nouhi Z, 2006, CANCER RES, V66, P1824, DOI 10.1158/0008-5472.CAN-05-2292; ORMANDY CJ, 2001, MAMMARY GLAND DEV PR, P219; Ren SX, 2002, ONCOGENE, V21, P4335, DOI 10.1038/sj.onc.1205484; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Sultan AS, 2005, ONCOGENE, V24, P746, DOI 10.1038/sj.onc.1208203; Tworoger SS, 2006, CANCER LETT, V243, P160, DOI 10.1016/j.canlet.2006.01.032; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vincenti MP, 2000, METH MOL B, V151, P121, DOI 10.1385/1-59259-046-2:121; Vonderhaar BK, 2000, CONT ENDOCRINOL, P101; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Watson CJ, 2001, J MAMMARY GLAND BIOL, V6, P115, DOI 10.1023/A:1009524817155; Weaver AM, 2006, MOL ENDOCRINOL, V20, P2392, DOI 10.1210/me.2005-0418; Yang E, 2003, J BIOL CHEM, V278, P15794, DOI 10.1074/jbc.M213073200; Zhang XK, 1999, MOL CELL BIOL, V19, P7138	44	37	38	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2007	26	43					6341	6348		10.1038/sj.onc.1210454	http://dx.doi.org/10.1038/sj.onc.1210454			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17438530	Green Accepted			2022-12-17	WOS:000249583300010
J	Merolla, F; Pentimalli, F; Pacelli, R; Vecchio, G; Fusco, A; Grieco, M; Celetti, A				Merolla, F.; Pentimalli, F.; Pacelli, R.; Vecchio, G.; Fusco, A.; Grieco, M.; Celetti, A.			Involvement of H4(D10S170) protein in ATM-dependent response to DNA damage	ONCOGENE			English	Article						H4(D10S170); RET/PTC1; DNA damage; ATM; thyroid	THYROID PAPILLARY CARCINOMAS; FACTOR RECEPTOR-BETA; GENOMIC INSTABILITY; CHECKPOINT PATHWAY; IONIZING-RADIATION; CANCER; RET; REARRANGEMENTS; KINASE; CELLS	H4(D10S170) gene has been identified upon its frequent rearrangement with RET in papillary thyroid tumours (RET/PTC1). The kinase ataxia telangectasia mutated (ATM) phosphorylates a limited number of downstream protein targets in response to DNA damage. We investigated the potential role of H4( D10S170) in DNA damage signaling pathways. We found that in cells treated with etoposide or ionizing radiation (IR), H4( D10S170) underwent ATM-mediated phosphorylation at Thr 434, stabilizing nuclear H4. In ataxia telangectasia cells (A-T), endogenous H4( D10S170) was localized to cytoplasm and was excluded from the nucleus. Moreover, H4( D10S170) was not phosphorylated in ATM-deficient lymphoblasts after ionizing irradiation. Inhibition of ATM kinase interfered with H4( D10S170) apoptotic activity, and expression of H4 with threonine 434 mutated in Alanine, H4(T434A), protected the cells from genotoxic stress-induced apoptosis. Most importantly, after exposure to IR we found that silencing of H4( D10S170) in mammalian cells increased cell survival, as shown by clonogenic assay, allows for DNA synthesis as evaluated by bromodeoxyuridine incorporation and permits cells to progress into mitosis as demonstrated by phosphorylation on Histone H3. Our results suggest that H4( D10S170) is involved in cellular response to DNA damage ATM-mediated, and that the impairment of H4( D10S170) gene function might have a role in thyroid carcinogenesis.	Univ Naples Federico II, Dipartimento Biol Patol Cellulare Mol, Naples, Italy; CNR, Ist Biostrutt Bioimmagini, Naples, Italy; Magna Graecia Univ Catanzaro, Dipartimento Med Speriment Clin, Catanzaro, Italy; Ist Endocrinol Oncol Speriment, CNR, Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biostrutture e Bioimmagini (IBB-CNR); Magna Graecia University of Catanzaro; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR)	Celetti, A (corresponding author), Univ Naples Federico II, Ist Endocrinol Oncol Sperimentale, CNR, Dipartimento Biol Patol Cellulare Mol, Via S Parsini, Naples, Italy.	celetti@unina.it2	Pentimalli, Francesca/K-4936-2014; Pacelli, Roberto/AFS-0333-2022; Celetti, Angela/AAY-7172-2020	Pentimalli, Francesca/0000-0003-4740-6801; Grieco, Michele/0000-0002-4212-7814; Pacelli, Roberto/0000-0002-2048-7675; Fusco, Alfredo/0000-0003-3332-5197				Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; Caudill CM, 2005, J CLIN ENDOCR METAB, V90, P2364, DOI 10.1210/jc.2004-1811; Celetti A, 2004, ONCOGENE, V23, P109, DOI 10.1038/sj.onc.1206981; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GOODHEAD DT, 1994, INT J RADIAT BIOL, V65, P7, DOI 10.1080/09553009414550021; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIECO M, 1994, ONCOGENE, V9, P25331; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Jossart GH, 1996, CYTOGENET CELL GENET, V75, P254, DOI 10.1159/000134495; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kulkarni S, 2000, CANCER RES, V60, P3592; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Leskov KS, 2001, SEMIN RADIAT ONCOL, V11, P352, DOI 10.1053/srao.2001.26912; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Little JB, 2003, ONCOGENE, V22, P6978, DOI 10.1038/sj.onc.1206988; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; Nikiforova MN, 2000, SCIENCE, V290, P138, DOI 10.1126/science.290.5489.138; Nikiforova MN, 2004, CANCER LETT, V209, P1, DOI 10.1016/j.canlet.2003.12.004; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Penserga ETP, 2007, ONCOGENE, V26, P11, DOI 10.1038/sj.onc.1209756; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; Puxeddu E, 2005, MUTAT RES-FUND MOL M, V570, P17, DOI 10.1016/j.mrfmmm.2004.09.010; Radivoyevitch T, 2001, RADIAT ENVIRON BIOPH, V40, P191, DOI 10.1007/s004110100108; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; Schwaller J, 2001, BLOOD, V97, P3910, DOI 10.1182/blood.V97.12.3910; Sheils OM, 2000, J PATHOL, V192, P32; Shiloh Y, 2003, CELL CYCLE, V2, P116, DOI 10.4161/cc.2.2.342; Smith LE, 2003, HEALTH PHYS, V85, P23, DOI 10.1097/00004032-200307000-00006; Tong Q, 1997, J BIOL CHEM, V272, P9043; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARD JF, 1995, RADIAT RES, V142, P362, DOI 10.2307/3579145	38	37	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2007	26	42					6167	6175		10.1038/sj.onc.1210446	http://dx.doi.org/10.1038/sj.onc.1210446			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17420723				2022-12-17	WOS:000249401300007
J	Angeloni, D; Danilkovitch-Miagkova, A; Ivanova, T; Braga, E; Zabarovsky, E; Lerman, MI				Angeloni, D.; Danilkovitch-Miagkova, A.; Ivanova, T.; Braga, E.; Zabarovsky, E.; Lerman, M. I.			Hypermethylation of Ron proximal promoter associates with lack of full-length Ron and transcription of oncogenic short-Ron from an internal promoter	ONCOGENE			English	Article						3p21.3; differentiation; erythroleukemia; lung cancer; promoter methylation; Ron (MST1R)	RECEPTOR TYROSINE KINASE; ACTIVATION; FAMILY; CANCER; GENE; MET; PROGRESSION; DOMAIN; MOUSE; CELLS	The gene for tyrosine-kinase receptor Ron (MST1R) resides in the chromosome 3p21.3 region, frequently affected in common human malignancies. The gene generates two transcripts, 5 and 2 kb-long, full-length Ron (flRon) and short-form Ron (sfRon), respectively. Here, we show for the first time that the variegated Ron expression is associated with variations in the methylation patterns of two distinct CpG islands in Ron proximal promoter. Widespread hypermethylation associates with lack of flRon whereas hypermethylation of the distal island associates with transcription of sfRon, a constitutively active tyrosine-kinase that drives cell proliferation. sfRon inhibition with kinase-dead transgenes decreases cancer cell growth and induces cellular differentiation. sfRon could be a new drug target in cancer types in which it contributes to tumor progression.	NCI, Ctr Canc Res, Immunol Lab, Frederick, MD USA; Karolinska Inst, MTC, Stockholm, Sweden; Russian Acad Med Sci, Blokhin Canc Res Ctr, Inst Carcinogenesis, Moscow, Russia; CNR, Scuola Super St Anna, Inst Clin Physiol, Pisa, Italy; Russian State Genet Ctr, Lab Mol Diagnost, Moscow, Russia; Osiris Therapeut Inc, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Karolinska Institutet; N.N. Blokhin Russian Cancer Research Center; Russian Academy of Medical Sciences; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); Scuola Superiore Sant'Anna; Osiris Therapeutics	Angeloni, D (corresponding author), Scuola Super Sant Anna, Inst Clin Physiol, Via Mourzzi,1, I-56124 Pisa, Italy.	angeloni@ifc.cnr.it	Zabarovsky, Eugene R/A-6645-2010; Braga, Eleonora A./P-5574-2016	Braga, Eleonora/0000-0001-5188-4094; Angeloni, Debora/0000-0002-3850-5392	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC008579] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angeloni D, 2004, J BIOL CHEM, V279, P3726, DOI 10.1074/jbc.M309342200; Angeloni D, 2000, GENE CHROMOSOME CANC, V29, P147, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.3.CO;2-E; Bardella C, 2004, CANCER RES, V64, P5154, DOI 10.1158/0008-5472.CAN-04-0600; Bix M, 1998, SCIENCE, V281, P1352, DOI 10.1126/science.281.5381.1352; Camp ER, 2005, ANN SURG ONCOL, V12, P273, DOI 10.1245/ASO.2005.08.013; Carninci P, 2006, NAT GENET, V38, P626, DOI 10.1038/ng1789; Correll Pamela H., 1997, Genes and Function, V1, P69; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Danilkovitch-Miagkova A, 2000, J BIOL CHEM, V275, P14783, DOI 10.1074/jbc.C000028200; DELGATTO F, 1995, BBA-GENE STRUCT EXPR, V1263, P93, DOI 10.1016/0167-4781(95)00082-R; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Ghigna C, 2005, MOL CELL, V20, P881, DOI 10.1016/j.molcel.2005.10.026; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; JOHNSON BE, 1988, CANCER RES, V48, P5163; Momparler RL, 2005, SEMIN ONCOL, V32, P443, DOI 10.1053/j.seminoncol.2005.07.008; Muraoka RS, 1999, J CLIN INVEST, V103, P1277, DOI 10.1172/JCI6091; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; Phelps RM, 1996, J CELL BIOCHEM, P32; RONSIN C, 1993, ONCOGENE, V8, P1195; Saleh A, 2004, IMMUNITY, V21, P55, DOI 10.1016/j.immuni.2004.06.005; Sambrook J, 2001, MOL CLONING LAB MANU; SUDA T, 1997, LEUKEMIA, V3, P451; Talley CJ, 1997, AM J HEMATOL, V54, P301, DOI 10.1002/(SICI)1096-8652(199704)54:4<301::AID-AJH7>3.0.CO;2-Z; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Villa-Moruzzi E, 1998, BIOCHEM J, V336, P235, DOI 10.1042/bj3360235; Waltz SE, 2001, J CLIN INVEST, V108, P567, DOI 10.1172/JCI200111881; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; Wei X, 2005, J BIOL CHEM, V280, P40241, DOI 10.1074/jbc.M506806200	29	37	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	31					4499	4512		10.1038/sj.onc.1210238	http://dx.doi.org/10.1038/sj.onc.1210238			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17297469				2022-12-17	WOS:000247836100004
J	Hsieh, PC; Chang, JC; Sun, WT; Hsieh, SC; Wang, MC; Wang, FF				Hsieh, P-C; Chang, J-C; Sun, W-T; Hsieh, S-C; Wang, M-C; Wang, F-F			p53 downstream target DDA3 is a novel microtubule-associated protein that interacts with end-binding protein EB3 and activates ss-catenin pathway	ONCOGENE			English	Article						DDA3; microtubule; EB3; p53; ss-catenin	CELL-LINES; GENE; IDENTIFICATION; FAMILY; EXPRESSION; INDUCTION; HOMOLOG; SYSTEM; GROWTH; APC2	We have previously identified mouse DDA3 as a p53-inducible gene. To explore the functional role of DDA3, we screened a mouse brain cDNA library by the yeast two-hybrid assay, and identi. ed the microtubule plus-end binding protein EB3 as a DDA3-interacting protein. Binding of DDA3 to EB3 was veri. ed by glutathione S-transferase (GST) pull-down assay and subcellular colocalization; co-immunoprecipitation further indicated that interaction of these two proteins within cells required intact microtubules. Domains of DDA3-EB3 interaction were mapped by GST pull-down assay to amino acids 118-241 and 242-329 of DDA3 and the N-and C-termini of EB3. Immuno. uorescence analysis revealed colocalization of DDA3 with microtubules in various cell phases, and regions encompassing aa 118-241 and 242-329 contained microtubule-interacting and bundling activities. In vitro microtubule-binding assay showed that DDA3 and EB3 associated directly with microtubules, and cooperated with each other for microtubule binding. In addition, DDA3 bound to the EB3 interacting partner adenomatous polyposis coli 2 (APC2), a homolog of the tumor suppressor APC, which is a component of the beta-catenin destruction complex. Ectopic expression of DDA3 and EB3 enhanced b-catenin-dependent transactivation and cyclin D1 production, whereas knockdown of endogenous DDA3 or EB3 inhibited b-catenin-mediated transactivation and the ability of cells to form colonies. Together, our results identify DDA3 as a novel microtubule-associated protein that binds to EB3, and implicate DDA3 and EB3 in the b-catenin-mediated growth signaling.	Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan; Ind Technol Res Inst, Biomed Engn Ctr, Div Biomat & Tissue Engn, Hsinchu, Taiwan	National Yang Ming Chiao Tung University; Industrial Technology Research Institute - Taiwan	Wang, FF (corresponding author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan.	ffwang@ym.edu.tw		HSIEH, SHU-CHEN/0000-0002-0844-7435; Wang, Mei-Chih/0000-0003-0520-9316				Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bu W, 2003, J BIOL CHEM, V278, P49721, DOI 10.1074/jbc.M306194200; Bu W, 2001, ONCOGENE, V20, P3185, DOI 10.1038/sj.onc.1204429; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Hanson CA, 2005, GENE, V361, P1, DOI 10.1016/j.gene.2005.07.024; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Honnappa S, 2005, EMBO J, V24, P261, DOI 10.1038/sj.emboj.7600529; Hsieh SC, 2002, ONCOGENE, V21, P3050, DOI 10.1038/sj.onc.1205417; Iwai A, 2004, ONCOGENE, V23, P7593, DOI 10.1038/sj.onc.1208016; Jarrett CR, 2001, CANCER RES, V61, P7978; Johnsen JI, 2000, INT J CANCER, V88, P685, DOI 10.1002/1097-0215(20001201)88:5<685::AID-IJC1>3.0.CO;2-Z; Levine Arnold J., 2004, Cell, VS116, pS67, DOI 10.1016/S0092-8674(04)00036-4; Lo PK, 1999, ONCOGENE, V18, P7765, DOI 10.1038/sj.onc.1203167; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Miller SJ, 2006, CANCER RES, V66, P2584, DOI 10.1158/0008-5472.CAN-05-3330; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Nakagawa H, 1998, CANCER RES, V58, P5176; Nakagawa H, 2000, ONCOGENE, V19, P210, DOI 10.1038/sj.onc.1203308; Nakamura M, 2001, CURR BIOL, V11, P1062, DOI 10.1016/S0960-9822(01)00297-4; Ongusaha PP, 2003, EMBO J, V22, P1289, DOI 10.1093/emboj/cdg129; Park WR, 2005, CANCER RES, V65, P1197, DOI 10.1158/0008-5472.CAN-04-3339; Senda Takao, 2005, Anatomical Science International, V80, P121, DOI 10.1111/j.1447-073x.2005.00106.x; SU LK, 1995, CANCER RES, V55, P2972; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; van Es JH, 1999, CURR BIOL, V9, P105, DOI 10.1016/S0960-9822(99)80024-4; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang YH, 2005, ONCOGENE, V24, P6637, DOI 10.1038/sj.onc.1208819	34	37	41	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4928	4940		10.1038/sj.onc.1210304	http://dx.doi.org/10.1038/sj.onc.1210304			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310996				2022-12-17	WOS:000248322500005
J	Dormoy-Raclet, V; Markovits, J; Malato, Y; Huet, S; Lagarde, P; Montaudon, D; Jacquemin-Sablon, A; Jacquemin-Sablon, H				Dormoy-Raclet, V.; Markovits, J.; Malato, Y.; Huet, S.; Lagarde, P.; Montaudon, D.; Jacquemin-Sablon, A.; Jacquemin-Sablon, H.			Unr, a cytoplasmic RNA-binding protein with cold-shock domains, is involved in control of apoptosis in ES and HuH7 cells	ONCOGENE			English	Article						Unr; RNA-binding protein; ES and HuH7 cells; gamma-irradiation; apoptosis; proliferation	RIBOSOME ENTRY SITES; NUCLEIC-ACID BINDING; Y-BOX PROTEIN; MESSENGER-RNA; DNA-DAMAGE; N-RAS; TRANSLATIONAL REPRESSION; GLOBAL ANALYSIS; IN-VITRO; P53	Unr (upstream of N-ras) is a cytoplasmic RNA-binding protein involved in the regulation of messenger RNA stability and internal initiation of translation. We have used Unr-deficient murine embryonic stem (ES) cells to analyse Unr role in cell proliferation and response to stress. Disruption of both unr gene copies had no effect on ES cell proliferation. However, after ionizing radiation (IR), clonogenic survival of unr(-/-) ES cells was similar to 3-fold enhanced as compared to unr(+/+) cells. We further determined that IR-induced apoptosis was decreased in unr2/2 ES cells, and that reintroduction of the unr gene in unr(+/+) cells restored normal IR-induced apoptosis. Three pro-apoptotic genes, p53, caspase-3 and Gadd45 gamma, were downregulated in unr(-/-) ES cells, indicating that Unr, as other cytoplasmic RNA-binding proteins, regulates a complex genetic program, promoting cell death after IR. In contrast, in the human hepatoma cell line HuH7, Unr knockdown using unr-specific small interfering RNAs induced apoptosis, both in untreated and c-irradiated cells. Thus, our results establish that Unr acts as a positive or negative regulator of cell death, depending on the cell type. Manipulating the level of Unr may constitute a specific approach to sensitize cancer cells to anticancer treatments.	Univ Bordeaux 2, INSERM E362, GREF, F-33076 Bordeaux, France; Inst Bergonie, CNRS, FRE 2618, Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Institut Bergonie	Jacquemin-Sablon, H (corresponding author), Univ Bordeaux 2, INSERM E362, GREF, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	helene.jacquemin-sablon@gref.u-bordeaux2.fr						Abaza I, 2006, GENE DEV, V20, P380, DOI 10.1101/gad.371906; Audic Y, 2004, BIOL CELL, V96, P479, DOI 10.1016/j.biolcel.2004.05.002; Boussadia O, 1997, FEBS LETT, V420, P20, DOI 10.1016/S0014-5793(97)01479-8; Boussadia O, 2003, J VIROL, V77, P3353, DOI 10.1128/JVI.77.6.3353-3359.2003; Brown EC, 2004, J GEN VIROL, V85, P2279, DOI 10.1099/vir.0.80045-0; CARTER MS, 2000, J BIOL CHEM, V276, P37916; Chang TC, 2004, GENE DEV, V18, P2010, DOI 10.1101/gad.1219104; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Chung HK, 2003, J CLIN ENDOCR METAB, V88, P3913, DOI 10.1210/jc.2002-022031; Corbet SW, 1999, ONCOGENE, V18, P1537, DOI 10.1038/sj.onc.1202436; Dinur M, 2006, MOL ENDOCRINOL, V20, P1652, DOI 10.1210/me.2005-0333; DORMOYRACLET V, 2005, RNA BIOL, V2, P112; Duncan K, 2006, GENE DEV, V20, P368, DOI 10.1101/gad.371406; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Evans JR, 2003, ONCOGENE, V22, P8012, DOI 10.1038/sj.onc.1206645; Fan JS, 2002, P NATL ACAD SCI USA, V99, P10611, DOI 10.1073/pnas.162212399; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Hawkins DS, 1996, CANCER RES, V56, P892; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Heyer BS, 2000, GENE DEV, V14, P2072; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirose T, 2003, ONCOGENE, V22, P7762, DOI 10.1038/sj.onc.1207091; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Holland EC, 2004, ONCOGENE, V23, P3138, DOI 10.1038/sj.onc.1207590; Hong YL, 2004, P NATL ACAD SCI USA, V101, P14443, DOI 10.1073/pnas.0401346101; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Hunt SL, 1999, GENE DEV, V13, P437, DOI 10.1101/gad.13.4.437; JACQUEMINSABLON H, 1994, NUCLEIC ACIDS RES, V22, P2643, DOI 10.1093/nar/22.13.2643; JEFFERS M, 1990, NUCLEIC ACIDS RES, V18, P4891; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Kim JM, 2002, EMBO J, V21, P2168, DOI 10.1093/emboj/21.9.2168; KOHN KW, 1981, DNA REPAIR LABORATOR, P379; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Kubicka S, 1997, HEPATOLOGY, V25, P867, DOI 10.1002/hep.510250414; Lal A, 2005, EMBO J, V24, P1852, DOI 10.1038/sj.emboj.7600661; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Li XL, 2005, GENE DEV, V19, P2705, DOI 10.1101/gad.1359305; LOPEZFERNANDEZ LA, 1995, BBA-GENE STRUCT EXPR, V1263, P10, DOI 10.1016/0167-4781(95)00065-O; Lu ZH, 2005, MOL CELL BIOL, V25, P4625, DOI 10.1128/MCB.25.11.4625-4637.2005; MARKOVITS J, 1989, CANCER RES, V49, P5111; Masuda K, 2002, ARTHRITIS RES, V4, DOI 10.1186/ar427; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Mazan-Mamczarz K, 2003, P NATL ACAD SCI USA, V100, P8354, DOI 10.1073/pnas.1432104100; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; NAKABAYASHI H, 1984, GANN, V75, P151; NICOLAIEW N, 1991, ONCOGENE, V6, P721; Ohga T, 1996, CANCER RES, V56, P4224; Patry C, 2003, CANCER RES, V63, P7679; Rajasekhar VK, 2004, ONCOGENE, V23, P3248, DOI 10.1038/sj.onc.1207546; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Swamynathan SK, 2002, BIOCHEM BIOPH RES CO, V296, P451, DOI 10.1016/S0006-291X(02)00875-6; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Thieringer HA, 1997, NUCLEIC ACIDS RES, V25, P4764, DOI 10.1093/nar/25.23.4764; TINTON S, 2004, BIOCHEM J, V385, P155; Triqueneaux G, 1999, NUCLEIC ACIDS RES, V27, P1926, DOI 10.1093/nar/27.8.1926; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; VERBENKO N, 2003, RUSS J GENET, V39, P748; Wilson HL, 2003, BLOOD, V102, P1661, DOI 10.1182/blood-2002-08-2426; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Yamanaka K, 1998, MOL MICROBIOL, V27, P247, DOI 10.1046/j.1365-2958.1998.00683.x; Yang DQ, 2006, ONCOGENE, V25, P4613, DOI 10.1038/sj.onc.1209483; Yoshida T, 2005, ONCOL REP, V14, P1299; Zerbini LF, 2004, P NATL ACAD SCI USA, V101, P13618, DOI 10.1073/pnas.0402069101	73	37	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2595	2605		10.1038/sj.onc.1210068	http://dx.doi.org/10.1038/sj.onc.1210068			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17086213				2022-12-17	WOS:000245831200007
J	Kundu, CN; Balusu, R; Jaiswal, AS; Gairola, CG; Narayan, S				Kundu, C. N.; Balusu, R.; Jaiswal, A. S.; Gairola, C. G.; Narayan, S.			Cigarette smoke condensate-induced level of adenomatous polyposis coli blocks long-patchbase excision repair in breast epithelial cells	ONCOGENE			English	Article						adenomatous polyposis coli; long-patch base excision repair; benzo[a] pyrene; cigarette smoke condensate; breast carcinogenesis	RAS ONCOGENE ACTIVATION; APC GENE-EXPRESSION; TOBACCO-SMOKE; TRANSCRIPTIONAL REGULATION; CHEMICAL-COMPOSITION; PASSIVE SMOKING; ACTIVE SMOKING; DNA-ADDUCTS; CANCER RISK; MUTATIONS	Our previous studies have shown that treatment with cigarette smoke condensate (CSC) transforms normal breast epithelial cell line, MCF-10A. In the present study, the mechanism of CSC-induced transformation of breast epithelial cells was examined. We first determined whether benzo[ a] pyrene (B[a]P)- and CSC-induced levels of APC are capable of inhibiting long-patch base excision repair (LP-BER) since our earlier studies had shown that an interaction of APC with DNA polymerase beta (pol-beta) blocks strand-displacement synthesis. With the use of a novel in vivo LP-BER assay, it was demonstrated that increased and decreased APC levels in different breast cancer cell lines were associated witha decrease or increase in LP-BER activity, respectively. The effect of APC on LP-BER in malignant and pre- malignant breast epithelial cell lines was produced by either overexpression or knockdown of APC. Furthermore, it was shown that the decreased LP-BER in B[a]P- or CSC-treated premalignant breast epithelial cells is associated with an increased level of APC and decreased cell growth. Our results suggest that the decreased growth allows cells to repair the damaged DNA before mitosis, and failure to repair damaged DNA has the potential to transform premalignant breast epithelial cells.	Univ Florida, Shands Canc Ctr, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ Kentucky, Coll Med, Grad Ctr Toxicol, Lexington, KY USA	State University System of Florida; University of Florida; University of Kentucky	Narayan, S (corresponding author), Univ Florida, Shands Canc Ctr, Dept Anat & Cell Biol, Canc & Genet Res Complex,Room 255,POB 103633,1376, Gainesville, FL 32610 USA.	snarayan@ufscc.ufl.edu		Kundu, Chanakya/0000-0003-0297-1030	NCI NIH HHS [CA-100247-01, CA-097031-01, R01 CA100247, R01 CA097031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097031, R01CA100247] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BARON JA, 1984, AM J EPIDEMIOL, V119, P9, DOI 10.1093/oxfordjournals.aje.a113730; Baron JA, 1996, CANCER EPIDEM BIOMAR, V5, P399; BASOLO F, 1991, MOL CARCINOGEN, V4, P25, DOI 10.1002/mc.2940040106; Beral V, 2002, BRIT J CANCER, V87, P1234, DOI 10.1038/sj.bjc.6600596; Braithwaite E, 1998, CARCINOGENESIS, V19, P1239, DOI 10.1093/carcin/19.7.1239; CAVLIERI EL, 1998, HDB ENV CHEM J, V3, P81; CHAKRAVARTI D, 1995, P NATL ACAD SCI USA, V92, P10422, DOI 10.1073/pnas.92.22.10422; Chakravarti D, 1998, ONCOGENE, V16, P3203, DOI 10.1038/sj.onc.1201853; Chakravarti D, 2000, MUTAT RES-FUND MOL M, V456, P17, DOI 10.1016/S0027-5107(00)00102-0; Coates PJ, 2005, J PATHOL, V205, P221, DOI 10.1002/path.1701; Currier N, 2005, TOXICOL PATHOL, V33, P726, DOI 10.1080/01926230500352226; DeMarini DM, 2004, MUTAT RES-REV MUTAT, V567, P447, DOI 10.1016/j.mrrev.2004.02.001; DEMARINI DM, 1995, CARCINOGENESIS, V16, P2535, DOI 10.1093/carcin/16.10.2535; Duell EJ, 2001, CANCER EPIDEM BIOMAR, V10, P217; Egan KM, 2002, EPIDEMIOLOGY, V13, P138, DOI 10.1097/00001648-200203000-00007; ELBAYOUMY K, 1995, CARCINOGENESIS, V16, P431, DOI 10.1093/carcin/16.2.431; Fink AK, 2003, CANCER CAUSE CONTROL, V14, P497, DOI 10.1023/A:1024922824237; Gram IT, 2005, CANCER EPIDEM BIOMAR, V14, P61; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hecht SS, 2002, ENVIRON MOL MUTAGEN, V39, P119, DOI 10.1002/em.10071; HSU TC, 1991, MUTAT RES, V259, P67, DOI 10.1016/0165-1218(91)90110-8; HUSGAFVELPURSIAINEN K, 1993, INT J CANCER, V53, P250, DOI 10.1002/ijc.2910530213; Jaiswal AS, 2001, J BIOL CHEM, V276, P18193, DOI 10.1074/jbc.M101298200; Jaiswal AS, 2002, ONCOGENE, V21, P5912, DOI 10.1038/sj.onc.1205789; Jaiswal AS, 2006, CARCINOGENESIS, V27, P252, DOI 10.1093/carcin/bgi225; Jaiswal AS, 2001, J CELL BIOCHEM, V81, P262, DOI 10.1002/1097-4644(20010501)81:2<262::AID-JCB1041>3.0.CO;2-R; Johnson KC, 2000, CANCER CAUSE CONTROL, V11, P211, DOI 10.1023/A:1008906105790; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; LONDON SJ, 1989, JNCI-J NATL CANCER I, V81, P1625, DOI 10.1093/jnci/81.21.1625; Mei JX, 2003, BREAST CANCER RES TR, V79, P95, DOI 10.1023/A:1023326121951; MILLER FR, 1993, J NATL CANCER I, V85, P1725, DOI 10.1093/jnci/85.21.1725; Morabia A, 1996, AM J EPIDEMIOL, V143, P918, DOI 10.1093/oxfordjournals.aje.a008835; Narayan S, 1997, J BIOL CHEM, V272, P30619, DOI 10.1074/jbc.272.49.30619; Narayan S, 2005, J BIOL CHEM, V280, P6942, DOI 10.1074/jbc.M409200200; Narayan S, 2004, ONCOGENE, V23, P5880, DOI 10.1038/sj.onc.1207792; Nishikawa A, 2004, CURR DRUG METAB, V5, P363, DOI 10.2174/1389200043335441; Pachkowski BF, 2006, CANCER RES, V66, P2860, DOI 10.1158/0008-5472.CAN-05-3388; PALMER JR, 1993, EPIDEMIOL REV, V15, P145, DOI 10.1093/oxfordjournals.epirev.a036098; Patel AV, 2005, BREAST CANCER RES, V7, pR1168, DOI 10.1186/bcr1355; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; PILLSBURY HC, 1972, J ASSOC OFF ANA CHEM, V55, P636; Porter PC, 2005, DNA REPAIR, V4, P341, DOI 10.1016/j.dnarep.2004.10.007; Raptis S, 2006, EXP SUPPL, V96, P303; Reynolds P, 2004, JNCI-J NATL CANCER I, V96, P29, DOI 10.1093/jnci/djh002; Roemer E, 2004, TOXICOLOGY, V195, P31, DOI 10.1016/j.tox.2003.08.006; RUSSO J, 1991, J CELL SCI, V99, P453; SHORTLE D, 1983, METHOD ENZYMOL, V100, P457; SLEBOS RJC, 1991, J NATL CANCER I, V83, P1024, DOI 10.1093/jnci/83.14.1024; Smith CJ, 2000, FOOD CHEM TOXICOL, V38, P637, DOI 10.1016/S0278-6915(00)00051-X; SOULE HD, 1990, CANCER RES, V50, P6075; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Stabbert R, 2003, J APPL TOXICOL, V23, P329, DOI 10.1002/jat.924; Steinetz BG, 2006, CARCINOGENESIS, V27, P1146, DOI 10.1093/carcin/bgi353; Terry PD, 2002, CANCER EPIDEM BIOMAR, V11, P953; Terry PD, 2006, CANCER EPIDEM BIOMAR, V15, P602, DOI 10.1158/1055-9965.EPI-05-0853; Wani MA, 2002, MUTAT RES-FUND MOL M, V505, P13, DOI 10.1016/S0027-5107(02)00107-0; WESTRA WH, 1993, CANCER-AM CANCER SOC, V72, P432, DOI 10.1002/1097-0142(19930715)72:2<432::AID-CNCR2820720219>3.0.CO;2-#; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0	59	37	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1428	1438		10.1038/sj.onc.1209925	http://dx.doi.org/10.1038/sj.onc.1209925			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16924228				2022-12-17	WOS:000244558800007
J	Pasder, O; Shpungin, S; Salem, Y; Makovsky, A; Vilchick, S; Michaeli, S; Malovani, H; Nir, U				Pasder, O.; Shpungin, S.; Salem, Y.; Makovsky, A.; Vilchick, S.; Michaeli, S.; Malovani, H.; Nir, U.			Downregulation of Fer induces PP1 activation and cell-cycle arrest in malignant cells	ONCOGENE			English	Article						malignant cells; Fer kinase; cell; cycle; PP1; pRB	TYROSINE KINASE FER; SERINE/THREONINE PROTEIN PHOSPHATASES; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; CATALYTIC SUBUNIT; G(1)/S TRANSITION; CANCER-CELLS; HELPER-FREE; HIGH-TITER; IN-VIVO	Fer is a nuclear and cytoplasmic intracellular tyrosine kinase. Herein we show that Fer is required for cell-cycle progression in malignant cells. Decreasing the level of Fer using the RNA interference (RNAi) approach impeded the proliferation of prostate and breast carcinoma cells and led to their arrest at the G0/G1 phase. At the molecular level, knockdown of Fer resulted in the activation of the retinoblastoma protein (pRB), and this was reflected by profound hypo-phosphorylation of pRB on both cyclin-dependent kinase CDK4 and CDK2 phosphorylation sites. Dephosphorylation of pRB was not seen upon the direct targeting of either CDK4 or CDK2 expression, and was only partially achieved by the simultaneous depletion of these two kinases. Amino-acid sequence analysis revealed two protein phosphatase 1 (PP1) binding motifs in the kinase domain of Fer and the association of Fer with the pRB phosphatase PP1 alpha was verified using co-immunoprecipitation analysis. Downregulation of Fer potentiated the activation of PP1 alpha and overexpression of Fer decreased the enzymatic activity of that phosphatase. Our findings portray Fer as a regulator of cell-cycle progression in malignant cells and as a potential target for cancer intervention.	Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel	Bar Ilan University	Nir, U (corresponding author), Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel.	nir@mail.biu.ac.il	SILVERSTEIN, ADAR MAKOVSKI/P-1300-2019; Michaeli, Shulamit/AAC-8255-2022					ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Allard P, 2000, MOL CELL ENDOCRINOL, V159, P63, DOI 10.1016/S0303-7207(99)00205-1; Ayllon V, 2002, EUR J IMMUNOL, V32, P1847, DOI 10.1002/1521-4141(200207)32:7<1847::AID-IMMU1847>3.0.CO;2-7; Ben-Dor I, 1999, CELL GROWTH DIFFER, V10, P113; Bennett D, 2002, NAT GENET, V31, P419, DOI 10.1038/ng938; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Ceulemans H, 2002, BIOESSAYS, V24, P371, DOI 10.1002/bies.10069; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chow JPH, 2003, MOL BIOL CELL, V14, P3989, DOI 10.1091/mbc.E03-03-0168; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Craig AWB, 2002, MOL CELL BIOL, V22, P6363, DOI 10.1128/MCB.22.18.6363-6374.2002; Craig AWB, 2001, MOL CELL BIOL, V21, P603, DOI 10.1128/MCB.21.2.603-613.2001; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; Garcia A, 2003, BIOCHIMIE, V85, P721, DOI 10.1016/j.biochi.2003.09.004; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Honkanen RE, 2002, CURR MED CHEM, V9, P2055, DOI 10.2174/0929867023368836; Iwanishi M, 2000, J BIOL CHEM, V275, P38995, DOI 10.1074/jbc.M006665200; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kogata N, 2003, MOL BIOL CELL, V14, P3553, DOI 10.1091/mbc.E03-02-0080; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; LETWIN K, 1988, ONCOGENE, V3, P621; Liu CWY, 1999, J BIOL CHEM, V274, P29470, DOI 10.1074/jbc.274.41.29470; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Lunter PC, 2002, BIOCHEM BIOPH RES CO, V296, P904, DOI 10.1016/S0006-291X(02)02007-7; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Miravet S, 2003, MOL CELL BIOL, V23, P7391, DOI 10.1128/MCB.23.20.7391-7402.2003; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Orlovsky K, 2000, BIOCHEMISTRY-US, V39, P11084, DOI 10.1021/bi0005153; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Pan WJ, 1998, CARCINOGENESIS, V19, P765, DOI 10.1093/carcin/19.5.765; PENHALLOW RC, 1995, J BIOL CHEM, V270, P23362, DOI 10.1074/jbc.270.40.23362; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Priel-Halachmi S, 2000, J BIOL CHEM, V275, P28902, DOI 10.1074/jbc.M003402200; Reed SI, 1997, CANCER SURV, V29, P7; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; Rubin E, 2001, ONCOGENE, V20, P3776, DOI 10.1038/sj.onc.1204518; Salem Y, 2005, CELL SIGNAL, V17, P341, DOI 10.1016/j.cellsig.2004.08.001; Sellin JH, 2001, CANCER RES, V61, P2899; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sugiyama K, 2002, ONCOGENE, V21, P3103, DOI 10.1038/sj.onc.1205432; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Wang RH, 2001, ONCOGENE, V20, P6111, DOI 10.1038/sj.onc.1204829; Yamasaki Lili, 2003, Cancer Treat Res, V115, P209; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	60	37	39	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	30					4194	4206		10.1038/sj.onc.1209695	http://dx.doi.org/10.1038/sj.onc.1209695			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16732323				2022-12-17	WOS:000239004800007
J	Schiller, M; Bohm, M; Dennler, S; Ehrchen, JM; Mauviel, A				Schiller, M.; Boehm, M.; Dennler, S.; Ehrchen, J. M.; Mauviel, A.			Mitogen- and stress-activated protein kinase 1 is critical for interleukin-1-induced, CREB-mediated, c-fos gene expression in keratinocytes	ONCOGENE			English	Article						cAMP; c-fos; CREB; PKA; MAP kinases; interleukin-1	KINASE SIGNALING CASCADES; SERUM RESPONSE ELEMENT; PROTEIN-KINASE; MAP KINASE; METALLOPROTEINASE EXPRESSION; TRANSGENIC MICE; TRANSCRIPTION; INDUCTION; AP-1; CELLS	c-fos, which encodes a transcription factor of the AP-1 family, is a prototypical immediate-early gene induced by a number of proinflammatory cytokines including interleukin-1 (IL-1), the latter being an important regulator of skin homeostasis. Using the human keratinocyte cell line HaCaT as an in vitro model, we dissected the molecular pathways leading to IL-1-induced c-fos gene induction. Phosphorylation of the transcription factor cAMP response element binding protein (CREB) at Ser133 was found to be essential for IL-1-induced c-fos gene induction and was closely paralleled by protein kinase A (PKA) activation. In contrast to other cell types, the cyclooxy-genase/prostaglandin pathway, known to activate the cAMP/PKA cascade, plays little, if any, role in c-fos expression downstream of the IL-1 receptor in keratinocytes. Simultaneous activation of several of the mitogen-activated protein kinase (MAPK) cascades occurred in response to IL-1, but each differentially contributed to c-fos induction by IL-1, with the p38/MAPK being the most crucial of all, the extracellular signal-regulated kinase pathway contributing in an additive manner and the Jun N-terminal kinase pathway playing little, if any, role. We also demonstrate that p38-dependent activation of mitogen- and stress-activated kinase 1 (MSK1), a CREB kinase, is a key step for c-fos gene activation by IL-1. Finally, we identify MSK1 as playing a positive role in the control of cell proliferation of both HaCaT keratinocytes and the A431 human epidermoid carcinoma line.	Hop St Louis, INSERM, U697, F-75010 Paris, France; Univ Munster, Ludwig Boltzmann Inst Cell Biol & Immunobiol, Dept Dermatol, Munster, Germany	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Munster	Mauviel, A (corresponding author), Hop St Louis, INSERM, U697, Pavillon Bazin,1 Ave Claude Vellefaux, F-75010 Paris, France.	alain.mauviel@stlouis.inserm.fr	MAUVIEL, Alain/F-6251-2013	Mauviel, Alain/0000-0002-0438-2793				Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Andrisani OM, 1999, CRIT REV EUKAR GENE, V9, P19, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.20; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Braddock M, 2004, NAT REV DRUG DISCOV, V3, P1, DOI 10.1038/nrd1342; Caivano M, 2000, J IMMUNOL, V164, P3018, DOI 10.4049/jimmunol.164.6.3018; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; Dayer JM, 2003, RHEUMATOLOGY, V42, P3, DOI 10.1093/rheumatology/keg326; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Dinarello CA, 2002, CLIN EXP RHEUMATOL, V20, pS1; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI200112466; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kumar S, 2001, J CELL PHYSIOL, V187, P294, DOI 10.1002/jcp.1082; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LUGER TA, 1990, J INVEST DERMATOL, V95, pS100, DOI 10.1111/1523-1747.ep12874944; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; Podolsky DK, 1997, J GASTROENTEROL, V32, P122, DOI 10.1007/BF01213309; Price MA, 1996, PHILOS T ROY SOC B, V351, P551, DOI 10.1098/rstb.1996.0054; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Schuck S, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-6; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Song KS, 2003, J BIOL CHEM, V278, P23243, DOI 10.1074/jbc.M300096200; Strniskova M, 2002, GEN PHYSIOL BIOPHYS, V21, P231; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; WANG ZQ, 1995, CANCER RES, V55, P6244; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WESTMAYS JA, 1995, P NATL ACAD SCI USA, V92, P6768, DOI 10.1073/pnas.92.15.6768; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Yang SH, 2003, GENE, V320, P3, DOI 10.1016/S0378-1119(03)00816-3	38	37	41	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	32					4449	4457		10.1038/sj.onc.1209479	http://dx.doi.org/10.1038/sj.onc.1209479			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16532028				2022-12-17	WOS:000239326000008
J	Verissimo, F; Silva, E; D Morris, J; Pepperkok, R; Jordan, P				Verissimo, F.; Silva, E.; D Morris, J.; Pepperkok, R.; Jordan, P.			Protein kinase WNK3 increases cell survival in a caspase-3-dependent pathway	ONCOGENE			English	Article						apoptosis; Hsp70; procaspase-3; WNK protein kinases	HEAT-SHOCK-PROTEIN-70 INHIBITS APOPTOSIS; HEAT-SHOCK PROTEINS; DEATH; HSP70; CHAPERONES; EXPRESSION; SPAK; COTRANSPORTERS; DOWNSTREAM; PROTECTION	The subfamily of WNK (with no K lysine) protein kinases has four human members and germline mutations in the WNK1 and WNK4 genes were recently found to cause pseudohypoaldosteronism type II, a familial hypertension disease. Here, we describe cloning and functional analysis of a further WNK member, human WNK3. Endogenous WNK3 protein is an active protein kinase when immunoprecipitated from cells and its overexpression increases the survival of HeLa cells by delaying the onset of apoptosis. Suppression of endogenous WNK3 protein by RNA interference accelerates the apoptotic response and promotes the activation of caspase-3. The mechanism of WNK3 action involves interaction with procaspase-3 and heat-shock protein 70. These results demonstrate a role for WNK3 in promoting cell survival and suggest a mechanism at the level of procaspase-3 activation.	Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, P-1649016 Lisbon, Portugal; Kings Coll London, Sch Med & Dent, Rayne Inst, London SE5 9NU, England; European Mol Biol Lab, Cell Biophys Programme, Heidelberg, Germany	Instituto Nacional de Saude Dr. Ricardo Jorge; University of London; King's College London; European Molecular Biology Laboratory (EMBL)	Jordan, P (corresponding author), Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, Ave Padre Cruz, P-1649016 Lisbon, Portugal.	peter.jordan@insa.min-saude.pt	Jordan, Peter/G-9335-2012	Jordan, Peter/0000-0002-1425-9211; Pepperkok, Rainer/0000-0002-9762-3583				Bagci EZ, 2006, BIOPHYS J, V90, P1546, DOI 10.1529/biophysj.105.068122; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Cosulich SC, 1999, CURR BIOL, V9, P147, DOI 10.1016/S0960-9822(99)80068-2; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dmitrieva NI, 2005, MUTAT RES-FUND MOL M, V569, P65, DOI 10.1016/j.mrfmmm.2004.06.053; Eischen CM, 2004, ONCOGENE, V23, P8931, DOI 10.1038/sj.onc.1208052; Gagnon KBE, 2006, MOL CELL BIOL, V26, P689, DOI 10.1128/MCB.26.2.689-698.2006; Gamba G, 2005, AM J PHYSIOL-RENAL, V288, pF245, DOI 10.1152/ajprenal.00311.2004; Gotz R, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-85; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Holden S, 2004, GENE, V335, P109, DOI 10.1016/j.gene.2004.03.009; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; JAATTELA M, 1993, J EXP MED, V177, P231, DOI 10.1084/jem.177.1.231; Jiang ZY, 2005, J BIOL CHEM, V280, P21622, DOI 10.1074/jbc.m414464200; Jordan P, 2000, BIOCHEM BIOPH RES CO, V279, P741, DOI 10.1006/bbrc.2000.3901; Kahle KT, 2005, P NATL ACAD SCI USA, V102, P16783, DOI 10.1073/pnas.0508307102; Kahle KT, 2004, CURR OPIN NEPHROL HY, V13, P557, DOI 10.1097/00041552-200409000-00012; Kahle KT, 2004, P NATL ACAD SCI USA, V101, P2064, DOI 10.1073/pnas.0308434100; Kaur J, 2000, INT J CANCER, V85, P1; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; Komarova EY, 2004, CELL STRESS CHAPERON, V9, P265, DOI 10.1379/CSC-27R1.1; Kostich M, 2002, GENOME BIOL, V3; Lee BH, 2004, MOL CELL, V15, P741, DOI 10.1016/j.molcel.2004.07.018; Lenertz LY, 2005, J BIOL CHEM, V280, P26653, DOI 10.1074/jbc.M502598200; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nollen EAA, 2002, J CELL SCI, V115, P2809; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Parcellier A, 2003, BIOCHEM BIOPH RES CO, V304, P505, DOI 10.1016/S0006-291X(03)00623-5; Rinehart J, 2005, P NATL ACAD SCI USA, V102, P16777, DOI 10.1073/pnas.0508303102; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Verissimo F, 2001, ONCOGENE, V20, P5562, DOI 10.1038/sj.onc.1204726; Vitari AC, 2005, BIOCHEM J, V391, P17, DOI 10.1042/BJ20051180; Vitari AC, 2004, BIOCHEM J, V378, P257, DOI 10.1042/BJ20031692; WEI YQ, 1995, CANCER IMMUNOL IMMUN, V40, P73, DOI 10.1007/s002620050146; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Xu BE, 2005, P NATL ACAD SCI USA, V102, P10315, DOI 10.1073/pnas.0504422102; Xu BE, 2004, J BIOL CHEM, V279, P7826, DOI 10.1074/jbc.M313465200; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795	54	37	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4172	4182		10.1038/sj.onc.1209449	http://dx.doi.org/10.1038/sj.onc.1209449			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501604				2022-12-17	WOS:000239004800005
J	Yin, W; Rossin, A; Clifford, JL; Gronemeyer, H				Yin, W.; Rossin, A.; Clifford, J. L.; Gronemeyer, H.			Co-resistance to retinoic acid and TRAIL by insertion mutagenesis into RAM	ONCOGENE			English	Article						retinoic acid; rexinoid; apoptosis; TRAIL; insertion mutagenesis; retrovirus	APOPTOSIS-INDUCING LIGAND; NF-KAPPA-B; TUMOR-SELECTIVE APOPTOSIS; INDUCED-PROXIMITY MODEL; ACUTE MYELOID-LEUKEMIA; CYTOCHROME-C; DEATH RECEPTORS; DEFICIENT MICE; CELL-LINES; ACTIVATION	Retinoic acid ( RA), used as first-line therapy for acute promyelocytic leukemia ( APL), exerts its antileukemic activity by inducing blast differentiation and activating tumor-selective TNF-related apoptosis-inducing ligand ( TRAIL) signaling. To identify downstream mediators of RA signaling, we used retrovirus-mediated insertion mutagenesis in PLB985 leukemia cells and established the RA-resistant cell line WY-1. In PLB985, but not WY-1 cells, RA induced TRAIL and its DR4 and DR5 receptors. Knocking down TRAIL expression by RNA interference blocked RA-induced apoptosis. WY-1 cells are defective for RA-induced differentiation, G1 arrest and exhibit coresistance to TRAIL. In WY-1 cells, a single virus copy is integrated into a novel RA-regulated gene termed RAM ( retinoic acid modulator). RAM is expressed in the myelomonocytic lineage and extinguished by RA in PLB985, but not WY-1 cells. Whereas knocking down RAM expression by RNA interference promoted RA-induced differentiation and TRAIL- triggered apoptosis of PLB985 and WY-1 cells, overexpression of the predicted 109 amino-acid RAM open reading frame did not alter RA signaling in PLB985 cells. This indicates that, apart from encoding the putative RAM protein, RAM RNA may exert additional functions that are impaired by the retrovirus insertion. Our study demonstrates that RA induction of the TRAIL pathway is also operative in leukemia cells lacking an RAR alpha oncofusion protein and identifies RAM as a novel RA-dependent modulator of myeloid differentiation and death.	UPL, INSERM, CNRS, IGBMC,Dept Cell Biol & Signal Transduct, Illkirch Graffenstaden, France; CU Strasbourg, Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Gronemeyer, H (corresponding author), LSUHSC, Dept Biochem & Mol Biol, POB 33932,1501 Kings Highway, Shreveport, LA 71130 USA.	hg@igbmc.u-strasbg.fr	Gronemeyer, Hinrich/H-7002-2016; Gronemeyer, Hinrich/G-6240-2011; Gronemeyer, Hinrich/AAH-5575-2019	Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Rossin, Aurelie/0000-0002-6110-1249				Altucci L, 2005, CANCER RES, V65, P8754, DOI 10.1158/0008-5472.CAN-04-3569; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Altucci L, 2004, VITAM HORM, V67, P319; Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164; Bernard D, 2001, J BIOL CHEM, V276, P27322, DOI 10.1074/jbc.M011183200; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; Clagett-Dame M, 2002, ANNU REV NUTR, V22, P347, DOI 10.1146/annurev.nutr.22.010402.102745E; Clarke N, 2004, EMBO J, V23, P3051, DOI 10.1038/sj.emboj.7600302; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Drexler HG, 2003, LEUKEMIA, V17, P416, DOI 10.1038/sj.leu.2402799; Gavalas A, 2002, TRENDS NEUROSCI, V25, P61, DOI 10.1016/S0166-2236(02)02067-2; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Laudet V., 2002, NUCL RECEPTOR FACTS; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Monczak Y, 1997, BLOOD, V90, P3345, DOI 10.1182/blood.V90.9.3345; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; NAGY L, 1995, MOL CELL BIOL, V15, P3540; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Secchiero P, 2003, J LEUKOCYTE BIOL, V74, P223, DOI 10.1189/jlb.0103004; Sedger LM, 2002, EUR J IMMUNOL, V32, P2246, DOI 10.1002/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO;2-6; Shiozaki EN, 2002, P NATL ACAD SCI USA, V99, P4197, DOI 10.1073/pnas.072544399; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Takeda K, 2004, J EXP MED, V199, P437, DOI 10.1084/jem.20031457; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; TUCKER KA, 1987, BLOOD, V70, P372; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Watabe E, 2001, JPN J CANCER RES, V92, P140, DOI 10.1111/j.1349-7006.2001.tb01076.x; Yin WH, 2005, INT J BIOCHEM CELL B, V37, P1696, DOI 10.1016/j.biocel.2005.03.003; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	51	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3735	3744		10.1038/sj.onc.1209410	http://dx.doi.org/10.1038/sj.onc.1209410			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16449964				2022-12-17	WOS:000238448300012
J	Hashiramoto, A; Mizukami, H; Yamashita, T				Hashiramoto, A.; Mizukami, H.; Yamashita, T.			Ganglioside GM3 promotes cell migration by regulating MAPK and c-Fos/AP-1	ONCOGENE			English	Article						GM3; MAPK; cell cycle; c-Fos; AP-1	SIGNAL-TRANSDUCTION; MICE LACKING; C-FOS; GROWTH; KINASE; EXPRESSION; PROLIFERATION; ACTIVATION; APOPTOSIS; TRANSFORMATION	Gangliosides have been proposed as modulators of transmembrane signaling. Recently, GM3, a glycosphingolipid containing monosaialic acids, is thought to be one of the key molecules of signal transduction in mammalian cells. In this study, we used mouse embryonic fibroblast cell lines (MEFs) established from sialyltransferase-I knockout mice (GM3 synthase KO mice) to evaluate the regulation of mitogenic signals by gangliosides. Cell proliferation assay revealed a higher growth potential of GM3 KO MEFs. Immunoblots showed upregulation of Ras/Raf/MEK/ERK pathway in GM3 KO MEFs, and these signals resulted in enhanced translocation of ERK into the nuclei. Further, both exogenous and endogenous add-back of GM3 decreased the activities of MAPK in GM3 KO MEFs. In addition, GM3 KO MEFs formed foci in high-density culture condition, and analyses of cell cycle modulators revealed the resistance of GM3 KO MEFs for entering cell cycle arrest. Finally, sustained expressions of c-Fos in GM3 KO MEFs were shown to correlate with DNA-binding activity between c-Fos and AP-1. These results demonstrate that the deletion of sialyltransferase-I changes the character of MEFs to a highly activated state of the MAPK pathway, indicating the critical role of GM3 as a regulator of membrane-transmitted signals.	Kobe Univ, Dept Rheumatol, FHS Sch Med, Kobe, Hyogo 6540142, Japan; NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; Hirosaki Univ, Sch Med, Dept Pathol, Hirosaki, Aomori 036, Japan; Univ Tokyo, Inst Med Sci, Dept Cell Proc, Tokyo, Japan	Kobe University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Hirosaki University; University of Tokyo	Hashiramoto, A (corresponding author), Kobe Univ, Dept Rheumatol, FHS Sch Med, 7-10-2 Tomogaoka, Kobe, Hyogo 6540142, Japan.	hash@kobe-u.ac.jp	Mizukami, Hiroki/ABE-7877-2021	Mizukami, Hiroki/0000-0003-2920-582X				Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Blagosklonny MV, 1999, BIOESSAYS, V21, P704, DOI 10.1002/(SICI)1521-1878(199908)21:8<704::AID-BIES10>3.0.CO;2-5; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cullen PJ, 2001, CURR BIOL, V11, pR342, DOI 10.1016/S0960-9822(01)00189-0; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Garofalo T, 2002, J LIPID RES, V43, P971; Gorbacheva VY, 2002, J BIOL CHEM, V277, P6080, DOI 10.1074/jbc.M110542200; Gouni-Berthold L, 2001, HYPERTENSION, V38, P1030, DOI 10.1161/hy1101.093104; Groth A, 2005, CELL SIGNAL, V17, P1063, DOI 10.1016/j.cellsig.2004.11.021; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Hakomori SI, 1998, ANN NY ACAD SCI, V845, P1, DOI 10.1111/j.1749-6632.1998.tb09657.x; HANAI N, 1988, J BIOL CHEM, V263, P10915; Hashiramoto A, 1999, ARTHRITIS RHEUM, V42, P954, DOI 10.1002/1529-0131(199905)42:5<954::AID-ANR14>3.0.CO;2-J; Hoffmann E, 2005, J BIOL CHEM, V280, P9706, DOI 10.1074/jbc.M407071200; Huwiler A, 2000, BBA-MOL CELL BIOL L, V1485, P63, DOI 10.1016/S1388-1981(00)00042-1; Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; Kono M, 1998, BIOCHEM BIOPH RES CO, V253, P170, DOI 10.1006/bbrc.1998.9768; Li A, 2001, NAT CELL BIOL, V3, pE182, DOI 10.1038/35087119; Li RX, 2000, J BIOL CHEM, V275, P34213, DOI 10.1074/jbc.M906368199; Li RX, 2001, J BIOL CHEM, V276, P42782, DOI 10.1074/jbc.M101481200; MATYAS GR, 1987, P NATL ACAD SCI USA, V84, P6065, DOI 10.1073/pnas.84.17.6065; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nakatsuji Y, 2001, J NEUROSCI RES, V66, P487, DOI 10.1002/jnr.1240; NANAI N, 1998, J BIOL CHEM, V263, P10915; Noll ENE, 2001, EXP NEUROL, V168, P300, DOI 10.1006/exnr.2000.7603; PALLER AS, 1993, J INVEST DERMATOL, V100, P841, DOI 10.1111/1523-1747.ep12476755; Pestana ES, 1999, ONCOGENE, V18, P4069, DOI 10.1038/sj.onc.1202794; Radeff-Huang J, 2004, J CELL BIOCHEM, V92, P949, DOI 10.1002/jcb.20094; Scorrano L, 1999, J BIOL CHEM, V274, P24657, DOI 10.1074/jbc.274.35.24657; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; VANBROCKLYN J, 1993, J NEUROCHEM, V61, P371; VANMEER G, 2000, BIOCHIM BIOPHYS ACTA, V26, P145; Wang XQ, 2003, J BIOL CHEM, V278, P48770, DOI 10.1074/jbc.M308818200; Wang XQ, 2001, GLYCOBIOLOGY, V11, P515, DOI 10.1093/glycob/11.7.515; Yamashita T, 2003, P NATL ACAD SCI USA, V100, P3445, DOI 10.1073/pnas.0635898100; Zou YP, 1998, INT J MOL MED, V1, P827	45	37	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3948	3955		10.1038/sj.onc.1209416	http://dx.doi.org/10.1038/sj.onc.1209416			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16491123				2022-12-17	WOS:000238668800008
J	Lannutti, BJ; Minear, J; Blake, N; Drachman, JG				Lannutti, B. J.; Minear, J.; Blake, N.; Drachman, J. G.			Increased megakaryocytopoiesis in Lyn-deficient mice	ONCOGENE			English	Article						megakaryocyte; Lyn; Mp1; MAPK; Akt	SRC-FAMILY KINASES; PROTEIN-TYROSINE KINASES; THROMBOPOIETIN-INDUCED PROLIFERATION; PRIMARY MURINE MEGAKARYOCYTES; SIGNAL-TRANSDUCTION; CELL-LINES; MAST-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; SUSTAINED ACTIVATION; AUTOIMMUNE-DISEASE	Previous studies in cell lines have shown Lyn kinase to be a negative regulator of thrombopoietin (TPO)-induced proliferation. To further investigate the role of Lyn during megakaryocytopoiesis, Lyn-deficient mice (lyn(-/-)) were analyzed. We observed that lyn(-/-) mice have more bone marrow-derived GPIIB (CD41) and Mpl(+) cells when compared to their wild-type littermates. In addition, colony-forming unit-megakaryocytes (CFU-MK) are increased and TPO-induced expansion of primary marrow cells yielded a greater number of mature megakaryocytes (MKs) with increased nuclear ploidy. Histopathology of bone marrow and spleens from lyn(-/-) mice showed an increase in the number of MKs. Mechanistic studies revealed that TPO stimulation of MKs from lyn(-/-) mice did not affect phosphorylation of Janus kinase 2 (JAK2), signal transducer and activator of transcription ( STAT) 3, STAT5, or MAP kinase kinase (MEK). Lyn-deficient MKs supported greater TPO-mediated phosphorylation and kinase activity of both Erk1/2 (mitogen-activated protein kinase, MAPK) and Akt. In contrast, there was a reduction of tyrosine phosphorylation of the inositol phosphatase, SHIP. This is the first direct evidence using primary MKs from Lyn-deficient mice that confirms our prior data from cell lines that Lyn kinase is a negative regulator of TPO signaling.	Univ Washington, Puget Sound Blood Ctr, Seattle, WA 98195 USA; Univ Washington, Med Ctr, Div Hematol, Seattle, WA 98195 USA	Puget Sound Blood Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lannutti, BJ (corresponding author), Univ Washington, Puget Sound Blood Ctr, 921 Terry Ave, Seattle, WA 98195 USA.	brianl@psbc.org			NHLBI NIH HHS [R01HL65498] Funding Source: Medline; NIDDK NIH HHS [K01DK065129] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK065129] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON SM, 1995, J IMMUNOL, V155, P1660; Baran CP, 2003, J BIOL CHEM, V278, P38628, DOI 10.1074/jbc.M305021200; Beavitt SJE, 2005, J IMMUNOL, V175, P1867, DOI 10.4049/jimmunol.175.3.1867; Chan VWF, 1998, CURR BIOL, V8, P545, DOI 10.1016/S0960-9822(98)70223-4; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Cheng JJ, 2001, J BIOL CHEM, V276, P31368, DOI 10.1074/jbc.M011317200; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; Drachman JG, 1999, J BIOL CHEM, V274, P13480, DOI 10.1074/jbc.274.19.13480; Drachman JG, 1997, BLOOD, V89, P483, DOI 10.1182/blood.V89.2.483; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; Ezumi Y, 1998, EUR J BIOCHEM, V258, P976, DOI 10.1046/j.1432-1327.1998.2580976.x; Filippi MD, 2002, BLOOD, V99, P1174, DOI 10.1182/blood.V99.4.1174; Freeburn RW, 2002, J IMMUNOL, V169, P5441, DOI 10.4049/jimmunol.169.10.5441; Gardai S, 2002, J BIOL CHEM, V277, P5236, DOI 10.1074/jbc.M110005200; Gauld SB, 2004, ONCOGENE, V23, P8001, DOI 10.1038/sj.onc.1208075; Geddis AE, 2002, CYTOKINE GROWTH F R, V13, P61, DOI 10.1016/S1359-6101(01)00030-2; Geddis AE, 2001, J BIOL CHEM, V276, P34473, DOI 10.1074/jbc.M105178200; Hallek M, 1997, EXP HEMATOL, V25, P1367; Harder KW, 2001, IMMUNITY, V15, P603, DOI 10.1016/S1074-7613(01)00208-4; Hernandez-Hansen V, 2004, J IMMUNOL, V173, P100, DOI 10.4049/jimmunol.173.1.100; Hernandez-Hansen V, 2004, J LEUKOCYTE BIOL, V75, P143, DOI 10.1189/jlb.0503224; Hibbs ML, 2002, J EXP MED, V196, P1593, DOI 10.1084/jem.20020515; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; Horn S, 2004, LEUKEMIA, V18, P1839, DOI 10.1038/sj.leu.2403529; Kamata T, 2004, BLOOD, V103, P2568, DOI 10.1182/blood-2003-06-1803; Kitaura J, 2000, J EXP MED, V192, P729, DOI 10.1084/jem.192.5.729; Lannutti BJ, 2005, BLOOD, V105, P3875, DOI 10.1182/blood-2004-10-3934; Lannutti BJ, 2004, BLOOD, V103, P3736, DOI 10.1182/blood-2003-10-3566; Lannutti BJ, 2003, EXP HEMATOL, V31, P1268, DOI 10.1016/j.exphem.2003.09.009; Maxwell MJ, 2004, J BIOL CHEM, V279, P32196, DOI 10.1074/jbc.M400746200; Miyakawa Y, 2001, J BIOL CHEM, V276, P2494, DOI 10.1074/jbc.M002633200; Nishizumi H, 1997, J IMMUNOL, V158, P2350; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; Pereira S, 2003, J IMMUNOL, V171, P1319, DOI 10.4049/jimmunol.171.3.1319; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Rojnuckarin P, 1999, BLOOD, V94, P1273, DOI 10.1182/blood.V94.4.1273.416k04_1273_1282; Rojnuckarin P, 2001, J BIOL CHEM, V276, P41014, DOI 10.1074/jbc.M106508200; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; Santini V, 2002, HAEMATOLOGICA, V87, P1242; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Smith KGC, 1998, J EXP MED, V187, P807, DOI 10.1084/jem.187.5.807; Stafford S, 2002, J IMMUNOL, V168, P1978, DOI 10.4049/jimmunol.168.4.1978; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; Vara JAF, 2001, MOL BIOL CELL, V12, P2171, DOI 10.1091/mbc.12.7.2171; Wang JY, 1996, J EXP MED, V184, P831, DOI 10.1084/jem.184.3.831	50	37	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3316	3324		10.1038/sj.onc.1209351	http://dx.doi.org/10.1038/sj.onc.1209351			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16418722				2022-12-17	WOS:000237951200010
J	Vasilcanu, D; Weng, WH; Girnita, A; Lui, WO; Vasilcanu, R; Axelson, M; Larsson, O; Larsson, C; Girnita, L				Vasilcanu, D.; Weng, W-H; Girnita, A.; Lui, W-O; Vasilcanu, R.; Axelson, M.; Larsson, O.; Larsson, C.; Girnita, L.			The insulin-like growth factor-1 receptor inhibitor PPP produces only very limitedresistance in tumor cells exposed to long-term selection	ONCOGENE			English	Article						IGF-1 receptor; drug resistance; PPP	TYROSINE KINASE-ACTIVITY; SINGLE-CHAIN ANTIBODY; BREAST-CANCER CELLS; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; IGF-I; ANTITUMOR-ACTIVITY; CYCLOLIGNAN PPP; MULTIDRUG-RESISTANCE; MOLECULAR-MECHANISMS; MULTIPLE-MYELOMA	The cyclolignan PPP was recently demonstrated to inhibit the activity of insulin-like growth factor-1 receptor (IGF-1R), without affecting the highly homologous insulin receptor. In addition, PPP caused complete regression of xenografts derived from various types of cancer. These data highlight the use of this compound in cancer treatment. However, a general concern with antitumor agents is development of resistance. In light of this problem, we aimed to investigate whether malignant cells may develop serious resistance to PPP. After trying to select 10 malignant cell lines, with documented IGF-1R expression and apoptotic responsiveness to PPP treatment (IC(50)s less than 0.1 mu M), only two survived an 80-week selection but could only tolerate maximal PPP doses of 0.2 and 0.5 mu M, respectively. Any further increase in the PPP dose resulted in massive cell death. These two cell lines were demonstrated not to acquire any essential alteration in responsiveness to PPP regarding IGF-1-induced IGF-1R phosphorylation. Neither did they exhibit any increase in expression of the multidrug resistance proteins MDR1 or MRP1. Consistently, they did not exhibit decreased sensitivity to conventional cytostatic drugs. Rather, the sensitivity was increased. During the first half of the selection period, both cell lines responded with a temporary and moderate increase in IGF-1R expression, which appeared to be because of an increased transcription of the IGF-1R gene. This increase in IGF-1R might be necessary to make cells competent for further selection but only up to a PPP concentration of 0.2 and 0.5 mu M. In conclusion, malignant cells develop no or remarkably weak resistance to the IGF-1R inhibitor PPP.	Karolinska Univ Hosp, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; Karolinska Univ Hosp, Dept Mol Med, SE-17176 Stockholm, Sweden; Karolinska Univ Hosp, Dept Clin Chem, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Larsson, O (corresponding author), Karolinska Univ Hosp, Dept Pathol & Oncol, CCK R8-04, SE-17176 Stockholm, Sweden.	olllar@ki.se	Girnita, Leonard/A-4168-2008; Weng, Wen Hui/AAV-7260-2021; Lui, Weng-Onn/X-5957-2019; Girnita, Ada/AAC-4518-2020; Lui, Weng-Onn/G-6703-2013	Girnita, Leonard/0000-0003-0280-9500; Lui, Weng-Onn/0000-0003-4717-4473; Lui, Weng-Onn/0000-0003-4717-4473				Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; Ahlen J, 2005, CLIN CANCER RES, V11, P206; Alexia C, 2004, BIOCHEM PHARMACOL, V68, P1003, DOI 10.1016/j.bcp.2004.05.029; All-Ericsson C, 2002, INVEST OPHTH VIS SCI, V43, P1; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; Blum G, 2003, J BIOL CHEM, V278, P40442, DOI 10.1074/jbc.M305490200; Blum G, 2000, BIOCHEMISTRY-US, V39, P15705, DOI 10.1021/bi001516y; Bohula EA, 2003, J BIOL CHEM, V278, P15991, DOI 10.1074/jbc.M300714200; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; BUCHARDT O, 1986, J PHARM SCI, V75, P1076, DOI 10.1002/jps.2600751111; Catrina SB, 2005, BRIT J CANCER, V92, P1467, DOI 10.1038/sj.bjc.6602408; Chen LL, 2004, CANCER RES, V64, P5913, DOI 10.1158/0008-5472.CAN-04-0085; DAmbrosio C, 1996, CANCER RES, V56, P4013; De Meyts P, 2002, NAT REV DRUG DISCOV, V1, P769, DOI 10.1038/nrd917; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Garcia-Echeverria C, 2004, CANCER CELL, V5, P231, DOI 10.1016/S1535-6108(04)00051-0; Girnita A, 2004, CANCER RES, V64, P236, DOI 10.1158/0008-5472.CAN-03-2522; GIRNITA A, 2005, IN PRESS CLIN CANC R; Girnita L, 2000, CANCER RES, V60, P5278; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Girnita L, 2000, ANTI-CANCER DRUG DES, V15, P67; Girnita L, 2005, J BIOL CHEM, V280, P24412, DOI 10.1074/jbc.M501129200; Goetsch L, 2005, INT J CANCER, V113, P316, DOI 10.1002/ijc.20543; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Guo YS, 1998, J CELL PHYSIOL, V175, P141, DOI 10.1002/(SICI)1097-4652(199805)175:2<141::AID-JCP3>3.0.CO;2-O; HernandezSanchez C, 1997, J BIOL CHEM, V272, P4663, DOI 10.1074/jbc.272.8.4663; HIRSCHERNST KI, 1995, BIOCHEM BIOPH RES CO, V215, P179, DOI 10.1006/bbrc.1995.2450; Jerome L, 2003, ENDOCR-RELAT CANCER, V10, P561, DOI 10.1677/erc.0.0100561; Jones HE, 2004, ENDOCR-RELAT CANCER, V11, P793, DOI 10.1677/erc.1.00799; Kanter-Lewensohn L, 2000, MOL CELL ENDOCRINOL, V165, P131, DOI 10.1016/S0303-7207(00)00253-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsson O, 2005, BRIT J CANCER, V92, P2097, DOI 10.1038/sj.bjc.6602627; Le Roith D, 1999, ISR MED ASSOC J, V1, P25; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706; Lu YH, 2004, INT J CANCER, V108, P334, DOI 10.1002/ijc.11445; Menu E, 2006, BLOOD, V107, P655, DOI 10.1182/blood-2005-01-0293; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nair PN, 2001, ONCOGENE, V20, P8203, DOI 10.1038/sj.onc.1205044; Navab R, 2001, J BIOL CHEM, V276, P13644, DOI 10.1074/jbc.M100019200; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Pautsch A, 2001, STRUCTURE, V9, P955, DOI 10.1016/S0969-2126(01)00655-4; Peggs K, 2004, CLIN EXP MED, V4, P1, DOI 10.1007/s10238-004-0032-5; Reinmuth N, 2002, CLIN CANCER RES, V8, P3259; RESNICOFF M, 1994, CANCER RES, V54, P4848; ROHLIK QT, 1987, BIOCHEM BIOPH RES CO, V149, P276, DOI 10.1016/0006-291X(87)91635-4; Sachdev D, 2003, CANCER RES, V63, P627; Scotlandi K, 2005, CANCER RES, V65, P3868, DOI 10.1158/0008-5472.CAN-04-3192; Stromberg T, 2006, BLOOD, V107, P669, DOI 10.1182/blood-2005-01-0306; Ulfarsson E, 2005, CLIN CANCER RES, V11, P4674, DOI 10.1158/1078-0432.CCR-05-0129; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; VANWYK JJ, 1985, J CLIN ENDOCR METAB, V61, P639; Vasilcanu D, 2004, ONCOGENE, V23, P7854, DOI 10.1038/sj.onc.1208065; Yang K, 2002, ONCOGENE, V21, P4181, DOI 10.1038/sj.onc.1205569; Ye JJ, 2003, HORM METAB RES, V35, P836; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472	59	37	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3186	3195		10.1038/sj.onc.1209339	http://dx.doi.org/10.1038/sj.onc.1209339			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16407828				2022-12-17	WOS:000237951000009
J	Furuta, T; Hayward, RL; Meng, LH; Takemura, H; Aune, GJ; Bonner, WM; Aladjem, MI; Kohn, KW; Pommier, Y				Furuta, T.; Hayward, R. L.; Meng, L-H; Takemura, H.; Aune, G. J.; Bonner, W. M.; Aladjem, M. I.; Kohn, K. W.; Pommier, Y.			P21(CDKN1A) allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine	ONCOGENE			English	Article						UCN-01 (7-hydroxystaurosporine); p21; p53; gamma H2AX; camptothecin; cell cycle; DNA repair; DNA double-strand break	CELL-CYCLE ARREST; HISTONE H2AX PHOSPHORYLATION; HUMAN COLON-CARCINOMA; S-PHASE CHECKPOINT; DAMAGE CHECKPOINT; PROTEIN-KINASE; CLEAVAGE COMPLEXES; UP-REGULATION; CANCER CELLS; G(2) ARREST	This study provides evidence for the importance of p21(CDKN1A) for the repair of replication- mediated DNA double- strand breaks ( DSBs) induced by topoisomerase I. We report that defects of p21(CDKN1A) and p53 enhance camptothecin- induced histone H2AX phosphorylation ( gamma H2AX), a marker for DNA DSBs. In human colon carcinoma HCT116 cells with wild- type ( wt) p53, gamma H2AX reverses after camptothecin removal. By contrast, gamma H2AX increases after camptothecin removal in HCT116 cells deficient for p53 ( p53-/-) or p21(CDKN1A) ( p21-/-) as the cells reach the late- S and G2 phases. Since p21-/- cells exhibit similar S- phase arrest as wt cells in response to camptothecin and aphidicolin does not abrogate the enhanced gamma H2AX formation in p21-/- cells, we conclude that enhanced gamma H2AX formation in p21-/- cells is not due to re- replication. The cell cycle checkpoint abrogator and Chk1/ Chk2 inhibitor 7- hydroxystaurosporine ( UCN- 01) also increases camptothecin- induced gamma H2AX formation and inhibits camptothecin- induced p21(CDKN1A) upregulation in HCT116 wt cells. TUNEL ( terminal deoxynucleotidyl transferase ( TdT)- mediated dUTP- biotin nick end labeling) assays demonstrate that gamma H2AX formation in late S and G2 cells following CPT treatment corresponds to DNA breaks. However, these breaks are not related to apoptotic DNA fragmentation. We propose that p21(CDKN1A) prevents the collapse of replication forks damaged by stabilized topoisomerase I cleavage complexes.	NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, 37 Convent Dr,Bldg 37,Room 5060, Bethesda, MD 20892 USA.	pommier@nih.gov	Aune, Gregory/I-5895-2015; meng, linghua/Y-8110-2019; Aladjem, Mirit/G-2169-2010	Aune, Gregory/0000-0002-2750-6461; Aladjem, Mirit/0000-0002-1875-3110	NATIONAL CANCER INSTITUTE [ZIABC006150, Z01BC006150] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abraham RT, 2004, DNA REPAIR, V3, P883, DOI 10.1016/j.dnarep.2004.04.002; Antony S, 2004, NUCLEIC ACIDS RES, V32, P5685, DOI 10.1093/nar/gkh902; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Busby EC, 2000, CANCER RES, V60, P2108; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Dancey J, 2003, NAT REV DRUG DISCOV, V2, P296, DOI 10.1038/nrd1066; FAN SJ, 1995, CANCER RES, V55, P1649; Foiani M, 1998, BIOL CHEM, V379, P1019; Fujimori A, 1996, MOL PHARMACOL, V50, P1472; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Godthelp BC, 2002, NUCLEIC ACIDS RES, V30, P2172, DOI 10.1093/nar/30.10.2172; Goldwasser F, 1996, CANCER RES, V56, P4430; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Guo CY, 1999, RADIAT RES, V151, P125, DOI 10.2307/3579762; Gupta M, 1997, CLIN CANCER RES, V3, P1653; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Hayward RL, 2003, CLIN CANCER RES, V9, P2856; Hinz JM, 2003, CARCINOGENESIS, V24, P249, DOI 10.1093/carcin/24.2.249; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Huang X, 2004, CYTOM PART A, V58A, P99, DOI 10.1002/cyto.a.20018; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; Kachnic LA, 1999, J BIOL CHEM, V274, P13111, DOI 10.1074/jbc.274.19.13111; Kohn EA, 2002, J BIOL CHEM, V277, P26553, DOI 10.1074/jbc.M202040200; Kohn KW, 2005, BIOCHEM BIOPH RES CO, V331, P816, DOI 10.1016/j.bbrc.2005.03.186; Larminat F, 2004, BIOL CELL, V96, P545, DOI 10.1016/j.biolcel.2004.06.001; Levesque AA, 2005, ONCOGENE, V24, P3786, DOI 10.1038/sj.onc.1208451; Liu LF, 2000, ANN NY ACAD SCI, V922, P1; Liu WM, 1998, INT J ONCOL, V12, P793; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Monks A, 2000, INVEST NEW DRUG, V18, P95, DOI 10.1023/A:1006313611677; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Pommier Y, 2005, CURR PHARM DESIGN, V11, P2855, DOI 10.2174/1381612054546716; Pommier Y, 2005, TRENDS PHARMACOL SCI, V26, P138, DOI 10.1016/j.tips.2005.01.008; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; Pommier Y, 2002, J BIOL CHEM, V277, P13666, DOI 10.1074/jbc.M200209200; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P2040, DOI 10.1073/pnas.040397497; POMMIER Y, 2006, PROG NUCL ACID RES M; Pourquier P, 2001, ADV CANCER RES, V80, P189, DOI 10.1016/S0065-230X(01)80016-6; Raderschall E, 2002, J CELL SCI, V115, P153; Rao VA, 2005, MOL CELL BIOL, V25, P8925, DOI 10.1128/MCB.25.20.8925-8937.2005; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Senderowicz AM, 2002, ONCOLOGIST, V7, P12; Shao RG, 2004, ACTA PHARMACOL SIN, V25, P756; Shao RG, 1997, CANCER RES, V57, P4029; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Shi Z, 2001, CANCER RES, V61, P1065; Shieh SY, 2000, GENE DEV, V14, P289; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stivala LA, 2001, ONCOGENE, V20, P563, DOI 10.1038/sj.onc.1204132; Strumberg D, 2000, MOL CELL BIOL, V20, P3977, DOI 10.1128/MCB.20.11.3977-3987.2000; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; TORNUSCIOLO DRZ, 1995, BIOTECHNIQUES, V19, P800; Tse AN, 2004, CANCER RES, V64, P6635, DOI 10.1158/0008-5472.CAN-04-0841; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Waga S, 1998, MOL CELL BIOL, V18, P4177, DOI 10.1128/MCB.18.7.4177; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wan SH, 1999, YEAST, V15, P821, DOI 10.1002/(SICI)1097-0061(199907)15:10A<821::AID-YEA422>3.3.CO;2-R; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Wu JX, 2002, MOL PHARMACOL, V61, P742, DOI 10.1124/mol.61.4.742; Wyllie FS, 1996, ONCOGENE, V12, P1077; Yu Q, 2002, CANCER RES, V62, P5743; Zhivotovsky B, 2004, NAT REV MOL CELL BIO, V5, P752, DOI 10.1038/nrm1443	79	37	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2839	2849		10.1038/sj.onc.1209313	http://dx.doi.org/10.1038/sj.onc.1209313			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16407843				2022-12-17	WOS:000237448200002
J	Talukder, AH; Meng, Q; Kumar, R				Talukder, AH; Meng, Q; Kumar, R			CRIPak, a novel endogenous Pak1 inhibitor	ONCOGENE			English	Article						Pak1; negative regulation; ER	P21-ACTIVATED-KINASE-1 PHOSPHORYLATES; CYCLIN D1; KINASE; ACTIVATION; EXPRESSION; ALPHA; INTERACTS; CELLS	p21-activated protein kinase 1 (Pak1) plays an important role in several cellular processes, including cytoskeleton reorganization, promotion of the cell survival, and the estrogen receptor ( ER) signaling. Pak1 expression and activity is deregulated in a number of cancers. Pak1 is activated by a variety of physiological signals; however, less is known about the negative regulators of Pak1. Here, we report a negative regulator of Pak1. By performing a yeast two-hybrid screen of a mammary gland library, we identified cysteine-rich inhibitor of Pak1 (CRIPak) as a novel Pak1-interacting protein. We found that CRIPak is an intronless gene that localized to chromosome 4p16.3. It contains 13 zinc-finger domains and has three trypsin inhibitor-like, cysteine-rich domains and is widely expressed in a number of human cells and tissues. We further found that CRIPak interacted with Pak1 through the N-terminal regulatory domain and inhibited Pak1 kinase in both in vitro and in vivo assays. CRIPak inhibited Pak1-mediated LIM kinase activation and enhancement of ER transactivation. Conversely, selective inhibition of the endogenous CRIPak resulted in an increased Pak1 activity, and consequently, increased cytoskeleton remodeling and Pak1-mediated ER transactivation activity. The hormonal stimulation of cells enhanced CRIPak expression and promoted its colocalization with ER in the nuclear compartment. Our findings suggest that CRIPak is a novel negative regulator of the Pak1 and has a role in the modulation of Pak1-mediated ER transactivation in breast cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA090970, R01CA098823] Funding Source: NIH RePORTER; NCI NIH HHS [CA98823, CA90970, CA80066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alahari SK, 2004, EMBO J, V23, P2777, DOI 10.1038/sj.emboj.7600291; Balasenthil S, 2004, FEBS LETT, V567, P243, DOI 10.1016/j.febslet.2004.04.071; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Banerjee M, 2002, CURR BIOL, V12, P1233, DOI 10.1016/S0960-9822(02)00956-9; Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Carter JH, 2004, CLIN CANCER RES, V10, P3448, DOI 10.1158/1078-0432.CCR-03-0210; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Ku GM, 2001, EMBO J, V20, P457, DOI 10.1093/emboj/20.3.457; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Schraml P, 2003, AM J PATHOL, V163, P985, DOI 10.1016/S0002-9440(10)63458-X; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; Shivapurkar N, 1999, CANCER RES, V59, P3576; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Talukder AH, 2004, MOL CELL BIOL, V24, P6581, DOI 10.1128/mcb.24.15.6581-6591.2004; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Vadlamudi RK, 2004, CANCER CELL, V5, P575, DOI 10.1016/j.ccr.2004.05.022; Vadlamudi RK, 2003, CANCER METAST REV, V22, P385, DOI 10.1023/A:1023729130497; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Xia CZ, 2001, P NATL ACAD SCI USA, V98, P6174, DOI 10.1073/pnas.101137298	27	37	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1311	1319		10.1038/sj.onc.1209172	http://dx.doi.org/10.1038/sj.onc.1209172			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16278681				2022-12-17	WOS:000235708200004
J	Hu, B; Tack, DC; Liu, T; Wu, Z; Ullenbruch, MR; Phan, SH				Hu, B; Tack, DC; Liu, T; Wu, Z; Ullenbruch, MR; Phan, SH			Role of Smad3 in the regulation of rat telomerase reverse transcriptase byTGF beta	ONCOGENE			English	Article						telomerase; Smad3; c-myc; TGF beta	CATALYTIC SUBUNIT HTERT; CANCER-CELLS; IN-VITRO; C-MYC; HEPATOCELLULAR CARCINOMAS; PROMOTER REGION; GENE-EXPRESSION; DIRECT BINDING; RNA COMPONENT; ACTIVATION	Telomerase is induced in certain pathological conditions such as cancer and tissue injury and repair. This induction in fibroblasts from injured lung is repressed by trans forming growth factor beta(TGF beta) via yet unknown mechanisms. In this study, the role of Smad3 in the inhibition of telomerase reverse transcriptase ( TERT) gene transcription by TGF beta was investigated. The rat TERT (rTERT) gene promoter was cloned by PCR amplification and fused with a luciferase reporter gene. This construct was used to analyse regulation of promoter activity in. broblasts isolated from bleomycin-injured lung with induced telomerase activity. The results showed that TGFb inhibited rTERT transcription while stimulating Smad3 expression. Interestingly, TGFb also inhibited the expression of c-myc. Cotransfection with a Smad3 expressing plasmid further repressed rTERT transcription and c-myc expression, while cotransfection with the corresponding antisense Smad3 construct had the opposite effect. Mutation of an E-box in the rTERT promoter suppressed its activity, which could be further reduced by TGF beta treatment. In contrast, mutation at a Smad binding element enhanced promoter activity whose inhibition was impaired by TGF beta treatment. Thus TGFb inhibition of rTERT gene expression was directly mediated by Smad3 via the Smad binding element, while c-myc appears to primarily regulate its constitutive or induced expression.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Phan, SH (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1150 W Med Ctr Dr,MSI 4204, Ann Arbor, MI 48109 USA.	shphan@umich.edu	Hu, Biao/G-6084-2010; Phan, Sem H/A-7033-2009	Phan, Sem H/0000-0002-3711-2159	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052285, R01HL077297] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL77297, HL52285] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; Avilion AA, 1996, CANCER RES, V56, P645; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dessain SK, 2000, CANCER RES, V60, P537; Devereux TR, 1999, CANCER RES, V59, P6087; Djojosubroto MW, 2003, MOL CELLS, V15, P164; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; Fujimoto K, 2000, NUCLEIC ACIDS RES, V28, P2557, DOI 10.1093/nar/28.13.2557; Fuxe J, 2000, CELL GROWTH DIFFER, V11, P373; Gilley D, 2005, INT J BIOCHEM CELL B, V37, P1000, DOI 10.1016/j.biocel.2004.09.003; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GREIDER C W, 1992, Current Biology, V2, P62, DOI 10.1016/0960-9822(92)90190-L; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Groneberg DA, 2004, EXP LUNG RES, V30, P223, DOI 10.1080/01902140490276320; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Horikawa I, 1999, CANCER RES, V59, P826; Hu B, 2004, J IMMUNOL, V173, P4661, DOI 10.4049/jimmunol.173.7.4661; Hu B, 2003, AM J RESP CELL MOL, V29, P397, DOI 10.1165/rcmb.2003-0063OC; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Li H, 1999, ONCOGENE, V18, P6785, DOI 10.1038/sj.onc.1203061; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Liu KB, 1999, P NATL ACAD SCI USA, V96, P5147, DOI 10.1073/pnas.96.9.5147; Liu TJ, 2002, AM J RESP CELL MOL, V26, P534, DOI 10.1165/ajrcmb.26.5.4668; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Muniyappa K, 1998, CRIT REV BIOCHEM MOL, V33, P297, DOI 10.1080/10409239891204242; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Nozaki Y, 2000, AM J RESP CELL MOL, V23, P460, DOI 10.1165/ajrcmb.23.4.3958; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; PAYS E, 1985, ANN INST PASTEUR IMM, VC136, P25, DOI 10.1016/S0769-2625(85)80037-4; PHAN SH, 1985, J CLIN INVEST, V76, P241, DOI 10.1172/JCI111953; Satyanarayana A, 2004, HEPATOLOGY, V40, P276, DOI 10.1002/hep.20308; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; TAHARA H, 1995, CANCER RES, V55, P2734; Takakura M, 1999, CANCER RES, V59, P551; Taylor RS, 1996, J INVEST DERMATOL, V106, P759, DOI 10.1111/1523-1747.ep12345811; Tsujiuchi T, 1998, CANCER LETT, V122, P115, DOI 10.1016/S0304-3835(97)00378-9; Vaziri H, 1996, EXP GERONTOL, V31, P295, DOI 10.1016/0531-5565(95)02025-X; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yang H, 2001, CELL GROWTH DIFFER, V12, P119; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhao Hong, 2003, Yan Ke Xue Bao, V19, P60	57	37	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1030	1041		10.1038/sj.onc.1209140	http://dx.doi.org/10.1038/sj.onc.1209140			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16205635				2022-12-17	WOS:000235361000008
J	Koshikawa, N; Maejima, C; Miyazaki, K; Nakagawara, A; Takenaga, K				Koshikawa, N; Maejima, C; Miyazaki, K; Nakagawara, A; Takenaga, K			Hypoxia selects for high-metastatic Lewis lung carcinoma cells overexpressing Mcl-1 and exhibiting reduced apoptotic potential in solid tumors	ONCOGENE			English	Article						hypoxia; ER stress; apoptosis; Mcl-1; metastasis	CANCER-CELLS; REGULATED PROTEIN; UP-REGULATION; RESISTANCE; PROGRESSION; EXPRESSION; MITOCHONDRIAL; INDUCTION; BNIP3; DEATH	Low oxygen tension (hypoxia) is a common feature of solid tumors and stimulates the expressions of a variety of genes including those related to angiogenesis, apoptosis and endoplasmic reticulum (ER) stress response. Here we show a close correlation between metastatic potential and the resistance to hypoxia- and ER stress-induced apoptosis among the cell lines with differing metastatic potential derived from Lewis lung carcinoma. An apoptosis-specific expression pro. ling and immunoblot analyses revealed that the expression of antiapoptotic Mcl-1 increased as the resistance to apoptosis increased. Downregulation of the Mcl-1 expression in the high-metastatic cells by Mcl-1 small interfering RNA increased the sensitivity to hypoxia-induced apoptosis and decreased the metastatic ability. The hypoxia-induced apoptosis was not associated with p53 accumulation, although at present it is not possible to conclude that apoptosis-induced apoptosis is p53-independent. There was no correlation between the expression levels of ER stress-response proteins GADD153, GRP78 and ORP150 and the resistance to hypoxia or ER stresses. In vitro, small numbers of the high-metastatic cells overtook the low-metastatic cells after exposure to several rounds of hypoxia and reoxygenation. In solid tumors initially established from equal mixtures, the proportion of the high-metastatic cells to low-metastatic cells was significantly higher in hypoxic areas. Moreover, the high-metastatic cells were overtaking the low-metastatic cells in some of the tumors. Thus, tumor hypoxia and ER stress may provide a physiological selective pressure for the expansion of the high-metastatic cells overexpressing Mcl-1 and exhibiting reduced apoptotic potential in solid tumors.	Chiba Canc Ctr, Div Chemotherapy, Res Inst, Chuoh Ku, Chiba 2608717, Japan; Chiba Canc Ctr, Res Inst, Div Pathol, Chuoh Ku, Chiba, Japan; Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, Chiba, Japan	Chiba Cancer Center; Chiba Cancer Center; Chiba Cancer Center	Takenaga, K (corresponding author), Chiba Canc Ctr, Div Chemotherapy, Res Inst, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	keizo@chiba-cc.jp						Brizel DM, 1996, CANCER RES, V56, P941; Brizel DM, 1997, INT J RADIAT ONCOL, V38, P285, DOI 10.1016/S0360-3016(97)00101-6; Brown JM, 1998, CANCER RES, V58, P1408; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; BUFALO DD, 1997, FASEB J, V11, P947; Cairns RA, 2001, CANCER RES, V61, P8903; CHAPLIN DJ, 1995, BRIT J CANCER, V71, P1210, DOI 10.1038/bjc.1995.235; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; Dachs GU, 1998, SEMIN RADIAT ONCOL, V8, P208, DOI 10.1016/S1053-4296(98)80046-5; Durand RE, 1998, INT J RADIAT ONCOL, V42, P711, DOI 10.1016/S0360-3016(98)00305-8; Fernandez Y, 2000, CELL DEATH DIFFER, V7, P350, DOI 10.1038/sj.cdd.4400662; Friedman AD, 1996, CANCER RES, V56, P3250; Glinsky GV, 1997, CRIT REV ONCOL HEMAT, V25, P175, DOI 10.1016/S1040-8428(97)00234-5; Glinsky GV, 1996, CANCER LETT, V101, P43, DOI 10.1016/0304-3835(96)04112-2; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Graham CH, 1999, INT J CANCER, V80, P617, DOI 10.1002/(SICI)1097-0215(19990209)80:4<617::AID-IJC22>3.0.CO;2-C; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HILL RP, 1990, CANCER METAST REV, V9, P137, DOI 10.1007/BF00046340; Hockel M, 1999, CANCER RES, V59, P4525; Hockel M, 1996, CANCER RES, V56, P4509; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Kim CY, 1997, CANCER RES, V57, P4200; Kinoshita M, 2001, INT J CANCER, V91, P322, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1064>3.0.CO;2-P; Koshikawa N, 2003, ONCOGENE, V22, P6717, DOI 10.1038/sj.onc.1206765; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; LORD EM, 1993, CANCER RES, V53, P5721; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Maeta Yoshihiko, 2004, Gastric Cancer, V7, P78; McConkey DJ, 1996, CANCER RES, V56, P5594; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; Piret JP, 2005, J BIOL CHEM, V280, P9336, DOI 10.1074/jbc.M411858200; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; RICE GC, 1986, P NATL ACAD SCI USA, V83, P5978, DOI 10.1073/pnas.83.16.5978; RUSSO CA, 1995, CANCER RES, V55, P1122; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; Takasu M, 1999, CLIN EXP METASTAS, V17, P409, DOI 10.1023/A:1006632819086; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Wong CW, 2001, CANCER RES, V61, P333; YOUNG SD, 1990, JNCI-J NATL CANCER I, V82, P371, DOI 10.1093/jnci/82.5.371	44	37	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					917	928		10.1038/sj.onc.1209128	http://dx.doi.org/10.1038/sj.onc.1209128			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16247470				2022-12-17	WOS:000235212700011
J	Liu, F; Lei, W; O'Rourke, JP; Ness, SA				Liu, F; Lei, W; O'Rourke, JP; Ness, SA			Oncogenic mutations cause dramatic, qualitative changes in the transcriptional activity of c-Myb	ONCOGENE			English	Article						Myb oncogene; leukemia; hematopoiesis; differentiation; transformation	DNA-BINDING DOMAIN; V-MYB; GENE-EXPRESSION; DIFFERENTIATION; TRANSFORMATION; SPECIFICITY; PROMOTER; TARGET; TRANSACTIVATION; PRODUCT	The v-Myb oncoprotein encoded by Avian Myeloblastosis Virus is highly oncogenic, induces leukemias in chickens and mice and transforms immature hematopoietic cells in vitro. The v-Myb protein is a mutated and truncated version of c-Myb, a DNA-binding transcription factor expressed in many cell types that is essential for normal hematopoiesis. Previous studies suggested that two types of differences, DNA binding domain mutations and the deletion of a C-terminal negative regulatory domain were important for increasing the transforming activity of v-Myb. Here, we combined structure-function studies of the v-Myb and c-Myb proteins with unbiased microarray-based transcription assays to compare the transcriptional specificities of the two proteins. In human cells, the v-Myb and c-Myb proteins displayed strikingly different activities and regulated overlapping, but largely distinct sets of target genes. Each type of mutation that distinguished v-Myb from c-Myb, including the N- and C-terminal deletions, DNA binding domain changes and mutations in the transcriptional activation domain, affected different sets of target genes and contributed to the different activities of c-Myb and v-Myb. The results suggest that v-Myb is not just a de-repressed version of c-Myb. Instead, it is a distinct transcriptional regulator with a unique set of activities.	Univ New Mexico, HSC, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA	University of New Mexico	Ness, SA (corresponding author), Univ New Mexico, HSC, Dept Mol Genet & Microbiol, MSC08 4660, Albuquerque, NM 87131 USA.	ness@unm.edu	Ness, Scott/AAV-4009-2020	Ness, Scott/0000-0001-6965-8909	NATIONAL CANCER INSTITUTE [R01CA058443, P30CA118100] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58443, P30 CA118100, R01 CA058443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Butz NV, 2004, GENE, V342, P67, DOI 10.1016/j.gene.2004.07.024; Chayka O, 2005, MOL CELL BIOL, V25, P499, DOI 10.1128/MCB.25.1.499-511.2005; Chen XY, 2004, MOL CELL BIOL, V24, P10416, DOI 10.1128/MCB.24.23.10416-10424.2004; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; Frykberg L, 1988, Oncogene Res, V3, P313; Fu SL, 1996, J VIROL, V70, P5600, DOI 10.1128/JVI.70.8.5600-5610.1996; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GRASSER FA, 1992, ONCOGENE, V7, P1005; Hodges LC, 2003, MOL CANCER RES, V1, P300; Hou DX, 1997, FEBS LETT, V413, P60, DOI 10.1016/S0014-5793(97)00879-X; INOUE T, 1994, J BIOL CHEM, V269, P32451; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; Kouskouti A, 2004, MOL CELL, V14, P175, DOI 10.1016/S1097-2765(04)00182-0; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; Lang G, 2005, ONCOGENE, V24, P1375, DOI 10.1038/sj.onc.1208301; Lei WL, 2005, BLOOD, V105, P3855, DOI 10.1182/blood-2004-08-3342; Lei WL, 2004, J BIOL CHEM, V279, P29519, DOI 10.1074/jbc.M403133200; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; Lipsick JS, 1996, ONCOGENE, V13, P223; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Muller C, 1999, BLOOD, V94, P4255, DOI 10.1182/blood.V94.12.4255.424k32_4255_4262; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; Ness SA, 2003, BLOOD CELL MOL DIS, V31, P192, DOI 10.1016/S1079-9796(03)00151-7; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NESS SA, 1996, BIOCHIM BIOPHYS ACTA, V1288, P123; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; PLAZA S, 1995, ONCOGENE, V10, P329; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; Rushton JJ, 2001, BLOOD CELL MOL DIS, V27, P459, DOI 10.1006/bcmd.2001.0405; SunHoffman L, 1996, ONCOGENE, V13, P1037; SZCZYLIK C, 1993, J EXP MED, V178, P997, DOI 10.1084/jem.178.3.997; Takahashi H, 2005, DEV GROWTH DIFFER, V47, P173; TANNO B, 2002, J BIOL CHEM, V24, P24; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TRAVALI S, 1991, ONCOGENE, V6, P887; Weston K M, 1990, Semin Cancer Biol, V1, P371; Winn LM, 2003, CELL CYCLE, V2, P258, DOI 10.4161/cc.2.3.383	43	37	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					795	805		10.1038/sj.onc.1209105	http://dx.doi.org/10.1038/sj.onc.1209105			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16205643				2022-12-17	WOS:000235068800014
J	Datta, K; Mondal, S; Sinha, S; Li, JP; Wang, EF; Knebelmann, B; Karumanchi, SA; Mukhopadhyay, D				Datta, K; Mondal, S; Sinha, S; Li, JP; Wang, EF; Knebelmann, B; Karumanchi, SA; Mukhopadhyay, D			Role of elongin-binding domain of von Hippel Lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma	ONCOGENE			English	Article						VPF; VPF/VEGF; mRNA stability; angiogenesis; renal cell carcinoma; VHL; HuR	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; 3' UNTRANSLATED REGION; INDUCIBLE FACTOR-ALPHA; KINASE-C-ZETA; POSTTRANSCRIPTIONAL REGULATION; TUMOR ANGIOGENESIS; HIF-ALPHA; PROTEIN; HYPOXIA	Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), is a key mediator of angiogenesis for both physiological and pathological conditions. It is well established that the hypoxic induction of VPF/VEGF is in large part an increase in the stability of its mRNA. A Hu family ubiquitously expressed RNA-binding protein HuR has recently been shown to be important for VPF/VEGF mRNA stabilization. In renal cancer cells, the inactivation of the tumor suppressor protein von Hippel Lindau (VHL) leads to an increase in VPF/VEGF expression. VHL not only inhibits the transcription of VPF/VEGF but also plays a significant role in decreasing its mRNA stability. Here we delineate a possible mechanism by which VHL can control the function of HuR in order to regulate the stability of VPF/VEGF mRNA. The experiments presented here suggest that the association of the elongin-binding domain of VHL with a specific RNA-binding domain of HuR (RRM1) is important for the destabilizing function of VHL on VPF/VEGF mRNA.	Mayo Clin Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin Fdn, Mayo Clin Canc Ctr, Rochester, MN 55905 USA; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Hop Necker Enfants Malad, Paris, France	Mayo Clinic; Mayo Clinic; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Mukhopadhyay, D (corresponding author), Mayo Clin Fdn, Dept Biochem & Mol Biol, Gugg 1401A,200 1st St SW, Rochester, MN 55905 USA.	mukhopadhyay.debabrata@mayo.edu	Karumanchi, Subbian Ananth/AAI-1694-2021		NCI NIH HHS [CA78383] Funding Source: Medline; NHLBI NIH HHS [HL70567] Funding Source: Medline; NIDDK NIH HHS [DK 02825] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078383, R29CA078383] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002825] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; Chung J, 2004, CANCER RES, V64, P4711, DOI 10.1158/0008-5472.CAN-04-0347; Ciais D, 2004, ONCOGENE, V23, P8673, DOI 10.1038/sj.onc.1207939; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Datta K, 2004, CANCER RES, V64, P456, DOI 10.1158/0008-5472.CAN-03-2706; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Dibbens JA, 1999, MOL BIOL CELL, V10, P907, DOI 10.1091/mbc.10.4.907; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Dvorak HF, 2000, SEMIN PERINATOL, V24, P75, DOI 10.1016/S0146-0005(00)80061-0; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; FOLKMAN J, 1991, PRINCESS TAKAMATSU S, V11, P339; Galban S, 2003, MOL CELL BIOL, V23, P7083, DOI 10.1128/MCB.23.20.7083-7095.2003; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; Gnarra JR, 1997, P NATL ACAD SCI USA, V94, P9102, DOI 10.1073/pnas.94.17.9102; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1997, CANCER RES, V57, P5328; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Levy AP, 1997, KIDNEY INT, V51, P575, DOI 10.1038/ki.1997.82; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pal S, 2001, J BIOL CHEM, V276, P2395, DOI 10.1074/jbc.M007818200; Papetti M, 2002, AM J PHYSIOL-CELL PH, V282, pC947, DOI 10.1152/ajpcell.00389.2001; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Pioli PA, 2001, J BIOL CHEM, V276, P40346, DOI 10.1074/jbc.M105391200; Raineri I, 2004, NUCLEIC ACIDS RES, V32, P1279, DOI 10.1093/nar/gkh282; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1986, CANCER RES, V46, P5629; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shi W, 2002, BRIT J CANCER, V87, P119, DOI 10.1038/sj.bjc.6600416; Shim J, 2002, MOL CELL, V10, P1331, DOI 10.1016/S1097-2765(02)00730-X; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Wilusz CJ, 2004, TRENDS GENET, V20, P491, DOI 10.1016/j.tig.2004.07.011; Zhang T, 2002, BIOCHEM SOC T, V30, P952, DOI 10.1042/BST0300952	54	37	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7850	7858		10.1038/sj.onc.1208912	http://dx.doi.org/10.1038/sj.onc.1208912			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16170373				2022-12-17	WOS:000233463000004
J	Kronblad, A; Hedenfalk, I; Nilsson, E; Pahlmann, S; Landberg, G				Kronblad, A; Hedenfalk, I; Nilsson, E; Pahlmann, S; Landberg, G			ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ER alpha: a combination therapy potentially targeting hypoxic and dormant tumor cells	ONCOGENE			English	Article						breast cancer; ERK1/2; MAPK; ER alpha; hypoxia; tamoxifen	HUMAN BREAST-CANCER; ACTIVATED PROTEIN-KINASE; ESTROGEN-RECEPTOR-ALPHA; POOR RESPONSE; BONE-MARROW; RT-PCR; EXPRESSION; GROWTH; RESISTANCE; PATHWAYS	Tumor hypoxia is associated with cancer invasiveness, metastasis and treatment failure. Recent data suggest that the major target for endocrine treatment in breast cancer, ER alpha, is downregulated during hypoxia, but the mechanism behind this remains unknown. MAPK signaling as well as ER alpha regulation has earlier been independently linked to hypoxia and we now demonstrate HIF-1 alpha and ERK1/2-activation in vivo towards the necrotic zone in DCIS of the breast, parallel with ER alpha downregulation. Hypoxia further caused transcriptional downregulation of ER alpha via activation of ERK1/2 in cell lines and, importantly, MEK1/2 inhibitors (U0126 or PD184352) or ERK1/2 suppression by siRNA partially restored the ERa expression. U0126 combined with tamoxifen accordingly produced an increased efficacy of the anti-estrogens during hypoxia. Base don these findings, we suggest a promising novel therapy for ER alpha-positive breast cancer where a combination of endocrine treatment and ERK1/2 inhibitors may increase treatment response by improved targeting of dormant hypoxic tumor cells.	Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Pathol, S-20502 Malmo, Sweden; Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Mol Med, S-20502 Malmo, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital	Landberg, G (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Lab Med, Div Pathol, S-20502 Malmo, Sweden.	goran.landberg@pat.mas.lu.se		Hedenfalk, Ingrid/0000-0002-6840-3397				Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Bhat-Nakshatri P, 2004, BRIT J CANCER, V90, P853, DOI 10.1038/sj.bjc.6601541; Brunnberg S, 2003, P NATL ACAD SCI USA, V100, P6517, DOI 10.1073/pnas.1136688100; Chen DS, 2002, ONCOGENE, V21, P4921, DOI 10.1038/sj.onc.1205420; Cho JY, 2005, MOL ENDOCRINOL, V19, P1191, DOI 10.1210/me.2004-0162; Clarke M, 1998, LANCET, V351, P1451; Cooper C, 2004, CLIN CANCER RES, V10, P8720, DOI 10.1158/1078-0432.CCR-04-1235; Coutts AS, 1998, CANCER RES, V58, P4071; Dokladda K, 2005, FEBS LETT, V579, P236, DOI 10.1016/j.febslet.2004.11.084; Duncia JV, 1998, BIOORG MED CHEM LETT, V8, P2839, DOI 10.1016/S0960-894X(98)00522-8; Gee JMW, 2003, ENDOCRINOLOGY, V144, P5105, DOI 10.1210/en.2003-0705; Gee JMW, 2001, INT J CANCER, V95, P247, DOI 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Harrison JS, 2002, BLOOD, V99, P394, DOI 10.1182/blood.V99.1.394; Hedenfalk Ingrid, 2005, Cancer Genomics & Proteomics, V2, P83; Helczynska K, 2003, CANCER RES, V63, P1441; Holloway JN, 2004, MOL ENDOCRINOL, V18, P1396, DOI 10.1210/me.2004-0048; Hutcheson IR, 2003, BREAST CANCER RES TR, V81, P81, DOI 10.1023/A:1025484908380; Jogi A, 2004, EXP CELL RES, V295, P469, DOI 10.1016/j.yexcr.2004.01.013; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Johnston SRD, 2003, NAT REV CANCER, V3, P821, DOI 10.1038/nrc1211; Kronblad A, 2003, IN VIVO, V17, P311; Kurebayashi J, 2001, JPN J CANCER RES, V92, P1093, DOI 10.1111/j.1349-7006.2001.tb01064.x; Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584; LICHTMAN MA, 1981, EXP HEMATOL, V9, P391; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Nicholson RI, 2004, CLIN CANCER RES, V10, p346S, DOI 10.1158/1078-0432.CCR-031206; Oh AS, 2001, MOL ENDOCRINOL, V15, P1344, DOI 10.1210/me.15.8.1344; Rostagno P, 1996, BREAST CANCER RES TR, V37, P77, DOI 10.1007/BF01806634; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Shim WS, 2000, ENDOCRINOLOGY, V141, P396, DOI 10.1210/en.141.1.396; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SPATARO V, 1992, ANN ONCOL, V3, P733, DOI 10.1093/oxfordjournals.annonc.a058330; Stoner M, 2002, MOL ENDOCRINOL, V16, P2231, DOI 10.1210/me.2001-0347; Vandesompele J, 2002, ANAL BIOCHEM, V303, P95, DOI 10.1006/abio.2001.5564; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; VAUPEL P, 1989, CANCER RES, V49, P6449; Woelfle U, 2003, CANCER RES, V63, P5679; Yang ZB, 2004, CLIN CANCER RES, V10, P3621, DOI 10.1158/1078-0432.CCR-0740-3	40	37	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 13	2005	24	45					6835	6841		10.1038/sj.onc.1208830	http://dx.doi.org/10.1038/sj.onc.1208830			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007158				2022-12-17	WOS:000232527800011
J	Andrianifahanana, M; Agrawal, A; Singh, AP; Moniaux, N; van Seuningen, I; Aubert, JP; Meza, J; Batra, SK				Andrianifahanana, M; Agrawal, A; Singh, AP; Moniaux, N; van Seuningen, I; Aubert, JP; Meza, J; Batra, SK			Synergistic induction of the MUC4 mucin gene by interferon-gamma and retinoic acid in human pancreatic tumour cells involves a reprogramming of signalling pathways	ONCOGENE			English	Article						MUC4 mucin; IFN gamma; retinoic acid; synergism; gene regulation; pancreatic cancer	MEMBRANE-ASSOCIATED MUCIN; SIALOMUCIN COMPLEX; CANCER-CELLS; MOLECULAR-CLONING; EPISIALIN MUC1; EXPRESSION; GROWTH; LINES; INHIBITION; RECEPTOR	The transmembrane mucin, MUC4, is aberrantly expressed with a high incidence in human pancreatic adenocarcinomas and plays an important role in the pathogenesis of the disease. Our recent studies have shown that interferon-gamma ( IFN gamma) and retinoic acid ( RA) are important regulators of MUC4 in pancreatic tumour cells. Induction of MUC4 by IFN gamma occurs via a novel pathway involving upregulation of the signal transducer and activator of transcription 1 ( STAT-1), whereas its stimulation by RA requires mediation by the transforming growth factor beta-2 ( TGF beta-2). In this study, we have investigated the molecular mechanisms underlying the interaction of IFN gamma and RA in MUC4 regulation in pancreatic tumour cells. We demonstrate that these reagents exert a synergistic induction of MUC4. Interestingly, while the upregulation of STAT-1 by IFN gamma is partially inhibited by RA, IFN gamma is shown to repress RA-driven TGFb-2 induction, pointing to the involvement of alternative mechanism( s) in IFN gamma-RA synergism. Moreover, a dose-dependent and cooperative induction of MUC4 promoter activity suggests a regulation at the transcriptional level, most likely by STAT-1 and RAR/RXR ( RA receptor/retinoic X receptor) or other IFN gamma/RA-induced secondary intermediate effectors. Our findings provide potential mechanisms that may account for the aberrant expression of MUC4 in pancreatic tumour cells and expose a novel molecular mechanism of gene induction, whereby a reprogramming of signalling pathway through alternative route(s) operates during a synergistic interaction of biological modifiers.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Prevent & Societal Med, Omaha, NE 68198 USA; INSERM, F-59045 Lille, France	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Institut National de la Sante et de la Recherche Medicale (Inserm)	Batra, SK (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, 600 S 42nd St, Omaha, NE 68198 USA.	sbatra@unmc.edu	Singh, Ajay/AAF-4414-2020; Moniaux, Nicolas/Y-3243-2018; VAN SEUNINGEN, Isabelle/N-6176-2016	Moniaux, Nicolas/0000-0001-9718-1386; VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; Singh, Ajay/0000-0003-3492-6330	NATIONAL CANCER INSTITUTE [R01CA078590] Funding Source: NIH RePORTER; NCI NIH HHS [CA 78590] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Andrianifahanana Mahefatiana, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P607; Andrianifahanana Mahefatiana, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P1135; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; Detjen KM, 2001, GUT, V49, P251, DOI 10.1136/gut.49.2.251; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; Guzhova I, 2001, INT J CANCER, V94, P97, DOI 10.1002/ijc.1443; Hara I, 2001, INT J ONCOL, V19, P959; HO CK, 1985, CANCER RES, V45, P5348; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Hu W, 2002, INT J GYNECOL CANCER, V12, P202, DOI 10.1046/j.1525-1438.2002.01084.x; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jesnowski R, 2002, PANCREATOLOGY, V2, P421, DOI 10.1159/000065091; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; Komatsu M, 1999, CANCER RES, V59, P2229; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Kondo K, 1998, CANCER RES, V58, P2014; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; MATSUBARA N, 1991, INT J PANCREATOL, V8, P235; Moniaux N, 2004, J HISTOCHEM CYTOCHEM, V52, P253, DOI 10.1177/002215540405200213; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; Moniaux N, 2001, FRONT BIOSCI-LANDMRK, V6, pD1192, DOI 10.2741/Moniaux; Niitsu N, 2002, LEUKEMIA RES, V26, P745, DOI 10.1016/S0145-2126(01)00202-8; Park C, 1998, METHODS, V15, P175, DOI 10.1006/meth.1998.0622; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Reber H, 1998, PANCREATIC CANC PATH; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Sirivatanauksorn V, 1998, LANGENBECK ARCH SURG, V383, P105, DOI 10.1007/s004230050101; Soto P, 2003, J BIOL CHEM, V278, P20338, DOI 10.1074/jbc.M301886200; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; VANDEWIELVANKEMENADE E, 1993, J IMMUNOL, V151, P767; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; Widschwendter M, 1997, INT J CANCER, V71, P497; Windbichler GH, 1996, GYNECOL ONCOL, V61, P387, DOI 10.1006/gyno.1996.0162; WU K, 1994, J BIOL CHEM, V269, P11950; Yang JB, 2001, J BIOL CHEM, V276, P20989, DOI 10.1074/jbc.M011488200	43	37	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6143	6154		10.1038/sj.onc.1208756	http://dx.doi.org/10.1038/sj.onc.1208756			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	16007204				2022-12-17	WOS:000231718100008
J	Gapuzan, MER; Schmah, O; Pollock, AD; Hoffmann, A; Gilmore, TD				Gapuzan, MER; Schmah, O; Pollock, AD; Hoffmann, A; Gilmore, TD			Immortalized fibroblasts from NF-kappa B RelA knockout mice show phenotypic heterogeneity and maintain increased sensitivity to tumor necrosis factor alpha after transformation by v-Ras	ONCOGENE			English	Article						RelA; NF-kappa B; Ras; malignant transformation; mouse knockout cells; tumor necrosis factor	CELLULAR-TRANSFORMATION; MEDIATED TRANSFORMATION; EMBRYONIC LETHALITY; INCREASED APOPTOSIS; ONCOGENIC RAS; C-MYC; ACTIVATION; P53; MOUSE; SUPPRESSOR	Activation of the NF-kappa B pathway can either promote or block apoptosis and oncogenesis in different cell types and circumstances. In this report, we show that independently derived immortalized mouse embryonic fibroblast cell lines prepared from RelA knockout mice have different phenotypes, based on their sensitivity to tumor necrosis factor alpha (TNF alpha)-induced apoptosis, morphology, ability to form colonies in soft agar, and the presence of distinct kappa B site-binding complexes. In addition, these RelA-deficient cell lines appear to have distinct alterations in the p53 pathway, which correlate with the normal vs transformed status of individual cell lines. We have also infected mouse embryonic fibroblasts lacking RelA, c-Rel or p50 with a retrovirus for the expression of v-Ha-Ras to determine whether individual NF-kappa B family members are required for Ras-mediated transformation. All three NF-kappa B-deficient cell types could be transformed by v-Ha-Ras. However, v-Ras-infected RelA-deficient cells formed colonies in soft agar at an approximately fourfold reduced efficiency compared to v-Ras-transformed control mouse 3T3 and p50-deficient cells. Ras transformation did not alter the sensitivity of RelA-deficient cells to TNF alpha-induced apoptosis, and Ras transformation did not affect the general resistance of 3T3, c-Rel-deficient, and p50-deficient cells to TNF alpha-induced apoptosis. However, TNF alpha specifically and dose-dependently decreased the ability of v-Ras-transformed RelA-deficient cells to form colonies in soft agar. These results suggest that RelA is a potential protein target for human tumors driven by oncogenic Ras mutations, but caution that inhibition of RelA may promote tumorigenesis in some circumstances.	Boston Univ, Dept Biol, Boston, MA 02215 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Boston University; University of California System; University of California San Diego	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu			NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; Aguilera C, 2004, P NATL ACAD SCI USA, V101, P16537, DOI 10.1073/pnas.0404429101; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Alcamo E, 2001, J IMMUNOL, V167, P1592, DOI 10.4049/jimmunol.167.3.1592; Ayrault O, 2004, ONCOGENE, V23, P8097, DOI 10.1038/sj.onc.1207968; Baldwin AS, 2003, NUCLEAR FACTOR KB: REGULATION AND ROLE IN DISEASE, P393; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chang NS, 2002, J BIOL CHEM, V277, P10323, DOI 10.1074/jbc.M106607200; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FERNANDEZ A, 1994, ONCOGENE, V9, P2009; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Gapuzan MER, 2002, ONCOGENE, V21, P2484, DOI 10.1038/sj.onc.1205333; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Hanson JL, 2004, CANCER RES, V64, P7248, DOI 10.1158/0008-5472.CAN-03-3898; Hanson JL, 2003, J BIOL CHEM, V278, P34910, DOI 10.1074/jbc.M304189200; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hoffmann A, 2003, EMBO J, V22, P5530, DOI 10.1093/emboj/cdg534; Jeay S, 2003, MOL CELL BIOL, V23, P2251, DOI 10.1128/MCB.23.7.2251-2263.2003; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Li JN, 2003, BIOCHEMISTRY-US, V42, P13476, DOI 10.1021/bi035390r; Loop T, 2003, NUCLEAR FACTOR KB: REGULATION AND ROLE IN DISEASE, P1; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mayo MW, 2001, METHOD ENZYMOL, V333, P73; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Pando MP, 2000, J BIOL CHEM, V275, P21278, DOI 10.1074/jbc.M002532200; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Rosenfeld ME, 2000, AM J PATHOL, V156, P997, DOI 10.1016/S0002-9440(10)64967-X; Sigal A, 2000, CANCER RES, V60, P6788; Suzuki J, 2004, ONCOGENE, V23, P8527, DOI 10.1038/sj.onc.1207894; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; VAN AD, 1996, SCIENCE, V274, P787; van Hogerlinden M, 1999, CANCER RES, V59, P3299; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904; Zhou MX, 2003, ONCOGENE, V22, P8137, DOI 10.1038/sj.onc.1206911; Zong WX, 1998, CELL DEATH DIFFER, V5, P963, DOI 10.1038/sj.cdd.4400441	51	37	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6574	6583		10.1038/sj.onc.1208809	http://dx.doi.org/10.1038/sj.onc.1208809			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16027734				2022-12-17	WOS:000232204100011
J	Gu, CK; Shim, S; Shin, J; Kim, J; Park, J; Han, K; Park, S				Gu, CK; Shim, S; Shin, J; Kim, J; Park, J; Han, K; Park, S			The EphA8 receptor induces sustained MAP kinase activation to promote neurite outgrowth in neuronal cells	ONCOGENE			English	Article						Eph; ephrin; EphA8; MAP kinase	TYROSINE KINASE; EPHRIN LIGANDS; PATHWAY; DIFFERENTIATION; IDENTIFICATION; MECHANISMS; RESIDUES; BINDING; FAMILY; DOMAIN	Recent studies in our laboratory demonstrate that ligand-mediated activation of the EphA8 receptor critically regulates cell adhesion and migration. In this report, we show that the EphA8 receptor induces neurite outgrowth in NG108-15 cells in the absence of ligand stimulation. Using various deletion mutants lacking specific intracytoplasmic regions, we confirm that the tyrosine kinase domain of EphA8 is important for inducing neurite outgrowth. However, the tyrosine kinase activity of EphA8 is not crucial for neurite outgrowth induction. Treatment with various inhibitors further reveals that the mitogen-activated protein kinase ( MAPK) signaling pathway is critical for neurite outgrowth induced by EphA8. Consistent with these results, EphA8 expression induced a sustained increase in the activity of MAPK, whereas ligand-mediated EphA8 activation had no further modulatory effects on MAP kinase activity. Additionally, activated MAPK relocalized from the cytoplasm to the nucleus in response to EphA8 transfection. These results collectively suggest that the EphA8 receptor is capable of inducing a sustained increase in MAPK activity, thereby promoting neurite outgrowth in neuronal cells.	Sookmyung Womens Univ, Dept Life Sci, Seoul 140742, South Korea; Sookmyung Womens Univ, Inst Nat Sci, Seoul 140742, South Korea; Hallym Univ, Dept Genet Engn, Chunchon 200702, South Korea	Sookmyung Women's University; Sookmyung Women's University; Hallym University	Park, S (corresponding author), Sookmyung Womens Univ, Dept Life Sci, 53-12 Chungpa Dong 2 Ka, Seoul 140742, South Korea.	scpark@sookmyung.ac.kr		Park, Soochul/0000-0002-7029-3414				Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Choi S, 1999, MOL CELLS, V9, P440; Choi S, 1999, ONCOGENE, V18, P5413, DOI 10.1038/sj.onc.1202917; Coulthard MG, 2002, INT J DEV BIOL, V46, P375; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; Gendron L, 2003, J BIOL CHEM, V278, P3606, DOI 10.1074/jbc.M202446200; Gu C, 2003, FEBS LETT, V540, P65, DOI 10.1016/S0014-5793(03)00223-0; Gu C, 2001, MOL CELL BIOL, V21, P4579, DOI 10.1128/MCB.21.14.4579-4597.2001; Himanen JP, 2003, INT J BIOCHEM CELL B, V35, P130, DOI 10.1016/S1357-2725(02)00096-1; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Jeong J, 2000, DNA CELL BIOL, V19, P291, DOI 10.1089/10445490050021203; Klein R, 2001, CURR OPIN CELL BIOL, V13, P196, DOI 10.1016/S0955-0674(00)00197-6; Koo J, 2003, DEV DYNAM, V226, P596, DOI 10.1002/dvdy.10253; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; Mellitzer G, 2000, CURR OPIN NEUROBIOL, V10, P400, DOI 10.1016/S0959-4388(00)00095-7; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; NELSON P, 1976, P NATL ACAD SCI USA, V73, P123, DOI 10.1073/pnas.73.1.123; Park S, 1997, ONCOGENE, V14, P533, DOI 10.1038/sj.onc.1200857; Park S, 1997, EMBO J, V16, P3106, DOI 10.1093/emboj/16.11.3106; Pratt RL, 2002, ONCOGENE, V21, P7690, DOI 10.1038/sj.onc.1205758; Schmucker D, 2001, CELL, V105, P701, DOI 10.1016/S0092-8674(01)00391-9; Tepass U, 2002, CURR OPIN GENET DEV, V12, P572, DOI 10.1016/S0959-437X(02)00342-8; Tong JF, 2003, J BIOL CHEM, V278, P6111, DOI 10.1074/jbc.M208972200; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Vindis C, 2003, J CELL BIOL, V162, P661, DOI 10.1083/jcb.200302073; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515; YAN MH, 1994, J BIOL CHEM, V269, P19067	28	37	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 16	2005	24	26					4243	4256		10.1038/sj.onc.1208584	http://dx.doi.org/10.1038/sj.onc.1208584			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15782114				2022-12-17	WOS:000229815300008
J	Belaidouni, N; Peuchmaur, M; Perret, C; Florentin, A; Benarous, R; Besnard-Guerin, C				Belaidouni, N; Peuchmaur, M; Perret, C; Florentin, A; Benarous, R; Besnard-Guerin, C			Overexpression of human beta TrCP1 deleted of its F box induces tumorigenesis in transgenic mice	ONCOGENE			English	Article						beta TrCP; beta-catenin; transgenic mice; tumors	PROTEIN BETA-TRCP; I-KAPPA-B; CATENIN GENE; DEGRADATION; LIVER; PROGRESSION; EXPRESSION; PATHWAY; COMPLEX; CANCER	Genetic alterations affecting beta-catenin, adenomatous polyposis coli or axin proteins are associated with the pathogenesis of numerous human tumors. All these mutations result in the synthesis of unphosphorylated beta-catenin that escapes recognition by the beta transducin repeat protein (beta TrCP1), the receptor of an ubiquitin. The stabilized beta-catenin translocates to the nucleus and activates the transcription of genes crucial for tumorigenesis. Recent evidence implicates mutations and overexpresssion of bTrCP1 in human prostate and colon tumors, respectively, suggesting that deregulated bTrCP1 may be involved in tumorigenesis. To explore this possibility further, we generated transgenic mice that specifically express a dominant-negative mutant of beta TrCP1 (Delta F beta TrCP1) or full-length beta TrCP1 in intestine, liver and kidney. We found that 46% (16/35) of the transgenic mice that overexpressed the transgenes developed either intestinal adenomas (10/35) or hepatic (4/35) or urothelial (2/35) tumors. Immunohistological analysis of the tumors revealed that upregulation of cyclin D1, glutamine synthetase and chemotaxin 2 was associated with nuclear accumulation of beta-catenin. These results show that the overexpression of DFbTrCP1 or bTrCP1 in vivo induce tumors through beta-catenin activation.	Univ Paris 05, CNRS, UMR 8104, Dept INSERM U567,Dept Infect Dis,Inst Cochin, F-75014 Paris, France; Hop Robert Debre, Serv Anatomapathol, F-75019 Paris, France; Univ Paris 05, CNRS, UMR 8104, Inst Cochin,U567,Dept INSERM,Dept Genet Dev & Mol, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Benarous, R (corresponding author), Univ Paris 05, CNRS, UMR 8104, Dept INSERM U567,Dept Infect Dis,Inst Cochin, 27,Rue Faubourg St Jacques, F-75014 Paris, France.	benarous@cochin.inserm.fr; besnard-guerin@cochin.inserm.fr	Besnard-Guerin, Corinne/J-3985-2017; Perret-Mayeux, Christine/L-3297-2017	perret, christine/0000-0003-4710-7051				Besnard-Guerin C, 2004, J BIOL CHEM, V279, P788, DOI 10.1074/jbc.M308068200; Cadoret A, 2002, ONCOGENE, V21, P8293, DOI 10.1038/sj.onc.1206118; Cadoret A, 2001, CANCER RES, V61, P3245; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Gerstein AV, 2002, GENE CHROMOSOME CANC, V34, P9, DOI 10.1002/gcc.10037; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Harada N, 2002, CANCER RES, V62, P1971; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Nakayama K, 2003, P NATL ACAD SCI USA, V100, P8752, DOI 10.1073/pnas.1133216100; Ovejero C, 2004, HEPATOLOGY, V40, P167, DOI 10.1002/hep.20286; Polakis P, 2000, GENE DEV, V14, P1837; Romagnolo B, 1999, CANCER RES, V59, P3875; Sadot E, 2000, ONCOGENE, V19, P1992, DOI 10.1038/sj.onc.1203519; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5	21	37	38	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2271	2276		10.1038/sj.onc.1208418	http://dx.doi.org/10.1038/sj.onc.1208418			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15735746				2022-12-17	WOS:000227857900014
J	Lang, G; White, JR; Argent-Katwala, MJG; Allinson, CG; Weston, K				Lang, G; White, JR; Argent-Katwala, MJG; Allinson, CG; Weston, K			Myb proteins regulate the expression of diverse target genes	ONCOGENE			English	Article						c-Myb; B-Myb; transcription; hematopoiesis; T cell	C-MYB; B-MYB; TRANSCRIPTION FACTORS; TUMOR-SUPPRESSOR; A-MYB; V-MYB; APOPTOSIS; DIFFERENTIATION; CELLS; IDENTIFICATION	Hematopoiesis, the process by which mature blood cells arise, is controlled by multiple transcription factors, which act in stage- and lineage-specific complexes. It is a major goal to elucidate the genes regulated by these transcription factors, in order to obtain a full understanding of the process and its malignant counterpart, leukemia. Myb family transcription factors play a central role in hematopoicsis. To identify new Myb family target genes, we have used an inducible dominant-negative protein for a subtraction cloning protocol in a model cell system (FDCP-Mix) with many characteristics of normal hematopoiesis. We present here a novel group of 29 validated Myb family target genes of diverse functions. Published online 20 December 2004.	Ctr Cell & Mol Biol, CRUK, Inst Canc Res, London SW3 6JB, England	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Weston, K (corresponding author), Ctr Cell & Mol Biol, CRUK, Inst Canc Res, 237 Fulham Rd, London SW3 6JB, England.	kathy.weston@icr.ac.uk						ADACHI Y, 1994, J BIOL CHEM, V269, P2258; Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; Aramburu J, 2004, EMBO REP, V5, P343, DOI 10.1038/sj.embor.7400133; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Bartley PA, 2001, BLOOD CELL MOL DIS, V27, P409, DOI 10.1006/bcmd.2001.0398; Bender TP, 2004, NAT IMMUNOL, V5, P721, DOI 10.1038/ni1085; Bergholtz S, 2001, NUCLEIC ACIDS RES, V29, P3546, DOI 10.1093/nar/29.17.3546; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; BIES J, 1995, CANCER RES, V55, P501; Bies J, 1996, ONCOGENE, V12, P355; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; Boyd KE, 1999, P SOC EXP BIOL MED, V222, P9, DOI 10.1111/j.1525-1373.1999.09992.x; Briggs MW, 2003, EMBO REP, V4, P571, DOI 10.1038/sj.embor.embor867; Chan VSF, 2002, EUR J IMMUNOL, V32, P1223, DOI 10.1002/1521-4141(200205)32:5<1223::AID-IMMU1223>3.0.CO;2-5; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Clarke D, 2000, ONCOGENE, V19, P3343, DOI 10.1038/sj.onc.1203661; Coligan JKA, 1991, CURRENT PROTOCOLS IM; Derrien V, 2002, J CELL SCI, V115, P2867; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Emambokus N, 2003, EMBO J, V22, P4478, DOI 10.1093/emboj/cdg434; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; Iwanaga Y, 2002, CANCER RES, V62, P2618; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; Kumar A, 2003, MOL CELL BIOL, V23, P6631, DOI 10.1128/MCB.23.18.6631-6645.2003; Lagaudriere-Gesbert C, 1997, CELL IMMUNOL, V182, P105, DOI 10.1006/cimm.1997.1223; Lauder A, 2001, MOL CELL BIOL, V21, P5797, DOI 10.1128/MCB.21.17.5797-5805.2001; Lei WL, 2004, J BIOL CHEM, V279, P29519, DOI 10.1074/jbc.M403133200; Mataraza JM, 2003, J BIOL CHEM, V278, P41237, DOI 10.1074/jbc.M304838200; MCMAHON J, 1988, ONCOGENE, V3, P717; Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Nabeshima K, 2002, CANCER LETT, V176, P101, DOI 10.1016/S0304-3835(01)00742-X; Ness SA, 2003, BLOOD CELL MOL DIS, V31, P192, DOI 10.1016/S1079-9796(03)00151-7; Orkin SH, 2003, IMMUNITY, V19, P633, DOI 10.1016/S1074-7613(03)00302-9; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rantanen A, 2003, MAMM GENOME, V14, P1, DOI 10.1007/s00335-002-2218-z; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; Sala A, 1996, CANCER RES, V56, P1991; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sasaki H, 2001, LUNG CANCER-J IASLC, V34, P53, DOI 10.1016/S0169-5002(01)00213-6; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Steingrimsson E, 2002, P NATL ACAD SCI USA, V99, P4477, DOI 10.1073/pnas.072071099; Sumner R, 2000, ONCOGENE, V19, P3335, DOI 10.1038/sj.onc.1203660; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Tewari M, 1997, CANCER RES, V57, P4063; Tsukasaki K, 2001, ONCOGENE, V20, P3301, DOI 10.1038/sj.onc.1204421; Vandenbark GR, 1996, CELL GROWTH DIFFER, V7, P1383; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; White JR, 2000, ONCOGENE, V19, P1196, DOI 10.1038/sj.onc.1203394; Wilkinson JC, 2004, J BIOL CHEM, V279, P51082, DOI 10.1074/jbc.M408655200; Won KA, 1998, MOL CELL BIOL, V18, P7584, DOI 10.1128/MCB.18.12.7584; Yunta M, 2003, ONCOGENE, V22, P1219, DOI 10.1038/sj.onc.1206183; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	61	37	37	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1375	1384		10.1038/sj.onc.1208301	http://dx.doi.org/10.1038/sj.onc.1208301			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608679				2022-12-17	WOS:000227092600007
J	Dasgupta, R; Perrimon, N				Dasgupta, R; Perrimon, N			Using RNAi to catch Drosophila genes in a web of interactions: insights into cancer research	ONCOGENE			English	Article						functional genomics; proteomics; RNA interference; chemical genetics; high-throughput screens; network; genome-wide	SMALL-MOLECULE INHIBITOR; SMALL INTERFERING RNAS; SIGNAL-TRANSDUCTION; SCREENS; GENOME; NETWORKS; SEQUENCE; PATHWAY; COMPLEX; BIOLOGY	The completion of whole-genome sequencing of various model organisms and the recent explosion of new technologies in the field of Functional Genomics and Proteomics is poised to revolutionize the way scientists identify and characterize gene function. One of the most significant advances in recent years has been the application of RNA interference (RNAi) as a means of assaying gene function. In the post-genomic era, advances in the field of cancer biology will rely upon the rapid identification and characterization of genes that regulate cell growth, proliferation, and apoptosis. Significant efforts are being directed towards cancer therapy and devising efficient means of selectively delivering drugs to cancerous cells. In this review, we discuss the promise of integrating genome-wide RNAi screens with proteomic approaches and small-molecule chemical genetic screens, towards improving our ability to understand and treat cancer.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Perrimon, N (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.	perrimon@receptor.med.harvard.edu		Perrimon, Norbert/0000-0001-7542-472X; Dasgupta, Ramanuj/0000-0001-9015-3729				Adams MD, 2002, NAT REV GENET, V3, P189, DOI 10.1038/nrg752; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Auerbach D, 2002, PROTEOMICS, V2, P611, DOI 10.1002/1615-9861(200206)2:6<611::AID-PROT611>3.0.CO;2-Y; Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2; Bak M, 2003, PHARMACOGENOMICS, V4, P411, DOI 10.1517/phgs.4.4.411.22751; Bale AE, 2002, ANNU REV GENOM HUM G, V3, P47, DOI 10.1146/annurev.genom.3.022502.103031; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Billadeau DD, 2002, J GASTROINTEST CANC, V31, P5, DOI 10.1385/IJGC:31:1-3:5; BOS JL, 1989, CANCER RES, V49, P4682; Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266; Bray D, 2003, SCIENCE, V301, P1864, DOI 10.1126/science.1089118; Buckholz Richard G., 1999, Journal of Molecular Microbiology and Biotechnology, V1, P135; Carmell MA, 2004, NAT STRUCT MOL BIOL, V11, P214, DOI 10.1038/nsmb729; Carpenter AE, 2004, NAT REV GENET, V5, P11, DOI 10.1038/nrg1248; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Denli AM, 2003, TRENDS BIOCHEM SCI, V28, P196, DOI 10.1016/S0968-0004(03)00058-6; Diaz-Camino C, 2003, ANAL BIOCHEM, V316, P171, DOI 10.1016/S0003-2697(02)00706-6; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Evans CJ, 2003, DEV CELL, V5, P673, DOI 10.1016/S1534-5807(03)00335-6; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Grimm S, 2004, NAT REV GENET, V5, P179, DOI 10.1038/nrg1291; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Hild M, 2004, GENOME BIOL, V5; Hucka M, 2003, BIOINFORMATICS, V19, P524, DOI 10.1093/bioinformatics/btg015; Kamath RS, 2003, METHODS, V30, P313, DOI 10.1016/S1046-2023(03)00050-1; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Kiger A A, 2003, J Biol, V2, P27, DOI 10.1186/1475-4924-2-27; Li H, 2003, CURR OPIN GENET DEV, V13, P611, DOI 10.1016/j.gde.2003.10.012; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Martinez LA, 2002, P NATL ACAD SCI USA, V99, P14849, DOI 10.1073/pnas.222406899; Matise MP, 1999, ONCOGENE, V18, P7852, DOI 10.1038/sj.onc.1203243; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Mercurio A M, 2001, Surg Oncol Clin N Am, V10, P313; MICHELSON AM, 2003, SCI STKE; Milhavet O, 2003, PHARMACOL REV, V55, P629, DOI 10.1124/pr.55.4.1; Milo R, 2004, SCIENCE, V303, P1538, DOI 10.1126/science.1089167; Miyagishi M, 2003, OLIGONUCLEOTIDES, V13, P325, DOI 10.1089/154545703322617005; Montell DJ, 1999, CELL BIOCHEM BIOPHYS, V31, P219, DOI 10.1007/BF02738240; Murone M, 1999, EXP CELL RES, V253, P25, DOI 10.1006/excr.1999.4676; Nagy A, 2003, NAT GENET, V33, P276, DOI 10.1038/ng1115; Oldak M, 2001, INT J MOL MED, V8, P445; Oliver B, 2004, GENOME BIOL, V5; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pandur P, 2002, BIOESSAYS, V24, P881, DOI 10.1002/bies.10164; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rosamond L, 2000, SCIENCE, V287, P1973, DOI 10.1126/science.287.5460.1973; Rubin G M, 2000, Novartis Found Symp, V229, P79; Rubin G. M., 2000, NOVART FDN SYMP, p[229, 82]; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Sanchez-Carbayo M, 2003, BRIT J CANCER, V89, P2172, DOI 10.1038/sj.bjc.6601406; Scherr M, 2003, CURR MED CHEM, V10, P245, DOI 10.2174/0929867033368493; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Spirin V, 2003, P NATL ACAD SCI USA, V100, P12123, DOI 10.1073/pnas.2032324100; St Johnston D, 2002, NAT REV GENET, V3, P176, DOI 10.1038/nrg751; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; TAKAI Y, 1994, MOLECULAR AND CELLULAR BASIS FOR CELL TO CELL INTERACTION: ITS SIGNIFICANCE IN CANCER, P338; Tewari M, 2004, MOL CELL, V13, P469, DOI 10.1016/S1097-2765(04)00033-4; van Duin M, 2003, BIOCHEM SOC T, V31, P429, DOI 10.1042/BST0310429; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; Venter JC, 1998, SCIENCE, V280, P1540, DOI 10.1126/science.280.5369.1540; Wajant H, 2004, PROG MOLEC, V34, P47; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; Zheng LX, 2004, P NATL ACAD SCI USA, V101, P135, DOI 10.1073/pnas.2136685100	77	37	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2004	23	51					8359	8365		10.1038/sj.onc.1208028	http://dx.doi.org/10.1038/sj.onc.1208028			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517017				2022-12-17	WOS:000224815900006
J	Casanovas, O; Jaumot, M; Paules, AB; Agell, N; Bachs, O				Casanovas, O; Jaumot, M; Paules, AB; Agell, N; Bachs, O			P38(SAPK2) phosphorylates cyclin D3 at Thr-283 and targets it for proteasomal degradation	ONCOGENE			English	Article						cell cycle; cyclin D3; p38(SAPK); proteasome; cancer	ACTIVATED PROTEIN-KINASE; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; CELL CARCINOMA; D GENES; D1; EXPRESSION; COMPLEXES; PROLIFERATION; LOCALIZATION	Cyclin D3 plays a critical role in maturation of precursor T cells and their levels are tightly regulated during this process. Alteration of cyclin D3 levels has been proposed to be important in the development of different human cancers, including malignancies of the lymphoid system. Thus, we have analysed the mechanisms involved in the regulation of cyclin D3 levels. Our results indicate that cyclin D3 is degraded via proteasome and that Thr-283 is essential for its degradation. Wild-type cyclin D3 but not the Thr-283A mutant accumulated ubiquitylated forms after treatment with proteasome inhibitors. We also observed that different type of stresses promote the Thr-283-dependent in vivo degradation of cyclin D3. The analysis of the kinases involved in Thr-283 phosphorylation indicates that all the members of the p38(SAPK) family of serine - threonine kinases are able to phosphorylate cyclin D3 at this specific site. Moreover, we found that the overexpression of p38alpha(SAPK2) induce the decrease of cyclin D3 in vivo. These results indicate that p38(SAPK) might be involved in the regulation of cyclin D3 levels and suggest that this mechanism is involved in the maturation of precursor T-cells. Alterations of this mechanism might be important for oncogenesis.	Univ Barcelona, IDIBAPS, Fac Med, Dept Biol Cellular & Anat Patol, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Bachs, O (corresponding author), Univ Barcelona, IDIBAPS, Fac Med, Dept Biol Cellular & Anat Patol, Casanova 143, E-08036 Barcelona, Spain.	obachs@.ub.edu	Jaumot, Montserrat/F-2640-2016; Agell, Neus/E-9640-2016; Casanovas, Oriol/L-5210-2014	Agell, Neus/0000-0002-1205-6074; Casanovas, Oriol/0000-0002-4298-3995; Jaumot, Montserrat/0000-0003-2864-357X				Bagui TK, 2003, MOL CELL BIOL, V23, P7285, DOI 10.1128/MCB.23.20.7285-7290.2003; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Buschges R, 1999, BRAIN PATHOL, V9, P435; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Chen QH, 2003, ONCOGENE, V22, P992, DOI 10.1038/sj.onc.1206193; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Diehl NL, 2000, J EXP MED, V191, P321, DOI 10.1084/jem.191.2.321; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Filipits M, 2002, CLIN CANCER RES, V8, P729; Florenes VA, 2000, CLIN CANCER RES, V6, P3614; GRANA X, 1995, ONCOGENE, V11, P211; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Gutzkow KB, 2003, CELL SIGNAL, V15, P871, DOI 10.1016/S0898-6568(03)00038-X; Hedberg Y, 2002, ACTA ONCOL, V41, P175, DOI 10.1080/028418602753669562; Hu XT, 2002, J BIOL CHEM, V277, P16528, DOI 10.1074/jbc.M109929200; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; Ito Y, 2001, ANTICANCER RES, V21, P1043; Iyoda K, 2003, CANCER-AM CANCER SOC, V97, P3017, DOI 10.1002/cncr.11425; Jaumot M, 1999, HEPATOLOGY, V29, P385, DOI 10.1002/hep.510290226; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Ma YH, 2003, J BIOL CHEM, V278, P16770, DOI 10.1074/jbc.M212702200; MATSUSHIME H, 1991, COLD SH Q B, V56, P69; MAYOL X, 1995, ONCOGENE, V11, P801; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Morin CI, 2004, CANCER RES, V64, P1893, DOI 10.1158/0008-5472.CAN-03-3448; NEET K, 1995, MOL CELL BIOL, V15, P4908; Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007; Pirkmaier A, 2003, ONCOGENE, V22, P4425, DOI 10.1038/sj.onc.1206488; Rickheim DG, 2002, HEPATOLOGY, V36, P30, DOI 10.1053/jhep.2002.33996; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; Sen J, 1996, J IMMUNOL, V156, P4535; Shaughnessy J, 2001, BLOOD, V98, P217, DOI 10.1182/blood.V98.1.217; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Sonoki T, 2001, BLOOD, V98, P2837, DOI 10.1182/blood.V98.9.2837; Tao GZ, 2002, J BIOL CHEM, V277, P19295, DOI 10.1074/jbc.M109654200; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E	44	37	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7537	7544		10.1038/sj.onc.1208040	http://dx.doi.org/10.1038/sj.onc.1208040			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326477				2022-12-17	WOS:000224176500010
J	Hoang, T				Hoang, T			The origin of hematopoietic cell type diversity	ONCOGENE			English	Review						lineage diversification; chaos theory; nonlinear dynamics; transcription factor networks; hematopoietic growth factors	COLONY-STIMULATING FACTOR; EMBRYONIC STEM-CELLS; SELF-RENEWAL; IN-VIVO; LINEAGE COMMITMENT; PROGENITOR CELLS; TRANSGENIC MICE; GENE-EXPRESSION; SIGNALING PATHWAY; ALPHA-BETA	The hematopoietic system remains robust with regards to extrinsic perturbations, in sharp contrast with the stochastic behavior of hematopoeitic stem cells (HSCs) at the single cell level, suggesting that stability may be achieved within a stem cell system that undergoes constant self-renewal, commitment to differentiation and generates cell type diversification. Converging evidence at the interface of cellular, molecular and numerical studies suggests that diversity is generated by the chaotic dynamics of transcription factor networks within a cell and of the combination of growth factors and cytokines in the environment, both involving cooperation and competition. Current evidence indicates that HSCs are primed for multilineage gene expression. A subtle shift in transcription factor dosage is sufficient to perturb this equilibrium and to drive lineage commitment that involves a resolution of complexity at the molecular level and a transition towards less chaotic behavior. This dynamical instability establishes a state of responsiveness to extrinsic signals. Evolutionary conserved environmental cues that drive pattern formation or migratory behavior during embryonic development operate in the adult to influence the decision between self-renewal and differentiation in HSCs, as exemplified by the role of Notch1, Wnt proteins, BMPs and VEGF. In contrast, a network of cytokines uniquely present in mammalians influences later developmental stages, from progenitors with more restricted potentials (tri-, bi- or unipotent) to mature functional cells. The se cytokines have co-opted the ancient Jak-STAT pathway but also appear to trigger lineage-affiliated transcription factors, thus linking environmental signaling to cell fate decisions.	Univ Montreal, Inst Immunovirol & Canc IRIC, Montreal, PQ H3C 2J7, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Mol Biol, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal	Hoang, T (corresponding author), Univ Montreal, Inst Immunovirol & Canc IRIC, POB 6128,Downtown Stn, Montreal, PQ H3C 2J7, Canada.	trang.hoang@umontreal.ca						Abkowitz JL, 1996, NAT MED, V2, P190, DOI 10.1038/nm0296-190; Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Amsellem S, 2003, NAT MED, V9, P1423, DOI 10.1038/nm953; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; Bain G, 1997, IMMUNITY, V6, P145, DOI 10.1016/S1074-7613(00)80421-5; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; Barndt R, 1999, J IMMUNOL, V163, P3331; Barndt RJ, 2000, MOL CELL BIOL, V20, P6677, DOI 10.1128/MCB.20.18.6677-6685.2000; BECKER AJ, 1963, NATURE, V197, P452, DOI 10.1038/197452a0; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; Benveniste P, 2003, NAT IMMUNOL, V4, P708, DOI 10.1038/ni940; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; Billia F, 2001, BLOOD, V97, P2257, DOI 10.1182/blood.V97.8.2257; Brown S, 2001, CURR BIOL, V11, P1700, DOI 10.1016/S0960-9822(01)00524-3; Bruno L, 2004, MOL CELL BIOL, V24, P741, DOI 10.1128/MCB.24.2.741-756.2004; Busslinger M, 2000, CURR OPIN IMMUNOL, V12, P151, DOI 10.1016/S0952-7915(99)00065-5; Caceres-Cortes JR, 2001, STEM CELLS, V19, P59, DOI 10.1634/stemcells.19-1-59; CACERESCORTES J, 1994, J BIOL CHEM, V269, P12084; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chang AN, 2002, P NATL ACAD SCI USA, V99, P9237, DOI 10.1073/pnas.142302099; CHEN HM, 1995, ONCOGENE, V11, P1549; Chervinsky DS, 1999, MOL CELL BIOL, V19, P5025; Dahl R, 2003, BLOOD CELL MOL DIS, V31, P229, DOI 10.1016/S1079-9796(03)00152-9; Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; DICK JE, 1985, CELL, V42, P71, DOI 10.1016/S0092-8674(85)80102-1; Furusawa C, 2000, PHYS REV LETT, V84, P6130, DOI 10.1103/PhysRevLett.84.6130; Furusawa C, 2001, J THEOR BIOL, V209, P395, DOI 10.1006/jtbi.2001.2264; Geiger H, 1998, CELL, V93, P1055, DOI 10.1016/S0092-8674(00)81210-6; Goardon N, 2002, BLOOD, V100, P491, DOI 10.1182/blood.V100.2.491; Gratrix S, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.014101; Guidos CJ, 2002, SEMIN IMMUNOL, V14, P395, DOI 10.1016/S104453230200074X; Halsey TC, 2004, NATURE, V428, P127, DOI 10.1038/428127a; Harrison DA, 1998, GENE DEV, V12, P3252, DOI 10.1101/gad.12.20.3252; HARRISON DE, 1988, P NATL ACAD SCI USA, V85, P822, DOI 10.1073/pnas.85.3.822; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; Herblot S, 2002, MOL CELL BIOL, V22, P886, DOI 10.1128/MCB.22.3.886-900.2002; Herbomel P, 2001, DEV BIOL, V238, P274, DOI 10.1006/dbio.2001.0393; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; Ikawa T, 2004, IMMUNITY, V20, P349, DOI 10.1016/S1074-7613(04)00049-4; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; JOYNER A, 1983, NATURE, V305, P556, DOI 10.1038/305556a0; JUST U, 1991, CELL, V64, P1163, DOI 10.1016/0092-8674(91)90271-Y; Kieran MW, 1996, P NATL ACAD SCI USA, V93, P9126, DOI 10.1073/pnas.93.17.9126; King AG, 2002, P NATL ACAD SCI USA, V99, P4508, DOI 10.1073/pnas.072087899; Kondo M, 2000, NATURE, V407, P383, DOI 10.1038/35030112; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; Kumano K, 2003, IMMUNITY, V18, P699, DOI 10.1016/S1074-7613(03)00117-1; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Lecuyer E, 2004, EXP HEMATOL, V32, P11, DOI 10.1016/j.exphem.2003.10.010; Lecuyer E, 2002, BLOOD, V100, P2430, DOI 10.1182/blood-2002-02-0568; Lemischka IR, 2003, NATURE, V425, P778, DOI 10.1038/425778a; Lin HF, 1997, TRENDS GENET, V13, P33, DOI 10.1016/S0168-9525(96)10050-0; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lundgren M, 2000, CELL, V103, P733, DOI 10.1016/S0092-8674(00)00177-X; Martin R, 2004, DEVELOPMENT, V131, P693, DOI 10.1242/dev.00968; Massari ME, 1999, MOL CELL, V4, P63, DOI 10.1016/S1097-2765(00)80188-4; Matsuzaki Y, 2004, IMMUNITY, V20, P87, DOI 10.1016/S1074-7613(03)00354-6; MAYANI H, 1993, J CELL PHYSIOL, V157, P579, DOI 10.1002/jcp.1041570318; METCALF D, 1980, P NATL ACAD SCI-BIOL, V77, P5327, DOI 10.1073/pnas.77.9.5327; Miller CL, 1997, BLOOD, V89, P1214, DOI 10.1182/blood.V89.4.1214; Miller CL, 1996, EXP HEMATOL, V24, P185; Miyamoto T, 2002, DEV CELL, V3, P137, DOI 10.1016/S1534-5807(02)00201-0; Murdoch B, 2003, P NATL ACAD SCI USA, V100, P3422, DOI 10.1073/pnas.0130233100; NAKAHATA T, 1982, J CELL PHYSIOL, V113, P455, DOI 10.1002/jcp.1041130314; Nakajima H, 2001, BLOOD, V98, P897, DOI 10.1182/blood.V98.4.897; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; OGAWA M, 1993, BLOOD, V81, P2844; Oh IH, 2002, ONCOGENE, V21, P4778, DOI 10.1038/sj.onc.1205592; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Parichy DM, 2000, DEVELOPMENT, V127, P3031; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Rajotte D, 1996, BLOOD, V88, P2906, DOI 10.1182/blood.V88.8.2906.bloodjournal8882906; Raya A, 2003, GENE DEV, V17, P1213, DOI 10.1101/gad.1084403; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Riley RL, 2002, EXP HEMATOL, V30, P1412, DOI 10.1016/S0301-472X(02)00953-0; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; Shibata Y, 2001, IMMUNITY, V15, P557, DOI 10.1016/S1074-7613(01)00218-7; Sieweke MH, 1998, CURR OPIN GENET DEV, V8, P545, DOI 10.1016/S0959-437X(98)80009-9; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; Stoffel R, 1999, P NATL ACAD SCI USA, V96, P698, DOI 10.1073/pnas.96.2.698; Strogatz S. H., 1994, NONLINEAR DYNAMICS C, P1; SZILVASSY SJ, 1990, P NATL ACAD SCI USA, V87, P8736, DOI 10.1073/pnas.87.22.8736; THUAN TX, 2001, CHAOS HARMONY PERSPE, P63; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; Tremblay M, 2003, J BIOL CHEM, V278, P12680, DOI 10.1074/jbc.M209870200; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Voas MG, 2004, DEV DYNAM, V229, P162, DOI 10.1002/dvdy.10449; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wallenfang MR, 2003, SCIENCE, V301, P1490, DOI 10.1126/science.1090070; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; WILLIAMS DA, 1984, NATURE, V310, P476, DOI 10.1038/310476a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Xie T, 1998, CELL, V94, P251, DOI 10.1016/S0092-8674(00)81424-5; Yamashita YM, 2003, SCIENCE, V301, P1547, DOI 10.1126/science.1087795; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; Zon LI, 2001, NAT IMMUNOL, V2, P142, DOI 10.1038/84239	115	37	37	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2004	23	43					7188	7198		10.1038/sj.onc.1207937	http://dx.doi.org/10.1038/sj.onc.1207937			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	855TZ	15378079				2022-12-17	WOS:000223998800005
J	Pettersson, F; Couture, MC; Hanna, N; Miller, WH				Pettersson, F; Couture, MC; Hanna, N; Miller, WH			Enhanced retinoid-induced apoptosis of MDA-MB-231 breast cancer cells by PKC inhibitors involves activation of ERK	ONCOGENE			English	Review						ER-negative breast cancer; retinoids; protein kinase C inhibitors; MAPK; apoptosis	PROTEIN-KINASE-C; HUMAN HEPATOCELLULAR-CARCINOMA; RECEPTOR-ALPHA EXPRESSION; SIGNAL-REGULATED KINASE; GROWTH-FACTOR RECEPTOR; ACID RECEPTOR; X-RECEPTOR; LEUKEMIA-CELLS; RAR-GAMMA; DIFFERENTIAL REGULATION	Retinoids are vitamin A derivatives, which cause growth inhibition, differentiation and/or apoptosis in various cell types, including some breast cancer cells. In general, estrogen receptor (ER)-positive cells are retinoic acid (RA) sensitive, whereas ER-negative cells are resistant. In this report, we show that ER-negative MDA-MB-231 cells are strongly growth inhibited by retinoids in combination with a PKC inhibitor. While neither RA nor GF109203X (GF) has a significant growth inhibitory effect in these cells, RA+GF potently suppress proliferation. We found that RA+GF induce apoptosis, as shown by an increase in fragmented DNA, Annexin-V-positive cells and caspase-3 activation. Apoptosis was also induced by GF in combination with two synthetic retinoids. Expression of phosphorylated as well as total PKC was decreased by GF and this was potentiated by RA. In addition, treatment with GF caused a strong and sustained activation of ERK1/2 and p38-MAPK, as well as a weaker activation of JNK. Importantly, inhibition of ERK but not p38 or JNK suppressed apoptosis induced by RA+GF, indicating that activation of ERK is specifically required. In support of this novel finding, the ability of other PKC inhibitors to cause apoptosis in combination with RA correlates with ability to cause sustained activation of ERK.	McGill Univ, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University	Miller, WH (corresponding author), McGill Univ, Lady Davis Inst Med Res, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.	wmiller@ldi.jgh.mcgill.ca	Pettersson, Frank/AAZ-5408-2020					Adachi S, 2002, HEPATOLOGY, V35, P332, DOI 10.1053/jhep.2002.31164; Adan Y, 2003, CANCER LETT, V194, P67, DOI 10.1016/S0304-3835(03)00146-0; Appierto V, 2004, CELL DEATH DIFFER, V11, P270, DOI 10.1038/sj.cdd.4401349; Basu A, 2001, BIOCHEM BIOPH RES CO, V280, P883, DOI 10.1006/bbrc.2000.4209; Boskovic G, 2002, J BIOL CHEM, V277, P26113, DOI 10.1074/jbc.M201185200; Bost F, 2002, BIOCHEM J, V361, P621, DOI 10.1042/0264-6021:3610621; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Busby EC, 2000, CANCER RES, V60, P2108; Cho YH, 2001, EXP CELL RES, V269, P97, DOI 10.1006/excr.2001.5298; Cho YH, 1997, J CELL PHYSIOL, V172, P306, DOI 10.1002/(SICI)1097-4652(199709)172:3<306::AID-JCP4>3.0.CO;2-S; Clark AS, 2003, CANCER RES, V63, P780; Crowe DL, 2003, MOL CANCER RES, V1, P532; del Rincon SV, 2003, ONCOGENE, V22, P3353, DOI 10.1038/sj.onc.1206485; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; Delmotte MH, 1999, J BIOL CHEM, V274, P38225, DOI 10.1074/jbc.274.53.38225; DeLuca LM, 1995, SCI AM SCI MED, V2, P28; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Drew L, 1998, INT IMMUNOL, V10, P877, DOI 10.1093/intimm/10.7.877; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fitzgerald P, 1997, CANCER RES, V57, P2642; Gauthier ML, 2003, BIOCHEM BIOPH RES CO, V307, P839, DOI 10.1016/S0006-291X(03)01273-7; Giannini G, 1997, J BIOL CHEM, V272, P26693, DOI 10.1074/jbc.272.42.26693; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Gschwend JE, 2000, MOL PHARMACOL, V57, P1224; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hail N, 2001, CANCER RES, V61, P6698; Hofmann J, 2001, REV PHYSIOL BIOCH P, V142, P1, DOI 10.1007/BFb0117491; Hsu SL, 2000, EXP CELL RES, V258, P322, DOI 10.1006/excr.2000.4933; Huigsloot M, 2003, MOL PHARMACOL, V64, P965, DOI 10.1124/mol.64.4.965; Irie N, 2002, BIOCHEM BIOPH RES CO, V298, P738, DOI 10.1016/S0006-291X(02)02531-7; JIANG HP, 1994, ONCOGENE, V9, P3397; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kambhampati S, 2003, J BIOL CHEM, V278, P32544, DOI 10.1074/jbc.M301523200; Kawakami K, 1996, BIOCHEM BIOPH RES CO, V219, P778, DOI 10.1006/bbrc.1996.0310; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Kitareewan S, 1999, ONCOGENE, V18, P5747, DOI 10.1038/sj.onc.1202981; Kizaki M, 1996, BLOOD, V87, P1977; Le XF, 2001, ONCOGENE, V20, P8258, DOI 10.1038/sj.onc.1205039; Le XF, 2000, CLIN CANCER RES, V6, P260; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; Lee MO, 2000, BIOCHEM PHARMACOL, V59, P485, DOI 10.1016/S0006-2952(99)00355-X; Lee YJ, 2003, BBA-MOL CELL RES, V1593, P219, DOI 10.1016/S0167-4889(02)00392-0; Li D, 2002, J BIOL CHEM, V277, P31416, DOI 10.1074/jbc.M204818200; Li LW, 1999, MOL CELL BIOL, V19, P8547; Lin HY, 2002, J UROLOGY, V168, P748, DOI 10.1016/S0022-5347(05)64739-8; LIPPMAN SM, 1995, J CELL BIOCHEM, P1; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Mandil R, 2001, CANCER RES, V61, P4612; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Mangiarotti R, 1998, BRIT J CANCER, V77, P186, DOI 10.1038/bjc.1998.32; Mann K K, 2001, Curr Oncol Rep, V3, P209, DOI 10.1007/s11912-001-0052-1; Marchetti P, 1999, CANCER RES, V59, P6257; Martelli AM, 1999, J CELL BIOCHEM, V74, P499, DOI 10.1002/(SICI)1097-4644(19990915)74:4<499::AID-JCB1>3.0.CO;2-X; Matsushima-Nishiwaki R, 2001, CANCER RES, V61, P7675; McCracken MA, 2003, MOL CANCER THER, V2, P273; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Miller WH, 1998, CANCER, V83, P1471, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1471::AID-CNCR1>3.0.CO;2-6; Miranda MB, 2002, LEUKEMIA, V16, P683, DOI 10.1038/sj.leu.2402400; NAGY L, 1995, MOL CELL BIOL, V15, P3540; Ni HY, 2003, BRIT J HAEMATOL, V121, P849, DOI 10.1046/j.1365-2141.2003.04368.x; Ortiz MA, 2001, CANCER RES, V61, P8504; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Pepper C, 2002, EUR J HAEMATOL, V69, P227, DOI 10.1034/j.1600-0609.2002.02799.x; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Pettersson F, 2002, BRIT J CANCER, V87, P555, DOI 10.1038/sj.bjc.6600496; Platet N, 1998, INT J CANCER, V75, P750, DOI 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A; Radominska-Pandya A, 2000, J BIOL CHEM, V275, P22324, DOI 10.1074/jbc.M907722199; Rigobello MP, 1999, BIOCHEM PHARMACOL, V58, P665, DOI 10.1016/S0006-2952(99)00149-5; Rochefort H, 2003, ENDOCR-RELAT CANCER, V10, P261, DOI 10.1677/erc.0.0100261; Rosenauer A, 1998, CANCER RES, V58, P5110; Rousseau C, 2003, J STEROID BIOCHEM, V86, P1, DOI 10.1016/S0960-0760(03)00255-3; RUBIN M, 1994, CANCER RES, V54, P6549; Sah JF, 2002, J BIOL CHEM, V277, P9728, DOI 10.1074/jbc.M110897200; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; Sausville Edward A., 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P47, DOI 10.2174/1568011033353560; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; She QB, 2001, CANCER RES, V61, P1604; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; Shih A, 2002, J CLIN ENDOCR METAB, V87, P1223, DOI 10.1210/jc.87.3.1223; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Solomon C, 1999, J CLIN INVEST, V103, P1729, DOI 10.1172/JCI6871; Spanjaard RA, 1997, J BIOL CHEM, V272, P18990, DOI 10.1074/jbc.272.30.18990; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Sun SY, 1999, CANCER RES, V59, P2493; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Tenzer A, 2001, CANCER RES, V61, P8203; Tillman DM, 2003, CANCER RES, V63, P5118; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621; Yen A, 1998, CANCER RES, V58, P3163; Yung Benjamin Yat-Ming, 1995, Journal of Biomedical Science, V2, P154, DOI 10.1007/BF02253066; Zhao X, 2001, CELL DEATH DIFFER, V8, P878, DOI 10.1038/sj.cdd.4400894; Zhu WY, 1997, EXP CELL RES, V234, P293, DOI 10.1006/excr.1997.3589	102	37	38	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7053	7066		10.1038/sj.onc.1207956	http://dx.doi.org/10.1038/sj.onc.1207956			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15273718				2022-12-17	WOS:000223885100006
J	Olschlager, V; Pleschka, S; Fischer, T; Rziha, HJ; Wurzer, W; Stitz, L; Rapp, UR; Ludwig, S; Planz, O				Olschlager, V; Pleschka, S; Fischer, T; Rziha, HJ; Wurzer, W; Stitz, L; Rapp, UR; Ludwig, S; Planz, O			Lung-specific expression of active Raf kinase results in increased mortality of influenza A virus-infected mice	ONCOGENE			English	Article						influenza A virus; lung tumor; C-Raf; MEK; ERK; in vivo; mouse	PSEUDORABIES VIRUS; TRANSGENIC MICE; GENE-EXPRESSION; CANCER; PROTEIN; VACCINATION; PROPAGATION; ACTIVATION; TUMORS	Alterations in signalling via the Raf/MEK/ERK pathway interfere with influenza A virus replication in cell culture. While virus yields are reduced in cells expressing dominant-negative Raf or ERK, virus propagation is enhanced upon expression of constitutively active Raf or MEK. To study the impact of active Raf on influenza virus propagation in vivo, we investigated transgenic mice expressing an activated mutant of c-Raf (Raf-BxB) in the main target tissue of influenza virus, the lung. Raf-BxB expression results in multicentric alveolar adenomas. Influenza virus A infection of Raf-BxB mice results in increased disease symptoms and higher mortality rates. The immune response against viral pathogens in transgenic animals did not differ from wild-type mice as determined by the use of a Pseudorabies virus (PRV) as a model for a viral infection not affecting the lung. No significant differences of influenza virus titers in the lung of Raf-BxB and wild-type mice were observed. However, immunohistology revealed increased numbers of influenza NP-positive cells in the alveolar linings of Raf-BxB mice, demonstrating the strong tropism of influenza virus for cells expressing active Raf. These findings disclose the possibility to use modified influenza virus for the therapy of tumors with an activated Ras/Raf signalling pathway.	Bundesforsch Anstalt Viruskrankheiten Tiere, Inst Immunol, Tubingen, Germany; Univ Giessen, Inst Med Virol, D-35390 Giessen, Germany; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97070 Wurzburg, Germany; Univ Dusseldorf, Inst Mol Med, D-4000 Dusseldorf, Germany	Justus Liebig University Giessen; University of Wurzburg; Heinrich Heine University Dusseldorf	Planz, O (corresponding author), Bundesforsch Anstalt Viruskrankheiten Tiere, Inst Immunol, Paul Ehrlich Str 28, Tubingen, Germany.	oliver.planz@tue.bfav.de	Pleschka, Stephan/HGU-9354-2022	Pleschka, Stephan/0000-0002-7372-7089; Ludwig, Stephan/0000-0003-4490-3052				Anderson H, 1999, BRIT J CANCER, V80, P219, DOI 10.1038/sj.bjc.6690342; Arrowood JR, 2002, ANN PHARMACOTHER, V36, P1219; Bergmann M, 2001, CANCER RES, V61, P8188; BOS JL, 1989, CANCER RES, V49, P4682; Brydak LB, 2000, DRUGS, V60, P35, DOI 10.2165/00003495-200060010-00004; CARD JP, 1995, CRIT REV NEUROBIOL, V9, P137; Couch Robert B., 1997, American Journal of Medicine, V102, P2, DOI 10.1016/S0002-9343(97)00003-X; Fischer T, 2003, J VIROL, V77, P9312, DOI 10.1128/JVI.77.17.9312-9323.2003; HALL WJ, 1976, AM REV RESPIR DIS, V113, P141; Kerkhoff E, 2000, CELL GROWTH DIFFER, V11, P185; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; LITTLE JW, 1976, ANN INTERN MED, V85, P177, DOI 10.7326/0003-4819-85-2-177; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; Ludwig S, 2003, TRENDS MOL MED, V9, P46, DOI 10.1016/S1471-4914(02)00010-2; Ludwig S, 2001, J BIOL CHEM, V276, P10990, DOI 10.1074/jbc.M009902200; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Naumann U, 1997, Recent Results Cancer Res, V143, P237; Ober BT, 1998, J VIROL, V72, P4866, DOI 10.1128/JVI.72.6.4866-4873.1998; Olshaker JS, 2003, EMERG MED CLIN N AM, V21, P353, DOI 10.1016/S0733-8627(03)00018-X; Palese P, 1996, P NATL ACAD SCI USA, V93, P11354, DOI 10.1073/pnas.93.21.11354; PESCHKE T, 1993, IMMUNOBIOLOGY, V189, P340, DOI 10.1016/S0171-2985(11)80365-7; Pleschka S, 2001, NAT CELL BIOL, V3, P301, DOI 10.1038/35060098; Porter DD, 1999, CLIN INFECT DIS, V29, P437, DOI 10.1086/520230; Ramakrishna G, 2000, EXP LUNG RES, V26, P659, DOI 10.1080/01902140150216747; SCHOLTISSEK C, 1997, ARCH VIROL         S, V13, P99; Steinhauer DA, 2002, ANNU REV GENET, V36, P305, DOI 10.1146/annurev.genet.36.052402.152757; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Wurzer WJ, 2003, EMBO J, V22, P2717, DOI 10.1093/emboj/cdg279	29	37	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6639	6646		10.1038/sj.onc.1207883	http://dx.doi.org/10.1038/sj.onc.1207883			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15235583				2022-12-17	WOS:000223530800011
J	Khan, S; Guevara, C; Fujii, G; Parry, D				Khan, S; Guevara, C; Fujii, G; Parry, D			P14ARF is a component of the p53 response following ionizing irradiation of normal human fibroblasts	ONCOGENE			English	Article						ARF; DNA damage; ionizing radiation; MDM2; p53	ARF TUMOR-SUPPRESSOR; DNA-DAMAGE; NUCLEOLAR-LOCALIZATION; RIBONUCLEOTIDE DEPLETION; CELLULAR-RESPONSE; DEFICIENT MICE; FEEDBACK LOOP; MDM2; P19(ARF); P14(ARF)	Ionizing radiation leads to rapid stabilization and activation of the p53 tumor suppressor. Previous reports demonstrate that murine p19ARF cooperates with p53 in the cellular response to gamma irradiation. Here, we show that endogenous ARF sequentially interacts with p53 and MDM2 following irradiation of primary human and mouse embryonic fibroblasts. Shortly after irradiation, p14ARF binds p53 independently of MDM2. As nuclear pools of p53 decline, endogenous p14ARF co-immunoprecipitates with MDM2 and is localized within the nucleolus. Interestingly, p14ARF nucleolar localization during this response is abrogated in cells lacking functional p53. Taken together, our data suggest that human and murine ARF contribute to the mammalian DNA damage response.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Discovery Res, Palo Alto, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Parry, D (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Discovery Res, 901 Calif Ave, Palo Alto, CA 94304 USA.	david.parry@dnax.org						Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEOCALUNA R, 1995, NATURE, V0378; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Groth A, 2000, J BIOL CHEM, V275, P27473; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1999, CANCER RES, V59, P2464; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KASTAN MB, 1991, CANCER RES, V51, P6304; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; KHANNA KK, 1993, ONCOGENE, V8, P3307; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Lyakhovich A, 2003, MOL CELL BIOL, V23, P2463, DOI 10.1128/MCB.23.7.2463-2475.2003; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rubbi CP, 2000, ONCOGENE, V19, P85, DOI 10.1038/sj.onc.1203378; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xu Y, 1998, MOL CELL BIOL, V18, P4385, DOI 10.1128/MCB.18.7.4385; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	41	37	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6040	6046		10.1038/sj.onc.1207824	http://dx.doi.org/10.1038/sj.onc.1207824			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15195142				2022-12-17	WOS:000223261000003
J	Knight-Krajewski, S; Welsh, CF; Liu, YQ; Lyons, LS; Faysal, JM; Yang, ES; Burnstein, KL				Knight-Krajewski, S; Welsh, CF; Liu, YQ; Lyons, LS; Faysal, JM; Yang, ES; Burnstein, KL			Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21(CIP1) levels in androgen-independent human prostate cancer cells	ONCOGENE			English	Article						Rho GTPases; Rac1; Cdc42; cyclin-dependent kinase inhibitor; p21; cell cycle	INFLAMMATORY BREAST-CANCER; ACTIVATED PROTEIN-KINASE; GROWTH-INHIBITION; TUMOR-CELLS; DNA-REPLICATION; FAMILY GTPASES; IN-VIVO; EXPRESSION; PROLIFERATION; LNCAP	Abnormally suppressed levels of cyclin-dependent kinase inhibitors (CKIs) are associated with aggressive androgen-independent prostate cancer and contribute to uncontrolled proliferation. The androgen-independent human prostate cancer cell lines, LNCaP-104R1, ALVA31 and PC-3, express low levels of the CKI, p21(CIP1), compared to the less-malignant, androgen-dependent LNCaP cells. We investigated the mechanism underlying this suppression by examining the role of Rho GTPases, signaling proteins that play important roles in cell cycle progression, at least in part through regulation of CKIs. Inhibition of Rac1 induced p21 expression in androgen-independent lines but had no effect on the higher p21 levels characteristic of LNCaP cells. This induction of p21 was functionally significant as evidenced by inhibition of cyclin-dependent kinase 2 activity and decreased cell proliferation. Conversely, overexpression of constitutively active Rac1 suppressed the higher p21 levels seen in LNCaP cells. Thus, Rac1 activity is both necessary and sufficient for suppression of p21 in prostate cancer cells. Furthermore, Rac1 Activity was significantly higher in all three androgen-independent cell lines compared to LNCaP cells. Thus in three models of aggressive human prostate cancer, hyperactivity of Rac1 corresponds to suppressed levels of p21. These results are unique in describing a role for Rac1 in p21 regulation and may implicate the Rac1 signaling pathway as a potential therapeutic target for controlling prostate cancer cell growth following progression to androgen independence.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Med, Miami, FL 33136 USA; Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami	Burnstein, KL (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, R-189,1600 NW 10th Ave, Miami, FL 33136 USA.	kburnste@miami.edu			NCI NIH HHS [CA 87668] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA087668] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaltomaa S, 1999, PROSTATE, V39, P8; Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Agus DB, 1999, J NATL CANCER I, V91, P1869, DOI 10.1093/jnci/91.21.1869; AKTORIES K, 1995, TRENDS CELL BIOL, V5, P441, DOI 10.1016/S0962-8924(00)89107-2; Auer KL, 1998, BIOCHEM J, V336, P551, DOI 10.1042/bj3360551; Bao WJ, 2002, MOL CELL BIOL, V22, P4587, DOI 10.1128/MCB.22.13.4587-4597.2002; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chen H, 2002, GENOMICS, V79, P573, DOI 10.1006/geno.2002.6739; Cheng L, 2000, CLIN CANCER RES, V6, P1896; Cipriano SC, 1998, ONCOGENE, V17, P1549, DOI 10.1038/sj.onc.1202069; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Fizazi K, 2002, CLIN CANCER RES, V8, P775; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Ghosh PM, 1999, ONCOGENE, V18, P4120, DOI 10.1038/sj.onc.1202792; Ghosh PM, 2002, CANCER RES, V62, P2630; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; Guo YP, 1997, CLIN CANCER RES, V3, P2269; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Ingram DA, 2001, J EXP MED, V194, P57, DOI 10.1084/jem.194.1.57; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; KOKONTIS J, 1994, CANCER RES, V54, P1566; Kokontis JM, 1998, MOL ENDOCRINOL, V12, P941, DOI 10.1210/me.12.7.941; Liberto M, 2002, ONCOGENE, V21, P1590, DOI 10.1038/sj.onc.1205242; LOOP SM, 1995, PROSTATE, V26, P179, DOI 10.1002/pros.2990260403; LOOP SM, 1993, PROSTATE, V22, P93, DOI 10.1002/pros.2990220202; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Matsushima H, 1998, HUM PATHOL, V29, P778, DOI 10.1016/S0046-8177(98)90445-2; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Navone NM, 1998, CANCER METAST REV, V17, P361, DOI 10.1023/A:1006165017279; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; ORDONEZ NG, 2002, CLIN CANCER RES, V8, P775; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Reed N, 2001, TRENDS MOL MED, V7, P157, DOI 10.1016/S1471-4914(01)01955-4; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; STAHLEBACKDHAL M, 1995, AM J PATHOL, V146, P1073; TILLEY WD, 1990, CANCER RES, V50, P5382; Tsihlias J, 1999, ANNU REV MED, V50, P401; Umekita Y, 1996, P NATL ACAD SCI USA, V93, P11802, DOI 10.1073/pnas.93.21.11802; VAN AL, 1997, GENE DEV, V11, P2295; van Bokhoven A, 2001, PROSTATE, V47, P36; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van Golen KL, 2000, CANCER RES, V60, P5832; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waltregny D, 2001, MOL ENDOCRINOL, V15, P765, DOI 10.1210/me.15.5.765; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; Welsh CF, 2000, BBA-REV CANCER, V1471, pM21, DOI 10.1016/S0304-419X(00)00016-0; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Yang ES, 2002, MOL CELL ENDOCRINOL, V186, P69, DOI 10.1016/S0303-7207(01)00671-2; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhuang SH, 1998, ENDOCRINOLOGY, V139, P1197, DOI 10.1210/en.139.3.1197; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	66	37	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5513	5522		10.1038/sj.onc.1207708	http://dx.doi.org/10.1038/sj.onc.1207708			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15077174				2022-12-17	WOS:000222588400011
J	Saleem, A; Dutta, J; Malegaonkar, D; Rasheed, F; Rasheed, Z; Rajendra, R; Marshall, H; Luo, MJ; Li, HH; Rubin, EH				Saleem, A; Dutta, J; Malegaonkar, D; Rasheed, F; Rasheed, Z; Rajendra, R; Marshall, H; Luo, MJ; Li, HH; Rubin, EH			The topoisomerase I- and p53-binding protein topors is differentially expressed in normal and malignant human tissues and may function as a tumor suppressor	ONCOGENE			English	Article						topors; tumor suppressor; topoisomerase I; p53; ubiquitin E3 ligase	CHROMOSOME 9P; HUMAN CANCERS; PROSTATE-CANCER; HIGH-FREQUENCY; GENE; DELETION; LUNG; IDENTIFICATION; METHYLATION; REGION	Topors was identified recently as a human protein that binds to topoisomerase I and p53. Topors contains a highly conserved RING domain and localizes in promyelocytic leukemia nuclear bodies. Relatively little is known regarding topors expression patterns or function. We now demonstrate that topors mRNA and protein are widely expressed in normal human tissues. By contrast, topors mRNA and protein levels are decreased or undetectable in colon adenocarcinomas relative to normal colon tissue, and expression of the topors protein is not detectable in several colon cancer cell lines. The human TOPORS gene is located on chromosome 9p21, with loss of heterozygosity in this region frequently observed in several different malignancies. While we were unable to detect loss of heterozygosity of the TOPORS gene in 16 sporadic colon cancer cases, increased methylation of a CpG island in the TOPORS promoter was evident in colon adenocarcinoma specimens relative to matched normal tissues. Additional studies indicate that forced expression of topors inhibits cellular proliferation and is associated with an accumulation of cells in the G(0)/G(1) phase of the cell cycle. This effect is independent of the topors RING domain and maps to a C-terminal region of the protein. These results suggest that topors functions as a negative regulator of cell growth, and possibly as a tumor suppressor.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Pharmacol, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Mol Genet & Microbiol, New Brunswick, NJ USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Med, New Brunswick, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Rubin, EH (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Pharmacol, New Brunswick, NJ 08903 USA.	ehrubin@umdnj.edu			NATIONAL CANCER INSTITUTE [R01CA039662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059170] Funding Source: NIH RePORTER; NCI NIH HHS [CA39662] Funding Source: Medline; NIGMS NIH HHS [GM59170] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boutell C, 2003, J BIOL CHEM, V278, P36596, DOI 10.1074/jbc.M300776200; Boutell C, 2002, J VIROL, V76, P841, DOI 10.1128/JVI.76.2.841-850.2002; CHANG JY, 1992, BIOCHEM PHARMACOL, V43, P2443, DOI 10.1016/0006-2952(92)90325-D; Chu D, 2001, J BIOL CHEM, V276, P14004, DOI 10.1074/jbc.M010262200; Cui XF, 2000, J MOL DIAGN, V2, P29, DOI 10.1016/S1525-1578(10)60612-5; Devlin J, 1996, BRIT J CANCER, V73, P420, DOI 10.1038/bjc.1996.75; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GIOVANELLA BC, 1989, SCIENCE, V246, P1046, DOI 10.1126/science.2555920; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; He DL, 2003, CHINESE MED J-PEKING, V116, P1394; HERMAN JG, 1995, CANCER RES, V55, P4525; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KAMB A, 1994, SCIENCE, V264, P440; Kim SK, 1997, CANCER RES, V57, P400; LI HH, 1995, GENOMICS, V26, P199, DOI 10.1016/0888-7543(95)80201-V; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Perinchery G, 1999, INT J CANCER, V83, P610, DOI 10.1002/(SICI)1097-0215(19991126)83:5<610::AID-IJC7>3.0.CO;2-2; Pollock PM, 2001, CANCER RES, V61, P1154; PUIG S, 1995, AM J HUM GENET, V57, P395; Rasheed ZA, 2002, EXP CELL RES, V277, P152, DOI 10.1006/excr.2002.5550; Schraml P, 2001, AM J PATHOL, V158, P593, DOI 10.1016/S0002-9440(10)64001-1; Waber P, 1997, ONCOGENE, V15, P1699, DOI 10.1038/sj.onc.1201336; Weger S, 2003, EXP CELL RES, V290, P13, DOI 10.1016/S0014-4827(03)00292-1; Wiest JS, 1997, CANCER RES, V57, P1; Zhou R, 1999, GENE, V235, P93, DOI 10.1016/S0378-1119(99)00203-6	30	37	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5293	5300		10.1038/sj.onc.1207700	http://dx.doi.org/10.1038/sj.onc.1207700			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15107820				2022-12-17	WOS:000222491600005
J	Fujii, K; Goldman, EH; Park, HR; Zhang, LX; Chen, J; Fu, HA				Fujii, K; Goldman, EH; Park, HR; Zhang, LX; Chen, J; Fu, HA			Negative control of apoptosis signal-regulating kinase 1 through phosphorylation of Ser-1034	ONCOGENE			English	Article						ASK1; apoptosis; phosphorylation; 14-3-3; kinase; survival signaling	ACTIVATED PROTEIN-KINASE; CELL-DEATH; 1 ASK1; PATHWAYS; STRESS; DISSOCIATION; THIOREDOXIN; INHIBITOR; SURVIVAL; LIFE	Apoptosis signal-regulating kinase 1 (ASK1) is a serine/threonine kinase that mediates cell stress signaling initiated by diverse stimuli, such as H2O2 and TNFalpha. Owing to its critical role in promoting apoptosis, ASK1 activity is highly controlled in cells. Phosphorylation of ASK1 at Thr-845 has been correlated with its activation, while phosphorylation at Ser-967 negatively controls its death promoting activity. Here, we report the identification of a novel phosphorylation site at Ser-1034 in the C-terminal regulatory domain of ASK1. Mutating Ser-1034 to an unphosphorylatable Ala led to increased catalytic activity of ASK1 and enhanced proapoptotic function of ASK1. Thus, the proapoptotic function of ASK1 is suppressed in part by phosphorylation at its C-terminal regulatory domain, which may couple upstream survival kinases to the death regulatory machinery.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Mol & Syst Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Fu, HA (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA.	hfu@emory.edu		Zhang, Lixin/0000-0003-0894-9520; Park, Hae Ryoun/0000-0003-1908-0824	NIGMS NIH HHS [GM53165, GM60033] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060033, R01GM053165, R29GM053165] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Goldman EH, 2004, J BIOL CHEM, V279, P10442, DOI 10.1074/jbc.M311129200; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Matsuura H, 2002, J BIOL CHEM, V277, P40703, DOI 10.1074/jbc.M202004200; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Song JJ, 2002, J BIOL CHEM, V277, P46566, DOI 10.1074/jbc.M206826200; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zou XH, 2001, MOL CELL BIOL, V21, P4818, DOI 10.1128/MCB.21.14.4818-4828.2001	28	37	40	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5099	5104		10.1038/sj.onc.1207668	http://dx.doi.org/10.1038/sj.onc.1207668			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15094778				2022-12-17	WOS:000222237300018
J	Yamamoto, Y; Irie, K; Asada, M; Mino, A; Mandai, K; Takai, Y				Yamamoto, Y; Irie, K; Asada, M; Mino, A; Mandai, K; Takai, Y			Direct binding of the human homologue of the Drosophila disc large tumor suppressor gene to seven-pass transmembrane proteins, tumor endothelial marker 5 (TEM5), and a novel TEM5-like protein	ONCOGENE			English	Article						hDlg; TEM5; tumor suppressor; G-protein-coupled receptor; PDZ domain	COUPLED RECEPTORS; CELL-ADHESION; GUANYLATE KINASES; K+ CHANNELS; SAP97; MEMBRANE; FAMILY; JUNCTIONS; DLG; PROLIFERATION	The human homologue of the Drosophila discs large tumor suppressor gene ( hDlg) is a member of the membrane-associated guanylate kinase family with three PSD-95/Dlg/ZO-1 (PDZ) domains. hDlg has been shown to bind tumor suppressor proteins, adenomatous polyposis coli (APC) and protein tyrosine phosphatase and tensin homologue ( PTEN), and several viral oncoproteins, and has been implicated in the negative regulation of cell proliferation. hDlg has furthermore been shown to localize at the plasma membrane of synapses and to scaffold cell surface receptors and channels. In epithelial cells, hDlg localizes at the basolateral plasma membrane, but its localization mechanism is unknown. We searched here for a transmembrane protein that directly bound to hDlg. hDlg bound tumor endothelial marker 5 (TEM5), a seven-pass transmembrane protein that is homologous to the family B of G-protein-coupled receptors (GPCRs). TEM5 has previously been reported to display elevated expression during tumor angiogenesis and neoangiogenesis. The PDZ domains of hDlg bound the C-terminal PDZ-binding motif of TEM5. The expression of TEM5 was detected in endothelial cells of embryonic liver, where hDlg colocalized with TEM5. hDlg furthermore bound a novel seven-pass transmembrane protein, which was homologous to TEM5, and was named here a TEM5-like protein (TEM5-like). These results suggest that hDlg localizes at the plasma membrane through TEM5 and TEM5-like and furthermore scaffolds these GPCRs in endothelial cells during tumor angiogenesis and neoangiogenesis.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp		Mandai, Kenji/0000-0002-0115-6635				BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budnik V, 1996, CURR OPIN NEUROBIOL, V6, P858, DOI 10.1016/S0959-4388(96)80038-9; Cai C, 2002, J BIOL CHEM, V277, P31484, DOI 10.1074/jbc.M204354200; Carson-Walter EB, 2001, CANCER RES, V61, P6649; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Fredriksson R, 2003, BIOCHEM BIOPH RES CO, V301, P725, DOI 10.1016/S0006-291X(03)00026-3; Fujiwara T, 1998, MOL BIOL CELL, V9, P1221, DOI 10.1091/mbc.9.5.1221; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Murata M, 2001, AM J PHYSIOL-HEART C, V281, pH2575, DOI 10.1152/ajpheart.2001.281.6.H2575; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Reuver SM, 1998, J CELL SCI, V111, P1071; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	31	37	45	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3889	3897		10.1038/sj.onc.1207495	http://dx.doi.org/10.1038/sj.onc.1207495			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15021905				2022-12-17	WOS:000221382000001
J	Lyakhovich, A; Shekhar, MPV				Lyakhovich, A; Shekhar, MPV			RAD6B overexpression confers chemoresistance: RAD6 expression during cell cycle and its redistribution to chromatin during DNA damage-induced response	ONCOGENE			English	Article						postreplication repair; ubiquitin conjugating enzyme; cell cycle; adriamycin; cisplatin	SACCHAROMYCES-CEREVISIAE RAD6; UBIQUITIN-CONJUGATING ENZYMES; 2 HUMAN HOMOLOGS; POSTREPLICATION REPAIR; GENE-PRODUCT; PROTEIN; MUTAGENESIS; HHR6A; P53; INACTIVATION	The HR6A and HR6B genes, homologs of the yeast RAD6 gene, encode ubiquitin conjugating enzymes that are required for postreplication repair (PRR) of DNA and damage-induced mutagenesis. We show here that consistent with its role as a PRR protein, HR6 protein (referred as RAD6) expression is cell cycle regulated, with maximal levels expressed in late S/G2 phases of the cell cycle. Exposure of MCF10A cells to adriamycin (ADR) causes enhancement in the levels of RAD6B mRNA and protein. Inclusion of actinomycin D abolishes both basal and ADR-induced RAD6B transcription indicating that ADR-induced effects on RAD6B transcription result from an increase in transcriptional activity rather than from regulation of RAD6B mRNA stability. The increase in RAD6 protein expression observed in ADR-treated cells is dependent upon transcription and de novo protein synthesis, as addition of actinomycin D and cycloheximide eliminated the induction effects. Using in vivo crosslinking experiments, we demonstrate that only a small proportion of RAD6 is associated with chromatin in untreated MCF10A cells. However, treatment with ADR or cisplatin is accompanied by a significant increase and redistribution of RAD6 to DNA, and RAD6, RAD18, PCNA, phosphohistone H3, as well as p53 proteins are all found in the DNA fractions. These findings suggest that although RAD6 protein is present in the nucleus, its recruitment to the chromatin appears to be modulated by DNA damage. Whereas MCF10A cells engineered to overexpress ectopic RAD6B are significantly more resistant to ADR and cisplatin as compared to empty vector-transfected cells, MCF10A cells stably transfected with antisense RAD6B display hypersensitivity to these damage-inducing drugs. Analysis of PRR capacities in cisplatin-treated MCF10A cells stably transfected with empty vector, RAD6B or antisense RAD6B showed that whereas RAD6B-overexpressing and vector control MCF10A cells possessed the ability to convert newly synthesized DNA to higher molecular weight species, MCF10A cells depleted of RAD6B are PRR-compromised. Although no human diseases have been linked to mutations in the PRR pathway genes, these data suggest that RAD6 may play an essential role in DNA damage tolerance and recovery via modulation of PRR, and that imbalances in the levels of RAD6 could lead to changes in drug sensitivity and damage-induced mutagenesis.	Karmanos Canc Inst, Breast Canc Program, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Shekhar, MPV (corresponding author), Karmanos Canc Inst, Breast Canc Program, 110 E Warren Ave, Detroit, MI 48201 USA.	shekharm@karmanos.org	Lyakhovich, Alex/B-4410-2008; Lyakhovich, Alex/B-4410-2008	Lyakhovich, Alex/0000-0002-8279-4697; Shekhar, Malathy/0000-0003-2721-7202; Lyakhovich, Alex/0000-0001-5347-403X				Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; Broomfield S, 1998, P NATL ACAD SCI USA, V95, P5678, DOI 10.1073/pnas.95.10.5678; Broomfield S, 2001, MUTAT RES-DNA REPAIR, V486, P167, DOI 10.1016/S0921-8777(01)00091-X; Cejka P, 2001, GENETICS, V159, P953; ELLISON KS, 1991, J BIOL CHEM, V266, P24116; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Haynes R.H., 1981, MOL BIOL YEAST SACCH, P371; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Kim H, 2001, ONCOGENE, V20, P3306, DOI 10.1038/sj.onc.1204423; KOKEN MHM, 1992, GENOMICS, V12, P447, DOI 10.1016/0888-7543(92)90433-S; Koken MHM, 1996, DEV BIOL, V173, P119, DOI 10.1006/dbio.1996.0011; KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865; KUPIEC M, 1984, CURR GENET, V8, P559, DOI 10.1007/BF00395700; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; LAWRENCE CW, 1982, ADV GENET, V21, P173, DOI 10.1016/S0065-2660(08)60299-0; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; LEHMANN AR, 1972, J MOL BIOL, V66, P319, DOI 10.1016/0022-2836(72)90418-4; Lyakhovich A, 2003, MOL CELL BIOL, V23, P2463, DOI 10.1128/MCB.23.7.2463-2475.2003; McDonald JP, 1997, GENETICS, V147, P1557; PRAKASH S, 1990, EUKARYOTIC NUCLEUS, V1, P275; REYNOLDS P, 1985, P NATL ACAD SCI USA, V82, P168, DOI 10.1073/pnas.82.1.168; ROCHE H, 1995, GENETICS, V140, P443; Roest HP, 1996, CELL, V86, P799, DOI 10.1016/S0092-8674(00)80154-3; Shekhar MPV, 2002, CANCER RES, V62, P2115; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SOLOMON MJ, 1985, P NATL ACAD SCI USA, V82, P6470, DOI 10.1073/pnas.82.19.6470; SOULE HD, 1990, CANCER RES, V50, P6075; SUNG P, 1991, J MOL BIOL, V221, P745, DOI 10.1016/0022-2836(91)80169-U; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; Torres-Ramos CA, 2002, MOL CELL BIOL, V22, P2419, DOI 10.1128/MCB.22.7.2419-2426.2002; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Xiao W, 2000, GENETICS, V155, P1633; Xin H, 2000, NUCLEIC ACIDS RES, V28, P2847, DOI 10.1093/nar/28.14.2847	35	37	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3097	3106		10.1038/sj.onc.1207449	http://dx.doi.org/10.1038/sj.onc.1207449			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14981545				2022-12-17	WOS:000220845200014
J	Tambe, Y; Isono, T; Haraguchi, S; Yoshioka-Yamashita, A; Yutsudo, M; Inoue, H				Tambe, Y; Isono, T; Haraguchi, S; Yoshioka-Yamashita, A; Yutsudo, M; Inoue, H			A novel apoptotic pathway induced by the drs tumor suppressor gene	ONCOGENE			English	Article						drs; apoptosis; endoplasmic reticulum caspase-12; ASY/Nogo-B/RTN-x(S)	ENDOPLASMIC-RETICULUM STRESS; MESSENGER-RNA; DOWN-REGULATION; CYTOCHROME-C; CASPASE-12; RECEPTOR; PROTEIN; CELLS; BCL-2; SELECTINS	The drs gene was originally isolated as a suppressor against v-src transformation. Expression of drs mRNA was markedly downregulated in a variety of human cancer cell lines and tissues, suggesting that the drs gene acts as a tumor suppressor. In this study, we found that ectopic expression of the Drs protein induced apoptosis in human cancer cell lines. Analyses using deletion mutants of drs revealed that both the C-terminal region and the three consensus repeats in the N-terminal region are essential for the induction of apoptosis. Caspase-12, -9, and -3 were sequentially activated by drs, and specific inhibitors of caspase-3 and -9 suppressed drs-induced apoptosis. The release of cytochrome c from the mitochondria into the cytoplasm was not observed in apoptosis by drs, suggesting that the mitochondrial pathway does not mediate drs-induced apoptosis. Furthermore, we found that the Drs protein can interact with ASY/Nogo-B/RTN-x(S), an apoptosis-inducing protein localized in the endoplasmic reticulum, and that coexpression of these genes increased the efficiency of apoptosis. These results indicated that Drs induces apoptosis by a novel pathway mediated by ASY/Nogo-B/RTN-x(S), caspase-12, -9, and -3.	Shiga Univ Med Sci, Dept Microbiol, Shiga 5202192, Japan; Shiga Univ Med Sci, Cent Res Lab, Shiga 5202192, Japan; Osaka Univ, Microbial Dis Res Inst, Osaka 5650871, Japan	Shiga University of Medical Science; Shiga University of Medical Science; Osaka University	Inoue, H (corresponding author), Shiga Univ Med Sci, Dept Microbiol, Shiga 5202192, Japan.	hirokazu@belle.shiga-med.ac.jp						Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; Bitko V, 2001, J CELL BIOCHEM, V80, P441, DOI 10.1002/1097-4644(20010301)80:3<441::AID-JCB170>3.0.CO;2-C; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hetz C, 2003, EMBO J, V22, P5435, DOI 10.1093/emboj/cdg537; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Inoue H, 1998, J VIROL, V72, P2532, DOI 10.1128/JVI.72.3.2532-2537.1998; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kim CJ, 2003, HUM PATHOL, V34, P654, DOI 10.1016/S0046-8177(03)00240-5; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li Q, 2001, ONCOGENE, V20, P3929, DOI 10.1038/sj.onc.1204536; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Mukaisho K, 2002, JPN J CANCER RES, V93, P888, DOI 10.1111/j.1349-7006.2002.tb01334.x; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; Oertle T, 2003, ONCOGENE, V22, P1390, DOI 10.1038/sj.onc.1206278; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Pan J, 1996, FEBS LETT, V383, P21; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; Rudner J, 2001, J CELL SCI, V114, P4161; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Shimakage M, 2000, INT J CANCER, V87, P5, DOI 10.1002/1097-0215(20000701)87:1<5::AID-IJC2>3.0.CO;2-Y; Shimakage M, 2002, HUM PATHOL, V33, P615, DOI 10.1053/hupa.2002.125373; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; Tagami S, 2000, ONCOGENE, V19, P5736, DOI 10.1038/sj.onc.1203948; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Yamashita A, 1999, ONCOGENE, V18, P4777, DOI 10.1038/sj.onc.1202852	36	37	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					2977	2987		10.1038/sj.onc.1207419	http://dx.doi.org/10.1038/sj.onc.1207419			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	15021917				2022-12-17	WOS:000220845200001
J	Menez, J; Chansac, BL; Dorothee, G; Vergnon, I; Jalil, A; Carlier, MF; Chouaib, S; Mami-Chouaib, F				Menez, J; Chansac, BL; Dorothee, G; Vergnon, I; Jalil, A; Carlier, MF; Chouaib, S; Mami-Chouaib, F			Mutant alpha-actinin-4 promotes tumorigenicity and regulates cell motility of a human lung carcinoma	ONCOGENE			English	Article						alpha-actinin-4; tumor suppressor gene; cytoskeleton; cell migration; lung carcinoma	HUMAN NEUROBLASTOMA-CELLS; ALPHA-ACTININ; T-LYMPHOCYTES; POINT MUTATION; TUMOR; EXPRESSION; ADHESION; PROTEIN; FIBRONECTIN; INVASION	The precise role of alpha-actinin-4 encoding gene (ACTN4) is not very well understood. It has been reported to elicit tumor suppressor activity and to regulate cellular motility. To further assess the function of human ACTN4, we studied a lung carcinoma cell line expressing a mutated alpha-actinin-4, which is recognized as a tumor antigen by autologous CD8(+) cytotoxic T lymphocytes (CTL). Confocal immunofluorescence microscopy indicated that, while wild-type (WT) alpha-actinin-4 stains into actin cytoskeleton and cell surface ruffles, the mutated protein is only dispersed in the cytoplasm of the lung carcinoma cells. This loss of association with the cell surface did not appear to correlate with a decrease in in vitro alpha-actinin-4 crosslinking to filamentous (F)-actin. Interestingly, experiments using cell lines stably expressing ACTN4 demonstrated that as opposed to WT gene, mutant ACTN4 was unable to inhibit tumor cell growth in vitro and in vivo. Moreover, the expression of mutant alpha-actinin-4 resulted in the loss of tumor cell capacity to migrate. The identification of an inactivating mutation in ACTN4 emphasizes its role as a tumor suppressor gene and underlines the involvement of cytoskeleton alteration in tumor development and metastasis.	Inst Gustave Roussy, INSERM, U487,Inst Federat Rech 54, Lab Cytokines & Immunol Tumeurs Humaines, F-94805 Villejuif, France; CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Mami-Chouaib, F (corresponding author), Inst Gustave Roussy, INSERM, U487,Inst Federat Rech 54, Lab Cytokines & Immunol Tumeurs Humaines, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	cfathia@igr.fr	Chouaib, Salem/F-7939-2016; Mami-Chouaib, Fathia/E-5267-2016; DOROTHEE, Guillaume/O-9760-2016	DOROTHEE, Guillaume/0000-0001-5763-3632; JALIL, Abdelali/0000-0003-2710-8735				Akamatsu H, 1996, CANCER RES, V56, P4541; Araki N, 2000, J CELL SCI, V113, P3329; Asselin-Paturel C, 1998, INT J CANCER, V77, P7, DOI 10.1002/(SICI)1097-0215(19980703)77:1<7::AID-IJC2>3.0.CO;2-Y; Beck-Engeser GB, 2001, J EXP MED, V194, P285, DOI 10.1084/jem.194.3.285; BEGGS AH, 1992, J BIOL CHEM, V267, P9281; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; BENZEEV A, 1994, ADV EXP MED BIOL, V358, P147; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; Bullions LC, 1997, MOL CELL BIOL, V17, P4501, DOI 10.1128/MCB.17.8.4501; BURRIDGE K, 1990, CELL DIFFER DEV, V32, P337, DOI 10.1016/0922-3371(90)90048-2; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; Dorothee G, 2002, J IMMUNOL, V169, P809, DOI 10.4049/jimmunol.169.2.809; Echchakir H, 2001, CANCER RES, V61, P4078; Echchakir H, 2002, P NATL ACAD SCI USA, V99, P9358, DOI 10.1073/pnas.142308199; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; FUJIMORI T, 1993, MOL BIOL CELL, V4, P37, DOI 10.1091/mbc.4.1.37; GEIGER B, 1992, COLD SPRING HARB SYM, V57, P631, DOI 10.1101/SQB.1992.057.01.069; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; GLUCK U, 1994, J CELL SCI, V107, P1773; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Gonzalez AM, 2001, J CELL SCI, V114, P4197; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Hynes RO, 1992, CURR OPIN GENET DEV, V2, P621, DOI 10.1016/S0959-437X(05)80182-0; JANMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111, DOI 10.1016/0955-0674(95)80052-2; Jiang W G, 1995, Eur J Surg Oncol, V21, P307, DOI 10.1016/S0748-7983(95)91690-3; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kos CH, 2003, J CLIN INVEST, V111, P1683, DOI 10.1172/JCI200317988; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Nikolopoulos SN, 2000, ONCOGENE, V19, P380, DOI 10.1038/sj.onc.1203310; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; Spengler BA, 1997, ONCOL RES, V9, P467; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X; Wang HY, 2002, J EXP MED, V195, P1397, DOI 10.1084/jem.20020141; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	46	37	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2630	2639		10.1038/sj.onc.1207347	http://dx.doi.org/10.1038/sj.onc.1207347			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15048094				2022-12-17	WOS:000220714900004
J	Hasskarl, J; Duensing, S; Manuel, E; Munger, K				Hasskarl, J; Duensing, S; Manuel, E; Munger, K			The helix-loop-helix protein ID1 localizes to centrosomes and rapidly induces abnormal centrosome numbers	ONCOGENE			English	Article						centrosomes; ID1 protein; genomic instability; cancer	SENESCENT HUMAN FIBROBLASTS; SQUAMOUS-CELL CARCINOMA; MAMMALIAN-CELLS; DNA-BINDING; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; GENOMIC INSTABILITY; PANCREATIC-CANCER; G(1) PROGRESSION; BREAST-CANCER	ID1 is a member of the inhibitor of DNA binding/differentiation ( ID) family of dominant negative helix loop-helix transcription factors. ID-proteins have been implicated in the control of differentiation and transcriptional modulation of various cell cycle regulators and high levels of ID1 expression are frequently detected in various cancer types. However, it is unclear whether ID1 is a marker of highly proliferative cancer cells or whether it directly contributes to the tumor phenotype. A detailed analysis of ID1-expressing human cells revealed that a fraction of ID1 localizes to centrosomes. Ectopic expression of ID1 in primary cells and tumor cell lines resulted in accumulation of cells with abnormal centrosome numbers. There was no evidence for centrosomal localization or induction of centrosome abnormalities by the other ID family members. Hence, ID1 may contribute to oncogenesis not only by inhibiting transcriptional activity of basic helix-loop-helix transcription factors and abrogate differentiation but also by subverting centrosome duplication.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 77 Ave Louis Pasteur,NRB 958C, Boston, MA 02115 USA.	karl_munger@hms.harvard.edu	Hasskarl, Jens/E-8980-2011	Manuel, Edwin/0000-0002-4602-7060; Munger, Karl/0000-0003-3288-9935	NCI NIH HHS [R01 CA66980] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066980] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Andres-Barquin PJ, 1999, EXP CELL RES, V247, P347, DOI 10.1006/excr.1998.4360; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGS JR, 1995, J CELL PHYSIOL, V164, P249, DOI 10.1002/jcp.1041640205; Bounpheng MA, 1999, FASEB J, V13, P2257, DOI 10.1096/fasebj.13.15.2257; BOVERI T, 1914, FRAGEENTSTEHUNG MALI; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; D'Assoro AB, 2001, MARC MALPIG SYMP SER, V7, P103; De Souza CPC, 2000, EXP CELL RES, V257, P11, DOI 10.1006/excr.2000.4872; DEED RW, 1993, ONCOGENE, V8, P599; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; Doxsey SJ, 2001, NAT CELL BIOL, V3, pE105, DOI 10.1038/35074618; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2001, CANCER RES, V61, P2356; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hara E, 1996, DEV GENET, V18, P161; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; HARA E, 1994, J BIOL CHEM, V269, P2139; Hasskarl J, 2000, J MOL MED-JMM, V78, P94, DOI 10.1007/s001090000083; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hu YC, 2001, CLIN CANCER RES, V7, P2213; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Kebebew E, 2000, SURGERY, V128, P952, DOI 10.1067/msy.2000.111082; Kleeff J, 1998, CANCER RES, V58, P3769; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Langlands K, 2000, CANCER RES, V60, P5929; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Lauricella M, 2001, FEBS LETT, V499, P191, DOI 10.1016/S0014-5793(01)02553-4; Lin CQ, 2000, CANCER RES, V60, P1332; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Maruyama H, 1999, AM J PATHOL, V155, P815, DOI 10.1016/S0002-9440(10)65180-2; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Matsumura ME, 2002, J BIOL CHEM, V277, P7293, DOI 10.1074/jbc.M108986200; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Meraldi P, 2002, FEBS LETT, V521, P9, DOI 10.1016/S0014-5793(02)02865-X; Mueller C, 2002, CIRCULATION, V105, P2423, DOI 10.1161/01.CIR.0000016047.19488.91; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Nehlin JO, 1997, BIOCHEM BIOPH RES CO, V231, P628, DOI 10.1006/bbrc.1997.6152; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Pagliuca A, 2000, CANCER RES, V60, P1376; Paoletti A, 1996, J CELL SCI, V109, P3089; PESCE S, 1993, MOL CELL BIOL, V13, P7874, DOI 10.1128/MCB.13.12.7874; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Piboonniyom SO, 2003, CANCER RES, V63, P476; Polsky D, 2001, CANCER RES, V61, P6008; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; Schindl M, 2003, CLIN CANCER RES, V9, P779; Schindl M, 2001, CANCER RES, V61, P5703; Schoppmann SF, 2003, INT J CANCER, V104, P677, DOI 10.1002/ijc.11009; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Takai N, 2001, CANCER LETT, V165, P185, DOI 10.1016/S0304-3835(01)00433-5; Tanaka K, 1998, J BIOL CHEM, V273, P25922, DOI 10.1074/jbc.273.40.25922; Tang J, 2002, LAB INVEST, V82, P1073, DOI 10.1097/01.LAB.0000022223.65962.3A; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	72	37	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1930	1938		10.1038/sj.onc.1207310	http://dx.doi.org/10.1038/sj.onc.1207310			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14755252				2022-12-17	WOS:000220129500015
J	Abal, M; Bras-Goncalves, R; Judde, JG; Fsihi, H; de Cremoux, P; Louvard, D; Magdelenat, H; Robine, S; Poupon, MF				Abal, M; Bras-Goncalves, R; Judde, JG; Fsihi, H; de Cremoux, P; Louvard, D; Magdelenat, H; Robine, S; Poupon, MF			Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line	ONCOGENE			English	Article						colorectal cancer; irinotecan; p53-dependent sensitivity; cdk-inh1; CYC-202; Roscovitine	COLORECTAL-CANCER; TOPOISOMERASE-I; CARCINOMA CELLS; MICROSATELLITE INSTABILITY; DIFFERENT P53; DNA-DAMAGE; CAMPTOTHECIN; APOPTOSIS; CYTOTOXICITY; XENOGRAFTS	Mutations in the tumor-suppressor gene p53 have been associated with advanced colorectal cancer (CRC). Irinotecan (CPT-11), a DNA topoisomerase 1 inhibitor, has been recently incorporated to the adjuvant therapy. Since the DNA-damage checkpoint depends on p53 activation, the status of p53 might critically influence the response to CPT-11. We analysed the sensitivity to CPT-11 in the human colon cancer cell line HT29 (mut p53) and its wild-type (wt)-p53 stably transfected subclone HT29-A4. Cell-cycle analysis in synchronised cells demonstrated the activation of transfected wt-p53 and a p21(WAF1/CIP1)-dependent cell-cycle blockage in the S phase. Activated wt-p53 increased apoptosis and enhanced sensitivity to CPT-11. In p53-deficient cells, cDNA-macroarray analysis and western blotting showed an accumulation of the cyclin-dependent kinase (cdk) 1/cyclin B complex. Subsequent p53-independent activation of the cdk-inhibitor (cdk-I) p21(WAF1/CIP1) prevented cell-cycle progression. Cdk1 induction was exploited in vivo to improve the sensitivity to CPT-11 by additional treatment with the cdk-I CYC-202. We demonstrate a gain of sensitivity to CPT-11 in a p53-mutated colon cancer model either by restoring wild-type p53 function or by sequential treatment with cdk-Is. Considering that mutations in p53 are among the most common genetic alterations in CRC, a therapeutic approach specifically targeting p53-deficient tumors could greatly improve the treatment outcomes.	Inst Curie, UMR 147, CNRS, F-75248 Paris, France; Inst Curie, Transfer Lab, CNRS, F-75248 Paris, France; Inst Curie, UMR 144, CNRS, F-75248 Paris, France; Inst Curie, Dept Tumor Biol, CNRS, Med Sect, F-75248 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite	Poupon, MF (corresponding author), Inst Curie, UMR 147, CNRS, Rue Ulm, F-75248 Paris, France.	Marie-France.Poupon@curie.fr	FSIHI, Hafida/H-9852-2014	Abal Posada, Miguel/0000-0003-3533-7781				Arends JW, 2000, J PATHOL, V190, P412; Blagosklonny MV, 1998, INT J CANCER, V75, P933, DOI 10.1002/(SICI)1097-0215(19980316)75:6<933::AID-IJC17>3.0.CO;2-3; Bras-Goncalves RA, 2001, GASTROENTEROLOGY, V120, P874, DOI 10.1053/gast.2001.22440; Bras-Goncalves RA, 2000, BRIT J CANCER, V82, P913, DOI 10.1054/bjoc.1999.1019; Chauvier D, 2002, INT J ONCOL, V20, P855; de Cremoux P, 1999, J NATL CANCER I, V91, P641, DOI 10.1093/jnci/91.7.641; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fishman A D, 2001, Clin Colorectal Cancer, V1, P20, DOI 10.3816/CCC.2001.n.002; Gryfe R, 1997, CURR PROB CANCER, V21, P238, DOI 10.1016/S0147-0272(97)80003-7; Gupta M, 1997, CLIN CANCER RES, V3, P1653; Janssen KP, 2002, GASTROENTEROLOGY, V123, P492, DOI 10.1053/gast.2002.34786; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; KJELDSEN E, 1992, J MOL BIOL, V228, P1025, DOI 10.1016/0022-2836(92)90310-G; Lansiaux A, 2001, ANTICANCER RES, V21, P471; Liu WM, 1998, INT J ONCOL, V12, P793; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Magrini R, 2002, INT J CANCER, V101, P23, DOI 10.1002/ijc.10565; McClue SJ, 2002, INT J CANCER, V102, P463, DOI 10.1002/ijc.10738; Motwani M, 2001, CLIN CANCER RES, V7, P4209; Oren M, 2002, BIOCHEM PHARMACOL, V64, P865, DOI 10.1016/S0006-2952(02)01149-8; Pocard M, 1996, ONCOGENE, V12, P875; Rougier P, 2001, Clin Colorectal Cancer, V1, P87, DOI 10.3816/CCC.2001.n.008; Shao RG, 1997, CANCER RES, V57, P4029; Shao RG, 2001, ONCOGENE, V20, P1852, DOI 10.1038/sj.onc.1204264; SHIMIZU T, 1995, CANCER RES, V55, P228; Smith G, 2002, P NATL ACAD SCI USA, V99, P9433, DOI 10.1073/pnas.122612899; Sobrero A, 2000, EUR J CANCER, V36, P559, DOI 10.1016/S0959-8049(99)00314-7; TANIZAWA A, 1994, J NATL CANCER I, V86, P836, DOI 10.1093/jnci/86.11.836; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vanhoefer U, 2001, J CLIN ONCOL, V19, P1501, DOI 10.1200/JCO.2001.19.5.1501; Whitacre CM, 1999, CLIN CANCER RES, V5, P665; Xie XJ, 2000, CANCER CHEMOTH PHARM, V45, P362, DOI 10.1007/s002800051003	32	37	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1737	1744		10.1038/sj.onc.1207299	http://dx.doi.org/10.1038/sj.onc.1207299			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	15001986				2022-12-17	WOS:000220029300009
J	Dirsch, VM; Kirschke, SO; Estermeier, M; Steffan, B; Vollmar, AM				Dirsch, VM; Kirschke, SO; Estermeier, M; Steffan, B; Vollmar, AM			Apoptosis signaling triggered by the marine alkaloid ascididemin is routed via caspase-2 and JNK to mitochondria	ONCOGENE			English	Article						apoptosis; ascididemin; caspase-2; mitochondria	CYTOCHROME-C RELEASE; HUMAN PROMYELOLEUKEMIC CELLS; DEATH; ACTIVATION; PROTEIN; DNA; INHIBITION; GENERATION; INDUCTION; THYMOCYTE	The marine alkaloid ascididemin (ASC) was shown to exert cytotoxicity even against multidrug-resistant cancer cells. Here, we address the signaling pathways utilized by ASC to trigger apoptosis in Jurkat leukemia T cells. We show that ASC (0.5-20 muM) induces a mitochondrial pathway that requires the activation of the initiator caspase-2 upstream of mitochondria. ASC-triggered apoptosis occurred independent of CD95, but required mitochondrial dysfunction. The activation of caspase-2 was shown to precede the processing of caspase-8, -9 and -3. The specific caspase-2 inhibitor zVDVADfmk abrogated ASC-induced DNA fragmentation almost completely. Overexpression of Bcl-x(L) blocked caspase-8 but not caspase-2 processing. Conversely, caspase-2 inhibition strongly reduced caspase-9 activation. As a possible link between caspase-2 and mitochondrial dysfunction, Bid was found to be cleaved by ASC. In addition, JNK was activated by ASC upstream of mitochondria via reactive oxygen species. The specific JNK inhibitor SP600125 partially inhibited caspase-2 and -9 processing as well as cytochrome c release and DNA fragmentation indicating that JNK contributes to, but is not necessary for ASC-mediated apoptosis. Thus, ASC triggers a pathway in which early activation of caspase-2 provides a possible link between its DNA-damaging activity and the induction of mitochondrial dysfunction. The activation of JNK contributes to this signaling upstream of mitochondria.	Univ Munich, Ctr Drug Res, Dept Pharm, D-81377 Munich, Germany; Univ Munich, Dept Chem, D-81377 Munich, Germany	University of Munich; University of Munich	Dirsch, VM (corresponding author), Univ Munich, Ctr Drug Res, Dept Pharm, Butenandstr 5-13, D-81377 Munich, Germany.	Verena.Dirsch@cup.uni-muenchen.de		Dirsch, Verena/0000-0002-9261-5293				Antlsperger DSM, 2003, ONCOGENE, V22, P582, DOI 10.1038/sj.onc.1206161; Barr RK, 2001, INT J BIOCHEM CELL B, V33, P1047, DOI 10.1016/S1357-2725(01)00093-0; Beck WT, 2001, BIOCHEM SOC T, V29, P702, DOI 10.1042/0300-5127:0290702; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BONNARD I, 1995, ANTI-CANCER DRUG DES, V10, P333; BRACHER F, 1993, J HETEROCYCLIC CHEM, V30, P157, DOI 10.1002/jhet.5570300128; Bratton SB, 2001, TRENDS PHARMACOL SCI, V22, P306, DOI 10.1016/S0165-6147(00)01718-1; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Dassonneville L, 2000, BIOCHEM PHARMACOL, V60, P527, DOI 10.1016/S0006-2952(00)00351-8; Dirsch VM, 2001, CANCER RES, V61, P5817; Dirsch VM, 1998, MOL PHARMACOL, V53, P402, DOI 10.1124/mol.53.3.402; Droin N, 2001, BLOOD, V97, P1835, DOI 10.1182/blood.V97.6.1835; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; KOBAYASHI J, 1988, TETRAHEDRON LETT, V29, P1177, DOI 10.1016/S0040-4039(00)86681-2; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Leist M, 1998, MOL PHARMACOL, V54, P789, DOI 10.1124/mol.54.5.789; LINDSAY BS, 1995, BIOORG MED CHEM LETT, V5, P739, DOI 10.1016/0960-894X(95)00106-4; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsumoto SS, 2003, CHEM RES TOXICOL, V16, P113, DOI 10.1021/tx025618w; Mendelsohn AR, 2002, P NATL ACAD SCI USA, V99, P6871, DOI 10.1073/pnas.072290599; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Shearwin-Whyatt LM, 2000, CELL DEATH DIFFER, V7, P155, DOI 10.1038/sj.cdd.4400632; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Stefanis L, 1998, J NEUROSCI, V18, P9204; Walczak H, 2000, CANCER RES, V60, P3051; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	38	37	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1586	1593		10.1038/sj.onc.1207281	http://dx.doi.org/10.1038/sj.onc.1207281			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14716300				2022-12-17	WOS:000189219500012
J	Morimoto, AM; Tan, N; West, K; McArthur, G; Toner, GC; Manning, WC; Smolich, BD; Cherrington, JM				Morimoto, AM; Tan, N; West, K; McArthur, G; Toner, GC; Manning, WC; Smolich, BD; Cherrington, JM			Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor	ONCOGENE			English	Article						SU11248; biomarker; in vivo; microarray; immunohistochemistry	GROWTH-FACTOR RECEPTOR; BREAST-CANCER; MOLECULAR CLASSIFICATION; IN-VIVO; IDENTIFICATION; CADHERIN-11; MICROARRAY; CARCINOMA; APOPTOSIS; PROTEIN	Biomarkers that indicate biological activity and/or efficacy are a potentially useful tool in the development of molecularly targeted therapeutics. It is useful, though challenging, to identify biomarkers during preclinical development in order to impact decision-making during early clinical development. SU11248 is an oral, selective multitargeted tyrosine kinase inhibitor currently in Phase II oncology clinical trials. It exhibits direct antitumor and antiangiogenic activity via inhibition of the receptor tyrosine kinases PDGFR, VEGFR, KIT and FLT3. To identify clinically translatable biomarkers of SU11248 activity, expression pro. ling was performed on Colo205 human xenograft tumors following treatment with SU11248. Over 100 transcripts changed in abundance in SU11248 as compared to vehicle-treated tumors. Nine candidate transcripts, chosen based on putative function, were also analysed and validated by TaqMan. One such potential biomarker, cadherin-11, was further evaluated at the protein level and was found to have increased expression in xenograft tumors after SU11248 treatment. Interestingly, cadherin-11 expression was also detected via immunohistochemical analysis of archived solid tumors, indicating the technical feasibility of translating this putative biomarker to clinical studies. Importantly, SU11248 treatment also resulted in increased expression of cadherin-11 protein in human tumor biopsies in three out of seven patients examined and confirms the feasibility of using transcriptional pro. ling of preclinical models to identify clinically translatable biomarkers.	SUGEN Inc, Dept Preclin Res & Exploratory Dev, San Francisco, CA 94080 USA; Peter MacCallum Canc Inst, Melbourne, Vic 3002, Australia	Pfizer; Peter Maccallum Cancer Center	Morimoto, AM (corresponding author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	morimoto@gene.com	Toner, Guy C/G-1738-2011	Toner, Guy/0000-0001-9873-3592				Adjei AA, 2000, CANCER RES, V60, P1871; Albanell J, 2002, J CLIN ONCOL, V20, P110, DOI 10.1200/JCO.20.1.110; Bae SK, 1998, CANCER LETT, V126, P97, DOI 10.1016/S0304-3835(97)00538-7; Bertucci F, 2002, ANN NY ACAD SCI, V975, P217, DOI 10.1111/j.1749-6632.2002.tb05954.x; Brockstedt E, 1999, J PROTEIN CHEM, V18, P225, DOI 10.1023/A:1020636308270; Cheadle C, 2003, J MOL DIAGN, V5, P73, DOI 10.1016/S1525-1578(10)60455-2; Clarke PA, 2000, ONCOGENE, V19, P4125, DOI 10.1038/sj.onc.1203753; DePrimo SE, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-3; DeRisi J, 1996, NAT GENET, V14, P457; Devilard E, 2002, ONCOGENE, V21, P3095, DOI 10.1038/sj.onc.1205418; Druker BJ, 2002, TRENDS MOL MED, V8, pS14, DOI 10.1016/S1471-4914(02)02305-5; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Feltes CM, 2002, CANCER RES, V62, P6688; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Fleming JA, 2002, P NATL ACAD SCI USA, V99, P1461, DOI 10.1073/pnas.032516399; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Glaser KB, 2003, MOL CANCER THER, V2, P151; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gupta S, 2002, FEBS LETT, V532, P61, DOI 10.1016/S0014-5793(02)03628-1; He LZ, 2001, J CLIN INVEST, V108, P1321, DOI 10.1172/JCI200111537; Hedenfalk I, 2003, P NATL ACAD SCI USA, V100, P2532, DOI 10.1073/pnas.0533805100; Herbst RS, 2002, EXPERT OPIN INV DRUG, V11, P837, DOI 10.1517/13543784.11.6.837; Kashima T, 2003, INT J CANCER, V104, P147, DOI 10.1002/ijc.10931; Kawaguchi J, 1999, J BONE MINER RES, V14, P764, DOI 10.1359/jbmr.1999.14.5.764; Koong AC, 2000, CANCER RES, V60, P883; Laird AD, 2002, FASEB J, V16, DOI 10.1096/fj.01-0700com; Lecanda F, 2000, J CELL BIOCHEM, V77, P499, DOI 10.1002/(SICI)1097-4644(20000601)77:3<499::AID-JCB14>3.0.CO;2-0; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Mendel DB, 2003, CLIN CANCER RES, V9, P327; Nutt CL, 2003, CANCER RES, V63, P1602; OFARRELL AM, 2003, IN PRESS CLIN CAN RE; OKAZAKI M, 1994, J BIOL CHEM, V269, P12092; Potapova O, 2002, EUR J CANCER, V38, pS61; RAGIONE FD, 2001, FEBS LETT, V499, P199; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schueneman AJ, 2003, CANCER RES, V63, P4009; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Shibata T, 1996, CANCER LETT, V99, P147, DOI 10.1016/0304-3835(95)04047-1; Shimono R, 2000, ANTICANCER RES, V20, P917; Slamon D, 2001, SEMIN ONCOL, V28, P13, DOI 10.1053/sonc.2001.22812; Sonna LA, 2003, PHYSIOL GENOMICS, V12, P195, DOI 10.1152/physiolgenomics.00104.2002; SUNDBERG C, 1993, AM J PATHOL, V143, P1377; Tomita K, 2000, CANCER RES, V60, P3650; TONER GC, 2003, P AN M AM SOC CLIN, V22, P234; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; VanLint C, 1996, GENE EXPRESSION, V5, P245; Zembutsu H, 2003, INT J ONCOL, V23, P29; Zhou RX, 2000, DIFFERENTIATION, V66, P165, DOI 10.1046/j.1432-0436.2000.660402.x	50	37	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1618	1626		10.1038/sj.onc.1207268	http://dx.doi.org/10.1038/sj.onc.1207268			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14985702				2022-12-17	WOS:000189219500016
J	Kusam, S; Vasanwala, FH; Dent, AL				Kusam, S; Vasanwala, FH; Dent, AL			Transcriptional repressor BCL-6 immortalizes germinal center-like B cells in the absence of p53 function	ONCOGENE			English	Article						B-cell lymphoma; BCL-6; germinal center; CD40; p53	LYMPHOMA; EXPRESSION; GENE; DIFFERENTIATION; APOPTOSIS; ABERRATIONS; SURVIVAL; BLIMP-1	Chromosomal rearrangements in non-Hodgkin's B-cell lymphoma implicate BCL-6 as an oncogene, yet direct evidence for BCL-6 acting as an oncogene in B cells has been lacking. Here, we show that BCL-6 can immortalize primary B cells, but only in the absence of p53 tumor suppressor function. The expression of BCL-6 led to greatly increased B-cell proliferation, particularly in response to CD40 stimulation. Furthermore, BCL-6-infected p53-deficient B cells gave rise to immortalized cell lines that could be maintained by CD40 stimulation. We found that in primary mouse B cells, BCL-6 repressed expression of the Blimp-1, p27kip1, and cyclin D2 target genes. BCL-6 did not markedly repress the PDCD2 and BCL-XL target genes. The BCL-6 immortalized cell lines had a phenotype consistent with germinal center B cells, they expressed the germinal center-specific M17 gene, and a significant fraction of the cells stained positive with PNA. Our data indicate that BCL-6 may act to maintain B cells in a germinal center-like state, and repression of Blimp-1 by BCL-6 may be particularly crucial for stabilization of the germinal center phenotype. Our data also suggest that disruption of the p53 pathway may be crucial for the development of BCL-6- expressing B-cell lymphomas.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46208 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Dent, AL (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, 1044 W Walnut St,R4 302, Indianapolis, IN 46202 USA.	adent2@iupui.edu						Akasaka T, 2000, J CLIN ONCOL, V18, P510, DOI 10.1200/JCO.2000.18.3.510; Albagli-Curiel O, 2003, ONCOGENE, V22, P507, DOI 10.1038/sj.onc.1206152; Baron BW, 2002, P NATL ACAD SCI USA, V99, P2860, DOI 10.1073/pnas.042702599; Bellido M, 2002, HAEMATOLOGICA, V87, P908; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Cervenak L, 2001, IMMUNOL LETT, V78, P89, DOI 10.1016/S0165-2478(01)00239-5; CHRISTOPH T, 1994, INT IMMUNOL, V6, P1203, DOI 10.1093/intimm/6.8.1203; DALLAFAVERA R, 1994, ANN ONCOL, V5, pS55, DOI 10.1093/annonc/5.suppl_1.S55; Dent AL, 2002, CRIT REV ONCOL HEMAT, V41, P1, DOI 10.1016/S1040-8428(01)00164-0; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fanzo JC, 2003, J EXP MED, V197, P303, DOI 10.1084/jem.20020717; Gupta S, 1999, J EXP MED, V190, P1837, DOI 10.1084/jem.190.12.1837; HATZ P, 1994, J BIOL CHEM, V269, P16802; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; Lossos IS, 2001, BLOOD, V98, P945, DOI 10.1182/blood.V98.4.945; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; Messika EJ, 1998, J EXP MED, V188, P515, DOI 10.1084/jem.188.3.515; Moller MB, 1999, LEUKEMIA, V13, P453, DOI 10.1038/sj.leu.2401315; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Reljic R, 2000, J EXP MED, V192, P1841, DOI 10.1084/jem.192.12.1841; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shvarts A, 2002, GENE DEV, V16, P681, DOI 10.1101/gad.929302; Starostik P, 2000, BLOOD, V95, P1180, DOI 10.1182/blood.V95.4.1180.004k14_1180_1187; Staudt L M, 1999, Int Rev Immunol, V18, P381, DOI 10.3109/08830189909088490; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Toney LM, 2000, NAT IMMUNOL, V1, P214, DOI 10.1038/79749; Volpe G, 1996, GENE CHROMOSOME CANC, V16, P21, DOI 10.1002/(SICI)1098-2264(199605)16:1<21::AID-GCC3>3.0.CO;2-5; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; Yu DN, 2002, ONCOGENE, V21, P1922, DOI 10.1038/sj.onc.1205244	29	37	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					839	844		10.1038/sj.onc.1207065	http://dx.doi.org/10.1038/sj.onc.1207065			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737119	Bronze			2022-12-17	WOS:000188304900023
J	Miyagawa, S; Katsu, Y; Watanabe, H; Iguchi, T				Miyagawa, S; Katsu, Y; Watanabe, H; Iguchi, T			Estrogen-independent activation of erbBs signaling and estrogen receptor alpha in the mouse vagina exposed neonatally to diethylstilbestrol	ONCOGENE			English	Article						mouse; diethylstilbestrol; vagina; erbBs signaling; estrogen receptor	AUTOCRINE GROWTH-FACTOR; GENITAL-TRACT; CROSS-TALK; IN-VITRO; MOLECULAR-MECHANISM; EPITHELIAL-CELLS; AMPHIREGULIN; REQUIREMENT; EXPRESSION; TAMOXIFEN	Growth factors and estrogen receptor (ER) signaling cooperate to play essential roles in cell proliferation, differentiation and tumor progression in mouse reproductive organs. Treatment of neonatal mice with diethylstilbestrol (DES) induces an estrogen-independent persistent proliferation and cornification of the vaginal epithelium, which results in cancerous lesions later in life. However, the mechanisms of the estrogen-dependent and -independent pathways essentially remain unknown. We characterized the expression of epidermal growth factor (EGF)-like growth factors (EGF, transforming growth factor alpha (TGF-alpha), heparin-binding EGF-like growth factor (HB-EGF), betacellulin (BTC), amphiregulin (APR), epiregulin (EPR) and neuregulin (NRG) 1) and erbB receptors (EGF receptor (EGFR), erbB/neu, erbB3 and erbB4) in the vaginae of mice treated either neonatally (0-4 day) or as adults (55-59 day) with estrogens. EGFR and erbB2 were activated in the vaginal epithelium of mice by estrogen treatment. This activation was also encountered in vaginae from neonatally DES-exposed mice, along with the expression of EGF, TGF-alpha, HB-EGF, BTC, APR, EPR and NRG1. Immunohistochemical analysis indicated that erbB2 was primarily expressed in vaginal epithelium. Finally, we found that serine 118 and 167 located in the AF-1 domain of ERalpha were phosphorylated in these vaginae. AG825, AG1478 or ICI 182,780 administration blocked proliferation of vaginal epithelium induced by neonatal DES exposure. Thus, signal transduction via EGFR and erbB2 could be related to the estrogen-induced vaginal changes and persistent erbBs phosphorylation and sustained expression of EGF-like growth factors, leading to ERalpha activation that may result in cancerous lesions in vaginae from neonatally DES-exposed mice later in life.	Okazaki Natl Res Inst, Ctr Integrat Biosci, Aichi 4448585, Japan; Grad Univ Adv Studies, Sch Life Sci, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan	National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Graduate University for Advanced Studies - Japan; Japan Science & Technology Agency (JST)	Iguchi, T (corresponding author), Okazaki Natl Res Inst, Ctr Integrat Biosci, 5-1 Higashiyama, Aichi 4448585, Japan.	taisen@nibb.ac.jp	WATANABE, Hajime/AAJ-8904-2021; Katsu, Yoshinao/F-9122-2012; Iguchi, Taisen/AAL-4225-2021; Watanabe, Hajime/S-8957-2019	Katsu, Yoshinao/0000-0003-2625-4626; Watanabe, Hajime/0000-0001-9657-6554				Atanaskova N, 2002, ONCOGENE, V21, P4000, DOI 10.1038/sj.onc.1205506; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Buckanan DL, 1998, ENDOCRINOLOGY, V139, P4345, DOI 10.1210/en.139.10.4345; CUNHA GR, 1977, DEV BIOL, V56, P52, DOI 10.1016/0012-1606(77)90154-3; Curtis SW, 1996, P NATL ACAD SCI USA, V93, P12626, DOI 10.1073/pnas.93.22.12626; DAS SK, 1995, MOL ENDOCRINOL, V9, P691, DOI 10.1210/me.9.6.691; DIAUGUSTINE RP, 1988, ENDOCRINOLOGY, V122, P2355, DOI 10.1210/endo-122-6-2355; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; DUNN TB, 1963, J NATL CANCER I, V31, P425; Falck L, 1996, ANAT REC, V245, P459; Forsberg J G, 1979, Natl Cancer Inst Monogr, P41; HASHIMOTO K, 1994, J BIOL CHEM, V269, P20060; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Herbst AL, 2000, GYNECOL ONCOL, V76, P147, DOI 10.1006/gyno.1999.5471; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; IGUCHI T, 1993, P SOC EXP BIOL MED, V204, P110, DOI 10.3181/00379727-204-43642; IGUCHI T, 1986, ACTA ANAT, V127, P110; IGUCHI T, 1992, INT REV CYTOL, V139, P1, DOI 10.1016/S0074-7696(08)61409-6; IGUCHI T, 1983, P NATL ACAD SCI-BIOL, V80, P3743, DOI 10.1073/pnas.80.12.3743; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; Kato S, 1998, ONCOLOGY-BASEL, V55, P5, DOI 10.1159/000055253; Kato S, 2000, GENES CELLS, V5, P593, DOI 10.1046/j.1365-2443.2000.00354.x; Klotz DM, 2002, J BIOL CHEM, V277, P8531, DOI 10.1074/jbc.M109592200; Klotz DM, 2000, ENDOCRINOLOGY, V141, P3430, DOI 10.1210/en.141.9.3430; Kurokawa H, 2000, CANCER RES, V60, P5887; Lahooti H, 1995, J STEROID BIOCHEM, V55, P305, DOI 10.1016/0960-0760(95)00188-3; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; MARSELOS M, 1992, EUR J CANCER, V28A, P1182, DOI 10.1016/0959-8049(92)90482-H; MARSELOS M, 1993, EUR J CANCER, V29A, P149, DOI 10.1016/0959-8049(93)90597-9; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MCLACHLAN JA, 1980, CANCER RES, V40, P3988; McLachlan JA, 2001, ENDOCR REV, V22, P319, DOI 10.1210/er.22.3.319; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; NELSON KG, 1992, ENDOCRINOLOGY, V131, P1657, DOI 10.1210/en.131.4.1657; NELSON KG, 1994, CELL GROWTH DIFFER, V5, P595; NELSON KG, 1991, P NATL ACAD SCI USA, V88, P21, DOI 10.1073/pnas.88.1.21; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; PASTAN I, 1983, TRENDS BIOCHEM SCI, V8, P250, DOI 10.1016/0968-0004(83)90351-1; PIEPKORN M, 1994, J CELL PHYSIOL, V159, P114, DOI 10.1002/jcp.1041590115; Sato T, 1996, ANAT REC, V244, P374; Sato T, 2003, REPROD TOXICOL, V17, P289, DOI 10.1016/S0890-6238(03)00011-X; SATO T, 1996, P 10 INT C END SAN F, P1; TAKASUGI N, 1962, SCIENCE, V138, P438, DOI 10.1126/science.138.3538.438; TAKASUGI N, 1976, INT REV CYTOL, V44, P193, DOI 10.1016/S0074-7696(08)61650-2; TSAI PS, 1991, IN VITRO CELL DEV B, V27, P461; Yee D, 2000, J MAMMARY GLAND BIOL, V5, P107, DOI 10.1023/A:1009575518338	47	37	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					340	349		10.1038/sj.onc.1207207	http://dx.doi.org/10.1038/sj.onc.1207207			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14647453				2022-12-17	WOS:000188098300003
J	Obungu, VH; Burns, AL; Agarwal, SK; Chandrasekharapa, SC; Adelstein, RS; Marx, SJ				Obungu, VH; Burns, AL; Agarwal, SK; Chandrasekharapa, SC; Adelstein, RS; Marx, SJ			Menin, a tumor suppressor, associates with nonmuscle myosin II-A heavy chain	ONCOGENE			English	Article						MEN1; menin; TAP; nonmuscle myosin; cytokinesis	ENDOCRINE NEOPLASIA TYPE-1; MOLD PHYSARUM-POLYCEPHALUM; MESSENGER-RNAS; NONHISTONE PROTEINS; NUCLEAR-ENVELOPE; GENE-PRODUCT; EXPRESSION; INTERACTS; DROSOPHILA; MORPHOGENESIS	MEN1 is a likely tumor suppressor gene that encodes a novel protein, menin. Menin is a 610 amino-acid residue protein with as yet unknown function(s). We have used tandem affinity purification and mass spectroscopy to isolate and identify proteins associating with menin from cultured HeLa cell extracts. This strategy has resulted in the isolation and identification of nonmuscle myosin type II-A heavy chain (NMHC II-A) as a menin interacting protein. This interaction was confirmed by glutathione-S-transferase pulldown assays, by coimmunoprecipitation, and by actin selection of myosin. We have further identified the amino-terminal region of menin and the head domain of NMHC II-A to be regions required for this interaction. Moreover menin was seen to colocalize with this myosin isoform in the cleavage furrow of dividing cells by indirect immunofluoresence. These data indicate that menin through binding to NMHC II-A could participate in cell division and in other processes that involve NMHC II-A.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Obungu, VH (corresponding author), Eli Lilly & Co, Lilly Res Lab, Lilly Corp Ctr, DC 1505, Indianapolis, IN 46285 USA.	Obunguvi@lilly.com	Agarwal, Sunita K/D-1428-2016	Agarwal, Sunita K/0000-0002-7557-3191; Adelstein, Robert/0000-0002-8683-2144	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004218, Z01HL004218] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABMAYR SM, 1992, SHORT PROTOCOLS MOL; Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; Agarwal SK, 1997, HUM MOL GENET, V6, P1169, DOI 10.1093/hmg/6.7.1169; BERRIOS M, 1986, J CELL BIOL, V103, P711, DOI 10.1083/jcb.103.3.711; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUVAS AS, 1975, P NATL ACAD SCI USA, V72, P3902, DOI 10.1073/pnas.72.10.3902; Dreger M, 2001, P NATL ACAD SCI USA, V98, P11943, DOI 10.1073/pnas.211201898; Guo SS, 2001, MOL ENDOCRINOL, V15, P1653, DOI 10.1210/me.15.10.1653; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Harden N, 2002, DIFFERENTIATION, V70, P181, DOI 10.1046/j.1432-0436.2002.700408.x; Heath KE, 2001, AM J HUM GENET, V69, P1033, DOI 10.1086/324267; Heppner C, 1997, NAT GENET, V16, P375, DOI 10.1038/ng0897-375; Heppner C, 2001, ONCOGENE, V20, P4917, DOI 10.1038/sj.onc.1204529; Huang SC, 1999, LAB INVEST, V79, P301; JOCKUSCH BM, 1971, J BACTERIOL, V108, P705, DOI 10.1128/JB.108.2.705-714.1971; JOCKUSCH BM, 1970, J BACTERIOL, V103, P356, DOI 10.1128/JB.103.2.356-363.1970; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; Kelley MJ, 2000, NAT GENET, V26, P106, DOI 10.1038/79069; KIEHART DP, 1990, CELL, V60, P347, DOI 10.1016/0092-8674(90)90583-Z; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; Lemmens IH, 2001, BIOCHEM BIOPH RES CO, V286, P426, DOI 10.1006/bbrc.2001.5405; LESTOURGEON WM, 1975, BIOCHIM BIOPHYS ACTA, V379, P529, DOI 10.1016/0005-2795(75)90160-9; Lopez-Egido JR, 2002, EXP CELL RES, V278, P175, DOI 10.1006/excr.2002.5575; Manickam P, 2000, MAMM GENOME, V11, P448, DOI 10.1007/s003350010085; Marx SJ, 2001, METABOLIC MOL BASES, P943; MAUPIN P, 1994, J CELL SCI, V107, P3077; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; Noselli S, 1999, CURR OPIN GENET DEV, V9, P466, DOI 10.1016/S0959-437X(99)80071-9; Ohkura N, 2001, BIOCHEM BIOPH RES CO, V282, P1206, DOI 10.1006/bbrc.2001.4723; OHNISHI T, 1963, J BIOCHEM, V54, P298, DOI 10.1093/oxfordjournals.jbchem.a127789; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; Poisson A, 2003, CANCER LETT, V189, P1, DOI 10.1016/S0304-3835(02)00509-8; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; SCHINDLER M, 1986, J CELL BIOL, V102, P859, DOI 10.1083/jcb.102.3.859; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; Seri M, 2000, NAT GENET, V26, P103; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; Stewart C, 1998, ONCOGENE, V17, P2485, DOI 10.1038/sj.onc.1202164; STRAND D, 1995, ONCOGENE, V11, P291; Sukhodolets KE, 2003, MOL CELL BIOL, V23, P493, DOI 10.1128/MCB.23.2.493-509.2003; Suphapeetiporn K, 2001, AM J HUM GENET, V69, P206; Tonini R, 1999, FASEB J, V13, P1395, DOI 10.1096/fasebj.13.11.1395; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; Wautot V, 2000, INT J CANCER, V85, P877, DOI 10.1002/(SICI)1097-0215(20000315)85:6<877::AID-IJC23>3.0.CO;2-F; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29	55	37	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6347	6358		10.1038/sj.onc.1206658	http://dx.doi.org/10.1038/sj.onc.1206658			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508515				2022-12-17	WOS:000185535300005
J	Heckman, CA; Wheeler, MA; Boxer, LM				Heckman, CA; Wheeler, MA; Boxer, LM			Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells	ONCOGENE			English	Article						bcl-2; lymphoma; transcription; C/EBP	NF-KAPPA-B; ACUTE MYELOID-LEUKEMIA; BINDING PROTEIN-BETA; TRANSCRIPTION FACTOR; C-MYB; NEGATIVE REGULATOR; GENE PROMOTER; CREB PROTEINS; ALPHA; DIFFERENTIATION	In follicular lymphomas with the t(14;18) translocation, there is increased expression of the bcl-2 gene, which is dependent upon regulatory elements within the bcl-2 5' flanking region and the immunoglobulin heavy-chain gene enhancers. We found that t(14;18) lymphomas expressed C/EBPalpha, which is not normally expressed in B lymphocytes. Expression of C/EBPalpha increased bcl-2 expression, and two regions of the bcl-2 P2 promoter that mediated this effect were identified. C/EBPbeta was also able to increase bcl-2 promoter activity through these sites. The 5' site was GC-rich and did not contain a C/EBP consensus sequence; however, C/EBP was observed to interact with this site both in vitro by EMSA and in vivo by chromatin immunoprecipitation assay. The 3' region contained the Cdx site, which mediates the effect of A-Myb on the bcl-2 promoter. In vivo binding studies revealed that C/EBP interacted with this region of the bcl-2 promoter as well. Decreased expression of C/EBP factors due to targeting of their transcripts by siRNA molecules resulted in downregulation of Bcl-2 protein. We conclude that C/EBPalpha and C/EBPbeta contribute to the deregulated expression of Bcl-2 in t(14;18) lymphoma cells.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Mol Biol Med, Palo Alto, CA 94304 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Boxer, LM (corresponding author), Stanford Univ, Sch Med, Dept Med, CCSR 1155,269 Campus Dr, Stanford, CA 94305 USA.			Heckman, Caroline/0000-0002-4324-8706	NATIONAL CANCER INSTITUTE [R56CA056764, R01CA056764] Funding Source: NIH RePORTER; NCI NIH HHS [CA56764] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; Chen XN, 1997, BLOOD, V90, P156; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; COOPER CL, 1994, J IMMUNOL, V153, P5049; Dearth LR, 2001, J CELL BIOCHEM, V82, P357, DOI 10.1002/jcb.1167; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LEGRAVEREND C, 1993, NUCLEIC ACIDS RES, V21, P1735, DOI 10.1093/nar/21.8.1735; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Ondrey FG, 1999, MOL CARCINOGEN, V26, P119, DOI 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Tahirov TH, 2002, CELL, V108, P57, DOI 10.1016/S0092-8674(01)00636-5; Tenen DG, 2001, LEUKEMIA, V15, P688, DOI 10.1038/sj.leu.2402088; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; Verbeek W, 1999, BLOOD, V93, P3327, DOI 10.1182/blood.V93.10.3327; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299	32	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7891	7899		10.1038/sj.onc.1206639	http://dx.doi.org/10.1038/sj.onc.1206639			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970736				2022-12-17	WOS:000185388200003
J	Monti, P; Campomenosi, P; Ciribilli, Y; Iannone, R; Aprile, A; Inga, A; Tada, M; Menichini, P; Abbondandolo, A; Fronza, G				Monti, P; Campomenosi, P; Ciribilli, Y; Iannone, R; Aprile, A; Inga, A; Tada, M; Menichini, P; Abbondandolo, A; Fronza, G			Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay	ONCOGENE			English	Article						P73 beta; P53 mutants; yeast; functional assay	WILD-TYPE P53; KINASE C-ABL; DNA-DAMAGE; APOPTOTIC RESPONSE; INDUCE APOPTOSIS; TUMOR-SUPPRESSOR; GENE FAMILY; P73; MUTATIONS; P63	p53 is the most frequently altered tumor suppressor gene in a wide spectrum of human tumors. The large majority of p53 mutations observed in tumors are missense mutations. The p73 gene, encoding a protein with significant sequence similarity to p53, expresses multiple transcription-competent spliced variants, or transcription-incompetent forms (i.e. DeltaNp73). It was clearly shown that p73 transactivation from a p53-responsive promoter is inhibited by some tumor-derived p53 mutants in eucaryotic cells. In this study, we adapted a yeast-based p53 functional assay for the analysis of the influences of different p53 mutants on the activity of one of the p73 isoforms, namely p73beta. We determined the ability of a panel of 61 p53 mutants to inhibit p73beta activity following the net transcription of the ADE2 color (red/white) reporter gene driven by a p53-responsive promoter. By analysing a large number of mutants, we could conclude that interference: (a) is a quite frequent phenomenon (more than 70% of p53 mutants analysed are interfering); (b) is not confined to p53 mutations located in particular topological regions of the DNA binding domain; (c) does not appear to be dependent on the kind of side chains introduced at a specific position; (d) appears to significantly correlate with evolutionary conservation of the mutated p53 codon, frequency of occurrence of the mutation in tumors. The influence of a common R/P polymorphism at codon 72 on the ability of p53 mutants to interfere with p73beta was also studied. Two sets of polymorphic variants (R and P) for 14 mutants were constructed and analysed. In all cases, the R/P 72 polymorphism was phenotypically irrelevant. In conclusion, our results suggest that the interpretation of the biological effects of p53 mutants should take into consideration the possibility that p53 mutants show loss or gain of function also through the interference with p53 family members.	Natl Canc Res Inst IST, Mutagenesis Lab, I-16132 Genoa, Italy; Univ Insubria, Dept Struct & Funct Biol, Human Genet Lab, Varese, Italy; Hokkaido Univ, Inst Med Genet, Div Canc Related Genes, Sapporo, Hokkaido, Japan; Univ Genoa, Dept Oncol Biol & Genet, Genoa, Italy	University of Insubria; Hokkaido University; University of Genoa	Fronza, G (corresponding author), Natl Canc Res Inst IST, Mutagenesis Lab, Lgo R Benzi 10, I-16132 Genoa, Italy.		Monti, Paola/Y-1118-2019; Inga, Alberto/AAC-3815-2022; Fronza, Gilberto/AAG-8735-2019; Campomenosi, Paola/C-9729-2011; Menichini, Paola/K-9422-2016; Ciribilli, Yari/K-2751-2018	Monti, Paola/0000-0002-1978-4998; Inga, Alberto/0000-0002-8767-1637; Fronza, Gilberto/0000-0003-3722-553X; Campomenosi, Paola/0000-0002-8853-1134; Ciribilli, Yari/0000-0001-9231-379X; Menichini, Paola/0000-0003-0057-6184				Agami R, 1999, NATURE, V399, P809; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gong JG, 1999, NATURE, V399, P806; Inga A, 1997, CARCINOGENESIS, V18, P2019, DOI 10.1093/carcin/18.10.2019; Inga A, 1997, ONCOGENE, V14, P1307, DOI 10.1038/sj.onc.1200952; Inga A, 1999, CANCER RES, V59, P689; Inga A, 1998, CARCINOGENESIS, V19, P741, DOI 10.1093/carcin/19.5.741; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kelly JD, 1999, J BIOL CHEM, V274, P18327, DOI 10.1074/jbc.274.26.18327; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Monti P, 2002, ONCOGENE, V21, P1641, DOI 10.1038/sj.onc.1205250; Monti P, 2000, MUTAGENESIS, V15, P127, DOI 10.1093/mutage/15.2.127; Nozaki M, 2001, BRAIN PATHOL, V11, P296; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Prives C, 1999, J PATHOL, V187, P112; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Tada M, 2001, CARCINOGENESIS, V22, P515, DOI 10.1093/carcin/22.3.515; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179	39	37	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5252	5260		10.1038/sj.onc.1206511	http://dx.doi.org/10.1038/sj.onc.1206511			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917626	Green Published			2022-12-17	WOS:000184734900004
J	Ivins, S; Pemberton, K; Guidez, F; Howell, L; Krumlauf, R; Zelent, A				Ivins, S; Pemberton, K; Guidez, F; Howell, L; Krumlauf, R; Zelent, A			Regulation of Hoxb2 by APL-associated PLZF protein	ONCOGENE			English	Article						leukaemia; transcription; repressor; fusion protein; retinoic acid receptor	ACID RECEPTOR-ALPHA; ACUTE PROMYELOCYTIC LEUKEMIA; ZINC-FINGER GENE; ACUTE MYELOID-LEUKEMIA; RETINOIC ACID; RAR-ALPHA; DNA-BINDING; POZ-DOMAIN; HISTONE DEACETYLASE; BTB/POZ DOMAIN	The PLZF gene is translocated in a subset of all-trans-retinoic acid resistant acute promyelocytic leukaemia (APL) cases, encodes a DNA binding transcription factor and is expressed highly in haematopoietic progenitor cells as well-developing central nervous system (CNS). The spatially restricted and temporally dynamic pattern of PLZF expression in the developing CNS suggested that it might play a role in the circuitry regulating hindbrain segmentation. We have now identified a PLZF binding site (PLZF-RE) in an enhancer region of Hoxb2 that itself is required for directing high-level expression in rhombomers 3 and 5 of the developing hindbrain. The wild-type r3/r5 enhancer linked to a heterologous promoter was responsive to regulation by PLZF, and this activity was lost in variants containing a mutated PLZF-RE. Compared with the wild-type protein, the binding of the APL-associated reciprocal RARalpha-PLZF fusion to PLZF-RE was much stronger, suggesting that the N-terminal PLZF sequences missing from the fusion may play a role in the regulation of DNA binding. Consistent with this, the N-terminal POZ domain was required for cooperative binding of PLZF to a multimerized PLZF-RE. In the context of the r3/r5 enhancer, the PLZF-RE cooperated for PLZF binding with an additional A/T-rich motif positioned downstream of the PLZF-RE. This A/T motif was previously shown to be essential for the regulation of Hoxb2 expression in r3 and r5 in cooperation with another Kruppel-like zinc finger protein Krox 20. The presence of both the PLZF-RE and the A/T-rich motif was required for a maximal effect of PLZF on a heterologous promoter and was essential in vivo to direct the expression of a lacZ reporter in the chick neural tube. Hence, both PLZF and Krox20 cooperate with a common A/T motif in mediating in vivo activity of the Hoxb2 enhancer. Our findings indicate that Hoxb2 is a direct target for regulation by PLZF in the developing CNS and suggest that deregulation of Hox gene expression may contribute to APL pathogenesis.	Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England; Stowers Inst Med Res, Kansas City, MO 64110 USA	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Stowers Institute for Medical Research	Zelent, A (corresponding author), Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, 237 Fulham Rd, London SW3 6JB, England.	a.zelent@icr.ac.uk	Guidez, Fabien/B-3750-2009; Zelent, Arthur/B-3532-2009; Guidez, Fabien/P-4220-2019; Krumlauf, Robb/AAH-5012-2019	Guidez, Fabien/0000-0003-1380-4473; Krumlauf, Robb/0000-0001-9102-7927; Zelent, Arthur/0000-0002-7968-9888	NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NCI NIH HHS [CA59936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Barrow JR, 1996, DEVELOPMENT, V122, P3817; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CARE A, 1994, MOL CELL BIOL, V14, P4872, DOI 10.1128/MCB.14.7.4872; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; Davenne M, 1999, NEURON, V22, P677, DOI 10.1016/S0896-6273(00)80728-X; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Espinas ML, 1999, J BIOL CHEM, V274, P16461, DOI 10.1074/jbc.274.23.16461; GENDRONMAGUIRE M, 1993, CELL, V75, P1317, DOI 10.1016/0092-8674(93)90619-2; GIAMPAOLO A, 1994, BLOOD, V84, P3637, DOI 10.1182/blood.V84.11.3637.bloodjournal84113637; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Itasaki N, 1999, NAT CELL BIOL, V1, pE203, DOI 10.1038/70231; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Katsani KR, 1999, EMBO J, V18, P698, DOI 10.1093/emboj/18.3.698; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Licht JD, 1996, ONCOGENE, V12, P323; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Magli MC, 1997, J CELL PHYSIOL, V173, P168, DOI 10.1002/(SICI)1097-4652(199711)173:2<168::AID-JCP16>3.0.CO;2-C; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MATHEWS CHE, 1991, BLOOD, V78, P2248; Melnick A, 2000, MOL CELL BIOL, V20, P6550, DOI 10.1128/MCB.20.17.6550-6567.2000; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Miaw SC, 2000, IMMUNITY, V12, P323, DOI 10.1016/S1074-7613(00)80185-5; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Quaranta MT, 1996, J IMMUNOL, V157, P2462; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; RIJLI FM, 1993, CELL, V75, P1333, DOI 10.1016/0092-8674(93)90620-6; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seyfert VL, 1996, ONCOGENE, V12, P2331; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; Vesque C, 1996, EMBO J, V15, P5383, DOI 10.1002/j.1460-2075.1996.tb00922.x; VIEILLEGROSJEAN I, 1992, BIOCHEM BIOPH RES CO, V183, P1124, DOI 10.1016/S0006-291X(05)80307-9; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WILKINSON DG, 1993, BIOESSAYS, V15, P499, DOI 10.1002/bies.950150802; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	66	37	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2003	22	24					3685	3697		10.1038/sj.onc.1206328	http://dx.doi.org/10.1038/sj.onc.1206328			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802276				2022-12-17	WOS:000183551000003
J	Ongusaha, PP; Ouchi, T; Kim, KT; Nytko, E; Kwak, JC; Duda, RB; Deng, CX; Lee, SW				Ongusaha, PP; Ouchi, T; Kim, KT; Nytko, E; Kwak, JC; Duda, RB; Deng, CX; Lee, SW			BRCA1 shifts p53-mediated cellular outcomes towards irreversible growth arrest	ONCOGENE			English	Article						BRCA1; p53; senescence; microarray; DNA damage	DNA-DAMAGE RESPONSE; TRANSCRIPTIONAL ACTIVATION; P53; CHECKPOINT; CYCLE; GADD45; PHOSPHORYLATION; REPAIR; CELLS; EXPRESSION	The tumor suppressor protein BRCA1 has been shown to enhance p53 transcription, whereas activated p53 represses BRCA1 transcription. To further understand the functional interaction of these proteins, we investigated the role of BRCA1 in p53-induced phenotypes. We found that BRCA1 when subjected to forced expression acts synergistically with wild-type p53, resulting in irreversible growth arrest, as shown by VhD mouse fibroblast cells expressing a temperature-sensitive mutant of p53. Furthermore, reintroduction of both BRCA1 and p53 into BRCA1(-/-)/p53(-/-) mouse embryonic fibroblasts markedly increased the senescence phenotype compared to that induced by Ill alone. In particular, we found that BRCA1 expression attenuated p53-mediated cell death in response to gamma-irradiation. Moreover, microarray screening of 11 000 murine genes demonstrated that a set of genes upregulated by p53 is enhanced by coexpression of BRCA1 and p53, suggesting that BRCA1 and p53 exert a promoter selectivity leading to a specific phenotype. Taken together, our results provide evidence that BRCA1 is involved in p53-mediated growth suppression rather than apoptosis.	Harvard Univ, Inst Med, Sch Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Canc Biol Program, Div Hematol Oncol, Boston, MA 02115 USA; CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA; NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Beth Israel Deaconess Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Lee, SW (corresponding author), Harvard Univ, Inst Med, Sch Med, Room 921,4 Blackfan Circle, Boston, MA 02115 USA.	slee2@caregroup.harvard.edu	deng, chuxia/N-6713-2016		NCI NIH HHS [CA85214, CA80058, CA78356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085214, R01CA078356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056001] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Arizti P, 2000, MOL CELL BIOL, V20, P7450, DOI 10.1128/MCB.20.20.7450-7459.2000; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Deng CX, 2000, BIOESSAYS, V22, P728; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lee EYHP, 2002, CELL CYCLE, V1, P178, DOI 10.4161/cc.1.3.121; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; MacLachlan TK, 2000, J BIOL CHEM, V275, P31869, DOI 10.1074/jbc.M003338200; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang SC, 2001, CANCER RES, V61, P2838; Wang Y, 2000, GENE DEV, V14, P927; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	44	37	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2003	22	24					3749	3758		10.1038/sj.onc.1206439	http://dx.doi.org/10.1038/sj.onc.1206439			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802282				2022-12-17	WOS:000183551000009
J	McKay, TR; Bell, S; Tenev, T; Stoll, V; Lopes, R; Lemoine, NR; McNeish, IA				McKay, TR; Bell, S; Tenev, T; Stoll, V; Lopes, R; Lemoine, NR; McNeish, IA			Procaspase 3 expression in ovarian carcinoma cells increases survivin transcription which can be countered with a dominant-negative mutant, survivin T34A; a combination gene therapy strategy	ONCOGENE			English	Article						survivin; caspase; ovarian carcinoma; gene therapy	ADENOVIRUS-MEDIATED TRANSFER; CASPASE ACTIVATION; DIRECT INHIBITOR; CANCER-CELLS; IN-VIVO; APOPTOSIS; PROTEIN; DEATH; IAP; PATHWAY	Increased survivin expression is a negative prognostic marker in many tumours, including ovarian cancer. We show here that ovarian carcinoma cells upregulate survivin transcription in response to increased expression of the proapoptotic protein procaspase 3. We have utilized this observation in a combination gene therapy strategy using adenoviral constructs expressing the dominant-negative mutant survivin T34A (Ad Survivin T34A) and procaspase 3 (Ad Caspase 3) in ovarian carcinoma cell lines. Transfection of ovarian carcinoma cells with Ad Survivin T34A induces apoptosis via a caspase 9-mediated pathway that is not affected by cell cycle block prior to G2/M. Ad Survivin T34A-induced apoptosis can be significantly enhanced by cotransfection with Ad Caspase 3, and the combination of Ad Survivin T34A and Ad Caspase 3 leads to a significant increase in survival in a murine intraperitoneal ovarian carcinoma model with some long-term survivors. This suggests that inhibiting endogenous survivin activity while also delivering high levels of procaspase 3 allow proteolytic cleavage and activation of the terminal caspase cascade leading to tumour cell death.	Hammersmith Hosp, Imperial Coll Sch Med, Canc Res UK Mol Oncol Unit, London W12 0NN, England	Cancer Research UK; Imperial College London	McNeish, IA (corresponding author), Hammersmith Hosp, Canc Res UK Mol Oncol Unit, MRC Cyclotron Bldg, London W12 0HS, England.			Tenev, Tencho/0000-0001-8762-1069; McNeish, Iain/0000-0002-9387-7586; McKay, Tristan/0000-0002-9128-9115				Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Asanuma K, 2000, JPN J CANCER RES, V91, P1204, DOI 10.1111/j.1349-7006.2000.tb00906.x; Banks DP, 2000, BLOOD, V96, P4002, DOI 10.1182/blood.V96.12.4002.h8004000c_4002_4003; Blanc-Brude OP, 2002, NAT MED, V8, P987, DOI 10.1038/nm750; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Dong Z, 2002, BIOCHEM J, V364, P413, DOI 10.1042/BJ20011431; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Ikeguchi M, 2002, ONCOL REP, V9, P1121; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Livne A, 2001, J VIROL, V75, P789, DOI 10.1128/JVI.75.2.789-798.2001; McNeish IA, 2001, CANCER GENE THER, V8, P308, DOI 10.1038/sj.cgt.7700305; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Sarela AI, 2000, GUT, V46, P645, DOI 10.1136/gut.46.5.645; Shariat SF, 2001, CANCER RES, V61, P2562; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Shinoura N, 2000, EXP CELL RES, V256, P423, DOI 10.1006/excr.2000.4848; Silke J, 2001, EMBO J, V20, P3114, DOI 10.1093/emboj/20.12.3114; Silke J, 2001, J CELL SCI, V114, P1821; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Suzuki A, 2000, ONCOGENE, V19, P3225, DOI 10.1038/sj.onc.1203665; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tamm I, 1998, CANCER RES, V58, P5315; Tenev T, 2001, CELL DEATH DIFFER, V8, P256, DOI 10.1038/sj.cdd.4400808; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Vasquez RJ, 1997, MOL BIOL CELL, V8, P973, DOI 10.1091/mbc.8.6.973; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wall NR, 2003, CANCER RES, V63, P230; Yamabe K, 1999, GENE THER, V6, P1952, DOI 10.1038/sj.gt.3301041; Yoshitake T, 2000, J MATER SCI LETT, V19, P537, DOI 10.1023/A:1006722205010; Zhao J, 2000, J CELL SCI, V113, P4363; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	46	37	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3539	3547		10.1038/sj.onc.1206417	http://dx.doi.org/10.1038/sj.onc.1206417			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789262	Bronze			2022-12-17	WOS:000183399200004
J	Arlt, A; Kruse, ML; Breitenbroich, M; Gehrz, A; Koc, B; Minkenberg, J; Folsch, UR; Schafer, H				Arlt, A; Kruse, ML; Breitenbroich, M; Gehrz, A; Koc, B; Minkenberg, J; Folsch, UR; Schafer, H			The early response gene IEX-1 attenuates NF-kappa B activation in 293 cells, a possible counter-regulatory process leading to enhanced cell death	ONCOGENE			English	Article						programmed cell death; cytokines; transcription factor; ribozyme	IMMEDIATE-EARLY GENE; TARGET GENE; IMMUNE-RESPONSES; IN-VIVO; APOPTOSIS; GROWTH; IDENTIFICATION; EXPRESSION; P53; KERATINOCYTES	The early response gene IEX-1 is involved in the regulation of cellular growth and survival, and its expression is related to stress-, growth- and death-inducing signals. Addressing the role of IEX-1 in the promotion of apoptosis, we investigated the effect of IEX-1 on nuclear factor-kappaB (NF-kappaB) activation. Stably transfected HEK-293 cells conditionally overexpressing IEX-1 exhibit decreased levels of NF-kappaB activity, either basal or TNFalpha induced, as shown by gel-shift and luciferase reporter gene assay. Furthermore, activated p65 accumulated in the nuclei of 293 cells to a lower degree, if IEX-1 expression was increased. This inhibited NF-kappaB activation was preceded by an altered turnover of IkappaBalpha and phospho-IkappaBalpha. In addition, IEX-1 expression also inhibited the activity of the 26S-proteasome, as shown by a fluorometric proteasome assay. Conversely, disruption of IEX-1 expression in 293 cells by stable transfection with specific anti-IEX-1 hammerhead ribozymes increased NF-kappaB activity, and accelerated the degradation of IkappaBalpha. Along with these opposite effects of IEX-1 expression and IEX-1 disruption on NF-kappaB activation, the sensitivity of 293 cells towards various apoptotic stimuli also changed. In contrast to ribozyme-transduced 293 cells that were significantly less sensitive to apoptosis, this sensitivity was enhanced if IEX-1 expression was increased. Our data suggest that IEX-1 itself an NF-kappaB target gene - inhibits the activation of this transcription factor, and hereby may counteract the antiapoptodc potential of NF-kappaB.	Univ Kiel, Dept Med 1, Lab Mol Gastroenterol & Hepatol, D-24105 Kiel, Germany	University of Kiel	Schafer, H (corresponding author), Univ Kiel, Dept Med 1, Lab Mol Gastroenterol & Hepatol, Schittenhelmstr 12, D-24105 Kiel, Germany.		Schäfer, Heiner/C-1055-2011; Arlt, Alexander/G-7308-2019	Arlt, Alexander/0000-0002-6160-1059				Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; CHARLES CH, 1993, ONCOGENE, V8, P797; Chen BC, 2002, J BIOL CHEM, V277, P24169, DOI 10.1074/jbc.M106014200; Chen DY, 2002, J BIOL CHEM, V277, P15985, DOI 10.1074/jbc.M108675200; De Keulenaer GW, 2002, CIRC RES, V90, P690, DOI 10.1161/01.RES.0000012922.40318.05; Garcia J, 2002, EMBO J, V21, P5151, DOI 10.1093/emboj/cdf488; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Grobe O, 2001, FEBS LETT, V494, P196, DOI 10.1016/S0014-5793(01)02344-4; Huang YH, 2002, ONCOGENE, V21, P6819, DOI 10.1038/sj.onc.1205854; IM HJ, 2002, J BIOL CHEM, V21, P3706; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kobayashi T, 1998, BIOCHEM BIOPH RES CO, V251, P868, DOI 10.1006/bbrc.1998.9556; Kondratyev AD, 1996, CANCER RES, V56, P1498; Kumar R, 1998, BIOCHEM BIOPH RES CO, V253, P336, DOI 10.1006/bbrc.1998.9692; Masdehors P, 2000, BLOOD, V96, P269, DOI 10.1182/blood.V96.1.269.013k10_269_274; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Ohki R, 2002, J HYPERTENS, V20, P685, DOI 10.1097/00004872-200204000-00026; Pietzsch A, 1997, BIOCHEM BIOPH RES CO, V235, P4, DOI 10.1006/bbrc.1997.6715; Pietzsch A, 1998, BIOCHEM BIOPH RES CO, V245, P651, DOI 10.1006/bbrc.1998.8500; Schafer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Schafer H, 1996, CANCER RES, V56, P2641; Schafer H, 1999, PANCREAS, V18, P378, DOI 10.1097/00006676-199905000-00008; Schafer H, 1998, ONCOGENE, V16, P2479, DOI 10.1038/sj.onc.1201788; Schilling D, 2001, ONCOGENE, V20, P7992, DOI 10.1038/sj.onc.1204965; Segev DL, 2000, J BIOL CHEM, V275, P28371, DOI 10.1074/jbc.M004554200; Segev DL, 2001, J BIOL CHEM, V276, P26799, DOI 10.1074/jbc.M103092200; Seitz CS, 2000, CANCER RES, V60, P4085; Spitkovsky D, 2002, J BIOL CHEM, V277, P25576, DOI 10.1074/jbc.M201884200; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Tone Y, 2002, GENE DEV, V16, P3142, DOI 10.1101/gad.1025602; Um JH, 2001, ONCOGENE, V20, P6048, DOI 10.1038/sj.onc.1204732; VAN AD, 1996, SCIENCE, V274, P787; van Hogerlinden M, 2002, ONCOGENE, V21, P4969, DOI 10.1038/sj.onc.1205620; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Zhang Y, 2002, P NATL ACAD SCI USA, V99, P878, DOI 10.1073/pnas.022326699	40	37	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 22	2003	22	21					3343	3351		10.1038/sj.onc.1206524	http://dx.doi.org/10.1038/sj.onc.1206524			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761504				2022-12-17	WOS:000183040000016
J	Zada, AAP; Singh, SM; Reddy, VA; Elsasser, A; Meisel, A; Haferlach, T; Tenen, DG; Hiddemann, W; Behre, G				Zada, AAP; Singh, SM; Reddy, VA; Elsasser, A; Meisel, A; Haferlach, T; Tenen, DG; Hiddemann, W; Behre, G			Downregulation of c-Jun expression and cell cycle regulatory molecules in acute myeloid leukemia cells upon CD44 ligation	ONCOGENE			English	Article						CD44; c-Jun; AML; differentiation; proliferation; cell cycle	TRANS-RETINOIC ACID; ADHESION MOLECULE; C/EBP-ALPHA; TRANSCRIPTIONAL ACTIVITY; RETINOBLASTOMA PROTEIN; KINASE-ACTIVITY; DIFFERENTIATION; PHOSPHORYLATION; AP-1; P21	In the present study, we investigated the mechanism of CD44 ligation with the anti-CD44 monoclonal antibody A3D8 to inhibit the proliferation of human acute myeloid leukemia (AML) cells. The effects of A3D8 on myeloid cells were associated with specific disruption of cell cycle events and induction of G0/G1 arrest. Induction of G0/G1 arrest was accompanied by an increase in the expression of p21, attenuation of pRb phosphorylation and associated with decreased Cdk2 and Cdk4 kinase activities. Since c-Jun is an important regulator of proliferation and cell cycle progression, we analysed its role in A3D8-mediated growth arrest. We observed that A3D8 treatment of AML patient blasts and HL60/U937 cells led to the down-regulation of c-Jun expression at mRNA and protein level. Transient transfection studies showed the inhibition of c-jun promoter activity by A3D8, involving both AP-1 sites. Furthermore, A3D8 treatment caused a decrease in JNK protein expression and a decrease in the level of phosphorylated c-Jun. Ectopic overexpression of c-Jun in HL60 cells was able to induce proliferation and prevent the antiproliferative effects of A3D8. In summary, these data identify an important functional role of c-Jun in the induction of cell cycle arrest and proliferation arrest of myeloid leukemia cells because of the ligation of the cell surface adhesion receptor CD44 by anti-CD44 antibody. Moreover, targeting of G1 regulatory proteins and the resulting induction of G I arrest by A3D8 may provide new insights into antiproliferative and differentiation therapy of AML.	Univ Munich, Klinikum Grosshadern, D-81377 Munich, Germany; GSF Munich, Hematologikum, D-81377 Munich, Germany; Harvard Univ, Sch Med, Harvard Inst Med, Boston, MA 02115 USA	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Harvard University; Harvard Medical School	Behre, G (corresponding author), Univ Munich, Klinikum Grosshadern, Marchioninistr 15, D-81377 Munich, Germany.	gerdbehre@aol.com		Tenen, Daniel/0000-0002-6423-3888				Allouche M, 2000, BLOOD, V96, P1187, DOI 10.1182/blood.V96.3.1187.015k01_1187_1190; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; BATES S, 1994, ONCOGENE, V9, P1633; Behre G, 1999, METHODS, V17, P231, DOI 10.1006/meth.1998.0733; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Behre G, 1999, BIOTECHNIQUES, V26, P24, DOI 10.2144/99261bm03; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Charrad RS, 2002, BLOOD, V99, P290, DOI 10.1182/blood.V99.1.290; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; DANOVA M, 1990, LEUKEMIA RES, V14, P417, DOI 10.1016/0145-2126(90)90027-7; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; ELSASSER A, 2002, ASH, V100, P200; Emig M, 1999, LEUKEMIA, V13, P1825, DOI 10.1038/sj.leu.2401566; Gitig DM, 2000, METH MOL B, V142, P109; HARPER JW, 1993, CELL, V75, P805; HILBERG F, 1992, ONCOGENE, V7, P2371; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HORIGUCHIYAMADA J, 1994, MOL CELL BIOCHEM, V132, P31, DOI 10.1007/BF00925672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kantarjian H, 1999, SEMIN HEMATOL, V36, P16; Kiaris H, 1999, ONCOGENE, V18, P7168, DOI 10.1038/sj.onc.1203213; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KUHN LC, 1994, BAILLIERE CLIN HAEM, V7, P763, DOI 10.1016/S0950-3536(05)80123-4; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIESVELD JL, 1994, LEUKEMIA LYMPHOMA, V14, P19, DOI 10.3109/10428199409049647; Lowell CA, 1999, J LEUKOCYTE BIOL, V65, P313, DOI 10.1002/jlb.65.3.313; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Milde-Langosch K, 2000, INT J CANCER, V87, P468, DOI 10.1002/1097-0215(20000815)87:4<468::AID-IJC2>3.0.CO;2-R; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; Moll J, 1998, J CLIN INVEST, V102, P1024, DOI 10.1172/JCI2494; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; Patel R, 1998, J CELL SCI, V111, P2247; Pisani F, 1997, ANN HEMATOL, V75, P145, DOI 10.1007/s002770050332; Rangatia J, 2002, MOL CELL BIOL, V22, P8681, DOI 10.1128/MCB.22.24.8681-8694.2002; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; REUSSBORST MA, 1992, ANN HEMATOL, V65, P169, DOI 10.1007/BF01703110; SANFORD JS, 1998, BLOOD, V91, P2645; SAVATIER P, 1994, ONCOGENE, V9, P809; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SHERR CJ, 1994, STEM CELLS, V12, P47; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Sievers EL, 2000, CURR OPIN ONCOL, V12, P30, DOI 10.1097/00001622-200001000-00005; SLACK RS, 1993, ONCOGENE, V8, P1585; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH MJ, 1992, BLOOD, V79, P2107; Steinman RA, 1998, BLOOD, V91, P4531, DOI 10.1182/blood.V91.12.4531.412k10_4531_4542; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; THEIL EC, 1990, J BIOL CHEM, V265, P4771; Trayner ID, 1998, LEUKEMIA RES, V22, P537, DOI 10.1016/S0145-2126(98)00041-1; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Verfaillie CM, 1998, BLOOD, V92, P2609, DOI 10.1182/blood.V92.8.2609; Waxman S, 2000, LEUKEMIA, V14, P491, DOI 10.1038/sj.leu.2401714; Wei P, 1998, MOL ENDOCRINOL, V12, P1322, DOI 10.1210/me.12.9.1322; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188	67	37	47	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2296	2308		10.1038/sj.onc.1206330	http://dx.doi.org/10.1038/sj.onc.1206330			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700665				2022-12-17	WOS:000182231500008
J	Jabbur, JR; Tabor, AD; Cheng, XD; Wang, H; Uesugi, M; Lozano, G; Zhang, W				Jabbur, JR; Tabor, AD; Cheng, XD; Wang, H; Uesugi, M; Lozano, G; Zhang, W			Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21	ONCOGENE			English	Article						phosphorylation; radiation; p53; p21; Mdm-2; TAF(II)31; hydrogen bond	DAMAGE-INDUCED PHOSPHORYLATION; ACTIVATION DOMAIN; TRANSCRIPTIONAL ACTIVATION; IONIZING-RADIATION; ONCOPROTEIN MDM2; DNA-BINDING; IN-VITRO; PROTEIN; KINASE; DEGRADATION	Analyses of five wild-type p53 containing cell lines revealed lineage specific differences in phosphorylation of Thr18 after treatment with ionizing (IR) or ultraviolet (UV) radiation. Importantly, Thr18 phosphorylation correlated with induction of the p53 downstream targets p21(Waf1/Cip1) (p21) and Mdm-2, suggesting a transactivation enhancing role. Thr18 phosphorylation has been shown to abolish side-chain hydrogen bonding between Thr18 and Asp21, an interaction necessary for stabilizing alpha-helical conformation within the transactivation domain. Mutagenesis-derived hydrogen bond disruption attenuated the interaction of p53 with the transactivation repressor Mdm-2 but had no direct effect on the interaction of p53 with the basal transcription factor TAF(II)31. However, prior incubation of p53 mutants with Mdm-2 modulated TAF(II)31 interaction with p53, suggesting Mdm-2 blocks the accessibility of p53 to TAF(II)31. Consistently, p53-null cells transfected with hydrogen bond disrupting p53 mutants demonstrated enhanced endogenous p21 expression, whereas p53/Mdm-2-double null cells exhibited no discernible differences in p21 expression. We conclude disruption of intramolecular hydrogen bonding between Thr18 and Asp21 enhances p53 transactivation by modulating Mdm-2 binding, facilitating TAF(II)31 recruitment.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Canc Genom Lab, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Grad Program Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Grad Program Genes & Dev, Houston, TX 77030 USA; Univ Texas, Med Branch, Sealy Ctr Struct Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Baylor College of Medicine	Zhang, W (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Canc Genom Lab, Box 85,1515 Holcombe Blvd, Houston, TX 77030 USA.	wzhang@mdanderson.org	Uesugi, Motonari/AAM-9777-2020		NATIONAL CANCER INSTITUTE [R29CA067987] Funding Source: NIH RePORTER; NCI NIH HHS [CA67987] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; Choi Y, 2000, J BIOL CHEM, V275, P15912, DOI 10.1074/jbc.275.21.15912; COLLINS A, 1987, INT J RADIAT BIOL, V51, P971, DOI 10.1080/09553008714551271; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Drouin R, 1997, PHOTOCHEM PHOTOBIOL, V66, P719, DOI 10.1111/j.1751-1097.1997.tb03213.x; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Jabbur JR, 2000, ONCOGENE, V19, P6203, DOI 10.1038/sj.onc.1204017; Jabbur JR, 2002, CANCER BIOL THER, V1, P277, DOI 10.4161/cbt.81; Jabbur JR, 2001, INT J MOL MED, V7, P163; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kobayashi T, 1998, CELL DEATH DIFFER, V5, P584, DOI 10.1038/sj.cdd.4400382; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Lai ZH, 2000, ARCH BIOCHEM BIOPHYS, V381, P278, DOI 10.1006/abbi.2000.1998; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu L, 1999, MOL CELL BIOL, V19, P1202; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUNA RMD, 1995, NATURE, V378, P203; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; Mayo LD, 1997, CANCER RES, V57, P5013; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MIYASHITA T, 1995, CELL, V80, P293; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Scolnick DM, 1997, CANCER RES, V57, P3693; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TRUANT R, 1993, J BIOL CHEM, V268, P2284; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	85	37	37	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					7100	7113		10.1038/sj.onc.1205856	http://dx.doi.org/10.1038/sj.onc.1205856			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370832				2022-12-17	WOS:000178424900013
J	Giaccone, G				Giaccone, G			Clinical impact of novel treatment strategies	ONCOGENE			English	Review						lung cancer; targeted therapy; growth hormones	CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; P53 GENE-TRANSFER; TYROSINE KINASE INHIBITOR; CHRONIC MYELOID-LEUKEMIA; K-RAS MUTATIONS; HUMAN-BREAST; MATRIX METALLOPROTEINASES; ANTITUMOR-ACTIVITY; PHASE-I	Following two decades of research on the biology of cancer and in particular of lung cancer, we have now a large number of molecular targets that can be utilized to create specific medicines against these cancers. Non-small cell lung cancer represents numerically the most important solid tumor in Western world, and is poorly affected by current therapies, where surgery represents almost the only curative therapy for about 25% of patients who are resectable at diagnosis. An abundant number of targeted therapies are being investigated in NSCLC. Among them are the metalloproteinase inhibitors, several tyrosine kinase inhibitors and several attempts of gene replacement have also been made. Promising results have so far been obtained with some of these approaches, and the outcome of large randomized studies is awaited. Small cell lung cancer (SCLC) represents about 20% of lung carcinomas, and several of the novel approaches that are being attempted for NSCLC, are also being investigated for SCLC. All these novel therapies open a new era of anticancer treatment that will likely complement the currently available therapies in the near future.	Free Univ Amsterdam, Med Ctr, Div Med Oncol, NL-1081 HV Amsterdam, Netherlands	Vrije Universiteit Amsterdam	Giaccone, G (corresponding author), Free Univ Amsterdam, Med Ctr, Div Med Oncol, 1117 Boelelaan, NL-1081 HV Amsterdam, Netherlands.	G.Giaccone@vumc.nl	Giaccone, Giuseppe/E-8297-2017	Giaccone, Giuseppe/0000-0002-5023-7562				Achiwa H, 1999, CLIN CANCER RES, V5, P1001; Adlard JW, 2000, ANTI-CANCER DRUG, V11, P787, DOI 10.1097/00001813-200011000-00002; Albelda SM, 1997, CHEST, V111, pS144, DOI 10.1378/chest.111.6_Supplement.144S; Albelda SM, 2000, ANN INTERN MED, V132, P649, DOI 10.7326/0003-4819-132-8-200004180-00008; ARTEAGA CL, 1994, CANCER RES, V54, P3758; Arteaga CL, 2001, J CLIN ONCOL, V19, p32S; Askari FK, 1996, NEW ENGL J MED, V334, P316, DOI 10.1056/NEJM199602013340508; Averbuch SD, 2002, CLIN CANCER RES, V8, P1; BAILEY HH, 2001, P AN M AM SOC CLIN, V20, pA79; Baselga J, 2000, DRUGS, V60, P33, DOI 10.2165/00003495-200060001-00004; Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; Baselga J, 1998, CANCER RES, V58, P2825; BASELGA J, 2001, CLIN CANC RES S, V7, pA630; Bauer KS, 1998, BIOCHEM PHARMACOL, V55, P1827, DOI 10.1016/S0006-2952(98)00046-X; BLAESE RM, 1994, EUR J CANCER, V30A, P1190, DOI 10.1016/0959-8049(94)90482-0; Blanke CD., 2001, P AN M AM SOC CLIN, V20, p1a; Bos M, 1997, CLIN CANCER RES, V3, P2099; BROWN PD, 1993, J NATL CANCER I, V85, P574, DOI 10.1093/jnci/85.7.574; CAMACHO LH, 2001, P AN M AM SOC CLIN, V20, pA79; Carbone DP, 1997, SEMIN ONCOL, V24, P388; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; CHEN C, 1995, CANCER RES, V55, P4230; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; Clarke MR, 1997, HUM PATHOL, V28, P54, DOI 10.1016/S0046-8177(97)90279-3; COHEN RB, 2000, P AN M AM SOC CLIN, V19, pA474; CONRY RM, 1995, GENE THER, V2, P59; DANG T, 2001, P AN M AM SOC CLIN, V20, pA332; DEVORE RF, 2000, P AN M AM SOC CLIN, V19, P485; Dickler MN, 1999, CLIN CANCER RES, V5, P2773; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; ESCUDIER B, 2000, LUNG CANCER S1, V29, P184; Eskens FALM, 2001, J CLIN ONCOL, V19, P1167, DOI 10.1200/JCO.2001.19.4.1167; FAN Z, 1993, CANCER RES, V53, P4637; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Ferrara N, 1996, Curr Opin Nephrol Hypertens, V5, P35, DOI 10.1097/00041552-199601000-00008; FIGLIN RA, 2001, P AN M AM SOC CLIN, V20, pA276; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Fong TAT, 1999, CANCER RES, V59, P99; Forgacs Eva, 2001, Pathology and Oncology Research, V7, P6; Frederiksen KS, 1999, LUNG CANCER, V23, P191, DOI 10.1016/S0169-5002(99)00012-4; Gatzemeier U., 2001, European Journal of Cancer, V37, pS50, DOI 10.1016/S0959-8049(01)80665-1; Giatromanolaki A, 1996, ANTICANCER RES, V16, P3819; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GORDON MS, 1998, P AN M AM SOC CLIN, V17, P210; Grant SC, 1999, CLIN CANCER RES, V5, P1319; Guddo F, 1999, HUM PATHOL, V30, P788, DOI 10.1016/S0046-8177(99)90139-9; HALBERT CL, 1995, J VIROL, V69, P1473, DOI 10.1128/JVI.69.3.1473-1479.1995; Herbst RS, 2001, EXPERT OPIN BIOL TH, V1, P719, DOI 10.1517/14712598.1.4.719; Hida T, 1998, CANCER RES, V58, P3761; Hida T, 1998, ANTICANCER RES, V18, P775; HIDALGO M, 2001, P AN M AM SOC CLIN, V20, pA71; HOLDEN SN, 2001, P AN M AM SOC CLIN, V20, pA80; Hosomi Y, 2000, LUNG CANCER, V30, P73, DOI 10.1016/S0169-5002(00)00132-X; Ichimura E, 1996, JPN J CANCER RES, V87, P1063, DOI 10.1111/j.1349-7006.1996.tb03111.x; Johnson DH, 2001, P AN M AM SOC CLIN, V20, p315a; Kenyon BM, 1997, EXP EYE RES, V64, P971, DOI 10.1006/exer.1997.0292; KERN JA, 1994, J CLIN INVEST, V93, P516, DOI 10.1172/JCI117001; KERN JA, 1990, CANCER RES, V50, P5184; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Khuri FR, 2001, J CLIN ONCOL, V19, P2626, DOI 10.1200/JCO.2001.19.10.2626; Kim YC, 1998, LUNG CANCER-J IASLC, V22, P181, DOI 10.1016/S0169-5002(98)00086-5; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; Kris MG, 2000, LUNG CANCER, V29, P72; KRUG LM, 2001, P AN M AM SOC CLIN, V20, pA333; KUBBA S, 2000, P AN M AM SOC CLIN, V19, pA487; Kuenen BC, 2002, J CLIN ONCOL, V20, P1657, DOI 10.1200/JCO.20.6.1657; LANGER CJ, 2001, P AN M AM SOC CLIN, V20, pA315; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LoRusso PM, 1996, INVEST NEW DRUG, V14, P349; MARGOLIN K, 1999, P AN M AM SOC CLIN, V18, pA435; Mendel DB, 2000, ANTI-CANCER DRUG DES, V15, P29; NEGORO S, 2001, P AN M AM SOC CLIN, V20, pA324; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nemunaitis J, 1998, AM J CLIN ONCOL-CANC, V21, P155, DOI 10.1097/00000421-199804000-00013; Nemunaitis J, 2000, J CLIN ONCOL, V18, P609, DOI 10.1200/JCO.2000.18.3.609; Nguyen DM, 1997, CANCER GENE THER, V4, P191; NIE ZR, 1995, CANCER RES, V55, P4760; Noda W, 2002, NEW ENGL J MED, V346, P85, DOI 10.1056/NEJMoa003034; O-Charoenrat P, 2000, INT J CANCER, V86, P307, DOI 10.1002/(SICI)1097-0215(20000501)86:3<307::AID-IJC2>3.0.CO;2-I; Olivero M, 1996, BRIT J CANCER, V74, P1862, DOI 10.1038/bjc.1996.646; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Parsons SL, 1997, BRIT J SURG, V84, P160, DOI 10.1046/j.1365-2168.1997.02719.x; PEREZSOLER R, 1998, P AN M AM SOC CLIN, V17, P1514; PEREZSOLER R, 2001, P AN M AM SOC CLIN, V20, pA310; PICCARTGEBHART MJ, 2001, P AN M AM SOC CLIN, V20, pA80; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; Pietras RJ, 1999, CANCER RES, V59, P1347; Prakash S, 2001, INVEST NEW DRUG, V19, P1, DOI 10.1023/A:1006489328324; Rizvi NA, 1999, CLIN CANCER RES, V5, P1658; RODENHUIS S, 1990, AM REV RESPIR DIS, V142, pS27, DOI 10.1164/ajrccm/142.6_Pt_2.S27; ROSEN L, 1999, P AN M AM SOC CLIN, V18, pA161; Roth JA, 1997, J NATL CANCER I, V89, P21, DOI 10.1093/jnci/89.1.21; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; SALGIA R, 2000, LUNG CANCER S1, V29, P186; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Schiller JH, 2001, J CLIN ONCOL, V19, P448, DOI 10.1200/JCO.2001.19.2.448; Schuler M, 2001, J CLIN ONCOL, V19, P1750, DOI 10.1200/JCO.2001.19.6.1750; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SHAWVER LK, 1999, AM SOC CLIN ONCOLOGY, P29; Shepherd FA, 2001, P AN M AM SOC CLIN, V20, p4a; SHIN DM, 2001, P AN M AM SOC CLIN, V20, pA82; Singhal S, 1998, Surg Oncol Clin N Am, V7, P505; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; Sirotnak FM, 2000, CLIN CANCER RES, V6, P4885; Smolich BD, 2001, BLOOD, V97, P1413, DOI 10.1182/blood.V97.5.1413; SMYLIE M, 2001, P AN M AM SOC CLIN, V20, pA307; Soriano AF, 1999, CANCER RES, V59, P6178; Stein Cy A., 1994, Current Opinion in Oncology, V6, P587, DOI 10.1097/00001622-199411000-00010; StetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147, DOI 10.1006/scbi.1996.0020; Stewart AK, 1999, HUM GENE THER, V10, P2037; Swisher SG, 1999, J NATL CANCER I, V91, P763, DOI 10.1093/jnci/91.9.763; TEICHER BA, 1994, CANCER CHEMOTH PHARM, V33, P515, DOI 10.1007/s002800050093; Thomas DA, 2000, CURR OPIN ONCOL, V12, P564, DOI 10.1097/00001622-200011000-00009; Traxler P, 1999, CLIN CANCER RES, V5, p3750S; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; Tsubouchi Y, 2000, ANTICANCER RES, V20, P2867; VERSLYPE C, 2001, P AN M AM SOC CLIN, V20, pA171; VERWEIJ J, 2001, P AN M AM SOC CLIN, V20, pA81; Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698; WINQUIST E, 2001, P AN M AM SOC CLIN, V20, pA197; Wolff H, 1998, CANCER RES, V58, P4997; Yang XD, 2001, CRIT REV ONCOL HEMAT, V38, P17, DOI 10.1016/S1040-8428(00)00134-7; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YU DH, 1994, CANCER RES, V54, P3260; YUEN A, 2001, P AN M AM SOC CLIN, V20, pA309; Zou YY, 1998, J NATL CANCER I, V90, P1130, DOI 10.1093/jnci/90.15.1130; Zujewski J, 2000, J CLIN ONCOL, V18, P927, DOI 10.1200/JCO.2000.18.4.927	135	37	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2002	21	45					6970	6981		10.1038/sj.onc.1205565	http://dx.doi.org/10.1038/sj.onc.1205565			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604UV	12362278	Bronze			2022-12-17	WOS:000178640200011
J	Reis, PP; Rogatto, SR; Kowalski, LP; Nishimoto, IN; Montovani, JC; Corpus, G; Squire, JA; Kamel-Reid, S				Reis, PP; Rogatto, SR; Kowalski, LP; Nishimoto, IN; Montovani, JC; Corpus, G; Squire, JA; Kamel-Reid, S			Quantitative real-time PCR identifies a critical region of deletion on 22q13 related to prognosis in oral cancer	ONCOGENE			English	Article						oral cavity cancer; chromosome 22q; quantitative real time PCR	POLYMERASE-CHAIN-REACTION; COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; BREAST-CANCER; CHROMOSOME 22Q; GROWTH-FACTOR; ALLELIC LOSS; NECK-CANCER; RT-PCR; HEAD	Quantitative real time PCR was performed on genomic DNA from 40 primary oral carcinomas and the normal adjacent tissues. The target genes ECGFB, DIA1, BIK, and PDGFB and the microsatellite markers D22S274 and D22S277, mapped on 22q13, were selected according to our previous loss of heterozygosity findings in head and neck tumors. Quantitative PCR relies on the comparison of the amount of product generated from a target gene and that generated from a disomic reference gene (GAPDH-housekeeping gene). Reactions have been performed with normal control in triplicates, using the 7700 Sequence Detection System (PE Applied Biosystems). Losses in the sequences D22S274 (22q13.31) and in the DIA1 (22q13.2-13.31) gene were detected in 10 out of 40 cases (25%) each. Statistically significant correlations were observed for patients with relative copy number loss of the marker D22S274 and stages T3-T4 of disease (P=0.025), family history of cancer (P = 0.001), and death (P = 0.021). Relative copy number loss involving the DIA1 gene was correlated to family history of cancer (P<0.001), death (P=0.002), and consumption of alcohol (P=0.026). Log-rank test revealed a significant decrease in survival (P=0.0018) for patients with DIA1 gene loss. Relative copy number losses detected in these sequences may be related to disease progression and a worse prognosis in patients with oral cancer.	Univ Estadual Paulista, Dept Genet, Sao Paulo, Brazil; Hosp AC Carmargo Fundacao Antonio Prudente, Sao Paulo, Brazil; Univ Estadual Paulista, Hosp Clin, Sao Paulo, Brazil; Univ Hlth Network, Dept Pathol, Toronto, ON, Canada; Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M4X 1K9, Canada	Universidade Estadual Paulista; A.C.Camargo Cancer Center; Universidade de Sao Paulo; Universidade Estadual Paulista; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Rogatto, SR (corresponding author), Univ Estadual Paulista, Dept Genet, Sao Paulo, Brazil.		Kowalski, Luiz P/D-1701-2012; Squire, Jeremy A/F-4437-2012; dos Reis, Patricia Pintor/F-4701-2012; Squire, Jeremy A/A-9352-2012; Rogatto, Silvia R/E-6535-2012	Kowalski, Luiz P/0000-0002-0481-156X; dos Reis, Patricia Pintor/0000-0003-3775-3797; Squire, Jeremy A/0000-0002-9863-468X; Kamel-Reid, Suzanne/0000-0002-4386-0292; Rogatto, Silvia/0000-0003-4637-5687				*AJCC, 1998, CANC STAG HDB AJCC C; Bergamo NA, 2000, CANCER GENET CYTOGEN, V119, P48, DOI 10.1016/S0165-4608(99)00213-7; Bieche I, 1998, INT J CANCER, V78, P661, DOI 10.1002/(SICI)1097-0215(19981123)78:5<661::AID-IJC22>3.3.CO;2-9; Biegel JA, 2000, GENE CHROMOSOME CANC, V28, P31, DOI 10.1002/(SICI)1098-2264(200005)28:1<31::AID-GCC4>3.0.CO;2-Y; Blancato JK, 1999, PRINCIPLES OF CLINICAL CYTOGENETICS, P443; Bockmuhl U, 1998, HEAD NECK-J SCI SPEC, V20, P145, DOI 10.1002/(SICI)1097-0347(199803)20:2<145::AID-HED8>3.0.CO;2-2; BOYD JM, 1995, ONCOGENE, V11, P1921; Bryan EJ, 2000, INT J CANCER, V87, P798, DOI 10.1002/1097-0215(20000915)87:6<798::AID-IJC6>3.0.CO;2-X; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Castells A, 1999, GASTROENTEROLOGY, V117, P831, DOI 10.1016/S0016-5085(99)70341-0; Cortesina G, 2000, INT J CANCER, V89, P286, DOI 10.1002/1097-0215(20000520)89:3<286::AID-IJC12>3.3.CO;2-L; Dracopoli N. C., 2000, CURRENT PROTOCOLS HU; ENGLEFIELD P, 1994, BRIT J CANCER, V70, P905, DOI 10.1038/bjc.1994.418; Goff LK, 2000, BRIT J HAEMATOL, V111, P618, DOI 10.1046/j.1365-2141.2000.02352.x; Grati FR, 2000, CANCER GENET CYTOGEN, V118, P57, DOI 10.1016/S0165-4608(99)00199-5; HAGIWARA K, 1991, MOL CELL BIOL, V11, P2125, DOI 10.1128/MCB.11.4.2125; Helenius MA, 2001, CANCER RES, V61, P5340; JOSEPHS SF, 1984, SCIENCE, V225, P636, DOI 10.1126/science.6740330; Kim NG, 2000, INT J CANCER, V85, P633, DOI 10.1002/(SICI)1097-0215(20000301)85:5<633::AID-IJC6>3.3.CO;2-X; Kitamura Y, 2000, GENE CHROMOSOME CANC, V27, P244; Lehmann U, 2000, AM J PATHOL, V156, P1855, DOI 10.1016/S0002-9440(10)65059-6; Lo YMD, 2000, CANCER RES, V60, P6878; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; Mitas M, 2001, INT J CANCER, V93, P162, DOI 10.1002/ijc.1312; Miyakawa A, 1998, INT J ONCOL, V13, P705; Nakanishi H, 2000, INT J CANCER, V89, P411, DOI 10.1002/1097-0215(20000920)89:5<411::AID-IJC3>3.0.CO;2-5; Oskam NT, 2000, INT J CANCER, V85, P336, DOI 10.1002/(SICI)1097-0215(20000201)85:3<336::AID-IJC7>3.0.CO;2-9; Peter M, 2001, LAB INVEST, V81, P905, DOI 10.1038/labinvest.3780299; Poli-Frederico RC, 2000, HEAD NECK-J SCI SPEC, V22, P585, DOI 10.1002/1097-0347(200009)22:6<585::AID-HED7>3.0.CO;2-4; Quon H, 2001, HEAD NECK-J SCI SPEC, V23, P147, DOI 10.1002/1097-0347(200102)23:2<147::AID-HED1010>3.0.CO;2-#; REIS PP, 2002, MED SCI MONIT, V8, pBR89; RENAN MJ, 1993, MOL CARCINOGEN, V7, P139; Rogatto SR, 1999, CANCER GENET CYTOGEN, V110, P23, DOI 10.1016/S0165-4608(98)00192-7; Ruiz-Ponte C, 2000, CLIN CHEM, V46, P1574; SHIN E, 1993, JPN J CANCER RES, V84, P402, DOI 10.1111/j.1349-7006.1993.tb00150.x; Simpson D, 2000, MOL VIS, V6, P178; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; Ueki K, 1999, CANCER RES, V59, P5995; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; *WHO, 1990, INT CLASS DIS ONC; Wight AJ, 1998, ORAL ONCOL, V34, P441, DOI 10.1016/S1368-8375(98)00022-0	42	37	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2002	21	42					6480	6487		10.1038/sj.onc.1205864	http://dx.doi.org/10.1038/sj.onc.1205864			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226751				2022-12-17	WOS:000177925300008
J	Gu, LY; Cline-Brown, B; Zhang, FJ; Qiu, L; Li, GM				Gu, LY; Cline-Brown, B; Zhang, FJ; Qiu, L; Li, GM			Mismatch repair deficiency in hematological malignancies with microsatellite instability	ONCOGENE			English	Article						hMSH2; hMLH1; microsatellite instability; hematological malignancy	NUCLEAR EXTRACTS; CELL-LINES; CANCER; GENE; LEUKEMIA; BETA; HETERODIMER; SUPPRESSION; MUTATIONS; EXPRESSION	Mutations in human mismatch repair (MMR) genes are the genetic basis for certain types of solid tumors displaying microsatellite instability (MSI). MSI has also been observed in hematological malignancies, but whether these hematological malignancies are associated with MMR deficiency is still unclear. Using both biochemical and genetic approaches, this study analysed MMR proficiency in 11 cell lines derived from patients with hematological malignancies and demonstrated that six out of seven hematological cancer cell lines with MSI were defective in strand-specific MMR. In vitro complementation experiments, using characterized MMR mutant extracts or purified proteins, showed that these hematological cancer cells were defective in either hMutSalpha (a heterodimer of hMSH2 and hMSH6) or hMutLalpha (a heterodimer of hMLH1 and hPMS2). Furthermore, cell lines deficient in hMutSalpha showed large deletions or point mutations in hMSH2, while those deficient in hMutLalpha. exhibited point mutations in hMLH1 or a lack of expression of hPMS2. From these results, we conclude that, as in solid tumors, hematological malignancies with MSI are also associated with MMR deficiency, and that the cause of MMR deficiency in these cell lines is due to a defective MutSalpha or MutLalpha. We also report here, for the first time, that an MSI-positive cell line derived from Burkitt's lymphoma is proficient in MMR.	Univ Kentucky, Ctr Med, Dept Pathol & Lab Med, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Grad Ctr Nutr Sci, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky	Gu, LY (corresponding author), Univ Kentucky, Ctr Med, Dept Pathol & Lab Med, 800 Rose St, Lexington, KY 40536 USA.	lgu0@uky.edu	Li, Guo-Min/I-5016-2014	Li, Guo-Min/0000-0002-9842-4578	NCI NIH HHS [CA85377] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085377] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Boland CR, 1998, CANCER RES, V58, P5248; BOYER JC, 1995, CANCER RES, V55, P6063; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; DeVita S, 1997, BRIT J HAEMATOL, V97, P463, DOI 10.1046/j.1365-2141.1997.252670.x; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Hangaishi A, 1997, BLOOD, V89, P1740, DOI 10.1182/blood.V89.5.1740.1740_1740_1747; Hayami Y, 1999, LEUKEMIA LYMPHOMA, V32, P345, DOI 10.3109/10428199909167395; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Hsieh P, 2001, MUTAT RES-DNA REPAIR, V486, P71, DOI 10.1016/S0921-8777(01)00088-X; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Kaneko H, 1996, INT J CANCER, V69, P480, DOI 10.1002/(SICI)1097-0215(19961220)69:6<480::AID-IJC11>3.0.CO;2-5; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kodera T, 1999, GENE CHROMOSOME CANC, V26, P267, DOI 10.1002/(SICI)1098-2264(199911)26:3<267::AID-GCC13>3.0.CO;2-V; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; Larson RS, 1997, BLOOD, V89, P1114, DOI 10.1182/blood.V89.3.1114; Leung WK, 2000, J BIOL CHEM, V275, P15728, DOI 10.1074/jbc.M908768199; Levati L, 1998, GENE CHROMOSOME CANC, V23, P159, DOI 10.1002/(SICI)1098-2264(199810)23:2<159::AID-GCC9>3.0.CO;2-1; Li GM, 1999, ONCOL RES, V11, P393; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Lipkin SM, 2000, NAT GENET, V24, P27, DOI 10.1038/71643; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Molenaar JJ, 1998, BLOOD, V92, P230, DOI 10.1182/blood.V92.1.230.413k17_230_233; Myung K, 2001, NATURE, V411, P1073, DOI 10.1038/35082608; Myung KJ, 2001, CELL, V104, P397, DOI 10.1016/S0092-8674(01)00227-6; Nakagawa T, 1999, P NATL ACAD SCI USA, V96, P14186, DOI 10.1073/pnas.96.25.14186; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; SU SS, 1988, J BIOL CHEM, V263, P6829; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367; Zhu YM, 1999, BLOOD, V94, P733, DOI 10.1182/blood.V94.2.733.414k03_733_740	41	37	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5758	5764		10.1038/sj.onc.1205695	http://dx.doi.org/10.1038/sj.onc.1205695			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173046				2022-12-17	WOS:000177463400011
J	Clark, PA; Llanos, S; Peters, G				Clark, PA; Llanos, S; Peters, G			Multiple interacting domains contribute to p14(ARF) mediated inhibition of MDM2	ONCOGENE			English	Article						p53; tumour suppressor; INK4a/ARF; MDM2; nucleolus	TUMOR-SUPPRESSOR; NUCLEOLAR LOCALIZATION; P53; ARF; MUTATIONS; LOCUS; DEGRADATION; P16(INK4A); PROMOTES; P19(ARF)	The small basic protein p14(Arf), encoded by one of the alternative transcripts from the human INK4A/ARF locus, interferes with MDM2-mediated ubiquitination of the p53 tumour suppressor protein. The resultant stabilization of p53 leads to increased expression of p53-regulated genes, such as MDM2 itself and the cyclin-dependent kinase inhibitor p21(CIP1). Here we relate physical interactions between p][4111 and MDM2, as determined using synthetic peptides and systematic deletions of p14(Arf), with consequential effects on p53 stabilization and transcriptional activity. The data imply that the amino terminal half of p14(Arf), encoded by the alternative first exon (exon 1beta) contacts MDM2 through multiple domains that can independently impede MDM2-mediated degradation of p53, provided that they are localized in the cell nucleus. As well as identifying previously unrecognized functional domains, our findings offer an explanation for the relative paucity of missense mutations in exon 1beta in human tumours.	London Res Inst, Canc Res UK, Lincolns Inn Fields Labs, London WC2A 3PX, England	Cancer Research UK	Peters, G (corresponding author), London Res Inst, Canc Res UK, Lincolns Inn Fields Labs, 61 Lincolns Inn Fields, London WC2A 3PX, England.	g.peters@cancer.org.uk	, Susana/AAA-9282-2019	Llanos, Susana/0000-0002-8555-9326				Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; BATES S, 1994, ONCOGENE, V9, P1633; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; DiGiammarino EL, 2001, BIOCHEMISTRY-US, V40, P2379, DOI 10.1021/bi0024005; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MIYASHITA T, 1995, CELL, V80, P293; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	35	37	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2002	21	29					4498	4507		10.1038/sj.onc.1205558	http://dx.doi.org/10.1038/sj.onc.1205558			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085228				2022-12-17	WOS:000176476700004
J	Tureci, O; Sahin, U; Koslowski, M; Buss, B; Bell, C; Ballweber, P; Zwick, C; Eberle, T; Zuber, M; Villena-Heinsen, C; Seitz, G; Pfreundschuh, M				Tureci, O; Sahin, U; Koslowski, M; Buss, B; Bell, C; Ballweber, P; Zwick, C; Eberle, T; Zuber, M; Villena-Heinsen, C; Seitz, G; Pfreundschuh, M			A novel tumour associated leucine zipper protein targeting to sites of gene transcription and splicing	ONCOGENE			English	Article						tumour-associated; antigen; N-myc; leucine zipper	CYTOLYTIC T-LYMPHOCYTES; PRE-MESSENGER-RNA; SECONDARY STRUCTURE PREDICTION; SEROLOGICAL IDENTIFICATION; AUTOIMMUNE SERA; HUMAN-MELANOMA; CDNA CLONING; ANTIGENS; CANCER; LOCALIZATION	We describe here the definition and characterization of antigen CT-8/HOM-TES-85 encoded by a previously unknown gene and identified by serological expression screening using antibodies from a seminoma patient. Intriguingly, the leucine zipper region of CT-8/HOM-TES-85 shows an atypical amphipathy with clusters of hydrophobic residues that is exclusively shared by the N-myc proto-oncogene. CT-8/HOM-TES-85 gene is tightly silenced in normal tissues except for testis. However, it is frequently activated in human neoplasms of different types including lung cancer, ovarian cancer, melanoma and glioma. Endogenous as well as heterogeneously expressed CT-8/HOM-TES-85 targets predominantly, to the nucleus forming a distinctive speckled pattern of nuclear dots arranged in macromolecular structures. By co-localization studies these speckles were identified as loci of transcriptional activity and splicing, suggesting that CT-8/HOM-TES-85 may be involved in these processes. The aberrant expression of CT-8/HOM-TES-85 in human neoplasms might therefore be involved in cancer associated alterations of transcriptional or post-transcriptional processes and thus may disclose new mechanisms involved in the manifestation of the cancer phenotype.	Univ Mainz, Med Klin & Poliklin 3, D-55131 Mainz, Germany; Klinikum Bamberg, Abt Pathol, Bamberg, Germany; Stadtklin, Abt Gynakol, Baden, Switzerland; Univ Leipzig, Inst Humangenet, Leipzig, Germany; Univ Klinikun Saarlandes, Med Klin & Poliklin 1, Saarlandes, Germany	Johannes Gutenberg University of Mainz; Leipzig University; Universitatsklinikum des Saarlandes	Sahin, U (corresponding author), Univ Mainz, Med Klin 3, D-55131 Mainz, Germany.	Sahin@mail.uni-mainz.de	Sahin, Ugur/L-4818-2017	Sahin, Ugur/0000-0003-0363-1564				ANDRADE LEC, 1991, J EXP MED, V173, P1407, DOI 10.1084/jem.173.6.1407; Bergsagel P L, 1992, Curr Top Microbiol Immunol, V182, P223; BOEL P, 1995, IMMUNITY, V2, P167, DOI 10.1016/S1074-7613(95)80053-0; Boon T, 1997, CURR OPIN IMMUNOL, V9, P681, DOI 10.1016/S0952-7915(97)80049-0; Boon T, 1997, IMMUNOL TODAY, V18, P267, DOI 10.1016/S0167-5699(97)80020-5; CHAN EKL, 1989, J AUTOIMMUN, V2, P321, DOI 10.1016/0896-8411(89)90159-5; Chen YT, 1999, CANCER J SCI AM, V5, P16; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; De Smet C, 1999, MOL CELL BIOL, V19, P7327; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Disis ML, 1996, CURR OPIN IMMUNOL, V8, P637, DOI 10.1016/S0952-7915(96)80079-3; Eichmuller S, 2001, P NATL ACAD SCI USA, V98, P629, DOI 10.1073/pnas.021386498; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Garnier J, 1996, METHOD ENZYMOL, V266, P540; GAUGLER B, 1995, J EXP MED, V79, P921; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; Gure AO, 2000, P NATL ACAD SCI USA, V97, P4198, DOI 10.1073/pnas.97.8.4198; Halle JP, 1996, TRENDS GENET, V12, P161, DOI 10.1016/0168-9525(96)30035-8; KALLENBERG CGM, 1990, CLIN RHEUMATOL, V9, P136, DOI 10.1007/BF02205562; Kim J, 2000, GENOME RES, V10, P1138, DOI 10.1101/gr.10.8.1138; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; Kramer H, 1996, J CELL BIOL, V133, P1205, DOI 10.1083/jcb.133.6.1205; Lethe B, 1998, INT J CANCER, V76, P903, DOI 10.1002/(SICI)1097-0215(19980610)76:6<903::AID-IJC22>3.0.CO;2-1; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; MCCAULIFFE DP, 1989, J AUTOIMMUN, V2, P375, DOI 10.1016/0896-8411(89)90166-2; MEUWISSEN RJL, 1997, GENOMICS, V37, P101; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Neugebauer KM, 1997, GENE DEV, V11, P1148, DOI 10.1101/gad.11.9.1148; OCHS RL, 1985, BIOL CELL, V54, P123, DOI 10.1111/j.1768-322X.1985.tb00387.x; Old LJ, 1998, J EXP MED, V187, P1163, DOI 10.1084/jem.187.8.1163; Ono T, 2001, P NATL ACAD SCI USA, V98, P3282, DOI 10.1073/pnas.041625098; RUBINFELD B, 1997, CANCER RES, V57, P462; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Sahin U, 1997, CURR OPIN IMMUNOL, V9, P709, DOI 10.1016/S0952-7915(97)80053-2; Sahin U, 1998, INT J CANCER, V78, P387, DOI 10.1002/(SICI)1097-0215(19981029)78:3<387::AID-IJC22>3.0.CO;2-2; Sleeman JE, 1999, CURR OPIN CELL BIOL, V11, P372, DOI 10.1016/S0955-0674(99)80052-0; Stockert E, 1998, J EXP MED, V187, P1349, DOI 10.1084/jem.187.8.1349; SZOSTECKI C, 1987, CLIN EXP IMMUNOL, V68, P108; Tureci O, 1996, CANCER RES, V56, P4766; Tureci O, 1997, MOL MED TODAY, V3, P342, DOI 10.1016/S1357-4310(97)01081-2; Tureci O, 1998, P NATL ACAD SCI USA, V95, P5211, DOI 10.1073/pnas.95.9.5211; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; VENROOIJ WJ, 1989, CLIN EXP RHEUMATOL, V7, P635; WANG J, 1991, P NATL ACAD SCI USA, V88, P7391, DOI 10.1073/pnas.88.16.7391; Wang RF, 1999, SCIENCE, V284, P1351, DOI 10.1126/science.284.5418.1351; Wei XY, 1999, J CELL BIOL, V146, P543, DOI 10.1083/jcb.146.3.543; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Wynshaw-Boris A, 2001, GENE DEV, V15, P639, DOI 10.1101/gad.886801	53	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3879	3888		10.1038/sj.onc.1205481	http://dx.doi.org/10.1038/sj.onc.1205481			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032826				2022-12-17	WOS:000175847200007
J	Lui, WO; Chen, JD; Glasker, S; Bender, BU; Madura, C; Khoo, SK; Kort, E; Larsson, C; Neumann, HPH; Teh, BT				Lui, WO; Chen, JD; Glasker, S; Bender, BU; Madura, C; Khoo, SK; Kort, E; Larsson, C; Neumann, HPH; Teh, BT			Selective loss of chromosome 11 in pheochromocytomas associated with the VHL syndrome	ONCOGENE			English	Article						von Hippel-Lindau; VHL; pheochromocytoma; comparative genomic hybridization	COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; MUTATIONS; DISEASE; TUMORIGENESIS; COMPLEX; PROTEIN; 1P; 3Q	By using comparative genomic hybridization (CGH), we characterized the genetic profiles of 36 VHL-related pheochromocytomas. We then compared the results with those of sporadic and MEN 2-related pheochromocytomas. In 36 VHL-related tumors, loss of chromosome 3 and chromosome 11 were found in 34 tumors (94%) and 31 tumors (86%), respectively. There was significant concordance of deletions in chromosomes 3 and 11 (Kappa = 0.64, P = 0.0095), suggesting that they are involved in two different but necessary and complementary genetic pathways. The loss of chromosome 11 appeared to be specific for VHL-related pheochromocytoma as it was not present in any of the 10 VHL-related CNS hemangioblastomas studied and was significantly less common when compared with (a) sporadic pheochromocytomas from previously published results (13%; P = <0.0001), and (b) MEN 2-related pheochromocytomas from this and previously published studies (30%; P = 0.0012). In summary, this is the first report of a novel consistent genetic alteration that is selected and specific for VHL-related pheochromocytoma, besides the two hits of the VHL gene.	Van Andel Res Inst, Canc Genet Lab, Grand Rapids, MI 49503 USA; Karolinska Hosp, Dept Mol Med, S-10401 Stockholm, Sweden; Univ Freiburg, Dept Hypertens & Nephrol, Freiburg, Germany; Van Andel Res Inst, Lab Analyt Cellular & Mol Microscopy, Grand Rapids, MI 49503 USA	Van Andel Institute; Karolinska Institutet; Karolinska University Hospital; University of Freiburg; Van Andel Institute	Teh, BT (corresponding author), Van Andel Res Inst, Canc Genet Lab, 333 Bostwick NE, Grand Rapids, MI 49503 USA.		Lui, Weng-Onn/X-5957-2019; Lui, Weng-Onn/G-6703-2013; Gläsker, Sven/AAB-9362-2022	Lui, Weng-Onn/0000-0003-4717-4473; Lui, Weng-Onn/0000-0003-4717-4473; Khoo, Sok Kean/0000-0003-3836-5497				Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Bender BU, 2000, J CLIN ENDOCR METAB, V85, P4568, DOI 10.1210/jc.85.12.4568; Benn DE, 2000, CANCER RES, V60, P7048; BRAUCH H, 1995, HUM GENET, V95, P551, DOI 10.1007/BF00223868; Canzian F, 1996, CANCER RES, V56, P3331; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; Dannenberg H, 2000, AM J PATHOL, V157, P353, DOI 10.1016/S0002-9440(10)64547-6; Edstrom E, 2000, AM J PATHOL, V156, P651, DOI 10.1016/S0002-9440(10)64769-4; Farnebo F, 1999, J CLIN ENDOCR METAB, V84, P3775, DOI 10.1210/jc.84.10.3775; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Gimm O, 2000, CANCER RES, V60, P6822; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ramus SJ, 1999, GENE CHROMOSOME CANC, V25, P91, DOI 10.1002/(SICI)1098-2264(199906)25:2<91::AID-GCC3>3.0.CO;2-5; Schussheim DH, 2001, TRENDS ENDOCRIN MET, V12, P173, DOI 10.1016/S1043-2760(00)00372-6; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565	20	37	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2002	21	7					1117	1122		10.1038/sj.onc.1205149	http://dx.doi.org/10.1038/sj.onc.1205149			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850829				2022-12-17	WOS:000173580100015
J	Crish, JF; Bone, F; Banks, EB; Eckert, RL				Crish, JF; Bone, F; Banks, EB; Eckert, RL			The human involucrin gene contains spatially distinct regulatory elements that regulate expression during early versus late epidermal differentiation	ONCOGENE			English	Article						transgenic mice; activator protein-1; AP1; jun; fos; Sp1; gene regulation; epidermal keratinocyte; keratinocyte differentiation; tissue specific	PROTEIN-KINASE-C; CORNIFIED CELL-ENVELOPE; CROSS-LINKED ENVELOPE; HUMAN KERATIN-1 GENE; PROMOTER ACTIVITY; TRANSGENIC MICE; TERMINAL DIFFERENTIATION; AP-1 ELEMENT; TRANSCRIPTION; FOS	Human involucrin (hINV) is a keratinocyte protein that is expressed in the suprabasal compartment of the epidermis and other stratifying surface epithelia. Involucrin gene expression is initiated early in the differentiation process and is maintained until terminal cell death. The distal regulatory region (DRR) is a segment of the hINV promoter (nucleotides -2473/ -1953) that accurately recapitulates the normal pattern of suprabasal (spinous and granular layer) expression in transgenic mouse epithelia. To identify sequences that mediate expression at specific stages of differentiation, we divided the DRR into two segments, a 376 nucleotide upstream region (DRR-2473/-2100) and a 147 nucleotide downstream region (DRR-2100/-1953), and evaluated the ability of these sequences to drive expression in transgenic mice. The DRR-2473/-2100 segment drives expression at a level comparable to that observed for the DRR, but expression is restricted to the upper granular layers (i.e., no spinous layer expression). In contrast, the DRR-2100/-1953 segment does not drive expression. However, reassembling the DRR restores the complete range of expression. These results suggest that two distinct, spatially-separate elements are required to specify the complete differenation-dependent program of involucrin gene expression. To identify specific transcription factor binding sites involved in this regulation, we mutated an activator protein-1 binding site, AP1-5, located within DRR-2473/-2100 segment. This site binds AP1 transcription factors present in mouse epidermal extracts, and its mutation eliminates appropriate hINV expression. This result suggests that AP1 factors participate as components of a multicomponent transcription factor complex that is required for regulation.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Room E532,2109 Adelbert Rd, Cleveland, OH 44106 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39750] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Banks EB, 1999, BIOCHEM J, V337, P507, DOI 10.1042/0264-6021:3370507; Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; Bernerd Francoise, 1993, Gene Expression, V3, P187; BICKENBACH JR, 1995, J INVEST DERMATOL, V104, P405, DOI 10.1111/1523-1747.ep12665896; BRIATA P, 1993, EXP CELL RES, V204, P136, DOI 10.1006/excr.1993.1018; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; Crish JF, 1998, J BIOL CHEM, V273, P30460, DOI 10.1074/jbc.273.46.30460; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Efimova T, 2000, J BIOL CHEM, V275, P1601, DOI 10.1074/jbc.275.3.1601; FEI YJ, 1995, BIOTECHNIQUES, V18, P984; FISHER C, 1991, DEVELOPMENT, V111, P253; Green H, 1980, Harvey Lect, V74, P101; HOHL D, 1993, DIFFERENTIATION, V54, P25, DOI 10.1111/j.1432-0436.1993.tb00656.x; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; HUFF CA, 1993, J BIOL CHEM, V268, P377; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; LaCelle PT, 1998, SKIN PHARMACOL APPL, V11, P214, DOI 10.1159/000029830; LU B, 1994, J BIOL CHEM, V269, P7443; Medvedev A, 1999, J BIOL CHEM, V274, P3887, DOI 10.1074/jbc.274.6.3887; MURPHY GF, 1984, J INVEST DERMATOL, V82, P453, DOI 10.1111/1523-1747.ep12260945; MURTHY S, 1993, J STRUCT BIOL, V111, P68, DOI 10.1006/jsbi.1993.1037; Ng DC, 2000, J BIOL CHEM, V275, P24080, DOI 10.1074/jbc.M002508200; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; Rutberg SE, 1996, ONCOGENE, V13, P167; Steinert P M, 1995, Cell Death Differ, V2, P33; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; Takahashi H, 1998, J INVEST DERMATOL, V110, P218, DOI 10.1046/j.1523-1747.1998.00110.x; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; Welter JF, 1996, J BIOL CHEM, V271, P14727, DOI 10.1074/jbc.271.25.14727; Welter JF, 1995, ONCOGENE, V11, P2681; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yamada K, 1997, HUM MOL GENET, V6, P2223, DOI 10.1093/hmg/6.13.2223	49	37	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					738	747		10.1038/sj.onc.1205038	http://dx.doi.org/10.1038/sj.onc.1205038			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850802				2022-12-17	WOS:000173427000005
J	Yao, Z; Flash, I; Raviv, Z; Yung, Y; Asscher, YD; Pleban, S; Seger, R				Yao, Z; Flash, I; Raviv, Z; Yung, Y; Asscher, YD; Pleban, S; Seger, R			Non-regulated and stimulated mechanisms cooperate in the nuclear accumulation of MEK1	ONCOGENE			English	Article						MAPK; MEK; leptomycin B; nuclear translocation	ACTIVATED PROTEIN-KINASE; MAP KINASE; EXPORT SIGNAL; TRANSPORT; ERK; LOCALIZATION; CELLS; PHOSPHORYLATION; TRANSLOCATION; TRANSDUCTION	MEKs, which operate within the ERK cascade, shuttle into the nucleus, but are rapidly exported from this location, forming an apparent cytosolic distribution both before and after stimulation. Two different mechanisms have been proposed for the nuclear translocation of MEKs. One of them involves a constant and nonregulated shuttling of MEKs into the nucleus operating both before and after mitogenic stimulation. The other mechanism seems to require the activity of MEKs and is facilitated in response to mitogenic stimulation. Here we show that these two mechanisms may coexist in the same cells. We found that leptomycin B (LMB), a potent inhibitor of nuclear export, induces a nuclear accumulation of MEKs, and this was significantly facilitated by stimulation of LMB-treated cells with EGF, TPA and peroxovanadate. The EGF-stimulated, but not the LMB-induced translocation was attenuated by MEK inhibitors and by using inactive forms of MEK1. We also show that LMB slightly activates the ERK cascade, but this activity only partially induces the nuclear accumulation of MEKs in cells treated by LMB alone. Thus, MEKs translocate into the nucleus by a combination of nonregulated and stimulated processes that contribute to the nuclear translocation of MEKs either in resting cells or upon mitogenic stimulation.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Sigma Aldrich Israel Ltd, Jerusalem, Israel	Weizmann Institute of Science; Merck KGaA; MilliporeSigma	Seger, R (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.							Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Akey C W, 1991, Semin Cell Biol, V2, P167; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gotoh I, 1999, J BIOL CHEM, V274, P11874, DOI 10.1074/jbc.274.17.11874; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEGER R, 1992, J BIOL CHEM, V267, P14373; Tolwinski NS, 1999, J BIOL CHEM, V274, P6168, DOI 10.1074/jbc.274.10.6168; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0; Yung Y, 2001, J BIOL CHEM, V276, P35280, DOI 10.1074/jbc.M105995200; Yung YV, 2000, J BIOL CHEM, V275, P15799, DOI 10.1074/jbc.M910060199; ZHENG CF, 1993, J BIOL CHEM, V268, P23933	27	37	39	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2001	20	52					7588	7596		10.1038/sj.onc.1204963	http://dx.doi.org/10.1038/sj.onc.1204963			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753637				2022-12-17	WOS:000172124100002
J	De Toledo, M; Coulon, V; Schmidt, S; Fort, P; Blangy, A				De Toledo, M; Coulon, V; Schmidt, S; Fort, P; Blangy, A			The gene for a new brain specific RhoA exchange factor maps to the highly unstable chromosomal region 1p36.2-1p36.3.	ONCOGENE			English	Article						Rho GTPase; Dbl exchange factor; transformation; 1p36; chromosome 1	HETEROTRIMERIC G-PROTEINS; NEUROBLASTOMA CELL-LINE; GTP-BINDING PROTEIN; SIGNALING PATHWAYS; ACTIVATION; FAMILY; IDENTIFICATION; GTPASES; DELETION; RAC1	Guanine nucleotide exchange factors from the Dbl family are proto-oncogenic proteins that activate small GTPases of the Rho family. Here we report the characterization of GEF720, a novel Dbl-like protein related to p115Rho-GEF. GEF720 activated RhoA both in our recently developed Yeast Exchange Assay and in biochemical in vitro exchange assays. GEF720 induced RhoA dependent assembly of actin stress fibers in REF52 fibroblastic cells. In NIH3T3 cells this Dbl-like protein elicited formation of transformation foci with a morphology similar to RhoA-V14 induced foci. In the PC12 neuron-like cell line, expression of GEF720, whose mRNA is brain specific, inhibited NGF-induced neurite outgrowth. Finally, GEF720 gene is located on human chromosome 1 on band 1p36, between Tumor Protein 73 and Tumor Necrosis Factor Receptor 12, two genes rearranged in many neuroblastoma cell lines. Together, these results show that this new Dbl related protein, GEF720, is an exchange factor that can directly activate RhoA in vivo and is potentially involved in the control of neuronal cell differentiation. GEF720 is also a new candidate gene involved in the progression of neuroblastoma and developmental abnormalities associated with rearrangements in the 1p36 chromosomal region.	Ctr Rech Biochim Macromol, CNRS IFR24 UPR 1086, F-34293 Montpellier 5, France; Inst Genet Mol Montpellier, CNRS IFR24 UMR 5535, F-34293 Montpellier 5, France	Universite de Montpellier	Blangy, A (corresponding author), Ctr Rech Biochim Macromol, CNRS IFR24 UPR 1086, 1919 Route Mende, F-34293 Montpellier 5, France.	blangy@crbm.cnrs-mop.fr	Coulon, Vincent/AFF-7934-2022; Coulon, Vincent/B-2437-2009; Fort, Philippe/M-9498-2015	Coulon, Vincent/0000-0002-3168-8755; Coulon, Vincent/0000-0002-3168-8755; Fort, Philippe/0000-0001-5997-8722; BLANGY, Anne/0000-0001-7043-0784				Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Aman AK, 2000, GENE CHROMOSOME CANC, V29, P292, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1038>3.0.CO;2-C; Amler LC, 2000, GENOMICS, V64, P195, DOI 10.1006/geno.1999.6097; Aronheim A, 1998, CURR BIOL, V8, P1125, DOI 10.1016/S0960-9822(98)70468-3; Bellanger JM, 1998, ONCOGENE, V16, P147, DOI 10.1038/sj.onc.1201532; Blangy A, 2000, J CELL SCI, V113, P729; Blomquist A, 2000, BIOCHEM J, V352, P319, DOI 10.1042/0264-6021:3520319; Caron H, 2001, GENE CHROMOSOME CANC, V30, P168, DOI 10.1002/1098-2264(200102)30:2<168::AID-GCC1072>3.0.CO;2-E; Cho JH, 2000, HUM MOL GENET, V9, P1425, DOI 10.1093/hmg/9.9.1425; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Coulon V, 1999, J BIOL CHEM, V274, P30439, DOI 10.1074/jbc.274.43.30439; De Toledo M, 2000, FEBS LETT, V480, P287, DOI 10.1016/S0014-5793(00)01953-0; Ejeskar K, 2000, CYTOGENET CELL GENET, V89, P62, DOI 10.1159/000015566; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Fort P, 1999, Prog Mol Subcell Biol, V22, P159; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Fukushima S, 2000, EXP HEMATOL, V28, P391, DOI 10.1016/S0301-472X(00)00129-6; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Grenet J, 1998, GENOMICS, V49, P385, DOI 10.1006/geno.1998.5300; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Heilstedt HA, 1999, CLIN GENET, V56, P123, DOI 10.1034/j.1399-0004.1999.560205.x; Hogarty MD, 2000, MED PEDIATR ONCOL, V35, P512, DOI 10.1002/1096-911X(20001201)35:6<512::AID-MPO2>3.0.CO;2-D; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Janssen JWG, 1999, INT J CANCER, V80, P857; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Knight-Jones E, 2000, DEV MED CHILD NEUROL, V42, P201, DOI 10.1017/S0012162200000347; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kutsche K, 2000, NAT GENET, V26, P247, DOI 10.1038/80002; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Marsters SA, 1998, CURR BIOL, V8, P525, DOI 10.1016/S0960-9822(98)70204-0; McWhirter JR, 1997, ONCOGENE, V15, P1625, DOI 10.1038/sj.onc.1201342; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Murphy GA, 1999, ONCOGENE, V18, P3831, DOI 10.1038/sj.onc.1202758; NOGUCHI T, 1988, ONCOGENE, V3, P709; Nomoto S, 2000, GENE CHROMOSOME CANC, V28, P342, DOI 10.1002/1098-2264(200007)28:3<342::AID-GCC13>3.0.CO;2-A; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; Ridley A J, 1999, Prog Mol Subcell Biol, V22, P1; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Rumenapp U, 1999, FEBS LETT, V459, P313, DOI 10.1016/S0014-5793(99)01270-3; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Sebok A, 1999, J NEUROCHEM, V73, P949, DOI 10.1046/j.1471-4159.1999.0730949.x; Singh R, 1999, J CLIN INVEST, V103, P1561, DOI 10.1172/JCI5754; Slavotinek A, 1999, J MED GENET, V36, P657; Stam J C, 1999, Prog Mol Subcell Biol, V22, P51; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Tirode F, 1997, J BIOL CHEM, V272, P22995, DOI 10.1074/jbc.272.37.22995; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; Vignal E, 2000, J BIOL CHEM, V275, P36457, DOI 10.1074/jbc.M003487200; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759	66	37	38	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7307	7317		10.1038/sj.onc.1204921	http://dx.doi.org/10.1038/sj.onc.1204921			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704860				2022-12-17	WOS:000171894200003
J	Burek, C; Roth, J; Koch, HG; Harzer, K; Los, M; Schulze-Osthoff, K				Burek, C; Roth, J; Koch, HG; Harzer, K; Los, M; Schulze-Osthoff, K			The role of ceramide in receptor- and stress-induced apoptosis studied in acidic ceramidase-deficient Farber disease cells	ONCOGENE			English	Article						apoptosis; ceramide; ceramidase; CD95; Farber disease	NIEMANN-PICK-DISEASE; GD3 GANGLIOSIDE; SPHINGOMYELINASE; DEATH; CD95; MICE; FAS; ACTIVATION; CASPASE-3; ABSENCE	The activation of sphingomyelinases leading to the generation of ceramide has been implicated in various apoptotic pathways. However, the role of ceramide as an essential death mediator remains highly controversial. In the present study, we investigated the functional relevance of ceramide in a genetic model by using primary cells from a Farber disease patient. These cells accumulate ceramide as the result of an inherited deficiency of acidic ceramidase. We demonstrate that Farber disease lymphocytes and fibroblasts underwent apoptosis induced by various stress stimuli, including staurosporine, anticancer drugs and gamma -irradiation, equally as normal control cells. In addition, caspase activation by these proapoptotic agents occurred rather similarly in Farber disease and control fibroblasts. Interestingly, Farber disease lymphoid cells underwent apoptosis induced by the CD95 death receptor more rapidly than control cells. Our data therefore suggest that ceramide does not play an essential role as a second messenger in stress-induced apoptosis. However, in accordance with a role in lipid-rich microdomains, ceramide by altering membrane composition may function as an amplifier in CD95-mediated apoptosis.	Univ Munich, Dept Immunol & Cell Biol, D-48149 Munster, Germany; Univ Munster, Dept Pediat, D-4400 Munster, Germany; Univ Tubingen, Neurochem Lab, Tubingen, Germany	University of Munich; University of Munster; Eberhard Karls University of Tubingen	Schulze-Osthoff, K (corresponding author), Univ Munich, Dept Immunol & Cell Biol, Rontgenstr 21, D-48149 Munster, Germany.		Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Los, Marek/0000-0001-9518-1411				Bezombes C, 2001, FASEB J, V15, P297; Boesen-de Cock JGR, 1998, J BIOL CHEM, V273, P7560, DOI 10.1074/jbc.273.13.7560; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Chatelut M, 1998, FEBS LETT, V426, P102, DOI 10.1016/S0014-5793(98)00325-1; Chatelut M, 1996, CLIN CHIM ACTA, V245, P61, DOI 10.1016/0009-8981(95)06173-8; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Farina F, 2000, J HISTOCHEM CYTOCHEM, V48, P57, DOI 10.1177/002215540004800106; FUJIWAKI T, 1992, Acta Paediatrica Japonica, V34, P72; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Gulbins E, 2000, AM J PHYSIOL-RENAL, V279, pF605, DOI 10.1152/ajprenal.2000.279.4.F605; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; Holopainen JM, 1998, BIOCHEMISTRY-US, V37, P17562, DOI 10.1021/bi980915e; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Hsu SC, 1998, BLOOD, V91, P2658, DOI 10.1182/blood.V91.8.2658.2658_2658_2663; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kolodny EH, 2000, CURR OPIN HEMATOL, V7, P48, DOI 10.1097/00062752-200001000-00009; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Lin T, 2000, J BIOL CHEM, V275, P8657, DOI 10.1074/jbc.275.12.8657; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Los M, 2000, BIOCHEMISTRY-US, V39, P7365, DOI 10.1021/bi000158w; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; MOSER HW, 1969, AM J MED, V47, P869, DOI 10.1016/0002-9343(69)90202-2; Nishioka K, 1998, ARTHRITIS RHEUM, V41, P1; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; Qualman S J, 1987, Am J Med Genet Suppl, V3, P233; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Schissel SL, 1998, J BIOL CHEM, V273, P18250, DOI 10.1074/jbc.273.29.18250; Segui B, 2000, FASEB J, V14, P36, DOI 10.1096/fasebj.14.1.36; Spinedi A, 1999, BIOCHEM BIOPH RES CO, V255, P456, DOI 10.1006/bbrc.1999.0230; Strelow A, 2000, J EXP MED, V192, P601, DOI 10.1084/jem.192.5.601; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; SUGITA M, 1972, SCIENCE, V178, P1100, DOI 10.1126/science.178.4065.1100; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000	49	37	39	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6493	6502		10.1038/sj.onc.1204841	http://dx.doi.org/10.1038/sj.onc.1204841			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641773	Green Published			2022-12-17	WOS:000171404200001
J	Mehta, PB; Robson, CN; Neal, DE; Leung, HY				Mehta, PB; Robson, CN; Neal, DE; Leung, HY			Keratinocyte growth factor activates p38 MAPK to induce stress fibre formation in human prostate DU145 cells	ONCOGENE			English	Article						fibroblast growth factor; mitogen-activated protein kinase; Elk-1; MEF2A; actin; prostate	SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; KINASE PATHWAYS; PROTEIN-KINASES; POINT MUTATION; FGF RECEPTORS; EXPRESSION; TRANSCRIPTION; CANCER; PROLIFERATION	FGF7/Keratinocyte growth factor (KGF) regulates the differentiation and development of the prostate epithelium, while over-expression of FGF8 and FGF1 are implicated in carcinogenesis of the prostate. We tested the hypothesis that different members of the FGF family function through different signalling molecules. In prostate DU145 cells, both FGF1 and FGF2 activated ERK1/2 potently and p38 moderately. KGF was however most efficient in inducing p38 activities but had no effect on ERK1/2 function. JNK and STAT activities were not induced by FGFs in prostate cells. fn vitro expression of the transcription factors Elk-1 and MEF2A (substrates for ERK1/2 and p38, respectively) for functional quantification, confirmed the pattern of FGF-induced MAPK activations in COS-7 cells. Furthermore, KGF was more efficient than FGF1 and FGF2 in inducing actin stress fibres, and the specific p38 inhibitor SB202190 completely abolished this in a dose-dependent manner. The MEK1/2 inhibitor, U0126, had no effect on FGF-induced stress fibre formation. This study demonstrates the selective activation of MAPK family members by FGFs resulting in activation of transcription factors and stress fibre formation. As multiple FGFs are overexpressed in human prostate cancer, characterization of the distinct signalling pathway by FGFs may reveal new specific targets for therapy.	Univ Newcastle Upon Tyne, Sch Med, Sch Surg & Reprod Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Leung, HY (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Sch Surg & Reprod Sci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Leung, Hing Y./0000-0002-3933-3975; Neal, David/0000-0002-6033-5086				BRUNK U, 1976, EXP CELL RES, V103, P295, DOI 10.1016/0014-4827(76)90266-4; Byrne RL, 1996, BRIT J UROL, V77, P627, DOI 10.1046/j.1464-410X.1996.09721.x; Carstens RP, 1997, J AM SOC NEPHROL, V8, pA1849; Chandler LA, 1999, INT J CANCER, V81, P451, DOI 10.1002/(SICI)1097-0215(19990505)81:3<451::AID-IJC20>3.3.CO;2-8; Dieckgraefe BK, 1997, BIOCHEM BIOPH RES CO, V233, P389, DOI 10.1006/bbrc.1997.6469; Dorkin TJ, 1999, J PATHOL, V189, P564, DOI 10.1002/(SICI)1096-9896(199912)189:4<564::AID-PATH480>3.0.CO;2-1; Dorkin TJ, 1999, ONCOGENE, V18, P2755, DOI 10.1038/sj.onc.1202624; Feng SJ, 1997, CANCER RES, V57, P5369; Foster BA, 1999, PROSTATE CANCER P D, V2, P76; Ghosh PM, 1999, ONCOGENE, V18, P4120, DOI 10.1038/sj.onc.1202792; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Landgren E, 1998, ONCOGENE, V17, P283, DOI 10.1038/sj.onc.1201936; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Leung HY, 1997, ONCOGENE, V15, P1115, DOI 10.1038/sj.onc.1201256; Ling Y, 1997, EMBO J, V16, P2431, DOI 10.1093/emboj/16.9.2431; Matsubara A, 1998, CANCER RES, V58, P1509; McGarvey TW, 1995, EXP MOL PATHOL, V63, P52, DOI 10.1006/exmp.1995.1030; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; POTOSKY AL, 1995, JAMA-J AM MED ASSOC, V273, P548, DOI 10.1001/jama.273.7.548; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Velmuri GS, 1996, BIOCHEM J, V314, P805, DOI 10.1042/bj3140805; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710	36	37	37	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5359	5365		10.1038/sj.onc.1204688	http://dx.doi.org/10.1038/sj.onc.1204688			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536048				2022-12-17	WOS:000170575500011
J	Niu, MY; Menard, M; Reed, JC; Krajewski, S; Pratt, MAC				Niu, MY; Menard, M; Reed, JC; Krajewski, S; Pratt, MAC			Ectopic expression of cyclin D1 amplifies a retinoic acid-induced mitochondrial death pathway in breast cancer cells	ONCOGENE			English	Article						apoptosis; cyclin D1; retinoic acid; breast cancer	INDUCED CONFORMATIONAL CHANGE; MAMMARY EPITHELIAL-CELLS; CYTOCHROME-C RELEASE; RECEPTOR-BETA; BCL-2 FAMILY; IN-VITRO; HISTONE ACETYLTRANSFERASE; CHEMOPREVENTIVE AGENTS; GROWTH-INHIBITION; GENE-EXPRESSION	All-trans retinoic acid inhibits growth associated with downregulation of cyclin D1 and can cause lon level apoptosis in estrogen receptor positive breast cancer cell lines, The cyclin D1 gene is amplified and/or the protein overexpressed in about one-third of breast cancers. Constitutive expression of cyclin D1 in estrogen receptor positive MCF-7 and ZR-75 breast cancer cells (MCF-7(cycD1) and ZR-75(cycD1)) Increased the fraction of cells in S phase and reduced the G1 accumulation following retinoic acid treatment compared with control cells, However, culture of MCF-7(cycD1) with 1 muM all-trans retinoic acid resulted in about threefold greater growth inhibition compared with vector-transfected cells. Hoechst staining of DNA and lit situ DNA end-labeling analysis indicated that MCF-7(cycD1) and ZR-75(cycD1) cultures contained 4-6-fold more retinoic acid-induced apoptotic nuclei as vector-transfected cells. Retinoic acid treatment of vector-transfected clones resulted in Bax protein activation as assessed by exposure of the NH2-terminus of Bax but the proportion of cells containing activated Bax was increased in cyclin D-expressing cells treated with retinoic acid. The latter cells also displayed both immunocytochemical and biochemical evidence of translocation of cytochrome c into the cytosol following RA-treatment, Retinoic acid markedly decreased the Bcl-2 levels in MCF-7 and ZR-75 cells. Accordingly, coexpression of Bcl-2 and cyclin D1 rendered the cells resistant to retinoic acid-induced apoptosis, We conclude that constitutive expression of cyclin D1 sensitizes ER-positive breast cancer cells to a retinoic acid-induced mitochondrial death pathway involving Bax activation, cytochrome c release and caspase-9 cleavage.	Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Burnham Inst Canc Res, La Jolla, CA USA	University of Ottawa; Sanford Burnham Prebys Medical Discovery Institute	Pratt, MAC (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.				NIGMS NIH HHS [GM60554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060554] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bardon S, 1998, INT J ONCOL, V12, P355; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eck KM, 1998, BRIT J CANCER, V77, P2129, DOI 10.1038/bjc.1998.357; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949; Gianni M, 2000, CELL DEATH DIFFER, V7, P447, DOI 10.1038/sj.cdd.4400673; Glass CK, 1997, BIOCHEM SOC T, V25, P602, DOI 10.1042/bst0250602; Green A, 1999, CARCINOGENESIS, V20, P1535, DOI 10.1093/carcin/20.8.1535; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; LAMMIE GA, 1991, ONCOGENE, V6, P439; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lippman M.E., 1985, TXB ENDOCRINOLOGY, P1309; Lippman SC, 2000, J NUTR, V130, p479S, DOI 10.1093/jn/130.2.479S; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Mangiarotti R, 1998, BRIT J CANCER, V77, P186, DOI 10.1038/bjc.1998.32; Manna SK, 2000, ONCOGENE, V19, P2110, DOI 10.1038/sj.onc.1203547; Meier CA, 1997, J RECEPT SIGNAL TR R, V17, P319, DOI 10.3109/10799899709036612; MOON RC, 1992, CANCER DETECT PREV, V16, P73; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Nagy L, 1998, CELL DEATH DIFFER, V5, P11, DOI 10.1038/sj.cdd.4400337; Oh Youngman, 1995, Progress in Growth Factor Research, V6, P503, DOI 10.1016/0955-2235(95)00025-9; OSWALD F, 1994, ONCOGENE, V9, P2029; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Raffo P, 2000, ANTICANCER RES, V20, P1535; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; ROMAN SD, 1992, CANCER RES, V52, P2236; SALO S, 1994, P NATL ACAD SCI USA, V91, P923; Schmidt EV, 1996, BIOESSAYS, V18, P6, DOI 10.1002/bies.950180104; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Seewaldt VL, 1997, CELL GROWTH DIFFER, V8, P631; Seewaldt VL, 1999, EXP CELL RES, V249, P70, DOI 10.1006/excr.1999.4462; SGAMBATO A, 1995, CARCINOGENESIS, V16, P2193, DOI 10.1093/carcin/16.9.2193; Shang YF, 1999, J BIOL CHEM, V274, P18005, DOI 10.1074/jbc.274.25.18005; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Sukumar S, 1995, MUTAT RES-FUND MOL M, V333, P37, DOI 10.1016/0027-5107(95)00129-8; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; VANDERVELDEN J, 1992, INT J GYNECOL CANCER, V2, P157, DOI 10.1046/j.1525-1438.1992.02030157.x; Wang Q, 2000, CANCER RES, V60, P2040; Zhang DM, 2000, J CELL PHYSIOL, V185, P1, DOI 10.1002/1097-4652(200010)185:1<1::AID-JCP1>3.0.CO;2-O; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142; Zwijsen RML, 1996, MOL CELL BIOL, V16, P2554	64	37	38	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3506	3518		10.1038/sj.onc.1204453	http://dx.doi.org/10.1038/sj.onc.1204453			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429697				2022-12-17	WOS:000169478300006
J	Leone, A; Mitsiades, N; Ward, Y; Spinelli, B; Poulaki, V; Tsokos, M; Kelly, K				Leone, A; Mitsiades, N; Ward, Y; Spinelli, B; Poulaki, V; Tsokos, M; Kelly, K			The Gem GTP-binding protein promotes morphological differentiation in neuroblastoma	ONCOGENE			English	Article						Gem; neuroblastoma; ganglia; morphology; RGK proteins; cytoskeleton	RAS-FAMILY; MEMBER; CELLS; PHOSPHORYLATION; ACTIVATION; KIR; REM	Gem is a small GTP-binding protein within the Ras superfamily whose function has not been determined. We report here that ectopic Gem expression is sufficient to stimulate cell flattening and neurite extension in N1E-115 and SH-SY5Y neuroblastoma cells, suggesting a role for Gem in cytoskeletal rearrangement and/or morphological differentiation of neurons. Consistent with this potential function, in clinical samples of neuroblastoma, Gem protein was most highly expressed within cells which had differentiated to express ganglionic morphology. Gem was also observed in developing trigeminal nerve ganglia in 12.5 day mouse embryos, demonstrating that Gem expression is a property of normal ganglionic development. Although Gem expression is rare in epithelial and hematopoietic cancer cell lines, constitutive Gem levels were detected in several neuroblastoma cell lines and could be further induced as much as 10-fold following treatment with PMA or the acetylcholine muscarinic agonist, carbachol.	NCI, Div Clin Sci, Med Branch, Cell & Canc Biol Dept, Bethesda, MD 20892 USA; NCI, Pathol Lab, Div Clin Sci, Pediat Tumor Biol Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kelly, K (corresponding author), NCI, Div Clin Sci, Med Branch, Cell & Canc Biol Dept, Bldg 10,Room 3B43,9000, Bethesda, MD 20892 USA.		Leone, Alvaro/K-6410-2016; leone, alvaro/AAQ-7051-2020	Leone, Alvaro/0000-0003-3815-9052; 				AMBROS IM, 1995, EUR J CANCER, V31A, P429, DOI 10.1016/0959-8049(95)00051-J; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; Cool RH, 1999, MOL CELL BIOL, V19, P6297; Dorin D, 1995, ONCOGENE, V11, P2267; Finlin BS, 1999, ARCH BIOCHEM BIOPHYS, V368, P401, DOI 10.1006/abbi.1999.1316; Finlin BS, 1997, J BIOL CHEM, V272, P21982, DOI 10.1074/jbc.272.35.21982; Finlin BS, 2000, BIOCHEM J, V347, P223, DOI 10.1042/0264-6021:3470223; HACHITANDA Y, 1994, HUM PATHOL, V25, P67, DOI 10.1016/0046-8177(94)90173-2; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; KIMHI Y, 1976, P NATL ACAD SCI USA, V73, P462, DOI 10.1073/pnas.73.2.462; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; Moyers JS, 1998, BIOCHEM J, V333, P609, DOI 10.1042/bj3330609; Pan JY, 2000, J CELL BIOL, V149, P1107, DOI 10.1083/jcb.149.5.1107; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Shimada H, 1999, CANCER, V86, P349, DOI 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.3.CO;2-P; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; SHIMADA H, 1985, HUM PATHOL, V16, P471, DOI 10.1016/S0046-8177(85)80085-X; Son JH, 1996, MOL BRAIN RES, V36, P300, DOI 10.1016/0169-328X(95)00255-Q; Vanhove B, 1997, ENDOTHELIUM-J ENDOTH, V5, P51, DOI 10.3109/10623329709044158; Wess J, 1997, LIFE SCI, V60, P1007, DOI 10.1016/S0024-3205(97)00041-6	21	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3217	3225		10.1038/sj.onc.1204420	http://dx.doi.org/10.1038/sj.onc.1204420			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423971				2022-12-17	WOS:000169163500005
J	Powell, DJ; Russell, JP; Li, GQ; Kuo, BA; Fidanza, V; Huebner, K; Rothstein, JL				Powell, DJ; Russell, JP; Li, GQ; Kuo, BA; Fidanza, V; Huebner, K; Rothstein, JL			Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from RET/PTC3p53 mice	ONCOGENE			English	Article						anaplastic carcinoma; Fhit; neoplasia; RET/PTC; SCID; thyroid carcinoma	THYROTROPIN RECEPTOR GENE; RET TYROSINE KINASE; PAPILLARY CARCINOMA; FHIT GENE; ONCOGENE ACTIVATION; P53 GENE; NEOPLASTIC TRANSFORMATION; CLINICAL IMPLICATIONS; PREMALIGNANT LESIONS; EPITHELIAL-CELLS	Cancers develop and progress via activation of oncogenes and loss of tumor suppressor genes, a progression that can be recapitulated through cross breeding mouse strains harboring genetic mutations. To define the role of RET/PTC3, p53 and Fhit in thyroid carcinogenesis, we intercrossed RET/PTC3 transgenics with p53-/-mice. This new strain, RET/PTC3(p53-/-), succumb to rapidly growing and strikingly large multilobed thyroid tumors containing mixtures of both well and poorly differentiated, highly proliferative follicular epithelial cells. Interestingly, transplanted tumors from RET/PTC3(p53-/-) mice grew in SCID but not syngeneic immunocompetent mice indicating that these advanced tumors were immunogenic, RET/PTC3 protein expression was reduced to undetectable levels in tumors of older mice suggesting that the continued elevated expression of RET/PTC3 may not be necessary for tumor progression. Similarly, expression of Fhit protein was reduced in early tumors and undetected in older tumors irrespective of tumor histopathology, In contrast to RET/PTC3(p53-/-) mice, RET/PTC3(Fhit-/-) mice did not develop advanced thyroid carcinomas, These studies support a model of human thyroid cancer whereby thyroid epithelium expresses RET/PTC3 protein at early stages of tumor development, followed by the reduction of RET/PTC3 and loss of p53 function with progressive reduction of Fhit protein expression coincident with malignant progression.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol Immunol & Otolaryngol Head & Neck, Philadelphia, PA 19107 USA	Jefferson University	Rothstein, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol Immunol & Otolaryngol Head & Neck, 233 S 10th St,BLSB 909, Philadelphia, PA 19107 USA.				NCI NIH HHS [CA21124, T32-CA09678, T32-CA72318, CA76259] Funding Source: Medline; NIAID NIH HHS [T32-AI07492] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA021124, P01CA076259, T32CA072318, T32CA009678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007492] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arezzo A, 1998, AM SURGEON, V64, P307; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BATTISTA S, 1995, ONCOGENE, V11, P2029; BECKER KL, 1995, PRINCIPLES PRACTICES; Birrer MJ, 1999, CANCER RES, V59, P5270; BOUNACER A, 1997, ONCOGENE, V15, P1236; BRAVERMAN LE, 1995, THYROID FUNDAMENTAL; CALIFANO D, 1995, ONCOGENE, V11, P107; Canaris GJ, 2000, ARCH INTERN MED, V160, P526, DOI 10.1001/archinte.160.4.526; CARCANGIU ML, 1985, AM J CLIN PATHOL, V83, P135, DOI 10.1093/ajcp/83.2.135; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chang RS, 1998, ACAD EMERG MED, V5, P247, DOI 10.1111/j.1553-2712.1998.tb02621.x; Chen ST, 2000, J ENDOCRINOL, V165, P379, DOI 10.1677/joe.0.1650379; Corvi R, 2000, ONCOGENE, V19, P4236, DOI 10.1038/sj.onc.1203772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUH QY, 1995, SURG CLIN N AM, V75, P421; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; FABBRO D, 1994, CANCER RES, V54, P4744; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; FUSCO A, 1995, J ENDOCRINOL INVEST, V18, P127, DOI 10.1007/BF03349720; Gatalica Z, 2000, CANCER-AM CANCER SOC, V88, P1378, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1378::AID-CNCR15>3.3.CO;2-9; Giannini R, 2000, INT J ONCOL, V16, P485; Gire V, 2000, ONCOGENE, V19, P737, DOI 10.1038/sj.onc.1203399; Glover TW, 1998, CANCER RES, V58, P3409; Hao XP, 2000, CANCER RES, V60, P18; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Ivan M, 1997, ONCOGENE, V14, P2417, DOI 10.1038/sj.onc.1201083; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; Jossart GH, 1996, J CLIN ENDOCR METAB, V81, P3498, DOI 10.1210/jc.81.10.3498; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kholodnyuk ID, 2000, CANCER RES, V60, P7119; Klugbauer S, 2000, CANCER RES, V60, P7028; Komminoth P, 1997, VIRCHOWS ARCH, V431, P1, DOI 10.1007/s004280050062; La Perle KMD, 2000, AM J PATHOL, V157, P671, DOI 10.1016/S0002-9440(10)64577-4; Manning AP, 1999, MOL CARCINOGEN, V24, P218, DOI 10.1002/(SICI)1098-2744(199903)24:3<218::AID-MC8>3.0.CO;2-A; Marchetti A, 1998, J PATHOL, V184, P240, DOI 10.1002/(SICI)1096-9896(199803)184:3<240::AID-PATH20>3.0.CO;2-B; Mayr B, 1999, LANGENBECK ARCH SURG, V384, P54, DOI 10.1007/s004230050174; McIver B, 2000, CLIN ENDOCRINOL, V52, P749, DOI 10.1046/j.1365-2265.2000.01009.x; Mizuno T, 1997, ONCOGENE, V15, P1455, DOI 10.1038/sj.onc.1201313; Moretti F, 1997, ONCOGENE, V14, P729, DOI 10.1038/sj.onc.1200887; Mori M, 2000, CANCER RES, V60, P1177; Mueller J, 2000, Recent Results Cancer Res, V155, P29; Nikiforov YE, 1997, CANCER RES, V57, P1690; Nikiforova MN, 2000, SCIENCE, V290, P138, DOI 10.1126/science.290.5489.138; OKAYASU I, 1995, CANCER-AM CANCER SOC, V76, P2312, DOI 10.1002/1097-0142(19951201)76:11<2312::AID-CNCR2820761120>3.0.CO;2-H; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Papadimitrakopoulou VA, 1996, CANCER METAST REV, V15, P53, DOI 10.1007/BF00049487; Pellegrini S, 1999, INT J MOL MED, V4, P419; Pisarchik AV, 2000, THYROID, V10, P25, DOI 10.1089/thy.2000.10.25; Powell DJ, 1998, CANCER RES, V58, P5523; Qin GZ, 1999, INT J CANCER, V80, P345, DOI 10.1002/(SICI)1097-0215(19990129)80:3<345::AID-IJC2>3.3.CO;2-E; Rabes HM, 2000, CLIN CANCER RES, V6, P1093; ROSAI J, 1990, TUMORS THYROID GLAND; Russell JP, 2000, ONCOGENE, V19, P5729, DOI 10.1038/sj.onc.1203922; Salassidis K, 2000, CANCER RES, V60, P2786; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; Santoro M, 1996, ONCOGENE, V12, P1821; Sheils OM, 2000, INT J SURG PATHOL, V8, P185, DOI 10.1177/106689690000800305; SHI YF, 1993, CLIN ENDOCRINOL, V39, P269, DOI 10.1111/j.1365-2265.1993.tb02365.x; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Soravia C, 1999, AM J PATHOL, V154, P127, DOI 10.1016/S0002-9440(10)65259-5; Sozzi G, 1998, CANCER RES, V58, P5032; Sugg SL, 1998, J CLIN ENDOCR METAB, V83, P4116, DOI 10.1210/jc.83.11.4116; Sweetser DA, 1997, ONCOGENE, V15, P2783, DOI 10.1038/sj.onc.1201452; Tallini G, 1998, CLIN CANCER RES, V4, P287; THOMPSON TC, 1995, ONCOGENE, V10, P869; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; VINETTE DSJ, 1991, DIAGN CYTOPATHOL, V7, P75, DOI 10.1002/dc.2840070120; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wirtschafter A, 1997, LARYNGOSCOPE, V107, P95, DOI 10.1097/00005537-199701000-00019; Xiao GH, 1997, AM J PATHOL, V151, P1541; Yokota T, 2000, J HUM GENET, V45, P6, DOI 10.1007/s100380050002; Yoshino K, 2000, INT J CANCER, V85, P6, DOI 10.1002/(SICI)1097-0215(20000101)85:1<6::AID-IJC2>3.0.CO;2-6; Zou M, 1999, EUR J CANCER, V35, P467, DOI 10.1016/S0959-8049(98)00370-0; ZOU MJ, 1993, J CLIN ENDOCR METAB, V77, P1054, DOI 10.1210/jc.77.4.1054	80	37	37	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2001	20	25					3235	3246		10.1038/sj.onc.1204425	http://dx.doi.org/10.1038/sj.onc.1204425			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423973				2022-12-17	WOS:000169163500007
J	Bouscary, D; Lecoq-Lafon, C; Chretien, S; Zompi, S; Fichelson, S; Muller, O; Porteu, F; Dusanter-Fourt, I; Gisselbrecht, S; Mayeux, P; Lacombe, C				Bouscary, D; Lecoq-Lafon, C; Chretien, S; Zompi, S; Fichelson, S; Muller, O; Porteu, F; Dusanter-Fourt, I; Gisselbrecht, S; Mayeux, P; Lacombe, C			Role of Gab proteins in phosphatidylinositol 3-kinase activation by thrombopoietin (Tpo)	ONCOGENE			English	Article						Gab proteins; phosphatidylinositol 3-kinase; Akt; thrombopoietin; cytokines; signal transduction	C-MPL LIGAND; PLECKSTRIN HOMOLOGY DOMAIN; GROWTH-FACTOR RECEPTOR; INDUCED MEGAKARYOCYTIC DIFFERENTIATION; PHOSPHOTYROSINE-BINDING DOMAIN; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; INSULIN-RECEPTOR; EPITHELIAL MORPHOGENESIS; SHC PHOSPHORYLATION	In this study, we show that upon thrombopoietin (Tpo) stimulation the two adapter proteins Gab1 and Gab2 are strongly tyrosine phosphorylated and associated with Shc, SHP2, PI 3-kinase and Grb2 in mpl-expressing UT7 cells. Although Gab1 and Gab2 seem to mediate overlapping biological signals in many cells, only Gab1 is expressed and phosphorylated in response to Tpo in primary human megakaryocytic progenitors; furthermore, it associates with the same proteins. Although a Low level of tyrosine phosphorylated IRS-2 protein is also detected in PI 3-kinase immunoprecipitates, cab proteins are the essential proteins associated with PI 3-kinase after Tpo stimulation. We demonstrate that, albeit no association is detected between the Tpo receptor mpl and Gab proteins, Y112 located in the C-terminal cytoplasmic domain of mpl is required for Gab1/2 tyrosine phosphorylation, Gab proteins are not tyrosine phosphorylated after Tpo stimulation of UT-7 and Ba/F3 cells expressing a mpl mutant lacking Y112. Moreover, no activation of the PI 3-kinase/Akt pathway is observed in cells expressing this mpl mutant. Finally, we show that this mutant does not allow cell proliferation, thereby confirming that PI 3-kinase activation is required for Tpo-induced cell proliferation.	Univ Paris 05, Hop Cochin, ICGM, INSERM,U363, F-75014 Paris, France; AP HP, Hop Cochin, Serv Hematol, Paris, France; Hop Cochin, Lab Rech Hemobiol, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Lacombe, C (corresponding author), Univ Paris 05, Hop Cochin, ICGM, INSERM,U363, 27 Rue Faubourg St Jacques, F-75014 Paris, France.		Chretien, Stany/M-5166-2018; PORTEU, Françoise/I-8445-2016; Dusanter-Fourt, Isabelle/P-4558-2017	PORTEU, Françoise/0000-0002-2403-4163; Dusanter-Fourt, Isabelle/0000-0002-9286-1021; Bouscary, Didier/0000-0003-3654-5064				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alexander WS, 1996, EMBO J, V15, P6531, DOI 10.1002/j.1460-2075.1996.tb01044.x; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; BENIT L, 1994, J VIROL, V68, P5270; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CASE RD, 1994, J BIOL CHEM, V269, P10467; DAMEN JE, 1993, BLOOD, V82, P2296; Debili N, 1996, BLOOD, V88, P1284, DOI 10.1182/blood.V88.4.1284.bloodjournal8841284; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Geltz NR, 1998, BLOOD, V91, P930, DOI 10.1182/blood.V91.3.930.930_930_939; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Ingham RJ, 1998, J BIOL CHEM, V273, P30630, DOI 10.1074/jbc.273.46.30630; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; Korhonen JM, 1999, J BIOL CHEM, V274, P37307, DOI 10.1074/jbc.274.52.37307; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Matsumura I, 1998, MOL CELL BIOL, V18, P4282, DOI 10.1128/MCB.18.7.4282; Miyakawa Y, 2001, J BIOL CHEM, V276, P2494, DOI 10.1074/jbc.M002633200; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Porteu F, 1996, MOL CELL BIOL, V16, P2473; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; Sattler M, 1997, J CELL PHYSIOL, V171, P28; SATTLER M, 1995, EXP HEMATOL, V23, P1040; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VIGON I, 1993, ONCOGENE, V8, P2607; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	37	47	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2197	2204		10.1038/sj.onc.1204317	http://dx.doi.org/10.1038/sj.onc.1204317			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402314				2022-12-17	WOS:000168404500001
J	Liu, RG; Li, BL; Qiu, MS				Liu, RG; Li, BL; Qiu, MS			Elevated superoxide production by active H-ras enhances human lung WI-38VA-13 cell proliferation, migration and resistance to TNF-alpha	ONCOGENE			English	Article						superoxide; H-ras; NADPH oxidase; signal transduction; WI-38VA-13 cells; TNF-alpha	CARCINOMA SCC-25 CELLS; REACTIVE OXYGEN; SIGNAL-TRANSDUCTION; NADPH OXIDASE; FREE-RADICALS; CHROMOSOMAL-ABERRATIONS; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; ENDOTHELIAL-CELLS; HUMAN-FIBROBLASTS	Accumulating evidence has suggested that cellular production of superoxide acts as an intracellular messenger to regulate gene expression and modulate cellular activities, In this report, we set out to investigate the role of active H-ras-mediated superoxide production on tumor cell malignancy in a SV-40 transformed human lung WI-38 VA-13 cell line, Stable transfection and expression of constitutively active mutant V12-H-ras (V12-H-ras) dramatically increased intracellular production of superoxide, The expression of V12-H-ras significantly enhanced cell proliferation, migration and resistance to TNF-alpha treatment compared to that of parental and vector control cells, while expression of wild type H-ras (WT-H-ras) only had modest effects. Upon scavenging by superoxide dismutase and other molecules that decrease the intracellular level of active H-ras mediated superoxide production, cell proliferation, migration and resistance to TNF-alpha were significantly reduced. Furthermore, we demonstrated that the activation of membrane NADPH oxidase activity by expression of active I-P-ras contributed to the intracellular superoxide production. The causal relationship between membrane superoxide production and increased cell proliferation, migration, and resistance to TNF-alpha by the expression of active H-ras, has provided direct evidence to demonstrate that superoxide acts as an intracellular messenger to cascade res oncogenic signal relay and to modulate turner malignant activity.	Univ Louisville, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA; Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA	University of Louisville; Eli Lilly	Liu, RG (corresponding author), Univ Louisville, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA.							Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Atlante A, 2000, J BIOL CHEM, V275, P37159, DOI 10.1074/jbc.M002361200; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Bohler T, 2000, CYTOKINE, V12, P986, DOI 10.1006/cyto.1999.0633; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Crawford LE, 1996, J BIOL CHEM, V271, P26863, DOI 10.1074/jbc.271.43.26863; DAGHER MC, 1995, BIOCHIMIE, V77, P651, DOI 10.1016/0300-9084(96)88180-6; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; EMERIT I, 1981, NATURE, V293, P144, DOI 10.1038/293144a0; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; Giri U, 1999, CANCER LETT, V135, P53; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; IWATA K, 1984, TOXICOL LETT, V22, P75, DOI 10.1016/0378-4274(84)90048-1; JARUGA P, 1994, FEBS LETT, V341, P59, DOI 10.1016/0014-5793(94)80240-8; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; JONES SA, 1994, FEBS LETT, V355, P178, DOI 10.1016/0014-5793(94)01201-6; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Kamata H, 1996, J BIOL CHEM, V271, P33018, DOI 10.1074/jbc.271.51.33018; KENNEDY AR, 1984, CARCINOGENESIS, V5, P1213, DOI 10.1093/carcin/5.10.1213; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P543, DOI 10.1042/bj3070543; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Li N, 1998, PROSTATE, V35, P221, DOI 10.1002/(SICI)1097-0045(19980515)35:3<221::AID-PROS8>3.0.CO;2-J; Li SJ, 2000, CANCER RES, V60, P3927; Liu RG, 1997, HUM GENE THER, V8, P585, DOI 10.1089/hum.1997.8.5-585; Liu RG, 1999, RADIAT RES, V151, P133, DOI 10.2307/3579763; Liu RG, 2000, FREE RADICAL BIO MED, V28, P1197, DOI 10.1016/S0891-5849(00)00237-9; Liu RG, 1998, CELL GROWTH DIFFER, V9, P239; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; LOSCHEN G, 1974, FEBS LETT, V42, P6874; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; Moldovan L, 2000, CIRC RES, V86, P549, DOI 10.1161/01.RES.86.5.549; NAKAMURA Y, 1985, CARCINOGENESIS, V6, P229, DOI 10.1093/carcin/6.2.229; OBERLEY LW, 1979, CANCER RES, V39, P1141; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Pani G, 2000, CANCER RES, V60, P4654; Pick E, 1986, Methods Enzymol, V132, P407; PRETONE WF, 1980, P NATL ACAD SCI USA, V77, P1159; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUINN MT, 1995, J LEUKOCYTE BIOL, V58, P263, DOI 10.1002/jlb.58.3.263; SOFUNI T, 1984, MUTAT RES, V140, P27, DOI 10.1016/0165-7992(84)90067-8; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Thannickal VJ, 1998, J BIOL CHEM, V273, P23611, DOI 10.1074/jbc.273.36.23611; Ward RA, 2000, J BIOL CHEM, V275, P36713, DOI 10.1074/jbc.M003017200; Yan T, 1996, CANCER RES, V56, P2864; Yang JQ, 1999, MOL CARCINOGEN, V26, P180; Zhai QW, 2000, J CELL PHYSIOL, V184, P161, DOI 10.1002/1097-4652(200008)184:2<161::AID-JCP3>3.3.CO;2-E; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852; ZIMMERMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P2085, DOI 10.1073/pnas.81.7.2085	59	37	39	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1486	1496		10.1038/sj.onc.1204214	http://dx.doi.org/10.1038/sj.onc.1204214			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313892				2022-12-17	WOS:000167595200009
J	Lucas, L; Hernandez-Alcoceba, R; Penalva, V; Lacal, JC				Lucas, L; Hernandez-Alcoceba, R; Penalva, V; Lacal, JC			Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity	ONCOGENE			English	Article						phospholipase D; antitumor drug; hexadecylphosphorylcholine; choline kinase	CHOLINE KINASE INHIBITORS; XENOPUS-LAEVIS OOCYTES; CANINE KIDNEY-CELLS; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; ANALOG HEXADECYLPHOSPHOCHOLINE; GROWTH-FACTORS; SIGNAL-TRANSDUCTION; D ACTIVATION; PROTEIN; RAS	Hexadecylphosphorylcholine (HePC, D-18506, INN: Mitelfosine) belongs to the family of alkylphosphocholines with anticancer activity. Previous reports have related its antitumoral activity to their ability to interfere with phospholipid metabolism, However a clear mechanism of action has not been established yet, We have investigated the effect of HePC on two enzymes recently reported to play a role in cell growth proliferation, phospholipase D (PLD) and choline kinase (ChoK). Our results demonstrate that treatment with HePC induces a rapid stimulation of PLD, that may be achieved by PKC dependent or independent mechanisms, depending on the cell line investigated. Both PLD1 and PLD2 isoenzymes are sensitive to HePC activation. By contrast, no effect was observed by HePC on Cho, a new target for anticancer drug development. Furthermore, in all cell lines tested, a chronic exposure of the cells to HePC abrogates PLD activation by either phorbol esters or HePC itself with no effect on total cellular PLD levels. This is reflected in a strong inhibition of PLD activity. We suggest that the inhibitory effects on PLD by HePC may be related to its antitumoral action.	CSIC, Inst Invest Biomed, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, Madrid, Spain.		Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	Lacal, Juan Carlos/0000-0002-1908-2777				BERKOVIC D, 1994, EUR J CANCER, V30A, P509, DOI 10.1016/0959-8049(94)90428-6; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bhakoo KK, 1996, CANCER RES, V56, P4630; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; CARNERO A, 1994, J CELL BIOCHEM, V54, P478, DOI 10.1002/jcb.240540415; CARNERO A, 1994, ONCOGENE, V9, P1387; CARNERO A, 1995, MOL CELL BIOL, V15, P1094; CUADRADO A, 1993, ONCOGENE, V8, P2959; DECHAVES EP, 1995, BIOCHEM J, V312, P411, DOI 10.1042/bj3120411; delPeso L, 1997, BIOCHEM J, V322, P519; DELPESO L, 1996, J CELL BIOCHEM, V60, P1; DETMAR M, 1994, J INVEST DERMATOL, V102, P490, DOI 10.1111/1523-1747.ep12373109; Exton JH, 2000, ANN NY ACAD SCI, V905, P61; GEILEN CC, 1992, J BIOL CHEM, V267, P6719; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HAASE R, 1991, FEBS LETT, V288, P129, DOI 10.1016/0014-5793(91)81018-4; Han JS, 1998, BIOCHEM MOL BIOL INT, V45, P1089; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; Hernandez-Alcoceba R, 2000, CELL MOL LIFE SCI, V57, P65, DOI 10.1007/s000180050499; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; HOULIHAN WJ, 1995, MED RES REV, V15, P157, DOI 10.1002/med.2610150302; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JALINK K, 1990, J BIOL CHEM, V265, P12232; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; Ku WC, 1997, BIOCHEM BIOPH RES CO, V241, P730, DOI 10.1006/bbrc.1997.7874; LACAL JC, 1994, ONCOL REP, V1, P677; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; Lacal JC, 1997, FEBS LETT, V410, P73, DOI 10.1016/S0014-5793(97)00444-4; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Lucas L, 2000, ONCOGENE, V19, P431, DOI 10.1038/sj.onc.1203323; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; Malcolm KC, 1996, BIOCHEM BIOPH RES CO, V225, P514, DOI 10.1006/bbrc.1996.1204; MALY K, 1995, ANTI-CANCER DRUG DES, V10, P411; Montaner S, 1999, J BIOL CHEM, V274, P8506, DOI 10.1074/jbc.274.13.8506; PAWELCZYK T, 1993, BIOCHEM PHARMACOL, V45, P493, DOI 10.1016/0006-2952(93)90087-D; PAZIT BA, 1989, FEBS LETT, V259, P64; PLEVIN R, 1991, BIOCHEM J, V279, P559, DOI 10.1042/bj2790559; POWIS G, 1995, MED RES REV, V15, P121, DOI 10.1002/med.2610150204; SEEWALD MJ, 1990, CANCER RES, V50, P4458; SINGER S, 1995, CANCER RES, V55, P5140; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; STORME G, 1983, P AM ASSOC CANC RES, V24, P31; UBERALL F, 1991, CANCER RES, V51, P807; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WIEDER T, 1993, BIOCHEM J, V291, P561, DOI 10.1042/bj2910561; Wieder T, 1996, CANCER LETT, V100, P71, DOI 10.1016/0304-3835(95)04072-2; Wieder T, 1999, PROG LIPID RES, V38, P249, DOI 10.1016/S0163-7827(99)00004-1; ZENG B, 1990, CANCER RES, V50, P3025	50	37	39	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1110	1117		10.1038/sj.onc.1204216	http://dx.doi.org/10.1038/sj.onc.1204216			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314048				2022-12-17	WOS:000167232100011
J	Nip, J; Strom, DK; Eischen, CM; Cleveland, JL; Zambetti, GP; Hiebert, SW				Nip, J; Strom, DK; Eischen, CM; Cleveland, JL; Zambetti, GP; Hiebert, SW			E2F-1 induces the stabilization of p53 but blocks p53-mediated transactivation	ONCOGENE			English	Article						E2F-1; p53; stability; cell cycle progression; apoptosis	WILD-TYPE P53; S-PHASE ENTRY; TRANSCRIPTION FACTOR E2F-1; ARF TUMOR-SUPPRESSOR; CELL-CYCLE CONTROL; E1B 19K PROTEIN; RETINOBLASTOMA PROTEIN; GENE-PRODUCT; DNA-SYNTHESIS; P53-DEPENDENT APOPTOSIS	E2F-1 induces p53 accumulation and E2F-1 and p53 form a physical complex, which affects the ability of E2F-1 to activate transcription. We mapped the domains on E2F-1 that interact with p53 and found two p53-binding domains. To understand the functional consequences of the E2F-1/p53 association on p53 activities we identified the domains of E2F-1 that were responsible for the accumulation of p53. Unexpectedly, we found that the E2F-1 transactivation domain was dispensable for p53 induction. By contrast, further deletion of the DP-1 interaction/'marked' box domain eliminated p53 accumulation. Radiolabeling pulse/chase analysis demonstrated that E2F-1 caused post-translational stabilization of p53. Although E2F-1 caused the stabilization of p53, E2F-1 expression impaired p53-dependent transactivation. Thus, the E2F-1:p53 interaction may provide a checkpoint function to inactivate overactive E2F-1, but the association may also inactivate p53 transactivation to allow cell cycle progression.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	Vanderbilt University; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Hiebert, SW (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.		Zambetti, Gerard/N-8093-2018	Zambetti, Gerard/0000-0002-0929-5007	NCI NIH HHS [CA63230, CA64140, CA76379, CA77274, 5 P30 CA27165] Funding Source: Medline; NIA NIH HHS [AG13726] Funding Source: Medline; NIDDK NIH HHS [DK44158] Funding Source: Medline; PHS HHS [C09346] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076379, R01CA064140, R01CA077274, R01CA063230] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044158] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013726] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KATO J, 1993, GENE DEV, V7, P331; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OLSON DC, 1994, CELL GROWTH DIFFER, V5, P61; OLSON DC, 1993, ONCOGENE, V8, P2353; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUELLE DE, 1995, CELL, V83, P993; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SALA A, 1994, CANCER RES, V54, P1402; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHAULSKY G, 1991, CELL GROWTH DIFFER, V2, P661; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	83	37	37	2	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					910	920		10.1038/sj.onc.1204171	http://dx.doi.org/10.1038/sj.onc.1204171			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314026				2022-12-17	WOS:000167097000002
J	Bradley, G; Irish, J; MacMillan, C; Mancer, K; Witterick, I; Hartwick, W; Gullane, P; Kamel-Reid, S; Benchimol, S				Bradley, G; Irish, J; MacMillan, C; Mancer, K; Witterick, I; Hartwick, W; Gullane, P; Kamel-Reid, S; Benchimol, S			Abnormalities of the ARF-p53 pathway in oral squamous cell carcinoma	ONCOGENE			English	Article						p53; mutation; immunohistochemistry; p14ARF; homozygous deletion; oral squamous carcinoma	NECK-CANCER; TUMOR-SUPPRESSOR; P53 ALTERATIONS; HEAD; MUTATIONS; SMOKING; GENE; OVEREXPRESSION; INACTIVATION; PROGRESSION	Oral squamous cell carcinoma (OSCC) is associated with heavy smoking and drinking, but the molecular pathway of tumorigenesis is not understood. Inactivation of the p53 tumor suppressor gene is likely to play an important role since p53 mutation is frequently found. The p14ARF tumor suppressor gene is functionally linked to p53, because it is activated by oncogenes and causes p53-dependent growth arrest and apoptosis, The relationship between p14ARF and p53 inactivation has not been described for OSCC, We studied 25 cases of OSCC to determine if there is an inverse correlation between p53 mutation and p14ARF inactivation by homozygous deletion or mutation. p53 mutation was found in 16 of 25 cases (64%), including nine missense and seven truncating mutations, While all cases with missense mutations showed abnormal accumulation of p53 protein, there were also five carcinomas which showed increased p53 staining in the absence of mutation. p14ARF deletion or mutation was found in eight cases (32%), six of which also demonstrated p53 mutation. Our findings indicate that OSCC often involves loss of both p14ARF and p53 function and suggest that inactivation of these two tumor suppressor genes are not functionally equivalent during tumorigenesis.	Univ Toronto, Fac Dent, Toronto, ON M5G 1G6, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Princess Margaret Hosp, Dept Otolaryngol Surg Oncol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Toronto Gen Hosp, Dept Pathol, Toronto, ON M5G 2C4, Canada; Univ Toronto, Mt Sinai Hosp, Dept Otolaryngol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Mt Sinai Hosp, Dept Pathol, Toronto, ON M5G 1X5, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Bradley, G (corresponding author), Univ Toronto, Fac Dent, 124 Edward St, Toronto, ON M5G 1G6, Canada.			Kamel-Reid, Suzanne/0000-0002-4386-0292; Benchimol, Samuel/0000-0003-3433-890X				AHOMADEGBE JC, 1995, ONCOGENE, V10, P1217; BLOT WJ, 1988, CANCER RES, V48, P3282; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; BOYLE JO, 1993, CANCER RES, V53, P4477; BRENNAN JA, 1995, NEW ENGL J MED, V332, P712, DOI 10.1056/NEJM199503163321104; Califano J, 1996, CANCER RES, V56, P2488; Casey G, 1996, ONCOGENE, V13, P1971; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; Erber R, 1998, ONCOGENE, V16, P1671, DOI 10.1038/sj.onc.1201690; Field J K, 1992, Eur J Cancer B Oral Oncol, V28B, P67, DOI 10.1016/0964-1955(92)90016-T; Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HALL PA, 1994, J PATHOL, V172, P1, DOI 10.1002/path.1711720103; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Ichimura K, 2000, CANCER RES, V60, P417; Koch WM, 1999, LARYNGOSCOPE, V109, P1544, DOI 10.1097/00005537-199910000-00002; Liloglou T, 1997, CANCER RES, V57, P4070; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Markl IDC, 1998, CANCER RES, V58, P5348; MASHBERG A, 1993, CANCER-AM CANCER SOC, V72, P1369, DOI 10.1002/1097-0142(19930815)72:4<1369::AID-CNCR2820720436>3.0.CO;2-L; Prives C, 1999, J PATHOL, V187, P112; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Shahnavaz SA, 2000, J PATHOL, V190, P417; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; XU L, 1994, DIAGN MOL PATHOL, V3, P83, DOI 10.1097/00019606-199406000-00004; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	29	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	2001	20	5					654	658		10.1038/sj.onc.1204131	http://dx.doi.org/10.1038/sj.onc.1204131			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313998				2022-12-17	WOS:000166755000013
J	Strom, A; Arai, N; Leers, J; Gustafsson, JA				Strom, A; Arai, N; Leers, J; Gustafsson, JA			The hairy and enhancer of split homologue-1 (HES-1) mediates the proliferative effect of 17 beta-estradiol on breast cancer cell lines	ONCOGENE			English	Article						proliferation; HES-1; PCNA; antiestrogen; 17 beta-estradiol	LOOP-HELIX FACTORS; NEURONAL DIFFERENTIATION; TRANSCRIPTION FACTORS; MAMMALIAN HAIRY; EXPRESSION; GENE; INHIBITION; PROTEINS	The mechanism behind hormone dependent growth of breast cancer is presently not well understood. We show that the HES-1 protein level in the breast cancer cell lines T47D and MCF-7 is down regulated by 17 beta -estradiol treatment. This regulation could be reversed by addition of the anti-estrogens 4OH tamoxifen, raloxifen and Imperial Chemical Industries (ICI) 182,780, In T47D cells with inducible exogenous HES-1 expression, induced expression of HES-1 protein presented the proliferative Effect of 17 beta -estradiol and subsequent up regulation of proliferating cell nuclear antigen (PCNA), An inverse correlation between the HES-1 and PCNA protein levels respectively,vas found in colon cancer cell lines. These findings point to a potential role of HES-l as a tumor suppressor in epithelial cells, and as a mediator of 17 beta -estradiols proliferative effect on breast cancer cells.	Karolinska Inst, Novum, Ctr Biotechnol, S-14157 Huddinge, Sweden; Tokyo Med & Dent Univ, Grad Sch, Dept Maxillofacial Surg, Bunkyo Ku, Tokyo 1138549, Japan; Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden	Karolinska Institutet; Tokyo Medical & Dental University (TMDU); Karolinska Institutet	Strom, A (corresponding author), Karolinska Inst, Novum, Ctr Biotechnol, S-14157 Huddinge, Sweden.							Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Castella P, 2000, MOL CELL BIOL, V20, P6170, DOI 10.1128/MCB.20.16.6170-6183.2000; Castella P, 1999, J NEUROSCI RES, V56, P229, DOI 10.1002/(SICI)1097-4547(19990501)56:3<229::AID-JNR2>3.0.CO;2-Z; Chen H, 1997, P NATL ACAD SCI USA, V94, P5355, DOI 10.1073/pnas.94.10.5355; FEDER JN, 1993, MOL CELL BIOL, V13, P105, DOI 10.1128/MCB.13.1.105; Ferguson AT, 1997, CRIT REV ONCOGENESIS, V8, P29, DOI 10.1615/CritRevOncog.v8.i1.20; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; FRIEDL A, 1994, EUR J CANCER, V30A, P1559, DOI 10.1016/0959-8049(94)00293-E; Harlow E LD, 1988, ANTIBODIES LAB MANUA; Hong JT, 1998, ONCOL REP, V5, P1025; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Kyo S, 1999, CANCER RES, V59, P5917; Lundin A, 2000, METHOD ENZYMOL, V305, P346; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; Strom A, 1997, GENE DEV, V11, P3168, DOI 10.1101/gad.11.23.3168; Tomita K, 1999, GENE DEV, V13, P1203, DOI 10.1101/gad.13.9.1203; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8	20	37	41	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5951	5953		10.1038/sj.onc.1203990	http://dx.doi.org/10.1038/sj.onc.1203990			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127827				2022-12-17	WOS:000165563100015
J	Alexandrova, A; Ivanov, A; Chumakov, P; Kopnin, B; Vasiliev, J				Alexandrova, A; Ivanov, A; Chumakov, P; Kopnin, B; Vasiliev, J			Changes in p53 expression in mouse fibroblasts can modify motility and extracellular matrix organization	ONCOGENE			English	Article						p53; cell shape; motility; fibronectin; focal contacts	TUMOR-SUPPRESSOR P53; WILD-TYPE P53; TRANSCRIPTIONAL REPRESSION; GENE-EXPRESSION; BINDING PROTEIN; BAX GENE; APOPTOSIS; PATHWAY; ARREST; MUTANT	Effects of p53 expression on cell morphology and motility were studied using the derivatives of p53-null 10(1) mouse fibroblasts with tetracycline-regulated expression of exogenous human p53, Induction of p53 expression was accompanied by significant decrease in extracellular matrix (fibronectin) and reduction of matrix fibrils, diminution of the number and size of focal contacts, decrease of cell areas, establishment of more elongated cell shape and alterations of actin cytoskeleton (actin bundles became thinner, their number and size decreased). Expression of His175 and Gln22/Ser23 p53 mutants caused no such effects. To study the influence of p53 expression on cell motility we used wound technique and videomicroscopy observation of single living cells. It was found that induction of p53 expression led to increase of lamellar activity of cell edge, However, in spite of enhanced lamellar activity p53-expressing cells migrated to shorter distance and filled the narrow wound in longer time as compared with their p53-null counterparts. Possible mechanisms of the influence of p53 expression on cell morphology and motility are discussed.	Russian Acad Sci, Engelgart Inst Mol Biol, Moscow, Russia; Moscow State Univ, Belozersky Inst Physicochem Biol, Moscow, Russia; Russian Canc Res Ctr, Inst Cancerogenesis, Moscow, Russia	Russian Academy of Sciences; Lomonosov Moscow State University	Chumakov, P (corresponding author), Russian Acad Sci, Engelgart Inst Mol Biol, Moscow, Russia.		Kopnin, Boris/R-8240-2019; Chumakov, Peter M/E-7731-2014	Kopnin, Boris/0000-0003-3100-2212; Ivanov, Alexey/0000-0002-8617-4604; Chumakov, Peter/0000-0002-8078-2908				Agapova LS, 1999, ONCOGENE, V18, P3135, DOI 10.1038/sj.onc.1202386; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; BERSHADSKY AD, 1991, CELL MOTIL CYTOSKEL, V19, P152, DOI 10.1002/cm.970190303; BERSHADSKY AD, 1988, CYTOSKELETON, P268; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; Dunn G. A., 1986, J CELL SCI, V108, P1659; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gloushankova N, 1997, ONCOGENE, V15, P2985, DOI 10.1038/sj.onc.1201483; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Iotsova V, 1996, CELL GROWTH DIFFER, V7, P629; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Metcalfe AMJ, 1997, NUCLEIC ACIDS RES, V25, P983, DOI 10.1093/nar/25.5.983; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Prives C, 1999, J PATHOL, V187, P112; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhao RB, 2000, GENE DEV, V14, P981	32	37	37	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5826	5830		10.1038/sj.onc.1203944	http://dx.doi.org/10.1038/sj.onc.1203944			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126371				2022-12-17	WOS:000165477700016
J	Silvany, RE; Eliazer, S; Wolff, NC; Ilaria, RL				Silvany, RE; Eliazer, S; Wolff, NC; Ilaria, RL			Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation	ONCOGENE			English	Article						Ewing's sarcoma; ERK; MAPK; ras; EWS/FLI-1	EWINGS-SARCOMA TRANSLOCATION; EWS/FLI-1 FUSION GENE; PROTEIN-KINASE; DNA-BINDING; EWS GENE; TRANSCRIPTIONAL ACTIVATOR; CHROMOSOME-TRANSLOCATION; HUMAN TUMORS; FAMILY; GROWTH	The chimeric gene EWS/FLI-1, the hallmark of the Ewing's sarcoma and primitive neuroectodermal tumor family, encodes a fusion protein with enhanced transcriptional activation properties and preserved recognition of canonical ETS binding sites. Although EWS/FLI-1 alters the expression of various genes, the precise mechanism by which EWS/FLI-1 acts as an oncogene remains to be defined, In this study we report that members of the mitogen-activated protein kinase (MAPK) signaling pathway, ERK1 and ERK2, are constitutively activated in NTH 3T3 cells expressing EWS/FLI-1, Interference with ERK activation by either highly specific inhibitors of MEK1 or a dominant negative ras mutant profoundly impaired the ability of EWS/FLI-1 to transform NIH3T3 cells to growth in semi-solid medium. An EWS/FLI-1 mutant defective in DNA-binding and transcriptional activation failed to activate ERK ana was also defective in 3T3 cell transformation, Constitutive ERK activation was also evident in several human Ewing's sarcoma tumor-derived cell lines, Interestingly, cells expressing the type II EWS/FLI-1 fusion, recently demonstrated more potent in transcriptional activation, showed even greater MAPK activation than cells expressing the more common type I fusion, These results implicate ERK activation in EWS/ FLI-1 transformation and suggest that this signaling pathway may be important in the pathogenesis of Ewing's sarcoma.	UT, SW Med Ctr, Simmons Canc Ctr, Dept Med,Div Hematol Oncol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ilaria, RL (corresponding author), UT, SW Med Ctr, Simmons Canc Ctr, Dept Med,Div Hematol Oncol, 5323 Harry Hines Blvd,MC 8593, Dallas, TX 75390 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003310] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03310] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; CHEN SY, 1994, ONCOGENE, V9, P2691; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; de Alava E, 2000, J CLIN ONCOL, V18, P204, DOI 10.1200/JCO.2000.18.1.204; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FINER MH, 1994, BLOOD, V83, P43; Gioeli D, 1999, CANCER RES, V59, P279; Hahn RG, 1999, SCAND J UROL NEPHROL, V33, P222; HAWLEY RG, 1994, GENE THER, V1, P136; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; LESSNICK SL, 1995, ONCOGENE, V10, P423; Lin PP, 1999, CANCER RES, V59, P1428; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MAO XH, 1994, J BIOL CHEM, V269, P18216; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; Patton SE, 1998, CANCER RES, V58, P2253; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Porras A, 1998, MOL ENDOCRINOL, V12, P825, DOI 10.1210/me.12.6.825; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Ries L. A. G., 1999, SEER CANC STAT REV 1; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Swantek JL, 1999, ENDOCRINOLOGY, V140, P3163, DOI 10.1210/en.140.7.3163; Thompson AD, 1996, ONCOGENE, V13, P2649; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu X, 1996, ONCOGENE, V13, P135; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	46	37	38	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4523	4530		10.1038/sj.onc.1203811	http://dx.doi.org/10.1038/sj.onc.1203811			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002425				2022-12-17	WOS:000089236800009
J	Hayette, S; Tigaud, I; Vanier, A; Martel, S; Corbo, L; Charrin, C; Beillard, E; Deleage, G; Magaud, JP; Rimokh, R				Hayette, S; Tigaud, I; Vanier, A; Martel, S; Corbo, L; Charrin, C; Beillard, E; Deleage, G; Magaud, JP; Rimokh, R			AF15q14, a novel partner gene fused to the MLL gene in an acute myeloid leukaemia with a t(11;15)(q23;q14)	ONCOGENE			English	Article						t(11;15)(q23;q14); 11q23; MLL; AF15q14; leukaemogenesis	DROSOPHILA-TRITHORAX; ACUTE LEUKEMIAS; ALL-1 GENE; TRANSLOCATION; PROTEIN; FUSION; REARRANGEMENTS; INVOLVEMENT; BREAKPOINT; PRODUCTS	In haematopoietic malignancies the MLL gene, located on chromosome 11q23, is frequently disrupted by chromosome rearrangement, generally resulting in fusion to various partner genes. We have previously reported a t(11;15)(q23;q14) in a case of acute myeloblastic leukaemia. Here, we report the cloning of a novel MLL partner, AF15q14, at chromosome 15q14, In this translocation, the breakpoint occurred in exon 8 of MLL and exon 10 of AF15q14. The normal AF15q14 transcripts of approximately 8.5 kb in size, are expressed in different tumoral cell lines, in variety of normal tissues, and in all the foetal tissues tested. Sequencing of AF15q14 cDNA revealed a putative open reading frame of 1833 amino acids that had no homology with any other known protein. The C-terminal end of the putative AF15q14 contained a bipartite nuclear localization site. The translocation t(11;15) preserved the open reading frame between MLL and the 3' end of AF15q14. The contribution of AF15q14 to the fusion protein was only 85 amino acids, Immunofluorescence staining experiments with expression vectors encoding these 85 amino acids confirmed the functionality of the predicted nuclear localization site.	Ctr Leon Berard, INSERM, U453, F-69373 Lyon 08, France; Fac Med Nord, Lab Biochim & Biol Mol, F-13916 Marseille, France; IBCP, UMR 5086, F-69367 Lyon 07, France; Hop Edouard Herriot, Lab Cytogenet Mol, F-69437 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); CHU Lyon	Rimokh, R (corresponding author), Ctr Leon Berard, INSERM, U453, F-69373 Lyon 08, France.		HAYETTE, sandrine/Z-2283-2019; Rimokh, Ruth/G-7506-2014; Deléage, Gilbert/F-7163-2010	Deléage, Gilbert/0000-0003-1939-1614				Archimbaud E, 1998, LEUKEMIA, V12, P25, DOI 10.1038/sj.leu.2400853; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Fidanza V, 1996, CANCER RES, V56, P1179; GEOURJON C, 1995, J MOL GRAPHICS, V13, P209, DOI 10.1016/0263-7855(95)00035-5; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1994, CANCER RES, V54, P2326; Harrison CJ, 1998, LEUKEMIA, V12, P811, DOI 10.1038/sj.leu.2401017; HERNANDEZ JM, 1995, LEUKEMIA, V9, P1162; HUNGER SP, 1993, BLOOD, V81, P3197; Joh T, 1997, ONCOGENE, V15, P1681, DOI 10.1038/sj.onc.1201332; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Marschalek R, 1997, LEUKEMIA LYMPHOMA, V27, P417, DOI 10.3109/10428199709058308; Rogaia D, 1997, CANCER RES, V57, P799; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; RUBNITZ JE, 1994, BLOOD, V84, P570; Schreiner SA, 1999, LEUKEMIA, V13, P1525, DOI 10.1038/sj.leu.2401534; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	21	37	42	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4446	4450		10.1038/sj.onc.1203789	http://dx.doi.org/10.1038/sj.onc.1203789			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980622				2022-12-17	WOS:000089271900017
J	Dicker, AJ; Popa, C; Dahler, AL; Serewko, MM; Hilditch-Maguire, PA; Frazer, IH; Saunders, NA				Dicker, AJ; Popa, C; Dahler, AL; Serewko, MM; Hilditch-Maguire, PA; Frazer, IH; Saunders, NA			E2F-1 induces proliferation-specific genes and suppresses squamous differentiation-specific genes in human epidermal keratinocytes	ONCOGENE			English	Article						keratinocyte; E2F-1; differentiation; carcinogenesis	HUMAN PAPILLOMAVIRUS TYPE-16; SKIN TUMOR-DEVELOPMENT; CARCINOMA CELL-LINE; S-PHASE ENTRY; WILD-TYPE P53; TRANSCRIPTION FACTOR; DNA-BINDING; EPITHELIAL-CELLS; IN-VIVO; TERMINAL DIFFERENTIATION	Squamous differentiation of keratinocytes is associated with decreases in E2F-1 mRNA expression and E2F activity, and these processes are disrupted in squamous cell carcinoma cell lines. We now show that E2F-1 mRNA expression is increased in primary squamous cell carcinomas of the skin relative to normal epidermis, To explore the relationship between E2F-1 and squamous differentiation further, we examined the effect of altering E2F activity in primary human keratinocytes induced to differentiate. Promoter activity for the proliferation-associated genes, cdc2 and keratin 14, are inhibited during squamous differentiation. This inhibition can be inhibited by overexpression of E2F-1 in keratinocytes, Overexpression of E2F-1 also suppressed the expression of differentiation markers (transglutaminase type 1 and keratin 10) in differentiated keratinocytes, Blocking E2F activity by transfecting proliferating keratinocytes with dominant negative E2F-1 constructs inhibited the expression of cdc2 and E2F-1, but did not induce differentiation. Furthermore, expression of the dominant negative construct in epithelial carcinoma cell lines and normal keratinocytes decreased expression from the cdc2 promoter. These data indicate that E2F-1 promotes keratinocyte proliferation-specific marker genes and suppresses squamous differentiation-specific marker genes. Moreover, these data indicate that targeted disruption of E2F-1 activity may have therapeutic potential for the treatment of squamous carcinomas.	Univ Queensland, Princess Alexandra Hosp, Dept Med, Ctr Immunol & Canc Res,Epithelial Pathobiol Grp, Brisbane, Qld 4102, Australia	University of Queensland	Saunders, NA (corresponding author), Univ Queensland, Princess Alexandra Hosp, Dept Med, Ctr Immunol & Canc Res,Epithelial Pathobiol Grp, Brisbane, Qld 4102, Australia.		saunders, nicholas/AAJ-6101-2020; McTaggart, Jill/G-4696-2010; Dicker, Tony/F-6007-2010; Frazer, Ian/A-1137-2007	saunders, nicholas/0000-0002-2478-3420; McTaggart, Jill/0000-0002-9000-8529; Dicker, Tony/0000-0001-8539-2960; Frazer, Ian/0000-0002-8002-4680				ADAMS JC, 1988, J CELL BIOL, V107, P1927, DOI 10.1083/jcb.107.5.1927; ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; Arany I, 1997, IN VIVO, V11, P157; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; Bandara LR, 1997, NAT BIOTECHNOL, V15, P896, DOI 10.1038/nbt0997-896; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BETZ NA, 1995, MOL CARCINOGEN, V12, P66, DOI 10.1002/mc.2940120203; Blessing M, 1996, J CELL BIOL, V135, P227, DOI 10.1083/jcb.135.1.227; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BUCK V, 1995, ONCOGENE, V11, P31; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; Chiang SY, 1998, BIOCHEMISTRY-US, V37, P3109, DOI 10.1021/bi9721142; Chiang SY, 1997, P NATL ACAD SCI USA, V94, P2811, DOI 10.1073/pnas.94.7.2811; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; Dahler AL, 1998, J CELL PHYSIOL, V177, P474, DOI 10.1002/(SICI)1097-4652(199812)177:3<474::AID-JCP10>3.3.CO;2-D; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; GILLES C, 1994, INT J CANCER, V58, P847, DOI 10.1002/ijc.2910580617; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; Guy CT, 1996, MOL CELL BIOL, V16, P685; Harvat BL, 1998, J CELL SCI, V111, P1185; Hauser PJ, 1998, CELL GROWTH DIFFER, V9, P847; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HILDITCHMAGUIRE PA, 1998, THESIS U QUEENSLAND, P275; HUANG PS, 1993, MOL CELL BIOL, V13, P953, DOI 10.1128/MCB.13.2.953; Ishizaki J, 1996, NAT MED, V2, P1386, DOI 10.1038/nm1296-1386; ITOH A, 1995, CELL MOL BIOL RES, V41, P147; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JETTEN AM, 1989, CANCER RES, V49, P3990; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Jones SJ, 1997, J INVEST DERMATOL, V109, P187, DOI 10.1111/1523-1747.ep12319308; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kikuchi Arata, 1992, Journal of Dermatological Science, V4, P83, DOI 10.1016/0923-1811(92)90063-H; LANE EB, 1985, ANN NY ACAD SCI, V455, P241, DOI 10.1111/j.1749-6632.1985.tb50415.x; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lymboussaki A, 1996, BRIT J CANCER, V73, P1347, DOI 10.1038/bjc.1996.257; Maeshima Y, 1998, J CLIN INVEST, V101, P2589, DOI 10.1172/JCI429; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; Mayol X, 1997, Prog Cell Cycle Res, V3, P157; Medvedev A, 1999, J BIOL CHEM, V274, P3887, DOI 10.1074/jbc.274.6.3887; Moll I, 1997, J INVEST DERMATOL, V108, P139, DOI 10.1111/1523-1747.ep12332388; MOORE GE, 1975, CANCER RES, V35, P2684; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEUMAN T, 1995, EXP CELL RES, V217, P363, DOI 10.1006/excr.1995.1098; PAGANO M, 1992, ONCOGENE, V7, P1681; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RIEGER M, 1988, J MOL BIOL, V204, P841, DOI 10.1016/0022-2836(88)90045-9; Rogers KT, 1996, P NATL ACAD SCI USA, V93, P7594, DOI 10.1073/pnas.93.15.7594; Rook A, 1998, TXB DERMATOLOGY; Saunders N, 1999, CANCER RES, V59, P399; Saunders NA, 1998, CANCER RES, V58, P1646; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; SAUNDERS NA, 1994, J BIOL CHEM, V269, P2016; SAUNDERS NA, 1993, BIOCHEM BIOPH RES CO, V197, P46, DOI 10.1006/bbrc.1993.2439; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHARPE GR, 1994, ARCH DERMATOL RES, V286, P476, DOI 10.1007/BF00371575; Sladek TL, 1996, CELL PROLIFERAT, V29, P579, DOI 10.1111/j.1365-2184.1996.tb00973.x; Steenbergen RDM, 1996, ONCOGENE, V13, P1249; STIRDIVANT SM, 1992, MOL CELL BIOL, V12, P1905, DOI 10.1128/MCB.12.5.1905; Strom DK, 1998, CELL GROWTH DIFFER, V9, P59; SUDA K, 1994, NEUROREPORT, V5, P1749, DOI 10.1097/00001756-199409080-00015; Tiainen M, 1996, CELL GROWTH DIFFER, V7, P1039; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; WANG J, 1995, CELL GROWTH DIFFER, V6, P1299; Wang J, 1996, J CELL BIOCHEM, V62, P405; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welter JF, 1996, J BIOL CHEM, V271, P11034; WOODCOCKMITCHELL J, 1982, J CELL BIOL, V95, P580, DOI 10.1083/jcb.95.2.580; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yang Xiao-He, 1995, Gene Expression, V4, P195; Yee Amy S., 1998, Frontiers in Bioscience, V3, pD532; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	84	37	37	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 8	2000	19	25					2887	2894		10.1038/sj.onc.1203610	http://dx.doi.org/10.1038/sj.onc.1203610			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871839				2022-12-17	WOS:000087544500002
J	Saitou, M; Sugimoto, J; Hatakeyama, T; Russo, G; Isobe, M				Saitou, M; Sugimoto, J; Hatakeyama, T; Russo, G; Isobe, M			Identification of the TCL6 genes within the breakpoint cluster region on chromosome 14q32 in T-cell leukemia	ONCOGENE			English	Article						chromosome 14q32; T-cell leukemia; TML1; TCL1; MTCP-1; translocation	ATAXIA-TELANGIECTASIA; LOCUS; TRANSLOCATIONS; RECEPTOR; NEOPLASIA; PATIENT; REVEALS; SUBUNIT; GROWTH; 14Q11	A region on chromosome 14q32.1 is often involved in chromosomal translocations and inversions with one of the T-cell receptor loci in T-cell lymphoproliferative diseases. The breakpoints of the different rearrangements segregate into two clusters; a cluster due to inversion on the centromeric side and a cluster due to simple balanced translocations on the telomeric side. If the target gene activated by these different types of chromosomal rearrangements is the same, the gene must be localized between the two clusters of breakpoints in a region of around 160 kb, Within this breakpoint cluster region, we isolated two genes; namely, TCL1 and TML1/TCL1b genes. In the course of characterizing the TML1 gene, we further identified a third novel gene, which we named TCL6 (T-cell leukemia/lymphoma 6), from a region 7 kb upstream of the TML1 locus. The TCL6 gene expressed at least 11 isoforms through very complex alternative-splicing, including splicing with the TML1 gene. Those isoforms encode at least five open reading frames (ORFs) with no homology to known sequences. The localization of the proteins corresponding to these ORF was determined by fusing green fluorescence protein at the carboxyl terminal of each ORF. ORF141 and ORF72 were observed in the cytoplasmic region, while ORF105, ORF119, and ORF163 were predominantly localized in the nuclear region. Since the TCL6 gene was expressed in T-cell leukemia carrying a t(14;14) (q11;q32.1) chromosome translocation and was not expressed in normal T-cells (just like the TML1 and TCL1 genes), it is also a candidate gene potentially involved in leukemogenesis.	Toyama Univ, Fac Engn, Dept Mat & Biosyst Engn, Toyama 9308555, Japan; IDI IRCCS, Res Labs, I-00167 Rome, Italy	University of Toyama; IRCCS Istituto Dermopatico dell'Immacolata (IDI)	Isobe, M (corresponding author), Toyama Univ, Fac Engn, Dept Mat & Biosyst Engn, Toyama 9308555, Japan.		Russo, Giandomenico/K-9566-2016	Russo, Giandomenico/0000-0002-7718-9687				BRITOBABAPULLE V, 1991, CANCER GENET CYTOGEN, V55, P1, DOI 10.1016/0165-4608(91)90228-M; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; DAVEY MP, 1988, P NATL ACAD SCI USA, V85, P9287, DOI 10.1073/pnas.85.23.9287; Goswami S, 1998, J NEUROCHEM, V71, P1837; Hallas C, 1999, P NATL ACAD SCI USA, V96, P14418, DOI 10.1073/pnas.96.25.14418; ISOBE M, 1985, SCIENCE, V228, P580, DOI 10.1126/science.3983641; ISOBE M, 1988, P NATL ACAD SCI USA, V85, P3933, DOI 10.1073/pnas.85.11.3933; KANZAKI T, 1992, CANCER, V69, P1034, DOI 10.1002/1097-0142(19920215)69:4<1034::AID-CNCR2820690434>3.0.CO;2-E; KUBONISHI I, 1991, AM J HEMATOL, V37, P179, DOI 10.1002/ajh.2830370309; MENGLEGAW L, 1988, P NATL ACAD SCI USA, V85, P9171, DOI 10.1073/pnas.85.23.9171; MENGLEGAW L, 1987, EMBO J, V6, P2273, DOI 10.1002/j.1460-2075.1987.tb02501.x; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURRE C, 1985, NATURE, V316, P549, DOI 10.1038/316549a0; NARDUCCI MG, 1995, BLOOD, V86, P2358, DOI 10.1182/blood.V86.6.2358.bloodjournal8662358; RUSSO G, 1989, P NATL ACAD SCI USA, V86, P602, DOI 10.1073/pnas.86.2.602; SMITH SD, 1989, BLOOD, V73, P2182; STEM MH, 1996, PATHOL BIOL PARIS, V44, P689; Sugimoto J, 1999, CANCER RES, V59, P2313; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; VIRGILIO L, 1993, P NATL ACAD SCI USA, V90, P9275, DOI 10.1073/pnas.90.20.9275	20	37	38	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 25	2000	19	23					2796	2802		10.1038/sj.onc.1203604	http://dx.doi.org/10.1038/sj.onc.1203604			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851082				2022-12-17	WOS:000087318500010
J	Kanamori, M; Kon, H; Nobukuni, T; Nomura, S; Sugano, K; Mashiyama, S; Kumabe, T; Yoshimoto, T; Meuth, M; Sekiya, T; Murakami, Y				Kanamori, M; Kon, H; Nobukuni, T; Nomura, S; Sugano, K; Mashiyama, S; Kumabe, T; Yoshimoto, T; Meuth, M; Sekiya, T; Murakami, Y			Microsatellite instability and the PTEN1 gene mutation in a subset of early onset gliomas carrying germline mutation or promoter methylation of the hMLH1 gene	ONCOGENE			English	Article						glioma; the hMLH1 gene; microsatellite instability; Turcot's syndrome; promotor methylation; the PTEN1 gene	POLYMERASE CHAIN-REACTION; CONFORMATION POLYMORPHISM ANALYSIS; COLORECTAL-CANCER; RECEPTOR GENE; COLON-CANCER; BRAIN-TUMORS; CELL-LINES; HYPERMETHYLATION; AMPLIFICATION; INACTIVATION	High-frequent microsatellite instability (MSI-H) was detected in two of the 80 gliomas examined, while the other 78 gliomas showed microsatellite stable (MSS) phenotype. Both of the two MSI-H tumors were glioblastomas which developed in teenage patients. One of the patient was diagnosed as having Turcot's syndrome and had a germline mutation in the hMLH1 gene. Loss of expression due to promoter methylation was selectively observed in the mild type allele of the hMLH1 gene in the tumor of this patient. The other patient had neither a family history nor a past personal history of malignancy. Although no mutation in the mismatch repair genes was detected in the tumor of this patient, the level of expression of the RMLH1 gene,vas markedly decreased and the promoter sequence of the gene was highly methylated. In the tumor of this patient, the PTEN1 gene, one of the genes carrying microsatellite sequences in their coding regions, was altered by a slippage mutation within five adenine repeat sequences, These findings indicate that the genetic or epigenentic inactivation of the hMLH1 gene is involved in a subset of early-onset gliomas and the PTEN1 gene could be a downstream target for mutation as observed in glioblastoma without MST.	Natl Canc Ctr, Res Inst, Div Oncogene, Chuo Ku, Tokyo 1040045, Japan; Tohoku Univ, Sch Med, Div Neurosurg, Sendai, Miyagi 9808575, Japan; Natl Canc Ctr Hosp, Clin Lab, Tokyo 1040045, Japan; Iwaki Kyoritu Hosp, Iwaki, Fukushima, Japan; Univ Sheffield, Inst Canc Studies, Sheffield S10 2RX, S Yorkshire, England	National Cancer Center - Japan; Tohoku University; National Cancer Center - Japan; University of Sheffield	Murakami, Y (corresponding author), Natl Canc Ctr, Res Inst, Div Oncogene, Chuo Ku, 1-1 Tsukiji,5 Chome, Tokyo 1040045, Japan.		Nomura, Sachio/GYU-4930-2022	Nomura, Sachio/0000-0001-9214-4041				BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; Chan TL, 1999, GENE CHROMOSOME CANC, V25, P75, DOI 10.1002/(SICI)1098-2264(199906)25:2<75::AID-GCC1>3.3.CO;2-T; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLLINS VP, 1993, FASEB J, V7, P926, DOI 10.1096/fasebj.7.10.8344489; Cunningham JM, 1998, CANCER RES, V58, P3455; Dietmaier W, 1997, CANCER RES, V57, P4749; Esteller M, 1999, CANCER RES, V59, P67; FULTS D, 1990, CANCER RES, V50, P5784; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; HE J, 1994, GENE CHROMOSOME CANC, V11, P91, DOI 10.1002/gcc.2870110205; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HUNTER SB, 1995, J NEUROPATH EXP NEUR, V54, P57, DOI 10.1097/00005072-199501000-00007; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kane MF, 1997, CANCER RES, V57, P808; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; Kon H, 1998, ONCOGENE, V16, P257, DOI 10.1038/sj.onc.1201488; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Kuchiki H, 2000, INT J CANCER, V85, P113, DOI 10.1002/(SICI)1097-0215(20000101)85:1<113::AID-IJC20>3.0.CO;2-3; KUMABE T, 1992, ONCOGENE, V7, P627; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; Leung SY, 1998, AM J PATHOL, V153, P1181, DOI 10.1016/S0002-9440(10)65662-3; Leung SY, 1999, CANCER RES, V59, P159; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; Miyaki M, 1997, ONCOGENE, V15, P2877, DOI 10.1038/sj.onc.1201668; MURAKAMI Y, 1991, ONCOGENE, V6, P37; Myohanen SK, 1998, CANCER RES, V58, P591; Nelen MR, 1999, EUR J HUM GENET, V7, P267, DOI 10.1038/sj.ejhg.5200289; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Schutte M, 1997, CANCER RES, V57, P3126; SONODA Y, 1995, CANCER RES, V55, P2166; Sonoda Y, 1996, JPN J CANCER RES, V87, P363, DOI 10.1111/j.1349-7006.1996.tb00231.x; SONODA Y, 1995, ONCOGENE, V11, P2145; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SUZUKI Y, 1991, ANAL BIOCHEM, V192, P82, DOI 10.1016/0003-2697(91)90188-Y; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Yoshitaka T, 1996, BIOCHEM BIOPH RES CO, V227, P553, DOI 10.1006/bbrc.1996.1544	42	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	2000	19	12					1564	1571		10.1038/sj.onc.1203454	http://dx.doi.org/10.1038/sj.onc.1203454			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734316				2022-12-17	WOS:000086108100009
J	Gire, V; Wynford-Thomas, D				Gire, V; Wynford-Thomas, D			RAS oncogene activation induces proliferation in normal human thyroid epithelial cells without loss of differentiation	ONCOGENE			English	Article						differentiation; thyroid; epithelial; oncogene; RAS	PROTEIN-KINASE-A; THYROGLOBULIN GENE; MUTANT RAS; EXPRESSION; GROWTH; TRANSFORMATION; PHOSPHORYLATION; INTERFERENCE; PATHWAYS; TTF-1	Neoplastic transformation of rodent thyroid epithelial cell lines by mutant RAS genes has been widely studied as an experimental model of oncogene-induced loss of tissue-specific differentiation. However, separate evidence strongly implicates RAS mutation as an early event in human thyroid tumour development at a stage prior to loss of differentiation. To resolve this controversy we examined the short- and long-term responses of normal human thyroid epithelial cells to mutant RAS introduced by micro-injection and retroviral transduction respectively. In both cases, expression of RAS at a level sufficient to induce rapid proliferation did not lead to loss of differentiation as shown by expression of cytokeratin 18, E-cadherin, thyroglobulin, TTF-1 and Pax-8 proteins. Indeed, RAS was able to prevent, and to reverse, the loss of thyroglobulin expression which occurs normally in TSH-deficient culture medium. These responses were partially mimicked by activation of RAF, a major RAS effector, indicating involvement of the MAP Kinase signal pathway. The striking contrast between the effect of mutant RAS on differentiation in primary human, compared to immortalized rodent, epithelial cultures is most likely explained by the influence of additional co-operating abnormalities in the latter, and highlights the need for caution in extrapolating from cell line data.	Univ Wales Coll Med, Canc Res Campaign Labs, Dept Pathol, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Wynford-Thomas, D (corresponding author), Univ Wales Coll Med, Canc Res Campaign Labs, Dept Pathol, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.		Gire, Veronique/N-7553-2017; Gire, Véronique/AAC-2218-2020	Gire, Veronique/0000-0002-9009-2185				ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; AVVEDIMENTO VE, 1988, P NATL ACAD SCI USA, V85, P1744, DOI 10.1073/pnas.85.6.1744; BOND J, 1992, MOL CARCINOGEN, V5, P129, DOI 10.1002/mc.2940050208; BOND JA, 1994, ONCOGENE, V9, P281; BROCAS H, 1982, FEBS LETT, V137, P189, DOI 10.1016/0014-5793(82)80346-3; Cobellis G, 1998, ONCOGENE, V17, P2047, DOI 10.1038/sj.onc.1202130; FABBRO D, 1994, CANCER RES, V54, P4744; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gallagher AP, 1998, CANCER RES, V58, P2029; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Kupperman E, 1996, ENDOCRINOLOGY, V137, P96, DOI 10.1210/en.137.1.96; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1990, ONCOGENE, V5, P1833; LIBERT F, 1987, NUCLEIC ACIDS RES, V15, P6735, DOI 10.1093/nar/15.16.6735; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; Missero C, 1998, MOL CELL ENDOCRINOL, V140, P37, DOI 10.1016/S0303-7207(98)00027-6; POHL V, 1990, J CELL BIOL, V111, P663, DOI 10.1083/jcb.111.2.663; Roger PP, 1997, EUR J ENDOCRINOL, V137, P579, DOI 10.1530/eje.0.1370579; SUAREZ HG, 1990, ONCOGENE, V5, P565; VANRENTERGHEM P, 1993, BIOCHIM BIOPHYS ACTA, V1307, P97; VANRENTGERHEM P, 1995, MOL CELL ENDOCRINOL, V112, P83; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; Velasco JA, 1998, ENDOCRINOLOGY, V139, P2796, DOI 10.1210/en.139.6.2796; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; Zannini M, 1996, J BIOL CHEM, V271, P2249, DOI 10.1074/jbc.271.4.2249	30	37	38	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2000	19	6					737	744		10.1038/sj.onc.1203399	http://dx.doi.org/10.1038/sj.onc.1203399			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698491				2022-12-17	WOS:000085192100003
J	Balajee, AS; DeSantis, LP; Brosh, RM; Selzer, R; Bohr, VA				Balajee, AS; DeSantis, LP; Brosh, RM; Selzer, R; Bohr, VA			Role of the ATPase domain of the Cockayne syndrome group B protein in UV induced apoptosis	ONCOGENE			English	Article						Cockayne syndrome; transcription coupled repair; neurodegeneration; RNA pol II transcription; apoptosis; p53 independent pathway	RNA-POLYMERASE-II; TRANSCRIPTION-COUPLED REPAIR; CSB ERCC6 GENE; DNA-DAMAGE; HUMAN FIBROBLASTS; FACTOR CSB/ERCC6; P53 PROTEIN; CELLS; ACCUMULATION; SENSITIVITY	Cockayne syndrome (CS) is a human autosomal recessive disorder characterized by many neurological and developmental abnormalities, CS cells are defective in the transcription coupled repair (TCR) pathway that removes DNA damage from the transcribed strand of active genes, The individuals suffering from CS do not generally develop cancer but show increased neurodegeneration, Two genetic complementation groups (CS-A and CS-B) have been identified, The lack of cancer formation in CS may be due to selective elimination of cells containing DNA damage by a suicidal pathway. In this study, we have evaluated the role of the CSB gene in UV induced apoptosis in human and hamster cells. The hamster cell line UV61 carries a mutation in the homolog of the human CSB gene, We show that both human CS-B and hamster UV61 cells display increased apoptotic response following UV exposure compared with normal cells, The increased sensitivity of UV61 cells to apoptosis is complemented by the transfection of the wild type human CSB gene, In order to determine which functional domain of the CSB gene participates in the apoptotic pathway, we constructed stable cell lines with different CSB domain disruptions, UV61 cells were stably transfected with the human CSB cDNA containing a point mutation in the highly conserved glutamic acid residue in ATPase motif II, This cell line (UV61/pc3.1-CSBE646Q) showed the same increased apoptosis as the UV61 cells, In contrast, cells containing a deletion in the acidic domain at the N-terminal end of the CSB protein had no effect on apoptosis, This indicates that the integrity of the ATPase domain of CSB protein is critical for preventing the UV induced apoptotic pathway, In primary human CS-B cells, the induction and stabilization of the p53 protein seems to correlate with their increased apoptotic potential, In contrast, no change in the level of either p53 or activation of mdm2 protein by p53 was observed in hamster UV61 cells after UV exposure. This suggests that the CSB dependent apoptotic pathway can occur independently of the transactivation potential of p53 in hamster cells.	NIA, Genet Mol Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Bohr, VA (corresponding author), NIA, Genet Mol Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Bohr, Vilhelm/AAP-5931-2020	Proietti De Santis, Luca/0000-0002-2715-9113				Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Balajee AS, 1997, P NATL ACAD SCI USA, V94, P4306, DOI 10.1073/pnas.94.9.4306; Brosh RM, 1999, MOL BIOL CELL, V10, P3583, DOI 10.1091/mbc.10.11.3583; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; Dianov GL, 1997, NUCLEIC ACIDS RES, V25, P3636, DOI 10.1093/nar/25.18.3636; Dumaz N, 1997, MOL CARCINOGEN, V20, P340, DOI 10.1002/(SICI)1098-2744(199712)20:4<340::AID-MC3>3.0.CO;2-N; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; Guillouf C, 1998, INT J ONCOL, V13, P107; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LEE AT, 1994, FASEB J, V8, P545, DOI 10.1096/fasebj.8.8.8181674; Lee HY, 1997, P NATL ACAD SCI USA, V94, P526, DOI 10.1073/pnas.94.2.526; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Mallery DL, 1998, AM J HUM GENET, V62, P77, DOI 10.1086/301686; MAYNE LV, 1982, CANCER RES, V42, P1473; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; Ohta M, 1999, MUTAT RES-DNA REPAIR, V433, P23, DOI 10.1016/S0921-8777(98)00058-5; Orren DK, 1997, MOL BIOL CELL, V8, P1129, DOI 10.1091/mbc.8.6.1129; Orren DK, 1996, NUCLEIC ACIDS RES, V24, P3317, DOI 10.1093/nar/24.17.3317; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Selby CP, 1997, J BIOL CHEM, V272, P1885, DOI 10.1074/jbc.272.3.1885; Stecca C, 1998, BIOCHEM PHARMACOL, V55, P941, DOI 10.1016/S0006-2952(97)00448-6; Tantin D, 1997, MOL CELL BIOL, V17, P6803, DOI 10.1128/MCB.17.12.6803; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TROELSTRA C, 1990, MOL CELL BIOL, V10, P5806, DOI 10.1128/MCB.10.11.5806; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; vanOosterwijk MF, 1996, NUCLEIC ACIDS RES, V24, P4653, DOI 10.1093/nar/24.23.4653; Wang JS, 1998, J BIOL CHEM, V273, P31068, DOI 10.1074/jbc.273.47.31068; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775	36	37	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2000	19	4					477	489		10.1038/sj.onc.1203372	http://dx.doi.org/10.1038/sj.onc.1203372			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698517				2022-12-17	WOS:000085104200001
J	Karsunky, H; Geisen, C; Schmidt, T; Haas, K; Zevnik, B; Gau, E; Moroy, T				Karsunky, H; Geisen, C; Schmidt, T; Haas, K; Zevnik, B; Gau, E; Moroy, T			Oncogenic potential of cyclin E in T-cell lymphomagenesis in transgenic mice: evidence for cooperation between cyclin E and Ras but not Myc	ONCOGENE			English	Article						cyclin E; Ki-ras; p27(KIP1); MNU; lymphoma; oncogene cooperation	BREAST-CANCER CELLS; CDK INHIBITORS; RETINOBLASTOMA PROTEIN; RESTRICTION POINT; DEPENDENT KINASES; THYMIC LYMPHOMAS; NUCLEAR-PROTEIN; EXPRESSION; PROLIFERATION; P27(KIP1)	To study the oncogenic activity of cyclin E in an in vivo system we generated transgenic mice expressing high levels of cyclin Ii: in T-lymphocytes by using a construct containing the CD2 locus control region. These animals were neither predisposed to develop any tumors spontaneously nor showed an increased incidence when crossbred with E mu L-myc transgenic mice but developed hyperplasia in peripheral lymphoid organs at later age with an incidence of 27%. When treated with the DNA methylating carcinogen N-methylnitrosourea (MNU) that provokes the development of T-cell lymphomas, CD2-cyclin E transgenic animals came down with T-cell neoplasia showing a significant higher incidence (54%) than normal non transgenic controls (31%). In one of eight tumors that arose in normal MNU treated mice me could find an expected activating point mutation in the Ki-ras gene (12.5%). In contrast, the same mutation occurred in five of 16 tumors from CD2-cyclin E transgenic mice (31.2%). Whereas cyclin E overexpression alone did not lead to an increased CDK2 activity we observed in ail tumors that emerged from either MNU treated normal mice or treated CD2-cyclin E transgenics a downregulation of p27(KIP1) and a higher histone HI kinase activity: in CDK2 immunoprecipitates compared to normal tissue. These findings demonstrate that high level expression of cyclin E can predispose T-cells for hyperplasia and malignant transformation. However, the results also suggest that this activity of cyclin E is manifest only when other cooperating oncogenes in particular I as genes are present and activated. This would be consistent with our previous finding that cyclin E and Ha-Ras cooperate in focus formation assays in rat embryo fibroblasts.	Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany	University of Duisburg Essen	Moroy, T (corresponding author), Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, Virchowstr 173, D-45122 Essen, Germany.		Moroy, Tarik/D-9923-2011; Zevnik, Branko/AAB-7853-2020	Zevnik, Branko/0000-0001-7845-9522				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Erlanson M, 1998, BLOOD, V92, P770; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; HALL M, 1995, ONCOGENE, V11, P1581; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HOGAN B, 1994, MANIPULATING MOUSE E; JOSHI VV, 1970, J NATL CANCER I, V44, P185; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LIU LL, 1994, CANCER RES, V54, P4648; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; NEWCOMB EW, 1995, MOL CARCINOGEN, V13, P89, DOI 10.1002/mc.2940130205; NEWCOMB EW, 1989, ANTICANCER RES, V9, P1407; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sambrook J, 1989, MOL CLONING LAB MANU; Schmidt T, 1998, EMBO J, V17, P5349, DOI 10.1093/emboj/17.18.5349; SEWING A, 1993, J CELL SCI, V104, P545; Sgambato A, 1996, CANCER RES, V56, P1389; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WOLOWIEC D, 1995, LEUKEMIA, V9, P1382; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S	45	37	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	1999	18	54					7816	7824		10.1038/sj.onc.1203205	http://dx.doi.org/10.1038/sj.onc.1203205			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618723				2022-12-17	WOS:000084256900012
J	Lo, PK; Chen, JY; Lo, WC; Chen, BF; Hsin, JP; Tang, PP; Wang, FF				Lo, PK; Chen, JY; Lo, WC; Chen, BF; Hsin, JP; Tang, PP; Wang, FF			Identification of a novel mouse p53 target gene DDA3	ONCOGENE			English	Article						p53; growth suppression; DDA3	WILD-TYPE P53; DNA-DAMAGE; P53-INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION; FUNCTIONAL DOMAIN; PROTEIN; INHIBITOR; GROWTH; CELLS; CHECKPOINT	We have identified a novel p53 regulated gene designated DDA3 through differential mRNA display on IW32 erythroleukemia cells containing a temperature sensitive p53 allele, tsp53val-135. DDA3 mRNA induction could be observed in all sublines expressing tsp53val-135 cultured at permissive temperature as well as in NIH3T3 cells undergoing DNA damage. Upregulation of DDA3 could be detected within 2 h after down-shifting the temperature to 32.5 degrees C; upon shifting back to 38.5 degrees C, DDA3 mRNA rapidly degraded with a half-life of less than 2 h. Actinomycin D, but not cycloheximide, inhibited the p53 dependent DDA3 induction, suggesting that the activation is through transcriptional regulation and does not require de novo protein synthesis. DDA3 was expressed in multiple mouse tissues including brain, spleen, lung, kidney and testis. Full-length DDA3 cDNA was cloned and it contained an open reading frame predicted to encode a proline rich protein of 329 amino acids. Overexpression of DDA3 in H1299 lung carcinoma cells suppressed colony formation. These results suggest that DDA3 is a p53-regulated gene that might participate in the p53-mediated growth suppression.	Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan; Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Mackay Mem Hosp, Dept Pathol, Taipei 104, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; Mackay Memorial Hospital	Wang, FF (corresponding author), Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan.		Chen, Joanne Jeou-Yuan/S-7022-2018					Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHEN CM, 1991, J BIOL CHEM, V266, P7754; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHOPPIN J, 1984, BLOOD, V64, P341; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISRAELI D, 1997, EMBO J, V16, P4382; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; VOGELSTEIN B, 1994, NATURE, V370, P174, DOI 10.1038/370174a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wyllie A, 1997, NATURE, V389, P237, DOI 10.1038/38405	48	37	41	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	1999	18	54					7765	7774		10.1038/sj.onc.1203167	http://dx.doi.org/10.1038/sj.onc.1203167			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618717				2022-12-17	WOS:000084256900006
J	Elson, A				Elson, A			Protein tyrosine phosphatase epsilon increases the risk of mammary hyperplasia and mammary tumors in transgenic mice	ONCOGENE			English	Article						breast cancer; adenocarcinoma; sarcoma	SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; GROWTH-FACTOR; HA-RAS; CARCINOMA CELLS; NEU ONCOGENE; EXPRESSION; BREAST; GENE; TRANSFORMATION	Accurate phosphorylation of tyrosine residues in proteins plays a central role in regulation of cellular function. Although connections between aberrant tyrosine kinase activity and malignancy are well-established, significantly less Is known about the roles of protein tyrosine phosphatases (PTPases) in tumorigenesis. We have previously shown that the transmembranal form of PTPase Epsilon (PTP epsilon) is upregulated in mouse mammary tumors initiated specifically by ras or neu, suggesting that PTP epsilon may play a role in transformation by these two oncogenes, In order to test this notion lit vivo, we created transgenic mice that express elevated le, els of PTP epsilon in their mammary epithelium by use of the MMTV promoter/enhancer, Following several cycles of pregnancy female MMTV-PTP epsilon mice uniformly de, eloped pronounced and persistent mammary hyperplasia which was accompanied by residual milk production. Solitary mammary tumors were often detected secondary to mammary hyperplasia. The sporadic nature of the tumors, the long latency period prior to their development, and low levels of transgene expression in the tumors indicate that PTP epsilon provides a necessary, but insufficient, signal for oncogenesis. The results provide genetic evidence that PTP epsilon plays an accessory role in production of mammary tumors in a manner consistent with its upregulation in mammary tumors induced by ras or neu.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elson, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.			Elson, Ari/0000-0001-9808-9135				Ahmad A, 1998, AM J PATHOL, V152, P721; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Barford D, 1998, STRUCTURE, V6, P249, DOI 10.1016/S0969-2126(98)00027-6; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; Birchmeier C, 1996, ACTA ANAT, V156, P217; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cao LG, 1998, J BIOL CHEM, V273, P21077, DOI 10.1074/jbc.273.33.21077; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; FAERMAN A, 1995, J HISTOCHEM CYTOCHEM, V43, P461, DOI 10.1177/43.5.7730585; Frearson JA, 1997, BIOESSAYS, V19, P417, DOI 10.1002/bies.950190509; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gilles C, 1997, CLIN EXP METASTAS, V15, P519, DOI 10.1023/A:1018427027270; HAO L, 1997, J BIOL CHEM, V272, P29332; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Kitsberg DI, 1996, ONCOGENE, V13, P2507; Krane IM, 1996, ONCOGENE, V12, P1781; LEDER A, 1992, DEVELOPMENT, V116, P1041; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Quarrie LH, 1996, J CELL PHYSIOL, V168, P559, DOI 10.1002/(SICI)1097-4652(199609)168:3<559::AID-JCP8>3.0.CO;2-O; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Shin DY, 1997, ONCOGENE, V14, P2633, DOI 10.1038/sj.onc.1201106; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Solic N, 1997, EXP CELL RES, V234, P465, DOI 10.1006/excr.1997.3635; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; TOLEDANOKATCHAL.H, IN PRESS ONCOGENE; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; ZHAI YF, 1995, MOL CARCINOGEN, V14, P103, DOI 10.1002/mc.2940140206; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	45	37	37	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7535	7542		10.1038/sj.onc.1203098	http://dx.doi.org/10.1038/sj.onc.1203098			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602512				2022-12-17	WOS:000084119600014
J	Roubin, R; Naert, K; Popovici, C; Vatcher, G; Coulier, F; Thierry-Mieg, J; Pontarotti, P; Birnbaum, D; Baillie, D; Thierry-Mieg, D				Roubin, R; Naert, K; Popovici, C; Vatcher, G; Coulier, F; Thierry-Mieg, J; Pontarotti, P; Birnbaum, D; Baillie, D; Thierry-Mieg, D			let-756, a C-elegans fgf essential for worm development	ONCOGENE			English	Article						C-elegans; FGF; nematode; let-756; egl-17; worm development	FIBROBLAST GROWTH-FACTOR; CAENORHABDITIS-ELEGANS; SKELETAL DISORDERS; CHROMOSOME-III; SEX MYOBLASTS; FACTOR FAMILY; MUTATIONS; SEQUENCE; GENE; EXPRESSION	In vertebrates, Fibroblast Growth Factors (FGFs) and their receptors are involved in various developmental and pathological processes, including neoplasia. The number of FGFs and their large range of activities have made the understanding of their precise functions difficult. Investigating their biology in other species might be enlightening. A sequence encoding a putative protein presenting 30-40% identity with the conserved core of vertebrate FGFs has been identified by the C. elegans sequencing consortium. We show here that this gene is transcribed and encodes a putative protein of 425 amino acids (aa), The gene is expressed at all stages of development beyond late embryogenesis, peaking at the larval stages. Loss-of-function mutants of the let-756 gene are rescued by the wild type fgf gene in germline transformation experiments. Two partial loss-of-function alleles, s2613 and s2809, have a mutation that replaces aa 317 by a stop. The truncated protein retains the FGF core but lacks a C-terminus portion. These worms are small and develop slowly into clear and scrawny, yet viable and fertile adults. A third allele, s2887, is inactivated by an inversion that disrupts the first exon. It causes a developmental arrest early in the larval stages. Thus, in contrast to the other nematode fgf gene egl-17, let-756/fgf is essential for worm development.	INSERM, U119, Oncol Mol Lab, F-13009 Marseille, France; INSERM, U119, Lab Plast Genome & Evolut, F-13009 Marseille, France; CNRS, Ctr Rech Biochim Macromol, F-34293 Montpellier 5, France; Simon Fraser Univ, Inst Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Simon Fraser University	Roubin, R (corresponding author), INSERM, U119, Oncol Mol Lab, 27 Blvd Lei Roure, F-13009 Marseille, France.		THIERRY-MIEG, Jean/F-1975-2017; , pontarotti/ABB-1753-2021; POPOVICI, Cornel/A-2027-2009; Coulier, François/G-6098-2015	THIERRY-MIEG, Jean/0000-0002-0396-6789; POPOVICI, Cornel/0000-0001-8226-3127; Coulier, François/0000-0002-6288-7773; Birnbaum, Daniel/0000-0001-7920-9883; Thierry-Mieg, Danielle/0000-0001-9568-4211; Pierre, Pontarotti/0000-0001-7202-3648				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BRENNER S, 1974, GENETICS, V77, P71; Burdine RD, 1998, DEVELOPMENT, V125, P1083; Burdine RD, 1997, P NATL ACAD SCI USA, V94, P2433, DOI 10.1073/pnas.94.6.2433; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; DeMoerlooze L, 1997, CURR OPIN GENET DEV, V7, P378, DOI 10.1016/S0959-437X(97)80152-9; DEVORE DL, 1995, CELL, V83, P611, DOI 10.1016/0092-8674(95)90101-9; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Fiore F, 1997, INT J DEV BIOL, V41, P639; Floss T, 1997, GENE DEV, V11, P2040, DOI 10.1101/gad.11.16.2040; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; Green PJ, 1996, BIOESSAYS, V18, P639, DOI 10.1002/bies.950180807; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; Janke DL, 1997, GENOME RES, V7, P974, DOI 10.1101/gr.7.10.974; KIEFER P, 1983, MOL CELL BIOL, V13, P5781; MANSOUR SL, 1994, MOL REPROD DEV, V39, P62, DOI 10.1002/mrd.1080390111; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Popovici C, 1998, P NATL ACAD SCI USA, V95, P5712, DOI 10.1073/pnas.95.10.5712; RAPPOLEE DA, 1994, DEVELOPMENT, V120, P2259; ROGALSKI TM, 1993, GENE DEV, V7, P1471, DOI 10.1101/gad.7.8.1471; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Stewart HI, 1998, MOL GEN GENET, V260, P280, DOI 10.1007/PL00013816; STEWART HI, 1991, MUTAT RES, V248, P37; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; WILLIAMS BD, 1992, GENETICS, V131, P609; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wood WB., 1988, NEMATODE CAENORHABDI; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201	42	37	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	1999	18	48					6741	6747		10.1038/sj.onc.1203074	http://dx.doi.org/10.1038/sj.onc.1203074			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597282				2022-12-17	WOS:000083792000016
J	Ferrigno, P; Silver, PA				Ferrigno, P; Silver, PA			Regulated nuclear localization of stress-responsive factors: how the nuclear trafficking of protein kinases and transcription factors contributes to cell survival	ONCOGENE			English	Review						nuclear transport; protein phosphorylation; p53; Akt/PKB; NF-AT; STATs	NF-KAPPA-B; NUCLEOCYTOPLASMIC TRANSPORT; MAP KINASE; MOLECULAR-CLONING; TUMOR-SUPPRESSOR; EXPORT RECEPTOR; TRANSFER-RNA; INTRAMOLECULAR MASKING; IMPORT RECEPTOR; PORE COMPLEX	The details of nuclear transport mechanisms are emerging rapidly, Largely through work with model organisms. Here, we briefly describe these advances, with an emphasis on the remaining challenges. We then address the nuclear transport of some high profile cellular regulators, including p53 and the proto-oncogene PKB/Akt, We discuss the mechanisms that contribute to the differential subcellular localization of these proteins. Finally, me analyse the provocative patterns that emerge from our overview.	Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Silver, PA (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, 44 Binney St, Boston, MA 02115 USA.			Ko Ferrigno, Paul/0000-0002-5922-4100				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Arts GJ, 1998, EMBO J, V17, P7430, DOI 10.1093/emboj/17.24.7430; Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; BRUGERING BM, 1995, NATURE, V376, P599; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Cole CN, 1998, CURR BIOL, V8, pR368, DOI 10.1016/S0960-9822(98)70239-8; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gaits F, 1999, MOL BIOL CELL, V10, P1395, DOI 10.1091/mbc.10.5.1395; Gaits F, 1998, GENE DEV, V12, P1464, DOI 10.1101/gad.12.10.1464; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; Izaurralde E, 1998, RNA, V4, P351; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kehlenbach RH, 1999, J CELL BIOL, V145, P645, DOI 10.1083/jcb.145.4.645; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; KREBBER H, 1999, IN PRESS GENES DEV, V13; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEWIS T, 1995, J CELL SCI, V108, P2885; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Melchior F, 1998, TRENDS CELL BIOL, V8, P175, DOI 10.1016/S0962-8924(98)01252-5; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; Moroianu J, 1998, J CELL BIOCHEM, V70, P231; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reiser V, 1999, MOL BIOL CELL, V10, P1147, DOI 10.1091/mbc.10.4.1147; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Saavedra C, 1996, GENE DEV, V10, P1608, DOI 10.1101/gad.10.13.1608; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Schlenstedt G, 1997, EMBO J, V16, P6237, DOI 10.1093/emboj/16.20.6237; SHAULSKY G, 1990, ONCOGENE, V5, P1707; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sweet DJ, 1996, J CELL BIOL, V133, P971, DOI 10.1083/jcb.133.5.971; Tolwinski NS, 1999, J BIOL CHEM, V274, P6168, DOI 10.1074/jbc.274.10.6168; Torgerson TR, 1998, J IMMUNOL, V161, P6084; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	101	37	37	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	1999	18	45			SI		6129	6134		10.1038/sj.onc.1203132	http://dx.doi.org/10.1038/sj.onc.1203132			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251LL	10557104				2022-12-17	WOS:000083447100007
J	Mengubas, K; Riordan, FA; Bravery, CA; Lewin, J; Owens, DL; Mehta, AB; Hoffbrand, AV; Wickremasinghe, RG				Mengubas, K; Riordan, FA; Bravery, CA; Lewin, J; Owens, DL; Mehta, AB; Hoffbrand, AV; Wickremasinghe, RG			Ceramide-induced killing of normal and malignant human lymphocytes is by a non-apoptotic mechanism	ONCOGENE			English	Article						ceramide; leukaemia; apoptosis; necrosis	RADIATION-INDUCED APOPTOSIS; DAUNORUBICIN-INDUCED APOPTOSIS; ACTIVATED PROTEIN-KINASES; CELL-DEATH; HL-60 CELLS; DNA-DAMAGE; IN-VITRO; B-CELL; LEUKEMIA; RESISTANCE	Synthetic ceramides induce apoptotic death of Jurkat and HL60 leukaemia cell lines. By contrast we show here that ceramide induces non-apoptotic killing of malignant cells from patients with B-chronic lymphocytic leukaemia (B-CLL) and of normal B lymphocytes, The protein phosphatase inhibitor okadaic acid readily induces apoptosis of B-CLL cells, indicating that this death pathway is fully functional in these cells. The ability of ceramide to activate the apoptotic protease caspase 3 in HL60 cells but not in B-CLL cells, as well as the lack of correlation of ceramide-mediated killing of different B-CLL isolates with expression of the apoptosis-regulating proteins bcl-2 and bax reinforce the conclusion that ceramide killing of B-CLL cells is by a non-apoptotic mechanism. Fludarabine treatment or gamma-irradiation of B-CLL cells resulted in ceramide elevation and in killing by both apoptotic and non-apoptotic mechanisms, suggesting that a ceramide-triggered non-apoptotic mechanism may play a role in the killing of these cells. Therefore, the results here show that ceramide can induce either apoptotic or non-apoptotic death, depending on the cellular conte it. The inability of synthetic dihydroceramide to kill B-CLL cells or normal B lymphocytes suggests that non-apoptotic killing by ceramide is via interaction with a specific, but unidentified, cellular target.	UCL Royal Free & Univ Coll Sch Med, Dept Hematol, London NW3 2PF, England; UCL Royal Free & Univ Coll Sch Med, Dept Histopathol, London NW3 2PF, England; UCL Royal Free & Univ Coll Sch Med, Hemophilia Ctr, London NW3 2PF, England	University of London; University College London; University of London; University College London; University of London; University College London	Wickremasinghe, RG (corresponding author), UCL Royal Free & Univ Coll Sch Med, Dept Hematol, Rowland Hill St, London NW3 2PF, England.		Mehta, Atul/GPC-7364-2022					Allouche M, 1997, ONCOGENE, V14, P1837, DOI 10.1038/sj.onc.1201023; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Chmura SJ, 1997, CANCER RES, V57, P1270; Consoli U, 1998, BLOOD, V91, P1742, DOI 10.1182/blood.V91.5.1742.1742_1742_1748; Cotter T.G., 1996, TECHNIQUES APOPTOSIS; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Eguchi Y, 1997, CANCER RES, V57, P1835; FernandezSanchez MT, 1996, FEBS LETT, V398, P106, DOI 10.1016/S0014-5793(96)01192-1; FOON KA, 1990, ANN INTERN MED, V113, P525, DOI 10.7326/0003-4819-113-7-525; Haimovitz-Friedman A, 1997, BRIT MED BULL, V53, P539; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Jarvis WD, 1997, MOL PHARMACOL, V52, P935, DOI 10.1124/mol.52.6.935; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Kojima H, 1996, ONCOL RES, V8, P497; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Michael JM, 1997, CANCER RES, V57, P3600; Naito M, 1997, BLOOD, V89, P2060, DOI 10.1182/blood.V89.6.2060; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Ohmori M, 1997, CANCER RES, V57, P4714; PANAYIOTIDIS P, 1993, BRIT J HAEMATOL, V85, P439; Panayiotidis P., 1995, Blood, V86, p607A; Pepper C, 1997, BRIT J CANCER, V76, P935, DOI 10.1038/bjc.1997.487; PUSHKAREVA M, 1995, BIOCHEMISTRY-US, V34, P1885, DOI 10.1021/bi00006a009; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Shimizu S, 1996, ONCOGENE, V12, P2045; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Tay DLM, 1996, EXP HEMATOL, V24, P277; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Thomas A, 1996, ONCOGENE, V12, P1055; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Wright SC, 1996, FASEB J, V10, P325, DOI 10.1096/fasebj.10.2.8641566; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	48	37	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2499	2506		10.1038/sj.onc.1202622	http://dx.doi.org/10.1038/sj.onc.1202622			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229201				2022-12-17	WOS:000079703300010
J	Hatakeyama, S; Osawa, M; Omine, M; Ishikawa, F				Hatakeyama, S; Osawa, M; Omine, M; Ishikawa, F			JTB: A novel membrane protein gene at 1q21 rearranged in a jumping translocation	ONCOGENE			English	Article						jumping translocation; JTB; leukemia	COMPARATIVE GENOMIC HYBRIDIZATION; GAINS; LIPOSARCOMAS; LYMPHOMA; FAMILY; LOSSES; CANCER	1q21 is frequently involved in different types of translocation in many types of cancers. Jumping translocation (JT) is an unbalanced translocation that comprises amplified chromosomal segments jumping to various telomeres. In this study, we identified a novel gene human JTB (Jumping Translocation Breakpoint) at 1q21, which fused with the telomeric repeats of acceptor telomeres in a case of JT. hJTB (human JTB) encodes a trans-membrane protein that is highly conserved among divergent eukaryotic species. JT results in a hJTB truncation, which potentially produces an hJTB product devoid of the trans-membrane domain. hJTB is located in a gene-rich region at 1q21, called EDC (Epidermal Differentiation Complex). This is the first report identifying the gene involved in unbalanced translocations at 1q21.	Tokyo Inst Technol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Kirin Pharmaceut Res Lab, Takasaki, Gumma 3701202, Japan; Showa Univ, Fujigaoka Hosp, Div Hematol, Aoba Ku, Yokohama, Kanagawa 2270043, Japan	Tokyo Institute of Technology; Showa University	Ishikawa, F (corresponding author), Tokyo Inst Technol, Dept Life Sci, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.		Ishikawa, Fuyuki/AAU-4056-2021; Hatakeyama, Shinji/I-8873-2019	Ishikawa, Fuyuki/0000-0002-5580-2305; Hatakeyama, Shinji/0000-0002-0166-2773				Armengol G, 1997, BRIT J CANCER, V75, P1403, DOI 10.1038/bjc.1997.242; BERNHEIM A, 1988, CANCER GENET CYTOGEN, V32, P67, DOI 10.1016/0165-4608(88)90313-5; Flint J, 1997, NAT GENET, V15, P252, DOI 10.1038/ng0397-252; Gronwald J, 1997, CANCER RES, V57, P481; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; Hatakeyama S, 1998, BLOOD, V91, P1514, DOI 10.1182/blood.V91.5.1514.1514_1514_1519; Ishikawa F, 1997, BIOCHEM BIOPH RES CO, V230, P1, DOI 10.1006/bbrc.1996.5928; Lioumi M, 1998, GENOMICS, V49, P200, DOI 10.1006/geno.1998.5234; Marenholz I, 1996, GENOMICS, V37, P295, DOI 10.1006/geno.1996.0563; OFFIT K, 1991, BLOOD, V77, P1508; SALTMAN D, 1993, CHROMOSOMA, V102, P121, DOI 10.1007/BF00356029; SHIPPEY C A, 1990, Genes Chromosomes and Cancer, V2, P14, DOI 10.1002/gcc.2870020104; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; Szymanska J, 1996, GENE CHROMOSOME CANC, V15, P89, DOI 10.1002/(SICI)1098-2264(199602)15:2<89::AID-GCC2>3.0.CO;2-#; Szymanska J, 1997, CANCER GENET CYTOGEN, V99, P14, DOI 10.1016/S0165-4608(96)00436-0; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4	16	37	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2085	2090		10.1038/sj.onc.1202510	http://dx.doi.org/10.1038/sj.onc.1202510			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321732				2022-12-17	WOS:000079346200005
J	Hagemann, D; Troppmair, J; Rapp, UR				Hagemann, D; Troppmair, J; Rapp, UR			Cot protooncoprotein activates the dual specificity kinases MEK-1 and SEK-1 and induces differentiation of PC12 cells	ONCOGENE			English	Article						cot; classic cytoplasmic cascade; stress kinase pathway; transformation; differentiation	PROTEIN-KINASE; SIGNAL-TRANSDUCTION; C-JUN; MAMMALIAN-CELLS; GENE-PRODUCT; MAP KINASES; RAF; GROWTH; TPL-2; TRANSFORMATION	Mitogenic signals initiated at the plasma membrane are transmitted to the nucleus through an intricate signalling network. We identified the protooncoprotein Cot as a new component of mitogenic signalling cascades, which activates both the classic cytoplasmic cascade and the SAFE stress pathway. Wildtype and activated Cot phosphorylate and activate MEK-1 and SEK-1 in vitro. These findings are consistent with the sequence homology between Cot and the rat gene Tpl-2. Expression of oncogenic Cot in 293, NIH3T3 and PC12 cells leads to in vivo phosphorylation of endogenous c-Jun and Erk-1/2 suggesting that the serine/threonine kinase Cot functions beside c-Raf-l and Mos asa direct activator of MEK-1. Furthermore, we have examined the biological effects of Cot on the phenotype of fibroblastic and neuronal cells. In order to test a potential c-Raf-l dependency of Cot transformation, the effect of oncogenic Cot on Raf revertant CHP25 cells was determined. Cot could restore the transformed phenotype indicating that Cot transformation is not dependent on active c-Raf-l and that Cot is not a target for the putative Raf inhibitor, which is presumably active in the revertant cell line. Expression of oncogenic versions of Raf as well as v-Mos leads to differentiation of PC12 cells. Cot also induces neurite outgrowth of PC12 cells. These data are consistent with the role of Cot in the classic mitogenic cascade and suggest that the simultaneously activated JNK/SAPK stress pathway has no antagonistic effects in this context.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany	University of Wurzburg	Rapp, UR (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, Versbacher Str 5, D-97078 Wurzburg, Germany.			Troppmair, Jakob/0000-0002-0611-3837				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; AOKI M, 1993, J BIOL CHEM, V268, P22723; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HEIDECKER G, 1989, GENES SIGNAL TRANSDU, P339; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; KOLCH W, 1993, ONCOGENE, V8, P361; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1983, J VIROL, V45, P914, DOI 10.1128/JVI.45.3.914-924.1983; RAPP UR, 1978, P NATL ACAD SCI USA, V75, P2468, DOI 10.1073/pnas.75.5.2468; RAPP UR, 1988, HDB ONCOGENES, P213; RAPP UR, 1994, FOS JUN FAMILIES TRA, P221; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUPSKY JR, 1998, CELL GROWTH ONCOGENE, P75; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Wixler V, 1996, FEBS LETT, V385, P131, DOI 10.1016/0014-5793(96)00363-8; Woodgett JR, 1996, CANCER SURV, V27, P127; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798	45	37	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1391	1400		10.1038/sj.onc.1202431	http://dx.doi.org/10.1038/sj.onc.1202431			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050876				2022-12-17	WOS:000078651600001
J	Liu, JH; Wei, S; Burnette, PK; Gamero, AM; Hutton, M; Djeu, JY				Liu, JH; Wei, S; Burnette, PK; Gamero, AM; Hutton, M; Djeu, JY			Functional association of TGF-beta receptor II with cyclin B	ONCOGENE			English	Article						transforming growth factor receptor; cyclin B; cdc-2; cell cycle control	GROWTH-FACTOR-BETA; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; DEPENDENT KINASE; PROTEIN-KINASE; HUMAN WEE1; PHOSPHORYLATION; INHIBITION; G1; ACTIVATION	Utilizing the cytoplasmic tail of Transforming Growth Factor Receptor Type II (TGF beta RII) as bait in a yeast two hybrid system, we have identified human cyclin B2 as a direct physical partner of TGF beta RII. Analysis of deletion mutants of glutathione-S-transferase (GST)-cyclin B2 mapped its binding domain for TGF beta RII to the C-terminal and revealed a negative regulatory region immediately upstream of the cyclin box. Using recombinant proteins, Cdc2 was demonstrated to indirectly interact with TGF beta RII via cyclin B2. This interaction was reproduced in THP-1 monocytic cells, where TGF beta treatment markedly enhanced the ability of cyclin B2 and, correspondingly, Cdc2 from TGF beta-treated THP-1 cells, to bind the GST-TGF beta RII fusion protein. More importantly, TGF beta RII co-precipitated with cyclin B2 in TGF beta-treated THP-1 cells. TGF beta treatment also caused threonine phosphorylation of Cdc2 in the TGF beta RII-cyclin B2-Cdc2 complex in THP1 cells, in parallel with down regulation of Cdc2 function as measured by histone H1 kinase activity. Cyclin B1 had the same capacity to bind TGF beta RII and mediate indirect Cdc2 binding. These results suggest an alternative mechanism that cell cycle arrest in the G1/S phase caused by TGF beta may, in part, be due to inactivation of cyclin B/Cdc2 kinase, which is needed for entry into the G2/M phase.	Univ S Florida, Dept Biochem & Mol Biol, H Lee Moffit Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA; Mayo Clin, Jacksonville, FL 32224 USA	State University System of Florida; University of South Florida; Mayo Clinic	Djeu, JY (corresponding author), Univ S Florida, Dept Biochem & Mol Biol, H Lee Moffit Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA.				NATIONAL CANCER INSTITUTE [R01CA063724] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA63724] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARKE PR, 1994, CUR BIOL, V5, P40; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GUARENTE L, 1993, P NATL ACAD SCI USA, V90, P1639, DOI 10.1073/pnas.90.5.1639; HARPER JW, 1993, CELL, V75, P805; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Lock Leslie F., 1994, Trends in Cell Biology, V4, P404, DOI 10.1016/0962-8924(94)90054-X; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; Moore DD, 1995, GLOB MOB SURV; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RAVITZ MJ, 1995, CANCER RES, V55, P1413; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	39	37	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					269	275		10.1038/sj.onc.1202263	http://dx.doi.org/10.1038/sj.onc.1202263			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926943				2022-12-17	WOS:000078166000030
J	Choi, SW; Park, SW; Lee, KY; Kim, KM; Chung, YJ; Rhyu, MG				Choi, SW; Park, SW; Lee, KY; Kim, KM; Chung, YJ; Rhyu, MG			Fractional allelic loss in gastric carcinoma correlates with growth patterns	ONCOGENE			English	Article						gastric carcinoma; fractional allelic loss; loss of heterozygosity; growth pattern	TUMOR-SUPPRESSOR GENES; P53; HETEROZYGOSITY; RETINOBLASTOMA; CARCINOGENESIS; DELETIONS; CANCER	To gain an insight into the genetic events underlying morphological phenotypes, we analysed 58 gastric carcinoma tissues for the genome-wide allelotype study using microsatellite markers. Based on a binomial distribution, loss of heterozygosity (LOH) that was significantly more frequent than expected (P < 0.05) thus interpreted as nonrandom LOH selected during tumorigenesis. The overall extent of chromosomes undergoing LOH i.e. fractional allelic loss (FAL, the ratio of LOH-positive markers to the total number of informative markers) was measured in each tumor patient. Nonrandom LOH was found on 17p (48.0%), 18q (38.4%), 13q (38.1%) and 9p (36.4%). Overall, there were no significant phenotypes correlated with allelic loss on specific chromosome regions. Based on a bimodal distribution of FAL values with two peaks bordered by a mean of 0.233, tumors were classified into LOH-related (> 0.233) and LOH-unrelated (< 0.233) types. Among 24 patients with LOH-related tumors, increase in the infiltrative type of growth pattern was found to correspond with a significant trend of increasing FAL values. This study shows that the growth pattern of gastric carcinoma is correlated with FAL, suggesting that a malignant phenotype is influenced by LOH event.	Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Microbiol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Clin Pathol, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Rhyu, MG (corresponding author), Catholic Univ Korea, Coll Med, Dept Internal Med, 505 Bampo Dong,Socho Gu, Seoul 137701, South Korea.							BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Barrett MT, 1996, ONCOGENE, V12, P1873; Cho JH, 1996, LAB INVEST, V74, P835; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUCHS CS, 1995, NEW ENGL J MED, V333, P32, DOI 10.1056/NEJM199507063330107; HARPER JW, 1993, CELL, V75, P805; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kerangueven F, 1997, CANCER RES, V57, P5469; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MCKIE AB, 1993, INT J CANCER, V55, P598, DOI 10.1002/ijc.2910550414; MING SC, 1977, CANCER, V39, P2475, DOI 10.1002/1097-0142(197706)39:6<2475::AID-CNCR2820390626>3.0.CO;2-L; RHYU MG, 1994, GASTROENTEROLOGY, V106, P1584, DOI 10.1016/0016-5085(94)90414-6; Schultz DC, 1996, CANCER RES, V56, P1997; TAHARA E, 1993, J CANCER RES CLIN, V119, P265, DOI 10.1007/BF01212724; Visser M, 1997, ONCOGENE, V15, P1309, DOI 10.1038/sj.onc.1201302; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850	21	37	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2655	2659		10.1038/sj.onc.1202188	http://dx.doi.org/10.1038/sj.onc.1202188			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840929				2022-12-17	WOS:000077058900013
J	Genot, E; Reif, K; Beach, S; Kramer, I; Cantrell, D				Genot, E; Reif, K; Beach, S; Kramer, I; Cantrell, D			P21ras initiates Rac-1 but not phosphatidyl inositol 3 kinase PKB, mediated signaling pathways in T lymphocytes	ONCOGENE			English	Article						p21ras; Akt/PKB; signalling pathways; T cells	CELL ANTIGEN RECEPTOR; RAS EFFECTOR PATHWAYS; PHOSPHOINOSITIDE 3-KINASE; NEGATIVE SELECTION; REGULATED KINASE-2; PROTEIN-KINASE; ACTIVATION; DIFFERENTIATION; TRANSFORMATION; P21(RAS)	p21ras is activated by the T cell antigen receptor (TCR) and then co-ordinates important signaling pathways for T lymphocyte activation. Effector pathways for this guanine nucleotide binding protein in T cells are mediated by the serine/threonine kinase Raf-l and the Ras-related GTPase Rac-1. In fibroblasts, an important effector for the Ras oncogene is Phosphatidylinositol 3-kinase (PtdIns 3-kinase). Activation of this lipid kinase is able to induce critical Rac-1 signaling pathways and can couple p21ras to cell survival mechanisms via the serine/threonine kinase Akt/PKB, The role of PtdIns 3-kinase in Ras signaling in T cells has not been explored. In the present study, we examined the ability of PtdIns 3-kinase to initiate the Rac-1 signaling pathways important for T cell activation. We also examined the possibility that Akt/PKB is regulated by Ras signaling pathways in T lymphocytes. The results show that Ras can initiate a Rac-1 mediated pathway that regulates the transcriptional function of AP-1 complexes. PtdIns 3-kinase signals cannot mimic p21ras and induce the Rac mediated responses of AP-1 transcriptional activation. Moreover, neither TCR or Ras activation of AP-I is dependent on PtdIns 3-kinase. PKB is activated in response to triggering of the T cell antigen receptor; PtdIns 3-kinase activity is both required and sufficient for this TCR response. In contrast, p21ras signals are unable to induce Akt/PKB activity in T cell nor is Ras function required for Akt/PKB activation in response to the TCR. The present data thus highlight that PtdIns 3-kinase and Akt/PKB are not universal Ras effector molecules. Ras can initiate Rac-1 regulated signaling pathways in the context of T cell antigen receptor function independently of PtdIns 3-kinase activity.	Imperial Canc Res Fund, Lymphocyte Activat Lab, London WC2A 3PX, England; Univ London Univ Coll, Dept Pharmacol, London WC1E 6BT, England	Cancer Research UK; University of London; University College London	Genot, E (corresponding author), Hammersmith Hosp, Imperial Coll, Dept Immunol, Du Cane Rd, London W12 0NN, England.		Genot, Elisabeth/G-8031-2014; Reif, Karin/AAD-4692-2020	Reif, Karin/0000-0001-5490-8389				AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; Crompton T, 1996, CELL, V86, P243, DOI 10.1016/S0092-8674(00)80096-3; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; IZQUIERDO M, 1994, J EXP MED, V180, P401, DOI 10.1084/jem.180.1.401; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RODRIGUEZVICIAN.P, 1997, CELL, V89; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; Swat W, 1996, P NATL ACAD SCI USA, V93, P4683, DOI 10.1073/pnas.93.10.4683; Turner H, 1997, J EXP MED, V185, P43, DOI 10.1084/jem.185.1.43; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; YAN MH, 1994, NATURE, V372, P798	30	37	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	1998	17	13					1731	1738		10.1038/sj.onc.1202101	http://dx.doi.org/10.1038/sj.onc.1202101			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796702				2022-12-17	WOS:000076200100011
J	Gallia, GL; Khalili, K				Gallia, GL; Khalili, K			Evaluation of an autoregulatory tetracycline regulated system	ONCOGENE			English	Article						tetracycline; inducible promoter; gene expression regulation; transactivator	INDUCIBLE GENE-EXPRESSION; S-PHASE ENTRY; TRANSGENIC MICE; DEREGULATED EXPRESSION; CYCLIN-E; APOPTOSIS; ACCELERATION; SUPPRESSION; PROMOTER; CELLS	Tetracycline controlled gene expression systems have become powerful tools in the analysis of gene function in mammalian cell culture as well as transgenic animals and plants. The original description of a tetracycline-regulated gene expression system is based on two plasmids, one of which constitutively expresses a tetracycline-controlled transactivator protein (tTA), a fusion protein between the tetracycline repressor of E. coli and the transcriptional activation domain of the VP16 protein of herpes simplex virus. The second plasmid contains the gene to be regulated by tTA under the control of an inducible promoter which consists of seven copies of the tetracycline resistance operator (tetO). Since this original description, many modifications have been described. In this report, we evaluate an autoregulatory tetracycline controlled system, in which the tTA is itself under the control of the tetO. We demonstrate that this autoregulatory tetracycline system produces adverse effects including cellular morphologic changes, growth rate attenuation and alterations in cell cycle distribution.	Allegheny Univ Hlth Sci, Dept Neurol, Ctr NeuroVirol & NeuroOncol, Philadelphia, PA 19102 USA; Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA	Drexel University; Jefferson University	Khalili, K (corresponding author), Allegheny Univ Hlth Sci, Dept Neurol, Ctr NeuroVirol & NeuroOncol, Broad & Vine,MS 406, Philadelphia, PA 19102 USA.							BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; CHEN YQ, 1995, CANCER RES, V55, P4536; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; FISHMAN GI, 1994, J CLIN INVEST, V93, P1864, DOI 10.1172/JCI117174; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; Gil P, 1996, EMBO J, V15, P1678, DOI 10.1002/j.1460-2075.1996.tb00513.x; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; Iida A, 1996, J VIROL, V70, P6054, DOI 10.1128/JVI.70.9.6054-6059.1996; LONDON WT, 1978, SCIENCE, V201, P1246, DOI 10.1126/science.211583; Lukas J, 1996, MOL CELL BIOL, V16, P1047; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; Masgrau C, 1997, PLANT J, V11, P465, DOI 10.1046/j.1365-313X.1997.11030465.x; Qin XQ, 1997, ONCOGENE, V14, P53, DOI 10.1038/sj.onc.1200809; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Schultze N, 1996, NAT BIOTECHNOL, V14, P499, DOI 10.1038/nbt0496-499; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; WEINMANN P, 1994, PLANT J, V5, P559, DOI 10.1046/j.1365-313X.1994.5040559.x; WIMMEL A, 1994, ONCOGENE, V9, P995	26	37	40	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 9	1998	16	14					1879	1884		10.1038/sj.onc.1201706	http://dx.doi.org/10.1038/sj.onc.1201706			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583685				2022-12-17	WOS:000072994600011
J	Wicking, C; Evans, T; Henk, B; Hayward, N; Simms, LA; Chenevix-Trench, G; Pietsch, T; Wainwright, B				Wicking, C; Evans, T; Henk, B; Hayward, N; Simms, LA; Chenevix-Trench, G; Pietsch, T; Wainwright, B			No evidence for the H133Y mutation in SONIC HEDGEHOG in a collection of common tumour types	ONCOGENE			English	Article						Hedgehog; patched; mutation	SUPPRESSOR GENE; HUMAN HOMOLOG; CARCINOMA; RECEPTOR; ENCODES	The homologue of the Drosophila segment polarity gene patched is mutated in the cancer predisposition syndrome naevoid basal cell carcinoma syndrome (NBCCS), as well as in several types of tumour associated with the disorder, It was recently reported that a single recurrent mutation in the SONIC HEDGEHOG gene, which encodes the PATCHED ligand, was found in one of 43 basal cell carcinomas (BCCs), one of 14 medulloblastomas and one of six breast carcinomas analysed (Ore ef al., 1997), We have searched extensively for this same mutation in a large collection of BCCs, medulloblastomas and carcinomas of the breast, ovary and colorectum and have failed to detect the mutation in any sample analysed.	Univ Queensland, Ctr Mol & Cellular Biol, St Lucia, Qld 4072, Australia; Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany; Queensland Inst Med Res, Queensland Canc Fund Res Unit, Joint Expt Oncol Programme, Herston, Qld 4029, Australia; Glaxo Gastroenterol Lab, Bancroft Ctr, Herston, Qld 4029, Australia	University of Queensland; University of Bonn; QIMR Berghofer Medical Research Institute	Wainwright, B (corresponding author), Univ Queensland, Ctr Mol & Cellular Biol, St Lucia, Qld 4072, Australia.		hayward, nicholas k/C-1367-2015; hayward, nick/AAV-8802-2020; Chenevix-Trench, Georgia/AAV-2014-2020; Wicking, Carol/J-1814-2014	hayward, nicholas k/0000-0003-4760-1033; Chenevix-Trench, Georgia/0000-0002-1878-2587; Evans, Timothy/0000-0001-7962-6863; Wicking, Carol/0000-0002-7225-3803; Wainwright, Brandon/0000-0003-0406-2092				Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Pietsch T, 1997, CANCER RES, V57, P2085; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Xie JW, 1997, CANCER RES, V57, P2369	11	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	1998	16	8					1091	1093		10.1038/sj.onc.1201644	http://dx.doi.org/10.1038/sj.onc.1201644			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519883				2022-12-17	WOS:000072335900015
J	Shin, DY; Ishibashi, T; Choi, TS; Chung, EM; Chung, IY; Aaronson, SA; Bottaro, DP				Shin, DY; Ishibashi, T; Choi, TS; Chung, EM; Chung, IY; Aaronson, SA; Bottaro, DP			A novel human ERK phosphatase regulates H-ras and v-raf signal transduction	ONCOGENE			English	Article						protein tyrosine phosphatase; map kinase phosphatase; protein dephosphorylation	DUAL-SPECIFICITY PHOSPHATASE; ACTIVATED PROTEIN-KINASE; IMMEDIATE-EARLY GENE; MAP KINASE; TYROSINE-PHOSPHATASE; VACCINIA VIRUS; CLONING SYSTEM; EXPRESSION; GROWTH; DEPHOSPHORYLATES	A cDNA encoding a novel human extracellularly regulated kinase (ERK) phosphatase, designated B59, was isolated from a B5/589 human mammary epithelial cell cDNA library, The 1104 nucleotide open reading frame encodes 368 amino acids including the highly conserved catalytic site sequence of protein phosphotyrosine phosphatases (PTPs), VXVHCXXGXXR, at amino acid position 276-287, The predicted 70 amino acid stretch surrounding the HC motif shares significant sequence identity with other human dual specificity PTPs (dsPTPs), including the known ERK PTPs CL100, PAC1, B23, as well as the dsPTPs VH-1 and VHR, B59 protein synthesized in vitro in a rabbit reticulocyte lysate dephosphorylated rat ERK1 and ERK2 proteins whose phosphorylation had been stimulated by v-mos kinase added to the lysate, Ectopic expression of B59 in NIH3T3 fibroblasts inhibited the induction of an oncogene-responsive promoter by the dominant-activating paf mutant, raf-BXB, Moreover, cotransfection of NIH3T3 cells with B59 inhibited morphological transformation by H-ras and v-raf oncogenes. These results suggest that B59 suppresses the transforming activity of H-ras or v-raf oncogenes through ERK dephosphorylation and inactivation.	NCI, CELLULAR & MOL BIOL LAB, DIV BASIC SCI, BETHESDA, MD 20892 USA; MT SINAI MED CTR, DERALD H RUTTENBERG CANC CTR, NEW YORK, NY 10029 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Bottaro, Donald P/AAF-3853-2020; Bottaro, Donald P/F-8550-2010	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334				ALESSI DR, 1993, ONCOGENE, V8, P2015; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; DEVEREAUX J, 1992, GCG PROCEDURE LIB VE; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN K, 1992, P NATL ACAD SCI USA, V89, P12175, DOI 10.1073/pnas.89.24.12175; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KRAUS MH, 1991, METHOD ENZYMOL, V200, P547; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P4319; PHAM CD, 1995, ONCOGENE, V10, P1683; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WASYLYK B, 1988, P NATL ACAD SCI USA, V85, P7952, DOI 10.1073/pnas.85.21.7952; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	50	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	1997	14	22					2633	2639		10.1038/sj.onc.1201106	http://dx.doi.org/10.1038/sj.onc.1201106			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178761	Bronze			2022-12-17	WOS:A1997XB97800002
J	Yen, L; ZengRong, N; You, XL; Richard, S; LangtonWebster, BC; AlaouiJamali, MA				Yen, L; ZengRong, N; You, XL; Richard, S; LangtonWebster, BC; AlaouiJamali, MA			Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway	ONCOGENE			English	Article						p185(erbB-2); drug resistance; TAb-250 antibody; tyrosine kinase inhibitors; DNA repair, ras signaling pathway	EPIDERMAL GROWTH-FACTOR; HUMAN-BREAST-CANCER; GENE-PRODUCT P185; TYROSINE KINASE; FACTOR RECEPTOR; NEU-ONCOGENE; BENZOQUINOID ANSAMYCINS; MONOCLONAL-ANTIBODIES; CARCINOMA CELLS; LUNG-CANCER	We have examined the role of erbB-2 expression in the modulation of cellular toxicity to cisplatin. We have demonstrated that treatment of NIH3T3-erbB-2 cells, which overexpress the p185(erbB-2) product of the human erbB-2 gene, with a monoclonal antibody directed against the extracellular domain (TAb-250), results in enhanced cisplatin cytotoxicity. A similar enhancement was obtained when cells were exposed to herbimycin A and its analogue CP127 374, both of which inhibit tyrosine kinase activity. Using the host cell. reactivation (HCR) of reporter gene expression from cisplatin-damaged plasmid and unscheduled DNA synthesis (UDS) following cisplatin treatment of cells, we have found that modulation of erbB-2 by TAb-250 was associated with inhibition of DNA repair. TAb-250 alone, under conditions which modulate DNA repair, slightly reduces the S-phase of the cell cycle, while cisplatin induced arrest at S and G(2) phases. Combination of TAb-250 and cisplatin only slightly prevented cisplatin-induced S and G(2) blocks. Since the ras pathway is one of the major signaling components coupled to erbB-2, we have examined the role of ras in DNA repair regulation. Transient expression of a ras dominant negative mutant, Asn-17-ras(H), prevents DNA repair modulation by TAb-250, suggesting that the erbB-2 receptor regulates DNA repair mechanism(s), at least in part, through ras-coupled pathway(s).	MCGILL UNIV, DEPT MED, SIR MORTIMER B DAVIS JEWISH GEN HOSP, LADY DAVIS INST, MONTREAL, PQ H3T 1E2, CANADA; MCGILL UNIV, DEPT ONCOL, MONTREAL, PQ H3T 1E2, CANADA; MCGILL UNIV, MCGILL TRANSLAT CTR CANC, MONTREAL, PQ H3T 1E2, CANADA; BERLEX BIO SCI INC, DEPT ONCOL RES, STRATEG RES UNIT 1, RICHMOND, CA 94804 USA	Lady Davis Institute; McGill University; McGill University; McGill University								Ariza RR, 1996, NUCLEIC ACIDS RES, V24, P433, DOI 10.1093/nar/24.3.433; ARTEAGA CL, 1994, CANCER RES, V54, P3758; Bacus SS, 1996, ONCOGENE, V12, P2535; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; Chaney SG, 1996, JNCI-J NATL CANCER I, V88, P1346, DOI 10.1093/jnci/88.19.1346; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DICKSTEIN BM, 1995, MOL CELL ENDOCRINOL, V110, P205, DOI 10.1016/0303-7207(95)03535-F; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Gately DP, 1996, BRIT J CANCER, V73, P18, DOI 10.1038/bjc.1996.4; HANCOCK MC, 1991, CANCER RES, V51, P4575; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; JALLAL B, 1992, J BIOL CHEM, V267, P4357; JOHNSON RT, 1987, J CELL SCI, P263; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KATSUMATA M, 1995, NAT MED, V1, P644, DOI 10.1038/nm0795-644; KERN JA, 1990, CANCER RES, V50, P5184; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kumar R, 1996, CLIN CANCER RES, V2, P1215; Kuzumaki T, 1996, BBA-MOL CELL RES, V1310, P185, DOI 10.1016/0167-4889(95)00166-2; Liu Y, 1996, CANCER RES, V56, P31; LOCK RB, 1990, CANCER RES, V50, P3761; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER P, 1994, CANCER RES, V54, P2724; MILLER P, 1994, BIOCHEM BIOPH RES CO, V201, P1313, DOI 10.1006/bbrc.1994.1847; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; NIE ZR, 1995, CANCER RES, V55, P4760; NISHIKAWA K, 1992, CANCER RES, V52, P4758; Paterson J., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P363; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; Shearer MC, 1996, FASEB J, V10, pP64; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; VICHI P, 1992, CANCER RES, V52, P4135; WEINER DB, 1990, CANCER RES, V50, P421; Wood Richard D., 1995, Methods (Orlando), V7, P163, DOI 10.1006/meth.1995.1022; YEN L, 1995, MUTAT RES-DNA REPAIR, V337, P179, DOI 10.1016/0921-8777(95)00022-C; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZHANG LS, 1995, CANCER RES, V55, P3890	58	37	39	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	1997	14	15					1827	1835		10.1038/sj.onc.1201019	http://dx.doi.org/10.1038/sj.onc.1201019			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150389				2022-12-17	WOS:A1997WW16600009
J	Adachi, M; Ishino, M; Torigoe, T; Minami, Y; Matozaki, T; Miyazaki, T; Taniguchi, T; Hinoda, Y; Imai, K				Adachi, M; Ishino, M; Torigoe, T; Minami, Y; Matozaki, T; Miyazaki, T; Taniguchi, T; Hinoda, Y; Imai, K			Interleukin-2 induces tyrosine phosphorylation of SHP-2 through IL-2 receptor beta chain	ONCOGENE			English	Article						SHP-2; IL-2; tyrosine phosphorylation; signal transduction	GROWTH-FACTOR RECEPTOR; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; CYTOLYTIC EFFECTOR FUNCTION; C-MYC; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; GAMMA-CHAIN; T-CELL; PROTEIN	Coupling of interleukin-2 (IL-2) to the IL-2 receptor (IL-2R) induces rapid increase in tyrosine phosphorylation of cellular substrates through activation of non-receptor protein tyrosine kinases, Here, we report that stimulation through the IL-2R induced tyrosine phosphorylation of the SH2-containing protein-tyrosine phosphatase SHP-2 in F7, a hematopoietic BAF-B03 transfectant clone expressing the IL-2R beta chain. The tyrosine phosphorylation of SHP-2 was specific since another protein-tyrosine phosphatase SHP-1, which is structurally homologous to SHP-2, was not tyrosine phosphorylated, The IL-2-induced tyrosine phosphorylation of SHP-2 required the acidic region within the IL-2R beta chain where Src-family PTKs interact. Though the serine-rich region within IL-2R beta chain was also required for the phosphorylation of SHP-2, Jak3 activation was dispensable, In COS-7 cells, co-expression of SHP-2 with Lyn resulted in increased tyrosine phosphorylation levels of SHP-2, whereas coexpression of SHP-2 with Fyn failed to alter the levels significantly. Considering that Lyn and Fyn are major Src-family PTKs expressed in BAF-B03 cells, our data suggest that Lyn may be principally responsible for the tyrosine phosphorylation of SHP-2 in F7 cells. Furthermore, the IL-2 stimulation also induced tyrosine phosphorylation of SHP-2 in the human IL-2-dependent T-cell line ILT-Mat. Taken together, these studies demonstrate an involvement of SHP-2 in the IL-2-mediated signaling events through the activation of specific PTKs.	HOKKAIDO UNIV,SCH MED,DEPT BIOCHEM,CANC RES INST,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,SCH MED,DEPT PATHOL,SAPPORO,HOKKAIDO 060,JAPAN; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE 650,JAPAN; KOBE UNIV,SCH MED,DEPT BIOCHEM 1,CHUO KU,KOBE 650,JAPAN; UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN	Hokkaido University; Hokkaido University; Kobe University; Kobe University; University of Tokyo	Adachi, M (corresponding author), HOKKAIDO UNIV,SCH MED,DEPT INTERNAL MED 1,SAPPORO,HOKKAIDO 060,JAPAN.		Miyazaki, Tadaaki/D-9368-2012					ADACHI M, 1995, FEBS LETT, V372, P113, DOI 10.1016/0014-5793(95)00952-6; Adachi M, 1996, CELL, V85, P15; ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CASE RD, 1994, J BIOL CHEM, V269, P10467; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FUHRER DK, 1995, J BIOL CHEM, V270, P24826, DOI 10.1074/jbc.270.42.24826; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; Ishino M, 1995, ONCOGENE, V11, P2331; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KAWAHARA A, 1995, P NATL ACAD SCI USA, V92, P8724, DOI 10.1073/pnas.92.19.8724; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; MATOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874, DOI 10.1006/bbrc.1994.2541; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PENG ZY, 1995, ONCOGENE, V11, P1955; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; TORIGOE T, 1992, BLOOD, V80, P617; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; TORIGOE T, 1994, J EXP MED, V180, P1115, DOI 10.1084/jem.180.3.1115; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	36	37	37	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1629	1633		10.1038/sj.onc.1200981	http://dx.doi.org/10.1038/sj.onc.1200981			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129156				2022-12-17	WOS:A1997WQ54800016
J	Marechal, V; Elenbaas, B; Taneyhill, L; Piette, J; Mechali, M; Nicolas, JC; Levine, AJ; Moreau, J				Marechal, V; Elenbaas, B; Taneyhill, L; Piette, J; Mechali, M; Nicolas, JC; Levine, AJ; Moreau, J			Conservation of structural domains and biochemical activities of the MDM2 protein from Xenopus laevis	ONCOGENE			English	Article						MDM2; p53; ribosomal L5 protein; RING finger	WILD-TYPE P53; SOFT-TISSUE SARCOMAS; RING FINGER; TRANSCRIPTIONAL ACTIVATION; P53-ASSOCIATED PROTEIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ONCOGENE PRODUCT; ONCOPROTEIN MDM2; BINDING DOMAIN	The Mdn2 gene is the best known cellular regulator of p53 tumor suppressor activity. We report here the cloning and characterization of Xdm2, its homolog in Xenopus laevis. Human, mouse and Xenopus MDM2 proteins are more than 65% identical in several regions which are likely to be important for the biological activities of MDM2. Region I is sufficient for binding p53 and inhibiting its G(I) arrest and apoptosis functions. Region II contains most of a central acidic region required for interaction with the L5 ribosomal protein and a putative C4 zinc finger. Region III is nearly identical from Xenopus to human and comprises the RING finger domain. We show that this structural conservation is associated with the conservation of three biochemical activities of MDM2; binding to the p53 and L5 proteins and specifically to RNA. Lastly, Xdm2 expression during early development is mainly restricted from the oocyte stage I/II to the blastula stage and is possibly independent of transcriptional activation by p53. These data as web as the utilization of Xenopus laevis to investigate the roles of MDM2 and p53 during early embryogenesis are discussed.	PRINCETON UNIV, DEPT MOL BIOL, PRINCETON, NJ 08544 USA; INST MOL GENET, UMR 5535, F-34033 MONTPELLIER, FRANCE; INST JACQUES MONOD, DEPT DEV BIOL, F-75251 PARIS, FRANCE	Princeton University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; UDICE-French Research Universities; Universite Paris Cite	Marechal, V (corresponding author), HOP ROTHSCHILD, MICROBIOL SERV, F-75571 PARIS, FRANCE.		marechal, vincent/P-7719-2017; Taneyhill, Lisa/K-1815-2013					Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; AUGIAS D, 1966, IN PRESS; BAE I, 1995, EXP CELL RES, V217, P541, DOI 10.1006/excr.1995.1120; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BERBERICH S, 1994, ONCOGENE, V9, P1469; BISBEE CA, 1977, SCIENCE, V195, P785, DOI 10.1126/science.65013; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CORDONCARDO C, 1994, CANCER RES, V54, P794; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; COX LS, 1994, ONCOGENE, V9, P2951; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FREEDMAN D, 1996, UNPUB; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOEVER M, 1994, ONCOGENE, V9, P109; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LADANYI M, 1993, CANCER RES, V53, P16; LANDERS JE, 1994, ONCOGENE, V9, P2745; LEACH FS, 1993, CANCER RES, V53, P2231; LENG P, 1995, ONCOGENE, V10, P1275; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LUNA RMD, 1995, NATURE, V378, P203; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; REIFENBERGER G, 1993, CANCER RES, V53, P2736; RIDGWAY PJ, 1994, J VIROL, V68, P7178, DOI 10.1128/JVI.68.11.7178-7187.1994; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SOUSSI T, 1987, ONCOGENE, V1, P71; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; WANG Y, 1995, ONCOGENE, V10, P779; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	61	37	38	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	1997	14	12					1427	1433		10.1038/sj.onc.1200967	http://dx.doi.org/10.1038/sj.onc.1200967			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136986				2022-12-17	WOS:A1997WT58400005
J	Inga, A; Iannone, R; Monti, P; Molina, F; Bolognesi, M; Abbondandolo, A; Iggo, R; Fronza, G				Inga, A; Iannone, R; Monti, P; Molina, F; Bolognesi, M; Abbondandolo, A; Iggo, R; Fronza, G			Determining mutational fingerprints at the human p53 locus with a yeast functional assay: A new tool for molecular epidemiology	ONCOGENE			English	Article						CCNU; mutation spectrum; p53; ADE2	METHYL-N-NITROSOUREA; ALKYLATING-AGENTS; ESCHERICHIA-COLI; BASE SEQUENCE; CROSS-LINKING; DNA-REPAIR; SPECIFICITY; CANCER; CELLS; GENE	In order to isolate experimentally induced p53 mutations, a yeast expression vector harbouring a human wild-type p53 cDNA was treated in vitro with the antineoplastic drug chloroethyl-cyclohexyl-nitroso-urea (CCNU) and transfected into a yeast strain containing the ADE2 gene regulated by a p53-responsive promoter, p53 mutations were identified in 32 out of 39 plasmids rescued from independent ade- transformants. Ninety-two percent of CCNU induced mutations were CC-targeted single base pair substitutions, and GC>AT transitions represented 73% of all single base pair substitutions, In 70% of the cases the mutated C was preceded 5' by a purine. The distribution of the mutations along the p53 cDNA was not random: positions 734 and 785 appeared as CCNU mutational hotspots (n=3, P<0.0003) and CCNU induced only GC>AT transitions at those positions, The features of these CCNU-induced mutations are consistent with the hypothesis that O6-alkylguanine is the major causative lesion, One third of the CCNU-induced mutants were absent from a huge collection of 4496 p53 mutations in human tumours and cell lines, thus demonstrating that CCNU has a mutational spectrum which is uniquely different from that of naturally selected mutations, This strategy allows direct comparison of observed natural mutation spectra with experimentally induced mutation spectra and opens the way to a more rigorous approach in the field of molecular epidemiology.	NATL INST CANC RES,IST,CSTA,MUTAGENESIS LAB,I-16132 GENOA,ITALY; IST,ADV BIOTECHNOL CTR,BIOSTRUCT UNIT,I-16132 GENOA,ITALY; UNIV GENOA,CHAIR GENET,GENOA,ITALY; SWISS INST EXPT CANC RES,CH-1066 EPALINGES,SWITZERLAND	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; Swiss Institute Experimental Cancer Research			Bolognesi, Martino/B-7924-2017; Iggo, Richard/G-3546-2014; Fronza, Gilberto/AAG-8735-2019; Monti, Paola/Y-1118-2019; Inga, Alberto/AAC-3815-2022	Bolognesi, Martino/0000-0002-9253-5170; Fronza, Gilberto/0000-0003-3722-553X; Monti, Paola/0000-0002-1978-4998; Inga, Alberto/0000-0002-8767-1637; Molina, Francesco Stefano/0000-0003-0171-5297				AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284; BRISCOE WT, 1990, BIOCHEM PHARMACOL, V40, P1201, DOI 10.1016/0006-2952(90)90384-W; BURNS PA, 1988, CANCER RES, V48, P4455; CARIELLO NF, 1994, CARCINOGENESIS, V15, P2281, DOI 10.1093/carcin/15.10.2281; Cariello NF, 1996, NUCLEIC ACIDS RES, V24, P119, DOI 10.1093/nar/24.1.119; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ERICKSON LC, 1980, NATURE, V288, P727, DOI 10.1038/288727a0; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FLAMAN JM, 1994, NUCLEIC ACIDS RES, V22, P3259, DOI 10.1093/nar/22.15.3259; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; Gerson Stanton L., 1993, Current Opinion in Oncology, V5, P136; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Guthrie C, 1991, METHOD ENZYMOL, P194; Hainaut Pierre, 1995, Current Opinion in Oncology, V7, P76; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HARTLEY JA, 1986, CANCER RES, V46, P1943; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HORSFALL MJ, 1990, ENVIRON MOL MUTAGEN, V15, P107, DOI 10.1002/em.2850150208; INGA A, 1995, CANCER RES, V55, P4658; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Jurado J, 1995, MOL CARCINOGEN, V14, P233, DOI 10.1002/mc.2940140403; KUNZ BA, 1989, CANCER RES, V49, P279; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARSELOS M, 1991, CARCINOGENESIS, V12, P1751, DOI 10.1093/carcin/12.10.1751; MINNICK DT, 1992, CANCER RES, V52, P4688; MORIWAKI S, 1991, CANCER RES, V51, P6219; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PALOMBO F, 1992, J MOL BIOL, V223, P587, DOI 10.1016/0022-2836(92)90974-O; POUZAND C, 1993, MUTAT RES, V288, P113; PRAKASH AS, 1992, CARCINOGENESIS, V13, P425, DOI 10.1093/carcin/13.3.425; PUSIEUX A, 1991, CANCER RES, V51, P6185; RICHARDSON KK, 1987, P NATL ACAD SCI USA, V84, P344, DOI 10.1073/pnas.84.2.344; ROLDANARJONA T, 1994, MOL CARCINOGEN, V9, P200, DOI 10.1002/mc.2940090404; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1992, NATURE, V355, P209, DOI 10.1038/355209a0; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	38	37	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 20	1997	14	11					1307	1313		10.1038/sj.onc.1200952	http://dx.doi.org/10.1038/sj.onc.1200952			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178891				2022-12-17	WOS:A1997WP10900006
J	Jouanneau, J; Plouet, J; Moens, G; Thiery, JP				Jouanneau, J; Plouet, J; Moens, G; Thiery, JP			FGF-2 and FGF-1 expressed in rat bladder carcinoma cells have similar angiogenic potential but different tumorigenic properties in vivo	ONCOGENE			English	Article						FGF-2; angiogenesis; tumor proliferation	FIBROBLAST GROWTH-FACTOR; DNA-SYNTHESIS; FACTOR CDNA; 3T3 CELLS; PROGRESSION; SECRETION; FAMILY; FORMS; LINE; TRANSFORMATION	The comparative biological properties of NET-II cells, a rat bladder carcinoma cell line constitutively expressing FGF-1 and FGF-2 were analysed in nude mice, FGF-1 is not secreted by the transfected cells unless the cDNA contains a signal sequence; conversely, NET-II cells transfected with FGF-2 coding sequence produce and secrete the factor in a biologically active form, Bovine brain capillary endothelial cells are stimulated to proliferate upon addition of medium conditioned by the FGF-2-producing cells and this activity can be abrogated by the addition of anti-FGF-2 blocking antibodies, In addition, the FGF-2-containing medium, which cannot stimulate NET-II cells due to absence of appropriate receptors, is able to induce scattering of NET-II cells expressing the FGFR1, It has been reported previously that FGF-1-producing cells are highly tumorigenic in nude mice and induce carcinoma with a period of latency reduced from 6 to 5 weeks when compared to parental NET-II cells, In contrast, NET-II cells producing FGF-2 are no more tumorigenic than parental cells, indicating are no more tumorigenic than parental cells, indicating that FGF-1 and FGF-2 have different oncogenic properties in carcinoma, FGF-1 and FGF-2 are potent antiogenic factors that trigger the host endothelial cells, VEGF, another potent angiogen was found to be expressed in small amounts by NET-II cells and to be expressed in reduced amount in the FGF-producing cells, In the NET-II system in vivo FGF-1 and FGF-2 are highly and comparatively angiogenic in the resultant carcinoma and this occurs in the absence of production of significant amounts of VEGF by the carcinoma cells, Taken together, our results indicate that activated angiogenesis is not sufficient for rapid tumor expansion, FGF-1 behaves as a tumorigenic factor in the NET-II bladder carcinoma cell model, whereas expression and secretion of large amounts of FGF-2 are not sufficient for increasing tumor growth.	UPR 9006 CNRS,F-31062 TOULOUSE,FRANCE	Centre National de la Recherche Scientifique (CNRS)	Jouanneau, J (corresponding author), INST CURIE,UMR 144 CNRS,26 RUE ULM,F-75248 PARIS 05,FRANCE.		Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020	NATIONAL CANCER INSTITUTE [R01CA049417] Funding Source: NIH RePORTER; NCI NIH HHS [(NIH, 2RO1 CA 49417-06)] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLUSCI S, 1994, J CELL SCI, V107, P1277; BELLUSCI S, 1995, INVAS METAST, V14, P319; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CARUELLE D, 1989, J CELL BIOCHEM, V39, P117, DOI 10.1002/jcb.240390204; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; COLBEREGARAPIN F, 1982, J MOL BIOL, V105, P1; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; DAMORE PA, 1990, CANCER METAST REV, V9, P227, DOI 10.1007/BF00046362; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; JOUANNEAU J, 1994, P NATL ACAD SCI USA, V91, P286, DOI 10.1073/pnas.91.1.286; JOUANNEAU J, 1995, GROWTH FACTORS, V12, P37, DOI 10.3109/08977199509003212; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; MIGNATTI P, 1991, J CELL BIOCHEM, V47, P201, DOI 10.1002/jcb.240470303; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOSCATELLI D, 1986, P NATL ACAD SCI USA, V83, P2091, DOI 10.1073/pnas.83.7.2091; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; PLOUET J, 1990, J BIOL CHEM, V265, P22071; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; QUARTO N, 1989, ONCOGENE RES, V5, P101; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; SONNENBERG A, 1987, EMBO J, V6, P121, DOI 10.1002/j.1460-2075.1987.tb04728.x; TAKAHASHI JB, 1992, BIOCHEM BIOPH RES CO, V189, P398, DOI 10.1016/0006-291X(92)91572-8; TOYOSHIMA K, 1971, JNCI-J NATL CANCER I, V47, P979; TSAI JC, 1995, J NEUROSURG, V82, P864, DOI 10.3171/jns.1995.82.5.0864; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; YAYON A, 1990, CANC METASTASIS REV, V9, P192	40	37	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					671	676		10.1038/sj.onc.1200883	http://dx.doi.org/10.1038/sj.onc.1200883			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038374				2022-12-17	WOS:A1997WG43000005
J	Wallace, H; Clarke, AR; Harrison, DJ; Hooper, ML; Bishop, JO				Wallace, H; Clarke, AR; Harrison, DJ; Hooper, ML; Bishop, JO			Ganciclovir-induced ablation of non-proliferating thyrocytes expressing herpesvirus thymidine kinase occurs by p53-independent apoptosis	ONCOGENE			English	Article						herpes simplex virus; thymidine kinase; apoptosis; p53; transgenic mice	CELLS; DNA; GROWTH	In adult mice of the transgenic strain TG66.19, in which expression of herpes simplex type 1 virus thymidine kinase (HSV1-TK) is driven in thyrocytes from the thyroglobulin promoter, the drug Ganciclovir causes the death (ablation) of thyrocytes. Ablation occurred in the absence of thyrocyte proliferation or nuclear DNA synthesis, but was accompanied by transient expression of proliferating cell nuclear antigen and the dying thyrocytes exhibited the ultrastructural features of apoptosis, Control experiments show that the apoptosis is a result of the production of Ganciclovir phosphates in thyrocytes that express HSV1-TK. However, cell death was not dependent upon the presence of a functional copy of the oncosuppressor gene p53, We conclude that the apoptosis is probably not mediated by induction of DNA damage and occurs via a pathway that is independent of p53, The fact that Ganciclovir phosphate can kill cells by a p53-independent apoptotic pathway is encouraging in relation to tumour ablation by methods based on transfection with HSV1-tk genes and administration of Ganciclovir.	UNIV EDINBURGH, CTR GENOME RES, EDINBURGH EH9 3JQ, MIDLOTHIAN, SCOTLAND; UNIV EDINBURGH, DEPT PATHOL, CRC LABS, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND	University of Edinburgh; University of Edinburgh			clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Clarke, Alan/0000-0002-4281-426X				BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; BURTON K, 1967, METHOD ENZYMOL, V8, P162; CHENG YC, 1983, P NATL ACAD SCI-BIOL, V80, P2767, DOI 10.1073/pnas.80.9.2767; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKE AR, 1995, ONCOGENE, V11, P1913; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLOMBEL M, 1992, CANCER RES, V52, P4313; COLOMBO BM, 1995, HUM GENE THER, V6, P763, DOI 10.1089/hum.1995.6.6-763; CULVER KW, 1994, TRENDS GENET, V10, P174, DOI 10.1016/0168-9525(94)90095-7; DEMARTYNOFF G, 1987, EUR J BIOCHEM, V164, P591, DOI 10.1111/j.1432-1033.1987.tb11168.x; FARQUHARSON C, 1990, BONE MINER, V10, P121, DOI 10.1016/0169-6009(90)90087-V; FREEMAN SM, 1993, CANCER RES, V53, P5274; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOWIE SEM, 1994, CLIN EXP IMMUNOL, V95, P195; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KANEKO Y, 1995, CANCER LETT, V96, P105, DOI 10.1016/0304-3835(95)03919-N; Kato Kyozo, 1994, Neurologia Medico-Chirurgica, V34, P339, DOI 10.2176/nmc.34.339; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MERRITT AJ, 1994, CANCER RES, V54, P614; ROUACH EY, 1991, NATURE, V352, P345; RUBNITZ J, 1985, MOL CELL BIOL, V5, P529, DOI 10.1128/MCB.5.3.529; SAMEJIMA Y, 1995, GENE THER, V2, P50; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMEDS S, 1983, ENDOCRINOLOGY, V112, P1718, DOI 10.1210/endo-112-5-1718; SMEE DF, 1983, ANTIMICROB AGENTS CH, V23, P676, DOI 10.1128/AAC.23.5.676; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P844, DOI 10.1128/AAC.31.6.844; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; UEDA N, 1992, J CLIN INVEST, V90, P2593, DOI 10.1172/JCI116154; WALLACE H, 1995, J ENDOCRINOL, V145, P251, DOI 10.1677/joe.0.1450251; WALLACE H, 1991, ENDOCRINOLOGY, V129, P3217, DOI 10.1210/endo-129-6-3217; WALLACE H, 1994, J ENDOCRINOL, V143, P107, DOI 10.1677/joe.0.1430107; WARTERS RL, 1992, CANCER RES, V52, P883; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3	38	37	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					55	61						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700554				2022-12-17	WOS:A1996UX31900007
J	Wang, BL; Kruh, GD				Wang, BL; Kruh, GD			Subcellular localization of the Arg protein tyrosine kinase	ONCOGENE			English	Article						tyrosine kinase; localization; Arg, Abl	POSITIVE HUMAN LEUKEMIAS; C-ABL; CELL-CYCLE; DROSOPHILA-ABL; SIGNAL-TRANSDUCTION; GENE-PRODUCT; BINDING; PHOSPHORYLATION; TRANSFORMATION; ACTIVATION	and c-Abl are ubiquitously expressed proteins which represent the mammalian members of the Abelson family of nonreceptor protein tyrosine kinases (PTKs), In contrast to most nonreceptor PTKs, c-Abl is located in the nucleus and cytoplasm, In this study the subcellular localization of Arg was examined to gain insight into its possible functions, Using indirect immunofluorescence, Arg was detected in the cytoplasm but not the nucleus of both transiently transfected COS cells and stable NIH3T3 transfectants, Arg is expressed as IA and IB isoforms which bear alternative amino termini, with the IB isoform containing a potential myristic acid acceptor sequence, Modification of ArgIB by myristic acid was confirmed by the detection of [H-3]myristic acid labeling and the observation that labeling was abolished by mutating Gig-2, These results indicate that the subcellular localization of Arg is distinct from that of c-Abl and thus suggest that the two proteins have different functions in intracellular signaling, In addition, Arg, Like c-Abl, is expressed as myristoylated and nonmyristoylated isoforms, suggesting that it may have dual cytoplasmic subcellular localizations, and possibly participate in diverse signaling pathways.	FOX CHASE CANC CTR, DEPT MED ONCOL, PHILADELPHIA, PA 19111 USA; UNIV PENN, DEPT BIOL, PHILADELPHIA, PA 19104 USA	Fox Chase Cancer Center; University of Pennsylvania					NCI NIH HHS [CA57273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA057273, R01CA057273] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BOLEN JB, 1993, ONCOGENE, V8, P2025; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HOFFMANN FM, 1989, CURR TOP MICROBIOL, V147, P1; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; MATTIONI T, 1995, ONCOGENE, V10, P1325; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MORRIS JF, 1991, ONCOGENE, V6, P2339; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PEREGO R, 1991, ONCOGENE, V6, P1899; PIENTA KJ, 1992, J CELL BIOCHEM, V49, P357, DOI 10.1002/jcb.240490406; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RESH MD, 1990, ONCOGENE, V5, P1437; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E	33	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					193	197						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700546				2022-12-17	WOS:A1996UX31900022
J	Rodenhiser, D; Chakraborty, P; Andrews, J; Ainsworth, P; Mancini, D; Lopes, E; Singh, S				Rodenhiser, D; Chakraborty, P; Andrews, J; Ainsworth, P; Mancini, D; Lopes, E; Singh, S			Heterogeneous point mutations in the BRCA1 breast cancer susceptibility gene occur in high frequency at the site of homonucleotide tracts, short repeats and methylatable CpG/CpNpG motifs	ONCOGENE			English	Article						BRCA1; mutation; mutagenesis; homonucleotides; repeats; CpG	NF1 GENE; DNA; DELETIONS; MUTAGENESIS; DISEASE; COLON	Heterogeneous mutations in the BRCA1 tumour suppressor gene are responsible for a large percentage of inherited breast cancers as well as breast/ovarian cancers in families with a high incidence of both cancer types, Over a hundred BRCA1 mutations have been reported, but little is known of the mechanism(s) responsible for BRCA1 mutagenesis, To determine the significance of specific nucleotide sequences at mutational sites within the BRCA1 gene, are assessed how frequently independent BRCA1 mutations occur at the site of short direct repeats, single nucleotide repeats (homonucleotides) and at CpG and CpNpG motifs, We found that homonucleotide and short direct repeats are commonly associated with small deletions and insertions, Substitution mutations are frequently associated with homonucleotide repeats and with methylatable CpG dinucleotides and CpNpG trinucleotides, Our methylation and sequencing experiments show that CpG and certain CpNpG motifs are methylated, supporting the hypothesis that DNA methylation specificity at these sites may be an important contributor to BRCA1 mutagenesis. We suggest that BRCA1 mutations are acquired by replication errors and are retained by cells through an intricate balancing of replication and repair mechanisms, Such mutations may provide a proliferative advantage for a cell, leading to the tumour phenotype.	UNIV WESTERN ONTARIO, DEPT PAEDIAT, LONDON, ON, CANADA; UNIV WESTERN ONTARIO, DEPT ZOOL, LONDON, ON, CANADA; UNIV WESTERN ONTARIO, DEPT BIOCHEM, LONDON, ON, CANADA; VICTORIA HOSP, MOL DIAGNOST LAB, LONDON, ON N6A 4G5, CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of Victoria; Western University (University of Western Ontario)	Rodenhiser, D (corresponding author), CHILDRENS HOSP WESTERN ONTARIO, CHILD HLTH RES INST, MOL MED GENET PROGRAM, LONDON, ON N6C 2V5, CANADA.							AINSWORTH PJ, 1993, HUM GENET, V91, P151; Andrews JD, 1996, HUM MOL GENET, V5, P503, DOI 10.1093/hmg/5.4.503; BOTTEMA CDK, 1993, HUM GENET, V91, P496; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CLAUS EB, 1991, AM J HUM GENET, V48, P232; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1995, AM J HUM GENET, V57, P1284; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; INOUE R, 1995, CANCER RES, V55, P3521; JEGO N, 1993, ONCOGENE, V8, P209; KRAWCZAK M, 1991, HUM GENET, V86, P425; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; MAGEWU AN, 1994, MOL CELL BIOL, V14, P4225, DOI 10.1128/MCB.14.6.4225; MATSUSHIMA M, 1995, HUM MOL GENET, V4, P1953, DOI 10.1093/hmg/4.10.1953; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; PLUMMER SJ, 1995, HUM MOL GENET, V4, P1989, DOI 10.1093/hmg/4.10.1989; REDSTON MS, 1994, CANCER RES, V54, P3025; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; RODENHISER DI, 1993, HUM MOL GENET, V2, P439, DOI 10.1093/hmg/2.4.439; RODENHISER DI, 1995, AM J HUM GENET, V57, P1829; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; SCHMUTTE C, 1995, CANCER RES, V55, P3742; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; Sinden Richard R., 1992, Current Opinion in Biotechnology, V3, P612, DOI 10.1016/0958-1669(92)90005-4; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; STRUEWING JP, 1995, AM J HUM GENET, V57, P1; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; TAKAHASHI H, 1995, CANCER RES, V55, P2998; TASHEVA ES, 1993, SOMAT CELL MOLEC GEN, V19, P275, DOI 10.1007/BF01233075; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; TORNALETTI S, 1995, ONCOGENE, V10, P1493; UPADHYAYA M, 1994, HUM MUTAT, V4, P83, DOI 10.1002/humu.1380040202; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152	49	37	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2623	2629						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700521				2022-12-17	WOS:A1996UW48700016
J	Spitkovsky, D; JansenDurr, P; Karsenti, E; Hoffmann, I				Spitkovsky, D; JansenDurr, P; Karsenti, E; Hoffmann, I			S-phase induction by adenovirus E1A requires activation of cdc25A tyrosine phosphatase	ONCOGENE			English	Article						E1A; oncogene; cdc25 phosphatase; cell cycle	CELL-CYCLE; PROTEIN-KINASE; PHOSPHORYLATION; IDENTIFICATION; MICROINJECTION; MITOSIS; BINDING; SYSTEM; GROWTH; CDK2	Adenovirus EIA proteins can induce quiescent cells to enter S-phase and also affect the expression of cellular genes including various cell cycle regulators. Here we show that human cdc25A, a tyrosine phosphatase involved in regulation of the G1/S-phase transition of the cell cycle, is a target of the adenovirus E1A protein in virus-infected human fibroblasts, Expression of E1A in quiescent fibroblasts leads to a rapid increase in cdc25A phosphatase activity and also increases both cdc25A and cyclin E gene expression. Inhibition of cdc25A function by antibody injection prevents virus-induced entry into S-phase. These results indicate that induction of high levels of cdc25A and its potential positive regulator cyclin E mediates the ability of E1A to induce S-phase in the presence of antiproliferative signals.	DEUTSCH KREBSFORSCHUNGSZENTRUM, D-69120 HEIDELBERG, GERMANY; EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAMME, D-69012 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); European Molecular Biology Laboratory (EMBL)			Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429				ANSORGE W, 1988, J BIOCHEM BIOPH METH, V16, P283, DOI 10.1016/0165-022X(88)90062-0; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOFFMANN I, 1994, J CELL SCI, P75; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORRIS GF, 1994, MOL CELL BIOL, V14, P543, DOI 10.1128/MCB.14.1.543; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1992, ONCOGENE, V7, P1681; PEPPERKOK R, 1988, P NATL ACAD SCI USA, V85, P6748, DOI 10.1073/pnas.85.18.6748; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SPITKOVSKY D, 1994, J VIROL, V68, P2206, DOI 10.1128/JVI.68.4.2206-2214.1994; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7	32	37	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2549	2554						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700513				2022-12-17	WOS:A1996UW48700008
J	Hengstschlager, M; HengstschlagerOttnad, E; Pusch, O; Wawra, E				Hengstschlager, M; HengstschlagerOttnad, E; Pusch, O; Wawra, E			The role of p16 in the E2F-dependent thymidine kinase regulation	ONCOGENE			English	Article						p16; thymidine kinase; E2F; pRb; cell cycle	E2F TRANSCRIPTION FACTOR; CELL-CYCLE; RETINOBLASTOMA-PROTEIN; DEOXYCYTIDINE KINASE; BINDING-SITE; GENE; FAMILY; OVEREXPRESSION; IDENTIFICATION; INHIBITION	The role of alterations of the MTS1 tumor suppressor gene on chromosome 9p21, which encodes p16, the inhibitor of cyclin-dependent-kinase-4 and 6, in tumorigenesis is not yet clear, Phosphorylation of the retinoblastoma protein by cyclin-dependent-kinases 4 and 6 prevents its interaction with the transcription factor E2F, which subsequently promotes the expression of S phase regulated genes, such as thymidine kinase, Although a role of p16 in this regulation has been presumed, there is no proof so far that loss of this tumor suppressor gene really affects E2F-mediated regulations, We investigated the regulation of thymidine kinase in phytohemagglutinin-stimulated normal human lymphocytes and in the p16-negative human acute lymphoblastic leukemia cell lines, MOLT-4 and GEM. Compared to normal lymphocytes, MOLT-4 and CEM cells exhibited an altered cell cycle regulation of thymidine kinase, a much higher intracellular activity of this enzyme, and higher thymidine kinase mRNA expression, Transient expression of p16 in normal human lymphocytes caused arrest in G1, but was without effect on the cell growth of MOLT-4 and CEM cells, although all of them express functional retinoblastoma protein, Nevertheless, in the two leukemia cell lines transient overexpression of p16 reestablished the normal regulation of thymidine kinase, paralleled by an increase of the underphosphorylated form of retinoblastoma protein and a decrease of free E2F bound to its motif in the thymidine kinase promoter, We demonstrate that loss of p16 causes upregulation of this DNA precursor pathway enzyme via activation of E2F by a mechanism involving retinoblastoma protein.	UNIV VIENNA, VIENNA BIOCTR,INST MOLEC GENET, A-1030 VIENNA, AUSTRIA; UNIV VIENNA, VIENNA BIOCTR,INST MOLEC BIOL, A-1030 VIENNA, AUSTRIA	University of Vienna; Vienna Biocenter (VBC); University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Hengstschlager, M (corresponding author), UNIV VIENNA, DEPT PRENATAL DIAG & THERAPY, AKH-EBO-E6, WAHRINGER GURTEL 18-20, A-1090 VIENNA, AUSTRIA.			Pusch, Oliver/0000-0001-7166-2800				ADLER R, 1974, CELL, V2, P113, DOI 10.1016/0092-8674(74)90100-7; ARAP W, 1995, CANCER RES, V55, P1351; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BELLO LJ, 1974, EXP CELL RES, V89, P263, DOI 10.1016/0014-4827(74)90790-3; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN EH, 1995, J CLIN INVEST, V95, P1660, DOI 10.1172/JCI117841; DOU QP, 1994, J BIOL CHEM, V269, P1306; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; HENGSTSCHLAGER M, 1993, FEBS LETT, V321, P237, DOI 10.1016/0014-5793(93)80116-C; HENGSTSCHLAGER M, 1994, J BIOL CHEM, V269, P13836; HENGSTSCHLAGER M, 1994, CELL GROWTH DIFFER, V5, P1389; HENGSTSCHLAGER M, 1993, CYTOMETRY, V14, P39, DOI 10.1002/cyto.990140108; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KIM YK, 1992, J BIOL CHEM, V267, P2723; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Maniatis T, 1989, MOL CLONING; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NEVINS JR, 1992, SCIENCE, V258, P424; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SCHULZE A, 1994, ONCOGENE, V9, P3475; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHOWS TB, 1979, CYTOGENET CELL GENET, V25, P96, DOI 10.1159/000131404; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; WALKER DG, 1995, CANCER RES, V55, P20; WAWRA E, 1981, J VIROL, V38, P973, DOI 10.1128/JVI.38.3.973-981.1981; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WINTERSBERGER E, 1992, ADV ENZYME REGUL, V32, P241; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572	46	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1635	1643						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622883				2022-12-17	WOS:A1996UG45800005
J	Jones, J; Sugiyama, M; Speight, PM; Watt, FM				Jones, J; Sugiyama, M; Speight, PM; Watt, FM			Restoration of alpha(v)beta(5) integrin expression in neoplastic keratinocytes results in increased capacity for terminal differentiation and suppression of anchorage-independent growth	ONCOGENE			English	Article						squamous cell carcinoma; adhesion; extracellular matrix; vitronectin	SQUAMOUS-CELL CARCINOMAS; MONOCLONAL-ANTIBODIES; HUMAN-SKIN; FIBRONECTIN; ADHESION; VITRONECTIN; INVOLUCRIN; RECEPTOR; LOCALIZATION; ALPHA-5-BETA-1-INTEGRIN	Loss of expression of specific integrins is a feature of poorly differentiated oral squamous cell carcinomas (SCCs) and cell lines derived from them. In order to test whether there is a direct link between loss of integrins and abnormal keratinocyte growth and differentiation, we 'repaired' an SCC line, H357, by transfection of its missing integrin subunit, alpha(v). We analysed seven independent alpha(v)-expressing clones and compared them with four empty vector controls and with the parental cell line. alpha(v) was expressed on the cell surface as a functional alpha(v) beta(5) heterodimer. The parental cells expressed beta(5) mRNA and introduction of alpha(v) had no effect on beta(5) mRNA levels nor on cell surface levels of any other integrins examined. Introduction of alpha(v) had no consistent effect on the growth rate of cells on tissue culture plastic. However, anchorage-independent growth was strongly suppressed and the alpha(v)-transfectants showed an increased capacity for terminal differentiation, as assayed by expression of involucrin. These results are consistent with the known role of integrins in regulating keratinocyte terminal differentiation and suggest that integrin loss may be directly responsible for the abnormal behaviour of keratinocytes in a subset of oral SCCs.	IMPERIAL CANC RES FUND, KERATINOCYTE LAB, LONDON WC2A 3PX, ENGLAND; UCL EASTMAN DENT HOSP, INST DENT SURG, DEPT ORAL PATHOL, LONDON WC1X 8LD, ENGLAND	Cancer Research UK; University College London Hospitals NHS Foundation Trust; University of London; University College London			Watt, Fiona/AHB-0226-2022	Watt, Fiona/0000-0001-9151-5154				ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALBELDA SM, 1993, LAB INVEST, V68, P4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; DITTEL BN, 1993, BLOOD, V81, P2272; DOWNER CS, 1993, J PATHOL, V171, P183, DOI 10.1002/path.1711710306; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; EISENBERG E, 1987, ORAL SURG ORAL MED O, V64, P313, DOI 10.1016/0030-4220(87)90011-9; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GLADSON CL, 1994, INTEGRINS BIOL PROBL, P83; GRINNELL F, 1992, J INVEST DERMATOL, V98, P410, DOI 10.1111/1523-1747.ep12499839; HOTCHIN NA, 1992, J BIOL CHEM, V267, P14852; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; HOTCHIN NA, 1993, J CELL SCI, V106, P1131; HUDSON DL, 1992, HYBRIDOMA, V11, P367, DOI 10.1089/hyb.1992.11.367; HUGHES DE, 1994, J PATHOL, V173, P97, DOI 10.1002/path.1711730205; JONES J, 1993, J PATHOL, V169, P235, DOI 10.1002/path.1711690210; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KAUFMANN R, 1989, J CELL BIOL, V109, P1807, DOI 10.1083/jcb.109.4.1807; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NICHOLSON LJ, 1991, J CELL SCI, V98, P225; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; PRIME SS, 1990, J PATHOL, V160, P259, DOI 10.1002/path.1711600313; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; REILLY JT, 1988, J CLIN PATHOL, V41, P1269, DOI 10.1136/jcp.41.12.1269; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; RYYNANEN J, 1991, J INVEST DERMATOL, V97, P562, DOI 10.1111/1523-1747.ep12481896; SCHREINER C, 1991, CANCER RES, V51, P1738; SONNENBERG A, 1986, J HISTOCHEM CYTOCHEM, V34, P1037, DOI 10.1177/34.8.2426332; SUGIYAMA M, 1993, CARCINOGENESIS, V14, P2171, DOI 10.1093/carcin/14.10.2171; SUMITOMO S, 1986, ORAL SURG ORAL MED O, V62, P155, DOI 10.1016/0030-4220(86)90038-1; TENCHINI ML, 1993, CELL ADHES COMMUN, V1, P55, DOI 10.3109/15419069309095681; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONDEMBORNE AEG, 1989, LEUCOCYTE TYPING, V4, P951; WATT FM, 1993, J CELL SCI, V106, P175; WATT FM, 1993, DEVELOPMENT, P185; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; Wolf G T, 1992, J Natl Cancer Inst Monogr, P67; WOLF GT, 1990, JNCI-J NATL CANCER I, V82, P1566, DOI 10.1093/jnci/82.19.1566; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853	47	37	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					119	126						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552382				2022-12-17	WOS:A1996TQ01400015
J	Zwerschke, W; Joswig, S; JansenDurr, P				Zwerschke, W; Joswig, S; JansenDurr, P			Identification of domains required for transcriptional activation and protein dimerization in the human papillomavirus type-16 E7 protein	ONCOGENE			English	Article						papillomavirus; transformation; E7; transcriptional activation; dimerization	ADENOVIRUS E1A; RETINOBLASTOMA PROTEIN; HUMAN KERATINOCYTES; DNA-SYNTHESIS; TRANSFORMATION; SEQUENCES; GENE; ONCOPROTEIN; BINDING; TRANSACTIVATION	To analyse the potential of the E7 oncogene of HPV-16 to activate transcription, we constructed hybrid proteins containing various portions of the HPV-16 E7 protein fused to the DNA binding region of the bacterial LexA repressor. We found that full length HPV-16 E7 is capable to mediate activation of two different reporter genes, which carry LexA binding sites in their promoters. In contrast, E7 from HPV-11, a low-risk type papillomavirus, was unable to activate transcription, when analysed in the same assay. Mutations in the transforming domains of HPV-16 E7 did not affect the ability of the protein to activate transcription, indicating that it represents a novel function of the oncoprotein, which is not sensitive to any known inactivating mutations. Analysis of E7 subdomains revealed that the N-terminal part of HPV-16 E7 retains the capacity to activate transcription. A second trans-activation domain is located in the C-terminal part of E7; however, in the context of the full length E7 protein this activity is blocked by an adjacent domain. These results reveal a second pathway for transcriptional activation by HPV-16 E7, independent of its interaction with pRB-E2F complexes. Using the E7-LexA hybrid proteins, it is shown that E7 can form homodimers and this property involves a zinc finger structure in the C-terminal part of the protein, partially overlapping with the domain that negatively regulates transcriptional activation by E7.	DEUTSCH KREBSFORSCHUNGSZENTRUM, FORSCH SCHWERPUNKT ANGEW TUMORVIROL, ABT 620, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)			Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; Zwerschke, Werner/0000-0003-1137-2953				ARROYO M, 1993, MOL CELL BIOL, V13, P6537, DOI 10.1128/MCB.13.10.6537; BANKS L, 1990, ONCOGENE, V5, P1383; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; CICCOLINI F, 1994, ONCOGENE, V9, P2633; DEFEOJONES D, 1993, J VIROL, V67, P716, DOI 10.1128/JVI.67.2.716-725.1993; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIORE F, 1995, CELL CYCLE MATERIALS, P211; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; KAMENS J, 1991, NEW BIOL, V3, P1005; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MUNGER K, 1991, J VIROL, V65, P3943; MUNGER K, 1989, J VIROL, V63, P4417; PATRICK DR, 1994, J BIOL CHEM, V269, P6842; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; RAWLS JA, 1990, J VIROL, V64, P6121, DOI 10.1128/JVI.64.12.6121-6129.1990; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; TOMMASINO M, 1993, ONCOGENE, V8, P195; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245; ZURHAUSEN H, 1985, VIRUSES CANCER, P82	37	37	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	1996	12	1					213	220						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552395				2022-12-17	WOS:A1996TQ01400027
J	MALIK, KTA; WALLACE, JI; IVINS, SM; BROWN, KW				MALIK, KTA; WALLACE, JI; IVINS, SM; BROWN, KW			IDENTIFICATION OF AN ANTISENSE WT1 PROMOTER IN INTRON-1 - IMPLICATIONS FOR WT1 GENE-REGULATION	ONCOGENE			English	Article						WT1 AUTOREGULATION; ANTISENSE PROMOTER	WILMS-TUMOR GENE; FACTOR-A-CHAIN; GROWTH-FACTOR; GENITOURINARY DEVELOPMENT; TRANSCRIPTION FACTORS; GENOMIC ORGANIZATION; UROGENITAL SYSTEM; SUPPRESSOR WT1; EXPRESSION; DELETION	Expression of the Wilms' tumour suppressor gene, WT1, is tightly regulated during nephrogenesis, and loss of function of its gene product correlates with malignancy. By using luciferase reporter gene constructs containing DNA sequences from the first intron of the WT1 gene, we have identified an antisense WT1 promoter operational in the opposite direction relative to the 5' promoter. Transcription directed by the promoter is negatively regulated by upstream elements, but is activated by expression of WT1. This effect of WT1 is reciprocal to that observed on the 5' promoter, suggesting that antisense promoter activity is involved in WT1 gene regulation. By mimicking expression of the transcript regulated by the antisense promoter, we demonstrate that cellular levels of WT1 can be effectively down-regulated by antisense mRNA complementary to sequences in the first exon of WT1.			MALIK, KTA (corresponding author), UNIV BRISTOL, SCH MED SCI, DEPT PATHOL & MICROBIOL, CLIC RES UNIT, UNIV WALK, BRISTOL BS8 1TD, AVON, ENGLAND.		Brown, Keith/C-3355-2009	Brown, Keith/0000-0002-4258-5129; Malik, Karim/0000-0002-8965-200X				BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BENNINGTON JL, 1975, ATLAS TUMOR PATHOLOG; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; BRENNER B, 1992, ONCOGENE, V7, P1431; BROWN KW, 1992, ONCOGENE, V7, P763; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAMPBELL CE, 1994, ONCOGENE, V9, P583; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; COWELL JK, 1991, ONCOGENE, V6, P595; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ECCLES MR, 1994, ONCOGENE, V9, P2059; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAMILTON TB, 1995, NUCLEIC ACIDS RES, V23, P277, DOI 10.1093/nar/23.2.277; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; Hastie Nicholas D., 1992, Human Molecular Genetics, V1, P293; HILDEBRANDT M, 1992, CELL, V69, P197, DOI 10.1016/0092-8674(92)90130-5; HOFMANN W, 1993, ONCOGENE, V8, P3123; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1991, AM J HUM GENET, V48, P997; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; MALIK KTA, 1994, FEBS LETT, V349, P75, DOI 10.1016/0014-5793(94)00642-3; MATSUNAGA E, 1981, HUM GENET, V57, P231; MIWA H, 1992, LEUKEMIA, V6, P405; MIYAGI T, 1993, LEUKEMIA, V7, P970; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1991, ONCOGENE, V6, P2211; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RICCARDI VM, 1978, PEDIATRICS, V61, P604; ROYERPOKORA B, 1991, GENE CHROMOSOME CANC, V3, P89, DOI 10.1002/gcc.2870030203; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; Sambrook J., 1989, MOL CLONING, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARMA PM, 1992, CANCER RES, V52, P6407; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; TADOKORO K, 1992, JPN J CANCER RES, V83, P1198, DOI 10.1111/j.1349-7006.1992.tb02745.x; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1995, ONCOGENE, V10, P1243; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WINNING RS, 1991, NUCLEIC ACIDS RES, V19, P3709, DOI 10.1093/nar/19.13.3709; WOODRUFF KA, 1995, ONCOGENE, V10, P1335; YEGER H, 1992, CELL GROWTH DIFFER, V3, P855	56	37	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1589	1595						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478583				2022-12-17	WOS:A1995TC53500017
J	RACHMILEWITZ, J; ELKIN, M; ROSENSAFT, J; GELMANKOHAN, Z; ARIEL, I; LUSTIG, O; SCHNEIDER, T; GOSHEN, R; BIRAN, H; DEGROOT, N; HOCHBERG, A				RACHMILEWITZ, J; ELKIN, M; ROSENSAFT, J; GELMANKOHAN, Z; ARIEL, I; LUSTIG, O; SCHNEIDER, T; GOSHEN, R; BIRAN, H; DEGROOT, N; HOCHBERG, A			H19 EXPRESSION AND TUMORIGENICITY OF CHORIOCARCINOMA DERIVED CELL-LINES	ONCOGENE			English	Article						H19; CHORIOCARCINOMA CELL LINES; TUMOR SUPPRESSOR GENE; ONCOGENE	GROWTH FACTOR-II; IMPRINTED GENES; WILMS-TUMORS; CANCER; CHROMOSOME-11; DIFFERENTIATION; RELAXATION; MUTATION; INVITRO; INVIVO	Certain embryonal tumors demonstrate a loss of heterozygosity at the parentally imprinted region of chromosome 11p15.5. It has been hypothesized that this implicates a tumor suppressor gene at this locus. The human H19 gene maps to 11p15.5, is expressed in fetal tissues including the placenta and is paternally imprinted, Here we show that the abundance of H19 transcripts in cells of two choriocarcinoma derived cell lines (JAr and JEG-3) differs greatly. While JAr cells express high levels of H19 RNA, the expression of H19 in JEG-3 cells is much lower than that of normal trophoblasts, Cells of these two cell lines were subcutaneously injected into nude mice with subsequent tumor formation, A fivefold increase in the H19 RNA level was measured in tumors derived from JEG-3 cell lines as compared to these cells before injection, However this increase in H19 RNA did not alter the clonogenicity in soft agar nor the growth rate of the cells derived from these tumors as compared to the original JEG-3 cells, Nevertheless, the cells retaining the elevated level of H19 transcripts were more tumorigenic than the original cells, We propose that there is a selection of cells expressing high levels of H19 from the total JEG-3 cell population during the microevolution of tumor formation. These observations, together with our previous publications on H19 expression in human cancers, do not support the notion of a tumor suppressor role for the H19 gene.	HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL; KAPLAN HOSP,CLIN GENET UNIT,REHOVOT,ISRAEL; HADASSAH UNIV HOSP,DEPT PATHOL,IL-91120 JERUSALEM,ISRAEL; KAPLAN HOSP,DEPT ONCOL,REHOVOT,ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Kaplan Medical Center; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Kaplan Medical Center								ARIEL I, 1994, GYNECOL ONCOL, V53, P212, DOI 10.1006/gyno.1994.1118; ARIEL I, 1995, UROLOGY, V45, P335, DOI 10.1016/0090-4295(95)80030-1; BIRANNAN C, 1994, MOL CELL BIOL, V15, P123; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FRESHNEY RI, 1990, CULTURE ANIMAL CELLS, P142; GILEADI O, 1988, PLACENTAL PROTEIN HO, P251; GLASER A, 1992, MOL REPROD DEV, V33, P7, DOI 10.1002/mrd.1080330103; GLASER T, 1989, SOMAT CELL MOLEC GEN, V15, P477, DOI 10.1007/BF01534910; GLEN AE, 1993, CURR OPIN GENE DEV, V3, P418; GOSHEN R, 1993, MOL REPROD DEV, V34, P374, DOI 10.1002/mrd.1080340405; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HASHIMOTO K, 1995, NAT GENET, V9, P109, DOI 10.1038/ng0295-109; HOCHBERG A, 1992, CANCER RES, V52, P3713; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JONES NJ, 1990, MUTAGENESIS, V5, P15, DOI 10.1093/mutage/5.1.15; JUNIEN C, 1992, GENOMICS, V12, P620, DOI 10.1016/0888-7543(92)90461-Z; Junien C, 1992, CURR OPIN GENET DEV, V2, P431, DOI 10.1016/S0959-437X(05)80154-6; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; LU X, 1988, EXP CELL RES, V174, P199, DOI 10.1016/0014-4827(88)90155-3; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; Mazur M. T., 1987, GESTATIONAL TROPHOBL, P45; MCDONALD RJ, 1987, METHOD ENZYMOL, V152, P221; MUTTER GL, 1993, AM J HUM GENET, V53, P1096; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; RACHMILEWITZ J, 1992, MOL REPROD DEV, V32, P196, DOI 10.1002/mrd.1080320303; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; RACHMILEWITZ J, 1993, CELL GROWTH DIFFER, V4, P395; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; ROTHMAN PA, 1992, MOL REPROD DEV, V33, P1, DOI 10.1002/mrd.1080330102; Sambrook J., 1989, MOL CLONING LAB MANU; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; SEKIYA S, 1987, ARCH GYNECOL OBSTET, V241, P111, DOI 10.1007/BF00931231; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	38	37	41	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					863	870						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7545806				2022-12-17	WOS:A1995RU79800006
J	SOMMERS, CL; HUANG, K; SHORES, EW; GRINBERG, A; CHARLICK, DA; KOZAK, CA; LOVE, PE				SOMMERS, CL; HUANG, K; SHORES, EW; GRINBERG, A; CHARLICK, DA; KOZAK, CA; LOVE, PE			MURINE TXK - A PROTEIN-TYROSINE KINASE GENE REGULATED BY T-CELL ACTIVATION	ONCOGENE			English	Article						TXK; PROTEIN TYROSINE KINASE; THYMUS; T LYMPHOCYTES; SIGNAL TRANSDUCTION	X-LINKED AGAMMAGLOBULINEMIA; LYMPHOCYTES-T; ZETA-CHAIN; RECEPTOR; MOUSE; EXPRESSION; IDENTIFICATION; INTERLEUKIN-2; CLONING; FAMILY	To identify genes involved in signal transduction pathways that regulate T cell activation and development, murine fetal thymocytes were screened for expression of protein tyrosine kinase family members by the polymerase chain reaction, Using this approach, a nonreceptor protein tyrosine kinase, txk, was identified and cloned. Txk is expressed in thymocytes as early as fetal day 13.5 and its expression at the mRNA level continues throughout development, Txk transcripts are present in thymocytes, peripheral T cells and mast cell lines, but are not detectable in B cell macrophage/monocyte cell lines or in non-hematopoietic fetal or adult tissues, In both thymocytes and T cells, txk transcripts are down-regulated after activation with PMA and ionomycin, concanavalin A or T cell receptor cross-linking, Sequence analysis indicates that txk contains SH2, SH3 and kinase catalytic domains and belongs to the tec family of cytoplasmic protein tyrosine kinases which includes tec, itk and btk, Its unique N-terminus contains a proline-rich region, but unlike the other dec family members, does not contain a pleckstrin homology domain, The restricted expression pattern of txk and its regulation by T cell activation make it an excellent candidate for involvement in signal transduction during thymocyte development.	NIAID, MOLEC MICROBIOL LAB, BETHESDA, MD 20892 USA; US FDA, CTR BIOL EVALUAT & RES, DIV HEMATOL PROD, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); US Food & Drug Administration (FDA)	SOMMERS, CL (corresponding author), NICHHD, MAMMALIAN GENES & DEV LAB,BLDG 6B,ROOM 2B-210, 6 CTR DR, MSC 2780, BETHESDA, MD 20892 USA.							ADAMSON MC, 1991, VIROLOGY, V183, P778, DOI 10.1016/0042-6822(91)91010-E; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BROWN T, 1994, CURRENT PROTOCOLS; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DANCIGER M, 1993, GENOMICS, V16, P361, DOI 10.1006/geno.1993.1198; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207, DOI 10.1016/S0065-2776(08)60643-4; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GIBSON S, 1993, BLOOD, V82, P1561; GODFREY DI, 1992, J IMMUNOL, V149, P2281; Green EL, 1981, GENETICS PROBABILITY, P77; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HUANG HJS, 1987, P NATL ACAD SCI USA, V84, P204, DOI 10.1073/pnas.84.1.204; KOZAK CA, 1990, GENOMICS, V8, P519, DOI 10.1016/0888-7543(90)90039-W; KOZAK CA, 1994, MAMM GENOME, V5, pS65; LEO O, 1987, J IMMUNOL, V139, P1214; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LOVE PE, 1994, J EXP MED, V179, P1485, DOI 10.1084/jem.179.5.1485; LUNDIN LG, 1993, GENOMICS, V16, P1, DOI 10.1006/geno.1993.1133; MANO H, 1994, ONCOGENE, V9, P3205; MANO H, 1993, ONCOGENE, V8, P417; MARTH JD, 1987, EMBO J, V6, P2727, DOI 10.1002/j.1460-2075.1987.tb02566.x; MILLER J, 1985, J IMMUNOL, V134, P4212; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; PALACIOS R, 1992, DEVELOPMENT, V115, P1133; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; RAWLINGS DJ, 1994, IMMUNOL REV, V138, P105, DOI 10.1111/j.1600-065X.1994.tb00849.x; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SATO K, 1994, LEUKEMIA, V8, P1663; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SINGH G, 1991, P NATL ACAD SCI USA, V88, P10706, DOI 10.1073/pnas.88.23.10706; SMITH CIE, 1994, J IMMUNOL, V152, P557; TANAKA N, 1993, FEBS LETT, V324, P1, DOI 10.1016/0014-5793(93)81520-A; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VONBOEHMER H, 1992, BONE MARROW TRANSPL, V9, P46; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZUNIGAPFLUCKER JC, 1993, J EXP MED, V178, P1139, DOI 10.1084/jem.178.4.1139	52	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	1995	11	2					245	251						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7542761				2022-12-17	WOS:A1995RK95700005
J	FUJII, M; CHUHJO, T; MINAMINO, T; MASAAKI, N; MIYAMOTO, K; SEIKI, M				FUJII, M; CHUHJO, T; MINAMINO, T; MASAAKI, N; MIYAMOTO, K; SEIKI, M			IDENTIFICATION OF THE TAX INTERACTION REGION OF SERUM RESPONSE FACTOR THAT MEDIATES THE ABERRANT INDUCTION OF IMMEDIATE-EARLY GENES THROUGH CARG BOXES BY HTLV-I TAX	ONCOGENE			English	Article						HTLV-I; TAX; SRF; TRANSCRIPTION	T-CELL LEUKEMIA; VIRUS TYPE-I; C-FOS PROMOTER; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATION; AUTO-REGULATION; PROTEIN ELK-1; ELEMENT; EXPRESSION; TRANSACTIVATION	Tax of human T-cell leukemia virus type I (HTLV-I) activates transcription at a CArG box of various immediate early genes such as the proto-oncogene c-fos. To do this, Tax does not directly bind to the CArG box, but instead binds to the CArG binding factor SRF. In this study, we investigated the domain of SRF required for the activation by Tax and studied the role of this domain on transcriptional regulation at the CArG box. Using a fusion protein of SRF with a yeast transcription factor GAL4, the 14 amino acid (aa) portion (aa 422-435) of SRF was identified as the domain required for Tax activation [Tax-responsive region of SRF (TRRS)]. By means of a two hybrid system, we showed that TRRS was essential for the interaction of SRF with Tax in vivo. The over-expression of SRF with a deletion of TRRS inhibited the Tax activation at the CArG box. Thus, TRRS is the domain of SRF that is essential for Tax activation at the CArG box. Unlike to Tax activation, TRRS was not required for TPA (12-o-tetradecanoylphobol-13-acetate) induction at the CArG box, but a TRRS deletion enhanced the basal activity at the CArG box both under serum-starved and TPA-stimulated conditions. These results suggest that TRRS negatively regulates the transcriptional activation function of SRF, and consequently contributes to the low basal activity at the CArG box before TPA induction.	KANAZAWA UNIV,CANC RES INST,DEPT MOLEC ONCOL & VIROL,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,DEPT INTERNAL MED 3,KANAZAWA,ISHIKAWA 920,JAPAN; HOKURIKU UNIV,SCH PHARM,DEV MED RES LAB,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University; Kanazawa University; Hokuriku University			Seiki, Motoharu/K-9443-2015					AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; ALEXANDRE C, 1991, ONCOGENE, V6, P1851; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DECAPRIO JA, 1988, CELL, V15, P275; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1994, J VIROL, V68, P7275, DOI 10.1128/JVI.68.11.7275-7283.1994; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P2349; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HIRAI H, 1992, ONCOGENE, V7, P1737; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOW KG, 1994, MOL CELL BIOL, V14, P4958, DOI 10.1128/MCB.14.7.4958; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; NAGATA K, 1989, J VIROL, V68, P3220; NERENBERG M, 1988, SCIENCE, V237, P1324; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OSAME M, 1986, LANCET, V1, P1031; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; SUGAMURA K, 1993, RETROVIRIDAE, V2, P399; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; TSUCHIYA H, 1994, ONCOGENE, V9, P337; UCHIJIMA M, 1994, J BIOL CHEM, V269, P14946; WHITE P, 1988, NATURE, V334, P124; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	55	37	37	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					7	14						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624133				2022-12-17	WOS:A1995RJ29500002
J	GALLINGER, S; VIVONA, AA; ODZE, RD; MITRI, A; OBEIRNE, CP; BERK, TC; BAPAT, BV				GALLINGER, S; VIVONA, AA; ODZE, RD; MITRI, A; OBEIRNE, CP; BERK, TC; BAPAT, BV			SOMATIC APC AND K-RAS CODON-12 MUTATIONS IN PERIAMPULLARY ADENOMAS AND CARCINOMAS FROM FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS	ONCOGENE			English	Note						AMPULLARY CANCER; FAP; APC; K-RAS; DUODENAL CANCER	DUODENAL ADENOMAS; GENE-MUTATIONS; COLI GENE; IDENTIFICATION; CANCER; TUMORS; VATER; FAP	Periampullary adenomas in the duodenum of Familial Adenomatous Polyposis (FAP) patients are among the most frequent and clinically important extracolonic neoplasms in FAP. The purpose of this study was to characterize the frequency and nature of somatic adenomatous polyposis coli (APC) gene and K-ras codon 12 mutations in periampullary adenomas and carcinomas in FAP. These molecular changes have been shown to be important during the early stages of colorectal carcinogenesis. DNA was prepared from endoscopic periampullary biopsies and paraffin blocks from 49 FAP patients. Of 143 samples, 77 were histologically normal, 29 were biopsies from small periampullary adenomas, 29 biopsies were from 19 large adenomas and eight samples were from periampullary cancers. APC mutations in the mutation cluster region and K-ras codon 12 mutations were detected by polymerase chain reaction based techniques. Somatic APC mutations consisting of deletions at codons 1464 and 1465 were detected in one small and two large periampullary adenomas. Loss of heterozygosity was seen in one periampullary carcinoma, K-ras codon 12 mutations were detected in seven of 19 large periampullary adenomas and in one of eight periampullary carcinomas. These data suggest that K-ras codon 12 mutations may be important during periampullary tumorigenesis in FAP but somatic APC mutations in the mutation cluster region are infrequent. Local environmental factors in the duodenum may contribute to differences in the molecular changes which occur during the adenoma-to-carcinoma sequence in periampullary compared to colonic tumorigenesis.	UNIV TORONTO,MT SINAI HOSP,STEVE ATANAS STAVRO FAP REGISTRY,DEPT PATHOL,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	GALLINGER, S (corresponding author), UNIV TORONTO,MT SINAI HOSP,STEVE ATANAS STAVRO FAP REGISTRY,DEPT SURG,TORONTO,ON M5G 1X5,CANADA.		Gallinger, Steven/E-4575-2013; Bapat, Bharati/B-5839-2014					BACZAKO K, 1985, HUM PATHOL, V16, P305, DOI 10.1016/S0046-8177(85)80018-6; BAPAT B, 1993, HUM MOL GENET, V2, P1957, DOI 10.1093/hmg/2.11.1957; BECKWITH PS, 1991, ARCH SURG-CHICAGO, V126, P825; BOS JL, 1989, CANCER RES, V49, P4682; CHURCH JM, 1992, DIS COLON RECTUM, V35, P1170, DOI 10.1007/BF02251971; FARR CJ, 1988, ONCOGENE, V3, P673; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAYES DH, 1987, ANN SURG, V206, P572; HORII A, 1992, CANCER RES, V52, P3231; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JAGELMAN DG, 1988, LANCET, V1, P1149; JOHAN G, 1992, GASTROENTEROLOGY, V102, P1980; KURTZ RC, 1987, DIGEST DIS SCI, V32, P459, DOI 10.1007/BF01296027; LEVI S, 1991, CANCER RES, V51, P3497; MIYAKI M, 1993, CANCER RES, V53, P5079; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; ODZE RD, 1993, HUM PATHOL, V24, P442, DOI 10.1016/0046-8177(93)90095-X; PENNA C, 1993, BRIT J SURG, V80, P1027, DOI 10.1002/bjs.1800800833; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RHODES M, 1992, GUT, V33, P125, DOI 10.1136/gut.33.1.125; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	25	37	37	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1875	1878						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753564				2022-12-17	WOS:A1995QX46900022
J	MOLINARI, M; MILNER, J				MOLINARI, M; MILNER, J			P53 IN COMPLEX WITH DNA IS RESISTANT TO UBIQUITIN-DEPENDENT PROTEOLYSIS IN THE PRESENCE OF HPV-16 E6	ONCOGENE			English	Article						P53-DNA; UBIQUITIN-DEPENDENT PROTEOLYSIS; HPV-16 E6	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; CELL-CYCLE; GENE AMPLIFICATION; PROTEIN; CONFORMATION; BINDING; DEGRADATION; ONCOPROTEIN; PHOSPHORYLATION	The tumour suppressor p53 is a transcription factor with high affinity for specific DNA target sequences. Wild type p53 has a very short half life in normal cells but the protein shows transient accumulation in response to DNA damage, accompanied by up-regulation of target genes such as p21 and induction of growth arrest in G1 of the cell cycle. The rapid turnover of p53 may involve the ubiquitin-dependent proteolytic pathway. In order to investigate p53 turnover we have employed an in vitro system with rabbit reticulocyte lysate, in which ubiquitin-dependent degradation of p53 is mediated by the oncoprotein E6 of human papilloma virus type 16 (HPV-16). Using this system we have previously shown that E6-mediated degradation is preferential for p53 in the 1620(+) conformation (reactive with the monoclonal antibody PAb1620). p53-1620(+) is a pre-requisite for specific DNA binding and we have now asked if p53 in complex with DNA remains susceptible to ubiquitin-dependent proteolysis in the presence of E6. Our results indicate that p53-DNA complexes are resistant to degradation, whereas the 'free' protein is completely degraded within 20 min. Moreover, E6 did not complex with p53-DNA, possibly due to masking of sites recognised either by E6 or by the E6-associated protein (E6-AP) which facilitates E6-p53 interaction. Preincubation with E6 inhibited the DNA binding capacity of p53 and this effect could be explained, at least in part, by ubiquitination of the p53 protein.	UNIV YORK,DEPT BIOL,YORKSHIRE CANC RES CAMPAIGAN P53 GRP,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK								ANDERSON C, 1994, IN PRESS SEMINARS CA; BLUMENFELD N, 1994, J BIOL CHEM, V13, P9574; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CIECHANOVER A, 1994, J BIOL CHEM, V13, P9582; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1994, ONCOGENE, V9, P1225; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442; GU ZM, 1994, ONCOGENE, V9, P629; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1995, ONCOGENE, V10, P27; HAINAUT P, 1994, ONCOGENE, V9, P299; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALL AR, 1995, ONCOGENE, V10, P561; HARPER JW, 1993, CELL, V75, P805; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JOHNSTON NL, 1991, BIOCHEMISTRY-US, V30, P7514, DOI 10.1021/bi00244a021; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MILNER J, 1990, ONCOGENE, V5, P1683; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIM D, 1994, ONCOGENE, V9, P1869; PINES J, 1994, NATURE, V371, P742, DOI 10.1038/371742a0; RIVAS CI, 1992, BLOOD, V79, P1982; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SRINIVASAN R, 1993, CANCER RES, V53, P5361; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHANG W, 1992, ONCOGENE, V7, P1646	53	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1849	1854						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753560				2022-12-17	WOS:A1995QX46900018
J	SZEKELY, L; POKROVSKAJA, K; JIANG, WQ; SELIVANOVA, G; LOWBEER, M; RINGERTZ, N; WIMAN, KG; KLEIN, G				SZEKELY, L; POKROVSKAJA, K; JIANG, WQ; SELIVANOVA, G; LOWBEER, M; RINGERTZ, N; WIMAN, KG; KLEIN, G			RESTING B-CELLS, EBV-INFECTED B-BLASTS AND ESTABLISHED LYMPHOBLASTOID CELL-LINES DIFFER IN THEIR RB, P53 AND EBNA-5 EXPRESSION PATTERNS	ONCOGENE			English	Note						EBV; RB; P53; B-CELL; EBNA	EPSTEIN-BARR-VIRUS; ENCODED NUCLEAR ANTIGEN; TUMOR-SUPPRESSOR GENES; RETINOBLASTOMA PROTEIN; TRANSFORMATION INVITRO; GROWTH TRANSFORMATION; BURKITTS-LYMPHOMA; LYMPHOCYTES-B; ANTIBODIES; DIFFERENTIATION	Using immunofluorescence technique we have analysed the Rb, p53, EBNA-2 and EBNA-5 expression pattern in EBV infected human B-cells and established lymphoblastoid cell lines (LCL-s). Resting B-cells showed only a faint Rb and no p53 immunostaining. The expression of both Rb and p53 increased after EBV infection. The change was first detectable 6 h after infection. The frequency of brilliantly Rb positive cells increased more than p53 positives. EBNA-2 and EBNA-5 first detectable 12 h after infection. The frequency of EBNA positive cells in the freshly infected cultures was concordant with the proportion of CD23 and PCNA positives, but remained consistently below the frequency of Rb and p53 positive cells. Double immunofluorescence staining showed that all EBNA-5 positive cells were strongly Rb and p53 positive. LCL-s did not stain for p53, whereas the Rb staining was maintained at a high level. The EBNA-5 staining pattern changed from brilliant almost homogeneous nuclear staining in the freshly infected B-cells, to a nonhomogeneous pattern with a small number of strongly fluorescent nuclear bodies in established LCL-s. There was no change in the EBNA-2 staining pattern. Our findings indicate that the immortalization of B-cells by EBV may initially involve a high expression of EBNA-5, p53 and Rb, but only cells with low p53 and focal expression of EBNA-5 in nuclear bodies have the selective advantage required to grow into immortalized lines.	KAROLINSKA INST, DEPT CELL & MOLEC BIOL, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet	SZEKELY, L (corresponding author), KAROLINSKA INST, CTR MICROBIOL & TUMOR BIOL, S-17177 STOCKHOLM, SWEDEN.		Szekely, Laszlo/B-1268-2009; Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Selivanova, Galina/0000-0002-8698-4332; Pokrovskaja Tamm, Katja/0000-0001-6359-1256; Szekely, Laszlo/0000-0001-6144-6573	NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER; NCI NIH HHS [2 R01 CA14054-19] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALFIERI C, 1991, VIROLOGY, V181, P595, DOI 10.1016/0042-6822(91)90893-G; COHEN JI, 1991, J VIROL, V65, P2545, DOI 10.1128/JVI.65.5.2545-2554.1991; COHEN JI, 1991, J VIROL, V65, P5880, DOI 10.1128/JVI.65.11.5880-5885.1991; COHEN JI, 1992, J VIROL, V66, P7555, DOI 10.1128/JVI.66.12.7555-7559.1992; DILLNER J, 1988, INT J CANCER, V42, P721, DOI 10.1002/ijc.2910420516; DILLNER J, 1988, ADV CANCER RES, V50, P95, DOI 10.1016/S0065-230X(08)60436-4; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FINKE J, 1987, J VIROL, V61, P3870, DOI 10.1128/JVI.61.12.3870-3878.1987; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; JIANG WQ, 1991, EXP CELL RES, V197, P314, DOI 10.1016/0014-4827(91)90438-Z; JIANG WQ, 1991, J CELL SCI, V99, P497; KNUTSON JC, 1990, J VIROL, V64, P2530, DOI 10.1128/JVI.64.6.2530-2536.1990; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LING PD, 1994, J VIROL, V68, P5375, DOI 10.1128/JVI.68.9.5375-5383.1994; MANNICK JB, 1991, J VIROL, V65, P6826, DOI 10.1128/JVI.65.12.6826-6837.1991; MIDDLETON T, 1991, ADV VIRUS RES, V40, P19; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; RING CJA, 1994, J GEN VIROL, V75, P1, DOI 10.1099/0022-1317-75-1-1; SAMPLE J, 1990, J VIROL, V64, P1667, DOI 10.1128/JVI.64.4.1667-1674.1990; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; SWAMINATHAN S, 1991, P NATL ACAD SCI USA, V88, P1546, DOI 10.1073/pnas.88.4.1546; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; SZEKELY L, 1991, CELL GROWTH DIFFER, V2, P287; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; TOMKINSON B, 1992, J VIROL, V66, P2893, DOI 10.1128/JVI.66.5.2893-2903.1992; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; WANG F, 1991, J VIROL, V65, P4101, DOI 10.1128/JVI.65.8.4101-4106.1991; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WIMAN KG, 1993, FASEB J, V7, P841, DOI 10.1096/fasebj.7.10.8393817	32	37	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1869	1874						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753563				2022-12-17	WOS:A1995QX46900021
J	AFINK, GB; NISTER, M; STASSEN, BHGJ; JOOSTEN, PHLJ; RADEMAKERS, PJH; BONGCAMRUDLOFF, E; VANZOELEN, EJJ; MOSSELMAN, S				AFINK, GB; NISTER, M; STASSEN, BHGJ; JOOSTEN, PHLJ; RADEMAKERS, PJH; BONGCAMRUDLOFF, E; VANZOELEN, EJJ; MOSSELMAN, S			MOLECULAR-CLONING AND FUNCTIONAL-CHARACTERIZATION OF THE HUMAN PLATELET-DERIVED GROWTH-FACTOR-ALPHA RECEPTOR GENE PROMOTER	ONCOGENE			English	Note						PDGF; RECEPTOR; CAMP; GENE; RETINOIC ACID; TRANSCRIPTION	DEVELOPMENTAL EXPRESSION; PDGF RECEPTOR; TRANSCRIPTION FACTOR; RETINOIC ACID; CELLS; TISSUE; BETA; EMBRYOGENESIS; ESTABLISHES; SEQUENCE	Expression of the platelet-derived growth factor alpha receptor (PDGF alpha R) is strictly regulated during mammalian development and tumorigenesis. The molecular mechanisms involved in the specific regulation of PDGF alpha R expression are unknown, but transcriptional regulation of the PDGF alpha R gene is most likely to be involved, This study describes the molecular cloning of the non-coding exon 1 and approximately 2 kb of 5' flanking region of the human PDGF alpha R gene, This 5' flanking region is a functional promoter of the PDGF alpha R gene as concluded from its capacity to drive luciferase reporter gene expression in an orientation dependent way, Analysis of 5' promoter deletion mutants revealed that the region from -441 to +118, relative to the transcription initiation site, is sufficient to establish high level promoter activity, In addition, the morphogen retinoic acid, alone or in combination with dibutyryl cAMP, gives a 22-fold induction of PDGF alpha R gene promoter activity in human teratocarcinoma cells, This effect is mediated through specific transcription factor binding within the -52/+118 region of the PDGF alpha R gene.	UNIV UPPSALA HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital	AFINK, GB (corresponding author), CATHOLIC UNIV NIJMEGEN,DEPT CELL BIOL,TOERNOOIVELD 1,6525 ED NIJMEGEN,NETHERLANDS.		Afink, Gijs/AAB-2832-2021; Afink, Gijs/A-2025-2009	Afink, Gijs/0000-0002-2155-725X				BOWENPOPE DF, 1991, TRENDS GENET, V7, P413, DOI 10.1016/0168-9525(91)90222-C; CHAUDHRY A, 1992, CANCER RES, V52, P1006; Claesson-Welsh Lena, 1994, Progress in Growth Factor Research, V5, P37, DOI 10.1016/0955-2235(94)90016-7; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; DO MS, 1992, ONCOGENE, V7, P1567; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FITZERATTAS C, 1993, INT J CANCER, V53, P315, DOI 10.1002/ijc.2910530224; GRONWALD RGK, 1989, J BIOL CHEM, V264, P8120; HAMPE A, 1989, ONCOGENE RES, V4, P9; HENRIKSEN R, 1993, CANCER RES, V53, P4550; HERMANSON M, 1992, CANCER RES, V52, P3213; HOGAN BLM, 1981, NATURE, V291, P235, DOI 10.1038/291235a0; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; KUMABE T, 1992, ONCOGENE, V7, P627; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MERCOLA M, 1990, DEV BIOL, V138, P114, DOI 10.1016/0012-1606(90)90181-H; MERCOLA M, 1988, SCIENCE, V241, P1223, DOI 10.1126/science.3413486; MOSSELMAN S, 1989, FEBS LETT, V247, P154, DOI 10.1016/0014-5793(89)81260-8; MOSSELMAN S, 1994, CANCER RES, V54, P220; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NISTER M, 1991, J BIOL CHEM, V266, P16755; ORRURTREGER A, 1992, DEVELOPMENT, V115, P289; OUELLETTE MM, 1992, ONCOGENE, V7, P1075; PRINGLE NP, 1992, DEVELOPMENT, V115, P535; RAINES EW, 1991, PEPTIDE GROWTH FACTO, V1, P173; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; ROBERTS WM, 1992, BLOOD, V79, P586; ROSS R, 1990, PHILOS T ROY SOC B, V327, P155, DOI 10.1098/rstb.1990.0051; Sambrook J., 1989, MOL CLONING LAB MANU; SCHATTEMAN GC, 1992, DEVELOPMENT, V115, P123; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SMITH EA, 1991, P NATL ACAD SCI USA, V88, P4811, DOI 10.1073/pnas.88.11.4811; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; TSUKAMOTO T, 1991, J BIOL CHEM, V266, P10143; VANDIJK MA, 1991, MOL CELL ENDOCRINOL, V81, P81, DOI 10.1016/0303-7207(91)90207-9; WANG CY, 1994, P NATL ACAD SCI USA, V91, P7061, DOI 10.1073/pnas.91.15.7061; WANG CY, 1990, MOL CELL BIOL, V10, P6781, DOI 10.1128/MCB.10.12.6781; WATSON AJ, 1992, MOL REPROD DEV, V31, P87, DOI 10.1002/mrd.1080310202; WESTERMARK B, 1993, ACTA ONCOL, V32, P101, DOI 10.3109/02841869309083897; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YEH HJ, 1993, P NATL ACAD SCI USA, V90, P1952, DOI 10.1073/pnas.90.5.1952; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	43	37	39	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1667	1672						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731723				2022-12-17	WOS:A1995QU68100025
J	HORTNAGEL, K; MAUTNER, J; STROBL, LJ; WOLF, DA; CHRISTOPH, B; GELTINGER, C; POLACK, A				HORTNAGEL, K; MAUTNER, J; STROBL, LJ; WOLF, DA; CHRISTOPH, B; GELTINGER, C; POLACK, A			THE ROLE OF IMMUNOGLOBULIN-KAPPA ELEMENTS IN C-MYC ACTIVATION	ONCOGENE			English	Article						BURKITTS LYMPHOMA; C-MYC; IMMUNOGLOBULIN KAPPA GENE REGULATORY ELEMENTS; MATRIX ATTACHMENT REGION; TRANSCRIPT ELONGATION	BURKITTS-LYMPHOMA CELLS; HEAVY-CHAIN GENE; DOWN-REGULATION; PROMOTER SHIFT; 1ST EXON; NUCLEOTIDE-SEQUENCE; CHROMATIN STRUCTURE; LOCATED DOWNSTREAM; STABLE INTEGRATION; INTRONIC MAR	Burkitt's lymphoma cells are characterized by chromosomal translocations involving the proto-oncogene c-myc on chromosome 8 and one of the immunoglobulin gene loci on chromosomes 2, 14 or 22, The translocated c-myc allele is transcriptionally activated, shows a preferential usage of promoter P1 over P2 (promoter shift) and lacks the ability to retain the transcription complex at the P2 promoter. In order to define the elements of the immunoglobulin kappa gene involved in deregulation of c-myc in a t(2;8) translocation, we designed constructs consisting of c-myc and different parts of the immunoglobulin kappa gene locus. Chromatin analysis of these stably transfected constructs revealed DNase I hypersensitive sites within the c-myc 5' region characteristic for an actively transcribed c-myc gene and three sites within the immunoglobulin kappa locus corresponding to the matrix attachment region, the intron and 3' enhancers, respectively. These three regulatory elements were necessary and sufficient for maximal c-myc activation and formation of the promoter shift. Kinetic nuclear run on experiments were performed to study the distribution of transcription complexes on c-myc exon 1 on constructs with and without the immunoglobulin kappa regulatory elements. The absence of a pausing polymerase complex at the c-myc P2 promoter could be demonstrated for constructs consisting of c-myc and the two kappa enhancers. Therefore the two enhancers are sufficient to relief the elongational block at the P2 promoter, however, the matrix attachment region is additionally required for maximal c-myc activation observed in Burkitt's lymphoma cells.	GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT, INST KLIN MOLEK BIOL, D-81377 MUNICH, GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health			Strobl, Lothar J/M-7357-2014	Strobl, Lothar J/0000-0001-8389-1862; Wolf, Dieter/0000-0002-3761-1070				ALLEN RW, 1987, J BIOL CHEM, V262, P649; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; BLASQUEZ VC, 1992, J BIOL CHEM, V267, P23888; BLASQUEZ VC, 1989, J BIOL CHEM, V264, P21183; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; BOULIKAS T, 1993, J CELL BIOCHEM, V52, P14, DOI 10.1002/jcb.240520104; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EICK D, 1987, ONCOGENE, V2, P61; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; EICK D, 1988, ONCOGENE, V3, P397; EICK D, 1994, ANAL BIOCHEM, V218, P347, DOI 10.1006/abio.1994.1190; FULTON R, 1993, NUCLEIC ACIDS RES, V21, P4941, DOI 10.1093/nar/21.21.4941; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; HORTNAGEL K, 1994, CURR TOP MICROBIOL I, V194, P415; JUDDE JG, 1992, MOL CELL BIOL, V12, P5206, DOI 10.1128/MCB.12.11.5206; KAS E, 1992, EMBO J, V11, P705, DOI 10.1002/j.1460-2075.1992.tb05103.x; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; KOHLHUBER F, 1993, ONCOGENE, V8, P1099; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LINDSTEN T, 1988, EMBO J, V7, P2787, DOI 10.1002/j.1460-2075.1988.tb03133.x; MAGRATH I, 1990, ADV CANCER RES, V55, P134; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NEUBERGER MS, 1983, EMBO J, V2, P1373, DOI 10.1002/j.1460-2075.1983.tb01594.x; PICARD D, 1984, NATURE, V307, P80, DOI 10.1038/307080a0; POLACK A, 1991, ONCOGENE, V6, P2033; POLACK A, 1993, EMBO J, V12, P3913, DOI 10.1002/j.1460-2075.1993.tb06069.x; POLACK A, 1987, EMBO J, V6, P2959, DOI 10.1002/j.1460-2075.1987.tb02601.x; QUEEN C, 1984, MOL CELL BIOL, V4, P1042, DOI 10.1128/MCB.4.6.1042; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RICHMAN A, 1989, MOL CELL BIOL, V9, P4962, DOI 10.1128/MCB.9.11.4962; RICHMAN A, 1989, SCIENCE, V246, P494, DOI 10.1126/science.2683072; Sambrook J., 1989, MOL CLONING LAB MANU; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STROBL LJ, 1993, ONCOGENE, V8, P1437; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; STROBL UZ, 1993, EMBO J, V12, P167; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TONEGUZZO F, 1986, MOL CELL BIOL, V6, P703, DOI 10.1128/MCB.6.2.703; WHITEHURST C, 1992, NUCLEIC ACIDS RES, V20, P4929, DOI 10.1093/nar/20.18.4929; XU M, 1989, J BIOL CHEM, V264, P21190; ZAJAC-KAYE M, 1990, J BIOL CHEM, V265, P4547; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZIRBEL RM, 1994, CHROMOSOME RES, V11, P93	62	37	37	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1393	1401						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731690				2022-12-17	WOS:A1995QR65100017
J	MA, QF; HERSCHMAN, HR				MA, QF; HERSCHMAN, HR			THE YEAST HOMOLOG YTIS11, OF THE MAMMALIAN TIS11 GENE FAMILY IS A NONESSENTIAL, GLUCOSE REPRESSIBLE GENE	ONCOGENE			English	Article						TIS11; IMMEDIATE-EARLY GENE; YEAST; PRIMARY RESPONSE GENE	PRIMARY RESPONSE GENE; TETRADECANOYL PHORBOL ACETATE; SWISS 3T3 CELLS; SCHIZOSACCHAROMYCES-POMBE; GROWTH-FACTORS; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; MIG1 REPRESSOR; PROTEINS; CDNA	The murine TIS11 primary response gene is rapidly and transiently induced in response to many extracellular signals, A CX(8)CX(5)CX(3)H sequence is present twice in the TIS11 protein, in two additional murine proteins, TIS11B and TIS11D, that share regions of strong sequence conservation with THS11, and in a Drosophila homologue (DTIS11). Although immunolocalization of TIS11 protein to the nucleus and zinc binding have lead to the speculation that the TIS11 family proteins are transcription factors, no function for these proteins has yet been clearly determined. We have now identified a TIS11 homologue, YTIS11, from Saccharomyces cerevisiae. The Ytis11p protein conserves both the two putative zinc finger CX(8)CX(5)CX(3)H sequences and the spacing between them, as web as additional amino acids in this region. The amino terminal 169 amino acid portion of Ytis11p protein, which contains a large number of acidic amino acids, can serve as transactivator when fused to the Ga14 DNA-binding domain. Expression of the YTIS11 gene is not induced in response to DNA damaging agents, heat shock, sporulation conditions, or mating factor. However, YTIS11 expression is subjected to rapid glucose repression. Disruption of the YTIS11 gene in the M12B strain of Saccharomyces cerevisiae does not effect viability, growth in rich or synthetic medium, mating, or spore formation. However, YTIS11 gene disruption causes an alteration in metabolism that is reflected by a pH color change when cells are grown on YP plates supplemented with 2% glucose. Overexpression of murine TIS11 or TIS11B proteins dramatically attenuates the growth of both ytis11 and wild-type yeast.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,CTR HLTH SCI,US DOE,STRUCT BIOL & MOLEC MED LAB,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; United States Department of Energy (DOE); University of California System; University of California Los Angeles					PHS HHS [M24797] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARNARD RC, 1993, NUCLEIC ACIDS RES, V21, P3580, DOI 10.1093/nar/21.15.3580; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BOUTRY M, 1977, BIOCHIM BIOPHYS ACTA, V464, P602, DOI 10.1016/0005-2736(77)90034-7; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CONWAY EJ, 1950, BIOCHEM J, V47, P360, DOI 10.1042/bj0470360; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; FOURY F, 1975, J BIOL CHEM, V250, P2354; FOURY F, 1977, J BIOL CHEM, V252, P4577; GOMPERTS M, 1990, ONCOGENE, V5, P1081; HEXIMER SP, 1993, DNA CELL BIOL, V12, P73, DOI 10.1089/dna.1993.12.73; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KANEDA N, 1992, GENE, V118, P289, DOI 10.1016/0378-1119(92)90202-Z; LAI WS, 1990, J BIOL CHEM, V265, P16556; LIM RW, 1987, ONCOGENE, V1, P263; MA QF, 1991, ONCOGENE, V6, P1277; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; NIE XF, 1994, IN PRESS GENE; ROSE MD, 1990, COLD SPRING HARBOR L; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; SIGLER K, 1980, FOLIA MICROBIOL, V25, P311, DOI 10.1007/BF02876611; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V79, P3454; ULASZEWSKI S, 1987, J BIOL CHEM, V262, P223; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; VARNUM BC, 1989, ONCOGENE, V4, P119; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; WESTERBEEKMARRE.CA, 1988, EUR J BIOCHEM, V174, P611	33	37	39	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					487	494						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845673				2022-12-17	WOS:A1995QF64800009
J	HERBST, R; MUNEMITSU, S; ULLRICH, A				HERBST, R; MUNEMITSU, S; ULLRICH, A			ONCOGENIC ACTIVATION OF V-KIT INVOLVES DELETION OF A PUTATIVE TYROSINE-SUBSTRATE INTERACTION SITE	ONCOGENE			English	Article						RECEPTOR TYROSINE KINASE; ONCOGENIC MUTATION; V-KIT; SIGNAL TRANSDUCTION	EPIDERMAL GROWTH-FACTOR; FMS PROTO-ONCOGENE; STEM-CELL FACTOR; MALIGNANT HUMAN HEMATOPOIESIS; ACUTE MYELOBLASTIC-LEUKEMIA; C-KIT; KINASE RECEPTOR; SIGNAL TRANSDUCTION; NEU ONCOGENE; SRC FAMILY	The transforming gene of the Hardy-Zuckerman-4 strain of feline sarcoma virus, v-kit, arose by transduction of the cellular c-kit gene, which encodes the receptor tyrosine kinase (RTK) p145(c-kit). To gain insight into the molecular basis of the v-kit transforming potential, we characterized the feline c-kit by cDNA cloning. Comparison of the feline v-kit and c-kit sequences revealed, in addition to deletions of the extracellular and transmembrane domains, three additional mutations in the v-kit oncogene product: deletion of tyrosine-569 and valine-570, the exchange of aspartate at position 761 to glycine, and replacement of the C-terminal 50 amino acids by five unrelated residues, Examinations of individual v-kit mutations in the context of chimeric receptors yielded inhibitory effects for some mutants on both autophosphorylation and substrate phosphorylation functions. In contrast, deletion of tyrosine-569 and valine-570 significantly enhanced transforming and mitogenic activities of p145(c-kit), while the other mutations had no significant effects. Conservation in subclass III RTKs and the identification of the corresponding residue in beta PDGF-R, Y579, as a binding site for src family tyrosine kinases suggests an important role for Y568 in kit signal regulation and the definition of its oncogenic potential, Repositioning of Y571 by an in-frame two codon deletion may be the crucial alteration resulting in enhancement of v-kit oncogenic activity.	MAX PLANCK INST BIOCHEM,DEPT BIOL MOLEC,D-82152 MARTINSRIED,GERMANY	Max Planck Society								ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERRETI A, 1991, BLOOD S, V78, pA373; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BROWNING PJ, 1986, P NATL ACAD SCI USA, V83, P7800, DOI 10.1073/pnas.83.20.7800; BUHRING HJ, 1993, CANCER RES, V53, P4424; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FENDLY BM, 1990, CANCER RES, V50, P1550; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HERBST R, 1991, J BIOL CHEM, V266, P19908; HERBST R, 1992, J BIOL CHEM, V267, P13210; HIBI K, 1991, ONCOGENE, V6, P2291; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HUANG E, 1990, CELL, V63, P223; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LASSAM N, 1992, ONCOGENE, V7, P51; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; MAJUMDER S, 1990, ONCOGENE RES, V5, P329; Maniatis T., 1982, MOL CLONING; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MILLER AD, 1985, MOL CELL BIOL, V5, P431, DOI 10.1128/MCB.5.3.431; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MOSTOV KE, 1984, NATURE, V318, P37; NATALI PG, 1992, INT J CANCER, V52, P713, DOI 10.1002/ijc.2910520508; NATALI PG, 1992, INT J CANCER, V52, P197, DOI 10.1002/ijc.2910520207; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P1710, DOI 10.1073/pnas.89.5.1710; RATAJCZAK MZ, 1992, INT J CELL CLONING, V10, P205; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROUSSEL MF, 1990, ONCOGENE, V5, P25; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SACCA R, 1986, P NATL ACAD SCI USA, V83, P3331, DOI 10.1073/pnas.83.10.3331; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKIDO Y, 1991, CANCER RES, V51, P2416; SHERR CJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P225, DOI 10.1016/0304-419X(88)90011-X; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG C, 1989, LEUKEMIA, V3, P699; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	67	37	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					369	379						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7530827				2022-12-17	WOS:A1995QC62400016
J	KRIEF, P; AUGERYBOURGET, Y; PLAISANCE, S; MERCK, MF; ASSIER, E; TANCHOU, V; BILLARD, M; BOUCHEIX, C; JASMIN, C; AZZARONE, B				KRIEF, P; AUGERYBOURGET, Y; PLAISANCE, S; MERCK, MF; ASSIER, E; TANCHOU, V; BILLARD, M; BOUCHEIX, C; JASMIN, C; AZZARONE, B			A NEW CYTOKINE (IK) DOWN-REGULATING HLA CLASS-II - MONOCLONAL-ANTIBODIES, CLONING AND CHROMOSOME LOCALIZATION	ONCOGENE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CELL-LINES; EXPRESSION; DNA; ANTIGENS; GAMMA; GENE; INTERFERON; MOLECULES; SEQUENCE	The role of HLA class II Antigens in the control of the immune response is determined not only by the genetic polymorphism of these molecules, but also by their density on the cell surface. It is therefore essential to identify the signals that modulate HLA Class II gene activity in normal and neoplastic cells. We have purified a cytokine (IK factor, 19 kDa) secreted by the leukemic cell line K562 and several cancer cells, which inhibits HLA Class II antigen induction by IFN-gamma. We produced specific mAbs which antagonize the biological effect of IK in colon carcinoma Cole 205 cells induced to express HLA-DR molecules by IFN-gamma. Moreover, in Cole 205, HLA-DR can also be induced by the protein synthesis inhibitor Cycloheximide (0.1 mu g ml(-1)) and addition of IK factor almost completely abolishes HLA class II expression. We have also performed the cloning and the sequencing of a specific cDNA. This probe recognizes a 2.1 Kb mRNA in different eel types. The nucleotide sequence exhibits no homologies with known cytokines. IK gene localization shows that it maps on chromosome 2p15-p14. The transient transfection of the cDNA in COS cells induces the secretion of a biologically active 19 kDa protein which is recognized in Western blot by 1C5B11 blocking mAb. This paper reports the characterization of a new cytokine downregulating HLA class II Antigens, whose analysis will help to better understand HLA class II gene regulation and the mechanism of escape from immunorecognition in cancer cells,	INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE; INST COCHIN GENET MOLEC,INSERM,U332,F-75014 PARIS 14,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	KRIEF, P (corresponding author), HOP PAUL BROUSSE,INSERM,U268,114 AVE PAUL VAILLANT COUTURIER,F-94800 VILLEJUIF,FRANCE.		Krief, Patricia/M-6073-2014; Plaisance, Stephane/ABI-6307-2020; Azzarone, Bruno/AAH-9251-2019; Plaisance, Stephane/B-3488-2009	Krief, Patricia/0000-0001-5106-466X; Plaisance, Stephane/0000-0002-1651-241X; Azzarone, Bruno/0000-0002-5962-3849; Plaisance, Stephane/0000-0002-1651-241X; Assier, Eric/0000-0001-8366-1645; Boucheix, Claude/0000-0003-4184-7008				BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BOSS JM, 1986, P NATL ACAD SCI USA, V83, P9139, DOI 10.1073/pnas.83.23.9139; BOUCHEIX C, 1986, METHOD ENZYMOL, V121, P580; CHENG JH, 1993, BIOCHEM J, V294, P589, DOI 10.1042/bj2940589; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DOHERTY PC, 1985, ADV CANCER RES, V42, P1; DOUKAS J, 1990, J IMMUNOL, V145, P1088; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FESTENSTEIN H, 1986, NATURE, V322, P502, DOI 10.1038/322502a0; GUERRASIO A, 1981, BLOOD CELLS, V7, P165; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; JANEWAY CA, 1984, IMMUNOL TODAY, V5, P99, DOI 10.1016/0167-5699(84)90043-4; KOELER G, 1975, NATURE, V256, P495; KRIEF P, 1989, INT J CANCER, V43, P658, DOI 10.1002/ijc.2910430420; KRIEF P, 1987, EUR J IMMUNOL, V17, P1021, DOI 10.1002/eji.1830170719; KRIEF P, 1988, VIRAL HEPATITIS LIVE, P217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHLER RI, 1985, J IMMUNOL, V135, P2914; LEVESQUE JP, 1991, BIOTECHNIQUES, V11, P313; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MATIS LA, 1983, P NATL ACAD SCI-BIOL, V80, P6019, DOI 10.1073/pnas.80.19.6019; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MERCK MFR, 1991, HUMAN GENET, V86, P350; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; POVEY S, 1989, CYTOGENET CELL GENET, V51, P91, DOI 10.1159/000132782; RADKA SF, 1986, HUM IMMUNOL, V16, P390, DOI 10.1016/0198-8859(86)90065-0; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; TABILIO A, 1983, CANCER RES, V43, P4569; UCER U, 1985, INT J CANCER, V36, P103, DOI 10.1002/ijc.2910360116; VIRELIZIER JL, 1984, EUR J IMMUNOL, V14, P106, DOI 10.1002/eji.1830140120; YUNIS JJ, 1978, CYTOGENET CELL GENET, V22, P679, DOI 10.1159/000131052	34	37	39	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3449	3456						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970704				2022-12-17	WOS:A1994PT39200006
J	SKINNER, A; HURST, HC				SKINNER, A; HURST, HC			TRANSCRIPTIONAL REGULATION OF THE C-ERBB-3 GENE IN HUMAN BREAST-CARCINOMA CELL-LINES	ONCOGENE			English	Article							OVEREXPRESSION; AMPLIFICATION; MECHANISMS; EXPRESSION; PROMOTER; ONCOGENE; MEMBER; FAMILY; CANCER; ERBB3	The c-erbB-3 gene is a member of the EGF receptor family of membrane tyrosine kinases. Previous work has shown that the expression of this gene is frequently unregulated in human breast carcinoma-derived cell lines and in tumour biopsy material. As there is no evidence of gene amplification, we decided to examine the control of c-erbB-3 transcription in overexpressing cells. In this paper we describe the cloning of the c-erbB-3 promoter and its functional analysis within mammary-derived cell lines. We show that the promoter is more active in overexpressing cells and this is largely due to the action of the OB2-1 transcription factor which we have recently identified as mediating overexpression of the c-erbB-2 promoter in similar cell lines.	HAMMERSMITH HOSP,RPMS,ICRF,ONCOL GRP,GENE TRANSCRIPT LAB,LONDON W12 0HS,ENGLAND	Imperial College London								Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HURST HC, 1991, METHOD MOL BIOL, V8, P141; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; Maniatis T, 1989, DECONTAMINATION DILU; Merlino G T, 1990, Semin Cancer Biol, V1, P277; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597	19	37	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3393	3401						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247542				2022-12-17	WOS:A1993MG78200024
J	THOMAS, JE; AGUZZI, A; SORIANO, P; WAGNER, EF; BRUGGE, JS				THOMAS, JE; AGUZZI, A; SORIANO, P; WAGNER, EF; BRUGGE, JS			INDUCTION OF TUMOR-FORMATION AND CELL-TRANSFORMATION BY POLYOMA MIDDLE T-ANTIGEN IN THE ABSENCE OF SRC	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; RAT-CELLS; ONCOGENIC TRANSFORMATION; YES PROTEIN; VIRUS; PP60C-SRC; ASSOCIATION; EXPRESSION; BINDING; MICE	In polyomavirus-transformed cells, middle T antigen binds to and activates the protein tyrosine kinase, Src. To determine whether this interaction is critical for middle T transformation, we examined the ability of middle T to transform cells that lack endogenous Src (because of a targeted disruption of both Src alleles). Infection of newborn or 2-week-old Src-negative mice with a retrovirus encoding middle T led to the induction of visceral hemangiomas that were indistinguishable from tumors in wild-type mice with respect to their morphology, frequency or latency period. In addition, middle T was able to induce foci formation on cell monolayers and colony formation in soft agar in Src-negative immortalized fibroblasts. These results indicated that Src is not essential for middle T-induced transformation of the cells targeted in these assays. To examine the protein tyrosine kinases that interact with middle T in the absence of Src, we compared the level of middle T phosphorylation in immune complex kinase assays from Src-negative and Src-positive cell lysates, and identified the middle T-associated kinases in these cells. In Src-positive cell lysates, there was a similar level of middle T phosphorylation in Src and Yes immunoprecipitates, suggesting that middle T can bind to Src and Yes to a similar extent in this cell type. Fyn immunoprecipitates displayed fourfold lower levels of middle T phosphorylation than that detected in the Src and Yes immunoprecipitates. In Src-negative cells, the level of middle T phosphorylation in Yes and Fyn immunoprecipitates was not significantly different from that detected in the Src-positive cells, suggesting that the absence of Src does not lead to a compensating increase in the proportion of middle T associated with these kinases. The level of middle T-associated phosphatidylinositol 3'-kinase was also examined since this kinase is known to interact with middle T-kinase complexes. Phosphatidylinositol 3'-kinase activity associated with middle T was reduced 30-60% in Src-negative cells, suggesting that Src contributes at least one-third of the total middle T associated in wild-type cells. Taken together, these results indicate that Src is not required for middle T-induced hemangiomas in mice or for focus induction in immortalized fibroblasts, and that the residual level of Yes, Fyn and phosphatidylinositol kinase activity associated with middle T in Src-negative cells may compensate for the absence of Src.	UNIV PENN, HOWARD HUGHES MED INST, DEPT MICROBIOL, PHILADELPHIA, PA 19104 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST MOLEC GENET, HOUSTON, TX 77030 USA; UNIV ZURICH, DEPT PATHOL, INST NEUROPATHOL, CH-8006 ZURICH, SWITZERLAND; RES INST MOLEC PATHOL, VIENNA, AUSTRIA	Howard Hughes Medical Institute; University of Pennsylvania; Baylor College of Medicine; University of Zurich; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Aguzzi, Adriano/A-3351-2008; Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X; Wagner, Erwin F/0000-0001-7872-0196; Aguzzi, Adriano/0000-0002-0344-6708				AGUZZI A, 1991, ONCOGENE, V6, P113; AGUZZI A, 1990, New Biologist, V2, P533; AMINI S, 1986, MOL CELL BIOL, V6, P2305, DOI 10.1128/MCB.6.7.2305; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOLEN JB, 1987, J VIROL, V61, P3299, DOI 10.1128/JVI.61.10.3299-3305.1987; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KORNBLUTH S, 1990, J VIROL, V64, P1584, DOI 10.1128/JVI.64.4.1584-1589.1990; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOO D, 1988, CELL GROWTH DIVISION, P17; MARKLAND W, 1986, J VIROL, V59, P82, DOI 10.1128/JVI.59.1.82-89.1986; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; RAPTIS L, 1985, MOL CELL BIOL, V6, P1545; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RASSOULZADEGAN M, 1990, ONCOGENE, V5, P1507; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TALMAGE DA, 1991, CELL GROWTH DIFFER, V2, P51; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WILLIAMS RL, 1988, CELL, V52, P121; YONEMOTO W, 1987, MOL CELL BIOL, V7, P905, DOI 10.1128/MCB.7.2.905; ZHAO YH, 1990, ONCOGENE, V5, P1629	42	37	37	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1993	8	9					2521	2529						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	7689725				2022-12-17	WOS:A1993LT36800024
J	ZACKSENHAUS, E; GILL, RM; PHILLIPS, RA; GALLIE, BL				ZACKSENHAUS, E; GILL, RM; PHILLIPS, RA; GALLIE, BL			MOLECULAR-CLONING AND CHARACTERIZATION OF THE MOUSE RB1 PROMOTER	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; CELL-CYCLE; SUSCEPTIBILITY GENE; REGULATORY ELEMENT; C-MYC; EXPRESSION; PROTEIN; PHOSPHORYLATION; DIFFERENTIATION	We report the isolation and characterization of the mouse RB1 promoter and surrounding DNA sequences, and the identification of elements required for basal transcriptional activity. The mouse RB1 promoter, like the human homologue, has a high G + C content, constitutes a CpG island and is devoid of typical TATA and CAAT boxes. The first 235 base-pairs upstream of the translation initiation codon in the mouse promoter exhibit 80% sequence homology with the human sequence. This homology includes a region which contains putative binding sites for the transcription factors Sp1, ATF and E2F/DRTF1. Four major transcription initiation sites were identified downstream of this conserved region. Mutational analysis revealed that the Sp1 and ATF binding sites, but not the putative E2F/DRTF1 binding site, are critical for promoter activity. Complete disruption of the putative Sp1 and ATF sites abrogated transcription, whereas the introduction of point mutations, previously identified in the Sp1 and ATF sites in two low penetrance retinoblastoma families, reduced promoter activity in a cell type specific manner. Less reduction in activity occured in retinoic acid induced differentiated P19 cells and NIH3T3 mouse fibroblasts than in undifferentiated embryonal carcinoma P19 cells. Activity of the RB1 promoter was found to be stimulated in retinoic-acid induced differentiated P19 cells compared to undifferentiated P19; this stimulation required intact Sp1 and ATF sites but not the putative E2F/DRTF1 binding site. Our results indicate that basal level of RB1 expression is governed by Sp1 and ATF.			ZACKSENHAUS, E (corresponding author), HOSP SICK CHILDREN,DIV IMMUNOL & CANC RES,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.		Zacksenhaus, Eldad/AAD-3584-2020	Gallie, Brenda/0000-0002-9697-9211				BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COPPOLA JA, 1990, ONCOGENE, V5, P1731; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DUNN JM, 1989, MOL CELL BIOL, V9, P4594; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORD GM, 1990, GENOMICS, V6, P284, DOI 10.1016/0888-7543(90)90568-F; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; PARTRIDGE JF, 1991, EMBO J, V10, P3819, DOI 10.1002/j.1460-2075.1991.tb04951.x; PUGH BF, 1992, J BIOL CHEM, V267, P679; RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SLACK RS, 1993, IN PRES ONCOGENE; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STARNAUD R, 1988, ONCOGENE, V3, P553; TANG A, 1989, ONCOGENE, V4, P401; TASSIOS P T, 1990, New Biologist, V2, P1123; ZACHSENHAUS E, 1993, ADV CANCER RES, V61, P115; ZACKSENHAUS E, 1990, EMBO J, V9, P2923, DOI 10.1002/j.1460-2075.1990.tb07483.x	39	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2343	2351						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361753				2022-12-17	WOS:A1993LT36800004
J	CATLING, AD; WYKE, JA; FRAME, MC				CATLING, AD; WYKE, JA; FRAME, MC			MITOGENESIS OF QUIESCENT CHICK FIBROBLASTS BY V-SRC - DEPENDENCE ON EVENTS AT THE MEMBRANE LEADING TO EARLY CHANGES IN AP-1	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; DNA-BINDING ACTIVITY; C-JUN; TRANSFORMING PROTEIN; PHOSPHORYLATION; FOS; PP60V-SRC; SEQUENCE; PROMOTER; INVITRO	Activation of rapidly reversible temperature-sensitive (ts) v-Src in quiescent chicken embryo fibroblasts (CEFs) results in both morphological transformation and exit from G0 to G1, resulting in mitosis. This phenomenon permits examination of cellular responses very soon after activating the oncoprotein, and we have used this to study changes in endogenous AP-1, and the regulation of its major components, in the first few hours after activating v-Src. This approach contrasts with a number of studies that have demonstrated enhanced activity of exogenously added AP-1 components in cells transformed by v-Src. Reactivation of a membrane-associated tyrosine kinase (tsRCAN-29) results in a several-fold increase in AP-1 DNA binding and a similar increase in the activity of an AP-1-responsive reporter soon after temperature shift. c-Jun and c-Fos are regulated at a number of levels in response to both stimuli. In quiescent RCAN-29-infected CEFs stimulated into cycle by shift to permissive temperature, c-fos transcripts are elevated by 15 min and remain above basal level for at least 4 h. Serum induces much greater elevation of c-fos transcripts, although this response is transient. Despite the difference in magnitude of the transcript responses, the stimulation of nuclear c-Fos protein is similar in both serum and v-Src-stimulated cultures. No elevation in c-jun transcripts or nuclear c-Jun protein level is evident in v-Src-stimulated quiescent CEFs. However, there is an early change in the tryptic phosphopeptide map of p39 c-Jun in response to both v-Src and serum. Upon stimulation we observed a novel redistribution of phosphate in the carboxy-terminal tryptic phosphopeptide that may be responsible in part for the increase in AP-1 DNA binding. Phosphorylation of amino-terminal serines 63 and 73 on peptides Y and X, believed to be responsible for regulation of the transactivation function of c-Jun, is constitutively high in resting CEF cultures; stimulation with serum or v-Src results in only a modest increase in phosphorylation at these sites. Significantly, reactivation of a non-myristylated, transformation-defective version of the tsRCAN-29 v-Src protein (RCAN-29A2) is unable to induce resting CEFs to reenter cycle. In addition, this mutant fails to induce early increases in AP-1 activity, implying that these nuclear changes require crucial signalling events at the cell periphery, and that these events correlate with the biological consequences of expression of v-Src.	BEATSON INST CANC RES,CANC RES CAMPAIGN,BEATSON LABS,WOLFSON LAB MOLEC PATHOL,GLASGOW G61 1BD,SCOTLAND	Beatson Institute								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BELL JG, 1975, J GEN VIROL, V27, P127, DOI 10.1099/0022-1317-27-2-127; BEUG H, 1978, CELL, V14, P843, DOI 10.1016/0092-8674(78)90340-9; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CALOTHY G, 1987, J VIROL, V61, P1678, DOI 10.1128/JVI.61.5.1678-1681.1987; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; COOPER JA, 1988, PEPTIDES PROTEIN PHO, P85; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; CROUCH DH, 1990, ONCOGENE, V5, P683; CURRAN T, 1984, CELL, V36, P259; DURKIN JP, 1984, J CELL PHYSIOL, V120, P135, DOI 10.1002/jcp.1041200205; Fourney R.M., 1988, FOCUS, V10, P5; FRAME MC, 1991, ONCOGENE, V6, P205; GILLESPIE DAF, 1991, SEMINARS VIROLOGY, V2, P329; GILMER TM, 1983, J VIROL, V45, P462, DOI 10.1128/JVI.45.1.462-465.1983; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HARLOW E, 1988, ANTIBODIES LABORATOR, P641; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JACKSON JA, 1992, J BIOL CHEM, V267, P17444; JAHNER D, 1991, ONCOGENE, V6, P1259; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; LUO K, 1990, ONCOGENE, V5, P921; Maniatis T., 1982, MOL CLONING; MULLER R, 1987, ONCOGENE RES, V2, P19; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STOKER AW, 1984, MOL CELL BIOL, V4, P1508, DOI 10.1128/MCB.4.8.1508; STOKER AW, 1986, J VIROL, V58, P876, DOI 10.1128/JVI.58.3.876-883.1986; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VOSATKA RJ, 1989, J CELL PHYSIOL, V138, P493, DOI 10.1002/jcp.1041380308; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988; WELHAM MJ, 1990, ONCOGENE, V5, P161; WHITE MK, 1988, MOL CELL BIOL, V8, P135; WYKE JA, 1973, VIROLOGY, V53, P152, DOI 10.1016/0042-6822(73)90474-1	52	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1875	1886						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510932				2022-12-17	WOS:A1993LG68200020
J	CROUCH, DH; FISHER, F; CLARK, W; JAYARAMAN, PS; GODING, CR; GILLESPIE, DAF				CROUCH, DH; FISHER, F; CLARK, W; JAYARAMAN, PS; GODING, CR; GILLESPIE, DAF			GENE-REGULATORY PROPERTIES OF MYC HELIX-LOOP-HELIX LEUCINE-ZIPPER MUTANTS - MAX-DEPENDENT DNA-BINDING AND TRANSCRIPTIONAL ACTIVATION IN YEAST CORRELATES WITH TRANSFORMING CAPACITY	ONCOGENE			English	Article							HUMAN C-MYC; SACCHAROMYCES-CEREVISIAE; PROTEIN EXPRESSION; ESCHERICHIA-COLI; CELL-CYCLE; MOTIF; DIFFERENTIATION; OLIGOMERIZATION; SPECIFICITY; RECOGNITION	Max is a basic helix-loop-helix/leucine zipper (bHLH/LZ) protein that forms sequence-specific DNA-binding complexes with the c-Myc oncoprotein (Myc). Using Saccharomyces cerevisiae, we have shown that the Max bHLH/LZ domain enables Myc to activate transcription through CACGTG and CACATG sequences in vivo, and that the number and context of such sites determines the level of activation. In addition, we have used yeast to investigate the role of the Myc helix-loop-helix (HLH) and leucine zipper (LZ) motifs in mediating Max-dependent DNA-binding and transcriptional activation in vivo using HLH/LZ mutants generated by site-directed mutagenesis. The results show that, while both motifs are essential for Myc to activate transcription, helix 2 of the HLH together with the contiguous LZ suffice to mediate complex formation with Max, whilst helix 1 is essential for sequence-specific DNA binding of Myc-Max complexes. Furthermore, the ability of Myc HLH/LZ mutants to hind DNA and activate transcription in collaboration with Max correlates closely with their neoplastic transforming activity in higher eukaryotic cells.	BEATSON INST CANC RES, CANC RES CAMPAIGN,BEATSON LABS,GARSCUBE ESTATE, SWITCHBACK RD, GLASGOW G61 1BD, SCOTLAND; MARIE CURIE RES INST, EUKARYOT TRANSCRIPT LAB, OXTED RH8 0TL, SURREY, ENGLAND	Beatson Institute			Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544; /0000-0002-6500-9095; Goding, Colin/0000-0002-1614-3909				Abate C, 1990, Semin Cancer Biol, V1, P19; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CROUCH DH, 1990, ONCOGENE, V5, P683; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FISHER F, 1991, ONCOGENE, V6, P1099; FISHER F, 1992, EMBO J, V11, P4103, DOI 10.1002/j.1460-2075.1992.tb05503.x; GIBOSN TJ, 1993, IN PRESS PROTEIN ENG; GILLESPIE DAF, 1991, SEMINARS VIROLOGY, V2, P329; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MIN SY, 1992, ONCOGENE, V7, P1531; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Penn L J, 1990, Semin Cancer Biol, V1, P69; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; REDDY CD, 1992, ONCOGENE, V7, P2085; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; STAROVASNIK MA, 1992, BIOCHEMISTRY-US, V31, P9891, DOI 10.1021/bi00156a006; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; VINSON CR, 1992, NEW BIOL, V4, P396; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WATERS CM, 1991, ONCOGENE, V6, P797; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448	51	37	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1993	8	7					1849	1855						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510929				2022-12-17	WOS:A1993LG68200017
J	DELEEUW, B; SUIJKERBUIJK, RF; BALEMANS, M; SINKE, RJ; DEJONG, B; MOLENAAR, WM; MELONI, AM; SANDBERG, AA; GERAGHTY, M; HOFKER, M; ROPERS, HH; VANKESSEL, AG				DELEEUW, B; SUIJKERBUIJK, RF; BALEMANS, M; SINKE, RJ; DEJONG, B; MOLENAAR, WM; MELONI, AM; SANDBERG, AA; GERAGHTY, M; HOFKER, M; ROPERS, HH; VANKESSEL, AG			SUBLOCALIZATION OF THE SYNOVIAL SARCOMA-ASSOCIATED T(X-18) CHROMOSOMAL BREAKPOINT IN XP11.2 USING COSMID CLONING AND FLUORESCENCE INSITU HYBRIDIZATION	ONCOGENE			English	Article							EPITHELIAL DIFFERENTIATION; TUMORS; TRANSLOCATION; ABERRATIONS; SEQUENCES; FEATURES	In a previous study we localized the synovial sarcoma-associated t(X;18)(p11;q11) breakpoint within the ornithine aminotransferase-like 1 (OATL1) cluster on the X chromosome. This localization was delineated from both somatic cell hybrid and fluorescence in situ hybridization (FISH) analysis of patient material, using OAT-specific cDNA and YAC probes. Simultaneously, Knight et al. (1992, MoL Hum. Genet, in press) mapped this same breakpoint in their patient material adjacent to the more proximal OATL2 region on the X chromosome. Here we report the analysis of two additional tumors and demonstrate that again in these cases the chromosomal break occurs within the OATL1 cluster. In order to further specify the breakpoint, we subcloned the OATL1 YAC (no. 2) into cosmids. At least one of these cosmids (0.38) hybridizes to sequences that bracket the translocation breakpoint, as demonstrated by both Southern blot and FISH analysis. These observations confirm and substantiate our previous findings. In addition, cosmid 0.38 should be a valuable instrument for the ultimate isolation and identification of the gene(s) involved in the development of synovial sarcoma.	UNIV GRONINGEN,DEPT HUMAN GENET,9700 AB GRONINGEN,NETHERLANDS; UNIV GRONINGEN,DEPT PATHOL,9700 AB GRONINGEN,NETHERLANDS; GENET CTR,SCOTTSDALE,AZ; CANC CTR,SCOTTSDALE,AZ; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; LEIDEN UNIV,DEPT HUMAN GENET,2300 RA LEIDEN,NETHERLANDS	University of Groningen; University of Groningen; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Leiden University; Leiden University - Excl LUMC	DELEEUW, B (corresponding author), CATHOLIC UNIV NIJMEGEN,DEPT HUMAN GENET,POB 9101,6500 HB NIJMEGEN,NETHERLANDS.		Sinke, Richard J/A-1462-2009; van Kessel, Ad Geurts/A-2810-2010					ARNOLDUS EPJ, 1989, HUM GENET, V83, P231, DOI 10.1007/BF00285162; BATES PF, 1983, GENE, V26, P137, DOI 10.1016/0378-1119(83)90183-X; BERGER W, 1992, NAT GENET, V1, P199, DOI 10.1038/ng0692-199; DRIESEN MS, 1991, GENOMICS, V11, P1079, DOI 10.1016/0888-7543(91)90035-D; ENZINGER FM, 1988, SOFT TISSUE TUMORS, P658; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISHER C, 1986, HUM PATHOL, V17, P996, DOI 10.1016/S0046-8177(86)80083-1; FLETCHER JA, 1991, NEW ENGL J MED, V324, P436, DOI 10.1056/NEJM199102143240702; GILGENKRANTZ S, 1990, ONCOGENE, V5, P1063; KNIGHT JC, 1992, IN PRESS MOL HUM GEN; LANDEGENT JE, 1987, HUM GENET, V77, P366, DOI 10.1007/BF00291428; LEEUW BD, 1993, GENE CHROMOSOME CANC, V6, P182; LIMON J, 1991, GENE CHROMOSOME CANC, V3, P338, DOI 10.1002/gcc.2870030504; MIETTINEN M, 1983, VIRCHOWS ARCH B, V44, P187, DOI 10.1007/BF02890169; MITCHELL GA, 1988, J BIOL CHEM, V263, P1488; MITELMAN F, 1990, CATALOG CHROMOSOME A; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; SUIJKERBUIJK RF, 1992, CANCER GENET CYTOGEN, V63, P8, DOI 10.1016/0165-4608(92)90056-E; SUIJKERBUIJK RF, 1991, AM J HUM GENET, V48, P269; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; WIEACKER P, 1984, AM J HUM GENET, V36, P265	22	37	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1457	1463						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389029				2022-12-17	WOS:A1993LE06400008
J	MORGAN, IM; ASANO, M; HAVARSTEIN, LS; ISHIKAWA, H; HIIRAGI, T; ITO, Y; VOGT, PK				MORGAN, IM; ASANO, M; HAVARSTEIN, LS; ISHIKAWA, H; HIIRAGI, T; ITO, Y; VOGT, PK			AMINO-ACID SUBSTITUTIONS MODULATE THE EFFECT OF JUN ON TRANSFORMATION, TRANSCRIPTIONAL ACTIVATION AND DNA-REPLICATION	ONCOGENE			English	Article							C-JUN; V-JUN; BINDING PROTEINS; MAMMALIAN-CELLS; LEUCINE ZIPPER; FOS; ONCOGENE; AP-1; INVITRO; ENCODES	The retroviral oncogene v-jun and its cellular counterpart code for proteins that function as major components of the transcription factor complex AP-1. Jun proteins bind to the AP-1 consensus sequence as homodimers or heterodimers with members of the Fos protein family. This report compares the ability of viral and cellular Jun proteins (v-Jun and c-Jun) to activate transcription and to stimulate DNA synthesis. The effect of amino acid substitutions on cellular transformation is also described. In F9 cells c-Jun is a more effective transactivator than v-Jun, which carries two amino acid substitutions in the carboxy-terminal region that together down-regulate transactivation. The delta deletion, present in the amino-terminal region of v-Jun, does not affect transactivation in F9 cells; however, it does modulate the stimulation of DNA synthesis. When delta is deleted, the amino acid substitutions are without consequence on DNA synthesis. In the presence of delta the amino acid substitutions down-regulate DNA synthesis. Deletion of the Jun transactivation domain, which is required for cellular transformation, abolishes both transactivation and stimulation of DNA synthesis. We conclude that transformation, transactivation and stimulation of DNA synthesis all depend on the presence of the transactivation domain. The three functions are, however, not tightly correlated, and further work is needed to define the role of the biochemical activities of Jun in oncogenesis.	USC,SCH MED,DEPT MICROBIOL,2011 ZONAL AVE,HMR 401,LOS ANGELES,CA 90033; KYOTO UNIV,INST VIRUS RES,SAKYO KU,KYOTO 606,JAPAN; NORRIS CANC CTR,LOS ANGELES,CA 90033	University of Southern California; Kyoto University			Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500; Havarstein, Leiv Sigve/0000-0001-8250-4322	NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL R, 1990, NEW BIOL, V1, P35; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; FRAME MC, 1991, ONCOGENE, V6, P205; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MORGAN IM, 1992, ONCOGENE, V7, P1119; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OLIVIERO S, 1992, IN PRESS GENES DEV; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SASSONECORSI P, 1990, ONCOGENE, V5, P427; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WASYLYK C, 1990, ONCOGENE, V5, P1055; WONG WY, 1992, IN PRESS ONCOGENE; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	36	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1135	1140						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479738				2022-12-17	WOS:A1993KY32800004
J	STEPHENS, EV; KALINEC, G; BRANN, MR; GUTKIND, JS				STEPHENS, EV; KALINEC, G; BRANN, MR; GUTKIND, JS			TRANSFORMING G-PROTEIN-COUPLED RECEPTORS TRANSDUCE POTENT MITOGENIC SIGNALS IN NIH 3T3 CELLS INDEPENDENT ON CAMP INHIBITION OR CONVENTIONAL PROTEIN-KINASE-C	ONCOGENE			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; STIMULATES DNA-SYNTHESIS; GROWTH-FACTOR RECEPTOR; S PHASE PROGRESSION; A9 L-CELLS; PERSISTENT ACTIVATION; HAMSTER FIBROBLASTS; CARBACHOL ACTION; PHORBOL ESTERS; EXPRESSION	We have used the expression of human acetylcholine muscarinic receptor (mAChR) genes in NIH 3T3 cells as a model for dissecting the molecular basis of cellular transformation induced by G protein-coupled receptors. Those mAChR subtypes efficiently coupled to PIP, hydrolysis (m1, m3 and m5) induced agonist-dependent celt transformation whereas those inhibiting adenylyl cyclase (m2, m4) lack transforming activity. In the present study, we demonstrate that in cells expressing ml but not m2 mAChRs the cholinergic agonist (carbachol) is alone as potent a stimulant for DNA synthesis as platelet-derived growth factor (PDGF) or serum. Furthermore, induction of DNA synthesis is shown to correlate with activation of PIP, hydrolysis but not with inhibition of adenylyl cyclase. We also examined the rote of protein kinase C (PKC) in mitogenic signalling through ml mAChRs, and found that NIH 3T3 cells express PKC-alpha and PCK-zeta as the only conventional or Ca2+-independent PKC isozyme, respectively. Prolonged treatment with TPA depleted cells of PKC-alpha but not of PKC-zeta. In TPA-treated NIH 3T3 celts, the mitogenic response to a subsequent stimulation with TPA was absolutely abolished, but the response to PDGF or serum was not. Moreover, PKC depletion did not decrease DNA synthesis induced by carbachol. We conclude that carbachol potently induces reinitiation of DNA synthesis through the activation of transforming mAChR subtypes, independently of inhibition of adenylyl cyclase and conventional PKCs.	NIDR,MOLEC SIGNALING GRP,CELLULAR REV & ONCOL LAB,9000 ROCKVILLE PIKE,BETHESDA,MD 20892; UNIV VERMONT,COLL MED,DEPT PSYCHIAT,NEUROSCI RES UNIT,BURLINGTON,VT 05405	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Vermont			Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 				AKITA Y, 1990, J BIOL CHEM, V265, P354; ASHKENAZI A, 1989, NATURE, V340, P146, DOI 10.1038/340146a0; BERNARDS R, 1991, EMBO J, V10, P1119, DOI 10.1002/j.1460-2075.1991.tb08052.x; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FINZI E, 1987, P NATL ACAD SCI USA, V84, P3733, DOI 10.1073/pnas.84.11.3733; GUSOVSKY F, 1991, MOL PHARMACOL, V39, P124; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JONES SVP, 1988, MOL PHARMACOL, V34, P421; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; LEAL F, 1985, SCIENCE, V230, P327, DOI 10.1126/science.2996133; MOOLENAAR WH, 1991, CELL GROWTH DIFFER, V2, P359; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PASTI G, 1986, NATURE, V324, P375, DOI 10.1038/324375a0; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SEUWEN K, 1988, NATURE, V335, P254, DOI 10.1038/335254a0; SEUWEN K, 1990, BIOCHEM PHARMACOL, V39, P985, DOI 10.1016/0006-2952(90)90276-Q; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; STRULOVICI B, 1991, J BIOL CHEM, V266, P168; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	46	37	37	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					19	26						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380916				2022-12-17	WOS:A1993KN00500003
J	ONNO, M; NAKAMURA, T; HILLOVA, J; HILL, M				ONNO, M; NAKAMURA, T; HILLOVA, J; HILL, M			REARRANGEMENT OF THE HUMAN TRE ONCOGENE BY HOMOLOGOUS RECOMBINATION BETWEEN ALU REPEATS OF NUCLEOTIDE-SEQUENCES FROM 2 DIFFERENT CHROMOSOMES	ONCOGENE			English	Note							B-CELL NEOPLASMS; BCR GENE; FAMILIAL HYPERCHOLESTEROLEMIA; STRUCTURAL ALTERATIONS; RECIPROCAL PARTNERS; MOLECULAR-CLONING; TRANSFORMING GENE; ACUTE LEUKEMIAS; DNA FRAGMENTS; C-MYC	The rearranged region of the tre oncogene originating from chromosomes 5q23q31 and 18q12 was cloned from tumor genomic DNA, sequenced and aligned with wild-type sequences cloned from a normal human genomic library. In the breakpoint region each wild-type sequence contained two Alu repeats. The recombination occurred between the 3'-most Alu from chromosome 5 and the 5'-most Alu from chromosome 18 and, consequently, resulted in a hybrid Alu flanked with one Alu on either side. The recombinant joint was located to a 20-bp homology region in left arms of the Alu repeats involved in recombination. The same homology region was identified in the hybrid Alu of the rearranged tre. At its 5' extremity the homology region overlaps the B box of Alu-borne RNA polymerase III promoter. The 100% identity score in the region of homology suggests that the recombination process was conservative and not error prone.	INST CANC & IMMUNOGENET, CELLULAR & MOLEC BIOL LAB, 14 AVE PAUL VAILLANT COUTURIER, F-94804 VILLEJUIF, FRANCE; INST CANC & IMMUNOGENET, CNRS, UNITE SDI 6204, F-94804 VILLEJUIF, FRANCE	Centre National de la Recherche Scientifique (CNRS)								ANACHKOVA B, 1985, BIOCHEM BIOPH RES CO, V128, P101, DOI 10.1016/0006-291X(85)91650-X; ANDERSON RA, 1986, MOL CELL BIOL, V6, P3246, DOI 10.1128/MCB.6.9.3246; AVIDI L, 1980, HUMAN GENET, V55, P281; BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; BULLOCK P, 1985, SCIENCE, V230, P954, DOI 10.1126/science.2997924; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; CHEN SJ, 1989, NUCLEIC ACIDS RES, V17, P7631, DOI 10.1093/nar/17.19.7631; CHEN SJ, 1989, ONCOGENE, V4, P195; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; DEKLEIN A, 1986, NUCLEIC ACIDS RES, V14, P7071, DOI 10.1093/nar/14.17.7071; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; EVA A, 1987, ONCOGENE, V1, P355; HALVERSON D, 1990, ONCOGENE, V5, P1085; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIRST MC, 1991, ONCOGENE, V6, P153; HUEBNER K, 1988, ONCOGENE, V3, P449; HYRIEN O, 1987, EMBO J, V6, P2401, DOI 10.1002/j.1460-2075.1987.tb02518.x; IHLE JN, 1989, J VIROL, V63, P2959, DOI 10.1128/JVI.63.7.2959-2966.1989; JURKA J, 1988, P NATL ACAD SCI USA, V85, P4775, DOI 10.1073/pnas.85.13.4775; KORNREICH R, 1990, J BIOL CHEM, V265, P9319; LANGLOIS S, 1988, AM J HUM GENET, V43, P60; LAZO PA, 1988, J VIROL, V62, P788, DOI 10.1128/JVI.62.3.788-794.1988; LEBEAU MM, 1986, BLOOD, V67, P849; LEHRMAN MA, 1987, CELL, V48, P827, DOI 10.1016/0092-8674(87)90079-1; MARKERT ML, 1988, J CLIN INVEST, V81, P1323, DOI 10.1172/JCI113458; MATERA AG, 1990, MOL CELL BIOL, V10, P5424, DOI 10.1128/MCB.10.10.5424; MONTIEL JF, 1984, NUCLEIC ACIDS RES, V12, P1049, DOI 10.1093/nar/12.2.1049; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; NALBANTOGLU J, 1988, J MOL BIOL, V200, P449, DOI 10.1016/0022-2836(88)90535-9; NICHOLLS RD, 1987, CELL, V49, P369, DOI 10.1016/0092-8674(87)90289-3; NOTTENBURG C, 1987, J VIROL, V61, P1828, DOI 10.1128/JVI.61.6.1828-1833.1987; PAOLELLA G, 1983, EMBO J, V2, P691, DOI 10.1002/j.1460-2075.1983.tb01486.x; PICCOLI SP, 1984, NATURE, V310, P327, DOI 10.1038/310327a0; ROUYER F, 1987, CELL, V51, P417, DOI 10.1016/0092-8674(87)90637-4; SILVER J, 1989, J VIROL, V63, P1924, DOI 10.1128/JVI.63.5.1924-1928.1989; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; STOPPALYONNET D, 1990, P NATL ACAD SCI USA, V87, P1551, DOI 10.1073/pnas.87.4.1551; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TSUJIMOTO Y, 1988, ONCOGENE, V2, P347; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TURCCAREL C, 1984, CANCER GENET CYTOGEN, V12, P1, DOI 10.1016/0165-4608(84)90002-5; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	49	37	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1992	7	12					2519	2523						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461655				2022-12-17	WOS:A1992KA85600018
J	JELINEK, MA; HASSELL, JA				JELINEK, MA; HASSELL, JA			REVERSION OF MIDDLE T ANTIGEN-TRANSFORMED RAT-2 CELLS BY KREV-1 - IMPLICATIONS FOR THE ROLE OF P21C-RAS IN POLYOMAVIRUS-MEDIATED TRANSFORMATION	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; PUTATIVE EFFECTOR DOMAIN; GENE-PRODUCT; CELLULAR PROTEINS; TUMOR-ANTIGEN; BOVINE BRAIN; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; MOLECULAR-CLONING	Polyomavirus middle T antigen mediates transformation of cells, at least in part, by its association with and activation of the intrinsic protein tyrosine kinase activity of pp60c-src. pp60c-src, by analogy with pp60v-src, elicits cell proliferation through a signal transduction pathway that includes p21c-ras. Therefore, we tested the possibility that middle T antigen acts upstream of and in the same proliferative signaling pathway as p21c-ras. Co-transfection of Rat-2 cells with plasmids expressing human Krev-1, a dominant suppressor of Ki-ras transformation, and mT antigen resulted in a dose-dependent reduction of mT antigen-induced foci. Krev-1 did not affect the transforming activity of SV40 large T antigen, demonstrating that the transformation-suppressing activity of Krev-1 is specific. To determine the effect of Krev-1 on stably transformed cell lines, Krev-1 DNA was introduced into middle T antigen-transformed Rat-2 cells along with a G418 resistance marker. Of the G418-resistant colonies examined, 1% were morphologically untransformed. Characterization of several morphological revertants revealed that, with the exception of one cell line, all of the cell lines expressed middle T antigen, which was associated with pp60c-src, whose tyrosine kinase activity was similar to that found in the parental transformed cell lines. To determine whether other phenotypic traits associated with transformation were altered in these cell lines, their growth rates and ability to form colonies in agar suspension were examined. The majority of the revertants had longer doubling times, and grew less efficiently in agar suspension compared with their transformed parents. A direct correlation was observed between Krev-1 RNA and protein expression and the efficiency with which the revertants formed colonies in suspension. These results suggest that p21c-ras lies downstream of middle T antigen and pp60c-src in the same proliferative signal transduction pathway.	MCMASTER UNIV,INST MOLEC BIOL & BIOTECHNOL,1280 MAIN ST W,HAMILTON L8S 4K1,ONTARIO,CANADA	McMaster University								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AMINI S, 1986, MOL CELL BIOL, V6, P2305, DOI 10.1128/MCB.6.7.2305; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BOLEN JB, 1985, J VIROL, V53, P114, DOI 10.1128/JVI.53.1.114-119.1985; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOLEN JB, 1987, J VIROL, V61, P3299, DOI 10.1128/JVI.61.10.3299-3305.1987; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAPRENTER CL, 1990, J BIOL CHEM, V265, P19704; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHENG SH, 1986, EMBO J, V5, P325, DOI 10.1002/j.1460-2075.1986.tb04216.x; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COOK DN, 1990, J VIROL, V64, P1879, DOI 10.1128/JVI.64.5.1879-1887.1990; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DAVIDSON D, 1987, J VIROL, V61, P1226, DOI 10.1128/JVI.61.4.1226-1239.1987; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FEATHERSTONE MS, 1984, NUCLEIC ACIDS RES, V12, P7235, DOI 10.1093/nar/12.18.7235; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FUKUI Y, 1991, ONCOGENE, V6, P407; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; GRUSSENMEYER T, 1987, J VIROL, V61, P3902, DOI 10.1128/JVI.61.12.3902-3909.1987; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HART PA, 1990, ONCOGENE, V5, P1099; HATA Y, 1990, J BIOL CHEM, V265, P7104; HOSHIJIMA M, 1988, BIOCHEM BIOPH RES CO, V157, P851, DOI 10.1016/S0006-291X(88)80953-7; HUNTER T, 1984, EMBO J, V3, P73, DOI 10.1002/j.1460-2075.1984.tb01763.x; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KORNBLUTH S, 1990, J VIROL, V64, P1584, DOI 10.1128/JVI.64.4.1584-1589.1990; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LIPS DL, 1989, J BIOL CHEM, V264, P19911; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MARUYAMA K, 1981, J VIROL, V37, P1028, DOI 10.1128/JVI.37.3.1028-1043.1981; MATHEYPREVOT B, 1984, J VIROL, V50, P325, DOI 10.1128/JVI.50.2.325-334.1984; MATTHEWS JT, 1986, J VIROL, V58, P239, DOI 10.1128/JVI.58.2.239-246.1986; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; NAGATA K, 1989, BIOCHEM BIOPH RES CO, V160, P235, DOI 10.1016/0006-291X(89)91646-X; NILSSON SV, 1983, J VIROL, V46, P284, DOI 10.1128/JVI.46.1.284-287.1983; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; RAPTIS L, 1986, BIOCHEM BIOPH RES CO, V136, P995, DOI 10.1016/0006-291X(86)90431-6; RAPTIS L, 1991, J VIROL, V65, P5203, DOI 10.1128/JVI.65.10.5203-5210.1991; ROEBROEK AJM, 1986, VIRUS RES, V6, P15, DOI 10.1016/0168-1702(86)90053-5; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STEINBERG B, 1978, CELL, V13, P19, DOI 10.1016/0092-8674(78)90134-4; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TALMAGE DA, 1988, MOL CELL BIOL, V8, P2309, DOI 10.1128/MCB.8.6.2309; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4616; VARMUS HE, 1981, VIROLOGY, V108, P28, DOI 10.1016/0042-6822(81)90525-0; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	86	37	38	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1687	1698						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1380149				2022-12-17	WOS:A1992JJ37600003
J	MARONEY, AC; QURESHI, SA; FOSTER, DA; BRUGGE, JS				MARONEY, AC; QURESHI, SA; FOSTER, DA; BRUGGE, JS			CLONING AND CHARACTERIZATION OF A THERMOLABILE V-SRC GENE FOR USE IN REVERSIBLE TRANSFORMATION OF MAMMALIAN-CELLS	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; PROTEIN KINASE-C; 3T3 CELLS; GROWTH; DIFFERENTIATION; FIBROBLASTS; EXPRESSION; PP60V-SRC; COMMUNICATION; POLYMERASE	The use of temperature-sensitive (ts) src mutants for studies of cell transformation and differentiation has been limited by the availability of cloned ts-src genes that are inactivated at temperatures compatible with growth of mammalian celts. In this report, we describe the cloning and characterization of the tsLA90src gene, which displays tight thermal sensitivity at 39.5-degrees-C. Nucleotide sequence comparison of tsLA90 and wild-type src genes from the Schmidt-Ruppin subgroup A and D strains of Rous sarcoma virus (RSV) revealed four amino acid differences in tsLA90src. Substitution of one of these residues (Lys-280) from tsLA90src with its wild-type homolog (Glu-280) caused a reversion to a wild-type src phenotype. The cloned tsLA90 gene, designated tsUP1, was introduced into avian and mammalian retroviral vectors. Chicken embryo fibroblasts and immortalized mouse 3T3 cells infected with these viral vectors displayed a temperature-dependent transformed phenotype as assessed by cell morphology, secretion of plasminogen activator, transcriptional activation of the primary response genes, Egr-1 and TIS 10, and stimulation of tyrosine phosphorylation. In addition, chicken myoblasts (infected with RSVtsUP1) showed a temperature-dependent differentiation into myotubes. Thus, this cloned src gene should be ideally suited for inducing reversible transformation and differentiation of mammalian cells in culture.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,DEPT MICROBIOL,PHILADELPHIA,PA 19104; CUNY HUNTER COLL,DEPT BIOL SCI,INST BIOMOLEC STRUCT & FUNCT,NEW YORK,NY 10021	Howard Hughes Medical Institute; University of Pennsylvania; City University of New York (CUNY) System; Hunter College (CUNY)					NCI NIH HHS [CA46677, CA27951, CA08900-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027951, R01CA046677, R29CA046677, R37CA027951, F32CA008900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; AZARNIA R, 1984, J MEMBRANE BIOL, V82, P191, DOI 10.1007/BF01871629; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CRISANTICOMBES P, 1982, CELL DIFFER DEV, V11, P45, DOI 10.1016/0045-6039(82)90016-1; CZERNILOFSKY AP, 1983, NATURE, V301, P736, DOI 10.1038/301736b0; DAVIS LG, 1986, BASIC METHODS MOL BI, P286; GIOTTA GJ, 1980, BRAIN RES, V202, P445, DOI 10.1016/0006-8993(80)90154-7; GOLDBERG AR, 1974, CELL, V2, P95, DOI 10.1016/0092-8674(74)90097-X; GRAY GM, 1988, J BIOL CHEM, V263, P10714; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAN JW, 1990, ONCOGENE, V5, P467; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATCH CL, 1987, ANAL BIOCHEM, V162, P283, DOI 10.1016/0003-2697(87)90038-8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIM RW, 1987, ONCOGENE, V1, P263; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUTO M, 1977, P NATL ACAD SCI USA, V74, P4173, DOI 10.1073/pnas.74.10.4173; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; OSSWOSKI L, 1973, J EXP MED, V138, P1056; PANET R, 1985, J BIOL CHEM, V260, P5752; PATWARDHAN S, 1991, ONCOGENE, V6, P917; QURESHI SA, 1991, MOL CELL BIOL, V11, P102, DOI 10.1128/MCB.11.1.102; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1991, ONCOGENE, V6, P995; REDDY S, 1990, J VIROL, V64, P3545, DOI 10.1128/JVI.64.7.3545-3550.1990; ROSE B, 1986, J MEMBRANE BIOL, V94, P129, DOI 10.1007/BF01871193; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; STOKER AW, 1984, MOL CELL BIOL, V4, P1508, DOI 10.1128/MCB.4.8.1508	36	37	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1207	1214						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1375718				2022-12-17	WOS:A1992HU64200019
J	BLAKE, TJ; LANGDON, WY				BLAKE, TJ; LANGDON, WY			A REARRANGEMENT OF THE C-CBL PROTOONCOGENE IN HUT78 T-LYMPHOMA CELLS RESULTS IN A TRUNCATED PROTEIN	ONCOGENE			English	Article							BCR GENE; CHROMOSOMAL TRANSLOCATION; ACUTE-LEUKEMIA; ALU SEQUENCES; IDENTIFICATION; BREAKPOINTS; RETROVIRUS; NEOPLASIA; REGION	The murine Cas NS-1 retrovirus carries the v-cbl oncogene and induces pro-B, pre-B and myeloid tumors in mice inoculated at birth. The human homolog of v-cbl is located on chromosome 11q23.3, which is in the region of translocation breakpoints in a range of acute leukemias. The sequencing of the human and murine c-cbl proto-oncogenes has revealed v-cbl as a markedly truncated form of c-cbl that encompasses 40% of the amino terminus. This truncation deletes a proline- and serine/threonine-rich domain and a putative leucine zipper. In this study we describe the nature of a truncated form of c-cbl present in the cutaneous T-cell lymphoma line HUT78. In these cells a genetic rearrangement involving unknown sequences and Alu repeat sequences results in the insertion of a premature stop codon that removes 259 amino acids from the carboxy terminus. This results in the translation of a 72 kDa protein, compared with the 120 kDa protein encoded by full-length c-cbl, which lacks a portion of the proline-rich domain and the entire leucine zipper.	INST MED & VET SCI,HANSON CTR CANC RES,ADELAIDE,SA 5000,AUSTRALIA	Institute Medical & Veterinary Science Australia								BLAKE TJ, 1991, ONCOGENE, V6, P653; CHEN SJ, 1989, ONCOGENE, V4, P195; COTTER FE, 1991, GENE CHROMOSOME CANC, V3, P8, DOI 10.1002/gcc.2870030103; DAS S, 1991, GENE CHROMOSOME CANC, V3, P44, DOI 10.1002/gcc.2870030108; FAN YS, 1988, CANCER GENET CYTOGEN, V31, P263, DOI 10.1016/0165-4608(88)90226-9; FINGER LR, 1988, P NATL ACAD SCI USA, V85, P9158, DOI 10.1073/pnas.85.23.9158; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; GAZDAR AF, 1980, BLOOD, V55, P409; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; JURKA J, 1988, P NATL ACAD SCI USA, V85, P4775, DOI 10.1073/pnas.85.13.4775; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LANGDON WY, 1984, CURR TOP MICROBIOL, V113, P241; NAGASAKA M, 1983, BLOOD, V61, P1174; ROGERS J, 1985, NATURE, V317, P559, DOI 10.1038/317559a0; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRONG RC, 1985, BLOOD, V65, P21; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; TUNNACLIFFE A, 1990, GENOMICS, V8, P447, DOI 10.1016/0888-7543(90)90030-X; VANDERFELTZ MJM, 1989, NUCLEIC ACIDS RES, V17, P1, DOI 10.1093/nar/17.1.1	23	37	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					757	762						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565471				2022-12-17	WOS:A1992HQ68200019
J	LARGAESPADA, DA; KAEHLER, DA; MISHAK, H; WEISSINGER, E; POTTER, M; MUSHINSKI, JF; RISSER, R				LARGAESPADA, DA; KAEHLER, DA; MISHAK, H; WEISSINGER, E; POTTER, M; MUSHINSKI, JF; RISSER, R			A RETROVIRUS THAT EXPRESSES V-ABL AND C-MYC ONCOGENES RAPIDLY INDUCES PLASMACYTOMAS	ONCOGENE			English	Note							MURINE LEUKEMIA-VIRUS; DROSOPHILA-MELANOGASTER ABL; ABELSON VIRUS; MOUSE PLASMACYTOMAS; NUCLEOTIDE-SEQUENCE; FIBROBLAST LINES; MAMMALIAN-CELLS; BALB/C MICE; H-RAS; GENE	ABL-MYC, a murine retrovirus that encodes the v-abl and c-myc oncogenes, was constructed from Abelson murine leukemia virus (A-MuLV) in order to assess the biological consequences of co-expression of these genes in lymphoid cells. When inoculated into mice this retrovirus induced plasmacytomas in up to 100% of infected mice and less frequently induced pre-B lymphomas. Both tumor types contained genome-length proviruses in one or a few chromosomal locations, were mono- or oligoclonal as judged by immunoglobulin gene rearrangement and had unrearranged endogenous c-myc loci. The type of tumor induced depended upon the age and strain of mouse, and whether helper virus was present in the inoculated virus pool. ABL-MYC induced plasmacytomas with or without helper virus, with or without pretreatment of the mice with pristane, and in strains of mice resistant to pristane-induced plasmacytomas. Pristane treatment prior to ABL-MYC infection shortened the latent period of plasmacytomagenesis and produced mostly IgM-secreting tumors rather than IgA-secreting tumors, which predominantly arose in the absence of pristane. Control viruses for ABL-MYC with either a deletion in v-abl or a frameshift mutation in c-myc caused predominantly monocyte/macrophage tumors and pre-B-cell lymphomas respectively. Histopathological analysis of ABL-MYC-infected mice showed foci of transformed plasma cells as early as 14 days after infection. These results indicate that v-abl and c-myc act synergistically to transform mature B cells with high efficiency.	NCI, GENET LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	LARGAESPADA, DA (corresponding author), UNIV WISCONSIN, MCARDLE LAB CANC RES, MADISON, WI 53706 USA.		Largaespada, David/C-9832-2014		NATIONAL CANCER INSTITUTE [R01CA041302, T32CA009135] Funding Source: NIH RePORTER; NCI NIH HHS [CA 41302, T32-CA09135] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CHUMAKOV I, 1982, J VIROL, V42, P1088, DOI 10.1128/JVI.42.3.1088-1098.1982; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; CLYNES R, 1988, P NATL ACAD SCI USA, V85, P6067, DOI 10.1073/pnas.85.16.6067; COLLEDGE WH, 1989, ONCOGENE, V4, P753; CORY S, 1987, ONCOGENE RES, V1, P61; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GREEN PL, 1989, J VIROL, V63, P1989, DOI 10.1128/JVI.63.5.1989-1994.1989; GREEN PL, 1988, ONCOGENE, V2, P585; GREEN PL, 1985, J IMMUNOL, V134, P1268; GREEN PL, 1987, P NATL ACAD SCI USA, V84, P5932, DOI 10.1073/pnas.84.16.5932; HOLLAND GD, 1990, J VIROL, V64, P2226, DOI 10.1128/JVI.64.5.2226-2235.1990; HOROWITZ JM, 1982, J VIROL, V44, P950, DOI 10.1128/JVI.44.3.950-957.1982; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JOLLEY ME, 1984, J IMMUNOL METHODS, V67, P21, DOI 10.1016/0022-1759(84)90082-6; KEATH EJ, 1984, CELL, V37, P521, DOI 10.1016/0092-8674(84)90382-9; KESSLER SW, 1975, J IMMUNOL, V115, P1617; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANGDON WY, 1989, ONCOGENE RES, V4, P253; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MATHEYPREVOT B, 1985, EMBO J, V4, P1769, DOI 10.1002/j.1460-2075.1985.tb03849.x; MAX EE, 1979, P NATL ACAD SCI USA, V76, P3450, DOI 10.1073/pnas.76.7.3450; NEPVEU A, 1985, NATURE, V317, P440, DOI 10.1038/317440a0; OHNO S, 1984, J EXP MED, V159, P1762, DOI 10.1084/jem.159.6.1762; POIRIER Y, 1988, J VIROL, V62, P3985, DOI 10.1128/JVI.62.11.3985-3992.1988; POTTER M, 1973, SCIENCE, V182, P592, DOI 10.1126/science.182.4112.592; POTTER M, 1973, SEMIN HEMATOL, V10, P19; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; RISSER R, 1989, CURR TOP MICROBIOL, V147, P129; RISSER R, 1978, J EXP MED, V148, P714, DOI 10.1084/jem.148.3.714; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; TROPPMAIR J, 1989, P NATL ACAD SCI USA, V86, P9941, DOI 10.1073/pnas.86.24.9941; WAGNER MJ, 1981, P NATL ACAD SCI-BIOL, V78, P1441, DOI 10.1073/pnas.78.3.1441; WEISSINGER EM, 1991, P NATL ACAD SCI USA, V88, P8735, DOI 10.1073/pnas.88.19.8735; WEISSINGER EM, 1990, CURR TOP MICROBIOL, V166, P121; WHITLOCK CA, 1983, MOL CELL BIOL, V3, P596, DOI 10.1128/MCB.3.4.596	52	37	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1992	7	4					811	819						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565479				2022-12-17	WOS:A1992HQ68200029
J	SHAY, JW; BABA, TO; ZHAN, QM; KAMIMURA, N; CUTHBERT, JA				SHAY, JW; BABA, TO; ZHAN, QM; KAMIMURA, N; CUTHBERT, JA			HELATG CELLS HAVE MITOCHONDRIAL-DNA INSERTED INTO THE C-MYC ONCOGENE	ONCOGENE			English	Article							HEPATOMA-CELLS; SEQUENCES; EXPRESSION; MUTATIONS; GENES; CARCINOMA; NUCLEUS; RNAS	To determine whether mitochondrial DNA (mtDNA) fragments found within the nucleus are transcribed, we have differentially screened a HeLaTG cDNA library. A clone that hybridized to mtDNA as well as to c-myc was identified. Analysis of the cDNA disclosed that it contained a mtDNA sequence, encoding cytochrome-c oxidase subunit III (coxIII) that was contiguous with and 5' of a c-myc sequence corresponding to part of exon 2 and exon 3. Hybridization of ScaI-digested DNA with a 1.05 kb c-myc probe revealed a unique band in HeLaTG cells, as well as a band common to HeLaTG and 13 other cell types examined. Solution hybridization of HeLaTG RNA with a radiolabeled, single-stranded cDNA probe containing the coxIII-c-myc junction demonstrated a nuclease-resistant band that matched the full length of the junctional cDNA probe. A smaller band that equaled the size of the c-myc portion alone was also detected. Only the smaller band coinciding with the c-myc sequences was protected from nuclease digestion by RNA from other cells. When a radiolabeled probe synthesized in the opposite orientation was used, nuclease-resistant bands equal in length to the coxIII portion of the probe were detected after hybridization with RNA from all cells. These results indicate that insertion of mtDNA fragments into nuclear genes occurs and that subsequent transcription of a 'chimaeric' or 'fusion' mRNA containing both mitochondrial and nuclear sequences can ensue.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	SHAY, JW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235, USA.		Shay, Jerry W/F-7878-2011		NCI NIH HHS [CA40065, CA50195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050195, R01CA040065] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cb.04.110188.001445; ATTARDI G, 1987, BIOESSAYS, V5, P34; BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9; CHOMYN A, 1985, NATURE, V314, P592, DOI 10.1038/314592a0; CORCORAN LM, 1985, CELL, V40, P71, DOI 10.1016/0092-8674(85)90310-1; CORRAL M, 1989, BIOCHEM BIOPH RES CO, V162, P258, DOI 10.1016/0006-291X(89)91990-6; CORRAL M, 1989, NUCLEIC ACIDS RES, V17, P5191, DOI 10.1093/nar/17.13.5191; CUTHBERT JA, 1989, J BIOL CHEM, V264, P1298; ERISMAN MD, 1988, ONCOGENE HDB, P341; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; GELLISSEN G, 1987, ANN NY ACAD SCI, V503, P391, DOI 10.1111/j.1749-6632.1987.tb40625.x; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAYASHI JI, 1986, CANCER RES, V46, P4001; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERRDT BG, 1990, CANCER RES, V50, P1596; KAMIMURA N, 1989, J MOL BIOL, V210, P703, DOI 10.1016/0022-2836(89)90103-4; KOCH I, 1989, VIROLOGY, V170, P591, DOI 10.1016/0042-6822(89)90454-6; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; MARCU KB, 1983, P NATL ACAD SCI-BIOL, V80, P519, DOI 10.1073/pnas.80.2.519; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAY JW, 1987, MUTAT RES, V186, P149, DOI 10.1016/0165-1110(87)90028-5; SHAY JW, 1990, MECHANISMS DIFFERENT, V1, P135; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THORSNESS PE, 1990, NATURE, V346, P376, DOI 10.1038/346376a0; TOURMENTE S, 1990, CELL DIFFER DEV, V31, P137, DOI 10.1016/0922-3371(90)90017-Q; Tzagoloff A, 1982, MITOCHONDRIA	30	37	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1869	1874						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923509				2022-12-17	WOS:A1991GX11800020
J	AOKI, M; AKIYAMA, T; MIYOSHI, J; TOYOSHIMA, K				AOKI, M; AKIYAMA, T; MIYOSHI, J; TOYOSHIMA, K			IDENTIFICATION AND CHARACTERIZATION OF PROTEIN PRODUCTS OF THE COT ONCOGENE WITH SERINE KINASE-ACTIVITY	ONCOGENE			English	Article							GROWTH-FACTORS; ACTIVATION; INVITRO; INSULIN; FAMILY	The products of the cot gene, a novel oncogene isolated by DNA transfection assay using the hamster cell line SHOK, were identified as 46 kDa and 52 kDa proteins by using anti-peptide antibodies. The 46kDa and 52kDa proteins both showed autophosphorylation activity at serine residues. The two forms of the Cot protein were suggested to differ in their amino-terminal structures as a result of alternative initiation of translation. Subcellular fractionation revealed that the 46kDa and 52kDa proteins are both predominantly localized in the cytosol. These Cot proteins are the fourth oncogene products with serine kinase activity identified.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT ONCOGENE RES,3-1 YAMADA OKA,SUITA,OSAKA 565,JAPAN	Osaka University			Aoki, Masahiro/A-5149-2016	Aoki, Masahiro/0000-0003-4316-9490				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; ERIKSON E, 1987, MOL CELL BIOL, V7, P3147, DOI 10.1128/MCB.7.9.3147; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIGASHI T, 1990, P NATL ACAD SCI USA, V87, P2409, DOI 10.1073/pnas.87.7.2409; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KLOETZER WS, 1984, VIROLOGY, V138, P143, DOI 10.1016/0042-6822(84)90154-5; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MIYOSHI J, 1991, IN PRESS MOL CELL BI; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1986, CELL, V46, P606; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	25	37	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1515	1519						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1833717				2022-12-17	WOS:A1991GX27400004
J	MAY, E; JENKINS, JR; MAY, P				MAY, E; JENKINS, JR; MAY, P			ENDOGENOUS HELA P53 PROTEINS ARE EASILY DETECTED IN HELA-CELLS TRANSFECTED WITH MOUSE DELETION MUTANT P53 GENE	ONCOGENE			English	Article							T-ANTIGEN; ONCOGENE	It has been reported [Matlashewski et al. (1986). Eur. J. Biochem., 154, 665-6721 that HeLa cells contain no detectable p53 protein, although they contain p53 mRNA which is translationally active. Here it is shown that endogenous HeLa p53 proteins were easily detected in HeLa cells transiently expressing mouse deletion mutant p53 gene after transfection with the appropriate recombinant plasmid. This detection was obtained by immunoprecipitation coupled with SDS-PAGE as well as by Western blotting experiments. Our results strongly suggest that HeLa p53 mRNA is actually translated in vivo, generating an extremely unstable p53 protein. Considering that the HeLa cell line is a HPV-18-positive human cervical carcinoma cell line, this high instability of HeLa p53 proteins is in keeping with the finding that E6 oncoprotein encoded by human papillomavirus 16 or 18 promotes the degradation of p53 proteins [Scheffner et al. (1990). Cell, 63, 1129-1136].	MARIE SKLODOWSKA CURIE MEM INST,OXTED RH8 0TL,SURREY,ENGLAND		MAY, E (corresponding author), INST RECH SCI CANC,7 RUE GUY MOQUET,F-94801 VILLEJUIF,FRANCE.							CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MAY E, 1991, VIROLOGY, V180, P285, DOI 10.1016/0042-6822(91)90033-8; ROMANO JW, 1989, ONCOGENE, V4, P1483; ROVINSKI B, 1988, ONCOGENE, V2, P445; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8	11	37	39	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1363	1365						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886712				2022-12-17	WOS:A1991GX27200011
J	ONG, G; SIKORA, K; GULLICK, WJ				ONG, G; SIKORA, K; GULLICK, WJ			INACTIVATION OF THE RETINOBLASTOMA GENE DOES NOT LEAD TO LOSS OF TGF-BETA RECEPTORS OR RESPONSE TO TGF-BETA IN BREAST-CANCER CELL-LINES	ONCOGENE			English	Note							TRANSFORMING GROWTH-FACTOR; INHIBITION; EXPRESSION; PATTERN; PRODUCT		HAMMERSMITH HOSP,ICRF,ONCOL GRP,CYCLOTRON BLDG,DU CANE RD,LONDON W12 0HS,ENGLAND	Imperial College London	GULLICK, WJ (corresponding author), HAMMERSMITH HOSP,ICRF,ONCOL GRP,CYCLOTRON BLDG,DU CANE RD,LONDON W12 0HS,ENGLAND.							CHAMBARD JC, 1988, J CELL PHYSIOL, V135, P101, DOI 10.1002/jcp.1041350114; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LIKE B, 1986, J BIOL CHEM, V261, P3426; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SHIPLEY GD, 1985, P NATL ACAD SCI USA, V82, P4147, DOI 10.1073/pnas.82.12.4147; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; XU HJ, 1989, ONCOGENE, V4, P807	17	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					761	763						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1646985				2022-12-17	WOS:A1991GT82500011
J	CHEN, JM; HELLER, D; POON, B; KANG, L; WANG, LH				CHEN, JM; HELLER, D; POON, B; KANG, L; WANG, LH			THE PROTOONCOGENE C-ROS CODES FOR A TRANSMEMBRANE TYROSINE PROTEIN-KINASE SHARING SEQUENCE AND STRUCTURAL HOMOLOGY WITH SEVENLESS PROTEIN OF DROSOPHILA-MELANOGASTER	ONCOGENE			English	Article							AVIAN-SARCOMA VIRUS-UR2; HUMAN INSULIN-RECEPTOR; NUCLEOTIDE-SEQUENCE; TRANSFORMING SEQUENCE; GENETIC-STRUCTURE; C-ROS-1 GENE; SRC GENE; EXPRESSION; CDNA; PRODUCT	Our earlier study predicted that proto-oncogene c-ros codes for a receptor-like tyrosine protein kinase (TPK). To further understand its protein structure and physiological function, we have analysed its expression in various tissues of chicken and have isolated and sequenced cDNA clones containing the entire coding region of the gene. Confirming our earlier study, we found that kidney is the organ that expresses the highest level of c-ros mRNA, in addition, we found a lower level of expression in gonad, thymus, bursa and brain. A distinctive 8.3 kb c-ros mRNA is present in kidney. No detectable amount of c-ros mRNA was found in the rest of tissues examined. Nucleotide sequence of the c-ros cDNA predicts that it codes for a transmembrane (TM) TPK molecule of 2311 amino acids (aa). The extracellular domain consists of 1873 amino acids which share 20 to 43% homology with that of the Drosophila sevenless protein and TPK domains of the two genes have 58 to 74% homology. The extracellular domain containing 37 potential N-linked glycosylation sites is preceded by a 5' hydrophobic sequence resembling a typical signal peptide. An internal hydrophobic domain of 26 amino acids, the presumed transmembrane domain, is followed by a spacer sequence of 58 amino acids, a TPK domain of 270 amino acids and a carboxyl tail of 84 amino acids. Overall, our result indicates that c-ros codes for a glycosylated transmembrane TPK molecule which shares a remarkable sequence and structural homology with that of Drosophila sevenless protein.	CUNY MT SINAI SCH MED,DEPT MICROBIOL,ONE GUSTAVE L LEVY PL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NCI NIH HHS [CA29339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASLER K, 1988, CELL, V54, P299; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; BIRCHMEIER C, 1987, P NATL ACAD SCI USA, V84, P9270, DOI 10.1073/pnas.84.24.9270; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P1122; BOWTELL DDL, 1988, GENE DEV, V2, P620, DOI 10.1101/gad.2.6.620; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DORAI T, 1990, MOL CELL BIOL, V10, P4068, DOI 10.1128/MCB.10.8.4068; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FELDMAN RA, 1982, J VIROL, V42, P228, DOI 10.1128/JVI.42.1.228-236.1982; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JONG SMJ, 1987, ONCOGENE RES, V1, P7; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.bi.54.070185.003215; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MATSUSHIME H, 1990, J VIROL, V64, P2117, DOI 10.1128/JVI.64.5.2117-2125.1990; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; NAGARAJAN L, 1986, P NATL ACAD SCI USA, V83, P6568, DOI 10.1073/pnas.83.17.6568; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; PODELL SB, 1987, ONCOGENE, V2, P9; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; RUBIN GM, 1989, CELL, V57, P519, DOI 10.1016/0092-8674(89)90120-7; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARMA S, 1989, ONCOGENE RES, V5, P91; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIBUYA M, 1982, J VIROL, V42, P143, DOI 10.1128/JVI.42.1.143-152.1982; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG LH, 1981, J VIROL, V40, P258, DOI 10.1128/JVI.40.1.258-267.1981; WANG LH, 1982, J VIROL, V41, P833, DOI 10.1128/JVI.41.3.833-841.1982; WATSON CJ, 1985, DNA CLONING PRACTICA, V1, P79; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5	40	37	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					257	264						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1900358				2022-12-17	WOS:A1991FZ13400011
J	HILLION, J; MECUCCI, C; AVENTIN, A; LEROUX, D; WLODARSKA, I; VANDENBERGHE, H; LARSEN, CJ				HILLION, J; MECUCCI, C; AVENTIN, A; LEROUX, D; WLODARSKA, I; VANDENBERGHE, H; LARSEN, CJ			A VARIANT TRANSLOCATION T(2-18) IN FOLLICULAR LYMPHOMA INVOLVES THE 5' END OF BCL-2 AND IG-KAPPA LIGHT CHAIN GENE	ONCOGENE			English	Note							T(14-18) CHROMOSOMAL TRANSLOCATION; CHRONIC LYMPHOCYTIC-LEUKEMIA; B-CELL; REGION; PRODUCT; CLONING	We have examined three cases of human lymphoma bearing a t(2;18)(p11;q21) chromosome translocation. The bcl-2 gene appeared to be rearranged in all three cases and breakpoints were clustered in the 5' flanking region of the gene. In all three cases, bcl-2 was juxta-posed to J segments of the Igk gene. This juxtaposition of the bcl-2 and Igk genes is very similar to the variant chromosome translocations of Burkitt lymphoma that juxtapose the c-myc locus to IgL genes.	INST GENET MOLEC,INSERM,U301,27 RUE J DODU,F-75010 PARIS,FRANCE; INST GENET MOLEC,CNRS,SDI 15954 I,F-75010 PARIS,FRANCE; CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,B-3000 LOUVAIN,BELGIUM; UNIV PERUGIA,MED CLIN,I-06100 PERUGIA,ITALY; HOSP SAN PAU,SERV HEMATOL,BARCELONA,SPAIN; UNIV JOSEPH FOURIER,FAC MED GRENOBLE,DEPT CYTOGENET,F-38706 LA TRONCHE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; KU Leuven; University of Perugia; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)			Leroux, Dominique/G-7309-2014					ADACHI M, 1990, J EXP MED, V171, P559, DOI 10.1084/jem.171.2.559; ADACHI M, 1989, P NATL ACAD SCI USA, V86, P2771, DOI 10.1073/pnas.86.8.2771; ADACHI M, 1989, ONCOGENE, V4, P1073; AVENTIN A, 1990, BRIT J HAEMATOL, V74, P367, DOI 10.1111/j.1365-2141.1990.tb02599.x; BAKSHI A, 1985, CELL, V41, P899; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLEARY JM, 1987, J EXP MED, V164, P315; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; CROCE CM, 1986, COLD SPRING HARB SYM, V51, P891, DOI 10.1101/SQB.1986.051.01.102; HEITER PA, 1982, J BIOL CHEM, V257, P1516; LEROUX D, 1990, BRIT J HAEMATOL, V75, P290, DOI 10.1111/j.1365-2141.1990.tb02669.x; MATHIEUMAHUL D, 1985, EMBO J, V4, P3427, DOI 10.1002/j.1460-2075.1985.tb04100.x; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NGAN BY, 1988, NEW ENGL J MED, V318, P1638, DOI 10.1056/NEJM198806233182502; PEZZELLA F, 1990, AM J PATHOL, V137, P225; SCHLISSEL MS, 1989, CELL, V59, P1035; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; TAKAHASHI N, 1980, NUCLEIC ACIDS RES, V8, P5983, DOI 10.1093/nar/8.24.5983; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204	26	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					169	172						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1899478				2022-12-17	WOS:A1991EY03900025
J	LONGO, L; DONTI, E; MENCARELLI, A; AVANZI, G; PEGORARO, L; ALIMENA, G; TABILIO, A; VENTI, G; GRIGNANI, F; PELICCI, PG				LONGO, L; DONTI, E; MENCARELLI, A; AVANZI, G; PEGORARO, L; ALIMENA, G; TABILIO, A; VENTI, G; GRIGNANI, F; PELICCI, PG			MAPPING OF CHROMOSOME-17 BREAKPOINTS IN ACUTE MYELOID LEUKEMIAS	ONCOGENE			English	Article									UNIV PERUGIA, MONTELUCE POLICLIN, IST CLIN MED 1, I-06100 PERUGIA, ITALY; UNIV ROME, CATTEDRA EMATOL, I-00161 ROME, ITALY; UNIV TURIN, OSPED MAGGIORE S GIOVANNI, IST MED INTERNA, I-10126 TURIN, ITALY	University of Perugia; Sapienza University Rome; University of Turin			Pelicci, Pier Giuseppe/AAL-6572-2020					BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BURGESS AW, 1980, BLOOD, V56, P947; CANAANI E, 1984, LANCET, V1, P593; CHANDLER ME, 1978, CYTOGENET CELL GENET, V22, P352, DOI 10.1159/000130970; CHANG KS, 1987, LEUKEMIA, V1, P458; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DALTON WT, 1988, BLOOD, V71, P242; DAYTON AI, 1984, P NATL ACAD SCI-BIOL, V81, P4495, DOI 10.1073/pnas.81.14.4495; DEBRAEKELEER M, 1986, CANCER GENET CYTOGEN, V19, P311, DOI 10.1016/0165-4608(86)90060-9; DONTI E, 1989, SCIENCE, V244, P824, DOI 10.1126/science.244.4906.824; DONTI E, 1989, MED ONCOL TUMOR PHAR, V6, P233; GALLAGHER R, 1979, BLOOD, V54, P713; GERHARD DS, 1981, P NATL ACAD SCI-BIOL, V78, P3755, DOI 10.1073/pnas.78.6.3755; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; JOHNSON KR, 1987, NUCLEIC ACIDS RES, V15, P2013, DOI 10.1093/nar/15.5.2013; JONES ME, 1978, AM J MED, V65, P673, DOI 10.1016/0002-9343(78)90856-2; KANEKO Y, 1987, JPN J CANCER RES, V78, P16; KOEFFLER HP, 1987, ANN INTERN MED, V107, P748, DOI 10.7326/0003-4819-107-5-748; KOEFFLER HP, 1985, BLOOD, V65, P484; KUN SC, 1986, BLOOD, V68, P1411; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LARSON RA, 1983, CANCER GENET CYTOGEN, V10, P219, DOI 10.1016/0165-4608(83)90050-X; LIANG JC, 1988, CANCER GENET CYTOGEN, V30, P103, DOI 10.1016/0165-4608(88)90097-0; MATTEI MG, 1988, HUM GENET, V80, P186, DOI 10.1007/BF00702866; MISAWA S, 1986, CANCER GENET CYTOGEN, V22, P239, DOI 10.1016/0165-4608(86)90160-3; MITELMAN F, 1986, CANCER GENET CYTOGEN, V22, P95, DOI 10.1016/0165-4608(86)90168-8; MITELMAN F, 1981, HEREDITAS, V95, P79; Mitelman F., 1988, CATALOG CHROMOSOME A; NICOLA NA, 1983, J BIOL CHEM, V258, P9017; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; POPESCU NC, 1989, GENOMICS, V4, P362, DOI 10.1016/0888-7543(89)90343-1; ROWLEY JD, 1984, CANCER RES, V44, P3159; ROWLEY JD, 1983, NATURE, V301, P290, DOI 10.1038/301290a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SIMMERS RN, 1987, BLOOD, V70, P330; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPURR NK, 1984, EMBO J, V3, P159, DOI 10.1002/j.1460-2075.1984.tb01777.x; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TESTA JR, 1985, CANCER RES, V45, P430; TWEARDY DJ, 1987, ONCOGENE RES, V1, P209; VANDENBERGHE H, 1979, CANCER, V43, P558, DOI 10.1002/1097-0142(197902)43:2<558::AID-CNCR2820430223>3.0.CO;2-6; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WOLMAN SR, 1985, CANCER GENET CYTOGEN, V17, P133, DOI 10.1016/0165-4608(85)90023-8; XU WM, 1988, P NATL ACAD SCI USA, V85, P8563, DOI 10.1073/pnas.85.22.8563; YAMADA M, 1984, J BIOL CHEM, V259, P3021; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310; ZILE MH, 1987, P NATL ACAD SCI USA, V84, P2208, DOI 10.1073/pnas.84.8.2208; 1978, CYTOGENET CELL GENET, V21, P399; 1987, CYTOGENET CELL GENET, V46, P22	55	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1990	5	10					1557	1563						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	1701231				2022-12-17	WOS:A1990EK50200016
J	GODWIN, AK; LIEBERMAN, MW				GODWIN, AK; LIEBERMAN, MW			EARLY AND LATE RESPONSES TO INDUCTION OF RAST24 EXPRESSION IN RAT-1 CELLS	ONCOGENE			English	Article									FOX CHASE CANC INST,DEPT PATHOL,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NCI NIH HHS [R37-CA39392, CA-06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA039392, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1982, ADV CANCER RES, V37, P111, DOI 10.1016/S0065-230X(08)60883-0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; CHIN JR, 1985, J BIOL CHEM, V260, P2367; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DENHARDT DT, 1987, ONCOGENE, V2, P55; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DEVOUGE MW, 1982, VIROLOGY, V121, P327, DOI 10.1016/0042-6822(82)90172-6; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; GREIG RG, 1985, P NATL ACAD SCI USA, V82, P3698, DOI 10.1073/pnas.82.11.3698; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; Iten E, 1989, Recent Results Cancer Res, V113, P78; JAKOWLEW SB, 1988, ONCOGENE RES, V2, P135; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P5936; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LANIA L, 1980, VIROLOGY, V101, P217, DOI 10.1016/0042-6822(80)90497-3; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; LI YC, 1988, P NATL ACAD SCI USA, V85, P344, DOI 10.1073/pnas.85.2.344; LIAU G, 1985, J BIOL CHEM, V260, P531; MANIATIS T, 1985, COLD SPRING HARBOR L; MANNE V, 1984, P NATL ACAD SCI-BIOL, V81, P6953, DOI 10.1073/pnas.81.22.6953; MARTIN GS, 1971, P NATL ACAD SCI USA, V6, P2739; MARTINSSON T, 1988, ONCOGENE, V3, P437; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; MUSCHEL R, 1988, CARCINOGENESIS, V9, P705, DOI 10.1093/carcin/9.5.705; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NAGATA K, 1989, J BIOL CHEM, V264, P17000; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; REDMOND SMS, 1988, ONCOGENE, V2, P259; REYNOLDS VL, 1987, ONCOGENE, V1, P323; RICKETTS MH, 1988, MOL CELL BIOL, V8, P1460, DOI 10.1128/MCB.8.4.1460; RULEY HE, 1983, NATURE, V304, P596; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SISTONEN L, 1987, EXP CELL RES, V168, P518, DOI 10.1016/0014-4827(87)90024-3; SORRENTINO V, 1988, ONCOGENE RES, V2, P189; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; SPANDIDOS DA, 1987, MUTAT RES, V185, P271, DOI 10.1016/0165-1110(87)90020-0; SUAREZ HG, 1987, ONCOGENE RES, V1, P201; TAYA Y, 1984, EMBO J, V3, P2943, DOI 10.1002/j.1460-2075.1984.tb02236.x; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROEN BR, 1988, J BIOL CHEM, V263, P254; TSUBOI K, 1987, BIOCHEM BIOPH RES CO, V146, P699, DOI 10.1016/0006-291X(87)90585-7; VALENZUELA P, 1981, NATURE, V289, P650, DOI 10.1038/289650a0; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WEEKS MO, 1985, J VIROL, V54, P586, DOI 10.1128/JVI.54.2.586-597.1985; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINBERG RA, 1989, CANCER RES, V49, P3713; WHITE BA, 1982, J BIOL CHEM, V257, P8569; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659; YASWEN P, 1985, MOL CELL BIOL, V5, P780, DOI 10.1128/MCB.5.4.780; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	76	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1231	1241						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	2202952				2022-12-17	WOS:A1990DX36100017
J	WADA, T; MYERS, JN; KOKAI, Y; BROWN, VI; HAMURO, J; LEVEA, CM; GREENE, MI				WADA, T; MYERS, JN; KOKAI, Y; BROWN, VI; HAMURO, J; LEVEA, CM; GREENE, MI			ANTIRECEPTOR ANTIBODIES REVERSE THE PHENOTYPE OF CELLS TRANSFORMED BY 2 INTERACTING PROTOONCOGENE ENCODED RECEPTOR PROTEINS	ONCOGENE			English	Article											WADA, T (corresponding author), UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,JOHN MORGAN BLDG,36TH & HAMILTON WALK,PHILADELPHIA,PA 19104, USA.							AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1988, ONCOGENE, V2, P273; HOUGHTON AN, 1985, P NATL ACAD SCI USA, V82, P1242, DOI 10.1073/pnas.82.4.1242; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8489; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEBERMANN TA, 1985, NATURE, V313, P144; MEEKER TC, 1985, BLOOD, V65, P1349, DOI 10.1182/blood.V65.6.1349.bloodjournal6561349; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; RODECK U, 1987, CANCER RES, V47, P3692; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; VOLLMERS HP, 1983, P NATL ACAD SCI-BIOL, V80, P6863, DOI 10.1073/pnas.80.22.6863; YAMAMOTO T, 1986, CANCER RES, V46, P414; YOKOTA J, 1986, LANCET, V1, P765	30	37	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					489	495						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	1970151				2022-12-17	WOS:A1990DB85300006
J	UEHARA, Y; ONO, T; KURISHITA, A; KOKURYU, H; OKADA, S				UEHARA, Y; ONO, T; KURISHITA, A; KOKURYU, H; OKADA, S			AGE-DEPENDENT AND TISSUE-SPECIFIC CHANGES OF DNA METHYLATION WITHIN AND AROUND THE C-FOS GENE IN MICE	ONCOGENE			English	Article									TOHOKU UNIV,SCH MED,DEPT RADIAT RES,SEIRYO CHO 2-1,SENDAI,MIYAGI 980,JAPAN; KYOTO UNIV,FAC MED,CTR RADIAT BIOL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT INTERNAL MED,DIV 2,KYOTO 606,JAPAN	Tohoku University; Kyoto University; Kyoto University								ADAMS RLP, 1985, MOL BIOL DNA METHYLA, P115; BENVENISTY N, 1985, P NATL ACAD SCI USA, V82, P267, DOI 10.1073/pnas.82.2.267; BUCKLEY I, 1988, ADV CANCER RES, V50, P71, DOI 10.1016/S0065-230X(08)60435-2; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COOPER DN, 1983, HUM GENET, V64, P315, DOI 10.1007/BF00292363; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; ETKIND PR, 1983, J VIROL, V45, P114, DOI 10.1128/JVI.45.1.114-123.1983; GREENGARD O, 1972, J CELL BIOL, V52, P261, DOI 10.1083/jcb.52.2.261; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; ICHINOSE M, 1988, CANCER RES, V48, P1603; KANAMURA S, 1980, ANAT EMBRYOL, V158, P151, DOI 10.1007/BF00315902; KANAMURA S, 1974, ANAT REC, V181, P635; KASIK JW, 1987, MOL CELL BIOL, V7, P3349, DOI 10.1128/MCB.7.9.3349; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; MAYSHOOPES LL, 1985, MOL BIOL AGING GENE, P49; MILLER AD, 1984, CELL, V36, P51; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; MULLINS LJ, 1987, MOL CELL BIOL, V7, P3916, DOI 10.1128/MCB.7.11.3916; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; ONO T, 1985, MECH AGEING DEV, V32, P227, DOI 10.1016/0047-6374(85)90082-X; ONO T, 1989, MUTAT RES, V219, P39, DOI 10.1016/0921-8734(89)90039-8; PAUL J, 1969, CELL TISSUE KINET, V2, P283, DOI 10.1111/j.1365-2184.1969.tb00238.x; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RAZIN A, 1984, INT REV CYTOL, V92, P159; RIGGS AD, 1983, ADV CANCER RES, V40, P1, DOI 10.1016/S0065-230X(08)60678-8; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; TANAKA K, 1986, P NATL ACAD SCI USA, V83, P7598, DOI 10.1073/pnas.83.20.7598; TIMIRAS PS, 1972, DEV PHYSL AGING, P129; TRATNER I, 1988, NUCLEIC ACIDS RES, V16, P2749, DOI 10.1093/nar/16.7.2749; VARMUS HE, 1987, MOL BASIS BLOOD DISE, P271; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; VERMA IM, 1987, ADV CANCER RES, V49, P29, DOI 10.1016/S0065-230X(08)60793-9	37	37	37	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					1023	1028						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2503800				2022-12-17	WOS:A1989AJ29700012
J	OLSON, EN; CAPETANAKI, YG				OLSON, EN; CAPETANAKI, YG			DEVELOPMENTAL REGULATION OF INTERMEDIATE FILAMENT AND ACTIN MESSENGER-RNAS DURING MYOGENESIS IS DISRUPTED BY ONCOGENIC RAS GENES	ONCOGENE			English	Article									BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine	OLSON, EN (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BAINS W, 1984, MOL CELL BIOL, V4, P1449, DOI 10.1128/MCB.4.8.1449; BENNETT GS, 1979, J CELL BIOL, V82, P577, DOI 10.1083/jcb.82.2.577; CAFFREY JM, 1987, SCIENCE, V236, P570, DOI 10.1126/science.2437651; CAPETANAKI YG, 1983, CELL, V35, P411, DOI 10.1016/0092-8674(83)90174-5; CAPETANAKI YG, 1984, P NATL ACAD SCI-BIOL, V81, P6909, DOI 10.1073/pnas.81.22.6909; CAPETANAKI YG, 1984, MOL BIOL CYTOSKELETO, P415; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FERRARI S, 1986, MOL CELL BIOL, V6, P3614, DOI 10.1128/MCB.6.11.3614; FINKEL T, 1984, CELL, V37, P151, DOI 10.1016/0092-8674(84)90310-6; FLORINI JR, 1986, J BIOL CHEM, V261, P6509; GARD DL, 1980, CELL, V19, P263, DOI 10.1016/0092-8674(80)90408-0; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GIBSON CW, 1986, MOL CELL BIOCHEM, V71, P61; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GOSSETT LA, 1988, J CELL BIOL, V106, P2127, DOI 10.1083/jcb.106.6.2127; HAYWARD LJ, 1986, J CELL BIOL, V102, P1485, DOI 10.1083/jcb.102.4.1485; HIRSCHHORN RR, 1984, P NATL ACAD SCI-BIOL, V81, P6004, DOI 10.1073/pnas.81.19.6004; HOLTZER H, 1975, P NATL ACAD SCI USA, V72, P4051, DOI 10.1073/pnas.72.10.4051; HYNES RO, 1976, DEV BIOL, V48, P35, DOI 10.1016/0012-1606(76)90043-9; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KACZMAREK L, 1985, P NATL ACAD SCI USA, V82, P5375, DOI 10.1073/pnas.82.16.5375; KAMATA T, 1984, NATURE, V310, P147, DOI 10.1038/310147a0; KAUFMAN SJ, 1988, P NATL ACAD SCI USA, V85, P9606, DOI 10.1073/pnas.85.24.9606; KELVIN DJ, 1989, J CELL BIOL, V108, P169, DOI 10.1083/jcb.108.1.169; MCGRATH JP, 1984, NATURE, V313, P241; MOSS PS, 1979, EXP CELL RES, V123, P95, DOI 10.1016/0014-4827(79)90425-7; NGAI J, 1984, J CELL BIOL, V99, P306, DOI 10.1083/jcb.99.1.306; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1983, J BIOL CHEM, V258, P2644; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; PATERSON BM, 1984, SCIENCE, V224, P1436, DOI 10.1126/science.6729461; PAYNE PA, 1987, P NATL ACAD SCI USA, V84, P8956, DOI 10.1073/pnas.84.24.8956; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; SASSONECORSI P, 1988, CELL, V54, P533; SCHWARTZ RJ, 1981, BIOCHEMISTRY-US, V20, P4122, DOI 10.1021/bi00517a027; SCONTHAL A, 1988, CELL, V54, P325; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; STERNBERG EA, 1989, IN PRESS MOL CELL BI; SULLIVAN N, 1985, CANCER CELL, V3, P243; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	52	37	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					907	913						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2666910				2022-12-17	WOS:A1989AE58400014
J	BOULTER, CA; WAGNER, EF				BOULTER, CA; WAGNER, EF			THE EFFECTS OF V-SRC EXPRESSION ON THE DIFFERENTIATION OF EMBRYONAL CARCINOMA-CELLS	ONCOGENE			English	Article											BOULTER, CA (corresponding author), EUROPEAN MOLEC BIOL LAB,POSTFACH 102209,D-6900 HEIDELBERG,FED REP GER.		Boulter, Catherine/A-6607-2010	Wagner, Erwin F/0000-0001-7872-0196				ADAMSON ED, 1987, DEVELOPMENT, V99, P449; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ANDERSON SM, 1983, J VIROL, V46, P594, DOI 10.1128/JVI.46.2.594-605.1983; BELL JC, 1986, MOL CELL BIOL, V6, P617, DOI 10.1128/MCB.6.2.617; BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3899, DOI 10.1073/pnas.70.12.3899; BOETTIGER D, 1983, MOL CELL BIOL, V3, P1518, DOI 10.1128/MCB.3.8.1518; BOETTIGER D, 1977, CELL, V11, P881, DOI 10.1016/0092-8674(77)90299-9; BOETTIGER D, 1984, CELL, V36, P763, DOI 10.1016/0092-8674(84)90356-8; BOULTER CA, 1987, NUCLEIC ACIDS RES, V15, P7194, DOI 10.1093/nar/15.17.7194; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; CZERNILOFSKY AP, 1983, NATURE, V301, P736, DOI 10.1038/301736b0; DOLBERG DS, 1984, NATURE, V309, P552, DOI 10.1038/309552a0; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; EDWARDS MKS, 1983, DEV BIOL, V98, P187, DOI 10.1016/0012-1606(83)90348-2; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISZMAN MY, 1975, NATURE, V254, P429, DOI 10.1038/254429a0; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; Graham C.F, 1977, CONCEPTS MAMMALIAN E, P315; HEATH JK, 1985, CIBA F SYMP, V116, P3; HEATH JK, 1983, CANCER SURV, V2, P141; HOLTZER H, 1975, P NATL ACAD SCI USA, V72, P4051, DOI 10.1073/pnas.72.10.4051; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KAHN P, 1984, P NATL ACAD SCI-BIOL, V81, P7122, DOI 10.1073/pnas.81.22.7122; KEANE RW, 1984, DEV BIOL, V103, P38, DOI 10.1016/0012-1606(84)90005-8; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KELLERMANN O, 1986, DIFFERENTIATION, V32, P74, DOI 10.1111/j.1432-0436.1986.tb00558.x; LEV Z, 1984, MOL CELL BIOL, V4, P982, DOI 10.1128/MCB.4.5.982; LEVINE JM, 1986, J NEUROSCI, V6, P3374; LEVY BT, 1984, DEV BIOL, V104, P9, DOI 10.1016/0012-1606(84)90031-9; LINNEY E, 1984, NATURE, V308, P470, DOI 10.1038/308470a0; LYNCH SA, 1986, SCIENCE, V234, P873, DOI 10.1126/science.3095923; MANESS PF, 1986, DEV BIOL, V117, P83, DOI 10.1016/0012-1606(86)90350-7; MANIATIS T, 1982, MOL CLONING LABORATO; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; MUMMERY CL, 1987, DEV BIOL, V121, P10, DOI 10.1016/0012-1606(87)90133-3; PACIFICI M, 1977, CELL, V11, P891, DOI 10.1016/0092-8674(77)90300-2; ROSSANT J, 1982, J EMBRYOL EXP MORPH, V70, P99; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SEJERSEN T, 1985, EXP CELL RES, V160, P19, DOI 10.1016/0014-4827(85)90232-0; SEJERSEN T, 1986, J CELL PHYSIOL, V127, P274, DOI 10.1002/jcp.1041270213; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SLAMON DJ, 1984, P NATL ACAD SCI-BIOL, V81, P7141, DOI 10.1073/pnas.81.22.7141; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SPOONCER E, 1984, NATURE, V310, P228, DOI 10.1038/310228a0; STEWART CL, 1985, EMBO J, V4, P3701, DOI 10.1002/j.1460-2075.1985.tb04138.x; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; WEISS RA, 1982, RNA TUMOUR VIRUSES; YU SF, 1986, P NATL ACAD SCI USA, V83, P3194, DOI 10.1073/pnas.83.10.3194	56	37	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					207	214						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	3127777				2022-12-17	WOS:A1988M593100001
